<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39308687</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1837-9664</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>17</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Journal of Cancer</Title><ISOAbbreviation>J Cancer</ISOAbbreviation></Journal><ArticleTitle>Pan-cancer analysis of the role of &#x3b1;2C-adrenergic receptor (ADRA2C) in human tumors and validation in glioblastoma multiforme models.</ArticleTitle><Pagination><StartPage>5691</StartPage><EndPage>5709</EndPage><MedlinePgn>5691-5709</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/jca.98240</ELocationID><Abstract><AbstractText><b>Background:</b> Several studies have reported the relationship between &#x3b1;2C-adrenergic receptor (ADRA2C) and both neoplastic and non-neoplastic diseases. However, a comprehensive pan-cancer analysis is currently lacking. <b>Methods:</b> Utilizing the RNA sequencing (RNA-seq) datasets from The Cancer Genome Atlas (TCGA) database, the roles of ADRA2C in human pan-cancer were analyzed through a variety of bioinformatics approaches, including R programming language and single-cell sequencing data analysis, <i>et al</i>. Besides, cell migration assay and immunochemistry were employed to further validate the role of ADRA2C in glioblastoma multiforme (GBM) cell lines and GBM mouse model. <b>Results:</b> A total of 33 cancer types were involved in this study. It was revealed that the expression level of ADRA2C varied across different clinical stages in patients with breast invasive carcinoma (BRCA), esophageal adenocarcinoma (ESCA), kidney renal papillary cell carcinoma (KIRP) and lung squamous cell carcinoma (LUSC). Meanwhile, it was found that ADRA2C may play roles in prognosis of adrenocortical carcinoma (ACC), glioblastoma multiforme and lower grade glioma (GBM-LGG), and uveal melanoma (UVM). Functional enrichment analysis suggested that ADRA2C expression level was highly correlated with neuronal system-related pathways. Moreover, ADRA2C may be a promising diagnostic marker for cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), GBM, GBMLGG, kidney chromophobe (KICH), and KIRP. Additionally, ADRA2C expression level was correlated with the levels of several infiltrating cells and immune checkpoint genes. Besides, the single-cell sequencing data analysis indicated that ADRA2C played a role in multiple tumor development processes in GBM, retinoblastoma (RB), and UVM. Finally, <i>in vitro</i> and <i>in vivo</i> experiments confirmed that the expression level of ADRA2C may be associated with glioma cell migration, apoptosis, and invasion. <b>Conclusion:</b> ADRA2C exhibited to play a notable role in several cancer types, suggesting that ADRA2C could serve as a promising biomarker or target for cancer diagnosis, prognosis, and treatment, particularly for GBM.</AbstractText><CopyrightInformation>&#xa9; The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoxiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, West China School of Basic Medical Sciences &amp; Forensic Medicine, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Huitong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, West China School of Basic Medical Sciences &amp; Forensic Medicine, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chenyang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, West China School of Basic Medical Sciences &amp; Forensic Medicine, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Liyan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, West China School of Basic Medical Sciences &amp; Forensic Medicine, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Shuangfa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, West China School of Basic Medical Sciences &amp; Forensic Medicine, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Junli</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, West China School of Basic Medical Sciences &amp; Forensic Medicine, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Chronobiology (Sichuan University), Chengdu 610041, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>J Cancer</MedlineTA><NlmUniqueID>101535920</NlmUniqueID><ISSNLinking>1837-9664</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">apoptosis</Keyword><Keyword MajorTopicYN="N">glioblastoma multiforme</Keyword><Keyword MajorTopicYN="N">invasion</Keyword><Keyword MajorTopicYN="N">pan-cancer analysis</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">&#x3b1;2C-adrenergic receptor</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39308687</ArticleId><ArticleId IdType="pmc">PMC11414618</ArticleId><ArticleId IdType="doi">10.7150/jca.98240</ArticleId><ArticleId IdType="pii">jcav15p5691</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu Z, Shi M, Ren Y. et al. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. Mol Cancer. 2023;22:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933290</ArticleId><ArticleId IdType="pubmed">36797756</ArticleId></ArticleIdList></Reference><Reference><Citation>Llovet JM, Kelley RK, Villanueva A. et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33479224</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Fuchs HE. et al. Cancer statistics, 2022. A Cancer J Clin. 2022;72:7&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">35020204</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:a001008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827900</ArticleId><ArticleId IdType="pubmed">20182602</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandi D, Cheema PS, Jaiswal N. et al. FoxM1: Repurposing an oncogene as a biomarker. Semin Cancer Biol. 2018;52:74&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">28855104</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381:1058&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3931461</ArticleId><ArticleId IdType="pubmed">23668556</ArticleId></ArticleIdList></Reference><Reference><Citation>Brocos-Mosquera I, Miranda-Azpiazu P, Muguruza C. et al. Differential brain ADRA2A and ADRA2C gene expression and epigenetic regulation in schizophrenia. Effect of antipsychotic drug treatment. Transl Psychiatry. 2021;11:643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8688495</ArticleId><ArticleId IdType="pubmed">34930904</ArticleId></ArticleIdList></Reference><Reference><Citation>Small KM, Wagoner LE, Levin AM. et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002;347:1135&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374873</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsutsui H, Shimokawa T, Miura T. et al. Inhibition of alpha2C-adrenoceptors ameliorates cisplatin-induced acute renal failure in rats. Eur J Pharmacol. 2018;838:113&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30201375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivero EM, Martinez LM, Bruque CD. et al. Prognostic significance of &#x3b1;- and &#x3b2;2-adrenoceptor gene expression in breast cancer patients. Br J Clin Pharmacol. 2019;85:2143&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6710529</ArticleId><ArticleId IdType="pubmed">31218733</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Flaherty P, Ji HP. Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis. BMC medical genomics. 2013;6:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3907018</ArticleId><ArticleId IdType="pubmed">24308539</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivian J, Rao AA, Nothaft FA. et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35:314&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546205</ArticleId><ArticleId IdType="pubmed">28398314</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Lichtenberg T, Hoadley KA. et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018;173:400&#x2013;16. e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6066282</ArticleId><ArticleId IdType="pubmed">29625055</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC bioinformatics. 2013;14:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618321</ArticleId><ArticleId IdType="pubmed">23323831</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang LG, Han Y. et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Bindea G, Mlecnik B, Tosolini M. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">24138885</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan H, Yan M, Zhang G. et al. CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 2019;47:D900&#x2013;D8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324047</ArticleId><ArticleId IdType="pubmed">30329142</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa DM, Fernandes V, Lourenco C. et al. Profiling the Adrenergic System in Breast Cancer and the Development of Metastasis. Cancers (Basel) 2022;14:5518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9688855</ArticleId><ArticleId IdType="pubmed">36428611</ArticleId></ArticleIdList></Reference><Reference><Citation>Su H, Hailin Z, Dongdong L. et al. Long non-coding RNA LINC01018 inhibits human glioma cell proliferation and metastasis by directly targeting miRNA-182-5p. J Neurooncol. 2022;160:67&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">36094613</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Flaherty P, Ji HP. Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis. BMC Med Genomics. 2013;6:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3907018</ArticleId><ArticleId IdType="pubmed">24308539</ArticleId></ArticleIdList></Reference><Reference><Citation>Powe DG, Voss MJ, Habashy HO. et al. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat. 2011;130:457&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">21298476</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Cao J, Topatana W. et al. Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol. 2021;14:157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8480024</ArticleId><ArticleId IdType="pubmed">34583722</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol. 2021;18:645&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">34131315</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez J, Frigola J, Vendrell E. et al. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res. 2006;66:8462&#x2013;9468.</Citation><ArticleIdList><ArticleId IdType="pubmed">16951157</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301:89&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">6185846</ArticleId></ArticleIdList></Reference><Reference><Citation>Klutstein M, Nejman D, Greenfield R. et al. DNA Methylation in Cancer and Aging. Cancer Res. 2016;76:3446&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">27256564</ArticleId></ArticleIdList></Reference><Reference><Citation>Paleari RG, Peres RMR, Florentino JO. et al. Reduced Prevalence of the C825T Polymorphism of the G-Protein Beta Subunit Gene in Women with Breast Cancer. Int J Biol Markers. 2018;26:234&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">22034052</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal M, Conole D, Nautiyal J. et al. UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology. Br J Cancer. 2021;126:24&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727673</ArticleId><ArticleId IdType="pubmed">34497382</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jonge HJM, Woolthuis CM, Vos AZ. et al. Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML. Leukemia. 2011;25:1825&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">21760593</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan Y, Ye F, He XX. The role of YWHAZ in cancer: A maze of opportunities and challenges. J Cancer. 2020;11:2252&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7052942</ArticleId><ArticleId IdType="pubmed">32127952</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y, French B, Tillman B. et al. Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH) Exp Mol Pathol. 2018;105:144&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093215</ArticleId><ArticleId IdType="pubmed">30009772</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder ZA, Thorne AH, Bakas S. et al. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer Cell. 2018;34:163&#x2013;177.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6424337</ArticleId><ArticleId IdType="pubmed">29990498</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahme G, Israel M. Id4 suppresses MMP2-mediated invasion of glioblastoma-derived cells by direct inactivation of Twist1 function. 2015 Jan 2;34(1):53-62. Oncogene. 2015;34:53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24413082</ArticleId></ArticleIdList></Reference><Reference><Citation>Du R, Petritsch C, Lu K. et al. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol. 2008;10:254&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2563048</ArticleId><ArticleId IdType="pubmed">18359864</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartron P, Loussouarn D, Campone M. et al. Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme. Cell Death Dis. 2012;3:e421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3542591</ArticleId><ArticleId IdType="pubmed">23152057</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao M, Ventura PB, Jiang Y. et al. Astrocytic trans-Differentiation Completes a Multicellular Paracrine Feedback Loop Required for Medulloblastoma Tumor Growth. Cell. 2020;180:502&#x2013;20.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7259679</ArticleId><ArticleId IdType="pubmed">31983537</ArticleId></ArticleIdList></Reference><Reference><Citation>Denkert C, von Minckwitz G, Darb-Esfahani S. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">29233559</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer cell. 2023;41:450&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">36917950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P, Wagner K, Wolchok JD. et al. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11:805&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426440</ArticleId><ArticleId IdType="pubmed">22020206</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients. Clin Cancer Res. 2013;19:5300&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24089443</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell A, Bod L, Madi A. et al. The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. Cell Res. 2020;30:285&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118128</ArticleId><ArticleId IdType="pubmed">31974523</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser AS, Chavali S, Masuho I. et al. Pharmacogenomics of GPCR Drug Targets. Cell. 2018;172:41&#x2013;54. e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5766829</ArticleId><ArticleId IdType="pubmed">29249361</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser AS, Attwood MM, Rask-Andersen M. et al. Trends in GPCR drug discovery: new agents, targets and indications. Nature Reviews Drug Discovery. 2017;16:829&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6882681</ArticleId><ArticleId IdType="pubmed">29075003</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39268267</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Pan-Cancer Analysis Confirms the Prognostic and Immunological Implications of the 1,25-Dihydroxy Vitamin D3 Receptor in Cervical Squamous Cell Carcinoma.</ArticleTitle><Pagination><StartPage>e66743</StartPage><MedlinePgn>e66743</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e66743</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.66743</ELocationID><Abstract><AbstractText>Vitamin D receptor (VDR), specifically the 1,25-dihydroxy form, holds significant importance in various types of cancer, including cervical squamous cell carcinoma (CESC), which&#xa0;poses a significant public health challenge. A pan-cancer analysis was conducted on VDR in CESC, with a focus on its expression and relationship with immune infiltration and genetic alterations. Bioinformatics databases, including TIMER, GEPIA, UALCAN, cBioportal, and Kaplan-Meier Plotter, have been utilized. VDR expression in CESC has been validated using publicly available data. Results were significantly upregulated (P=0.05) in THCA, BRCA, KICH, LUAD, LIHC, STAD, UCEC, CESC, CHOL, ESCA, and HNSC samples. We analyzed the correlation between VDR expression and various clinicopathological factors such as age, race, and cancer stage. VDR expression was significantly upregulated across all age groups, with the highest levels observed in older adults followed by young and middle-aged adults. VDR gene expression was significantly elevated across all races, including Caucasians, African-Americans, and Asians, compared to that in the normal group. Furthermore, VDR expression was significantly upregulated in cancer stages 1, 2, 3, and 4, with the highest increase observed in stage 3 compared to that in normal individuals. We analyzed the expression of the VDR&#xa0;in relation to immune cell type and tumor cell purity in CESC. Our results indicated that VDR expression was positively correlated with neutrophils and dendritic cells and negatively correlated with tumor cell purity in CESC patients. There was no significant correlation between VDR expression and the abundance of B cells, CD8+ T cells, CD4+ T cells, and macrophages. Our study found no significant effect of VDR expression on patient prognosis, although it was positively correlated with CD4+ T cells. The Cox proportional hazards model indicated that age and immune cells did not significantly affect prognosis. Most VDR mutations are concentrated in diffuse large B-cell lymphoma, with an amplification frequency of 4% and a deep deletion frequency of 2.2%. GEO confirmed VDR expression in CESC, identifying 1515 upregulated and 1877 downregulated genes, with volcano plots showing CESC downregulation in patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024, Faris et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faris</LastName><ForeName>Israa Faris M</ForeName><Initials>IFM</Initials><AffiliationInfo><Affiliation>Faculty of Veterinary Medicine, University of Khartoum, Khartoum, SDN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Fertilization and Artificial Insemination, Istanbul University-Cerrahpasa, Istanbul, TUR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Noon</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Public Health/Health Policy, Planning and Management, Ahfad University for Women, Omdurman, SDN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeanelabdeen</LastName><ForeName>Tomador S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Department of Allergy and Immunology, Private Practice, Mecca, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfaki</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Research, Sidra Medicine, Doha, QAT.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cervical squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">cesc</Keyword><Keyword MajorTopicYN="N">immune cell infiltration</Keyword><Keyword MajorTopicYN="N">prognostic biomarkers</Keyword><Keyword MajorTopicYN="N">vdr</Keyword><Keyword MajorTopicYN="N">vitamin d3 receptor</Keyword><Keyword MajorTopicYN="N">volcano plot</Keyword></KeywordList><CoiStatement>Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>13</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>13</Day><Hour>23</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>13</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39268267</ArticleId><ArticleId IdType="pmc">PMC11391166</ArticleId><ArticleId IdType="doi">10.7759/cureus.66743</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Papillary squamotransitional cell carcinoma of the uterine cervix with atypical presentation: a case report with a literature review. Yordanov A, Karaivanov M, Kostov S, et al. Medicina (Kaunas) 2022;58</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9785399</ArticleId><ArticleId IdType="pubmed">36557040</ArticleId></ArticleIdList></Reference><Reference><Citation>Primary vaginal invasive squamous cell carcinoma: a rare case report. Santosh T, Sahu P, Patro MK, Mishra B. J Cytol Histol. 2017;8:2.</Citation></Reference><Reference><Citation>Diagnostic value of VDR in bone metastasis and prognosis of patients with breast cancer and expression correlation between vitamin D receptor and hairless protein. Ding P, Du X, Wan L, et al. Oncol Res Treat. 2022;45:166&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">34818655</ArticleId></ArticleIdList></Reference><Reference><Citation>Novel mechanisms for the vitamin D receptor (VDR) in the skin and in skin cancer. Bikle DD, Oda Y, Tu CL, Jiang Y. J Steroid Biochem Mol Biol. 2015;148:47&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4361259</ArticleId><ArticleId IdType="pubmed">25445917</ArticleId></ArticleIdList></Reference><Reference><Citation>Exploiting vitamin D receptor and its ligands to target squamous cell carcinomas of the head and neck. Koll L, G&#xfc;l D, Elnouaem MI, et al. Int J Mol Sci. 2023;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10002563</ArticleId><ArticleId IdType="pubmed">36902107</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitamin D receptor gene (VDR) associations with cancer. Slattery ML. Nutr Rev. 2007;65:0&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2409269</ArticleId><ArticleId IdType="pubmed">17867381</ArticleId></ArticleIdList></Reference><Reference><Citation>TIMER: Tumor IMmune Estimation Resource. Li B, Li T. https://zenodo.org/records/57669 Zenodo. 2016</Citation></Reference><Reference><Citation>Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Li B, Severson E, Pignon JC, et al. Genome Biol. 2016;17:174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4993001</ArticleId><ArticleId IdType="pubmed">27549193</ArticleId></ArticleIdList></Reference><Reference><Citation>Comprehensive characterization of cancer driver genes and mutations. Bailey MH, Tokheim C, Porta-Pardo E, et al. Cell. 2018;173:371&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029450</ArticleId><ArticleId IdType="pubmed">29625053</ArticleId></ArticleIdList></Reference><Reference><Citation>Exploring the biomarkers and potential therapeutic drugs for sepsis via integrated bioinformatic analysis. Liang P, Wu Y, Qu S, Younis M, Wang W, Wu Z, Huang X. BMC Infect Dis. 2024;24:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10763157</ArticleId><ArticleId IdType="pubmed">38166628</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics analysis for circulating cell-free DNA in cancer. Huang CC, Du M, Wang L. Cancers (Basel) 2019;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6627444</ArticleId><ArticleId IdType="pubmed">31212602</ArticleId></ArticleIdList></Reference><Reference><Citation>Modeling precision treatment of breast cancer. Daemen A, Griffith OL, Heiser LM, et al. Gene Biol. 2013;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3937590</ArticleId><ArticleId IdType="pubmed">24176112</ArticleId></ArticleIdList></Reference><Reference><Citation>Analysis of the Cancer Genome Atlas data reveals novel putative ncRNAs targets in hepatocellular carcinoma. Falcon T, Freitas M, Mello AC, Coutinho L, Alvares-da-Silva MR, Matte U. Biomed Res Int. 2018;2018:2864120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6038674</ArticleId><ArticleId IdType="pubmed">30046591</ArticleId></ArticleIdList></Reference><Reference><Citation>The relevance of the vitamin D endocrine system (VDES) for tumorigenesis, prevention, and treatment of non-melanoma skin cancer (NMSC) Reichrath J, Reichrath S. Pres Conc Fut Pers. 2013;5:38&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3897597</ArticleId><ArticleId IdType="pubmed">24494041</ArticleId></ArticleIdList></Reference><Reference><Citation>Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Kim S, Chen G, King AN, et al. Elsevier BV. 2012;77:265&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3396768</ArticleId><ArticleId IdType="pubmed">22564539</ArticleId></ArticleIdList></Reference><Reference><Citation>CYP24 inhibition preserves 1&#x3b1;,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. Zhang Q, Kanterewicz B, Buch S, et al. Mol Cell Endocrinol. 2012;355:153&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312998</ArticleId><ArticleId IdType="pubmed">22386975</ArticleId></ArticleIdList></Reference><Reference><Citation>Targeting vitamin D receptor (VDR)/immune checkpoint inhibitor receptor ligand PD-L1 axis for immunotherapy of ovarian cancer. Singh RK, Turner R, Kim K, et al. Gynec Oncol. 2018;149:48.</Citation></Reference><Reference><Citation>Assessment of functional variants and expression of long noncoding RNAs in vitamin D receptor signaling in breast cancer. Kholghi Oskooei V, Geranpayeh L, Omrani MD, Ghafouri-Fard S. Cancer Manag Res. 2018;10:3451&#x2013;3462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6140719</ArticleId><ArticleId IdType="pubmed">30254488</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitamin D receptor is a novel drug target for ovarian cancer treatment. Zhang X, Nicosia SV, Bai W. Curr Cancer Drug Targets. 2006;6:229&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16712459</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytoplasmic VDR expression as an independent risk factor for ovarian cancer. Czogalla B, Deuster E, Liao Y, et al.  https://doi.org/10.1007/s00418-020-01894-6. Histochem Cell Biol. 2020;154:421&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7532962</ArticleId><ArticleId IdType="pubmed">32572587</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitamins in gynecologic malignancies. Wierzbowska N, Olszowski T, Chlubek D, Koz&#x142;owski M, Cymbaluk-P&#x142;oska A. Nutrients. 2024;16:1392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11085130</ArticleId><ArticleId IdType="pubmed">38732639</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39154046</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Elucidating the pan-oncologic landscape of S100A9: prognostic and therapeutic corollaries from an integrative bioinformatics and Mendelian randomization analysis.</ArticleTitle><Pagination><StartPage>19071</StartPage><MedlinePgn>19071</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">19071</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-70223-x</ELocationID><Abstract><AbstractText>The calcium-binding protein S100A9 has emerged as a pivotal biomolecular actor in oncology, implicated in numerous malignancies. This comprehensive bioinformatics study transcends traditional boundaries, investigating the prognostic and therapeutic potential of S100A9 across diverse neoplastic entities. Leveraging a wide array of bioinformatics tools and publicly available cancer genomics databases, such as TCGA, we systematically examined the S100A9 gene. Our approach included differential expression analysis, mutational burden assessment, protein interaction networks, and survival analysis. This robust computational framework provided a high-resolution view of S100A9's role in cancer biology. The study meticulously explored S100A9's oncogenic facets, incorporating comprehensive analyses of its relationship with prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), DNA methylation, and immune cell infiltration across various tumor types. This study presents a panoramic view of S100A9 expression across a spectrum of human cancers, revealing a heterogeneous expression landscape. Elevated S100A9 expression was detected in malignancies such as BLCA (Bladder Urothelial Carcinoma), CESC (Cervical squamous cell carcinoma and endocervical adenocarcinoma), COAD (Colon adenocarcinoma), ESCA (Esophageal carcinoma), and GBM (Glioblastoma multiforme), while reduced expression was noted in BRCA (Breast invasive carcinoma), HNSC (Head and Neck squamous cell carcinoma), and KICH (Kidney Chromophobe). This disparate expression pattern suggests that S100A9's role in cancer biology is multifaceted and context-dependent. Prognostically, S100A9 expression correlates variably with patient outcomes across different cancer types. Furthermore, its expression is intricately associated with TMB and MSI in nine cancer types. Detailed examination of six selected tumors-BRCA, CESC, KIRC (Kidney renal clear cell carcinoma), LUSC (Lung squamous cell carcinoma), SKCM (Skin Cutaneous Melanoma); STAD (Stomach adenocarcinoma)-revealed a negative correlation of S100A9 expression with the infiltration of most immune cells, but a positive correlation with neutrophils, M1 macrophages, and activated NK cells, highlighting the complex interplay between S100A9 and the tumor immune environment. This bioinformatics synthesis posits S100A9 as a significant player in cancer progression, offering valuable prognostic insights. The data underscore the utility of S100A9 as a prognostic biomarker and its potential as a therapeutic target. The therapeutic implications are profound, suggesting that modulation of S100A9 activity could significantly impact cancer management strategies.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yingying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zixuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Hunan University of Chinese Medicine, Changsha, 410128, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Xingxing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China. 1037603220@qq.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>B2024049</GrantID><Agency>2022 State Administration of Traditional Chinese Medicine</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D040502">Calgranulin B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000628744">S100A9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040502" MajorTopicYN="Y">Calgranulin B</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="Y">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053842" MajorTopicYN="N">Microsatellite Instability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer heterogeneity</Keyword><Keyword MajorTopicYN="N">Immune infiltration</Keyword><Keyword MajorTopicYN="N">Microsatellite instability</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">S100A9</Keyword><Keyword MajorTopicYN="N">Tumor mutational burden</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>18</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>17</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39154046</ArticleId><ArticleId IdType="pmc">PMC11330479</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-70223-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-70223-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abdelgawad, I. Y. et al. Molecular mechanisms and cardiovascular implications of cancer therapy-induced senescence. Pharmacol. Ther.221, 107751 (2021). 10.1016/j.pharmthera.2020.107751</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2020.107751</ArticleId><ArticleId IdType="pmc">PMC8084867</ArticleId><ArticleId IdType="pubmed">33275998</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, G. et al. GPC2 is a potential diagnostic, immunological, and prognostic biomarker in pan-cancer. Front. Immunol.13, 857308 (2022). 10.3389/fimmu.2022.857308</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.857308</ArticleId><ArticleId IdType="pmc">PMC8957202</ArticleId><ArticleId IdType="pubmed">35345673</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. et al. Pan-cancer analysis on the role of PIK3R1 and PIK3R2 in human tumors. Sci. Rep.12(1), 5924 (2022). 10.1038/s41598-022-09889-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-09889-0</ArticleId><ArticleId IdType="pmc">PMC8993854</ArticleId><ArticleId IdType="pubmed">35395865</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomonobu, N., Kinoshita, R. &amp; Sakaguchi, M. S100 soil sensor receptors and molecular targeting therapy against them in cancer metastasis. Transl. Oncol.13(4), 100753 (2020). 10.1016/j.tranon.2020.100753</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2020.100753</ArticleId><ArticleId IdType="pmc">PMC7078545</ArticleId><ArticleId IdType="pubmed">32193075</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner, N. B. et al. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. J. Immunother. Cancer7(1), 343 (2019). 10.1186/s40425-019-0828-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-019-0828-1</ArticleId><ArticleId IdType="pmc">PMC6896585</ArticleId><ArticleId IdType="pubmed">31806053</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, L. et al. Targeting the IRAK1-S100A9 axis overcomes resistance to paclitaxel in nasopharyngeal carcinoma. Cancer Res.81(5), 1413&#x2013;1425 (2021). 10.1158/0008-5472.CAN-20-2125</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-20-2125</ArticleId><ArticleId IdType="pubmed">33402387</ArticleId></ArticleIdList></Reference><Reference><Citation>Inciarte-Mundo, J., Frade-Sosa, B. &amp; Sanmarti, R. From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis. Front. Immunol.13, 1001025 (2022). 10.3389/fimmu.2022.1001025</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1001025</ArticleId><ArticleId IdType="pmc">PMC9672845</ArticleId><ArticleId IdType="pubmed">36405711</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao, X. et al. An immunometabolism subtyping system identifies S100A9(+) macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis. Cell Rep. Med.4(4), 100987 (2023). 10.1016/j.xcrm.2023.100987</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.100987</ArticleId><ArticleId IdType="pmc">PMC10140461</ArticleId><ArticleId IdType="pubmed">36990096</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y., Ouyang, Y., Li, Z., Wang, X. &amp; Ma, J. S100A8 and S100A9 in cancer. Biochim. Biophys. Acta Rev. Cancer1878(3), 188891 (2023). 10.1016/j.bbcan.2023.188891</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2023.188891</ArticleId><ArticleId IdType="pubmed">37001615</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong, C. et al. S100A9 derived from chemoembolization-induced hypoxia governs mitochondrial function in hepatocellular carcinoma progression. Adv. Sci. (Weinh)9(30), e2202206 (2022). 10.1002/advs.202202206</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202202206</ArticleId><ArticleId IdType="pmc">PMC9596847</ArticleId><ArticleId IdType="pubmed">36041055</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinkovic, G. et al. S100A9 links inflammation and repair in myocardial infarction. Circ. Res.127(5), 664&#x2013;676 (2020). 10.1161/CIRCRESAHA.120.315865</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.315865</ArticleId><ArticleId IdType="pubmed">32434457</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott, M. &amp; Ustoyev, Y. Cancer and the immune system: The history and background of immunotherapy. Semin. Oncol. Nurs.35(5), 150923 (2019). 10.1016/j.soncn.2019.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.soncn.2019.08.002</ArticleId><ArticleId IdType="pubmed">31526550</ArticleId></ArticleIdList></Reference><Reference><Citation>Giese, M. A., Hind, L. E. &amp; Huttenlocher, A. Neutrophil plasticity in the tumor microenvironment. Blood133(20), 2159&#x2013;2167 (2019). 10.1182/blood-2018-11-844548</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-11-844548</ArticleId><ArticleId IdType="pmc">PMC6524564</ArticleId><ArticleId IdType="pubmed">30898857</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson, N. M. &amp; Simon, M. C. The tumor microenvironment. Curr. Biol.30(16), R921&#x2013;R925 (2020). 10.1016/j.cub.2020.06.081</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2020.06.081</ArticleId><ArticleId IdType="pmc">PMC8194051</ArticleId><ArticleId IdType="pubmed">32810447</ArticleId></ArticleIdList></Reference><Reference><Citation>Elhanani, O., Ben-Uri, R. &amp; Keren, L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell41(3), 404&#x2013;420 (2023). 10.1016/j.ccell.2023.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2023.01.010</ArticleId><ArticleId IdType="pubmed">36800999</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinshaw, D. C. &amp; Shevde, L. A. The tumor microenvironment innately modulates cancer progression. Cancer Res.79(18), 4557&#x2013;4566 (2019). 10.1158/0008-5472.CAN-18-3962</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-18-3962</ArticleId><ArticleId IdType="pmc">PMC6744958</ArticleId><ArticleId IdType="pubmed">31350295</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitale, I., Manic, G., Coussens, L. M., Kroemer, G. &amp; Galluzzi, L. Macrophages and metabolism in the tumor microenvironment. Cell Metab.30(1), 36&#x2013;50 (2019). 10.1016/j.cmet.2019.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2019.06.001</ArticleId><ArticleId IdType="pubmed">31269428</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejarano, L., Jordao, M. &amp; Joyce, J. A. Therapeutic targeting of the tumor microenvironment. Cancer Discov.11(4), 933&#x2013;959 (2021). 10.1158/2159-8290.CD-20-1808</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-1808</ArticleId><ArticleId IdType="pubmed">33811125</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Z., Jensen, M. A. &amp; Zenklusen, J. C. A practical guide to the cancer genome atlas (TCGA). Methods Mol. Biol.1418, 111&#x2013;141 (2016). 10.1007/978-1-4939-3578-9_6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3578-9_6</ArticleId><ArticleId IdType="pubmed">27008012</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami, E. et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov.2(5), 401&#x2013;404 (2012). 10.1158/2159-8290.CD-12-0095</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-12-0095</ArticleId><ArticleId IdType="pmc">PMC3956037</ArticleId><ArticleId IdType="pubmed">22588877</ArticleId></ArticleIdList></Reference><Reference><Citation>Greillier, L., Tomasini, P. &amp; Barlesi, F. The clinical utility of tumor mutational burden in non-small cell lung cancer. Transl. Lung Cancer Res.7(6), 639&#x2013;646 (2018). 10.21037/tlcr.2018.10.08</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tlcr.2018.10.08</ArticleId><ArticleId IdType="pmc">PMC6249623</ArticleId><ArticleId IdType="pubmed">30505708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause, R. J., Pritchard, C. C., Shendure, J. &amp; Salipante, S. J. Classification and characterization of microsatellite instability across 18 cancer types. Nat. Med.22(11), 1342&#x2013;1350 (2016). 10.1038/nm.4191</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4191</ArticleId><ArticleId IdType="pubmed">27694933</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA102(43), 15545&#x2013;15550 (2005). 10.1073/pnas.0506580102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung, Y. H. et al. Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis. Proc. Natl. Acad. Sci. USA120(43), e2073108176 (2023).10.1073/pnas.2221859120</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2221859120</ArticleId><ArticleId IdType="pmc">PMC10614828</ArticleId><ArticleId IdType="pubmed">37844250</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, S. et al. S100A8/A9 in inflammation. Front. Immunol.9, 1298 (2018). 10.3389/fimmu.2018.01298</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01298</ArticleId><ArticleId IdType="pmc">PMC6004386</ArticleId><ArticleId IdType="pubmed">29942307</ArticleId></ArticleIdList></Reference><Reference><Citation>Albinger, N. et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer J.12(4), 61 (2022). 10.1038/s41408-022-00660-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-022-00660-2</ArticleId><ArticleId IdType="pmc">PMC9007937</ArticleId><ArticleId IdType="pubmed">35418180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei, R., Zhang, L., Hu, W., Wu, J. &amp; Zhang, W. CSTA plays a role in osteoclast formation and bone resorption by mediating the DAP12/TREM2 pathway. Biochem. Biophys. Res. Commun.627, 12&#x2013;20 (2022). 10.1016/j.bbrc.2022.08.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2022.08.033</ArticleId><ArticleId IdType="pubmed">36007331</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva, D. M. B. et al. S100A9 drives the chronification of psoriasiform inflammation by inducing IL-23/type 3 immunity. J. Investig. Dermatol.143(9), 1678&#x2013;1688 (2023). 10.1016/j.jid.2023.02.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jid.2023.02.026</ArticleId><ArticleId IdType="pubmed">36921684</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, L. et al. CELF2 is a candidate prognostic and immunotherapy biomarker in triple-negative breast cancer and lung squamous cell carcinoma: A pan-cancer analysis. J. Cell. Mol. Med.25(15), 7559&#x2013;7574 (2021). 10.1111/jcmm.16791</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.16791</ArticleId><ArticleId IdType="pmc">PMC8335674</ArticleId><ArticleId IdType="pubmed">34288370</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunaldi, M. et al. Diagnostic importance of S100A9 and S100A12 in breast cancer. Biomed. Pharmacother.76, 52&#x2013;56. 10.1016/j.biopha.2015.10.029 (2015). 10.1016/j.biopha.2015.10.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2015.10.029</ArticleId><ArticleId IdType="pubmed">26653550</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedjadi, T. et al. S100A8 and S100A9 proteins form part of a paracrine feedback loop between pancreatic cancer cells and monocytes. BMC Cancer18, 1255. 10.1186/s12885-018-5161-4 (2018). 10.1186/s12885-018-5161-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-018-5161-4</ArticleId><ArticleId IdType="pmc">PMC6296088</ArticleId><ArticleId IdType="pubmed">30558665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim, S. Y., Yuzhalin, A. E., Gordon-Weeks, A. N. &amp; Muschel, R. J. Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells. Oncogene35, 5735&#x2013;5745. 10.1038/onc.2016.107 (2016). 10.1038/onc.2016.107</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2016.107</ArticleId><ArticleId IdType="pmc">PMC4961254</ArticleId><ArticleId IdType="pubmed">27086923</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorrami, S., Tavakoli, M. &amp; Safari, E. Clinical value of serum S100A8/A9 and CA15-3 in the diagnosis of breast cancer. Iran. J. Pathol.14(2), 104&#x2013;112 (2019). 10.30699/ijp.14.2.104</Citation><ArticleIdList><ArticleId IdType="doi">10.30699/ijp.14.2.104</ArticleId><ArticleId IdType="pmc">PMC6679667</ArticleId><ArticleId IdType="pubmed">31528166</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirza, Z. et al. Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: Transcriptional profiling and molecular docking study for kidney cancer therapeutics. PLoS&#xa0;One10(3), e119765 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366044</ArticleId><ArticleId IdType="pubmed">25789858</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ponti, A. et al. A pro-tumorigenic function of S100A8/A9 in carcinogen-induced hepatocellular carcinoma. Cancer Lett.369(2), 396&#x2013;404 (2015). 10.1016/j.canlet.2015.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2015.09.005</ArticleId><ArticleId IdType="pubmed">26404752</ArticleId></ArticleIdList></Reference><Reference><Citation>Gielen, P. R. et al. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function. Neuro Oncol.18(9), 1253&#x2013;1264 (2016). 10.1093/neuonc/now034</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/now034</ArticleId><ArticleId IdType="pmc">PMC4998996</ArticleId><ArticleId IdType="pubmed">27006175</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, C. et al. S100A8/S100A9 promote progression of multiple myeloma via expansion of megakaryocytes. Cancer Res. Commun.3(3), 420&#x2013;430 (2023). 10.1158/2767-9764.CRC-22-0368</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2767-9764.CRC-22-0368</ArticleId><ArticleId IdType="pmc">PMC10010194</ArticleId><ArticleId IdType="pubmed">36923707</ArticleId></ArticleIdList></Reference><Reference><Citation>Razmkhah, F., Kim, S., Lim, S., Dania, A. J. &amp; Choi, J. S100A8 and S100A9 in hematologic malignancies: From development to therapy. Int. J. Mol. Sci.24(17), 13382 (2023). 10.3390/ijms241713382</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241713382</ArticleId><ArticleId IdType="pmc">PMC10488294</ArticleId><ArticleId IdType="pubmed">37686186</ArticleId></ArticleIdList></Reference><Reference><Citation>Willers, M. et al. S100A8 and S100A9 are important for postnatal development of gut microbiota and immune system in mice and infants. Gastroenterology159(6), 2130&#x2013;2145 (2020). 10.1053/j.gastro.2020.08.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.08.019</ArticleId><ArticleId IdType="pubmed">32805279</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshioka, Y. et al. Neutrophils and the S100A9 protein critically regulate granuloma formation. Blood Adv.1(3), 184&#x2013;192 (2016). 10.1182/bloodadvances.2016000497</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2016000497</ArticleId><ArticleId IdType="pmc">PMC5737174</ArticleId><ArticleId IdType="pubmed">29296934</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, H. &amp; Ballantyne, C. M. Skeletal muscle inflammation and insulin resistance in obesity. J. Clin. Investig.127(1), 43&#x2013;54 (2017). 10.1172/JCI88880</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI88880</ArticleId><ArticleId IdType="pmc">PMC5199705</ArticleId><ArticleId IdType="pubmed">28045398</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogl, T. et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood104(13), 4260&#x2013;4268 (2004). 10.1182/blood-2004-02-0446</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-02-0446</ArticleId><ArticleId IdType="pubmed">15331440</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike, A. et al. Dynamic mobility of immunological cells expressing S100A8 and S100A9 in vivo: A variety of functional roles of the two proteins as regulators in acute inflammatory reaction. Inflammation35(2), 409&#x2013;419 (2012). 10.1007/s10753-011-9330-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-011-9330-8</ArticleId><ArticleId IdType="pubmed">21487906</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. Ann. Oncol.30(1), 44&#x2013;56 (2019). 10.1093/annonc/mdy495</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdy495</ArticleId><ArticleId IdType="pmc">PMC6336005</ArticleId><ArticleId IdType="pubmed">30395155</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto, H. &amp; Imai, K. An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine. Semin. Oncol.46(3), 261&#x2013;270 (2019). 10.1053/j.seminoncol.2019.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminoncol.2019.08.003</ArticleId><ArticleId IdType="pubmed">31537299</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg, V. et al. miRs-138 and -424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in CLL. Blood125(19), 2948&#x2013;2957 (2015). 10.1182/blood-2014-07-586511</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-07-586511</ArticleId><ArticleId IdType="pmc">PMC4654424</ArticleId><ArticleId IdType="pubmed">25670628</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39131609</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2167-8359</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PeerJ</Title><ISOAbbreviation>PeerJ</ISOAbbreviation></Journal><ArticleTitle>Ferroptosis-related gene transferrin receptor protein 1 expression correlates with the prognosis and tumor immune microenvironment in cervical cancer.</ArticleTitle><Pagination><StartPage>e17842</StartPage><MedlinePgn>e17842</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e17842</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7717/peerj.17842</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Ferroptosis is a non-apoptotic iron-dependent form of cell death implicated in various cancer pathologies. However, its precise role in tumor growth and progression of cervical cancer (CC) remains unclear. Transferrin receptor protein 1 (TFRC), a key molecule associated with ferroptosis, has been identified as influencing a broad range of pathological processes in different cancers. However, the prognostic significance of TFRC in CC remains unclear. The present study utilized bioinformatics to explore the significance of the ferroptosis-related gene TFRC in the progression and prognosis of CC.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We obtained RNA sequencing data and corresponding clinical information on patients with CC from The Cancer Genome Atlas (TCGA), Genotype Tissue Expression (GTEx) and Gene Expression Omnibus (GEO) databases. Using least absolute shrinkage and selection operator (LASSO) Cox regression, we then generated a multigene signature of five ferroptosis-related genes (FRGs) for the prognostic prediction of CC. We investigated the relationship between TFRC gene expression and immune cell infiltration by employing single-sample GSEA (ssGSEA) analysis. The potential functional role of the TFRC gene was evaluated through gene set enrichment analysis (GSEA). Immunohistochemistry and qPCR was employed to assess TFRC mRNA and protein expression in 33 cases of cervical cancer. Furthermore, the relationship between TFRC mRNA expression and overall survival (OS) was investigated in patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">CC samples had significantly higher TFRC gene expression levels than normal tissue samples. Higher TFRC gene expression levels were strongly associated with higher cancer T stages and OS events. The findings of multivariate analyses illustrated that the OS in CC patients with high TFRC expression is shorter than in patients with low TFRC expression. Significant increases were observed in the levels of TFRC mRNA and protein expression in patients diagnosed with CC.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Increased TFRC expression in CC was associated with disease progression, an unfavorable prognosis, and dysregulated immune cell infiltration. In addition, it highlights ferroptosis as a promising therapeutic target for CC.</AbstractText><CopyrightInformation>&#xa9; 2024 Shang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Shang</LastName><ForeName>Xiujuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine, Lianyungang, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Hongdong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Lianyungang Maternal and Child Health Hospital, Lianyungang, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine, Lianyungang, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine, Lianyungang, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Bohao</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xinming</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine, Lianyungang, Jiangsu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PeerJ</MedlineTA><NlmUniqueID>101603425</NlmUniqueID><ISSNLinking>2167-8359</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C068126">CD71 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011990" MajorTopicYN="Y">Receptors, Transferrin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059016" MajorTopicYN="Y">Tumor Microenvironment</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Ferroptosis</Keyword><Keyword MajorTopicYN="N">Immune cell infiltration</Keyword><Keyword MajorTopicYN="N">Prognostic signature</Keyword><Keyword MajorTopicYN="N">TFRC</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>12</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>12</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39131609</ArticleId><ArticleId IdType="pmc">PMC11313409</ArticleId><ArticleId IdType="doi">10.7717/peerj.17842</ArticleId><ArticleId IdType="pii">17842</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arora R, Haynes L, Kumar M, McNeil R, Ashkani J, Nakoneshny SC, Matthews TW, Chandarana S, Hart RD, Jones SJM, Dort JC, Itani D, Chanda A, Bose P. NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma. Cancer Gene Therapy. 2023;30(5):752&#x2013;765. doi: 10.1038/s41417-022-00578-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41417-022-00578-8</ArticleId><ArticleId IdType="pmc">PMC10191846</ArticleId><ArticleId IdType="pubmed">36635327</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia D, Grozdanov V, Ruf WP, Kassubek J, Ludolph AC, Weishaupt JH, Danzer KM. T-cell dysregulation is associated with disease severity in Parkinson&#x2019;s disease. Journal of Neuroinflammation. 2021;18(1):250. doi: 10.1186/s12974-021-02296-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02296-8</ArticleId><ArticleId IdType="pmc">PMC8556877</ArticleId><ArticleId IdType="pubmed">34717679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokulich NA, &#x141;aniewski P, Adamov A, Chase DM, Caporaso JG, Herbst-Kralovetz MM. Multi-omics data integration reveals metabolome as the top predictor of the cervicovaginal microenvironment. PLOS Computational Biology. 2022;18(2):e1009876. doi: 10.1371/journal.pcbi.1009876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1009876</ArticleId><ArticleId IdType="pmc">PMC8901057</ArticleId><ArticleId IdType="pubmed">35196323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Ren Y, Chen S, Wang Y, Chu L. Ferroptosis and tumor immunotherapy: a promising combination therapy for tumors. Frontiers in Oncology. 2023;13:1119369. doi: 10.3389/fonc.2023.1119369.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2023.1119369</ArticleId><ArticleId IdType="pmc">PMC9945274</ArticleId><ArticleId IdType="pubmed">36845720</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Zhao X, Li Y, Zhang S, Wang Y, Wang L, Ma W. High expression of TMEM33 predicts poor prognosis and promotes cell proliferation in cervical cancer. Frontiers in Genetics. 2022;13:908807. doi: 10.3389/fgene.2022.908807.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2022.908807</ArticleId><ArticleId IdType="pmc">PMC9271802</ArticleId><ArticleId IdType="pubmed">35832191</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J, Meng Y, Han Z, Luo X, Guo X, Li Y, Liu S, Zhuang K. Pan-cancer analysis of the oncogenic and immunological role of RCN3: a potential biomarker for prognosis and immunotherapy. Frontiers in Oncology. 2022;12:811567. doi: 10.3389/fonc.2022.811567.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2022.811567</ArticleId><ArticleId IdType="pmc">PMC9149440</ArticleId><ArticleId IdType="pubmed">35651805</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Zhou Y, Wei L, Feng Z, Chen Y, Liu P, Peng Y, Huang Q, Gao L, Liu Y, Han Y, Shen H, Cai C, Zeng S. Hsa_Circ_0066351 acts as a prognostic and immunotherapeutic biomarker in colorectal cancer. Frontiers in Immunology. 2022;13:927811. doi: 10.3389/fimmu.2022.927811.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.927811</ArticleId><ArticleId IdType="pmc">PMC9667793</ArticleId><ArticleId IdType="pubmed">36405685</ArticleId></ArticleIdList></Reference><Reference><Citation>Gian&#xec; F, Vella V, Tumino D, Malandrino P, Frasca F. The possible role of cancer stem cells in the resistance to kinase inhibitors of advanced thyroid cancer. Cancers. 2020;12(8):2249. doi: 10.3390/cancers12082249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12082249</ArticleId><ArticleId IdType="pmc">PMC7465706</ArticleId><ArticleId IdType="pubmed">32796774</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Hwang N, Seok BG, Lee S, Lee SJ, Chung SW. Autophagy mediates an amplification loop during ferroptosis. Cell Death &amp; Disease. 2023;14(7):464. doi: 10.1038/s41419-023-05978-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-023-05978-8</ArticleId><ArticleId IdType="pmc">PMC10368698</ArticleId><ArticleId IdType="pubmed">37491375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei T, Qian H, Lei P, Hu Y. Ferroptosis-related gene signature associates with immunity and predicts prognosis accurately in patients with osteosarcoma. Cancer Science. 2021;112(11):4785&#x2013;4798. doi: 10.1111/cas.15131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.15131</ArticleId><ArticleId IdType="pmc">PMC8586685</ArticleId><ArticleId IdType="pubmed">34506683</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Sun B, Huang Y, Zhang J, Xu X, Shen Y, Chen Z, Yang J, Shen L, Hu Y, Gu H. Gene therapy of yeast NDI1 on mitochondrial complex I dysfunction in rotenone-induced Parkinson&#x2019;s disease models in vitro and vivo. Molecular Medicine. 2022;28(1):29. doi: 10.1186/s10020-022-00456-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-022-00456-x</ArticleId><ArticleId IdType="pmc">PMC8900322</ArticleId><ArticleId IdType="pubmed">35255803</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Wan C, Li X, Quan C, Li X, Wu X. Characterization of tumor microenvironment and tumor immunology based on the double-stranded RNA-binding protein related genes in cervical cancer. Journal of Translational Medicine. 2023;21(1):647. doi: 10.1186/s12967-023-04505-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-023-04505-9</ArticleId><ArticleId IdType="pmc">PMC10515034</ArticleId><ArticleId IdType="pubmed">37735483</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Chen H, Zhao R, Zhu M, Nie G. Nanomedicine targets iron metabolism for cancer therapy. Cancer Science. 2022;113(3):828&#x2013;837. doi: 10.1111/cas.15250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.15250</ArticleId><ArticleId IdType="pmc">PMC8898713</ArticleId><ArticleId IdType="pubmed">34962017</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Lin Y, Long W, Yi R, Zhang X, Xie C, Jin N, Qiu Z, Liu X. The kinesin-14 family motor protein KIFC2 promotes prostate cancer progression by regulating p65. Journal of Biological Chemistry. 2023;299(11):105253. doi: 10.1016/j.jbc.2023.105253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2023.105253</ArticleId><ArticleId IdType="pmc">PMC10590982</ArticleId><ArticleId IdType="pubmed">37716704</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X, Zhang W, Zhang J, Ren D, Zhao P, Ying Y. EPAS1, a hypoxia- and ferroptosis-related gene, promotes malignant behaviour of cervical cancer by ceRNA and super-enhancer. Journal of Cellular and Molecular Medicine. 2024;28(9):e18361. doi: 10.1111/jcmm.18361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.18361</ArticleId><ArticleId IdType="pmc">PMC11081013</ArticleId><ArticleId IdType="pubmed">38722283</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Wang Y, Gao X, Dai Y, Zhang Y, Wang Z, Wang X, Wang L, Jiang J, Jing X, Yang C, Zhao F, Lang J, Qiao Y. Economic evaluation of cervical cancer screening strategies in urban China. Chinese Journal of Cancer Research. 2019;31(6):974&#x2013;983. doi: 10.21147/j.issn.1000-9604.2019.06.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.21147/j.issn.1000-9604.2019.06.13</ArticleId><ArticleId IdType="pmc">PMC6955165</ArticleId><ArticleId IdType="pubmed">31949399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Zhang X, Wang W, Zhang R, Du M, Shan L, Li Y, Wang X, Liu Y, Zhang W, Li X, Qiao Y, Wei M, Chen H, Zhou J, Li J. Knowledge of HPV, its vaccines, and attitudes toward HPV vaccines among obstetrician-gynecologists, pediatricians and immunization services providers in Western China. Human Vaccines &amp; Immunotherapeutics. 2022;18(1):1&#x2013;7. doi: 10.1080/21645515.2021.1962150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.1962150</ArticleId><ArticleId IdType="pmc">PMC8920158</ArticleId><ArticleId IdType="pubmed">34520323</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijer CJ, Snijders PJ. Cervical cancer in 2013: screening comes of age and treatment progress continues. Nature Reviews Clinical Oncology. 2014;11(2):77&#x2013;78. doi: 10.1038/nrclinonc.2013.252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2013.252</ArticleId><ArticleId IdType="pubmed">24445518</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng J, Yang X, Huang J, Tuo Z, Hu Y, Liao Z, Tian Y, Deng S, Deng Y, Zhou Z, Lovell JF, Jin H, Liu Y, Yang K. Ferroptosis-enhanced immunotherapy with an injectable dextran-chitosan hydrogel for the treatment of malignant ascites in hepatocellular carcinoma. Advanced Science. 2023;10(20):e2300517. doi: 10.1002/advs.202300517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202300517</ArticleId><ArticleId IdType="pmc">PMC10369279</ArticleId><ArticleId IdType="pubmed">37132587</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao TW, Yang DQ, Chen FY, Zhu Q, Chen X. A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma. Bioscience Reports. 2022;42(8):25. doi: 10.1042/BSR20212835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20212835</ArticleId><ArticleId IdType="pmc">PMC9434561</ArticleId><ArticleId IdType="pubmed">35866375</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi X, Fu Y, Sheng J, Zhang M, Zhang M, Wang Y, Li G. A novel ferroptosis-related gene signature for predicting outcomes in cervical cancer. Bioengineered. 2021;12(1):1813&#x2013;1825. doi: 10.1080/21655979.2021.1925003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2021.1925003</ArticleId><ArticleId IdType="pmc">PMC8806749</ArticleId><ArticleId IdType="pubmed">33989111</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;z J, Espina C. The eleventh hour to enforce rigorous primary cancer prevention. Molecular Oncology. 2021;15(3):741&#x2013;743. doi: 10.1002/1878-0261.12927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1878-0261.12927</ArticleId><ArticleId IdType="pmc">PMC7931125</ArticleId><ArticleId IdType="pubmed">33660939</ArticleId></ArticleIdList></Reference><Reference><Citation>Senyilmaz D, Virtue S, Xu X, Tan CY, Griffin JL, Miller AK, Vidal-Puig A, Teleman AA. Regulation of mitochondrial morphology and function by stearoylation of TFR1. Nature. 2015;525(7567):124&#x2013;128. doi: 10.1038/nature14601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14601</ArticleId><ArticleId IdType="pmc">PMC4561519</ArticleId><ArticleId IdType="pubmed">26214738</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X, Xue Y, Cong H, Wang X, Fan Z, Cui X, Ju S. Circulating lncRNA DANCR as a potential auxillary biomarker for the diagnosis and prognostic prediction of colorectal cancer. Bioscience Reports. 2020;40(3):7. doi: 10.1042/BSR20191481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20191481</ArticleId><ArticleId IdType="pmc">PMC7103578</ArticleId><ArticleId IdType="pubmed">32159208</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Shui D, Su S, Xiong Z, Zai W. Gene enrichment and co-expression analysis shed light on transcriptional responses to Ralstonia solanacearum in tomato. BMC Genomics. 2023;24(1):159. doi: 10.1186/s12864-023-09237-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-023-09237-0</ArticleId><ArticleId IdType="pmc">PMC10061692</ArticleId><ArticleId IdType="pubmed">36991339</ArticleId></ArticleIdList></Reference><Reference><Citation>Small W, Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: a global health crisis. Cancer. 2017;123(13):2404&#x2013;2412. doi: 10.1002/cncr.30667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.30667</ArticleId><ArticleId IdType="pubmed">28464289</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui X, Hu N, Zhang Z, Wang Y, Wang P, Xiu G. ASMTL-AS1 impedes the malignant progression of lung adenocarcinoma by regulating SAT1 to promote ferroptosis. Pathology International. 2021;71(11):741&#x2013;751. doi: 10.1111/pin.13158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pin.13158</ArticleId><ArticleId IdType="pubmed">34658100</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang R, Wang H, Liu J, Song L, Hou H, Liu M, Wang J, Wang J. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer. European Journal of Medical Research. 2024;29(1):112. doi: 10.1186/s40001-024-01688-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-024-01688-9</ArticleId><ArticleId IdType="pmc">PMC10854140</ArticleId><ArticleId IdType="pubmed">38336764</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HC, Chan LP, Cho SF. Targeting the immune microenvironment in the treatment of head and neck squamous cell carcinoma. Frontiers in Oncology. 2019;9:1084. doi: 10.3389/fonc.2019.01084.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.01084</ArticleId><ArticleId IdType="pmc">PMC6803444</ArticleId><ArticleId IdType="pubmed">31681613</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Ji Y, Qi J, Zhou S, Wan S, Fan C, Gu Z, An P, Luo Y, Luo J. Mitochondrial carrier 1 (MTCH1) governs ferroptosis by triggering the FoxO1-GPX4 axis-mediated retrograde signaling in cervical cancer cells. Cell Death &amp; Disease. 2023b;14(8):508. doi: 10.1038/s41419-023-06033-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-023-06033-2</ArticleId><ArticleId IdType="pmc">PMC10406804</ArticleId><ArticleId IdType="pubmed">37550282</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Xu WQ, Zhang WQ, Xu RC, Sun JL, Zhang GC, Liu ZY, Qi ZR, Dong L, Weng SQ, Shen XZ, Liu TT, Fang Y, Zhu JM. Transferrin receptor 1 promotes hepatocellular carcinoma progression and metastasis by activating the mTOR signaling pathway. Hepatology International. 2023a;18(2):636&#x2013;650. doi: 10.1007/s12072-023-10607-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-023-10607-9</ArticleId><ArticleId IdType="pubmed">37982952</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zou Y, Zhang Y, Li C. Developing a risk scoring system based on immune-related lncRNAs for patients with gastric cancer. Bioscience Reports. 2021;41(1):394. doi: 10.1042/BSR20202203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20202203</ArticleId><ArticleId IdType="pmc">PMC7789809</ArticleId><ArticleId IdType="pubmed">33295609</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C, Wang R, Yang Y, Xu T, Li Y, Xu J, Jiang Z. Expression of OPN3 in lung adenocarcinoma promotes epithelial-mesenchymal transition and tumor metastasis. Thoracic Cancer. 2020a;11(2):286&#x2013;294. doi: 10.1111/1759-7714.13254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1759-7714.13254</ArticleId><ArticleId IdType="pmc">PMC6996998</ArticleId><ArticleId IdType="pubmed">31802643</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M, Zhu S, Xu R, Lin N. Identification of CELSR2 as a novel prognostic biomarker for hepatocellular carcinoma. BMC Cancer. 2020b;20(1):313. doi: 10.1186/s12885-020-06813-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-020-06813-5</ArticleId><ArticleId IdType="pmc">PMC7161135</ArticleId><ArticleId IdType="pubmed">32293343</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav AK, Singh TR. Computational approach for assessing the involvement of SMYD2 protein in human cancers using TCGA data. Journal of Genetic Engineering and Biotechnology. 2023;21(1):122. doi: 10.1186/s43141-023-00594-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43141-023-00594-7</ArticleId><ArticleId IdType="pmc">PMC10654300</ArticleId><ArticleId IdType="pubmed">37971632</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi P, Xu X, Yao J, Qiu B. Analysis of mRNA expression and DNA methylation datasets according to the genomic distribution of CpG sites in osteoarthritis. Frontiers in Genetics. 2021;12:618803. doi: 10.3389/fgene.2021.618803.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.618803</ArticleId><ArticleId IdType="pmc">PMC8082497</ArticleId><ArticleId IdType="pubmed">33936160</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Jia J, Zheng J, Zhou Y, Jia D, Wang J. Recent progress of ferroptosis in lung diseases. Frontiers in Cell and Developmental Biology. 2021;9:789517. doi: 10.3389/fcell.2021.789517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.789517</ArticleId><ArticleId IdType="pmc">PMC8635032</ArticleId><ArticleId IdType="pubmed">34869391</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Li X, Ma M, Yang R, Zhang J, Wu S. The immunological contribution of a novel metabolism-related signature to the prognosis and anti-tumor immunity in cervical cancer. Cancers. 2022;14(10):2399. doi: 10.3390/cancers14102399.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14102399</ArticleId><ArticleId IdType="pmc">PMC9139200</ArticleId><ArticleId IdType="pubmed">35626004</ArticleId></ArticleIdList></Reference><Reference><Citation>Zengin T, &#xd6;nal-S&#xfc;zek T. Comprehensive profiling of genomic and transcriptomic differences between risk groups of lung adenocarcinoma and lung squamous cell carcinoma. Journal of Personalized Medicine. 2021;11(2):154. doi: 10.3390/jpm11020154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm11020154</ArticleId><ArticleId IdType="pmc">PMC7926392</ArticleId><ArticleId IdType="pubmed">33672117</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Li S, Li C, Li T, Huang Y. Remodeling tumor microenvironment with natural products to overcome drug resistance. Frontiers in Immunology. 2022;13:1051998. doi: 10.3389/fimmu.2022.1051998.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1051998</ArticleId><ArticleId IdType="pmc">PMC9685561</ArticleId><ArticleId IdType="pubmed">36439106</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Pei Y, Zhu F. Multi-omic analysis of glycolytic signatures: exploring the predictive significance of heterogeneity and stemness in immunotherapy response and outcomes in hepatocellular carcinoma. Frontiers in Molecular Biosciences. 2023;10:1210111. doi: 10.3389/fmolb.2023.1210111.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2023.1210111</ArticleId><ArticleId IdType="pmc">PMC10282758</ArticleId><ArticleId IdType="pubmed">37351550</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Shen G, Meng T, Lv Z, Li X, Li J, Li K. Eicosapentaenoic acid enhances the sensitivity of osteosarcoma to cisplatin by inducing ferroptosis through the DNA-PKcs/AKT/NRF2 pathway and reducing PD-L1 expression to attenuate immune evasion. International Immunopharmacology. 2023;125:111181. doi: 10.1016/j.intimp.2023.111181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.111181</ArticleId><ArticleId IdType="pubmed">37951196</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhen L, Ning G, Wu L, Zheng Y, Yang F, Chen T, Xu W, Liu Y, Xie C, Peng L. Prognostic value of aberrantly expressed methylation genes in human hepatocellular carcinoma. Bioscience Reports. 2020;40(10):938. doi: 10.1042/bsr20192593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bsr20192593</ArticleId><ArticleId IdType="pmc">PMC7536330</ArticleId><ArticleId IdType="pubmed">32955083</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng T, Qian T, Zhou H, Cheng Z, Liu G, Huang C, Dou R, Liu F, You X. Galectin-1-mediated high NCAPG expression correlates with poor prognosis in gastric cancer. Aging. 2023;15:5535&#x2013;5549. doi: 10.18632/aging.204806.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.204806</ArticleId><ArticleId IdType="pmc">PMC10333058</ArticleId><ArticleId IdType="pubmed">37335105</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S, Jin Q, Yao H, Ying J, Tian L, Jiang X, Yang Y, Jiang X, Gao W, Zhang W, Zhu Y, Cao W. Pain-related gene solute carrier family 24 member 3 is a prognostic biomarker and correlated with immune infiltrates in cervical squamous cell carcinoma and endocervical adenocarcinoma: a study via integrated bioinformatics analyses and experimental verification. Computational and Mathematical Methods in Medicine. 2023;2023(12):4164232. doi: 10.1155/2023/4164232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2023/4164232</ArticleId><ArticleId IdType="pmc">PMC9928512</ArticleId><ArticleId IdType="pubmed">36798148</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Li S. Ferroptosis, necroptosis, and pyroptosis in gastrointestinal cancers: the chief culprits of tumor progression and drug resistance. Advanced Science. 2023;10(26):e2300824. doi: 10.1002/advs.202300824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202300824</ArticleId><ArticleId IdType="pmc">PMC10502844</ArticleId><ArticleId IdType="pubmed">37436087</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38963237</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1364-6893</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology</Title><ISOAbbreviation>J Obstet Gynaecol</ISOAbbreviation></Journal><ArticleTitle>The bioinfomatics analysis of the M1 macrophage-related gene CXCL9 signature in cervical cancer.</ArticleTitle><Pagination><StartPage>2373951</StartPage><MedlinePgn>2373951</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/01443615.2024.2373951</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The expression and function of coexpression genes of M1 macrophage in cervical cancer have not been identified. And the CXCL9-expressing tumour-associated macrophage has been poorly reported in cervical cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">To clarify the regulatory gene network of M1 macrophage in cervical cancer, we downloaded gene expression profiles of cervical cancer patients in TCGA database to identify M1 macrophage coexpression genes. Then we constructed the protein-protein interaction networks by STRING database and performed functional enrichment analysis to investigate the biological effects of the coexpression genes. Next, we used multiple bioinformatics databases and experiments to overall investigate coexpression gene CXCL9, including western blot assay and immunohistochemistry assay, GeneMANIA, Kaplan-Meier Plotter, Xenashiny, TISCH2, ACLBI, HPA, TISIDB, GSCA and cBioPortal databases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">There were 77 positive coexpression genes and 5 negative coexpression genes in M1 macrophage. The coexpression genes in M1 macrophage participated in the production and function of chemokines and chemokine receptors. Especially, CXCL9 was positively correlated with M1 macrophage infiltration levels in cervical cancer. CXCL9 expression would significantly decrease and high CXCL9 levels were linked to good prognosis in the cervical cancer tumour patients, it manifestly expressed in blood immune cells, and was positively related to immune checkpoints. CXCL9 amplification was the most common type of mutation. The CXCL9 gene interaction network could regulate immune-related signalling pathways, and CXCL9 amplification was the most common mutation type in cervical cancer. Meanwhile, CXCL9 may had clinical significance for the drug response in cervical cancer, possibly mediating resistance to chemotherapy and targeted drug therapy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our findings may provide new insight into the M1 macrophage coexpression gene network and molecular mechanisms in cervical cancer, and indicated that M1 macrophage association gene CXCL9 may serve as a good prognostic gene and a potential therapeutic target for cervical cancer therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Wenxin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Juexiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Fujin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Obstet Gynaecol</MedlineTA><NlmUniqueID>8309140</NlmUniqueID><ISSNLinking>0144-3615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054370">Chemokine CXCL9</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C080810">CXCL9 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054370" MajorTopicYN="Y">Chemokine CXCL9</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000084582" MajorTopicYN="N">Tumor-Associated Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>Cervical cancer is a common gynaecological malignancy, investigating the precise gene expression regulation of M1 macrophage is crucial for understanding the changes in the immune microenvironment of cervical cancer. In our study, a total of 82 coexpression genes with M1 macrophages were identified, and these genes were involved in the production and biological processes of chemokines and chemokine receptors. Especially, the chemokine CXCL9 was positively correlated with M1 macrophage infiltration levels in cervical cancer. CXCL9 as a protective factor, it manifestly expressed in blood immune cells, and was positively related to immune checkpoints. CXCL9 amplification was the most common type of mutation. And CXCL9 expression could have an effect on the sensitivity of some chemicals or targeted drugs against cervical cancer. These findings may provide new insight into the M1 macrophage coexpression gene network and molecular mechanisms, and shed light on the role of CXCL9 in cervical cancer.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CXCL9</Keyword><Keyword MajorTopicYN="N">M1 macrophage</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">chemokine</Keyword><Keyword MajorTopicYN="N">coexpression gene</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>4</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>4</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>4</Day><Hour>8</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38963237</ArticleId><ArticleId IdType="doi">10.1080/01443615.2024.2373951</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38949075</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1521-2254</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The journal of gene medicine</Title><ISOAbbreviation>J Gene Med</ISOAbbreviation></Journal><ArticleTitle>Decoding dysregulated genes, molecular pathways and microRNAs involved in cervical cancer.</ArticleTitle><Pagination><StartPage>e3713</StartPage><MedlinePgn>e3713</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jgm.3713</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The present study aimed to identify dysregulated genes, molecular pathways,&#xa0;and regulatory mechanisms in human papillomavirus (HPV)-associated cervical cancers. We have investigated the disease-associated genes along with the Gene Ontology, survival prognosis, transcription factors and the microRNA (miRNA) that are involved in cervical carcinogenesis, enabling a deeper comprehension of cervical cancer linked to HPV.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used 10 publicly accessible Gene Expression Omnibus (GEO) datasets to examine the patterns of gene expression in cervical cancer. Differentially expressed genes (DEGs), which showed a clear distinction between cervical cancer and healthy tissue samples, were analyzed using the GEO2R tool. Additional bioinformatic techniques were used to carry out pathway analysis and functional enrichment, as well as to analyze the connection between altered gene expression and HPV infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 48 DEGs were identified to be differentially expressed in cervical cancer tissues in comparison to healthy tissues. Among DEGs, CCND1, CCNA2 and SPP1 were the key dysregulated genes involved in HPV-associated cervical cancer. The five common miRNAs that were identified against these genes are miR-7-5p, miR-16-5p, miR-124-3p, miR-10b-5p and miR-27a-3p. The hub-DEGs targeted by miRNA hsa-miR-27a-3p are controlled by the common transcription factor SP1.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present study has identified DEGs involved in HPV-associated cervical cancer progression and the various molecular pathways and transcription factors regulating them. These findings have led to a better understanding of cervical cancer resulting in the development and identification of possible therapeutic and intervention targets, respectively.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). The Journal of Gene Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khokhar</LastName><ForeName>Manoj</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, All India Institute of Medical Sciences Jodhpur, Jodhpur, Rajasthan, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kartha</LastName><ForeName>Purnima</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Sana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, Manipal Academy of Higher Education, Dubai, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Rajan Kumar</ForeName><Initials>RK</Initials><Identifier Source="ORCID">0000-0002-2135-5287</Identifier><AffiliationInfo><Affiliation>Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Gene Med</MedlineTA><NlmUniqueID>9815764</NlmUniqueID><ISSNLinking>1099-498X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="Y">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="Y">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="Y">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063990" MajorTopicYN="N">Gene Ontology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CCNA2</Keyword><Keyword MajorTopicYN="N">CCND1</Keyword><Keyword MajorTopicYN="N">HPV</Keyword><Keyword MajorTopicYN="N">SPP1</Keyword><Keyword MajorTopicYN="N">cell cycle dysregulation</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">gene expression</Keyword><Keyword MajorTopicYN="N">human papillomavirus</Keyword><Keyword MajorTopicYN="N">microRNA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>1</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>1</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38949075</ArticleId><ArticleId IdType="doi">10.1002/jgm.3713</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Sosnik A, Seremeta KP, Imperiale JC, Chiappetta DA. Novel formulation and drug delivery strategies for the treatment of pediatric poverty&#x2010;related diseases. Expert Opin Drug Deliv. 2012;9(3):303&#x2010;323. doi:10.1517/17425247.2012.655268</Citation></Reference><Reference><Citation>Castellsagu&#xe9; X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol. 2008;110(3):S4&#x2010;S7. doi:10.1016/j.ygyno.2008.07.045</Citation></Reference><Reference><Citation>Tjalma WA, Fiander A, Reich O, et al. Differences in human papillomavirus type distribution in high&#x2010;grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer. 2013;132(4):854&#x2010;867. doi:10.1002/ijc.27713</Citation></Reference><Reference><Citation>zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol. 1994;186:131&#x2010;156. doi:10.1007/978&#x2010;3&#x2010;642&#x2010;78487&#x2010;3_8</Citation></Reference><Reference><Citation>Bosch FX, de Sanjos&#xe9; S. Chapter 1: human papillomavirus and cervical cancer&#x2014;burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;2003(31):3&#x2010;13. doi:10.1093/oxfordjournals.jncimonographs.a003479</Citation></Reference><Reference><Citation>Brenna SM, Syrj&#xe4;nen KJ. Regulation of cell cycles is of key importance in human papillomavirus (HPV)&#x2010;associated cervical carcinogenesis. Sao Paulo Med J. 2003;121(3):128&#x2010;132. doi:10.1590/s1516&#x2010;31802003000300009</Citation></Reference><Reference><Citation>Tyagi A, Vishnoi K, Mahata S, et al. Cervical cancer stem cells selectively overexpress HPV oncoprotein E6 that controls stemness and self&#x2010;renewal through upregulation of HES1. Clinical Cancer Res. 2016;22(16):4170&#x2010;4184. doi:10.1158/1078&#x2010;0432.ccr&#x2010;15&#x2010;2574</Citation></Reference><Reference><Citation>Senba M, Mori N. Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection. Oncol Rev. 2012;6(2):e17. doi:10.4081/oncol.2012.e17</Citation></Reference><Reference><Citation>Deftereos G, Corrie SR, Feng Q, et al. Expression of mir&#x2010;21 and mir&#x2010;143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS ONE. 2011;6(12):e28423. doi:10.1371/journal.pone.0028423</Citation></Reference><Reference><Citation>Park S, Eom K, Kim J, et al. MiR&#x2010;9, miR&#x2010;21, and miR&#x2010;155 as potential biomarkers for HPV positive and negative cervical cancer. BMC Cancer. 2017;17(1):658. doi:10.1186/s12885&#x2010;017&#x2010;3642&#x2010;5</Citation></Reference><Reference><Citation>Zhu X, Er K, Mao C, et al. miR&#x2010;203 suppresses tumor growth and angiogenesis by targeting VEGFA in cervical cancer. Cell Physiol Biochem. 2013;32(1):64&#x2010;73. doi:10.1159/000350125</Citation></Reference><Reference><Citation>Cai N, Hu L, Xie Y, et al. MiR&#x2010;17&#x2010;5p promotes cervical cancer cell proliferation and metastasis by targeting transforming growth factor&#x2010;&#x3b2; receptor 2. Eur Rev Med Pharmacol Sci. 2018;22(7):1899&#x2010;1906. doi:10.26355/eurrev_201804_14712</Citation></Reference><Reference><Citation>Yu Y, Zhang Y, Zhang S. MicroRNA&#x2010;92 regulates cervical tumorigenesis and its expression is upregulated by human papillomavirus&#x2010;16 E6 in cervical cancer cells. Oncol Lett. 2013;6(2):468&#x2010;474. doi:10.3892/ol.2013.1404</Citation></Reference><Reference><Citation>Chellappan S, Kraus VB, Kroger B, et al. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci U S a. 1992;89(10):4549&#x2010;4553. doi:10.1073/pnas.89.10.4549</Citation></Reference><Reference><Citation>Prusty BK, Das BC. Constitutive activation of transcription factor AP&#x2010;1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP&#x2010;1 activity in HeLa cells by curcumin. Int J Cancer. 2005;113(6):951&#x2010;960. doi:10.1002/ijc.20668</Citation></Reference><Reference><Citation>Scotto L, Narayan G, Nandula SV, et al. Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer. 2008;47(9):755&#x2010;765. doi:10.1002/gcc.20577</Citation></Reference><Reference><Citation>Zhai Y, Kuick R, Nan B, et al. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res. 2007;67(21):10163&#x2010;10172. doi:10.1158/0008&#x2010;5472.can&#x2010;07&#x2010;2056</Citation></Reference><Reference><Citation>Babion I, Miok V, Jaspers A, et al. Identification of deregulated pathways, key regulators, and novel miRNA&#x2010;mRNA interactions in HPV&#x2010;mediated transformation. Cancer. 2020;12(3):700. doi:10.3390/cancers12030700</Citation></Reference><Reference><Citation>den Boon JA, Pyeon D, Wang SS, et al. Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S a. 2015;112(25):E3255&#x2010;E3264. doi:10.1073/pnas.1509322112</Citation></Reference><Reference><Citation>Espinosa AM, Alfaro A, Roman&#x2010;Basaure E, et al. Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PLoS ONE. 2013;8(2):e55975. doi:10.1371/journal.pone.0055975</Citation></Reference><Reference><Citation>Medina&#x2010;Martinez I, Barr&#xf3;n V, Roman&#x2010;Bassaure E, et al. Impact of gene dosage on gene expression, biological processes and survival in cervical cancer: a genome&#x2010;wide follow&#x2010;up study. PLoS ONE. 2014;9(5):e97842. doi:10.1371/journal.pone.0097842</Citation></Reference><Reference><Citation>Saha SS, Chowdhury RR, Mondal NR, Roy S, Sengupta S. Expression signatures of HOX cluster genes in cervical cancer pathogenesis: impact of human papillomavirus type 16 oncoprotein E7. Oncotarget. 2017;8(22):36591&#x2010;36602. doi:10.18632/oncotarget.16619</Citation></Reference><Reference><Citation>Thomas A, Mahantshetty U, Kannan S, et al. Expression profiling of cervical cancers in Indian women at different stages to identify gene signatures during progression of the disease. Cancer Med. 2013;2(6):836&#x2010;848. doi:10.1002/cam4.152</Citation></Reference><Reference><Citation>Guardado&#x2010;Estrada M, Medina&#x2010;Mart&#xed;nez I, Ju&#xe1;rez&#x2010;Torres E, et al. The Amerindian mtDNA haplogroup B2 enhances the risk of HPV for cervical cancer: de&#x2010;regulation of mitochondrial genes may be involved. J Hum Genet. 2012;57(4):269&#x2010;276. doi:10.1038/jhg.2012.17</Citation></Reference><Reference><Citation>Biewenga P, Buist MR, Moerland PD, et al. Gene expression in early stage cervical cancer. Gynecol Oncol. 2008;108(3):520&#x2010;526. doi:10.1016/j.ygyno.2007.11.024</Citation></Reference><Reference><Citation>Dem&#x161;ar J, Curk T, Erjavec A, et al. Orange: data mining toolbox in python. J Mach Learn Res. 2013;14(1):2349&#x2010;2353.</Citation></Reference><Reference><Citation>Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein&#x2013;protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2022;51(D1):D638&#x2010;D646. doi:10.1093/nar/gkac1000</Citation></Reference><Reference><Citation>Shamsaei B, Chojnacki S, Pilarczyk M, et al. piNET: a versatile web platform for downstream analysis and visualization of proteomics data. Nucleic Acids Res. 2020;48(W1):W85&#x2010;W93. doi:10.1093/nar/gkaa436</Citation></Reference><Reference><Citation>Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18&#x2010;27. doi:10.1016/j.neo.2022.01.001</Citation></Reference><Reference><Citation>Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large&#x2010;scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556&#x2010;W560. doi:10.1093/nar/gkz430</Citation></Reference><Reference><Citation>Gy&#x151;rffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101&#x2010;4109. doi:10.1016/j.csbj.2021.07.014</Citation></Reference><Reference><Citation>Chang L, Xia J. MicroRNA regulatory network analysis using miRNet 2.0. Methods Mol Biol. 2023;2594:185&#x2010;204. doi:10.1007/978&#x2010;1&#x2010;0716&#x2010;2815&#x2010;7_14</Citation></Reference><Reference><Citation>Licursi V, Conte F, Fiscon G, Paci P. MIENTURNET: an interactive web tool for microRNA&#x2010;target enrichment and network&#x2010;based analysis. BMC Bioinformatics. 2019;20(1):545. doi:10.1186/s12859&#x2010;019&#x2010;3105&#x2010;x</Citation></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498&#x2010;2504. doi:10.1101/gr.1239303</Citation></Reference><Reference><Citation>Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor&#x2010;infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509&#x2010;W514. doi:10.1093/nar/gkaa407</Citation></Reference><Reference><Citation>Zhao K, Ma Z, Zhang W. Comprehensive analysis to identify SPP1 as a prognostic biomarker in cervical cancer. Front Genet. 2021;12:732822. doi:10.3389/fgene.2021.732822</Citation></Reference><Reference><Citation>Deepti P, Pasha A, Kumbhakar DV, et al. Overexpression of secreted phosphoprotein 1 (SPP1) predicts poor survival in HPV positive cervical cancer. Gene. 2022;824:146381. doi:10.1016/j.gene.2022.146381</Citation></Reference><Reference><Citation>Li M, Wang K, Pang Y, et al. Secreted phosphoprotein 1 (SPP1) and fibronectin 1 (FN1) are associated with progression and prognosis of esophageal cancer as identified by integrated expression profiles analysis. Med Sci Monit. 2020;26:e920355. doi:10.12659/msm.920355</Citation></Reference><Reference><Citation>Zhang W, Fan J, Chen Q, Lei C, Qiao B, Liu Q. SPP1 and AGER as potential prognostic biomarkers for lung adenocarcinoma. Oncol Lett. 2018;15(5):7028&#x2010;7036. doi:10.3892/ol.2018.8235</Citation></Reference><Reference><Citation>G&#xf6;thlin Eremo A, Lagergren K, Othman L, Montgomery S, Andersson G, Tina E. Evaluation of SPP1/osteopontin expression as predictor of recurrence in tamoxifen treated breast cancer. Sci Rep. 2020;10(1):1451. doi:10.1038/s41598&#x2010;020&#x2010;58323&#x2010;w</Citation></Reference><Reference><Citation>Xu C, Sun L, Jiang C, et al. SPP1, analyzed by bioinformatics methods, promotes the metastasis in colorectal cancer by activating EMT pathway. Biomed Pharmacother. 2017;91:1167&#x2010;1177. doi:10.1016/j.biopha.2017.05.056</Citation></Reference><Reference><Citation>Huveneers S, Danen EH. Adhesion signaling&#x2014;crosstalk between integrins, Src and rho. J Cell Sci. 2009;122(Pt 8):1059&#x2010;1069. doi:10.1242/jcs.039446</Citation></Reference><Reference><Citation>Chen ZH, Jing YJ, Yu JB, et al. ESRP1 induces cervical cancer cell G1&#x2010;phase arrest via regulating cyclin A2 mRNA stability. Int J Mol Sci. 2019;20(15):3705. doi:10.3390/ijms20153705</Citation></Reference><Reference><Citation>Wu Y, Li H, Wang H, Zhang F, Cao H, Xu S. MSK2 promotes proliferation and tumor formation in squamous cervical cancer via PAX8/RB&#x2010;E2F1/cyclin A2 axis. J Cell Biochem. 2019;120(7):11432&#x2010;11440. doi:10.1002/jcb.28421</Citation></Reference><Reference><Citation>Rozenblatt&#x2010;Rosen O, Deo RC, Padi M, et al. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature. 2012;487(7408):491&#x2010;495. doi:10.1038/nature11288</Citation></Reference><Reference><Citation>Lehn S, Tobin NP, Berglund P, et al. Down&#x2010;regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. Am J Pathol. 2010;177(6):2886&#x2010;2897. doi:10.2353/ajpath.2010.100303</Citation></Reference><Reference><Citation>Novotn&#xfd; J, Band&#xfa;rov&#xe1; V, Strnad H, et al. Analysis of HPV&#x2010;positive and HPV&#x2010;negative head and neck squamous cell carcinomas and paired normal mucosae reveals cyclin D1 deregulation and compensatory effect of cyclin D2. Cancer. 2020;12(4):792. doi:10.3390/cancers12040792</Citation></Reference><Reference><Citation>Bouwman P, Philipsen S. Regulation of the activity of Sp1&#x2010;related transcription factors. Mol Cell Endocrinol. 2002;195(1&#x2013;2):27&#x2010;38. doi:10.1016/s0303&#x2010;7207(02)00221&#x2010;6</Citation></Reference><Reference><Citation>Opitz OG, Rustgi AK. Interaction between Sp1 and cell cycle regulatory proteins is important in transactivation of a differentiation&#x2010;related gene. Cancer Res. 2000;60(11):2825&#x2010;2830.</Citation></Reference><Reference><Citation>Fojas de Borja P, Collins NK, Du P, Azizkhan&#x2010;Clifford J, Mudryj M. Cyclin A&#x2010;CDK phosphorylates Sp1 and enhances Sp1&#x2010;mediated transcription. Embo j. 2001;20(20):5737&#x2010;5747. doi:10.1093/emboj/20.20.5737</Citation></Reference><Reference><Citation>Rotheneder H, Geymayer S, Haidweger E. Transcription factors of the Sp1 family: interaction with E2F and regulation of the murine thymidine kinase promoter. J Mol Biol. 1999;293(5):1005&#x2010;1015. doi:10.1006/jmbi.1999.3213</Citation></Reference><Reference><Citation>Watanabe G, Albanese C, Lee RJ, et al. Inhibition of cyclin D1 kinase activity is associated with E2F&#x2010;mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Mol Cell Biol. 1998;18(6):3212&#x2010;3222. doi:10.1128/mcb.18.6.3212</Citation></Reference><Reference><Citation>Takami Y, Russell MB, Gao C, et al. Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells. Surgery. 2007;142(2):163&#x2010;169. doi:10.1016/j.surg.2007.02.015</Citation></Reference><Reference><Citation>Zhao X, Yang L, Hu J. Down&#x2010;regulation of miR&#x2010;27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res. 2011;30(1):55. doi:10.1186/1756&#x2010;9966&#x2010;30&#x2010;55</Citation></Reference><Reference><Citation>Ben W, Zhang G, Huang Y, Sun Y. MiR&#x2010;27a&#x2010;3p regulated the aggressive phenotypes of cervical cancer by targeting FBXW7. Cancer Manag Res. 2020;12:2925&#x2010;2935. doi:10.2147/cmar.s234897</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38863714</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Integrated bioinformatics combined with machine learning to analyze shared biomarkers and pathways in psoriasis and cervical squamous cell carcinoma.</ArticleTitle><Pagination><StartPage>1351908</StartPage><MedlinePgn>1351908</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1351908</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1351908</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Psoriasis extends beyond its dermatological inflammatory manifestations, encompassing systemic inflammation. Existing studies have indicated a potential risk of cervical cancer among patients with psoriasis, suggesting a potential mechanism of co-morbidity. This study aims to explore the key genes, pathways, and immune cells that may link psoriasis and cervical squamous cell carcinoma (CESC).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The cervical squamous cell carcinoma dataset (GSE63514) was downloaded from the Gene Expression Omnibus (GEO). Two psoriasis-related datasets (GSE13355 and GSE14905) were merged into one comprehensive dataset after removing batch effects. Differentially expressed genes were identified using Limma and co-expression network analysis (WGCNA), and machine learning random forest algorithm (RF) was used to screen the hub genes. We analyzed relevant gene enrichment pathways using GO and KEGG, and immune cell infiltration in psoriasis and CESC samples using CIBERSORT. The miRNA-mRNA and TFs-mRNA regulatory networks were then constructed using Cytoscape, and the biomarkers for psoriasis and CESC were determined. Potential drug targets were obtained from the cMAP database, and biomarker expression levels in hela and psoriatic cell models were quantified by RT-qPCR.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In this study, we identified 27 key genes associated with psoriasis and cervical squamous cell carcinoma. NCAPH, UHRF1, CDCA2, CENPN and MELK were identified as hub genes using the Random Forest machine learning algorithm. Chromosome mitotic region segregation, nucleotide binding and DNA methylation are the major enrichment pathways for common DEGs in the mitotic cell cycle. Then we analyzed immune cell infiltration in psoriasis and cervical squamous cell carcinoma samples using CIBERSORT. Meanwhile, we used the cMAP database to identify ten small molecule compounds that interact with the central gene as drug candidates for treatment. By analyzing miRNA-mRNA and TFs-mRNA regulatory networks, we identified three miRNAs and nine transcription factors closely associated with five key genes and validated their expression in external validation datasets and clinical samples. Finally, we examined the diagnostic effects with ROC curves, and performed experimental validation in hela and psoriatic cell models.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">We identified five biomarkers, <i>NCAPH, UHRF1, CDCA2, CENPN</i>, and <i>MELK</i>, which may play important roles in the common pathogenesis of psoriasis and cervical squamous cell carcinoma, furthermore predict potential therapeutic agents. These findings open up new perspectives for the diagnosis and treatment of psoriasis and squamous cell carcinoma of the cervix.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Liu, Yin, Yang, Zhang, Wu, Zheng, Wu and Liu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Luyu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yin</LastName><ForeName>Pan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Ruida</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Guanfei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Cong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Shaobo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011565" MajorTopicYN="Y">Psoriasis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="Y">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="Y">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">cervical squamous cell carcinoma (CESC)</Keyword><Keyword MajorTopicYN="N">immune cell infiltration</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">psoriasis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>12</Day><Hour>4</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38863714</ArticleId><ArticleId IdType="pmc">PMC11165063</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1351908</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blauvelt A, Lebwohl M, Langley RG, Rowland K, Yang YW, Chan D, et al. . Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. (2023) 89:274&#x2013;82. doi:&#xa0;10.1016/j.jaad.2023.03.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2023.03.035</ArticleId><ArticleId IdType="pubmed">37019386</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. (2022) 36(6):797&#x2013;806. doi:&#xa0;10.1111/jdv.18044</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.18044</ArticleId><ArticleId IdType="pmc">PMC9313585</ArticleId><ArticleId IdType="pubmed">35238067</ArticleId></ArticleIdList></Reference><Reference><Citation>Canli &#xd6;, Nicolas AM, Gupta J, Finkelmeier F, Goncharova O, Pesic M, et al. . Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis. Cancer Cell. (2017) 32:797&#x2013;806. doi:&#xa0;10.1016/j.ccell.2017.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2017.11.004</ArticleId><ArticleId IdType="pubmed">29232557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccarelli M, Venanzi Rullo E, Vaccaro M, Facciol&#xe0; A, d'Aleo F, Paolucci IA, et al. . HIV-associated psoriasis: Epidemiology, pathogenesis, and management. Dermatol Ther. (2019) 32:e12806. doi:&#xa0;10.1111/dth.12806</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.12806</ArticleId><ArticleId IdType="pubmed">30588732</ArticleId></ArticleIdList></Reference><Reference><Citation>Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. (2019) 51:27&#x2013;41. doi:&#xa0;10.1016/j.immuni.2019.06.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.06.025</ArticleId><ArticleId IdType="pmc">PMC6831096</ArticleId><ArticleId IdType="pubmed">31315034</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijnen D, Knol EF, Gent YY, Giovannone B, Beijn SJP, Kupper TS, et al. . CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-&#x3b3;, IL-13, IL-17, and IL-22. J Invest Dermatol. (2013) 133:973&#x2013;9. doi:&#xa0;10.1038/jid.2012.456</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.2012.456</ArticleId><ArticleId IdType="pmc">PMC3835628</ArticleId><ArticleId IdType="pubmed">23223131</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of psoriasis and comorbid diseases: A narrative review. Front Immunol. (2022) 13:880201. doi:&#xa0;10.3389/fimmu.2022.880201</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.880201</ArticleId><ArticleId IdType="pmc">PMC9226890</ArticleId><ArticleId IdType="pubmed">35757712</ArticleId></ArticleIdList></Reference><Reference><Citation>Balda A, Wani I, Roohi TF, Suman, Krishna KL, Mehdi S, et al. . Psoriasis and skin cancer - Is there a link? Int Immunopharmacol. (2023) 121:110464. doi:&#xa0;10.1016/j.intimp.2023.110464</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.110464</ArticleId><ArticleId IdType="pubmed">37390565</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademaker M, Rubel DM, Agnew K, Andrews M, Armour KS, Baker C, et al. . Psoriasis and cancer. An Australian/New Zealand narrative. Australas J Dermatol. (2019) 60:12&#x2013;8. doi:&#xa0;10.1111/ajd.12889</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajd.12889</ArticleId><ArticleId IdType="pubmed">29992535</ArticleId></ArticleIdList></Reference><Reference><Citation>Loft ND, Vaengebjerg S, Skov L. Cancer risk in patients with psoriasis: should we be paying more attention? Expert Rev Clin Immunol. (2020) 16:479&#x2013;92. doi:&#xa0;10.1080/1744666X.2020.1754194</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2020.1754194</ArticleId><ArticleId IdType="pubmed">32279582</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: A systematic review and meta-analysis. JAMA Dermatol. (2020) 156:421&#x2013;9. doi:&#xa0;10.1001/jamadermatol.2020.0024</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2020.0024</ArticleId><ArticleId IdType="pmc">PMC7042857</ArticleId><ArticleId IdType="pubmed">32074260</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung JM, Lee KH, Kim Y-J, Chang SE, Lee MW, Choi JH, et al. . Assessment of overall and specific cancer risks in patients with Hidradenitis suppurativa. JAMA Dermatol. (2020) 156:844&#x2013;53. doi:&#xa0;10.1001/jamadermatol.2020.1422</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2020.1422</ArticleId><ArticleId IdType="pmc">PMC7254443</ArticleId><ArticleId IdType="pubmed">32459291</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyaert R, Beaugerie L, Van Assche G, Brochez L, Renauld J-C, Viguier M, et al. . Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer. (2013) 12:98. doi:&#xa0;10.1186/1476-4598-12-98</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-4598-12-98</ArticleId><ArticleId IdType="pmc">PMC3765952</ArticleId><ArticleId IdType="pubmed">23987103</ArticleId></ArticleIdList></Reference><Reference><Citation>Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol. (2010) 28:88&#x2013;92. doi:&#xa0;10.1016/j.clindermatol.2009.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clindermatol.2009.03.003</ArticleId><ArticleId IdType="pubmed">20082957</ArticleId></ArticleIdList></Reference><Reference><Citation>Buskwofie A, David-West G, Clare CA. A review of cervical cancer: incidence and disparities. J Natl Med Assoc. (2020) 112:229&#x2013;32. doi:&#xa0;10.1016/j.jnma.2020.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnma.2020.03.002</ArticleId><ArticleId IdType="pubmed">32278478</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Rodr&#xed;guez F, Limones-Gonz&#xe1;lez JE, Mendoza-Almanza B, Esparza-Ibarra EL, Gallegos-Flores PI, Ayala-Luj&#xe1;n JL, et al. . Understanding cervical cancer through proteomics. Cells. (2021) 10(8):1854. doi:&#xa0;10.3390/cells10081854</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10081854</ArticleId><ArticleId IdType="pmc">PMC8391734</ArticleId><ArticleId IdType="pubmed">34440623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogani G, Raspagliesi F, di Donato V, Brusadelli C, Guerrisi R, Pinelli C, et al. . Spotlight on the role of human papillomavirus vaccines. Gynecologic Oncol. (2021) 160:346&#x2013;50. doi:&#xa0;10.1016/j.ygyno.2020.08.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2020.08.034</ArticleId><ArticleId IdType="pubmed">32943207</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: Cancer J Clin. (2023) 73:17&#x2013;48. doi:&#xa0;10.3322/caac.21763</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21763</ArticleId><ArticleId IdType="pubmed">36633525</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M, Weiderpass E, Bruni L, de Sanjos&#xe9; S, Saraiya M, Ferlay J, et al. . Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.?Lancet Global Health. (2020) 8:e191&#x2013;203. doi:&#xa0;10.1016/S2214-109X(19)30482-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(19)30482-6</ArticleId><ArticleId IdType="pmc">PMC7025157</ArticleId><ArticleId IdType="pubmed">31812369</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng H, He X, Wang Q. Immune checkpoint blockades in gynecological cancers: A review of clinical trials. Acta Obstet Gynecol Scand. (2022) 101:941&#x2013;51. doi:&#xa0;10.1111/aogs.14412</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aogs.14412</ArticleId><ArticleId IdType="pmc">PMC9564814</ArticleId><ArticleId IdType="pubmed">35751489</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. (2022) 36(6):797&#x2013;806. doi:&#xa0;10.1111/jdv.18044</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.18044</ArticleId><ArticleId IdType="pmc">PMC9313585</ArticleId><ArticleId IdType="pubmed">35238067</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscicki AB, Flowers L, Huchko MJ, Long ME, MacLaughlin KL, Murphy J, et al. . Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis. (2019) 23:87&#x2013;101. doi:&#xa0;10.1097/LGT.0000000000000468</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/LGT.0000000000000468</ArticleId><ArticleId IdType="pubmed">30907775</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennigens C, Jerusalem G, Lapaille L, De Cuypere M, Streel S, Kridelka F, et al. . Recurrent or primary metastatic cervical cancer: current and future treatments. ESMO Open. (2022) 7:100579. doi:&#xa0;10.1016/j.esmoop.2022.100579</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esmoop.2022.100579</ArticleId><ArticleId IdType="pmc">PMC9588874</ArticleId><ArticleId IdType="pubmed">36108558</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Huang Q, Zhang Y, He X. The external use of Wolf poison in the treatment of skin diseases. 2023 National Conference on Dermatology and venereal Diseases. (2023).</Citation></Reference><Reference><Citation>Wu M, Deng Y, Li S, Chen Y, Guo D. The immunoregulatory effects of traditional chinese medicine on psoriasis via its action on interleukin: advances and considerations. Am J Chin Med. (2018) 46(4):739&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">29737208</ArticleId></ArticleIdList></Reference><Reference><Citation>Tison A, Qu&#xe9;r&#xe9; G, Misery L, Funck-Brentano E, Danlos FX, Routier E, et al. . Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: A nationwide, multicenter cohort study. Arthritis Rheumatol (Hoboken NJ). (2019) 71:2100&#x2013;11. doi:&#xa0;10.1002/art.41068</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41068</ArticleId><ArticleId IdType="pubmed">31379105</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CY, Wang CW, Chen CB, Chen WT, Chang YC, Hui RC, et al. . Pharmacogenomics on the treatment response in patients with psoriasis: an updated review. Int J Mol Sci. (2023) 24(8):7329. doi:&#xa0;10.3390/ijms24087329</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24087329</ArticleId><ArticleId IdType="pmc">PMC10138383</ArticleId><ArticleId IdType="pubmed">37108492</ArticleId></ArticleIdList></Reference><Reference><Citation>Furue K, Ito T, Tsuji G, Kadono T, Furue M. Psoriasis and the TNF/IL23/IL17 axis. Giornale italiano di dermatologia e venereologia: organo ufficiale Societa italiana di dermatologia e sifilografia. (2019) 154:418&#x2013;24. doi:&#xa0;10.23736/S0392-0488.18.06202-8</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0392-0488.18.06202-8</ArticleId><ArticleId IdType="pubmed">30648836</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbalshy AEM, El-Refaie AM, Akl EM. Expression of pigment epithelium-derived factor in psoriasis, verrucae, squamous cell carcinoma and normal skin: An immunohistochemical study. Indian J Dermatol Venereol Leprol. (2020) 86:469. doi:&#xa0;10.4103/ijdvl.IJDVL_396_19</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijdvl.IJDVL_396_19</ArticleId><ArticleId IdType="pubmed">32372761</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HW, Kim EH, Lee M, Jung I, Ahn SS. Risk of cancer, tuberculosis and serious infections in patients with ankylosing spondylitis, psoriatic arthritis and psoriasis treated with IL-17 and TNF-&#x3b1; inhibitors: a nationwide nested case-control analysis. Clin Exp Rheumatol. (2023) 41:1491&#x2013;9. doi:&#xa0;10.55563/clinexprheumatol/qkiorp</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/qkiorp</ArticleId><ArticleId IdType="pubmed">36533975</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. . Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. (2017) 76:393&#x2013;403. doi:&#xa0;10.1016/j.jaad.2016.07.065</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2016.07.065</ArticleId><ArticleId IdType="pmc">PMC5839668</ArticleId><ArticleId IdType="pubmed">28212760</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudley AC, Griffioen AW. Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis. (2023) 26:313&#x2013;47. doi:&#xa0;10.1007/s10456-023-09876-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10456-023-09876-7</ArticleId><ArticleId IdType="pmc">PMC10105163</ArticleId><ArticleId IdType="pubmed">37060495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. (2015) 43:e47. doi:&#xa0;10.1093/nar/gkv007</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>The Gene Ontology Consortium . Gene Ontology Consortium: going forward. Nucleic Acids Res. (2015) 43(D1):D1049&#x2013;56. doi:&#xa0;10.1093/nar/gku1179</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku1179</ArticleId><ArticleId IdType="pmc">PMC4383973</ArticleId><ArticleId IdType="pubmed">25428369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. (2017) 45:D353&#x2013;d61. doi:&#xa0;10.1093/nar/gkw1092</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw1092</ArticleId><ArticleId IdType="pmc">PMC5210567</ArticleId><ArticleId IdType="pubmed">27899662</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x15a;cie&#x17c;y&#x144;ska A, Nogowska A, Sikorska M, Konys J, Karpi&#x144;ska A, Komorowski M, et al. . Isolation and culture of human primary keratinocytes-a methods review. Exp Dermatol. (2019) 28:107&#x2013;12. doi:&#xa0;10.1111/exd.13860</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/exd.13860</ArticleId><ArticleId IdType="pubmed">30548893</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Zhang G, Wang Z, Liu X, He K, Luo R, et al. . FOXE1 contributes to the development of psoriasis by regulating WNT5A. J Invest Dermatol. (2023) 143(12):2366&#x2013;2377.e7. doi:&#xa0;10.1016/j.jid.2023.04.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jid.2023.04.035</ArticleId><ArticleId IdType="pubmed">37394057</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J, Li C, Luo S, Liu-Smith F, Yang J, Wang X, et al. . Yes-associated protein contributes to the development of human cutaneous squamous cell carcinoma via activation of RAS. J Invest Dermatol. (2016) 136:1267&#x2013;77. doi:&#xa0;10.1016/j.jid.2016.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jid.2016.02.005</ArticleId><ArticleId IdType="pubmed">26902922</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao L, Cheng H, Liu S. Non-SMC condensin I complex subunit H promotes the Malignant progression and cisplatin resistance of breast cancer MCF-7 cells. Oncol letters. (2022) 24:317. doi:&#xa0;10.3892/ol</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol</ArticleId><ArticleId IdType="pmc">PMC9353870</ArticleId><ArticleId IdType="pubmed">35949592</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin RE, Scullion C, Thursby SJ, Sun M, Thakur A, Hilman L, et al. . The UHRF1 protein is a key regulator of retrotransposable elements and innate immune response to viral RNA in human cells. Epigenetics. (2023) 18:2216005. doi:&#xa0;10.1080/15592294.2023.2216005</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15592294.2023.2216005</ArticleId><ArticleId IdType="pmc">PMC10228402</ArticleId><ArticleId IdType="pubmed">37246786</ArticleId></ArticleIdList></Reference><Reference><Citation>Mousli M, Hopfner R, Abbady AQ, Mont&#xe9; D, Jeanblanc M, Oudet P, et al. . ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J cancer. (2003) 89:120&#x2013;7. doi:&#xa0;10.1038/sj.bjc.6601068</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6601068</ArticleId><ArticleId IdType="pmc">PMC2394215</ArticleId><ArticleId IdType="pubmed">12838312</ArticleId></ArticleIdList></Reference><Reference><Citation>Pros&#xe9;e RF, Wenda JM, Steiner FA. Adaptations for centromere function in meiosis. Essays Biochem. (2020) 64:193&#x2013;203. doi:&#xa0;10.1042/EBC20190076</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/EBC20190076</ArticleId><ArticleId IdType="pmc">PMC7475650</ArticleId><ArticleId IdType="pubmed">32406496</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui XH, Peng QJ, Li RZ, Lyu XJ, Zhu CF, Qin XH. Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma. J Cell Mol Med. (2021) 25:11097&#x2013;112. doi:&#xa0;10.1111/jcmm.17032</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.17032</ArticleId><ArticleId IdType="pmc">PMC8650035</ArticleId><ArticleId IdType="pubmed">34741389</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitner MK, Taliaferro JM, Dalby KN, Bartholomeusz C. MELK: a potential novel therapeutic target for TNBC and other aggressive Malignancies. Expert Opin Ther Targets. (2017) 21:849&#x2013;59. doi:&#xa0;10.1080/14728222.2017.1363183</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2017.1363183</ArticleId><ArticleId IdType="pubmed">28764577</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang B, Zhu J, Fang S, Wang Y, Vinothkumar R, Li M, et al. . Pharmacological inhibition of MELK restricts ferroptosis and the inflammatory response in colitis and colitis-propelled carcinogenesis. Free Radical Biol Med. (2021) 172:312&#x2013;29. doi:&#xa0;10.1016/j.freeradbiomed.2021.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2021.06.012</ArticleId><ArticleId IdType="pubmed">34144192</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Huang Z, Fan Y, He L, Ye M, Shi K, et al. . FOXC1 promotes proliferation and epithelial-mesenchymal transition in cervical carcinoma through the PI3K-AKT signal pathway. Am J Trans Res. (2017) 9:1297&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5376020</ArticleId><ArticleId IdType="pubmed">28386355</ArticleId></ArticleIdList></Reference><Reference><Citation>Sena MM, Trugilo KP, Okuyama NCM, Pereira &#xc9;R, Cezar-Dos-Santos F, Ferreira RS, et al. . The role of NFKB1/NFKBIA genetic variants in HPV infection: A cross-sectional cohort study. Exp Mol Pathol. (2022) 124:104716. doi:&#xa0;10.1016/j.yexmp.2021.104716</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2021.104716</ArticleId><ArticleId IdType="pubmed">34767808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X, Yarbrough WG. Negative regulation of RelA phosphorylation: emerging players and their roles in cancer. Cytokine Growth Factor Rev. (2015) 26:7&#x2013;13. doi:&#xa0;10.1016/j.cytogfr.2014.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2014.09.003</ArticleId><ArticleId IdType="pubmed">25438737</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Min L, Zhang P, Zhang L, Xu Y, Li D, et al. . ORP5 promotes migration and invasion of cervical cancer cells by inhibiting endoplasmic reticulum stress. Cell Stress Chaperones. (2023) 28:395&#x2013;407. doi:&#xa0;10.1007/s12192-023-01357-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-023-01357-6</ArticleId><ArticleId IdType="pmc">PMC10352219</ArticleId><ArticleId IdType="pubmed">37314629</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Zhang S, Zhang Y. Nrf1 is paved as a new strategic avenue to prevent and treat cancer, neurodegenerative and other diseases. Toxicol Appl Pharmacol. (2018) 360:273&#x2013;83. doi:&#xa0;10.1016/j.taap.2018.09.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2018.09.037</ArticleId><ArticleId IdType="pubmed">30267745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kori M, Gov E, Arga KY. Novel genomic biomarker candidates for cervical cancer as identified by differential co-expression network analysis. Omics: J Integr Biol. (2019) 23:261&#x2013;73. doi:&#xa0;10.1089/omi.2019.0025</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2019.0025</ArticleId><ArticleId IdType="pubmed">31038390</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Hou Q, Yue Q. MiR-204&#x2013;5p/TFAP2A feedback loop positively regulates the proliferation, migration, invasion and EMT process in cervical cancer. Cancer biomarkers: section A Dis markers. (2020) 28:381&#x2013;90. doi:&#xa0;10.3233/CBM-191064</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/CBM-191064</ArticleId><ArticleId IdType="pubmed">32474464</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Gao Y, Yao S, Wan S, Cai H. TFAP2A promotes cervical cancer via a positive feedback pathway with PD&#x2212;L1. Oncol Rep. (2023) 49(6):114. doi:&#xa0;10.3892/or</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or</ArticleId><ArticleId IdType="pmc">PMC10170487</ArticleId><ArticleId IdType="pubmed">37083077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Yao S, Jiang H, Dong J, Cui X, Tian X, et al. . Upstream transcription factor 1 prompts Malignancies of cervical cancer primarily by transcriptionally activating p65 expression. Exp Ther Med. (2018) 16:4415&#x2013;22. doi:&#xa0;10.3892/etm</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm</ArticleId><ArticleId IdType="pmc">PMC6257725</ArticleId><ArticleId IdType="pubmed">30542391</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi TF, Khoder-Agha F, Mennerich D, Kellokumpu S, Miinalainen I, Kietzmann T, et al. . Loss of USF2 promotes proliferation, migration and mitophagy in a redox-dependent manner. Redox Biol. (2020) 37:101750. doi:&#xa0;10.1016/j.redox.2020.101750</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2020.101750</ArticleId><ArticleId IdType="pmc">PMC7566946</ArticleId><ArticleId IdType="pubmed">33059314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Zhang L, Zhang J, Xu G. MicroRNA-124&#x2013;3p inhibits cell growth and metastasis in cervical cancer by targeting IGF2BP1. Exp Ther Med. (2018) 15:1385&#x2013;93. doi:&#xa0;10.3892/etm.2017.5528</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2017.5528</ArticleId><ArticleId IdType="pmc">PMC5774538</ArticleId><ArticleId IdType="pubmed">29399123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilting SM, Miok V, Jaspers A, Boon D, S&#xf8;rg&#xe5;rd H, Lando M, et al. . Aberrant methylation-mediated silencing of microRNAs contributes to HPV-induced anchorage independence. Oncotarget. (2016) 7:43805&#x2013;19. doi:&#xa0;10.18632/oncotarget.v7i28</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.v7i28</ArticleId><ArticleId IdType="pmc">PMC5190061</ArticleId><ArticleId IdType="pubmed">27270309</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao YL, Zhang MY, Xu B, Han LJ, Lan SF, Chen J, et al. . Circular RNA expression profiles reveal that hsa_circ_0018289 is up-regulated in cervical cancer and promotes the tumorigenesis. Oncotarget. (2017) 8:86625&#x2013;33. doi:&#xa0;10.18632/oncotarget.v8i49</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.v8i49</ArticleId><ArticleId IdType="pmc">PMC5689712</ArticleId><ArticleId IdType="pubmed">29156822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Z, Cai Y, Zhang L, Tian C, Lyu L. LINC00319 promotes cervical cancer progression via targeting miR-147a/IGF1R pathway. Cancer Biother Radiopharm. (2020). doi:&#xa0;10.1089/cbr.2020.3722</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/cbr.2020.3722</ArticleId><ArticleId IdType="pubmed">32644822</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. (2021) 71:209&#x2013;49. doi:&#xa0;10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. (2019) 393:169&#x2013;82. doi:&#xa0;10.1016/S0140-6736(18)32470-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32470-X</ArticleId><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. . Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. (2017) 76:377&#x2013;90. doi:&#xa0;10.1016/j.jaad.2016.07.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2016.07.064</ArticleId><ArticleId IdType="pmc">PMC5731650</ArticleId><ArticleId IdType="pubmed">28212759</ArticleId></ArticleIdList></Reference><Reference><Citation>Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. (2010) 163:586&#x2013;92. doi:&#xa0;10.1111/j.1365-2133.2010.09941.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2010.09941.x</ArticleId><ArticleId IdType="pmc">PMC2966545</ArticleId><ArticleId IdType="pubmed">20633008</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard MA, et al. . Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. (2013) 27 Suppl 3:36&#x2013;46. doi:&#xa0;10.1111/jdv.12165</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.12165</ArticleId><ArticleId IdType="pubmed">23845151</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: A population-based cohort study in the health improvement network. JAMA Dermatol. (2016) 152:282&#x2013;90. doi:&#xa0;10.1001/jamadermatol.2015.4847</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2015.4847</ArticleId><ArticleId IdType="pmc">PMC5273859</ArticleId><ArticleId IdType="pubmed">26676102</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbieri JS, Wang S, Ogdie AR, Shin DB, Takeshita J. Age-appropriate cancer screening: A cohort study of adults with psoriasis prescribed biologics, adults in the general population, and adults with hypertension. J Am Acad Dermatol. (2021) 84:1602&#x2013;9. doi:&#xa0;10.1016/j.jaad.2020.10.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.10.045</ArticleId><ArticleId IdType="pubmed">33470207</ArticleId></ArticleIdList></Reference><Reference><Citation>Rust A, McGovern RM, Gostout BS, Persing DH, Pittelkow MR. Human papillomavirus in cutaneous squamous cell carcinoma and cervix of a patient with psoriasis and extensive ultraviolet radiation exposure. J Am Acad Dermatol. (2001) 44:681&#x2013;6. doi:&#xa0;10.1067/mjd.2001.112359</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mjd.2001.112359</ArticleId><ArticleId IdType="pubmed">11260548</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehncke WH, Sch&#xf6;n MP. Psoriasis. Lancet. (2015) 386:983&#x2013;94. doi:&#xa0;10.1016/S0140-6736(14)61909-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61909-7</ArticleId><ArticleId IdType="pubmed">26025581</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Youn Y, Hwang JH. NCAPH stabilizes GEN1 in chromatin to resolve ultra-fine DNA bridges and maintain chromosome stability. Molecules Cells. (2022) 45:792&#x2013;805. doi:&#xa0;10.14348/molcells.2022.0048</Citation><ArticleIdList><ArticleId IdType="doi">10.14348/molcells.2022.0048</ArticleId><ArticleId IdType="pmc">PMC9676985</ArticleId><ArticleId IdType="pubmed">36380731</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Ma X, Feng L, Lin Z, Zhou X. An integrative pan-cancer analysis reveals the carcinogenic effects of NCAPH in human cancer. Math Biosci Eng: MBE. (2023) 20:76&#x2013;92. doi:&#xa0;10.3934/mbe.2023005</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/mbe.2023005</ArticleId><ArticleId IdType="pubmed">36650758</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Qiao X, Cooper T, Pan W, Liu L, Hayball J, et al. . HPV E7-mediated NCAPH ectopic expression regulates the carcinogenesis of cervical carcinoma via PI3K/AKT/SGK pathway. Cell Death Disease. (2020) 11:1049. doi:&#xa0;10.1038/s41419-020-03244-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-03244-9</ArticleId><ArticleId IdType="pmc">PMC7732835</ArticleId><ArticleId IdType="pubmed">33311486</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhu H, Capalash N. UHRF1: The key regulator of epigenetics and molecular target for cancer therapeutics. Tumor Biol. (2017) 39:1010428317692205. doi:&#xa0;10.1177/1010428317692205</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1010428317692205</ArticleId><ArticleId IdType="pubmed">28218043</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue B, Zhao J, Feng P, Xing J, Wu H, Li Y. Epigenetic mechanism and target therapy of UHRF1 protein complex in Malignancies. OncoTargets Ther. (2019) 12:549&#x2013;59. doi:&#xa0;10.2147/OTT</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT</ArticleId><ArticleId IdType="pmc">PMC6334784</ArticleId><ArticleId IdType="pubmed">30666134</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MJ, Lee HJ, Choi MY, Kang SS, Kim YS, Shin JK, et al. . UHRF1 induces methylation of the TXNIP promoter and down-regulates gene expression in cervical cancer. Molecules Cells. (2021) 44:146&#x2013;59. doi:&#xa0;10.14348/molcells.2021.0001</Citation><ArticleIdList><ArticleId IdType="doi">10.14348/molcells.2021.0001</ArticleId><ArticleId IdType="pmc">PMC8019600</ArticleId><ArticleId IdType="pubmed">33795533</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhu H, Capalash N. Plumbagin downregulates UHRF1, p-Akt, MMP-2 and?suppresses survival, growth and migration of cervical cancer CaSki cells. Toxicol vitro: an Int J published Assoc BIBRA. (2023) 86:105512. doi:&#xa0;10.1016/j.tiv.2022.105512</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tiv.2022.105512</ArticleId><ArticleId IdType="pubmed">36336213</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi X, Liu Y, Peng Y, Fu Y, Fu Y, Yin L, et al. . UHRF1 promotes spindle assembly and chromosome congression by catalyzing EG5 polyubiquitination. J Cell Biol. (2023) 222(11):e202210093. doi:&#xa0;10.1083/jcb.202210093</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.202210093</ArticleId><ArticleId IdType="pmc">PMC10510743</ArticleId><ArticleId IdType="pubmed">37728657</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. (2019) 43:582&#x2013;92. doi:&#xa0;10.1002/cbin.11137</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbin.11137</ArticleId><ArticleId IdType="pubmed">30958602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chittori S, Hong J, Saunders H, Feng H, Ghirlando R, Kelly AE, et al. . Structural mechanisms of centromeric nucleosome recognition by the kinetochore protein CENP-N. Sci (New York NY). (2018) 359:339&#x2013;43. doi:&#xa0;10.1126/science.aar2781</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aar2781</ArticleId><ArticleId IdType="pmc">PMC6292214</ArticleId><ArticleId IdType="pubmed">29269420</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou K, Gebala M, Woods D, Sundararajan K, Edwards G, Krzizike D, et al. . CENP-N promotes the compaction of centromeric chromatin. Nat Struct Mol Biol. (2022) 29:403&#x2013;13. doi:&#xa0;10.1038/s41594-022-00758-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-022-00758-y</ArticleId><ArticleId IdType="pmc">PMC9010303</ArticleId><ArticleId IdType="pubmed">35422519</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. (2010) 140:883&#x2013;99. doi:&#xa0;10.1016/j.cell.2010.01.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.01.025</ArticleId><ArticleId IdType="pmc">PMC2866629</ArticleId><ArticleId IdType="pubmed">20303878</ArticleId></ArticleIdList></Reference><Reference><Citation>Das D, Sarkar B, Mukhopadhyay S, Banerjee C, Biswas Mondal S. An altered ratio of CD4+ And CD8+ T lymphocytes in cervical cancer tissues and peripheral blood &#x2013; A prognostic clue? Asian Pac J Cancer Prev: APJCP. (2018) 19:471&#x2013;8. doi:&#xa0;10.22034/APJCP.2018.19.2.471</Citation><ArticleIdList><ArticleId IdType="doi">10.22034/APJCP.2018.19.2.471</ArticleId><ArticleId IdType="pmc">PMC5980936</ArticleId><ArticleId IdType="pubmed">29480666</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. (2012) 7:385&#x2013;422. doi:&#xa0;10.1146/annurev-pathol-011811-132448</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathol-011811-132448</ArticleId><ArticleId IdType="pubmed">22054142</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark RA, Kupper TS. Misbehaving macrophages in the pathogenesis of psoriasis. J Clin Invest. (2006) 116:2084&#x2013;7. doi:&#xa0;10.1172/JCI29441</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI29441</ArticleId><ArticleId IdType="pmc">PMC1523394</ArticleId><ArticleId IdType="pubmed">16886055</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Peters T, Kess D, Sindrilaru A, Oreshkova T, Van Rooijen N, et al. . Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest. (2006) 116:2105&#x2013;14. doi:&#xa0;10.1172/JCI27180</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI27180</ArticleId><ArticleId IdType="pmc">PMC1523400</ArticleId><ArticleId IdType="pubmed">16886059</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorthois I, Asselineau D, Seyler N, Pouliot R. Contribution of in vivo and organotypic 3D models to understanding the role of macrophages and neutrophils in the pathogenesis of psoriasis. Mediators Inflamm. (2017) 2017:7215072. doi:&#xa0;10.1155/2017/7215072</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7215072</ArticleId><ArticleId IdType="pmc">PMC5698795</ArticleId><ArticleId IdType="pubmed">29249871</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook PW, Pittelkow MR, Piepkorn M. Overexpression of amphiregulin in the epidermis of transgenic mice induces a psoriasis-like cutaneous phenotype. J Invest Dermatol. (1999) 113:860. doi:&#xa0;10.1046/j.1523-1747.1999.00753.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1747.1999.00753.x</ArticleId><ArticleId IdType="pubmed">10571748</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W, Yang Z, Wang S, Li Y, Wei H, Tian X, et al. . Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures. Eur J Med Chem. (2019) 164:615&#x2013;39. doi:&#xa0;10.1016/j.ejmech.2019.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.01.003</ArticleId><ArticleId IdType="pubmed">30639897</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Roy L, Letondor A, Le Roux C, Amara A, Timsit S. Cellular and molecular mechanisms of R/S-roscovitine and CDKs related inhibition under both focal and global cerebral ischemia: A focus on neurovascular unit and immune cells. Cells. (2021) 10(1):104. doi:&#xa0;10.3390/cells10010104</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10010104</ArticleId><ArticleId IdType="pmc">PMC7827530</ArticleId><ArticleId IdType="pubmed">33429982</ArticleId></ArticleIdList></Reference><Reference><Citation>Phoomvuthisarn P, Cross A, Glennon-Alty L, Wright HL, Edwards SW. The CDK inhibitor purvalanol A induces neutrophil apoptosis and increases the turnover rate of Mcl-1: potential role of p38-MAPK in regulation of Mcl-1 turnover. Clin Exp Immunol. (2018) 192:171&#x2013;80. doi:&#xa0;10.1111/cei.13107</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13107</ArticleId><ArticleId IdType="pmc">PMC5904697</ArticleId><ArticleId IdType="pubmed">29377076</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Wahab AF, Mahmoud W, Al-Harizy RM. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. (2019) 150:104511. doi:&#xa0;10.1016/j.phrs.2019.104511</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2019.104511</ArticleId><ArticleId IdType="pubmed">31678210</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Che Q, Tan H, Qi X, Li D, Zhu T, et al. . A novel antimycin analogue antimycin A2c, derived from marine Streptomyces sp., suppresses HeLa cells via disrupting mitochondrial function and depleting HPV oncoproteins E6/E7. Life Sci. (2023) 330:121998. doi:&#xa0;10.1016/j.lfs.2023.121998</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2023.121998</ArticleId><ArticleId IdType="pubmed">37536615</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR. A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. Bioorg Med Chem Lett. (2017) 27:406&#x2013;12. doi:&#xa0;10.1016/j.bmcl.2016.12.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2016.12.056</ArticleId><ArticleId IdType="pmc">PMC5295499</ArticleId><ArticleId IdType="pubmed">28049589</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz CW, Nevler A. Pyrvinium pamoate: past, present, and future as an anti-cancer drug. Biomedicines. (2022) 10(12):3249. doi:&#xa0;10.3390/biomedicines10123249</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10123249</ArticleId><ArticleId IdType="pmc">PMC9775650</ArticleId><ArticleId IdType="pubmed">36552005</ArticleId></ArticleIdList></Reference><Reference><Citation>Karamian A, Nazarian H, Ziai SA, Zarnani AH, Salehpour S, Paktinat S, et al. . Pyrvinium pamoate inhibits proliferation and invasion of human endometriotic stromal cells. Hum Exp Toxicol. (2020) 39:662&#x2013;72. doi:&#xa0;10.1177/0960327119896612</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0960327119896612</ArticleId><ArticleId IdType="pubmed">31880170</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38850798</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1936-5233</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Translational oncology</Title><ISOAbbreviation>Transl Oncol</ISOAbbreviation></Journal><ArticleTitle>Construction of a novel cancer-associated fibroblast-related signature to predict clinical outcome and immune response in cervical cancer.</ArticleTitle><Pagination><StartPage>102001</StartPage><MedlinePgn>102001</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102001</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tranon.2024.102001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1936-5233(24)00128-1</ELocationID><Abstract><AbstractText>This study developed a prognostic signature for cervical cancer using transcriptome profiling and clinical data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and TISCH database, focusing on cancer-associated fibroblasts (CAFs). Through LASSO Cox regression and integrated bioinformatics analyses, we identified 144 differentially expressed genes (DEGs) related to CAFs, from which an 11-gene CAF-related signature (CAFRSig) was constructed. The CAFRSig effectively stratified patients into high- and low-risk categories, demonstrating significant prognostic capability in predicting overall survival. Gene ontology (GO) and gene set variation analysis (GSVA) linked the DEGs to crucial pathways in tumor malignancy, immune response, and fatty acid metabolism. The immune landscape analysis, utilizing the TIMER platform and CIBERSORT algorithm, revealed a positive correlation between immune cell effector functions and CAFRSig scores, highlighting the model's potential to identify patients likely to respond to immune checkpoint blockade (ICB) therapies. Furthermore, neuropilin 1 (NRP1), a key gene in the CAFRSig, was upregulated in cervical cancer tissues and associated with disease progression and differentiation. The downregulation of NRP1 curbed cell proliferation and influenced the epithelial-mesenchymal transition (EMT), implicating the PI3K/AKT pathway and modulating PD-L1 expression. This comprehensive analysis establishes a robust prognostic signature based on CAF-related genes, offering valuable insights for optimizing therapeutic strategies in cervical cancer management.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gui</LastName><ForeName>Zhongxuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Oncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Yingquan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Oncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Liver Diseases of Anhui Medical University, School of Pharmacy, Anhui Medical University, Hefei, Anhui, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Zhengting</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Anhui Second People's Hospital, Hefei, Anhui, PR China; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Oncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR China. Electronic address: qq296901523@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR China; The Traditional and Western Medicine (TCM)-Integrated Cancer Center of Anhui Medical University, Hefei, Anhui, PR China; Graduate School of Anhui University of Chinese Medicine, Hefei, China. Electronic address: zhangmei@ahmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Oncol</MedlineTA><NlmUniqueID>101472619</NlmUniqueID><ISSNLinking>1936-5233</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer-associated fibroblasts</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Immune response</Keyword><Keyword MajorTopicYN="N">Neuropilin 1</Keyword><Keyword MajorTopicYN="N">Risk score signature</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>8</Day><Hour>18</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38850798</ArticleId><ArticleId IdType="pmc">PMC11214323</ArticleId><ArticleId IdType="doi">10.1016/j.tranon.2024.102001</ArticleId><ArticleId IdType="pii">S1936-5233(24)00128-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H., Ferlay J., Siegel R.L. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71(3):209&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Wu X. Advances in diagnosis and treatment of metastatic cervical cancer. 2016; 27(4): e43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4864519</ArticleId><ArticleId IdType="pubmed">27171673</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M., Weiderpass E., Bruni L., de Sanjos&#xe9; S., Saraiya M., Ferlay J. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob. Health. 2020;8(2):e191&#x2013;e203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7025157</ArticleId><ArticleId IdType="pubmed">31812369</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen P.A., Jhingran A., Oaknin A., Denny L. Cervical cancer. Lancet. 2019;393(10167):169&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>Canfell K., Kim J.J., Brisson M., Keane A., Simms K.T., Caruana M. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):591&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7043006</ArticleId><ArticleId IdType="pubmed">32007142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kossa&#xef; M., Leary A., Scoazec J.Y., Genestie C. Ovarian cancer: a heterogeneous disease. Pathobiology. 2018;85(1&#x2013;2):41&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">29020678</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas V., Hirshfield K.M., Ganesan S., Rodriguez-Rodriguez L. Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment. Int. J. Mol. Sci. 2016;17(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5187913</ArticleId><ArticleId IdType="pubmed">27983698</ArticleId></ArticleIdList></Reference><Reference><Citation>Baghban R., Roshangar L., Jahanban-Esfahlan R., Seidi K., Ebrahimi-Kalan A., Jaymand M. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 2020;18(1):59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7140346</ArticleId><ArticleId IdType="pubmed">32264958</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 2019;18(2):99&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">30470818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahai E., Astsaturov I. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer. 2020;20(3):174&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7046529</ArticleId><ArticleId IdType="pubmed">31980749</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiori M.E., Di Franco S., Villanova L., Bianca P., Stassi G., De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol. Cancer. 2019;18(1):70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6441236</ArticleId><ArticleId IdType="pubmed">30927908</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra Jena B., Kanta Das C., Banerjee I., Das S., Bharadwaj D., Majumder R. Paracrine TGF-&#x3b2;1 from breast cancer contributes to chemoresistance in cancer associated fibroblasts via upregulation of the p44/42 MAPK signaling pathway. Biochem. Pharmacol. 2021;186</Citation><ArticleIdList><ArticleId IdType="pubmed">33607074</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong A.L., Pei D.T., Hurst C.G., Gimble J.M., Burow M.E., Bunnell B.A. Obesity enhances the conversion of adipose-derived stromal/stem cells into carcinoma-associated fibroblast leading to cancer cell proliferation and progression to an invasive phenotype. Stem Cells Int. 2017;2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748106</ArticleId><ArticleId IdType="pubmed">29527228</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz Y., Cohen N., Shani O., Bell R.E., Novitskiy S.V., Abramovitz L. Bone marrow-derived fibroblasts are a functionally distinct stromal cell population in breast cancer. J. Exp. Med. 2018;215(12):3075&#x2013;3093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6279405</ArticleId><ArticleId IdType="pubmed">30470719</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeon J.H., Jeong H.E., Seo H., Cho S., Kim K., Na D. Cancer-derived exosomes trigger endothelial to mesenchymal transition followed by the induction of cancer-associated fibroblasts. Acta Biomater. 2018;76:146&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">30078422</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H., Liu H., Ge Y., Wang X. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer. Cancer Cell Int. 2021;21(1):552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8529760</ArticleId><ArticleId IdType="pubmed">34670584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y., Zhang S., Jiang Y., Huang Y., Wang G., Zhang M. Identification of a cancer associated fibroblasts-related index to predict prognosis and immune landscape in ovarian cancer. Sci. Rep. 2023;13(1):21565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10700659</ArticleId><ArticleId IdType="pubmed">38057405</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Meng H., Nie S., Sun Y., Jiang P., Li S. Identification of a prognostic signature of epithelial ovarian cancer based on tumor immune microenvironment exploration. Genomics. 2020;112(6):4827&#x2013;4841.</Citation><ArticleIdList><ArticleId IdType="pubmed">32890701</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Geng R., Ni S., Cai L., Yang S., Shao F. Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC. Mol. Ther. Nucleic Acids. 2022;27:1036&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8844853</ArticleId><ArticleId IdType="pubmed">35228898</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Chen C., Wang Y., Qian C., Wei J., Xing Y. Comprehensive of N1-methyladenosine modifications patterns and immunological characteristics in ovarian cancer. Front. Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8588846</ArticleId><ArticleId IdType="pubmed">34777359</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y., Zhao Q., Wu Y., Wang G., Huang Y., Sun W. Construction of a cancer-associated fibroblasts-related long non-coding RNA signature to predict prognosis and immune landscape in pancreatic adenocarcinoma. Front. Genet. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538573</ArticleId><ArticleId IdType="pubmed">36212154</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;nzelmann S., Castelo R., Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618321</ArticleId><ArticleId IdType="pubmed">23323831</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Fan J., Wang B., Traugh N., Chen Q., Liu J.S. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108&#x2013;e110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6042652</ArticleId><ArticleId IdType="pubmed">29092952</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Fu J., Zeng Z., Cohen D., Li J., Chen Q. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucl. Acids Res. 2020;48(W1):W509&#x2013;w514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319575</ArticleId><ArticleId IdType="pubmed">32442275</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U S A. 2005;102(43):15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman A.M., Liu C.L., Green M.R. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods. 2015;12(5):453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739640</ArticleId><ArticleId IdType="pubmed">25822800</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara K., Shahmoradgoli M., Mart&#xed;nez E., Vegesna R., Kim H., Torres-Garcia W. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 2013;4:2612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826632</ArticleId><ArticleId IdType="pubmed">24113773</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi M., Niu M., Xu L., Luo S., Wu K. Regulation of PD-L1 expression in the tumor microenvironment. 2021; 14(1): 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7792099</ArticleId><ArticleId IdType="pubmed">33413496</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W., Hang D., Han S., Fu S., Ma H., Dong X. Construction of circRNA-associated ceRNA network reveals the regulation of fibroblast proliferation in cervical cancer. Gene. 2022;844</Citation><ArticleIdList><ArticleId IdType="pubmed">35995117</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Y., Zhang B., Xing B., Liu Z., Chang Y., Wu G. Cancer-associated fibroblasts exposed to high-dose ionizing radiation promote M2 polarization of macrophages, which induce radiosensitivity in cervical cancer. Cancers (Basel) 2023;15(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10001412</ArticleId><ArticleId IdType="pubmed">36900416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou Z., Lin S., Qiu J., Ding W., Ren P., Chen D., et al. Single-nucleus RNA sequencing and spatial transcriptomics reveal the immunological microenvironment of cervical squamous cell carcinoma. 2022; 9(29): e2203040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9561780</ArticleId><ArticleId IdType="pubmed">35986392</ArticleId></ArticleIdList></Reference><Reference><Citation>Belkacemi L., Zhang S.X. Anti-tumor effects of pigment epithelium-derived factor (PEDF): implication for cancer therapy. A mini-review. J. Exp. Clin. Cancer Res. 2016;35:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4706649</ArticleId><ArticleId IdType="pubmed">26746675</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonovic M., Gettins P.G., Volz K. Crystal structure of human PEDF, a potent anti-angiogenic and neurite growth-promoting factor. Proc. Natl. Acad. Sci. U S A. 2001;98(20):11131&#x2013;11135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58695</ArticleId><ArticleId IdType="pubmed">11562499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagdadi N., Sawaied A., AbuMadighem A. The expression levels and cellular localization of pigment epithelium derived factor (PEDF) in mouse testis: its possible involvement in the differentiation of spermatogonial cells. Int. J. Mol. Sci. 2021;22(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7865766</ArticleId><ArticleId IdType="pubmed">33498962</ArticleId></ArticleIdList></Reference><Reference><Citation>Robl B., Botter S.M., Boro A., Meier D., Neri D., Fuchs B. Evaluation of F8-TNF-&#x3b1; in models of early and progressive metastatic osteosarcoma. Transl. Oncol. 2017;10(3):419&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5406547</ArticleId><ArticleId IdType="pubmed">28448958</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Z.H., Jiang X.M., Huang M.Y., Xu Y.L., Chen Y.C., Yuan L.W. Regulation of CD47 expression by interferon-gamma in cancer cells. Transl. Oncol. 2021;14(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8243019</ArticleId><ArticleId IdType="pubmed">34171557</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata T., Mizushima H., Chinen I., Moribe H., Yagi S., Hoffman R.M. HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers. Cancer Res. 2011;71(21):6633&#x2013;6642.</Citation><ArticleIdList><ArticleId IdType="pubmed">22009535</ArticleId></ArticleIdList></Reference><Reference><Citation>Geretti E., Shimizu A., Klagsbrun M. Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis. 2008;11(1):31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">18283547</ArticleId></ArticleIdList></Reference><Reference><Citation>Plein A., Fantin A., Ruhrberg C. Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability. Microcirculation. 2014;21(4):315&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4230468</ArticleId><ArticleId IdType="pubmed">24521511</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Somasundaram A., Manne S., Gocher A.M., Szymczak-Workman A.L., Vignali K.M., et al. Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. 2020; 21(9): 1010&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442600</ArticleId><ArticleId IdType="pubmed">32661362</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X., Ye Q., Chen M., Li A., Mi W., Fang Y., et al. N-glycosylation-defective splice variants of neuropilin-1 promote metastasis by activating endosomal signals. 2019; 10(1): 3708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697747</ArticleId><ArticleId IdType="pubmed">31420553</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin Y., Li J., Wu J., Kinard R., Weekes C.D., Patnaik A. Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors. Clin. Cancer Res. 2012;18(21):6040&#x2013;6048.</Citation><ArticleIdList><ArticleId IdType="pubmed">22962439</ArticleId></ArticleIdList></Reference><Reference><Citation>Vescarelli E., Gerini G., Megiorni F., Anastasiadou E., Pontecorvi P., Solito L., et al. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1. 2020; 39(1): 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939329</ArticleId><ArticleId IdType="pubmed">31898520</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuckran C.A., Liu C., Bruno T.C., Workman C.J., Vignali D.A. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. J. Immunother. Cancer. 2020;8(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7368550</ArticleId><ArticleId IdType="pubmed">32675311</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei B., Chen J., Yang N., Peng Y. The regulatory mechanism and biological significance of the Snail-miR590-VEGFR-NRP1 axis in the angiogenesis, growth and metastasis of gastric cancer. Cell Death Dis. 2020;11(4):241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165172</ArticleId><ArticleId IdType="pubmed">32303680</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38800011</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2008-3866</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>7</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Iranian journal of basic medical sciences</Title><ISOAbbreviation>Iran J Basic Med Sci</ISOAbbreviation></Journal><ArticleTitle>Comprehensive analysis of autophagy associated genes and immune infiltrates in cervical cancer.</ArticleTitle><Pagination><StartPage>813</StartPage><EndPage>824</EndPage><MedlinePgn>813-824</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.22038/IJBMS.2024.74431.16168</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Cervical cancer (CC) is the most common gynecological malignant tumor and the fourth leading cause of cancer-related death in women. The progression of CC is significantly affected by autophagy. Our objective was to use bioinformatics analysis to explore the expression, prognostic significance, and immune infiltration of autophagy-related genes in CC.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">We identified a set of autophagy-related differentially expressed genes (ARDEGs) from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. ARDEGs were further validated by The Human Protein Atlas (HPA), GSE52903, and GSE39001 dataset. Hub genes were found by the STRING network and Cytoscape. We performed Gene Set Enrichment Analysis (GSEA), Gene ontology analysis (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and immune infiltration analysis to further understand the functions of the hub genes. Kaplan-Meier (K-M) and receiver operating characteristic (ROC) were used to check the hub genes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 10 up-regulated (CXCR4, BAX, SPHK1, EIF2AK2, TBK1, TNFSF10, ITGB4, CDKN2A, IL24, and BIRC5) and 19 down-regulated (PINK1, ATG16L2, ATG4D, IKBKE, MLST8, MAPK3, ERBB2, ULK3, TP53INP2, MTMR14, BNIP3, FOS, CCL2, FAS, CAPNS1, HSPB8, PTK6, FKBP1B , and DNAJB1) ARDEGs were identified. The ARDEGs were enriched in cell growth, apoptosis, human papillomavirus infection, and cytokine-mediated. Then, we found that low expression of MAPK3 was associated with poor prognosis in CC patients and was significantly enriched in immune pathways. In addition, the expression of MAPK3 was significantly positively correlated with the infiltration levels of macrophages, B cells, mast cell activation, and cancer-associated fibroblasts. Furthermore, MAPK3 was positively correlated with LGALS9, and negatively correlated with CTLA4 and CD40.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our results show that MAPK3 can be used as a new prognostic biomarker to predict the prognosis of patients with CC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shuzhen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital Nanning, Guangxi Zhuang Autonomous Region 530021, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital Nanning, Guangxi Zhuang Autonomous Region 530021, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Desheng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital Nanning, Guangxi Zhuang Autonomous Region 530021, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>Iran J Basic Med Sci</MedlineTA><NlmUniqueID>101517966</NlmUniqueID><ISSNLinking>2008-3866</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autophagy</Keyword><Keyword MajorTopicYN="N">Bioinformatics</Keyword><Keyword MajorTopicYN="N">Immune Infiltrates</Keyword><Keyword MajorTopicYN="N">Mitogen-activated protein - kinase 3</Keyword><Keyword MajorTopicYN="N">Uterine cervical neoplasms</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest in this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>27</Day><Hour>4</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38800011</ArticleId><ArticleId IdType="pmc">PMC11127083</ArticleId><ArticleId IdType="doi">10.22038/IJBMS.2024.74431.16168</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, Wang J, Cui N, Liu X, Wang H. Autophagy-related long non-coding RNA signature for potential prognostic biomarkers of patients with cervical cancer: a study based on public databases. Ann Transl Med. 2021;9:1668&#x2013;1683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8667135</ArticleId><ArticleId IdType="pubmed">34988177</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, Petroni G, Amaravadi RK, Baehrecke EH, Ballabio A, Boya P, et al. Autophagy in major human diseases. EMBO J. 2021;40:1&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8488577</ArticleId><ArticleId IdType="pubmed">34459017</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Ot&#xed;n C, Kroemer G. Decelerating ageing and biological clocks by autophagy. Nat Rev Mol Cell Biol. 2019;20:385&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">31164727</ArticleId></ArticleIdList></Reference><Reference><Citation>Venida A, Perera RM. Host control of tumor feeding: autophagy holds the key. Cell Metab. 2019;29:236&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">30726755</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao C-C, Hwang W, Chu L-Y, Yang L-H, Ha C-T, Chen P-Y, et al. LC3A-mediated autophagy regulates lung cancer cell plasticity. Autophagy. 2022;18:921&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9037431</ArticleId><ArticleId IdType="pubmed">34470575</ArticleId></ArticleIdList></Reference><Reference><Citation>yingBai Y, meiCheng Y, Wang W, Yang L, Yang Y. In vivo and in vitro studies of alloimperatorin induced autophagy in cervical cancer cells via reactive oxygen species pathway. Bioengineered. 2022;13:14299&#x2013;14314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9995126</ArticleId><ArticleId IdType="pubmed">36708242</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell KL, Gorgulho CM, Allen A, Vakaki M, Wang Y, Facciabene A, et al. Inhibiting autophagy in renal cell cancer and the associated tumor endothelium. Cancer J. 2019;25:165&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10395074</ArticleId><ArticleId IdType="pubmed">31135523</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao X, Qian H, Wang S, Fulte S, Ding W-X. Autophagy and liver cancer. Clin Mol Hepatol. 2020;26:606&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7641568</ArticleId><ArticleId IdType="pubmed">33053934</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Zhang G, Bai X, Liang T. Reviving the role of MET in liver cancer therapy and vaccination: an autophagic perspective. OncoImmunology. 2020;9:1818438&#x2013;1818441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781811</ArticleId><ArticleId IdType="pubmed">33457099</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Han Q, Zheng H, Liu M, Shi S, Zhang T, et al. MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer. Cell Death Dis. 2021;13:13&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8688448</ArticleId><ArticleId IdType="pubmed">34930918</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Sun Y, Cheng S, Yao Y, Hua X, Shi Y, et al. CDK6 increases glycolysis and suppresses autophagy by mTORC1-HK2 pathway activation in cervical cancer cells. Cell Cycle. 2022;21:984&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9037534</ArticleId><ArticleId IdType="pubmed">35167417</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Shen B, Li J, Zhang H, Zhang K, Yang Y, et al. STAT3 exerts pro-tumor and anti-autophagy roles in cervical cancer. Diagn Pathol. 2022;17:13&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8772194</ArticleId><ArticleId IdType="pubmed">35057825</ArticleId></ArticleIdList></Reference><Reference><Citation>Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R/bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:71&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4856967</ArticleId><ArticleId IdType="pubmed">26704973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:47&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>den Boon JA, Pyeon D, Wang SS, Horswill M, Schiffman M, Sherman M, et al. Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S A. 2015;112:3255&#x2013;3264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4485108</ArticleId><ArticleId IdType="pubmed">26056290</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y, Kuick R, Nan B, Ota I, Weiss SJ, Trimble CL, et al. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res. 2007;67:10163&#x2013;10172.</Citation><ArticleIdList><ArticleId IdType="pubmed">17974957</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Martinez I, Barr&#xf3;n V, Roman-Bassaure E, Ju&#xe1;rez-Torres E, Guardado-Estrada M, Espinosa AM, et al. Impact of gene dosage on gene expression, biological processes and survival in cervical cancer: a genome-wide follow-up study. PloS One. 2014;9:1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4039463</ArticleId><ArticleId IdType="pubmed">24879114</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa AM, Alfaro A, Roman-Basaure E, Guardado-Estrada M, Palma &#xcd;, Serralde C, et al. Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PloS One. 2013;8:1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3566100</ArticleId><ArticleId IdType="pubmed">23405241</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41:991&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S, Meltzer PS. GEOquery: a bridge between the gene expression omnibus (GEO) and bioconductor. Bioinforma Oxf Engl. 2007;23:1846&#x2013;1847.</Citation><ArticleIdList><ArticleId IdType="pubmed">17496320</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N-N, Dong J, Zhang L, Ouyang D, Cheng Y, Chen AF, et al. HAMdb: a database of human autophagy modulators with specific pathway and disease information. J Cheminformatics. 2018;10:34&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6068059</ArticleId><ArticleId IdType="pubmed">30066211</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32:2847&#x2013;2849.</Citation><ArticleIdList><ArticleId IdType="pubmed">27207943</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ontology Consortium. Gene ontology consortium: going forward. Nucleic Acids Res. 2015;43:1049&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383973</ArticleId><ArticleId IdType="pubmed">25428369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102409</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang L-G, Han Y, He Q-Y. Cluster profiler: an R package for comparing biological themes among gene clusters. Omics J Integr Biol. 2012;16:284&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy &#xc1;, Munk&#xe1;csy G, Gy&#x151;rffy B. Pancancer survival analysis of cancer hallmark genes. Sci Rep. 2021;11:6047&#x2013;6057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7961001</ArticleId><ArticleId IdType="pubmed">33723286</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n M, Fagerberg L, Hallstr&#xf6;m BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419&#x2013;1260430.</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618321</ArticleId><ArticleId IdType="pubmed">23323831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">24138885</ArticleId></ArticleIdList></Reference><Reference><Citation>White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12:401&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664381</ArticleId><ArticleId IdType="pubmed">22534666</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Han Q, Zheng H, Liu M, Shi S, Zhang T, et al. MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer. Cell Death Dis. 2021;13:13&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8688448</ArticleId><ArticleId IdType="pubmed">34930918</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Liu X, Song L, Zhai H, Chang C. MAP7 promotes migration and invasion and progression of human cervical cancer through modulating the autophagy. Cancer Cell Int. 2020;20:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6958635</ArticleId><ArticleId IdType="pubmed">31956295</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Shen B, Li J, Zhang H, Zhang K, Yang Y, et al. STAT3 exerts pro-tumor and anti-autophagy roles in cervical cancer. Diagn Pathol. 2022;17:13&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8772194</ArticleId><ArticleId IdType="pubmed">35057825</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Wang Q, Song D, Zen R, Zhang L, Wang Y, et al. Lysosomal dysfunction and autophagy blockade contribute to autophagy-related cancer suppressing peptide-induced cytotoxic death of cervical cancer cells through the AMPK/mTOR pathway. J Exp Clin Cancer Res CR. 2020;39:197&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510096</ArticleId><ArticleId IdType="pubmed">32962728</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G, Long Y, Lu Y, Feng Y, Yang X, Xu X, et al. Kindlin2 suppresses cervical cancer cell migration through AKT/mTORmediated autophagy induction. Oncol Rep. 2020;44:69&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251777</ArticleId><ArticleId IdType="pubmed">32377753</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Chang L, Hu J. Activating transcription factor 6 regulated cell growth, migration and inhibiteds cell apoptosis and autophagy via MAPK pathway in cervical cancer. J Reprod Immunol. 2020;139:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32234634</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang W, Zhang R-J, Jin G-L, Tian L, Cheng F, Wang J-Z, et al. RCE4, a potential anticervical cancer drug isolated from Reineckia carnea, induces autophagy via the dual blockade of PI3K and ERK pathways in cervical cancer CaSki cells. Int J Mol Med. 2020;45:245&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">31746346</ArticleId></ArticleIdList></Reference><Reference><Citation>Slattery ML, Herrick JS, Torres-Mejia G, John EM, Giuliano AR, Hines LM, et al. Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the breast cancer health disparities study. Carcinogenesis. 2014;35:1750&#x2013;1759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123645</ArticleId><ArticleId IdType="pubmed">24670917</ArticleId></ArticleIdList></Reference><Reference><Citation>Omrane I, Medimegh I, Baroudi O, Ayari H, Bedhiafi W, Stambouli N, et al. Involvement of IL17A, IL17F and IL23R polymorphisms in colorectal cancer therapy. PloS One. 2015;10:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4470506</ArticleId><ArticleId IdType="pubmed">26083022</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B, Guenther JF, Pociask DA, Wang Y, Kolls JK, You Z, et al. Promotion of lung tumor growth by interleukin-17. Am J Physiol Lung Cell Mol Physiol. 2014;307:497&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4166785</ArticleId><ArticleId IdType="pubmed">25038189</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Q, Wu K, Liu F, Wu W, Chen Y, Zhang W. Interleukin17A and heparanase promote angiogenesis and cell proliferation and invasion in cervical cancer. Int J Oncol. 2018;53:1809&#x2013;1817.</Citation><ArticleIdList><ArticleId IdType="pubmed">30066843</ArticleId></ArticleIdList></Reference><Reference><Citation>Roskoski R. Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacol Res. 2019;142:151&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">30794926</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L-T, Liu K-Y, Chiou S-S, Huang S-K, Hsu S-H, Wang S-N. Phosphorylation of intestine-specific homeobox by ERK1 modulates oncogenic activity and sorafenib resistance. Cancer Lett. 2021;520:160&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">34265398</ArticleId></ArticleIdList></Reference><Reference><Citation>Akula SM, Abrams SL, Steelman LS, Emma MR, Augello G, Cusimano A, et al. RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. Expert Opin Ther Targets. 2019;23:915&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">31657972</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Lu Y, Xing F, Hsu W. FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression. Cancer Lett. 2022;547:215867.</Citation><ArticleIdList><ArticleId IdType="pubmed">35985510</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Qian C, Ma F, Liu M, Sun X, Liu X, et al. MAPK/ERK-CBP-RFPL-3 mediates adipose-derived stem cell-induced tumor growth in breast cancer cells by activating telomerase reverse transcriptase expression. Stem Cells Int. 2022;2022:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9197637</ArticleId><ArticleId IdType="pubmed">35711680</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashatus JA, Nascimento A, Myers LJ, Sher A, Byrne FL, Hoehn KL, et al. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell. 2015;57:537&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393013</ArticleId><ArticleId IdType="pubmed">25658205</ArticleId></ArticleIdList></Reference><Reference><Citation>Mele L, del Vecchio V, Liccardo D, Prisco C, Schwerdtfeger M, Robinson N, et al. The role of autophagy in resistance to targeted therapies. Cancer Treat Rev. 2020;88:102043&#x2013;102057.</Citation><ArticleIdList><ArticleId IdType="pubmed">32505806</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert CJ, Longenecker JZ, Accornero F. ERK1/2: an integrator of signals that alters cardiac homeostasis and growth. Biology. 2021;10:346&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8072600</ArticleId><ArticleId IdType="pubmed">33923899</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennanen P, Kallionp&#xe4;&#xe4; RA, Peltonen S, Nissinen L, K&#xe4;h&#xe4;ri V-M, Heerv&#xe4; E, et al. Signaling pathways in human osteoclasts differentiation: ERK1/2 as a key player. Mol Biol Rep. 2021;48:1243&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7925492</ArticleId><ArticleId IdType="pubmed">33486672</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Zhang J, Meng Y, Huang M, Yan W, Wu Z. MicroRNA-143 targets MAPK3 to regulate the proliferation and bone metastasis of human breast cancer cells. AMB Express. 2020;10:134&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7394972</ArticleId><ArticleId IdType="pubmed">32737620</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramanik KK, Mishra R. ERK-mediated upregulation of matrix metalloproteinase-2 promotes the invasiveness in human oral squamous cell carcinoma (OSCC) Exp Cell Res. 2022;411:112984.</Citation><ArticleIdList><ArticleId IdType="pubmed">34951997</ArticleId></ArticleIdList></Reference><Reference><Citation>Song X, Wang Y, Du H, Fan Y, Yang X, Wang X, et al. Overexpression of HepaCAM inhibits cell viability and motility through suppressing nucleus translocation of androgen receptor and ERK signaling in prostate cancer. Prostate. 2014;74:1023&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">24811146</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavathiotis E, Reyna DE, Davis ML, Bird GH, Walensky LD. BH3-triggered structural reorganization drives the activation of proapoptotic BAX. Mol Cell. 2010;40:481&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050027</ArticleId><ArticleId IdType="pubmed">21070973</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleicken S, Landeta O, Landajuela A, Basa&#xf1;ez G, Garc&#xed;a-S&#xe1;ez AJ. Proapoptotic Bax and Bak proteins form stable protein-permeable pores of tunable size. J Biol Chem. 2013;288:33241&#x2013;33252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829170</ArticleId><ArticleId IdType="pubmed">24100034</ArticleId></ArticleIdList></Reference><Reference><Citation>Metur SP, Klionsky DJ. Adaptive immunity at the crossroads of autophagy and metabolism. Cell Mol Immunol. 2021;18:1096&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8093269</ArticleId><ArticleId IdType="pubmed">33785844</ArticleId></ArticleIdList></Reference><Reference><Citation>Deretic V. Autophagy in inflammation, infection, and immunometabolism. Immunity. 2021;54:437&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8026106</ArticleId><ArticleId IdType="pubmed">33691134</ArticleId></ArticleIdList></Reference><Reference><Citation>Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6705396</ArticleId><ArticleId IdType="pubmed">30755690</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao H, Jiang X, Fu H, Yang Y, Jin Q, Zhang W, et al. Exploration of the immune-related long noncoding RNA prognostic signature and inflammatory microenvironment for cervical cancer. Front Pharmacol. 2022;13:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9161697</ArticleId><ArticleId IdType="pubmed">35662687</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Zhu Y, Du R, Pang N, Zhang F, Dong D, et al. Role of regulatory B cells in the progression of cervical cancer. Mediators Inflamm. 2019;2019:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6604409</ArticleId><ArticleId IdType="pubmed">31316301</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38532933</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>Novel biomarkers of inflammation-associated immunity in cervical cancer.</ArticleTitle><Pagination><StartPage>1351736</StartPage><MedlinePgn>1351736</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1351736</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2024.1351736</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Cervical cancer (CC) is a highly malignant gynecological cancer with a direct causal link to inflammation, primarily resulting from persistent high-risk human papillomavirus (HPV) infection. Given the challenges in early detection and mid to late-stage treatment, our research aims to identify inflammation-associated immune biomarkers in CC.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Using a bioinformatics approach combined with experimental validation, we integrated two CC datasets (GSE39001 and GSE63514) in the Gene Expression Omnibus (GEO) to eliminate batch effects. Immune-related inflammation differentially expressed genes (DGEs) were obtained by R language identification.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">This analysis identified 37 inflammation-related DEGs. Subsequently, we discussed the different levels of immune infiltration between CC cases and controls. Weighted gene co-expression network analysis (WGCNA) identified seven immune infiltration-related modules in CC. We identified 15 immune DEGs associated with inflammation at the intersection of these findings. In addition, we constructed a protein interaction network using the String database and screened five hub genes using "CytoHubba": CXC chemokine ligand 8 (CXCL8), CXC chemokine ligand 10 (CXCL10), CX3C chemokine receptor 1 (CX3CR1), Fc gamma receptors 3B (FCGR3B), and SELL. The expression of these five genes in CC was determined by PCR experiments. In addition, we assessed their diagnostic value and further analyzed the association of immune cells with them.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Five inflammation- and immune-related genes were identified, aiming to provide new directions for early diagnosis and mid to late-stage treatment of CC from multiple perspectives.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Zhao, Li, Wen, Li, Bai and Tian.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhao</LastName><ForeName>Weihong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Songquan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yaqin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Zhiyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CIBERSORT</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">differentially expressed inflammation-related genes</Keyword><Keyword MajorTopicYN="N">immune infiltration</Keyword><Keyword MajorTopicYN="N">inflammation-associated immune biomarkers</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>27</Day><Hour>3</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38532933</ArticleId><ArticleId IdType="pmc">PMC10964772</ArticleId><ArticleId IdType="doi">10.3389/fonc.2024.1351736</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209&#x2013;49. doi:&#xa0;10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. (2003) 16 (1):1&#x2013;17. doi:&#xa0;10.1128/CMR.16.1.1-17.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.16.1.1-17.2003</ArticleId><ArticleId IdType="pmc">PMC145302</ArticleId><ArticleId IdType="pubmed">12525422</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeles MA, Mart&#xed;nez-G&#xf3;mez C, Migliorelli F, Voglimacci M, Figurelli J, Motton S, et al. . Novel surgical strategies in the treatment of gynecological Malignancies. Curr Treat Options Oncol. (2018) 19:73. doi:&#xa0;10.1007/s11864-018-0582-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11864-018-0582-5</ArticleId><ArticleId IdType="pubmed">30411170</ArticleId></ArticleIdList></Reference><Reference><Citation>Revathidevi S, Murugan AK, Nakaoka H, Inoue I, Munirajan AK. APOBEC: A molecular driver in cervical cancer pathogenesis. Cancer Lett. (2021) 496:104&#x2013;16. doi:&#xa0;10.1016/j.canlet.2020.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2020.10.004</ArticleId><ArticleId IdType="pmc">PMC7539941</ArticleId><ArticleId IdType="pubmed">33038491</ArticleId></ArticleIdList></Reference><Reference><Citation>Della Fera AN, Warburton A, Coursey TL, Khurana S, McBride AA. Persistent human papillomavirus infection. Viruses. (2021) 13 (2):321. doi:&#xa0;10.3390/v13020321</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020321</ArticleId><ArticleId IdType="pmc">PMC7923415</ArticleId><ArticleId IdType="pubmed">33672465</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamseddine AA, Burman B, Lee NY, Zamarin D, Riaz N. Tumor immunity and immunotherapy for HPV-related cancers. Cancer Discovery. (2021) 11:1896&#x2013;912. doi:&#xa0;10.1158/2159-8290.CD-20-1760</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-1760</ArticleId><ArticleId IdType="pmc">PMC8338882</ArticleId><ArticleId IdType="pubmed">33990345</ArticleId></ArticleIdList></Reference><Reference><Citation>Smola S. Immunopathogenesis of HPV-associated cancers and prospects for immunotherapy. Viruses. (2017) 9 (9):254. doi:&#xa0;10.3390/v9090254</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v9090254</ArticleId><ArticleId IdType="pmc">PMC5618020</ArticleId><ArticleId IdType="pubmed">28895886</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. (2021) 221:107753. doi:&#xa0;10.1016/j.pharmthera.2020.107753</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2020.107753</ArticleId><ArticleId IdType="pmc">PMC8084948</ArticleId><ArticleId IdType="pubmed">33259885</ArticleId></ArticleIdList></Reference><Reference><Citation>Du S, Qian J, Tan S, Li W, Liu P, Zhao J, et al. . Tumor cell-derived exosomes deliver TIE2 protein to macrophages to promote angiogenesis in cervical cancer. Cancer Lett. (2022) 529:168&#x2013;79. doi:&#xa0;10.1016/j.canlet.2022.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2022.01.005</ArticleId><ArticleId IdType="pubmed">35007697</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Nie C-P, Liu X-F, Song B, Yue J-H, Xu J-X, et al. . Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer. J Clin Invest. (2022) 132 (15):e157726. doi:&#xa0;10.1172/JCI157726</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI157726</ArticleId><ArticleId IdType="pmc">PMC9337833</ArticleId><ArticleId IdType="pubmed">35727633</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou Z, Lin S, Qiu J, Ding W, Ren P, Chen D, et al. . Single-nucleus RNA sequencing and spatial transcriptomics reveal the immunological microenvironment of cervical squamous cell carcinoma. Adv Sci (Weinh). (2022) 9:e2203040. doi:&#xa0;10.1002/advs.202203040</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202203040</ArticleId><ArticleId IdType="pmc">PMC9561780</ArticleId><ArticleId IdType="pubmed">35986392</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. (2012) 28:882&#x2013;3. doi:&#xa0;10.1093/bioinformatics/bts034</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts034</ArticleId><ArticleId IdType="pmc">PMC3307112</ArticleId><ArticleId IdType="pubmed">22257669</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. (2019) 37:773&#x2013;82. doi:&#xa0;10.1038/s41587-019-0114-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0114-2</ArticleId><ArticleId IdType="pmc">PMC6610714</ArticleId><ArticleId IdType="pubmed">31061481</ArticleId></ArticleIdList></Reference><Reference><Citation>Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinf. (2011) 12:77. doi:&#xa0;10.1186/1471-2105-12-77</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-77</ArticleId><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference><Reference><Citation>Juneja A, Sehgal A, Mitra AB, Pandey A. A survey on risk factors associated with cervical cancer. Indian J Cancer. (2003) 40:15&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">14716127</ArticleId></ArticleIdList></Reference><Reference><Citation>Guti&#xe9;rrez-Hoya A, Soto-Cruz I. NK cell regulation in cervical cancer and strategies for immunotherapy. Cells. (2021) 10 (11):3104. doi:&#xa0;10.3390/cells10113104</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10113104</ArticleId><ArticleId IdType="pmc">PMC8619016</ArticleId><ArticleId IdType="pubmed">34831327</ArticleId></ArticleIdList></Reference><Reference><Citation>Curty G, de Carvalho PS, Soares MA. The role of the cervicovaginal microbiome on the genesis and as a biomarker of premalignant cervical intraepithelial neoplasia and invasive cervical cancer. Int J Mol Sci. (2019) 21 (1):222. doi:&#xa0;10.3390/ijms21010222</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21010222</ArticleId><ArticleId IdType="pmc">PMC6981542</ArticleId><ArticleId IdType="pubmed">31905652</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Y, Cai X, Shen F, Ma F. HPV post-infection microenvironment and cervical cancer. Cancer Lett. (2021) 497:243&#x2013;54. doi:&#xa0;10.1016/j.canlet.2020.10.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2020.10.034</ArticleId><ArticleId IdType="pubmed">33122098</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EY, Lee Z-H, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev. (2009) 8:379&#x2013;83. doi:&#xa0;10.1016/j.autrev.2008.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2008.12.002</ArticleId><ArticleId IdType="pubmed">19105984</ArticleId></ArticleIdList></Reference><Reference><Citation>Asokan S, Bandapalli OR. CXCL8 signaling in the tumor microenvironment. Adv Exp Med Biol. (2021) 1302:25&#x2013;39. doi:&#xa0;10.1007/978-3-030-62658-7_3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-62658-7_3</ArticleId><ArticleId IdType="pubmed">34286439</ArticleId></ArticleIdList></Reference><Reference><Citation>Cambier S, Gouwy M, Proost P. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention. Cell Mol Immunol. (2023) 20:217&#x2013;51. doi:&#xa0;10.1038/s41423-023-00974-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-023-00974-6</ArticleId><ArticleId IdType="pmc">PMC9890491</ArticleId><ArticleId IdType="pubmed">36725964</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Shuai H, Luo X, Wang X, Guan B. The clinical and prognostic value of CXCL8 in cervical carcinoma patients: immunohistochemical analysis. Biosci Rep. (2017) 37 (5):BSR20171021. doi:&#xa0;10.1042/BSR20171021</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20171021</ArticleId><ArticleId IdType="pmc">PMC5629562</ArticleId><ArticleId IdType="pubmed">28883082</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, He H, Xiao Y, Hasim A, Yuan J, Ye M, et al. . CXCL10 produced by HPV-positive cervical cancer cells stimulates exosomal PDL1 expression by fibroblasts via CXCR3 and JAK-STAT pathways. Front Oncol. (2021) 11:629350. doi:&#xa0;10.3389/fonc.2021.629350</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.629350</ArticleId><ArticleId IdType="pmc">PMC8377428</ArticleId><ArticleId IdType="pubmed">34422627</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Cai J, Du S, Guo Z, Xin B, Wang J, et al. . Fractalkine/CX3CR1 induces apoptosis resistance and proliferation through the activation of the AKT/NF-&#x3ba;B cascade in pancreatic cancer cells. Cell Biochem Funct. (2017) 35:315&#x2013;26. doi:&#xa0;10.1002/cbf.3278</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbf.3278</ArticleId><ArticleId IdType="pubmed">28845524</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue Y, Zhang Q, Sun Z. CX3CR1 acts as a protective biomarker in the tumor microenvironment of colorectal cancer. Front Immunol. (2021) 12:758040. doi:&#xa0;10.3389/fimmu.2021.758040</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.758040</ArticleId><ArticleId IdType="pmc">PMC8818863</ArticleId><ArticleId IdType="pubmed">35140706</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X. Structure and function of ligand CX3CL1 and its receptor CX3CR1 in cancer. Curr Med Chem. (2022) 29:6228&#x2013;46. doi:&#xa0;10.2174/0929867329666220629140540</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867329666220629140540</ArticleId><ArticleId IdType="pubmed">35770395</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagelkerke SQ, Schmidt DE, de Haas M, Kuijpers TW. Genetic variation in low-to-medium-affinity fc&#x3b3; Receptors: functional consequences, disease associations, and opportunities for personalized medicine. Front Immunol. (2019) 10:2237. doi:&#xa0;10.3389/fimmu.2019.02237</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02237</ArticleId><ArticleId IdType="pmc">PMC6786274</ArticleId><ArticleId IdType="pubmed">31632391</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J-Y, Wang C-M, Chang S-W, Cheng C-H, Wu Y-JJ, Lin J-C, et al. . Association of FCGR3A and FCGR3B copy number variations with systemic lupus erythematosus and rheumatoid arthritis in Taiwanese patients. Arthritis Rheumatol. (2014) 66:3113&#x2013;21. doi:&#xa0;10.1002/art.38813</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38813</ArticleId><ArticleId IdType="pmc">PMC4232894</ArticleId><ArticleId IdType="pubmed">25154742</ArticleId></ArticleIdList></Reference><Reference><Citation>Le TM, Nguyen HDT, Lee E, Lee D, Choi YS, Cho J, et al. . Transcriptomic immune profiles can represent the tumor immune microenvironment related to the tumor budding histology in uterine cervical cancer. Genes (Basel). (2022) 13 (8):1405. doi:&#xa0;10.3390/genes13081405</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13081405</ArticleId><ArticleId IdType="pmc">PMC9407871</ArticleId><ArticleId IdType="pubmed">36011316</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Qiu B, Zeng X, Hu L, Huang D, Chen K, et al. . Identification of a tumor microenvironment-related gene signature to improve the prediction of cervical cancer prognosis. Cancer Cell Int. (2021) 21:182. doi:&#xa0;10.1186/s12935-021-01867-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-021-01867-2</ArticleId><ArticleId IdType="pmc">PMC7992856</ArticleId><ArticleId IdType="pubmed">33766042</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y-P, Zhang Y, Lv J-W, Li Y-Q, Wang Y-Q, He Q-M, et al. . Genomic analysis of tumor microenvironment immune types across 14 solid cancer types: immunotherapeutic implications. Theranostics. (2017) 7:3585&#x2013;94. doi:&#xa0;10.7150/thno.21471</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.21471</ArticleId><ArticleId IdType="pmc">PMC5596445</ArticleId><ArticleId IdType="pubmed">28912897</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweis RF, Galsky MD. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Urol Oncol. (2016) 34:556&#x2013;65. doi:&#xa0;10.1016/j.urolonc.2016.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urolonc.2016.10.006</ArticleId><ArticleId IdType="pmc">PMC5709811</ArticleId><ArticleId IdType="pubmed">27836246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C, He H, Liu H, Li R, Chen Y, Qi Y, et al. . Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut. (2019) 68:1764&#x2013;73. doi:&#xa0;10.1136/gutjnl-2018-316324</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2018-316324</ArticleId><ArticleId IdType="pubmed">30661053</ArticleId></ArticleIdList></Reference><Reference><Citation>Li E, Yang X, Du Y, Wang G, Chan DW, Wu D, et al. . CXCL8 associated dendritic cell activation marker expression and recruitment as indicators of favorable outcomes in colorectal cancer. Front Immunol. (2021) 12:667177. doi:&#xa0;10.3389/fimmu.2021.667177</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.667177</ArticleId><ArticleId IdType="pmc">PMC8138166</ArticleId><ArticleId IdType="pubmed">34025668</ArticleId></ArticleIdList></Reference><Reference><Citation>Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. (2018). 50 (12):1&#x2013;11. doi:&#xa0;10.1038/s12276-018-0191-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-018-0191-1</ArticleId><ArticleId IdType="pmc">PMC6292890</ArticleId><ArticleId IdType="pubmed">30546008</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38446431</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2180</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>Carcinogenesis</Title><ISOAbbreviation>Carcinogenesis</ISOAbbreviation></Journal><ArticleTitle>Unfurling the functional association between long intergenic noncoding RNAs (lincRNAs) and HPV16-related cervical cancer pathogenesis through weighted gene co-expression network analysis of differentially expressed lincRNAs and coding genes.</ArticleTitle><Pagination><StartPage>451</StartPage><EndPage>462</EndPage><MedlinePgn>451-462</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/carcin/bgae019</ELocationID><Abstract><AbstractText>Long intergenic noncoding RNAs (lincRNAs) do not overlap annotated coding genes and are located in intergenic regions, as opposed to antisense and sense-intronic lncRNAs, located in genic regions. LincRNAs influence gene expression profiles and are thereby key to disease pathogenesis. In this study, we assessed the association between lincRNAs and HPV16-positive cervical cancer (CaCx) pathogenesis using weighted gene co-expression network analysis (WGCNA) with coding genes, comparing differentially expressed lincRNA and coding genes (DElincGs and DEcGs, respectively) in HPV16-positive patients with CaCx (n&#x2005;=&#x2005;44) with those in HPV-negative healthy individuals (n&#x2005;=&#x2005;34). Our analysis revealed five DElincG modules, co-expressing and correlating with DEcGs. We validated a substantial number of such module-specific correlations in the HPV16-positive cancer TCGA-CESC dataset. Four such modules, displayed significant correlations with patient traits, such as HPV16 physical status, lymph node involvement and overall survival (OS), highlighting a collaborative effect of all genes within specific modules on traits. Using the DAVID bioinformatics knowledgebase, we identified the underlying biological processes associated with these modules as cancer development and progression-associated pathways. Next, we identified the top 10 DElincGs with the highest connectivity within each functional module. Focusing on the prognostic module hub genes, downregulated CTD-2619J13.13 expression was associated with poor patient OS. This lincRNA gene interacted with 25 coding genes of its module and was associated with such biological processes as keratinization loss and keratinocyte differentiation, reflecting severe disease phenotypes. This study has translational relevance in fighting various cancers with high mortality rates in underdeveloped countries.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x2014;for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>Abarna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute of Biomedical Genomics, Kalyani, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Sahana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Institute of Biomedical Genomics, Kalyani, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Abhisikta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute of Biomedical Genomics, Kalyani, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Arnab</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute of Biomedical Genomics, Kalyani, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathai</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tata Medical Center, Kolkata, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhaumik</LastName><ForeName>Jaydip</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Tata Medical Center, Kolkata, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukhopadhyay</LastName><ForeName>Asima</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Kolkata Gynecological Oncology Trials and Translational Research Group, Kolkata, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maitra</LastName><ForeName>Arindam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute of Biomedical Genomics, Kalyani, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biswas</LastName><ForeName>Nidhan K</ForeName><Initials>NK</Initials><Identifier Source="ORCID">0000-0001-7960-3290</Identifier><AffiliationInfo><Affiliation>National Institute of Biomedical Genomics, Kalyani, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sengupta</LastName><ForeName>Sharmila</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2462-5198</Identifier><AffiliationInfo><Affiliation>National Institute of Biomedical Genomics, Kalyani, West Bengal, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BT/Med-II/NIBMG/SyMeC/2014/Vol. II</GrantID><Agency>Department of Biotechnology, Ministry of Science and Technology, Government of India</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Carcinogenesis</MedlineTA><NlmUniqueID>8008055</NlmUniqueID><ISSNLinking>0143-3334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062085" MajorTopicYN="Y">RNA, Long Noncoding</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052162" MajorTopicYN="Y">Human papillomavirus 16</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="Y">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>8</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>6</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>6</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38446431</ArticleId><ArticleId IdType="doi">10.1093/carcin/bgae019</ArticleId><ArticleId IdType="pii">7623214</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38298716</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>HIF-1A as a prognostic biomarker related to invasion, migration and immunosuppression of cervical cancer.</ArticleTitle><Pagination><StartPage>e24664</StartPage><MedlinePgn>e24664</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e24664</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e24664</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The incidence of cervical cancer ranks second among malignant tumors in women, exerting a significant impact on their quality of life and overall well-being. The hypoxic microenvironment plays a pivotal role in the initiation and progression of tumorigenesis. The present study aims to investigate the fundamental genes and pathways associated with the hypoxia-inducible factor (HIF-1A) in cervical cancer, aiming to identify potential downstream targets for diagnostic and therapeutic purposes.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We obtained dataset GSE63514 from the Comprehensive Gene Expression Database (GEO). The dataset comprised of 24 patients in the normal group and 28 patients in the tumor group. Gene set difference analysis (GSVA) and gene set enrichment analysis (GSEA) were used to identify the genes related to HIF-1A expression and the specific signaling pathways involved.The association between HIF-1A and tumor immune infiltration was examined in the TCGA dataset. The WGCAN network was constructed to identify key genes within the blue module, and subsequent gene ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted to determine the pathways and functional annotations associated with HIF-1A. The protein interaction network of the HIF-1A gene was obtained from the STRING database and visualized using Cytoscape in the meantime.The function of HIF-1A and its related gene expression were verified in vivo.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">HIF-1A was a risk factor in both univariate and multivariate Cox regression analysis of cervical cancer patients. A total of 344 genes significantly correlated with the expression of HIF-1A were identified through correlation analysis, and the genes exhibiting the strongest correlation were obtained. The major signaling pathways involved in HIF-1A encompass TNF-&#x3b1;/NF-&#x3ba;B, PI3K/AKT/MTOR, TGF-&#x3b2;, JAK-STAT, and various other signaling cascades. Reinforced by qRT-PCR, we identified Integrin beta-1 (ITGB1), C-C motif chemokine ligand 2 (CCL2), striatin 3 (STRN3), and endothelin-1 (EDN1) as pivotal downstream genes influenced by HIF-1A. HIF-1A is associated with immune infiltration of natural killer (NK) cells, mast cells, CD4<sup>+</sup>T cells, M0 macrophages, neutrophils, follicular helper T cells, CD8<sup>+</sup>T cells, and regulatory T cells (Treg). HIF-1A is associated with sensitivity to chemotherapy drugs. The identification of the HIF-1A pathway and its function primarily focuses on cytoplasmic translation, aerobic respiration, cellular respiration, oxidative phosphorylation, thermogenesis, among others. The results of in vivo experiments have confirmed that HIF-1A plays a crucial role in promoting the migration and invasion of cervical cancer cells. Moreover, the overexpression of HIF-1A led to an upregulation in the expressions of ITGB1, CCL2, STRN3, and EDN1.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The role of HIF-1A in cervical cancer was determined through a combination of bioinformatics analysis and experimental validation. The genes potentially implicated in the tumorigenesis mechanism of HIF-1A were identified. These findings has the potential to enhance our comprehension of the progression of cervical cancer and offer promising therapeutic targets for its clinical management.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhenyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Shunyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Oncology &amp;Hematology, Xishan People's Hospital of Wuxi City, Wuxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Lingsuo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Differential gene</Keyword><Keyword MajorTopicYN="N">Epithelial mesenchymal transformation</Keyword><Keyword MajorTopicYN="N">HIF-1A</Keyword><Keyword MajorTopicYN="N">Hypoxia</Keyword><Keyword MajorTopicYN="N">Immune infiltration</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>1</Day><Hour>4</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38298716</ArticleId><ArticleId IdType="pmc">PMC10828096</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e24664</ArticleId><ArticleId IdType="pii">S2405-8440(24)00695-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singh D., Vignat J., Lorenzoni V., Eslahi M., Ginsburg O., Lauby-Secretan B., Arbyn M., Basu P., Bray F., Vaccarella S. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Global Health. 2023;11(2):e197&#x2013;e206. doi: 10.1016/S2214-109X(22)00501-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00501-0</ArticleId><ArticleId IdType="pmc">PMC9848409</ArticleId><ArticleId IdType="pubmed">36528031</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Yu G., Yang Y., Wang Y., Guo M., Yin Q., Yan C., Tian J., Fu F., Wang H. A small-molecule inhibitor of MDMX suppresses cervical cancer cells via the inhibition of E6-E6AP-p53 axis. Pharmacol. Res. 2022:177.</Citation><ArticleIdList><ArticleId IdType="pubmed">35150860</ArticleId></ArticleIdList></Reference><Reference><Citation>Buskwofie A., David-West G., Clare C.A. A review of cervical cancer: incidence and disparities. J. Natl. Med. Assoc. 2020;112(2):229&#x2013;232. doi: 10.1016/j.jnma.2020.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnma.2020.03.002</ArticleId><ArticleId IdType="pubmed">32278478</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x141;uczak M. Increased expression of HIF-1A and its implication in the hypoxia pathway in primary advanced uterine cervical carcinoma. Oncol. Rep. 2011 doi: 10.3892/or.2011.1397.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2011.1397</ArticleId><ArticleId IdType="pubmed">21887475</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiga D., Bhat S., Chakrabarty S., Kabekkodu S.P. DOC2B is a negative regulator of Wnt/&#x3b2;-catenin signaling pathway in cervical cancer. Pharmacol. Res. 2022:180. doi: 10.1016/j.phrs.2022.106239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2022.106239</ArticleId><ArticleId IdType="pubmed">35500882</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X., Chen M., Zhang Y., Li L., Peng Y., Li J., Zhou W. Hemin-incorporating DNA nanozyme enabling catalytic oxygenation and GSH depletion for enhanced photodynamic therapy and synergistic tumor ferroptosis. J. Nanobiotechnol. 2022;20(1) doi: 10.1186/s12951-022-01617-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-022-01617-0</ArticleId><ArticleId IdType="pmc">PMC9479271</ArticleId><ArticleId IdType="pubmed">36109814</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu K., Li J., Wang Z., Yan Y., Cai Y., Peng B., Huang J., He D., Zhou L., Xu Z., et al. BTB/POZ domain&#x2010;containing protein 7/hypoxia&#x2010;inducible factor 1 alpha signalling axis modulates hepatocellular carcinoma metastasis. Clin. Transl. Med. 2021;11(10) doi: 10.1002/ctm2.556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.556</ArticleId><ArticleId IdType="pmc">PMC8506631</ArticleId><ArticleId IdType="pubmed">34709740</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M., Zhong K., Tan J., Meng M., Liu C.M., Chen B., Huang C., Wong H.L.X., Bian Z., Su T., et al. Baicalein is a novel TLR4&#x2010;targeting therapeutics agent that inhibits TLR4/HIF&#x2010;1&#x3b1;/VEGF signaling pathway in colorectal cancer. Clin. Transl. Med. 2021;11(11) doi: 10.1002/ctm2.564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.564</ArticleId><ArticleId IdType="pmc">PMC8567042</ArticleId><ArticleId IdType="pubmed">34841696</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Hu X., Feng L., Lin Y., Liang S., Zhu Z., Shi S., Dong C. Carbonic anhydrase IX-targeted H-APBC nanosystem combined with phototherapy facilitates the efficacy of PI3K/mTOR inhibitor and resists HIF-1&#x3b1;-dependent tumor hypoxia adaptation. J. Nanobiotechnol. 2022;20(1) doi: 10.1186/s12951-022-01394-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-022-01394-w</ArticleId><ArticleId IdType="pmc">PMC9004111</ArticleId><ArticleId IdType="pubmed">35413842</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Xing C., Deng Y., Ye C., Peng H. HIF-1&#x3b1; signaling: essential roles in tumorigenesis and implications in targeted therapies. Genes &amp; Diseases. 2024;11(1):234&#x2013;251. doi: 10.1016/j.gendis.2023.02.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gendis.2023.02.039</ArticleId><ArticleId IdType="pmc">PMC10425810</ArticleId><ArticleId IdType="pubmed">37588219</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Wang Y., Dou C., Xu M., Sun L., Wang L., Yao B., Li Q., Yang W., Tu K., et al. Hypoxia-induced up-regulation of VASP promotes invasiveness and metastasis of hepatocellular carcinoma. Theranostics. 2018;8(17):4649&#x2013;4663. doi: 10.7150/thno.26789.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.26789</ArticleId><ArticleId IdType="pmc">PMC6160773</ArticleId><ArticleId IdType="pubmed">30279729</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q., You L., Nepovimova E., Heger Z., Wu W., Kuca K., Adam V. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J. Hematol. Oncol. 2022;15(1) doi: 10.1186/s13045-022-01292-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-022-01292-6</ArticleId><ArticleId IdType="pmc">PMC9166526</ArticleId><ArticleId IdType="pubmed">35659268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonneville Russell, et al. Landscape of microsatellite instability across 39 cancer types. JCO precision oncology. 2017;2017 doi: 10.1200/PO.17.00073. PO.17.00073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/PO.17.00073</ArticleId><ArticleId IdType="pmc">PMC5972025</ArticleId><ArticleId IdType="pubmed">29850653</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsson V., Gibbs D.L., Brown S.D., Wolf D., Bortone D.S., Ou Yang T.-H., Porta-Pardo E., Gao G.F., Plaisier C.L., Eddy J.A., et al. The immune landscape of cancer. Immunity. 2018;48(4):812&#x2013;830. doi: 10.1016/j.immuni.2018.03.023. e814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.03.023</ArticleId><ArticleId IdType="pmc">PMC5982584</ArticleId><ArticleId IdType="pubmed">29628290</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225&#x2013;239. doi: 10.1007/s10555-007-9055-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10555-007-9055-1</ArticleId><ArticleId IdType="pubmed">17440684</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh J.C., Lebedev A., Aten E., Madsen K., Marciano L., Kolb H.C. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxidants Redox Signal. 2014;21(10):1516&#x2013;1554. doi: 10.1089/ars.2013.5378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2013.5378</ArticleId><ArticleId IdType="pmc">PMC4159937</ArticleId><ArticleId IdType="pubmed">24512032</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirpe A.A., Gulei D., Ciortea S.M., Crivii C., Berindan-Neagoe I. Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. Int. J. Mol. Sci. 2019;20(24) doi: 10.3390/ijms20246140.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20246140</ArticleId><ArticleId IdType="pmc">PMC6941045</ArticleId><ArticleId IdType="pubmed">31817513</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Shen J., Wang Z., Xu H., Wang Q., Chai S., Fu P., Huang T., Anas O., Zhao H., et al. ELTD1 facilitates glioma proliferation, migration and invasion by activating JAK/STAT3/HIF-1&#x3b1; signaling axis. Sci. Rep. 2019;9(1) doi: 10.1038/s41598-019-50375-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-50375-x</ArticleId><ArticleId IdType="pmc">PMC6761139</ArticleId><ArticleId IdType="pubmed">31554859</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagao A., Kobayashi M., Koyasu S., Chow C.C.T., Harada H. HIF-1-Dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance. Int. J. Mol. Sci. 2019;20(2) doi: 10.3390/ijms20020238.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20020238</ArticleId><ArticleId IdType="pmc">PMC6359724</ArticleId><ArticleId IdType="pubmed">30634433</ArticleId></ArticleIdList></Reference><Reference><Citation>Paredes F., Williams H.C., San Martin A. Metabolic adaptation in hypoxia and cancer. Cancer Lett. 2021;502:133&#x2013;142. doi: 10.1016/j.canlet.2020.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2020.12.020</ArticleId><ArticleId IdType="pmc">PMC8158653</ArticleId><ArticleId IdType="pubmed">33444690</ArticleId></ArticleIdList></Reference><Reference><Citation>Infantino V., Santarsiero A., Convertini P., Todisco S., Iacobazzi V. Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target. Int. J. Mol. Sci. 2021;22(11) doi: 10.3390/ijms22115703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22115703</ArticleId><ArticleId IdType="pmc">PMC8199012</ArticleId><ArticleId IdType="pubmed">34071836</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo J., Jeong D.-W., Park J.-W., Lee K.-W., Fukuda J., Chun Y.-S. Fatty-acid-induced FABP5/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells. Commun. Biol. 2020;3(1) doi: 10.1038/s42003-020-01367-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-01367-5</ArticleId><ArticleId IdType="pmc">PMC7599230</ArticleId><ArticleId IdType="pubmed">33128030</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Fuxing, et al. Signatures of immune cell infiltration for predicting immune escape and immunotherapy in cervical cancer. Aging. 2023;15(5):1685&#x2013;1698. doi: 10.18632/aging.204583.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.204583</ArticleId><ArticleId IdType="pmc">PMC10042703</ArticleId><ArticleId IdType="pubmed">36917087</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuillefroy de Silly R., Dietrich P.-Y., Walker P.R. Hypoxia and antitumor CD8+ T cells: an incompatible alliance? OncoImmunology. 2016;5(12) doi: 10.1080/2162402X.2016.1232236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2016.1232236</ArticleId><ArticleId IdType="pmc">PMC5214994</ArticleId><ArticleId IdType="pubmed">28123871</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia I., Rowe J.H., Johnson S., Joshi S., Notarangelo G., Kurmi K., Weiss S., Freeman G.J., Sharpe A.H., Haigis M.C. Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells. Cell Metabol. 2022;34(8):1137&#x2013;1150. doi: 10.1016/j.cmet.2022.06.008. e1136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2022.06.008</ArticleId><ArticleId IdType="pmc">PMC9357162</ArticleId><ArticleId IdType="pubmed">35820416</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim A.R., Rathmell W.K., Rathmell J.C. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. Elife. 2020;9 doi: 10.7554/eLife.55185.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.55185</ArticleId><ArticleId IdType="pmc">PMC7200151</ArticleId><ArticleId IdType="pubmed">32367803</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J., Hsueh P.-C., Li Z., Ho P.-C. Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunity. Immunity. 2023;56(1):32&#x2013;42. doi: 10.1016/j.immuni.2022.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.12.008</ArticleId><ArticleId IdType="pubmed">36630916</ArticleId></ArticleIdList></Reference><Reference><Citation>Melaiu O., Lucarini V., Cifaldi L., Fruci D. Influence of the tumor microenvironment on NK cell function in solid tumors. Front. Immunol. 2020:10. doi: 10.3389/fimmu.2019.03038.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.03038</ArticleId><ArticleId IdType="pmc">PMC6985149</ArticleId><ArticleId IdType="pubmed">32038612</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni J., Wang X., Stojanovic A., Zhang Q., Wincher M., B&#xfc;hler L., Arnold A., Correia M.P., Winkler M., Koch P.-S., et al. Single-cell RNA sequencing of tumor-infiltrating NK cells reveals that inhibition of transcription factor HIF-1&#x3b1; unleashes NK cell activity. Immunity. 2020;52(6):1075&#x2013;1087. doi: 10.1016/j.immuni.2020.05.001. e1078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.05.001</ArticleId><ArticleId IdType="pubmed">32445619</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J.H., Zappasodi R. Modulating Treg stability to improve cancer immunotherapy. Trends in Cancer. 2023;9(11):911&#x2013;927. doi: 10.1016/j.trecan.2023.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trecan.2023.07.015</ArticleId><ArticleId IdType="pubmed">37598003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu T.-S., Lai M.-Z. Hypoxia-inducible factor 1&#x3b1; plays a predominantly negative role in regulatory T cell functions. J. Leukoc. Biol. 2018;104(5):911&#x2013;918. doi: 10.1002/JLB.MR1217-481R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.MR1217-481R</ArticleId><ArticleId IdType="pubmed">29901858</ArticleId></ArticleIdList></Reference><Reference><Citation>Guti&#xe9;rrez-Melo N., Baumjohann D. T follicular helper cells in cancer. Trends in Cancer. 2023;9(4):309&#x2013;325. doi: 10.1016/j.trecan.2022.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trecan.2022.12.007</ArticleId><ArticleId IdType="pubmed">36642575</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong, He Zhou, Cao Li, Bi Liu. HIF1&#x3b1;-Dependent metabolic signals control the differentiation of follicular helper T cells. Cells. 2019;8(11) doi: 10.3390/cells8111450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8111450</ArticleId><ArticleId IdType="pmc">PMC6912655</ArticleId><ArticleId IdType="pubmed">31744227</ArticleId></ArticleIdList></Reference><Reference><Citation>Segura-Villalobos D., Ram&#xed;rez-Moreno I.G., Mart&#xed;nez-Aguilar M., Ibarra-S&#xe1;nchez A., Mu&#xf1;oz-Bello J.O., Anaya-Rubio I., Padilla A., Mac&#xed;as-Silva M., Lizano M., Gonz&#xe1;lez-Espinosa C. Mast cell&#x2013;tumor interactions: molecular mechanisms of recruitment, intratumoral communication and potential therapeutic targets for tumor growth. Cells. 2022;11(3) doi: 10.3390/cells11030349.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11030349</ArticleId><ArticleId IdType="pmc">PMC8834237</ArticleId><ArticleId IdType="pubmed">35159157</ArticleId></ArticleIdList></Reference><Reference><Citation>Bereswill S., Yang Z., Zhang B., Li D., Lv M., Huang C., Shen G.-X., Huang B. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS One. 2010;5(1) doi: 10.1371/journal.pone.0008922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008922</ArticleId><ArticleId IdType="pmc">PMC2811741</ArticleId><ArticleId IdType="pubmed">20111717</ArticleId></ArticleIdList></Reference><Reference><Citation>Mempel T.R., Lill J.K., Altenburger L.M. How chemokines organize the tumour microenvironment. Nat. Rev. Cancer. 2023 doi: 10.1038/s41568-023-00635-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-023-00635-w</ArticleId><ArticleId IdType="pubmed">38066335</ArticleId></ArticleIdList></Reference><Reference><Citation>Korbecki J., Kojder K., Barczak K., Simi&#x144;ska D., Gutowska I., Chlubek D., Baranowska-Bosiacka I. Hypoxia alters the expression of CC chemokines and CC chemokine receptors in a tumor&#x2013;A literature review. Int. J. Mol. Sci. 2020;21(16) doi: 10.3390/ijms21165647.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21165647</ArticleId><ArticleId IdType="pmc">PMC7460668</ArticleId><ArticleId IdType="pubmed">32781743</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X.-J., Deng Y.-R., Wang Z.-C., Wei W.-F., Zhou C.-F., Zhang Y.-M., Yan R.-M., Liang L.-J., Zhong M., Liang L., et al. Hypoxia-induced ZEB1 promotes cervical cancer progression via CCL8-dependent tumour-associated macrophage recruitment. Cell Death Dis. 2019;10(7) doi: 10.1038/s41419-019-1748-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1748-1</ArticleId><ArticleId IdType="pmc">PMC6602971</ArticleId><ArticleId IdType="pubmed">31263103</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora L., Patra D., Roy S., Nanda S., Singh N., Verma A.K., Chakraborti A., Dasgupta S., Pal D. Hypoxia&#x2010;induced miR&#x2010;210&#x2010;3p expression in lung adenocarcinoma potentiates tumor development by regulating CCL2&#x2010;mediated monocyte infiltration. Mol. Oncol. 2022 doi: 10.1002/1878-0261.13260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1878-0261.13260</ArticleId><ArticleId IdType="pmc">PMC11077004</ArticleId><ArticleId IdType="pubmed">35658112</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu M., Hu Y., Lan T., Guan K.-L., Luo T., Luo M. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct. Targeted Ther. 2022;7(1) doi: 10.1038/s41392-022-01191-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01191-9</ArticleId><ArticleId IdType="pmc">PMC9643504</ArticleId><ArticleId IdType="pubmed">36347846</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., Fang G., Guo F., Zhang H., Chen X., An L., Chen M., Zhou L., Wang W., Ye T., et al. Selective inhibition of STRN3-containing PP2A phosphatase restores Hippo tumor-suppressor activity in gastric cancer. Cancer Cell. 2020;38(1):115&#x2013;128. doi: 10.1016/j.ccell.2020.05.019. e119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2020.05.019</ArticleId><ArticleId IdType="pubmed">32589942</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Xiao-Hui, et al. Hypoxic glioma cell-secreted exosomal circ101491 promotes the progression of glioma by regulating miR-125b-5p/EDN1. Brain Res. Bull. 2023;195:55&#x2013;65. doi: 10.1016/j.brainresbull.2023.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2023.02.006</ArticleId><ArticleId IdType="pubmed">36796652</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianconi D., Unseld M., Prager G. Integrins in the spotlight of cancer. Int. J. Mol. Sci. 2016;17(12) doi: 10.3390/ijms17122037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms17122037</ArticleId><ArticleId IdType="pmc">PMC5187837</ArticleId><ArticleId IdType="pubmed">27929432</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Hou Y., Zhou M., Wen S., Zhou J., Xu L., Tang X., Du Y-e, Hu P., Liu M. Twist induces epithelial-mesenchymal transition and cell motility in breast cancer via ITGB1-FAK/ILK signaling axis and its associated downstream network. Int. J. Biochem. Cell Biol. 2016;71:62&#x2013;71. doi: 10.1016/j.biocel.2015.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2015.12.004</ArticleId><ArticleId IdType="pubmed">26693891</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Li T. Ropivacaine inhibits the proliferation and migration of colorectal cancer cells through ITGB1. Bioengineered. 2020;1(1):44&#x2013;53. doi: 10.1080/21655979.2020.1857120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2020.1857120</ArticleId><ArticleId IdType="pmc">PMC8806321</ArticleId><ArticleId IdType="pubmed">33345684</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020;468:72&#x2013;81. doi: 10.1016/j.canlet.2019.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2019.10.013</ArticleId><ArticleId IdType="pubmed">31605776</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang H., Zhou Z., Ma Z., Li Z., Liu C., Huang S., Zhang C., Hou B. Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer. J. Cell Mol. Med. 2020;24(22):13481&#x2013;13493. doi: 10.1111/jcmm.15990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15990</ArticleId><ArticleId IdType="pmc">PMC7701563</ArticleId><ArticleId IdType="pubmed">33073486</ArticleId></ArticleIdList></Reference><Reference><Citation>Urner S., Planas&#x2010;Paz L., Hilger L.S., Henning C., Branopolski A., Kelly&#x2010;Goss M., Stanczuk L., Pitter B., Montanez E., Peirce S.M., et al. Identification of ILK as a critical regulator of VEGFR3 signalling and lymphatic vascular growth. EMBO J. 2018;38(2) doi: 10.15252/embj.201899322.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201899322</ArticleId><ArticleId IdType="pmc">PMC6331728</ArticleId><ArticleId IdType="pubmed">30518533</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q., Xie Z., Yan C., Ding Y., Ma Z., Wu S., Qiu Y., Cossette S.M., Bordas M., Ramchandran R., et al. SNRK (sucrose nonfermenting 1-related kinase) promotes angiogenesis in vivo. Arterioscler. Thromb. Vasc. Biol. 2018;38(2):373&#x2013;385. doi: 10.1161/ATVBAHA.117.309834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.117.309834</ArticleId><ArticleId IdType="pmc">PMC5785416</ArticleId><ArticleId IdType="pubmed">29242271</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun R., Yuan L., Jiang Y., Wan Y., Ma X., Yang J., Sun G., Zhou S., Wang H., Qiu J., et al. ALKBH5 activates FAK signaling through m6A demethylation in ITGB1 mRNA and enhances tumor-associated lymphangiogenesis and lymph node metastasis in ovarian cancer. Theranostics. 2023;13(2):833&#x2013;848. doi: 10.7150/thno.77441.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.77441</ArticleId><ArticleId IdType="pmc">PMC9830429</ArticleId><ArticleId IdType="pubmed">36632222</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao X-g, Xue X-y, Lv R., Ji A., Shi T-y, Chen X-y, Jiang X-f, Zhang X. CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway. Cell Death Dis. 2023;14(4) doi: 10.1038/s41419-023-05788-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-023-05788-y</ArticleId><ArticleId IdType="pmc">PMC10104878</ArticleId><ArticleId IdType="pubmed">37059730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda R., Kawahara A., Watari K., Murakami Y., Sonoda K., Maeda M., Fujita H., Kage M., Uramoto H., Costa C., et al. Erlotinib resistance in lung cancer cells mediated by integrin &#x3b2;1/src/akt-driven bypass signaling. Cancer Res. 2013;73(20):6243&#x2013;6253. doi: 10.1158/0008-5472.CAN-12-4502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-12-4502</ArticleId><ArticleId IdType="pubmed">23872583</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbonell W.S., DeLay M., Jahangiri A., Park C.C., Aghi M.K. &#x3b2;1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res. 2013;73(10):3145&#x2013;3154. doi: 10.1158/0008-5472.CAN-13-0011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-13-0011</ArticleId><ArticleId IdType="pmc">PMC4040366</ArticleId><ArticleId IdType="pubmed">23644530</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D., Tang Y., Fu H., Xu J., Hu Z., Zhang Y., Cai Q. Integrin &#x3b2;1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110&#x3b2; signaling. Biochem. Biophys. Res. Commun. 2018;505(1):215&#x2013;221. doi: 10.1016/j.bbrc.2018.09.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2018.09.061</ArticleId><ArticleId IdType="pubmed">30243721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju L., Zhou C., Li W., Yan L. Integrin beta1 over&#x2010;expression associates with resistance to tyrosine kinase inhibitor gefitinib in non&#x2010;small cell lung cancer. J. Cell. Biochem. 2010;111(6):1565&#x2013;1574. doi: 10.1002/jcb.22888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.22888</ArticleId><ArticleId IdType="pubmed">21053345</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Sun C., Tan Y., Zhang H., Li Y., Zou H. ITGB1 enhances the radioresistance of human non-small cell lung cancer cells by modulating the DNA damage response and YAP1-induced epithelial-mesenchymal transition. Int. J. Biol. Sci. 2021;17(2):635&#x2013;650. doi: 10.7150/ijbs.52319.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.52319</ArticleId><ArticleId IdType="pmc">PMC7893583</ArticleId><ArticleId IdType="pubmed">33613118</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Zhang S., Gao S., Ma Y., Tan X., Kang Y., Ren W. p&gt;HIF-1&#x3b1;, TWIST-1 and ITGB-1, associated with tumor stiffness, as novel predictive markers for the pathological response to neoadjuvant chemotherapy in breast cancer&lt;/p&gt;. Cancer Manag. Res. 2020;12:2209&#x2013;2222. doi: 10.2147/CMAR.S246349.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CMAR.S246349</ArticleId><ArticleId IdType="pmc">PMC7102918</ArticleId><ArticleId IdType="pubmed">32273760</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H.-Y., Yuan Y., Fu Y.-H., Wang Y., Gao X.-Y. Hypoxia-inducible factor-1&#x3b1;: a promising therapeutic target for vasculopathy in diabetic retinopathy. Pharmacol. Res. 2020;159 doi: 10.1016/j.phrs.2020.104924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104924</ArticleId><ArticleId IdType="pubmed">32464323</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H.J., Sivaraman A., Kim M., Min K.H., Song M.E., Choi Y., Choi W.-J., Han H.-K., Han J., Jang J.-P., et al. HIF-1&#x3b1; inhibition by MO-2097, a novel chiral-free benzofuran targeting hnRNPA2B1. J. Adv. Res. 2023 doi: 10.1016/j.jare.2023.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jare.2023.11.016</ArticleId><ArticleId IdType="pubmed">37977260</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng L., Cheng Y., Tong X., Gan S., Ding Y., Zhang Y., Wang C., Xu L., Zhu Y., Wu J., et al. Tumor oxygenation and hypoxia inducible factor-1 functional inhibition via a reactive oxygen species responsive nanoplatform for enhancing radiation therapy and abscopal effects. ACS Nano. 2018;12(8):8308&#x2013;8322. doi: 10.1021/acsnano.8b03590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.8b03590</ArticleId><ArticleId IdType="pubmed">30102510</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeber L.M.S., Horr&#xe9;e N., Vooijs M.A.G.G., Heintz A.P.M., van der Wall E., Verheijen R.H.M., van Diest P.J. The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit. Rev. Oncol. Hematol. 2011;78(3):173&#x2013;184. doi: 10.1016/j.critrevonc.2010.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2010.05.003</ArticleId><ArticleId IdType="pubmed">20627616</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38205938</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2045-7634</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Cancer medicine</Title><ISOAbbreviation>Cancer Med</ISOAbbreviation></Journal><ArticleTitle>HPV16 E6 promoting cervical cancer progression through down-regulation of miR-320a to increase TOP2A expression.</ArticleTitle><Pagination><StartPage>e6875</StartPage><MedlinePgn>e6875</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e6875</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.6875</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cervical cancer (CC) has become the fourth most common cancer worldwide and it is mainly caused by the infection of human papillomavirus (HPV), especially high-risk HPV16. Aberrant miRNA expression in CC is closely related to HPV16 infection, and the regulation of HPV16 E6 expression can affect a variety of miRNA expression. This study aims to exploring the miRNAs involved in E6 regulation in CC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Our study screened differentially expressed miRNAs in cervical cells of HPV16 infected and uninfected cervical cancer patients by analyzing the GSE81137 dataset of the gene expression omnibus database (GEO), and identified miR-320a that plays an anti-tumor role and is associated with good prognosis of cervical cancer. Explore the effect of HPV16 E6 on the expression of miR-320a in cervical cancer, and verify whether HPV16 E6 regulates the downstream target gene TOP2A expression through miR-320a, thereby affecting cervical cancer cell proliferation, apoptosis, migration, invasion, and EMT in&#xa0;vitro and in&#xa0;vivo.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The bioinformatic methods selected the miR-320a, which was differentially expressed in cervical cells from HPV16-infected patients compared to uninfected patients. We further demonstrated that miR-320a level was regulated by HPV16 E6, which promoted the CC cell proliferation, migration, invasion, and inhibited apoptosis. In addition, we predicted the downstream target genes of miR-320a and confirmed that TOP2A was one of its targeting proteins. Moreover, HPV16 E6 promoted the TOP2A expression in CC cells through down-regulating miR-320a, leading to promoting CC development.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We confirmed that HPV16 E6 promoted the TOP2A expression through down-regulation of miR-320a, thus promoting CC development, and the HPV16 E6/miR-320a/TOP2A axis may perform as a potential target for CC treatment.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jianing</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0004-7787-7625</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, Dalian Women and Children's Medical Group, Dalian, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Dalian Women and Children's Medical Group, Dalian, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Hospital of China Medical University, Shenyang, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Daqing</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Dalian Women and Children's Medical Group, Dalian, Liaoning, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81572054</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Med</MedlineTA><NlmUniqueID>101595310</NlmUniqueID><ISSNLinking>2045-7634</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000726528">MIRN320A microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.99.1.3</RegistryNumber><NameOfSubstance UI="C000618811">TOP2A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052162" MajorTopicYN="N">Human papillomavirus 16</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HPV16 E6</Keyword><Keyword MajorTopicYN="N">TOP2A</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">invasion</Keyword><Keyword MajorTopicYN="N">miR-320a</Keyword><Keyword MajorTopicYN="N">migration</Keyword><Keyword MajorTopicYN="N">proliferation</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>11</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>11</Day><Hour>8</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38205938</ArticleId><ArticleId IdType="pmc">PMC10905336</ArticleId><ArticleId IdType="doi">10.1002/cam4.6875</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, et&#xa0;al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021;71(3):209&#x2010;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler TA. Cervical cancer: prevention and early detection. Seminars in Oncology Nursing. Vol 33. Elsevier; 2017:172&#x2010;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">28343836</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha AD, Neupane D, Vedsted P, Kallestrup P. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pacific J Cancer Prevent. 2018;19(2):319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5980914</ArticleId><ArticleId IdType="pubmed">29479954</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiga D, Eswaran S, Pandey D, Sharan K, Kabekkodu SP. Molecular landscape of recurrent cervical cancer. Crit Rev Oncol/Hematol. 2021;157:103178.</Citation><ArticleIdList><ArticleId IdType="pubmed">33279812</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson CA, James D, Marzan A, Armaos M. Cervical cancer: an overview of pathophysiology and management. Seminars in Oncology Nursing. Vol 35. Elsevier; 2019:166&#x2010;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">30878194</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannach C, Brinkert P, Kuhling L, Greune L, Schmidt MA, Schelhaas M. Epidermal growth factor receptor and Abl2 kinase regulate distinct steps of human papillomavirus 16 endocytosis. J Virol. 2020;94(11):1&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269448</ArticleId><ArticleId IdType="pubmed">32188731</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV&#x2010;related disease. Best Pract Res Clin Obstet Gynaecol. 2018;47:14&#x2010;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">29037457</ArticleId></ArticleIdList></Reference><Reference><Citation>Szymonowicz KA, Chen J. Biological and clinical aspects of HPV&#x2010;related cancers. Cancer Biol Med. 2020;17(4):864&#x2010;878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7721094</ArticleId><ArticleId IdType="pubmed">33299640</ArticleId></ArticleIdList></Reference><Reference><Citation>Basukala O, Banks L. The not&#x2010;so&#x2010;good, the bad and the ugly: HPV E5, E6 and E7 oncoproteins in the orchestration of carcinogenesis. Viruses. 2021;13(10):1892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8541208</ArticleId><ArticleId IdType="pubmed">34696321</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y&#x2010;F, Yan G&#x2010;J, Liu G&#x2010;C, et&#xa0;al. HPV16 E6 promotes the progression of HPV infection&#x2010;associated cervical cancer by upregulating glucose&#x2010;6&#x2010;phosphate dehydrogenase expression. Front Oncol. 2021;11:718781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8529275</ArticleId><ArticleId IdType="pubmed">34692493</ArticleId></ArticleIdList></Reference><Reference><Citation>Honegger A, Schilling D, S&#xfc;ltmann H, Hoppe&#x2010;Seyler K, Hoppe&#x2010;Seyler F. Identification of E6/E7&#x2010;dependent MicroRNAs in HPV&#x2010;positive cancer cells. MicroRNA Cancer: Methods Protocol. 2018;1699:119&#x2010;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">29086374</ArticleId></ArticleIdList></Reference><Reference><Citation>Laszlo B, Antal L, Gyongyosi E, et&#xa0;al. Coordinated action of human papillomavirus type 16 E6 and E7 oncoproteins on competitive endogenous RNA (ceRNA) network members in primary human keratinocytes. BMC Cancer. 2021;21(1):673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185923</ArticleId><ArticleId IdType="pubmed">34098875</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Wang N, Ren L, Tian J, Yang S, Cheng H. MiR&#x2010;125a&#x2010;5p post&#x2010;transcriptionally suppresses GALNT7 to inhibit proliferation and invasion in cervical cancer cells via the EGFR/PI3K/AKT pathway. Cancer Cell Int. 2020;20(3):117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147043</ArticleId><ArticleId IdType="pubmed">32308562</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Han S. MiR&#x2010;150&#x2010;5p promotes the proliferation and epithelial&#x2010;mesenchymal transition of cervical carcinoma cells via targeting SRCIN1. Pathol Res Pract. 2019;215(4):738&#x2010;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">30679084</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkova LV, Pashov AI, Omelchuk NN. Cervical carcinoma: oncobiology and biomarkers. Int J Mol Sci. 2021;22(22):125&#x2010;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8624663</ArticleId><ArticleId IdType="pubmed">34830452</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Hu H, Luo Z, et&#xa0;al. miR&#x2010;4454 up&#x2010;regulated by HPV16 E6/E7 promotes invasion and migration by targeting ABHD2/NUDT21 in cervical cancer. Biosci Rep. 2020;40(9):BSR20200796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7468098</ArticleId><ArticleId IdType="pubmed">32816024</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Lai Y, Sun Y, et&#xa0;al. HPV16 E6 regulates the proliferation, invasion, and apoptosis of cervical cancer cells by downregulating miR&#x2010;504. Transl Cancer Res. 2020;9(12):7588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8799100</ArticleId><ArticleId IdType="pubmed">35117358</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing S, Tian Z, Zheng W, et&#xa0;al. Hypoxia downregulated miR&#x2010;4521 suppresses gastric carcinoma progression through regulation of IGF2 and FOXM1. Mol Cancer. 2021;20(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7786912</ArticleId><ArticleId IdType="pubmed">33407516</ArticleId></ArticleIdList></Reference><Reference><Citation>McCreight JC, Schneider SE, Wilburn DB, Swanson WJ. Evolution of microRNA in primates. PLoS One. 2017;12(6):e0176596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5480830</ArticleId><ArticleId IdType="pubmed">28640911</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi C, Zhang Z. MicroRNA&#x2011;320 suppresses cervical cancer cell viability, migration and invasion via directly targeting FOXM1. Oncol Lett. 2017;14(3):3809&#x2010;3816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5588065</ArticleId><ArticleId IdType="pubmed">28927151</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong H, Zhu H, Zhao S, et&#xa0;al. The novel circCLK3/miR&#x2010;320a/FoxM1 axis promotes cervical cancer progression. Cell Death Dis. 2019;10(12):950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6908646</ArticleId><ArticleId IdType="pubmed">31831728</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z, Tie Y, Lv G, Zhu J, Fu H, Zheng X. Transcriptional activation of miR&#x2010;320a by ATF2, ELK1 and YY1 induces cancer cell apoptosis under ionizing radiation conditions. Int J Oncol. 2018;53(4):1691&#x2010;1702.</Citation><ArticleIdList><ArticleId IdType="pubmed">30066913</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech. 2021;14 4:dmm047662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8077553</ArticleId><ArticleId IdType="pubmed">33973623</ArticleId></ArticleIdList></Reference><Reference><Citation>Peres AL, Paz e Silva KM, de Ara&#xfa;jo RFF, et&#xa0;al. Immunocytochemical study of TOP2A and Ki&#x2010;67 in cervical smears from women under routine gynecological care. J Biomed Sci. 2016;23:1&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4864931</ArticleId><ArticleId IdType="pubmed">27175798</ArticleId></ArticleIdList></Reference><Reference><Citation>Hj Y, Jm X, Li J, Wan L, Yx Z. Identification of key genes and pathways of diagnosis and prognosis in cervical cancer by bioinformatics analysis. Mol Genet Genomic Med. 2020;8(6):e1200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7284022</ArticleId><ArticleId IdType="pubmed">32181600</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, Li H, Zhu L, et&#xa0;al. Bioinformatics analysis shows that TOP2A functions as a key candidate gene in the progression of cervical cancer. Biomed Rep. 2020;13(4):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7403841</ArticleId><ArticleId IdType="pubmed">32765860</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Shen Y, Zou Y, et&#xa0;al. TOP2A Promotes Cell Migration, Invasion and Epithelial&#x2013;Mesenchymal Transition in Cervical Cancer via Activating the PI3K/AKT Signaling. Cancer Manag Res. 2020;12:3807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251484</ArticleId><ArticleId IdType="pubmed">32547216</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian S, Zhang L, Li Y, et&#xa0;al. Human papillomavirus E7 oncoprotein promotes proliferation and migration through the transcription factor E2F1 in cervical cancer cells. Anticancer Agents Med Chem. 2021;21(13):1689&#x2010;1696.</Citation><ArticleIdList><ArticleId IdType="pubmed">33155930</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38021159</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1837-9664</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>18</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of Cancer</Title><ISOAbbreviation>J Cancer</ISOAbbreviation></Journal><ArticleTitle>APOBEC3A suppresses cervical cancer via apoptosis.</ArticleTitle><Pagination><StartPage>3429</StartPage><EndPage>3443</EndPage><MedlinePgn>3429-3443</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/jca.89044</ELocationID><Abstract><AbstractText><b>Background:</b> Family members of Apolipoprotein B mRNA-editing enzyme catalytic 3 (APOBEC3) play critical roles in cancer evolution and development. However, the role of APOBEC3A in cervical cancer remains to be clarified. <b>Methods:</b> We used bioinformatics to investigate APOBEC3A expression and outcomes using The Cancer Genome Atlas (TCGA)-cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) dataset, GTEx, and GSE7803. Immunohistochemistry was then used to identify APOBEC3A's expression pattern. We performed Cell Counting Kit-8, wound-healing, Transwell, and flow cytometry assays to measure proliferation, migration, invasion, and apoptosis, respectively, using the SiHa and HeLa cell lines transfected with APOBEC3A. BALB/c nude mice were used to investigate the effects of APOBEC3A <i>in vivo</i>. The phosphorylated gamma-H2AX staining assay was applied to measure DNA damage. RNA sequencing (RNA-Seq) was applied to explore APOBEC3A-related signaling pathways. <b>Results:</b> APOBEC3A was more significantly expressed in cancer tissues than in adjacent normal tissues. Higher expression of APOBEC3A was associated with better outcomes in TCGA-CESC and GTEx. Immunohistochemistry showed that the expression of APOBEC3A was significantly higher in cancer tissues than in normal tissues. Transfection experiments showed that APOBEC3A inhibited proliferation, upregulated S-phase cells, inhibited migration and invasion, induced DNA damage, and promoted apoptosis. Overexpression of APOBEC3A inhibited tumor formation in the mouse model. RNA-seq analysis showed that ectopic expression of APOBEC3A inhibited several cancer-associated signaling pathways. <b>Conclusions:</b> APOBEC3A is significantly upregulated in cervical cancer, and higher expression of APOBEC3A is associated with better outcomes. APOBEC3A is a tumor suppressor whose overexpression induces apoptosis in cervical cancer.</AbstractText><CopyrightInformation>&#xa9; The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zishuai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Second Military Medical University, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Medical Bioprotection, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Biological Defense, Ministry of Education, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Haiwei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, the 1st Affiliated Hospital, Second Military Medical University, Shanghai 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Xiangyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Second Military Medical University, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Medical Bioprotection, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Biological Defense, Ministry of Education, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yifan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Second Military Medical University, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Medical Bioprotection, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Biological Defense, Ministry of Education, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wenbin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Second Military Medical University, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Medical Bioprotection, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Biological Defense, Ministry of Education, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pu</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Second Military Medical University, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Medical Bioprotection, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Biological Defense, Ministry of Education, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Letian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Second Military Medical University, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Medical Bioprotection, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Biological Defense, Ministry of Education, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yiwei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Second Military Medical University, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Medical Bioprotection, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Biological Defense, Ministry of Education, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Donghong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Hepatic Surgery, the 3rd Affiliated Hospital, Second Military Medical University, Shanghai, 200438, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Second Military Medical University, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Medical Bioprotection, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Biological Defense, Ministry of Education, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Zheyun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Shanghai East Hospital, Key Laboratory of Arrhythmias, Ministry of Education, Tongji University School of Medicine Tongji University, Shanghai 200120, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Mingjuan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, the 1st Affiliated Hospital, Second Military Medical University, Shanghai 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Guangwen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Second Military Medical University, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Medical Bioprotection, Shanghai, 200433, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Biological Defense, Ministry of Education, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>J Cancer</MedlineTA><NlmUniqueID>101535920</NlmUniqueID><ISSNLinking>1837-9664</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">apolipoprotein B mRNA-editing enzyme catalytic 3 A (APOBEC3A)</Keyword><Keyword MajorTopicYN="N">apoptosis</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">proliferation</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>14</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38021159</ArticleId><ArticleId IdType="pmc">PMC10647198</ArticleId><ArticleId IdType="doi">10.7150/jca.89044</ArticleId><ArticleId IdType="pii">jcav14p3429</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singh D, Vignat J, Lorenzoni V. et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11:e197&#x2013;e206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9848409</ArticleId><ArticleId IdType="pubmed">36528031</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Wagle NS. et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">36633525</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang D, Niu Z, Tan X. et al. The mortalities of female-specific cancers in China and other countries with distinct socioeconomic statuses: A longitudinal study. J Adv Res. 2023;49:127&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10334254</ArticleId><ArticleId IdType="pubmed">36130684</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahangdale L, Mungo C, O'Connor S. et al. Human papillomavirus vaccination and cervical cancer risk. Bmj. 2022;379:e070115.</Citation><ArticleIdList><ArticleId IdType="pubmed">36521855</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Qiu X, Zhang N. et al. APOBEC-mediated genomic alterations link immunity and viral infection during human papillomavirus-driven cervical carcinogenesis. Biosci Trends. 2017;11:383&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28717061</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmanbar A, Firouzi S, Kneller R. et al. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers. J Transl Med. 2022;20:65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8812249</ArticleId><ArticleId IdType="pubmed">35109853</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvis MC, Ebrahimi D, Temiz NA, Mutation Signatures Including APOBEC in Cancer Cell Lines. JNCI Cancer Spectr. 2018. 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5993214</ArticleId><ArticleId IdType="pubmed">29888758</ArticleId></ArticleIdList></Reference><Reference><Citation>Zammataro L, Lopez S, Bellone S. et al. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proc Natl Acad Sci U S A. 2019;116:22730&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6842590</ArticleId><ArticleId IdType="pubmed">31624127</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson S, Chakravarthy A, Su X. et al. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 2014;7:1833&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">24910434</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira GR, Carvalho PS, Vieira VC, High APOBEC3B mRNA Expression Is Associated with Human Papillomavirus Type 18 Infection in Cervical Cancer. Viruses. 2022. 14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9784603</ArticleId><ArticleId IdType="pubmed">36560657</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z, Gan J, Feng X. et al. APOBEC3B is overexpressed in cervical cancer and promotes the proliferation of cervical cancer cells through apoptosis, cell cycle, and p53 pathway. Front Oncol. 2022;12:864889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556651</ArticleId><ArticleId IdType="pubmed">36249021</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Q, Huang T, Sun X. et al. HPV-16/18 E6-induced APOBEC3B expression associates with proliferation of cervical cancer cells and hypomethylation of Cyclin D1. Mol Carcinog. 2021;60:313&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">33631046</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X, Xia X, Su W. et al. Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma. Gynecol Oncol. 2022;165:105&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">35151492</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu B, Xiao Y, Yeager M. et al. Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. Nat Commun. 2020;11:886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7021686</ArticleId><ArticleId IdType="pubmed">32060290</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Deng Y, Li Z. et al. Cancer Evo-Dev: A Theory of Inflammation-Induced Oncogenesis. Front Immunol. 2021;12:768098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8645856</ArticleId><ArticleId IdType="pubmed">34880864</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojesina AI, Lichtenstein L, Freeman SS. et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014;506:371&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161954</ArticleId><ArticleId IdType="pubmed">24390348</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao GW. Cancer Evo-Dev, a novel hypothesis derived from studies on hepatitis B virus-induced carcinogenesis. Hepatoma Res. 2017. 3.</Citation></Reference><Reference><Citation>Wakae K, Nishiyama T, Kondo S. et al. Keratinocyte differentiation induces APOBEC3A, 3B, and mitochondrial DNA hypermutation. Sci Rep. 2018;8:9745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6021414</ArticleId><ArticleId IdType="pubmed">29950685</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Wu J, Yang F. et al. Genetic Polymorphisms Predisposing the Interleukin 6-Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations. Clin Cancer Res. 2019;25:5525&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">31152021</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, Du Y, Zhang Q. et al. Human cytidine deaminases facilitate hepatitis B virus evolution and link inflammation and hepatocellular carcinoma. Cancer Lett. 2014;343:161&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">24120759</ArticleId></ArticleIdList></Reference><Reference><Citation>Petljak M, Dananberg A, Chu K. et al. Mechanisms of APOBEC3 mutagenesis in human cancer cells. Nature. 2022;607:799&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9329121</ArticleId><ArticleId IdType="pubmed">35859169</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Liu T, Zhou Z. et al. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer. Front Immunol. 2021;12:749369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8568129</ArticleId><ArticleId IdType="pubmed">34745121</ArticleId></ArticleIdList></Reference><Reference><Citation>Argyris PP, Wilkinson PE, Jarvis MC. et al. Endogenous APOBEC3B overexpression characterizes HPV-positive and HPV-negative oral epithelial dysplasias and head and neck cancers. Mod Pathol. 2021;34:280&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261524</ArticleId><ArticleId IdType="pubmed">32632179</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, He S, Han Y. et al. Establishment and characterization of clear cell renal cell carcinoma cell lines with different metastatic potential from Chinese patients. Cancer Cell Int. 2013;13:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3599881</ArticleId><ArticleId IdType="pubmed">23442546</ArticleId></ArticleIdList></Reference><Reference><Citation>Vartanian JP, Gu&#xe9;tard D, Henry M. et al. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science. 2008;320:230&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">18403710</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren CJ, Xu T, Guo K. et al. APOBEC3A functions as a restriction factor of human papillomavirus. J Virol. 2015;89:688&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301161</ArticleId><ArticleId IdType="pubmed">25355878</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilborghs S, Corthouts J, Verhoeven Y. et al. The role of Nuclear Factor-kappa B signaling in human cervical cancer. Crit Rev Oncol Hematol. 2017;120:141&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">29198328</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Li X, Li J. et al. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression. Gut. 2019;68:1846&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">31154396</ArticleId></ArticleIdList></Reference><Reference><Citation>Serebrenik AA, Starrett GJ, Leenen S. et al. The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase. Proc Natl Acad Sci U S A. 2019;116:22158&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6825264</ArticleId><ArticleId IdType="pubmed">31611371</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Li X, Qin J. et al. APOBEC3A possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer. Int J Clin Exp Med. 2015;8:10548&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4565227</ArticleId><ArticleId IdType="pubmed">26379844</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Wei Z, Zhao H. et al. The role of APOBEC3A in cervical cancer development and progression: A retrospective study. Drug Discov Ther. 2023;17:191&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">36889736</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Ji H, Zhao J. et al. Transcriptional repression and apoptosis influence the effect of APOBEC3A/3B functional polymorphisms on biliary tract cancer risk. Int J Cancer. 2022;150:1825&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">35020946</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Zheng S, Liu W. et al. Effect of APOBEC3A functional polymorphism on renal cell carcinoma is influenced by tumor necrosis factor-&#x3b1; and transcriptional repressor ETS1. Am J Cancer Res. 2021;11:4347&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8493372</ArticleId><ArticleId IdType="pubmed">34659891</ArticleId></ArticleIdList></Reference><Reference><Citation>Caval V, Bouzidi MS, Susp&#xe8;ne R. et al. Molecular basis of the attenuated phenotype of human APOBEC3B DNA mutator enzyme. Nucleic Acids Res. 2015;43:9340&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4627089</ArticleId><ArticleId IdType="pubmed">26384561</ArticleId></ArticleIdList></Reference><Reference><Citation>DeWeerd RA, N&#xe9;meth E, P&#xf3;ti &#xc1;. et al. Prospectively defined patterns of APOBEC3A mutagenesis are prevalent in human cancers. Cell Rep. 2022;38:110555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9283007</ArticleId><ArticleId IdType="pubmed">35320711</ArticleId></ArticleIdList></Reference><Reference><Citation>Landry S, Narvaiza I, Linfesty DC. et al. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep. 2011;12:444&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090015</ArticleId><ArticleId IdType="pubmed">21460793</ArticleId></ArticleIdList></Reference><Reference><Citation>Green AM, Budagyan K, Hayer KE. et al. Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint. Cancer Res. 2017;77:4579&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5581702</ArticleId><ArticleId IdType="pubmed">28655787</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Liu H, Yang Y, Genome-Wide Profiling of Cervical RNA-Binding Proteins Identifies Human Papillomavirus Regulation of RNASEH2A Expression by Viral E7 and E2F1. mBio. 2019. 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6355981</ArticleId><ArticleId IdType="pubmed">30696738</ArticleId></ArticleIdList></Reference><Reference><Citation>Revathidevi S, Manikandan M, Rao AK. et al. Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation. Tumour Biol. 2016;37:11983&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">27155849</ArticleId></ArticleIdList></Reference><Reference><Citation>Castilha EP, Curti RRJ, de Oliveira JN, APOBEC3A/B Polymorphism Is Not Associated with Human Papillomavirus Infection and Cervical Carcinogenesis. Pathogens. 2023. 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10223315</ArticleId><ArticleId IdType="pubmed">37242306</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37978469</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2407</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>17</Day></PubDate></JournalIssue><Title>BMC cancer</Title><ISOAbbreviation>BMC Cancer</ISOAbbreviation></Journal><ArticleTitle>Expression and gene regulatory network of S100A16 protein in cervical cancer cells based on data mining.</ArticleTitle><Pagination><StartPage>1124</StartPage><MedlinePgn>1124</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1124</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-023-11574-y</ELocationID><Abstract><AbstractText>S100A16 protein belongs to the S100 family of calcium-binding proteins, which is widely distributed in human tissues and highly conserved. S100 calcium-binding proteins possess broad biological functions, such as cancer cell proliferation, apoptosis, tumor metastasis, and inflammation (Nat Rev Cancer 15:96-109, 2015). The S100A16 protein was initially isolated from a cell line derived from astrocytoma. The S100A16 protein, consisting of 103 amino acids, is a small acidic protein with a molecular weight of 11,801.4&#xa0;Da and an isoelectric point (pI) of 6.28 (Biochem Biophys Res Commun 313:237-244, 2004). This protein exhibits high conservation among mammals and is widely expressed in various human tissues (Biochem Biophys Res Commun 322:1111-1122, 2004). Like other S100 proteins, S100A16 contains two EF-hand motifs that form a helix-loop-helix structural domain. The N-terminal domain and the C-terminal domain of S100A16 are connected by a "hinge" linker.S100A16 protein exhibits distinct characteristics that distinguish it from other S100 proteins. A notable feature is the presence of a single functional Ca2&#x2009;+&#x2009;binding site located in the C-terminal EF-hand, consisting of 12 amino acids per protein monomer (J Biol Chem 281:38905-38917, 2006). In contrast, the N-terminal EF-hand of S100A16 comprises 15 amino acids instead of the typical 14, and it lacks the conserved glutamate residue at the final position. This unique attribute may contribute to the impaired Ca2&#x2009;+&#x2009;binding capability in the N-terminal region (J Biol Chem 281:38905-38917, 2006). Studies have shown an integral role of S100 calcium-binding proteins in the diagnosis, treatment, and prognosis of certain diseases (Cancers 12:2037, 2020). Abnormal expression of S100A16 protein is implicated in the progression of breast and prostate cancer, but an inhibitor of oral cancer and acute lymphoblastic leukemia tumor cell proliferation (BMC Cancer 15:53, 2015; BMC Cancer 15:631, 2015). Tu et al. (Front Cell Dev Biol 9:645641, 2021) indicate that the overexpression of S100A16 mRNA in cervical cancer(CC) such as cervical squamous cell carcinoma and endocervical adenocarcinoma as compared to the control specimens. Tomiyama N. and co-workers (Oncol Lett 15:9929-9933, 2018) (Tomiyama, N) investigated the role of S100A16 in cancer stem cells using Yumoto cells (a CC cell line),The authors found upregulation of S100A16 in Yumoto cells following sphere formation as compared to monolayer culture.Despite a certain degree of understanding, the exact biological function of S100A16 in CC is still unclear. This article explores the role of S100A16 in CC through a bioinformatics analysis. Referencing the mRNA expression and SNP data of cervical cancer available through The Cancer Genome Atlas (TCGA) database, we analyzed S100A16 and its associated regulatory gene expression network in cervical cancer. We further screened genes co-expressed with S100A16 to hypothesize their function and relationship to the S100A16 cervical cancer phenotype.Our results showed that data mining can effectively elucidate the expression and gene regulatory network of S100A16 in cervical cancer, laying the foundation for further investigations into S100A16 cervical tumorigenesis.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Haibin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine of Lanzhou University, Lanzhou, 730013, Gansu Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, the Second Hospital of Lanzhou University, Lanzhou, 730013, Gansu Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The First Hospital of Lanzhou University, Lanzhou, 730013, Gansu Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Gynecological Tumors in Gansu Province, Lanzhou, 730013, Gansu Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yongxiu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine of Lanzhou University, Lanzhou, 730013, Gansu Province, China. yongxiu_yang@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The First Hospital of Lanzhou University, Lanzhou, 730013, Gansu Province, China. yongxiu_yang@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of Gynecological Tumors in Gansu Province, Lanzhou, 730013, Gansu Province, China. yongxiu_yang@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Wenhu</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Gynecology, the Second Hospital of Lanzhou University, Lanzhou, 730013, Gansu Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yufeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology, the Second Hospital of Lanzhou University, Lanzhou, 730013, Gansu Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Second School of Clinical Medicine of Lanzhou University, Lanzhou, 730013, Gansu Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cancer</MedlineTA><NlmUniqueID>100967800</NlmUniqueID><ISSNLinking>1471-2407</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009418">S100 Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000589580">S100A16 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009418" MajorTopicYN="N">S100 Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057225" MajorTopicYN="N">Data Mining</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Molecular mechanisms</Keyword><Keyword MajorTopicYN="N">S100A16 protein</Keyword><Keyword MajorTopicYN="N">TCGA</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>18</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>18</Day><Hour>2</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37978469</ArticleId><ArticleId IdType="pmc">PMC10656989</ArticleId><ArticleId IdType="doi">10.1186/s12885-023-11574-y</ArticleId><ArticleId IdType="pii">10.1186/s12885-023-11574-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394&#x2013;424r. doi: 10.3322/caac.21492.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn WS, Bae SM, Lee JM, Namkoong SE, Han SJ, Cho YL, Nam GH, Seo JS, Kim CK, Kim YW. Searching for pathogenic gene functions to cervical cancer. Gynecol Oncol. 2004;93(1):41&#x2013;48. doi: 10.1016/j.ygyno.2003.11.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2003.11.031</ArticleId><ArticleId IdType="pubmed">15047212</ArticleId></ArticleIdList></Reference><Reference><Citation>Panjkovic M, Ivkovic-Kapicl T. Etiology and pathogenesis of precancerous lesions and invasive cervical carcinoma. Med Pregl. 2008;61(7&#x2013;8):364&#x2013;368. doi: 10.2298/MPNS0808364P.</Citation><ArticleIdList><ArticleId IdType="doi">10.2298/MPNS0808364P</ArticleId><ArticleId IdType="pubmed">19097373</ArticleId></ArticleIdList></Reference><Reference><Citation>Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature) Biochem Biophys Res Commun. 2004;322(4):1111&#x2013;1122. doi: 10.1016/j.bbrc.2004.07.096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2004.07.096</ArticleId><ArticleId IdType="pubmed">15336958</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler E, Cox JA, Durussel I, Weibel M, Heizmann CW. S100A16, a novel calcium-binding protein of the EF-hand superfamily. J Biol Chem. 2006;281(50):38905&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030513</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Xu C, Jin Q, Liu Z. S100 protein family in human cancer. Am J Cancer Res. 2014;4(2):89&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960449</ArticleId><ArticleId IdType="pubmed">24660101</ArticleId></ArticleIdList></Reference><Reference><Citation>Katono K, Sato Y, Kobayashi M, Nagashio R, Ryuge S, Igawa S, Ichinoe M, Murakumo Y, Saegusa M, Masuda N. S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma. Onco Targets Ther. 2017;10:5273&#x2013;9. doi: 10.2147/OTT.S145072.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S145072</ArticleId><ArticleId IdType="pmc">PMC5679695</ArticleId><ArticleId IdType="pubmed">29138580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Ichikawa-Tomikawa N, Shishito N, Nishiura K, Miura T, Hozumi A, Chiba H, Yoshida S, Ohtake T, Sugino T. Coexpression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion. BMC Cancer. 2015;15:53. doi: 10.1186/s12885-015-1059-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-015-1059-6</ArticleId><ArticleId IdType="pmc">PMC4348405</ArticleId><ArticleId IdType="pubmed">25884418</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y, Li LD, Li J, Lu X. Prognostic values of S100 family members in ovarian cancer patients. BMC Cancer. 2018;18(1):1256. doi: 10.1186/s12885-018-5170-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-018-5170-3</ArticleId><ArticleId IdType="pmc">PMC6296138</ArticleId><ArticleId IdType="pubmed">30558666</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapkota D, Bruland O, Parajuli H, Osman TA, Teh MT, Johannessen AC, Costea DE. S100A16 promotes differentiation and contributes to a less aggressive tumor phenotype in oral squamous cell carcinoma. BMC Cancer. 2015;15:631. doi: 10.1186/s12885-015-1622-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-015-1622-1</ArticleId><ArticleId IdType="pmc">PMC4564982</ArticleId><ArticleId IdType="pubmed">26353754</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito K, Kobayashi M, Nagashio R, Ryuge S, Katono K, Nakashima H, Tsuchiya B, Jiang SX, Saegusa M, Satoh Y, et al. S100A16 is a prognostic marker for lung adenocarcinomas. Asian Pac J Cancer Prev. 2015;16(16):7039&#x2013;44. doi: 10.7314/APJCP.2015.16.16.7039.</Citation><ArticleIdList><ArticleId IdType="doi">10.7314/APJCP.2015.16.16.7039</ArticleId><ArticleId IdType="pubmed">26514487</ArticleId></ArticleIdList></Reference><Reference><Citation>Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat Rev Cancer. 2015;15(2):96&#x2013;109. doi: 10.1038/nrc3893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3893</ArticleId><ArticleId IdType="pmc">PMC4369764</ArticleId><ArticleId IdType="pubmed">25614008</ArticleId></ArticleIdList></Reference><Reference><Citation>Marenholz I, Heizmann CW. S100A16, a ubiquitously expressed EF-hand protein which is up-regulated in tumors. Biochem Biophys Res Commun. 2004;313(2):237&#x2013;44. doi: 10.1016/j.bbrc.2003.11.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2003.11.115</ArticleId><ArticleId IdType="pubmed">14684152</ArticleId></ArticleIdList></Reference><Reference><Citation>Allgower C, Kretz AL, von Karstedt S, Wittau M, Henne-Bruns D, Lemke J. Friend or Foe: S100 Proteins in Cancer. Cancers. 2020;12(8):2037. doi: 10.3390/cancers12082037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12082037</ArticleId><ArticleId IdType="pmc">PMC7465620</ArticleId><ArticleId IdType="pubmed">32722137</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu G, Gao W, Li Y, Dian Y, Xue B, Niu L, Yu X, Zhu H. Expressional and prognostic value of S100A16 in pancreatic cancer via integrated bioinformatics analyses. Front Cell Dev Biol. 2021;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8072221</ArticleId><ArticleId IdType="pubmed">33912559</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Yang J, Qian J, Liu Z, Chen H, Cui Z. S100A14, a mediator of epithelial-mesenchymal transition, regulates proliferation, migration and invasion of human cervical cancer cells. Am J Cancer Res. 2015;5(4):1484&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4473325</ArticleId><ArticleId IdType="pubmed">26101712</ArticleId></ArticleIdList></Reference><Reference><Citation>Graeber SH, H&#xfc;lser DF. Connexin transfection induces invasive properties in HeLa cells. Exp Cell Res. 1998;243(1):142&#x2013;9. doi: 10.1006/excr.1998.4130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/excr.1998.4130</ArticleId><ArticleId IdType="pubmed">9716458</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W, Xue Y, Liang C, Zhang R, Zhang Z, Li H, Su D, Liang X, Zhang Y, Huang Q, et al. S100A16 promotes cell proliferation and metastasis via AKT and ERK cell signaling pathways in human prostate cancer. Tumour Biol. 2016;37(9):12241&#x2013;50. doi: 10.1007/s13277-016-5096-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-016-5096-9</ArticleId><ArticleId IdType="pubmed">27240591</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Wang T, Zhang C, Ning K, Guan ZR, Chen SX, Hong TT, Hua D. S100A16 is a prognostic marker for colorectal cancer. J Surg Oncol. 2018;117(2):275&#x2013;83. doi: 10.1002/jso.24822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jso.24822</ArticleId><ArticleId IdType="pubmed">28876468</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomiyama N, Ikeda R, Nishizawa Y, Masuda S, Tajitsu Y, Takeda Y. S100A16 up-regulates Oct4 and Nanog expression in cancer stem-like cells of Yumoto human cervical carcinoma cells. Oncol Lett. 2018;15(6):9929&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6004699</ArticleId><ArticleId IdType="pubmed">29928366</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan JQ, Wang MF, Chen HL, Shang D, Das JK, Song J. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Mol Cancer. 2020;19(1):32. doi: 10.1186/s12943-020-01151-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-020-01151-3</ArticleId><ArticleId IdType="pmc">PMC7023714</ArticleId><ArticleId IdType="pubmed">32061257</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267&#x2013;96. doi: 10.1146/annurev.immunol.25.022106.141609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.25.022106.141609</ArticleId><ArticleId IdType="pmc">PMC2895922</ArticleId><ArticleId IdType="pubmed">17134371</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5(4):263&#x2013;74. doi: 10.1038/nrc1586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc1586</ArticleId><ArticleId IdType="pubmed">15776005</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Liu G, Wang R. The intercellular metabolic interplay between tumor and immune cells. Front Immunol. 2014;5:358. doi: 10.3389/fimmu.2014.00358.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00358</ArticleId><ArticleId IdType="pmc">PMC4112791</ArticleId><ArticleId IdType="pubmed">25120544</ArticleId></ArticleIdList></Reference><Reference><Citation>Komi DEA, Redegeld FA. Role of Mast Cells in Shaping the Tumor Microenvironment. Clin Rev Allergy Immunol. 2020;58(3):313&#x2013;25. doi: 10.1007/s12016-019-08753-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-019-08753-w</ArticleId><ArticleId IdType="pmc">PMC7244463</ArticleId><ArticleId IdType="pubmed">31256327</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao J, Zhao J, Winter E, Cattral MS. Tumors suppress in situ proliferation of cytotoxic T cells by promoting differentiation of Gr-1(+) conventional dendritic cells through IL-6. J Immunol. 2011;186(9):5058&#x2013;67. doi: 10.4049/jimmunol.1004125.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1004125</ArticleId><ArticleId IdType="pubmed">21430223</ArticleId></ArticleIdList></Reference><Reference><Citation>Egeland NG, Jonsdottir K, Aure MR, Sahlberg K, Kristensen VN, Cronin-Fenton D, Skaland I, Gudlaugsson E, Baak JPA, Janssen EAM. MiR-18a and miR-18b are expressed in the stroma of oestrogen receptor alpha negative breast cancers. BMC Cancer. 2020;20(1):377. doi: 10.1186/s12885-020-06857-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-020-06857-7</ArticleId><ArticleId IdType="pmc">PMC7201801</ArticleId><ArticleId IdType="pubmed">32370743</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, Sullivan SA, Nichols AG, Rathmell JC. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011;186(6):3299&#x2013;303. doi: 10.4049/jimmunol.1003613.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1003613</ArticleId><ArticleId IdType="pmc">PMC3198034</ArticleId><ArticleId IdType="pubmed">21317389</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707&#x2013;23. doi: 10.1016/j.cell.2017.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.01.017</ArticleId><ArticleId IdType="pmc">PMC5391692</ArticleId><ArticleId IdType="pubmed">28187290</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah P, Wolf K, Lammerding J. Bursting the bubble - nuclear envelope rupture as a path to genomic instability? Trends Cell Biol. 2017;27(8):546&#x2013;55. doi: 10.1016/j.tcb.2017.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2017.02.008</ArticleId><ArticleId IdType="pmc">PMC5524594</ArticleId><ArticleId IdType="pubmed">28285738</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;m&#xe4;list&#xf6; S, Stahl JL, Favaro E, Yang Q, Liu B, Christoffersen L, Loos B, Guasch Bold&#xfa; C, Joyce JA, Reinheckel T, et al. Spatially and temporally defined lysosomal leakage facilitates mitotic chromosome segregation. Nat Commun. 2020;11(1):229. doi: 10.1038/s41467-019-14009-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-14009-0</ArticleId><ArticleId IdType="pmc">PMC6957743</ArticleId><ArticleId IdType="pubmed">31932607</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q, Qu QX, Xie F, Hu JM, Chen YG, Zhang XG. Sensitization of SiHa cell to gemcitabine by CD40 activation and its overexpression in cervical carcinoma. Med Oncol. 2011;28(3):781&#x2013;8. doi: 10.1007/s12032-010-9538-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12032-010-9538-8</ArticleId><ArticleId IdType="pubmed">20467921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutch DG, Bloss JD. Gemcitabine in cervical cancer. Gynecol Oncol. 2003;90(2 Pt 2):S8&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928000</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol. 2012;7(8):1315&#x2013;26. doi: 10.1097/JTO.0b013e31825493eb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JTO.0b013e31825493eb</ArticleId><ArticleId IdType="pubmed">22648207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Wang Z, Liu L, Chen L. Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells. Lung Cancer (Amsterdam, Netherlands). 2011;71(3):291&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20599289</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Pan H, Xia T, Xue J, Cheng L, Fan P, Zhang Y, Zhu W, Xue Y, Liu X, et al. Up-regulation of S100A16 expression promotes epithelial-mesenchymal transition via Notch1 pathway in breast cancer. J Biomed Sci. 2014;21(1):97. doi: 10.1186/s12929-014-0097-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-014-0097-8</ArticleId><ArticleId IdType="pmc">PMC4197258</ArticleId><ArticleId IdType="pubmed">25287362</ArticleId></ArticleIdList></Reference><Reference><Citation>Du B, Shim JS. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules. 2016;21(7):965r.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6273543</ArticleId><ArticleId IdType="pubmed">27455225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung WJ, Park KS, Kwak SG, Hyun DS, Jang JS, Park KK. Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: correlation with cancer stem cell markers and prognosis. Int J Clin Exp Pathol. 2015;8(8):8997&#x2013;9009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4583874</ArticleId><ArticleId IdType="pubmed">26464642</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Ren T, Huang C, Li Y, Yang P, Che G, Luo L, Chen Y, Peng S, Lin Y, et al. S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine. Biochem Pharmacol. 2021;189:114396.</Citation><ArticleIdList><ArticleId IdType="pubmed">33359364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou S, Liao Y, Shi J, Tang J, Ye Y, Wu F, Wang W, Fei J, Xie F, Bai L. S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway. Mol Med Rep. 2021;23(2):164. doi: 10.3892/mmr.2020.11803.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2020.11803</ArticleId><ArticleId IdType="pmc">PMC7789101</ArticleId><ArticleId IdType="pubmed">33355370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Yang Y, Ma X, Xin W, Fan X. S100A16 regulates HeLa cell through the phosphatidylinositol 3 Kinase (PI3K)/AKT signaling pathway. Med Sci Monit. 2020;26:e919757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6977613</ArticleId><ArticleId IdType="pubmed">31894756</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Sun Z, Qi M, Wang X, Zhang W, Chen C, Liu J, Zhao W. INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway. J Cell Mol Med. 2018;22(5):2935&#x2013;43. doi: 10.1111/jcmm.13595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.13595</ArticleId><ArticleId IdType="pmc">PMC5908107</ArticleId><ArticleId IdType="pubmed">29516642</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu XR, Wu J, Sun H, Chi LQ, Wang JH. PAK4 confers the malignance of cervical cancers and contributes to the cisplatinresistance in cervical cancer cells via PI3K/AKT pathway. Diagn Pathol. 2015;10:177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584462</ArticleId><ArticleId IdType="pubmed">26411419</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae SN, Lee KH, Kim JH, Lee SJ, Park LO. Zinc induces apoptosis on cervical carcinoma cells by p53-dependent and -independent pathway. Biochem Biophys Res Commun. 2017;484(1):218&#x2013;23. doi: 10.1016/j.bbrc.2016.12.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.12.093</ArticleId><ArticleId IdType="pubmed">27998772</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanisavljevic D, Petrovic I, Vukovic V, Schwirtlich M, Gredic M, Stevanovic M, Popovic J. SOX14 activates the p53 signaling pathway and induces apoptosis in a cervical carcinoma cell line. PLoS ONE. 2017;12(9):e0184686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5604970</ArticleId><ArticleId IdType="pubmed">28926586</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37971632</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2090-5920</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal, genetic engineering &amp; biotechnology</Title><ISOAbbreviation>J Genet Eng Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Computational approach for assessing the involvement of SMYD2 protein in human cancers using TCGA data.</ArticleTitle><Pagination><StartPage>122</StartPage><MedlinePgn>122</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">122</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s43141-023-00594-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">SMYD2 is a protein of the SET and MYND domain-containing family SMYD. It can methylate the lysine residue of various histone and nonhistone cancer-related proteins and plays a critical role in tumorigenesis. Although emerging evidence supports the association of SMYD2 in the progression of cancers, but its definitive effect is not yet clear. Therefore, further study of the gene in relation with cancer progression needs to be conducted. In the current study, investigators used TCGA data to determine the potential carcinogenic effect of SMYD2 in 11 cancer types. The transcriptional expression, survival rate, mutations, enriched pathways, and Gene Ontology of the SMYD2 were explored using different bioinformatics tools and servers. In addition, we also examined&#xa0;the correlation between SMYD2 gene expression and immunocyte infiltration in multiple cancer types.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Findings revealed that higher expression of SMYD2 was significantly correlated with cancer incidents. In CESC and KIRC, the mRNA expression of SMYD2 was significantly correlated with overall survival (OS). In BRCA, KIRC, COAD, and HNSC, the mRNA expression of SMYD2 was significantly correlated with disease-free survival (DFS). We detected 15 missense, 4 truncating, 4 fusions, and 1 splice type of mutation. The expression of SMYD2 was significantly correlated with tumor purity and immunocyte infiltration in six cancer types. The gene GNPAT was highly associated with SMYD2. Significant pathways and Gene Ontology (GO) terms for co-expressed genes were associated to various processes linked with cancer formation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Collectively, our data-driven results may provide reasonably comprehensive insights for understanding the carcinogenic effect of SMYD2. It&#xa0;suggests that SMYD2 might be used as a significant target for identifying&#xa0;new biomarkers for various human tumors.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>Arvind Kumar</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology, Solan-173234, Himachal Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Tiratha Raj</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology, Solan-173234, Himachal Pradesh, India. tiratharaj@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Excellence in Healthcare Technologies and Informatics (CHETI), Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology, Solan-173234, Himachal Pradesh, India. tiratharaj@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Genet Eng Biotechnol</MedlineTA><NlmUniqueID>101317150</NlmUniqueID><ISSNLinking>1687-157X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Mutational analysis</Keyword><Keyword MajorTopicYN="N">Pathways analysis</Keyword><Keyword MajorTopicYN="N">SMYD2</Keyword><Keyword MajorTopicYN="N">Survival analysis</Keyword><Keyword MajorTopicYN="N">mRNA expression</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>17</Day><Hour>15</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>17</Day><Hour>15</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>16</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37971632</ArticleId><ArticleId IdType="pmc">PMC10654300</ArticleId><ArticleId IdType="doi">10.1186/s43141-023-00594-7</ArticleId><ArticleId IdType="pii">10.1186/s43141-023-00594-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394&#x2013;424. doi: 10.3322/caac.21492.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209&#x2013;49. doi: 10.3322/caac.21660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehgal M, Gupta R, Moussa A, Singh TR. An integrative approach for mapping differentially expressed genes and network components using novel parameters to elucidate key regulatory genes in colorectal cancer. PLoS One. 2015;10:e0133901. doi: 10.1371/journal.pone.0133901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0133901</ArticleId><ArticleId IdType="pmc">PMC4519280</ArticleId><ArticleId IdType="pubmed">26222778</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Cathail SM, Wu C-H, Lewis A, Holmes C, Hawkins MA, Maughan T. NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. Cancer Genet. 2020;248&#x2013;249:1&#x2013;10. doi: 10.1016/j.cancergen.2020.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cancergen.2020.08.006</ArticleId><ArticleId IdType="pubmed">32871287</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009;8:724&#x2013;732. doi: 10.1038/nrd2974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2974</ArticleId><ArticleId IdType="pubmed">19721445</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav AK, Gupta PK, Singh T (2023) PMTPred: Machine Learning Based Prediction of Protein Methyltransferases using the&#xa0;Composition of k-spaced Amino Acid Pairs. BioRxiv 2023&#x2013;09.&#xa0;10.1101/2023.09.20.558595</Citation><ArticleIdList><ArticleId IdType="pubmed">39033257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamamoto R, Nakamura Y. Dysregulation of protein methyltransferases in human cancer: an emerging target class for anticancer therapy. Cancer Sci. 2016;107:377&#x2013;384. doi: 10.1111/cas.12884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.12884</ArticleId><ArticleId IdType="pmc">PMC4832871</ArticleId><ArticleId IdType="pubmed">26751963</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav AK, Singh TR. Novel structural and functional impact of damaging single nucleotide polymorphisms (SNPs) on human SMYD2 protein using computational approaches. Meta Gene. 2021;28:100871. doi: 10.1016/j.mgene.2021.100871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mgene.2021.100871</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13:343&#x2013;357. doi: 10.1038/nrg3173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3173</ArticleId><ArticleId IdType="pmc">PMC4073795</ArticleId><ArticleId IdType="pubmed">22473383</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggert E, Hillig RC, Koehr S, St&#xf6;ckigt D, Weiske J, Barak N, et al. Discovery and characterization of a highly potent and selective aminopyrazoline-based in vivo probe (BAY-598) for the protein lysine methyltransferase SMYD2. J Med Chem. 2016;59:4578&#x2013;4600. doi: 10.1021/acs.jmedchem.5b01890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b01890</ArticleId><ArticleId IdType="pmc">PMC4917279</ArticleId><ArticleId IdType="pubmed">27075367</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamamoto R, Saloura V, Nakamura Y. Critical roles of non-histone protein lysine methylation in human tumorigenesis. Nat Rev Cancer. 2015;15:110&#x2013;124. doi: 10.1038/nrc3884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3884</ArticleId><ArticleId IdType="pubmed">25614009</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H, Allali-Hassani A, Antonysamy S, Chang S, Chen LH, Curtis C, et al. LLY-507, a Cell-active, potent, and selective inhibitor of protein-lysine methyltransferase SMYD2. J Biol Chem. 2015;290:13641&#x2013;13653. doi: 10.1074/jbc.M114.626861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.626861</ArticleId><ArticleId IdType="pmc">PMC4447944</ArticleId><ArticleId IdType="pubmed">25825497</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav AK, Singh TR. Novel inhibitors design through structural investigations and simulation studies for human PKMTs (SMYD2) involved in cancer. Mol Simul. 2021;47:1149&#x2013;1158. doi: 10.1080/08927022.2021.1957882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08927022.2021.1957882</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, et al. Repression of p53 activity by Smyd2-mediated methylation. Nature. 2006;444:629&#x2013;632. doi: 10.1038/nature05287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05287</ArticleId><ArticleId IdType="pubmed">17108971</ArticleId></ArticleIdList></Reference><Reference><Citation>Voelkel T, Andresen C, Unger A, Just S, Rottbauer W, Linke WA. Lysine methyltransferase Smyd2 regulates Hsp90-mediated protection of the sarcomeric titin springs and cardiac function. Biochim Biophys Acta. 2013;1833:812&#x2013;822. doi: 10.1016/j.bbamcr.2012.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2012.09.012</ArticleId><ArticleId IdType="pubmed">23047121</ArticleId></ArticleIdList></Reference><Reference><Citation>Saddic LA, West LE, Aslanian A, Yates JR, Rubin SM, Gozani O, et al. Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem. 2010;285:37733&#x2013;37740. doi: 10.1074/jbc.M110.137612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.137612</ArticleId><ArticleId IdType="pmc">PMC2988378</ArticleId><ArticleId IdType="pubmed">20870719</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H-S, Hayami S, Toyokawa G, Maejima K, Yamane Y, Suzuki T, et al. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia. 2012;14:476&#x2013;486. doi: 10.1593/neo.12656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1593/neo.12656</ArticleId><ArticleId IdType="pmc">PMC3394190</ArticleId><ArticleId IdType="pubmed">22787429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Tanaka K, Yan J, Li J, Peng D, Jiang Y, et al. Regulation of estrogen receptor &#x3b1; by histone methyltransferase SMYD2-mediated protein methylation. Proc Natl Acad Sci USA. 2013;110:17284&#x2013;17289. doi: 10.1073/pnas.1307959110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1307959110</ArticleId><ArticleId IdType="pmc">PMC3808627</ArticleId><ArticleId IdType="pubmed">24101509</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakakido M, Deng Z, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R. Dysregulation of AKT pathway by SMYD2-mediated lysine methylation on PTEN. Neoplasia. 2015;17:367&#x2013;373. doi: 10.1016/j.neo.2015.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2015.03.002</ArticleId><ArticleId IdType="pmc">PMC4415136</ArticleId><ArticleId IdType="pubmed">25925379</ArticleId></ArticleIdList></Reference><Reference><Citation>Piao L, Kang D, Suzuki T, Masuda A, Dohmae N, Nakamura Y, et al. The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells. Neoplasia. 2014;16(257&#x2013;64):264.e2. doi: 10.1016/j.neo.2014.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2014.03.002</ArticleId><ArticleId IdType="pmc">PMC4094795</ArticleId><ArticleId IdType="pubmed">24726141</ArticleId></ArticleIdList></Reference><Reference><Citation>Li LX, Fan LX, Zhou JX, Grantham JJ, Calvet JP, Sage J, et al. Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease. J Clin Invest. 2017;127:2751&#x2013;2764. doi: 10.1172/JCI90921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90921</ArticleId><ArticleId IdType="pmc">PMC5490754</ArticleId><ArticleId IdType="pubmed">28604386</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrell DK, Hassell KN, Crans DC, Lanning S, Brown MA. Characterizing the role of SMYD2 in mammalian embryogenesis&#x2014;future directions. Vet Sci 2020;7. 10.3390/vetsci7020063</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357037</ArticleId><ArticleId IdType="pubmed">32408548</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 2020;48:W509&#x2013;14. 10.1093/nar/gkaa407</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319575</ArticleId><ArticleId IdType="pubmed">32442275</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556&#x2013;W560. doi: 10.1093/nar/gkz430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz430</ArticleId><ArticleId IdType="pmc">PMC6602440</ArticleId><ArticleId IdType="pubmed">31114875</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649&#x2013;658. doi: 10.1016/j.neo.2017.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2017.05.002</ArticleId><ArticleId IdType="pmc">PMC5516091</ArticleId><ArticleId IdType="pubmed">28732212</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401&#x2013;404. doi: 10.1158/2159-8290.CD-12-0095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-12-0095</ArticleId><ArticleId IdType="pmc">PMC3956037</ArticleId><ArticleId IdType="pubmed">22588877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1. 10.1126/scisignal.2004088</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4160307</ArticleId><ArticleId IdType="pubmed">23550210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90&#x2013;W97. doi: 10.1093/nar/gkw377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw377</ArticleId><ArticleId IdType="pmc">PMC4987924</ArticleId><ArticleId IdType="pubmed">27141961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal A, Singh TR. Chapter 9 - Epigenome-Wide DNA Methylation and histone modification of Alzheimer&#x2019;s disease. Wei LK, editor. Computational Epigenetics and Diseases, Academic Press; 2019; 9: 131&#x2013;48. 10.1016/B978-0-12-814513-5.00009-X</Citation></Reference><Reference><Citation>Shukla A, Sehgal M, Singh TR. Hydroxymethylation and its potential implication in DNA repair system: a review and future perspectives. Gene. 2015;564:109&#x2013;118. doi: 10.1016/j.gene.2015.03.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2015.03.075</ArticleId><ArticleId IdType="pubmed">25862923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27&#x2013;56. doi: 10.1016/B978-0-12-380866-0.60002-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-380866-0.60002-2</ArticleId><ArticleId IdType="pubmed">20920744</ArticleId></ArticleIdList></Reference><Reference><Citation>Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternative pathway to cancer. Ann Surg. 2001;234:10&#x2013;20. doi: 10.1097/00000658-200107000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-200107000-00003</ArticleId><ArticleId IdType="pmc">PMC1421942</ArticleId><ArticleId IdType="pubmed">11420478</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883&#x2013;899. doi: 10.1016/j.cell.2010.01.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.01.025</ArticleId><ArticleId IdType="pmc">PMC2866629</ArticleId><ArticleId IdType="pubmed">20303878</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904&#x2013;5912. doi: 10.1038/onc.2008.271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2008.271</ArticleId><ArticleId IdType="pmc">PMC3689267</ArticleId><ArticleId IdType="pubmed">18836471</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12:86. doi: 10.1186/s13045-019-0770-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-019-0770-1</ArticleId><ArticleId IdType="pmc">PMC6714445</ArticleId><ArticleId IdType="pubmed">31462327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ping Q, Yan R, Cheng X, Wang W, Zhong Y, Hou Z, et al. Cancer-associated fibroblasts: overview, progress, challenges, and directions. Cancer Gene Ther 2021:1&#x2013;16. 10.1038/s41417-021-00318-4</Citation><ArticleIdList><ArticleId IdType="pubmed">33712707</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174&#x2013;186. doi: 10.1038/s41568-019-0238-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-019-0238-1</ArticleId><ArticleId IdType="pmc">PMC7046529</ArticleId><ArticleId IdType="pubmed">31980749</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn E. Better cancer screening in resource-poor nations. Nature. 2020;579:S17&#x2013;S19. doi: 10.1038/d41586-020-00848-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-00848-1</ArticleId><ArticleId IdType="pubmed">32214256</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla A, Singh TR. Structure based inference of functional single nucleotide polymorphism and its role in TGF&#x3b2;1 allied colorectal cancer (CRC) Int J Bioinform Res Appl. 2021;17:80&#x2013;99. doi: 10.1504/IJBRA.2021.113965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1504/IJBRA.2021.113965</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Wang X, Shi E, Wang L, Nie M, Li L, et al. Comprehensive analysis of the value of SMYD family members in the prognosis and immune infiltration of malignant digestive system tumors. Front Genet. 2021;12:699910. doi: 10.3389/fgene.2021.699910.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.699910</ArticleId><ArticleId IdType="pmc">PMC8322783</ArticleId><ArticleId IdType="pubmed">34335697</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Sun B, Nie A, Yu D, Bian M. Roles of aminoacyl-tRNA synthetases in cancer. Front Cell Dev Biol. 2020;8:599765. doi: 10.3389/fcell.2020.599765.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.599765</ArticleId><ArticleId IdType="pmc">PMC7729087</ArticleId><ArticleId IdType="pubmed">33330488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, You S, Hwang D. Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nat Rev Cancer. 2011;11:708&#x2013;718. doi: 10.1038/nrc3124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3124</ArticleId><ArticleId IdType="pubmed">21941282</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo YR, Kelley MR, Smith ML. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. PNAS. 2002;99:14548&#x2013;14553. doi: 10.1073/pnas.212319799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.212319799</ArticleId><ArticleId IdType="pmc">PMC137920</ArticleId><ArticleId IdType="pubmed">12357032</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs Z, Jung I, Gurzu S. Arylsulfatases A and B: from normal tissues to malignant tumors. Pathol Res Pract. 2019;215:152516. doi: 10.1016/j.prp.2019.152516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prp.2019.152516</ArticleId><ArticleId IdType="pubmed">31262576</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua SH, Viera M, Yip GW, Bay BH. Theranostic applications of glycosaminoglycans in metastatic renal cell carcinoma. Cancers. 2023;15:266. doi: 10.3390/cancers15010266.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15010266</ArticleId><ArticleId IdType="pmc">PMC9818616</ArticleId><ArticleId IdType="pubmed">36612261</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendaszewska-Darmach E, Garstka MA, B&#x142;a&#x17c;ewska KM. Targeting small GTPases and their prenylation in diabetes mellitus. J Med Chem. 2021;64:9677&#x2013;9710. doi: 10.1021/acs.jmedchem.1c00410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c00410</ArticleId><ArticleId IdType="pmc">PMC8389838</ArticleId><ArticleId IdType="pubmed">34236862</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker AL, Teo WS, McCarroll JA, Kavallaris M. An emerging role for tubulin isotypes in modulating cancer biology and chemotherapy resistance. Int J Mol Sci. 2017;18:1434. doi: 10.3390/ijms18071434.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18071434</ArticleId><ArticleId IdType="pmc">PMC5535925</ArticleId><ArticleId IdType="pubmed">28677634</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoud GN, Li W. HIF-1&#x3b1; pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5:378&#x2013;389. doi: 10.1016/j.apsb.2015.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2015.05.007</ArticleId><ArticleId IdType="pmc">PMC4629436</ArticleId><ArticleId IdType="pubmed">26579469</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X, Dai L, Ma Y, Wang J, Liu Z. Implications of HIF-1&#x3b1; in the tumorigenesis and progression of pancreatic cancer. Cancer Cell Int. 2020;20:273. doi: 10.1186/s12935-020-01370-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-020-01370-0</ArticleId><ArticleId IdType="pmc">PMC7313137</ArticleId><ArticleId IdType="pubmed">32587480</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37805766</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2097-1109</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Zhonghua shao shang yu chuang mian xiu fu za zhi</Title><ISOAbbreviation>Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].</ArticleTitle><Pagination><StartPage>518</StartPage><EndPage>526</EndPage><MedlinePgn>518-526</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn501225-20230421-00137</ELocationID><Abstract><AbstractText><b>Objective:</b> To explore the biological role and clinical significance of ubiquitin-specific protease 7 (USP7) in the carcinogenesis of scar ulcer. <b>Methods:</b> A retrospective observational study combined with bioinformatics analysis was used. The RNA expression profile data of USP7 in tumor and/or its corresponding paracancular normal tissue were obtained from The Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus database, and the RNA sequencing data were transformed by log<sub>2</sub>. The variations of <i>USP7</i> gene were analyzed by cBioPortal database. The USP7 mRNA expression in tumor and adjacent normal tissue in TCGA database were obtained by using the "Gene_DE" module in TIMER 2.0 database. The survival rates of patients with high and low USP7 expression in cutaneous melanoma (SKCM), cervical squamous cell carcinoma (CESC), lung squamous cell carcinoma (LUSC), and head and neck squamous cell carcinoma (HNSC) were analyzed using the Gene Expression Profile Interactive Analysis 2 (GEPIA2) database, and the Kaplan-Meier survival curves were drawn. Sangerbox database was used to analyze the correlation of USP7 expression in pan-cancer with microsatellite instability (MSI) or tumor mutation burden (TMB) pan-cancer. Through the "correlation analysis" module in the GEPIA2 database, the correlation of USP7 expression in pan-cancer with the expression levels of five DNA mismatch repair genes (<i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, <i>PMS2</i>, and <i>EPCAM</i>) and three essential DNA methyltransferases (DNMT)--DNMT1, DNMT3A, and DNMT3B were evaluated. The USP7 expression in CESC, HNSC, LUSC, and SKCM and its correlation with infiltration of immune cells (B cells, CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, neutrophils, macrophages, and dendritic cells) were analyzed by the "Immune-Gene" module in TIMER 2.0 database. The "Similar Genes Detection" module of GEPIA2 database was used to obtain the top 100 protein sets with similar expression patterns to USP7. Intersection analysis was performed between the aforementioned protein sets and the top 50 protein sets that were directly physically bound to USP7 obtained by using the STRING database. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analysis were performed for the two protein sets mentioned above using the DAVID database. The samples of normal skin, hypertrophic scar, scar ulcer, and scar carcinoma with corresponding clinicopathologic features were collected from the Department of Pathology of Tongren Hospital of Wuhan University &amp; Wuhan Third Hospital from October 2018 to October 2022, and the USP7 expression in tissue was detected by immunohistochemical method, with the number of samples of 6. Data were statistically analyzed with Log-rank test, one-way analysis of variance, and Bonferroni test. <b>Results:</b> In pan-cancer, the main gene variations of <i>USP7</i> were mutation and amplification, and the top 3 tumors with the highest variation frequency (&gt;6%) were bladder urothelial carcinoma, SKCM, and endometrial carcinoma. The main mutation of <i>USP7</i> gene in pan-cancer was missense mutation. In SKCM with the highest mutation frequency, the main type of mutation was missense mutation in USP7_ICP0_bdg domain. USP7 mRNA expression in breast invasive carcinoma, bile duct carcinoma, colon carcinoma, esophageal carcinoma, HNSC, renal chromophobe cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, LUSC, prostate carcinoma, and gastric carcinoma was significantly higher than that in corresponding paracancer normal tissue (<i>P</i>&lt;0.05). USP7 mRNA expression in glioblastoma multiforme, renal clear cell carcinoma, renal papillary cell carcinoma, and thyroid carcinoma was significantly lower than that in corresponding paracancular normal tissue (<i>P</i>&lt;0.05). In addition, USP7 mRNA expression in SKCM metastases was much higher than that in primary tumor tissue (<i>P</i>&lt;0.05). Survival curves showed no significant difference in survival rate between patients with high USP7 expression and patients with low USP7 expression in CESC, HNSC, LUSC, and SKCM (Log-rank <i>P</i>&gt;0.05, with hazard ratios of 1.00, 0.99, 1.00, and 1.30, respectively). USP7 expression in colon cancer, colorectal cancer, thymic cancer, and thyroid cancer was negatively correlated with TMB (with Pearson correlation coefficients of -0.26, -0.19, -0.19, and 0.11, respectively, <i>P</i>&lt;0.05). USP7 expression in glioma, CESC, lung adenocarcinoma, mixed renal carcinoma, and LUSC was positively correlated with MSI expression (with Pearson correlation coefficients of 0.22, 0.14, 0.15, 0.08, and 0.14, respectively, <i>P</i>&lt;0.05), and USP7 expression in colon cancer, colorectal cancer, invasive breast cancer, prostate cancer, HNSC, thyroid cancer, and diffuse large B-cell lymphoma were significantly negatively correlated with MSI expression (with Pearson correlation coefficients of -0.31, -0.27, -0.13, -0.19, -0.16, -0.18, and -0.53, respectively, <i>P</i>&lt;0.05). The expression of USP7 in CESC was positively correlated with that of both MSH2 and MSH6 (with Spearman correlation coefficients of 0.51 and 0.44, respectively, <i>P</i>&lt;0.05), and the expression of USP7 in HNSC was positively correlated with the expression of EPCAM, MLH1, MSH2, MSH6, and PMS2 (with Spearman correlation coefficients of 0.39, 0.14, 0.49, 0.54, and 0.41, respectively, <i>P</i>&lt;0.05), and the expression of USP7 in LUSC was positively correlated with the expression of EPCAM, MSH2, MSH6, and PMS2 (with Spearman correlation coefficients of 0.20, 0.36, 0.40, and 0.34, respectively, <i>P</i>&lt;0.05), and the expression of USP7 in SKCM was positively correlated with the expression of EPCAM, MLH1, MSH2, MSH6, and PMS2 (with Spearman correlation coefficients of 0.11, 0.33, 0.42, 0.55, and 0.34, respectively, <i>P</i>&lt;0.05). The expression of USP7 in CESC, HNSC, LUSC, and SKCM was significantly positively correlated with the expression of DNMT1, DNMT3A, and DNMT3B (with Spearman correlation coefficients of 0.42, 0.34, 0.22, 0.45, 0.52, 0.22, 0.36, 0.36, 0.22, 0.38, 0.46, and 0.21, respectively, <i>P</i>&lt;0.05). The expression of USP7 in CESC, HNSC, LUSC, and SKCM was positively correlated with CD4<sup>+</sup> T cell infiltration (with Partial correlation coefficients of 0.14, 0.22, 0.13, and 0.16, respectively, <i>P</i>&lt;0.05). Being similar to the pattern of USP7 expression and ranked among top 100 protein sets, the top 5 proteins were C16orf72, BCLAF1, UBN, GSPT1, ERI2 (with Spearman correlation coefficients of 0.83, 0.74, 0.73, and 0.72, respectively, all <i>P</i> values&lt;0.05). The top 50 protein sets that directly physically bind to USP7 overlapped with the aforementioned protein set by only one protein, thyroid hormone receptor interaction factor 12. KEGG enrichment analysis showed that USP7 related genes were involved in cell cycle, spliceosome, cell senescence, and p53 signal pathway. GO enrichment analysis showed that USP7 related genes were involved in transcriptional regulation, protein ubiquitination, DNA repair, and cytoplasmic pattern recognition receptor signal pathways. Analysis of clinical samples showed that USP7 expression was significantly higher in hypertrophic scars (0.35&#xb1;0.05), scar ulcers (0.43&#xb1;0.04), and scar cancers (0.61&#xb1;0.03) than in normal skin (0.18&#xb1;0.04), <i>P</i>&lt;0.05. <b>Conclusions:</b> USP7 may be a clinical biomarker for the progression of cicatricial ulcer cancer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>S Y</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Institute of Burns, Tongren Hospital of Wuhan University &amp; Wuhan Third Hospital, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>J J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Institute of Burns, Tongren Hospital of Wuhan University &amp; Wuhan Third Hospital, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>D M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Tongren Hospital of Wuhan University &amp; Wuhan Third Hospital, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Burns, Tongren Hospital of Wuhan University &amp; Wuhan Third Hospital, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>W G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Institute of Burns, Tongren Hospital of Wuhan University &amp; Wuhan Third Hospital, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>Q F</ForeName><Initials>QF</Initials><AffiliationInfo><Affiliation>Institute of Burns, Tongren Hospital of Wuhan University &amp; Wuhan Third Hospital, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021CFB532</GrantID><Agency>Natural Science Foundation of Hubei Province</Agency><Country/></Grant><Grant><GrantID>WJ2021M260</GrantID><Agency>Scientific Research Project of Hubei Provincial Health Commission</Agency><Country/></Grant><Grant><GrantID>SZYZ-TR-10</GrantID><Agency>Project of Shanghai Wang Zhengguo Trauma Medicine Development Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi</MedlineTA><NlmUniqueID>9918751287306676</NlmUniqueID><ISSNLinking>2097-1109</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071858">Epithelial Cell Adhesion Molecule</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.3</RegistryNumber><NameOfSubstance UI="D000070976">Mismatch Repair Endonuclease PMS2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.3</RegistryNumber><NameOfSubstance UI="D051718">MutS Homolog 2 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.19.12</RegistryNumber><NameOfSubstance UI="D000076084">Ubiquitin-Specific Peptidase 7</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.19.12</RegistryNumber><NameOfSubstance UI="C464569">USP7 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017439" MajorTopicYN="N">Cicatrix, Hypertrophic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071858" MajorTopicYN="N">Epithelial Cell Adhesion Molecule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070976" MajorTopicYN="N">Mismatch Repair Endonuclease PMS2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051718" MajorTopicYN="N">MutS Homolog 2 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076084" MajorTopicYN="N">Ubiquitin-Specific Peptidase 7</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014456" MajorTopicYN="N">Ulcer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>&#x76ee;&#x7684;&#xff1a;</b> &#x63a2;&#x8ba8;&#x6cdb;&#x7d20;&#x7279;&#x5f02;&#x6027;&#x86cb;&#x767d;&#x9176;7&#xff08;USP7&#xff09;&#x5728;&#x7622;&#x75d5;&#x6e83;&#x75a1;&#x764c;&#x53d8;&#x8fc7;&#x7a0b;&#x4e2d;&#x7684;&#x751f;&#x7269;&#x5b66;&#x4f5c;&#x7528;&#x53ca;&#x5176;&#x4e34;&#x5e8a;&#x610f;&#x4e49;&#x3002; <b>&#x65b9;&#x6cd5;&#xff1a;</b> &#x91c7;&#x7528;&#x56de;&#x987e;&#x6027;&#x89c2;&#x5bdf;&#x6027;&#x7814;&#x7a76;&#x7ed3;&#x5408;&#x751f;&#x7269;&#x4fe1;&#x606f;&#x5b66;&#x5206;&#x6790;&#x65b9;&#x6cd5;&#x3002;&#x4ece;&#x764c;&#x75c7;&#x57fa;&#x56e0;&#x7ec4;&#x56fe;&#x8c31;&#xff08;TCGA&#xff09;&#x6570;&#x636e;&#x5e93;&#x548c;&#x57fa;&#x56e0;&#x8868;&#x8fbe;&#x7efc;&#x5408;&#x6570;&#x636e;&#x5e93;&#x4e2d;&#x83b7;&#x53d6;USP7&#x5728;&#x80bf;&#x7624;&#x548c;/&#x6216;&#x5176;&#x5bf9;&#x5e94;&#x764c;&#x65c1;&#x6b63;&#x5e38;&#x7ec4;&#x7ec7;&#x4e2d;&#x7684;RNA&#x8868;&#x8fbe;&#x8c31;&#x6570;&#x636e;&#xff0c;&#x5e76;&#x5c06;RNA&#x6d4b;&#x5e8f;&#x6570;&#x636e;&#x8fdb;&#x884c;log<sub>2</sub>&#x8f6c;&#x5316;&#x3002;&#x901a;&#x8fc7;&#x591a;&#x7ef4;&#x5ea6;&#x764c;&#x75c7;&#x57fa;&#x56e0;&#x96c6;cBioPortal&#x6570;&#x636e;&#x5e93;&#x5206;&#x6790;<i>USP7</i>&#x57fa;&#x56e0;&#x53d8;&#x5f02;&#x60c5;&#x51b5;&#xff0c;&#x5e76;&#x5206;&#x6790;&#x5176;&#x7a81;&#x53d8;&#x4f4d;&#x70b9;&#x3002;&#x901a;&#x8fc7;TIMER 2.0&#x6570;&#x636e;&#x5e93;&#x4e2d;&#x201c;&#x5dee;&#x5f02;&#x8868;&#x8fbe;&#x201d;&#x6a21;&#x5757;&#x83b7;&#x5f97;TCGA&#x6570;&#x636e;&#x5e93;&#x4e2d;&#x80bf;&#x7624;&#x3001;&#x764c;&#x65c1;&#x6b63;&#x5e38;&#x7ec4;&#x7ec7;USP7 mRNA&#x8868;&#x8fbe;&#x60c5;&#x51b5;&#x3002;&#x4f7f;&#x7528;&#x57fa;&#x56e0;&#x8868;&#x8fbe;&#x8c31;&#x4ea4;&#x4e92;&#x5206;&#x6790;2&#xff08;GEPIA2&#xff09;&#x6570;&#x636e;&#x5e93;&#x5206;&#x6790;&#x76ae;&#x80a4;&#x9ed1;&#x8272;&#x7d20;&#x7624;&#xff08;SKCM&#xff09;&#x3001;&#x5bab;&#x9888;&#x9cde;&#x72b6;&#x7ec6;&#x80de;&#x764c;&#xff08;CESC&#xff09;&#x3001;&#x80ba;&#x9cde;&#x72b6;&#x7ec6;&#x80de;&#x764c;&#xff08;LUSC&#xff09;&#x548c;&#x5934;&#x9888;&#x9cde;&#x72b6;&#x7ec6;&#x80de;&#x764c;&#xff08;HNSC&#xff09;&#x4e2d;&#x9ad8;&#x8868;&#x8fbe;USP7&#x60a3;&#x8005;&#x4e0e;&#x4f4e;&#x8868;&#x8fbe;USP7&#x60a3;&#x8005;&#x7684;&#x751f;&#x5b58;&#x7387;&#x5e76;&#x7ed8;&#x5236;Kaplan-Meier&#x751f;&#x5b58;&#x66f2;&#x7ebf;&#x3002;&#x5229;&#x7528;Sangerbox&#x6570;&#x636e;&#x5e93;&#x5206;&#x6790;USP7&#x5728;&#x6cdb;&#x764c;&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x4e0e;&#x5fae;&#x536b;&#x661f;&#x4e0d;&#x7a33;&#x5b9a;&#x6027;&#xff08;MSI&#xff09;&#x6216;&#x80bf;&#x7624;&#x7a81;&#x53d8;&#x8d1f;&#x62c5;&#xff08;TMB&#xff09;&#x7684;&#x76f8;&#x5173;&#x6027;&#x3002;&#x901a;&#x8fc7;GEPIA2&#x6570;&#x636e;&#x5e93;&#x4e2d;&#x201c;&#x76f8;&#x5173;&#x6027;&#x5206;&#x6790;&#x201d;&#x6a21;&#x5757;&#xff0c;&#x8bc4;&#x4f30;USP7&#x5728;&#x6cdb;&#x764c;&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x4e0e;5&#x79cd;DNA&#x9519;&#x914d;&#x4fee;&#x590d;&#x57fa;&#x56e0;&#xff08;<i>MLH1</i>&#x3001;<i>MSH2</i>&#x3001;<i>MSH6</i>&#x3001;<i>PMS2</i>&#x548c;<i>EPCAM</i>&#xff09;&#x8868;&#x8fbe;&#x6c34;&#x5e73;&#x548c;3&#x79cd;&#x5fc5;&#x9700;DNA&#x7532;&#x57fa;&#x8f6c;&#x79fb;&#x9176;&#xff08;DNMT&#xff09;&#x2014;&#x2014;DNMT1&#x3001;DNMT3A&#x3001;DNMT3B&#x8868;&#x8fbe;&#x6c34;&#x5e73;&#x7684;&#x76f8;&#x5173;&#x6027;&#x3002;&#x901a;&#x8fc7;TIMER 2.0&#x6570;&#x636e;&#x5e93;&#x4e2d;&#x201c;&#x514d;&#x75ab;-&#x57fa;&#x56e0;&#x201d;&#x6a21;&#x5757;&#x5206;&#x6790;USP7&#x5728;CESC&#x3001;HNSC&#x3001;LUSC&#x548c;SKCM&#x4e2d;&#x8868;&#x8fbe;&#x53ca;&#x5176;&#x4e0e;&#x514d;&#x75ab;&#x7ec6;&#x80de;&#xff08;B&#x7ec6;&#x80de;&#x3001;CD4<sup>+</sup>T&#x7ec6;&#x80de;&#x3001;CD8<sup>+</sup>T&#x7ec6;&#x80de;&#x3001;&#x4e2d;&#x6027;&#x7c92;&#x7ec6;&#x80de;&#x3001;&#x5de8;&#x566c;&#x7ec6;&#x80de;&#x548c;&#x6811;&#x7a81;&#x72b6;&#x7ec6;&#x80de;&#xff09;&#x6d78;&#x6da6;&#x7684;&#x76f8;&#x5173;&#x6027;&#x3002;&#x5229;&#x7528;GEPIA2&#x6570;&#x636e;&#x5e93;&#x7684;&#x201c;&#x76f8;&#x4f3c;&#x57fa;&#x56e0;&#x68c0;&#x6d4b;&#x201d;&#x6a21;&#x5757;&#x83b7;&#x5f97;&#x4e0e;USP7&#x8868;&#x8fbe;&#x6a21;&#x5f0f;&#x76f8;&#x4f3c;&#x4e14;&#x6392;&#x540d;&#x524d;100&#x7684;&#x86cb;&#x767d;&#x96c6;&#x3002;&#x5c06;&#x524d;&#x8ff0;&#x86cb;&#x767d;&#x96c6;&#x4e0e;&#x5229;&#x7528;STRING&#x6570;&#x636e;&#x5e93;&#x83b7;&#x5f97;&#x7684;&#x4e0e;USP7&#x6709;&#x76f4;&#x63a5;&#x7269;&#x7406;&#x7ed3;&#x5408;&#x4f5c;&#x7528;&#x4e14;&#x6392;&#x540d;&#x524d;50&#x7684;&#x86cb;&#x767d;&#x96c6;&#x8fdb;&#x884c;&#x4ea4;&#x96c6;&#x5206;&#x6790;&#x3002;&#x901a;&#x8fc7;DAVID&#x6570;&#x636e;&#x5e93;&#x5bf9;&#x4e0a;&#x8ff0;2&#x4e2a;&#x86cb;&#x767d;&#x96c6;&#x8fdb;&#x884c;&#x4eac;&#x90fd;&#x57fa;&#x56e0;&#x4e0e;&#x57fa;&#x56e0;&#x7ec4;&#x767e;&#x79d1;&#x5168;&#x4e66;&#xff08;KEGG&#xff09;&#x548c;&#x57fa;&#x56e0;&#x672c;&#x4f53;&#x8bba;&#xff08;GO&#xff09;&#x5bcc;&#x96c6;&#x5206;&#x6790;&#x3002;&#x6536;&#x96c6;2018&#x5e74;10&#x6708;&#x2014;2022&#x5e74;10&#x6708;&#x6b66;&#x6c49;&#x5927;&#x5b66;&#x9644;&#x5c5e;&#x540c;&#x4ec1;&#x533b;&#x9662;&#x66a8;&#x6b66;&#x6c49;&#x5e02;&#x7b2c;&#x4e09;&#x533b;&#x9662;&#x75c5;&#x7406;&#x79d1;&#x6709;&#x76f8;&#x5e94;&#x4e34;&#x5e8a;&#x75c5;&#x7406;&#x7279;&#x5f81;&#x7684;&#x6b63;&#x5e38;&#x76ae;&#x80a4;&#x3001;&#x589e;&#x751f;&#x6027;&#x7622;&#x75d5;&#x3001;&#x7622;&#x75d5;&#x6e83;&#x75a1;&#x3001;&#x7622;&#x75d5;&#x764c;&#x7684;&#x672f;&#x540e;&#x6807;&#x672c;&#xff0c;&#x91c7;&#x7528;&#x514d;&#x75ab;&#x7ec4;&#x7ec7;&#x5316;&#x5b66;&#x6cd5;&#x68c0;&#x6d4b;&#x7ec4;&#x7ec7;&#x4e2d;USP7&#x8868;&#x8fbe;&#x60c5;&#x51b5;&#xff0c;&#x6837;&#x672c;&#x6570;&#x4e3a;6&#x3002;&#x5bf9;&#x6570;&#x636e;&#x884c;Log-rank&#x68c0;&#x9a8c;&#x3001;&#x5355;&#x56e0;&#x7d20;&#x65b9;&#x5dee;&#x5206;&#x6790;&#x53ca;Bonferroni&#x68c0;&#x9a8c;&#x3002; <b>&#x7ed3;&#x679c;&#xff1a;</b> &#x5728;&#x6cdb;&#x764c;&#x4e2d;&#xff0c;<i>USP7</i>&#x7684;&#x4e3b;&#x8981;&#x57fa;&#x56e0;&#x53d8;&#x5f02;&#x7c7b;&#x578b;&#x4e3a;&#x7a81;&#x53d8;&#x548c;&#x6269;&#x589e;&#xff0c;&#x53d8;&#x5f02;&#x9891;&#x7387;&#xff08;&gt;6%&#xff09;&#x5c45;&#x524d;3&#x4f4d;&#x7684;&#x80bf;&#x7624;&#x4f9d;&#x6b21;&#x4e3a;&#x8180;&#x80f1;&#x5c3f;&#x8def;&#x4e0a;&#x76ae;&#x764c;&#x3001;SKCM&#x548c;&#x5b50;&#x5bab;&#x5185;&#x819c;&#x764c;&#x3002;<i>USP7</i>&#x57fa;&#x56e0;&#x5728;&#x6cdb;&#x764c;&#x4e2d;&#x7684;&#x4e3b;&#x8981;&#x7a81;&#x53d8;&#x4e3a;&#x9519;&#x4e49;&#x7a81;&#x53d8;&#x3002;&#x5728;&#x7a81;&#x53d8;&#x9891;&#x7387;&#x6700;&#x9ad8;&#x7684;SKCM&#x4e2d;&#xff0c;&#x4e3b;&#x8981;&#x7a81;&#x53d8;&#x7c7b;&#x578b;&#x662f;USP7_ICP0_bdg&#x7ed3;&#x6784;&#x57df;&#x7684;&#x9519;&#x4e49;&#x7a81;&#x53d8;&#x3002;USP7 mRNA&#x5728;&#x4e73;&#x817a;&#x6d78;&#x6da6;&#x764c;&#x3001;&#x80c6;&#x7ba1;&#x764c;&#x3001;&#x7ed3;&#x80a0;&#x764c;&#x3001;&#x98df;&#x7ba1;&#x764c;&#x3001;HNSC&#x3001;&#x80be;&#x5acc;&#x8272;&#x7ec6;&#x80de;&#x764c;&#x3001;&#x809d;&#x7ec6;&#x80de;&#x809d;&#x764c;&#x3001;&#x80ba;&#x817a;&#x764c;&#x3001;LUSC&#x3001;&#x524d;&#x5217;&#x817a;&#x764c;&#x548c;&#x80c3;&#x764c;&#x80bf;&#x7624;&#x7ec4;&#x7ec7;&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x5747;&#x660e;&#x663e;&#x9ad8;&#x4e8e;&#x5176;&#x5bf9;&#x5e94;&#x7684;&#x764c;&#x65c1;&#x6b63;&#x5e38;&#x7ec4;&#x7ec7;&#xff08;<i>P</i>&lt;0.05&#xff09;&#xff0c;&#x5728;&#x591a;&#x5f62;&#x6210;&#x6027;&#x80f6;&#x8d28;&#x7ec6;&#x80de;&#x7624;&#x3001;&#x80be;&#x900f;&#x660e;&#x7ec6;&#x80de;&#x764c;&#x3001;&#x80be;&#x4e73;&#x5934;&#x72b6;&#x7ec6;&#x80de;&#x764c;&#x548c;&#x7532;&#x72b6;&#x817a;&#x764c;&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x5747;&#x660e;&#x663e;&#x4f4e;&#x4e8e;&#x5176;&#x5bf9;&#x5e94;&#x7684;&#x764c;&#x65c1;&#x6b63;&#x5e38;&#x7ec4;&#x7ec7;&#xff08;<i>P</i>&lt;0.05&#xff09;&#xff1b;&#x6b64;&#x5916;&#xff0c;USP7 mRNA&#x5728;SKCM&#x8f6c;&#x79fb;&#x7ec4;&#x7ec7;&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x8fdc;&#x9ad8;&#x4e8e;&#x5176;&#x539f;&#x53d1;&#x80bf;&#x7624;&#x7ec4;&#x7ec7;&#xff08;<i>P</i>&lt;0.05&#xff09;&#x3002;&#x751f;&#x5b58;&#x66f2;&#x7ebf;&#x663e;&#x793a;&#xff0c;&#x5728;CESC&#x3001;HNSC&#x3001;LUSC&#x548c;SKCM&#x4e2d;&#xff0c;&#x9ad8;&#x8868;&#x8fbe;USP7&#x60a3;&#x8005;&#x4e0e;&#x4f4e;&#x8868;&#x8fbe;USP7&#x60a3;&#x8005;&#x7684;&#x5b58;&#x6d3b;&#x7387;&#x6bd4;&#x8f83;&#xff0c;&#x5dee;&#x5f02;&#x5747;&#x65e0;&#x7edf;&#x8ba1;&#x5b66;&#x610f;&#x4e49;&#xff08;Log-rank <i>P</i>&gt;0.05&#xff0c;&#x98ce;&#x9669;&#x6bd4;&#x5206;&#x522b;&#x4e3a;1.00&#x3001;0.99&#x3001;1.00&#x3001;1.30&#xff09;&#x3002;USP7&#x5728;&#x7ed3;&#x80a0;&#x764c;&#x3001;&#x7ed3;&#x76f4;&#x80a0;&#x764c;&#x3001;&#x80f8;&#x817a;&#x764c;&#x3001;&#x7532;&#x72b6;&#x817a;&#x764c;&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x5747;&#x4e0e;TMB&#x5448;&#x663e;&#x8457;&#x8d1f;&#x76f8;&#x5173;&#xff08;Pearson&#x76f8;&#x5173;&#x7cfb;&#x6570;&#x5206;&#x522b;&#x4e3a;-0.26&#x3001;-0.19&#x3001;-0.19&#x548c;-0.11&#xff0c;<i>P</i>&lt;0.05&#xff09;&#xff1b;USP7&#x5728;&#x795e;&#x7ecf;&#x80f6;&#x8d28;&#x7624;&#x3001;CESC&#x3001;&#x80ba;&#x817a;&#x764c;&#x3001;&#x6df7;&#x5408;&#x80be;&#x764c;&#x3001;LUSC&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x5747;&#x4e0e;MSI&#x5448;&#x663e;&#x8457;&#x6b63;&#x76f8;&#x5173;&#xff08;Pearson&#x76f8;&#x5173;&#x7cfb;&#x6570;&#x5206;&#x522b;&#x4e3a;0.22&#x3001;0.14&#x3001;0.15&#x3001;0.08&#x548c;0.14&#xff0c;<i>P</i>&lt;0.05&#xff09;&#xff0c;&#x5728;&#x7ed3;&#x80a0;&#x764c;&#x3001;&#x7ed3;&#x76f4;&#x80a0;&#x764c;&#x3001;&#x4e73;&#x817a;&#x6d78;&#x6da6;&#x764c;&#x3001;&#x524d;&#x5217;&#x817a;&#x764c;&#x3001;HNSC&#x3001;&#x7532;&#x72b6;&#x817a;&#x764c;&#x548c;&#x5f25;&#x6f2b;&#x6027;&#x5927;B&#x7ec6;&#x80de;&#x6dcb;&#x5df4;&#x7624;&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x5747;&#x4e0e;MSI&#x5448;&#x663e;&#x8457;&#x8d1f;&#x76f8;&#x5173;&#xff08;Pearson&#x76f8;&#x5173;&#x7cfb;&#x6570;&#x5206;&#x522b;&#x4e3a;-0.31&#x3001;-0.27&#x3001;-0.13&#x3001;-0.19&#x3001;-0.16&#x3001;-0.18&#x548c;-0.53&#xff0c;<i>P</i>&lt;0.05&#xff09;&#x3002;USP7&#x5728;CESC&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x4e0e;MSH2&#x548c;MSH6&#x7684;&#x8868;&#x8fbe;&#x5747;&#x5448;&#x660e;&#x663e;&#x6b63;&#x76f8;&#x5173;&#xff08;Spearman&#x76f8;&#x5173;&#x7cfb;&#x6570;&#x5206;&#x522b;&#x4e3a;0.51&#x548c;0.44&#xff0c;<i>P</i>&lt;0.05&#xff09;&#xff0c;&#x5728;HNSC&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x4e0e;EPCAM&#x3001;MLH1&#x3001;MSH2&#x3001;MSH6&#x3001;PMS2&#x7684;&#x8868;&#x8fbe;&#x5747;&#x5448;&#x660e;&#x663e;&#x6b63;&#x76f8;&#x5173;&#xff08;Spearman&#x76f8;&#x5173;&#x7cfb;&#x6570;&#x5206;&#x522b;&#x4e3a;0.39&#x3001;0.14&#x3001;0.49&#x3001;0.54&#x548c;0.41&#xff0c;<i>P</i>&lt;0.05&#xff09;&#xff0c;&#x5728;LUSC&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x4e0e;EPCAM&#x3001;MSH2&#x3001;MSH6&#x548c;PMS2&#x7684;&#x8868;&#x8fbe;&#x5747;&#x5448;&#x660e;&#x663e;&#x6b63;&#x76f8;&#x5173;&#xff08;Spearman&#x76f8;&#x5173;&#x7cfb;&#x6570;&#x5206;&#x522b;&#x4e3a;0.20&#x3001;0.36&#x3001;0.40&#x548c;0.34&#xff0c;<i>P</i>&lt;0.05&#xff09;&#xff0c;&#x5728;SKCM&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x4e0e;EPCAM&#x3001;MLH1&#x3001;MSH2&#x3001;MSH6&#x548c;PMS2&#x7684;&#x8868;&#x8fbe;&#x5747;&#x5448;&#x660e;&#x663e;&#x6b63;&#x76f8;&#x5173;&#xff08;Spearman&#x76f8;&#x5173;&#x7cfb;&#x6570;&#x5206;&#x522b;&#x4e3a;0.11&#x3001;0.33&#x3001;0.42&#x3001;0.55&#x548c;0.34&#xff0c;<i>P</i>&lt;0.05&#xff09;&#xff1b;USP7&#x5728;CESC&#x3001;HNSC&#x3001;LUSC&#x548c;SKCM&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x4e0e;DNMT1&#x3001;DNMT3A&#x548c;DNMT3B&#x7684;&#x8868;&#x8fbe;&#x5747;&#x5448;&#x663e;&#x8457;&#x6b63;&#x76f8;&#x5173;&#xff08;Spearman&#x76f8;&#x5173;&#x7cfb;&#x6570;&#x5206;&#x522b;&#x4e3a;0.42&#x3001;0.34&#x548c;0.22&#xff0c;0.45&#x3001;0.52&#x548c;0.22&#xff0c;0.36&#x3001;0.36&#x548c;0.22&#xff0c;0.38&#x3001;0.46&#x548c;0.21&#xff0c;<i>P</i>&lt;0.05&#xff09;&#x3002;USP7&#x5728;CESC&#x3001;HNSC&#x3001;LUSC&#x548c;SKCM&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x4ec5;&#x4e0e;CD4<sup>+</sup>T&#x7ec6;&#x80de;&#x6d78;&#x6da6;&#x5448;&#x663e;&#x8457;&#x6b63;&#x76f8;&#x5173;&#xff08;Partial&#x76f8;&#x5173;&#x7cfb;&#x6570;&#x5206;&#x522b;&#x4e3a;0.14&#x3001;0.22&#x3001;0.13&#x3001;0.16&#xff0c;<i>P</i>&lt;0.05&#xff09;&#x3002;&#x4e0e;USP7&#x8868;&#x8fbe;&#x6a21;&#x5f0f;&#x76f8;&#x4f3c;&#x4e14;&#x6392;&#x540d;&#x524d;100&#x7684;&#x86cb;&#x767d;&#x96c6;&#x4e2d;&#xff0c;&#x6392;&#x540d;&#x524d;5&#x7684;&#x86cb;&#x767d;&#x4f9d;&#x6b21;&#x662f;C16orf72&#x3001;BCLAF1&#x3001;UBN&#x3001;GSPT1&#x3001;ERI2&#xff08;Spearman&#x76f8;&#x5173;&#x7cfb;&#x6570;&#x5206;&#x522b;&#x4e3a;0.83&#x3001;0.74&#x3001;0.73&#x3001;0.73&#x548c;0.72&#xff0c;<i>P</i>&#x503c;&#x5747;&lt;0.05&#xff09;&#x3002;&#x4e0e;USP7&#x6709;&#x76f4;&#x63a5;&#x7269;&#x7406;&#x7ed3;&#x5408;&#x4f5c;&#x7528;&#x4e14;&#x6392;&#x540d;&#x524d;50&#x7684;&#x86cb;&#x767d;&#x96c6;&#x4e0e;&#x524d;&#x8ff0;&#x86cb;&#x767d;&#x96c6;&#x7684;&#x4ea4;&#x96c6;&#x4ec5;&#x6709;1&#x4e2a;&#x86cb;&#x767d;&#xff0c;&#x5373;&#x4e3a;&#x7532;&#x72b6;&#x817a;&#x6fc0;&#x7d20;&#x53d7;&#x4f53;&#x76f8;&#x4e92;&#x4f5c;&#x7528;&#x56e0;&#x5b50;12&#x3002;KEGG&#x5bcc;&#x96c6;&#x5206;&#x6790;&#x663e;&#x793a;&#xff0c;USP7&#x76f8;&#x5173;&#x57fa;&#x56e0;&#x6d89;&#x53ca;&#x7ec6;&#x80de;&#x5468;&#x671f;&#x3001;&#x526a;&#x63a5;&#x4f53;&#x3001;&#x7ec6;&#x80de;&#x8870;&#x8001;&#x548c;p53&#x4fe1;&#x53f7;&#x901a;&#x8def;&#x7b49;&#x3002;GO&#x5bcc;&#x96c6;&#x5206;&#x6790;&#x663e;&#x793a;&#xff0c;USP7&#x76f8;&#x5173;&#x57fa;&#x56e0;&#x6d89;&#x53ca;&#x8f6c;&#x5f55;&#x8c03;&#x63a7;&#x3001;&#x86cb;&#x767d;&#x8d28;&#x6cdb;&#x7d20;&#x5316;&#x3001;DNA&#x4fee;&#x590d;&#x548c;&#x7ec6;&#x80de;&#x8d28;&#x6a21;&#x5f0f;&#x8bc6;&#x522b;&#x53d7;&#x4f53;&#x4fe1;&#x53f7;&#x901a;&#x8def;&#x7b49;&#x3002;&#x4e34;&#x5e8a;&#x6837;&#x672c;&#x5206;&#x6790;&#x663e;&#x793a;&#xff0c;USP7&#x5728;&#x589e;&#x751f;&#x6027;&#x7622;&#x75d5;&#xff08;0.35&#xb1;0.05&#xff09;&#x3001;&#x7622;&#x75d5;&#x6e83;&#x75a1;&#xff08;0.43&#xb1;0.04&#xff09;&#x548c;&#x7622;&#x75d5;&#x764c;&#xff08;0.61&#xb1;0.03&#xff09;&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x5747;&#x660e;&#x663e;&#x9ad8;&#x4e8e;&#x6b63;&#x5e38;&#x76ae;&#x80a4;&#xff08;0.18&#xb1;0.04&#xff09;&#xff0c;<i>P</i>&lt;0.05&#x3002; <b>&#x7ed3;&#x8bba;&#xff1a;</b> USP7&#x53ef;&#x80fd;&#x4e3a;&#x4e34;&#x5e8a;&#x7622;&#x75d5;&#x6e83;&#x75a1;&#x764c;&#x53d8;&#x6076;&#x5316;&#x7684;&#x751f;&#x7269;&#x6807;&#x5fd7;&#x7269;&#x3002;.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>1</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>8</Day><Hour>1</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37805766</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn501225-20230421-00137</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37784026</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2407</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>BMC cancer</Title><ISOAbbreviation>BMC Cancer</ISOAbbreviation></Journal><ArticleTitle>Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer.</ArticleTitle><Pagination><StartPage>929</StartPage><MedlinePgn>929</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">929</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-023-11426-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immunoglobulin lambda (Ig&#x3bb;) has been reported to be expressed in many normal and tumor tissues and cells. However, the function and clinical significance of tumor-derived Ig&#x3bb; remain unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The differential expressions of Immunoglobulin Lambda Constants (IGLCs) in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) were examined with The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Human Protein Atlas (HPA) databases. The effects of IGLCs on patient clinical phenotypes and prognosis were explored via bioinformatics analyses based on the TCGA databases. We used the bioinformatics analyses based on the TCGA and GTEx databases to elucidate the correlations among IGLC expressions, immunomodulator expressions, tumor stemness, and infiltration scores of tumor infiltrating immune cells. Co-immunoprecipitation (Co-IP) and silver staining combined with liquid chromatography-tandem mass spectrometry (LC-MS/MS) were used to obtain potential tumor-derived Ig&#x3bb;-interacting proteins. Functional annotation of candidate proteins identified by LC-MS/MS was performed in Database for Annotation, Visualization and Integrated Discovery (DAVID). The bioinformatics analyses of 7 IGLCs in CESC and normal cervical tissues were performed based on TCGA, GTEx, and Gene Expression Profiling Interactive Analysis 2 (GEPIA2) databases. Protein-protein interaction (PPI) network was analyzed based on tumor-derived Ig&#x3bb;-interacting proteins in Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database. Immunohistochemistry (IHC) was used to validate the expressions of IGLCs in CESC.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that the expressions of the majority of IGLCs (IGLC1, IGLC2, IGLC3, IGLC4, IGLC5, IGLC6, and IGLC7) were upregulated in CESC tissues, compared with those in normal cervical tissues. The expressions of IGLC5 and IGLC7 had significant difference in different pathologic metastasis (M), one of tumor, node, and metastasis (TNM) staging system, categories of CESC. Except for disease-free interval (DFI), 4 IGLC (IGLC1, IGLC2, IGLC3, and IGLC7) expression levels were positively associated with patient overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) respectively in CESC tissues. 5 IGLC (IGLC1, IGLC2, IGLC3, IGLC6, and IGLC7) expressions were positively correlated with the expressions of a majority of immunomodulators respectively in CESC tissues. Tumor stemness was negatively correlated with the expressions of 4 IGLCs (IGLC1, IGLC2, IGLC3, and IGLC7) respectively in CESC tissues. Except for IGLC4, IGLC5, and IGLC7, 4 IGLC (IGLC1, IGLC2, IGLC3, and IGLC6) expressions were positively correlated with infiltration scores of 6 tumor-infiltrating immune cells (B cell, T cell CD4, T cell CD8, neutrophil, macrophage, and DC). After analyses of the above bioinformatics data of tumor-derived Ig&#x3bb;, Co-IP and LC-MS/MS were used to confirm that 4 proteins (RPL7, RPS3, H1-5, and H1-6) might interact with tumor-derived Ig&#x3bb; in cervical cancer cells. Functional analyses of these candidate proteins showed that they interacted with many proteins and were involved in various cellular biological processes. Finally, IHC was used to further confirm the above bioinformatics results, it was indicated that the expression level of Ig&#x3bb; in cervical adenocarcinoma and cervical squamous cell carcinoma was higher than that in normal cervical tissue.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study comprehensively investigated the functions of tumor-derived Ig&#x3bb; and its interacting proteins based on bioinformatics analysis and the potential value of Ig&#x3bb; as a prognostic and therapeutic marker for CESC, providing new direction and evidence for CESC therapy.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Juping</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. juping0128@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Binhai Branch of National Regional Medical Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. juping0128@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Jiangni</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ding</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Haohua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fanlu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yupeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Fujian Provincial Institutes of Brain Disorders and Brain Sciences, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. 1933752059@qq.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, The First Affiliated Hospital, Neurosurgery Research Institute, Fujian Medical University, Fuzhou, China. 1933752059@qq.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cancer</MedlineTA><NlmUniqueID>100967800</NlmUniqueID><ISSNLinking>1471-2407</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007146">Immunoglobulin lambda-Chains</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007146" MajorTopicYN="N">Immunoglobulin lambda-Chains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Analysis</Keyword><Keyword MajorTopicYN="N">Bioinformatics</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Function</Keyword><Keyword MajorTopicYN="N">Immunoglobulin lambda</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37784026</ArticleId><ArticleId IdType="pmc">PMC10544594</ArticleId><ArticleId IdType="doi">10.1186/s12885-023-11426-9</ArticleId><ArticleId IdType="pii">10.1186/s12885-023-11426-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lv WQ, Peng J, Wang HC, Chen DP, Yang Y, Zhao Y, et al. Expression of cancer cell-derived IgG and extra domain A-containing fibronectin in salivary adenoid cystic carcinoma. Arch Oral Biol. 2017;81:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">28460248</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J, Wang HC, Liu Y, Jiang JH, Lv WQ, Yang Y, et al. Involvement of non-B cell-derived immunoglobulin G in the metastasis and prognosis of salivary adenoid cystic carcinoma. Oncol Lett. 2017;14(4):4491&#x2013;4498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5649563</ArticleId><ArticleId IdType="pubmed">29085446</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Tang M, Deng X. Positive immunoglobulin A expression in human epithelial carcinoma cell lines. Zhonghua Zhong Liu Za Zhi. 2001;23(6):451&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">11859707</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Li M, Ren W, Zeng L, Liu HD, Hu D, et al. Expression and secretion of immunoglobulin alpha heavy chain with diverse VDJ recombinations by human epithelial cancer cells. Mol Immunol. 2007;44(9):2221&#x2013;2227.</Citation><ArticleIdList><ArticleId IdType="pubmed">17174398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimoto Y. Expression of heavy-chain constant region of immunoglobulin and T-cell receptor gene transcripts in human non-hematopoietic tumor cell lines. Genes Chromosomes Cancer. 1998;22(1):83&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591639</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui M, Hu Y, Zheng B, Zhang S, Zhang X, Wang M, et al. Cancer-derived immunoglobulin G, A novel marker for differential diagnosis and relapse prediction in parathyroid carcinoma. Clin Endocrinol (Oxf) 2020;92(5):461&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">31943291</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu JB, Zheng S, Deng YC. Expression of a novel immunoglobulin gene SNC73 in human cancer and non-cancerous tissues. World J Gastroenterol. 2003;9(5):1054&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4611371</ArticleId><ArticleId IdType="pubmed">12717855</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Ge B. Cancer cell expressions of immunoglobulin heavy chains with unique carbohydrate-associated biomarker. Cancer Biomark. 2009;5(4):177&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">19729827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F, Zhang L, Zheng J, Zhao L, Huang J, Shao W. Spontaneous production of immunoglobulin M in human epithelial cancer cells. PLoS ONE. 2012;7(12):e51423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3520907</ArticleId><ArticleId IdType="pubmed">23251529</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J, Zhang J, Liu Y, Liao Q, Huang J, Geng Z, et al. Lung squamous cell carcinoma cells express non-canonically glycosylated IgG that activates integrin-FAK signaling. Cancer Lett. 2018;430:148&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">29778566</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Yang X, Zhu G. Expression and clinical significance of cancer-derived Immunoglobulin G in non-small cell lung cancer by bioinformatics and immunohistochemistry. Zhongguo Fei Ai Za Zhi. 2019;22(6):341&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580082</ArticleId><ArticleId IdType="pubmed">31196367</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X, Zhu X, Zhang L, Mao Y, Zhang J, Hao P, et al. Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells. Cancer Res. 2003;63(19):6488&#x2013;6495.</Citation><ArticleIdList><ArticleId IdType="pubmed">14559841</ArticleId></ArticleIdList></Reference><Reference><Citation>Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray, identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 2001;61(5):2129&#x2013;2137.</Citation><ArticleIdList><ArticleId IdType="pubmed">11280777</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Tan C, Xiang Q, Zhang X, Ma J, Wang JR, et al. Proteomic detection of changes in protein synthesis induced by NGX6 transfected in human nasopharyngeal carcinoma cells. J Protein Chem. 2001;20(3):265&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">11565907</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, Lei Y, Li Z, Wang J, Chen Z, McNutt M, et al. Pancreatic expression of immunoglobulin G in human pancreatic cancer and associated diabetes. Pancreas. 2015;44(8):1304&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pubmed">26390427</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Wang J, Zhang Q, Zhang J, Lou Y, Yang J, et al. Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. Br J Cancer. 2019;121(9):786&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6889176</ArticleId><ArticleId IdType="pubmed">31588122</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui M, You L, Zheng B, Huang X, Liu Q, Huang J, et al. High expression of cancer-derived glycosylated immunoglobulin G predicts poor prognosis in pancreatic ductal adenocarcinoma. J Cancer. 2020;11(8):2213&#x2013;2221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7052941</ArticleId><ArticleId IdType="pubmed">32127948</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui M, You L, Zheng B, Huang X, Liu Q, Huang J, et al. Erratum, high expression of cancer-derived glycosylated immunoglobulin G predicts poor prognosis in pancreatic ductal adenocarcinoma, erratum. J Cancer. 2021;12(21):6497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8489131</ArticleId><ArticleId IdType="pubmed">34659540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Z, Liu Y, Qin C, Liu Z, Yuan Y, Hu F, et al. IgG is involved in the migration and invasion of clear cell renal cell carcinoma. J Clin Pathol. 2016;69(6):497&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893138</ArticleId><ArticleId IdType="pubmed">26519488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Lin D, Peng H, Huang Y, Huang J, Gu J. Cancer-derived immunoglobulin G promotes tumor cell growth and proliferation through inducing production of reactive oxygen species. Cell Death Dis. 2013;4(12):e945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877547</ArticleId><ArticleId IdType="pubmed">24309932</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Z, Liu Y, Qin C, Liu Z, Yuan Y, Yin H, et al. Involvement of cancer-derived IgG in the proliferation, migration and invasion of bladder cancer cells. Oncol Lett. 2016;12(6):5113&#x2013;5121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5228517</ArticleId><ArticleId IdType="pubmed">28105218</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang PY, Li HY, Zhou ZY, Jin YX, Wang SX, Peng XH, et al. Overexpression of immunoglobulin G prompts cell proliferation and inhibits cell apoptosis in human urothelial carcinoma. Tumour Biol. 2013;34(3):1783&#x2013;1791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661916</ArticleId><ArticleId IdType="pubmed">23483488</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui M, Liao Q, Li J, Habib JR, Kinny-K&#xf6;ster B, Dong Y, et al. Expression of cancer-derived immunoglobulin G during malignant progression in intraductal papillary mucinous neoplasms, a pilot study. Pancreas. 2020;49(6):e51&#x2013;e54.</Citation><ArticleIdList><ArticleId IdType="pubmed">32590623</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonegawa S. Reiteration frequency of immunoglobulin light chain genes, further evidence for somatic generation of antibody diversity. Proc Natl Acad Sci U S A. 1976;73(1):203&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC335869</ArticleId><ArticleId IdType="pubmed">813222</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieber M. Immunoglobulin diversity, rearranging by cutting and repairing. Curr Biol. 1996;6(2):134&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">8673457</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambin P. Les g&#xe8;nes des immunoglobulinesetl'origine de la diversit&#xe9; des anticorps [Immunoglobulin genes and the origin of antibody diversity. Rev Fr Transfus Hemobiol. 1992;35(1):47&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">1590884</ArticleId></ArticleIdList></Reference><Reference><Citation>Feige MJ, Hendershot LM, Buchner J. How antibodies fold. Trends Biochem Sci. 2010;35(4):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4716677</ArticleId><ArticleId IdType="pubmed">20022755</ArticleId></ArticleIdList></Reference><Reference><Citation>Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry. 1981;20(9):2361&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">7236608</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuochi T, Taniguchi T, Shimizu A, Kobata A. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol. 1982;129(5):2016&#x2013;2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">6811655</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. Cell Immunol. 2018;333:65&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">30107893</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Azadi P. Peptide mapping and glycoanalysis of cancer cell-expressed glycoproteins CA215 recognized by RP215 Monoclonal Antibody. J Carbohydr Chem. 2012;31(1):10&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8597943</ArticleId><ArticleId IdType="pubmed">34795465</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Laflamme E, Chien CH, Ting HH. Molecular identity of a pan cancer marker, CA215. Cancer Biol Ther. 2008;7(12):2007&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">19158477</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Wu L, Zhang L, Hao P, Zhang S, Huang J, et al. Distinct regulatory mechanism of immunoglobulin gene transcription in epithelial cancer cells. Cell Mol Immunol. 2010;7(4):279&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003226</ArticleId><ArticleId IdType="pubmed">20473321</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Lin D, Peng H, Shao J, Gu J. Cancer-derived immunoglobulin G promotes LPS-induced proinflammatory cytokine production via binding to TLR4 in cervical cancer cells. Oncotarget. 2014;5(20):9727&#x2013;9743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4259433</ArticleId><ArticleId IdType="pubmed">25179302</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Cheung AP, Li B, Ge B, Chow PM. Molecular and immuno-characteristics of immunoglobulin-like glycoproteins in cancer cell-expressed biomarker, CA215. Immunol Invest. 2012;41(4):429&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">22417288</ArticleId></ArticleIdList></Reference><Reference><Citation>Crescence L, Beraud E, Sbarra V, Bernard JP, Lombardo D, Mas E. Targeting a novel onco-glycoprotein antigen at tumoral pancreatic cell surface by mAb16D10 induces cell death. J Immunol. 2012;189(7):3386&#x2013;3396.</Citation><ArticleIdList><ArticleId IdType="pubmed">22956586</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi X, Li Y, Qiu X. V(D)J recombination, somatic hypermutation and class switch recombination of immunoglobulins, mechanism and regulation. Immunology. 2020;160(3):233&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7341547</ArticleId><ArticleId IdType="pubmed">32031242</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder HJ, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125:S41&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3670108</ArticleId><ArticleId IdType="pubmed">20176268</ArticleId></ArticleIdList></Reference><Reference><Citation>Riesen W. Structure and biological properties of immunoglobulins and gamma-globulin preparations. I. Structure and function of immunoglobulins. Schweiz Med Wochenschr. 1980;110(3):74&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7394504</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Lin D, Peng H, Huang Y, Huang J, Gu J. Cancer-derived immunoglobulin G promotes tumor cell growth and proliferation through inducing production of reactive oxygen species. Cell Death Dis. 2013;4:e945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877547</ArticleId><ArticleId IdType="pubmed">24309932</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Kang B, Huang X, Yan Y, Wang S, Ye Y, et al. Cancer IgG, a potential prognostic marker, promotes colorectal cancer progression. Chin J Cancer Res. 2019;31:499&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613500</ArticleId><ArticleId IdType="pubmed">31354219</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Geng Z, Shao W, Liu E, Zhang J, Tang J, Wang P, Sun X, Xiao L, Xu W, Zhang Y, Cui H, Zhang L, Yang X, Chang X, Qiu X. Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells. Cell Mol Immunol. 2020;17(11):1148&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7784903</ArticleId><ArticleId IdType="pubmed">31754235</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan T, Liao Q, Zhao Y, Dai H, Song S, He T, Wang Z, Huang J, Zeng Z, Guo H, Zhang H, Qiu X. Sialylated IgG in epithelifal cancers inhibits antitumor function of T cells via Siglec-7. Cancer Sci. 2023;114(2):370&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9899632</ArticleId><ArticleId IdType="pubmed">36310398</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, Liu JF, Shao WW, Xiao L, Li GH, Chang XH, et al. Tumor derived IgG suppress the proliferation of T cells in cord blood. Beijing Da Xue Xue Bao Yi Xue Ban. 2017;49:824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">29045963</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Q, Liu W, Liu Y, Wang F, Wang C, Zhang J, et al. Aberrant high expression of immunoglobulin G in epithelial stem/progenitor-like cells contributes to tumor initiation and metastasis. Oncotarget. 2015;6:40081&#x2013;40094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4741881</ArticleId><ArticleId IdType="pubmed">26472025</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao S, Shu D, Zhu Y, Lu M, Zhang Q, Pei Y, et al. Cancer cell-derived immunoglobulin G activates platelets by binding to platelet Fc&#x3b3;RIIa. Cell Death Dis. 2019;10:87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6349849</ArticleId><ArticleId IdType="pubmed">30692520</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JP, Chen HY, Peng H. Functional analysis of cancer-derived immunoglobulin G whole molecule-interacting proteins identified by LC-MS/MS. Nan Fang Yi Ke Da Xue Xue Bao. 2015;35:93&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25613617</ArticleId></ArticleIdList></Reference><Reference><Citation>Amzel LM, Poljak RJ. Three-dimensional structure of immunoglobulins. Annu Rev Biochem. 1979;48:961&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">89832</ArticleId></ArticleIdList></Reference><Reference><Citation>Maibom-Thomsen SL, Trier NH, Holm BE, Hansen KB, Rasmussen MI, Chailyan A, et al. Immunoglobulin G structure and rheumatoid factor epitopes. PLoS ONE. 2019;14:e0217624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568389</ArticleId><ArticleId IdType="pubmed">31199818</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Wang M, You W. Co-expression of immunoglobulin light chain kappa and lambda in gastric carcinoma cell. Zhonghua Zhong Liu Za Zhi. 2002;24:465&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">12485500</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SB, Chen X, Wu BY, Wang MW, Cai CH, Cho DB, Chong J, Li P, Tang SG, Yang PC. Immunoglobulin kappa and immunoglobulin lambda are required for expression of the anti-apoptotic molecule Bcl-xL in human colorectal cancer tissue. Scand J Gastroenterol. 2009;44(12):1443&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pubmed">19883274</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber-Matthiesen K, Winkemann M, Grote W, Schlegelberger B. Kappa- and lambda-positive cells in centroblastic-centrocytic lymphoma (follicular lymphoma) may share a secondary chromosome aberration: reflections on early lymphoma development. Genes Chromosomes Cancer. 1995;14(1):22&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">8527380</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T, Kitabatake K, Iino M, Goto K. Immunohistochemical comparison of CD5, lambda, and kappa expression in primary and recurrent buccal mucosa-associated lymphoid tissue (MALT) lymphomas. Diagn Pathol. 2011;6:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3180694</ArticleId><ArticleId IdType="pubmed">21892966</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Xia M, Sun X, Han X, Zu Y, Jabbour EJ, et al. High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia. Eur J Haematol. 2020;105:449&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">32535947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SB, Kwon IS, Park J, Lee KH, Ahn Y, Lee C, et al. Ribosomal protein S3, a new substrate of Akt, serves as a signal mediator between neuronal apoptosis and DNA repair. J Biol Chem. 2010;285(38):29457&#x2013;29468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2937978</ArticleId><ArticleId IdType="pubmed">20605787</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Hardwidge PR. Ribosomal protein s3; a multifunctional target of attaching/effacing bacterial pathogens. Front Microbiol. 2011;2:137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125523</ArticleId><ArticleId IdType="pubmed">21738525</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Cao J, Hu K, Wang P, Li G, He X, et al. RNA-binding protein RPS3 contributes to hepatocarcinogenesis by post-transcriptionally up-regulating SIRT1. Nucleic Acids Res. 2019;47(4):2011&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6393244</ArticleId><ArticleId IdType="pubmed">30517713</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam E, Maaliki L, Nasr Z. Ribosomal protein S3 selectively affects colon cancer growth by modulating the levels of p53 and lactate dehydrogenase. Mol Biol Rep. 2020;47(8):6083&#x2013;6090.</Citation><ArticleIdList><ArticleId IdType="pubmed">32748020</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrends M, Engmann O. Linker histone H1.5 is an underestimated factor in differentiation and carcinogenesis. Environ Epigenet. 2020;6(1):dvaa013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7660118</ArticleId><ArticleId IdType="pubmed">33214908</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturov V, Xiao GQ, Kinoshita Y, Unger PD, Burstein DE. Histone H1.5, a novel prostatic cancer marker, an immunohistochemical study. Hum Pathol. 2014;45(10):2115&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25130394</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Rashidy MA, Bedeer AE, Kabel AM. Histone H1 5 expression in prostatic carcinoma, an immunohistochemical study. J Cancer Res Treat. 2016;4:21&#x2013;5.</Citation></Reference><Reference><Citation>Tani R, Hayakawa K, Tanaka S, Shiota K. Linker histone variant H1T targets rDNA repeats. Epigenetics. 2016;11(4):288&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4889250</ArticleId><ArticleId IdType="pubmed">27018843</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahadevan IA, Kumar S, Rao MRS. Linker histone variant H1t is closely associated with repressed repeat-element chromatin domains in pachytene spermatocytes. Epigenetics Chromatin. 2020;13(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7057672</ArticleId><ArticleId IdType="pubmed">32131873</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa K, Tani R, Nishitani K, Tanaka S. Linker histone variant H1T functions as a chromatin de-condenser on genic regions. Biochem Biophys Res Commun. 2020;528(4):685&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">32513538</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37773127</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>Cytosine-phosphate-guanine oligodeoxynucleotides alleviate radiation-induced kidney injury in cervical cancer by inhibiting DNA damage and oxidative stress through blockade of PARP1/XRCC1 axis.</ArticleTitle><Pagination><StartPage>679</StartPage><MedlinePgn>679</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">679</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-023-04548-y</ELocationID><Abstract><AbstractText Label="BACKGROUND">Radiotherapy can cause kidney injury in patients with cervical cancer. This study aims to investigate the possible molecular mechanisms by which CpG-ODNs (Cytosine phosphate guanine-oligodeoxynucleotides) regulate the PARP1 (poly (ADP-ribose) polymerase 1)/XRCC1 (X-ray repair cross-complementing 1) signaling axis and its impact on radiation kidney injury (RKI) in cervical cancer radiotherapy.</AbstractText><AbstractText Label="METHODS">The GSE90627 dataset related to cervical cancer RKI was obtained from the Gene Expression Omnibus (GEO) database. Bioinformatics databases and R software packages were used to analyze the target genes regulated by CpG-ODNs. A mouse model of RKI was established by subjecting C57BL/6JNifdc mice to X-ray irradiation. Serum blood urea nitrogen (BUN) and creatinine levels were measured using an automated biochemical analyzer. Renal tissue morphology was observed through HE staining, while TUNEL staining was performed to detect apoptosis in renal tubular cells. ELISA was conducted to measure levels of oxidative stress-related factors in mouse serum and cell supernatant. An in vitro cell model of RKI was established using X-ray irradiation on HK-2 cells for mechanism validation. RT-qPCR was performed to determine the relative expression of PARP1 mRNA. Cell proliferation activity was assessed using the CCK-8 assay, and Caspase 3 activity was measured in HK-2 cells. Immunofluorescence was used to determine &#x3b3;H2AX expression.</AbstractText><AbstractText Label="RESULTS">Bioinformatics analysis revealed that the downstream targets regulated by CpG-ODNs in cervical cancer RKI were primarily PARP1 and XRCC1. CpG-ODNs may alleviate RKI by inhibiting DNA damage and oxidative stress levels. This resulted in significantly decreased levels of BUN and creatinine in RKI mice, as well as reduced renal tubular and glomerular damage, lower apoptosis rate, decreased DNA damage index (8-OHdG), and increased levels of antioxidant factors associated with oxidative stress (SOD, CAT, GSH, GPx). Among the CpG-ODNs, CpG-ODN2006 had a more pronounced effect. CpG-ODNs mediated the inhibition of PARP1, thereby suppressing DNA damage and oxidative stress response in vitro in HK-2 cells. Additionally, PARP1 promoted the formation of the PARP1 and XRCC1 complex by recruiting XRCC1, which in turn facilitated DNA damage and oxidative stress response in renal tubular cells. Overexpression of either PARP1 or XRCC1 reversed the inhibitory effects of CpG-ODN2006 on DNA damage and oxidative stress in the HK-2 cell model and RKI mouse model.</AbstractText><AbstractText Label="CONCLUSION">CpG-ODNs may mitigate cervical cancer RKI by blocking the activation of the PARP1/XRCC1 signaling axis, inhibiting DNA damage and oxidative stress response in renal tubule epithelial cells.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Deyu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, No.36 Sanhao Street, Shenyang, 110004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shitai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, No.36 Sanhao Street, Shenyang, 110004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, No.36 Sanhao Street, Shenyang, 110004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Hospital of China Medical University, No. 155 Nanjing Bei Street, Shenyang, 110001, Liaoning, China. chenycmu1h@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8J337D1HZY</RegistryNumber><NameOfSubstance UI="D003596">Cytosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>5Z93L87A1R</RegistryNumber><NameOfSubstance UI="D006147">Guanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009838">Oligodeoxyribonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.2.30</RegistryNumber><NameOfSubstance UI="C499320">PARP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010710">Phosphates</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.2.30</RegistryNumber><NameOfSubstance UI="D000071137">Poly (ADP-Ribose) Polymerase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076105">X-ray Repair Cross Complementing Protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000619371">XRCC1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003596" MajorTopicYN="Y">Cytosine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006147" MajorTopicYN="N">Guanine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="Y">Kidney</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="N">injuries</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009838" MajorTopicYN="N">Oligodeoxyribonucleotides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010710" MajorTopicYN="N">Phosphates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071137" MajorTopicYN="N">Poly (ADP-Ribose) Polymerase-1</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076105" MajorTopicYN="N">X-ray Repair Cross Complementing Protein 1</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">CpG-ODNs</Keyword><Keyword MajorTopicYN="N">DNA damage</Keyword><Keyword MajorTopicYN="N">Kidney injury</Keyword><Keyword MajorTopicYN="N">Oxidative stress</Keyword><Keyword MajorTopicYN="N">PARP1</Keyword><Keyword MajorTopicYN="N">Radiotherapy</Keyword><Keyword MajorTopicYN="N">XRCC1</Keyword></KeywordList><CoiStatement>The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>12</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37773127</ArticleId><ArticleId IdType="pmc">PMC10541701</ArticleId><ArticleId IdType="doi">10.1186/s12967-023-04548-y</ArticleId><ArticleId IdType="pii">10.1186/s12967-023-04548-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen YF, Shen MR. The important role of ion transport system in cervical cancer. Int J Mol Sci. 2021 doi: 10.3390/ijms23010333.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23010333</ArticleId><ArticleId IdType="pmc">PMC8745646</ArticleId><ArticleId IdType="pubmed">35008759</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodin D, Burger EA, Atun R, Barton M, Gospodarowicz M, Grover S, et al. Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact. Lancet Oncol. 2019;20:915&#x2013;923. doi: 10.1016/S1470-2045(19)30308-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(19)30308-0</ArticleId><ArticleId IdType="pmc">PMC7055962</ArticleId><ArticleId IdType="pubmed">31151906</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaus R, Niyazi M, Lange-Sperandio B. Radiation-induced kidney toxicity: molecular and cellular pathogenesis. Radiat Oncol. 2021;16:43. doi: 10.1186/s13014-021-01764-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13014-021-01764-y</ArticleId><ArticleId IdType="pmc">PMC7905925</ArticleId><ArticleId IdType="pubmed">33632272</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D, Li H, Katsube T, Huang G, Liu J, Wang B, et al. Effects of concurrent exposure to chronic restraint-induced stress and total-body iron ion radiation on induction of kidney injury in mice. Int J Mol Sci. 2022 doi: 10.3390/ijms23094866.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23094866</ArticleId><ArticleId IdType="pmc">PMC9099542</ArticleId><ArticleId IdType="pubmed">35563256</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzam EI, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. Cancer Lett. 2012;327:48&#x2013;60. doi: 10.1016/j.canlet.2011.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2011.12.012</ArticleId><ArticleId IdType="pmc">PMC3980444</ArticleId><ArticleId IdType="pubmed">22182453</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Kuo JC, Yao S, Zhang C, Khan H, Lee RJ. CpG oligodeoxynucleotides for anticancer monotherapy from preclinical stages to clinical trials. Pharmaceutics. 2021 doi: 10.3390/pharmaceutics14010073.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14010073</ArticleId><ArticleId IdType="pmc">PMC8780291</ArticleId><ArticleId IdType="pubmed">35056969</ArticleId></ArticleIdList></Reference><Reference><Citation>Park K, Dhupal M, Kim CS, Jung SH, Choi D, Qi XF, et al. Ameliorating effect of CpG-ODN (oligodeoxynucleotide) against radiation-induced lung injury in mice. Radiat Environ Biophys. 2020;59:733&#x2013;741. doi: 10.1007/s00411-020-00871-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00411-020-00871-w</ArticleId><ArticleId IdType="pubmed">32914274</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Dong S, Guo J, Yang Y, Liu C, Li B, et al. CpG-oligodeoxynucleotides improved irradiation-induced injuries by G-CSF and IL-6 up-regulation. Cell Physiol Biochem. 2017;44:2368&#x2013;2377. doi: 10.1159/000486153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000486153</ArticleId><ArticleId IdType="pubmed">29262401</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn WJ, Lee KW, Choi SY, Chung E, Lee Y, Kim TY, et al. CpG-oligodeoxynucleotide protects immune cells from gamma-irradiation-induced cell death. Mol Immunol. 2006;43:1163&#x2013;1171. doi: 10.1016/j.molimm.2005.07.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2005.07.020</ArticleId><ArticleId IdType="pubmed">16122803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke J, Liu F, Tu Y, Cai Z, Luo Y, Wu X. PARP1-RNA interaction analysis: PARP1 regulates the expression of extracellular matrix-related genes in HK-2 renal proximal tubular epithelial cells. FEBS Lett. 2021;595:1375&#x2013;1387. doi: 10.1002/1873-3468.14065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.14065</ArticleId><ArticleId IdType="pubmed">33641169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W, Fu Y, Liu Z, Shu S, Wang Y, Tang C, et al. NAM protects against cisplatin-induced acute kidney injury by suppressing the PARP1/p53 pathway. Toxicol Appl Pharmacol. 2021;418:115492. doi: 10.1016/j.taap.2021.115492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2021.115492</ArticleId><ArticleId IdType="pubmed">33722665</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhopadhyay P, Horvath B, Kechrid M, Tanchian G, Rajesh M, Naura AS, et al. Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic Biol Med. 2011;51:1774&#x2013;1788. doi: 10.1016/j.freeradbiomed.2011.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2011.08.006</ArticleId><ArticleId IdType="pmc">PMC3207278</ArticleId><ArticleId IdType="pubmed">21884784</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA. Therapeutic strategies and biomarkers to modulate PARP activity for targeted cancer therapy. Cancers (Basel) 2020 doi: 10.3390/cancers12040972.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12040972</ArticleId><ArticleId IdType="pmc">PMC7226473</ArticleId><ArticleId IdType="pubmed">32295316</ArticleId></ArticleIdList></Reference><Reference><Citation>Reber JM, Bozic-Petkovic J, Lippmann M, Mazzardo M, Dilger A, Warmers R, et al. PARP1 and XRCC1 exhibit a reciprocal relationship in genotoxic stress response. Cell Biol Toxicol. 2022 doi: 10.1007/s10565-022-09739-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10565-022-09739-9</ArticleId><ArticleId IdType="pmc">PMC10042965</ArticleId><ArticleId IdType="pubmed">35778544</ArticleId></ArticleIdList></Reference><Reference><Citation>Buelow B, Uzunparmak B, Paddock M, Scharenberg AM. Structure/function analysis of PARP-1 in oxidative and nitrosative stress-induced monomeric ADPR formation. PLoS ONE. 2009;4:e6339. doi: 10.1371/journal.pone.0006339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0006339</ArticleId><ArticleId IdType="pmc">PMC2713433</ArticleId><ArticleId IdType="pubmed">19641624</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CC, Chen YT, Wallace CG, Chen KH, Cheng BC, Sung PH, et al. Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat. Biomed Pharmacother. 2019;109:658&#x2013;670. doi: 10.1016/j.biopha.2018.10.095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.10.095</ArticleId><ArticleId IdType="pubmed">30404073</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq MA, Soedipe A, Ramesh G, Wu H, Zhang Y, Shishodia S, et al. The effect of acute dose charge particle radiation on expression of DNA repair genes in mice. Mol Cell Biochem. 2011;349:213&#x2013;218. doi: 10.1007/s11010-010-0641-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-010-0641-0</ArticleId><ArticleId IdType="pubmed">21080036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebre MC, van der Aar AM, van Baarsen L, van Capel TM, Schuitemaker JH, Kapsenberg ML, et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol. 2007;127:331&#x2013;341. doi: 10.1038/sj.jid.5700530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.jid.5700530</ArticleId><ArticleId IdType="pubmed">17068485</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546&#x2013;549. doi: 10.1038/374546a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/374546a0</ArticleId><ArticleId IdType="pubmed">7700380</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis AP, Wiegers TC, Johnson RJ, Sciaky D, Wiegers J, Mattingly CJ. Comparative toxicogenomics database (CTD): update 2023. Nucl Acids Res. 2023;51:D1257&#x2013;D1262. doi: 10.1093/nar/gkac833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac833</ArticleId><ArticleId IdType="pmc">PMC9825590</ArticleId><ArticleId IdType="pubmed">36169237</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets-update. Nucl Acids Res. 2013;41:D991&#x2013;D995. doi: 10.1093/nar/gks1193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1193</ArticleId><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The genecards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 2016;54:1&#x2013;30. doi: 10.1002/cpbi.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpbi.5</ArticleId><ArticleId IdType="pubmed">27322403</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucl Acids Res. 2023;51:D638&#x2013;D646. doi: 10.1093/nar/gkac1000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac1000</ArticleId><ArticleId IdType="pmc">PMC9825434</ArticleId><ArticleId IdType="pubmed">36370105</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update) Nucl Acids Res. 2022;50:W216&#x2013;W221. doi: 10.1093/nar/gkac194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac194</ArticleId><ArticleId IdType="pmc">PMC9252805</ArticleId><ArticleId IdType="pubmed">35325185</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18&#x2013;27. doi: 10.1016/j.neo.2022.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2022.01.001</ArticleId><ArticleId IdType="pmc">PMC8788199</ArticleId><ArticleId IdType="pubmed">35078134</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Y, Yan R, Li A, Zhang Y, Li J, Du H, et al. Lentiviral vectors mediate long-term and high efficiency transgene expression in HEK 293T cells. Int J Med Sci. 2015;12:407&#x2013;415. doi: 10.7150/ijms.11270.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.11270</ArticleId><ArticleId IdType="pmc">PMC4441065</ArticleId><ArticleId IdType="pubmed">26005375</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Chen G, Wang J, Liu S, Su J. Platycodin D regulates high glucose-induced ferroptosis of HK-2 cells through glutathione peroxidase 4 (GPX4) Bioengineered. 2022;13:6627&#x2013;6637. doi: 10.1080/21655979.2022.2045834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2022.2045834</ArticleId><ArticleId IdType="pmc">PMC8973889</ArticleId><ArticleId IdType="pubmed">35226829</ArticleId></ArticleIdList></Reference><Reference><Citation>te Poele JA, van Kleef EM, van der Wal AF, Dewit LG, Stewart FA. Radiation-induced glomerular thrombus formation and nephropathy are not prevented by the ADP receptor antagonist clopidogrel. Int J Radiat Oncol Biol Phys. 2001;50:1332&#x2013;1338. doi: 10.1016/s0360-3016(01)01617-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0360-3016(01)01617-0</ArticleId><ArticleId IdType="pubmed">11483346</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzam P, Francis M, Youssef T, Mroueh M, Daher AA, Eid AA, et al. Crosstalk between SMPDL3b and NADPH oxidases mediates radiation-induced damage of renal podocytes. Front Med (Lausanne) 2021;8:732528. doi: 10.3389/fmed.2021.732528.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.732528</ArticleId><ArticleId IdType="pmc">PMC8511442</ArticleId><ArticleId IdType="pubmed">34660640</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng XM, Ren GL, Gao L, Yang Q, Li HD, Wu WF, et al. NADPH oxidase 4 promotes cisplatin-induced acute kidney injury via ROS-mediated programmed cell death and inflammation. Lab Invest. 2018;98:63&#x2013;78. doi: 10.1038/labinvest.2017.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.2017.120</ArticleId><ArticleId IdType="pubmed">29106395</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, Ren GL, Wei B, Jin J, Huang XR, Shao W, et al. Conditional knockout of TGF-betaRII/Smad2 signals protects against acute renal injury by alleviating cell necroptosis, apoptosis and inflammation. Theranostics. 2019;9:8277&#x2013;8293. doi: 10.7150/thno.35686.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.35686</ArticleId><ArticleId IdType="pmc">PMC6857044</ArticleId><ArticleId IdType="pubmed">31754396</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Xie D, Xie H, Huang W, Zhang J, Jin W, et al. ARHGAP10 inhibits the proliferation and metastasis of CRC cells via blocking the activity of RhoA/AKT signaling pathway. Onco Targets Ther. 2019;12:11507&#x2013;11516. doi: 10.2147/OTT.S222564.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S222564</ArticleId><ArticleId IdType="pmc">PMC6938210</ArticleId><ArticleId IdType="pubmed">31920339</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Zhang C, Wu H, Sun XX, Li Y, Huang S, et al. Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression. J Clin Invest. 2020;130:3253&#x2013;3269. doi: 10.1172/JCI132876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI132876</ArticleId><ArticleId IdType="pmc">PMC7260041</ArticleId><ArticleId IdType="pubmed">32478681</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M, Wei Q, Wang J, Du Q, Yu J, Zhang L, et al. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene. 2006;25:4056&#x2013;4066. doi: 10.1038/sj.onc.1209440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1209440</ArticleId><ArticleId IdType="pubmed">16491117</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Yuan Q, Ling X, Tan Q, Liang H, Chen J, et al. PARP-1 may be involved in hydroquinone-induced apoptosis by poly ADP-ribosylation of ZO-2. Mol Med Rep. 2017;16:8076&#x2013;8084. doi: 10.3892/mmr.2017.7643.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2017.7643</ArticleId><ArticleId IdType="pmc">PMC5779892</ArticleId><ArticleId IdType="pubmed">28983606</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YF, Niu WB, Hu R, Wang LJ, Huang ZY, Ni SH, et al. FIBP knockdown attenuates growth and enhances chemotherapy in colorectal cancer via regulating GSK3beta-related pathways. Oncogenesis. 2018;7:77. doi: 10.1038/s41389-018-0088-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41389-018-0088-9</ArticleId><ArticleId IdType="pmc">PMC6167373</ArticleId><ArticleId IdType="pubmed">30275459</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XS, Sheng Z, Ruan YB, Guang Y, Yang ML. CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma. World J Gastroenterol. 2005;11:1220&#x2013;1224. doi: 10.3748/wjg.v11.i8.1220.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v11.i8.1220</ArticleId><ArticleId IdType="pmc">PMC4250718</ArticleId><ArticleId IdType="pubmed">15754409</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamad R, Jayakumar C, Ranganathan P, Mohamed R, El-Hamamy MM, Dessouki AA, et al. Honey feeding protects kidney against cisplatin nephrotoxicity through suppression of inflammation. Clin Exp Pharmacol Physiol. 2015;42:843&#x2013;848. doi: 10.1111/1440-1681.12433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1440-1681.12433</ArticleId><ArticleId IdType="pmc">PMC5558866</ArticleId><ArticleId IdType="pubmed">26041312</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Zeng R, Teng G, Cai C, Pan T, Tu H, et al. Menstrual blood-derived mesenchymal stem cells attenuate inflammation and improve the mortality of acute liver failure combining with A2AR agonist in mice. J Gastroenterol Hepatol. 2021;36:2619&#x2013;2627. doi: 10.1111/jgh.15493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.15493</ArticleId><ArticleId IdType="pmc">PMC8518829</ArticleId><ArticleId IdType="pubmed">33729623</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai B, Han L, Zhong J, Shu J, Cao Z, Fang J, et al. Rhoifolin alleviates alcoholic liver disease in vivo and in vitro via inhibition of the TLR4/NF-kappaB signaling pathway. Front Pharmacol. 2022;13:878898. doi: 10.3389/fphar.2022.878898.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.878898</ArticleId><ArticleId IdType="pmc">PMC9171502</ArticleId><ArticleId IdType="pubmed">35685625</ArticleId></ArticleIdList></Reference><Reference><Citation>Heale JT, Ball AR, Jr, Schmiesing JA, Kim JS, Kong X, Zhou S, et al. Condensin I interacts with the PARP-1-XRCC1 complex and functions in DNA single-strand break repair. Mol Cell. 2006;21:837&#x2013;848. doi: 10.1016/j.molcel.2006.01.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2006.01.036</ArticleId><ArticleId IdType="pmc">PMC7115950</ArticleId><ArticleId IdType="pubmed">16543152</ArticleId></ArticleIdList></Reference><Reference><Citation>Keil C, Grobe T, Oei SL. MNNG-induced cell death is controlled by interactions between PARP-1, poly(ADP-ribose) glycohydrolase, and XRCC1. J Biol Chem. 2006;281:34394&#x2013;34405. doi: 10.1074/jbc.M606470200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M606470200</ArticleId><ArticleId IdType="pubmed">16963444</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucl Acids Res. 2003;31:5526&#x2013;5533. doi: 10.1093/nar/gkg761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkg761</ArticleId><ArticleId IdType="pmc">PMC206461</ArticleId><ArticleId IdType="pubmed">14500814</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson LA, Kavanagh BD, Paulino AC, Das SK, Miften M, Li XA, et al. Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys. 2010;76:S108&#x2013;S115. doi: 10.1016/j.ijrobp.2009.02.089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2009.02.089</ArticleId><ArticleId IdType="pubmed">20171504</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Zhao H, Li BL, Fu G, Liu H, Cai JM, et al. CpG-oligodeoxynucleotides may be effective for preventing ionizing radiation induced pulmonary fibrosis. Toxicol Lett. 2018;292:181&#x2013;189. doi: 10.1016/j.toxlet.2018.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxlet.2018.04.009</ArticleId><ArticleId IdType="pubmed">29679710</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Tian X, Mei Z, Wang Y, Yao Y, Zhang S, et al. The effect of the TLR9 ligand CpG-oligodeoxynucleotide on the protective immune response to radiation-induced lung fibrosis in mice. Mol Immunol. 2016;80:33&#x2013;40. doi: 10.1016/j.molimm.2016.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2016.11.001</ArticleId><ArticleId IdType="pubmed">27825048</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Ni J, Gao F, Sun D, Zhou C, Cheng Y, et al. The mechanism for the ameliorative effect of CpG-oligodeoxynucleotides on bone marrow hemopoiesis radiation injury. Basic Clin Pharmacol Toxicol. 2011;109:11&#x2013;16. doi: 10.1111/j.1742-7843.2011.00695.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-7843.2011.00695.x</ArticleId><ArticleId IdType="pubmed">21385323</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Zheng M, Zhu XH, Li S, Ni J, Li BL, et al. Protective effect of CpG-oligodeoxynucleotides against low- and high-LET irradiation. Cell Physiol Biochem. 2014;34:1663&#x2013;1674. doi: 10.1159/000366368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000366368</ArticleId><ArticleId IdType="pubmed">25401481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ignacio RM, Kim CS, Kim YD, Lee HM, Qi XF, Kim SK. Therapeutic effect of active hexose-correlated compound (AHCC) combined with CpG-ODN (oligodeoxynucleotide) in B16 melanoma murine model. Cytokine. 2015;76:131&#x2013;137. doi: 10.1016/j.cyto.2015.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2015.06.002</ArticleId><ArticleId IdType="pubmed">26082022</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Xu G, Qiao T, Yuan S, Zhuang X. Effects of CpG oligodeoxynucleotide 1826 on acute radiation-induced lung injury in mice. Biol Res. 2016;49:8. doi: 10.1186/s40659-016-0068-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40659-016-0068-5</ArticleId><ArticleId IdType="pmc">PMC4739121</ArticleId><ArticleId IdType="pubmed">26842986</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Magied N, Shedid SM, Ahmed AG. Mitigating effect of biotin against irradiation-induced cerebral cortical and hippocampal damage in the rat brain tissue. Environ Sci Pollut Res Int. 2019;26:13441&#x2013;13452. doi: 10.1007/s11356-019-04806-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11356-019-04806-x</ArticleId><ArticleId IdType="pubmed">30911963</ArticleId></ArticleIdList></Reference><Reference><Citation>Said RS, El-Demerdash E, Nada AS, Kamal MM. Resveratrol inhibits inflammatory signaling implicated in ionizing radiation-induced premature ovarian failure through antagonistic crosstalk between silencing information regulator 1 (SIRT1) and poly(ADP-ribose) polymerase 1 (PARP-1) Biochem Pharmacol. 2016;103:140&#x2013;150. doi: 10.1016/j.bcp.2016.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2016.01.019</ArticleId><ArticleId IdType="pubmed">26827941</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu JT, Hu XW, Yang Q, Shan RR, Zhang Y, Dong ZH, et al. Insulin-like growth factor binding protein 7 promotes acute kidney injury by alleviating poly ADP ribose polymerase 1 degradation. Kidney Int. 2022;102:828&#x2013;844. doi: 10.1016/j.kint.2022.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2022.05.026</ArticleId><ArticleId IdType="pubmed">35752325</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin HJ, Kwon HK, Lee JH, Gui X, Achek A, Kim JH, et al. Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53. Sci Rep. 2015;5:15798. doi: 10.1038/srep15798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep15798</ArticleId><ArticleId IdType="pmc">PMC4629133</ArticleId><ArticleId IdType="pubmed">26522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh MP, Chauhan AK, Kang SC. Morin hydrate ameliorates cisplatin-induced ER stress, inflammation and autophagy in HEK-293 cells and mice kidney via PARP-1 regulation. Int Immunopharmacol. 2018;56:156&#x2013;167. doi: 10.1016/j.intimp.2018.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.01.031</ArticleId><ArticleId IdType="pubmed">29414646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Long KE, Tang K, Padanilam BJ. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity. Kidney Int. 2012;82:193&#x2013;203. doi: 10.1038/ki.2012.64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2012.64</ArticleId><ArticleId IdType="pubmed">22437413</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanzlikova H, Gittens W, Krejcikova K, Zeng Z, Caldecott KW. Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin. Nucl Acids Res. 2017;45:2546&#x2013;2557. doi: 10.1093/nar/gkw1246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw1246</ArticleId><ArticleId IdType="pmc">PMC5389470</ArticleId><ArticleId IdType="pubmed">27965414</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo LM, Xu Y, Hornyak P, Garces F, Zeng Z, Hailstone R, et al. Efficient single-strand break repair requires binding to both poly(ADP-Ribose) and DNA by the central BRCT domain of XRCC1. Cell Rep. 2019;26:573&#x2013;81 e5. doi: 10.1016/j.celrep.2018.12.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.12.082</ArticleId><ArticleId IdType="pmc">PMC6334254</ArticleId><ArticleId IdType="pubmed">30650352</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CC, Yip HK, Chen KH, Sun CK, Chen YT, Chai HT, et al. Impact of impaired cardiac function on the progression of chronic kidney disease&#x2014;role of pharmacomodulation of valsartan. Am J Transl Res. 2017;9:2548&#x2013;2566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446536</ArticleId><ArticleId IdType="pubmed">28560004</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf N, Pendergrass W, Singh N, Swisshelm K, Schwartz J. Radiation cataracts: mechanisms involved in their long delayed occurrence but then rapid progression. Mol Vis. 2008;14:274&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2254966</ArticleId><ArticleId IdType="pubmed">18334943</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37768206</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1945-4589</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>18</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Aging</Title><ISOAbbreviation>Aging (Albany NY)</ISOAbbreviation></Journal><ArticleTitle>A cellular senescence-related genes model allows for prognosis and treatment stratification of cervical cancer: a bioinformatics analysis and external verification.</ArticleTitle><Pagination><StartPage>9408</StartPage><EndPage>9425</EndPage><MedlinePgn>9408-9425</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18632/aging.204981</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cervical cancer (CC) is highly lethal and aggressive with an increasing trend of mortality for females. Molecular characterization-based methods hold great promise for improving the diagnostic accuracy and for predicting treatment response.</AbstractText><AbstractText Label="METHODS">The mRNAs expression data of CC patients and cellular senescence-related genes were obtained from the Cancer Genome Atlas (TCGA) and CellAge databases, respectively. Differentially expressed genes (DEGs) of senescence related genes between tumor and normal tissues were used for Least absolute shrinkage and selection operator (LASSO) regression to construct a prognostic model. Univariate and LASSO regression analyses were applied to establish a predictive nomogram. The performance of the nomogram were evaluated by Kaplan-Meier curve, receiver operating characteristic (ROC), Harrell's concordance index (C-index), and calibration curve. GSE44001 and GSE52903 were used for external validation.</AbstractText><AbstractText Label="RESULTS">We established a cellular senescence-related genes-based stratified model, and a multivariable-based nomogram, which could accurately predict the prognosis of CC patients in the TCGA database. The Kaplan-Meier curve indicated that patients in the low-risk group had considerably better overall survival (OS, <i>P</i> =2.021e-05). The area under the ROC curve (AUC) of this model was 0.743 for OS. Multivariate analysis found that the 6-gene risk signature (HR=3.166, 95%CI: 1.660-6.041, <i>P</i>&lt;0.001) was an independent risk factor for CC patients. We then designed an OS-associated nomogram that included the risk signature and clinicopathological factors. The AUC reached 0.860 for predicting 5-year OS. The nomogram showed excellent consistency between the predictions and actual survival observations. Two external GEO validations were corresponding to the gene expression pattern in TCGA.</AbstractText><AbstractText Label="CONCLUSIONS">Our results suggested a six-senescence related signature and established a prognostic nomogram that reliably predicted the overall survival for CC. These findings may be beneficial to personalized treatment and medical decision-making.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Gynecology Department 2, Cangzhou Central Hospital, Yunhe District, Cangzhou 061000, Hebei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gynecology Department 2, Cangzhou Central Hospital, Yunhe District, Cangzhou 061000, Hebei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yanfei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gynecology Department 2, Cangzhou Central Hospital, Yunhe District, Cangzhou 061000, Hebei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Sumin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Gynecology Department 2, Cangzhou Central Hospital, Yunhe District, Cangzhou 061000, Hebei Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Aging (Albany NY)</MedlineTA><NlmUniqueID>101508617</NlmUniqueID><ISSNLinking>1945-4589</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049451" MajorTopicYN="N">Nomograms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016922" MajorTopicYN="N">Cellular Senescence</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TCGA</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">nomogram</Keyword><Keyword MajorTopicYN="N">prognostic model</Keyword><Keyword MajorTopicYN="N">senescence</Keyword></KeywordList><CoiStatement><b>CONFLICTS OF INTEREST:</b> The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>10</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37768206</ArticleId><ArticleId IdType="pmc">PMC10564413</ArticleId><ArticleId IdType="doi">10.18632/aging.204981</ArticleId><ArticleId IdType="pii">204981</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71:209&#x2013;49. 10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Seol HJ, Ulak R, Ki KD, Lee JM. Cytotoxic and targeted systemic therapy in advanced and recurrent cervical cancer: experience from clinical trials. Tohoku J Exp Med. 2014; 232:269&#x2013;76. 10.1620/tjem.232.269</Citation><ArticleIdList><ArticleId IdType="doi">10.1620/tjem.232.269</ArticleId><ArticleId IdType="pubmed">24695215</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal JF, Fominaya J, Casc&#xf3;n A, Guijarro MV, Blanco-Aparicio C, Lleonart M, Castro ME, Ramon Y Cajal S, Robledo M, Beach DH, Carnero A. Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene. 2008; 27:1961&#x2013;70. 10.1038/sj.onc.1210846</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1210846</ArticleId><ArticleId IdType="pubmed">17968325</ArticleId></ArticleIdList></Reference><Reference><Citation>Basisty N, Kale A, Jeon OH, Kuehnemann C, Payne T, Rao C, Holtz A, Shah S, Sharma V, Ferrucci L, Campisi J, Schilling B. A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol. 2020; 18:e3000599. 10.1371/journal.pbio.3000599</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3000599</ArticleId><ArticleId IdType="pmc">PMC6964821</ArticleId><ArticleId IdType="pubmed">31945054</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt CA, Wang B, Demaria M. Senescence and cancer - role and therapeutic opportunities. Nat Rev Clin Oncol. 2022; 19:619&#x2013;36. 10.1038/s41571-022-00668-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-022-00668-4</ArticleId><ArticleId IdType="pmc">PMC9428886</ArticleId><ArticleId IdType="pubmed">36045302</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Genome Atlas Research Network, et al.. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017; 543:378&#x2013;84. 10.1038/nature21386</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21386</ArticleId><ArticleId IdType="pmc">PMC5354998</ArticleId><ArticleId IdType="pubmed">28112728</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Xiao L, Long G, Cao J, Liu S, Tao Y, Zhou L, Tang J. Identification of senescence-related subtypes, establishment of a prognosis model, and characterization of a tumor microenvironment infiltration in breast cancer. Front Immunol. 2022; 13:921182. 10.3389/fimmu.2022.921182</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.921182</ArticleId><ArticleId IdType="pmc">PMC9441960</ArticleId><ArticleId IdType="pubmed">36072578</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira BI, Devine OP, Vukmanovic-Stejic M, Chambers ES, Subramanian P, Patel N, Virasami A, Sebire NJ, Kinsler V, Valdovinos A, LeSaux CJ, Passos JF, Antoniou A, et al.. Senescent cells evade immune clearance via HLA-E-mediated NK and CD8+ T cell inhibition. Nat Commun. 2019; 10:2387. 10.1038/s41467-019-10335-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10335-5</ArticleId><ArticleId IdType="pmc">PMC6547655</ArticleId><ArticleId IdType="pubmed">31160572</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Zhong F, Yi X, Shi Z, Ou F, Xu Z, Zuo Y. Application of an Autophagy-Related Gene Prognostic Risk Model Based on TCGA Database in Cervical Cancer. Front Genet. 2021; 11:616998. 10.3389/fgene.2020.616998</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.616998</ArticleId><ArticleId IdType="pmc">PMC7900625</ArticleId><ArticleId IdType="pubmed">33633773</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics. 2007; 23:3251&#x2013;3. 10.1093/bioinformatics/btm369</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btm369</ArticleId><ArticleId IdType="pubmed">17644558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and Management of Endometrial Cancer. Am Fam Physician. 2016; 93:468&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">26977831</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16:284&#x2013;7. 10.1089/omi.2011.0118</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo K, Machida H, Mandelbaum RS, Konishi I, Mikami M. Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol. 2019; 152:87&#x2013;93. 10.1016/j.ygyno.2018.10.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2018.10.026</ArticleId><ArticleId IdType="pmc">PMC7528458</ArticleId><ArticleId IdType="pubmed">30389105</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Qiu B, Zeng X, Hu L, Huang D, Chen K, Qiu X. Identification of a tumor microenvironment-related gene signature to improve the prediction of cervical cancer prognosis. Cancer Cell Int. 2021; 21:182. 10.1186/s12935-021-01867-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-021-01867-2</ArticleId><ArticleId IdType="pmc">PMC7992856</ArticleId><ArticleId IdType="pubmed">33766042</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin R, Cao L, Ye C, Wang J, Sun Z. A novel prognostic prediction model based on seven immune-related RNAs for predicting overall survival of patients in early cervical squamous cell carcinoma. BMC Med Genomics. 2021; 14:49. 10.1186/s12920-021-00885-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-021-00885-3</ArticleId><ArticleId IdType="pmc">PMC7885601</ArticleId><ArticleId IdType="pubmed">33588862</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao JS, Zhang H, Kobetz E, Aldrich MC, Conway D. Predicting DNA methylation from genetic data lacking racial diversity using shared classified random effects. Genomics. 2021; 113:1018&#x2013;28. 10.1016/j.ygeno.2020.10.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2020.10.036</ArticleId><ArticleId IdType="pubmed">33161089</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Gao C, Wu Y, Huang Z. Identification of Prognostic miRNA Signature and Lymph Node Metastasis-Related Key Genes in Cervical Cancer. Front Pharmacol. 2020; 11:544. 10.3389/fphar.2020.00544</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00544</ArticleId><ArticleId IdType="pmc">PMC7226536</ArticleId><ArticleId IdType="pubmed">32457603</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S, Fang J, Chen Y, Xie Y, Zhang S, Zhu X, Fang F. Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer. BMC Cancer. 2020; 20:1205. 10.1186/s12885-020-07695-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-020-07695-3</ArticleId><ArticleId IdType="pmc">PMC7720540</ArticleId><ArticleId IdType="pubmed">33287740</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhang C, He W, Gou X. Effect of m6A RNA Methylation Regulators on Malignant Progression and Prognosis in Renal Clear Cell Carcinoma. Front Oncol. 2020; 10:3. 10.3389/fonc.2020.00003</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.00003</ArticleId><ArticleId IdType="pmc">PMC6992564</ArticleId><ArticleId IdType="pubmed">32038982</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu XW, Song CQ. Identification and Validation of Pyroptosis-Related Gene Signature to Predict Prognosis and Reveal Immune Infiltration in Hepatocellular Carcinoma. Front Cell Dev Biol. 2021; 9:748039. 10.3389/fcell.2021.748039</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.748039</ArticleId><ArticleId IdType="pmc">PMC8606409</ArticleId><ArticleId IdType="pubmed">34820376</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Huang H, Zang L, Gao W, Zhu H, Yu X. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma. Front Immunol. 2021; 12:728062. 10.3389/fimmu.2021.728062</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.728062</ArticleId><ArticleId IdType="pmc">PMC8526937</ArticleId><ArticleId IdType="pubmed">34691034</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y, Ji L, Guan Y, Ma M, Li P, Xue Y, Zhang Y, Huang W, Gong Y, Jiang L, Wang X, Xie H, Zhou B, et al.. An epigenomic landscape of cervical intraepithelial neoplasia and cervical cancer using single-base resolution methylome and hydroxymethylome. Clin Transl Med. 2021; 11:e498. 10.1002/ctm2.498</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.498</ArticleId><ArticleId IdType="pmc">PMC8288011</ArticleId><ArticleId IdType="pubmed">34323415</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Han F, Qi N, Wen L, Li J, Feng C, Wang Q. Determination of a six-gene prognostic model for cervical cancer based on WGCNA combined with LASSO and Cox-PH analysis. World J Surg Oncol. 2021; 19:277. 10.1186/s12957-021-02384-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12957-021-02384-2</ArticleId><ArticleId IdType="pmc">PMC8447612</ArticleId><ArticleId IdType="pubmed">34530829</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo XC, Li L, Gao ZH, Zhou HW, Li J, Wang QQ. The long non-coding RNA PTTG3P promotes growth and metastasis of cervical cancer through PTTG1. Aging (Albany NY). 2019; 11:1333&#x2013;41. 10.18632/aging.101830</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101830</ArticleId><ArticleId IdType="pmc">PMC6428096</ArticleId><ArticleId IdType="pubmed">30853662</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Zhao Y. E2F Transcription Factor 1 Activates FKBP Prolyl Isomerase 4 to Promote Angiogenesis in Cervical Squamous Cell Carcinoma Via the PI3K/AKT Signaling Pathway. Reprod Sci. 2023; 30:1229&#x2013;40. 10.1007/s43032-022-01034-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43032-022-01034-6</ArticleId><ArticleId IdType="pubmed">35849266</ArticleId></ArticleIdList></Reference><Reference><Citation>Maimaitirexiati G, Tian P, Maimaiti H, Ding L, Ma C, Li Y, Wang J, Yan Q, Li R. Expression and correlation analysis of Skp2 and CBX7 in cervical cancer. J Clin Pathol. 2022; 75:851&#x2013;6. 10.1136/jclinpath-2021-207752</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jclinpath-2021-207752</ArticleId><ArticleId IdType="pubmed">34281957</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Wu Y, Guo Q, Chen S, Wang S, Wu X, Zhu J, Ju X. SPOP promotes cervical cancer progression by inducing the movement of PD-1 away from PD-L1 in spatial localization. J Transl Med. 2022; 20:384. 10.1186/s12967-022-03574-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03574-6</ArticleId><ArticleId IdType="pmc">PMC9429754</ArticleId><ArticleId IdType="pubmed">36042498</ArticleId></ArticleIdList></Reference><Reference><Citation>Latini FR, Hemerly JP, Freitas BC, Oler G, Riggins GJ, Cerutti JM. ABI3 ectopic expression reduces in vitro and in vivo cell growth properties while inducing senescence. BMC Cancer. 2011; 11:11. 10.1186/1471-2407-11-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-11-11</ArticleId><ArticleId IdType="pmc">PMC3032749</ArticleId><ArticleId IdType="pubmed">21223585</ArticleId></ArticleIdList></Reference><Reference><Citation>Floberg JM, Zhang J, Muhammad N, DeWees TA, Inkman M, Chen K, Lin AJ, Rashmi R, Jayachandran K, Edelson BT, Siegel BA, Dehdashti F, Grigsby PW, et al.. Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer. Clin Cancer Res. 2021; 27:4245&#x2013;55. 10.1158/1078-0432.CCR-20-4450</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-20-4450</ArticleId><ArticleId IdType="pmc">PMC8338789</ArticleId><ArticleId IdType="pubmed">33820781</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto M, Osada S, Imagawa M, Nishizuka M. FAD104, a regulator of adipogenesis, is a novel suppressor of TGF-&#x3b2;-mediated EMT in cervical cancer cells. Sci Rep. 2017; 7:16365. 10.1038/s41598-017-16555-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-16555-3</ArticleId><ArticleId IdType="pmc">PMC5703855</ArticleId><ArticleId IdType="pubmed">29180690</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian T, Dong Y, Zhu Y, Chen Y, Li X, Kuang Q, Liu X, Li P, Li J, Zhou L. Hypoxia-induced CNPY2 upregulation promotes glycolysis in cervical cancer through activation of AKT pathway. Biochem Biophys Res Commun. 2021; 551:63&#x2013;70. 10.1016/j.bbrc.2021.02.116</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.02.116</ArticleId><ArticleId IdType="pubmed">33721832</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Wang P, He Y, Liu X, Wang S, Ma C, Tian X, Wang J, Wu X. Graphene oxide inhibits cell migration and invasion by destroying actin cytoskeleton in cervical cancer cells. Aging (Albany NY). 2020; 12:17625&#x2013;33. 10.18632/aging.103821</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103821</ArticleId><ArticleId IdType="pmc">PMC7521503</ArticleId><ArticleId IdType="pubmed">32924971</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma D, Pan Z, Chang Q, Zhang JJ, Liu X, Hua N, Li GH. KLF5-mediated Eppk1 expression promotes cell proliferation in cervical cancer via the p38 signaling pathway. BMC Cancer. 2021; 21:377. 10.1186/s12885-021-08040-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-021-08040-y</ArticleId><ArticleId IdType="pmc">PMC8028205</ArticleId><ArticleId IdType="pubmed">33827480</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubor P, Dankova Z, Kolkova Z, Holubekova V, Brany D, Mersakova S, Samec M, Liskova A, Koklesova L, Kubatka P, Bujnak J, Kajo K, Mlyncek M, et al.. Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare. Cancers (Basel). 2020; 12:1292. 10.3390/cancers12051292</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12051292</ArticleId><ArticleId IdType="pmc">PMC7281750</ArticleId><ArticleId IdType="pubmed">32443784</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37686313</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>17</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>A Customized Human Mitochondrial DNA Database (hMITO DB v1.0) for Rapid Sequence Analysis, Haplotyping and Geo-Mapping.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">13505</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241713505</ELocationID><Abstract><AbstractText>The field of mitochondrial genomics has advanced rapidly and has revolutionized disciplines such as molecular anthropology, population genetics, and medical genetics/oncogenetics. However, mtDNA next-generation sequencing (NGS) analysis for matrilineal haplotyping and phylogeographic inference remains hindered by the lack of a consolidated mitogenome database and an efficient bioinformatics pipeline. To address this, we developed a customized human mitogenome database (hMITO DB) embedded in a CLC Genomics workflow for read mapping, variant analysis, haplotyping, and geo-mapping. The database was constructed from 4286 mitogenomes. The macro-haplogroup (A to Z) distribution and representative phylogenetic tree were found to be consistent with published literature. The hMITO DB automated workflow was tested using mtDNA-NGS sequences derived from Pap smears and cervical cancer cell lines. The auto-generated read mapping, variants track, and table of haplotypes and geo-origins were completed in 15 min for 47 samples. The mtDNA workflow proved to be a rapid, efficient, and accurate means of sequence analysis for translational mitogenomics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shen-Gunther</LastName><ForeName>Jane</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0876-9338</Identifier><AffiliationInfo><Affiliation>Gynecologic Oncology &amp; Clinical Investigation, Department of Clinical Investigation, Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunther</LastName><ForeName>Rutger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Nuclear Medicine &amp; Molecular Imaging, Department of Radiology, Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, University of Texas at San Antonio, San Antonio, TX 78249, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio, San Antonio, TX 78249, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yufeng</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9959-4149</Identifier><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, University of Texas at San Antonio, San Antonio, TX 78249, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio, San Antonio, TX 78249, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Defense Health Agency Intramural Funding</GrantID><Agency>Brooke Army Medical Center</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="Y">High-Throughput Nucleotide Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="Y">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030561" MajorTopicYN="N">Databases, Nucleic Acid</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">hypervariable region</Keyword><Keyword MajorTopicYN="N">mitochondrial DNA</Keyword><Keyword MajorTopicYN="N">mitochondrial genomics</Keyword><Keyword MajorTopicYN="N">mitochondrial haplogroup</Keyword><Keyword MajorTopicYN="N">molecular anthropology</Keyword><Keyword MajorTopicYN="N">next generation sequencing</Keyword><Keyword MajorTopicYN="N">oncogenetics</Keyword><Keyword MajorTopicYN="N">phylogeography</Keyword></KeywordList><CoiStatement>No potential conflict of interest were disclosed by the authors. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>9</Day><Hour>11</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>9</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37686313</ArticleId><ArticleId IdType="pmc">PMC10488239</ArticleId><ArticleId IdType="doi">10.3390/ijms241713505</ArticleId><ArticleId IdType="pii">ijms241713505</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sun N., Finkel T. Cardiac mitochondria: A surprise about size. J. Mol. Cell. Cardiol. 2015;82:213&#x2013;215. doi: 10.1016/j.yjmcc.2015.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2015.01.009</ArticleId><ArticleId IdType="pmc">PMC8760902</ArticleId><ArticleId IdType="pubmed">25626176</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke B. From bioblasts to mitochondria: Ever expanding roles of mitochondria in cell physiology. Front. Physiol. 2010;1:7. doi: 10.3389/fphys.2010.00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2010.00007</ArticleId><ArticleId IdType="pmc">PMC3059936</ArticleId><ArticleId IdType="pubmed">21423350</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera-Cruz M.S., Simmen T. Over Six Decades of Discovery and Characterization of the Architecture at Mitochondria-Associated Membranes (MAMs) Adv. Exp. Med. Biol. 2017;997:13&#x2013;31. doi: 10.1007/978-981-10-4567-7_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-10-4567-7_2</ArticleId><ArticleId IdType="pubmed">28815519</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon D.O. Calcium&#x2019;s Role in Orchestrating Cancer Apoptosis: Mitochondrial-Centric Perspective. Int. J. Mol. Sci. 2023;24:8982. doi: 10.3390/ijms24108982.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24108982</ArticleId><ArticleId IdType="pmc">PMC10218825</ArticleId><ArticleId IdType="pubmed">37240331</ArticleId></ArticleIdList></Reference><Reference><Citation>Nass M.M., Nass S. Intramitochondrial fibers with DNA characteristics I. Fixation and electron staining reactions. J. Cell Biol. 1963;19:593&#x2013;611. doi: 10.1083/jcb.19.3.593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.19.3.593</ArticleId><ArticleId IdType="pmc">PMC2106331</ArticleId><ArticleId IdType="pubmed">14086138</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson S., Bankier A.T., Barrell B.G., de Bruijn M.H., Coulson A.R., Drouin J., Eperon I.C., Nierlich D.P., Roe B.A., Sanger F., et al. Sequence and organization of the human mitochondrial genome. Nature. 1981;290:457&#x2013;465. doi: 10.1038/290457a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/290457a0</ArticleId><ArticleId IdType="pubmed">7219534</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandelt H.J., Kloss-Brandst&#xe4;tter A., Richards M.B., Yao Y.G., Logan I. The case for the continuing use of the revised Cambridge Reference Sequence (rCRS) and the standardization of notation in human mitochondrial DNA studies. J. Hum. Genet. 2014;59:66&#x2013;77. doi: 10.1038/jhg.2013.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jhg.2013.120</ArticleId><ArticleId IdType="pubmed">24304692</ArticleId></ArticleIdList></Reference><Reference><Citation>DiMauro S. A Brief History of Mitochondrial Pathologies. Int. J. Mol. Sci. 2019;22:5643. doi: 10.3390/ijms20225643.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20225643</ArticleId><ArticleId IdType="pmc">PMC6888695</ArticleId><ArticleId IdType="pubmed">31718067</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu. Rev. Genet. 2005;39:359&#x2013;407. doi: 10.1146/annurev.genet.39.110304.095751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.genet.39.110304.095751</ArticleId><ArticleId IdType="pmc">PMC2821041</ArticleId><ArticleId IdType="pubmed">16285865</ArticleId></ArticleIdList></Reference><Reference><Citation>Beadnell T.C., Scheid A.D., Vivian C.J., Welch D.R. Roles of the mitochondrial genetics in cancer metastasis: Not to be ignored any longer. Cancer Metastasis Rev. 2018;37:615&#x2013;632. doi: 10.1007/s10555-018-9772-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10555-018-9772-7</ArticleId><ArticleId IdType="pmc">PMC6358502</ArticleId><ArticleId IdType="pubmed">30542781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M., Mahmood M., Reznik E., Gammage P.A. Mitochondrial DNA is a major source of driver mutations in cancer. Trends Cancer. 2022;8:1046&#x2013;1059. doi: 10.1016/j.trecan.2022.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trecan.2022.08.001</ArticleId><ArticleId IdType="pmc">PMC9671861</ArticleId><ArticleId IdType="pubmed">36041967</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheid A.D., Beadnell T.C., Welch D.R. The second genome: Effects of the mitochondrial genome on cancer progression. Adv. Cancer Res. 2019;142:63&#x2013;105. doi: 10.1016/bs.acr.2019.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.acr.2019.01.001</ArticleId><ArticleId IdType="pmc">PMC6921473</ArticleId><ArticleId IdType="pubmed">30885364</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith D. The Past, Present and Future Of Mitochondrial Genomics: Have We Sequenced Enough Mtdnas? Brief. Funct. Genom. 2015;15:47&#x2013;54. doi: 10.1093/bfgp/elv027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bfgp/elv027</ArticleId><ArticleId IdType="pmc">PMC4812591</ArticleId><ArticleId IdType="pubmed">26117139</ArticleId></ArticleIdList></Reference><Reference><Citation>Embley T., Martin W. Eukaryotic Evolution, Changes and Challenges. Nature. 2006;440:623&#x2013;630. doi: 10.1038/nature04546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04546</ArticleId><ArticleId IdType="pubmed">16572163</ArticleId></ArticleIdList></Reference><Reference><Citation>Degli Esposti M., Chouaia B., Comandatore F., Crotti E., Sassera D., Lievens P.M., Daffonchio D., Bandi C. Evolution of mitochondria reconstructed from the energy metabolism of living bacteria. PLoS ONE. 2014;5:e96566. doi: 10.1371/journal.pone.0096566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0096566</ArticleId><ArticleId IdType="pmc">PMC4013037</ArticleId><ArticleId IdType="pubmed">24804722</ArticleId></ArticleIdList></Reference><Reference><Citation>Greiner S., Lehwark P., Bock R. OrganellarGenomeDRAW (OGDRAW) version 1.3.1: Expanded toolkit for the graphical visualization of organellar genomes. Nucleic Acids Res. 2019;47:W59&#x2013;W64. doi: 10.1093/nar/gkz238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz238</ArticleId><ArticleId IdType="pmc">PMC6602502</ArticleId><ArticleId IdType="pubmed">30949694</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari M., Nilsen H.L., Montaldo N.P. Dynamic features of human mitochondrial DNA maintenance and transcription. Front. Cell Dev. Biol. 2022;10:984245. doi: 10.3389/fcell.2022.984245.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2022.984245</ArticleId><ArticleId IdType="pmc">PMC9491825</ArticleId><ArticleId IdType="pubmed">36158192</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.Y., Lee H.Y., Oh S.Y., Jung S.E., Yang I.S., Lee Y.H., Yang W.I., Shin K.J. Massively parallel sequencing of the entire control region and targeted coding region SNPs of degraded mtDNA using a simplified library preparation method. Forensic Sci. Int. Genet. 2016;22:37&#x2013;43. doi: 10.1016/j.fsigen.2016.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fsigen.2016.01.014</ArticleId><ArticleId IdType="pubmed">26844917</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinueza-Espinosa D.C., Cuesta-Aguirre D.R., Malgosa A., Santos C. Mitochondrial DNA control region typing from highly degraded skeletal remains by single-multiplex next-generation sequencing. Electrophoresis. 2023 doi: 10.1002/elps.202200052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/elps.202200052</ArticleId><ArticleId IdType="pubmed">37379235</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodner M., Perego U.A., Gomez J.E., Cerda-Flores R.M., Rambaldi Migliore N., Woodward S.R., Parson W., Achilli A. The Mitochondrial DNA Landscape of Modern Mexico. Genes. 2021;12:1453. doi: 10.3390/genes12091453.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12091453</ArticleId><ArticleId IdType="pmc">PMC8467843</ArticleId><ArticleId IdType="pubmed">34573435</ArticleId></ArticleIdList></Reference><Reference><Citation>Cann R.L., Stoneking M., Wilson A.C. Mitochondrial DNA and human evolution. Nature. 1987;325:31&#x2013;36. doi: 10.1038/325031a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/325031a0</ArticleId><ArticleId IdType="pubmed">3025745</ArticleId></ArticleIdList></Reference><Reference><Citation>Torroni A., Schurr T.G., Yang C.C., Szathmary E.J., Williams R.C., Schanfield M.S., Troup G.A., Knowler W.C., Lawrence D.N., Weiss K.M. Native American mitochondrial DNA analysis indicates that the Amerind and the Nadene populations were founded by two independent migrations. Genetics. 1992;130:153&#x2013;162. doi: 10.1093/genetics/130.1.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/genetics/130.1.153</ArticleId><ArticleId IdType="pmc">PMC1204788</ArticleId><ArticleId IdType="pubmed">1346260</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Olivares V., Mu&#xf1;oz-Barrera A., Lorenzo-Salazar J.M., Zaragoza-Trello C., Rubio-Rodr&#xed;guez L.A., D&#xed;az-de Usera A., J&#xe1;spez D., I&#xf1;igo-Campos A., Gonz&#xe1;lez-Montelongo R., Flores C. A benchmarking of human mitochondrial DNA haplogroup classifiers from whole-genome and whole-exome sequence data. Sci. Rep. 2021;11:20510. doi: 10.1038/s41598-021-99895-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-99895-5</ArticleId><ArticleId IdType="pmc">PMC8519921</ArticleId><ArticleId IdType="pubmed">34654896</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oven M., Kayser M. Updated comprehensive phylogenetic tree of global human mitochondrial DNA variation. Hum. Mutat. 2009;30:E386&#x2013;E394. doi: 10.1002/humu.20921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.20921</ArticleId><ArticleId IdType="pubmed">18853457</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiagen Digital Insights.  [(accessed on 12 July 2023)].  Available online:  https://digitalinsights.qiagen.com/products-overview/discovery-insights-portfolio/analysis-and-visualization/qiagen-clc-microbial-genomics-module/</Citation></Reference><Reference><Citation>Lott M.T., Leipzig J.N., Derbeneva O., Xie H.M., Chalkia D., Sarmady M., Procaccio V., Wallace D.C. mtDNA Variation and Analysis Using Mitomap and Mitomaster. Curr. Protoc. Bioinform. 2013;44:1.23.1&#x2013;1.23.26. doi: 10.1002/0471250953.bi0123s44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471250953.bi0123s44</ArticleId><ArticleId IdType="pmc">PMC4257604</ArticleId><ArticleId IdType="pubmed">25489354</ArticleId></ArticleIdList></Reference><Reference><Citation>MITOMASTER.  [(accessed on 12 July 2023)].  Available online:  https://www.mitomap.org/foswiki/bin/view/MITOMASTER/WebHome.</Citation></Reference><Reference><Citation>Sch&#xf6;nherr S., Weissensteiner H., Kronenberg F., Forer L. Haplogrep 3&#x2014;An interactive haplogroup classification and analysis platform. Nucleic Acids Res. 2023;51:W263&#x2013;W268. doi: 10.1093/nar/gkad284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkad284</ArticleId><ArticleId IdType="pmc">PMC10320078</ArticleId><ArticleId IdType="pubmed">37070190</ArticleId></ArticleIdList></Reference><Reference><Citation>Halogrep 3.  [(accessed on 12 July 2023)].  Available online:  https://haplogrep.i-med.ac.at/</Citation></Reference><Reference><Citation>Behar D.M., van Oven M., Rosset S., Metspalu M., Loogv&#xe4;li E.L., Silva N.M., Kivisild T., Torroni A., Villems R. A &#x201c;Copernican&#x201d; reassessment of the human mitochondrial DNA tree from its root. Am. J. Hum. Genet. 2012;90:675&#x2013;684. doi: 10.1016/j.ajhg.2012.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2012.03.002</ArticleId><ArticleId IdType="pmc">PMC3322232</ArticleId><ArticleId IdType="pubmed">22482806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingman M., Gyllensten U. Mitochondrial genome variation and evolutionary history of Australian and New Guinean aborigines. Genome Res. 2003;13:1600&#x2013;1606. doi: 10.1101/gr.686603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.686603</ArticleId><ArticleId IdType="pmc">PMC403733</ArticleId><ArticleId IdType="pubmed">12840039</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagle N., van Oven M., Wilcox S., van Holst Pellekaan S., Tyler-Smith C., Xue Y., Ballantyne K.N., Wilcox L., Papac L., Cooke K., et al. Aboriginal Australian mitochondrial genome variation&#x2014;An increased understanding of population antiquity and diversity. Sci. Rep. 2017;7:43041. doi: 10.1038/srep43041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep43041</ArticleId><ArticleId IdType="pmc">PMC5347126</ArticleId><ArticleId IdType="pubmed">28287095</ArticleId></ArticleIdList></Reference><Reference><Citation>Dryomov S.V., Nazhmidenova A.M., Starikovskaya E.B., Shalaurova S.A., Rohland N., Mallick S., Bernardos R., Derevianko A.P., Reich D., Sukernik R.I. Mitochondrial genome diversity on the Central Siberian Plateau with particular reference to the prehistory of northernmost Eurasia. PLoS ONE. 2021;16:e0244228. doi: 10.1371/journal.pone.0244228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244228</ArticleId><ArticleId IdType="pmc">PMC7842996</ArticleId><ArticleId IdType="pubmed">33507977</ArticleId></ArticleIdList></Reference><Reference><Citation>Wielgus K., Danielewski M., Walkowiak J. Svante P&#xe4;&#xe4;bo, reader of the Neanderthal genome. Acta Physiol. 2023;237:e13902. doi: 10.1111/apha.13902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apha.13902</ArticleId><ArticleId IdType="pmc">PMC10078171</ArticleId><ArticleId IdType="pubmed">36394417</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Robles A. Dental evolutionary rates and its implications for the Neanderthal-modern human divergence. Sci. Adv. 2019;5:eaaw1268. doi: 10.1126/sciadv.aaw1268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaw1268</ArticleId><ArticleId IdType="pmc">PMC6520022</ArticleId><ArticleId IdType="pubmed">31106274</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera V.M., Marrero P., Abu-Amero K.K., Larruga J.M. Carriers of mitochondrial DNA macrohaplogroup L3 basal lineages migrated back to Africa from Asia around 70,000 years ago. BMC Evol. Biol. 2018;18:98. doi: 10.1186/s12862-018-1211-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12862-018-1211-4</ArticleId><ArticleId IdType="pmc">PMC6009813</ArticleId><ArticleId IdType="pubmed">29921229</ArticleId></ArticleIdList></Reference><Reference><Citation>Rito T., Vieira D., Silva M., Conde-Sousa E., Pereira L., Mellars P., Richards M.B., Soares P. A dispersal of Homo sapiens from southern to eastern Africa immediately preceded the out-of-Africa migration. Sci. Rep. 2019;9:4728. doi: 10.1038/s41598-019-41176-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41176-3</ArticleId><ArticleId IdType="pmc">PMC6426877</ArticleId><ArticleId IdType="pubmed">30894612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentley D.R., Balasubramanian S., Swerdlow H.P., Smith G.P., Milton J., Brown C.G., Hall K.P., Evers D.J., Barnes C.L., Bignell H.R., et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 2008;456:53&#x2013;59. doi: 10.1038/nature07517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07517</ArticleId><ArticleId IdType="pmc">PMC2581791</ArticleId><ArticleId IdType="pubmed">18987734</ArticleId></ArticleIdList></Reference><Reference><Citation>Head S.R., Komori H.K., LaMere S.A., Whisenant T., Van Nieuwerburgh F., Salomon D.R., Ordoukhanian P. Library construction for next-generation sequencing: Overviews and challenges. BioTechniques. 2014;56:61&#x2013;77. doi: 10.2144/000114133.</Citation><ArticleIdList><ArticleId IdType="doi">10.2144/000114133</ArticleId><ArticleId IdType="pmc">PMC4351865</ArticleId><ArticleId IdType="pubmed">24502796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bairoch A. The Cellosaurus, a Cell-Line Knowledge Resource. J. Biomol. Tech. JBT. 2018;29:25&#x2013;38. doi: 10.7171/jbt.18-2902-002.</Citation><ArticleIdList><ArticleId IdType="doi">10.7171/jbt.18-2902-002</ArticleId><ArticleId IdType="pmc">PMC5945021</ArticleId><ArticleId IdType="pubmed">29805321</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellosaurus.  [(accessed on 12 July 2023)].  Available online:  https://www.cellosaurus.org.</Citation></Reference><Reference><Citation>Wen B., Xie X., Gao S., Li H., Shi H., Song X., Qian T., Xiao C., Jin J., Su B., et al. Analyses of genetic structure of Tibeto-Burman populations reveals sex-biased admixture in southern Tibeto-Burmans. Am. J. Hum. Genet. 2004;74:856&#x2013;865. doi: 10.1086/386292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/386292</ArticleId><ArticleId IdType="pmc">PMC1181980</ArticleId><ArticleId IdType="pubmed">15042512</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.A., Moore B., Hwang E.K., Hickner A., Yeo H. The accuracy of race &amp; ethnicity data in US based healthcare databases: A systematic review. Am. J. Surg. :2023. doi: 10.1016/j.amjsurg.2023.05.011. in press .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2023.05.011</ArticleId><ArticleId IdType="pubmed">37230870</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh M.C., Pareti L.A., Chen V.W. Using NAPIIA to improve the accuracy of Asian race codes in registry data. J. Regist. Manag. 2011;38:190&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">23270092</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardena M.M., Ribeiro-Dos-Santos A., Santos S., Mansur A.J., Pereira A.C., Fridman C. Assessment of the relationship between self-declared ethnicity, mitochondrial haplogroups and genomic ancestry in Brazilian individuals. PLoS ONE. 2013;8:e62005. doi: 10.1371/journal.pone.0062005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0062005</ArticleId><ArticleId IdType="pmc">PMC3634831</ArticleId><ArticleId IdType="pubmed">23637946</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook L.A., Sachs J., Weiskopf N.G. The quality of social determinants data in the electronic health record: A systematic review. J. Am. Med. Inform. Assoc. JAMIA. 2021;29:187&#x2013;196. doi: 10.1093/jamia/ocab199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocab199</ArticleId><ArticleId IdType="pmc">PMC8714289</ArticleId><ArticleId IdType="pubmed">34664641</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones S.W., Ball A.L., Chadwick A.E., Alfirevic A. The Role of Mitochondrial DNA Variation in Drug Response: A Systematic Review. Front. Genet. 2021;12:698825. doi: 10.3389/fgene.2021.698825.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.698825</ArticleId><ArticleId IdType="pmc">PMC8416105</ArticleId><ArticleId IdType="pubmed">34484295</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Shi J., Stein R., Liu X., Baldassano R.N., Forrest C.B., Chen Y., Huang J. Missing data matter: An empirical evaluation of the impacts of missing EHR data in comparative effectiveness research. J. Am. Med. Inform. Assoc. JAMIA. 2023;30:1246&#x2013;1256. doi: 10.1093/jamia/ocad066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocad066</ArticleId><ArticleId IdType="pmc">PMC10280351</ArticleId><ArticleId IdType="pubmed">37337922</ArticleId></ArticleIdList></Reference><Reference><Citation>WorldAtlas Continents.  [(accessed on 12 July 2023)].  Available online:  https://www.worldatlas.com/continents.</Citation></Reference><Reference><Citation>United Nations Statistical Division-Geographic Regions.  [(accessed on 12 July 2023)].  Available online:  https://unstats.un.org/unsd/methodology/m49/</Citation></Reference><Reference><Citation>Wallace D.C., Chalkia D. Mitochondrial DNA genetics and the heteroplasmy conundrum in evolution and disease. Cold Spring Harb. Perspect. Biol. 2013;5:a021220. doi: 10.1101/cshperspect.a021220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a021220</ArticleId><ArticleId IdType="pmc">PMC3809581</ArticleId><ArticleId IdType="pubmed">24186072</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar M.G., Chan C.W., Santos D.R., Lynch D., Spathis R., Garruto R.M., Lum J.K. The origins and genetic distinctiveness of the Chamorros of the Marianas Islands: An mtDNA perspective. Am. J. Hum. Biol. Off. J. Hum. Biol. Counc. 2013;25:116&#x2013;122. doi: 10.1002/ajhb.22349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajhb.22349</ArticleId><ArticleId IdType="pmc">PMC4335639</ArticleId><ArticleId IdType="pubmed">23180676</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiagen CLC Genomics Workbench System Requirements.  [(accessed on 12 July 2023)].  Available online:  https://digitalinsights.qiagen.com/technical-support/system-requirements/</Citation></Reference><Reference><Citation>Shen-Gunther J., Xia Q., Stacey W., Asusta H.B. Molecular Pap Smear: Validation of HPV Genotype and Host Methylation Profiles of ADCY8, CDH8, and ZNF582 as a Predictor of Cervical Cytopathology. Front. Microbiol. 2020;11:595902. doi: 10.3389/fmicb.2020.595902.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.595902</ArticleId><ArticleId IdType="pmc">PMC7593258</ArticleId><ArticleId IdType="pubmed">33178175</ArticleId></ArticleIdList></Reference><Reference><Citation>How to BLAST Guide. National Center for Biotechnology Information.  [(accessed on 21 August 2023)]; Available online:  https://ftp.ncbi.nlm.nih.gov/pub/factsheets/HowTo_BLASTGuide.pdf.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37522542</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1045-4403</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>6</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Critical reviews in eukaryotic gene expression</Title><ISOAbbreviation>Crit Rev Eukaryot Gene Expr</ISOAbbreviation></Journal><ArticleTitle>CCT3 as a Diagnostic and Prognostic Biomarker in Cervical Cancer.</ArticleTitle><Pagination><StartPage>17</StartPage><EndPage>28</EndPage><MedlinePgn>17-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1615/CritRevEukaryotGeneExpr.2023048208</ELocationID><Abstract><AbstractText>The chaperonin-containing TCP1 complex subunit 3 (CCT3) has been reported to be involved in the development and prognosis of many tumors, including cervical cancer (CC). This study aimed to analyze the expression and prognostic value of CCT3 in CC by bioinformatics and retrospective study. CCT3 gene expression profiles and clinical information in CC were downloaded from the cancer genome atlas (TCGA) and gene expression omnibus (GEO) databases. CCT3 expression was verified by quantitative real-time polymerase chain reaction (RT-qPCR), Western blot, and immunohistochemistry (IHC). Logistic regression and chi-square testing were used to analyze the relationship between CCT3 expression and the clinical characteristics of CC. Kaplan-Meier and Cox analyses were used to evaluate whether CCT3 affects the prognosis of CC. Nomogram and calibration curves were used to test the predictive value of CCT3. The expression of CCT3 in CC tissues was significantly upregulated compared with that in adjacent benign tissues, and was related to HPV16/18 infection, grade, and positive lymph nodes. High expression of CCT3 is associated with poor prognosis of CC and can be used as an independent risk factor for CC. The prognostic model based on CCT3 and CC clinical features has good predictive ability. CCT3 is overexpressed in CC, which is related to poor prognosis and expected to become a biomarker for CC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Man</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, First Affiliated Hospital of Bengbu Medical College, Bengbu, 233030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Jianmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Affiliated Hospital of Kunming University of Science and Technology, First People's Hospital of Yunnan Province, Kunming, 650500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yuhuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, First Affiliated Hospital of Bengbu Medical College, Bengbu, 233030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, First Affiliated Hospital of Bengbu Medical College, Bengbu, 233030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Guoliu</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, First Affiliated Hospital of Bengbu Medical College, Bengbu, 233030, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Rev Eukaryot Gene Expr</MedlineTA><NlmUniqueID>9007261</NlmUniqueID><ISSNLinking>1045-4403</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C533299">CCT3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D056404">Chaperonin Containing TCP-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052162" MajorTopicYN="N">Human papillomavirus 16</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052161" MajorTopicYN="N">Human papillomavirus 18</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056404" MajorTopicYN="N">Chaperonin Containing TCP-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>7</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37522542</ArticleId><ArticleId IdType="doi">10.1615/CritRevEukaryotGeneExpr.2023048208</ArticleId><ArticleId IdType="pii">15d8f6711627d9a8,0398bc0f106359e8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37519664</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>CCL5 might be a prognostic biomarker and associated with immuno-therapeutic efficacy in cancers: A pan-cancer analysis.</ArticleTitle><Pagination><StartPage>e18215</StartPage><MedlinePgn>e18215</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e18215</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2023.e18215</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">Chemokine ligand 5 (CCL5), a vital member of the CC chemokine family, plays diverse roles in tumorigenesis, metastasis, and prognosis in various human tumors. However, no pan-cancer analysis has been conducted to illustrate its distinctive effects on clinical prognosis via underlying mechanisms and biological characteristics.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Herein, we exploited the existed public bioinformatics database, primarily TCGA database and GTEx data, to comprehensively analyze the value of CCL5 involved in patient prognosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">This study found that CCL5 was excessively expressed in most tumors and significantly associated with clinical prognosis in 10 out of 33 types of tumors. Notably, CCL5 might be an independent predictive biomarker of clinical outcome in SKCM patients, confirmed by univariate and multivariate Cox regression analysis. Furthermore, we acquired the genetic alteration status of CCL5 in multiple types of tumor tissues from TCGA cohorts. We revealed a potential correlation between the expression level of CCL5 and tumor mutational burden in 33 types of tumors. In addition, data showed that DNA methylation was associated with CCL5 gene expression in THCA, PRAD, LUSC, and BRCA cancers. Immune infiltration and immune checkpoints are fine indexes for evaluating immunotherapy. We uncovered that CCL5 was negatively correlated with the immune infiltration of CD8<sup>+</sup> T cell, CD4<sup>+</sup> T cell, macrophages, and gamma delta T cells in BRCA-basal and CESC tumors, while a significant positive correlation was observed in BLCA, COAD and other 7 types of tumors. Besides, CCL5 was closely associated with the immune checkpoint molecules in 8 types of tumors. The TIDE score was less in the CCL5 high-expressed group than in the CCL5 low-expressed group in SKCM patients, which indicated that CCL5 might be a fine monitor of immune response for immunotherapy. GO enrichment analysis data uncovered that cytokine-cytokine receptor interaction and chemokine signaling might be involved in the role of CCL5 in regulating tumor pathogenesis and prognosis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In conclusion, CCL5 was preliminarly identified as a biomarker of immune response and prognosis for tumors patients via our first comprehensive pan-cancer analysis.</AbstractText><CopyrightInformation>&#xa9; 2023 Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yanchun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The First People's Hospital of Longquanyi District, Chengdu, Chengdu 610100, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, West China Longquan Hospital Sichuan University, Chengdu 610100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The First People's Hospital of Longquanyi District, Chengdu, Chengdu 610100, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, West China Longquan Hospital Sichuan University, Chengdu 610100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jiwen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The First People's Hospital of Longquanyi District, Chengdu, Chengdu 610100, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, West China Longquan Hospital Sichuan University, Chengdu 610100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Clinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yeqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Oncology, Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University, Luzhou 646000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Clinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Sichong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Clinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemokine ligand 5</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">Pan-cancer analysis</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Tumor</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>4</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37519664</ArticleId><ArticleId IdType="pmc">PMC10375802</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2023.e18215</ArticleId><ArticleId IdType="pii">S2405-8440(23)05423-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tomczak K., Czerwinska P., Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp. Oncol. 2015;19(1A):A68&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322527</ArticleId><ArticleId IdType="pubmed">25691825</ArticleId></ArticleIdList></Reference><Reference><Citation>Clough E., Barrett T. The gene expression omnibus database. Methods Mol. Biol. 2016;1418:93&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944384</ArticleId><ArticleId IdType="pubmed">27008011</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum A., Wang P., Zenklusen J.C. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530.</Citation><ArticleIdList><ArticleId IdType="pubmed">29625059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribas A., Wolchok J.D. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391259</ArticleId><ArticleId IdType="pubmed">29567705</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira A., Leisgang W., Schuler G., Heinzerling L. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy. 2017;9(2):115&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">28128709</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan T.A., Yarchoan M., Jaffee E., Swanton C., Quezada S.A., Stenzinger A., Peters S. Development of tumor mutation burden as an immunotherapy biomarker utility for the oncology clinic. Ann. Oncol. 2019;30(1):44&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336005</ArticleId><ArticleId IdType="pubmed">30395155</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegde P.S., Chen D.S. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">31940268</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao X., Nawab O., Patel T., Kossenkov A.V., Halama N., Jaeger D., Pestell R.G. Recent advances targeting CCR5 for cancer and its role in immuno-oncology. Cancer Res. 2019;79(19):4801&#x2013;4807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810651</ArticleId><ArticleId IdType="pubmed">31292161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding H., Zhao L., Dai S., Li L., Wang F., Shan B. CCL5 secreted by tumor associated macrophages may be a new target in treatment of gastric cancer. Biomed. Pharmacother. 2016;77:142&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">26796278</ArticleId></ArticleIdList></Reference><Reference><Citation>Casagrande N., Borghese C., Visser L., Mongiat M., Colombatti A., Aldinucci D. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth. Haematologica. 2019;104(3):564&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6395337</ArticleId><ArticleId IdType="pubmed">30309853</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldinucci D., Lorenzon D., Cattaruzza L., Pinto A., Gloghini A., Carbone A., Colombatti A. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int. J. Cancer. 2008;122(4):769&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">17935139</ArticleId></ArticleIdList></Reference><Reference><Citation>Velasco-Velazquez M., Jiao X., De La Fuente M., Pestell T.G., Ertel A., Lisanti M.P., Pestell R.G. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012;72(15):3839&#x2013;3850.</Citation><ArticleIdList><ArticleId IdType="pubmed">22637726</ArticleId></ArticleIdList></Reference><Reference><Citation>Walens A., DiMarco A.V., Lupo R., Kroger B.R., Damrauer J.S., Alvarez J.V. CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors. Elife. 2019;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6478432</ArticleId><ArticleId IdType="pubmed">30990165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji L., Jiang X., Mao F., Tang Z., Zhong B. miR5895p is downregulated in prostate cancer and regulates tumor cell viability and metastasis by targeting CCL5. Mol. Med. Rep. 2019;20(2):1373&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pubmed">31173214</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs A., Kuttkat N., Rei&#xdf;ing J., Zimmermann H.W., Sonntag R., Proudfoot A., Youssef S.A., de Bruin A., Cubero F.J., Trautwein C. Functional role of CCL5/RANTES for HCC progression during chronic liver disease. J. Hepatol. 2017;66(4):743&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">28011329</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L., Wang Y., Xue Y., Lv W., Zhang Y., He S. Critical roles of chemokine receptor CCR5 in regulating glioblastoma proliferation and invasion. Acta Biochim. Biophys. Sin. 2015;47(11):890&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">26390883</ArticleId></ArticleIdList></Reference><Reference><Citation>Huffman A.P., Lin J.H., Kim S.I., Byrne K.T., Vonderheide R.H. CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity. JCI Insight. 2020;5(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7259512</ArticleId><ArticleId IdType="pubmed">32324594</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottcher J.P., Bonavita E., Chakravarty P., Blees H., Cabeza-Cabrerizo M., Sammicheli S., Rogers N.C., Sahai E., Zelenay S., Reis e Sousa C. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022&#x2013;1037 e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5847168</ArticleId><ArticleId IdType="pubmed">29429633</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz de Galarreta M., Bresnahan E., Molina-Sanchez P., Lindblad K.E., Maier B., Sia D., Puigvehi M., Miguela V., Casanova-Acebes M., Dhainaut M., Villacorta-Martin C., Singhi A.D., Moghe A., von Felden J., Tal Grinspan L., Wang S., Kamphorst A.O., Monga S.P., Brown B.D., Villanueva A., Llovet J.M., Merad M., Lujambio A. Beta-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6677618</ArticleId><ArticleId IdType="pubmed">31186238</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangaj D., Bruand M., Grimm A.J., Ronet C., Barras D., Duttagupta P.A., Lanitis E., Duraiswamy J., Tanyi J.L., Benencia F., Conejo-Garcia J., Ramay H.R., Montone K.T., Powell D.J., Gimotty P.A., Facciabene A., Jackson D.G., Weber J.S., Rodig S.J., Hodi S.F., Kandalaft L.E., Irving M., Zhang L., Foukas P., Rusakiewicz S., Delorenzi M., Coukos G. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885&#x2013;900.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6961655</ArticleId><ArticleId IdType="pubmed">31185212</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Wang H., Sun M., Deng X., Wu X., Ma Y., Li M., Shuoa S.M., You Q., Miao L. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun. 2020;40(2-3):69&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163794</ArticleId><ArticleId IdType="pubmed">32237072</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao M., De Clercq E., Li G. Clinical significance of chemokine receptor antagonists. Expet Opin. Drug Metabol. Toxicol. 2020;16(1):11&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">31903790</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentles A.J., Newman A.M., Liu C.L., Bratman S.V., Feng W., Kim D., Nair V.S., Xu Y., Khuong A., Hoang C.D., Diehn M., West R.B., Plevritis S.K., Alizadeh A.A. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 2015;21(8):938&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4852857</ArticleId><ArticleId IdType="pubmed">26193342</ArticleId></ArticleIdList></Reference><Reference><Citation>Soria G., Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008;267(2):271&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">18439751</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldinucci D., Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediat. Inflamm. 2014;2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910068</ArticleId><ArticleId IdType="pubmed">24523569</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedoni S., Campbell L.A., Harvey B.K., Avdoshina V., Mocchetti I. The orphan G-protein-coupled receptor 75 signaling is activated by the chemokine CCL5. J. Neurochem. 2018;146(5):526&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6198807</ArticleId><ArticleId IdType="pubmed">29772059</ArticleId></ArticleIdList></Reference><Reference><Citation>Udi J., Schuler J., Wider D., Ihorst G., Catusse J., Waldschmidt J., Schnerch D., Follo M., Wasch R., Engelhardt M. Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. Br. J. Haematol. 2013;161(1):104&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">23384035</ArticleId></ArticleIdList></Reference><Reference><Citation>Roscic-Mrkic B., Fischer M., Leemann C., Manrique A., Gordon C.J., Moore J.P., Proudfoot A.E., Trkola A. RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood. 2003;102(4):1169&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Wang H., Zhu K., Yang Y., Li J., Jiang H., Liu Z. Investigation of candidate molecular biomarkers for expression profile analysis of the Gene expression omnibus (GEO) in acute lymphocytic leukemia (ALL) Biomed. Pharmacother. 2019;120</Citation><ArticleIdList><ArticleId IdType="pubmed">31606621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E., Fertig E.J., Jin K., Sukumar S., Pandey N.B., Popel A.S. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nat. Commun. 2014;5:4715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351998</ArticleId><ArticleId IdType="pubmed">25178650</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbie T.U., Alexe G., Aref A.R., Li S., Zhu Z., Zhang X., Imamura Y., Thai T.C., Huang Y., Bowden M., Herndon J., Cohoon T.J., Fleming T., Tamayo P., Mesirov J.P., Ogino S., Wong K.K., Ellis M.J., Hahn W.C., Barbie D.A., Gillanders W.E. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J. Clin. Invest. 2014;124(12):5411&#x2013;5423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4348940</ArticleId><ArticleId IdType="pubmed">25365225</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero J.M., Grunwald B., Jang G.H., Bavi P.P., Jhaveri A., Masoomian M., Fischer S.E., Zhang A., Denroche R.E., Lungu I.M., De Luca A., Bartlett J.M.S., Xu J., Li N., Dhaliwal S., Liang S.B., Chadwick D., Vyas F., Bronsert P., Khokha R., McGaha T.L., Notta F., Ohashi P.S., Done S.J., O'Kane G.M., Wilson J.M., Knox J.J., Connor A., Wang Y., Zogopoulos G., Gallinger S. A four-chemokine signature is associated with a T-cell-inflamed phenotype in primary and metastatic pancreatic cancer. Clin. Cancer Res. 2020;26(8):1997&#x2013;2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">31964786</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavanagh M.E., Conroy M.J., Clarke N.E., Gilmartin N.T., Feighery R., MacCarthy F., O'Toole D., Ravi N., Reynolds J.V., J O.S., Lysaght J. Altered T cell migratory capacity in the progression from barrett oesophagus to oesophageal adenocarcinoma. Cancer Microenviron. 2019;12(1):57&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6529503</ArticleId><ArticleId IdType="pubmed">30834503</ArticleId></ArticleIdList></Reference><Reference><Citation>Sima A.R., Sima H.R., Rafatpanah H., Hosseinnezhad H., Ghaffarzadehgan K., Valizadeh N., Mehrabi Bahar M., Hakimi H.R., Masoom A., Noorbakhsh A., Razavi Satvati N., Raziee H.R. Serum chemokine ligand 5 (CCL5/RANTES) level might be utilized as a predictive marker of tumor behavior and disease prognosis in patients with gastric adenocarcinoma. J. Gastrointest. Cancer. 2014;45(4):476&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">25301002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J., Shayiti F., Ma J., Wei M., Hua T., Zhang R., Su J., Chen P. Tumor-associated macrophage-derived CCL5 promotes chemotherapy resistance and metastasis in prostatic cancer. Cell Biol. Int. 2021;45(10):2054&#x2013;2062.</Citation><ArticleIdList><ArticleId IdType="pubmed">34003531</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R., Guo L., Gao M., Li J., Xiang S. Research trends and regulation of CCL5 in prostate cancer. OncoTargets Ther. 2021;14:1417&#x2013;1427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7921632</ArticleId><ArticleId IdType="pubmed">33664576</ArticleId></ArticleIdList></Reference><Reference><Citation>De la Fuente Lopez M., Landskron G., Parada D., Dubois-Camacho K., Simian D., Martinez M., Romero D., Roa J.C., Chahuan I., Gutierrez R., Lopez K.F., Alvarez K., Kronberg U., Lopez S., Sanguinetti A., Moreno N., Abedrapo M., Gonzalez M.J., Quera R., Hermoso R.M. The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumor-associated macrophage markers in colorectal cancer. Tumour Biol. 2018;40(11)</Citation><ArticleIdList><ArticleId IdType="pubmed">30419802</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldinucci D., Borghese C., Casagrande N. The CCL5/CCR5 Axis in cancer progression. Cancers. 2020;12(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7407580</ArticleId><ArticleId IdType="pubmed">32630699</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv D., Zhang Y., Kim H.J., Zhang L., Ma X. CCL5 as a potential immunotherapeutic target in triple-negative breast cancer. Cell. Mol. Immunol. 2013;10(4):303&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003203</ArticleId><ArticleId IdType="pubmed">23376885</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto Y., Inoue N., Morimoto K., Watanabe T., Hirota S., Imamura M., Matsushita Y., Katagiri T., Okamura H., Miyoshi Y. Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer. Cancer Sci. 2020;111(1):209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942441</ArticleId><ArticleId IdType="pubmed">31724785</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo M., Frezzetti D., Roma C., Arra B.C., Scognamiglio G., Chicchinelli N., Botti G., Normanno N. RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells. Oncotarget. 2018;9:17543&#x2013;17553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5915136</ArticleId><ArticleId IdType="pubmed">29707128</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid A., Wolfram J., Mu C., Mai J., Yang Z., Wang F., Zhao Y., Ferrari M., Ma X., Yang Y., Shen H. Recent advances in discovering the role of CCL5 in metastatic breast cancer. Mini Rev. Med. Chem. 2015;15(13):1063&#x2013;1072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968951</ArticleId><ArticleId IdType="pubmed">26420723</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C., Mezzadra R., Schumacher T.N. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116507</ArticleId><ArticleId IdType="pubmed">29562194</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J.N., Kong X.S., Huang T., Wang R., Li W., Chen Q.F. Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: a pan-cancer study. Front. Immunol. 2020;11:2048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7539667</ArticleId><ArticleId IdType="pubmed">33072070</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews L.P., Marciscano A.E., Drake C.G., Vignali D.A. LAG3 (CD223) as a cancer immunotherapy target. Immunol. Rev. 2017;276(1):80&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338468</ArticleId><ArticleId IdType="pubmed">28258692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalbasi A., Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 2020;20(1):25&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8499690</ArticleId><ArticleId IdType="pubmed">31570880</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarsheth N., Wicha M.S., Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 2017;17(9):559&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5731833</ArticleId><ArticleId IdType="pubmed">28555670</ArticleId></ArticleIdList></Reference><Reference><Citation>Rot A., von Andrian U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 2004;22:891&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pubmed">15032599</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith J.W., Sokol C.L., Luster A.D. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 2014;32:659&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">24655300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding C., Shan Z., Li M., Chen H., Li X., Jin Z. Characterization of the fatty acid metabolism in colorectal cancer to guide clinical therapy. Mol Ther Oncolytics. 2021;20:532&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7941088</ArticleId><ArticleId IdType="pubmed">33738339</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar D.S., Karthikeyan S.K., Korla P.K., Patel H., Shovon A.R., Athar M., Netto G.J., Qin Z.S., Kumar S., Manne U., Creighton C.J., Varambally S. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8788199</ArticleId><ArticleId IdType="pubmed">35078134</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z., Kang B., Li C., Chen T., Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556&#x2013;W560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602440</ArticleId><ArticleId IdType="pubmed">31114875</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., Antipin Y., Reva B., Goldberg A.P., Sander C., Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3956037</ArticleId><ArticleId IdType="pubmed">22588877</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Fu J., Zeng Z., Cohen D., Li J., Chen Q., Li B., Liu X.S. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509&#x2013;W514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319575</ArticleId><ArticleId IdType="pubmed">32442275</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin A., Qi C., Wei T., Li M., Cheng Q., Liu Z., Luo P., Zhang J. CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer. Briefings Bioinf. 2022;23(3)</Citation><ArticleIdList><ArticleId IdType="pubmed">35395670</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T., Hu E., Xu S., Chen M., Guo P., Dai Z., Feng T., Zhou L., Tang W., Zhan L., Fu X., Liu S., Bo X., Yu G. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021;2(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8454663</ArticleId><ArticleId IdType="pubmed">34557778</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudnick P.A., Markey S.P., Roth J., Mirokhin Y., Yan X., Tchekhovskoi D.V., Edwards N.J., Thangudu R.R., Ketchum K.A., Kinsinger C.R., Mesri M., Rodriguez H., Stein S.E. A description of the clinical proteomic tumor analysis Consortium (CPTAC) common data analysis pipeline. J. Proteome Res. 2016;15(3):1023&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5117628</ArticleId><ArticleId IdType="pubmed">26860878</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37227120</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1364-6893</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology</Title><ISOAbbreviation>J Obstet Gynaecol</ISOAbbreviation></Journal><ArticleTitle>A bioinformatics analysis of the clinicopathological and prognostic significance of <i>FAM64A</i> mRNA expression in gynecological cancers.</ArticleTitle><Pagination><StartPage>2216280</StartPage><MedlinePgn>2216280</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/01443615.2023.2216280</ELocationID><Abstract><AbstractText>FAM64A is a mitotic regulator which promotes cell metaphase-anaphase transition and is highly expressed in a cell-cycle-dependent manner. In this study, we examined the clinicopathological and prognostic significance of <i>FAM64A</i> mRNA expression in gynecological cancers. We conducted a bioinformatics analysis of <i>FAM64A</i> mRNA expression using Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), xiantao, The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN), and Kaplan-Meier (KM) plotter databases. <i>FAM64A</i> expression was elevated in breast, cervical, endometrial, and ovarian cancers when compared with normal tissue. Expression was positively correlated with white race, low T stages, infiltrating ductal carcinoma, or favourable PAM50 classification in breast cancer patients, and with clinical stage, histological grade and TP53 mutation, and endometrial cancer serous subtype. <i>FAM64A</i> expression was negatively associated with overall and/or recurrence-free survival rates in breast and endometrial cancer patients, while the opposite was observed in cervical and ovarian cancer patients. <i>FAM64A</i> functioned as an independent predictor of overall and disease-specific survival in breast cancer patients. <i>FAM64A</i>-correlated genes were involved in ligand-receptor interactions, and chromosomal, cell cycle, and DNA replication processes in breast, cervical, endometrial and ovarian cancers. Top hub genes primarily included cell cycle-related proteins in breast cancer, mucins and acetylgalactosaminyl transferases in cervical cancer, kinesin family members in endometrial cancer, and synovial sarcoma X and the cancer/testis antigen in ovarian cancer. <i>FAM64A</i> mRNA expression was positively related to Th2 cell infiltration, but negatively associated with neutrophil and Th17 cell infiltration in breast, cervical, endometrial, and ovarian cancers. <i>FAM64A</i> expression may be considered a potential biomarker reflecting carcinogenesis, histogenesis, aggressive behaviour, and prognosis in gynecological cancers.Impact statement<b>What is already known on this subject?</b> FAM64A is located in cell nucleolar and nucleoplasmic regions, and during mitosis it putatively controls metaphase-to-anaphase transition. FAM64A appears to regulate different physiological processes, including apoptosis, tumorigenesis, neural differentiation, stress responses, and the cell cycle.<b>What</b> <b>the results of this study add?</b> <i>FAM64A</i> expression was up-regulated in breast, cervical, endometrial, and ovarian cancers, and positively correlated with white race, low T stages, infiltrating ductal carcinoma, or favourable PAM50 classification in breast cancer patients, and with clinical stage, histological grade, and TP53 mutation, and a serous subtype in endometrial cancer. <i>FAM64A</i> expression was negatively associated with overall and/or recurrence-free survival rates in breast and endometrial cancer patients, while the opposite was observed in cervical and ovarian cancer patients. <i>FAM64A</i> functioned as an independent predictor of overall and disease-specific survival in breast cancer. <i>FAM64A</i>-correlated genes were involved in ligand-receptor interactions, chromosomal, cell cycle, and DNA replication processes, while <i>FAM64A</i> mRNA expression was positively related to Th2 cell infiltration but negatively correlated with neutrophil and Th17 cell infiltration in four gynecological cancers.<b>What</b> <b>the implications of these findings for clinical practice and/or further research?</b> In the future, abnormal <i>FAM64A</i> mRNA expression may serve as a biomarker of carcinogenesis, histogenesis, aggressiveness, and prognosis in gynecological malignancies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hua-Chuan</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Oncology, The Affiliated Hospital of Chengde Medical University, Chengde, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Dong-Hui</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Oncology, The Affiliated Hospital of Chengde Medical University, Chengde, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Cong-Yu</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Cancer Center, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Oncology, The Affiliated Hospital of Chengde Medical University, Chengde, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Oncology, The Affiliated Hospital of Chengde Medical University, Chengde, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Obstet Gynaecol</MedlineTA><NlmUniqueID>8309140</NlmUniqueID><ISSNLinking>0144-3615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C512398">PIMREG protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044584" MajorTopicYN="Y">Carcinoma, Ductal</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016889" MajorTopicYN="Y">Endometrial Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010051" MajorTopicYN="Y">Ovarian Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FAM64A</Keyword><Keyword MajorTopicYN="N">aggressive behaviours</Keyword><Keyword MajorTopicYN="N">bioinformatics analysis</Keyword><Keyword MajorTopicYN="N">carcinogenesis</Keyword><Keyword MajorTopicYN="N">gynecological cancers</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>25</Day><Hour>13</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>25</Day><Hour>8</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37227120</ArticleId><ArticleId IdType="doi">10.1080/01443615.2023.2216280</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">37144663</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2046-5556</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>Biotechnology &amp; genetic engineering reviews</Title><ISOAbbreviation>Biotechnol Genet Eng Rev</ISOAbbreviation></Journal><ArticleTitle>Bioinformatics analysis illustrates the functions of miR-377-5p in cervical cancer.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>12</EndPage><MedlinePgn>1-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/02648725.2023.2208453</ELocationID><Abstract><AbstractText>Cervical cancer (CC) is a frequent disease in women whose development is related with miRNA disorder. MiR-377-5p plays a negative role in the development of some tumors, while few studies have revealed its role in CC. In this study, the functions of miR-377-5p in CC were investigated by bioinformatics. Briefly, the expression and survival curve of miR-377-5p in CC was analyzed with the Cancer Genome Atlas (TCGA) database, and the abundance of miR-377-5p in clinical samples and CC cell lines were measured by qRT-PCR. Moreover, the MicroRNA Data Integration Portal (miRDIP) database was used to predict targets of miR-377-5p, and the Database for Annotation Visualization and Integrated Discovery (David) was used for enrichment analysis of the functions of the miR-377-5p. The Search Tool for the Retrieval of Interacting Genes (STRING) database was used to screen the hub targets of miR-377-5p. Moreover, the Gene Expression Profiling Interactive Analysis (GEPIA) database was used to analyze the abundance of the genes in CC. Results showed that decreased miR-377-5p was found in the CC tissues and cell lines, and low miR-377-5p was connected with poor prognosis of patients. Besides, the targets of miR-377-5p were enriched in the PI3K/AKT, MAPK and RAS signaling pathways. Moreover, CDC42, FLT1, TPM3 and CAV1 were screened as hub nodes in the targets of miR-377-5p, and increased CDC42, FLT1, TPM3 and CAV1 also indicated the poor survival rates of the patients in the long term. In conclusion, this study suggests that miR-377-5p downregulation is a biomarker event for CC progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dongjie</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Gynaecology, The First People's Hospital of Yunnan Province, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynaecology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yifeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynaecology, The First People's Hospital of Yunnan Province, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynaecology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Dongyan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Gynaecology, The First People's Hospital of Yunnan Province, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynaecology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Chunmei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Gynaecology, The First People's Hospital of Yunnan Province, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynaecology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Liufeng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gynaecology, The First People's Hospital of Yunnan Province, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynaecology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biotechnol Genet Eng Rev</MedlineTA><NlmUniqueID>8510274</NlmUniqueID><ISSNLinking>0264-8725</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">MiR-377-5p</Keyword><Keyword MajorTopicYN="N">PPI-network</Keyword><Keyword MajorTopicYN="N">TCGA</Keyword><Keyword MajorTopicYN="N">bioinformatics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>5</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>5</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37144663</ArticleId><ArticleId IdType="doi">10.1080/02648725.2023.2208453</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37095983</PMID><DateRevised><Year>2023</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Identifying TME signatures for cervical cancer prognosis based on GEO and TCGA databases.</ArticleTitle><Pagination><StartPage>e15096</StartPage><MedlinePgn>e15096</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e15096</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2023.e15096</ELocationID><Abstract><AbstractText>The mortality rate from cervical cancer (CESC), a malignant tumor that affects women, has increased significantly globally in recent years. The discovery of biomarkers points to a direction for the diagnosis of cervical cancer with the advancement of bioinformatics technology. The goal of this study was to look for potential biomarkers for the diagnosis and prognosis of CESC using the GEO and TCGA databases. Because of the high dimension and small sample size of the omic data, or the use of biomarkers generated from a single omic data, the diagnosis of cervical cancer may be inaccurate and unreliable. The purpose of this study was to search the GEO and TCGA databases for potential biomarkers for the diagnosis and prognosis of CESC. We begin by downloading CESC (GSE30760) DNA methylation data from GEO, then perform differential analysis on the downloaded methylation data and screen out the differential genes. Then, using estimation algorithms, we score immune cells and stromal cells in the tumor microenvironment and perform survival analysis on the gene expression profile data and the most recent clinical data of CESC from TCGA. Then, using the 'limma' package and Venn plot in R language to perform differential analysis of genes and screen out overlapping genes, these overlapping genes were then subjected to GO and KEGG functional enrichment analysis. The differential genes screened by the GEO methylation data and the differential genes screened by the TCGA gene expression data were intersected to screen out the common differential genes. A protein-protein interaction (PPI) network of gene expression data was then created in order to discover important genes. The PPI network's key genes were crossed with previously identified common differential genes to further validate them. The Kaplan-Meier curve was then used to determine the prognostic importance of the key genes. Survival analysis has shown that CD3E and CD80 are important for the identification of cervical cancer and can be considered as potential biomarkers for cervical cancer.</AbstractText><CopyrightInformation>&#xa9;2023PublishedbyElsevierLtd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Wen-Tao</ForeName><Initials>WT</Initials><AffiliationInfo><Affiliation>School of Information Engineering, Jingdezhen Ceramic University, Jingdezhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Wang-Ren</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>School of Information Engineering, Jingdezhen Ceramic University, Jingdezhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Wang-Ke</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>School of Information Engineering, Jingdezhen Ceramic University, Jingdezhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhao-Chun</ForeName><Initials>ZC</Initials><AffiliationInfo><Affiliation>School of Information Engineering, Jingdezhen Ceramic University, Jingdezhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shou-Hua</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Jiangxi Provincial Children's Hospital, Nanchang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">DNA methylation</Keyword><Keyword MajorTopicYN="N">Differentially expressed genes</Keyword><Keyword MajorTopicYN="N">Tumor microenvironment</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>2</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37095983</ArticleId><ArticleId IdType="pmc">PMC10121839</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2023.e15096</ArticleId><ArticleId IdType="pii">S2405-8440(23)02303-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhao F., Wen Y., Li Y., Tao S., Ma L., Zhao Y., Dang L., Wang Y., Zhao F., Lang J., Qiao Y., Yang C.X. Epidemiologic and health economic evaluation of cervical cancer screening in rural China. Asian Pac. J. Cancer Prev. APJCP. 2020;21:1317&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7541874</ArticleId><ArticleId IdType="pubmed">32458639</ArticleId></ArticleIdList></Reference><Reference><Citation>Small W., Jr., Bacon M.A., Bajaj A., Chuang L.T., Fisher B.J., Harkenrider M.M., Jhingran A., Kitchener H.C., Mileshkin L.R., Viswanathan A.N., Gaffney D.K. Cervical cancer: a global health crisis. Cancer. 2017;123:2404&#x2013;2412.</Citation><ArticleIdList><ArticleId IdType="pubmed">28464289</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M., Weiderpass E., Bruni L., de Sanjos&#xe9; S., Saraiya M., Ferlay J., Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Global Health. 2020;8:e191&#x2013;e203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7025157</ArticleId><ArticleId IdType="pubmed">31812369</ArticleId></ArticleIdList></Reference><Reference><Citation>Twardella D., Geiss K., Radespiel-Troger M., Benner A., Ficker J.H., Meyer M. [Trends in incidence of lung cancer according to histological subtype among men and women in Germany : analysis of cancer registry data with the application of multiple imputation techniques] Bundesgesundheitsblatt - Gesundheitsforsch. - Gesundheitsschutz. 2018;61:20&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">29181809</ArticleId></ArticleIdList></Reference><Reference><Citation>Di J., Rutherford S., Chu C. Review of the cervical cancer burden and population-based cervical cancer screening in China. Asian Pac. J. Cancer Prev. APJCP. 2015;16:7401&#x2013;7407.</Citation><ArticleIdList><ArticleId IdType="pubmed">26625735</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuanyue L., Baloch Z., Shanshan L., Yasmeen N., Xiaomei W., Khan J.M., Xueshan X. Cervical cancer, human papillomavirus infection, and vaccine-related knowledge: awareness in Chinese women. Cancer Control. 2018;25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6144517</ArticleId><ArticleId IdType="pubmed">30213198</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Li X.M., Yin C.H., Wu Y.M. Killing cervical cancer cells by specific chimeric antigen receptor-modified T cells. J. Reprod. Immunol. 2020;139</Citation><ArticleIdList><ArticleId IdType="pubmed">32199196</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S., Li X., Zhang J., Wu S. Development of a novel immune infiltration-based gene signature to predict prognosis and immunotherapy response of patients with cervical cancer. Front. Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8446628</ArticleId><ArticleId IdType="pubmed">34539641</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao R., Yuan L., Ma B., Wang G., Tian Y. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC) Cancer Immunol. Immunother. 2021;70:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10973753</ArticleId><ArticleId IdType="pubmed">32617668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho W.J., Jaffee E.M., Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 2020;17:527&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442729</ArticleId><ArticleId IdType="pubmed">32398706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaglia V., Florescu A., Zuo M., Sheikh-Mohamed S., Gommerman J.L. Stromal cell-mediated coordination of immune cell recruitment, retention, and function in brain-adjacent regions. J. Immunol. 2021;206:282&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">33397742</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi J., Bi F., Pan X., Yang Q. Establishment of a novel glycolysis-related prognostic gene signature for ovarian cancer and its relationships with immune infiltration of the tumor microenvironment. J. Transl. Med. 2021;19:382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8425093</ArticleId><ArticleId IdType="pubmed">34496868</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.C., Fragala M.S., Kavouras S.A., Queen R.M., Pryor J.L., Casa D.J. Biomarkers in sports and exercise: tracking health, performance, and recovery in athletes. J. Strength Condit Res. 2017;31:2920&#x2013;2937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5640004</ArticleId><ArticleId IdType="pubmed">28737585</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei L., Zhou C., Chen H., Song J., Su R. ACPred-FL: a sequence-based predictor using effective feature representation to improve the prediction of anti-cancer peptides. Bioinformatics. 2018;34:4007&#x2013;4016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6247924</ArticleId><ArticleId IdType="pubmed">29868903</ArticleId></ArticleIdList></Reference><Reference><Citation>Su R., Liu X., Xiao G., Wei L. Meta-GDBP: a high-level stacked regression model to improve anticancer drug response prediction. Briefings Bioinf. 2020;21:996&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">30868164</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Lan W., Miller D. Handling high-dimension (High-Feature) MicroRNA data. Methods Mol. Biol. 2017;1617:179&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">28540685</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Z., Wang J., Xu B., Jin Z., Wu G., Zeng J., Peng M., Guo Y., Wen Z. Mining TCGA database for tumor microenvironment-related genes of prognostic value in hepatocellular carcinoma. BioMed Res. Int. 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6885833</ArticleId><ArticleId IdType="pubmed">31828095</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren N., Liang B., Li Y. Identification of prognosis-related genes in the tumor microenvironment of stomach adenocarcinoma by TCGA and GEO datasets. Biosci. Rep. 2020;40</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7560520</ArticleId><ArticleId IdType="pubmed">33015704</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu W.R., Qi B.B., Lin W.Z., Zhang S.H., Yu W.K., Huang S.F. Predicting the lung adenocarcinoma and its biomarkers by integrating gene expression and DNA methylation data. Front. Genet. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9280023</ArticleId><ArticleId IdType="pubmed">35846148</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A.M., Singer A. Biomarkers in cervical precancer management: the new frontiers. Future Oncol. 2008;4:515&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">18684062</ArticleId></ArticleIdList></Reference><Reference><Citation>Reza M.S., Harun-Or-Roshid M., Islam M.A., Hossen M.A., Hossain M.T., Feng S., Xi W., Mollah M.N.H., Wei M.S. Bioinformatics screening of potential biomarkers from mRNA expression profiles to discover drug targets and agents for cervical cancer. Int. J. Mol. Sci. 2022;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8999699</ArticleId><ArticleId IdType="pubmed">35409328</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Schottker B., Holleczek B., Brenner H. Associations of DNA methylation algorithms of aging and cancer risk: results from a prospective cohort study. EBioMedicine. 2022;81</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9157462</ArticleId><ArticleId IdType="pubmed">35636319</ArticleId></ArticleIdList></Reference><Reference><Citation>Papanicolau-Sengos A., Aldape K. DNA methylation profiling: an emerging paradigm for cancer diagnosis. Annu. Rev. Pathol. 2022;17:295&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">34736341</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M., Furumichi M., Tanabe M., Sato Y., Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45:D353&#x2013;D361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210567</ArticleId><ArticleId IdType="pubmed">27899662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M., Sato Y., Kawashima M. KEGG mapping tools for uncovering hidden features in biological data. Protein Sci. 2022;31:47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8740838</ArticleId><ArticleId IdType="pubmed">34423492</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang B., Lee J.H., Bang D. Single-cell RNA sequencing technologies and bioinformatics pipelines. Exp. Mol. Med. 2018;50:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6082860</ArticleId><ArticleId IdType="pubmed">30089861</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M., Weiderpass E., Bruni L., de Sanjose S., Saraiya M., Ferlay J., Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Global Health. 2020;8:e191&#x2013;e203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7025157</ArticleId><ArticleId IdType="pubmed">31812369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmeijer M.H., Korpershoek J.V., Crispim J.F., Chen L.T., Jonkheijm P., Krych A.J., Saris D.B.F., Vonk L.A. The regenerative effect of different growth factors and platelet lysate on meniscus cells and mesenchymal stromal cells and proof of concept with a functionalized meniscus implant. J Tissue Eng Regen Med. 2021;15:648&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362003</ArticleId><ArticleId IdType="pubmed">33982442</ArticleId></ArticleIdList></Reference><Reference><Citation>T G.S. Innate and adaptive immune cells in Tumor microenvironment. Gulf J Oncolog. 2021;1:77&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">33716216</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng H., Zhong L., Yang X., Wan Q., Pei X., Wang J. Development and validation of prognostic index based on autophagy-related genes in patient with head and neck squamous cell carcinoma. Cell Death Dis. 2020;6:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7360573</ArticleId><ArticleId IdType="pubmed">32695478</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabuig J.M., Garcia-Raffi L.M., Garcia-Valiente A., Sanchez-Perez E.A. Kaplan-meier type survival curves for COVID-19: a health data based decision-making tool. Front. Public Health. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8572972</ArticleId><ArticleId IdType="pubmed">34760856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hage A., Hage F. Kaplan-meier survival, actuarial survival, censoring, and competing events-what is what? Ann. Thorac. Surg. 2022;114:40&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">35367199</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreis J., Nedic B., Mazur J., Urban M., Schelhorn S.E., Grombacher T., Geist F., Brors B., Zuhlsdorf M., Staub E. RosettaSX: reliable gene expression signature scoring of cancer models and patients. Neoplasia. 2021;23:1069&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8479477</ArticleId><ArticleId IdType="pubmed">34583245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni J., Liu S., Qi F., Li X., Yu S., Feng J., Zheng Y. Screening TCGA database for prognostic genes in lower grade glioma microenvironment. Ann. Transl. Med. 2020;8:209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7154476</ArticleId><ArticleId IdType="pubmed">32309356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding L., Fan L., Xu X., Fu J., Xue Y. Identification of core genes and pathways in type 2 diabetes mellitus by bioinformatics analysis. Mol. Med. Rep. 2019;20:2597&#x2013;2608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6691242</ArticleId><ArticleId IdType="pubmed">31524257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J., Zhang Y. Comb Chem High Throughput Screen; 2017. Analysis of Key GO Terms and KEGG Pathways Associated with Carcinogenic Chemicals.</Citation><ArticleIdList><ArticleId IdType="pubmed">29256346</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan F., Lu L., Zhang Y., Wang S., Cai Y.D. Data mining of the cancer-related lncRNAs GO terms and KEGG pathways by using mRMR method. Math. Biosci. 2018;304:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30086268</ArticleId></ArticleIdList></Reference><Reference><Citation>Devraj R., Deshpande M. Demographic and health-related predictors of proton pump inhibitor (PPI) use and association with chronic kidney disease (CKD) stage in NHANES population. Res. Soc. Adm. Pharm. 2020;16:776&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">31445985</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J., Xiong W., Wang Y., Guan J. Protein function prediction based on PPI networks: network reconstruction vs edge enrichment. Front. Genet. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8712557</ArticleId><ArticleId IdType="pubmed">34970299</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahdipour E., Ghasemzadeh M. The protein-protein interaction network alignment using recurrent neural network. Med. Biol. Eng. Comput. 2021;59:2263&#x2013;2286.</Citation><ArticleIdList><ArticleId IdType="pubmed">34529185</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu T., Wang Q., Liu M. A network pharmacology approach to explore the potential mechanisms of huangqin-baishao herb pair in treatment of cancer. Med. Sci. Mon. Int. Med. J. Exp. Clin. Res. 2020;26</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7346753</ArticleId><ArticleId IdType="pubmed">32609659</ArticleId></ArticleIdList></Reference><Reference><Citation>Doncheva N.T., Morris J.H., Gorodkin J., Jensen L.J. Cytoscape StringApp: network analysis and visualization of proteomics data. J. Proteome Res. 2019;18:623&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800166</ArticleId><ArticleId IdType="pubmed">30450911</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich J.T., Neely J.G., Paniello R.C., Voelker C.C., Nussenbaum B., Wang E.W. A practical guide to understanding Kaplan-Meier curves. Otolaryngol. Head Neck Surg. 2010;143:331&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932959</ArticleId><ArticleId IdType="pubmed">20723767</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Li Q., Jing H., Zhao J., Zhang H., Ma X., Wei L., Dai R., Sun W., Suo Z. Expression and prognosis analysis of JMJD5 in human cancers. Front. Biosci. 2021;26:707&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">34719199</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Fu J., Zeng Z., Cohen D., Li J., Chen Q., Li B., Liu X.S. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509&#x2013;W514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319575</ArticleId><ArticleId IdType="pubmed">32442275</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Fan J., Wang B., Traugh N., Chen Q., Liu J.S., Li B., Liu X.S. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108&#x2013;e110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6042652</ArticleId><ArticleId IdType="pubmed">29092952</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Severson E., Pignon J.C., Zhao H., Li T., Novak J., Jiang P., Shen H., Aster J.C., Rodig S., Signoretti S., Liu J.S., Liu X.S. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17:174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4993001</ArticleId><ArticleId IdType="pubmed">27549193</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou X.D., An K., Wu Y.D., Ye Z.Q. PPI network analyses of human WD40 protein family systematically reveal their tendency to assemble complexes and facilitate the complex predictions. BMC Syst. Biol. 2018;12:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5998875</ArticleId><ArticleId IdType="pubmed">29745845</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann A.M., Gissmann L., Street D., Schreckenberger C., Hunter M., Qiao L. Expression of CD80 enhances immunogenicity of cervical carcinoma cells in vitro. Cell. Immunol. 1996;169:246&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">8620552</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Li P., Wu W. A systematic analysis of immune genes and overall survival in cancer patients. BMC Cancer. 2019;19:1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6915928</ArticleId><ArticleId IdType="pubmed">31842801</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37047006</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>23</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Identification of Mir-182-3p/FLI-1 Axis as a Key Signaling in Immune Response in Cervical Cancer: A Comprehensive Bioinformatic Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6032</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24076032</ELocationID><Abstract><AbstractText Label="UNLABELLED">miRNAs modulate gene expression and play critical functions as oncomiRs or tumor suppressors. The miR-182-3p is important in chemoresistance and cancer progression in breast, lung, osteosarcoma, and ovarian cancer. However, the role of miR-182-3p in cervical cancer (CC) has not been elucidated.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To analyze the role of miR-182-3p in CC through a comprehensive bioinformatic analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Gene Expression Omnibus (GEO) databases were used for the expression analysis. The mRNA targets of miR-182-3p were identified using miRDB, TargetScanHuman, and miRPathDB. The prediction of island CpG was performed using the MethPrimer program. The transcription factor binding sites in the FLI-1 promoter were identified using ConSite+, Alibaba2, and ALGGEN-PROMO. The protein-protein interaction (PPI) analysis was performed in STRING 11.5.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">miR-182-3p was significantly overexpressed in CC patients and has potential as a diagnostic. We identified 330 targets of miR-182-3p including FLI-1, which downregulates its expression in CC. Additionally, the aberrant methylation of the FLI-1 promoter and Ap2a transcription factor could be involved in downregulating FLI1 expression. Finally, we found that FLI-1 is a possible key gene in the immune response in CC.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The miR-182-3p/FLI-1 axis plays a critical role in immune response in CC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salmer&#xf3;n-B&#xe1;rcenas</LastName><ForeName>Eric Genaro</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Departamento de Biomedicina Molecular, Centro de Investigaci&#xf3;n y de Estudios Avanzados del Instituto Polit&#xe9;cnico Nacional, CINVESTAV, Ciudad de M&#xe9;xico 07360, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendoza-Catalan</LastName><ForeName>Miguel Angel</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-6247-8590</Identifier><AffiliationInfo><Affiliation>Laboratorio de Biomedicina Molecular, Facultad de Ciencias Qu&#xed;mico Biol&#xf3;gicas, Universidad Aut&#xf3;noma de Guerrero, Chilpancingo 39070, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez-Bautista</LastName><ForeName>&#xc1;ngela Uray</ForeName><Initials>&#xc1;U</Initials><AffiliationInfo><Affiliation>Laboratorio de Biomedicina Molecular, Facultad de Ciencias Qu&#xed;mico Biol&#xf3;gicas, Universidad Aut&#xf3;noma de Guerrero, Chilpancingo 39070, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lozano-Santos</LastName><ForeName>Rafael Acxel</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Laboratorio de Biomedicina Molecular, Facultad de Ciencias Qu&#xed;mico Biol&#xf3;gicas, Universidad Aut&#xf3;noma de Guerrero, Chilpancingo 39070, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres-Rojas</LastName><ForeName>Francisco Israel</ForeName><Initials>FI</Initials><Identifier Source="ORCID">0000-0003-4303-8677</Identifier><AffiliationInfo><Affiliation>Laboratorio de Biomedicina Molecular, Facultad de Ciencias Qu&#xed;mico Biol&#xf3;gicas, Universidad Aut&#xf3;noma de Guerrero, Chilpancingo 39070, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;vila-L&#xf3;pez</LastName><ForeName>Pedro Antonio</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0002-0104-0771</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zacapala-G&#xf3;mez</LastName><ForeName>Ana Elvira</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Laboratorio de Biomedicina Molecular, Facultad de Ciencias Qu&#xed;mico Biol&#xf3;gicas, Universidad Aut&#xf3;noma de Guerrero, Chilpancingo 39070, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C538984">Mirn182 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C098179">FLII protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AP2&#x3b1;</Keyword><Keyword MajorTopicYN="N">FLI-1</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">methylation</Keyword><Keyword MajorTopicYN="N">miR-182-3p</Keyword><Keyword MajorTopicYN="N">response immune</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37047006</ArticleId><ArticleId IdType="pmc">PMC10094573</ArticleId><ArticleId IdType="doi">10.3390/ijms24076032</ArticleId><ArticleId IdType="pii">ijms24076032</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics. CA Cancer J. Clin. 2022;72:7&#x2013;33. doi: 10.3322/caac.21708.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21708</ArticleId><ArticleId IdType="pubmed">35020204</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W., Xu M., Wang L., Zhou W., Xiang R., Shi Y., Zhang Y., Piao Y. Integrative analysis of DNA methylation and gene expression identified cervical cancer-specific diagnostic biomarkers. Signal Transduct. Target. Ther. 2019;4:55. doi: 10.1038/s41392-019-0081-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-019-0081-6</ArticleId><ArticleId IdType="pmc">PMC6908647</ArticleId><ArticleId IdType="pubmed">31871774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong L.M., Li W.T., Shende N., Tsai J.C., Ma J., Chakladar J., Gnanasekar A., Qu Y., Dereschuk K., Wang-Rodriguez J., et al. Analysis of the immune landscape in virus-induced cancers using a novel integrative mechanism discovery approach. Comput. Struct. Biotechnol. J. 2021;19:6240&#x2013;6254. doi: 10.1016/j.csbj.2021.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2021.11.013</ArticleId><ArticleId IdType="pmc">PMC8636736</ArticleId><ArticleId IdType="pubmed">34900135</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths-Jones S., Grocock R.J., van Dongen S., Bateman A., Enright A.J. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34:D140&#x2013;D144. doi: 10.1093/nar/gkj112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkj112</ArticleId><ArticleId IdType="pmc">PMC1347474</ArticleId><ArticleId IdType="pubmed">16381832</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon A., Abd-Aziz N., Khalid K., Poh C.L., Naidu R. miRNA: A Promising Therapeutic Target in Cancer. Int. J. Mol. Sci. 2022;23:11502. doi: 10.3390/ijms231911502.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911502</ArticleId><ArticleId IdType="pmc">PMC9569513</ArticleId><ArticleId IdType="pubmed">36232799</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Yu W., Li Z., Wang Q., Yang Q., Du Z., Zhang G., Song Y. Potential Regulatory Effects of miR-182-3p in Osteosarcoma via Targeting EBF2. Biomed. Res. Int. 2019;2019:4897905. doi: 10.1155/2019/4897905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/4897905</ArticleId><ArticleId IdType="pmc">PMC6434304</ArticleId><ArticleId IdType="pubmed">30993113</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z., Shi Y., Gong X., Li J., Zhang M. LINC00511 Knockdown Suppresses Resistance to Cisplatin in Lung Adenocarcinoma by Interacting with miR-182-3p and BIRC5. Mol. Biotechnol. 2022;64:252&#x2013;262. doi: 10.1007/s12033-021-00400-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12033-021-00400-0</ArticleId><ArticleId IdType="pubmed">34595724</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J., Su Y., Zhang M. Circ_0000140 restrains the proliferation, metastasis and glycolysis metabolism of oral squamous cell carcinoma through upregulating CDC73 via sponging miR-182-5p. Cancer Cell Int. 2020;20:407. doi: 10.1186/s12935-020-01501-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-020-01501-7</ArticleId><ArticleId IdType="pmc">PMC7448321</ArticleId><ArticleId IdType="pubmed">32863766</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinami R., Pompili L., Petti E., Porru M., D&#x2019;Angelo C., Di Vito S., Rizzo A., Campani V., De Rosa G., Bruna A., et al. MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer. EMBO Mol. Med. 2023;15:e16033. doi: 10.15252/emmm.202216033.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202216033</ArticleId><ArticleId IdType="pmc">PMC9832842</ArticleId><ArticleId IdType="pubmed">36426578</ArticleId></ArticleIdList></Reference><Reference><Citation>Soheilifar M.H., Vaseghi H., Seif F., Ariana M., Ghorbanifar S., Habibi N., Papari Barjasteh F., Pornour M. Concomitant overexpression of mir-182-5p and mir-182-3p raises the possibility of IL-17-producing Treg formation in breast cancer by targeting CD3d, ITK, FOXO1, and NFATs: A meta-analysis and experimental study. Cancer Sci. 2021;112:589&#x2013;603. doi: 10.1111/cas.14764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.14764</ArticleId><ArticleId IdType="pmc">PMC7893989</ArticleId><ArticleId IdType="pubmed">33283362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Zhu M.J., Ren A.M., Wu H.F., Han W.M., Tan R.Y., Tu R.Q. A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. PLoS ONE. 2014;9:e96472. doi: 10.1371/journal.pone.0096472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0096472</ArticleId><ArticleId IdType="pmc">PMC4015980</ArticleId><ArticleId IdType="pubmed">24816756</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z., Wang R., Huang L., Chen X., Xu M., Zha D., Ma Y. Integrative analysis of miRNAs-mRNAs reveals that miR-182 up-regulation contributes to proliferation and invasion of nasopharyngeal carcinoma by targeting PTEN. Aging. 2020;12:11568&#x2013;11578. doi: 10.18632/aging.103316.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103316</ArticleId><ArticleId IdType="pmc">PMC7343470</ArticleId><ArticleId IdType="pubmed">32541092</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W., Hu L., Li W., Wang G., Li Y., Yan L., Li A., Cui J. Oncogenic Fli-1 is a potential prognostic marker for the progression of epithelial ovarian cancer. BMC Cancer. 2014;14:424. doi: 10.1186/1471-2407-14-424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-14-424</ArticleId><ArticleId IdType="pmc">PMC4089852</ArticleId><ArticleId IdType="pubmed">24923303</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Luo H., Liu T., Zacksenhaus E., Ben-David Y. The ets transcription factor Fli-1 in development, cancer and disease. Oncogene. 2015;34:2022&#x2013;2031. doi: 10.1038/onc.2014.162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2014.162</ArticleId><ArticleId IdType="pmc">PMC5028196</ArticleId><ArticleId IdType="pubmed">24909161</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Song W., Yan X., Li A., Zhang X., Li W., Wen X., Zhou L., Yu D., Hu J.F., et al. Friend leukemia virus integration 1 promotes tumorigenesis of small cell lung cancer cells by activating the miR-17-92 pathway. Oncotarget. 2017;8:41975&#x2013;41987. doi: 10.18632/oncotarget.16715.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.16715</ArticleId><ArticleId IdType="pmc">PMC5522042</ArticleId><ArticleId IdType="pubmed">28410216</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan X., Yu Y., Li L., Chen N., Song W., He H., Dong J., Liu X., Cui J. Friend leukemia virus integration 1 is a predictor of poor prognosis of breast cancer and promotes metastasis and cancer stem cell properties of breast cancer cells. Cancer Med. 2018;7:3548&#x2013;3560. doi: 10.1002/cam4.1589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.1589</ArticleId><ArticleId IdType="pmc">PMC6089157</ArticleId><ArticleId IdType="pubmed">29869379</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Portillo A., Komissarova E.V., Bokhari A., Hills C., de Gonzalez A.K., Kongkarnka S., Remotti H.E., Sepulveda J.L., Sepulveda A.R. Downregulation of Friend Leukemia Integration 1 (FLI1) follows the stepwise progression to gastric adenocarcinoma. Oncotarget. 2019;10:3852&#x2013;3864. doi: 10.18632/oncotarget.26974.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.26974</ArticleId><ArticleId IdType="pmc">PMC6570468</ArticleId><ArticleId IdType="pubmed">31231464</ArticleId></ArticleIdList></Reference><Reference><Citation>Beger M., Butz K., Denk C., Williams T., Hurst H.C., Hoppe-Seyler F. Expression pattern of AP-2 transcription factors in cervical cancer cells and analysis of their influence on human papillomavirus oncogene transcription. J. Mol. Med. 2001;79:314&#x2013;320. doi: 10.1007/s001090100211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001090100211</ArticleId><ArticleId IdType="pubmed">11485026</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H.R., Zhang J. AP-2&#x3b1; expression in papillary thyroid carcinoma predicts tumor progression and poor prognosis. Cancer Manag. Res. 2018;10:2615&#x2013;2625. doi: 10.2147/CMAR.S167874.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CMAR.S167874</ArticleId><ArticleId IdType="pmc">PMC6095110</ArticleId><ArticleId IdType="pubmed">30147362</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheiber M.N., Watson P.M., Rumboldt T., Stanley C., Wilson R.C., Findlay V.J., Anderson P.E., Watson D.K. FLI1 expression is correlated with breast cancer cellular growth, migration, and invasion and altered gene expression. Neoplasia. 2014;16:801&#x2013;813. doi: 10.1016/j.neo.2014.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2014.08.007</ArticleId><ArticleId IdType="pmc">PMC4212256</ArticleId><ArticleId IdType="pubmed">25379017</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Wang Y., Yu C., Cao Y., Yu Y., Pan Y., Su D., Lu Q., Yang W., Zuo Y., et al. Characterization of the relationship between FLI1 and immune infiltrate level in tumour immune microenvironment for breast cancer. J. Cell. Mol. Med. 2020;24:5501&#x2013;5514. doi: 10.1111/jcmm.15205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15205</ArticleId><ArticleId IdType="pmc">PMC7214163</ArticleId><ArticleId IdType="pubmed">32249526</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z., Li C., Kang B., Gao G., Li C., Zhang Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98&#x2013;W102. doi: 10.1093/nar/gkx247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx247</ArticleId><ArticleId IdType="pmc">PMC5570223</ArticleId><ArticleId IdType="pubmed">28407145</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgar R., Domrachev M., Lash A.E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207&#x2013;210. doi: 10.1093/nar/30.1.207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/30.1.207</ArticleId><ArticleId IdType="pmc">PMC99122</ArticleId><ArticleId IdType="pubmed">11752295</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n M., Fagerberg L., Hallstr&#xf6;m B.M., Lindskog C., Oksvold P., Mardinoglu A., Sivertsson &#xc5;., Kampf C., Sj&#xf6;stedt E., Asplund A., et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. doi: 10.1126/science.1260419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1260419</ArticleId><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y., Kuick R., Nan B., Ota I., Weiss S.J., Trimble C.L., Fearon E.R., Cho K.R. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res. 2007;67:10163&#x2013;10172. doi: 10.1158/0008-5472.CAN-07-2056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2056</ArticleId><ArticleId IdType="pubmed">17974957</ArticleId></ArticleIdList></Reference><Reference><Citation>Den Boon J.A., Pyeon D., Wang S.S., Horswill M., Schiffman M., Sherman M., Zuna R.E., Wang Z., Hewitt S.M., Pearson R., et al. Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling. Proc. Natl. Acad. Sci. USA. 2015;112:E3255&#x2013;E3264. doi: 10.1073/pnas.1509322112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1509322112</ArticleId><ArticleId IdType="pmc">PMC4485108</ArticleId><ArticleId IdType="pubmed">26056290</ArticleId></ArticleIdList></Reference><Reference><Citation>Balacescu O., Balacescu L., Tudoran O., Todor N., Rus M., Buiga R., Susman S., Fetica B., Pop L., Maja L., et al. Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure. BMC Cancer. 2014;14:246. doi: 10.1186/1471-2407-14-246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-14-246</ArticleId><ArticleId IdType="pmc">PMC4021393</ArticleId><ArticleId IdType="pubmed">24708616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilting S.M., Snijders P.J., Verlaat W., Jaspers A., van de Wiel M.A., van Wieringen W.N., Meijer G.A., Kenter G.G., Yi Y., le Sage C., et al. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene. 2013;32:106&#x2013;116. doi: 10.1038/onc.2012.20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2012.20</ArticleId><ArticleId IdType="pubmed">22330141</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao D., Zhang Y., Zhu M., Liu S., Wang X. miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China. PLoS ONE. 2016;11:e0164701. doi: 10.1371/journal.pone.0164701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164701</ArticleId><ArticleId IdType="pmc">PMC5072605</ArticleId><ArticleId IdType="pubmed">27764149</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T., Wilhite S.E., Ledoux P., Evangelista C., Kim I.F., Tomashevsky M., Marshall K.A., Phillippy K.H., Sherman P.M., Holko M., et al. NCBI GEO: Archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41:D991&#x2013;D995. doi: 10.1093/nar/gks1193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1193</ArticleId><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang K., Creighton C.J., Davis C., Donehower L., Drummond J., Wheeler D., Ally A., Balasundaram M., Birol I., Butterfield Y.S.N., et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 2013;45:1113&#x2013;1120. doi: 10.1038/ng.2764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2764</ArticleId><ArticleId IdType="pmc">PMC3919969</ArticleId><ArticleId IdType="pubmed">24071849</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmer&#xf3;n-B&#xe1;rcenas E.G., Zacapala-G&#xf3;mez A.E., Lozano-Amado D., Castro-Mu&#xf1;oz L.J., Leyva-V&#xe1;zquez M.A., Manzo-Merino J., &#xc1;vila-L&#xf3;pez P.A. Comprehensive bioinformatic analysis reveals oncogenic role of H2A.Z isoforms in cervical cancer progression. Iran. J. Basic Med. Sci. 2021;24:1470. doi: 10.22038/ijbms.2021.58287.12944.</Citation><ArticleIdList><ArticleId IdType="doi">10.22038/ijbms.2021.58287.12944</ArticleId><ArticleId IdType="pmc">PMC8917839</ArticleId><ArticleId IdType="pubmed">35317119</ArticleId></ArticleIdList></Reference><Reference><Citation>Colaprico A., Silva T.C., Olsen C., Garofano L., Cava C., Garolini D., Sabedot T.S., Malta T.M., Pagnotta S.M., Castiglioni I., et al. TCGAbiolinks: An R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71. doi: 10.1093/nar/gkv1507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv1507</ArticleId><ArticleId IdType="pmc">PMC4856967</ArticleId><ArticleId IdType="pubmed">26704973</ArticleId></ArticleIdList></Reference><Reference><Citation>Love M.I., Huber W., Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham H. Ggplot2: Elegant Graphics for Data Analysis. Springer International Publishing; Cham, Switzerland: 2016.</Citation></Reference><Reference><Citation>Goksuluk D., Korkmaz S., Zararsiz G., Karaagaoglu A.E. easyROC: An interactive web-tool for ROC curve analysis using R language environment. R J. 2016;8:213. doi: 10.32614/RJ-2016-042.</Citation><ArticleIdList><ArticleId IdType="doi">10.32614/RJ-2016-042</ArticleId></ArticleIdList></Reference><Reference><Citation>Gy&#x151;rffy B.J.C., Journal S.B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput. Struct. Biotechnol. J. 2021;19:4101&#x2013;4109. doi: 10.1016/j.csbj.2021.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2021.07.014</ArticleId><ArticleId IdType="pmc">PMC8339292</ArticleId><ArticleId IdType="pubmed">34527184</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Wang X. miRDB: An online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48:D127&#x2013;D131. doi: 10.1093/nar/gkz757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz757</ArticleId><ArticleId IdType="pmc">PMC6943051</ArticleId><ArticleId IdType="pubmed">31504780</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal V., Bell G.W., Nam J.W., Bartel D.P. Predicting effective microRNA target sites in mammalian mRNAs. eLife. 2015;4:e05005. doi: 10.7554/eLife.05005.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.05005</ArticleId><ArticleId IdType="pmc">PMC4532895</ArticleId><ArticleId IdType="pubmed">26267216</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehl T., Kern F., Backes C., Fehlmann T., St&#xf6;ckel D., Meese E., Lenhof H.-P., Keller A. miRPathDB 2.0: A novel release of the miRNA Pathway Dictionary Database. Nucleic Acids Res. 2020;48:D142&#x2013;D147. doi: 10.1093/nar/gkz1022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz1022</ArticleId><ArticleId IdType="pmc">PMC7145528</ArticleId><ArticleId IdType="pubmed">31691816</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2012;2:401&#x2013;404. doi: 10.1158/2159-8290.CD-12-0095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-12-0095</ArticleId><ArticleId IdType="pmc">PMC3956037</ArticleId><ArticleId IdType="pubmed">22588877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., Sun Y., Jacobsen A., Sinha R., Larsson E., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013;6:pl1. doi: 10.1126/scisignal.2004088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2004088</ArticleId><ArticleId IdType="pmc">PMC4160307</ArticleId><ArticleId IdType="pubmed">23550210</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.H., Liu S., Zhou H., Qu L.H., Yang J.H. starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92&#x2013;D97. doi: 10.1093/nar/gkt1248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1248</ArticleId><ArticleId IdType="pmc">PMC3964941</ArticleId><ArticleId IdType="pubmed">24297251</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rier R.C., Junier T., Bucher P. The Eukaryotic Promoter Database EPD. Nucleic Acids Res. 1998;26:353&#x2013;357. doi: 10.1093/nar/26.1.353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/26.1.353</ArticleId><ArticleId IdType="pmc">PMC147208</ArticleId><ArticleId IdType="pubmed">9399872</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasteiger E., Gattiker A., Hoogland C., Ivanyi I., Appel R.D., Bairoch A. ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 2003;31:3784&#x2013;3788. doi: 10.1093/nar/gkg563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkg563</ArticleId><ArticleId IdType="pmc">PMC168970</ArticleId><ArticleId IdType="pubmed">12824418</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L.C., Dahiya R. MethPrimer: Designing primers for methylation PCRs. Bioinformatics. 2002;18:1427&#x2013;1431. doi: 10.1093/bioinformatics/18.11.1427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/18.11.1427</ArticleId><ArticleId IdType="pubmed">12424112</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y., Wei Y., Gu Y., Zhang S., Lyu J., Zhang B., Chen C., Zhu J., Wang Y., Liu H., et al. DiseaseMeth version 2.0: A major expansion and update of the human disease methylation database. Nucleic Acids Res. 2017;45:D888&#x2013;D895. doi: 10.1093/nar/gkw1123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw1123</ArticleId><ArticleId IdType="pmc">PMC5210584</ArticleId><ArticleId IdType="pubmed">27899673</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang J., Jones A., Lee S.H., Ng E., Fiegl H., Zikan M., Cibula D., Sargent A., Salvesen H.B., Jacobs I.J., et al. The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women&#x2019;s cancer. PLoS Genet. 2012;8:e1002517. doi: 10.1371/annotation/35f168f3-c509-4b4f-b245-f6682325838e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/annotation/35f168f3-c509-4b4f-b245-f6682325838e</ArticleId><ArticleId IdType="pmc">PMC3276553</ArticleId><ArticleId IdType="pubmed">22346766</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkas S.A., Milutin-Ga&#x161;perov N., Grce M., Nilsson T.K. Genome-wide DNA methylation assay reveals novel candidate biomarker genes in cervical cancer. Epigenetics. 2013;8:1213&#x2013;1225. doi: 10.4161/epi.26346.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/epi.26346</ArticleId><ArticleId IdType="pubmed">24030264</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandelin A., Wasserman W.W., Lenhard B. ConSite: Web-based prediction of regulatory elements using cross-species comparison. Nucleic Acids Res. 2004;32:W249&#x2013;W252. doi: 10.1093/nar/gkh372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh372</ArticleId><ArticleId IdType="pmc">PMC441510</ArticleId><ArticleId IdType="pubmed">15215389</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabe N. AliBaba2: Context specific identification of transcription factor binding sites. Silico Biol. 2002;2:S1&#x2013;S15.</Citation><ArticleIdList><ArticleId IdType="pubmed">11808873</ArticleId></ArticleIdList></Reference><Reference><Citation>Messeguer X., Escudero R., Farr&#xe9; D., N&#xfa;&#xf1;ez O., Mart&#xed;nez J., Alb&#xe0; M.M. PROMO: Detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 2002;18:333&#x2013;334. doi: 10.1093/bioinformatics/18.2.333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/18.2.333</ArticleId><ArticleId IdType="pubmed">11847087</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman A.M., Steen C.B., Liu C.L., Gentles A.J., Chaudhuri A.A., Scherer F., Khodadoust M.S., Esfahani M.S., Luca B.A., Steiner D., et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 2019;37:773&#x2013;782. doi: 10.1038/s41587-019-0114-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0114-2</ArticleId><ArticleId IdType="pmc">PMC6610714</ArticleId><ArticleId IdType="pubmed">31061481</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Gable A.L., Nastou K.C., Lyon D., Kirsch R., Pyysalo S., Doncheva N.T., Legeay M., Fang T., Bork P., et al. The STRING database in 2021: Customizable protein&#x2013;protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2020;49:D605&#x2013;D612. doi: 10.1093/nar/gkaa1074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa1074</ArticleId><ArticleId IdType="pmc">PMC7779004</ArticleId><ArticleId IdType="pubmed">33237311</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen E.Y., Tan C.M., Kou Y., Duan Q., Wang Z., Meirelles G.V., Clark N.R., Ma&#x2019;ayan A. Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 2013;14:128. doi: 10.1186/1471-2105-14-128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-14-128</ArticleId><ArticleId IdType="pmc">PMC3637064</ArticleId><ArticleId IdType="pubmed">23586463</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng R., Wan C., Mei S., Qin Q., Wu Q., Sun H., Chen C.H., Brown M., Zhang X., Meyer C.A., et al. Cistrome Data Browser: Expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res. 2019;47:D729&#x2013;D735. doi: 10.1093/nar/gky1094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1094</ArticleId><ArticleId IdType="pmc">PMC6324081</ArticleId><ArticleId IdType="pubmed">30462313</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 2005;102:15545&#x2013;15550. doi: 10.1073/pnas.0506580102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37033395</PMID><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1936-2625</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>International journal of clinical and experimental pathology</Title><ISOAbbreviation>Int J Clin Exp Pathol</ISOAbbreviation></Journal><ArticleTitle>APOBEC3B expression has prognostic significance in cervical cancer.</ArticleTitle><Pagination><StartPage>48</StartPage><EndPage>56</EndPage><MedlinePgn>48-56</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Cervical cancer is one of the leading fatal diseases in women, and the role of Apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) in cervical cancer is uncertain.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Four Gene Expression Omnibus (GEO) mRNA microarray datasets were analyzed to identify differentially expressed genes (DEGs) between cervical cancer and normal cervical tissues. The results were validated using a The Cancer Genome Atlas (TCGA)-cervical cancer (CESC) dataset. Expression profiles and patients' clinical data were used to investigate the relationship between APOBEC3B expression and cervical cancer survival. APOBEC3B co-expressed genes were subjected to enrichment analyses, and correlations between APOBEC3B expression and immunologic infiltrates were investigated using Tumor Immune Estimation Resource (TIMER). We generated receiver operating characteristic curve (ROC) curves to evaluate the performance of APOBEC3B expression in predicting cervical cancer prognosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fourteen overlapping DEGs were obtained, and APOBEC3B was chosen as a candidate gene. TCGA data further confirmed that APOBEC3B was significantly increased in cervical cancer, relative to normal adjacent tissues, and this expression was associated with poor clinical outcome. Results from quantitative real time polymerase chain reaction (RT-qPCR) and immunohistochemical staining of cervical carcinoma tissues supported these findings. Enrichment analysis showed that APOBEC3B co-expressed genes were mainly enriched in cell cycle, DNA replication and chromosomal region. Moreover, APOBEC3B expression was significantly associated with T stage, M stage, primary therapy outcome and poor clinical prognosis in cervical cancer. Similarly, APOBEC3B was closely correlated with gene markers of diverse immune cells. APOBEC3B expression was an independent indicator of cervical cancer prognosis, according to univariate Cox and ROC analyses.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">High APOBEC3B expression is strongly related to a poor prognosis in cervical cancer patients.</AbstractText><CopyrightInformation>IJCEP Copyright &#xa9; 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Si-Qi</ForeName><Initials>SQ</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Soochow University Changzhou 213003, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Medical Research Center, The Third Affiliated Hospital of Soochow University Changzhou 213003, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Medical Research Center, The Third Affiliated Hospital of Soochow University Changzhou 213003, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Miao-Mei</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Clinical Medical Research Center, The Third Affiliated Hospital of Soochow University Changzhou 213003, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Medical Research Center, The Third Affiliated Hospital of Soochow University Changzhou 213003, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Yan-Hong</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Soochow University Changzhou 213003, Jiangsu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Clin Exp Pathol</MedlineTA><NlmUniqueID>101480565</NlmUniqueID><ISSNLinking>1936-2625</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOBEC3B</Keyword><Keyword MajorTopicYN="N">GEO</Keyword><Keyword MajorTopicYN="N">TCGA</Keyword><Keyword MajorTopicYN="N">bioinformatics analysis</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>10</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37033395</ArticleId><ArticleId IdType="pmc">PMC10076974</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: a global health crisis. Cancer. 2017;123:2404&#x2013;2412.</Citation><ArticleIdList><ArticleId IdType="pubmed">28464289</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393:169&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanao H, Aoki Y, Hisa T, Takeshima N. Total laparoscopic pelvic exenteration for a laterally recurrent cervical carcinoma with a vesicovaginal fistula that developed after concurrent chemoradiotherapy. Gynecol Oncol. 2017;146:438&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">28576262</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning MS, Ahobila V, Jhingran A, Stecklein SR, Frumovitz M, Schmeler KM, Eifel PJ, Klopp AH. Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. Gynecol Oncol. 2018;148:132&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">29089122</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 2015;5:704&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4497973</ArticleId><ArticleId IdType="pubmed">26091828</ArticleId></ArticleIdList></Reference><Reference><Citation>Serebrenik AA, Argyris PP, Jarvis MC, Brown WL, Bazzaro M, Vogel RI, Erickson BK, Lee SH, Goergen KM, Maurer MJ, Heinzen EP, Oberg AL, Huang Y, Hou X, Weroha SJ, Kaufmann SH, Harris RS. The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer. Clin Cancer Res. 2020;26:3397&#x2013;3407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334080</ArticleId><ArticleId IdType="pubmed">32060098</ArticleId></ArticleIdList></Reference><Reference><Citation>Driscoll CB, Schuelke MR, Kottke T, Thompson JM, Wongthida P, Tonne JM, Huff AL, Miller A, Shim KG, Molan A, Wetmore C, Selby P, Samson A, Harrington K, Pandha H, Melcher A, Pulido JS, Harris R, Evgin L, Vile RG. APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nat Commun. 2020;11:790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7005822</ArticleId><ArticleId IdType="pubmed">32034147</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 2013;45:977&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3902892</ArticleId><ArticleId IdType="pubmed">23852168</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Q, Luo G, Wei J, Zheng L, Wang H, Yu M, Xu N. Apolipoprotein M promotes growth and inhibits apoptosis of colorectal cancer cells through upregulation of ribosomal protein S27a. EXCLI J. 2021;20:145&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7868641</ArticleId><ArticleId IdType="pubmed">33564284</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J, Shi Y, Zhang X, Feng Y, Luo G, Zhang J, Mu Q, Tang Y, Yu Y, Pan L, Nilsson-Ehle P, Xu N. Estrogen upregulates hepatic apolipoprotein M expression via the estrogen receptor. Biochim Biophys Acta. 2011;1811:1146&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">21816233</ArticleId></ArticleIdList></Reference><Reference><Citation>Serebrenik AA, Starrett GJ, Leenen S, Jarvis MC, Shaban NM, Salamango DJ, Nilsen H, Brown WL, Harris RS. The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase. Proc Natl Acad Sci U S A. 2019;116:22158&#x2013;22163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6825264</ArticleId><ArticleId IdType="pubmed">31611371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Jia M, He Z, Liu XS. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene. 2018;37:3924&#x2013;3936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6053356</ArticleId><ArticleId IdType="pubmed">29695832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma W, Ho DW, Sze KM, Tsui YM, Chan LK, Lee JM, Ng IO. APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity. Mol Carcinog. 2019;58:643&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">30575099</ArticleId></ArticleIdList></Reference><Reference><Citation>Argyris PP, Wilkinson PE, Jarvis MC, Magliocca KR, Patel MR, Vogel RI, Gopalakrishnan R, Koutlas IG, Harris RS. Endogenous APOBEC3B overexpression characterizes HPV-positive and HPV-negative oral epithelial dysplasias and head and neck cancers. Mod Pathol. 2021;34:280&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261524</ArticleId><ArticleId IdType="pubmed">32632179</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S, Gu Y, Zhang H, Fei Y, Cao Y, Fang H, Wang J, Lin C, Zhang H, Li H, He H, Xu J. Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer. Oncoimmunology. 2021;10:1975386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8451457</ArticleId><ArticleId IdType="pubmed">34552824</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu R, Oshi M, Asaoka M, Huyser MR, Tokumaru Y, Yamada A, Yan L, Endo I, Ishikawa T, Takabe K. APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival. Am J Cancer Res. 2022;12:744&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8899983</ArticleId><ArticleId IdType="pubmed">35261799</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Q, Huang T, Sun X, Wang YW, Wang J, Liu Y, Ni T, Gu SL, Li YH, Wang YD. HPV-16/18 E6-induced APOBEC3B expression associates with proliferation of cervical cancer cells and hypomethylation of Cyclin D1. Mol Carcinog. 2021;60:313&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">33631046</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan S, Angelova M, Puttick C, Zhai H, Caswell DR, Lu WT, Dietzen M, Galanos P, Evangelou K, Bellelli R, Lim EL, Watkins TBK, Rowan A, Teixeira VH, Zhao Y, Chen H, Ngo B, Zalmas LP, Al Bakir M, Hobor S, Gr&#xf6;nroos E, Pennycuick A, Nigro E, Campbell BB, Brown WL, Akarca AU, Marafioti T, Wu MY, Howell M, Boulton SJ, Bertoli C, Fenton TR, de Bruin RAM, Maya-Mendoza A, Santoni-Rugiu E, Hynds RE, Gorgoulis VG, Jamal-Hanjani M, McGranahan N, Harris RS, Janes SM, Bartkova J, Bakhoum SF, Bartek J, Kanu N, Swanton C. Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. Cancer Discov. 2021;11:2456&#x2013;2473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8487921</ArticleId><ArticleId IdType="pubmed">33947663</ArticleId></ArticleIdList></Reference><Reference><Citation>Middlebrooks CD, Banday AR, Matsuda K, Udquim KI, Onabajo OO, Paquin A, Figueroa JD, Zhu B, Koutros S, Kubo M, Shuin T, Freedman ND, Kogevinas M, Malats N, Chanock SJ, Garcia-Closas M, Silverman DT, Rothman N, Prokunina-Olsson L. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat Genet. 2016;48:1330&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583788</ArticleId><ArticleId IdType="pubmed">27643540</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, Law EK, Harris RS. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013;494:366&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3907282</ArticleId><ArticleId IdType="pubmed">23389445</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, Harris S, Shah RR, Resnick MA, Getz G, Gordenin DA. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013;45:970&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3789062</ArticleId><ArticleId IdType="pubmed">23852170</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris RS. Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. Breast Cancer Res. 2015;17:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4303225</ArticleId><ArticleId IdType="pubmed">25848704</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan JW, Zabidi MMA, Chong BK, Meng MY, Ng PS, Hasan SN, Sandey B, Bahnu S, Rajadurai P, Yip CH, Rueda OM, Caldas C, Chin SF, Teo SH. Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations, and immune activation. Int J Cancer. 2021 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">33423300</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirabayashi S, Shirakawa K, Horisawa Y, Matsumoto T, Matsui H, Yamazaki H, Sarca AD, Kazuma Y, Nomura R, Konishi Y, Takeuchi S, Stanford E, Kawaji H, Murakawa Y, Takaori-Kondo A. APOBEC3B is preferentially expressed at the G2/M phase of cell cycle. Biochem Biophys Res Commun. 2021;546:178&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">33592502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen WX, Soo JS, Kwan PY, Hong E, Khang TF, Mariapun S, Lee CS, Hasan SN, Rajadurai P, Yip CH, Mohd Taib NA, Teo SH. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. Breast Cancer Res. 2016;18:56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4884363</ArticleId><ArticleId IdType="pubmed">27233495</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu B, Tse LA, Wang D, Koka H, Zhang T, Abubakar M, Lee P, Wang F, Wu C, Tsang KH, Chan WC, Law SH, Li M, Li W, Wu S, Liu Z, Huang B, Zhang H, Tang E, Kan Z, Lee S, Park YH, Nam SJ, Wang M, Sun X, Jones K, Zhu B, Hutchinson A, Hicks B, Prokunina-Olsson L, Shi J, Garcia-Closas M, Chanock S, Yang XR. Immune gene expression profiling reveals heterogeneity in luminal breast tumors. Breast Cancer Res. 2019;21:147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924001</ArticleId><ArticleId IdType="pubmed">31856876</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Li X, Li J, Lu Y, Zhao S, Tang X, Chen X, Li J, Zheng Y, Li S, Sun R, Yan M, Yu D, Cao G, Yang Y. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression. Gut. 2019;68:1846&#x2013;1857.</Citation><ArticleIdList><ArticleId IdType="pubmed">31154396</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfc;der U, Denkert C, Kunze CA, Jank P, Lindner J, J&#xf6;hrens K, Kulbe H, Sehouli J, Dietel M, Braicu E, Darb-Esfahani S. APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma. Histol Histopathol. 2019;34:405&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">30289149</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36999051</PMID><DateRevised><Year>2023</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-8021</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in genetics</Title><ISOAbbreviation>Front Genet</ISOAbbreviation></Journal><ArticleTitle>Construction of a prognostic model based on eight ubiquitination-related genes <i>via</i> machine learning and potential therapeutics analysis for cervical cancer.</ArticleTitle><Pagination><StartPage>1142938</StartPage><MedlinePgn>1142938</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1142938</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fgene.2023.1142938</ELocationID><Abstract><AbstractText><b>Introduction:</b> Ubiquitination is involved in many biological processes and its predictive value for prognosis in cervical cancer is still unclear. <b>Methods:</b> To further explore the predictive value of the ubiquitination-related genes we obtained URGs from the Ubiquitin and Ubiquitin-like Conjugation Database, analyzed datasets from The Cancer Genome Atlas and Gene Expression Omnibus databases, and then selected differentially expressed ubiquitination-related genes between normal and cancer tissues. Then, DURGs significantly associated with overall survival were selected through univariate Cox regression. Machine learning was further used to select the DURGs. Then, we constructed and validated a reliable prognostic gene signature by multivariate analysis. In addition, we predicted the substrate proteins of the signature genes and did a functional analysis to further understand the molecular biology mechanisms. The study provided new guidelines for evaluating cervical cancer prognosis and also suggested new directions for drug development. <b>Results:</b> By analyzing 1,390 URGs in GEO and TCGA databases, we obtained 175 DURGs. Our results showed 19 DURGs were related to prognosis. Finally, eight DURGs were identified <i>via</i> machine learning to construct the first ubiquitination prognostic gene signature. Patients were stratified into high-risk and low-risk groups and the prognosis was worse in the high-risk group. In addition, these gene protein levels were mostly consistent with their transcript level. According to the functional analysis of substrate proteins, the signature genes may be involved in cancer development through the transcription factor activity and the classical P53 pathway ubiquitination-related signaling pathways. Additionally, 71 small molecular compounds were identified as potential drugs. <b>Conclusion:</b> We systematically studied the influence of ubiquitination-related genes on prognosis in cervical cancer, established a prognostic model through a machine learning algorithm, and verified it. Also, our study provides a new treatment strategy for cervical cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Hao, Guy, Liu, Li, Mao, Jiang, Wang, Cui and Zhang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Yiping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guy</LastName><ForeName>Mutangala Muloye</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qingqing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruowen</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Zhonghao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bingyu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Baoxia</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wenjing</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Genet</MedlineTA><NlmUniqueID>101560621</NlmUniqueID><ISSNLinking>1664-8021</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">potential therapeutics</Keyword><Keyword MajorTopicYN="N">prognosis model</Keyword><Keyword MajorTopicYN="N">ubiquitination-related genes</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>2</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36999051</ArticleId><ArticleId IdType="pmc">PMC10043205</ArticleId><ArticleId IdType="doi">10.3389/fgene.2023.1142938</ArticleId><ArticleId IdType="pii">1142938</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Duan K. B., Rajapakse J. C., Wang H., Azuaje F. (2005). Multiple SVM-RFE for gene selection in cancer classification with expression data. IEEE Trans. Nanobioscience 4 (3), 228&#x2013;234. 10.1109/tnb.2005.853657</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/tnb.2005.853657</ArticleId><ArticleId IdType="pubmed">16220686</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa A. M., Alfaro A., Roman-Basaure E., Guardado-Estrada M., Palma I., Serralde C., et al. (2013). Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PLoS One 8 (2), e55975. 10.1371/journal.pone.0055975</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0055975</ArticleId><ArticleId IdType="pmc">PMC3566100</ArticleId><ArticleId IdType="pubmed">23405241</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao T., Liu Z., Wang Y., Cheng H., Yang Q., Guo A., et al. (2013). Uucd: A family-based database of ubiquitin and ubiquitin-like conjugation. Nucleic Acids Res. 41 (D1), D445&#x2013;D451. 10.1093/nar/gks1103</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1103</ArticleId><ArticleId IdType="pmc">PMC3531133</ArticleId><ArticleId IdType="pubmed">23172288</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock A. K., Vousden K. H. (2014). The role of ubiquitin modification in the regulation of p53. Biochimica Biophysica Acta (BBA) - Mol. Cell. Res. 1843 (1), 137&#x2013;149. 10.1016/j.bbamcr.2013.05.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2013.05.022</ArticleId><ArticleId IdType="pubmed">23742843</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeller D., Dikic I. (2009). Targeting the ubiquitin system in cancer therapy. Nature 458 (7237), 438&#x2013;444. 10.1038/nature07960</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07960</ArticleId><ArticleId IdType="pubmed">19325623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu C., Zhang Q., Tang Q., Zhou H., Liu W., Huang J., et al. (2020). CBX4 promotes the proliferation and metastasis via regulating BMI&#x2010;1 in lung cancer. J. Cell. Mol. Med. 24 (1), 618&#x2013;631. 10.1111/jcmm.14771</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.14771</ArticleId><ArticleId IdType="pmc">PMC6933416</ArticleId><ArticleId IdType="pubmed">31724308</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X., Dixit V. M. (2016). Drugging the undruggables: Exploring the ubiquitin system for drug development. Cell. Res. 26 (4), 484&#x2013;498. 10.1038/cr.2016.31</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2016.31</ArticleId><ArticleId IdType="pmc">PMC4822129</ArticleId><ArticleId IdType="pubmed">27002218</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh K., Zhou X., Hayakawa H., Cho J. Y., Libermann T. A., Jin J., et al. (2007). Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virology 81 (18), 9737&#x2013;9747. 10.1128/JVI.00881-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00881-07</ArticleId><ArticleId IdType="pmc">PMC2045412</ArticleId><ArticleId IdType="pubmed">17609271</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry R. A., Hobbs B., Collin F., Beazer-Barclay Y. D., Antonellis K. J., Scherf U., et al. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4 (2), 249&#x2013;264. 10.1093/biostatistics/4.2.249</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biostatistics/4.2.249</ArticleId><ArticleId IdType="pubmed">12925520</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Xu H., Wang Y., Lu H. (2021). Identification and validation of autophagy-related gene nomograms to predict the prognostic value of patients with cervical cancer. J. Oncol. 2021, 5583400&#x2013;5583417. 10.1155/2021/5583400</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5583400</ArticleId><ArticleId IdType="pmc">PMC8253645</ArticleId><ArticleId IdType="pubmed">34257653</ArticleId></ArticleIdList></Reference><Reference><Citation>Komander D., Clague M. J., Urb&#xe9; S. (2009). Breaking the chains: Structure and function of the deubiquitinases. Nat. Rev. Mol. Cell. Biol. 10 (8), 550&#x2013;563. 10.1038/nrm2731</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2731</ArticleId><ArticleId IdType="pubmed">19626045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong L., Yu X. P., Bai X. H., Zhang W. F., Zhang Y., Zhao W. M., et al. (2007). RbAp48 is a critical mediator controlling the transforming activity of human papillomavirus type 16 in cervical cancer. J. Biol. Chem. 282 (36), 26381&#x2013;26391. 10.1074/jbc.M702195200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M702195200</ArticleId><ArticleId IdType="pubmed">17616526</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb J., Crawford E. D., Peck D., Modell J. W., Blat I. C., Wrobel M. J., et al. (2006). The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Sci. Am. Assoc. Adv. Sci. 313 (5795), 1929&#x2013;1935. 10.1126/science.1132939</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1132939</ArticleId><ArticleId IdType="pubmed">17008526</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y., Kim T. J., Kim J. Y., Choi C. H., Do I. G., Song S. Y., et al. (2013). Genetic profiling to predict recurrence of early cervical cancer. Gynecol. Oncol. 131 (3), 650&#x2013;654. 10.1016/j.ygyno.2013.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2013.10.003</ArticleId><ArticleId IdType="pubmed">24145113</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek J. T. (2014). svaseq: removing batch effects and other unwanted noise from sequencing data. Nucleic Acids Res. 42 (21), e161. 10.1093/nar/gku864</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku864</ArticleId><ArticleId IdType="pmc">PMC4245966</ArticleId><ArticleId IdType="pubmed">25294822</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Xie P., Lu L., Wang J., Diao L., Liu Z., et al. (2017). An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network. Nat. Commun. 8 (1), 347. 10.1038/s41467-017-00299-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00299-9</ArticleId><ArticleId IdType="pmc">PMC5570908</ArticleId><ArticleId IdType="pubmed">28839186</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Wu W., Deng S., Shao Z., Jin X. (2021). TRAIP modulates the IGFBP3/AKT pathway to enhance the invasion and proliferation of osteosarcoma by promoting KANK1 degradation. Cell. Death Dis. 12 (8), 767. 10.1038/s41419-021-04057-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-04057-0</ArticleId><ArticleId IdType="pmc">PMC8339131</ArticleId><ArticleId IdType="pubmed">34349117</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Zapien D., Ruiz F. X., Poirson J., Mitschler A., Ramirez J., Forster A., et al. (2016). Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature 529 (7587), 541&#x2013;545. 10.1038/nature16481</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature16481</ArticleId><ArticleId IdType="pmc">PMC4853763</ArticleId><ArticleId IdType="pubmed">26789255</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Martinez I., Barron V., Roman-Bassaure E., Juarez-Torres E., Guardado-Estrada M., Espinosa A. M., et al. (2014). Impact of gene dosage on gene expression, biological processes and survival in cervical cancer: A genome-wide follow-up study. PLoS One 9 (5), e97842. 10.1371/journal.pone.0097842</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0097842</ArticleId><ArticleId IdType="pmc">PMC4039463</ArticleId><ArticleId IdType="pubmed">24879114</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan E. L., Patterson M. R., Barba-Moreno D., Scarth J. A., Wilson A., Macdonald A. (2021). The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer. Oncogene 40 (11), 2112&#x2013;2129. 10.1038/s41388-021-01679-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-021-01679-8</ArticleId><ArticleId IdType="pmc">PMC7979541</ArticleId><ArticleId IdType="pubmed">33627786</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratani M., Tansey W. P. (2003). How the ubiquitin&#x2013;proteasome system controls transcription. Nat. Rev. Mol. Cell. Biol. 4 (3), 192&#x2013;201. 10.1038/nrm1049</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm1049</ArticleId><ArticleId IdType="pubmed">12612638</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura N. (2018). Ubiquitin system. Int. J. Mol. Sci. 19 (4), 1080. 10.3390/ijms19041080</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19041080</ArticleId><ArticleId IdType="pmc">PMC5979459</ArticleId><ArticleId IdType="pubmed">29617326</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J., Xu L., Pan H. (2020). Development and validation of an m6A RNA methylation regulator-based signature for prognostic prediction in cervical squamous cell carcinoma. Front. Oncol. 10, 1444. 10.3389/fonc.2020.01444</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.01444</ArticleId><ArticleId IdType="pmc">PMC7472601</ArticleId><ArticleId IdType="pubmed">32974164</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., Howley P. M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63 (6), 1129&#x2013;1136. 10.1016/0092-8674(90)90409-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(90)90409-8</ArticleId><ArticleId IdType="pubmed">2175676</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel R. L., Miller K. D., Fuchs H. E., Jemal A. (2021). Cancer statistics, 2021. CA a cancer J. Clin. 71 (1), 7&#x2013;33. 10.3322/caac.21654</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21654</ArticleId><ArticleId IdType="pubmed">33433946</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L., Luo Z. (2019). Post-translational regulation of ubiquitin signaling. J. Cell. Biol. 218 (6), 1776&#x2013;1786. 10.1083/jcb.201902074</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201902074</ArticleId><ArticleId IdType="pmc">PMC6548142</ArticleId><ArticleId IdType="pubmed">31000580</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA a cancer J. Clin. 71 (3), 209&#x2013;249. 10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen M., Fagerberg L., Hallstrom B. M., Lindskog C., Oksvold P., Mardinoglu A., et al. (2015). Proteomics. Tissue-based map of the human proteome. Science 347 (6220), 1260419. 10.1126/science.1260419</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1260419</ArticleId><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Bu F., Zhang W. (2019). The role of ubiquitination in regulating embryonic stem cell maintenance and cancer development. Int. J. Mol. Sci. 20 (11), 2667. 10.3390/ijms20112667</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20112667</ArticleId><ArticleId IdType="pmc">PMC6600158</ArticleId><ArticleId IdType="pubmed">31151253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Liu Y., Xuan C., Liu Y., Shi H., Gao Y. (2021). Identification of ubiquitination-related genes in human glioma as indicators of patient prognosis. PLOS ONE 16 (4), e0250239. 10.1371/journal.pone.0250239</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0250239</ArticleId><ArticleId IdType="pmc">PMC8084191</ArticleId><ArticleId IdType="pubmed">33914773</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Li Y., He M., Kong X., Jiang P., Liu X., et al. (2022). UbiBrowser 2.0: A comprehensive resource for proteome-wide known and predicted ubiquitin ligase/deubiquitinase&#x2013;substrate interactions in eukaryotic species. Nucleic Acids Res. 50 (D1), D719&#x2013;D728. 10.1093/nar/gkab962</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab962</ArticleId><ArticleId IdType="pmc">PMC8728189</ArticleId><ArticleId IdType="pubmed">34669962</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissman A. M. (2001). Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell. Biol. 2 (3), 169&#x2013;178. 10.1038/35056563</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35056563</ArticleId><ArticleId IdType="pubmed">11265246</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Wang J., Yuan X., Yang S., Xu X., Li K., et al. (2020). IU1 suppresses proliferation of cervical cancer cells through MDM2 degradation. Int. J. Biol. Sci. 16 (15), 2951&#x2013;2963. 10.7150/ijbs.47999</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.47999</ArticleId><ArticleId IdType="pmc">PMC7545697</ArticleId><ArticleId IdType="pubmed">33061808</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Yao B., Wu L., Liu Y., Liu K., Xu P., et al. (2021). Ubiquitin-related molecular classification and risk stratification of hepatocellular carcinoma. Mol. Ther. Oncolytics 21, 207&#x2013;219. 10.1016/j.omto.2021.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2021.04.003</ArticleId><ArticleId IdType="pmc">PMC8138213</ArticleId><ArticleId IdType="pubmed">34095460</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi S. A., Kim G. W., Yoo J., Han J. W., Kwon S. H. (2020). HP1&#x3b3; sensitizes cervical cancer cells to cisplatin through the suppression of UBE2L3. Int. J. Mol. Sci. 21 (17), 5976. 10.3390/ijms21175976</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21175976</ArticleId><ArticleId IdType="pmc">PMC7503686</ArticleId><ArticleId IdType="pubmed">32825184</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G., Wang L. G., Han Y., He Q. Y. (2012). clusterProfiler: an R Package for comparing biological themes among gene clusters. OMICS A J. Integr. Biol. 16 (5), 284&#x2013;287. 10.1089/omi.2011.0118</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao F., Qiao Y. (2019). Cervical cancer prevention in China: A key to cancer control. Lancet (British Ed. 393 (10175), 969&#x2013;970. 10.1016/S0140-6736(18)32849-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32849-6</ArticleId><ArticleId IdType="pubmed">30860036</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L., Tang W., Wei F., Wang H., Liu J., Lu Y., et al. (2013). Radiation-inducible protein RbAp48 contributes to radiosensitivity of cervical cancer cells. Gynecol. Oncol. 130 (3), 601&#x2013;608. 10.1016/j.ygyno.2013.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2013.06.002</ArticleId><ArticleId IdType="pubmed">23756179</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng N., Shabek N. (2017). Ubiquitin ligases: Structure, function, and regulation. Annu. Rev. Biochem. 86 (1), 129&#x2013;157. 10.1146/annurev-biochem-060815-014922</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-060815-014922</ArticleId><ArticleId IdType="pubmed">28375744</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong G., Zhao Z. B., Cheng Y., Wang Y. B., Qiu C., Mao L. H., et al. (2021). Epigenetic silencing of GCH1promotes hepatocellular carcinoma growth by activating superoxide anion-mediated ASK1/p38 signaling via inhibiting tetrahydrobiopterin de novo biosynthesis. Free Radic. Biol. Med. 168, 81&#x2013;94. 10.1016/j.freeradbiomed.2021.03.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2021.03.025</ArticleId><ArticleId IdType="pubmed">33781891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J., Xu Y., Lin S., Guo Y., Deng W., Zhang Y., et al. (2018). iUUCD 2.0: an update with rich annotations for ubiquitin and ubiquitin-like conjugations. Nucleic Acids Res. 46 (D1), D447&#x2013;D453. 10.1093/nar/gkx1041</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1041</ArticleId><ArticleId IdType="pmc">PMC5753239</ArticleId><ArticleId IdType="pubmed">29106644</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Piao C., Zhang Z., Jiang Y., Kong C. (2022). The potential role of c-MYC and polyamine metabolism in multiple drug resistance in bladder cancer investigated by metabonomics. Genomics 114 (1), 125&#x2013;137. 10.1016/j.ygeno.2021.11.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2021.11.028</ArticleId><ArticleId IdType="pubmed">34843906</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36968582</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-8021</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in genetics</Title><ISOAbbreviation>Front Genet</ISOAbbreviation></Journal><ArticleTitle>The construction and analysis of tricarboxylic acid cycle related prognostic model for cervical cancer.</ArticleTitle><Pagination><StartPage>1092276</StartPage><MedlinePgn>1092276</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1092276</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fgene.2023.1092276</ELocationID><Abstract><AbstractText><b>Introduction:</b> Cervical cancer (CC) is the fourth most common malignant tumor in term of in incidence and mortality among women worldwide. The tricarboxylic acid (TCA) cycle is an important hub of energy metabolism, networking one-carbon metabolism, fatty acyl metabolism and glycolysis. It can be seen that the reprogramming of cell metabolism including TCA cycle plays an indispensable role in tumorigenesis and development. We aimed to identify genes related to the TCA cycle as prognostic markers in CC. <b>Methods:</b> Firstly, we performed the differential expressed analysis the gene expression profiles associated with TCA cycle obtained from The Cancer Genome Atlas (TCGA) database. Differential gene list was generated and cluster analysis was performed using genes with detected fold changes &gt;1.5. Based on the subclusters of CC, we analysed the relationship between different clusters and clinical information. Next, Cox univariate and multivariate regression analysis were used to screen genes with prognostic characteristics, and risk scores were calculated according to the genes with prognostic characteristics. Additionally, we analyzed the correlation between the predictive signature and the treatment response of CC patients. Finally, we detected the expression of ench prognostic gene in clinical CC samples by quantitative polymerase chain reaction (RT-qPCR). <b>Results:</b> We constructed a prognostic model consist of seven TCA cycle associated gene (ACSL1, ALDOA, FOXK2, GPI, MDH1B, MDH2, and MTHFD1). Patients with CC were separated into two groups according to median risk score, and high-risk group had a worse prognosis compared to the low-risk group. High risk group had lower level of sensitivity to the conventional chemotherapy drugs including cisplatin, paclitaxel, sunitinib and docetaxel. The expression of ench prognostic signature in clinical CC samples was verified by qRT-PCR. <b>Conclusion:</b> There are several differentially expressed genes (DEGs) related to TCA cycle in CC. The risk score model based on these genes can effectively predict the prognosis of patients and provide tumor markers for predicting the prognosis of CC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Chen, Hong, He, Ou, Chen, Zhong, Lin and Luo.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Guanqiao</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Guangdong Women and Children Medical Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Xiaoshan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Guangdong Women and Children Medical Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Wanshan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Guangdong Women and Children Medical Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ou</LastName><ForeName>Lingling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Guangdong Women and Children Medical Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Guangdong Women and Children Medical Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Weitao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Surgical Neonatal Intensive Care Unit, Guangzhou Women and Children's Medical Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Xiping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Guangdong Women and Children Medical Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Genet</MedlineTA><NlmUniqueID>101560621</NlmUniqueID><ISSNLinking>1664-8021</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">metabolic reprogramming</Keyword><Keyword MajorTopicYN="N">prognostic signature</Keyword><Keyword MajorTopicYN="N">tricarboxylic acid cycle (TCA cycle)</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>3</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36968582</ArticleId><ArticleId IdType="pmc">PMC10033772</ArticleId><ArticleId IdType="doi">10.3389/fgene.2023.1092276</ArticleId><ArticleId IdType="pii">1092276</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arnold P. K., Jackson B. T., Paras K. I., Brunner J. S., Hart M. L., Newsom O. J., et al. (2022). A non-canonical tricarboxylic acid cycle underlies cellular identity. Nature 603 (7901), 477&#x2013;481. 10.1038/s41586-022-04475-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04475-w</ArticleId><ArticleId IdType="pmc">PMC8934290</ArticleId><ArticleId IdType="pubmed">35264789</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann M., Kappl A., Lang T., Brand K., Siegfried W., Paterok E. (1990). The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer. Cancer investig. 8 (3-4), 351&#x2013;356. 10.3109/07357909009012053</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/07357909009012053</ArticleId><ArticleId IdType="pubmed">2207761</ArticleId></ArticleIdList></Reference><Reference><Citation>Belizario J. E., Sangiuliano B. A., Perez-Sosa M., Neyra J. M., Moreira D. F. (2016). Using pharmacogenomic databases for discovering patient-target genes and small molecule candidates to cancer therapy. Front. Pharmacol. 7, 312. 10.3389/fphar.2016.00312</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2016.00312</ArticleId><ArticleId IdType="pmc">PMC5040751</ArticleId><ArticleId IdType="pubmed">27746730</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68 (6), 394&#x2013;424. 10.3322/caac.21492</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>CA Cancer J Clin (2020). Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 70 (4), 313. 10.3322/caac.21609</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21609</ArticleId><ArticleId IdType="pubmed">32767693</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z., Li C. F., Han F., Liu C., Zhang A., Hsu C. C., et al. (2020). Phosphorylation of PDHA by AMPK drives TCA cycle to promote cancer metastasis. Mol. Cell. 80 (2), 263&#x2013;278. 10.1016/j.molcel.2020.09.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2020.09.018</ArticleId><ArticleId IdType="pmc">PMC7534735</ArticleId><ArticleId IdType="pubmed">33022274</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y. S., Han J. M., Kang Y. J., Jung H. J. (2021). Chloroform extract of Citrus unshiu Markovich peel induces apoptosis and inhibits stemness in HeLa human cervical cancer cells. Mol. Med. Rep. 23, 86. 10.3892/mmr.2020.11727</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2020.11727</ArticleId><ArticleId IdType="pmc">PMC7716394</ArticleId><ArticleId IdType="pubmed">33236129</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosbie E. J., Einstein M. H., Franceschi S., Kitchener H. C. (2013). Human papillomavirus and cervical cancer. Lancet 382(9895), 889&#x2013;899. 10.1016/S0140-6736(13)60022-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)60022-7</ArticleId><ArticleId IdType="pubmed">23618600</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui M., Wang Y., Sun B., Xiao Z., Ye L., Zhang X. (2014). MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA. Biochem. Biophys. Res. Commun. 444 (2), 270&#x2013;275. 10.1016/j.bbrc.2014.01.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2014.01.051</ArticleId><ArticleId IdType="pubmed">24462768</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBerardinis R. J., Chandel N. S. (2016). Fundamentals of cancer metabolism. Sci. Adv. 2 (5), e1600200. 10.1126/sciadv.1600200</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.1600200</ArticleId><ArticleId IdType="pmc">PMC4928883</ArticleId><ArticleId IdType="pubmed">27386546</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBerardinis R. J., Cheng T. (2010). Q's next: The diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29 (3), 313&#x2013;324. 10.1038/onc.2009.358</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2009.358</ArticleId><ArticleId IdType="pmc">PMC2809806</ArticleId><ArticleId IdType="pubmed">19881548</ArticleId></ArticleIdList></Reference><Reference><Citation>Eniafe J., Jiang S. (2021). The functional roles of TCA cycle metabolites in cancer. Oncogene 40(19):3351&#x2013;3363. 10.1038/s41388-020-01639-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-020-01639-8</ArticleId><ArticleId IdType="pubmed">33864000</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong W., Jiang Y., Wang L., Wei D., Yao J., Huang S., et al. (2005). Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer. Clin. Cancer Res. 11 (16), 5778&#x2013;5783. 10.1158/1078-0432.CCR-05-0214</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-05-0214</ArticleId><ArticleId IdType="pubmed">16115916</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasso C., Jansen G., Giovannetti E. (2017). Drug resistance in pancreatic cancer: Impact of altered energy metabolism. Crit. Rev. Oncol. Hematol. 114, 139&#x2013;152. 10.1016/j.critrevonc.2017.03.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2017.03.026</ArticleId><ArticleId IdType="pubmed">28477742</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji S., Zhang B., Liu J., Qin Y., Liang C., Shi S., et al. (2016). ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Cancer Lett. 374 (1), 127&#x2013;135. 10.1016/j.canlet.2016.01.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2016.01.054</ArticleId><ArticleId IdType="pubmed">26854714</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W. G., Raz A., Douglas-Jones A., Mansel R. E. (2006). Expression of autocrine motility factor (AMF) and its receptor, AMFR, in human breast cancer. J. Histochem Cytochem 54 (2), 231&#x2013;241. 10.1369/jhc.5A6785.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/jhc.5A6785.2005</ArticleId><ArticleId IdType="pubmed">16204225</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., DeBerardinis R. J. (2019). Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab. 30 (3), 434&#x2013;446. 10.1016/j.cmet.2019.08.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2019.08.013</ArticleId><ArticleId IdType="pmc">PMC6730674</ArticleId><ArticleId IdType="pubmed">31484055</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Guo R., Liu Q., Sun J., Wang H. (2020). Circular RNA circ-ITCH inhibits the malignant behaviors of cervical cancer by microRNA-93-5p/FOXK2 Axis. Reprod. Sci. 27 (3), 860&#x2013;868. 10.1007/s43032-020-00140-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43032-020-00140-7</ArticleId><ArticleId IdType="pubmed">31993998</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao D., Liu X., Yuan X., Feng P., Ouyang Z., Liu Y., et al. (2022). Long non-coding RNA tumor protein 53 target gene 1 promotes cervical cancer development via regulating microRNA-33a-5p to target forkhead box K2. Cell Cycle 21(6), 572&#x2013;584. 10.1080/15384101.2022.2026705</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2022.2026705</ArticleId><ArticleId IdType="pmc">PMC8942495</ArticleId><ArticleId IdType="pubmed">35090377</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J., Solimini N. L., Elledge S. J. (2009). Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell. 136 (5), 823&#x2013;837. 10.1016/j.cell.2009.02.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.02.024</ArticleId><ArticleId IdType="pmc">PMC2894612</ArticleId><ArticleId IdType="pubmed">19269363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu Z., Chen Y., Guo X., Zhou F., Yan Z., Xing J., et al. (2016). Genetic variants in glucose-6-phosphate isomerase gene as prognosis predictors in hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol. 40 (6), 698&#x2013;704. 10.1016/j.clinre.2016.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinre.2016.05.001</ArticleId><ArticleId IdType="pubmed">27288297</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore D. H. (2006). Cervical cancer. Obstetrics Gynecol. 107 (5), 1152&#x2013;1161. 10.1097/01.AOG.0000215986.48590.79</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.AOG.0000215986.48590.79</ArticleId><ArticleId IdType="pubmed">16648423</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabi I. R., Watanabe H., Silletti S., Raz A. (1991). Tumor cell autocrine motility factor receptor. Exs 59, 163&#x2013;177. 10.1007/978-3-0348-7494-6_11</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-0348-7494-6_11</ArticleId><ArticleId IdType="pubmed">1655517</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik R., Ban H. S., Jang K., Kim I., Xu X., Harmalkar D., et al. (2017). Methyl 3-(3-(4-(2,4,4-Trimethylpentan-2-yl)phenoxy)-propanamido)benzoate as a novel and dual malate Dehydrogenase (MDH) 1/2 inhibitor targeting cancer metabolism. J. Med. Chem. 60 (20), 8631&#x2013;8646. 10.1021/acs.jmedchem.7b01231</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.7b01231</ArticleId><ArticleId IdType="pubmed">28991459</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan J., Bode A. M., Luo X. (2021). ACSL family: The regulatory mechanisms and therapeutic implications in cancer. Eur. J. Pharmacol. 909, 174397. 10.1016/j.ejphar.2021.174397</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.174397</ArticleId><ArticleId IdType="pubmed">34332918</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajnani K., Islam F., Smith R. A., Gopalan V., Lam A. K. (2017). Genetic alterations in Krebs cycle and its impact on cancer pathogenesis. Biochimie 135, 164&#x2013;172. 10.1016/j.biochi.2017.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2017.02.008</ArticleId><ArticleId IdType="pubmed">28219702</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawa K., Uematsu T., Korenaga Y., Hirasawa R., Kikuchi M., Murata K., et al. (2017). Krebs cycle intermediates protective against oxidative stress by modulating the level of reactive oxygen species in neuronal HT22 cells. Antioxidants (Basel) 6, 21. 10.3390/antiox6010021</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox6010021</ArticleId><ArticleId IdType="pmc">PMC5384184</ArticleId><ArticleId IdType="pubmed">28300753</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Wang Q., Zhang Y., Geng M., Wei Y., Liu Y., et al. (2020). Multigenerational maternal obesity increases the incidence of HCC in offspring via miR-27a-3p. J. Hepatol. 73 (3), 603&#x2013;615. 10.1016/j.jhep.2020.03.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.03.050</ArticleId><ArticleId IdType="pubmed">32593682</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsvetkov P., Coy S., Petrova B., Dreishpoon M., Verma A., Abdusamad M., et al. (2022). Copper induces cell death by targeting lipoylated TCA cycle proteins. Science 375 (6586), 1254&#x2013;1261. 10.1126/science.abf0529</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf0529</ArticleId><ArticleId IdType="pmc">PMC9273333</ArticleId><ArticleId IdType="pubmed">35298263</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivanco I. (2014). Targeting molecular addictions in cancer. Br. J. Cancer 111(11), 2033&#x2013;2038. 10.1038/bjc.2014.461</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2014.461</ArticleId><ArticleId IdType="pmc">PMC4260023</ArticleId><ArticleId IdType="pubmed">25268375</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. P., Zhou W., Wang J., Huang X., Zuo Y., Wang T. S., et al. (2016). Arginine methylation of MDH1 by CARM1 inhibits glutamine metabolism and suppresses pancreatic cancer. Mol. Cell. 64(4), 673&#x2013;687. 10.1016/j.molcel.2016.09.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2016.09.028</ArticleId><ArticleId IdType="pubmed">27840030</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Cui X. W., Ding Z. W., Jiang T. Y., Feng X. F., Pan Y. F., et al. (2022). Gankyrin and TIGAR cooperatively accelerate glucose metabolism toward the PPP and TCA cycle in hepatocellular carcinoma. Cancer Sci. 113, 4151. 10.1111/cas.15593</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.15593</ArticleId><ArticleId IdType="pmc">PMC9746032</ArticleId><ArticleId IdType="pubmed">36114745</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J. C., Phan A. T., Chang D. Z., Wolff R. A., Hess K., Gupta S., et al. (2008). Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: Results of a phase II study. J. Clin. Oncol. 26(26), 4311&#x2013;4318. 10.1200/JCO.2008.16.7858</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2008.16.7858</ArticleId><ArticleId IdType="pmc">PMC2653122</ArticleId><ArticleId IdType="pubmed">18779618</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang Y., Xiang J., Bao W., Sun Y., Wang L., Tan M., et al. (2017). MDH2 stimulated by estrogen-GPR30 pathway down-regulated PTEN expression promoting the proliferation and invasion of cells in endometrial cancer. Transl. Oncol. 10(2), 203&#x2013;210. 10.1016/j.tranon.2017.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2017.01.009</ArticleId><ArticleId IdType="pmc">PMC5300292</ArticleId><ArticleId IdType="pubmed">28189066</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36900213</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2072-6694</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>23</Day></PubDate></JournalIssue><Title>Cancers</Title><ISOAbbreviation>Cancers (Basel)</ISOAbbreviation></Journal><ArticleTitle>Prognostic Value and Immune Infiltration of HPV-Related Genes in the Immune Microenvironment of Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1419</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers15051419</ELocationID><Abstract><AbstractText>Mounting evidence has highlighted the immune environment as a critical feature in the development of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC). However, the relationship between the clinical characteristics of the immune environment and CESC remain unclear. Therefore, the aim of this study was to further characterize the relationship between the tumor and immune microenvironment and the clinical features of CESC using a variety of bioinformatic methods. Expression profiles (303 CESCs and three control samples) and relevant clinical data were obtained from The Cancer Genome Atlas. We divided CESC cases into different subtypes and performed a differential gene expression analysis. In addition, gene ontology (GO) and gene set enrichment analysis (GSEA) were performed to identify potential molecular mechanisms. Furthermore, data from 115 CESC patients from East Hospital were used to help identify the relationship between the protein expressions of key genes and disease-free survival using tissue microarray technology. Cases of CESC (<i>n</i> = 303) were divided into five subtypes (C1-C5) based on their expression profiles. A total of 69 cross-validated differentially expressed immune-related genes were identified. Subtype C4 demonstrated a downregulation of the immune profile, lower tumor immune/stroma scores, and worse prognosis. In contrast, the C1 subtype showed an upregulation of the immune profile, higher tumor immune/stroma scores, and better prognosis. A GO analysis suggested that changes in CESC were primarily enriched nuclear division, chromatin binding, and condensed chromosomes. In addition, GSEA demonstrated that cellular senescence, the p53 signaling pathway, and viral carcinogenesis are critical features of CESC. Moreover, high FOXO3 and low IGF-1 protein expression were closely correlated with decreased clinical prognosis. In summary, our findings provide novel insight into the relationship between the immune microenvironment and CESC. As such, our results may provide guidance for developing potential immunotherapeutic targets and biomarkers for CESC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Qiyu</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-0254-5587</Identifier><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Luning</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital &amp; Institute, Beijing 100021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Linlin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guozeng</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Jingxin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Shanghai United Family Hospital, Shanghai 200120, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>201840166</GrantID><Agency>Foundation of the Health and Family Planning Commission of Shanghai</Agency><Country/></Grant><Grant><GrantID>82260587</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cancers (Basel)</MedlineTA><NlmUniqueID>101526829</NlmUniqueID><ISSNLinking>2072-6694</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HPV</Keyword><Keyword MajorTopicYN="N">TCGA datasets</Keyword><Keyword MajorTopicYN="N">cervical squamous cell carcinoma and endocervical adenocarcinoma</Keyword><Keyword MajorTopicYN="N">immune microenvironment</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36900213</ArticleId><ArticleId IdType="pmc">PMC10000937</ArticleId><ArticleId IdType="doi">10.3390/cancers15051419</ArticleId><ArticleId IdType="pii">cancers15051419</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cohen P.A., Jhingran A., Oaknin A., Denny L. Cervical cancer. Lancet. 2019;393:169&#x2013;182. doi: 10.1016/S0140-6736(18)32470-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32470-X</ArticleId><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018, GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394&#x2013;424. doi: 10.3322/caac.21492.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosbie E.J., Einstein M.H., Franceschi S., Kitchener H.C. Human papillomavirus and cervical cancer. Lancet. 2013;382:889&#x2013;899. doi: 10.1016/S0140-6736(13)60022-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)60022-7</ArticleId><ArticleId IdType="pubmed">23618600</ArticleId></ArticleIdList></Reference><Reference><Citation>Marth C., Landoni F., Mahner S., McCormack M., Gonzalez-Martin A., Colombo N. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018;29((Suppl 4)):iv262. doi: 10.1093/annonc/mdy160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdy160</ArticleId><ArticleId IdType="pubmed">29741577</ArticleId></ArticleIdList></Reference><Reference><Citation>Selman T.J., Mann C., Zamora J., Appleyard T.L., Khan K. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: A systematic review and meta-analysis. CMAJ. 2008;178:855&#x2013;862. doi: 10.1503/cmaj.071124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.071124</ArticleId><ArticleId IdType="pmc">PMC2267838</ArticleId><ArticleId IdType="pubmed">18362381</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Wu Y., Deng Y., Zhou L., Yang P., Zheng Y., Zhang D., Zhai Z., Li N., Hao Q., et al. Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors. Oncoimmunology. 2019;8:e1659094. doi: 10.1080/2162402X.2019.1659094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2019.1659094</ArticleId><ArticleId IdType="pmc">PMC6844304</ArticleId><ArticleId IdType="pubmed">31741756</ArticleId></ArticleIdList></Reference><Reference><Citation>The Cancer Genome Atlas Research Network Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378&#x2013;384. doi: 10.1038/nature21386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21386</ArticleId><ArticleId IdType="pmc">PMC5354998</ArticleId><ArticleId IdType="pubmed">28112728</ArticleId></ArticleIdList></Reference><Reference><Citation>Borcoman E., Le Tourneau C. Pembrolizumab in cervical cancer: Latest evidence and clinical usefulness. Ther Adv. Med. Oncol. 2017;9:431&#x2013;439. doi: 10.1177/1758834017708742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1758834017708742</ArticleId><ArticleId IdType="pmc">PMC5455883</ArticleId><ArticleId IdType="pubmed">28607581</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H., Ros W., Delord J.-P., Perets R., Italiano A., Shapira-Frommer R., Manzuk L., Piha-Paul S., Xu L., Zeigenfuss S., et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J. Clin. Oncol. 2019;37:1470&#x2013;1478. doi: 10.1200/JCO.18.01265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.18.01265</ArticleId><ArticleId IdType="pubmed">30943124</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S.Y., Kim S., Son M.-J., Kim G., Singh P., Kim H.N., Choi H.-G., Yoo H.J., Ko Y.B., Lee B.S., et al. Dual oxidase 1 and NADPH oxidase 2 exert favorable effects in cervical cancer patients by activating immune response. BMC Cancer. 2019;19:1078. doi: 10.1186/s12885-019-6202-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-019-6202-3</ArticleId><ArticleId IdType="pmc">PMC6842485</ArticleId><ArticleId IdType="pubmed">31706280</ArticleId></ArticleIdList></Reference><Reference><Citation>Punt S., Houwing-Duistermaat J.J., Schulkens I.A., Thijssen V.L., Osse E.M., de Kroon C.D., Griffioen A.W., Fleuren G.J., Gorter A., Jordanova E.S. Correlations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer. Mol. Cancer. 2015;14:71. doi: 10.1186/s12943-015-0350-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-015-0350-0</ArticleId><ArticleId IdType="pmc">PMC4392729</ArticleId><ArticleId IdType="pubmed">25889974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge Y., Zhang C., Xiao S., Liang L., Liao S., Xiang Y., Cao K., Chen H., Zhou Y. Identification of differentially expressed genes in cervical cancer by bioinformatics analysis. Oncol. Lett. 2018;16:2549&#x2013;2558. doi: 10.3892/ol.2018.8953.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2018.8953</ArticleId><ArticleId IdType="pmc">PMC6036588</ArticleId><ArticleId IdType="pubmed">30013649</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Cai Y. Methylation-Based Classification of Cervical Squamous Cell Carcinoma into Two New Subclasses Differing in Immune-Related Gene Expression. Int. J. Mol. Sci. 2018;19:3607. doi: 10.3390/ijms19113607.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19113607</ArticleId><ArticleId IdType="pmc">PMC6275080</ArticleId><ArticleId IdType="pubmed">30445744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S.D., Chatterjee S., Alam S., Salzberg A.C., Milici J., van der Burg S.H., Meyers C. Effect of Productive Human Papillomavirus 16 Infection on Global Gene Expression in Cervical Epithelium. J. Virol. 2018;92 doi: 10.1128/JVI.01261-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01261-18</ArticleId><ArticleId IdType="pmc">PMC6158420</ArticleId><ArticleId IdType="pubmed">30045992</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomczak K., Czerwinska P., Wiznerowicz M. The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge. Contemp. Oncol. 2015;19:A68&#x2013;A77. doi: 10.5114/wo.2014.47136.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/wo.2014.47136</ArticleId><ArticleId IdType="pmc">PMC4322527</ArticleId><ArticleId IdType="pubmed">25691825</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie M.E., Phipson B., Wu D., Hu Y., Law C.W., Shi W., Smyth G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi: 10.1093/nar/gkv007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Becht E., Giraldo N.A., Lacroix L., Buttard B., Elarouci N., Petitprez F., Selves J., Laurent-Puig P., Sautes-Fridman C., Fridman W.H., et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218. doi: 10.1186/s13059-016-1070-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-016-1070-5</ArticleId><ArticleId IdType="pmc">PMC5073889</ArticleId><ArticleId IdType="pubmed">27765066</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium S.M.-I. A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium. Nat. Biotechnol. 2014;32:903&#x2013;914. doi: 10.1038/nbt.2957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2957</ArticleId><ArticleId IdType="pmc">PMC4321899</ArticleId><ArticleId IdType="pubmed">25150838</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez G., Orris B., Majumdar A., Bhat S., Stivers J.T. Macromolecular crowding induces compaction and DNA binding in the disordered N-terminal domain of hUNG2. DNA Repair. 2019;86:102764. doi: 10.1016/j.dnarep.2019.102764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dnarep.2019.102764</ArticleId><ArticleId IdType="pmc">PMC6990647</ArticleId><ArticleId IdType="pubmed">31855846</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara K., Shahmoradgoli M., Mart&#xed;nez E., Vegesna R., Kim H., Torres-Garcia W., Trevino V., Shen H., Laird P.W., Levine D.A., et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 2013;4:2612. doi: 10.1038/ncomms3612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3612</ArticleId><ArticleId IdType="pmc">PMC3826632</ArticleId><ArticleId IdType="pubmed">24113773</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J.-H., Zhou H., Cooper L., Huang J.-L., Zhu S.-B., Zhao X.-X., Ding H., Pan Y.-L., Rong L. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers. Front. Immunol. 2019;10:6. doi: 10.3389/fimmu.2019.00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00006</ArticleId><ArticleId IdType="pmc">PMC6362421</ArticleId><ArticleId IdType="pubmed">30761122</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X., Jia X., Wang C., Xu J., Gao S.J., Lu C. A DHX9-lncRNA-MDM2 interaction regulates cell invasion and angiogenesis of cervical cancer. Cell Death Differ. 2019;26:1750&#x2013;1765. doi: 10.1038/s41418-018-0242-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-018-0242-0</ArticleId><ArticleId IdType="pmc">PMC6748089</ArticleId><ArticleId IdType="pubmed">30518908</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris M.A., Clark J., Ireland A., Lomax J., Ashburner M., Foulger R., Eilbeck K., Lewis S., Marshall B., Mungall C., et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2004;32:D258&#x2013;D261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308770</ArticleId><ArticleId IdType="pubmed">14681407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T., Chen I.R., Lin Y., Wang A.Y., Yang J.Y.H., Yang P. Impact of similarity metrics on single-cell RNA-seq data clustering. Brief. Bioinform. 2018;20:2316&#x2013;2326. doi: 10.1093/bib/bby076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bby076</ArticleId><ArticleId IdType="pubmed">30137247</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiselev V.Y., Andrews T.S., Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Nat. Rev. Genet. 2019;20:273&#x2013;282. doi: 10.1038/s41576-018-0088-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-018-0088-9</ArticleId><ArticleId IdType="pubmed">30617341</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Hou Z., Wang C., Wang H., Zhang H. Gene expression profiles reveal key genes for early diagnosis and treatment of adamantinomatous craniopharyngioma. Cancer Gene Ther. 2018;25:227&#x2013;239. doi: 10.1038/s41417-018-0015-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41417-018-0015-4</ArticleId><ArticleId IdType="pubmed">29681617</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H., Liu Y., Yuan M., Marron J.S. Statistical Significance of Clustering using Soft Thresholding. J. Comput. Graph. Stat. 2015;24:975&#x2013;993. doi: 10.1080/10618600.2014.948179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10618600.2014.948179</ArticleId><ArticleId IdType="pmc">PMC4706235</ArticleId><ArticleId IdType="pubmed">26755893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratnapriya R., Sosina O.A., Starostik M., Kwicklis M., Kapphahn R.J., Fritsche L.G., Walton A., Arvanitis M., Gieser L., Pietraszkiewicz A., et al. Retinal transcriptome and eQTL analyses identify genes associated with age-related macular degeneration. Nat. Genet. 2019;51:606&#x2013;610. doi: 10.1038/s41588-019-0351-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0351-9</ArticleId><ArticleId IdType="pmc">PMC6441365</ArticleId><ArticleId IdType="pubmed">30742112</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., Liu Z., Ge W., Shou J., You L., Pan H., Han W. Analysis of potential genes and pathways associated with the colorectal normal mucosa-adenoma-carcinoma sequence. Cancer Med. 2018;7:2555&#x2013;2566. doi: 10.1002/cam4.1484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.1484</ArticleId><ArticleId IdType="pmc">PMC6010713</ArticleId><ArticleId IdType="pubmed">29659199</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y., Pan X., Yang J. Gene regulation and prognostic indicators of lung squamous cell carcinoma: TCGA-derived miRNA/mRNA sequencing and DNA methylation data. J. Cell Physiol. 2019;234:22896&#x2013;22910. doi: 10.1002/jcp.28852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.28852</ArticleId><ArticleId IdType="pubmed">31169310</ArticleId></ArticleIdList></Reference><Reference><Citation>Willforss J., Chawade A., Levander F. NormalyzerDE: Online Tool for Improved Normalization of Omics Expression Data and High-Sensitivity Differential Expression Analysis. J. Proteome. Res. 2019;18:732&#x2013;740. doi: 10.1021/acs.jproteome.8b00523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.8b00523</ArticleId><ArticleId IdType="pubmed">30277078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimie E., Fruzangohar M., Moussavi Nik S.H., Newman M. Gene Ontology-Based Analysis of Zebrafish Omics Data Using the Web Tool Comparative Gene Ontology. Zebrafish. 2017;14:492&#x2013;494. doi: 10.1089/zeb.2016.1290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/zeb.2016.1290</ArticleId><ArticleId IdType="pubmed">28873048</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K., Goto S., Kawano S., Aoki-Kinoshita K.F., Ueda N., Hamajima M., Kawasaki T., Kanehisa M. KEGG as a glycome informatics resource. Glycobiology. 2006;16:63R&#x2013;70R. doi: 10.1093/glycob/cwj010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/cwj010</ArticleId><ArticleId IdType="pubmed">16014746</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G., Wang L.G., Han Y., He Q.Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 2012;16:284&#x2013;287. doi: 10.1089/omi.2011.0118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 2005;102:15545&#x2013;15550. doi: 10.1073/pnas.0506580102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin P.C., Lee D.S., Fine J.P. Introduction to the Analysis of Survival Data in the Presence of Competing Risks. Circulation. 2016;133:601&#x2013;609. doi: 10.1161/CIRCULATIONAHA.115.017719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.017719</ArticleId><ArticleId IdType="pmc">PMC4741409</ArticleId><ArticleId IdType="pubmed">26858290</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Wu J., Wei P., Xu Y., Zhuo C., Wang Y., Li D., Cai S. Overexpression of forkhead Box C2 promotes tumor metastasis and indicates poor prognosis in colon cancer via regulating epithelial-mesenchymal transition. Am. J. Cancer Res. 2015;5:2022&#x2013;2034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4529621</ArticleId><ArticleId IdType="pubmed">26269761</ArticleId></ArticleIdList></Reference><Reference><Citation>Taieb J., Kourie H.R., Emile J.-F., Le Malicot K., Balogoun R., Tabernero J., Mini E., Folprecht G., Van Laethem J.-L., Mulot C., et al. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. JAMA Oncol. 2018;4:e173695. doi: 10.1001/jamaoncol.2017.3695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2017.3695</ArticleId><ArticleId IdType="pmc">PMC6145739</ArticleId><ArticleId IdType="pubmed">29167892</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi E., Carr A.J., Plitas G., Cornish A.E., Konopacki C., Prabhakaran S., Nainys J., Wu K., Kiseliovas V., Setty M., et al. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. Cell. 2018;174:1293&#x2013;1308.e36. doi: 10.1016/j.cell.2018.05.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.05.060</ArticleId><ArticleId IdType="pmc">PMC6348010</ArticleId><ArticleId IdType="pubmed">29961579</ArticleId></ArticleIdList></Reference><Reference><Citation>Spurgeon M.E., den Boon J.A., Horswill M., Barthakur S., Forouzan O., Rader J.S., Beebe D.J., Roopra A., Ahlquist P., Lambert P.F. Human papillomavirus oncogenes reprogram the cervical cancer microenvironment independently of and synergistically with estrogen. Proc. Natl. Acad. Sci. USA. 2017;114:E9076&#x2013;E9085. doi: 10.1073/pnas.1712018114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1712018114</ArticleId><ArticleId IdType="pmc">PMC5664542</ArticleId><ArticleId IdType="pubmed">29073104</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny P.A., Nelson C.M., Bissell M.J. The Ecology of Tumors: By perturbing the microenvironment, wounds and infection may be key to tumor development. Scientist. 2006;20:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995893</ArticleId><ArticleId IdType="pubmed">21132085</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W. Nasopharyngeal carcinoma ecology theory: Cancer as multidimensional spatiotemporal &#x201c;unity of ecology and evolution&#x201d; pathological ecosystem. Preprints. 2022:2022100226. doi: 10.20944/preprints202210.0226.v3.</Citation><ArticleIdList><ArticleId IdType="doi">10.20944/preprints202210.0226.v3</ArticleId><ArticleId IdType="pmc">PMC10086202</ArticleId><ArticleId IdType="pubmed">37056571</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijer C., Steenbergen R.D.M. Gynaecological cancer: Novel molecular subtypes of cervical cancer&#x2014;Potential clinical consequences. Nat. Rev. Clin. Oncol. 2017;14:397&#x2013;398. doi: 10.1038/nrclinonc.2017.52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2017.52</ArticleId><ArticleId IdType="pubmed">28397825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai X., Wang W., Zhao P., Wen J., Guo X., Shen T., Shen J., Yang X. LncRNA CRNDE acts as an oncogene in cervical cancer through sponging miR-183 to regulate CCNB1 expression. Carcinogenesis. 2019;41:111&#x2013;121. doi: 10.1093/carcin/bgz166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgz166</ArticleId><ArticleId IdType="pubmed">31605132</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu F., Wang T., Li J., Yan M., Li D., Li B., Jin T. The impact of genetic variants in IL1R2 on cervical cancer risk among Uygur females from China: A case-control study. Mol. Genet. Genomic Med. 2019;7:e00516. doi: 10.1002/mgg3.516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mgg3.516</ArticleId><ArticleId IdType="pmc">PMC6382450</ArticleId><ArticleId IdType="pubmed">30460760</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Wu Y., Peng Y., Liu X., Bie J., Li S. Systematic analysis to identify a key role of CDK1 in mediating gene interaction networks in cervical cancer development. Ir. J. Med. Sci. 2016;185:231&#x2013;239. doi: 10.1007/s11845-015-1283-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-015-1283-8</ArticleId><ArticleId IdType="pubmed">25786624</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicchini L., Westrich J.A., Xu T., Vermeer D.W., Berger J.N., Clambey E.T., Lee D., Song J.I., Lambert P.F., Greer R.O., et al. Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14. mBio. 2016;7 doi: 10.1128/mBio.00270-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00270-16</ArticleId><ArticleId IdType="pmc">PMC4959654</ArticleId><ArticleId IdType="pubmed">27143385</ArticleId></ArticleIdList></Reference><Reference><Citation>A Demoulin S., Somja J., Duray A., Gu&#xe9;nin S., Roncarati P., O Delvenne P., Herfs M.F., Hubert P.M. Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion. Oncoimmunology. 2015;4:e1008334. doi: 10.1080/2162402X.2015.1008334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2015.1008334</ArticleId><ArticleId IdType="pmc">PMC4485731</ArticleId><ArticleId IdType="pubmed">26155412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mine K.L., Shulzhenko N., Yambartsev A., Rochman M., Sanson G.F.O., Lando M., Varma S., Skinner J., Volfovsky N., Deng T., et al. Gene network reconstruction reveals cell cycle and antiviral genes as major drivers of cervical cancer. Nat. Commun. 2013;4:1806. doi: 10.1038/ncomms2693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2693</ArticleId><ArticleId IdType="pmc">PMC4237593</ArticleId><ArticleId IdType="pubmed">23651994</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoppe-Seyler K., Bossler F., Braun J.A., Herrmann A.L., Hoppe-Seyler F. The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets. Trends Microbiol. 2018;26:158&#x2013;168. doi: 10.1016/j.tim.2017.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2017.07.007</ArticleId><ArticleId IdType="pubmed">28823569</ArticleId></ArticleIdList></Reference><Reference><Citation>Burd E.M. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 2003;16:1&#x2013;17. doi: 10.1128/CMR.16.1.1-17.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.16.1.1-17.2003</ArticleId><ArticleId IdType="pmc">PMC145302</ArticleId><ArticleId IdType="pubmed">12525422</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Burg S.H., Piersma S.J., De Jong A., Van Der Hulst J.M., Kwappenberg K.M., Van Den Hende M., Welters M.J., Van Rood J.J., Fleuren G.J., Melief C.J., et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc. Natl. Acad. Sci. USA. 2007;104:12087&#x2013;12092. doi: 10.1073/pnas.0704672104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0704672104</ArticleId><ArticleId IdType="pmc">PMC1924590</ArticleId><ArticleId IdType="pubmed">17615234</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W., Yan X., Jing L., Zhou Y., Chen H., Wang Y. A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol. Immunol. 2011;8:59&#x2013;66. doi: 10.1038/cmi.2010.56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2010.56</ArticleId><ArticleId IdType="pmc">PMC4002991</ArticleId><ArticleId IdType="pubmed">21200385</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasper D.J., Tejera M.M., Suresh M. CD4 T-cell memory generation and maintenance. Crit. Rev. Immunol. 2014;34:121&#x2013;146. doi: 10.1615/CritRevImmunol.2014010373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/CritRevImmunol.2014010373</ArticleId><ArticleId IdType="pmc">PMC4062920</ArticleId><ArticleId IdType="pubmed">24940912</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLeod M.K., Clambey E.T., Kappler J.W., Marrack P. CD4 memory T cells: What are they and what can they do? Semin. Immunol. 2009;21:53&#x2013;61. doi: 10.1016/j.smim.2009.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2009.02.006</ArticleId><ArticleId IdType="pmc">PMC2679806</ArticleId><ArticleId IdType="pubmed">19269850</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley M.A. Epithelial cell responses to infection with human papillomavirus. Clin. Microbiol. Rev. 2012;25:215&#x2013;222. doi: 10.1128/CMR.05028-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.05028-11</ArticleId><ArticleId IdType="pmc">PMC3346303</ArticleId><ArticleId IdType="pubmed">22491770</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele J.C., Mann C.H., Rookes S., Rollason T., Murphy D., Freeth M.G., Gallimore P.H., Roberts S. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br. J. Cancer. 2005;93:248&#x2013;259. doi: 10.1038/sj.bjc.6602679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6602679</ArticleId><ArticleId IdType="pmc">PMC2361543</ArticleId><ArticleId IdType="pubmed">15986031</ArticleId></ArticleIdList></Reference><Reference><Citation>Monnier-Benoit S., Mauny F., Riethmuller D., Guerrini J.-S., C&#x103;p&#xee;lna M., F&#xe9;lix S., Seill&#xe8;s E., Mougin C., Pr&#xe9;tet J.-L. Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. Gynecol. Oncol. 2006;102:22&#x2013;31. doi: 10.1016/j.ygyno.2005.11.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2005.11.039</ArticleId><ArticleId IdType="pubmed">16427684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lheureux S., Butler M.O., Clarke B., Cristea M.C., Martin L.P., Tonkin K., Fleming G.F., Tinker A.V., Hirte H.W., Tsoref D., et al. Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. JAMA Oncol. 2018;4:e173776. doi: 10.1001/jamaoncol.2017.3776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2017.3776</ArticleId><ArticleId IdType="pmc">PMC6145732</ArticleId><ArticleId IdType="pubmed">29145543</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm K., Happel K., Eelen G., Schoors S., Oellerich M.F., Lim R., Zimmermann B., Aspalter I.M., Franco C.A., Boettger T., et al. FOXO1 couples metabolic activity and growth state in the vascular endothelium. Nature. 2016;529:216&#x2013;220. doi: 10.1038/nature16498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature16498</ArticleId><ArticleId IdType="pmc">PMC5380221</ArticleId><ArticleId IdType="pubmed">26735015</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves D.T., Milovanova T.N. Mucosal Immunity and the FOXO1 Transcription Factors. Front. Immunol. 2019;10:2530. doi: 10.3389/fimmu.2019.02530.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02530</ArticleId><ArticleId IdType="pmc">PMC6896163</ArticleId><ArticleId IdType="pubmed">31849924</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen S.K., Ahmad S.M., Idorn M., Met &#xd6;., Martinenaite E., Svane I.M., Straten P.T., Andersen M.H. Spontaneous presence of FOXO3-specific T cells in cancer patients. Oncoimmunology. 2014;3:e953411. doi: 10.4161/21624011.2014.953411.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/21624011.2014.953411</ArticleId><ArticleId IdType="pmc">PMC4368145</ArticleId><ArticleId IdType="pubmed">25960934</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem M.E., Puccini A., Xiu J., Raghavan D., Lenz H.-J., Korn W.M., Shields A.F., Philip P.A., Marshall J.L., Goldberg R.M. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. Oncologist. 2018;23:1319&#x2013;1327. doi: 10.1634/theoncologist.2018-0143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2018-0143</ArticleId><ArticleId IdType="pmc">PMC6291329</ArticleId><ArticleId IdType="pubmed">29866946</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Ma L., Jones T., Palomero L., Pujana M.A., Martinez-Ruiz H., Ha P.K., Murnane J., Cuartas I., Seoane J., et al. Subjugation of TGFbeta Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining. Clin. Cancer Res. 2018;24:6001&#x2013;6014. doi: 10.1158/1078-0432.CCR-18-1346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-18-1346</ArticleId><ArticleId IdType="pubmed">30087144</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter R.C. IGF binding proteins in cancer: Mechanistic and clinical insights. Nat. Rev. Cancer. 2014;14:329&#x2013;341. doi: 10.1038/nrc3720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3720</ArticleId><ArticleId IdType="pubmed">24722429</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X., Zhao W., Yang X., Wang Z., Hao M. miR-375 Affects the Proliferation, Invasion, and Apoptosis of HPV16-Positive Human Cervical Cancer Cells by Targeting IGF-1R. Int. J. Gynecol. Cancer. 2016;26:851&#x2013;858. doi: 10.1097/IGC.0000000000000711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IGC.0000000000000711</ArticleId><ArticleId IdType="pubmed">27206217</ArticleId></ArticleIdList></Reference><Reference><Citation>Merritt M.A., Strickler H.D., Einstein M.H., Yang H.P., Sherman M.E., Wentzensen N., Brouwer-Visser J., Cossio M.J., Whitney K.D., Yu H., et al. Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. Cancer Causes Control. 2016;27:737&#x2013;748. doi: 10.1007/s10552-016-0751-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10552-016-0751-4</ArticleId><ArticleId IdType="pmc">PMC4870288</ArticleId><ArticleId IdType="pubmed">27125830</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickard A., Durzynska J., McCance D.J., Barton E.R. The IGF axis in HPV associated cancers. Mutat. Res. Rev. Mutat. Res. 2017;772:67&#x2013;77. doi: 10.1016/j.mrrev.2017.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mrrev.2017.01.002</ArticleId><ArticleId IdType="pubmed">28528691</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh C.R., Ou Z.Y., Xiao G.Q., Guancial E., Yeh S. Infiltrating T cells promote renal cell carcinoma (RCC) progression via altering the estrogen receptor beta-DAB2IP signals. Oncotarget. 2015;6:44346&#x2013;44359. doi: 10.18632/oncotarget.5884.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.5884</ArticleId><ArticleId IdType="pmc">PMC4792561</ArticleId><ArticleId IdType="pubmed">26587829</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: Integrating immunity&#x2019;s roles in cancer suppression and promotion. Science. 2011;331:1565&#x2013;1570. doi: 10.1126/science.1203486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1203486</ArticleId><ArticleId IdType="pubmed">21436444</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahya M.A., Sharon S.M., Hantisteanu S., Hallak M., Bruchim I. The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies. Front. Endocrinol. 2018;9:297. doi: 10.3389/fendo.2018.00297.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2018.00297</ArticleId><ArticleId IdType="pmc">PMC5996273</ArticleId><ArticleId IdType="pubmed">29922232</ArticleId></ArticleIdList></Reference><Reference><Citation>Durzynska J., Barton E. IGF expression in HPV-related and HPV-unrelated human cancer cells. Oncol. Rep. 2014;32:893&#x2013;900. doi: 10.3892/or.2014.3329.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2014.3329</ArticleId><ArticleId IdType="pmc">PMC4121407</ArticleId><ArticleId IdType="pubmed">25018100</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Li J., Shi X., Li S., Tang P.M.K., Li Z., Li H., Wei C. Antimalarial Dihydroartemisinin triggers autophagy within HeLa cells of human cervical cancer through Bcl-2 phosphorylation at Ser70. Phytomedicine. 2019;52:147&#x2013;156. doi: 10.1016/j.phymed.2018.09.221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2018.09.221</ArticleId><ArticleId IdType="pubmed">30599894</ArticleId></ArticleIdList></Reference><Reference><Citation>Ming P., Cai T., Li J., Ning Y., Xie S., Tao T., Tang F. A novel arylbenzofuran induces cervical cancer cell apoptosis and G1/S arrest through ERK-mediated Cdk2/cyclin-A signaling pathway. Oncotarget. 2016;7:41843&#x2013;41856. doi: 10.18632/oncotarget.9731.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.9731</ArticleId><ArticleId IdType="pmc">PMC5173100</ArticleId><ArticleId IdType="pubmed">27259234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Ding W., Liu Y., Hu Z., Zhu D., Wang X., Yu L., Wang L., Shen H., Zhang W., et al. Proteomics-based identification of VDAC1 as a tumor promoter in cervical carcinoma. Oncotarget. 2016;7:52317&#x2013;52328. doi: 10.18632/oncotarget.10562.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.10562</ArticleId><ArticleId IdType="pmc">PMC5239554</ArticleId><ArticleId IdType="pubmed">27419626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Liu L., Chen Z. Transcriptome profiling of cervical cancer cells acquired resistance to cisplatin by deep sequencing. Artif. Cells Nanomed. Biotechnol. 2019;47:2820&#x2013;2829. doi: 10.1080/21691401.2019.1637882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21691401.2019.1637882</ArticleId><ArticleId IdType="pubmed">31293179</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K., Luo Z., Li Z., Liu Y., Zhao Q. PERP gene therapy attenuates lung cancer xenograft via inducing apoptosis and suppressing VEGF. Cancer Biol. Ther. 2011;12:1114&#x2013;1119. doi: 10.4161/cbt.12.12.18435.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cbt.12.12.18435</ArticleId><ArticleId IdType="pubmed">22236877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36798148</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1748-6718</ISSN><JournalIssue CitedMedium="Internet"><Volume>2023</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Computational and mathematical methods in medicine</Title><ISOAbbreviation>Comput Math Methods Med</ISOAbbreviation></Journal><ArticleTitle>Pain-Related Gene Solute Carrier Family 24 Member 3 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma: A Study via Integrated Bioinformatics Analyses and Experimental Verification.</ArticleTitle><Pagination><StartPage>4164232</StartPage><MedlinePgn>4164232</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4164232</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2023/4164232</ELocationID><Abstract><AbstractText>The aim of this study was to explore cervical carcinoma and screen a suitable gene as the biomarker used for prognosis evaluation as well as pain therapy. Low expression levels of solute carrier family 24 member 3 (SLC24A3) was involved in the appearance and development of numerous malignancies. Nevertheless, the prognostic value of SLC24A3 expression with cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) patients remains uncertain. During the present study, SLC24A3 expression in CESC was retrieved from TCGA, GEO, and MSigDB databases. Based on TCGA and GEO profiles, we performed survival and difference analyses about SLC24A3 both in two GEO (GSE44001 and GSE63514) and TCGA-CESC cohorts (all <i>p</i> &lt; 0.05), indicating that SLC24A3 was low expressed in tumors and associated with higher overall survival in CESC patients. Additionally, we programmed a series of analyses, including genomic profiling, enrichment analysis, immune infiltration analysis, and therapy-related analysis to identify the mechanism of the SLC24A3 in the process of cancer in CESC. Meanwhile, qRT-PCR was used to validate that the expression of SLC24A3 mRNA in Hela and SiHa cell lines was significantly lower than in PANC-1 and HUCEC cell lines. Our finding elucidated that the SLC24A3, a sodium-calcium regulator of cells, is an indispensable factor which can significantly influence the prognosis of patients with CESC and could provide novel clinical evidence to serve as a potential biological indicator for future diagnosis and pain therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Shuguang Zhou et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Shuguang</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0148-947X</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Province Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Linquan Maternity and Child Healthcare Hospital, Fuyang, Anhui 236400, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Qinqin</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-8221-8139</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Province Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Hui</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4609-6437</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Province Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Jie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0221-5529</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Province Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Lu</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1638-0170</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Province Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xiya</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-2760-8385</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Province Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yinting</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-8540-8870</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Province Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xiaomin</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-7446-2302</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Province Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-7074-7204</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Province Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Weiyu</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-8935-9383</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Province Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yuting</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9595-4688</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Province Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, Anhui Medical University Affiliated Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Wujun</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-2290-8939</Identifier><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Anhui Province Maternity and Child Healthcare Hospital, Hefei, Anhui 230001, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Comput Math Methods Med</MedlineTA><NlmUniqueID>101277751</NlmUniqueID><ISSNLinking>1748-670X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>2</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36798148</ArticleId><ArticleId IdType="pmc">PMC9928512</ArticleId><ArticleId IdType="doi">10.1155/2023/4164232</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Magee D., Bachtold S., Brown M., Farquhar-Smith P. Cancer pain: where are we now? Pain Management . 2019;9(1):63&#x2013;79. doi: 10.2217/pmt-2018-0031.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/pmt-2018-0031</ArticleId><ArticleId IdType="pubmed">30516438</ArticleId></ArticleIdList></Reference><Reference><Citation>Long H. J., Laack N. N. I., Gostout B. S. Prevention, Diagnosis, and Treatment of Cervical Cancer. Mayo Clinic Proceedings . 2007;82(12):1566&#x2013;1574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18053467</ArticleId></ArticleIdList></Reference><Reference><Citation>Paice J. A., Ferrell B. The management of cancer pain. CA: a Cancer Journal for Clinicians . 2011;61(3):157&#x2013;182. doi: 10.3322/caac.20112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.20112</ArticleId><ArticleId IdType="pubmed">21543825</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman T. A., Schiller J. T. Human papillomavirus in cervical cancer and oropharyngeal cancer: one cause, two diseases. Cancer . 2017;123(12):2219&#x2013;2229. doi: 10.1002/cncr.30588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.30588</ArticleId><ArticleId IdType="pubmed">28346680</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen P. A., Jhingran A., Oaknin A., Denny L. Cervical cancer. The Lancet . 2019;393(10167):169&#x2013;182. doi: 10.1016/S0140-6736(18)32470-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32470-X</ArticleId><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsikouras P., Zervoudis S., Manav B., et al. Cervical cancer: screening, diagnosis and staging. Journal of BUON . 2016;21(2):320&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">27273940</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., McNamara M., Batur P. Cervical cancer screening: what's new? Updates for the busy clinician. The American Journal of Medicine . 2018;131(6):702.e1&#x2013;702.e5. doi: 10.1016/j.amjmed.2018.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2018.01.020</ArticleId><ArticleId IdType="pubmed">29408216</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M., Weiderpass E., Bruni L., et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health . 2020;8(2):e191&#x2013;e203. doi: 10.1016/S2214-109X(19)30482-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(19)30482-6</ArticleId><ArticleId IdType="pmc">PMC7025157</ArticleId><ArticleId IdType="pubmed">31812369</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein J. B., Miaskowski C. Oral pain in the cancer patient. Journal of the National Cancer Institute. Monographs . 2019;2019, article lgz003(53) doi: 10.1093/jncimonographs/lgz003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jncimonographs/lgz003</ArticleId><ArticleId IdType="pubmed">31425595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai M., Yang S., Lin S., et al. Distinct gene expression patterns of ion channels and cytokines in rat primary sensory neurons during development of bone cancer and cancer pain. Frontiers in Molecular Neuroscience . 2021;14, article 665085 doi: 10.3389/fnmol.2021.665085.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2021.665085</ArticleId><ArticleId IdType="pmc">PMC8134751</ArticleId><ArticleId IdType="pubmed">34025351</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes-Gibby C. C., Spitz M. R., Yennurajalingam S., et al. Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiology, Biomarkers &amp; Prevention . 2009;18(10):2636&#x2013;2642. doi: 10.1158/1055-9965.EPI-09-0426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-09-0426</ArticleId><ArticleId IdType="pmc">PMC2759856</ArticleId><ArticleId IdType="pubmed">19773451</ArticleId></ArticleIdList></Reference><Reference><Citation>Breivik H., Cherny N., Collett B., et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Annals of Oncology . 2009;20(8):1420&#x2013;1433. doi: 10.1093/annonc/mdp001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdp001</ArticleId><ArticleId IdType="pubmed">19244085</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarborough B. M., Smith C. B. Optimal pain management for patients with cancer in the modern era. CA: a Cancer Journal for Clinicians . 2018;68(3):182&#x2013;196. doi: 10.3322/caac.21453.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21453</ArticleId><ArticleId IdType="pmc">PMC5980731</ArticleId><ArticleId IdType="pubmed">29603142</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone C. B., 2nd, Vapiwala N., Hampshire M. K., Metz J. M. Cancer patient attitudes toward analgesic usage and pain intervention. The Clinical Journal of Pain . 2012;28(2):157&#x2013;162. doi: 10.1097/AJP.0b013e318223be30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AJP.0b013e318223be30</ArticleId><ArticleId IdType="pmc">PMC3522466</ArticleId><ArticleId IdType="pubmed">21705874</ArticleId></ArticleIdList></Reference><Reference><Citation>Deandrea S., Montanari M., Moja L., Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Annals of Oncology . 2008;19(12):1985&#x2013;1991. doi: 10.1093/annonc/mdn419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdn419</ArticleId><ArticleId IdType="pmc">PMC2733110</ArticleId><ArticleId IdType="pubmed">18632721</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W., Soares J., Greninger P., et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research . 2013;41:D955&#x2013;D961. doi: 10.1093/nar/gks1111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1111</ArticleId><ArticleId IdType="pmc">PMC3531057</ArticleId><ArticleId IdType="pubmed">23180760</ArticleId></ArticleIdList></Reference><Reference><Citation>Geeleher P., Cox N., Huang R. S. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One . 2014;9(9) doi: 10.1371/journal.pone.0107468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0107468</ArticleId><ArticleId IdType="pmc">PMC4167990</ArticleId><ArticleId IdType="pubmed">25229481</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayakonda A., Lin D. C., Assenov Y., Plass C., Koeffler H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Research . 2018;28(11):1747&#x2013;1756. doi: 10.1101/gr.239244.118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.239244.118</ArticleId><ArticleId IdType="pmc">PMC6211645</ArticleId><ArticleId IdType="pubmed">30341162</ArticleId></ArticleIdList></Reference><Reference><Citation>Charoentong P., Finotello F., Angelova M., et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Reports . 2017;18(1):248&#x2013;262. doi: 10.1016/j.celrep.2016.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.12.019</ArticleId><ArticleId IdType="pubmed">28052254</ArticleId></ArticleIdList></Reference><Reference><Citation>Buskwofie A., David-West G., Clare C. A. A review of cervical cancer: incidence and disparities. Journal of the National Medical Association . 2020;112(2):229&#x2013;232. doi: 10.1016/j.jnma.2020.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnma.2020.03.002</ArticleId><ArticleId IdType="pubmed">32278478</ArticleId></ArticleIdList></Reference><Reference><Citation>Saei Ghare Naz M., Kariman N., Ebadi A., Ozgoli G., Ghasemi V., Rashidi F. F. Educational interventions for cervical cancer screening behavior of women: a systematic review. Asian Pacific Journal of Cancer Prevention . 2018;19(4):875&#x2013;884. doi: 10.22034/APJCP.2018.19.4.875.</Citation><ArticleIdList><ArticleId IdType="doi">10.22034/APJCP.2018.19.4.875</ArticleId><ArticleId IdType="pmc">PMC6031778</ArticleId><ArticleId IdType="pubmed">29693331</ArticleId></ArticleIdList></Reference><Reference><Citation>Musselwhite L. W., Oliveira C. M., Kwaramba T., et al. Racial/ethnic disparities in cervical cancer screening and outcomes. Acta Cytologica . 2016;60(6):518&#x2013;526. doi: 10.1159/000452240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000452240</ArticleId><ArticleId IdType="pubmed">27825171</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarm R. A., Paice J. A., Anghelescu D. L., et al. Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network . 2019;17(8):977&#x2013;1007. doi: 10.6004/jnccn.2019.0038.</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2019.0038</ArticleId><ArticleId IdType="pubmed">31390582</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallaway M. S., Townsend J. S., Shelby D., Puckett M. C. Pain among cancer survivors. Preventing Chronic Disease . 2020;17, article E54 doi: 10.5888/pcd17.190367.</Citation><ArticleIdList><ArticleId IdType="doi">10.5888/pcd17.190367</ArticleId><ArticleId IdType="pmc">PMC7367076</ArticleId><ArticleId IdType="pubmed">32644924</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripamonti C., Bandieri E. Pain therapy. Critical Reviews in Oncology/Hematology . 2009;70(2):145&#x2013;159. doi: 10.1016/j.critrevonc.2008.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2008.12.005</ArticleId><ArticleId IdType="pubmed">19188080</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng G. Integrative medicine therapies for pain management in cancer patients. Cancer Journal . 2019;25(5):343&#x2013;348. doi: 10.1097/PPO.0000000000000399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PPO.0000000000000399</ArticleId><ArticleId IdType="pmc">PMC6777858</ArticleId><ArticleId IdType="pubmed">31567462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtin S., Fuoto A. Pain management in the cancer survivor. Seminars in Oncology Nursing . 2019;35(3):284&#x2013;290. doi: 10.1016/j.soncn.2019.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.soncn.2019.04.010</ArticleId><ArticleId IdType="pubmed">31053398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura A., Yamasaki H., Ishii H., Yoshida H., Shimizu M., Mori T. Effects of polymorphisms in the serotonin transporter promoter-linked polymorphic region on postthoracotomy pain severity. Journal of Pain Research . 2021;14:1389&#x2013;1397. doi: 10.2147/JPR.S298685.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JPR.S298685</ArticleId><ArticleId IdType="pmc">PMC8164694</ArticleId><ArticleId IdType="pubmed">34079356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie M. U., Winsvold B., Gjerstad J., et al. The association between selected genetic variants and individual differences in experimental pain. Scand J Pain . 2021;21(1):163&#x2013;173. doi: 10.1515/sjpain-2020-0091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/sjpain-2020-0091</ArticleId><ArticleId IdType="pubmed">33108341</ArticleId></ArticleIdList></Reference><Reference><Citation>Benarroch E. E. Descending monoaminergic pain modulation: bidirectional control and clinical relevance. Neurology . 2008;71(3):217&#x2013;221. doi: 10.1212/01.wnl.0000318225.51122.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000318225.51122.63</ArticleId><ArticleId IdType="pubmed">18625968</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M., Wang Q., Wang Q., Jia P., Zhao Z. Computational tools for copy number variation (CNV) detection using next-generation sequencing data: features and perspectives. BMC Bioinformatics . 2013;14(Supplement 11):p. S1. doi: 10.1186/1471-2105-14-S11-S1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-14-S11-S1</ArticleId><ArticleId IdType="pmc">PMC3846878</ArticleId><ArticleId IdType="pubmed">24564169</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie C., Tammi M. T. CNV-seq, a new method to detect copy number variation using high-throughput sequencing. BMC Bioinformatics . 2009;10(1):p. 80. doi: 10.1186/1471-2105-10-80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-10-80</ArticleId><ArticleId IdType="pmc">PMC2667514</ArticleId><ArticleId IdType="pubmed">19267900</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts N. D., Kortschak R. D., Parker W. T., et al. A comparative analysis of algorithms for somatic SNV detection in cancer. Bioinformatics . 2013;29(18):2223&#x2013;2230. doi: 10.1093/bioinformatics/btt375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt375</ArticleId><ArticleId IdType="pmc">PMC3753564</ArticleId><ArticleId IdType="pubmed">23842810</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing D., Tan L., Chang C. H., Li H., Xie X. S. Accurate SNV detection in single cells by transposon-based whole-genome amplification of complementary strands. Proceedings of the National Academy of Sciences of the United States of America . 2021;118(8, article e2013106118) doi: 10.1073/pnas.2013106118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2013106118</ArticleId><ArticleId IdType="pmc">PMC7923680</ArticleId><ArticleId IdType="pubmed">33593904</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Fu J., Zeng Z., et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Research . 2020;48(W1):W509&#x2013;W514. doi: 10.1093/nar/gkaa407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa407</ArticleId><ArticleId IdType="pmc">PMC7319575</ArticleId><ArticleId IdType="pubmed">32442275</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular &amp; Molecular Immunology . 2020;17(8):807&#x2013;821. doi: 10.1038/s41423-020-0488-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0488-6</ArticleId><ArticleId IdType="pmc">PMC7395159</ArticleId><ArticleId IdType="pubmed">32612154</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochems C., Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Experimental Biology and Medicine . 2011;236(5):567&#x2013;579. doi: 10.1258/ebm.2011.011007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/ebm.2011.011007</ArticleId><ArticleId IdType="pmc">PMC3229261</ArticleId><ArticleId IdType="pubmed">21486861</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieto M. A. Epithelial-mesenchymal transitions in development and disease: old views and new perspectives. The International Journal of Developmental Biology . 2009;53(8-10):1541&#x2013;1547. doi: 10.1387/ijdb.072410mn.</Citation><ArticleIdList><ArticleId IdType="doi">10.1387/ijdb.072410mn</ArticleId><ArticleId IdType="pubmed">19247945</ArticleId></ArticleIdList></Reference><Reference><Citation>Hume D. A. The many alternative faces of macrophage activation. Frontiers in Immunology . 2015;6 doi: 10.3389/fimmu.2015.00370.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00370</ArticleId><ArticleId IdType="pmc">PMC4510422</ArticleId><ArticleId IdType="pubmed">26257737</ArticleId></ArticleIdList></Reference><Reference><Citation>Citterio L., Simonini M., Zagato L., et al. Genes involved in vasoconstriction and vasodilation system affect salt-sensitive hypertension. PLoS One . 2011;6(5, article e19620) doi: 10.1371/journal.pone.0019620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0019620</ArticleId><ArticleId IdType="pmc">PMC3090407</ArticleId><ArticleId IdType="pubmed">21573014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalloul A. H., Szerencsei R. T., Schnetkamp P. P. M. Cation dependencies and turnover rates of the human K+-dependent Na+-Ca2+ exchangers NCKX1, NCKX2, NCKX3 and NCKX4. Cell Calcium . 2016;59(1):1&#x2013;11. doi: 10.1016/j.ceca.2015.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2015.11.001</ArticleId><ArticleId IdType="pubmed">26631410</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Yoo Y. M., Jung E. M., Choi K. C., Jeung E. B. Uterine expression of sodium/potassium/calcium exchanger 3 and its regulation by sex-steroid hormones during the estrous cycle of rats. Molecular Reproduction and Development . 2010;77(11):971&#x2013;977. doi: 10.1002/mrd.21245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrd.21245</ArticleId><ArticleId IdType="pubmed">21104767</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Kim T. H., Lee H. H., Choi K. C., Jeung E. B. Distinct expression of the calcium exchangers, NCKX3 and NCX1, and their regulation by steroid in the human endometrium during the menstrual cycle. Reproductive Sciences . 2011;18(6):577&#x2013;585. doi: 10.1177/1933719110396229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1933719110396229</ArticleId><ArticleId IdType="pubmed">21321244</ArticleId></ArticleIdList></Reference><Reference><Citation>Naureen Z., Lorusso L., Manganotti P., et al. Genetics of pain: from rare Mendelian disorders to genetic predisposition to pain. Acta Biomed . 2020;91(13-S, article e2020010) doi: 10.23750/abm.v91i13-S.10682.</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v91i13-S.10682</ArticleId><ArticleId IdType="pmc">PMC8023138</ArticleId><ArticleId IdType="pubmed">33170156</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Henhena N., Khalifa S. A., Ying R. P., et al. Evaluation of chemopreventive potential of Strobilanthes crispus against colon cancer formation in vitro and in vivo. BMC Complementary and Alternative Medicine . 2015;15(1):p. 419. doi: 10.1186/s12906-015-0926-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12906-015-0926-7</ArticleId><ArticleId IdType="pmc">PMC4658747</ArticleId><ArticleId IdType="pubmed">26608653</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu X., Shi Z., Guo J., Guo C., Qiu J., Hua K. Identification of a novel six-gene signature with potential prognostic and therapeutic value in cervical cancer. Cancer Medicine . 2021;10(19):6881&#x2013;6896. doi: 10.1002/cam4.4054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.4054</ArticleId><ArticleId IdType="pmc">PMC8495282</ArticleId><ArticleId IdType="pubmed">34498424</ArticleId></ArticleIdList></Reference><Reference><Citation>Gormley P., Winsvold B. S., Nyholt D. R., Kallela M., Chasman D. I., Palotie A. Migraine genetics: from genome-wide association studies to translational insights. Genome Medicine . 2016;8(1) doi: 10.1186/s13073-016-0346-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-016-0346-4</ArticleId><ArticleId IdType="pmc">PMC4992240</ArticleId><ArticleId IdType="pubmed">27543003</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran D. N., Go S. M., Park S. M., Jung E. M., Jeung E. B. Loss of Nckx3 exacerbates experimental DSS-induced colitis in mice through p53/NF-&#x3ba;B pathway. International Journal of Molecular Sciences . 2021;22(5):p. 2645. doi: 10.3390/ijms22052645.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052645</ArticleId><ArticleId IdType="pmc">PMC7961925</ArticleId><ArticleId IdType="pubmed">33807999</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36776306</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.</ArticleTitle><Pagination><StartPage>1090779</StartPage><MedlinePgn>1090779</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1090779</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2023.1090779</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The incidence and mortality of uterine corpus endometrial carcinoma (UCEC) are increasing yearly. There is currently no screening test for UCEC, and progress in its treatment is limited. It is important to identify new biomarkers for screening, diagnosing and predicting the outcomes of UCEC. A large number of previous studies have proven that KNL1 is crucial in the development of lung cancer, colorectal cancer and cervical cancer, but there is a lack of studies about the role of KNL1 in the development of UCEC.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The mRNA and protein expression data of KNL1 in The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and UALCAN databases and related clinical data were used to analyze the expression differences and clinical correlations of KNL1 in UCEC. A total of 108 clinical samples were collected, and the results of bioinformatics analysis were verified by immunohistochemistry. KNL1 and its related differentially expressed genes were used to draw a volcano map, construct a PPI protein interaction network, and perform gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), gene set enrichment analysis (GSEA) and immune infiltration analysis to predict the function of KNL1 during UCEC progression. The prognostic data of TCGA and 108 clinical patients were used to analyze the correlation of KNL1 expression with the survival of patients, and KM survival curves were drawn. The UCEC cell lines Ishikawa and Hec-1-A were used to verify the function of KNL1.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">KNL1 is significantly overexpressed in UCEC and is associated with a poor prognosis. KNL1 overexpression is closely related to cell mitosis, the cell cycle and other functions and is correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage, histological grade and other characteristics of UCEC patients. Knockdown of KNL1 expression in UCEC cell lines can inhibit their proliferation, invasion, metastasis and other phenotypes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">KNL1 is a prognostic and diagnostic biomarker associated with immune evasion in patients with UCEC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 He, Li, Huang, Zhao, Wang, Wang, Chen, Wang, Yi, Zhao and Zhao.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Kang</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, School of Nursing, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jingze</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, School of Nursing, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xuemiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, School of Nursing, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Weixin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, School of Nursing, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Taiwei</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, School of Nursing, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Junyu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zeyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, School of Nursing, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, The Second Hospital of Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Shuhua</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Lijing</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, School of Nursing, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">KNL1</Keyword><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">uterine corpus endometrial carcinoma</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>13</Day><Hour>3</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36776306</ArticleId><ArticleId IdType="pmc">PMC9913269</ArticleId><ArticleId IdType="doi">10.3389/fonc.2023.1090779</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin (2021) 71(1):7&#x2013;33. doi: 10.3322/caac.21654</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21654</ArticleId><ArticleId IdType="pubmed">33433946</ArticleId></ArticleIdList></Reference><Reference><Citation>Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet (London England) (2005) 366(9484):491&#x2013;505. doi: 10.1016/S0140-6736(05)67063-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)67063-8</ArticleId><ArticleId IdType="pubmed">16084259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong YF, Cheung TH, Lo KWK, Yim SF, Siu NSS, Chan SCS, et al. . Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene (2007) 26(13):1971&#x2013;82. doi: 10.1038/sj.onc.1209986</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1209986</ArticleId><ArticleId IdType="pubmed">17043662</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Liu Z, Yu X, Zhang X, L&#xfc; S, Chen X, et al. . The association between metabolic abnormality and endometrial cancer: a large case-control study in China. Gynecol Oncol (2010) 117(1):41&#x2013;6. doi: 10.1016/j.ygyno.2009.12.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2009.12.029</ArticleId><ArticleId IdType="pubmed">20096921</ArticleId></ArticleIdList></Reference><Reference><Citation>Llaurad&#xf3; M, Ruiz A, Majem B, Ertekin T, Col&#xe1;s E, Pedrola N, et al. . Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. Mol Cell Endocrinol (2012) 358(2):244&#x2013;55. doi: 10.1016/j.mce.2011.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2011.10.003</ArticleId><ArticleId IdType="pubmed">22037169</ArticleId></ArticleIdList></Reference><Reference><Citation>Neri M, Peiretti M, Melis GB, Piras B, Vallerino V, Paoletti AM, et al. . Systemic therapy for the treatment of endometrial cancer. Expert Opin Pharmacother (2019) 20(16):2019&#x2013;32. doi: 10.1080/14656566.2019.1654996</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2019.1654996</ArticleId><ArticleId IdType="pubmed">31451034</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, et al. . Current recommendations and recent progress in endometrial cancer. CA: Cancer J For Clin (2019) 69(4):258&#x2013;79. doi: 10.3322/caac.21561</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21561</ArticleId><ArticleId IdType="pubmed">31074865</ArticleId></ArticleIdList></Reference><Reference><Citation>Dueholm M, Hjorth IMD, Dahl K, Hansen ES, &#xd8;rtoft G. Ultrasound scoring of endometrial pattern for fast-track identification or exclusion of endometrial cancer in women with postmenopausal bleeding. J Minim Invasive Gynecol (2019) 26(3):516&#x2013;25. doi: 10.1016/j.jmig.2018.06.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmig.2018.06.010</ArticleId><ArticleId IdType="pubmed">29944932</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke MA, Long BJ, Del Mar Morillo A, Arbyn M, Bakkum-Gamez JN, Wentzensen N. Association of endometrial cancer risk with postmenopausal bleeding in women: A systematic review and meta-analysis. JAMA Internal Med (2018) 178(9):1210&#x2013;22. doi: 10.1001/jamainternmed.2018.2820</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2018.2820</ArticleId><ArticleId IdType="pmc">PMC6142981</ArticleId><ArticleId IdType="pubmed">30083701</ArticleId></ArticleIdList></Reference><Reference><Citation>Takimoto M, Wei G, Dosaka-Akita H, Mao P, Kondo S, Sakuragi N, et al. . Frequent expression of new cancer/testis gene D40/AF15q14 in lung cancers of smokers. Br J Cancer (2002) 86(11):1757&#x2013;62. doi: 10.1038/sj.bjc.6600328</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6600328</ArticleId><ArticleId IdType="pmc">PMC2375411</ArticleId><ArticleId IdType="pubmed">12087463</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei G, Takimoto M, Yoshida I, Mao PZ, Koya RC, Miura T, et al. . Chromosomal assignment of a novel human gene D40. Nucleic Acids Symp Ser (1999) 1999(42):71&#x2013;2. doi: 10.1093/nass/42.1.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nass/42.1.71</ArticleId><ArticleId IdType="pubmed">10780384</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayette S, Tigaud I, Vanier A, Martel S, Corbo L, Charrin C, et al. . AF15q14, a novel partner gene fused to the MLL gene in an acute myeloid leukaemia with a t (11,15)(q23;q14). Oncogene (2000) 19(38):4446&#x2013;50. doi: 10.1038/sj.onc.1203789</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1203789</ArticleId><ArticleId IdType="pubmed">10980622</ArticleId></ArticleIdList></Reference><Reference><Citation>Vleugel M, Tromer E, Omerzu M, Groenewold V, Nijenhuis W, Snel B, et al. . Arrayed BUB recruitment modules in the kinetochore scaffold KNL1 promote accurate chromosome segregation. J Cell Biol (2013) 203(6):943&#x2013;55. doi: 10.1083/jcb.201307016</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201307016</ArticleId><ArticleId IdType="pmc">PMC3871444</ArticleId><ArticleId IdType="pubmed">24344183</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj R, Bollen M, Peti W, Page R. KNL1 binding to PP1 and microtubules is mutually exclusive. Structure (2018) 26(10). doi: 10.1016/j.str.2018.06.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2018.06.013</ArticleId><ArticleId IdType="pmc">PMC6601351</ArticleId><ArticleId IdType="pubmed">30100357</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Vleugel M, Backer CB, Hori T, Fukagawa T, Cheeseman IM, et al. . Regulated targeting of protein phosphatase 1 to the outer kinetochore by KNL1 opposes aurora b kinase. J Cell Biol (2010) 188(6):809&#x2013;20. doi: 10.1083/jcb.201001006</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201001006</ArticleId><ArticleId IdType="pmc">PMC2845083</ArticleId><ArticleId IdType="pubmed">20231380</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y, Zhang C, Ma S, Guo W, Cao W, Guan F. CASC5 is a potential tumour driving gene in lung adenocarcinoma. Cell Biochem Funct (2020) 38(6):733&#x2013;42. doi: 10.1002/cbf.3540</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbf.3540</ArticleId><ArticleId IdType="pubmed">32283571</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai T, Zhao Y, Liu Y, Cai B, Dong N, Li B. Effect of KNL1 on the proliferation and apoptosis of colorectal cancer cells. Technol Cancer Res Treat (2019) 18:1533033819858668. doi: 10.1177/1533033819858668</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533033819858668</ArticleId><ArticleId IdType="pmc">PMC6637841</ArticleId><ArticleId IdType="pubmed">31315522</ArticleId></ArticleIdList></Reference><Reference><Citation>Urata YN, Takeshita F, Tanaka H, Ochiya T, Takimoto M. Targeted knockdown of the kinetochore protein D40/Knl-1 inhibits human cancer in a p53 status-independent manner. Sci Rep (2015) 5:13676. doi: 10.1038/srep13676</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep13676</ArticleId><ArticleId IdType="pmc">PMC4562263</ArticleId><ArticleId IdType="pubmed">26348410</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivian J, Rao AA, Nothaft FA, Ketchum C, Armstrong J, Novak A, et al. . Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol (2017) 35(4):314&#x2013;6. doi: 10.1038/nbt.3772</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3772</ArticleId><ArticleId IdType="pmc">PMC5546205</ArticleId><ArticleId IdType="pubmed">28398314</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S, Meltzer PS. GEOquery: a bridge between the gene expression omnibus (GEO) and BioConductor. Bioinformatics (2007) 23(14):1846&#x2013;7. doi: 10.1093/bioinformatics/btm254</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btm254</ArticleId><ArticleId IdType="pubmed">17496320</ArticleId></ArticleIdList></Reference><Reference><Citation>Day RS, McDade KK, Chandran UR, Lisovich A, Conrads TP, Hood BL, et al. . Identifier mapping performance for integrating transcriptomics and proteomics experimental results. BMC Bioinf (2011) 12:213. doi: 10.1186/1471-2105-12-213</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-213</ArticleId><ArticleId IdType="pmc">PMC3124437</ArticleId><ArticleId IdType="pubmed">21619611</ArticleId></ArticleIdList></Reference><Reference><Citation>Day RS, McDade KK. A decision theory paradigm for evaluating identifier mapping and filtering methods using data integration. BMC Bioinf (2013) 14:223. doi: 10.1186/1471-2105-14-223</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-14-223</ArticleId><ArticleId IdType="pmc">PMC3734162</ArticleId><ArticleId IdType="pubmed">23855655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. . Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res (2015) 43(7):e47. doi: 10.1093/nar/gkv007</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen F, Chandrashekar DS, Varambally S, Creighton CJ. Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways. Nat Commun (2022) 13(1):2669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9106650</ArticleId><ArticleId IdType="pubmed">35562349</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, Chandrashekar DS, Varambally S, Creighton CJ. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun (2019) 10(1):5679. doi: 10.1038/s41467-019-13528-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13528-0</ArticleId><ArticleId IdType="pmc">PMC6908580</ArticleId><ArticleId IdType="pubmed">31831737</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol (2014) 15(12):550. doi: 10.1186/s13059-014-0550-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, et al. . STRING 8&#x2013;a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res (2009) 37(Database issue):D412&#x2013;D6. doi: 10.1093/nar/gkn760</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkn760</ArticleId><ArticleId IdType="pmc">PMC2686466</ArticleId><ArticleId IdType="pubmed">18940858</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf (2013) 14:7. doi: 10.1186/1471-2105-14-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-14-7</ArticleId><ArticleId IdType="pmc">PMC3618321</ArticleId><ArticleId IdType="pubmed">23323831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 39(4):782&#x2013;95. doi: 10.1016/j.immuni.2013.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.10.003</ArticleId><ArticleId IdType="pubmed">24138885</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. . An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell (2018) 173(2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6066282</ArticleId><ArticleId IdType="pubmed">29625055</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Xu D, Wang T, Yang Z, Yang Y, He K, et al. . HMGB1 promotes the development of castration&#x2212;resistant prostate cancer by regulating androgen receptor activation. Oncol Rep (2022) 48(5). doi: 10.3892/or.2022.8412</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2022.8412</ArticleId><ArticleId IdType="pmc">PMC9535630</ArticleId><ArticleId IdType="pubmed">36129149</ArticleId></ArticleIdList></Reference><Reference><Citation>Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. . Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer (2011) 104(9):1418&#x2013;25. doi: 10.1038/bjc.2011.109</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2011.109</ArticleId><ArticleId IdType="pmc">PMC3101927</ArticleId><ArticleId IdType="pubmed">21468050</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonsen SL, H&#xf8;gdall E, Christensen IJ, Lydolph M, Tabor A, Loft Jakobsen A, et al. . HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand (2013) 92(11):1313&#x2013;22. doi: 10.1111/aogs.12235</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aogs.12235</ArticleId><ArticleId IdType="pubmed">24032654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ri&#x17e;ner TL. Discovery of biomarkers for endometrial cancer: current status and prospects. Expert Rev Mol Diagn (2016) 16(12):1315&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">27817223</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo N, Creutzberg C, Amant F, Bosse T, Gonz&#xe1;lez-Mart&#xed;n A, Ledermann J, et al. . ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol (2016) 27(1):16&#x2013;41. doi: 10.1093/annonc/mdv484</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdv484</ArticleId><ArticleId IdType="pubmed">26634381</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundar S, Balega J, Crosbie E, Drake A, Edmondson R, Fotopoulou C, et al. . BGCS uterine cancer guidelines: Recommendations for practice. Eur J Obstet Gynecol Reprod Biol (2017) 213:71&#x2013;97. doi: 10.1016/j.ejogrb.2017.04.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejogrb.2017.04.015</ArticleId><ArticleId IdType="pubmed">28437632</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend MH, Ence ZE, Felsted AM, Parker AC, Piccolo SR, Robison RA, et al. . Potential new biomarkers for endometrial cancer. Cancer Cell Int (2019) 19:19. doi: 10.1186/s12935-019-0731-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-019-0731-3</ArticleId><ArticleId IdType="pmc">PMC6341571</ArticleId><ArticleId IdType="pubmed">30679932</ArticleId></ArticleIdList></Reference><Reference><Citation>Paizula X, Mutailipu D, Xu W, Wang H, Yi L. Identification of biomarkers related to tumorigenesis and prognosis in breast cancer. Gland Surg (2022) 11(9):1472&#x2013;88. doi: 10.21037/gs-22-449</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/gs-22-449</ArticleId><ArticleId IdType="pmc">PMC9547705</ArticleId><ArticleId IdType="pubmed">36221277</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Lin H, Hou L, Xiao H, Gong X, Guo X, et al. . Exploration of the breast ductal carcinoma in situ signature and its prognostic implications. Cancer Med (2022). doi: 10.1002/cam4.5071</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.5071</ArticleId><ArticleId IdType="pmc">PMC9939111</ArticleId><ArticleId IdType="pubmed">35880695</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardeman AA, Han YJ, Grushko TA, Mueller J, Gomez MJ, Zheng Y, et al. . Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer. PloS One (2022) 17(6):e0268693. doi: 10.1371/journal.pone.0268693</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0268693</ArticleId><ArticleId IdType="pmc">PMC9231703</ArticleId><ArticleId IdType="pubmed">35749404</ArticleId></ArticleIdList></Reference><Reference><Citation>Laha D, Grant RRC, Mishra P, Boufraqech M, Shen M, Zhang Y-Q, et al. . Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer. J Exp Clin Cancer Res (2022) 41(1):282. doi: 10.1186/s13046-022-02464-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-022-02464-5</ArticleId><ArticleId IdType="pmc">PMC9502945</ArticleId><ArticleId IdType="pubmed">36151566</ArticleId></ArticleIdList></Reference><Reference><Citation>Du J, Xiao J, Zhuo Y, Nie M, Yang J, Luo X, et al. . LncRNA OSTM1-AS1 acts as an oncogenic factor in wilms&#x2019; tumor by regulating the miR-514a-3p/MELK axis. Anticancer Drugs (2022) 33(8):720&#x2013;30. doi: 10.1097/CAD.0000000000001320</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CAD.0000000000001320</ArticleId><ArticleId IdType="pubmed">35946509</ArticleId></ArticleIdList></Reference><Reference><Citation>Makki Almansour N. Computational exploration of maternal embryonic leucine zipper kinase (MELK) as a cancer drug target. Saudi J Biol Sci (2022) 29(7):103335. doi: 10.1016/j.sjbs.2022.103335</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sjbs.2022.103335</ArticleId><ArticleId IdType="pmc">PMC9235044</ArticleId><ArticleId IdType="pubmed">35769060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao F, Wang N, Zhang Y, Xu W, Chen Y, Fei X, et al. . E2F7 enhances hepatocellular carcinoma growth by preserving the SP1/SOX4/Anillin axis via repressing miRNA-383-5p transcription. Mol Carcinog (2022) 61(11):975&#x2013;88. doi: 10.1002/mc.23454</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mc.23454</ArticleId><ArticleId IdType="pmc">PMC9804269</ArticleId><ArticleId IdType="pubmed">35924788</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z-G, Su J, Liu H, Yang X-J, Yang X, Wei Y, et al. . Comprehensive bioinformatics analysis of the E2F family in human clear cell renal cell carcinoma. Oncol Lett (2022) 24(4):351. doi: 10.3892/ol.2022.13471</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2022.13471</ArticleId><ArticleId IdType="pmc">PMC9478613</ArticleId><ArticleId IdType="pubmed">36168311</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y, Zhang M, Chen X, Deng Y. Identifying a three-gene signature and associated drugs for hepatitis b virus-related hepatocellular carcinoma using comprehensive bioinformatics analysis. Tohoku J Exp Med (2022) 258(2):149&#x2013;57. doi: 10.1620/tjem.2022.J069</Citation><ArticleIdList><ArticleId IdType="doi">10.1620/tjem.2022.J069</ArticleId><ArticleId IdType="pubmed">36002253</ArticleId></ArticleIdList></Reference><Reference><Citation>Vleugel M, Omerzu M, Groenewold V, Hadders MA, Lens SMA, Kops GJPL. Sequential multisite phospho-regulation of KNL1-BUB3 interfaces at mitotic kinetochores. Mol Cell (2015) 57(5):824&#x2013;35. doi: 10.1016/j.molcel.2014.12.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2014.12.036</ArticleId><ArticleId IdType="pubmed">25661489</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng K, Song G, Chen B, Gao X, Liu C, Miao J, et al. . Comprehensive analysis to identify the RP11-478C19.2/E2F7 axis as a novel biomarker for treatment decisions in clear cell renal cell carcinoma. Transl Oncol (2022) 25:101525. doi: 10.1016/j.tranon.2022.101525</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2022.101525</ArticleId><ArticleId IdType="pmc">PMC9445397</ArticleId><ArticleId IdType="pubmed">36054996</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie H, Wang Y, Yang X, Liao Z, He X, Zhou J, et al. . Clinical significance and integrative analysis of the SMC family in hepatocellular carcinoma. Front In Med (2021) 8:727965. doi: 10.3389/fmed.2021.727965</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.727965</ArticleId><ArticleId IdType="pmc">PMC8437102</ArticleId><ArticleId IdType="pubmed">34527684</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan W, Wang D-D, Zhang H-D, Huang J, Hou J-C, Yang S-J, et al. . Expression profile and prognostic values of SMC family members in HCC. Medicine (2022) 101(42):e31336. doi: 10.1097/MD.0000000000031336</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000031336</ArticleId><ArticleId IdType="pmc">PMC9592487</ArticleId><ArticleId IdType="pubmed">36281130</ArticleId></ArticleIdList></Reference><Reference><Citation>Houlard M, Cutts EE, Shamim MS, Godwin J, Weisz D, Presser Aiden A, et al. . MCPH1 inhibits condensin II during interphase by regulating its SMC2-kleisin interface. Elife (2021) 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8673838</ArticleId><ArticleId IdType="pubmed">34850681</ArticleId></ArticleIdList></Reference><Reference><Citation>Monroy-Iglesias MJ, Crescioli S, Beckmann K, Le N, Karagiannis SN, Van Hemelrijck M, et al. . Antibodies as biomarkers for cancer risk: a systematic review. Clin Exp Immunol (2022) 209(1):46&#x2013;63. doi: 10.1093/cei/uxac030</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cei/uxac030</ArticleId><ArticleId IdType="pmc">PMC9307228</ArticleId><ArticleId IdType="pubmed">35380164</ArticleId></ArticleIdList></Reference><Reference><Citation>Homberg M, Magin TM. Beyond expectations: novel insights into epidermal keratin function and regulation. Int Rev Cell Mol Biol (2014) 311:265&#x2013;306. doi: 10.1016/B978-0-12-800179-0.00007-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-800179-0.00007-6</ArticleId><ArticleId IdType="pubmed">24952920</ArticleId></ArticleIdList></Reference><Reference><Citation>Karsch S, B&#xfc;chau F, Magin TM, Janshoff A. An intact keratin network is crucial for mechanical integrity and barrier function in keratinocyte cell sheets. Cell Mol Life Sci (2020) 77(21):4397&#x2013;411. doi: 10.1007/s00018-019-03424-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-019-03424-7</ArticleId><ArticleId IdType="pmc">PMC11104923</ArticleId><ArticleId IdType="pubmed">31912195</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Zhang R, Zou K, Yu W, Guo W, Gao Y, et al. . Keratin 23 promotes telomerase reverse transcriptase expression and human colorectal cancer growth. Cell Death Dis (2017) 8(7):e2961. doi: 10.1038/cddis.2017.339</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2017.339</ArticleId><ArticleId IdType="pmc">PMC5550880</ArticleId><ArticleId IdType="pubmed">28749462</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozza WP, Zhang Y, Zhang B. Cytokeratin 8/18 protects breast cancer cell lines from TRAIL-induced apoptosis. Oncotarget (2018) 9(33):23264&#x2013;73. doi: 10.18632/oncotarget.25297</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.25297</ArticleId><ArticleId IdType="pmc">PMC5955420</ArticleId><ArticleId IdType="pubmed">29796187</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilandzic M, Rainczuk A, Green E, Fairweather N, Jobling TW, Plebanski M, et al. . Keratin-14 (KRT14) positive leader cells mediate mesothelial clearance and invasion by ovarian cancer cells. Cancers (2019) 11(9). doi: 10.3390/cancers11091228</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11091228</ArticleId><ArticleId IdType="pmc">PMC6769856</ArticleId><ArticleId IdType="pubmed">31443478</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquis C, Fonseca CL, Queen KA, Wood L, Vandal SE, Malaby HLH, et al. . Chromosomally unstable tumor cells specifically require KIF18A for proliferation. Nat Commun (2021) 12(1):1213. doi: 10.1038/s41467-021-21447-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21447-2</ArticleId><ArticleId IdType="pmc">PMC7900194</ArticleId><ArticleId IdType="pubmed">33619254</ArticleId></ArticleIdList></Reference><Reference><Citation>Noatynska A, Gotta M, Meraldi P. Mitotic spindle (DIS)orientation and DISease: cause or consequence? J Cell Biol (2012) 199(7):1025&#x2013;35. doi: 10.1083/jcb.201209015</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201209015</ArticleId><ArticleId IdType="pmc">PMC3529530</ArticleId><ArticleId IdType="pubmed">23266953</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyholm HC, Nielsen AL, Lyndrup J, Norup P, Thorpe SM. Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlations with stage and other clinicopathologic features. Am J Obstetrics Gynecol. (1992) 167(5):1334&#x2013;42. doi: 10.1016/S0002-9378(11)91712-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9378(11)91712-8</ArticleId><ArticleId IdType="pubmed">1442987</ArticleId></ArticleIdList></Reference><Reference><Citation>Sausville LN, Williams SM, Pozzi A. Cytochrome P450 epoxygenases and cancer: A genetic and a molecular perspective. Pharmacol Ther (2019) 196:183&#x2013;94. doi: 10.1016/j.pharmthera.2018.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2018.11.009</ArticleId><ArticleId IdType="pubmed">30521883</ArticleId></ArticleIdList></Reference><Reference><Citation>Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol (2021) 32(9):1101&#x2013;10. doi: 10.1016/j.annonc.2021.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2021.06.001</ArticleId><ArticleId IdType="pubmed">34089836</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Ou Y, Luo R, Wang J, Wang D, Guan J, et al. . SAR1B senses leucine levels to regulate mTORC1 signalling. Nature (2021) 596(7871):281&#x2013;4. doi: 10.1038/s41586-021-03768-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03768-w</ArticleId><ArticleId IdType="pubmed">34290409</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang CV. MYC on the path to cancer. Cell (2012) 149(1):22&#x2013;35. doi: 10.1016/j.cell.2012.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.03.003</ArticleId><ArticleId IdType="pmc">PMC3345192</ArticleId><ArticleId IdType="pubmed">22464321</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, He Y, Luo N, Patel SJ, Han Y, Gao R, et al. . Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell (2019) 179(4). doi: 10.1016/j.cell.2019.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.10.003</ArticleId><ArticleId IdType="pubmed">31675496</ArticleId></ArticleIdList></Reference><Reference><Citation>Yofe I, Dahan R, Amit I. Single-cell genomic approaches for developing the next generation of immunotherapies. Nat Med (2020) 26(2):171&#x2013;7. doi: 10.1038/s41591-019-0736-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0736-4</ArticleId><ArticleId IdType="pubmed">32015555</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Rajappa M, Saxena A, Sharma M. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. Int J gynecol. Cancer (2007) 17(4):879&#x2013;85. doi: 10.1111/j.1525-1438.2007.00883.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1438.2007.00883.x</ArticleId><ArticleId IdType="pubmed">17343606</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Beyer A, Aebersold R. On the dependency of cellular protein levels on mRNA abundance. Cell (2016) 165(3):535&#x2013;50. doi: 10.1016/j.cell.2016.03.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.03.014</ArticleId><ArticleId IdType="pubmed">27104977</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36750200</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1945-4589</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>05</Day></PubDate></JournalIssue><Title>Aging</Title><ISOAbbreviation>Aging (Albany NY)</ISOAbbreviation></Journal><ArticleTitle>The pan-cancer analysis identified DIAPH3 as a diagnostic biomarker of clinical cancer.</ArticleTitle><Pagination><StartPage>689</StartPage><EndPage>704</EndPage><MedlinePgn>689-704</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18632/aging.204459</ELocationID><Abstract><AbstractText Label="OBJECTIVE">This study aimed to determine prognostic biomarkers of cervical cancer by pan-cancer analysis.</AbstractText><AbstractText Label="MATERIALS AND METHODS">Common differentially expressed genes in Gene Expression Omnibus and The Cancer Genome Atlas (TCGA) database were demonstrated using R software analysis, and these genes were enriched by the Kyoto Encyclopedia of Genes and Genomes and Gene Ontology. Genes with prognostic value were identified by least absolute contraction and selection regression, Cox regression, and survival analysis, and pan-cancer analysis was conducted using the Tumor Immune Estimation Resource database and TCGA database. Western blot, qRT-PCR, and immunohistochemistry were used to preliminarily verify its expression in cervical cancer (S1).</AbstractText><AbstractText Label="RESULTS">The prognostic marker Diaphanous Related Formin 3 (DIAPH3) was obtained from us. The enrichment analysis revealed that DIAPH3 was involved in tumor proliferation, invasion, and inflammation. The pan-cancer analysis revealed that it was highly expressed in various cancers. Immune infiltration analysis revealed that its expression was related to B cells, effector T cells, and macrophage infiltration; however, immune checkpoint correlation analysis and tumor mutation burden analysis revealed the correlation between gene expression and immunotherapy. The expression of DIAPH3 in cervical cancer was significantly different from that in normal cervical tissues.</AbstractText><AbstractText Label="CONCLUSION">The expression of DIAPH3 in cervical cancer was significantly increased, which may be related to the proliferation, metastasis, immune invasion, and immunotherapy of cervical cancer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Xiaowei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Medical Laboratory, Guizhou Medical University, Guiyang, Guizhou Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Xie</LastName><ForeName>Luhong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>College of Medical Laboratory, Guizhou Medical University, Guiyang, Guizhou Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>College of Medical Laboratory, Guizhou Medical University, Guiyang, Guizhou Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Clinical Laboratory Center, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Ji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Medical Laboratory, Guizhou Medical University, Guiyang, Guizhou Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Yujie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Central Laboratory of Clinical Laboratory Diagnosis Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Aging (Albany NY)</MedlineTA><NlmUniqueID>101508617</NlmUniqueID><ISSNLinking>1945-4589</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484571">DIAPH3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000080865">Formins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080865" MajorTopicYN="N">Formins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DIAPH3</Keyword><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">tumor immunity</Keyword><Keyword MajorTopicYN="N">tumor markers</Keyword></KeywordList><CoiStatement><b>CONFLICTS OF INTEREST:</b> The authors declare no conflicts of interest related to this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36750200</ArticleId><ArticleId IdType="pmc">PMC9970313</ArticleId><ArticleId IdType="doi">10.18632/aging.204459</ArticleId><ArticleId IdType="pii">204459</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Di J, Rutherford S, Chu C. Review of the Cervical Cancer Burden and Population-Based Cervical Cancer Screening in China. Asian Pac J Cancer Prev. 2015; 16:7401&#x2013;7. 10.7314/apjcp.2015.16.17.7401</Citation><ArticleIdList><ArticleId IdType="doi">10.7314/apjcp.2015.16.17.7401</ArticleId><ArticleId IdType="pubmed">26625735</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimek R. Cervical cancer as a natural phenomenon. Eur J Obstet Gynecol Reprod Biol. 1990; 36:229&#x2013;38. 10.1016/0028-2243(90)90202-c</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0028-2243(90)90202-c</ArticleId><ArticleId IdType="pubmed">2199247</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, Bothou A, Galazios G. Cervical cancer: screening, diagnosis and staging. J BUON. 2016; 21:320&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27273940</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarth JA, Patterson MR, Morgan EL, Macdonald A. The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation. J Gen Virol. 2021; 102:001540. 10.1099/jgv.0.001540</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001540</ArticleId><ArticleId IdType="pmc">PMC8148304</ArticleId><ArticleId IdType="pubmed">33427604</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M, Weiderpass E, Bruni L, de Sanjos&#xe9; S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020; 8:e191&#x2013;203. 10.1016/S2214-109X(19)30482-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(19)30482-6</ArticleId><ArticleId IdType="pmc">PMC7025157</ArticleId><ArticleId IdType="pubmed">31812369</ArticleId></ArticleIdList></Reference><Reference><Citation>Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003; 16:1&#x2013;17. 10.1128/CMR.16.1.1-17.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.16.1.1-17.2003</ArticleId><ArticleId IdType="pmc">PMC145302</ArticleId><ArticleId IdType="pubmed">12525422</ArticleId></ArticleIdList></Reference><Reference><Citation>Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: A global health crisis. Cancer. 2017; 123:2404&#x2013;12. 10.1002/cncr.30667</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.30667</ArticleId><ArticleId IdType="pubmed">28464289</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018; 7:5217&#x2013;36. 10.1002/cam4.1501</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.1501</ArticleId><ArticleId IdType="pmc">PMC6198240</ArticleId><ArticleId IdType="pubmed">30589505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Y, Xu H, Ji X, Zhao J. BLM interaction with EZH2 regulates MDM2 expression and is a poor prognostic biomarker for prostate cancer. Am J Cancer Res. 2021; 11:1347&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8085859</ArticleId><ArticleId IdType="pubmed">33948362</ArticleId></ArticleIdList></Reference><Reference><Citation>Dongol S, Zhang Q, Qiu C, Sun C, Zhang Z, Wu H, Kong B. IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer. Oncol Lett. 2020; 20:1179&#x2013;92. 10.3892/ol.2020.11664</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2020.11664</ArticleId><ArticleId IdType="pmc">PMC7377165</ArticleId><ArticleId IdType="pubmed">32724358</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinawath N, Shiao MS, Chanpanitkitchote P, Svasti J, Furukawa Y, Nakamura Y. Enhancement of Migration and Invasion of Gastric Cancer Cells by IQGAP3. Biomolecules. 2020; 10:1194. 10.3390/biom10081194</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10081194</ArticleId><ArticleId IdType="pmc">PMC7465220</ArticleId><ArticleId IdType="pubmed">32824461</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu M, Pei Y, Lu F, Jiang H, Bi Y, Cheng J, Qin J. Identification of Potential Hub Genes and miRNA-mRNA Pairs Related to the Progression and Prognosis of Cervical Cancer Through Integrated Bioinformatics Analysis. Front Genet. 2021; 12:775006. 10.3389/fgene.2021.775006</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.775006</ArticleId><ArticleId IdType="pmc">PMC8727538</ArticleId><ArticleId IdType="pubmed">35003215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SS, Shen S, Miyauchi S, Sanders PD, Franiak-Pietryga I, Mell L, Gutkind JS, Cohen EEW, Califano JA, Sharabi AB. B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. Clin Cancer Res. 2020; 26:3345&#x2013;59. 10.1158/1078-0432.CCR-19-3211</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-19-3211</ArticleId><ArticleId IdType="pmc">PMC7334097</ArticleId><ArticleId IdType="pubmed">32193227</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer. 2010; 10:112. 10.1186/1471-2407-10-112</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-10-112</ArticleId><ArticleId IdType="pmc">PMC2851690</ArticleId><ArticleId IdType="pubmed">20338029</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, Zhao Y, Yan H, Yang Y, Shen S, Dai X, Ji X, Ji F, Gong XG, Li L, Bai X, Feng XH, Liang T, et al.. Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. Genes Dev. 2017; 31:247&#x2013;59. 10.1101/gad.294348.116</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.294348.116</ArticleId><ArticleId IdType="pmc">PMC5358722</ArticleId><ArticleId IdType="pubmed">28223311</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J, Zheng W, Chapman NM, Geiger TL, Chi H. T cell metabolism in homeostasis and cancer immunity. Curr Opin Biotechnol. 2021; 68:240&#x2013;50. 10.1016/j.copbio.2021.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.copbio.2021.02.003</ArticleId><ArticleId IdType="pmc">PMC8137568</ArticleId><ArticleId IdType="pubmed">33676144</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong J, Keskinov AA, Shurin GV, Shurin MR. Tumor-derived factors modulating dendritic cell function. Cancer Immunol Immunother. 2016; 65:821&#x2013;33. 10.1007/s00262-016-1820-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-016-1820-y</ArticleId><ArticleId IdType="pmc">PMC11028482</ArticleId><ArticleId IdType="pubmed">26984847</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang G, Weiwei H, Erji G, Haitao M. DIAPH3 promotes the tumorigenesis of lung adenocarcinoma. Exp Cell Res. 2019; 385:111662. 10.1016/j.yexcr.2019.111662</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2019.111662</ArticleId><ArticleId IdType="pubmed">31586548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong Y, Gao J, Kuang T, Chen J, Li JA, Huang Y, Xin H, Fang Y, Han X, Sun LQ, Deng YZ, Li Z, Lou W. DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects. J Cell Mol Med. 2021; 25:2163&#x2013;75. 10.1111/jcmm.16196</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.16196</ArticleId><ArticleId IdType="pmc">PMC7882936</ArticleId><ArticleId IdType="pubmed">33345387</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong L, Li Z, Xue L, Li G, Zhang C, Cai Z, Li H, Guo R. DIAPH3 promoted the growth, migration and metastasis of hepatocellular carcinoma cells by activating beta-catenin/TCF signaling. Mol Cell Biochem. 2018; 438:183&#x2013;90. 10.1007/s11010-017-3125-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-017-3125-7</ArticleId><ArticleId IdType="pubmed">28795316</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J. Diaphanous-related formin-3 overexpression inhibits the migration and invasion of triple-negative breast cancer by inhibiting RhoA-GTP expression. Biomed Pharmacother. 2017; 94:439&#x2013;45. 10.1016/j.biopha.2017.07.119</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.07.119</ArticleId><ArticleId IdType="pubmed">28779705</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan L, Zhu J, Wu Q. Knockdown of DIAPH3 Inhibits the Proliferation of Cervical Cancer Cells through Inactivating mTOR Signaling Pathway. J Oncol. 2021; 2021:4228241. 10.1155/2021/4228241</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/4228241</ArticleId><ArticleId IdType="pmc">PMC8514916</ArticleId><ArticleId IdType="pubmed">34659408</ArticleId></ArticleIdList></Reference><Reference><Citation>Guardado-Estrada M, Medina-Mart&#xed;nez I, Ju&#xe1;rez-Torres E, Roman-Bassaure E, Mac&#xed;as L, Alfaro A, Alc&#xe1;ntara-V&#xe1;zquez A, Alonso P, Gomez G, Cruz-Talonia F, Serna L, Mu&#xf1;oz-Cortez S, Borges-Iba&#xf1;ez M, et al.. The Amerindian mtDNA haplogroup B2 enhances the risk of HPV for cervical cancer: de-regulation of mitochondrial genes may be involved. J Hum Genet. 2012; 57:269&#x2013;76. 10.1038/jhg.2012.17</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jhg.2012.17</ArticleId><ArticleId IdType="pubmed">22357541</ArticleId></ArticleIdList></Reference><Reference><Citation>den Boon JA, Pyeon D, Wang SS, Horswill M, Schiffman M, Sherman M, Zuna RE, Wang Z, Hewitt SM, Pearson R, Schott M, Chung L, He Q, et al.. Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S A. 2015; 112:E3255&#x2013;64. 10.1073/pnas.1509322112</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1509322112</ArticleId><ArticleId IdType="pmc">PMC4485108</ArticleId><ArticleId IdType="pubmed">26056290</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Qu H, Wang S, Wei J, Zhang L, Ma R, Lu J, Zhu J, Zhong WD, Jia Z. GDCRNATools: an R/Bioconductor package for integrative analysis of lncRNA, miRNA and mRNA data in GDC. Bioinformatics. 2018; 34:2515&#x2013;7. 10.1093/bioinformatics/bty124</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty124</ArticleId><ArticleId IdType="pubmed">29509844</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43:e47. 10.1093/nar/gkv007</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, Fu X, Liu S, Bo X, Yu G. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2:100141. 10.1016/j.xinn.2021.100141</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xinn.2021.100141</ArticleId><ArticleId IdType="pmc">PMC8454663</ArticleId><ArticleId IdType="pubmed">34557778</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36685883</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-8021</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in genetics</Title><ISOAbbreviation>Front Genet</ISOAbbreviation></Journal><ArticleTitle>Pan-cancer analysis of the prognostic and immunological role of Fanconi anemia complementation group E.</ArticleTitle><Pagination><StartPage>1024989</StartPage><MedlinePgn>1024989</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1024989</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fgene.2022.1024989</ELocationID><Abstract><AbstractText>Fanconi anemia (FA) genes contribute to tumorigenesis by regulating DNA repair. Despite its importance for assembly and functionality of the FA core complex, no pan-cancer analysis of <i>FANCE</i> was performed. We aimed to provide a comprehensive understanding of the role of <i>FANCE</i> in cancers. Based on The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE), Genotype Tissue-Expression (GTEx), Human Protein Atlas (HPA), Gene Expression Omnibus (GEO), and Cancer Single-cell Atlas (CancerSEA) databases, we investigated the carcinogenicity of <i>FANCE</i> using various bioinformatics methods, including <i>FANCE</i> expression and prognosis, immune invasion, tumor mutation burden, microsatellite instability, and neoantigens. We monitored <i>Fance</i> mutations in mice that caused tumorigenesis. <i>FANCE</i> expression and activity scores were upregulated in 15 and 21 cancers. High expression of <i>FANCE</i> affected shorter overall survival (OS) in seven cancers and longer overall survival in three cancers. It was correlated with shorter overall survival and progression-free interval (PFI) in endometrial cancer and longer overall survival and PFI in cervical cancer. <i>FANCE</i> expression negatively correlated with stromal/immune scores in 21 cancers including cervical cancer, endometrial cancer, and ovarian cancer. <i>FANCE</i> expression negatively correlated with CD8 T cells in endometrial cancer and positively correlated with M1 macrophages in cervical cancer, possibly related to cancer prognosis. <i>FANCE</i> positively correlated with immune checkpoint inhibitors PD-1, PD-L1, and CTLA4 in endometrial cancer and ovarian cancer. <i>FANCE</i> expression positively correlated with microsatellite instability, tumor mutational burden, and neoantigens in 7, 22, and five cancers, especially in endometrial cancer, potentially increasing the effectiveness of immunotherapy. Single-cell sequencing data showed <i>FANCE</i> was primarily expressed in cancer cells in cervical and ovarian cancer, and in fibroblasts in endometrial cancer. <i>Fance</i> heterozygous mutant mice had increased tumor incidences and shorter overall survival and tumor-free survival (TFS) than <i>Fance</i> homozygous mutant mice and wild-type mice. Conclusively, <i>FANCE</i> potential to serve as a biomarker for cancer prognosis and may predict cancer immunotherapy responses. <i>Fance</i> heterozygous mutant resulted in increased tumorigenesis and poor prognosis in mice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Zhou, Yin, Suye, He and Fu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zhixian</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suye</LastName><ForeName>Suye</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Jiarong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Chun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Genet</MedlineTA><NlmUniqueID>101560621</NlmUniqueID><ISSNLinking>1664-8021</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FANCE</Keyword><Keyword MajorTopicYN="N">Fanconi anemia</Keyword><Keyword MajorTopicYN="N">pan-cancer</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">tumor immunity</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>23</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36685883</ArticleId><ArticleId IdType="pmc">PMC9846156</ArticleId><ArticleId IdType="doi">10.3389/fgene.2022.1024989</ArticleId><ArticleId IdType="pii">1024989</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akbari M. R., Malekzadeh R., Lepage P., Roquis D., Sadjadi A. R., Aghcheli K., et al. (2011). Mutations in Fanconi anemia genes and the risk of esophageal cancer. Hum. Genet. 129 (5), 573&#x2013;582. 10.1007/s00439-011-0951-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-011-0951-7</ArticleId><ArticleId IdType="pubmed">21279724</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali A. M., Kirby M., Jansen M., Lach F. P., Schulte J., Singh T. R., et al. (2009). Identification and characterization of mutations in FANCL gene: A second case of Fanconi anemia belonging to FA-L complementation group. Hum. Mutat. 30 (7), E761&#x2013;E770. 10.1002/humu.21032</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.21032</ArticleId><ArticleId IdType="pmc">PMC2760491</ArticleId><ArticleId IdType="pubmed">19405097</ArticleId></ArticleIdList></Reference><Reference><Citation>Allouch S., Malki A., Allouch A., Gupta I., Vranic S., Al Moustafa A. E. (2020). High-risk HPV oncoproteins and PD-1/PD-L1 interplay in human cervical cancer: Recent evidence and future directions. Front. Oncol. 10, 914. 10.3389/fonc.2020.00914</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.00914</ArticleId><ArticleId IdType="pmc">PMC7338567</ArticleId><ArticleId IdType="pubmed">32695664</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker S. T., van de Vrugt H. J., Rooimans M. A., Oostra A. B., Steltenpool J., Delzenne-Goette E., et al. (2009). Fancm-deficient mice reveal unique features of Fanconi anemia complementation group M. Hum. Mol. Genet. 18 (18), 3484&#x2013;3495. 10.1093/hmg/ddp297</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp297</ArticleId><ArticleId IdType="pubmed">19561169</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker S. T., van de Vrugt H. J., Visser J. A., Delzenne-Goette E., van der Wal A., Berns M. A., et al. (2012). Fancf-deficient mice are prone to develop ovarian tumours. J. Pathol. 226 (1), 28&#x2013;39. 10.1002/path.2992</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2992</ArticleId><ArticleId IdType="pubmed">21915857</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun M. M., Overbeek-Wager E. A., Grumbo R. J., Bremnes R. M., Busund L. T., Kilv&#xe6;r T. L., et al. (2016). The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung CancerThe role of tumor-infiltrating lymphocytes in development. Am. Fam. PhysicianJ Thorac. Oncol. 9311 (66), 468789&#x2013;474800. 10.1016/j.jtho.2016.01.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2016.01.015</ArticleId><ArticleId IdType="pubmed">26845192</ArticleId></ArticleIdList></Reference><Reference><Citation>Carazo-Casas C., Gil-Prieto R., Hern&#xe1;ndez-Barrera V., Gil de Miguel &#xc1;. (2022). Trends in hospitalization and death rates among patients with head and neck cancer in Spain, 2009 to 2019. Hum. Vaccin Immunother. 18 (5), 2082192. 10.1080/21645515.2022.2082192</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2082192</ArticleId><ArticleId IdType="pmc">PMC9621082</ArticleId><ArticleId IdType="pubmed">35930449</ArticleId></ArticleIdList></Reference><Reference><Citation>Che R., Zhang J., Nepal M., Han B., Fei P. (2018). Multifaceted Fanconi anemia signaling. Trends Genet. 34 (3), 171&#x2013;183. 10.1016/j.tig.2017.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2017.11.006</ArticleId><ArticleId IdType="pmc">PMC5858900</ArticleId><ArticleId IdType="pubmed">29254745</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Xie J., Fiskesund R., Dong W., Liang X., Lv J., et al. (2018). Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat. Commun. 9 (1), 873. 10.1038/s41467-018-03225-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03225-9</ArticleId><ArticleId IdType="pmc">PMC5830447</ArticleId><ArticleId IdType="pubmed">29491374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J. J., Wang G., Shi W. X., Zhou H. H., Zhao E. F. (2016). Promoter hypermethylation of FANCF and susceptibility and prognosis of epithelial ovarian cancer. Reprod. Sci. 23 (1), 24&#x2013;30. 10.1177/1933719115612136</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1933719115612136</ArticleId><ArticleId IdType="pubmed">26507869</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagerholm R., Sprott K., Heikkinen T., Bartkova J., Heikkil&#xe4; P., Aittom&#xe4;ki K., et al. (2013). Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer. Ann. Oncol. 24 (11), 2780&#x2013;2785. 10.1093/annonc/mdt290</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdt290</ArticleId><ArticleId IdType="pubmed">23897704</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhood B., Najafi M., Mortezaee K. (2019). CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review. J. Cell Physiol. 234 (6), 8509&#x2013;8521. 10.1002/jcp.27782</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27782</ArticleId><ArticleId IdType="pubmed">30520029</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L., Jin F. (2019). Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer. Oncol. Lett. 17 (4), 3687&#x2013;3700. 10.3892/ol.2019.10046</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2019.10046</ArticleId><ArticleId IdType="pmc">PMC6403512</ArticleId><ArticleId IdType="pubmed">30881493</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrall L., Lin K. Y., Roden R. B. S., Hung C. F., Wu T. C. (2021). Cervical cancer immunotherapy: Facts and hopes. Clin. Cancer Res. 27 (18), 4953&#x2013;4973. 10.1158/1078-0432.Ccr-20-2833</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-20-2833</ArticleId><ArticleId IdType="pmc">PMC8448896</ArticleId><ArticleId IdType="pubmed">33888488</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu C., Begum K., Jordan P. W., He Y., Overbeek P. A. (2016a). Dearth and delayed maturation of testicular germ cells in Fanconi anemia E mutant male mice. PLoS One 11 (8), e0159800. 10.1371/journal.pone.0159800</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0159800</ArticleId><ArticleId IdType="pmc">PMC4972424</ArticleId><ArticleId IdType="pubmed">27486799</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu C., Begum K., Overbeek P. A. (2016b). Primary ovarian insufficiency induced by Fanconi anemia E mutation in a mouse model. PLoS One 11 (3), e0144285. 10.1371/journal.pone.0144285</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0144285</ArticleId><ArticleId IdType="pmc">PMC4777492</ArticleId><ArticleId IdType="pubmed">26939056</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman A. M., Sokol E. S., Frampton G. M., Lippman S. M., Kurzrock R. (2019). Microsatellite-stable tumors with high mutational burden benefit from immunotherapy. Cancer Immunol. Res. 7 (10), 1570&#x2013;1573. 10.1158/2326-6066.Cir-19-0149</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.Cir-19-0149</ArticleId><ArticleId IdType="pmc">PMC6774837</ArticleId><ArticleId IdType="pubmed">31405947</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon S. M., Alon N., Buchwald M. (2005). FANCC, FANCE, and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway. J. Biol. Chem. 280 (43), 36118&#x2013;36125. 10.1074/jbc.M507758200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M507758200</ArticleId><ArticleId IdType="pubmed">16127171</ArticleId></ArticleIdList></Reference><Reference><Citation>Green A. K., Feinberg J., Makker V. (2020). A review of immune checkpoint blockade therapy in endometrial cancer. Am. Soc. Clin. Oncol. Educ. Book 40, 1&#x2013;7. 10.1200/edbk_280503</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/edbk_280503</ArticleId><ArticleId IdType="pubmed">32213091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartford S. A., Chittela R., Ding X., Vyas A., Martin B., Burkett S., et al. (2016). Interaction with PALB2 is essential for maintenance of genomic integrity by BRCA2. PLoS Genet. 12 (8), e1006236. 10.1371/journal.pgen.1006236</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1006236</ArticleId><ArticleId IdType="pmc">PMC4973925</ArticleId><ArticleId IdType="pubmed">27490902</ArticleId></ArticleIdList></Reference><Reference><Citation>Houghtaling S., Timmers C., Noll M., Finegold M. J., Jones S. N., Meyn M. S., et al. (2003). Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev. 17 (16), 2021&#x2013;2035. 10.1101/gad.1103403</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1103403</ArticleId><ArticleId IdType="pmc">PMC196256</ArticleId><ArticleId IdType="pubmed">12893777</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardim D. L., Goodman A., de Melo Gagliato D., Kurzrock R. (2021). The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 39 (2), 154&#x2013;173. 10.1016/j.ccell.2020.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7878292</ArticleId><ArticleId IdType="pubmed">33125859</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Wang C., Zhou S. (2020). Targeting tumor microenvironment in ovarian cancer: Premise and promise. Biochim. Biophys. Acta Rev. Cancer 1873 (2), 188361. 10.1016/j.bbcan.2020.188361</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2020.188361</ArticleId><ArticleId IdType="pubmed">32234508</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi S. S., Badgwell B. D. (2021). Current treatment and recent progress in gastric cancer. CA Cancer J. Clin. 71 (3), 264&#x2013;279. 10.3322/caac.21657</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21657</ArticleId><ArticleId IdType="pmc">PMC9927927</ArticleId><ArticleId IdType="pubmed">33592120</ArticleId></ArticleIdList></Reference><Reference><Citation>Keir M. E., Butte M. J., Freeman G. J., Sharpe A. H. (2008). PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677&#x2013;704. 10.1146/annurev.immunol.26.021607.090331</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.26.021607.090331</ArticleId><ArticleId IdType="pmc">PMC10637733</ArticleId><ArticleId IdType="pubmed">18173375</ArticleId></ArticleIdList></Reference><Reference><Citation>Kottemann M. C., Smogorzewska A. (2013). Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 493 (7432), 356&#x2013;363. 10.1038/nature11863</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11863</ArticleId><ArticleId IdType="pmc">PMC3700363</ArticleId><ArticleId IdType="pubmed">23325218</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutler D. I., Auerbach A. D., Satagopan J., Giampietro P. F., Batish S. D., Huvos A. G., et al. (2003a). High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch. Otolaryngol. Head. Neck Surg. 129 (1), 106&#x2013;112. 10.1001/archotol.129.1.106</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archotol.129.1.106</ArticleId><ArticleId IdType="pubmed">12525204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutler D. I., Singh B., Satagopan J., Batish S. D., Berwick M., Giampietro P. F., et al. (2003b). A 20-year perspective on the international Fanconi anemia registry (IFAR). Blood 101 (4), 1249&#x2013;1256. 10.1182/blood-2002-07-2170</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2002-07-2170</ArticleId><ArticleId IdType="pubmed">12393516</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee R. H., Kang H., Yom S. S., Smogorzewska A., Johnson D. E., Grandis J. R. (2021). Treatment of Fanconi anemia-associated head and neck cancer: Opportunities to improve outcomes. Clin. Cancer Res. 27 (19), 5168&#x2013;5187. 10.1158/1078-0432.Ccr-21-1259</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-21-1259</ArticleId><ArticleId IdType="pmc">PMC8626541</ArticleId><ArticleId IdType="pubmed">34045293</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W. Q., Hu N., Hyland P. L., Gao Y., Wang Z. M., Yu K., et al. (2013). Genetic variants in DNA repair pathway genes and risk of esophageal squamous cell carcinoma and gastric adenocarcinoma in a Chinese population. Carcinogenesis 34 (7), 1536&#x2013;1542. 10.1093/carcin/bgt094</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgt094</ArticleId><ArticleId IdType="pmc">PMC3697889</ArticleId><ArticleId IdType="pubmed">23504502</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Liu X., Han X. (2021). FANCI may serve as a prognostic biomarker for cervical cancer: A systematic review and meta-analysis. Med. Baltim. 100 (51), e27690. 10.1097/md.0000000000027690</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/md.0000000000027690</ArticleId><ArticleId IdType="pmc">PMC8702066</ArticleId><ArticleId IdType="pubmed">34941027</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowy D. R., Gillison M. L. (2003). A new link between Fanconi anemia and human papillomavirus-associated malignancies. J. Natl. Cancer Inst. 95 (22), 1648&#x2013;1650. 10.1093/jnci/djg125</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djg125</ArticleId><ArticleId IdType="pubmed">14625250</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Hartford S. A., Zeng R., Southard T. L., Shima N., Schimenti J. C. (2014). Hypersensitivity of primordial germ cells to compromised replication-associated DNA repair involves ATM-p53-p21 signaling. PLoS Genet. 10 (7), e1004471. 10.1371/journal.pgen.1004471</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004471</ArticleId><ArticleId IdType="pmc">PMC4091704</ArticleId><ArticleId IdType="pubmed">25010009</ArticleId></ArticleIdList></Reference><Reference><Citation>Malherbe K. (2021). Tumor microenvironment and the role of artificial intelligence in breast cancer detection and prognosis. Am. J. Pathol. 191 (8), 1364&#x2013;1373. 10.1016/j.ajpath.2021.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2021.01.014</ArticleId><ArticleId IdType="pubmed">33639101</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao H., Ren Q., Li H., Zeng M., Chen D., Xu C., et al. (2022). Comprehensive analysis of the autophagy-dependent ferroptosis-related gene FANCD2 in lung adenocarcinoma. BMC Cancer 22 (1), 225. 10.1186/s12885-022-09314-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-022-09314-9</ArticleId><ArticleId IdType="pmc">PMC8889748</ArticleId><ArticleId IdType="pubmed">35236309</ArticleId></ArticleIdList></Reference><Reference><Citation>Milletti G., Strocchio L., Pagliara D., Girardi K., Carta R., Mastronuzzi A., et al. (2020). Canonical and noncanonical roles of Fanconi anemia proteins: Implications in cancer predisposition. Cancers (Basel) 12 (9), 2684. 10.3390/cancers12092684</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12092684</ArticleId><ArticleId IdType="pmc">PMC7565043</ArticleId><ArticleId IdType="pubmed">32962238</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo J. L., Liu J. S., Xiao Q., Hong W. X., Yin J. Y., Chen J., et al. (2022). Association of variations in the Fanconi anemia complementation group and prognosis in Non-small cell lung cancer patients with Platinum-based chemotherapy. Gene 825, 146398. 10.1016/j.gene.2022.146398</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2022.146398</ArticleId><ArticleId IdType="pubmed">35306114</ArticleId></ArticleIdList></Reference><Reference><Citation>Moes-Sosnowska J., Rzepecka I. K., Chodzynska J., Dansonka-Mieszkowska A., Szafron L. M., Balabas A., et al. (2019). Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas. Cancer Biol. Ther. 20 (6), 843&#x2013;854. 10.1080/15384047.2019.1579955</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384047.2019.1579955</ArticleId><ArticleId IdType="pmc">PMC6606037</ArticleId><ArticleId IdType="pubmed">30822218</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalepa G., Clapp D. W. (2018). Fanconi anaemia and cancer: An intricate relationship. Nat. Rev. Cancer 18 (3), 168&#x2013;185. 10.1038/nrc.2017.116</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2017.116</ArticleId><ArticleId IdType="pubmed">29376519</ArticleId></ArticleIdList></Reference><Reference><Citation>Nepal M., Che R., Zhang J., Ma C., Fei P. (2017). Fanconi anemia signaling and cancer. Trends Cancer 3 (12), 840&#x2013;856. 10.1016/j.trecan.2017.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trecan.2017.10.005</ArticleId><ArticleId IdType="pmc">PMC5819365</ArticleId><ArticleId IdType="pubmed">29198440</ArticleId></ArticleIdList></Reference><Reference><Citation>Oura K., Morishita A., Tani J., Masaki T. (2021). Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: A review. Int. J. Mol. Sci. 22 (11), 8362. 10.3390/ijms21218362</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218362</ArticleId><ArticleId IdType="pmc">PMC8198390</ArticleId><ArticleId IdType="pubmed">34071550</ArticleId></ArticleIdList></Reference><Reference><Citation>Padella A., Fontana M. C., Marconi G., Fonzi E., Petracci E., Ferrari A., et al. (2021). Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway. Blood Cancer J. 11 (1), 7. 10.1038/s41408-020-00396-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-020-00396-x</ArticleId><ArticleId IdType="pmc">PMC7791026</ArticleId><ArticleId IdType="pubmed">33414401</ArticleId></ArticleIdList></Reference><Reference><Citation>Post C. C. B., Westermann A. M., Bosse T., Creutzberg C. L., Kroep J. R. (2020). PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Crit. Rev. Oncol. Hematol. 152, 102973. 10.1016/j.critrevonc.2020.102973</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2020.102973</ArticleId><ArticleId IdType="pubmed">32497971</ArticleId></ArticleIdList></Reference><Reference><Citation>Preissner S. H., Nahles S., Preissner S., Heiland M., Koerdt S. (2022). Influence of sex on survival rates of HPV-positive oropharyngeal cancers. Front. Oncol. 12, 917890. 10.3389/fonc.2022.917890</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2022.917890</ArticleId><ArticleId IdType="pmc">PMC9472547</ArticleId><ArticleId IdType="pubmed">36119465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren B., Cui M., Yang G., Wang H., Feng M., You L., et al. (2018). Tumor microenvironment participates in metastasis of pancreatic cancer. Mol. Cancer 17 (1), 108. 10.1186/s12943-018-0858-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-018-0858-1</ArticleId><ArticleId IdType="pmc">PMC6065152</ArticleId><ArticleId IdType="pubmed">30060755</ArticleId></ArticleIdList></Reference><Reference><Citation>Ries L. A. (1993). Ovarian cancer. Survival and treatment differences by age. Cancer 71 (2), 524&#x2013;529. 10.1002/cncr.2820710206</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.2820710206</ArticleId><ArticleId IdType="pubmed">8420672</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg P. S., Greene M. H., Alter B. P. (2003). Cancer incidence in persons with Fanconi anemia. Blood 101 (3), 822&#x2013;826. 10.1182/blood-2002-05-1498</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2002-05-1498</ArticleId><ArticleId IdType="pubmed">12393424</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher T. N., Schreiber R. D. (2015). Neoantigens in cancer immunotherapy. Science 348 (6230), 69&#x2013;74. 10.1126/science.aaa4971</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa4971</ArticleId><ArticleId IdType="pubmed">25838375</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai X., Van Laethem F., Pobezinsky L., Guinter T., Sharrow S. O., Adams A., et al. (2012). Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood 119 (22), 5155&#x2013;5163. 10.1182/blood-2011-11-388918</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-11-388918</ArticleId><ArticleId IdType="pmc">PMC3369608</ArticleId><ArticleId IdType="pubmed">22403258</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi J., Masuda T., Kitagawa A., Tobo T., Nakano Y., Abe T., et al. (2022). Fanconi anemia complementation group E, a DNA repair-related gene, is a potential marker of poor prognosis in hepatocellular carcinoma. Oncology 100 (2), 101&#x2013;113. 10.1159/000520582</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000520582</ArticleId><ArticleId IdType="pubmed">34724663</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka A., Sakaguchi S. (2017). Regulatory T cells in cancer immunotherapy. Cell Res. 27 (1), 109&#x2013;118. 10.1038/cr.2016.151</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2016.151</ArticleId><ArticleId IdType="pmc">PMC5223231</ArticleId><ArticleId IdType="pubmed">27995907</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsson V., Gibbs D. L., Brown S. D., Wolf D., Bortone D. S., Ou Yang T. H., et al. (2018). The immune landscape of cancer. Immunity 48 (4), 812&#x2013;830. e14. 10.1016/j.immuni.2018.03.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.03.023</ArticleId><ArticleId IdType="pmc">PMC5982584</ArticleId><ArticleId IdType="pubmed">29628290</ArticleId></ArticleIdList></Reference><Reference><Citation>van Velzen M. J. M., Derks S., van Grieken N. C. T., Haj Mohammad N., van Laarhoven H. W. M. (2020). MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treat. Rev. 86, 102024. 10.1016/j.ctrv.2020.102024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2020.102024</ArticleId><ArticleId IdType="pubmed">32388292</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhagen C. V. M., Vossen D. M., Borgmann K., Hageman F., Gr&#xe9;nman R., Verwijs-Janssen M., et al. (2018). Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma. Oncotarget 9 (26), 18198&#x2013;18213. 10.18632/oncotarget.24797</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.24797</ArticleId><ArticleId IdType="pmc">PMC5915066</ArticleId><ArticleId IdType="pubmed">29719599</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldman A. D., Fritz J. M., Lenardo M. J. (2020). A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20 (11), 651&#x2013;668. 10.1038/s41577-020-0306-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0306-5</ArticleId><ArticleId IdType="pmc">PMC7238960</ArticleId><ArticleId IdType="pubmed">32433532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan C., Keany M. P., Dong H., Al-Alem L. F., Pandya U. M., Lazo S., et al. (2021). Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high-grade serous ovarian cancer. Cancer Res. 81 (1), 158&#x2013;173. 10.1158/0008-5472.Can-20-1674</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.Can-20-1674</ArticleId><ArticleId IdType="pmc">PMC7878408</ArticleId><ArticleId IdType="pubmed">33158814</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Ding B., Cui M., Yan W., Xia Q., Meng D., et al. (2021). Fanconi anemia pathway genes advance cervical cancer via immune regulation and cell adhesion. Front. Cell Dev. Biol. 9, 734794. 10.3389/fcell.2021.734794</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.734794</ArticleId><ArticleId IdType="pmc">PMC8634638</ArticleId><ArticleId IdType="pubmed">34869316</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei S. C., Levine J. H., Cogdill A. P., Zhao Y., Anang N. A. S., Andrews M. C., et al. (2017). Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170 (6), 1120&#x2013;1133. e17. 10.1016/j.cell.2017.07.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.024</ArticleId><ArticleId IdType="pmc">PMC5591072</ArticleId><ArticleId IdType="pubmed">28803728</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong J. C., Alon N., McKerlie C., Huang J. R., Meyn M. S., Buchwald M. (2003). Targeted disruption of exons 1 to 6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia. Hum. Mol. Genet. 12 (16), 2063&#x2013;2076. 10.1093/hmg/ddg219</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddg219</ArticleId><ArticleId IdType="pubmed">12913077</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C., Zang Y., Zhao Y., Cui W., Zhang H., Zhu Y., et al. (2021a). Comprehensive pan-cancer analysis confirmed that ATG5 promoted the maintenance of tumor metabolism and the occurrence of tumor immune escape. Front. Oncol. 11, 652211. 10.3389/fonc.2021.652211</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.652211</ArticleId><ArticleId IdType="pmc">PMC8027486</ArticleId><ArticleId IdType="pubmed">33842365</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Xiong C., Chen Y., Zhang C., Bai D. (2021b). Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma. Bioengineered 12 (1), 2664&#x2013;2675. 10.1080/21655979.2021.1938470</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2021.1938470</ArticleId><ArticleId IdType="pmc">PMC8806544</ArticleId><ArticleId IdType="pubmed">34115569</ArticleId></ArticleIdList></Reference><Reference><Citation>Yancik R. (1993). Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71 (2), 517&#x2013;523. 10.1002/cncr.2820710205</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.2820710205</ArticleId><ArticleId IdType="pubmed">8420671</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarchoan M., Hopkins A., Jaffee E. M. (2017). Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377 (25), 2500&#x2013;2501. 10.1056/NEJMc1713444</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1713444</ArticleId><ArticleId IdType="pmc">PMC6549688</ArticleId><ArticleId IdType="pubmed">29262275</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z., Zhang J., Zhang Q., Wei S., Shi R., Zhao R., et al. (2022). Single-cell sequencing reveals the heterogeneity and intratumoral crosstalk in human endometrial cancer. Cell Prolif. 55 (6), e13249. 10.1111/cpr.13249</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cpr.13249</ArticleId><ArticleId IdType="pmc">PMC9201371</ArticleId><ArticleId IdType="pubmed">35560676</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Wang D., Chen X., Ji L., Yu M., Guo M., et al. (2022). Upregulation of ferroptosis-related Fanconi anemia group D2 is a poor prognostic factor and an indicator of tumor immune cell infiltration in lung adenocarcinoma. Front. Genet. 13, 825685. 10.3389/fgene.2022.825685</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2022.825685</ArticleId><ArticleId IdType="pmc">PMC9130730</ArticleId><ArticleId IdType="pubmed">35646059</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36589225</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-889X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in molecular biosciences</Title><ISOAbbreviation>Front Mol Biosci</ISOAbbreviation></Journal><ArticleTitle>CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study.</ArticleTitle><Pagination><StartPage>983410</StartPage><MedlinePgn>983410</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">983410</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmolb.2022.983410</ELocationID><Abstract><AbstractText><b>Background:</b> CKLF like MARVEL transmembrane domain containing 6 (CMTM6) is an important programmed cell death 1 ligand 1 regulator (PD-L1). CMTM6 was reported as an important regulator of PD-L1 by promoting PD-L1 expression in tumor cells against T cells. However, the function of CMTM6 in cervical cancer is not well characterized. In addition, the role of CMTM6 in the induction of epithelial-mesenchymal transition (EMT) in the context of cervical cancer is unknown. <b>Methods:</b> In this study, we evaluated the role of CMTM6, including gene expression analysis, miRNA target regulation, and methylation characteristic, using multiple bioinformatics tools based on The Cancer Genome Atlas (TCGA) database. The expression of CMTM6 in cervical cancer tissues and non-cancerous adjacent tissues was assessed using immunohistochemistry. <i>In vitro</i> and <i>in vivo</i> function experiments were performed to explore the effects of CMTM6 on growth and metastasis of cervical cancer. <b>Results:</b> Human cervical cancer tissues showed higher expression of CMTM6 than the adjacent non-cancerous tissues. <i>In vitro</i> assays showed that CMTM6 promoted cervical cancer cell invasion, migration, proliferation, and epithelial-mesenchymal transition <i>via</i> activation of mitogen-activated protein kinase (MAPK) c-jun N-terminal kinase (JNK)/p38 signaling pathway. We identified transcription factors (TFs), miRNAs, and immune cells that may interact with CMTM6. <b>Conclusion:</b> These results indicate that CMTM6 is a potential therapeutic target in the context of cervical cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Huang, Liu, Liu, Hu, Wang, Ren, Huang, Yuan, Liu and Li.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xiaoting</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chunshan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Jijie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Baiyao</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Anbang</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xiaona</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>TCM Hospital of Liwan District, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Yawei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jinquan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mingyi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Mol Biosci</MedlineTA><NlmUniqueID>101653173</NlmUniqueID><ISSNLinking>2296-889X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Front Mol Biosci. 2024 Jul 23;11:1452740. doi: 10.3389/fmolb.2024.1452740</RefSource><PMID Version="1">39108342</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CMTM6</Keyword><Keyword MajorTopicYN="N">MAPK signaling</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">migration</Keyword><Keyword MajorTopicYN="N">proliferation</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>2</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36589225</ArticleId><ArticleId IdType="pmc">PMC9798917</ArticleId><ArticleId IdType="doi">10.3389/fmolb.2022.983410</ArticleId><ArticleId IdType="pii">983410</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Burr M. L., Sparbier C. E., Chan Y. C., Williamson J. C., Woods K., Beavis P. A., et al. (2017). CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 549, 101&#x2013;105. 10.1038/nature23643</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23643</ArticleId><ArticleId IdType="pmc">PMC5706633</ArticleId><ArticleId IdType="pubmed">28813417</ArticleId></ArticleIdList></Reference><Reference><Citation>Caverly T. J., Hayward R. A., Reamer E., Zikmund-Fisher B. J., Connochie D., Heisler M., et al. (2016). Presentation of benefits and harms in US cancer screening and prevention guidelines: Systematic review. J. Natl. Cancer Inst. 108, djv436. 10.1093/jnci/djv436</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djv436</ArticleId><ArticleId IdType="pmc">PMC5009951</ArticleId><ArticleId IdType="pubmed">26917630</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel D., Meyer-Morse N., Bergsland E. K., Dehne K., Coussens L. M., Hanahan D. (2003). Immune enhancement of skin carcinogenesis by CD4+ T cells. J. Exp. Med. 197, 1017&#x2013;1028. 10.1084/jem.20021047</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20021047</ArticleId><ArticleId IdType="pmc">PMC2193878</ArticleId><ArticleId IdType="pubmed">12695493</ArticleId></ArticleIdList></Reference><Reference><Citation>Efimova I., Catanzaro E., Van Der Meeren L., Turubanova V. D., Hammad H., Mishchenko T. A., et al. (2020). Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J. Immunother. Cancer 8, e001369. 10.1136/jitc-2020-001369</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-001369</ArticleId><ArticleId IdType="pmc">PMC7668384</ArticleId><ArticleId IdType="pubmed">33188036</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Chagollan M., Jave-Suarez L. F., Haramati J., Bueno-Topete M. R., Aguilar-Lemarroy A., Estrada-Chavez C., et al. (2015). An approach to the immunophenotypic features of circulating CD4&#x207a;NKG2D&#x207a; T cells in invasive cervical carcinoma. J. Biomed. Sci. 22, 91. 10.1186/s12929-015-0190-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-015-0190-7</ArticleId><ArticleId IdType="pmc">PMC4615321</ArticleId><ArticleId IdType="pubmed">26486970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge Y.-Y., Duan H.-J., Deng X.-L. (2021). Possible effects of chemokine-like factor-like MARVEL transmembrane domain-containing family on antiphospholipid syndrome. Chin. Med. J. 134, 1661&#x2013;1668. 10.1097/CM9.0000000000001449</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000001449</ArticleId><ArticleId IdType="pmc">PMC8318642</ArticleId><ArticleId IdType="pubmed">33813507</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong J., Fan H., Deng J., Zhang Q. (2020). LncRNA HAND2&#x2010;AS1 represses cervical cancer progression by interaction with transcription factor E2F4 at the promoter of C16orf74. J. Cell. Mol. Med. 24, 6015&#x2013;6027. 10.1111/jcmm.15117</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15117</ArticleId><ArticleId IdType="pmc">PMC7294116</ArticleId><ArticleId IdType="pubmed">32314545</ArticleId></ArticleIdList></Reference><Reference><Citation>Haile Z. M., Nagpala-De Guzman E. G., Moretto M., Sonego P., Engelen K., Zoli L., et al. (2019). Transcriptome profiles of strawberry (Fragaria vesca) fruit interacting with Botrytis cinerea at different ripening stages. Front. Plant Sci. 10, 1131. 10.3389/fpls.2019.01131</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpls.2019.01131</ArticleId><ArticleId IdType="pmc">PMC6759788</ArticleId><ArticleId IdType="pubmed">31620156</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou X., He S., Zhang D., Yang C., Shi Y., Zhang K. (2020). Expression and clinical significance of CMTM6 in nonsmall cell lung cancer. DNA Cell Biol. 39, 2265&#x2013;2271. 10.1089/dna.2020.5564</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dna.2020.5564</ArticleId><ArticleId IdType="pubmed">33090010</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G., Wang X., Zhou Y., Zou C., Wang L., Wang W., et al. (2021). TMTP1-Modified, tumor microenvironment responsive nanoparticles Co-deliver cisplatin and paclitaxel prodrugs for effective cervical cancer therapy. Int. J. Nanomedicine 16, 4087&#x2013;4104. 10.2147/IJN.S298252</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S298252</ArticleId><ArticleId IdType="pmc">PMC8214535</ArticleId><ArticleId IdType="pubmed">34163161</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M. H., Nam A. R., Park J. E., Bang J. H., Bang Y. J., Oh D. Y. (2020). Therapeutic Co-targeting of WEE1 and ATM downregulates PD-L1 expression in pancreatic cancer. Cancer Res. Treat. 52, 149&#x2013;166. 10.4143/crt.2019.183</Citation><ArticleIdList><ArticleId IdType="doi">10.4143/crt.2019.183</ArticleId><ArticleId IdType="pmc">PMC6962488</ArticleId><ArticleId IdType="pubmed">31291716</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A., Das B. C., Abiha U., Sisodiya S., Chikara A., Nazir S. U., et al. (2021). Insights into the role of complement regulatory proteins in HPV mediated cervical carcinogenesis. Semin. Cancer Biol. S1044-579X, 583&#x2013;589. 10.1016/j.semcancer.2021.05.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2021.05.031</ArticleId><ArticleId IdType="pubmed">34087416</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight J. S., Meng H., Coit P., Yalavarthi S., Sule G., Gandhi A. A., et al. (2017). Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. JCI insight 2, e93897. 10.1172/jci.insight.93897</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.93897</ArticleId><ArticleId IdType="pmc">PMC5621930</ArticleId><ArticleId IdType="pubmed">28931754</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x141;aniewski P., Ilhan Z. E., Herbst-Kralovetz M. M. (2020). The microbiome and gynaecological cancer development, prevention and therapy. Nat. Rev. Urol. 17, 232&#x2013;250. 10.1038/s41585-020-0286-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41585-020-0286-z</ArticleId><ArticleId IdType="pmc">PMC9977514</ArticleId><ArticleId IdType="pubmed">32071434</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q.-q., Zhang L., Wan H.-y., Liu M., Li X., Tang H. (2015). CREB1-driven expression of miR-320a promotes mitophagy by down-regulating VDAC1 expression during serum starvation in cervical cancer cells. Oncotarget 6, 34924&#x2013;34940. 10.18632/oncotarget.5318</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.5318</ArticleId><ArticleId IdType="pmc">PMC4741499</ArticleId><ArticleId IdType="pubmed">26472185</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Zou J., Wang M., Ding X., Chepelev I., Zhou X., et al. (2014). Critical role of histone demethylase Jmjd3 in the regulation of CD4+ T-cell differentiation. Nat. Commun. 5, 5780. 10.1038/ncomms6780</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6780</ArticleId><ArticleId IdType="pmc">PMC4274750</ArticleId><ArticleId IdType="pubmed">25531312</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Li X., Zhang H., Zhang M., Wei Y. (2021). HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer. Oncogene 40, 2230&#x2013;2242. 10.1038/s41388-021-01689-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-021-01689-6</ArticleId><ArticleId IdType="pmc">PMC7994200</ArticleId><ArticleId IdType="pubmed">33649535</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezzadra R., Sun C., Jae L. T., Gomez-Eerland R., De Vries E., Wu W., et al. (2017). Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549, 106&#x2013;110. 10.1038/nature23669</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23669</ArticleId><ArticleId IdType="pmc">PMC6333292</ArticleId><ArticleId IdType="pubmed">28813410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosele F., Remon J., Mateo J., Westphalen C. B., Barlesi F., Lolkema M. P., et al. (2020). Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO precision medicine working group. Ann. Oncol. 31, 1491&#x2013;1505. 10.1016/j.annonc.2020.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.07.014</ArticleId><ArticleId IdType="pubmed">32853681</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen Q. P., Deng T. Z., Witherden D. A., Goldrath A. W. (2019). Origins of CD4(+) circulating and tissue-resident memory T-cells. Immunology 157, 3&#x2013;12. 10.1111/imm.13059</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13059</ArticleId><ArticleId IdType="pmc">PMC6459775</ArticleId><ArticleId IdType="pubmed">30897205</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang X., Wang S. S., Zhang M., Jiang J., Fan H. Y., Wu J. S., et al. (2021). OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway. Cancer Immunol. Immunother. 70, 1015&#x2013;1029. 10.1007/s00262-020-02741-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-020-02741-2</ArticleId><ArticleId IdType="pmc">PMC10991130</ArticleId><ArticleId IdType="pubmed">33104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi R. A., Nepal K., Cetinbas M., Sadreyev R. I., Luster A. D. (2020). Distinct functions of tissue-resident and circulating memory Th2 cells in allergic airway disease. J. Exp. Med. 217, e20190865. 10.1084/jem.20190865</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190865</ArticleId><ArticleId IdType="pmc">PMC7478729</ArticleId><ArticleId IdType="pubmed">32579670</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajitha B., Malla R. R., Vadde R., Kasa P., Prasad G. L. V., Farran B., et al. (2021). Horizons of nanotechnology applications in female specific cancers. Semin. Cancer Biol. 69, 376&#x2013;390. 10.1016/j.semcancer.2019.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2019.07.005</ArticleId><ArticleId IdType="pubmed">31301361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricketts T. D., Prieto-Dominguez N., Gowda P. S., Ubil E. (2021). Mechanisms of macrophage plasticity in the tumor environment: Manipulating activation state to improve outcomes. Front. Immunol. 1565, 642285. 10.3389/fimmu.2021.642285</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.642285</ArticleId><ArticleId IdType="pmc">PMC8139576</ArticleId><ArticleId IdType="pubmed">34025653</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbah M., Emami S., Redeuilh G., Julien S., Pr&#xe9;vost G., Zimber A., et al. (2008). Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug resist. updat. 11, 123&#x2013;151. 10.1016/j.drup.2008.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drup.2008.07.001</ArticleId><ArticleId IdType="pubmed">18718806</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan R., Basu P., Kaur P., Bhaskar R., Singh G. B., Denzongpa P., et al. (2019). Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts. Lancet. Oncol. 20, e637&#x2013;e644. 10.1016/s1470-2045(19)30531-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1470-2045(19)30531-5</ArticleId><ArticleId IdType="pubmed">31674322</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y., Wang Z., Jiang J., Piao Y., Li L., Xu C., et al. (2020). DEK-targeting aptamer DTA-64 attenuates bronchial EMT-mediated airway remodelling by suppressing TGF-&#x3b2;1/Smad, MAPK and PI3K signalling pathway in asthma. J. Cell. Mol. Med. 24, 13739&#x2013;13750. 10.1111/jcmm.15942</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15942</ArticleId><ArticleId IdType="pmc">PMC7754001</ArticleId><ArticleId IdType="pubmed">33124760</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava S., Koay E. J., Borowsky A. D., De Marzo A. M., Ghosh S., Wagner P. D., et al. (2019). Cancer overdiagnosis: A biological challenge and clinical dilemma. Nat. Rev. Cancer 19, 349&#x2013;358. 10.1038/s41568-019-0142-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-019-0142-8</ArticleId><ArticleId IdType="pmc">PMC8819710</ArticleId><ArticleId IdType="pubmed">31024081</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo S. J., Kim S. T., Costa G. L., Zhang X., Fathman C. G., Glimcher L. H. (2000). A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100, 655&#x2013;669. 10.1016/s0092-8674(00)80702-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(00)80702-3</ArticleId><ArticleId IdType="pubmed">10761931</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Sun X., Cheng G., Ji E., Yang S., Feng J., et al. (2021). The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer. Ann. Transl. Med. 9, 131. 10.21037/atm-20-7616</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-20-7616</ArticleId><ArticleId IdType="pmc">PMC7867887</ArticleId><ArticleId IdType="pubmed">33569433</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Zhang L., Zhao L., Zhou R., Ding Y., Li G., et al. (2017). LASP2 suppresses colorectal cancer progression through JNK/p38 MAPK pathway meditated epithelial-mesenchymal transition. Cell Commun. Signal. 15, 21. 10.1186/s12964-017-0179-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-017-0179-9</ArticleId><ArticleId IdType="pmc">PMC5469134</ArticleId><ArticleId IdType="pubmed">28606091</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Liu S., Guan Y., Ding J., Ma C., Xie Z. (2021). Vaginal drug delivery approaches for localized management of cervical cancer. Adv. Drug Deliv. Rev. 174, 114&#x2013;126. 10.1016/j.addr.2021.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2021.04.009</ArticleId><ArticleId IdType="pubmed">33857555</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T.-I., Huang R.-L., Su P.-H., Mao S.-P., Wu C.-H., Lai H.-C. (2019). Ovarian cancer detection by DNA methylation in cervical scrapings. Clin. Epigenetics 11, 166&#x2013;212. 10.1186/s13148-019-0773-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13148-019-0773-3</ArticleId><ArticleId IdType="pmc">PMC6881994</ArticleId><ArticleId IdType="pubmed">31775891</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Lan X., Hu W., Zhang W., Lai X., Xu S., et al. (2021). CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer. Cancer Immunol. Immunother. 70, 3235&#x2013;3248. 10.1007/s00262-021-02931-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-021-02931-6</ArticleId><ArticleId IdType="pmc">PMC8505364</ArticleId><ArticleId IdType="pubmed">33818637</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao M., Hasmim M., Lequeux A., Moer K. V., Tan T. Z., Gilles C., et al. (2021). Epithelial to mesenchymal transition regulates surface PD-L1 via CMTM6 and CMTM7 induction in breast cancer. Cancers (Basel) 13, 1165. 10.3390/cancers13051165</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13051165</ArticleId><ArticleId IdType="pmc">PMC7963182</ArticleId><ArticleId IdType="pubmed">33803139</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Jiang Y., Ren X., Feng D., Zhang L., He D., et al. (2020). FOXA1-induced circOSBPL10 potentiates cervical cancer cell proliferation and migration through miR-1179/UBE2Q1 axis. Cancer Cell Int. 20, 389&#x2013;412. 10.1186/s12935-020-01360-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-020-01360-2</ArticleId><ArticleId IdType="pmc">PMC7422615</ArticleId><ArticleId IdType="pubmed">32831649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanotelli M. R., Zhang J., Reinhart-King C. A. (2021). Mechanoresponsive metabolism in cancer cell migration and metastasis. Cell Metab. 33, 1307&#x2013;1321. 10.1016/j.cmet.2021.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.04.002</ArticleId><ArticleId IdType="pmc">PMC9015673</ArticleId><ArticleId IdType="pubmed">33915111</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Xu Y., Ye W., Jiang J., Wu C. (2020). Circular RNA S-7 promotes ovarian cancer EMT via sponging miR-641 to up-regulate ZEB1 and MDM2. Biosci. Rep. 40, BSR20200825. 10.1042/bsr20200825</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bsr20200825</ArticleId><ArticleId IdType="pmc">PMC7383824</ArticleId><ArticleId IdType="pubmed">32667627</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Zhang S. (2020). Downregulation of circRNA_0000285 suppresses cervical cancer development by regulating miR197-3p&#x2013;ELK1 Axis. Cancer Manag. Res. 12, 8663&#x2013;8674. 10.2147/CMAR.S253174</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CMAR.S253174</ArticleId><ArticleId IdType="pmc">PMC7509321</ArticleId><ArticleId IdType="pubmed">32982457</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H., Wang W., Zhao Q., Hu G., Deng K., Liu Y. (2016). BCL3 exerts an oncogenic function by regulating STAT3 in human cervical cancer. Onco. Targets. Ther. 9, 6619&#x2013;6629. 10.2147/OTT.S118184</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S118184</ArticleId><ArticleId IdType="pmc">PMC5087794</ArticleId><ArticleId IdType="pubmed">27822067</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y., Wang C., Song A., Jiang F., Zhou J., Li G., et al. (2020). CMTM6 promotes cell proliferation and invasion in oral squamous cell carcinoma by interacting with NRP1. Am. J. Cancer Res. 10, 1691&#x2013;1709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7339282</ArticleId><ArticleId IdType="pubmed">32642284</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Zheng Y., Zhang H., Liu Y., Sun H., Zhang P. (2019). Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway. Am. J. Transl. Res. 11, 3862&#x2013;3878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6614631</ArticleId><ArticleId IdType="pubmed">31312395</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36515824</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-4978</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Molecular biology reports</Title><ISOAbbreviation>Mol Biol Rep</ISOAbbreviation></Journal><ArticleTitle>Insulin-induced gene 2 expression is associated with cervical adenocarcinoma malignant behavior.</ArticleTitle><Pagination><StartPage>1553</StartPage><EndPage>1563</EndPage><MedlinePgn>1553-1563</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11033-022-08095-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The incidence of cervical adenocarcinoma (CA) as a malignant tumor has increased over the past few decades due to its low detection rate and malignant biological behaviors. Insulin-induced gene 2 (INSIG2), a membrane protein of the endoplasmic reticulum (ER), plays a crucial role in cancer progression. However, there is little known about the connection between INSIG2 and CA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Human Protein Atlas (HPA) and the Cancer Genome Atlas (TCGA) Cervical Cancer (CESC) data were applied to study the alteration in INSIG2 expression. Biological functions were performed to test the change of malignant behavior. Bioinformatics analysis was conducted to explore the potential affection of INSIG2 in CA progression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our study confirmed that the high INSIG2 expression levels had a poor prognosis. INSIG2-knockdown inhibited the CA cell proliferation, migration, and invasion of CA cells while downregulating the epithelial-mesenchymal transition (EMT)-associated gene expression levels. Moreover, the enrichment analysis of DEGs showed more potential functions of INSIG2 in the CA progression.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We found that INSIG2 knockdown may play a suppressor role in the CA progression, and may provide the potential functional influence in inhibiting of CA development.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Yingchen</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5928-4456</Identifier><AffiliationInfo><Affiliation>Department of Pathology, The Affiliated Jiangning Hospital of Nanjing Medical University, No.169, HuShan Road, 211100, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoxue</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-1158-764X</Identifier><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, No.101, LongMian Road, 211166, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Jin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7014-3531</Identifier><AffiliationInfo><Affiliation>Obstetrics and Gynecology Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No.1111, XianXia Road, 200336, Shanghai, China. m18917683152@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Runjie</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9777-9660</Identifier><AffiliationInfo><Affiliation>Hongqiao International Institute of Medicine,Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No.1111, XianXia Road, 200336, Shanghai, China. zrj9203@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Obstetrics and Gynecology Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No.1111, XianXia Road, 200336, Shanghai, China. zrj9203@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, School of Pharmacy, Fudan University, No.826, ZhangHeng Road, 201203, Shanghai, China. zrj9203@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81903006</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Mol Biol Rep</MedlineTA><NlmUniqueID>0403234</NlmUniqueID><ISSNLinking>0301-4851</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical adenocarcinoma</Keyword><Keyword MajorTopicYN="N">INSIG2</Keyword><Keyword MajorTopicYN="N">Malignant behavior</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>14</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36515824</ArticleId><ArticleId IdType="doi">10.1007/s11033-022-08095-5</ArticleId><ArticleId IdType="pii">10.1007/s11033-022-08095-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68:394&#x2013;424. https://doi.org/10.3322/caac.21492</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen PA, Jhingran A, Oaknin A, Denny L (2019) Cervical cancer. Lancet 393:169&#x2013;182. https://doi.org/10.1016/S0140-6736(18)32470-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32470-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, Hakama M, Weiderpass E (2005) Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer epidemiology, biomarkers &amp; prevention: a publication of the American Association for Cancer Research. cosponsored by the American Society of Preventive Oncology 14:2191&#x2013;2199. https://doi.org/10.1158/1055-9965.EPI-05-0231</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-05-0231</ArticleId></ArticleIdList></Reference><Reference><Citation>Loureiro J, Oliva E (2014) The spectrum of cervical glandular neoplasia and issues in differential diagnosis. Arch Pathol Lab Med 138:453&#x2013;483. https://doi.org/10.5858/arpa.2012-0493-RA</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/arpa.2012-0493-RA</ArticleId></ArticleIdList></Reference><Reference><Citation>Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC, Soslow RA, Park KJ (2015) Gastric-type Endocervical Adenocarcinoma: An Aggressive Tumor With Unusual Metastatic Patterns and Poor Prognosis. Am J Surg Pathol 39:1449&#x2013;1457. https://doi.org/10.1097/PAS.0000000000000532</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PAS.0000000000000532</ArticleId></ArticleIdList></Reference><Reference><Citation>Park KJ (2020) Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification. Histopathology 76:112&#x2013;127. https://doi.org/10.1111/his.13995</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/his.13995</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimada M, Kigawa J, Nishimura R, Yamaguchi S, Kuzuya K, Nakanishi T, Suzuki M, Kita T, Iwasaka T, Terakawa N (2006) Ovarian metastasis in carcinoma of the uterine cervix. Gynecol Oncol 101:234&#x2013;237. https://doi.org/10.1016/j.ygyno.2005.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2005.10.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KB, Lee JM, Park CY, Lee KB, Cho HY, Ha SY (2006) What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study. Int J Gynecol cancer: official J Int Gynecol Cancer Soc 16:1569&#x2013;1573. https://doi.org/10.1111/j.1525-1438.2006.00628.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1438.2006.00628.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JH, Duan H, Yu XB, Zhao HW, Chen X, Li P, Li ZQ, Li BX, Pan LY, Yan X et al (2021) Clinical features and prognostic factors of cervical villoglandular adenocarcinoma. Int J Gynecol cancer: official J Int Gynecol Cancer Soc 31:512&#x2013;517. https://doi.org/10.1136/ijgc-2020-002044</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ijgc-2020-002044</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Feng Q, Yu H, Zhou X, Shan C, Zhang Q, Liu S (2020) HBXIP: a potential prognosis biomarker of colorectal cancer which promotes invasion and migration via epithelial-mesenchymal transition. Life Sci 245:117354. https://doi.org/10.1016/j.lfs.2020.117354</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117354</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong L, Ding H, Li Y, Xue D, Li Z, Liu Y, Zhang T, Zhou J, Wang P (2019) TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer. Int J Biol Macromol 121:200&#x2013;206. https://doi.org/10.1016/j.ijbiomac.2018.09.168</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2018.09.168</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YP, Chen WD, Li WN, Zhang M (2019) Overexpression of FNDC1 Relates to Poor Prognosis and Its Knockdown Impairs Cell Invasion and Migration in Gastric Cancer. Technol Cancer Res Treat 18:1533033819869928. https://doi.org/10.1177/1533033819869928</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533033819869928</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Q, Chen C, Liu C, Zhang B, Ma Y, Zhang H, Huang W, Wang C (2021) Linc8087 predicts favorable prognosis and inhibits cell migration and invasion in NSCLC. Pathol Res Pract 225:153569. https://doi.org/10.1016/j.prp.2021.153569</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prp.2021.153569</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Y, Hu R, Zhang Y, Luo W (2020) MicroRNA-4317 predicts the prognosis of breast cancer and inhibits tumor cell proliferation, migration, and invasion. Clin experimental Med 20:417&#x2013;425. https://doi.org/10.1007/s10238-020-00625-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-020-00625-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Li J, You L, Dai M, Zhao Y (2020) High Expression of MUC15 Is Correlated with Poor Prognosis of Pancreatic Cancer and Promotes Migration, Invasion, and Chemo-Resistance In Vitro. Med Sci monitor: Int Med J experimental Clin Res 26:e926432. https://doi.org/10.12659/MSM.926432</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.926432</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal V (2018) Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev Pathol 13:395&#x2013;412. https://doi.org/10.1146/annurev-pathol-020117-043854</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathol-020117-043854</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S, Wang X, Ding J, Yang H, Xie Y (2021) Increased ATG5 Expression Predicts Poor Prognosis and Promotes EMT in Cervical Carcinoma. Front cell Dev biology 9:757184. https://doi.org/10.3389/fcell.2021.757184</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.757184</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Bai X, Jiang G, Jin S, Wang Q, Wang A, Peng R, Ke A, Bai D (2021) GIT1 overexpression promotes epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma. Bioengineered 12:30&#x2013;43. https://doi.org/10.1080/21655979.2020.1855914</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2020.1855914</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Xiang Z, Zou L, Chen X, Peng X, Xu D (2021) APMAP Promotes Epithelial-Mesenchymal Transition and Metastasis of Cervical Cancer Cells by Activating the Wnt/beta-catenin Pathway. J Cancer 12:6265&#x2013;6273. https://doi.org/10.7150/jca.59595</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.59595</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Zhang G, Sun Q, Wu Z, Shi W, Yang B, Li Y (2016) Insulin-induced gene 2 expression correlates with colorectal cancer metastasis and disease outcome. IUBMB Life 68:65&#x2013;71. https://doi.org/10.1002/iub.1461</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.1461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayashima T, Nakata K, Ohuchida K, Ueda J, Shirahane K, Fujita H, Cui L, Mizumoto K, Tanaka M (2011) Insig2 is overexpressed in pancreatic cancer and its expression is induced by hypoxia. Cancer Sci 102:1137&#x2013;1143. https://doi.org/10.1111/j.1349-7006.2011.01936.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2011.01936.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu N, Zhang M, Lu L, Liu YZ, Liu XD, Zhang HH (2021) Insulin-Induced Gene 2 Expression Is Associated with Breast Cancer Metastasis. Am J Pathol 191:385&#x2013;395. https://doi.org/10.1016/j.ajpath.2020.11.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2020.11.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakir B, Chiarella AM, Pitarresi JR, Rustgi AK (2020) EMT, MET, Plasticity, and Tumor Metastasis. Trends Cell Biol 30:764&#x2013;776. https://doi.org/10.1016/j.tcb.2020.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2020.07.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaffer CL, San Juan BP, Lim E, Weinberg RA (2016) EMT, cell plasticity and metastasis. Cancer Metastasis Rev 35:645&#x2013;654. https://doi.org/10.1007/s10555-016-9648-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10555-016-9648-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Wang M, Li X, Xie Y, Xia X, Tian J, Zhang K, Tang A (2018) Wnt signaling in cervical cancer? J Cancer 9:1277&#x2013;1286. https://doi.org/10.7150/jca.22005</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.22005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist D, Kvarnbrink S, Henriksson R, Hedman H (2014) LRIG and cancer prognosis. Acta Oncol 53:1135&#x2013;1142. https://doi.org/10.3109/0284186X.2014.953258</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/0284186X.2014.953258</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomao F, Santangelo G, Musacchio L, Di Donato V, Fischetti M, Giancotti A, Perniola G, Petrella MC, Monti M, Palaia I et al (2020) Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition? J Cell Physiol 235:5050&#x2013;5058. https://doi.org/10.1002/jcp.29440</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.29440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayen A, Jimenez Martinez Y, Boulaiz H (2020) Targeted Gene Delivery Therapies for Cervical Cancer. Cancers (Basel) 12. https://doi.org/10.3390/cancers12051301</Citation></Reference><Reference><Citation>Stolnicu S, Hoang L, Soslow RA (2019) Recent advances in invasive adenocarcinoma of the cervix. Virchows Archiv: an international journal of pathology 475:537&#x2013;549. https://doi.org/10.1007/s00428-019-02601-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00428-019-02601-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JS, Wang HJ, Qian HL (2018) Biological effects of radiation on cancer cells. Military Med Res 5:20. https://doi.org/10.1186/s40779-018-0167-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-018-0167-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Wang H (2015) [Cancer Genome Atlas Pan-cancer Analysis Project]. Zhongguo fei ai za zhi = Chinese. J lung cancer 18:219&#x2013;223. https://doi.org/10.3779/j.issn.1009-3419.2015.04.02</Citation><ArticleIdList><ArticleId IdType="doi">10.3779/j.issn.1009-3419.2015.04.02</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D, Wang Z, Xia Y, Shao F, Xia W, Wei Y, Li X, Qian X, Lee JH, Du L et al (2020) The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. Nature 580:530&#x2013;535. https://doi.org/10.1038/s41586-020-2183-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2183-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Granados-Lopez AJ, Manzanares-Acuna E, Lopez-Hernandez Y, Castaneda-Delgado JE, Fraire-Soto I, Reyes-Estrada CA, Gutierrez-Hernandez R, Lopez JA (2021) UVB Inhibits Proliferation, Cell Cycle and Induces Apoptosis via p53, E2F1 and Microtubules System in Cervical Cancer Cell Lines. Int J Mol Sci 22. https://doi.org/10.3390/ijms22105197</Citation></Reference><Reference><Citation>Zhang W, Xiong Z, Wei T, Li Q, Tan Y, Ling L, Feng X (2018) Nuclear factor 90 promotes angiogenesis by regulating HIF-1alpha/VEGF-A expression through the PI3K/Akt signaling pathway in human cervical cancer. Cell Death Dis 9:276. https://doi.org/10.1038/s41419-018-0334-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0334-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TC, Hung YC, Lin TY, Chang HW, Chiang IP, Chen YY, Chow KC (2011) Human papillomavirus infection and expression of ATPase family AAA domain containing 3A, a novel anti-autophagy factor, in uterine cervical cancer. Int J Mol Med 28:689&#x2013;696. https://doi.org/10.3892/ijmm.2011.743</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2011.743</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong XY, Tang SQ (2010) Insulin-induced gene: a new regulator in lipid metabolism. Peptides 31:2145&#x2013;2150. https://doi.org/10.1016/j.peptides.2010.07.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2010.07.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghow R, Yellaturu C, Deng X, Park EA, Elam MB (2008) SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab 19:65&#x2013;73. https://doi.org/10.1016/j.tem.2007.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2007.10.009</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36381423</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1936-2625</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>10</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>International journal of clinical and experimental pathology</Title><ISOAbbreviation>Int J Clin Exp Pathol</ISOAbbreviation></Journal><ArticleTitle>The lncRNA-miRNA-integrin alpha V ceRNA network can affect the occurrence and prognosis of gastric cancer.</ArticleTitle><Pagination><StartPage>388</StartPage><EndPage>402</EndPage><MedlinePgn>388-402</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to explore the role of integrin alpha V (ITGAV) and the related long noncoding RNA-microRNA-messenger RNA competing endogenous RNA (lncRNA-miRNA-mRNA ceRNA) network in the development and prognosis of cancers, especially gastric cancer (GC), through bioinformatic analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Pan-cancer and GC data were collected from the UCSC Xena website, and validation datasets were obtained from the Gene Expression Omnibus (GEO). R (version 3.6.3), GraphPad Prism 8, and SPSS 23.0 software were used to analyze data and prepare figures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The expression of ITGAV in tumor tissues was higher than that of normal tissues in ten cancer types. A lower expression of ITGAV in five tumors (CESC, LGG, LIHC, MESO, and STAD) predicted better patient prognosis. In GC, the mRNA and protein expression of ITGAV in tumor tissues was higher than that of normal tissues. Patients with high ITGAV expression had poor prognosis and clinical characteristics, including worse grades and more advanced stages. Patients with higher ITGAV expression had higher immune and stromal scores and lower purity (P&lt;0.05). In addition, seven miRNAs were found that were negatively correlated with ITGAV expression through the website; high expression of these miRNAs indicated a better prognosis. Using this correlation, the authors built the lncRNA-miRNA-ITGAV ceRNA network, to predict the prognosis of GC.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study showed that ITGAV could be considered a prognostic factor for GC, and an lncRNA-miRNA-ITGAV ceRNA network was built to promote the exploration of the mechanism and prognosis of GC.</AbstractText><CopyrightInformation>IJCEP Copyright &#xa9; 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ze-Zhong</ForeName><Initials>ZZ</Initials><AffiliationInfo><Affiliation>General Surgery Department, No. 1 People's Hospital of Ningyang County 872 Jinyang Street, Ningyang 271400, Shandong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wen-Peng</ForeName><Initials>WP</Initials><AffiliationInfo><Affiliation>General Surgery Department, No. 1 People's Hospital of Ningyang County 872 Jinyang Street, Ningyang 271400, Shandong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Hong-Mei</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>General Surgery Department, No. 1 People's Hospital of Ningyang County 872 Jinyang Street, Ningyang 271400, Shandong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>General Surgery Department, No. 1 People's Hospital of Ningyang County 872 Jinyang Street, Ningyang 271400, Shandong Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Clin Exp Pathol</MedlineTA><NlmUniqueID>101480565</NlmUniqueID><ISSNLinking>1936-2625</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ITGAV</Keyword><Keyword MajorTopicYN="N">ceRNA</Keyword><Keyword MajorTopicYN="N">gastric cancer</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>16</Day><Hour>2</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36381423</ArticleId><ArticleId IdType="pmc">PMC9638841</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359&#x2013;E386.</Citation><ArticleIdList><ArticleId IdType="pubmed">25220842</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung KW, Won YJ, Kong HJ, Oh CM, Shin A, Lee JS. Survival of Korean adult cancer patients by stage at diagnosis, 2006-2010: national cancer registry study. Cancer Res Treat. 2013;45:162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804727</ArticleId><ArticleId IdType="pubmed">24155674</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond) 2021;41:747&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8360643</ArticleId><ArticleId IdType="pubmed">34197702</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, Ye XS, Do IG, Liu S, Gong L, Fu J, Jin JG, Choi MG, Sohn TS, Lee JH, Bae JM, Kim ST, Park SH, Sohn I, Jung SH, Tan P, Chen R, Hardwick J, Kang WK, Ayers M, Hongyue D, Reinhard C, Loboda A, Kim S, Aggarwal A. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">25894828</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahgal P, Huffman BM, Patil DT, Chatila WK, Yaeger R, Cleary JM, Sethi NS. Early TP53 alterations shape gastric and esophageal cancer development. Cancers (Basel) 2021;13:5915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8657039</ArticleId><ArticleId IdType="pubmed">34885025</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455&#x2013;2465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3563263</ArticleId><ArticleId IdType="pubmed">22658128</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogner A, Thuss-Patience P. Immune checkpoint inhibition in oesophago-gastric carcinoma. Pharmaceuticals (Basel) 2021;14:151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7918118</ArticleId><ArticleId IdType="pubmed">33673374</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier J, Vincent AT, Charette SJ, Derome N. A brief history of bioinformatics. Brief Bioinform. 2019;20:1981&#x2013;1996.</Citation><ArticleIdList><ArticleId IdType="pubmed">30084940</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell ID, Humphries MJ. Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol. 2011;3:a004994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039929</ArticleId><ArticleId IdType="pubmed">21421922</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 2019;35:347&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6684107</ArticleId><ArticleId IdType="pubmed">30889378</ArticleId></ArticleIdList></Reference><Reference><Citation>Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383089</ArticleId><ArticleId IdType="pubmed">20029421</ArticleId></ArticleIdList></Reference><Reference><Citation>Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96:319&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">10025398</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu J, Li Z. The roles of integrin alphavbeta6 in cancer. Cancer Lett. 2017;403:128&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">28634043</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell MG, Cormier A, Ito S, Seed RI, Bondesson AJ, Lou J, Marks JD, Baron JL, Cheng Y, Nishimura SL. Cryo-EM reveals integrin-mediated TGF-beta activation without release from latent TGF-beta. Cell. 2020;180:490&#x2013;501. e416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7238552</ArticleId><ArticleId IdType="pubmed">31955848</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauvais DM, Ell BJ, McWhorter AR, Rapraeger AC. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med. 2009;206:691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2699122</ArticleId><ArticleId IdType="pubmed">19255147</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Liu H, Zhou W, Zhang F, Li C, Chen J, Tan C, Tang B, Yu P. GLI1 activation by non-classical pathway integrin alphavbeta3/ERK1/2 maintains stem cell-like phenotype of multicellular aggregates in gastric cancer peritoneal metastasis. Cell Death Dis. 2019;10:574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6668446</ArticleId><ArticleId IdType="pubmed">31366904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Cho YR, Kim HJ, Oh JS, Ahn EK, Ko HJ, Hwang BJ, Lee SJ, Cho Y, Kim YK, Stetler-Stevenson WG, Seo DW. Antagonism of VEGF-A-induced increase in vascular permeability by an integrin alpha3beta1-Shp-1-cAMP/PKA pathway. Blood. 2012;120:4892&#x2013;4902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3520626</ArticleId><ArticleId IdType="pubmed">23074279</ArticleId></ArticleIdList></Reference><Reference><Citation>Papo N, Silverman AP, Lahti JL, Cochran JR. Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin. Proc Natl Acad Sci U S A. 2011;108:14067&#x2013;14072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3161552</ArticleId><ArticleId IdType="pubmed">21825147</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheuk IW, Siu MT, Ho JC, Chen J, Shin VY, Kwong A. ITGAV targeting as a therapeutic approach for treatment of metastatic breast cancer. Am J Cancer Res. 2020;10:211&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7017729</ArticleId><ArticleId IdType="pubmed">32064162</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeser H, Scholz M, Fuchs H, Essakly A, Damanakis AI, Zander T, Buttner R, Schroder W, Bruns C, Quaas A, Gebauer F. Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival. Sci Rep. 2020;10:18411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7591891</ArticleId><ArticleId IdType="pubmed">33110104</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei Y, Zhang Y, Zheng K, Shang G, Wang Y, Wang W, Qiu E, Li S, Liu F, Zhang X. Ilex hainanensis Merr targets ITGAV to suppress the proliferation and metastasis of osteosarcoma cells. Onco Targets Ther. 2019;12:4499&#x2013;4507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6560189</ArticleId><ArticleId IdType="pubmed">31239718</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, Zhu J, Haussler D. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386072</ArticleId><ArticleId IdType="pubmed">32444850</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Ponten F. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964941</ArticleId><ArticleId IdType="pubmed">24297251</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang da W. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509&#x2013;W514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319575</ArticleId><ArticleId IdType="pubmed">32442275</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan K, Lu Y, Yan Z, Wang Y. 9-gene signature correlated with CD8(+) T cell infiltration activated by IFN-gamma: a biomarker of immune checkpoint therapy response in melanoma. Front Immunol. 2021;12:622563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248551</ArticleId><ArticleId IdType="pubmed">34220795</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18:534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8859863</ArticleId><ArticleId IdType="pubmed">31362118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18:533&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6629548</ArticleId><ArticleId IdType="pubmed">30002479</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdembri D, Serini G. The roles of integrins in cancer. Fac Rev. 2021;10:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8170687</ArticleId><ArticleId IdType="pubmed">34131655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">8970741</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hove I, Hu TT, Beets K, Van Bergen T, Etienne I, Stitt AW, Vermassen E, Feyen JHM. Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration. Prog Retin Eye Res. 2021;85:100966.</Citation><ArticleIdList><ArticleId IdType="pubmed">33775825</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori S, Hatori N, Kawaguchi N, Hamada Y, Shih TC, Wu CY, Lam KS, Matsuura N, Yamamoto H, Takada YK, Takada Y. The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis. Biosci Rep. 2017;37:BSR20170173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482197</ArticleId><ArticleId IdType="pubmed">28302677</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori S, Wu CY, Yamaji S, Saegusa J, Shi B, Ma Z, Kuwabara Y, Lam KS, Isseroff RR, Takada YK, Takada Y. Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling. J Biol Chem. 2008;283:18066&#x2013;18075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2440593</ArticleId><ArticleId IdType="pubmed">18441324</ArticleId></ArticleIdList></Reference><Reference><Citation>Saegusa J, Yamaji S, Ieguchi K, Wu CY, Lam KS, Liu FT, Takada YK, Takada Y. The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1 signaling. J Biol Chem. 2009;284:24106&#x2013;24114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782004</ArticleId><ArticleId IdType="pubmed">19578119</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita M, Zhu K, Fujita CK, Zhao M, Lam KS, Kurth MJ, Takada YK, Takada Y. Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins alphavbeta3, alpha4beta1, and alpha5beta1. J Biol Chem. 2015;290:259&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4281730</ArticleId><ArticleId IdType="pubmed">25398877</ArticleId></ArticleIdList></Reference><Reference><Citation>Saegusa J, Akakura N, Wu CY, Hoogland C, Ma Z, Lam KS, Liu FT, Takada YK, Takada Y. Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner. J Biol Chem. 2008;283:26107&#x2013;26115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2533795</ArticleId><ArticleId IdType="pubmed">18635536</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee JK, Jung YC, Kim KR, Yoo J, Kim J, Lee YJ, Ko YH, Lee HH, Cho BC, Kim TM. Impact of tumor purity on immune gene expression and clustering analyses across multiple cancer types. Cancer Immunol Res. 2018;6:87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">29141981</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Y, Feng Q, Zheng P, Yang L, Liu T, Xu Y, Zhu D, Chang W, Ji M, Ren L, Wei Y, He G, Xu J. Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. Cancer Manag Res. 2018;10:3569&#x2013;3577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6149864</ArticleId><ArticleId IdType="pubmed">30271205</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi X, Zhang DH, Wu N, Xiao JH, Wang X, Ma W. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52:710&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">26358722</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Yan Y, Cao S, Chen Y. Long non-coding RNA SNHG14 contributes to gastric cancer development through targeting miR-145/SOX9 axis. J Cell Biochem. 2018;119:6905&#x2013;6913.</Citation><ArticleIdList><ArticleId IdType="pubmed">29667771</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X, Wen L, Luo L. The effect and mechanism of lncRNA NR2F1-As1/miR-493-5p/MAP3K2 axis in the progression of gastric cancer. J Oncol. 2021;2021:3881932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8294992</ArticleId><ArticleId IdType="pubmed">34335755</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Xu M, Wang Z, Huang P, Huang C, Chen Z, Tang G, Zhu X, Cai M, Qin S. The EMT-induced lncRNA NR2F1-AS1 positively modulates NR2F1 expression and drives gastric cancer via miR-29a-3p/VAMP7 axis. Cell Death Dis. 2022;13:84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8791943</ArticleId><ArticleId IdType="pubmed">35082283</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv J, Zhang S, Liu Y, Li C, Guo T, Zhang S, Li Z, Jiao Z, Sun H, Zhang Y, Xu L. NR2F1-AS1/miR-190a/PHLDB2 induces the epithelial-mesenchymal transformation process in gastric cancer by promoting phosphorylation of AKT3. Front Cell Dev Biol. 2021;9:688949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8569557</ArticleId><ArticleId IdType="pubmed">34746118</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36353542</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>Identification and validation of novel biomarker TRIM8 related to cervical cancer.</ArticleTitle><Pagination><StartPage>1002040</StartPage><MedlinePgn>1002040</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1002040</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2022.1002040</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Cervical cancer, as a common gynecological disease, endangers female health. Give the lack of effective biomarkers for the diagnosis and treatment of cervical cancer, this paper aims to analyze the Gene Expression Omnibus (GEO) data sets using comprehensive bioinformatics tools, and to identify biomarkers associated with the cancer in patient samples.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The bioinformatics methods were used to extract genes related to cervical cancer from GSE39001, while the GEO2R online tool to elaborate on differentially expressed genes (DEGs) in normal and cancer samples, and to clarify related genes and functions. The results were verified by IHC, WB, CCK-8, clone formation and flow cytometry experiments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 2,859 DEGs were identified in the GEO microarray dataset. We extracted genes associated with both ubiquitination and autophagy from the key modules of weighted gene co-expression network analysis (WGCNA), and the analysis showed that TRIM8 was of great significance for the diagnosis and prognosis of cervical cancer. Besides, experimental validation showed the high TRIM8 expression in cervical cancer, as well as its involvement in the proliferation of cervical cancer cells.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">We identified a biomarker (TRIM8) that may be related to cervical cancer through a series of analyses on the GEO dataset. Experimental verification confirmed the inhibition of cervical cancer cells proliferation by lowering TRIM8 expression. Therefore, TRIM8 can be adopted as a new biomarker of cervical cancer to develop new therapeutic targets.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Zhang, Dan, Ou, Qian, Yin, Tang, He, Peng and He.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cancer Research Center, Nantong Tumor Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dan</LastName><ForeName>Youli</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology Oncology, Nantong Tumor Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ou</LastName><ForeName>Chaoyang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Gynecology Oncology, Nantong Tumor Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Hongyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cancer Research Center, Nantong Tumor Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology Oncology, Nantong Tumor Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory Diagnostics, Nantong Tumor Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Gynecology Oncology, Nantong Tumor Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, The Affiliated Hospital of Nantong University, Nantong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Aiqin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gynecology Oncology, Nantong Tumor Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GEO</Keyword><Keyword MajorTopicYN="N">TRIM8</Keyword><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>10</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36353542</ArticleId><ArticleId IdType="pmc">PMC9638460</ArticleId><ArticleId IdType="doi">10.3389/fonc.2022.1002040</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71(3):209&#x2013;49. doi:&#xa0;10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Islami F, Ward EM, Sung H, Cronin KA, Tangka FKL, Sherman RL, et al. . Annual report to the nation on the status of cancer, part 1: National cancer statistics. J Natl Cancer Inst (2021) 113(12):1648&#x2013;69. doi:&#xa0;10.1093/jnci/djab131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djab131</ArticleId><ArticleId IdType="pmc">PMC8634503</ArticleId><ArticleId IdType="pubmed">34240195</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. Cancer. (2017) 123(12):2219&#x2013;29. doi:&#xa0;10.1002/cncr.30588</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.30588</ArticleId><ArticleId IdType="pubmed">28346680</ArticleId></ArticleIdList></Reference><Reference><Citation>McLachlan J, Boussios S, Okines A, Glaessgen D, Bodlar S, Kalaitzaki R, et al. . The impact of systemic therapy beyond first-line treatment for advanced cervical cancer. Clin Oncol (R Coll Radiol). (2017) 29(3):153&#x2013;60. doi:&#xa0;10.1016/j.clon.2016.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clon.2016.10.002</ArticleId><ArticleId IdType="pubmed">27838135</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsu V, Jeronimo J. Saving the world's women from cervical cancer. N Engl J Med (2016) 374(26):2509&#x2013;11. doi:&#xa0;10.1056/NEJMp1604113</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1604113</ArticleId><ArticleId IdType="pubmed">27355529</ArticleId></ArticleIdList></Reference><Reference><Citation>Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, et al. . Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. (2020) 395(10224):591&#x2013;603. doi: 10.1016/S0140-6736(20)30157-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30157-4</ArticleId><ArticleId IdType="pmc">PMC7043006</ArticleId><ArticleId IdType="pubmed">32007142</ArticleId></ArticleIdList></Reference><Reference><Citation>The L. Eliminating cervical cancer. Lancet. (2020) 395(10221):312. doi:&#xa0;10.1016/S0140-6736(20)30247-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30247-6</ArticleId><ArticleId IdType="pubmed">32007146</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ZJ, Grover S, Scott AM, Woo S, Salama DH, Jones EC, et al. . The role and contribution of treatment and imaging modalities in global cervical cancer management: survival estimates from a simulation-based analysis. Lancet Oncol (2020) 21(8):1089&#x2013;98. doi: 10.1016/S1470-2045(20)30316-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30316-8</ArticleId><ArticleId IdType="pmc">PMC7574952</ArticleId><ArticleId IdType="pubmed">32758463</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Liu S, Wu L, Jiang M, Hou Y. High throughput single cell RNA sequencing, bioinformatics analysis and applications. Adv Exp Med Biol (2018) 1068:33&#x2013;43. doi: 10.1007/978-981-13-0502-3_4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-13-0502-3_4</ArticleId><ArticleId IdType="pubmed">29943294</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrick BA, London RE, Bushel PR, Grissom SF, Paules RS. Platforms for biomarker analysis using high-throughput approaches in genomics, transcriptomics, proteomics, metabolomics, and bioinformatics. IARC Sci Publ (2011) 163):121&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">22997859</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomczak K, Czerwinska P, Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) (2015) 19(1A):A68&#x2013;77. doi: 10.5114/wo.2014.47136</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/wo.2014.47136</ArticleId><ArticleId IdType="pmc">PMC4322527</ArticleId><ArticleId IdType="pubmed">25691825</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Lachmann A, Ma'ayan A. Mining data and metadata from the gene expression omnibus. Biophys Rev (2019) 11(1):103&#x2013;10. doi: 10.1007/s12551-018-0490-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12551-018-0490-8</ArticleId><ArticleId IdType="pmc">PMC6381352</ArticleId><ArticleId IdType="pubmed">30594974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Ren C, Yang L, Zhang Z, Gong M, Chen K. Identification and validation of the high expression of pseudogene TCAM1P in cervical cancer via integrated bioinformatics analysis. Cancer Cell Int (2022) 22(1):17. doi:&#xa0;10.1186/s12935-021-02440-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-021-02440-7</ArticleId><ArticleId IdType="pmc">PMC8753837</ArticleId><ArticleId IdType="pubmed">35016697</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Liu SH, Liu QY, Zou QQ, Lv L, Liu GL, et al. . Analysis of the role and regulatory mechanism of hsa-miR-504 in cervical cancer based on the cancer genome atlas database. Cancer Biother Radiopharm. (2021) 36(6):511&#x2013;20. doi: 10.1089/cbr.2020.3798</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/cbr.2020.3798</ArticleId><ArticleId IdType="pubmed">32589477</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Zhai J, Wang W, Liu T, Liu C, Zhu X, et al. . Identification of tumor microenvironment and DNA methylation-related prognostic signature for predicting clinical outcomes and therapeutic responses in cervical cancer. Front Mol Biosci (2022) 9:872932. doi: 10.3389/fmolb.2022.872932</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2022.872932</ArticleId><ArticleId IdType="pmc">PMC9061945</ArticleId><ArticleId IdType="pubmed">35517856</ArticleId></ArticleIdList></Reference><Reference><Citation>Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. . Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. (2018) 173(2):338&#x2013;354.e15. doi:&#xa0;10.1016/j.cell.2018.03.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.034</ArticleId><ArticleId IdType="pmc">PMC5902191</ArticleId><ArticleId IdType="pubmed">29625051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Khan H, Singh TG, Grewal AK, Najda A, Kawecka-Radomska M, et al. . Pharmacological modulation of ubiquitin-proteasome pathways in oncogenic signaling. Int J Mol Sci (2021) 22(21):11971. doi:&#xa0;10.3390/ijms222111971</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222111971</ArticleId><ArticleId IdType="pmc">PMC8584958</ArticleId><ArticleId IdType="pubmed">34769401</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagunas-Martinez A, Madrid-Marina V, Gomez-Ceron C, Deas J, Peralta-Zaragoza O. The autophagy process in cervical carcinogenesis: Role of non-Coding-RNAs, molecular mechanisms, and therapeutic targets. Cells. (2022) 11(8):1323. doi:&#xa0;10.3390/cells11081323</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11081323</ArticleId><ArticleId IdType="pmc">PMC9028856</ArticleId><ArticleId IdType="pubmed">35456001</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. (2019) 393(10167):169&#x2013;82. doi:&#xa0;10.1016/S0140-6736(18)32470-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32470-X</ArticleId><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. . The landscape of genomic alterations across childhood cancers. Nature. (2018) 555(7696):321&#x2013;7. doi:&#xa0;10.1038/nature25480</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25480</ArticleId><ArticleId IdType="pubmed">29489754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai X, Xue Q, Liu Q, Guo Y, Chen Z. Colon cancer recurrenceassociated genes revealed by WGCNA coexpression network analysis. Mol Med Rep (2017) 16(5):6499&#x2013;505. doi: 10.3892/mmr.2017.7412</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2017.7412</ArticleId><ArticleId IdType="pmc">PMC5865817</ArticleId><ArticleId IdType="pubmed">28901407</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. (1994) 79(1):13&#x2013;21. doi: 10.1016/0092-8674(94)90396-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(94)90396-4</ArticleId><ArticleId IdType="pubmed">7923371</ArticleId></ArticleIdList></Reference><Reference><Citation>Rol&#xe9;n U, Kobzeva V, Gasparjan N, Ovaa H, Winberg G, Kisseljov F, et al. . Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog. (2006) 45(4):260&#x2013;9. doi: 10.1002/mc.20177</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mc.20177</ArticleId><ArticleId IdType="pubmed">16402389</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y. E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia. (2006) 8(8):645&#x2013;54. doi: 10.1593/neo.06376</Citation><ArticleIdList><ArticleId IdType="doi">10.1593/neo.06376</ArticleId><ArticleId IdType="pmc">PMC1601942</ArticleId><ArticleId IdType="pubmed">16925947</ArticleId></ArticleIdList></Reference><Reference><Citation>Loopik DL, Bentley HA, Eijgenraam MN, IntHout J, Bekkers RLM, Bentley JR. The natural history of cervical intraepithelial neoplasia grades 1, 2, and 3: A systematic review and meta-analysis. J Low Genit Tract Dis (2021) 25(3):221&#x2013;31. doi: 10.1097/LGT.0000000000000604</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/LGT.0000000000000604</ArticleId><ArticleId IdType="pubmed">34176914</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Q, Qin J, Zhang Y, Cheng X, Wang X, Lu W, et al. . Autophagy maintains the stemness of ovarian cancer stem cells by FOXA2. J Exp Clin Cancer Res (2017) 36(1):171. doi: 10.1186/s13046-017-0644-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-017-0644-8</ArticleId><ArticleId IdType="pmc">PMC5707869</ArticleId><ArticleId IdType="pubmed">29187221</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HZ, Ma Y, Zhou Y, Xu LM, Chen XJ, Ding WB, et al. . Autophagy contributes to the enrichment and survival of colorectal cancer stem cells under oxaliplatin treatment. Cancer Lett (2015) 361(1):128&#x2013;36. doi: 10.1016/j.canlet.2015.02.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2015.02.045</ArticleId><ArticleId IdType="pubmed">25749420</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattoscio D, Medda A, Chiocca S. Human papilloma virus and autophagy. Int J Mol Sci (2018) 19(6):1775. doi: 10.3390/ijms19061775</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19061775</ArticleId><ArticleId IdType="pmc">PMC6032050</ArticleId><ArticleId IdType="pubmed">29914057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XY, Mao HW, Guan XH, Huang QM, Yu ZP, Wu J, et al. . TRIM65 promotes cervical cancer through selectively degrading p53-mediated inhibition of autophagy and apoptosis. Front Oncol (2022) 12:853935. doi: 10.3389/fonc.2022.853935</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2022.853935</ArticleId><ArticleId IdType="pmc">PMC8987532</ArticleId><ArticleId IdType="pubmed">35402260</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito D, Koliopoulos MG, Rittinger K. Structural determinants of TRIM protein function. Biochem Soc Trans (2017) 45(1):183&#x2013;91. doi: 10.1042/BST20160325</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20160325</ArticleId><ArticleId IdType="pubmed">28202672</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Y, Yang X. SUMO E3 ligase activity of TRIM proteins. Oncogene. (2011) 30(9):1108&#x2013;16. doi: 10.1038/onc.2010.462</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2010.462</ArticleId><ArticleId IdType="pmc">PMC3103664</ArticleId><ArticleId IdType="pubmed">20972456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T, Akira S. Regulation of innate immune signalling pathways by the tripartite motif (TRIM) family proteins. EMBO Mol Med (2011) 3(9):513&#x2013;27. doi: 10.1002/emmm.201100160</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201100160</ArticleId><ArticleId IdType="pmc">PMC3377094</ArticleId><ArticleId IdType="pubmed">21826793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozato K, Shin DM, Chang TH, Morse HC, 3rd. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol (2008) 8(11):849&#x2013;60. doi: 10.1038/nri2413</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2413</ArticleId><ArticleId IdType="pmc">PMC3433745</ArticleId><ArticleId IdType="pubmed">18836477</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Xia H. TRIM proteins in inflammation: from expression to emerging regulatory mechanisms. Inflammation. (2021) 44(3):811&#x2013;20. doi: 10.1007/s10753-020-01394-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-020-01394-8</ArticleId><ArticleId IdType="pubmed">33415537</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Gu Z, Zhang H, Hu H. To TRIM the immunity: From innate to adaptive immunity. Front Immunol (2020) 11:02157. doi: 10.3389/fimmu.2020.02157</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.02157</ArticleId><ArticleId IdType="pmc">PMC7578260</ArticleId><ArticleId IdType="pubmed">33117334</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer. (2011) 11(11):792&#x2013;804. doi: 10.1038/nrc3139</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3139</ArticleId><ArticleId IdType="pubmed">21979307</ArticleId></ArticleIdList></Reference><Reference><Citation>Caratozzolo MF, Marzano F, Mastropasqua F, Sbisa E, Tullo A. TRIM8: Making the right decision between the oncogene and tumour suppressor role. Genes (Basel). (2017) 8(12):354. doi: 10.3390/genes8120354</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes8120354</ArticleId><ArticleId IdType="pmc">PMC5748672</ArticleId><ArticleId IdType="pubmed">29182544</ArticleId></ArticleIdList></Reference><Reference><Citation>Caratozzolo MF, Marzano F, Abbrescia DI, Mastropasqua F, Petruzzella V, Calabro V, et al. . TRIM8 blunts the pro-proliferative action of DeltaNp63alpha in a p53 wild-type background. Front Oncol (2019) 9:1154. doi: 10.3389/fonc.2019.01154</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.01154</ArticleId><ArticleId IdType="pmc">PMC6856647</ArticleId><ArticleId IdType="pubmed">31781486</ArticleId></ArticleIdList></Reference><Reference><Citation>Caratozzolo MF, Micale L, Turturo MG, Cornacchia S, Fusco C, Marzano F, et al. . TRIM8 modulates p53 activity to dictate cell cycle arrest. Cell Cycle (2012) 11(3):511&#x2013;23. doi: 10.4161/cc.11.3.19008</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.11.3.19008</ArticleId><ArticleId IdType="pubmed">22262183</ArticleId></ArticleIdList></Reference><Reference><Citation>Toniato E, Chen XP, Losman J, Flati V, Donahue L, Rothman P. TRIM8/GERP RING finger protein interacts with SOCS-1. J Biol Chem (2002) 277(40):37315&#x2013;22. doi: 10.1074/jbc.M205900200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M205900200</ArticleId><ArticleId IdType="pubmed">12163497</ArticleId></ArticleIdList></Reference><Reference><Citation>Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, et al. . The tripartite motif family identifies cell compartments. EMBO J (2001) 20(9):2140&#x2013;51. doi: 10.1093/emboj/20.9.2140</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/20.9.2140</ArticleId><ArticleId IdType="pmc">PMC125245</ArticleId><ArticleId IdType="pubmed">11331580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomar D, Sripada L, Prajapati P, Singh R, Singh AK, Singh R. Nucleo-cytoplasmic trafficking of TRIM8, a novel oncogene, is involved in positive regulation of TNF induced NF-kappaB pathway. PloS One (2012) 7(11):e48662. doi:&#xa0;10.1371/journal.pone.0048662</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0048662</ArticleId><ArticleId IdType="pmc">PMC3495970</ArticleId><ArticleId IdType="pubmed">23152791</ArticleId></ArticleIdList></Reference><Reference><Citation>Carinci F, Arcelli D, Lo Muzio L, Francioso F, Valentini D, Evangelisti R, et al. . Molecular classification of nodal metastasis in primary larynx squamous cell carcinoma. Transl Res (2007) 150(4):233&#x2013;45. doi: 10.1016/j.trsl.2007.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2007.03.011</ArticleId><ArticleId IdType="pubmed">17900511</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Z, Tang J, Liao X, Gong Y, Yang Q, Wu Y, et al. . TRIM8 inhibits breast cancer proliferation by regulating estrogen signaling. Am J Cancer Res (2020) 10(10):3440&#x2013;57. doi: 10.21203/rs.3.rs-42521/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-42521/v1</ArticleId><ArticleId IdType="pmc">PMC7642662</ArticleId><ArticleId IdType="pubmed">33163282</ArticleId></ArticleIdList></Reference><Reference><Citation>Caratozzolo MF, Valletti A, Gigante M, Aiello I, Mastropasqua F, Marzano F, et al. . TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma. Oncotarget. (2014) 5(17):7446&#x2013;57. doi: 10.18632/oncotarget.2081</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.2081</ArticleId><ArticleId IdType="pmc">PMC4202135</ArticleId><ArticleId IdType="pubmed">25277184</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastropasqua F, Marzano F, Valletti A, Aiello I, Di Tullio G, Morgano A, et al. . TRIM8 restores p53 tumour suppressor function by blunting n-MYC activity in chemo-resistant tumours. Mol Cancer. (2017) 16(1):67. doi: 10.1186/s12943-017-0634-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-017-0634-7</ArticleId><ArticleId IdType="pmc">PMC5359838</ArticleId><ArticleId IdType="pubmed">28327152</ArticleId></ArticleIdList></Reference><Reference><Citation>Micale L, Fusco C, Fontana A, Barbano R, Augello B, De Nittis P, et al. . TRIM8 downregulation in glioma affects cell proliferation and it is associated with patients survival. BMC Cancer. (2015) 15:470. doi: 10.1186/s12885-015-1449-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-015-1449-9</ArticleId><ArticleId IdType="pmc">PMC4468980</ArticleId><ArticleId IdType="pubmed">26077989</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy M, Tomar D, Singh K, Lakshmi S, Prajapati P, Bhatelia K, et al. . TRIM8 regulated autophagy modulates the level of cleaved caspase-3 subunit to inhibit genotoxic stress induced cell death. Cell Signal (2018) 48:1&#x2013;12. doi: 10.1016/j.cellsig.2018.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2018.04.003</ArticleId><ArticleId IdType="pubmed">29678622</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36352147</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1335</ISSN><JournalIssue CitedMedium="Internet"><Volume>149</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of cancer research and clinical oncology</Title><ISOAbbreviation>J Cancer Res Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>Diagnostic, prognostic, and immunological roles of CD177 in cervical cancer.</ArticleTitle><Pagination><StartPage>173</StartPage><EndPage>189</EndPage><MedlinePgn>173-189</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00432-022-04465-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">CD177, an indicator of prognosis in diverse cancers, is involved in the physiological processes of various tumor cells, and acts as an immune molecule with novel functions in cancer pathogenesis. However, the diagnostic, prognostic, and immunological role of CD177 in cervical cancer remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Utilizing publicly available databases and integrating several bioinformatics analysis methods, we evaluated the expression level of CD177 in cervical cancer by GENT2, HPA, and GEO databases. And the experiments of western blot and immunohistochemical staining were used to test&#xa0;the&#xa0;hypothesis. The Kaplan-Meier Plotter database, Xena Shiny, and the constructed nomogram were clearly demonstrated its prognostic value for patients. Gene set enrichment analysis explored the relationship between CD177 and cervical cancer immune responses and immune cells infiltration level. In addition, we investigated the association between CD177 expression and stromal score, immune score, immune checkpoint, and drug sensitivity by TCGA RNA-seq data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CD177 was apparently expressed at low levels in cervical cancer and predicted a poor survival rate for patients. CD177 significantly activated immune-related signaling pathways and had a positive relationship with immune cell infiltration level. The high CD177 expression group possessed the high stromal score and immune score. CD177 had potential interactions with CTLA4, CD27, BLTA, CD200R1, CD80, NRP1, TNFRSF25, TIGIT, ICOS, and TNFSF9 checkpoint markers. And CD177 expression was positively relevant with drug sensitivity for Lapatinib, Belinostat, ATRA, Gefitinib, Navitoclax, and Tamoxifen.</AbstractText><AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">These findings may shed light on the vital role of CD177 in cervical cancer diagnosis, prognosis, and immunological functions, and it may be a promising predictor and potential factor for cervical cancer patients.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Liao</LastName><ForeName>Wenxin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Fujin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China. sfj296@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021CFB430</GrantID><Agency>The Natural Science Foundation of Hubei Province of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Cancer Res Clin Oncol</MedlineTA><NlmUniqueID>7902060</NlmUniqueID><ISSNLinking>0171-5216</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C407242">CD177 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058851">GPI-Linked Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007519">Isoantigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058851" MajorTopicYN="Y">GPI-Linked Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007519" MajorTopicYN="Y">Isoantigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049451" MajorTopicYN="N">Nomograms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="Y">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">CD177</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Diagnosis</Keyword><Keyword MajorTopicYN="N">Immune</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>9</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36352147</ArticleId><ArticleId IdType="doi">10.1007/s00432-022-04465-5</ArticleId><ArticleId IdType="pii">10.1007/s00432-022-04465-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alayed K, Meyerson JB, Osei ES, Blidaru G, Schlegelmilch J, Johnson M, Meyerson HJ (2020) CD177 enhances the detection of myelodysplastic syndrome by flow cytometry. Am J Clin Pathol 153:554&#x2013;565</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqz196</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai M, Grieshaber-Bouyer R, Wang J, Schmider AB, Wilson ZS, Zeng L, Halyabar O, Godin MD, Nguyen HN, Levescot A et al (2017) CD177 modulates human neutrophil migration through activation-mediated integrin and chemoreceptor regulation. Blood 130:2092&#x2013;2100</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-03-768507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilancia D, Rosati G, Dinota A, Germano D, Romano R, Manzione L (2007) Lapatinib in breast cancer. Ann Oncol. https://doi.org/10.1093/annonc/mdm220</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdm220</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AC, Roane BM, Leath CA (2020) Novel therapeutics for recurrent cervical cancer: moving towards personalized therapy. Drugs 80:217&#x2013;227</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-019-01249-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. https://doi.org/10.3390/ijms18071414</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18071414</ArticleId></ArticleIdList></Reference><Reference><Citation>Eulenberg-Gustavus C, B&#xe4;hring S, Maass PG, Luft FC, Kettritz R (2017) Gene silencing and a novel monoallelic expression pattern in distinct CD177 neutrophil subsets. J Exp Med 214:2089&#x2013;2101</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20161093</ArticleId></ArticleIdList></Reference><Reference><Citation>Gy&#x151;rffy B (2021) Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J 19:4101&#x2013;4109</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2021.07.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K et al (2020) Gefitinib Alone Versus Gefitinib Plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol 38:115&#x2013;123</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.19.01488</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Chen Y, Zhang M, Zhou H, Wu H (2020) Relationship between CD177 and the vasculogenic mimicry, clinicopathological parameters, and prognosis of epithelial ovarian cancer. Ann Palliat Med 9:3985&#x2013;3992</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm-20-1825</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M-C, Borcherding N, Ahmed KK, Voigt AP, Vishwakarma A, Kolb R, Kluz PN, Pandey G, De U, Drashansky T et al (2021) CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. Nat Commun 12:5764</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26091-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissel K, Santoso S, Hofmann C, Stroncek D, Bux J (2001) Molecular basis of the neutrophil glycoprotein NB1 (CD177) involved in the pathogenesis of immune neutropenias and transfusion reactions. Eur J Immunol 31:1301&#x2013;1309</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1521-4141(200105)31:5&lt;1301::AID-IMMU1301&gt;3.0.CO;2-J</ArticleId></ArticleIdList></Reference><Reference><Citation>Kluz PN, Kolb R, Xie Q, Borcherding N, Liu Q, Luo Y, Kim M-C, Wang L, Zhang Y, Li W et al (2020) Cancer cell-intrinsic function of CD177 in attenuating &#x3b2;-catenin signaling. Oncogene 39:2877&#x2013;2889</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-020-1203-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Severson E, Pignon J-C, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S et al (2016) Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol 17:174</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-016-1028-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS (2017) TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res 77:e108&#x2013;e110</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-17-0307</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Wang W, Zhu X, Yu M, Zhou C (2022) Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer. Sci Rep 12:9619</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13855-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Zhang C, Ma G, Zhang Q (2014) Expression of SPRR3 is associated with tumor cell proliferation and invasion in glioblastoma multiforme. Oncol Lett 7:427&#x2013;432</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2013.1736</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H, Xu X, Yang J, Wang K, Wang C, Yang P, Cai H (2020) Genome-wide somatic copy number alteration analysis and database construction for cervical cancer. Mol Genet Genomics 295:765&#x2013;773</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00438-019-01636-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal R, Chan TA (2016) Personalized oncology meets immunology: the path toward precision immunotherapy. Cancer Discov 6:703&#x2013;713</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-16-0146</ArticleId></ArticleIdList></Reference><Reference><Citation>Monk BJ, Pandite LN (2011) Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 29:4845</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.38.8777</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira LF, Maino MM, Garbin HI, Da Natividade GR, Volkweis BS, Kulczynski JU (2018) CD117 Expression in squamous cell carcinoma of the Oesophagus. Anticancer Res 38:3929&#x2013;3933</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.12678</ArticleId></ArticleIdList></Reference><Reference><Citation>Odiase O, Noah-Vermillion L, Simone BA, Aridgides PD (2021) The incorporation of immunotherapy and targeted therapy into chemoradiation for cervical cancer: a focused review. Front Oncol 11:663749</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.663749</ArticleId></ArticleIdList></Reference><Reference><Citation>Otter SJ, Chatterjee J, Stewart AJ, Michael A (2019) The role of biomarkers for the prediction of response to checkpoint immunotherapy and the rationale for the use of checkpoint immunotherapy in cervical cancer. Clin Oncol 31:834&#x2013;843</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clon.2019.07.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S-J, Yoon B-H, Kim S-K, Kim S-Y (2019) GENT2: an updated gene expression database for normal and tumor tissues. BMC Med Genomics 12:101</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-019-0514-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen VM, Guerra I, McCormack M, Nogueira-Rodrigues A, Sasse A, Munk VC, Shang A (2017) Systematic review and network meta-analysis of bevacizumab plus first-line Topotecan-Paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer. Int J Gynecol Cancer 27:1237&#x2013;1246</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IGC.0000000000001000</ArticleId></ArticleIdList></Reference><Reference><Citation>Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I et al (2019) TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics 15(35):4200&#x2013;4202 (Epub 2019/03/25)</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz210</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffmann LM, Fritsch M, Gebauer F, G&#xfc;nther SD, Stair NR, Seeger JM, Thangarajah F, Dieplinger G, Bludau M, Alakus H et al (2019) Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer. Br J Cancer 120:69&#x2013;78</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-018-0198-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestre-Roig C, Hidalgo A, Soehnlein O (2016) Neutrophil heterogeneity: implications for homeostasis and pathogenesis. Blood 127:2173&#x2013;2181</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-01-688887</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestre-Roig C, Fridlender ZG, Glogauer M, Scapini P (2019) Neutrophil diversity in health and disease. Trends Immunol 40:565&#x2013;583</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2019.04.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209&#x2013;249</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, von Mering C (2019) STRING v11: protein&#x2013;protein association networks with increased coverage supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research 47(D1):D607&#x2013;D613. https://doi.org/10.1093/nar/gky1131</Citation></Reference><Reference><Citation>Uhlen M, Zhang C, Lee S, Sj&#xf6;stedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, von Feilitzen K, Oksvold P, Lundberg E, Hober S, Nilsson P, Mattsson J, Schwenk JM, Brunnstr&#xf6;m H, Glimelius B, Sj&#xf6;blom T, Edqvist PH, Djureinovic D, Micke P, Lindskog C, Mardinoglu A, Ponten F (2017) A pathology atlas of the human cancer transcriptome. Sci 357(6352):eaan2507. https://doi.org/10.1126/science.aan2507</Citation></Reference><Reference><Citation>Vasaikar SV, Straub P, Wang J, Zhang B (2018) LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res 46:D956&#x2013;D963</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Xiong Y, Zhao L, Gu K, Li Y, Zhao F, Li J, Wang M, Wang H, Tao Z et al (2021) UCSCXenaShiny: An R/CRAN Package for Interactive analysis of UCSC Xena Data. Bioinformatics. https://doi.org/10.1093/bioinformatics/btab561</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btab561</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendel Naumann R, Leath CA (2020) Advances in immunotherapy for cervical cancer. Curr Opin Oncol 32:481&#x2013;487</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCO.0000000000000663</ArticleId></ArticleIdList></Reference><Reference><Citation>Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, Lawrence MS, Zhsng C-Z, Wala J, Mermel CH et al (2013) Pan-cancer patterns of somatic copy number alteration. Nat Genet 45:1134&#x2013;1140</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2760</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17:807&#x2013;821</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0488-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zhang R, Chen H, Wang L, Ren C, Pataer A, Wu S, Meng QH, Ha MJ, Morris J et al (2020) KRT-232 and navitoclax enhance trametinib&#x2019;s anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res 10:4464&#x2013;4475</Citation></Reference><Reference><Citation>Zhou C, Guo Z, Xu L, Jiang H, Sun P, Zhu X, Mu X (2020) PFND1 predicts poor prognosis of gastric cancer and promotes cell metastasis by activating the Wnt/&#x3b2;-catenin pathway. Onco Targets Ther 13:3177&#x2013;3186</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S236929</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36281082</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>42</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Identification and verification of a 4-gene signature predicting the overall survival of cervical cancer.</ArticleTitle><Pagination><StartPage>e31299</StartPage><MedlinePgn>e31299</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e31299</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000031299</ELocationID><Abstract><AbstractText>Cervical cancer (CC) is one of the most common gynecological malignancies, ranking fourth in both incidence and mortality in women worldwide. Early screening and treatment are of great significance in reducing the incidence and mortality of CC. Due to the complex molecular mechanisms of tumor progression, the predictive power of traditional clinical information is limited. In this study, an effective molecular model is established to assess prognosis of patients with CC and guide clinical treatment so as to improve their survival rate. Three high quality datasets (GSE138080, GSE52904, GSE67522) of expression profiling were obtained from gene expression omnibus (GEO) database. Another mRNA expression and clinicopathological data of CC were obtained from The Cancer Genome Atlas (TCGA) dataset. The bioinformatic analyses such as univariate analysis, multivariate Cox proportional-hazards model (Cox) analysis and lasso regression analysis were conducted to select survival-related differentially expressed genes (DEGs) and further establish a prognostic gene signature. Moreover, the performance of prognostic gene signature was evaluated based on Kaplan-Meier curve and receiver operating characteristic (ROC) curve. Gene set enrichment analysis (GSEA) and tumor immunity analysis were carried out to elucidate the molecular mechanisms and immune relevance. A 4-gene signature comprising procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2), spondin1 (SPON1), secreted phosphoprotein 1 (SPP1), ribonuclease H2 subunit A (RNASEH2A) was established to predict overall survival (OS) of CC. The ROC curve indicated good performance of the 4-gene signature in predicting OS of CC based on the TCGA dataset. The 4-gene signature classified the patients into high-risk and low-risk groups with distinct OS rates of CC. Univariate analysis and multivariate Cox regression analysis revealed that the 4-gene signature was an independent factor affecting the prognosis of patients with CC. Our study developed a 4-gene signature capable of predicting the OS of CC. The findings may be beneficial to individualized clinical treatment and timely follow-up for patients with CC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Department of Obstetrics, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, No. 745, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Zijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>From the Department of Gynecology and Obstetrics, Wuhan University of Science and Technology, No. 2, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Guoqiang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Department of Obstetrics, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, No. 745, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Dongmei</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4547-3752</Identifier><AffiliationInfo><Affiliation>From the Department of Obstetrics, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, No. 745, Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>106441-73-0</RegistryNumber><NameOfSubstance UI="D053495">Osteopontin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.11.4</RegistryNumber><NameOfSubstance UI="D008240">Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="D012260">Ribonucleases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053495" MajorTopicYN="N">Osteopontin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008240" MajorTopicYN="N">Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012260" MajorTopicYN="N">Ribonucleases</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>25</Day><Hour>1</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36281082</ArticleId><ArticleId IdType="pmc">PMC9592452</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000031299</ArticleId><ArticleId IdType="pii">00005792-202210210-00005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, et al. . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatla N, Aoki D, Sharma DN, et al. . Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018;143(Suppl 2):22&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">30306584</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">29115304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamps R, Brandao RD, Bosch BJ, et al. . Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci. 2017;18:308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5343844</ArticleId><ArticleId IdType="pubmed">28146134</ArticleId></ArticleIdList></Reference><Reference><Citation>Siow ZR, De Boer RH, Lindeman GJ, et al. . Spotlight on the utility of the Oncotype DX&#xae; breast cancer assay. Int J Womens Health. 2018;10:89&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5827461</ArticleId><ArticleId IdType="pubmed">29503586</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris LN, Ismaila N, Mcshane LM, et al. . Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:1134&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4933134</ArticleId><ArticleId IdType="pubmed">26858339</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly MB, Pilarski R, Berry M, et al. . NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Canc Netw. 2017;15:9&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">28040716</ArticleId></ArticleIdList></Reference><Reference><Citation>Senkus E, Kyriakides S, Ohno S, et al. . Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">26314782</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnant M, Harbeck N, St TC. Gallen/Vienna 2017: a brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment. Breast Care (Basel). 2017;12:102&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5447163</ArticleId><ArticleId IdType="pubmed">28559767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward S, Scope A, Rafia R, et al. . Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2013;17:1&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780957</ArticleId><ArticleId IdType="pubmed">24088296</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan IB, Tan P. Genetics: an 18-gene signature (ColoPrint&#xae;) for colon cancer prognosis. Nat Rev Clin Oncol. 2011;8:131&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">21304502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopetz S, Tabernero J, Rosenberg R, et al. . Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. Oncologist. 2015;20:127&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4319631</ArticleId><ArticleId IdType="pubmed">25561511</ArticleId></ArticleIdList></Reference><Reference><Citation>Maak M, Simon I, Nitsche U, et al. . Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg. 2013;257:1053&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23295318</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A, Birger C, Thorvaldsdottir H, et al. . The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707969</ArticleId><ArticleId IdType="pubmed">26771021</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Severson E, Pignon JC, et al. . Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17:174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4993001</ArticleId><ArticleId IdType="pubmed">27549193</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrami A, Hasanzadeh M, Shahidsales S, et al. . Genetic susceptibility in cervical cancer: from bench to bedside. J Cell Physiol. 2018;233:1929&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">28542881</ArticleId></ArticleIdList></Reference><Reference><Citation>Burki TK. Novel mutations in cervical cancer. Lancet Oncol. 2017;18:e137.</Citation><ArticleIdList><ArticleId IdType="pubmed">28163002</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamauchi M, Sricholpech M. Lysine post-translational modifications of collagen. Essays Biochem. 2012;52:113&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3499978</ArticleId><ArticleId IdType="pubmed">22708567</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisinger-Mathason TS, Zhang M, Qiu Q, et al. . Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov. 2013;3:1190&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3822914</ArticleId><ArticleId IdType="pubmed">23906982</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilkes DM, Bajpai S, Wong CC, et al. . Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol Cancer Res. 2013;11:456&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656974</ArticleId><ArticleId IdType="pubmed">23378577</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H, Chen Y, Hou X, et al. . PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC. Cell Death Dis. 2017;8:e3143&#x2013;e3143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5680920</ArticleId><ArticleId IdType="pubmed">29072684</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Terajima M, Yang Y, et al. . Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. J Clin Invest. 2015;125:1147&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362236</ArticleId><ArticleId IdType="pubmed">25664850</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Zhang J, Hu G, et al. . Hypoxia and TGF-beta1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation. Cancer Cell Int. 2017;17:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427545</ArticleId><ArticleId IdType="pubmed">28507454</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Chen Q, Alam A, et al. . The role of osteopontin in the progression of solid organ tumour. Cell Death Dis. 2018;9:356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5834520</ArticleId><ArticleId IdType="pubmed">29500465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng B, Zhou M, Wu H, et al. . SPP1 promotes ovarian cancer progression via Integrin beta1/FAK/AKT signaling pathway. Onco Targets Ther. 2018;11:1333&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856063</ArticleId><ArticleId IdType="pubmed">29559792</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Xu K, Chase M, et al. . Tiam1-regulated osteopontin in senescent fibroblasts contributes to the migration and invasion of associated epithelial cells. J Cell Sci. 2012;125(Pt 2):376&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3283874</ArticleId><ArticleId IdType="pubmed">22302986</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Xiong D, Ye L, et al. . SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines. Cancer Chemother Pharmacol. 2019;83:603&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">30627777</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Lin S, Liu L, et al. . Ribonuclease H2 subunit A impacts invasiveness and chemoresistance resulting in poor survivability of breast cancer in ER dependent manner. Am J Transl Res. 2020;12:2281&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270022</ArticleId><ArticleId IdType="pubmed">32509219</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai B, Zhang P, Zhang Y, et al. . RNaseH2A is involved in human gliomagenesis through the regulation of cell proliferation and apoptosis. Oncol Rep. 2016;36:173&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">27176716</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H, Dong T, Ma X, et al. . Spondin 1 promotes metastatic progression through Fak and Src dependent pathway in human osteosarcoma. Biochem Biophys Res Commun. 2015;464:45&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">26032498</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W, Yan X, Jing L, et al. . A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol. 2011;8:59&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4002991</ArticleId><ArticleId IdType="pubmed">21200385</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Li Z, Gao A, et al. . The prognostic landscape of tumor-infiltrating immune cells in cervical cancer. Biomed Pharmacother. 2019;120:109444.</Citation><ArticleIdList><ArticleId IdType="pubmed">31562978</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisdom AJ, Hong CS, Lin AJ, et al. . Neutrophils promote tumor resistance to radiation therapy. Proc Natl Acad Sci USA. 2019;116:18584&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6744874</ArticleId><ArticleId IdType="pubmed">31462499</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36249021</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>APOBEC3B is overexpressed in cervical cancer and promotes the proliferation of cervical cancer cells through apoptosis, cell cycle, and p53 pathway.</ArticleTitle><Pagination><StartPage>864889</StartPage><MedlinePgn>864889</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">864889</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2022.864889</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED"><i>APOBEC3B</i> (<i>A3B</i>), a member of the APOBEC family of cytidine deaminases, has been gradually regarded as a key cancerous regulator. However, its expression and mechanism in cervical cancer (CC) have not been fully elucidated. This study was to investigate its expression pattern and potential mechanism on the cell cycle, as well as HPV oncogenes in CC.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Data from The Cancer Genome Atlas (TCGA) and Gene Expression (GEO) were used to indicate the mRNA expression pattern of A3B in cervical cancer. Western blot assay was used to detect A3B levels in SiHa and Hela cell lines. Immunohistochemistry (IHC) was used to explore A3B protein abundance and sublocation in cervical cancer as well as normal cervical tissues. Based on the Protein atlas (www.proteinatlas.org), A3B expression in the SiHa cell line is lower than in the HeLa cell line. Therefore, the SiHa cell line was used for <i>A3B</i> gene overexpression experiments while the HeLa cell line was used for knockdown experiments. Flow cytometry analysis was used to detect cell apoptosis. Biological function and cancer-related pathways of <i>A3B</i> were conducted using bioinformatics analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED"><i>A3B</i> mRNA was significantly overexpressed in cervical cancer in TCGA-cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), GSE67522, and GSE7803. A3B was more highly expressed in cervical cancers than in high-grade squamous intraepithelial lesions and normal controls. A3B expression was found to be progressively activated during cervical cancer development. IHC results showed that A3B was significantly higher in cervical cancer tissues than in normal cervical tissues. <i>A3B</i> plasmid-mediated overexpression experiments and <i>A3B</i> siRNA-mediated knockdown experiments showed that A3B significantly promotes cell proliferation, migration, cell cycle, and chemoresistance in cervical cancer cells by the p53 pathway. GO and KEGG analyses showed that A3B expression was strikingly associated with cell proliferation, apoptosis, and immune-associated pathways.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Taken together, our study implies that A3B promotes cell proliferation, migration, and cell cycle and inhibits cancer cell apoptosis through the p53-mediated signaling pathway. Moreover, A3B could also contribute to chemoresistance in cervical cancer cells. It may be a potential diagnostic biomarker and therapeutic target for chemoresistant cervical&#xa0;cancers.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Wei, Gan, Feng, Zhang, Chen, Zhao and Du.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Jianfeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Mo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institutes of Integrative Medicine, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhixian</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hongbo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institutes of Integrative Medicine, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOBEC3B expression</Keyword><Keyword MajorTopicYN="N">apoptosis</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">chemoresistance</Keyword><Keyword MajorTopicYN="N">proliferation</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>17</Day><Hour>5</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36249021</ArticleId><ArticleId IdType="pmc">PMC9556651</ArticleId><ArticleId IdType="doi">10.3389/fonc.2022.864889</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, LA T, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin (2018) 68:394&#x2013;424. doi:&#xa0;10.3322/caac.21492</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 103:368&#x2013;83. doi:&#xa0;10.1093/jnci/djq562</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djq562</ArticleId><ArticleId IdType="pmc">PMC3046952</ArticleId><ArticleId IdType="pubmed">21282563</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper DM, DeMars LR. Hpv vaccines - a review of the first decade. Gynecol. Oncol (2017) 146:196&#x2013;204. doi:&#xa0;10.1016/j.ygyno.2017.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2017.04.004</ArticleId><ArticleId IdType="pubmed">28442134</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. . Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett (2020) 471:88&#x2013;102. doi:&#xa0;10.1016/j.canlet.2019.11.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2019.11.039</ArticleId><ArticleId IdType="pubmed">31812696</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, Du Y, Zhang Q, Han X, Cao G. Human cytidine deaminases facilitate hepatitis b virus evolution and link inflammation and hepatocellular carcinoma. Cancer Lett (2014) 343:161&#x2013;71. doi:&#xa0;10.1016/j.canlet.2013.09.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2013.09.041</ArticleId><ArticleId IdType="pubmed">24120759</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Qiu X, Zhang N, Wang Y, Wang M, Li D, et al. . Apobec-mediated genomic alterations link immunity and viral infection during human papillomavirus-driven cervical carcinogenesis. Biosci Trends (2017) 11:383&#x2013;8. doi:&#xa0;10.5582/bst.2017.01103</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/bst.2017.01103</ArticleId><ArticleId IdType="pubmed">28717061</ArticleId></ArticleIdList></Reference><Reference><Citation>Maciejowski J, Chatzipli A, Dananberg A, Chu K, Toufektchan E, Klimczak LJ, et al. . Apobec3-dependent kataegis and trex1-driven chromothripsis during telomere crisis. Nat Genet (2020) 52:884&#x2013;90. doi:&#xa0;10.1038/s41588-020-0667-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-020-0667-5</ArticleId><ArticleId IdType="pmc">PMC7484228</ArticleId><ArticleId IdType="pubmed">32719516</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. . Signatures of mutational processes in human cancer. Nature (2013) 500:415&#x2013;21. doi:&#xa0;10.1038/nature12477</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12477</ArticleId><ArticleId IdType="pmc">PMC3776390</ArticleId><ArticleId IdType="pubmed">23945592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng JCF, Quist J, Grigoriadis A, Malim MH, Fraternali F. Pan-cancer transcriptomic analysis dissects immune and proliferative functions of apobec3 cytidine deaminases. Nucleic Acids Res (2019) 47:1178&#x2013;94. doi:&#xa0;10.1093/nar/gky1316</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1316</ArticleId><ArticleId IdType="pmc">PMC6379723</ArticleId><ArticleId IdType="pubmed">30624727</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira VC, Leonard B, White EA, Starrett GJ, Temiz NA, Lorenz LD, et al. . Human papillomavirus e6 triggers upregulation of the antiviral and cancer genomic dna deaminase apobec3b. Mbio (2014) 5(6):e02234-14. doi:&#xa0;10.1128/mBio.02234-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02234-14</ArticleId><ArticleId IdType="pmc">PMC4278539</ArticleId><ArticleId IdType="pubmed">25538195</ArticleId></ArticleIdList></Reference><Reference><Citation>Janecka-Wid&#x142;a A, Majchrzyk K, Mucha-Ma&#x142;ecka A, Biesaga B. Egfr/pi3k/akt/mtor pathway in head and neck squamous cell carcinoma patients with different hpv status. Polish J Pathol Off J Polish Soc Pathol. (2021) 72:296&#x2013;314. doi:&#xa0;10.5114/pjp.2021.113073</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/pjp.2021.113073</ArticleId><ArticleId IdType="pubmed">35142162</ArticleId></ArticleIdList></Reference><Reference><Citation>Argyris PP, Wilkinson PE, Jarvis MC, Magliocca KR, Patel MR, Vogel RI, et al. . Endogenous apobec3b overexpression characterizes hpv-positive and hpv-negative oral epithelial dysplasias and head and neck cancers. Modern Pathol an Off J United States Can Acad Pathol. Inc. (2021) 34:280&#x2013;90. doi:&#xa0;10.1038/s41379-020-0617-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41379-020-0617-x</ArticleId><ArticleId IdType="pmc">PMC8261524</ArticleId><ArticleId IdType="pubmed">32632179</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohba K, Ichiyama K, Yajima M, Gemma N, Nikaido M, Wu Q, et al. . In vivo and in vitro studies suggest a possible involvement of hpv infection in the early stage of breast carcinogenesis via apobec3b induction. PloS One (2014) 9:e97787. doi:&#xa0;10.1371/journal.pone.0097787</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0097787</ArticleId><ArticleId IdType="pmc">PMC4032256</ArticleId><ArticleId IdType="pubmed">24858917</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuboi M, Yamane A, Horiguchi J, Yokobori T, Kawabata-Iwakawa R, Yoshiyama S, et al. . Apobec3b high expression status is associated with aggressive phenotype in japanese breast cancers. Breast Cancer (Tokyo Japan). (2016) 23:780&#x2013;8. doi:&#xa0;10.1007/s12282-015-0641-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12282-015-0641-8</ArticleId><ArticleId IdType="pubmed">26476745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Q, Huang T, Sun X, Wang Y, Wang J, Liu Y, et al. . Hpv-16/18 e6-induced apobec3b expression associates with proliferation of cervical cancer cells and hypomethylation of cyclin d1. Mol Carcinogen. (2021) 60:313&#x2013;30. doi:&#xa0;10.1002/mc.23292</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mc.23292</ArticleId><ArticleId IdType="pubmed">33631046</ArticleId></ArticleIdList></Reference><Reference><Citation>Taghizadeh E, Jahangiri S, Rostami D, Taheri F, Renani PG, Taghizadeh H, et al. . Roles of e6 and e7 human papillomavirus proteins in molecular pathogenesis of cervical cancer. Curr Protein Pept Sci (2019) 20:926&#x2013;34. doi:&#xa0;10.2174/1389203720666190618101441</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389203720666190618101441</ArticleId><ArticleId IdType="pubmed">31244421</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The e6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 63:1129&#x2013;36. doi: 10.1016/0092-8674(90)90409-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(90)90409-8</ArticleId><ArticleId IdType="pubmed">2175676</ArticleId></ArticleIdList></Reference><Reference><Citation>Sailer C, Offensperger F, Julier A, Kammer K, Walker-Gray R, Gold MG, et al. . Structural dynamics of the e6ap/ube3a-e6-p53 enzyme-substrate complex. Nat Commun (2018) 9:4441. doi:&#xa0;10.1038/s41467-018-06953-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06953-0</ArticleId><ArticleId IdType="pmc">PMC6202321</ArticleId><ArticleId IdType="pubmed">30361475</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Xu J, Zhao J, Yin W, Liu D, Chen W, et al. . Arf1-mediated lipid metabolism sustains cancer cells and its ablation induces anti-tumor immune responses in mice. Nat Commun (2020) 11:220. doi:&#xa0;10.1038/s41467-019-14046-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-14046-9</ArticleId><ArticleId IdType="pmc">PMC6954189</ArticleId><ArticleId IdType="pubmed">31924786</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T, Cai Z, Ma N, Xie W, Gao C, Huang M, et al. . A novel ten-gene signature predicting prognosis in hepatocellular carcinoma. Front Cell Dev Biol (2020) 8:629. doi:&#xa0;10.3389/fcell.2020.00629</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00629</ArticleId><ArticleId IdType="pmc">PMC7372135</ArticleId><ArticleId IdType="pubmed">32760725</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang L, Han Y, He Q. Clusterprofiler: An r package for comparing biological themes among gene clusters. Omics J Integr Biol (2012) 16:284&#x2013;7. doi:&#xa0;10.1089/omi.2011.0118</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Du Y, Lu Y, Luan B, Xu C, Yu Y, et al. . Cd44 expression predicts prognosis of ovarian cancer patients through promoting epithelial-mesenchymal transition (emt) by regulating snail, zeb1, and caveolin-1. Front Oncol (2019) 9:802. doi:&#xa0;10.3389/fonc.2019.00802</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.00802</ArticleId><ArticleId IdType="pmc">PMC6712994</ArticleId><ArticleId IdType="pubmed">31497537</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Tao X, Wu J, Yu H, Yu Y, Zhao H. Apobec3b up-regulation independently predicts ovarian cancer prognosis: A cohort study. Cancer Cell Int (2018) 18:78. doi:&#xa0;10.1186/s12935-018-0572-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-018-0572-5</ArticleId><ArticleId IdType="pmc">PMC5975489</ArticleId><ArticleId IdType="pubmed">29853799</ArticleId></ArticleIdList></Reference><Reference><Citation>Periyasamy M, Patel H, Lai CF, Nguyen V, Nevedomskaya E, Harrod A, et al. . Apobec3b-mediated cytidine deamination is required for estrogen receptor action in breast cancer. Cell Rep (2015) 13:108&#x2013;21. doi:&#xa0;10.1016/j.celrep.2015.08.066</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.08.066</ArticleId><ArticleId IdType="pmc">PMC4597099</ArticleId><ArticleId IdType="pubmed">26411678</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoesel B, Schmid JA. The complexity of nf-&#x3ba;b signaling in inflammation and cancer. Mol Cancer (2013) 12:86. doi:&#xa0;10.1186/1476-4598-12-86</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-4598-12-86</ArticleId><ArticleId IdType="pmc">PMC3750319</ArticleId><ArticleId IdType="pubmed">23915189</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour. Cell Death Differ (2018) 25:104&#x2013;13. doi:&#xa0;10.1038/cdd.2017.169</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2017.169</ArticleId><ArticleId IdType="pmc">PMC5729529</ArticleId><ArticleId IdType="pubmed">29149101</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine AJ. P53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. (2020) 20:471&#x2013;80. doi:&#xa0;10.1038/s41568-020-0262-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-020-0262-1</ArticleId><ArticleId IdType="pubmed">32404993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang R, Kroemer G, Tang D. The tumor suppressor protein p53 and the ferroptosis network. Free Radical Biol Med (2019) 133:162&#x2013;8. doi:&#xa0;10.1016/j.freeradbiomed.2018.05.074</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.05.074</ArticleId><ArticleId IdType="pmc">PMC6251771</ArticleId><ArticleId IdType="pubmed">29800655</ArticleId></ArticleIdList></Reference><Reference><Citation>Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: i have a. Cell Death Differ (2018) 25:114&#x2013;32. doi:&#xa0;10.1038/cdd.2017.172</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2017.172</ArticleId><ArticleId IdType="pmc">PMC5729532</ArticleId><ArticleId IdType="pubmed">29125603</ArticleId></ArticleIdList></Reference><Reference><Citation>SS P, Naresh P AJ, Wadhwani A M, Jubie S. Dual modulators of p53 and cyclin d in er alpha signaling by albumin nanovectors. Mini Rev Med Chem (2021) 21:792&#x2013;802. doi:&#xa0;10.2174/1389557520999201124212347</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389557520999201124212347</ArticleId><ArticleId IdType="pubmed">33238842</ArticleId></ArticleIdList></Reference><Reference><Citation>Engeland K. Cell cycle regulation: p53-p21-rb signaling. Cell Death Differ (2022) 29:946&#x2013;60. doi:&#xa0;10.1038/s41418-022-00988-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-022-00988-z</ArticleId><ArticleId IdType="pmc">PMC9090780</ArticleId><ArticleId IdType="pubmed">35361964</ArticleId></ArticleIdList></Reference><Reference><Citation>Zohny SF, Al-Malki AL, Zamzami MA, Choudhry H. P21(waf1/cip1): its paradoxical effect in the regulation of breast cancer. Breast Cancer (Tokyo Japan). (2019) 26:131&#x2013;7. doi:&#xa0;10.1007/s12282-018-0913-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12282-018-0913-1</ArticleId><ArticleId IdType="pubmed">30255294</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Huang J, Yang D, Xiang S, Sun J, Li H, et al. . Expression patterns of e2f transcription factors and their potential prognostic roles in breast cancer. Oncol Lett (2018) 15:9216&#x2013;30. doi:&#xa0;10.3892/ol.2018.8514</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2018.8514</ArticleId><ArticleId IdType="pmc">PMC5958806</ArticleId><ArticleId IdType="pubmed">29844824</ArticleId></ArticleIdList></Reference><Reference><Citation>Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: Past, present, and future. Lancet (London England) (2020) 395:817&#x2013;27. doi:&#xa0;10.1016/S0140-6736(20)30165-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30165-3</ArticleId><ArticleId IdType="pubmed">32145796</ArticleId></ArticleIdList></Reference><Reference><Citation>Periyasamy M, Singh AK, Gemma C, Farzan R, Allsopp RC, Shaw JA, et al. . Induction of apobec3b expression by chemotherapy drugs is mediated by. Oncogene (2021) 40:1077&#x2013;90. doi:&#xa0;10.1038/s41388-020-01583-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-020-01583-7</ArticleId><ArticleId IdType="pmc">PMC7116738</ArticleId><ArticleId IdType="pubmed">33323971</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama W, Shirakawa K, Matsui H, Matsumoto T, Yamazaki H, Sarca AD, et al. . Classical nf-&#x3ba;b pathway is responsible for apobec3b expression in cancer cells. Biochem Bioph. Res Co (2016) 478:1466&#x2013;71. doi:&#xa0;10.1016/j.bbrc.2016.08.148</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.08.148</ArticleId><ArticleId IdType="pubmed">27577680</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, et al. . Apobec3b is an enzymatic source of mutation in breast cancer. Nature (2013) 494:366&#x2013;70. doi:&#xa0;10.1038/nature11881</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11881</ArticleId><ArticleId IdType="pmc">PMC3907282</ArticleId><ArticleId IdType="pubmed">23389445</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Tao X, Wu J, Yu H, Yu Y, Zhao H. Apobec3b up-regulation independently predicts ovarian cancer prognosis: A cohort. Cancer Cell Int (2018) 18:78. doi:&#xa0;10.1186/s12935-018-0572-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-018-0572-5</ArticleId><ArticleId IdType="pmc">PMC5975489</ArticleId><ArticleId IdType="pubmed">29853799</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Li X, Li J, Lu Y, Zhao S, Tang X, et al. . Apobec3b interaction with prc2 modulates microenvironment to promote hcc. Gut (2019) 68:1846&#x2013;57. doi:&#xa0;10.1136/gutjnl-2018-317601</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2018-317601</ArticleId><ArticleId IdType="pubmed">31154396</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieuwerts AM, Schrijver WAME, Dalm SU, de Weerd V, Moelans CB, Ter Hoeve N, et al. . Progressive apobec3b mrna expression in distant breast cancer metastases. PloS One (2017) 12:e171343. doi:&#xa0;10.1371/journal.pone.0171343</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0171343</ArticleId><ArticleId IdType="pmc">PMC5283735</ArticleId><ArticleId IdType="pubmed">28141868</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieuwerts AM, Doebar SC, de Weerd V, Verhoef EI, Beauford CM, Agahozo MC, et al. . Apobec3b gene expression in ductal carcinoma in situ and synchronous invasive. Cancers (2019) 11(8):1062. doi:&#xa0;10.3390/cancers11081062</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11081062</ArticleId><ArticleId IdType="pmc">PMC6721358</ArticleId><ArticleId IdType="pubmed">31357602</ArticleId></ArticleIdList></Reference><Reference><Citation>Refsland EW, Harris RS. The apobec3 family of retroelement restriction factors. Curr Top Microbiol (2013) 371:1&#x2013;27. doi:&#xa0;10.1007/978-3-642-37765-5_1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-37765-5_1</ArticleId><ArticleId IdType="pmc">PMC3934647</ArticleId><ArticleId IdType="pubmed">23686230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J, Wang C, Ma X, Wang E, Peng G. Apobec3b, a molecular driver of mutagenesis in human cancers. Cell Biosci (2017) 7:29. doi:&#xa0;10.1186/s13578-017-0156-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13578-017-0156-4</ArticleId><ArticleId IdType="pmc">PMC5450379</ArticleId><ArticleId IdType="pubmed">28572915</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokunaga E, Yamashita N, Tanaka K, Inoue Y, Akiyoshi S, Saeki H, et al. . Expression of apobec3b mrna in primary breast cancer of japanese women. PloS One (2016) 11:e168090. doi:&#xa0;10.1371/journal.pone.0168090</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0168090</ArticleId><ArticleId IdType="pmc">PMC5158016</ArticleId><ArticleId IdType="pubmed">27977754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Wei W, Jin H, Ying R, Zhu A, Zhang F. The roles of apobec3b in gastric cancer. Int J Clin Exp Patho (2015) 8:5089&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503075</ArticleId><ArticleId IdType="pubmed">26191203</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z, Han Y, Han X. The role of apobec3b in chondrosarcoma. Oncol Rep (2014) 32:1867&#x2013;72. doi:&#xa0;10.3892/or.2014.3437</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2014.3437</ArticleId><ArticleId IdType="pubmed">25176183</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P, Chen Y, Kuo T, Lin H, Liu C, Chang L. Apobec3b: A potential factor suppressing growth of human hepatocellular carcinoma cells. Anticancer Res (2015) 35:1521&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25750306</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36237259</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2219-6803</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Translational cancer research</Title><ISOAbbreviation>Transl Cancer Res</ISOAbbreviation></Journal><ArticleTitle>A comprehensive pan-cancer analysis on the immunological role and prognostic value of <i>TYMP</i> in human cancers.</ArticleTitle><Pagination><StartPage>3187</StartPage><EndPage>3208</EndPage><MedlinePgn>3187-3208</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/tcr-22-502</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The <i>TYMP</i> gene encodes an important nucleoside metabolism enzyme which is a rate-limiting enzyme for chemotherapeutic drug metabolism. Previous studies have shown that <i>TYMP</i> is highly expressed in many different tumors, promoting invasiveness and progression, and that it helps to predict the response to chemotherapeutic drugs. However, the role of <i>TYMP</i> in tumor immunity and prognosis remains largely unclear. The purpose of this pan-cancer analysis was to acquire more data on the function of <i>TYMP</i> function and its clinical significance.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">To access the <i>TYMP</i> expression, we accessed datasets from The Cancer Genome Atlas (TCGA), Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), Cancer Cell Line Encyclopedia (CCLE) databases, and analyzed its differential expression between paired tumor and normal samples. We employed PrognoScan and Kaplan-Meier plotter for survival analyses. <i>TYMP</i> mutations were analyzed using cBioPortal. Correlations of <i>TYMP</i> with tumor stage, tumor mutational burden (TMB), microsatellite instability (MSI), immune checkpoint genes (ICGs), and immune cell infiltration were estimated via bioinformatics tools and methods. The CellMiner database was used to predict drug response. Gene set enrichment analysis (GSEA) was applied to explore the biological functions of <i>TYMP</i> in different tumors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Our results indicated that <i>TYMP</i> was overexpressed and also significantly associated with a worse prognosis in several human cancers, such as kidney clear cell carcinoma (KIRC) and lower grade glioma (LGG). <i>TYMP</i> was also associated with TMB, MSI, and ICGs across a variety of malignancies. <i>TYMP</i> was most significantly correlated with immune cell infiltration in five tumors, namely, breast cancer (BRCA), cervical cancer (CESC), KIRC, skin cutaneous melanoma (SKCM), and stomach adenocarcinoma (STAD). Moreover, <i>TYMP</i> expression predicted sensitivity to chemotherapy drugs and also influenced relevant biological pathways, according to enrichment analysis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">According to the results of this comprehensive analysis, <i>TYMP</i> is associated with prognosis and tumor immunology, which might make it be a potential therapeutic target for cancer treatment.</AbstractText><CopyrightInformation>2022 Translational Cancer Research. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yalan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Sixue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Mingyu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yuqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zeying</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Cancer Res</MedlineTA><NlmUniqueID>101585958</NlmUniqueID><ISSNLinking>2218-676X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TYMP</Keyword><Keyword MajorTopicYN="N">immune infiltration</Keyword><Keyword MajorTopicYN="N">pan-cancer analysis</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">tumor mutational burden (TMB)</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-502/coif). The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>2</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36237259</ArticleId><ArticleId IdType="pmc">PMC9552085</ArticleId><ArticleId IdType="doi">10.21037/tcr-22-502</ArticleId><ArticleId IdType="pii">tcr-11-09-3187</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. 10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Steeg PS. Targeting metastasis. Nat Rev Cancer 2016;16:201-18. 10.1038/nrc.2016.25</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2016.25</ArticleId><ArticleId IdType="pmc">PMC7055530</ArticleId><ArticleId IdType="pubmed">27009393</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishton RJ, Sukumar M, Restifo NP. Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab 2017;26:94-109. 10.1016/j.cmet.2017.06.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2017.06.016</ArticleId><ArticleId IdType="pmc">PMC5543711</ArticleId><ArticleId IdType="pubmed">28683298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359:1350-5. 10.1126/science.aar4060</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aar4060</ArticleId><ArticleId IdType="pmc">PMC7391259</ArticleId><ArticleId IdType="pubmed">29567705</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Chen W, Wang F, et al. Nutrition Therapy for Mitochondrial Neurogastrointestinal Encephalopathy with Homozygous Mutation of the TYMP Gene. Clin Nutr Res 2015;4:132-6. 10.7762/cnr.2015.4.2.132</Citation><ArticleIdList><ArticleId IdType="doi">10.7762/cnr.2015.4.2.132</ArticleId><ArticleId IdType="pmc">PMC4418417</ArticleId><ArticleId IdType="pubmed">25954734</ArticleId></ArticleIdList></Reference><Reference><Citation>Liekens S, Bronckaers A, P&#xe9;rez-P&#xe9;rez MJ, et al. Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. Biochem Pharmacol 2007;74:1555-67. 10.1016/j.bcp.2007.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2007.05.008</ArticleId><ArticleId IdType="pubmed">17572389</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacitti D, Levene M, Garone C, et al. Mitochondrial Neurogastrointestinal Encephalomyopathy: Into the Fourth Decade, What We Have Learned So Far. Front Genet 2018;9:669. 10.3389/fgene.2018.00669</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00669</ArticleId><ArticleId IdType="pmc">PMC6309918</ArticleId><ArticleId IdType="pubmed">30627136</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimminger PP, Schneider PM, Metzger R, et al. Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer. Clin Lung Cancer 2010;11:328-34. 10.3816/CLC.2010.n.041</Citation><ArticleIdList><ArticleId IdType="doi">10.3816/CLC.2010.n.041</ArticleId><ArticleId IdType="pubmed">20837458</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito K, Khan K, Yu SZ, et al. The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer. Laryngoscope 2009;119:82-8. 10.1002/lary.20003</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.20003</ArticleId><ArticleId IdType="pubmed">19117293</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumagai Y, Tachikawa T, Higashi M, et al. Thymidine phosphorylase and angiogenesis in early stage esophageal squamous cell carcinoma. Esophagus 2018;15:19-26. 10.1007/s10388-017-0588-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10388-017-0588-2</ArticleId><ArticleId IdType="pubmed">29892805</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Huang X, Chen Y, et al. Prognostic value of TP/PD-ECGF and thrombocytosis in gastric carcinoma. Eur J Surg Oncol 2012;38:568-73. 10.1016/j.ejso.2012.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejso.2012.04.008</ArticleId><ArticleId IdType="pubmed">22595739</ArticleId></ArticleIdList></Reference><Reference><Citation>Koumarianou A, Tzeveleki I, Mekras D, et al. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression. Anticancer Res 2014;34:4949-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">25202077</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Yue H. Thymidine phosphorylase: A potential new target for treating cardiovascular disease. Trends Cardiovasc Med 2018;28:157-71. 10.1016/j.tcm.2017.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2017.10.003</ArticleId><ArticleId IdType="pmc">PMC5856583</ArticleId><ArticleId IdType="pubmed">29108898</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa T, Tabata S, Yamamoto M, et al. Thymidine phosphorylase in cancer aggressiveness and chemoresistance. Pharmacol Res 2018;132:15-20. 10.1016/j.phrs.2018.03.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2018.03.019</ArticleId><ArticleId IdType="pubmed">29604437</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Zhang Y, Hu X, et al. Thymidine phosphorylase promotes metastasis and serves as a marker of poor prognosis in hepatocellular carcinoma. Lab Invest 2017;97:903-12. 10.1038/labinvest.2017.51</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.2017.51</ArticleId><ArticleId IdType="pubmed">28530649</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XR, Xu Y, Yu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010;59:953-62. 10.1136/gut.2008.176271</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2008.176271</ArticleId><ArticleId IdType="pubmed">20442200</ArticleId></ArticleIdList></Reference><Reference><Citation>Slager EH, Honders MW, van der Meijden ED, et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 2006;107:4954-60. 10.1182/blood-2005-09-3883</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2005-09-3883</ArticleId><ArticleId IdType="pubmed">16497972</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4. 10.1158/2159-8290.CD-12-0095</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-12-0095</ArticleId><ArticleId IdType="pmc">PMC3956037</ArticleId><ArticleId IdType="pubmed">22588877</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusco MJ, West HJ, Walko CM. Tumor Mutation Burden and Cancer Treatment. JAMA Oncol 2021;7:316. 10.1001/jamaoncol.2020.6371</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2020.6371</ArticleId><ArticleId IdType="pubmed">33331847</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilson P, Merlin JL, Harl&#xe9; A. Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA). Cancers (Basel) 2021;13:1491. 10.3390/cancers13071491</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13071491</ArticleId><ArticleId IdType="pmc">PMC8037825</ArticleId><ArticleId IdType="pubmed">33804907</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara K, Shahmoradgoli M, Mart&#xed;nez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013;4:2612. 10.1038/ncomms3612</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3612</ArticleId><ArticleId IdType="pmc">PMC3826632</ArticleId><ArticleId IdType="pubmed">24113773</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015;12:453-7. 10.1038/nmeth.3337</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3337</ArticleId><ArticleId IdType="pmc">PMC4739640</ArticleId><ArticleId IdType="pubmed">25822800</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhold WC, Sunshine M, Liu H, et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 2012;72:3499-511. 10.1158/0008-5472.CAN-12-1370</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-12-1370</ArticleId><ArticleId IdType="pmc">PMC3399763</ArticleId><ArticleId IdType="pubmed">22802077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett 2017;387:61-8. 10.1016/j.canlet.2016.01.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2016.01.043</ArticleId><ArticleId IdType="pubmed">26845449</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wei Q, Chen Y, et al. Identification of Hub Genes Associated With Sensitivity of 5-Fluorouracil Based Chemotherapy for Colorectal Cancer by Integrated Bioinformatics Analysis. Front Oncol 2021;11:604315. 10.3389/fonc.2021.604315</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.604315</ArticleId><ArticleId IdType="pmc">PMC8071956</ArticleId><ArticleId IdType="pubmed">33912443</ArticleId></ArticleIdList></Reference><Reference><Citation>Marangoni E, Laurent C, Coussy F, et al. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers. Clin Cancer Res 2018;24:2605-15. 10.1158/1078-0432.CCR-17-3490</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-17-3490</ArticleId><ArticleId IdType="pubmed">29463559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobashi N, Matsumoto H, Zhao S, et al. The Thymidine Phosphorylase Imaging Agent 123I-IIMU Predicts the Efficacy of Capecitabine. J Nucl Med 2016;57:1276-81. 10.2967/jnumed.115.165811</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.115.165811</ArticleId><ArticleId IdType="pubmed">27056620</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Yang H, Li K, et al. Thymidine phosphorylase promotes angiogenesis and tumour growth in intrahepatic cholangiocarcinoma. Cell Biochem Funct 2020;38:743-52. 10.1002/cbf.3541</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbf.3541</ArticleId><ArticleId IdType="pubmed">32476180</ArticleId></ArticleIdList></Reference><Reference><Citation>Naoe M, Ogawa Y, Morita J, et al. Expression of the fluoropyrimidine-metabolizing enzymes in bladder cancers as measured by the Danenberg tumor profile. Oncol Res 2009;18:153-62. 10.3727/096504009790217371</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096504009790217371</ArticleId><ArticleId IdType="pubmed">20112501</ArticleId></ArticleIdList></Reference><Reference><Citation>Zizzo N, Passantino G, D'alessio RM, et al. Thymidine Phosphorylase Expression and Microvascular Density Correlation Analysis in Canine Mammary Tumor: Possible Prognostic Factor in Breast Cancer. Front Vet Sci 2019;6:368. 10.3389/fvets.2019.00368</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fvets.2019.00368</ArticleId><ArticleId IdType="pmc">PMC6823610</ArticleId><ArticleId IdType="pubmed">31709268</ArticleId></ArticleIdList></Reference><Reference><Citation>Takebayashi Y, Natsugoe S, Baba M, et al. Thymidine phosphorylase in human esophageal squamous cell carcinoma. Cancer 1999;85:282-9. 10.1002/(SICI)1097-0142(19990115)85:2&lt;282::AID-CNCR3&gt;3.0.CO;2-T</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0142(19990115)85:2&lt;282::AID-CNCR3&gt;3.0.CO;2-T</ArticleId><ArticleId IdType="pubmed">10023693</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Pan Q, Xiao R, et al. A cluster of metabolism-related genes predict prognosis and progression of clear cell renal cell carcinoma. Sci Rep 2020;10:12949. 10.1038/s41598-020-67760-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-67760-6</ArticleId><ArticleId IdType="pmc">PMC7395775</ArticleId><ArticleId IdType="pubmed">32737333</ArticleId></ArticleIdList></Reference><Reference><Citation>Biagioni A, Staderini F, Peri S, et al. 5-Fluorouracil Conversion Pathway Mutations in Gastric Cancer. Biology (Basel) 2020;9:265. 10.3390/biology9090265</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology9090265</ArticleId><ArticleId IdType="pmc">PMC7563957</ArticleId><ArticleId IdType="pubmed">32887417</ArticleId></ArticleIdList></Reference><Reference><Citation>Peri S, Biagioni A, Versienti G, et al. Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line. Int J Mol Sci 2021;22:7698. 10.3390/ijms22147698</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22147698</ArticleId><ArticleId IdType="pmc">PMC8303918</ArticleId><ArticleId IdType="pubmed">34299320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruckh&#xe4;berle E, Karn T, Engels K, et al. Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data. Eur J Cancer 2010;46:549-57. 10.1016/j.ejca.2009.11.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2009.11.020</ArticleId><ArticleId IdType="pubmed">20022486</ArticleId></ArticleIdList></Reference><Reference><Citation>Saif MW, Hashmi S, Bell D, et al. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival. Expert Opin Drug Saf 2009;8:507-14. 10.1517/14740330903173217</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14740330903173217</ArticleId><ArticleId IdType="pubmed">19663627</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima M, Nakano T, Ametani Y, et al. Expression of thymidine phosphorylase as an effect prediction factor for uterine cervical squamous cell carcinoma after radiotherapy: an immunohistochemical study. Int J Gynecol Cancer 2006;16:1309-13. 10.1136/ijgc-00009577-200605000-00054</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ijgc-00009577-200605000-00054</ArticleId><ArticleId IdType="pubmed">16803522</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Wang L, Chen Y, et al. Poor Prognosis Associated with High Levels of Thymidine Phosphorylase and Thrombocytosis in Patients with Renal Cell Carcinoma. Urol Int 2017;98:162-8. 10.1159/000448483</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000448483</ArticleId><ArticleId IdType="pubmed">27532673</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardim DL, Goodman A, de Melo Gagliato D, et al. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell 2021;39:154-73. 10.1016/j.ccell.2020.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7878292</ArticleId><ArticleId IdType="pubmed">33125859</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol 2019;30:1096-103. 10.1093/annonc/mdz134</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdz134</ArticleId><ArticleId IdType="pubmed">31038663</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Jia Y, Zhu H, et al. Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy. Gastric Cancer 2021;24:1342-54. 10.1007/s10120-021-01207-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10120-021-01207-3</ArticleId><ArticleId IdType="pubmed">34406546</ArticleId></ArticleIdList></Reference><Reference><Citation>Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019;51:202-6. 10.1038/s41588-018-0312-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0312-8</ArticleId><ArticleId IdType="pmc">PMC6365097</ArticleId><ArticleId IdType="pubmed">30643254</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudley JC, Lin MT, Le DT, et al. Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res 2016;22:813-20. 10.1158/1078-0432.CCR-15-1678</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1678</ArticleId><ArticleId IdType="pubmed">26880610</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9; T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 2020;383:2207-18. 10.1056/NEJMoa2017699</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2017699</ArticleId><ArticleId IdType="pubmed">33264544</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R, Zhang J, Zeng D, et al. Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I-III colon cancer. Cancer Immunol Immunother 2019;68:433-42. 10.1007/s00262-018-2289-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-018-2289-7</ArticleId><ArticleId IdType="pmc">PMC6426802</ArticleId><ArticleId IdType="pubmed">30564892</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui S, An X, Xu C, et al. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. Theranostics 2020;10:11938-49. 10.7150/thno.49451</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.49451</ArticleId><ArticleId IdType="pmc">PMC7667685</ArticleId><ArticleId IdType="pubmed">33204321</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara A, Hattori S, Akiba J, et al. Infiltration of thymidine phosphorylase-positive macrophages is closely associated with tumor angiogenesis and survival in intestinal type gastric cancer. Oncol Rep 2010;24:405-15. 10.3892/or_00000873</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or_00000873</ArticleId><ArticleId IdType="pubmed">20596627</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaoka H, Iino Y, Takei H, et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer. Int J Oncol 1998;13:449-54. 10.3892/ijo.13.3.449</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.13.3.449</ArticleId><ArticleId IdType="pubmed">9683777</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36103746</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0534</ISSN><JournalIssue CitedMedium="Internet"><Volume>149</Volume><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Computers in biology and medicine</Title><ISOAbbreviation>Comput Biol Med</ISOAbbreviation></Journal><ArticleTitle>Interactive bioinformatics analysis for the screening of hub genes and molecular docking of phytochemicals present in kitchen spices to inhibit CDK1 in cervical cancer.</ArticleTitle><Pagination><StartPage>105994</StartPage><MedlinePgn>105994</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.compbiomed.2022.105994</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0010-4825(22)00718-1</ELocationID><Abstract><AbstractText>Cervical cancer (CC) is the world's fourth most prevalent cancer among women. The mortality rate of cervical cancer increases each year due to a lack of early diagnosis. Our study aims to find potential genes linked to cervical cancer and validate the findings using docking analysis. The microarray datasets (GSE6791, GSE7803, GSE9750, GSE39001, GSE52903, GSE63514, and GSE75132) were downloaded from the GEO (Gene Expression Omnibus) database. A total of 1160 Differentially Expressed Genes (DEGs) were discovered using the R statistical language, including 825 up-regulated and 335 down-regulated genes. STRING, which predicts the potential interaction between genes at the protein level, was used to build the PPI network of these DEGs. Moreover, hub gene expression analysis was carried out by CytoHubba plugin Cytoscape. CDK1 was considered for subsequent molecular docking because of its frequent appearance throughout the analysis. CDK1 was docked with the 399 phytochemicals of Indian kitchen spices. The top three compounds namely, Vicenin 2, 2-O,3-O,4-O,6-O-Tetragalloyl-d-glucopyranose and Pentagalloylglucose, were chosen based on their docking scores and their interactions with the key amino acids present in the ATP binding pocket, like the positive control Dinaciclib. In conclusion, the findings of this study may lead to new insights on CC diagnosis, aetiology, and treatment options. In the future, it may be possible to develop particular diagnostics and therapies for CC by identifying hub genes and studying overexpressed proteins as therapeutic targets.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vaghasia</LastName><ForeName>Harsha</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Microbiology &amp; Biotechnology, University School of Sciences, Gujarat University, Ahmedabad, 380009, Gujarat, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakaria</LastName><ForeName>Shiralee</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bioinnovations, Mumbai, 401101, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prajapati</LastName><ForeName>Jignesh</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry &amp; Forensic Science, University School of Sciences, Gujarat University, Ahmedabad, 380009, Gujarat, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saraf</LastName><ForeName>Meenu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology &amp; Biotechnology, University School of Sciences, Gujarat University, Ahmedabad, 380009, Gujarat, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rawal</LastName><ForeName>Rakesh M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry &amp; Forensic Science, University School of Sciences, Gujarat University, Ahmedabad, 380009, Gujarat, India; Department of Life Science, University School of Sciences, Gujarat University, Ahmedabad, 380009, Gujarat, India. Electronic address: rakeshrawal@gujaratuniversity.ac.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Comput Biol Med</MedlineTA><NlmUniqueID>1250250</NlmUniqueID><ISSNLinking>0010-4825</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064209">Phytochemicals</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="D016203">CDC2 Protein Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="C528899">CDK1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016203" MajorTopicYN="N">CDC2 Protein Kinase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="Y">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055088" MajorTopicYN="N">Early Detection of Cancer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064209" MajorTopicYN="N">Phytochemicals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CDK1</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Differentially expressed genes (DEGs)</Keyword><Keyword MajorTopicYN="N">Indian kitchen spices</Keyword><Keyword MajorTopicYN="N">Molecular docking</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>14</Day><Hour>18</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36103746</ArticleId><ArticleId IdType="doi">10.1016/j.compbiomed.2022.105994</ArticleId><ArticleId IdType="pii">S0010-4825(22)00718-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36049413</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0534</ISSN><JournalIssue CitedMedium="Internet"><Volume>149</Volume><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Computers in biology and medicine</Title><ISOAbbreviation>Comput Biol Med</ISOAbbreviation></Journal><ArticleTitle>Identification of potential crucial genes and key pathways shared in Inflammatory Bowel Disease and cervical cancer by machine learning and integrated bioinformatics.</ArticleTitle><Pagination><StartPage>105996</StartPage><MedlinePgn>105996</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.compbiomed.2022.105996</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0010-4825(22)00720-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">Recently, Inflammatory Bowel Disease (IBD) has been proven as a risk factor for the increasing incidence of cervical cancer (CC) development. In this study, we identify these potential hub genes and their significant pathways that commonly interact between IBD and CC and these pathological mechanisms. To this end, we use bioinformatics and systems biology approaches to analyze the miRNA-mRNA, TFs-mRNA regulatory network.</AbstractText><AbstractText Label="METHODS AND FINDINGS">The reanalysis dataset from Gene Expression Omnibus (GEO) and the cancer genome atlas (TCGA) found these common differentially expressed genes (DEGs) between IBD and CC, clustered via weighted gene co-expression network analysis, and the vital modules significantly related to cervical cancer were identified. These hub genes of the key module were identified and explored in biological mechanism pathway analysis. Organelle fission, nuclear envelope, protein serine/threonine kinase activity, and the Human T-cell leukemia virus 1 infection pathway were the major enriched pathways for the common DEGs. Due to the high connectivity, the common DEGs with protein-protein interaction (PPI) network disclosed hub proteins (CDK1, MAD2L1, and CCNB1). This study also showed the classification algorithms of ten hub genes (MAD2L1, CCNB2, CDK1, CCNA2, BUB1B, KIF11, TTK, BUB1, CCNB1, ASPM) with accuracy &gt;0.90 suggesting the novel biomarker potential of the hub genes. The microRNAs (miRNA), and transcription factors (TFs) mRNA regulatory network, five transcription factors, and twelve miRNAs are strongly linked to three hub genes. Gene drug interaction analysis found seven drugs compound that interacts with the hub gene.</AbstractText><AbstractText Label="CONCLUSIONS">In the current study, our procedure has hypothesized the comprehensive understanding of disease mechanisms vital for both CC and IBD that may mediate their interaction. Our results suggest the further investigation of the molecules for the treatment of IBD and CC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Thong Ba</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Biochemistry, and Physiology, John A. Burns School of Medicine, The University of Hawaii at Manoa, Honolulu, HI, 96813, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do</LastName><ForeName>Duy Ngoc</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Department of Animal Science and Aquaculture, Dalhousie University, Truro, Nova Scotia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen-Thi</LastName><ForeName>My-Le</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>VNUK Institute for Research and Executive Education, The University of Danang, 158A Le Loi Street, Hai Chau District, Danang, 550000, Viet Nam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoang-The</LastName><ForeName>Hiep</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Hue University of Medicine and Pharmacy, Hue University, Hue, 49000, Viet Nam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Thanh-Thoa</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Aptagen LLC, 250 North Main Street, Jacobus, Pennsylvania, 17407, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen-Thanh</LastName><ForeName>Tung</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Basic Science, University of Medicine and Pharmacy, Hue University, Hue, 49000, Viet Nam; Institute of Biomedicine, University of Medicine and Pharmacy, Hue University, Hue, 49000, Viet Nam. Electronic address: nguyenthanhtung@hueuni.edu.vn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Comput Biol Med</MedlineTA><NlmUniqueID>1250250</NlmUniqueID><ISSNLinking>0010-4825</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CCNB1</Keyword><Keyword MajorTopicYN="N">CDK1</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Inflammatory bowel disease</Keyword><Keyword MajorTopicYN="N">MAD2L1</Keyword><Keyword MajorTopicYN="N">Molecular pathways</Keyword><Keyword MajorTopicYN="N">WGCNA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>1</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36049413</ArticleId><ArticleId IdType="doi">10.1016/j.compbiomed.2022.105996</ArticleId><ArticleId IdType="pii">S0010-4825(22)00720-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35965520</PMID><DateRevised><Year>2022</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>Identification of critical genes associated with radiotherapy resistance in cervical cancer by bioinformatics.</ArticleTitle><Pagination><StartPage>967386</StartPage><MedlinePgn>967386</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">967386</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2022.967386</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Cervical cancer (CC) is one of the common malignant tumors in women, Currently, 30% of patients with intermediate to advanced squamous cervical cancer are still uncontrolled or recurrent after standard radical simultaneous radiotherapy; therefore, the search for critical genes affecting the sensitivity of radiotherapy may lead to new strategies for treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Firstly, differentially expressed genes (DEGs) between radiotherapy-sensitivity and radiotherapy-resistance were identified by GEO2R from the gene expression omnibus (GEO) website, and prognosis-related genes for cervical cancer were obtained from the HPA database. Subsequently, the DAVID database analyzed gene ontology (GO). Meanwhile, the protein-protein interaction network was constructed by STRING; By online analysis of DEGs, prognostic genes, and CCDB data that are associated with cervical cancer formation through the OncoLnc database, we aim to search for the key DEGs associated with CC, Finally, the key gene(s) was further validated by immunohistochemistry.</AbstractText><AbstractText Label="RESULT" NlmCategory="UNASSIGNED">298 differentially expressed genes, 712 genes associated with prognosis, and 509 genes related to cervical cancer formation were found. The results of gene function analysis showed that DEGs were mainly significant in functional pathways such as variable shear and energy metabolism. By further verification, two genes, ASPH and NKAPP1 were identified through validation as genes that affect both sensitivities to radiotherapy and survival finally. Then, immunohistochemical results showed that the ASPH gene was highly expressed in the radiotherapy-resistant group and had lower Overall survival (OS) and Progression-free survival (PFS).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study aims to better understand the characteristics of cervical cancer radiation therapy resistance-related genes through bioinformatics and provide further research ideas for finding new mechanisms and potential therapeutic targets related to cervical cancer radiation therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Zhang, Xiang, Tan, Du, He, Li, Li and Wen.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhenhua</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangxi Medical University Cancer Hospital, Nanning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Kechao</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Longjing</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Xiuju</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Huailin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Guangxi Medical University Cancer Hospital, Nanning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Qinglian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DEGs</Keyword><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">cervical squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">radiotherapy</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>15</Day><Hour>3</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35965520</ArticleId><ArticleId IdType="pmc">PMC9373049</ArticleId><ArticleId IdType="doi">10.3389/fonc.2022.967386</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shrivastava S, Mahantshetty U, Engineer R, Chopra S, Hawaldar R, Hande V, et al. . Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix. JAMA Oncol (2018) 4:506. doi:&#xa0;10.1001/jamaoncol.2017.5179</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2017.5179</ArticleId><ArticleId IdType="pmc">PMC5885185</ArticleId><ArticleId IdType="pubmed">29423520</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Huang E, Lin H. Optimal treatments for cervical adenocarcinoma. Am J Cancer Res (2019) 9:1224&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6610057</ArticleId><ArticleId IdType="pubmed">31285954</ArticleId></ArticleIdList></Reference><Reference><Citation>Santin AD, Sill MW, McMeekin DS, Leitao MM, Brown J, Sutton GP, et al. . Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A gynecologic oncology group study. Gynecol Oncol (2011) 122:495&#x2013;500. doi:&#xa0;10.1016/j.ygyno.2011.05.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2011.05.040</ArticleId><ArticleId IdType="pmc">PMC3152667</ArticleId><ArticleId IdType="pubmed">21684583</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MK, Kim T, Sung C, Choi CH, Lee J, Bae D, et al. . Clinical significance of HIF-2&#x3b1; immunostaining area in radioresistant cervical cancer. J Gynecol Oncol (2011) 22:44. doi:&#xa0;10.3802/jgo.2011.22.1.44</Citation><ArticleIdList><ArticleId IdType="doi">10.3802/jgo.2011.22.1.44</ArticleId><ArticleId IdType="pmc">PMC3097334</ArticleId><ArticleId IdType="pubmed">21607095</ArticleId></ArticleIdList></Reference><Reference><Citation>Wootipoom V, Lekhyananda N, Phungrassami T, Boonyaphiphat P, Thongsuksai P. Prognostic significance of bax, bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecol Oncol (2004) 94:636&#x2013;42. doi:&#xa0;10.1016/j.ygyno.2004.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2004.03.012</ArticleId><ArticleId IdType="pubmed">15350352</ArticleId></ArticleIdList></Reference><Reference><Citation>Petera J, Sirak I, Beranek M, Vosmik M, Drastikova M, Paulikova S, et al. . Molecular predictive factors of outcome of radiotherapy in cervical cancer. Neoplasma (2011) 58:469&#x2013;75. doi:&#xa0;10.4149/neo_2011_06_469</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/neo_2011_06_469</ArticleId><ArticleId IdType="pubmed">21895399</ArticleId></ArticleIdList></Reference><Reference><Citation>Balacescu O, Balacescu L, Tudoran O, Todor N, Rus M, Buiga R, et al. . Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure. BMC Cancer (2014) 14:246. doi:&#xa0;10.1186/1471-2407-14-246</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-14-246</ArticleId><ArticleId IdType="pmc">PMC4021393</ArticleId><ArticleId IdType="pubmed">24708616</ArticleId></ArticleIdList></Reference><Reference><Citation>Harima Y, Togashi A, Horikoshi K, Imamura M, Sougawa M, Sawada S, et al. . Prediction of outcome of advanced cervical cancer to chemoradiotherapyression profiles of 35 genes selected by cDNA microarray analysis. Int J Radiat Oncol Biol Phys (2004) 60:237&#x2013;48. doi:&#xa0;10.1016/j.ijrobp.2004.02.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2004.02.047</ArticleId><ArticleId IdType="pubmed">15337562</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitahara OO, Katagiri TT, Tsunoda TT, Harima YY, Nakamura YY. Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis1. Neoplasia (New York NY) (2002) 4:295&#x2013;303. doi: 10.1038/sj.neo.7900251</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.neo.7900251</ArticleId><ArticleId IdType="pmc">PMC1531706</ArticleId><ArticleId IdType="pubmed">12082545</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. . NCBI GEO: Archive for functional genomics data sets&#x2013;update. Nucleic Acids Res (2012) 41:D991&#x2013;5. doi:&#xa0;10.1093/nar/gks1193</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1193</ArticleId><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Retana J, Lasa-Gonsebatt F, Lopez-Urrutia E, Coronel-Mart&#xed;nez J, Cantu De Leon D, Jacobo-Herrera N, et al. . Transcript profiling distinguishes complete treatment responders with locally advanced cervical cancer. Transl Oncol (2015) 8:77&#x2013;84. doi:&#xa0;10.1016/j.tranon.2015.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2015.01.003</ArticleId><ArticleId IdType="pmc">PMC4415118</ArticleId><ArticleId IdType="pubmed">25926073</ArticleId></ArticleIdList></Reference><Reference><Citation>Manimaran S, Selby HM, Okrah K, Ruberman C, Leek JT, Quackenbush J, et al. . BatchQC: Interactive software for evaluating sample and batch effects in genomic data. Bioinformatics (2016) 32:3836&#x2013;8. doi:&#xa0;10.1093/bioinformatics/btw538</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw538</ArticleId><ArticleId IdType="pmc">PMC5167063</ArticleId><ArticleId IdType="pubmed">27540268</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. . STRING v11: Protein-proteintworks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res (2019) 47:D607&#x2013;13. doi:&#xa0;10.1093/nar/gky1131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM. Gene ontology: Tool for the unification of biology. Nat Genet (2000) 25:25&#x2013;9. doi:&#xa0;10.1038/75556</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen M, Zhang C, Lee S, Sj&#xf6;stedt E, Fagerberg L, Bidkhori G, et al. . A pathology atlas of the human cancer transcriptome. Science (2017) 357(6352):eaan2507. doi:&#xa0;10.1126/science.aan2507</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aan2507</ArticleId><ArticleId IdType="pubmed">28818916</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal SM, Raghav D, Singh H, Raghava GPS. CCDB: A curated database of genes involved in cervix cancer. Nucleic Acids Res (2010) 39:D975&#x2013;9. doi:&#xa0;10.1093/nar/gkq1024</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq1024</ArticleId><ArticleId IdType="pmc">PMC3013652</ArticleId><ArticleId IdType="pubmed">21045064</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaffney DK, Winter K, Fuhrman C, Flinner R, Greven K, Ryu J, et al. . Feasibility of RNA collection for micro-array gene expression analysis in the treatment of cervical carcinoma: A scientific correlate of RTOG c-0128. Gynecol Oncol (2005) 97:607&#x2013;11. doi:&#xa0;10.1016/j.ygyno.2005.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2005.01.014</ArticleId><ArticleId IdType="pubmed">15863167</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidhaas JB, Li S, Winter K, Ryu J, Jhingran A, Miller B, et al. . Changes in gene expression predicting local control in cervical cancer: Results from radiation therapy oncology group 0128. Clin Cancer Res (2009) 15:4199&#x2013;206. doi:&#xa0;10.1158/1078-0432.CCR-08-2257</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-08-2257</ArticleId><ArticleId IdType="pmc">PMC2758917</ArticleId><ArticleId IdType="pubmed">19509178</ArticleId></ArticleIdList></Reference><Reference><Citation>An JS, Huang MN, Song YM, Li N, Wu LY, Zhan QM. A preliminary study of genes related to concomitant chemoradiotherapy resistance n advanced uterine cervical squamous cell carcinoma. Chin Med J (Engl) (2013) 126:4109&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">24229683</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao-Jie L, Ai-Mei G, Li-Juan J, Jiang X. Pseudogene in cancer: Real functions and promising signature. J Med Genet (2014) 52:17&#x2013;24. doi:&#xa0;10.1136/jmedgenet-2014-102785</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2014-102785</ArticleId><ArticleId IdType="pubmed">25391452</ArticleId></ArticleIdList></Reference><Reference><Citation>Han L, Yuan Y, Zheng S, Yang Y, Li J, Edgerton ME, et al. . The pan-cancer analysis of pseudogene expression reveals biologically and clinically relevant tumor subtypes. Nat Commun (2014) 5:3963. doi:&#xa0;10.1038/ncomms4963</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4963</ArticleId><ArticleId IdType="pmc">PMC4339277</ArticleId><ArticleId IdType="pubmed">24999802</ArticleId></ArticleIdList></Reference><Reference><Citation>Ince N, de la Monte SM, Wands JR. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res (2000) 60:1261&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10728685</ArticleId></ArticleIdList></Reference><Reference><Citation>Song K, Xue X-p, Wang W, Huyan T, Wang H, Yang H, et al. . The distribution and expression profiles hydroxylasesome tumorous cell lines and tissues. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2010) 26:141&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20230674</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Song K, Xue T, Xue XP, Huyan T, Wang W, et al. . The distribution and expression profiles of human Aspartyl/Asparaginyl beta-hydroxylase in tumor cell lines and human tissues. Oncol Rep (2010) 24:1257&#x2013;64. doi:&#xa0;10.3892/or_00000980</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or_00000980</ArticleId><ArticleId IdType="pubmed">20878118</ArticleId></ArticleIdList></Reference><Reference><Citation>Jizong Z, Hai D. The diagnostic significance of serum aspartate-asparagine &#x3b2; hydroxylase (ASPH) molecule combined with AFP and GP73 in the diagnosis of primary liver cancer. J Shandong University (2014) 52:78&#x2013;80.</Citation></Reference><Reference><Citation>Wang K, Liu J, Yan Z, Li J, Shi L, Cong W, et al. . Overexpression of aspartyl-(asparaginyl)-&#x3b2;-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology (2010) 52:164&#x2013;73. doi:&#xa0;10.1002/hep.23650</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.23650</ArticleId><ArticleId IdType="pubmed">20578260</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Q, Hou Y, Wang H, Wang K, Xing X, Xia Y, et al. . Hydroxylase activity of ASPH promotes hepatocellular carcinoma metastasis through epithelial-to-Mesenchymal transition pathway. Ebiomedicine (2018) 31:287&#x2013;98. doi:&#xa0;10.1016/j.ebiom.2018.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.05.004</ArticleId><ArticleId IdType="pmc">PMC6013968</ArticleId><ArticleId IdType="pubmed">29764768</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CK, Iwagami Y, Zou J, Casulli S, Lu S, Nagaoka K, et al. . Aspartate beta-hydroxylasegiocarcinoma progression by modulating RB1 phosphorylation. Cancer Lett (2018) 429:1&#x2013;10. doi:&#xa0;10.1016/j.canlet.2018.04.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2018.04.041</ArticleId><ArticleId IdType="pmc">PMC5985220</ArticleId><ArticleId IdType="pubmed">29733964</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaoka K, Bai X, Ogawa K, Dong X, Zhang S, Zhou Y, et al. . Anti-tumor activity of antibody-druggingte-&#x3b2;-hydroxylase in pancreatic ductal adenocarcinoma. Cancer Lett (2019) 449:87&#x2013;98. doi:&#xa0;10.1016/j.canlet.2019.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2019.02.006</ArticleId><ArticleId IdType="pmc">PMC6411448</ArticleId><ArticleId IdType="pubmed">30768955</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoda M, Tomimaru Y, Charpentier KP, Safran H, Carlson RI, Wands J. Tumor progression-related transmembrane protein aspartate-beta-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. J Hepatol (2012) 56:1129&#x2013;35. doi:&#xa0;10.1016/j.jhep.2011.12.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2011.12.016</ArticleId><ArticleId IdType="pmc">PMC3328647</ArticleId><ArticleId IdType="pubmed">22245894</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35936685</PMID><DateRevised><Year>2022</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>The prognostic value and biological significance of gap junction beta protein 2 (GJB2 or Cx26) in cervical cancer.</ArticleTitle><Pagination><StartPage>907960</StartPage><MedlinePgn>907960</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">907960</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2022.907960</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To evaluate the prognostic value and explore the biological significance of gap junction protein beta 2 (GJB2 or Cx26) in cervical cancer (CC).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We first compared GJB2 expression between CC and normal tissues using public databases and immunohistochemistry (IHC). Based on The Cancer Genome Atlas data (TCGA cohort, n = 304) and tissue microarray samples (OBC cohort, n = 111), we explored the prognostic value of GJB2 for CC patients using bioinformatics analysis and IHC scoring. To explore the biological significance of GJB2, Gene set enrichment analysis (GSEA) and Gene Ontology (GO) were performed. The impact of GJB2 on the immune microenvironment was analyzed by CIBERSORTx and ESTIMATE algorithms. We finally investigated the relationship between GJB2 and drug sensitivity based on the Genomics of Drug Sensitivity in Cancer (GDSC).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The expression of GJB2 was significantly increased in CC over normal tissues. Both the TCGA and OBC cohort found that patients with high GJB2 expression had shorter overall survival (OS) time, and high GJB2 expression was the independent risk factor for prognosis (TCGA: HR, 2.566; 95% CI, 1.066-6.180; p = 0.036; OBC: HR, 2.198; 95% CI, 1.019-4.741; p = 0.045). GJB2 was correlated with patient clinical factors such as tumor size and differentiation grade. The p53 signaling pathway and toll-like receptor pathway may be regulated by GJB2. The abundance of various immune cells was significantly different between the low and high GJB2 expression groups. The ImmuneScore was significantly increased in the high GJB2 expression group. In addition, the expression level of GJB2 was positively correlated with the natural log of the half-maximal inhibitory concentration (LN_IC50) value of cisplatin/paclitaxel (Spearman r = 0.238/0.153, p &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">GJB2 can serve as a potential prognostic marker of poor survival and a therapeutic target in CC. Moreover, GJB2 may affect the immune microenvironment and is correlated with chemoresistance.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Meng, Liu, Wang, Wu, Xie, Kang, Liu, Guo and Wang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Silu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yuhuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Wan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Changyu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GJB2</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">chemoresistance</Keyword><Keyword MajorTopicYN="N">immune cell abundance</Keyword><Keyword MajorTopicYN="N">prognostic marker</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>8</Day><Hour>3</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35936685</ArticleId><ArticleId IdType="pmc">PMC9355537</ArticleId><ArticleId IdType="doi">10.3389/fonc.2022.907960</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71(3):209&#x2013;49. doi: 10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F, Carstensen B, M&#xf8;ller H, Zappa M, Zakelj MP, Lawrence G, et al. . Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev (2005) 14(9):2191&#x2013;9. doi: 10.1158/1055-9965.EPI-05-0231</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-05-0231</ArticleId><ArticleId IdType="pubmed">16172231</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, M&#xf8;ller H, et al. . Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev (2005) 14(3):677&#x2013;86. doi: 10.1158/1055-9965.EPI-04-0569</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-04-0569</ArticleId><ArticleId IdType="pubmed">15767349</ArticleId></ArticleIdList></Reference><Reference><Citation>Utada M, Chernyavskiy P, Lee WJ, Franceschi S, Sauvaget C, de Gonzalez AB, et al. . Increasing risk of uterine cervical cancer among young Japanese women: Comparison of incidence trends in Japan, south Korea and Japanese-americans between 1985 and 2012. Int J Cancer (2019) 144(9):2144&#x2013;52. doi: 10.1002/ijc.32014</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.32014</ArticleId><ArticleId IdType="pmc">PMC7478999</ArticleId><ArticleId IdType="pubmed">30474210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F, Lortet-Tieulent J, Znaor A, Brotons M, Poljak M, Arbyn M. Patterns and trends in human papillomavirus-related diseases in central and Eastern Europe and central Asia. Vaccine (2013) 31Suppl 7:H32&#x2013;45. doi: 10.1016/j.vaccine.2013.02.071</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.02.071</ArticleId><ArticleId IdType="pubmed">24332296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al. . The global burden of women's cancers: a grand challenge in global health. Lancet (2017) 389(10071):847&#x2013;60. doi: 10.1016/S0140-6736(16)31392-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)31392-7</ArticleId><ArticleId IdType="pmc">PMC6191029</ArticleId><ArticleId IdType="pubmed">27814965</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. . Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet (2006) 95 Suppl 1:S43&#x2013;103. doi: 10.1016/S0020-7292(06)60030-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0020-7292(06)60030-1</ArticleId><ArticleId IdType="pubmed">17161167</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao X, Song X, Wu H, You Y, Wu M, Li L. Selection of treatment regimens for recurrent cervical cancer. Front Oncol (2021) 11:618485. doi: 10.3389/fonc.2021.618485</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.618485</ArticleId><ArticleId IdType="pmc">PMC7884815</ArticleId><ArticleId IdType="pubmed">33604304</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JI, Wang LH. Emerging roles of gap junction proteins connexins in cancer metastasis, chemoresistance and clinical application. J Biomed Sci (2019) 26(1):8. doi: 10.1186/s12929-019-0497-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0497-x</ArticleId><ArticleId IdType="pmc">PMC6332853</ArticleId><ArticleId IdType="pubmed">30642339</ArticleId></ArticleIdList></Reference><Reference><Citation>Naoi Y, Miyoshi Y, Taguchi T, Kim SJ, Arai T, Tamaki Y, et al. . Connexin26 expression is associated with lymphatic vessel invasion and poor prognosis in human breast cancer. Breast Cancer Res Treat (2007) 106(1):11&#x2013;7. doi: 10.1007/s10549-006-9465-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-006-9465-8</ArticleId><ArticleId IdType="pubmed">17203385</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezumi K, Yamamoto H, Murata K, Higashiyama M, Damdinsuren B, Nakamura Y, et al. . Aberrant expression of connexin 26 is associated with lung metastasis of colorectal cancer. Clin Cancer Res (2008) 14(3):677&#x2013;84. doi: 10.1158/1078-0432.CCR-07-1184</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-07-1184</ArticleId><ArticleId IdType="pubmed">18245526</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Qin G, Luo M, Chen J, Zhang Q, Li L, et al. . Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT. Cell Death Dis (2015) 6(7):e1829. doi: 10.1038/cddis.2015.197</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2015.197</ArticleId><ArticleId IdType="pmc">PMC4650742</ArticleId><ArticleId IdType="pubmed">26203858</ArticleId></ArticleIdList></Reference><Reference><Citation>Teleki I, Krenacs T, Szasz MA, Kulka J, Wichmann B, Leo C, et al. . The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer. BMC Cancer (2013) 13:50. doi: 10.1186/1471-2407-13-50</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-13-50</ArticleId><ArticleId IdType="pmc">PMC3583680</ArticleId><ArticleId IdType="pubmed">23374644</ArticleId></ArticleIdList></Reference><Reference><Citation>Polusani SR, Kalmykov EA, Chandrasekhar A, Zucker SN, Nicholson BJ. Cell coupling mediated by connexin 26 selectively contributes to reduced adhesivity and increased migration. J Cell Sci (2016) 129(23):4399&#x2013;410. doi: 10.1242/jcs.185017</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.185017</ArticleId><ArticleId IdType="pmc">PMC5201008</ArticleId><ArticleId IdType="pubmed">27777264</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res (2017) 45(W1):W98&#x2013;W102. doi: 10.1093/nar/gkx247</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx247</ArticleId><ArticleId IdType="pmc">PMC5570223</ArticleId><ArticleId IdType="pubmed">28407145</ArticleId></ArticleIdList></Reference><Reference><Citation>Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. . TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res (2016) 44(8):e71. doi: 10.1093/nar/gkv1507</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv1507</ArticleId><ArticleId IdType="pmc">PMC4856967</ArticleId><ArticleId IdType="pubmed">26704973</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. . An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell (2018) 173(2):400&#x2013;16.e11. doi: 10.1016/j.cell.2018.02.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.02.052</ArticleId><ArticleId IdType="pmc">PMC6066282</ArticleId><ArticleId IdType="pubmed">29625055</ArticleId></ArticleIdList></Reference><Reference><Citation>Manawapat-Klopfer A, Thomsen LT, Martus P, Munk C, Russ R, Gmuender H, et al. . TMEM45A, SERPINB5 and p16INK4A transcript levels are predictive for development of high-grade cervical lesions. Am J Cancer Res (2016) 6(7):1524&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969401</ArticleId><ArticleId IdType="pubmed">27508094</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA (2005) 102(43):15545&#x2013;50. doi: 10.1073/pnas.0506580102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang LG, Han Y, He QY. clusterProfiler: an r package for comparing biological themes among gene clusters. OMICS (2012) 16(5):284&#x2013;7. doi: 10.1089/omi.2011.0118</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol (2019) 37(7):773&#x2013;82. doi: 10.1038/s41587-019-0114-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0114-2</ArticleId><ArticleId IdType="pmc">PMC6610714</ArticleId><ArticleId IdType="pubmed">31061481</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara K, Shahmoradgoli M, Mart&#xed;nez E, Vegesna R, Kim H, Torres-Garcia W, et al. . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 4:2612. doi: 10.1038/ncomms3612</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3612</ArticleId><ArticleId IdType="pmc">PMC3826632</ArticleId><ArticleId IdType="pubmed">24113773</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. . Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res (2013) 41:D955&#x2013;61. doi: 10.1093/nar/gks1111</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1111</ArticleId><ArticleId IdType="pmc">PMC3531057</ArticleId><ArticleId IdType="pubmed">23180760</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy K, Silva Costa CJ, Pieters A, Dos Santos Rodrigues B, Van Campenhout R, Cooreman A, et al. . Expression and functionality of connexin-based channels in human liver cancer cell lines. Int J Mol Sci (2021) 22(22):12187. doi: 10.3390/ijms222212187</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222212187</ArticleId><ArticleId IdType="pmc">PMC8623148</ArticleId><ArticleId IdType="pubmed">34830068</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomura S, Maeda K, Noda E, Inoue T, Fukunaga S, Nagahara H, et al. . Clinical significance of the expression of connexin26 in colorectal cancer. J Exp Clin Cancer Res (2010) 29(1):79. doi: 10.1186/1756-9966-29-79</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-9966-29-79</ArticleId><ArticleId IdType="pmc">PMC2907868</ArticleId><ArticleId IdType="pubmed">20565955</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Zhang YJ, Wu ZH. High GJB2 mRNA expression and its prognostic significance in lung adenocarcinoma: a study based on the TCGA database. Med (Baltimore) (2020) 99(14):e19054. doi: 10.1097/MD.0000000000019054</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000019054</ArticleId><ArticleId IdType="pmc">PMC7220691</ArticleId><ArticleId IdType="pubmed">32243356</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun D, Jin H, Zhang J, Tan X. Integrated whole genome microarray analysis and immunohistochemical assay identifies COL11A1, GJB2 and CTRL as predictive biomarkers for pancreatic cancer. Cancer Cell Int (2018) 18:174. doi: 10.1186/s12935-018-0669-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-018-0669-x</ArticleId><ArticleId IdType="pmc">PMC6219000</ArticleId><ArticleId IdType="pubmed">30410422</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucke T, Choudhry R, Thom R, Selmer IS, Burden AD, Hodgins MB. Upregulation of connexin 26 is a feature of keratinocyte differentiation in hyperproliferative epidermis, vaginal epithelium, and buccal epithelium. J Invest Dermatol (1999) 112(3):354&#x2013;61. doi: 10.1046/j.1523-1747.1999.00512.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1747.1999.00512.x</ArticleId><ArticleId IdType="pubmed">10084314</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe9;ndez-Mat&#xed;as G, Vel&#xe1;zquez-Vel&#xe1;zquez C, Castro-Oropeza R, Mantilla-Morales A, Ocampo-Sandoval D, Burgos-Gonz&#xe1;lez A, et al. . Prevalence of HPV in Mexican patients with head and neck squamous carcinoma and identification of potential prognostic biomarkers. Cancers (Basel) (2021) 13(22):5602. doi: 10.3390/cancers13225602</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13225602</ArticleId><ArticleId IdType="pmc">PMC8616077</ArticleId><ArticleId IdType="pubmed">34830760</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva MA, Altamura G, Corteggio A, Roperto F, Bocaneti F, Velescu E, et al. . Expression of connexin 26 and bovine papillomavirus E5 in cutaneous fibropapillomas of cattle. Vet J (2013) 195(3):337&#x2013;43. doi: 10.1016/j.tvjl.2012.07.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tvjl.2012.07.009</ArticleId><ArticleId IdType="pubmed">22892185</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu T, Gao YF, Chen YX, Wang ZB, Yin JY, Mao XY, et al. . Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer. Oncotarget (2017) 8(13):21281&#x2013;9. doi: 10.18632/oncotarget.15068</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.15068</ArticleId><ArticleId IdType="pmc">PMC5400583</ArticleId><ArticleId IdType="pubmed">28177904</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu A, Shi Y, Liu Y, Lin J, Zhang H, Guo Y, et al. . Integrative analyses identified ion channel genes GJB2 and SCNN1B as prognostic biomarkers and therapeutic targets for lung adenocarcinoma. Lung Cancer (2021) 158:29&#x2013;39. doi: 10.1016/j.lungcan.2021.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2021.06.001</ArticleId><ArticleId IdType="pubmed">34111567</ArticleId></ArticleIdList></Reference><Reference><Citation>Inose T, Kato H, Kimura H, Faried A, Tanaka N, Sakai M, et al. . Correlation between connexin 26 expression and poor prognosis of esophageal squamous cell carcinoma. Ann Surg Oncol (2009) 16(6):1704&#x2013;10. doi: 10.1245/s10434-009-0443-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-009-0443-3</ArticleId><ArticleId IdType="pubmed">19326169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashyap VK, Dan N, Chauhan N, Wang Q, Setua S, Nagesh PKB, et al. . VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway. Cancer Lett (2020) 470:64&#x2013;74. doi: 10.1016/j.canlet.2019.11.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2019.11.035</ArticleId><ArticleId IdType="pmc">PMC8059100</ArticleId><ArticleId IdType="pubmed">31809801</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Yu FS. Toll-like receptors and corneal innate immunity. Curr Mol Med (2006) 6(3):327&#x2013;37. doi: 10.2174/156652406776894572</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652406776894572</ArticleId><ArticleId IdType="pmc">PMC2666391</ArticleId><ArticleId IdType="pubmed">16712478</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Rao H, Jin C, Liu J. Involvement of the toll-like Receptor/Nitric oxide signaling pathway in the pathogenesis of cervical cancer caused by high-risk human papillomavirus infection. BioMed Res Int (2017) 2017:7830262. doi: 10.1155/2017/7830262</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7830262</ArticleId><ArticleId IdType="pmc">PMC5463171</ArticleId><ArticleId IdType="pubmed">28626766</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Li L, Li Y, Zhao X. Research progress on tumor-associated macrophages and inflammation in cervical cancer. BioMed Res Int (2020) 2020:6842963. doi: 10.1155/2020/6842963</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/6842963</ArticleId><ArticleId IdType="pmc">PMC7011341</ArticleId><ArticleId IdType="pubmed">32083131</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrillo M, Zannoni GF, Martinelli E, Pedone Anchora L, Ferrandina G, Tropeano G, et al. . Polarisation of tumor-associated macrophages toward M2 phenotype correlates with poor response to chemoradiation and reduced survival in patients with locally advanced cervical cancer. PloS One (2015) 10(9):e0136654. doi: 10.1371/journal.pone.0136654</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0136654</ArticleId><ArticleId IdType="pmc">PMC4559430</ArticleId><ArticleId IdType="pubmed">26335330</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XJ, Han LF, Wu XG, Wei WF, Wu LF, Yi HY, et al. . Clinical significance of CD163+ and CD68+ tumor-associated macrophages in high-risk HPV-related cervical cancer. J Cancer (2017) 8(18):3868&#x2013;75. doi: 10.7150/jca.21444</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.21444</ArticleId><ArticleId IdType="pmc">PMC5688941</ArticleId><ArticleId IdType="pubmed">29151975</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Xie S, Chen X, Pan S, Qian H, Zhu X. Effects of quercetin on the efficacy of various chemotherapeutic drugs in cervical cancer cells. Drug Des Devel Ther (2021) 15:577&#x2013;88. doi: 10.2147/DDDT.S291865</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S291865</ArticleId><ArticleId IdType="pmc">PMC7894806</ArticleId><ArticleId IdType="pubmed">33623367</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YP, Wu JI, Tseng CW, Chen HJ, Wang LH. Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via src activation. Oncogene (2019) 38(6):822&#x2013;37. doi: 10.1038/s41388-018-0471-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-018-0471-1</ArticleId><ArticleId IdType="pubmed">30177841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35924232</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.</ArticleTitle><Pagination><StartPage>851622</StartPage><MedlinePgn>851622</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">851622</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.851622</ELocationID><Abstract><AbstractText>Human leukocyte antigen G (HLA-G) is a potential checkpoint molecule that plays a key role in cervical carcinogenesis. The purpose of this study was to construct and validate a prognostic risk model to predict the overall survival (OS) of cervical cancer patients, providing a reference for individualized clinical treatment that may lead to better clinical outcomes. HLA-G-driven differentially expressed genes (DEGs) were obtained from two cervical carcinoma cell lines, namely, SiHa and HeLa, with stable overexpression of HLA-G by RNA sequencing (RNA-seq). The biological functions of these HLA-G-driven DEGs were analysed by GO enrichment and KEGG pathway using the "clusterProfiler" package. The protein-protein interactions (PPIs) were assessed using the STRING database. The prognostic relevance of each DEG was evaluated by univariate Cox regression using the TCGA-CESC dataset. After the TCGA-CESC cohort was randomly divided into training set and testing set, and a prognostic risk model was constructed by LASSO and stepwise multivariate Cox regression analysis in training set and validated in testing set or in different types of cervical cancer set. The predictive ability of the prognostic risk model or nomogram was evaluated by a series of bioinformatics methods. A total of 1108 candidate HLA-G-driven DEGs, including 391 upregulated and 717 downregulated genes, were obtained and were enriched mostly in the ErbB pathway, steroid biosynthesis, and MAPK pathway. Then, an HLA-G-driven DEG signature consisting of the eight most important prognostic genes <i>CD46, LGALS9, PGM1, SPRY4, CACNB3, PLIN2, MSMO1</i>, and <i>DAGLB</i> was identified as a key predictor of cervical cancer. Multivariate Cox regression analysis showed that this signature is an independent risk factor for the overall survival of CESC patients. Kaplan-Meier survival analysis showed that the 5-year overall survival rate is 23.0% and 84.6% for the high-risk and low-risk patients, respectively (<i>P</i>&lt;0.001). The receiver operating characteristic (ROC) curve of this prognostic model with an area under the curve (AUC)&#xa0;was 0.896 for 5 years, which was better than that of other clinical traits. This prognostic risk model was also successfully validated in different subtypes of cervical cancer, including the keratinizing squamous cell carcinoma, non-keratinizing squamous cell carcinoma, squamous cell neoplasms, non-squamous cell neoplasms set. Single-sample gene set enrichment (ssGSEA) algorithm and Tumor Immune Dysfunction and Exclusion (TIDE) analysis confirmed that this signature influence tumour microenvironment and immune checkpoint blockade. A nomogram that integrated risk score, age, clinical stage, histological grade, and pathological type was then built to predict the overall survival of CESC patients and evaluated by calibration curves, AUC, concordance index (C-index) and decision curve analysis (DCA). To summarize, we developed and validated a novel prognostic risk model for cervical cancer based on HLA-G-driven DEGs, and the prognostic signature showed great ability in predicting the overall survival of patients with cervical cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Xu, Wang, Xing and Wang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hui-Hui</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Medical Research Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Minimally Invasive Techniques &amp; Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province, Taizhou Hospital of Zhejiang Province, Linhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hui-Li</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Department of Burn, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Tong-Jin</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xue-Quan</ForeName><Initials>XQ</Initials><AffiliationInfo><Affiliation>Key Laboratory of Minimally Invasive Techniques &amp; Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province, Taizhou Hospital of Zhejiang Province, Linhai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059951">HLA-G Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059951" MajorTopicYN="N">HLA-G Antigens</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HLA-G</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">immune checkpoint</Keyword><Keyword MajorTopicYN="N">mRNA signature</Keyword><Keyword MajorTopicYN="N">prediction</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>4</Day><Hour>2</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35924232</ArticleId><ArticleId IdType="pmc">PMC9341272</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.851622</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68(6):394&#x2013;424. doi:&#xa0;10.3322/caac.21492</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO . Cervical Cancer . World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer (Accessed September 21, 2020).</Citation></Reference><Reference><Citation>Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical Cancer. Lancet (2019) 393(10167):169&#x2013;82. doi:&#xa0;10.1016/S0140-6736(18)32470-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32470-X</ArticleId><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y. Cancer Immunotherapy: Harnessing the Immune System to Battle Cancer. J Clin Invest (2015) 125(9):3335&#x2013;7. doi:&#xa0;10.1172/JCI83871</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI83871</ArticleId><ArticleId IdType="pmc">PMC4588312</ArticleId><ArticleId IdType="pubmed">26325031</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu HH, Zhang X, Zheng HH, Han QY, Lin AF, Yan WH. Association of HLA-G 3' UTR Polymorphism and Expression With the Progression of Cervical Lesions in Human Papillomavirus 18 Infections. Infect Agent Cancer (2018) 13:42. doi:&#xa0;10.1186/s13027-018-0217-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13027-018-0217-2</ArticleId><ArticleId IdType="pmc">PMC6311041</ArticleId><ArticleId IdType="pubmed">30619504</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu HH, Yan WH, Lin A. The Role of HLA-G in Human Papillomavirus Infections and Cervical Carcinogenesis. Front Immunol (2020) 11:1349. doi:&#xa0;10.3389/fimmu.2020.01349</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01349</ArticleId><ArticleId IdType="pmc">PMC7330167</ArticleId><ArticleId IdType="pubmed">32670296</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Wang L, Zhao L, He C, Wang G. The Role of HLA-G in Tumor Escape: Manipulating the Phenotype and Function of Immune Cells. Front Oncol (2020) 10:597468. doi:&#xa0;10.3389/fonc.2020.597468</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.597468</ArticleId><ArticleId IdType="pmc">PMC7786297</ArticleId><ArticleId IdType="pubmed">33425752</ArticleId></ArticleIdList></Reference><Reference><Citation>Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol (2015) 68(2):267&#x2013;79. doi:&#xa0;10.1016/j.eururo.2015.02.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2015.02.032</ArticleId><ArticleId IdType="pubmed">25824720</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#x142;asiuk P, Putowski M, Giannopoulos K. PD1/PD1L Pathway, HLA-G and T Regulatory Cells as New Markers of Immunosuppression in Cancers. Postepy Hig Med Dosw (Online) (2016) 70(0):1044&#x2013;58. doi:&#xa0;10.5604/17322693.1220994</Citation><ArticleIdList><ArticleId IdType="doi">10.5604/17322693.1220994</ArticleId><ArticleId IdType="pubmed">27708209</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumont C, Jacquier A, Verine J, Noel F, Goujon A, Wu CL, et al. . CD8+PD-1-ILT2+ T Cells Are an Intratumoral Cytotoxic Population Selectively Inhibited by the Immune-Checkpoint HLA-G. Cancer Immunol Res (2019) 7(10):1619&#x2013;32. doi:&#xa0;10.1158/2326-6066.CIR-18-0764</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-18-0764</ArticleId><ArticleId IdType="pubmed">31451484</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouas-Freiss N, LeMaoult J, Verine J, Tronik-Le Roux D, Culine S, Hennequin C, et al. . Intratumor Heterogeneity of Immune Checkpoints in Primary Renal Cell Cancer: Focus on HLA-G/Ilt2/Ilt4. Oncoimmunology (2017) 6(9):e1342023. doi:&#xa0;10.1080/2162402X.2017.1342023</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2017.1342023</ArticleId><ArticleId IdType="pmc">PMC5599087</ArticleId><ArticleId IdType="pubmed">28932645</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroki K, Matsubara H, Kanda R, Miyashita N, Shiroishi M, Fukunaga Y, et al. . Structural and Functional Basis for LILRB Immune Checkpoint Receptor Recognition of HLA-G Isoforms. J Immunol (2019) 203(12):3386&#x2013;94. doi:&#xa0;10.4049/jimmunol.1900562</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1900562</ArticleId><ArticleId IdType="pubmed">31694909</ArticleId></ArticleIdList></Reference><Reference><Citation>Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, Moreau P, LeMaoult J. HLA-G: An Immune Checkpoint Molecule. Adv Immunol (2015) 127:33&#x2013;144. doi:&#xa0;10.1016/bs.ai.2015.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.ai.2015.04.001</ArticleId><ArticleId IdType="pubmed">26073983</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XJ, Zhang X, Lin A, Ruan YY, Yan WH. Human Leukocyte Antigen-G (HLA-G) Expression in Cervical Cancer Lesions is Associated With Disease Progression. Hum Immunol (2012) 73(9):946&#x2013;9. doi:&#xa0;10.1016/j.humimm.2012.07.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2012.07.041</ArticleId><ArticleId IdType="pubmed">22820627</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng N, Wang CX, Zhang X, Du LT, Zhang J, Kan SF, et al. . Up-Regulation of HLA-G Expression in Cervical Premalignant and Malignant Lesions. Tissue Antigens (2011) 77(3):218&#x2013;24. doi:&#xa0;10.1111/j.1399-0039.2010.01607.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0039.2010.01607.x</ArticleId><ArticleId IdType="pubmed">21299526</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon BS, Kim YT, Kim JW, Kim SH, Kim JH, Kim SW. Expression of Human Leukocyte Antigen-G and its Correlation With Interleukin-10 Expression in Cervical Carcinoma. Int J Gynaecol Obstet (2007) 98(1):48&#x2013;53. doi:&#xa0;10.1016/j.ijgo.2007.03.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijgo.2007.03.041</ArticleId><ArticleId IdType="pubmed">17490670</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez JA, Galeano L, Palacios DM, G&#xf3;mez C, Serrano ML, Bravo MM, et al. . Altered HLA Class I and HLA-G Expression is Associated With IL-10 Expression in Patients With Cervical Cancer. Pathobiology (2012) 79(2):72&#x2013;83. doi:&#xa0;10.1159/000334089</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000334089</ArticleId><ArticleId IdType="pubmed">22213066</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin A, Yan WH, Xu HH, Gan MF, Cai JF, Zhu M, et al. . HLA-G Expression in Human Ovarian Carcinoma Counteracts NK Cell Function. Ann Oncol (2007) 18(11):1804&#x2013;9. doi:&#xa0;10.1093/annonc/mdm356</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdm356</ArticleId><ArticleId IdType="pubmed">17846022</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Liang X, Xuan Y, Geng C, Li Y, Lu H, et al. . A Reference Human Genome Dataset of the BGISEQ-500 Sequencer. Gigascience (2017) 6(5):1&#x2013;9. doi:&#xa0;10.1093/gigascience/gix024</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gigascience/gix024</ArticleId><ArticleId IdType="pmc">PMC5467036</ArticleId><ArticleId IdType="pubmed">28379488</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. . Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res (2003) 13(11):2498&#x2013;504. doi:&#xa0;10.1101/gr.1239303</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Pencina MJ, D'Agostino RB, Sr, D'Agostino RB, Jr, Vasan RS. Evaluating the Added Predictive Ability of a New Marker: From Area Under the ROC Curve to Reclassification and Beyond. Stat Med (2008) 27(2):157&#x2013;72 discussion 207-12. doi:&#xa0;10.1002/sim.2929</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2929</ArticleId><ArticleId IdType="pubmed">17569110</ArticleId></ArticleIdList></Reference><Reference><Citation>Pencina MJ, D'Agostino RB, Sr, Steyerberg EW. Extensions of Net Reclassification Improvement Calculations to Measure Usefulness of New Biomarkers. Stat Med (2011) 30(1):11&#x2013;21. doi:&#xa0;10.1002/sim.4085</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4085</ArticleId><ArticleId IdType="pmc">PMC3341973</ArticleId><ArticleId IdType="pubmed">21204120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju M, Qi A, Bi J, Zhao L, Jiang L, Zhang Q, et al. . A five-mRNA Signature Associated With Post-Translational Modifications can Better Predict Recurrence and Survival in Cervical Cancer. J Cell Mol Med (2020) 24(11):6283&#x2013;97. doi:&#xa0;10.1111/jcmm.15270</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15270</ArticleId><ArticleId IdType="pmc">PMC7294153</ArticleId><ArticleId IdType="pubmed">32306508</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu X, Shi Z, Guo J, Guo C, Qiu J, Hua K. Identification of a Novel Six-Gene Signature With Potential Prognostic and Therapeutic Value in Cervical Cancer. Cancer Med (2021) 10(19):6881&#x2013;96. doi:&#xa0;10.1002/cam4.4054</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.4054</ArticleId><ArticleId IdType="pmc">PMC8495282</ArticleId><ArticleId IdType="pubmed">34498424</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Li X, Zhang J, Wu S. Development of a Novel Immune Infiltration-Based Gene Signature to Predict Prognosis and Immunotherapy Response of Patients With Cervical Cancer. Front Immunol (2021) 12:709493. doi:&#xa0;10.3389/fimmu.2021.709493</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.709493</ArticleId><ArticleId IdType="pmc">PMC8446628</ArticleId><ArticleId IdType="pubmed">34539641</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J, Xu L, Pan H. Development and Validation of an M6a RNA Methylation Regulator-Based Signature for Prognostic Prediction in Cervical Squamous Cell Carcinoma. Front Oncol (2020) 10:1444. doi:&#xa0;10.3389/fonc.2020.01444</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.01444</ArticleId><ArticleId IdType="pmc">PMC7472601</ArticleId><ArticleId IdType="pubmed">32974164</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin R, Cao L, Ye C, Wang J, Sun Z. A Novel Prognostic Prediction Model Based on Seven Immune-Related RNAs for Predicting Overall Survival of Patients in Early Cervical Squamous Cell Carcinoma. BMC Med Genomics (2021) 14(1):49. doi:&#xa0;10.1186/s12920-021-00885-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-021-00885-3</ArticleId><ArticleId IdType="pmc">PMC7885601</ArticleId><ArticleId IdType="pubmed">33588862</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Z, Xiong J, Zeng C, Jiang Y, Xiong K, Tao H, et al. . Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma. Front Mol Biosci (2021) 8:625470. doi:&#xa0;10.3389/fmolb.2021.625470</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.625470</ArticleId><ArticleId IdType="pmc">PMC7967036</ArticleId><ArticleId IdType="pubmed">33748188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Li Y, Qi R, Zhang L. Constructe a Novel 5 Hypoxia Genes Signature for Cervical Cancer. Cancer Cell Int (2021) 21(1):345. doi:&#xa0;10.1186/s12935-021-02050-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-021-02050-3</ArticleId><ArticleId IdType="pmc">PMC8254931</ArticleId><ArticleId IdType="pubmed">34217310</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang C, Huang J, Guo H. Identification of an Metabolic Related Risk Signature Predicts Prognosis in Cervical Cancer and Correlates With Immune Infiltration. Front Cell Dev Biol (2021) 9:677831. doi:&#xa0;10.3389/fcell.2021.677831</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.677831</ArticleId><ArticleId IdType="pmc">PMC8264424</ArticleId><ArticleId IdType="pubmed">34249930</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y, Wang Z, Yang N, Liu S, Yan J, Song J, et al. . Identification of Biomarkers for Cervical Cancer Radiotherapy Resistance Based on RNA Sequencing Data. Front Cell Dev Biol (2021) 9:724172. doi:&#xa0;10.3389/fcell.2021.724172</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.724172</ArticleId><ArticleId IdType="pmc">PMC8369412</ArticleId><ArticleId IdType="pubmed">34414195</ArticleId></ArticleIdList></Reference><Reference><Citation>An R, Meng S, Qian H. Identification of Key Pathways and Establishment of a Seven-Gene Prognostic Signature in Cervical Cancer. J Oncol (2022) 2022:4748796. doi:&#xa0;10.1155/2022/4748796</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/4748796</ArticleId><ArticleId IdType="pmc">PMC8837458</ArticleId><ArticleId IdType="pubmed">35154316</ArticleId></ArticleIdList></Reference><Reference><Citation>Becht E, McInnes L, Healy J, Dutertre CA, Kwok IWH, Ng LG, et al. . Dimensionality Reduction for Visualizing Single-Cell Data Using UMAP. Nat Biotechnol (2019) 37:38&#x2013;44. doi:&#xa0;10.1038/nbt.4314</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4314</ArticleId><ArticleId IdType="pubmed">30531897</ArticleId></ArticleIdList></Reference><Reference><Citation>Krijgsman D, Roelands J, Hendrickx W, Bedognetti D, Kuppen PJK. HLA-G: A New Immune Checkpoint in Cancer? Int J Mol Sci (2020) 21(12):4528. doi:&#xa0;10.3390/ijms21124528</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21124528</ArticleId><ArticleId IdType="pmc">PMC7350262</ArticleId><ArticleId IdType="pubmed">32630545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiraoka N, Ino Y, Hori S, Yamazaki-Itoh R, Naito C, Shimasaki M, et al. . Expression of Classical Human Leukocyte Antigen Class I Antigens, HLA-E and HLA-G, is Adversely Prognostic in Pancreatic Cancer Patients. Cancer Sci (2020) 111(8):3057&#x2013;70. doi:&#xa0;10.1111/cas.14514</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.14514</ArticleId><ArticleId IdType="pmc">PMC7419048</ArticleId><ArticleId IdType="pubmed">32495519</ArticleId></ArticleIdList></Reference><Reference><Citation>Urabe F, Kosaka N, Ito K, Kimura T, Egawa S, Ochiya T. Extracellular Vesicles as Biomarkers and Therapeutic Targets for Cancer. Am J Physiol Cell Physiol (2020) 318(1):C29&#x2013;39. doi:&#xa0;10.1152/ajpcell.00280.2019</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00280.2019</ArticleId><ArticleId IdType="pubmed">31693397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Zhang S, Jin Z, Shi M. Lipid-Mediated Regulation of the Cancer-Immune Crosstalk. Pharmacol Res (2020) 161:105131. doi:&#xa0;10.1016/j.phrs.2020.105131</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.105131</ArticleId><ArticleId IdType="pubmed">32810628</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK Signalling Pathway and Tumorigenesis. Exp Ther Med (2020) 19(3):1997&#x2013;2007. doi:&#xa0;10.3892/etm.2020.8454</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2020.8454</ArticleId><ArticleId IdType="pmc">PMC7027163</ArticleId><ArticleId IdType="pubmed">32104259</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo-Merino J, Contreras-Paredes A, V&#xe1;zquez-Ulloa E, Rocha-Zavaleta L, Fuentes-Gonzalez AM, Lizano M. The Role of Signaling Pathways in Cervical Cancer and Molecular Therapeutic Targets. Arch Med Res (2014) 45(7):525&#x2013;39. doi:&#xa0;10.1016/j.arcmed.2014.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2014.10.008</ArticleId><ArticleId IdType="pubmed">25450584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, et al. . Whole-Exome Sequencing of Cervical Carcinomas Identifies Activating ERBB2 and PIK3CA Mutations as Targets for Combination Therapy. Proc Natl Acad Sci U.S.A. (2019) 116(45):22730&#x2013;6. doi:&#xa0;10.1073/pnas.1911385116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1911385116</ArticleId><ArticleId IdType="pmc">PMC6842590</ArticleId><ArticleId IdType="pubmed">31624127</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Genome Atlas Research Network. Albert Einstein College of Medicine. Analytical Biological Services. Barretos Cancer Hospital. Baylor College of Medicine. Beckman Research Institute of City of Hope et al. . Integrated Genomic and Molecular Characterization of Cervical Cancer. Nature (2017) 543(7645):378&#x2013;84. doi:&#xa0;10.1038/nature21386</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21386</ArticleId><ArticleId IdType="pmc">PMC5354998</ArticleId><ArticleId IdType="pubmed">28112728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni Choileain S, Hay J, Thomas J, Williams A, Vermeren MM, Benezech C, et al. . TCR-Stimulated Changes in Cell Surface CD46 Expression Generate Type 1 Regulatory T Cells. Sci Signal (2017) 10(502):eaah6163. doi:&#xa0;10.1126/scisignal.aah6163</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aah6163</ArticleId><ArticleId IdType="pubmed">29066539</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemper C, Verbsky JW, Price JD. Atkinson JP. T-Cell Stimulation and Regulation: With Complements From CD46. Immunol Res (2005) 32(1-3):31&#x2013;43. doi:&#xa0;10.1385/IR:32:1-3:031</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/IR:32:1-3:031</ArticleId><ArticleId IdType="pubmed">16106057</ArticleId></ArticleIdList></Reference><Reference><Citation>Punt S, Thijssen VL, Vrolijk J, de Kroon CD, Gorter A, Jordanova ES. Galectin-1, -3 and -9 Expression and Clinical Significance in Squamous Cervical Cancer. PloS One (2015) 10(6):e0129119. doi:&#xa0;10.1371/journal.pone.0129119</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0129119</ArticleId><ArticleId IdType="pmc">PMC4467041</ArticleId><ArticleId IdType="pubmed">26066796</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Zhao Y, Wang Y, Wu X. The Role of Galectins in Cervical Cancer Biology and Progression. BioMed Res Int (2018) 2018:2175927. doi:&#xa0;10.1155/2018/2175927</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/2175927</ArticleId><ArticleId IdType="pmc">PMC5964433</ArticleId><ArticleId IdType="pubmed">29854732</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Huang F, Yu D, Zhang Y, Xu H, Zhang L, et al. . Autoregulatory Loop Between TGF-&#x3b2;1/miR-411-5p/SPRY4 and MAPK Pathway in Rhabdomyosarcoma Modulates Proliferation and Differentiation. Cell Death Dis (2015) 6(8):e1859. doi:&#xa0;10.1038/cddis.2015.225</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2015.225</ArticleId><ArticleId IdType="pmc">PMC4558514</ArticleId><ArticleId IdType="pubmed">26291313</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui C, Merritt R, Fu L, Pan Z. Targeting Calcium Signaling in Cancer Therapy. Acta Pharm Sin B (2017) 7(1):3&#x2013;17. doi:&#xa0;10.1016/j.apsb.2016.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2016.11.001</ArticleId><ArticleId IdType="pmc">PMC5237760</ArticleId><ArticleId IdType="pubmed">28119804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin GZ, Zhang Y, Cong WM, Wu X, Wang X, Wu S, et al. . Phosphoglucomutase 1 Inhibits Hepatocellular Carcinoma Progression by Regulating Glucose Trafficking. PloS Biol (2018) 16(10):e2006483. doi:&#xa0;10.1371/journal.pbio.2006483</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.2006483</ArticleId><ArticleId IdType="pmc">PMC6193743</ArticleId><ArticleId IdType="pubmed">30335765</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte M, Franceschi C, Sandri M, Salvioli S. Perilipin 2 and Age-Related Metabolic Diseases: A New Perspective. Trends Endocrinol Metab (2016) 27(12):893&#x2013;903. doi:&#xa0;10.1016/j.tem.2016.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2016.09.001</ArticleId><ArticleId IdType="pubmed">27659144</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabitova L, Restifo D, Gorin A, Manocha K, Handorf E, Yang DH, et al. . Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR. Cell Rep (2015) 12(11):1927&#x2013;38. doi:&#xa0;10.1016/j.celrep.2015.08.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.08.023</ArticleId><ArticleId IdType="pmc">PMC4581991</ArticleId><ArticleId IdType="pubmed">26344763</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu KL, Tsuboi K, Adibekian A, Pugh H, Masuda K, Cravatt BF. Dagl&#x3b2; Inhibition Perturbs a Lipid Network Involved in Macrophage Inflammatory Responses. Nat Chem Biol (2012) 8(12):999&#x2013;1007. doi:&#xa0;10.1038/nchembio.1105</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1105</ArticleId><ArticleId IdType="pmc">PMC3513945</ArticleId><ArticleId IdType="pubmed">23103940</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller A, Yan J. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy. Front Immunol (2019) 10:1074. doi:&#xa0;10.3389/fimmu.2019.01074</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01074</ArticleId><ArticleId IdType="pmc">PMC6536589</ArticleId><ArticleId IdType="pubmed">31164885</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Deng Q, Wang W, Tao H, Gao Y. Identification of an Autophagy-Related Gene Signature for Survival Prediction in Patients With Cervical Cancer. J Ovarian Res (2020) 13(1):131. doi:&#xa0;10.1186/s13048-020-00730-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13048-020-00730-8</ArticleId><ArticleId IdType="pmc">PMC7648936</ArticleId><ArticleId IdType="pubmed">33160404</ArticleId></ArticleIdList></Reference><Reference><Citation>Elvington M, Liszewski MK, Atkinson JP. CD46 and Oncologic Interactions: Friendly Fire Against Cancer. Antibod (Basel) (2020) 9(4):59. doi:&#xa0;10.3390/antib9040059</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib9040059</ArticleId><ArticleId IdType="pmc">PMC7709105</ArticleId><ArticleId IdType="pubmed">33147799</ArticleId></ArticleIdList></Reference><Reference><Citation>Curley J, Conaway MR, Chinn Z, Duska L, Stoler M, Mills AM. Looking Past PD-L1: Expression of Immune Checkpoint TIM-3 and its Ligand Galectin-9 in Cervical and Vulvar Squamous Neoplasia. Mod Pathol (2020) 33(6):1182&#x2013;92. doi:&#xa0;10.1038/s41379-019-0433-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41379-019-0433-3</ArticleId><ArticleId IdType="pubmed">32139873</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Tian S, Pei M, Zhao M, Wang L, Jiang Y, et al. . Crosstalk Between Histone Modification and DNA Methylation Orchestrates the Epigenetic Regulation of the Costimulatory Factors, Tim-3 and Galectin-9, in Cervical Cancer. Oncol Rep (2019) 42(6):2655&#x2013;69. doi:&#xa0;10.3892/or.2019.7388</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2019.7388</ArticleId><ArticleId IdType="pmc">PMC6859457</ArticleId><ArticleId IdType="pubmed">31661141</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong J, Su M, Chang W, Zhang K, Wu S, Xu T. Long non-Coding RNAs on the Stage of Cervical Cancer (Review). Oncol Rep (2017) 38(4):1923&#x2013;31. doi:&#xa0;10.3892/or.2017.5905</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2017.5905</ArticleId><ArticleId IdType="pubmed">28849103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Liu Y, Lu X, Wang Y, Qiao H, Liu M. Upregulation of Long Noncoding RNA SPRY4-IT1 Correlates With Tumor Progression and Poor Prognosis in Cervical Cancer. FEBS Open Bio (2016) 6(9):954&#x2013;60. doi:&#xa0;10.1002/2211-5463.12102</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2211-5463.12102</ArticleId><ArticleId IdType="pmc">PMC5011494</ArticleId><ArticleId IdType="pubmed">27642559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H, Zhu H, Tian M, Wang D, He J, Xu T, et al. . and Hydroxymethylation in Cervical Cancer: Diagnosis, Prognosis and Treatment. Front Genet (2020) 11:347. doi:&#xa0;10.3389/fgene.2020.00347</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.00347</ArticleId><ArticleId IdType="pmc">PMC7160865</ArticleId><ArticleId IdType="pubmed">32328088</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Tian S, Zhao M, Yang T, Quan S, Yang Q, et al. . SUV39H1-DNMT3A-Mediated Epigenetic Regulation of Tim-3 and Galectin-9 in the Cervical Cancer. Cancer Cell Int (2020) 20:325. doi:&#xa0;10.1186/s12935-020-01380-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-020-01380-y</ArticleId><ArticleId IdType="pmc">PMC7370487</ArticleId><ArticleId IdType="pubmed">32699524</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Xie S, Yuan C, Jiang L, Huang X, Li L, et al. . Lower Expression of SPRY4 Predicts a Poor Prognosis and Regulates Cell Proliferation in Colorectal Cancer. Cell Physiol Biochem (2016) 40(6):1433&#x2013;42. doi:&#xa0;10.1159/000453195</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000453195</ArticleId><ArticleId IdType="pubmed">27997895</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35903112</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2295</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in neurology</Title><ISOAbbreviation>Front Neurol</ISOAbbreviation></Journal><ArticleTitle>Cervical Cancer Imaging Features Associated With <i>ADRB1</i> as a Risk Factor for Cerebral Neurovascular Metastases.</ArticleTitle><Pagination><StartPage>905761</StartPage><MedlinePgn>905761</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">905761</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneur.2022.905761</ELocationID><Abstract><AbstractText>Bioinformatics tools are used to create a clinical prediction model for cervical cancer metastasis and to investigate the neurovascular-related genes that are involved in brain metastasis of cervical cancer. One hundred eighteen patients with cervical cancer were divided into two groups based on the presence or absence of metastases, and the clinical data and imaging findings of the two groups were compared retrospectively. The nomogram-based model was successfully constructed by taking into account four clinical characteristics (age, stage, N, and T) as well as one imaging characteristic (original_glszm_GrayLevelVariance Rad-score). In patients with cervical cancer, headaches and vomiting were more often reported in the brain metastasis group than in the other metastasis groups. According to the TCGA data, mRNA differential gene expression analysis of patients with cervical cancer revealed an increase in the expression of neurovascular-related gene Adrenoceptor Beta 1 (<i>ADRB1</i>) in the brain metastasis group. An analysis of the correlation between imaging features and <i>ADRB1</i> expression revealed that <i>ADRB1</i> expression was significantly higher in the low Rad-score group compared with the high Rad-score group (<i>P</i> = 0.025). Therefore, <i>ADRB1</i> expression in cervical cancer was correlated with imaging features and was associated as a risk factor for cerebral neurovascular metastases. This study developed a nomogram prediction model for cervical cancer metastasis using age, stage, N, T and original_glszm_GrayLevelVariance. As a risk factor associated with the development of cerebral neurovascular metastases of cervical cancer, <i>ADRB1</i> expression was significantly higher in brain metastases from cervical cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Zheng, Xu and Wu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xingju</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiology, Guizhou Provincial People's Hospital, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Shilin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncology, Xichang People's Hospital, Liangshan High-Tech Tumor Hospital, Xichang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>JiaYing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gynaecology and Obstetrics, Zhejiang Xinda Hospital, Huzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol</MedlineTA><NlmUniqueID>101546899</NlmUniqueID><ISSNLinking>1664-2295</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ADRB1</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">brain metastasis</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">clinical prediction model</Keyword><Keyword MajorTopicYN="N">neurovascular</Keyword><Keyword MajorTopicYN="N">radiomics</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>29</Day><Hour>1</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35903112</ArticleId><ArticleId IdType="pmc">PMC9315067</ArticleId><ArticleId IdType="doi">10.3389/fneur.2022.905761</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vu M, Yu J, Awolude OA, Chuang L. Cervical cancer worldwide. Curr Probl Cancer. (2018) 42:457&#x2013;65. 10.1016/j.currproblcancer.2018.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.currproblcancer.2018.06.003</ArticleId><ArticleId IdType="pubmed">30064936</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M, Weiderpass E, Bruni L, de Sanjos&#xe9; S, Saraiya M, Ferlay J, et al. . Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Global Health. (2020) 8:e191&#x2013;203. 10.1016/S2214-109X(19)30482-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(19)30482-6</ArticleId><ArticleId IdType="pmc">PMC7025157</ArticleId><ArticleId IdType="pubmed">31812369</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Gao C, Wu Y, Huang Z. Identification of Prognostic miRNA signature and lymph node metastasis-related key genes in cervical cancer. Front Pharmacol. (2020) 11:544. 10.3389/fphar.2020.00544</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00544</ArticleId><ArticleId IdType="pmc">PMC7226536</ArticleId><ArticleId IdType="pubmed">32457603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Y, Lu Q, Qiu W, Luo Y. LINC00636 promotes lymph node metastasis and cervical cancer through targeting NM23. Biosci Rep. (2020) 40:BSR20200367. 10.1042/BSR20200367</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20200367</ArticleId><ArticleId IdType="pmc">PMC7601350</ArticleId><ArticleId IdType="pubmed">33034616</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Wan J-H, Zou W, Lian G-Y, Qin J-L, Wang Q-M. MiR-29a inhibits invasion and metastasis of cervical cancer via modulating methylation of tumor suppressor SOCS1. Future Oncol. (2019) 15:1729&#x2013;44. 10.2217/fon-2018-0497</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2018-0497</ArticleId><ArticleId IdType="pubmed">31038361</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi X, Wang J, Dai S, Qin L, Zhou J, Chen Y. Apolipoprotein C1 (APOC1): a novel diagnostic and prognostic biomarker for cervical cancer. OTT. Volume. (2020) 13:12881&#x2013;91. 10.2147/OTT.S280690</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S280690</ArticleId><ArticleId IdType="pmc">PMC7751697</ArticleId><ArticleId IdType="pubmed">33364782</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Zhai G, Bai Y. Values of miR-34a and miR-218 expression in the diagnosis of cervical cancer and the prediction of prognosis. Oncol Lett. (2018) 15:3580&#x2013;5. 10.3892/ol.2018.7791</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2018.7791</ArticleId><ArticleId IdType="pmc">PMC5795828</ArticleId><ArticleId IdType="pubmed">29456728</ArticleId></ArticleIdList></Reference><Reference><Citation>Hisamatsu T, Mabuchi S, Yoshino K, Fujita M, Enomoto T, Hamasaki T. Kimura T. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer. Int J Gynecol Cancer. (2012) 22:623&#x2013;9. 10.1097/IGC.0b013e3182473277</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IGC.0b013e3182473277</ArticleId><ArticleId IdType="pubmed">22343974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J-Y, Zheng S-R, Liu J, Shi R, Yu H-L, Wei M. MiR-519d facilitates the progression and metastasis of cervical cancer through direct targeting Smad7. Cancer Cell Int. (2016) 16:21. 10.1186/s12935-016-0298-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-016-0298-1</ArticleId><ArticleId IdType="pmc">PMC4802873</ArticleId><ArticleId IdType="pubmed">27006642</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J, Liu X, Li C, Gao M, Wang H. Sema4C modulates the migration of primary tumor-associated lymphatic endothelial cells via an ERK-mediated pathway. Exp Ther Med. (2021) 22:1102. 10.3892/etm.2021.10535</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.10535</ArticleId><ArticleId IdType="pmc">PMC8383750</ArticleId><ArticleId IdType="pubmed">34504556</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian C, Liu H, Feng Y, Meng S, Wang D, Nie M, et al. . Clinical characteristics and risk of second primary lung cancer after cervical cancer: a population-based study. PLoS ONE. (2020) 15:e0231807. 10.1371/journal.pone.0231807</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0231807</ArticleId><ArticleId IdType="pmc">PMC7406086</ArticleId><ArticleId IdType="pubmed">32756555</ArticleId></ArticleIdList></Reference><Reference><Citation>Piura E, Piura B. Brain metastases from cervical carcinoma: overview of pertinent literature. Eur J Gynaecol Oncol. (2012) 33:567&#x2013;73. 10.5402/2012/581749</Citation><ArticleIdList><ArticleId IdType="doi">10.5402/2012/581749</ArticleId><ArticleId IdType="pubmed">23327047</ArticleId></ArticleIdList></Reference><Reference><Citation>Cormio G, Pellegrino A, Landoni F, Regallo M, Zanetta G, Colombo A, et al. . Brain metastases from cervical carcinoma. Tumori. (1996) 82:394&#x2013;6. 10.1177/030089169608200420</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/030089169608200420</ArticleId><ArticleId IdType="pubmed">8890978</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. . Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. (2017) 14:749&#x2013;62. 10.1038/nrclinonc.2017.141</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2017.141</ArticleId><ArticleId IdType="pubmed">28975929</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Zheng H, Pan X, Chen L, Shi M, Guan Y, et al. . Texture analysis of CT imaging for assessment of esophageal squamous cancer aggressiveness. J Thorac Dis. (2017) 9:4724&#x2013;32. 10.21037/jtd.2017.06.46</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2017.06.46</ArticleId><ArticleId IdType="pmc">PMC5720997</ArticleId><ArticleId IdType="pubmed">29268543</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, Liu Z, Wang Z, Guo J, Zhang H, Wang Y, et al. . Building CT radiomics based nomogram for preoperative esophageal cancer patients lymph node metastasis prediction. Transl Oncol. (2018) 11:815&#x2013;24. 10.1016/j.tranon.2018.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2018.04.005</ArticleId><ArticleId IdType="pmc">PMC6154864</ArticleId><ArticleId IdType="pubmed">29727831</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu J, Shen C, Qin J, Wang Z, Liu Z, Guo J, et al. . The MR radiomic signature can predict preoperative lymph node metastasis in patients with esophageal cancer. Eur Radiol. (2019) 29:906&#x2013;14. 10.1007/s00330-018-5583-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-018-5583-z</ArticleId><ArticleId IdType="pubmed">30039220</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritz B, M&#xfc;ller DA, Sutter R, Wurnig MC, Wagner MW, Pfirrmann CWA, et al. . Magnetic resonance imaging&#x2013;based grading of cartilaginous bone tumors: added value of quantitative texture analysis. Invest Radiol. (2018) 53:663&#x2013;72. 10.1097/RLI.0000000000000486</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RLI.0000000000000486</ArticleId><ArticleId IdType="pubmed">29863601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, Su Y, Duan J, Qiu Q, Ge X, Wang A, et al. . Radiomics signature extracted from diffusion-weighted magnetic resonance imaging predicts outcomes in osteosarcoma. J Bone Oncol. (2019) 19:100263. 10.1016/j.jbo.2019.100263</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbo.2019.100263</ArticleId><ArticleId IdType="pmc">PMC6812010</ArticleId><ArticleId IdType="pubmed">31667064</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Mao Y, Chen X, Wu G, Liu X, Zhang P, et al. . Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study. Eur Radiol. (2019) 29:3358&#x2013;71. 10.1007/s00330-019-06124-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-019-06124-9</ArticleId><ArticleId IdType="pubmed">30963272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazi S, Collins DJ, Messiou C, Pennert K, Davidson RL, Giles SL, et al. . Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging&#x2014;value of histogram analysis of apparent diffusion coefficients. Radiology. (2011) 261:182&#x2013;92. 10.1148/radiol.11110577</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.11110577</ArticleId><ArticleId IdType="pubmed">21828186</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xf8;vik E, Yi D, Iv M, Tong E, Rubin D, Zaharchuk G. Deep learning enables automatic detection and segmentation of brain metastases on multisequence MRI. J Magn Reson Imaging. (2020) 51:175&#x2013;82. 10.1002/jmri.26766</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.26766</ArticleId><ArticleId IdType="pmc">PMC7199496</ArticleId><ArticleId IdType="pubmed">31050074</ArticleId></ArticleIdList></Reference><Reference><Citation>Artzi M, Bressler I, Ben Bashat D. Differentiation between glioblastoma, brain metastasis and subtypes using radiomics analysis: radiomics classification of brain tumors. J Magn Reson Imaging. (2019) 50:519&#x2013;28. 10.1002/jmri.26643</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.26643</ArticleId><ArticleId IdType="pubmed">30635952</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C-Y, Lee C-C, Yang H-C, Lin C-J, Wu H-M, Chung W-Y, et al. . Radiomics as prognostic factor in brain metastases treated with Gamma Knife radiosurgery. J Neurooncol. (2020) 146:439&#x2013;49. 10.1007/s11060-019-03343-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11060-019-03343-4</ArticleId><ArticleId IdType="pubmed">32020474</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen T, Liu L, Li W, Fu P, Xu K, Jiang Y, et al. . imaging-based histogram features for prediction of EGFR mutation status of bone metastases in patients with primary lung adenocarcinoma. Cancer Imaging. (2019) 19:34. 10.1186/s40644-019-0221-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40644-019-0221-9</ArticleId><ArticleId IdType="pmc">PMC6556025</ArticleId><ArticleId IdType="pubmed">31174617</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Shi Z, Lian Y, Li Z, Liu T, Gao Y, et al. . Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma. Eur Radiol. (2017) 27:3509&#x2013;22. 10.1007/s00330-016-4653-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-016-4653-3</ArticleId><ArticleId IdType="pubmed">28004160</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C, Kong Z, Liu S, Feng S, Zhang Y, Zhu R, et al. . Fusion radiomics features from conventional MRI predict MGMT promoter methylation status in lower grade gliomas. Eur J Radiol. (2019) 121:108714. 10.1016/j.ejrad.2019.108714</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejrad.2019.108714</ArticleId><ArticleId IdType="pubmed">31704598</ArticleId></ArticleIdList></Reference><Reference><Citation>Aerts HJWL. The potential of radiomic-based phenotyping in precision medicine: a review. JAMA Oncol. (2016) 2:1636. 10.1001/jamaoncol.2016.2631</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2016.2631</ArticleId><ArticleId IdType="pubmed">27541161</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu K, Wu C, Wang Z, Wang H, Yin F, Li W, et al. . Family gene expression as prognostic biomarkers for Alzheimer's disease and primary liver cancer. Comput Math Methods Med. (2021) 2021:1&#x2013;15. 10.1155/2021/3422393</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/3422393</ArticleId><ArticleId IdType="pmc">PMC8627334</ArticleId><ArticleId IdType="pubmed">34845413</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C, Guo H, Yan D, Liang T, Ye X, Li Z. Pancancer analysis of neurovascular-related NRP family genes as potential prognostic biomarkers of bladder urothelial carcinoma. Biomed Res Int. (2021) 2021:5546612. 10.1155/2021/5546612</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5546612</ArticleId><ArticleId IdType="pmc">PMC8062179</ArticleId><ArticleId IdType="pubmed">33937395</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A, Yeung S, Thakkar A, Huang KM, Liu MM, Kanassatega R-S, et al. . Prevention of skin carcinogenesis by the &#x3b2;-blocker carvedilol. Cancer Prev Res. (2015) 8:27&#x2013;36. 10.1158/1940-6207.CAPR-14-0193</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1940-6207.CAPR-14-0193</ArticleId><ArticleId IdType="pmc">PMC4289657</ArticleId><ArticleId IdType="pubmed">25367979</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang P-Y, Huang W-Y, Lin C-L, Huang T-C, Wu Y-Y, Chen J-H, et al. . Propranolol reduces cancer risk: a population-based cohort study. Medicine. (2015) 94:e1097. 10.1097/MD.0000000000001097</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000001097</ArticleId><ArticleId IdType="pmc">PMC4504645</ArticleId><ArticleId IdType="pubmed">26166098</ArticleId></ArticleIdList></Reference><Reference><Citation>Renz BW, Takahashi R, Tanaka T, Macchini M, Hayakawa Y, Dantes Z, et al. . &#x3b2;2 Adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell. (2018) 33:75&#x2013;90.e7. 10.1016/j.ccell.2018.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2018.10.010</ArticleId><ArticleId IdType="pmc">PMC5760435</ArticleId><ArticleId IdType="pubmed">29249692</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Liu X, Wang Z, Liu F. Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer. Eur J Cardiothorac Surg. (2010) 37:546&#x2013;51. 10.1016/j.ejcts.2009.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcts.2009.08.005</ArticleId><ArticleId IdType="pubmed">19758816</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing F, Liu Y, Sharma S, Wu K, Chan MD, Lo H-W, et al. . Activation of the c-Met pathway mobilizes an inflammatory network in the brain microenvironment to promote brain metastasis of breast cancer. Cancer Res. (2016) 76:4970&#x2013;80. 10.1158/0008-5472.CAN-15-3541</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-15-3541</ArticleId><ArticleId IdType="pmc">PMC5010459</ArticleId><ArticleId IdType="pubmed">27364556</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Rodr&#xed;guez F, Limones-Gonz&#xe1;lez JE, Mendoza-Almanza B, Esparza-Ibarra EL, Gallegos-Flores PI, Ayala-Luj&#xe1;n JL, et al. . understanding cervical cancer through proteomics. Cells. (2021) 10:1854. 10.3390/cells10081854</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10081854</ArticleId><ArticleId IdType="pmc">PMC8391734</ArticleId><ArticleId IdType="pubmed">34440623</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Sun X, Liu S, Liu L, Chen J. The overlap between regeneration and fibrosis in injured skeletal muscle is regulated by phosphatidylinositol 3-kinase/Akt signaling pathway - a bioinformatic analysis based on lncRNA microarray. Gene. (2018) 672:79&#x2013;87. 10.1016/j.gene.2018.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2018.06.001</ArticleId><ArticleId IdType="pubmed">29870770</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Z, Sun Y, Qi B, Lin J, Chen Y, Xu Y, Chen J. Human bone marrow mesenchymal stem cell-derived extracellular vesicles inhibit shoulder stiffness via let-7a/Tgfbr1 axis. Bioact Mater. (2022) 17:344&#x2013;59. 10.1016/j.bioactmat.2022.01.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioactmat.2022.01.016</ArticleId><ArticleId IdType="pmc">PMC8965035</ArticleId><ArticleId IdType="pubmed">35386460</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Liang X, Cai Z. A Potential ceRNA network for neurological damage in preterm infants. Biomed Res Int. (2021) 2021:2628824. 10.1155/2021/2628824</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/2628824</ArticleId><ArticleId IdType="pmc">PMC8405308</ArticleId><ArticleId IdType="pubmed">34471635</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q, Yan X, Wang J, Zhang X. Collagen family genes associated with risk of recurrence after radiation therapy for vestibular schwannoma and pan-cancer analysis. Dis Markers. (2021) 2021:1&#x2013;15. 10.1155/2021/7897994</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/7897994</ArticleId><ArticleId IdType="pmc">PMC8528601</ArticleId><ArticleId IdType="pubmed">34691289</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G-Y, Yu P, Zhang C, Deng H-Y, Lu M-X, Le J-H. The neuropeptide-related HERC5/TAC1 interactions may be associated with the dysregulation of lncRNA GAS5 expression in gestational diabetes mellitus exosomes. Dis Markers. (2022) 2022:1&#x2013;12. 10.1155/2022/8075285</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/8075285</ArticleId><ArticleId IdType="pmc">PMC8847027</ArticleId><ArticleId IdType="pubmed">35178132</ArticleId></ArticleIdList></Reference><Reference><Citation>Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. (2015) 16:e173&#x2013;80. 10.1016/S1470-2045(14)71116-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(14)71116-7</ArticleId><ArticleId IdType="pmc">PMC4465353</ArticleId><ArticleId IdType="pubmed">25846097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying C, Guo C, Wang Z, Chen Y, Sun J, Qi X, et al. . Prediction modeling based on the hospital for special surgery (HSS) knee score for poor postoperative functional prognosis of elderly patients with patellar fractures. Biomed Res Int. (2021) 2021:6620504. 10.1155/2021/6620504</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/6620504</ArticleId><ArticleId IdType="pmc">PMC8668305</ArticleId><ArticleId IdType="pubmed">34912895</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Ma S, Chen Y, Kim NH, Kailas S, Wang Y, et al. . Diagnostic value, prognostic value, and immune infiltration of LOX family members in liver cancer: bioinformatic analysis. Front Oncol. (2022) 12:843880. 10.3389/fonc.2022.843880</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2022.843880</ArticleId><ArticleId IdType="pmc">PMC8931681</ArticleId><ArticleId IdType="pubmed">35311155</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. (2005) 102:15545&#x2013;50. 10.1073/pnas.0506580102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. (2012) 16:284&#x2013;7. 10.1089/omi.2011.0118</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranasinghe AM. How does glucose insulin potassium improve hemodynamic performance? evidence for altered expression of beta-adrenoreceptor and calcium handling genes. Circulation. (2006) 114(1 Suppl):I239&#x2013;44. 10.1161/CIRCULATIONAHA.105.000760</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.000760</ArticleId><ArticleId IdType="pubmed">16820579</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SY, Zhang Y-Y, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. (2009) 10:273&#x2013;84. 10.1016/j.cmet.2009.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2009.08.015</ArticleId><ArticleId IdType="pmc">PMC2759401</ArticleId><ArticleId IdType="pubmed">19808020</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayerhoefer ME, Materka A, Langs G, H&#xe4;ggstr&#xf6;m I, Szczypi&#x144;ski P, Gibbs P, et al. . Introduction to radiomics. J Nucl Med. (2020) 61:488&#x2013;95. 10.2967/jnumed.118.222893</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.118.222893</ArticleId><ArticleId IdType="pmc">PMC9374044</ArticleId><ArticleId IdType="pubmed">32060219</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S-H, Park H, Ko ES. Radiomics in breast imaging from techniques to clinical applications: a review. Korean J Radiol. (2020) 21:779. 10.3348/kjr.2019.0855</Citation><ArticleIdList><ArticleId IdType="doi">10.3348/kjr.2019.0855</ArticleId><ArticleId IdType="pmc">PMC7289696</ArticleId><ArticleId IdType="pubmed">32524780</ArticleId></ArticleIdList></Reference><Reference><Citation>Kan Y, Dong D, Zhang Y, Jiang W, Zhao N, Han L, et al. . Radiomic signature as a predictive factor for lymph node metastasis in early-stage cervical cancer: radiomic signature of LNM in cervical cancer. J Magn Reson Imaging. (2019) 49:304&#x2013;10. 10.1002/jmri.26209</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.26209</ArticleId><ArticleId IdType="pubmed">30102438</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Wang S, Chen X, Wang Y, Dong L, Liu Z, et al. . Radiomics analysis of magnetic resonance imaging improves diagnostic performance of lymph node metastasis in patients with cervical cancer. Radiother Oncol. (2019) 138:141&#x2013;8. 10.1016/j.radonc.2019.04.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radonc.2019.04.035</ArticleId><ArticleId IdType="pubmed">31252296</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Li H, Wang S, Dong D, Yin F, Chen A, et al. . MR-based radiomics nomogram of cervical cancer in prediction of the lymph-vascular space invasion preoperatively: preoperative prediction of LVSI. J Magn Reson Imaging. (2019) 49:1420&#x2013;6. 10.1002/jmri.26531</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.26531</ArticleId><ArticleId IdType="pmc">PMC6587470</ArticleId><ArticleId IdType="pubmed">30362652</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. (2016) 278:563&#x2013;77. 10.1148/radiol.2015151169</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2015151169</ArticleId><ArticleId IdType="pmc">PMC4734157</ArticleId><ArticleId IdType="pubmed">26579733</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley EF, Snyder EM, Johnson BD. Influence of Beta-1 adrenergic receptor genotype on cardiovascular response to exercise in healthy subjects. Cardiol Res. (2018) 9:343&#x2013;9. 10.14740/cr785</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/cr785</ArticleId><ArticleId IdType="pmc">PMC6306116</ArticleId><ArticleId IdType="pubmed">30627284</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Liu H, Wang F, Xu R, Wang P, Tang F, et al. . Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells. Mol Med Rep. (2018) 17:5213&#x2013;21. 10.3892/mmr.2018.8476</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2018.8476</ArticleId><ArticleId IdType="pmc">PMC5865987</ArticleId><ArticleId IdType="pubmed">29393410</ArticleId></ArticleIdList></Reference><Reference><Citation>He J-J, Zhang W-H, Liu S-L, Chen Y-F, Liao C-X, Shen Q-Q, et al. . Activation of &#x3b2;-adrenergic receptor promotes cellular proliferation in human glioblastoma. Oncol Lett. (2017) 14:3846&#x2013;52. 10.3892/ol.2017.6653</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2017.6653</ArticleId><ArticleId IdType="pmc">PMC5587982</ArticleId><ArticleId IdType="pubmed">28927156</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvani M, Pelon F, Comito G, Taddei ML, Moretti S, Innocenti S, et al. . Norepinephrine promotes tumor microenvironment reactivity through &#x3b2;3-adrenoreceptors during melanoma progression. Oncotarget. (2015) 6:4615&#x2013;32. 10.18632/oncotarget.2652</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.2652</ArticleId><ArticleId IdType="pmc">PMC4467103</ArticleId><ArticleId IdType="pubmed">25474135</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrobel LJ, Bod L, Lengagne R, Kato M, Pr&#xe9;vost-Blondel A, Gal F-AL. Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma. Oncotarget. (2016) 7:77825&#x2013;37. 10.18632/oncotarget.12833</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.12833</ArticleId><ArticleId IdType="pmc">PMC5363624</ArticleId><ArticleId IdType="pubmed">27788481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmari N, Schmidt JT, Krane GA, Malphurs W, Cunningham BE, Owen JL, et al. . Loss of bone marrow adrenergic beta 1 and 2 receptors modifies transcriptional networks, reduces circulating inflammatory factors, and regulates blood pressure. Physiol Genomics. (2016) 48:526&#x2013;36. 10.1152/physiolgenomics.00039.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.00039.2016</ArticleId><ArticleId IdType="pubmed">27235450</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhang X, Li J, Ma X, Feng F, Liu L, et al. . ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration. Aging. (2021) 13:351&#x2013;63. 10.18632/aging.104204</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.104204</ArticleId><ArticleId IdType="pmc">PMC7835009</ArticleId><ArticleId IdType="pubmed">33234738</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrer S, Rheinstein PH. The ADRB1 (Adrenoceptor Beta 1) and ADRB2 genes significantly co-express with commonly mutated genes in prostate cancer. Discov Med. (2020) 30:163&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894950</ArticleId><ArticleId IdType="pubmed">33593484</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Chen W, Zhang M, Zhang C, Cao B, Dong B, et al. . Modulatory effects of Xihuang Pill on lung cancer treatment by an integrative approach. Biomed Pharmacother. (2020) 130:110533. 10.1016/j.biopha.2020.110533</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110533</ArticleId><ArticleId IdType="pubmed">32739739</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Liao X-X, Mai H-M, Zhou N, Wang D-Y, Peng J-B, et al. . Expression of beta adrenergic receptor in oral squamous cell carcinoma and its significance to the prognosis. Int J Clin Exp Pathol. (2017) 10:10431&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6965752</ArticleId><ArticleId IdType="pubmed">31966380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lois H. New advances in immunotherapy for prostate cancer. Life Res. (2019) 2:152. 10.53388/life2019-1025-302</Citation><ArticleIdList><ArticleId IdType="doi">10.53388/life2019-1025-302</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallavi VR, Devi KU, Mukherjee G, Ramesh C, Bafna UD. Relationship between lymph node metastases and histopathological parameters in carcinoma cervix: a multivariate analysis. J Obstet Gynaecol. (2012) 32:78&#x2013;80. 10.3109/01443615.2011.625455</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/01443615.2011.625455</ArticleId><ArticleId IdType="pubmed">22185544</ArticleId></ArticleIdList></Reference><Reference><Citation>Ki EY, Lee KH, Park JS, Hur SY. A clinicopathological review of pulmonary metastasis from uterine cervical cancer. Cancer Res Treat. (2016) 48:266&#x2013;72. 10.4143/crt.2014.206</Citation><ArticleIdList><ArticleId IdType="doi">10.4143/crt.2014.206</ArticleId><ArticleId IdType="pmc">PMC4720087</ArticleId><ArticleId IdType="pubmed">25715766</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Qin L, Chen H-M, Hsu H-C, Chuang C-C, Chen D, et al. . Overall survival, locoregional recurrence, and distant metastasis of definitive concurrent chemoradiotherapy for cervical squamous cell carcinoma and adenocarcinoma: before and after propensity score matching analysis of a cohort study. Am J Cancer Res. (2020) 10:1808&#x2013;20. 10.2139/ssrn.3582834</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3582834</ArticleId><ArticleId IdType="pmc">PMC7339279</ArticleId><ArticleId IdType="pubmed">32642292</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg K, Ternestedt B-M, T&#xf6;rnberg S, Tishelman C. How do women who choose not to participate in population-based cervical cancer screening reason about their decision? Psychooncology. (2008) 17:561&#x2013;9. 10.1002/pon.1270</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.1270</ArticleId><ArticleId IdType="pubmed">17886262</ArticleId></ArticleIdList></Reference><Reference><Citation>Imachi M, Tsukamoto N, Matsuyama T, Nakano H. Pulmonary metastasis from carcinoma of the uterine cervix. Gynecol Oncol. (1989) 33:189&#x2013;92. 10.1016/0090-8258(89)90549-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-8258(89)90549-0</ArticleId><ArticleId IdType="pubmed">2703179</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiromizu K, Kasamatsu T, Takahashi M, Kikuchi A, Yoshinari T, Matsuzawa M, et al. . Clinicopathological study of postoperative pulmonary metastasis of uterine cervical carcinomas. J Obstet Gynaecol Res. (1999) 25:245&#x2013;9. 10.1111/j.1447-0756.1999.tb01156.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1447-0756.1999.tb01156.x</ArticleId><ArticleId IdType="pubmed">10540526</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35853859</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2058-7716</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Cell death discovery</Title><ISOAbbreviation>Cell Death Discov</ISOAbbreviation></Journal><ArticleTitle>The splicing factor SF3B4 drives proliferation and invasion in cervical cancer by regulating SPAG5.</ArticleTitle><Pagination><StartPage>326</StartPage><MedlinePgn>326</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">326</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41420-022-01120-3</ELocationID><Abstract><AbstractText>Regulation of alternative splicing (AS) by the splicing factor 3b (SF3B) family plays an essential role in cancer. However, the biological function of SF3B family members in cervical cancer (CC) needs to be further elucidated. In this study, we found that splicing factor 3b subunit 4 (SF3B4) was highly expressed in CC by bioinformatics analysis using cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) data from The Cancer Genome Atlas (TCGA). Then, we demonstrated that high expression of SF3B4 promoted proliferation and invasion abilities of CC cells in vitro and in vivo and that reduced expression of SF3B4 performed the opposite effect. Further RNA-seq and AS analysis showed that sperm-associated antigen 5 (SPAG5) was a downstream target gene of SF3B4. Interestingly, SPAG5 expression was decreased after SF3B4 knockdown because of retained introns (RIs) and reduced maturation of SPAG5 pre-mRNA. Importantly, SPAG5 deficiency impaired the oncogenic effects of SF3B4 overexpression on CC cells. In conclusion, SF3B4 promotes CC progression by regulating the effective splicing of SPAG5. SF3B4 could be a promising target for CC.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Yingwei</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-1155-221X</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. sduliyingwei@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China. sduliyingwei@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Diao</LastName><ForeName>Yuchao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zixiang</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-5252-9764</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shourong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Jiali</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Beihua</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5911-0242</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. kongbeihua@sdu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81874107</GrantID><Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency><Country/></Grant><Grant><GrantID>82072871</GrantID><Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency><Country/></Grant><Grant><GrantID>81902650</GrantID><Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Death Discov</MedlineTA><NlmUniqueID>101665035</NlmUniqueID><ISSNLinking>2058-7716</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>19</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35853859</ArticleId><ArticleId IdType="pmc">PMC9296558</ArticleId><ArticleId IdType="doi">10.1038/s41420-022-01120-3</ArticleId><ArticleId IdType="pii">10.1038/s41420-022-01120-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115&#x2013;32. doi: 10.3322/caac.21338.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21338</ArticleId><ArticleId IdType="pubmed">26808342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394&#x2013;424. doi: 10.3322/caac.21492.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393:169&#x2013;82. doi: 10.1016/S0140-6736(18)32470-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32470-X</ArticleId><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87&#x2013;108. doi: 10.3322/caac.21262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21262</ArticleId><ArticleId IdType="pubmed">25651787</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003&#x2013;15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6:e555&#x2013;67. doi: 10.1016/S2214-109X(18)30127-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(18)30127-X</ArticleId><ArticleId IdType="pubmed">29653628</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhao LJ, Li MZ, Li MX, Wang JL, Wei LH. The number of positive pelvic lymph nodes and multiple groups of pelvic lymph node metastasis influence prognosis in stage IA-IIB cervical squamous cell carcinoma. Chin Med J (Engl) 2015;128:2084&#x2013;9. doi: 10.4103/0366-6999.161372.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0366-6999.161372</ArticleId><ArticleId IdType="pmc">PMC4717967</ArticleId><ArticleId IdType="pubmed">26228223</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida K, Ogawa S. Splicing factor mutations and cancer. Wiley Interdiscip Rev RNA. 2014;5:445&#x2013;59. doi: 10.1002/wrna.1222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wrna.1222</ArticleId><ArticleId IdType="pubmed">24523246</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnal SC, Lopez-Oreja I, Valcarcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020;17:457&#x2013;74. doi: 10.1038/s41571-020-0350-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-020-0350-x</ArticleId><ArticleId IdType="pubmed">32303702</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y. Mechanistic insights into precursor messenger RNA splicing by the spliceosome. Nat Rev Mol Cell Biol. 2017;18:655&#x2013;70. doi: 10.1038/nrm.2017.86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2017.86</ArticleId><ArticleId IdType="pubmed">28951565</ArticleId></ArticleIdList></Reference><Reference><Citation>Srebrow A, Kornblihtt AR. The connection between splicing and cancer. J Cell Sci. 2006;119:2635&#x2013;41. doi: 10.1242/jcs.03053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.03053</ArticleId><ArticleId IdType="pubmed">16787944</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 2018;23:282&#x2013;96 e284. doi: 10.1016/j.celrep.2018.01.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.01.088</ArticleId><ArticleId IdType="pmc">PMC5933844</ArticleId><ArticleId IdType="pubmed">29617667</ArticleId></ArticleIdList></Reference><Reference><Citation>Biamonti G, Catillo M, Pignataro D, Montecucco A, Ghigna C. The alternative splicing side of cancer. Semin Cell Dev Biol. 2014;32:30&#x2013;6. doi: 10.1016/j.semcdb.2014.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2014.03.016</ArticleId><ArticleId IdType="pubmed">24657195</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Weiss WA. Alternative splicing in cancer: implications for biology and therapy. Oncogene. 2015;34:1&#x2013;14. doi: 10.1038/onc.2013.570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2013.570</ArticleId><ArticleId IdType="pubmed">24441040</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberger S, De-Castro Arce J, Langbein L, Steenbergen RD, Rosl F. Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation. Proc Natl Acad Sci USA. 2010;107:7006&#x2013;11. doi: 10.1073/pnas.1002620107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1002620107</ArticleId><ArticleId IdType="pmc">PMC2872467</ArticleId><ArticleId IdType="pubmed">20351270</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Dai M, Xu Q, Zhu X, Zhou Y, Jiang S, et al. SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-kappaB-CD47 axis. Oncogene. 2018;37:2394&#x2013;409. doi: 10.1038/s41388-017-0119-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-017-0119-6</ArticleId><ArticleId IdType="pmc">PMC5931977</ArticleId><ArticleId IdType="pubmed">29429992</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao XY, Dong J, Zhang H, Wu YS, Zheng L. Prognostic value and potential role of alternative mRNA splicing events in cervical cancer. Front Genet. 2020;11:726. doi: 10.3389/fgene.2020.00726.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.00726</ArticleId><ArticleId IdType="pmc">PMC7394696</ArticleId><ArticleId IdType="pubmed">32793282</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang D, Yang P, Cai J, Sun S, Wang Z. Comprehensive analysis of prognostic alternative splicing signature in cervical cancer. Cancer Cell Int. 2020;20:221. doi: 10.1186/s12935-020-01299-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-020-01299-4</ArticleId><ArticleId IdType="pmc">PMC7282181</ArticleId><ArticleId IdType="pubmed">32528230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YX, Zheng MJ, Zhang WC, Li X, Gou R, Nie X, et al. Systematic profiling of alternative splicing signature reveals prognostic predictor for cervical cancer. J Transl Med. 2019;17:379. doi: 10.1186/s12967-019-02140-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-019-02140-x</ArticleId><ArticleId IdType="pmc">PMC6865056</ArticleId><ArticleId IdType="pubmed">31744495</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerasuolo A, Buonaguro L, Buonaguro FM, Tornesello ML. The role of RNA splicing factors in cancer: regulation of viral and human gene expression in human papillomavirus-related cervical cancer. Front Cell Dev Biol. 2020;8:474. doi: 10.3389/fcell.2020.00474.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00474</ArticleId><ArticleId IdType="pmc">PMC7303290</ArticleId><ArticleId IdType="pubmed">32596243</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia R, Ajiro M, Yu L, McCoy P, Jr., Zheng ZM. Oncogenic splicing factor SRSF3 regulates ILF3 alternative splicing to promote cancer cell proliferation and transformation. RNA. 2019;25:630&#x2013;44. doi: 10.1261/rna.068619.118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.068619.118</ArticleId><ArticleId IdType="pmc">PMC6467003</ArticleId><ArticleId IdType="pubmed">30796096</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi X, Ran L, Liu Y, Zhong SH, Zhou PP, Liao MX, et al. Knockdown of hnRNP A2/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway. Oncol Rep. 2018;39:939&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802035</ArticleId><ArticleId IdType="pubmed">29328485</ArticleId></ArticleIdList></Reference><Reference><Citation>Popli P, Richters MM, Chadchan SB, Kim TH, Tycksen E, Griffith O, et al. Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation. Cell Death Dis. 2020;11:842. doi: 10.1038/s41419-020-03055-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-03055-y</ArticleId><ArticleId IdType="pmc">PMC7548007</ArticleId><ArticleId IdType="pubmed">33040078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamura N, Nimura K, Saga K, Ishibashi A, Kitamura K, Nagano H, et al. SF3B2-mediated RNA splicing drives human prostate cancer progression. Cancer Res. 2019;79:5204&#x2013;17. doi: 10.1158/0008-5472.CAN-18-3965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-18-3965</ArticleId><ArticleId IdType="pubmed">31431456</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Xiao H, Zeng J, Yu G, Zhou H, Huang C, et al. Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer. Clin Cancer Res. 2017;23:3428&#x2013;41. doi: 10.1158/1078-0432.CCR-16-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-16-2020</ArticleId><ArticleId IdType="pmc">PMC5440213</ArticleId><ArticleId IdType="pubmed">27879367</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Li W, Pang Y, Zhou Z, Liu S, Cheng K, et al. SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma. EBioMedicine. 2018;38:57&#x2013;68. doi: 10.1016/j.ebiom.2018.10.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.10.067</ArticleId><ArticleId IdType="pmc">PMC6306498</ArticleId><ArticleId IdType="pubmed">30391496</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidogami S, Iguchi T, Sato K, Yoshikawa Y, Hu Q, Nambara S, et al. SF3B4 plays an oncogenic role in esophageal squamous cell carcinoma. Anticancer Res. 2020;40:2941&#x2013;6. doi: 10.21873/anticanres.14272.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.14272</ArticleId><ArticleId IdType="pubmed">32366446</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Di C, Yan J, Wang F, Qu T, Wang Y, et al. Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells. Artif Cells Nanomed Biotechnol. 2019;47:1273&#x2013;80. doi: 10.1080/21691401.2019.1596922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21691401.2019.1596922</ArticleId><ArticleId IdType="pubmed">30963795</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamano T, Kubo S, Yano A, Kominato T, Tanaka S, Ikeda M, et al. Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy. Oncotarget. 2019;10:352&#x2013;67. doi: 10.18632/oncotarget.26564.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.26564</ArticleId><ArticleId IdType="pmc">PMC6349454</ArticleId><ArticleId IdType="pubmed">30719229</ArticleId></ArticleIdList></Reference><Reference><Citation>Furumai R, Uchida K, Komi Y, Yoneyama M, Ishigami K, Watanabe H, et al. Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF. Cancer Sci. 2010;101:2483&#x2013;9. doi: 10.1111/j.1349-7006.2010.01686.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2010.01686.x</ArticleId><ArticleId IdType="pmc">PMC11158552</ArticleId><ArticleId IdType="pubmed">20726856</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert BJ, McPherson PA, O'Brien K, Czaicki NL, Destefino V, Osman S, et al. Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Mol Cancer Ther. 2009;8:2308&#x2013;18. doi: 10.1158/1535-7163.MCT-09-0051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-09-0051</ArticleId><ArticleId IdType="pmc">PMC2762647</ArticleId><ArticleId IdType="pubmed">19671752</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Q, Nam SW. SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma. BMB Rep. 2018;51:57&#x2013;58. doi: 10.5483/BMBRep.2018.51.2.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/BMBRep.2018.51.2.021</ArticleId><ArticleId IdType="pmc">PMC5836557</ArticleId><ArticleId IdType="pubmed">29397868</ArticleId></ArticleIdList></Reference><Reference><Citation>Baralle FE, Giudice J. Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017;18:437&#x2013;51. doi: 10.1038/nrm.2017.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2017.27</ArticleId><ArticleId IdType="pmc">PMC6839889</ArticleId><ArticleId IdType="pubmed">28488700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush SJ, Chen L, Tovar-Corona JM, Urrutia AO. Alternative splicing and the evolution of phenotypic novelty. Philos Trans R Soc Lond B Biol Sci. 2017;372:1713. doi: 10.1098/rstb.2015.0474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2015.0474</ArticleId><ArticleId IdType="pmc">PMC5182408</ArticleId><ArticleId IdType="pubmed">27994117</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Sun L, Cai Y, Shen S, Zhang T, Wang N, et al. Hypoxia-induced suppression of alternative splicing of MBD2 promotes breast cancer metastasis via activation of FZD1. Cancer Res. 2021;81:1265&#x2013;78. doi: 10.1158/0008-5472.CAN-20-2876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-20-2876</ArticleId><ArticleId IdType="pubmed">33402389</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Wang Z, Li J, Qin J, Song J, Li Y, et al. Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2. Cell Death Dis. 2021;12:294. doi: 10.1038/s41419-021-03581-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-03581-3</ArticleId><ArticleId IdType="pmc">PMC7969951</ArticleId><ArticleId IdType="pubmed">33731694</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellarin I, Dall'Acqua A, Gambelli A, Pellizzari I, D'Andrea S, Sonego M, et al. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity. Oncogene. 2020;39:4390&#x2013;403. doi: 10.1038/s41388-020-1292-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-020-1292-6</ArticleId><ArticleId IdType="pmc">PMC7253352</ArticleId><ArticleId IdType="pubmed">32332923</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N, Wu Z, Chen A, Wang Y, Cai D, Zheng J, et al. SNRPB promotes the tumorigenic potential of NSCLC in part by regulating RAB26. Cell Death Dis. 2019;10:667. doi: 10.1038/s41419-019-1929-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1929-y</ArticleId><ArticleId IdType="pmc">PMC6739327</ArticleId><ArticleId IdType="pubmed">31511502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Wang R, Li X, Yu L, Hua D, Sun C, et al. Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B. J Clin Invest. 2019;129:676&#x2013;93. doi: 10.1172/JCI120279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI120279</ArticleId><ArticleId IdType="pmc">PMC6355305</ArticleId><ArticleId IdType="pubmed">30481162</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan L, Yu W, Shen E, Sun W, Liu Y, Kong J, et al. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut. 2019;68:118&#x2013;29. doi: 10.1136/gutjnl-2017-314983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2017-314983</ArticleId><ArticleId IdType="pubmed">29114070</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo C, Cheng Y, Liu Y, Chen L, Liu L, Wei N, et al. SRSF2 regulates alternative splicing to drive hepatocellular carcinoma development. Cancer Res. 2017;77:1168&#x2013;78. doi: 10.1158/0008-5472.CAN-16-1919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-16-1919</ArticleId><ArticleId IdType="pubmed">28082404</ArticleId></ArticleIdList></Reference><Reference><Citation>Cretu C, Schmitzova J, Ponce-Salvatierra A, Dybkov O, De Laurentiis EI, Sharma K, et al. Molecular architecture of SF3b and structural consequences of its cancer-related mutations. Mol Cell. 2016;64:307&#x2013;19. doi: 10.1016/j.molcel.2016.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2016.08.036</ArticleId><ArticleId IdType="pubmed">27720643</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong JJ, Ritchie W, Ebner OA, Selbach M, Wong JW, Huang Y, et al. Orchestrated intron retention regulates normal granulocyte differentiation. Cell. 2013;154:583&#x2013;95. doi: 10.1016/j.cell.2013.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.06.052</ArticleId><ArticleId IdType="pubmed">23911323</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunschweig U, Barbosa-Morais NL, Pan Q, Nachman EN, Alipanahi B, Gonatopoulos-Pournatzis T, et al. Widespread intron retention in mammals functionally tunes transcriptomes. Genome Res. 2014;24:1774&#x2013;86. doi: 10.1101/gr.177790.114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.177790.114</ArticleId><ArticleId IdType="pmc">PMC4216919</ArticleId><ArticleId IdType="pubmed">25258385</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H, Lee D, Lee J, Park D, Kim YJ, Park WY, et al. Intron retention is a widespread mechanism of tumor-suppressor inactivation. Nat Genet. 2015;47:1242&#x2013;8. doi: 10.1038/ng.3414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3414</ArticleId><ArticleId IdType="pubmed">26437032</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouyama Y, Masuda T, Fujii A, Ogawa Y, Sato K, Tobo T, et al. Oncogenic splicing abnormalities induced by DEAD-Box Helicase 56 amplification in colorectal cancer. Cancer Sci. 2019;110:3132&#x2013;44. doi: 10.1111/cas.14163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.14163</ArticleId><ArticleId IdType="pmc">PMC6778637</ArticleId><ArticleId IdType="pubmed">31390121</ArticleId></ArticleIdList></Reference><Reference><Citation>Park EM, Scott PM, Clutario K, Cassidy KB, Zhan K, Gerber SA, et al. WBP11 is required for splicing the TUBGCP6 pre-mRNA to promote centriole duplication. J Cell Biol. 2020;219:1. doi: 10.1083/jcb.201904203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201904203</ArticleId><ArticleId IdType="pmc">PMC7039186</ArticleId><ArticleId IdType="pubmed">31874114</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou S, Qu D, Li Y, Zhu B, Liang D, Wei X, et al. XAB2 depletion induces intron retention in POLR2A to impair global transcription and promote cellular senescence. Nucleic Acids Res. 2019;47:8239&#x2013;54. doi: 10.1093/nar/gkz532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz532</ArticleId><ArticleId IdType="pmc">PMC6735682</ArticleId><ArticleId IdType="pubmed">31216022</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu X, Chen X, Wan Q, Zheng Z, Du Q. Nuclear mitotic apparatus (NuMA) interacts with and regulates astrin at the mitotic spindle. J Biol Chem. 2016;291:20055&#x2013;67. doi: 10.1074/jbc.M116.724831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.724831</ArticleId><ArticleId IdType="pmc">PMC5025691</ArticleId><ArticleId IdType="pubmed">27462074</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack GJ, Compton DA. Analysis of mitotic microtubule-associated proteins using mass spectrometry identifies astrin, a spindle-associated protein. Proc Natl Acad Sci USA. 2001;98:14434&#x2013;9. doi: 10.1073/pnas.261371298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.261371298</ArticleId><ArticleId IdType="pmc">PMC64699</ArticleId><ArticleId IdType="pubmed">11724960</ArticleId></ArticleIdList></Reference><Reference><Citation>Thein KH, Kleylein-Sohn J, Nigg EA, Gruneberg U. Astrin is required for the maintenance of sister chromatid cohesion and centrosome integrity. J Cell Biol. 2007;178:345&#x2013;54. doi: 10.1083/jcb.200701163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200701163</ArticleId><ArticleId IdType="pmc">PMC2064855</ArticleId><ArticleId IdType="pubmed">17664331</ArticleId></ArticleIdList></Reference><Reference><Citation>Canu V, Donzelli S, Sacconi A, Lo Sardo F, Pulito C, Bossel N, et al. Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation. Cell Death Differ. 2021;28:1493&#x2013;511. doi: 10.1038/s41418-020-00677-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-00677-9</ArticleId><ArticleId IdType="pmc">PMC8166963</ArticleId><ArticleId IdType="pubmed">33230261</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Li A, Zhou S, Lv H, Yang W. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. J Hematol Oncol. 2019;12:14. doi: 10.1186/s13045-019-0700-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-019-0700-2</ArticleId><ArticleId IdType="pmc">PMC6367803</ArticleId><ArticleId IdType="pubmed">30736840</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan LJ, Li JD, Zhang L, Wang JH, Wan T, Zhou Y, et al. SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway. Cell Death Dis. 2014;5:e1247. doi: 10.1038/cddis.2014.222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.222</ArticleId><ArticleId IdType="pmc">PMC4047857</ArticleId><ArticleId IdType="pubmed">24853425</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Hu J, Wei R, Zhou L, Pan H, Zhu H, et al. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying beta-catenin degradation. J Exp Clin Cancer Res. 2018;37:229. doi: 10.1186/s13046-018-0891-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-018-0891-3</ArticleId><ArticleId IdType="pmc">PMC6154423</ArticleId><ArticleId IdType="pubmed">30249289</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YF, Zhang MF, Tian QH, Fu J, Yang X, Zhang CZ, et al. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma. Mol Cancer. 2018;17:117. doi: 10.1186/s12943-018-0872-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-018-0872-3</ArticleId><ArticleId IdType="pmc">PMC6081940</ArticleId><ArticleId IdType="pubmed">30089483</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Disco. 2012;2:401&#x2013;4. doi: 10.1158/2159-8290.CD-12-0095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-12-0095</ArticleId><ArticleId IdType="pmc">PMC3956037</ArticleId><ArticleId IdType="pubmed">22588877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35791393</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-7156</ISSN><JournalIssue CitedMedium="Internet"><Volume>2022</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of immunology research</Title><ISOAbbreviation>J Immunol Res</ISOAbbreviation></Journal><ArticleTitle>A Systematic Pan-Cancer Analysis of YY1 Aberrations and their Relationship with Clinical Outcome, Tumor Microenvironment, and Therapeutic Targets.</ArticleTitle><Pagination><StartPage>5826741</StartPage><MedlinePgn>5826741</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5826741</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2022/5826741</ELocationID><Abstract><AbstractText>Yin-Yang 1 (YY1) has a crucial function in the development of several malignancies, according to recent research. However, nothing is known about its aberrant expression and prognostic significance in human pan-cancer. We first explored the potential carcinogenic effect of YY1 in 33 cancers using the cancer genome atlas (TCGA) project and gene expression omnibus (GEO) datasets in this research. Then, we contained a variety of elements, for instance, gene expression, the state of survival, gene alterations, protein phosphorylation, immune infiltration, and related cellular pathways, and used a series of bioinformatics methods to investigate the underlying molecular mechanism of YY1 in the etiology or clinical prognosis of various malignancies. In most malignancies, YY1 was expressed at high levels, and the level of YY1 expression was statistically associated with the prognosis of tumor patients. The S118 site of YY1 implied higher phosphorylation expression in breast cancer, colon cancer, uterine corpus endometrial carcinoma (UCEC), and lung adenocarcinoma (LUAD) tumor tissues, but lower phosphorylation levels in ovarian cancer and clear cell carcinoma tumor tissues. For S247, higher phosphorylation levels were found in colon cancer, UCEC, and LUAD tumor tissue, and lower phosphorylation expression was found in clear cell carcinoma tumor tissue. In TCGA database, YY1 expression in BRCA, BRCA-LumA, BRCA-LumB, CESC, CHOL, COAD, ESCA, HNSC, HNSC-HPV-, KIRP, LGG, LIHC, and PAAD tumor tissues was a statistically significant positive connection of the estimated infiltration value of cancer-associated fibroblasts but a negative correlation in TGCT. In addition, the functional mechanism of YY1 also involves viral carcinogenesis and ribonucleic acid (RNA) metabolism related functions. Our first pan-cancer analysis offers a pretty comprehensive knowledge of YY1's oncogenic involvement in various cancers.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Xinghao Fu et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Xinghao</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-6466-0273</Identifier><AffiliationInfo><Affiliation>Department of Thyroid Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Feihong</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3163-6250</Identifier><AffiliationInfo><Affiliation>Department of Thyroid Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-0023-7337</Identifier><AffiliationInfo><Affiliation>Department of Thyroid Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Xinguang</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-3816-1745</Identifier><AffiliationInfo><Affiliation>Department of Thyroid Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>J Immunol Res</MedlineTA><NlmUniqueID>101627166</NlmUniqueID><ISSNLinking>2314-7156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050986">YY1 Transcription Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494698">YY1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000077192" MajorTopicYN="Y">Adenocarcinoma of Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="Y">Colonic Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050986" MajorTopicYN="N">YY1 Transcription Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that there is no conflict of interest regarding the publication of this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>1</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35791393</ArticleId><ArticleId IdType="pmc">PMC9250692</ArticleId><ArticleId IdType="doi">10.1155/2022/5826741</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H., Ferlay J., Siegel R. L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians . 2021;71(3):209&#x2013;249. doi: 10.3322/caac.21660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng R. M., Zong Y. N., Cao S. M., Xu R. H. Current cancer situation in China: good or bad news from the 2018 global cancer statistics. Cancer Communications . 2019;39(1):p. 22. doi: 10.1186/s40880-019-0368-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40880-019-0368-6</ArticleId><ArticleId IdType="pmc">PMC6487510</ArticleId><ArticleId IdType="pubmed">31030667</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians . 2018;68(6):394&#x2013;424. doi: 10.3322/caac.21492.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Thandra K. C., Barsouk A., Saginala K., Aluru J. S., Barsouk A. Epidemiology of lung cancer. Contemporary oncology . 2021;25(1):45&#x2013;52. doi: 10.5114/wo.2021.103829.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/wo.2021.103829</ArticleId><ArticleId IdType="pmc">PMC8063897</ArticleId><ArticleId IdType="pubmed">33911981</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel R. L., Miller K. D., Fuchs H. E., Jemal A. Cancer statistics, 2022. CA: a Cancer Journal for Clinicians . 2022;72(1):7&#x2013;33. doi: 10.3322/caac.21708.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21708</ArticleId><ArticleId IdType="pubmed">35020204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Kang W., Sinn D. H., et al. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clinical and Molecular Hepatology . 2020;26(4):516&#x2013;528. doi: 10.3350/cmh.2020.0016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3350/cmh.2020.0016</ArticleId><ArticleId IdType="pmc">PMC7641570</ArticleId><ArticleId IdType="pubmed">32911589</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomczak K., Czerwi&#x144;ska P., Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). . 2015;19(1A):A68&#x2013;A77. doi: 10.5114/wo.2014.47136.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/wo.2014.47136</ArticleId><ArticleId IdType="pmc">PMC4322527</ArticleId><ArticleId IdType="pubmed">25691825</ArticleId></ArticleIdList></Reference><Reference><Citation>Clough E., Barrett T. The gene expression omnibus database. Methods in Molecular Biology . 2016;1418:93&#x2013;110. doi: 10.1007/978-1-4939-3578-9_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3578-9_5</ArticleId><ArticleId IdType="pmc">PMC4944384</ArticleId><ArticleId IdType="pubmed">27008011</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum A., Wang P., Zenklusen J. C. SnapShot: TCGA-analyzed tumors. Cell . 2018;173(2):p. 530. doi: 10.1016/j.cell.2018.03.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.059</ArticleId><ArticleId IdType="pubmed">29625059</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Seto E., Chang L. S., Shenk T. Transcriptional repression by YY1, a human GLI-Kruippel-related protein, and relief of repression by adenovirus E1A protein. Cell . 1991;67(2):377&#x2013;388. doi: 10.1016/0092-8674(91)90189-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(91)90189-6</ArticleId><ArticleId IdType="pubmed">1655281</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon S., Akopyan G., Garban H., Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene . 2006;25(8):1125&#x2013;1142. doi: 10.1038/sj.onc.1209080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1209080</ArticleId><ArticleId IdType="pubmed">16314846</ArticleId></ArticleIdList></Reference><Reference><Citation>de Nigris F., Rossiello R., Schiano C., et al. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis. Cancer Research . 2008;68(6):1797&#x2013;1808. doi: 10.1158/0008-5472.CAN-07-5582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-07-5582</ArticleId><ArticleId IdType="pubmed">18339860</ArticleId></ArticleIdList></Reference><Reference><Citation>de Nigris F., Crudele V., Giovane A., et al. CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proceedings of the National Academy of Sciences of the United States of America . 2010;107(32):14484&#x2013;14489. doi: 10.1073/pnas.1008256107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1008256107</ArticleId><ArticleId IdType="pmc">PMC2922579</ArticleId><ArticleId IdType="pubmed">20660740</ArticleId></ArticleIdList></Reference><Reference><Citation>Galloway N. R., Ball K. F., Stiff T., Wall N. R. Yin Yang 1 (YY1): regulation of survivin and its role in invasion and metastasis. Critical Reviews in Oncogenesis . 2017;22(1-2):23&#x2013;36. doi: 10.1615/CritRevOncog.2017020836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/CritRevOncog.2017020836</ArticleId><ArticleId IdType="pmc">PMC6108429</ArticleId><ArticleId IdType="pubmed">29604934</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao K., Ning S., Wan L., et al. Correction to: LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway. Journal of Experimental &amp; Clinical Cancer Research . 2020;39(1):p. 154. doi: 10.1186/s13046-020-01645-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-020-01645-4</ArticleId><ArticleId IdType="pmc">PMC7418315</ArticleId><ArticleId IdType="pubmed">32782003</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Han S., Huang W., et al. MicroRNA-215 suppresses cell proliferation, migration and invasion of colon cancer by repressing Yin-Yang 1. Biochemical and Biophysical Research Communications . 2016;479(3):482&#x2013;488. doi: 10.1016/j.bbrc.2016.09.089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.09.089</ArticleId><ArticleId IdType="pubmed">27663660</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L., Chen Y., Ye L., et al. miRNA-584-3p inhibits gastric cancer progression by repressing Yin Yang 1- facilitated MMP-14 expression. Scientific Reports . 2017;7(1):p. 8967. doi: 10.1038/s41598-017-09271-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09271-5</ArticleId><ArticleId IdType="pmc">PMC5566321</ArticleId><ArticleId IdType="pubmed">28827574</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C., Tsai Y. H., Galbo P. M., et al. Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer. Nucleic Acids Research . 2021;49(9):4971&#x2013;4988. doi: 10.1093/nar/gkab252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab252</ArticleId><ArticleId IdType="pmc">PMC8136773</ArticleId><ArticleId IdType="pubmed">33849067</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z., Kang B., Li C., Chen T., Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Research . 2019;47(W1):W556&#x2013;W560. doi: 10.1093/nar/gkz430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz430</ArticleId><ArticleId IdType="pmc">PMC6602440</ArticleId><ArticleId IdType="pubmed">31114875</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F., Chandrashekar D. S., Varambally S., Creighton C. J. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nature Communications . 2019;10(1):p. 5679. doi: 10.1038/s41467-019-13528-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13528-0</ArticleId><ArticleId IdType="pmc">PMC6908580</ArticleId><ArticleId IdType="pubmed">31831737</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n M., Fagerberg L., Hallstr&#xf6;m B. M., et al. Proteomics. Tissue-based map of the human proteome. Science . 2015;347(6220):p. 1260419. doi: 10.1126/science.1260419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1260419</ArticleId><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Thul P. J., &#xc5;kesson L., Wiking M., et al. A subcellular map of the human proteome. Science . 2017;356(6340) doi: 10.1126/science.aal3321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal3321</ArticleId><ArticleId IdType="pubmed">28495876</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen M., Zhang C., Lee S., et al. A pathology atlas of the human cancer transcriptome. Science . 2017;357(6352) doi: 10.1126/science.aan2507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aan2507</ArticleId><ArticleId IdType="pubmed">28818916</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami E., Gao J., Dogrusoz U., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery . 2012;2(5):401&#x2013;404. doi: 10.1158/2159-8290.CD-12-0095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-12-0095</ArticleId><ArticleId IdType="pmc">PMC3956037</ArticleId><ArticleId IdType="pubmed">22588877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J., Aksoy B. A., Dogrusoz U., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling . 2013;6(269):p. pl1. doi: 10.1126/scisignal.2004088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2004088</ArticleId><ArticleId IdType="pmc">PMC4160307</ArticleId><ArticleId IdType="pubmed">23550210</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy &#xc1;., Gy&#x151;rffy B. muTarget: a platform linking gene expression changes and mutation status in solid tumors. International Journal of Cancer . 2021;148(2):502&#x2013;511. doi: 10.1002/ijc.33283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.33283</ArticleId><ArticleId IdType="pubmed">32875562</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;nzelmann S., Castelo R., Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics . 2013;14(1):p. 7. doi: 10.1186/1471-2105-14-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-14-7</ArticleId><ArticleId IdType="pmc">PMC3618321</ArticleId><ArticleId IdType="pubmed">23323831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardou P., Mariette J., Escudi&#xe9; F., Djemiel C., Klopp C. jvenn: an interactive Venn diagram viewer. BMC bioinformatics . 2014;15(1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4261873</ArticleId><ArticleId IdType="pubmed">25176396</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G., Wang L. G., Han Y., He Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS . 2012;16(5):284&#x2013;287. doi: 10.1089/omi.2011.0118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Tamayo P., Mootha V. K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America . 2005;102(43):15545&#x2013;15550. doi: 10.1073/pnas.0506580102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Allouche A., Nolens G., Tancredi A., et al. The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. Breast Cancer Research . 2008;10(1):p. R9. doi: 10.1186/bcr1851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/bcr1851</ArticleId><ArticleId IdType="pmc">PMC2374961</ArticleId><ArticleId IdType="pubmed">18218085</ArticleId></ArticleIdList></Reference><Reference><Citation>Seligson D., Horvath S., Huerta-Yepez S., et al. Expression of transcription factor Yin Yang 1 in prostate cancer. International Journal of Oncology . 2005;27(1):131&#x2013;141. doi: 10.3892/ijo.27.1.131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.27.1.131</ArticleId><ArticleId IdType="pubmed">15942652</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinnappan D., Xiao D., Ratnasari A., Andry C., King T. C., Weber H. C. Transcription factor YY1 expression in human gastrointestinal cancer cells. International Journal of Oncology . 2009;34(5):1417&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">19360355</ArticleId></ArticleIdList></Reference><Reference><Citation>Berchuck A., Iversen E. S., Lancaster J. M., et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clinical Cancer Research . 2005;11(10):3686&#x2013;3696. doi: 10.1158/1078-0432.CCR-04-2398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-04-2398</ArticleId><ArticleId IdType="pubmed">15897565</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J., Zhou X., Ge X., et al. Upregulation of Ying Yang 1 (YY1) suppresses esophageal squamous cell carcinoma development through heme oxygenase-1. Cancer Science . 2013;104(11):1544&#x2013;1551. doi: 10.1111/cas.12248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.12248</ArticleId><ArticleId IdType="pmc">PMC7656543</ArticleId><ArticleId IdType="pubmed">23919806</ArticleId></ArticleIdList></Reference><Reference><Citation>Baritaki S., Chatzinikola A. M., Vakis A. F., et al. YY1 over-expression in human brain gliomas and meningiomas correlates with TGF-beta1, IGF-1 and FGF-2 mRNA levels. Cancer Investigation . 2009;27(2):184&#x2013;192. doi: 10.1080/07357900802210760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07357900802210760</ArticleId><ArticleId IdType="pubmed">19235591</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J. J., Zhu Y., Xie K. L., et al. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism. Molecular Cancer . 2014;13(1):p. 130. doi: 10.1186/1476-4598-13-130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-4598-13-130</ArticleId><ArticleId IdType="pmc">PMC4047260</ArticleId><ArticleId IdType="pubmed">24884523</ArticleId></ArticleIdList></Reference><Reference><Citation>de Nigris F., Botti C., de Chiara A., et al. Expression of transcription factor Yin Yang 1 in human osteosarcomas. European Journal of Cancer . 2006;42(15):2420&#x2013;2424. doi: 10.1016/j.ejca.2006.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2006.06.008</ArticleId><ArticleId IdType="pubmed">16962318</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao G., Li Q., Wang A., Jiao J. YY1 regulates melanoma tumorigenesis through a miR-9&#x2009;~&#x2009;RYBP axis. Journal of Experimental &amp; Clinical Cancer Research . 2015;34(1):p. 66. doi: 10.1186/s13046-015-0177-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-015-0177-y</ArticleId><ArticleId IdType="pmc">PMC4511530</ArticleId><ArticleId IdType="pubmed">26104682</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu S. Y., Sun Y. Y., Li Y. H., Xu Z. M., Fu W. N. YY1 directly suppresses MYCT1 leading to laryngeal tumorigenesis and progress. Cancer Medicine . 2017;6(6):1389&#x2013;1398. doi: 10.1002/cam4.1073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.1073</ArticleId><ArticleId IdType="pmc">PMC5463081</ArticleId><ArticleId IdType="pubmed">28485541</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonio-Andr&#xe9;s G., Rangel-Santiago J., Tirado-Rodr&#xed;guez B., et al. Role of Yin Yang-1 (YY1) in the transcription regulation of the multi-drug resistance (MDR1) gene. Leukemia &amp; Lymphoma . 2018;59(11):2628&#x2013;2638. doi: 10.1080/10428194.2018.1448083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10428194.2018.1448083</ArticleId><ArticleId IdType="pubmed">29616858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T., Donohoe M. E. Yy1 regulates Senp1 contributing to AMPA receptor GluR1 expression following neuronal depolarization. Journal of Biomedical Science . 2019;26(1):p. 79. doi: 10.1186/s12929-019-0582-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0582-1</ArticleId><ArticleId IdType="pmc">PMC6800989</ArticleId><ArticleId IdType="pubmed">31629407</ArticleId></ArticleIdList></Reference><Reference><Citation>Riman S., Rizkallah R., Kassardjian A., Alexander K. E., L&#xfc;scher B., Hurt M. M. Phosphorylation of the transcription factor YY1 by CK2&#x3b1; prevents cleavage by caspase 7 during apoptosis. Molecular and Cellular Biology . 2012;32(4):797&#x2013;807. doi: 10.1128/MCB.06466-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.06466-11</ArticleId><ArticleId IdType="pmc">PMC3272974</ArticleId><ArticleId IdType="pubmed">22184066</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C., Wheatherspoon A., Roncarati P., et al. The importance of the tumor microenvironment in the therapeutic management of cancer. Expert Review of Anticancer Therapy . 2015;15(8):943&#x2013;954. doi: 10.1586/14737140.2015.1059279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737140.2015.1059279</ArticleId><ArticleId IdType="pubmed">26098949</ArticleId></ArticleIdList></Reference><Reference><Citation>Spill F., Reynolds D. S., Kamm R. D., Zaman M. H. Impact of the physical microenvironment on tumor progression and metastasis. Current Opinion in Biotechnology . 2016;40:41&#x2013;48. doi: 10.1016/j.copbio.2016.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.copbio.2016.02.007</ArticleId><ArticleId IdType="pmc">PMC4975620</ArticleId><ArticleId IdType="pubmed">26938687</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Prete A., Schioppa T., Tiberio L., Stabile H., Sozzani S. Leukocyte trafficking in tumor microenvironment. Current Opinion in Pharmacology . 2017;35:40&#x2013;47. doi: 10.1016/j.coph.2017.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2017.05.004</ArticleId><ArticleId IdType="pubmed">28577499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hays E., Bonavida B. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resistance Updates . 2019;43:10&#x2013;28. doi: 10.1016/j.drup.2019.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drup.2019.04.001</ArticleId><ArticleId IdType="pubmed">31005030</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35722389</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2305-5839</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Annals of translational medicine</Title><ISOAbbreviation>Ann Transl Med</ISOAbbreviation></Journal><ArticleTitle>Screening of prognostic immune genes and establishment of prognostic model of cervical adenocarcinoma based on bioinformatics analysis.</ArticleTitle><Pagination><StartPage>548</StartPage><MedlinePgn>548</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">548</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.21037/atm-22-1851</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">There is currently a lack of clinical models to accurately predict the prognosis of cervical adenocarcinoma. This study aimed to explore the correlation between immune genes and the prognosis of cervical adenocarcinoma patients, and establish a prognostic model.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Transcriptome sequencing data sets and clinical data sets of cervical adenocarcinoma samples were downloaded from the Gene Expression Omnibus (GEO) database. Information about the immune gene was obtained from the ImmPort database. Differentially expressed genes and differentially expressed immune genes were screened in cervical adenocarcinoma tissue and normal cervical group by edgeR package. Differentially expressed immune genes were screened for prognosis-related immune genes by Cox analysis. Taking the immune genes related to prognosis as variables, a prognosis prediction model was established by multivariate Cox regression analysis. Kaplan-Meier analysis and a receiver operating characteristic (ROC) curve were used to test the effectiveness of the model. According to the clinical information and risk score, univariate multivariate Cox analyses were used to screen the independent prognostic risk factors of cervical adenocarcinoma.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED"><i>CXCL9</i> was an independent prognostic factor of cervical adenocarcinoma [hazard ratio (HR) =0.63; P=0.025]. <i>CGB5</i> (HR =1.22; P=0.034), <i>CXCL12</i> (HR =1.33; P=0.023), <i>PTX3</i> (HR =1.53; P=0.024), and <i>CXCL10</i> (HR =2.31; P=0.031) were prognostic risk factors for cervical adenocarcinoma. The risk score was calculated as follows: risk score = (0.005 &#xd7; <i>CXCL10</i>) + (0.076 &#xd7; <i>CGB5</i>) + (0.061 &#xd7; <i>CXCL12</i>) + (0.034 &#xd7; <i>PTX3</i>) + (-0.004 &#xd7; <i>CXCL9</i>). The prognosis of the low-risk score group was better than that of the high-risk score group (P=0.035). The area under the ROC curve (AUC) of the risk score was 0.713, and the predictive power was good. Multivariate Cox analysis showed that N stage (HR =1.34; P=0.035) and risk score (HR =1.37; P&lt;0.001) were independent risk factors for the prognosis of cervical adenocarcinoma (HR &gt;1; P&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">In this study, an immune gene prognosis prediction model for cervical adenocarcinoma was established based on the GEO and ImmPort databases. The prediction performance of the model is good, and the prognosis of patients can be evaluated according to the gene expression, which has clinical practicability.</AbstractText><CopyrightInformation>2022 Annals of Translational Medicine. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yi</LastName><ForeName>Yunhua</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Shanghai Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sheng</LastName><ForeName>Jiangxin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Shanghai Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Jichan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Shanghai Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Ann Transl Med</MedlineTA><NlmUniqueID>101617978</NlmUniqueID><ISSNLinking>2305-5839</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical adenocarcinoma</Keyword><Keyword MajorTopicYN="N">immune gene</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">risk score</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-1851/coif). The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>20</Day><Hour>4</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35722389</ArticleId><ArticleId IdType="pmc">PMC9201121</ArticleId><ArticleId IdType="doi">10.21037/atm-22-1851</ArticleId><ArticleId IdType="pii">atm-10-10-548</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>S&#xe1;nchez-Cuerda C, Cuadra M, G&#xe1;mir S, et al. Cervical adenocarcinoma in situ during pregnancy and subsequent fertility-sparing therapy challenge. Int J Gynaecol Obstet 2021. [Epub ahead of print]. doi: .10.1002/ijgo.13948</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijgo.13948</ArticleId><ArticleId IdType="pubmed">34559882</ArticleId></ArticleIdList></Reference><Reference><Citation>Park KJ. Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification. Histopathology 2020;76:112-27. 10.1111/his.13995</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/his.13995</ArticleId><ArticleId IdType="pubmed">31846527</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera-Colon G, Chen H, Niu S, et al. Cervical Adenocarcinoma: Histopathologic Features From Biopsies to Predict Tumor Behavior. Am J Surg Pathol 2020;44:247-54. 10.1097/PAS.0000000000001379</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PAS.0000000000001379</ArticleId><ArticleId IdType="pubmed">31567190</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu HT, Xia R, Zhang X. Clinical characteristics and prognostic factors of cervical adenocarcinoma. Asian J Surg 2021;44:1283-5. 10.1016/j.asjsur.2021.06.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.asjsur.2021.06.063</ArticleId><ArticleId IdType="pubmed">34556395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu SY, Huang EY, Lin H. Optimal treatments for cervical adenocarcinoma. Am J Cancer Res 2019;9:1224-34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6610057</ArticleId><ArticleId IdType="pubmed">31285954</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Z, Chen J, Luan T, et al. Proteomic analysis of human cervical adenocarcinoma mucus to identify potential protein biomarkers. PeerJ 2020;8:e9527. 10.7717/peerj.9527</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.9527</ArticleId><ArticleId IdType="pmc">PMC7394065</ArticleId><ArticleId IdType="pubmed">33194326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Chen Y, Xu X, et al. Postoperative clinicopathological factors affecting cervical adenocarcinoma: Stages I-IIB. Medicine (Baltimore) 2018;97:e9323. 10.1097/MD.0000000000009323</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000009323</ArticleId><ArticleId IdType="pmc">PMC5943842</ArticleId><ArticleId IdType="pubmed">29480826</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabuchi Y, Yahata T, Kobayashi A, et al. Clinicopathologic Factors of Cervical Adenocarcinoma Stages IB to IIB. Int J Gynecol Cancer 2015;25:1677-82. 10.1097/IGC.0000000000000542</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IGC.0000000000000542</ArticleId><ArticleId IdType="pubmed">26495760</ArticleId></ArticleIdList></Reference><Reference><Citation>Saida T, Sakata A, Tanaka YO, et al. Clinical and MRI Characteristics of Uterine Cervical Adenocarcinoma: Its Variants and Mimics. Korean J Radiol 2019;20:364-77. 10.3348/kjr.2018.0458</Citation><ArticleIdList><ArticleId IdType="doi">10.3348/kjr.2018.0458</ArticleId><ArticleId IdType="pmc">PMC6389813</ArticleId><ArticleId IdType="pubmed">30799567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronger H, Singer J, Windm&#xfc;ller C, et al. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br J Cancer 2016;115:553-63. 10.1038/bjc.2016.172</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2016.172</ArticleId><ArticleId IdType="pmc">PMC4997538</ArticleId><ArticleId IdType="pubmed">27490802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M, Liang LZ, Zhang CQ, et al. Correlation of CXCR4/CXCL12 overexpression to lymph node metastasis and chronic inflammation in cervical adenocarcinoma. Ai Zheng 2007;26:298-302.</Citation><ArticleIdList><ArticleId IdType="pubmed">17355795</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, He H, Xiao Y, et al. CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways. Front Oncol 2021;11:629350. 10.3389/fonc.2021.629350</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.629350</ArticleId><ArticleId IdType="pmc">PMC8377428</ArticleId><ArticleId IdType="pubmed">34422627</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M, Ma Q, Xu J, et al. Combining CXCL10 gene therapy and radiotherapy improved therapeutic efficacy in cervical cancer HeLa cell xenograft tumor models. Oncol Lett 2015;10:768-72. 10.3892/ol.2015.3281</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2015.3281</ArticleId><ArticleId IdType="pmc">PMC4508984</ArticleId><ArticleId IdType="pubmed">26622567</ArticleId></ArticleIdList></Reference><Reference><Citation>Doni A, Mantovani A, Bottazzi B, et al. PTX3 Regulation of Inflammation, Hemostatic Response, Tissue Repair, and Resolution of Fibrosis Favors a Role in Limiting Idiopathic Pulmonary Fibrosis. Front Immunol 2021;12:676702. 10.3389/fimmu.2021.676702</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.676702</ArticleId><ArticleId IdType="pmc">PMC8284251</ArticleId><ArticleId IdType="pubmed">34276664</ArticleId></ArticleIdList></Reference><Reference><Citation>Garlanda C, Bottazzi B, Magrini E, et al. PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer. Physiol Rev 2018;98:623-39. 10.1152/physrev.00016.2017</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00016.2017</ArticleId><ArticleId IdType="pmc">PMC5985957</ArticleId><ArticleId IdType="pubmed">29412047</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino M, Kunderfranco P, Basso G, et al. Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer. Oncoimmunology 2017;6:e1333215. 10.1080/2162402X.2017.1333215</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2017.1333215</ArticleId><ArticleId IdType="pmc">PMC5543905</ArticleId><ArticleId IdType="pubmed">28811977</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu LM, Wang WW, Qi R, et al. MicroRNA-224 inhibition prevents progression of cervical carcinoma by targeting PTX3. J Cell Biochem 2018;119:10278-90. 10.1002/jcb.27370</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.27370</ArticleId><ArticleId IdType="pubmed">30129088</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonavita E, Gentile S, Rubino M, et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 2015;160:700-14. 10.1016/j.cell.2015.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.004</ArticleId><ArticleId IdType="pubmed">25679762</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrusiewicz M, Skibi&#x144;ska I, G&#x105;siorowska E, et al. Fluorescence resonance energy transfer usage to track the sequence promoter changes in CGB5 gene in ovarian cancer patients. Biomed Pharmacother 2017;90:139-46. 10.1016/j.biopha.2017.02.113</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.02.113</ArticleId><ArticleId IdType="pubmed">28355589</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Yuan B, Zhou ZH, et al. Clinicopathological characteristics and prognostic factors of cervical adenocarcinoma. Sci Rep 2021;11:7506. 10.1038/s41598-021-86786-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-86786-y</ArticleId><ArticleId IdType="pmc">PMC8021550</ArticleId><ArticleId IdType="pubmed">33820927</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi T, Ishikawa H, Suzuki Y, et al. A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2000;79:289-93. 10.1006/gyno.2000.5935</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/gyno.2000.5935</ArticleId><ArticleId IdType="pubmed">11063659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabata T, Takeshima N, Tanaka N, et al. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. Tumour Biol 2000;21:375-80. 10.1159/000030143</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000030143</ArticleId><ArticleId IdType="pubmed">11006578</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35534796</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2407</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>09</Day></PubDate></JournalIssue><Title>BMC cancer</Title><ISOAbbreviation>BMC Cancer</ISOAbbreviation></Journal><ArticleTitle>RUNX1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers.</ArticleTitle><Pagination><StartPage>523</StartPage><MedlinePgn>523</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">523</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-022-09632-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Runt-related transcription factor 1 (RUNX1) is a vital regulator of mammalian expression. Despite multiple&#xa0;pieces of evidence indicating that dysregulation of RUNX1 is a common phenomenon in human cancers, there is no evidence from pan-cancer analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We comprehensively investigated the effect of RUNX1 expression on tumor prognosis across human&#xa0;malignancies by analyzing multiple cancer-related databases, including Gent2, Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), the Human Protein Atlas (HPA), UALCAN, PrognoScan, cBioPortal, STRING, and Metascape.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bioinformatics data indicated that RUNX1 was overexpressed in most of these human malignancies and was significantly associated with the prognosis of patients with cancer. Immunohistochemical results showed that most cancer tissues were moderately positive for granular cytoplasm, and RUNX1 was expressed at a medium level in four types of tumors, including cervical cancer, colorectal cancer, glioma, and renal cancer. RUNX1 expression was positively correlated with infiltrating levels of cancer-associated fibroblasts (CAFs) in 33 different cancers. Moreover, RUNX1 expression may influence patient prognosis by activating oncogenic signaling pathways in human cancers.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings suggest that RUNX1 expression correlates with patient outcomes and immune infiltrate levels of CAFs in multiple tumors. Additionally, the increased level of RUNX1 was linked to the activation of oncogenic signaling pathways in human cancers, suggesting a potential role of RUNX1 among cancer therapeutic targets. These findings suggest that RUNX1 can function as a potential prognostic biomarker and reflect the levels of immune infiltrates of CAFs in human cancers.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Tuo</LastName><ForeName>Zhouting</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Shuxin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Dian</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jinyou</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>Liangkuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China. biliangkuan118@yeah.net.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cancer</MedlineTA><NlmUniqueID>100967800</NlmUniqueID><ISSNLinking>1471-2407</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050676">Core Binding Factor Alpha 2 Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493728">RUNX1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072645" MajorTopicYN="Y">Cancer-Associated Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050676" MajorTopicYN="Y">Core Binding Factor Alpha 2 Subunit</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer-associated fibroblasts</Keyword><Keyword MajorTopicYN="N">Prognostic biomarker</Keyword><Keyword MajorTopicYN="N">RUNX1</Keyword><Keyword MajorTopicYN="N">TCGA</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>9</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35534796</ArticleId><ArticleId IdType="pmc">PMC9088136</ArticleId><ArticleId IdType="doi">10.1186/s12885-022-09632-y</ArticleId><ArticleId IdType="pii">10.1186/s12885-022-09632-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7&#x2013;33. doi: 10.3322/caac.21654.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21654</ArticleId><ArticleId IdType="pubmed">33433946</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-Analyzed&#xa0;Tumors&#xa0;. Cell. 2018;173(2):530. doi: 10.1016/j.cell.2018.03.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.059</ArticleId><ArticleId IdType="pubmed">29625059</ArticleId></ArticleIdList></Reference><Reference><Citation>Clough E, Barrett T. The Gene Expression Omnibus Database. Methods Mol Biol. 2016;1418:93&#x2013;110. doi: 10.1007/978-1-4939-3578-9_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3578-9_5</ArticleId><ArticleId IdType="pmc">PMC4944384</ArticleId><ArticleId IdType="pubmed">27008011</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Bae SC, Chuang LS. The RUNX family: developmental regulators in cancer. Nat Rev Cancer. 2015;15(2):81&#x2013;95. doi: 10.1038/nrc3877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3877</ArticleId><ArticleId IdType="pubmed">25592647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushweller JH. CBF&#x2013;a biophysical perspective. Semin Cell Dev Biol. 2000;11(5):377&#x2013;382. doi: 10.1006/scdb.2000.0182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/scdb.2000.0182</ArticleId><ArticleId IdType="pubmed">11105902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie-A-Ling M, Mevel R, Patel R, Blyth K, Baena E, Kouskoff V, Lacaud G. RUNX1 Dosage in Development and Cancer. Mol Cells. 2020;43(2):126&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7057845</ArticleId><ArticleId IdType="pubmed">31991535</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Xu D, Xue B, Liu B, Li J, Huang J. Upregulation of RUNX1 Suppresses Proliferation and Migration through Repressing VEGFA Expression in Hepatocellular Carcinoma. Pathol Oncol Res. 2020;26(2):1301&#x2013;1311. doi: 10.1007/s12253-019-00694-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12253-019-00694-1</ArticleId><ArticleId IdType="pubmed">31289995</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuda Y, Morita K, Kashiwazaki G, Taniguchi J, Bando T, Obara M, Hirata M, Kataoka TR, Muto M, Kaneda Y, et al. RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells. Sci Rep. 2018;8(1):6423. doi: 10.1038/s41598-018-24969-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-24969-w</ArticleId><ArticleId IdType="pmc">PMC5913281</ArticleId><ArticleId IdType="pubmed">29686309</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao L, Peng Z, Zhu A, Xue R, Lu R, Mi J, Xi S, Chen W, Jiang S. Inhibition of RUNX1 promotes cisplatin-induced apoptosis in ovarian cancer cells. Biochem Pharmacol. 2020;180:114116. doi: 10.1016/j.bcp.2020.114116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2020.114116</ArticleId><ArticleId IdType="pubmed">32579960</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheitz CJ, Lee TS, McDermitt DJ, Tumbar T. Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer. Embo J. 2012;31(21):4124&#x2013;4139. doi: 10.1038/emboj.2012.270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.270</ArticleId><ArticleId IdType="pmc">PMC3492731</ArticleId><ArticleId IdType="pubmed">23034403</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Lee BB, Kim D, Um S, Cho EY, Han J, Shim YM, Kim DH: Clinicopathological Significance of RUNX1 in Non-Small Cell Lung Cancer. J CLIN MED 2020, 9(6).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7356912</ArticleId><ArticleId IdType="pubmed">32498288</ArticleId></ArticleIdList></Reference><Reference><Citation>Takayama K, Suzuki T, Tsutsumi S, Fujimura T, Urano T, Takahashi S, Homma Y, Aburatani H, Inoue S. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer. Oncotarget. 2015;6(4):2263&#x2013;2276. doi: 10.18632/oncotarget.2949.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.2949</ArticleId><ArticleId IdType="pmc">PMC4385850</ArticleId><ArticleId IdType="pubmed">25537508</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, K&#xf6;hne CH, Horst HA, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016;30(11):2160&#x2013;2168. doi: 10.1038/leu.2016.126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2016.126</ArticleId><ArticleId IdType="pubmed">27137476</ArticleId></ArticleIdList></Reference><Reference><Citation>van Bragt MP, Hu X, Xie Y, Li Z. RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells. Elife. 2014;3:e3881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4381933</ArticleId><ArticleId IdType="pubmed">25415051</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L, Gao Y, Song Y, Li Y, Li Y, Zhang H, Li D, Li J, Liu C, Li F. PAK4 phosphorylating RUNX1 promotes ER&#x3b1;-positive breast cancer-induced osteolytic bone destruction. INT J BIOL SCI. 2020;16(12):2235&#x2013;2247. doi: 10.7150/ijbs.47225.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.47225</ArticleId><ArticleId IdType="pmc">PMC7294946</ArticleId><ArticleId IdType="pubmed">32549768</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SJ, Yoon BH, Kim SK, Kim SY. GENT2: an updated gene expression database for normal and tumor tissues. BMC MED GENOMICS. 2019;12(Suppl 5):101. doi: 10.1186/s12920-019-0514-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-019-0514-7</ArticleId><ArticleId IdType="pmc">PMC6624177</ArticleId><ArticleId IdType="pubmed">31296229</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune cells. NUCLEIC ACIDS RES 2020;48(W1):W509-W514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319575</ArticleId><ArticleId IdType="pubmed">32442275</ArticleId></ArticleIdList></Reference><Reference><Citation>Asplund A, Edqvist PH, Schwenk JM, Pont&#xe9;n F. Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research. Proteomics. 2012;12(13):2067&#x2013;2077. doi: 10.1002/pmic.201100504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201100504</ArticleId><ArticleId IdType="pubmed">22623277</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. NUCLEIC ACIDS RES. 2019;47(W1):W556&#x2013;W560. doi: 10.1093/nar/gkz430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz430</ArticleId><ArticleId IdType="pmc">PMC6602440</ArticleId><ArticleId IdType="pubmed">31114875</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar DS, Bashel B, Balasubramanya S, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017;19(8):649&#x2013;658. doi: 10.1016/j.neo.2017.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2017.05.002</ArticleId><ArticleId IdType="pmc">PMC5516091</ArticleId><ArticleId IdType="pubmed">28732212</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno H, Kitada K, Nakai K, Sarai A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC MED GENOMICS. 2009;2:18. doi: 10.1186/1755-8794-2-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1755-8794-2-18</ArticleId><ArticleId IdType="pmc">PMC2689870</ArticleId><ArticleId IdType="pubmed">19393097</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. SCI SIGNAL. 2013;6(269):l1. doi: 10.1126/scisignal.2004088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2004088</ArticleId><ArticleId IdType="pmc">PMC4160307</ArticleId><ArticleId IdType="pubmed">23550210</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M, Fang T, Bork P, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. NUCLEIC ACIDS RES. 2021;49(D1):D605&#x2013;D612. doi: 10.1093/nar/gkaa1074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa1074</ArticleId><ArticleId IdType="pmc">PMC7779004</ArticleId><ArticleId IdType="pubmed">33237311</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. NAT COMMUN. 2019;10(1):1523. doi: 10.1038/s41467-019-09234-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09234-6</ArticleId><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. NUCLEIC ACIDS RES. 2021;49(D1):D545&#x2013;D551. doi: 10.1093/nar/gkaa970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa970</ArticleId><ArticleId IdType="pmc">PMC7779016</ArticleId><ArticleId IdType="pubmed">33125081</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Zheng Z, Wang Y, Song G, Wang L, Zhang Z, Zhao J, Wang Q, Lun L. Elevated RUNX1 is a prognostic biomarker for human head and neck squamous cell carcinoma. Exp Biol Med (Maywood) 2021;246(5):538&#x2013;546. doi: 10.1177/1535370220969663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370220969663</ArticleId><ArticleId IdType="pmc">PMC7934153</ArticleId><ArticleId IdType="pubmed">33241710</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangpairoj K, Vivithanaporn P, Apisawetakan S, Chongthammakun S, Sobhon P, Chaithirayanon K. RUNX1 Regulates Migration, Invasion, and Angiogenesis via p38 MAPK Pathway in Human Glioblastoma. CELL MOL NEUROBIOL. 2017;37(7):1243&#x2013;1255. doi: 10.1007/s10571-016-0456-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-016-0456-y</ArticleId><ArticleId IdType="pubmed">28012022</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney N, Mason SM, McDonald L, D&#xe4;britz J, Campbell KJ, Hedley A, Howard S, Athineos D, Nixon C, Clark W, et al. RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome. CANCER RES. 2020;80(11):2325&#x2013;2339. doi: 10.1158/0008-5472.CAN-19-3870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-19-3870</ArticleId><ArticleId IdType="pubmed">32156779</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M, He J, Li D, Chu Y, Pu J, Tong Q, Joshi HC, Tang S, Li S. Runt-related transcription factor 1 promotes apoptosis and inhibits neuroblastoma progression in vitro and in vivo. J Exp Clin Cancer Res. 2020;39(1):52. doi: 10.1186/s13046-020-01558-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-020-01558-2</ArticleId><ArticleId IdType="pmc">PMC7082942</ArticleId><ArticleId IdType="pubmed">32197643</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulak AM, Schumacher SE, van Lieshout J, Imamura Y, Fox C, Shim B, Ramos AH, Saksena G, Baca SC, Baselga J, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. CANCER RES. 2012;72(17):4383&#x2013;4393. doi: 10.1158/0008-5472.CAN-11-3893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-11-3893</ArticleId><ArticleId IdType="pmc">PMC3432726</ArticleId><ArticleId IdType="pubmed">22751462</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng G, Wei J, Wang Y, Qu D, Zhang J. miR-21 regulates immunosuppression mediated by myeloid-derived suppressor cells by impairing RUNX1-YAP interaction in lung cancer. CANCER CELL INT. 2020;20:495. doi: 10.1186/s12935-020-01555-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-020-01555-7</ArticleId><ArticleId IdType="pmc">PMC7549228</ArticleId><ArticleId IdType="pubmed">33061847</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu SY, Wu QY, Zhang CX, Wang Q, Ling J, Huang XT, Sun X, Yuan M, Wu D, Yin HF. miR-20a inhibits the killing effect of natural killer cells to cervical cancer cells by downregulating RUNX1. Biochem Biophys Res Commun. 2018;505(1):309&#x2013;316. doi: 10.1016/j.bbrc.2018.09.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2018.09.102</ArticleId><ArticleId IdType="pubmed">30249397</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapusta P, Duli&#x144;ska-Litewka J, Toto&#x144;-&#x17b;ura&#x144;ska J, Borys A, Konieczny PS, Wo&#x142;kow PP, Seweryn MT: Dysregulation of Transcription Factor Activity During Formation of Cancer-Associated Fibroblasts. INT J MOL SCI 2020, 21(22).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7699520</ArticleId><ArticleId IdType="pubmed">33228208</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. SCI SIGNAL. 2014;7(344):e8. doi: 10.1126/scisignal.2005189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2005189</ArticleId><ArticleId IdType="pmc">PMC4372086</ArticleId><ArticleId IdType="pubmed">25249658</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Lai Q, He C, Fang Y, Yan Q, Zhang Y, Wang X, Gu C, Wang Y, Ye L, et al. RUNX1 promotes tumour metastasis by activating the Wnt/&#x3b2;-catenin signalling pathway and EMT in colorectal cancer. J Exp Clin Cancer Res. 2019;38(1):334. doi: 10.1186/s13046-019-1330-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-019-1330-9</ArticleId><ArticleId IdType="pmc">PMC6670220</ArticleId><ArticleId IdType="pubmed">31370857</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35530966</PMID><DateRevised><Year>2022</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2305-5839</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Annals of translational medicine</Title><ISOAbbreviation>Ann Transl Med</ISOAbbreviation></Journal><ArticleTitle>A predictive study of metabolism reprogramming in cervical carcinoma.</ArticleTitle><Pagination><StartPage>414</StartPage><MedlinePgn>414</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">414</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.21037/atm-22-981</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Metabolic reprogramming has been identified as a hallmark of cancer, influencing the immunity in the tumor microenvironment. Because of the high-heterogeneity of cervical carcinoma, we aim to figure out the metabolic subtypes of cervical carcinoma indicating the prognosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We profiled the distinct metabolic signatures using data from transcriptomes obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Bioinformatics analyses were conducted to identify the possible biomarkers of overall survival and chemotherapy resistance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Immune infiltration was closely related to metabolic pathways, especially in the carbohydrate pathway and the lipid and energy pathway. Two distinct clusters of differentially expressed genes were identified. Six genes were selected as possible indicators of prognosis, including <i>ELK3</i>, <i>BIN2</i>, <i>MEI1</i>, <i>CCR7</i>, <i>CYP4F12</i>, and <i>DUOX1,</i> relating to the immune status of tumor microenvironment. Under the risk score model based on metabolic genes, the high-risk group showed significantly lower survival (HR =6.802, with 95% CI: 3.637-12.721, P&lt;0.0001), higher possibility of chemotherapy resistance, and higher infiltration of anti-tumor immune cells compared to the low-risk group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Metabolic reprogramming, especially in the carbohydrate pathway and the lipid and energy metabolic pathway, is associated with the immune cell microenvironment, which is crucial for the prognosis of Invasive cervical carcinoma (ICC), providing potential therapeutic targets in clinic.</AbstractText><CopyrightInformation>2022 Annals of Translational Medicine. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Guoyu</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ou</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wu</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Gynaecology and Obstetrics, Hunan University of Medicine, Huaihua, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Ann Transl Med</MedlineTA><NlmUniqueID>101617978</NlmUniqueID><ISSNLinking>2305-5839</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical carcinoma</Keyword><Keyword MajorTopicYN="N">immune cell infiltration</Keyword><Keyword MajorTopicYN="N">metabolic reprogramming</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-981/coif). The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>9</Day><Hour>4</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35530966</ArticleId><ArticleId IdType="pmc">PMC9073800</ArticleId><ArticleId IdType="doi">10.21037/atm-22-981</ArticleId><ArticleId IdType="pii">atm-10-07-414</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. 10.3322/caac.21492</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization: Data visualization tools for exploring the global cancer burden in 2020. Available online: https://gco.iarc.fr/today/home (accessed January 22 2021.</Citation></Reference><Reference><Citation>Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet 2019;393:169-82. 10.1016/S0140-6736(18)32470-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32470-X</ArticleId><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>UICC. Cervical cancer elimination. Available online: https://www.uicc.org/what-we-do/thematic-areas-work/cervical-cancer-elimination (accessed January 22 2021).</Citation></Reference><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30. 10.3322/caac.21590</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21590</ArticleId><ArticleId IdType="pubmed">31912902</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosbie EJ, Einstein MH, Franceschi S, et al. Human papillomavi- rus and cervical cancer. Lancet 2013; 382:889-99. 10.1016/S0140-6736(13)60022-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)60022-7</ArticleId><ArticleId IdType="pubmed">23618600</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W, Yan X, Jing L, et al. A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol 2011;8:59-66. 10.1038/cmi.2010.56</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2010.56</ArticleId><ArticleId IdType="pmc">PMC4002991</ArticleId><ArticleId IdType="pubmed">21200385</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata T, Lieblong BJ, Sasagawa T, et al. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev 2019;78:8-16. 10.1016/j.ctrv.2019.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2019.07.001</ArticleId><ArticleId IdType="pmc">PMC6710123</ArticleId><ArticleId IdType="pubmed">31302573</ArticleId></ArticleIdList></Reference><Reference><Citation>Che Y, Yang Y, Suo J, et al. Induction of systemic immune responses and reversion of immunosuppression in the tumor micro- environment by a therapeutic vaccine for cervical cancer. Cancer Immunol Immunother 2020;69:2651-64. 10.1007/s00262-020-02651-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-020-02651-3</ArticleId><ArticleId IdType="pmc">PMC11027467</ArticleId><ArticleId IdType="pubmed">32607768</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 2016;214:22-30. 10.1016/j.ajog.2015.07.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2015.07.022</ArticleId><ArticleId IdType="pmc">PMC5613936</ArticleId><ArticleId IdType="pubmed">26212178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. 10.1016/j.cell.2011.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.02.013</ArticleId><ArticleId IdType="pubmed">21376230</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung JY, Cheong JH. Pan-Cancer Analysis Reveals Distinct Metabolic Reprogramming in Different Epithelial-Mesenchymal Transition Activity States. Cancers (Basel) 2021;13:1778. 10.3390/cancers13081778</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13081778</ArticleId><ArticleId IdType="pmc">PMC8068218</ArticleId><ArticleId IdType="pubmed">33917859</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan C, Zhang S, Gong Z, et al. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy. Sci China Life Sci 2021;64:534-47. 10.1007/s11427-019-1735-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-019-1735-4</ArticleId><ArticleId IdType="pubmed">32815067</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505:495-501. 10.1038/nature12912</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12912</ArticleId><ArticleId IdType="pmc">PMC4048962</ArticleId><ArticleId IdType="pubmed">24390350</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer 2020;20:74-88. 10.1038/s41568-019-0216-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-019-0216-7</ArticleId><ArticleId IdType="pmc">PMC7314312</ArticleId><ArticleId IdType="pubmed">31686003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H, Kim H, Lee S, et al. Role of Metabolic Reprogramming in Epithelial-Mesenchymal Transition (EMT). Int J Mol Sci 2019;20:2042. 10.3390/ijms20082042</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20082042</ArticleId><ArticleId IdType="pmc">PMC6514888</ArticleId><ArticleId IdType="pubmed">31027222</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Lu S, Wang S, et al. Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses. J Transl Med 2021;19:222. 10.1186/s12967-021-02894-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-02894-3</ArticleId><ArticleId IdType="pmc">PMC8142504</ArticleId><ArticleId IdType="pubmed">34030694</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35491469</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1447-0756</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The journal of obstetrics and gynaecology research</Title><ISOAbbreviation>J Obstet Gynaecol Res</ISOAbbreviation></Journal><ArticleTitle>Differentially expressed EREG and SPP1 are independent prognostic markers in cervical squamous cell carcinoma.</ArticleTitle><Pagination><StartPage>1848</StartPage><EndPage>1858</EndPage><MedlinePgn>1848-1858</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jog.15265</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Cervical squamous cell carcinoma (SCC) is one of the most frequent malignancies of the female reproductive system. The malignant mechanism of SCC has not been totally clarified. We aimed to discover a list of differentially expressed genes (DEGs) to identify the malignant mechanism of cervical SCC.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Three expression chips (GSE7803, GSE9750, and GSE64217) were downloaded from gene expression omnibus (GEO) datasets. After standardization, 50 cervical SCC tumor tissues and 33 normal cervical tissues (NCTs) were included for DEGs and clustering analysis. RobustRankAggreg (RRA) algorithm was used to extract the overlapping DEGs. Gene function and signaling pathway analysis was implemented based on Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway databases. Protein-protein interaction (PPI) analysis and prognostic analysis were also carried out to identify the DEGs as prognostic markers for cervical SCC.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Totally 100 DEGs were obtained from GSE7803, 319 DEGs from GSE9750, and 1639 DEGs from GSE64217. RRA analysis uncovered 17 upregulated DEGs and 25 downregulated DEGs. GO and KEGG analysis showed DEGs were involved in the mediation of extracellular functions, cell-cell interactions, and cell metabolism. PPI network showed a close interaction among the integrated DEGs. Prognostic analysis showed gene secreted phosphoprotein 1 (SPP1) and epiregulin (EREG) genes were independent prognostic predictors of cervical SCC.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The gene expression profile was changed in cervical SCC tumor tissues compared to NCTs. SPP1 and EREG were postulated as prognostic markers for cervical SCC, which might be potential targets for clinical therapy of cervical SCC.</AbstractText><CopyrightInformation>&#xa9; 2022 Japan Society of Obstetrics and Gynecology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Leilei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Binzhou Medical University Hospital, Binzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nan</LastName><ForeName>Fangfang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Binzhou Medical University Hospital, Binzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cancer Research Institute, Binzhou Medical University Hospital, Binzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Yanjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, Binzhou Medical University Hospital, Binzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Yongjie</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5093-1282</Identifier><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Shandong University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>J Obstet Gynaecol Res</MedlineTA><NlmUniqueID>9612761</NlmUniqueID><ISSNLinking>1341-8076</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C587880">EREG protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066260">Epiregulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506895">SPP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>106441-73-0</RegistryNumber><NameOfSubstance UI="D053495">Osteopontin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066260" MajorTopicYN="N">Epiregulin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063990" MajorTopicYN="N">Gene Ontology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053495" MajorTopicYN="N">Osteopontin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GEO microarray data</Keyword><Keyword MajorTopicYN="N">bioinformatic analysis</Keyword><Keyword MajorTopicYN="N">cervical squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">differentially expressed genes</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>2</Day><Hour>0</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35491469</ArticleId><ArticleId IdType="doi">10.1111/jog.15265</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6:e555-e67.</Citation></Reference><Reference><Citation>Papillomaviruses H. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France: IARC; 2011.</Citation></Reference><Reference><Citation>Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:CD009069.</Citation></Reference><Reference><Citation>Lei J, Ploner A, Elfstr&#xf6;m KM, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383:1340-8.</Citation></Reference><Reference><Citation>Mousavi SZ, Poortahmasebi V, Mokhtari-Azad T, Shahmahmoodi S, Farahmand M, Farzanehpour M, et al. The dysregulation of microarray gene expression in cervical cancer is associated with overexpression of a unique messenger RNA signature. Iran J Microbiol. 2020;12:629-35.</Citation></Reference><Reference><Citation>Wang S, Chen X. Identification of potential biomarkers in cervical cancer with combined public mRNA and miRNA expression microarray data analysis. Oncol Lett. 2018;16:5200-8.</Citation></Reference><Reference><Citation>Fan Y, Meng Y, Yang S, Wang L, Zhi W, Lazare C, et al. Screening of cervical cancer with self-collected cervical samples and next-generation sequencing. Dis Markers. 2018;2018:4826547.</Citation></Reference><Reference><Citation>Chen T, Yang S, Xu J, Lu W, Xie X. Transcriptome sequencing profiles of cervical cancer tissues and SiHa cells. Funct Integr Genomics. 2020;20:211-21.</Citation></Reference><Reference><Citation>Pan X, Liu W, Chai Y, Hu L, Wang J, Zhang Y. Identification of hub genes in atypical teratoid/rhabdoid tumor by bioinformatics analyses. J Mol Neurosci. 2020;70:1906-13.</Citation></Reference><Reference><Citation>Ni M, Liu X, Wu J, Zhang D, Tian J, Wang T, et al. Identification of candidate biomarkers correlated with the pathogenesis and prognosis of non-small cell lung cancer via integrated bioinformatics analysis. Front Genet. 2018;9:469.</Citation></Reference><Reference><Citation>Kolde R, Laur S, Adler P, Vilo J. Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics. 2012;28:573-80.</Citation></Reference><Reference><Citation>Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4:P3.</Citation></Reference><Reference><Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25-9.</Citation></Reference><Reference><Citation>Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45:D353-D61.</Citation></Reference><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.</Citation></Reference><Reference><Citation>Shendure J, Lieberman AE. The expanding scope of DNA sequencing. Nat Biotechnol. 2012;30:1084-94.</Citation></Reference><Reference><Citation>Rusan M, Li YY, Hammerman PS. Genomic landscape of human papillomavirus-associated cancers. Clin Cancer Res. 2015;21:2009-19.</Citation></Reference><Reference><Citation>Tang X, Xu Y, Lu L, Jiao Y, Liu J, Wang L, et al. Identification of key candidate genes and small molecule drugs in cervical cancer by bioinformatics strategy. Cancer Manag Res. 2018;10:3533-49.</Citation></Reference><Reference><Citation>Dou L, Zhang X. Upregulation of CCT3 promotes cervical cancer progression through FN1. Mol Med Rep. 2021;24(6):856.</Citation></Reference><Reference><Citation>Zhao S, Yu M. Identification of MMP1 as a potential prognostic biomarker and correlating with immune infiltrates in cervical squamous cell carcinoma. DNA Cell Biol. 2020;39:255-72.</Citation></Reference><Reference><Citation>Zhang W, He W, Shi Y, Gu H, Li M, Liu Z, et al. High expression of KIF20A is associated with poor overall survival and tumor progression in early-stage cervical squamous cell carcinoma. PLoS One. 2016;11:e0167449.</Citation></Reference><Reference><Citation>Amaro Filho SM, Nuovo GJ, Cunha CB, Ramos Pereira Lde O, Oliveira-Silva M, Russomano F, et al. Correlation of MCM2 detection with stage and virology of cervical cancer. Int J Biol Markers. 2014;29:e363-71.</Citation></Reference><Reference><Citation>Kaur G, Balasubramaniam SD, Lee YJ, Balakrishnan V, Oon CE. Minichromosome maintenance complex (MCM) genes profiling and MCM2 protein expression in cervical cancer development. Asian Pac J Cancer Prev. 2019;20:3043-9.</Citation></Reference><Reference><Citation>Acquaviva L, Drogat J, Dehe PM, de La Roche S-AC, Geli V. Spp1 at the crossroads of H3K4me3 regulation and meiotic recombination. Epigenetics. 2013;8:355-60.</Citation></Reference><Reference><Citation>Freed DM, Bessman NJ, Kiyatkin A, Salazar-Cavazos E, Byrne PO, Moore JO, et al. EGFR ligands differentially stabilize receptor dimers to specify signaling kinetics. Cell. 2017;171(3):683-695.e18.</Citation></Reference><Reference><Citation>Cheng WL, Feng PH, Lee KY, Chen KY, Sun WL, van Hiep N, et al. The role of EREG/EGFR pathway in tumor progression. Int J Mol Sci. 2021;22:12828.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35486636</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>The clinical value of miRNA-21 in cervical cancer: A comprehensive investigation based on microarray datasets.</ArticleTitle><Pagination><StartPage>e0267108</StartPage><MedlinePgn>e0267108</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0267108</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0267108</ELocationID><Abstract><AbstractText>Previous work has demonstrated that the expression of microRNA-21 (miR-21) is implicated in cervical cancer (CC). However, little is known regarding its associations with clinical parameters. We first conducted a meta-analysis using data from Gene Expression Omnibus (GEO) microarrays and The Cancer Genome Atlas (TCGA). Then, enrichment analysis and hub gene screening were performed by bioinformatic methods. Finally, the role of the screened target genes in CC was explored. According to the meta-analysis, the expression of miR-21 in cancer tissues was higher than in adjacent nontumor tissues (P &lt; 0.05). In addition, 46 genes were predicted as potential targets of miR-21. After enrichment analyses, it was detected that these genes were enriched in various cancer pathways, including the phosphatidylinositol signaling system and mammalian target of rapamycin (mTOR) signaling pathway. In this study, bioinformatic tools and meta-analysis validated that miR-21 may function as a highly sensitive and specific marker for the diagnosis of CC, which may provide a novel approach to the diagnosis and treatment of CC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Zhi-Min</ForeName><Initials>ZM</Initials><Identifier Source="ORCID">0000-0003-4760-4293</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Gan-Hong</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Department of Pathology, The People's Hospital of Honghu, Honghu, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Fang-Fang</ForeName><Initials>FF</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shi-Yi</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Dong-Yong</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>An-Yu</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Clinical laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yan-Xiang</ForeName><Initials>YX</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C524940">MIRN21 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35486636</ArticleId><ArticleId IdType="pmc">PMC9053781</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0267108</ArticleId><ArticleId IdType="pii">PONE-D-21-03458</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vu M, Yu J, Awolude OA, Chuang L. Cervical cancer worldwide. Current problems in cancer. 2018;42(5):457&#x2013;65. doi: 10.1016/j.currproblcancer.2018.06.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.currproblcancer.2018.06.003</ArticleId><ArticleId IdType="pubmed">30064936</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai L, Wang W, Li X, Dong T, Zhang Q, Zhu B, et al.. MicroRNA-21-5p induces the metastatic phenotype of human cervical carcinoma cells by targeting the von Hippel-Lindau tumor suppressor. Oncology letters. 2018;15(4):5213&#x2013;9. doi: 10.3892/ol.2018.7937 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2018.7937</ArticleId><ArticleId IdType="pmc">PMC5840692</ArticleId><ArticleId IdType="pubmed">29552160</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Li B, Li Q, Wei S, He Z, Huang X, et al.. Exosomal miR-21-5p derived from gastric cancer promotes peritoneal metastasis via mesothelial-to-mesenchymal transition. Cell Death Dis. 2018;9(9):854. Epub 2018/08/30. doi: 10.1038/s41419-018-0928-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0928-8</ArticleId><ArticleId IdType="pmc">PMC6113299</ArticleId><ArticleId IdType="pubmed">30154401</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HH, Huang ZX, Zhong SQ, Fei KL, Cao YH. miR21 inhibits autophagy and promotes malignant development in the bladder cancer T24 cell line. Int J Oncol. 2020;56(4):986&#x2013;98. Epub 2020/04/23. doi: 10.3892/ijo.2020.4984 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2020.4984</ArticleId><ArticleId IdType="pubmed">32319564</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrovic N. miR-21 Might be Involved in Breast Cancer Promotion and Invasion Rather than in Initial Events of Breast Cancer Development. Mol Diagn Ther. 2016;20(2):97&#x2013;110. Epub 2016/02/20. doi: 10.1007/s40291-016-0186-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40291-016-0186-3</ArticleId><ArticleId IdType="pubmed">26891730</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, Chen S, Zhu Z, Yu L, Ren Y, Jiang M, et al.. miR-21 promotes EGF-induced pancreatic cancer cell proliferation by targeting Spry2. Cell Death Dis. 2018;9(12):1157. Epub 2018/11/23. doi: 10.1038/s41419-018-1182-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-1182-9</ArticleId><ArticleId IdType="pmc">PMC6249286</ArticleId><ArticleId IdType="pubmed">30464258</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoudi MS, Mehrabian E, Mirzaei H. MiR-21: A key player in glioblastoma pathogenesis. J Cell Biochem. 2018;119(2):1285&#x2013;90. Epub 2017/07/21. doi: 10.1002/jcb.26300 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.26300</ArticleId><ArticleId IdType="pubmed">28727188</ArticleId></ArticleIdList></Reference><Reference><Citation>Bica-Pop C, Cojocneanu-Petric R, Magdo L, Raduly L, Gulei D, Berindan-Neagoe I. Overview upon miR-21 in lung cancer: focus on NSCLC. Cell Mol Life Sci. 2018;75(19):3539&#x2013;51. Epub 2018/07/22. doi: 10.1007/s00018-018-2877-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-018-2877-x</ArticleId><ArticleId IdType="pmc">PMC11105782</ArticleId><ArticleId IdType="pubmed">30030592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribas J, Lupold SE. The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle. 2010;9(5):923&#x2013;9. Epub 2010/02/18. doi: 10.4161/cc.9.5.10930 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.9.5.10930</ArticleId><ArticleId IdType="pmc">PMC3462654</ArticleId><ArticleId IdType="pubmed">20160498</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhan X, Yan D, Wang Z. Circulating MicroRNA-21 Is Involved in Lymph Node Metastasis in Cervical Cancer by Targeting RASA1. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2016;26(5):810&#x2013;6. doi: 10.1097/IGC.0000000000000694 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IGC.0000000000000694</ArticleId><ArticleId IdType="pubmed">27101583</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao T, Lin Z. MiR-21 is involved in cervical squamous cell tumorigenesis and regulates CCL20. Biochimica et biophysica acta. 2012;1822(2):248&#x2013;60. doi: 10.1016/j.bbadis.2011.09.018 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2011.09.018</ArticleId><ArticleId IdType="pubmed">22001440</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Liu K, Zhang T, Yang Z, Wang R, Chen G, et al.. A comprehensive investigation using meta-analysis and bioinformatics on miR-34a-5p expression and its potential role in head and neck squamous cell carcinoma. American journal of translational research. 2018;10(8):2246&#x2013;63. .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6129509</ArticleId><ArticleId IdType="pubmed">30210668</ArticleId></ArticleIdList></Reference><Reference><Citation>Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015;12(8):697. Epub 2015/08/01. doi: 10.1038/nmeth.3485 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3485</ArticleId><ArticleId IdType="pubmed">26226356</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic acids research. 2019;47(W1):W556&#x2013;W60. doi: 10.1093/nar/gkz430 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz430</ArticleId><ArticleId IdType="pmc">PMC6602440</ArticleId><ArticleId IdType="pubmed">31114875</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al.. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25&#x2013;9. Epub 2000/05/10. doi: 10.1038/75556 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic acids research. 2012;40(Database issue):D109&#x2013;D14. doi: 10.1093/nar/gkr988 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr988</ArticleId><ArticleId IdType="pmc">PMC3245020</ArticleId><ArticleId IdType="pubmed">22080510</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al.. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447&#x2013;52. Epub 2014/10/30. doi: 10.1093/nar/gku1003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku1003</ArticleId><ArticleId IdType="pmc">PMC4383874</ArticleId><ArticleId IdType="pubmed">25352553</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC systems biology. 2014;8 Suppl 4:S11. doi: 10.1186/1752-0509-8-S4-S11 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1752-0509-8-S4-S11</ArticleId><ArticleId IdType="pmc">PMC4290687</ArticleId><ArticleId IdType="pubmed">25521941</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic acids research. 2018;46(D1):D956&#x2013;D63. doi: 10.1093/nar/gkx1090 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1090</ArticleId><ArticleId IdType="pmc">PMC5753188</ArticleId><ArticleId IdType="pubmed">29136207</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan H, Kim P, Sun P, Zhou X. miRactDB characterizes miRNA-gene relation switch between normal and cancer tissues across pan-cancer. Brief Bioinform. 2021;22(3). doi: 10.1093/bib/bbaa089 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbaa089</ArticleId><ArticleId IdType="pmc">PMC8138827</ArticleId><ArticleId IdType="pubmed">32436932</ArticleId></ArticleIdList></Reference><Reference><Citation>Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, et al.. GeneCards Version 3: the human gene integrator. Database (Oxford). 2010;2010:baq020. doi: 10.1093/database/baq020 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/database/baq020</ArticleId><ArticleId IdType="pmc">PMC2938269</ArticleId><ArticleId IdType="pubmed">20689021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao D, Zhang Y, Zhu M, Liu S, Wang X. miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China. PLoS One. 2016;11(10):e0164701. Epub 2016/10/21. doi: 10.1371/journal.pone.0164701 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164701</ArticleId><ArticleId IdType="pmc">PMC5072605</ArticleId><ArticleId IdType="pubmed">27764149</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilting SM, Snijders PJ, Verlaat W, Jaspers A, van de Wiel MA, van Wieringen WN, et al.. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene. 2013;32(1):106&#x2013;16. Epub 2012/02/15. doi: 10.1038/onc.2012.20 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2012.20</ArticleId><ArticleId IdType="pubmed">22330141</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA. MicroRNA expression variability in human cervical tissues. PLoS One. 2010;5(7):e11780. Epub 2010/07/30. doi: 10.1371/journal.pone.0011780 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011780</ArticleId><ArticleId IdType="pmc">PMC2909898</ArticleId><ArticleId IdType="pubmed">20668671</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoudi MS, Mehrabian E, Mirzaei H. MiR-21: A key player in glioblastoma pathogenesis. Journal of cellular biochemistry. 2018;119(2):1285&#x2013;90. doi: 10.1002/jcb.26300 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.26300</ArticleId><ArticleId IdType="pubmed">28727188</ArticleId></ArticleIdList></Reference><Reference><Citation>Irimie-Aghiorghiesei AI, Pop-Bica C, Pintea S, Braicu C, Cojocneanu R, Zim&#x21b;a A-A, et al.. Prognostic Value of MiR-21: An Updated Meta-Analysis in Head and Neck Squamous Cell Carcinoma (HNSCC). Journal of clinical medicine. 2019;8(12). doi: 10.3390/jcm8122041 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8122041</ArticleId><ArticleId IdType="pmc">PMC6947266</ArticleId><ArticleId IdType="pubmed">31766478</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P-F, Chen S-C, Xia T, Jiang X-M, Shao Y-F, Xiao B-X, et al.. Non-coding RNAs and gastric cancer. World journal of gastroenterology. 2014;20(18):5411&#x2013;9. doi: 10.3748/wjg.v20.i18.5411 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i18.5411</ArticleId><ArticleId IdType="pmc">PMC4017056</ArticleId><ArticleId IdType="pubmed">24833871</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedaeinia R, Avan A, Ahmadian M, Nia SN, Ranjbar M, Sharifi M, et al.. Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer. Journal of cellular biochemistry. 2017;118(12):4129&#x2013;40. doi: 10.1002/jcb.26047 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.26047</ArticleId><ArticleId IdType="pubmed">28401648</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardini B, De Maria D, Francavilla A, Di Gaetano C, Ronco G, Naccarati A. MicroRNAs as markers of progression in cervical cancer: a systematic review. BMC cancer. 2018;18(1):696. doi: 10.1186/s12885-018-4590-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-018-4590-4</ArticleId><ArticleId IdType="pmc">PMC6020348</ArticleId><ArticleId IdType="pubmed">29945565</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan L, Ji Q, Cheng G, Xia J, Liu D, Wu C, et al.. Diagnostic value of circulating miR-21 for colorectal cancer: a meta-analysis. Cancer biomarkers: section A of Disease markers. 2015;15(1):47&#x2013;56. doi: 10.3233/CBM-140437 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/CBM-140437</ArticleId><ArticleId IdType="pubmed">25524942</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinling W, Sijing S, Jie Z, Guinian W. Prognostic value of circulating microRNA-21 for breast cancer: a systematic review and meta-analysis. Artificial cells, nanomedicine, and biotechnology. 2017;45(6):1&#x2013;6. doi: 10.1080/21691401.2016.1216856 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21691401.2016.1216856</ArticleId><ArticleId IdType="pubmed">27684463</ArticleId></ArticleIdList></Reference><Reference><Citation>Moridikia A, Mirzaei H, Sahebkar A, Salimian J. MicroRNAs: Potential candidates for diagnosis and treatment of colorectal cancer. Journal of cellular physiology. 2018;233(2):901&#x2013;13. doi: 10.1002/jcp.25801 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.25801</ArticleId><ArticleId IdType="pubmed">28092102</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Zhu W, Chen L, Liu L. MicroRNA&#x2011;433 inhibits cell growth and induces apoptosis in human cervical cancer through PI3K/AKT signaling by targeting FAK. Oncology reports. 2018;40(6):3469&#x2013;78. doi: 10.3892/or.2018.6718 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2018.6718</ArticleId><ArticleId IdType="pubmed">30272334</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddadi N, Lin Y, Travis G, Simpson AM, Nassif NT, McGowan EM. PTEN/PTENP1: &#x2019;Regulating the regulator of RTK-dependent PI3K/Akt signalling&#x2019;, new targets for cancer therapy. Mol Cancer. 2018;17(1):37. Epub 2018/02/20. doi: 10.1186/s12943-018-0803-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-018-0803-3</ArticleId><ArticleId IdType="pmc">PMC5817727</ArticleId><ArticleId IdType="pubmed">29455665</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrami A, Hasanzadeh M, Hassanian SM, ShahidSales S, Ghayour-Mobarhan M, Ferns GA, et al.. The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy. J Cell Biochem. 2017;118(12):4163&#x2013;9. doi: 10.1002/jcb.26118 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.26118</ArticleId><ArticleId IdType="pubmed">28475243</ArticleId></ArticleIdList></Reference><Reference><Citation>Albadari N, Deng S, Li W. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opin Drug Discov. 2019;14(7):667&#x2013;82. doi: 10.1080/17460441.2019.1613370 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2019.1613370</ArticleId><ArticleId IdType="pmc">PMC6559821</ArticleId><ArticleId IdType="pubmed">31070059</ArticleId></ArticleIdList></Reference><Reference><Citation>Elorza A, Soro-Arn&#xe1;iz I, Mel&#xe9;ndez-Rodr&#xed;guez F, Rodr&#xed;guez-Vaello V, Marsboom G, de C&#xe1;rcer G, et al.. HIF2&#x3b1; acts as an mTORC1 activator through the amino acid carrier SLC7A5. Molecular cell. 2012;48(5):681&#x2013;91. doi: 10.1016/j.molcel.2012.09.017 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2012.09.017</ArticleId><ArticleId IdType="pubmed">23103253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai J, Chen W-B, Zhang X-Y, Kang X-N, Jin L-J, Zhang H, et al.. HIF-2&#x3b1; regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer PI3K/AKT/mTOR signaling. World journal of stem cells. 2020;12(1):87&#x2013;99. doi: 10.4252/wjsc.v12.i1.87 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4252/wjsc.v12.i1.87</ArticleId><ArticleId IdType="pmc">PMC7031759</ArticleId><ArticleId IdType="pubmed">32110277</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35480115</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>Cyclin-Dependent Kinase 6 Identified as the Target Protein in the Antitumor Activity of <i>Tetrastigma hemsleyanum</i>.</ArticleTitle><Pagination><StartPage>865409</StartPage><MedlinePgn>865409</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">865409</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2022.865409</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED"><i>Tetrastigma hemsleyanum</i> (<i>T. hemsleyanum</i>) is widely used as an adjuvant drug for tumor therapy but its antitumor therapeutic targets and molecular mechanisms have remained unclear. The prediction and analysis of natural products has previously used only network pharmacology methods to identify potential target proteins from public databases. In this study, we use comprehensive bioinformatics analysis and experimental verification to determine the antitumor mechanism of <i>T. hemsleyanum</i>.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Network pharmacology analysis was used to predict the potential <i>in vivo</i> target proteins of <i>T. hemsleyanum</i>. The expression matrix and clinical data to perform an analysis of hub genes were collected from the TCGA and GTEx databases, specifically the analysis of expression, prognosis, tumor immune cell infiltration analysis, immune checkpoint genes, microsatellite instability, tumor mutational burden, tumor neoantigen, and immune microenvironment, which identify the roles and biological functions of the hub genes in pan-cancer. Finally, gene set enrichment analysis was used to verify the biological processes and signaling pathways involved in the pan-cancer expression profile.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We found 124 potential <i>in vivo</i> target proteins of <i>T. hemsleyanum</i> through network pharmacological analysis, and five hub genes (AKR1C1, MET, PTK2, PIK3R1, and CDK6) were then screened by protein-protein interaction (PPI) network analysis and molecular complex detection analysis (MCODE). Experimental intervention with an aqueous extract of <i>T. hemsleyanum</i> verified that these hub genes are the target proteins involved in the regulation of <i>T. hemsleyanum</i> in cells. A pan-cancer analysis then confirmed that CDK6 and MET are potential targets upon which <i>T. hemsleyanum</i> may exert antitumor action, especially in ACC, CESC, LGG, and PAAD. The CDK6 protein targeted by <i>T. hemsleyanum</i> is also involved in the immune and mutation process of pan-cancer, especially in the regulation of immune cell infiltration, immune checkpoint gene expression, microsatellite instability, tumor mutation burdens, and tumor neoantigens. Together, these analyses show that <i>T. hemsleyanum</i> affects tumor immune regulation and genomic stability. Finally, a gene set enrichment analysis confirmed that <i>T. hemsleyanum</i> regulates the cell cycle checkpoint.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">We found that <i>T. hemsleyanum</i> can behave as an antitumor agent by acting as a potential cell cycle checkpoint inhibitor in CDK6-driven tumors, such as ACC, CESC, LGG, and PAAD, and that it acts as a tyrosine kinase receptor inhibitor that inhibits the expression of the proto-oncogene MET. Combined with an analysis of immune and mutation correlations in pan-cancer, we determined that <i>T. hemsleyanum</i> may function biologically as an immune regulator and interfere with the stability of the tumor genome, which is worthy of further study.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Wei, Zhao, Ji, Sun, Cai and Peng.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Chaoguang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ningbo Municipal Hospital of TCM, Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>United New Drug Research and Development Center, Biotrans Technology Co., Ltd, Ningbo, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yuxiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ningbo Municipal Hospital of TCM, Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>United New Drug Research and Development Center, Biotrans Technology Co., Ltd, Ningbo, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ningbo Municipal Hospital of TCM, Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Xudong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Ningbo Municipal Hospital of TCM, Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Ningbo Municipal Hospital of TCM, Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CDK6</Keyword><Keyword MajorTopicYN="N">MET</Keyword><Keyword MajorTopicYN="N">Tetrastigma hemsleyanum</Keyword><Keyword MajorTopicYN="N">antitumor</Keyword><Keyword MajorTopicYN="N">pan-cancer analysis</Keyword></KeywordList><CoiStatement>CGW and YXZ were employed by Biotrans Technology Co., LTD. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35480115</ArticleId><ArticleId IdType="pmc">PMC9035993</ArticleId><ArticleId IdType="doi">10.3389/fonc.2022.865409</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peng X, Li MJ, Hao WU, Chen HJ, Zhang ZY. Co-Regulation Role of Endogenous Hormones and Transcriptomics Profiling Under Cold Stress in Tetrastigma Hemsleyanum. J Plant Growth Regul (2021) 40:1992&#x2013;2006. doi:&#xa0;10.1007/s00344-020-10246-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00344-020-10246-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou TL, Ji T, Peng X, Ji WW, Yuan LX, Wang J, et al. . Extract From Tetrastigma Hemsleyanum Leaf Alleviates Pseudomonas Aeruginosa Lung Infection: Network Pharmacology Analysis and Experimental Evidence. Front Pharmacol (2021) 12:587850. doi:&#xa0;10.3389/fphar.2021.587850</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.587850</ArticleId><ArticleId IdType="pmc">PMC8326761</ArticleId><ArticleId IdType="pubmed">34349638</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji W, Peng X, Lou T, Wang J, Qiu W. Total Flavonoids From Tetrastigma Hemsleyanum Ameliorates Inflammatory Stress in Concanavalin A&#x2212;induced Autoimmune Hepatitis Mice by Regulating Treg/Th17 Immune Homeostasis. Inflammopharmacol (2019) 27:1297&#x2013;307. doi:&#xa0;10.1007/s10787-019-00599-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-019-00599-0</ArticleId><ArticleId IdType="pubmed">31123967</ArticleId></ArticleIdList></Reference><Reference><Citation>Ru Y, Chen X, Wang J, Guo L, Lin Z, Peng X, et al. . Polysaccharides From Tetrastigma Hemsleyanum Diels et Gilg: Extraction Optimization, Structural Characterizations, Antioxidant and Antihyperlipidemic Activities in Hyperlipidemic Mice. Int J Biol Macromol (2019) 125:1033&#x2013;41. doi:&#xa0;10.1016/j.ijbiomac.2018.11.236</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2018.11.236</ArticleId><ArticleId IdType="pubmed">30500505</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YL, Zhang YR, Wang YX, Yu X, Yu T, Zheng XD, et al. . Tetrastigma Hemsleyanum Leaf Flavones Have Anti-NSCLC Ability by Triggering Apoptosis Using the Akt-mTOR Pathway. Food Biosci (2021) 41(5):100914. doi:&#xa0;10.1016/j.fbio.2021.100914</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fbio.2021.100914</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng X, Zhang YY, Wang J, Ji QY. Ethylacetate Extract From Tetrastigma Hemsleyanum Induces Apoptosis via the Mitochondrial Caspase-Dependent Intrinsic Pathway in HepG2 Cells. Tumor Biol (2016) 37(1):865&#x2013;76. doi:&#xa0;10.1007/s13277-015-3579-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-015-3579-8</ArticleId><ArticleId IdType="pubmed">26254612</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y, Wu XW, Rao LQ. Tetrastigma Hemsleyanum (Sanyeqing) Root Tuber Extracts Induces Apoptosis in Human Cervical Carcinoma HeLa Cells. J Ethnopharmacol (2015) 165:46&#x2013;53. doi:&#xa0;10.1016/j.jep.2015.02.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2015.02.030</ArticleId><ArticleId IdType="pubmed">25701754</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Q, Jia RY, Chen W, Liu YY, Li YL, Ye X, et al. . Purified Tetrastigma Hemsleyanum Vines Polysaccharide Attenuates EC-Induced Toxicity in Caco-2 Cells and Caenorhabditis Elegans via DAF-16/FOXO Pathway. Int J Biol Macromol (2020) 150:1192&#x2013;202. doi:&#xa0;10.1016/j.ijbiomac.2019.10.128</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2019.10.128</ArticleId><ArticleId IdType="pubmed">31739013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji T, Ji WW, Wang J, Chen HJ, Peng X, Cheng KJ, et al. . A Comprehensive Review on Traditional Uses, Chemical Compositions, Pharmacology Properties and Toxicology of Tetrastigma Hemsleyanum. J Ethnopharmacol (2021) 264:113247. doi:&#xa0;10.1016/j.jep.2020.113247</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2020.113247</ArticleId><ArticleId IdType="pmc">PMC7422820</ArticleId><ArticleId IdType="pubmed">32800929</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardone V, Barbarino M, Angrisani A, Correale P, Pastina P, Cappabianca S, et al. . CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy. Int J Mol Sci (2021) 22:8391. doi:&#xa0;10.3390/ijms22168391</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168391</ArticleId><ArticleId IdType="pmc">PMC8395054</ArticleId><ArticleId IdType="pubmed">34445095</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadesse S, Yu M, Kumarasiri M, Le BT, Wang SD. Targeting CDK6 in Cancer: State of the Art and New Insights. Cell Cycle (2015) 14(20):3220&#x2013;30. doi:&#xa0;10.1080/15384101.2015.1084445</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2015.1084445</ArticleId><ArticleId IdType="pmc">PMC4825601</ArticleId><ArticleId IdType="pubmed">26315616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji T, Ji WW, Wang J, Peng X, Xu Z, Cao W, et al. . Tetrastigma Hemsleyanum Alleviates Sarcoidosis Through Metabolomic Regulation and Th17/Treg Immune Homeostasis. J Funct Foods (2022) 88:104910. doi:&#xa0;10.1016/j.jff.2021.104910</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jff.2021.104910</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. . STRING V11: Protein&#x2013;Protein Association Networks With Increased Coverage, Supporting Functional Discovery in Genome-Wide Experimental Datasets. Nucleic Acids Res (2019) 47:D607&#x2013;613. doi: 10.1093/nar/gky1131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark C, Breitkreutz B-J, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: A General Repository for Interaction Datasets. Nucleic Acids Res (2006) 34:D535&#x2013;539. doi: 10.1093/nar/gkj109</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkj109</ArticleId><ArticleId IdType="pmc">PMC1347471</ArticleId><ArticleId IdType="pubmed">16381927</ArticleId></ArticleIdList></Reference><Reference><Citation>Turei D, Korcsm&#xe1;ros T, Saez-Rodriguez J. OmniPath: Guidelines and Gateway for Literature-Curated Signaling Pathway Resources. Nat Methods (2016) 13:966&#x2013;7. doi: 10.1038/nmeth.4077</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4077</ArticleId><ArticleId IdType="pubmed">27898060</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Wernersson R, Hansen RB, Horn H, Mercer J, Slodkowicz G, et al. . A Scored Human Protein&#x2013;Protein Interaction Network to Catalyze Genomic Interpretation. Nat Methods (2017) 14:61&#x2013;4. doi: 10.1038/nmeth.4083</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4083</ArticleId><ArticleId IdType="pmc">PMC5839635</ArticleId><ArticleId IdType="pubmed">27892958</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou YY, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. . Metascape Provides a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets. Nat Commun (2019) 10(1):1523. doi:&#xa0;10.1038/s41467-019-09234-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09234-6</ArticleId><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. . Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol (2017) 2017:PO.17.00073. doi:&#xa0;10.1200/PO.17.00073</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/PO.17.00073</ArticleId><ArticleId IdType="pmc">PMC5972025</ArticleId><ArticleId IdType="pubmed">29850653</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. . The Immune Landscape of Cancer. Immunity (2018) 48(4):812&#x2013;830.e14. doi:&#xa0;10.1016/j.immuni.2018.03.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.03.023</ArticleId><ArticleId IdType="pmc">PMC5982584</ArticleId><ArticleId IdType="pubmed">29628290</ArticleId></ArticleIdList></Reference><Reference><Citation>Qie S, Diehl JA. Cyclin D1, Cancer Progression and Opportunities in Cancer Treatment. J Mol Med (Berl) (2016) 94(12):1313&#x2013;26. doi:&#xa0;10.1007/s00109-016-1475-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-016-1475-3</ArticleId><ArticleId IdType="pmc">PMC5145738</ArticleId><ArticleId IdType="pubmed">27695879</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian C, Cohen MS. Over Expression of DNA Damage and Cell Cycle Dependent Proteins are Associated With Poor Survival in Patients With Adrenocortical Carcinoma. Surgery (2019) 165(1):202&#x2013;10. doi:&#xa0;10.1016/j.surg.2018.04.080</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2018.04.080</ArticleId><ArticleId IdType="pmc">PMC7226676</ArticleId><ArticleId IdType="pubmed">30413320</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin-Drubin ME, Park D, Munger K. Tumor Suppressor P16ink4ais Necessary for Survival of Cervical Carcinoma Cell Lines. PNAS (2013) 110(40):16175&#x2013;80. doi:&#xa0;10.1073/pnas.1310432110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1310432110</ArticleId><ArticleId IdType="pmc">PMC3791710</ArticleId><ArticleId IdType="pubmed">24046371</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Wang L, Li BL, Huo MP, Mu MT, Liu JJ, et al. . miR&#x2212;145 Downregulates the Expression of Cyclin&#x2212;Dependent Kinase 6 in Human Cervical Carcinoma Cells. Exp Ther Med (2014) 8:591&#x2013;4. doi:&#xa0;10.3892/etm.2014.1765</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2014.1765</ArticleId><ArticleId IdType="pmc">PMC4079406</ArticleId><ArticleId IdType="pubmed">25009625</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao R, Wang K, Long M, Guo M, Sheng L, Zhan M, et al. . miR-3613-5p Enhances the Metastasis of Pancreatic Cancer by Targeting CDK6. Cell Cycle (2020) 19(22):3086&#x2013;95. doi:&#xa0;10.1080/15384101.2020.1831254</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2020.1831254</ArticleId><ArticleId IdType="pmc">PMC7714463</ArticleId><ArticleId IdType="pubmed">33073681</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvador-Barbero B, Alvarez-Fernandez M, Zapatero-Solana E, Bakkali AE, Menendez M, Lopez-Casas P, et al. . CDK4/6 Inhibitors Impair Recovery From Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer Cell (2020) 37:340&#x2013;53. doi:&#xa0;10.1016/j.ccell.202.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.202.01.007</ArticleId><ArticleId IdType="pubmed">32109375</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, et al. . PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients With MET Exon 14 Altered Lung Cancers. Ann Oncol (2018) 29:2085&#x2013;91. doi:&#xa0;10.1093/annonc/mdy334</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdy334</ArticleId><ArticleId IdType="pmc">PMC6225900</ArticleId><ArticleId IdType="pubmed">30165371</ArticleId></ArticleIdList></Reference><Reference><Citation>Comoglio PM, Trusolino L, Boccaccio C. Known and Novel Roles of the MET Oncogene in Cancer: A Coherent Approach to Targeted Therapy. Nat Rev Cancer (2018) 18:341&#x2013;58. doi:&#xa0;10.1038/s41568-018-0002-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-018-0002-y</ArticleId><ArticleId IdType="pubmed">29674709</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardim D, Gagliato D, Falchook G, Zinner R, Wheler J, Janku F, et al. . MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With C-MET Inhibitors. Clin Genitourin Cancer (2015) 13(1):e19&#x2013;26. doi:&#xa0;10.1016/j.clgc.2014.06.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clgc.2014.06.017</ArticleId><ArticleId IdType="pmc">PMC5144738</ArticleId><ArticleId IdType="pubmed">25087088</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Li CW, Li XQ, Ding QQ, Guo L, Liu S, et al. . MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology (2019) 156:1849&#x2013;61. doi:&#xa0;10.1053/j.gastro.2019.01.252</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.01.252</ArticleId><ArticleId IdType="pmc">PMC6904924</ArticleId><ArticleId IdType="pubmed">30711629</ArticleId></ArticleIdList></Reference><Reference><Citation>Moosavi F, Giovannetti E, Peters G, Firuzi O. Combination of HGF/MET-Targeting Agents and Other Therapeutic Strategies in Cancer. Crit Rev Oncol Hemat (2021) 160:103234. doi:&#xa0;10.1016/j.critrevonc.2021.103234</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2021.103234</ArticleId><ArticleId IdType="pubmed">33497758</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35449547</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-875X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in surgery</Title><ISOAbbreviation>Front Surg</ISOAbbreviation></Journal><ArticleTitle>Exploring Potential Regulatory Anesthetic Drugs Based on RNA Binding Protein and Constructing CESC Prognosis Model: A Study Based on TCGA Database.</ArticleTitle><Pagination><StartPage>823566</StartPage><MedlinePgn>823566</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">823566</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fsurg.2022.823566</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To investigate the differential expression of RBPs in cervical squamous cell carcinoma (CESC), analyze the regulatory effect of narcotic drugs on RBPs, and establish the prognostic risk model of CESC patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">RNA-SEQ data and clinical case data of cancer and normal samples from CESC patients were obtained from the Cancer Genome Atlas (TCGA) database and Genotype-Tissue Expression (GTEx) database. Differentially expressed RBPs were screened by R language and enriched. The CMAP database is used to predict the anesthetic drugs that regulate the differential expression of RBPs. The prognostic risk score model was constructed by COX regression analysis. Risk score of each CESC patient was calculated and divided into high-risk group and low-risk group according to the median risk score. The prediction efficiency of prognostic risk model was evaluated by Kaplan-Meier (KM) analysis and receiver operating characteristic (ROC) curve, and the correlation between prognostic risk model and clinical characteristics was analyzed. Immunohistochemistry was used to detect the expression of RNASEH2A and HENMT1 in tissues.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">There were 65 differentially expressed RBPs in CESC. Five anesthetics, including benzocaine, procaine, pentoxyverine, and tetracaine were obtained to regulate RBPs. Survival analysis showed that seven genes were related to the prognosis of patients, and the CESC risk score model was constructed by COX regression. The risk score can be used as an independent prognostic factor. RNASEH2A and HENMT1 are up-regulated in tumors, which can effectively distinguish normal tissues from tumor tissues.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">It is found that different anesthetic drugs have different regulatory effects on the differential expression of RBPs. Based on the differentially expressed RBPs, the prognostic risk score model of CESC patients was constructed. To provide ideas for the formulation of individualized precise anesthesia scheme and cancer pain analgesia scheme, which is helpful to improve the perioperative survival rate of cancer patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Zheng, Meng and Yang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Xiao Wen</ForeName><Initials>XW</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jian Ping</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Surg</MedlineTA><NlmUniqueID>101645127</NlmUniqueID><ISSNLinking>2296-875X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">cervical squamous cell carcinoma (CESC)</Keyword><Keyword MajorTopicYN="N">narcotic drugs</Keyword><Keyword MajorTopicYN="N">predictors</Keyword><Keyword MajorTopicYN="N">risk score</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35449547</ArticleId><ArticleId IdType="pmc">PMC9018109</ArticleId><ArticleId IdType="doi">10.3389/fsurg.2022.823566</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Small W, Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, et al. . Cervical cancer: A global health crisis. Cancer. (2017) 123:2404&#x2013;12. 10.1002/cncr.30667</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.30667</ArticleId><ArticleId IdType="pubmed">28464289</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. (2018) 68:7&#x2013;30. 10.3322/caac.21442</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21442</ArticleId><ArticleId IdType="pubmed">29313949</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrami A, Hasanzadeh M, Shahidsales S, Farazestanian M, Hassanian SM, Moetamani Ahmadi M, et al. . Genetic susceptibility in cervical cancer: From bench to bedside. J Cell Physiol. (2018) 233:1929&#x2013;39. 10.1002/jcp.26019</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.26019</ArticleId><ArticleId IdType="pubmed">28542881</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu X, Guo XK, Chen BH, Gao XJ, Chen F, Liu Q. Prognostic and clinicopathological value of ZIC1 in patients with cervical squamous cell carcinoma. Oncol Lett. (2019) 18:6621&#x2013;7. 10.3892/ol.2019.11007</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2019.11007</ArticleId><ArticleId IdType="pmc">PMC6865731</ArticleId><ArticleId IdType="pubmed">31788119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao D, Qin W, Zhao C, Long J, Li M. CXCR7, a Prognostic Biomarker in Cervical Squamous Cell Carcinoma, May Be a Screening Index for Treatment Options at Stages IB1 and IIA1. Cancer Manag Res. (2019) 11:10287&#x2013;96. 10.2147/CMAR.S228684</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CMAR.S228684</ArticleId><ArticleId IdType="pmc">PMC6910105</ArticleId><ArticleId IdType="pubmed">31849518</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstberger S, Hafner M, Tuschl T. A census of human RNA-binding proteins. Nat Rev Genet. (2014) 15:829&#x2013;45. 10.1038/nrg3813</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3813</ArticleId><ArticleId IdType="pmc">PMC11148870</ArticleId><ArticleId IdType="pubmed">25365966</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda K, Kuwano Y. Diverse roles of RNA-binding proteins in cancer traits and their implications in gastrointestinal cancers. Wiley Interdiscip Rev RNA. (2019) 10:e1520. 10.1002/wrna.1520</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wrna.1520</ArticleId><ArticleId IdType="pubmed">30479000</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: old players and new actors. Trends Cancer. (2017) 3:506&#x2013;28. 10.1016/j.trecan.2017.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trecan.2017.05.003</ArticleId><ArticleId IdType="pubmed">28718405</ArticleId></ArticleIdList></Reference><Reference><Citation>Legrand N, Dixon DA, Sobolewski C. AU-rich element-binding proteins in colorectal cancer. World J Gastrointest Oncol. (2019) 11:71&#x2013;90. 10.4251/wjgo.v11.i2.71</Citation><ArticleIdList><ArticleId IdType="doi">10.4251/wjgo.v11.i2.71</ArticleId><ArticleId IdType="pmc">PMC6379757</ArticleId><ArticleId IdType="pubmed">30788036</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterji P, Rustgi AK. RNA. Binding proteins in intestinal epithelial biology and colorectal cancer trends. Mol Med. (2018) 24:490&#x2013;506. 10.1016/j.molmed.2018.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2018.03.008</ArticleId><ArticleId IdType="pmc">PMC5927824</ArticleId><ArticleId IdType="pubmed">29627433</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Wang Y, Dou J, Guo Y, He J, Li L, et al. . Acetylation of AGO2 promotes cancer progression by increasing oncogenic miR-19b biogenesis. Oncogene. (2019) 38:1410&#x2013;31. 10.1038/s41388-018-0530-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-018-0530-7</ArticleId><ArticleId IdType="pmc">PMC6372475</ArticleId><ArticleId IdType="pubmed">30305728</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong HM, Han J, Lee SH, Park HJ, Lee HJ, Choi JS, et al. . ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cells. Oncogenesis. (2017) 6:e389. 10.1038/oncsis.2017.89</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/oncsis.2017.89</ArticleId><ArticleId IdType="pmc">PMC5668885</ArticleId><ArticleId IdType="pubmed">28991261</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Liu J, Wang H, Cheng Q, Zhou C, Chen X, et al. . Inhibition of RNA-binding protein Musashi-1 suppresses malignant properties and reverses paclitaxel resistance in ovarian carcinoma. J Cancer. (2019) 10:1580&#x2013;92. 10.7150/jca.27352</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.27352</ArticleId><ArticleId IdType="pmc">PMC6485236</ArticleId><ArticleId IdType="pubmed">31031868</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf8;nnesen E, Wahlgreen C. Influence of extradural and general anaesthesia on natural killer cell activity and lymphocyte subpopulations in patients undergoing hysterectomy. Br J Anaesth. (1988) 60:500&#x2013;7. 10.1093/bja/60.5.500</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/60.5.500</ArticleId><ArticleId IdType="pubmed">3377925</ArticleId></ArticleIdList></Reference><Reference><Citation>Deegan CA, Murray D, Doran P, Moriarty DC, Sessler DI, Mascha E, et al. . Anesthetic technique and the cytokine and matrix metalloproteinase response to primary breast cancer surgery. Reg Anesth Pain Med. (2010) 35:490&#x2013;5. 10.1097/AAP.0b013e3181ef4d05</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AAP.0b013e3181ef4d05</ArticleId><ArticleId IdType="pubmed">20975461</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkley MA, Hildebrandt E, Podolsky RH, Arnouk H, Ferris DG, Dynan WS, et al. . Large-scale analysis of protein expression changes in human keratinocytes immortalized by human papilloma virus type 16 E6 and E7 oncogenes. Proteome Sci. (2009) 7:29. 10.1186/1477-5956-7-29</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-5956-7-29</ArticleId><ArticleId IdType="pmc">PMC2744660</ArticleId><ArticleId IdType="pubmed">19698150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang F, Liu J, Xia M, Lin C, Wu X, Ye L, et al. . GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer. Oncol Rep. (2017) 37:2652&#x2013;62. 10.3892/or.2017.5573</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2017.5573</ArticleId><ArticleId IdType="pmc">PMC5428920</ArticleId><ArticleId IdType="pubmed">28405687</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang R, Jiang Y, Tan A, Ye J, Xian X, Xie Y, et al. . 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones. Urolithiasis. (2018) 46:503&#x2013;14. 10.1007/s00240-018-1037-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00240-018-1037-y</ArticleId><ArticleId IdType="pubmed">29353409</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SL, Qu ZP, Kortschak RD, Lawrence DM, Geoghegan J, Hempfling AL, et al. . HENMT1 and piRNA stability are required for adult male germ cell transposon repression and to define the spermatogenic program in the mouse. PLoS Genet. (2015) 11:e1005620. 10.1371/journal.pgen.1005782</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1005782</ArticleId><ArticleId IdType="pmc">PMC4619860</ArticleId><ArticleId IdType="pubmed">26496356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hempfling AL, Lim SL, Adelson DL, Evans J, O'Connor AE, Qu ZP, et al. . Expression patterns of HENMT1 and PIWIL1 in human testis: implications for transposon expression. Reproduction. (2017) 154:363&#x2013;74. 10.1530/REP-16-0586</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/REP-16-0586</ArticleId><ArticleId IdType="pubmed">28676534</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E, Lokman NA, Oehler MK, Ricciardelli C, Grutzner F. A Comprehensive molecular and clinical analysis of the piRNA pathway genes in ovarian cancer. Cancers (Basel). (2020) 13:4. 10.3390/cancers13010004</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13010004</ArticleId><ArticleId IdType="pmc">PMC7792616</ArticleId><ArticleId IdType="pubmed">33374923</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai B, Zhang P, Zhang Y, Pan C, Meng G, Xiao X, et al. . RNaseH2A is involved in human gliomagenesis through the regulation of cell proliferation and apoptosis. Oncol Rep. (2016) 36:173&#x2013;80. 10.3892/or.2016.4802</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2016.4802</ArticleId><ArticleId IdType="pubmed">27176716</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Lin S, Liu L, Wang C. Ribonuclease H2 Subunit A impacts invasiveness and chemoresistance resulting in poor survivability of breast cancer in ER dependent manner. Am J Transl Res. (2020) 12:2281&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270022</ArticleId><ArticleId IdType="pubmed">32509219</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Ma D, Kang H, Zhao J, Yang M. Long noncoding RNA LINC01287 promotes proliferation and inhibits apoptosis of lung adenocarcinoma cells via the miR-3529-5p/RNASEH2A axis under the competitive endogenous RNA pattern. Environ Toxicol. (2021) 36:2093&#x2013;104. 10.1002/tox.23325</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/tox.23325</ArticleId><ArticleId IdType="pubmed">34254728</ArticleId></ArticleIdList></Reference><Reference><Citation>Sertic S, Quadri R, Lazzaro F, Muzi-Falconi M. EXO1: A tightly regulated nuclease. DNA Repair (Amst). (2020) 93:102929. 10.1016/j.dnarep.2020.102929</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dnarep.2020.102929</ArticleId><ArticleId IdType="pubmed">33087266</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Ge S, Chen J, Zhang L, Tai S, Liang C. Effects of RNA binding proteins on the prognosis and malignant progression in prostate cancer. Front Genet. (2020) 11:591667. 10.3389/fgene.2020.591667</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.591667</ArticleId><ArticleId IdType="pmc">PMC7606971</ArticleId><ArticleId IdType="pubmed">33193734</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Zhang J. Elevated EXO1 expression is associated with breast carcinogenesis and poor prognosis. Ann Transl Med. (2021) 9:135. 10.21037/atm-20-7922</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-20-7922</ArticleId><ArticleId IdType="pmc">PMC7867906</ArticleId><ArticleId IdType="pubmed">33569437</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou CS, Feng MT, Chen X, Gao Y, Chen L, Li LD Li DH, et al. . Exonuclease 1 (EXO1) is a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma. Onco Targets Ther. (2021) 14:1033&#x2013;48. 10.2147/OTT.S286274</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S286274</ArticleId><ArticleId IdType="pmc">PMC7894803</ArticleId><ArticleId IdType="pubmed">33623391</ArticleId></ArticleIdList></Reference><Reference><Citation>Abaji R, Ceppi F, Patel S, Gagn&#xe9; V, Xu CJ, Spinella JF, et al. . Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing. Pharmacogenomics. (2018) 19:1181&#x2013;93. 10.2217/pgs-2018-0093</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/pgs-2018-0093</ArticleId><ArticleId IdType="pubmed">30191766</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu G, Jiang Q, Liu L, Peng H, Wang Y, Li S, et al. . Integrated analysis of RNA-binding proteins associated with the prognosis and immunosuppression in squamous cell carcinoma of head and neck. Front Genet. (2021) 11:571403. 10.3389/fgene.2020.571403</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.571403</ArticleId><ArticleId IdType="pmc">PMC7831273</ArticleId><ArticleId IdType="pubmed">33505420</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YA, Liu HN, Zhu JM, Zhang DY, Shen XZ, Liu TT, et al. . binding protein Nova1 promotes tumor growth in vivo and its potential mechanism as an oncogene may due to its interaction with GABAA Receptor-&#x3b3;2. J Biomed Sci. (2016) 23:71. 10.1186/s12929-016-0288-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-016-0288-6</ArticleId><ArticleId IdType="pmc">PMC5062898</ArticleId><ArticleId IdType="pubmed">27733149</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EK, Yoon SO, Jung WY, Lee H, Kang Y, Jang YJ, et al. . Implications of NOVA1 suppression within the microenvironment of gastric cancer: association with immune cell dysregulation. Gastric Cancer. (2017) 20:438&#x2013;47. 10.1007/s10120-016-0623-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10120-016-0623-3</ArticleId><ArticleId IdType="pubmed">27318497</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35428744</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1643-3750</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><PubDate><Year>2022</Year><Month>Apr</Month><Day>16</Day></PubDate></JournalIssue><Title>Medical science monitor : international medical journal of experimental and clinical research</Title><ISOAbbreviation>Med Sci Monit</ISOAbbreviation></Journal><ArticleTitle>Identification of Novel Genes and Associated Drugs in Cervical Cancer by Bioinformatics Methods.</ArticleTitle><Pagination><StartPage>e934799</StartPage><MedlinePgn>e934799</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12659/MSM.934799</ELocationID><Abstract><AbstractText>BACKGROUND Cervical cancer is one of the common gynecological tumors that seriously harm women's health, so it is particularly important to accurately explore the underlying mechanism of its occurrence and clinical prognosis. MATERIAL AND METHODS In the GEO database, GEO2R was used to analyze the differentially expressed genes from the 4 databases: GSE6791, GSE9750, GSE63514, and GSE67522. Then, the DAVID website was used to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. These protein-protein interaction (PPI) networks of DEGS were visualized and analyzed using the STRING website and the hub genes were further screened using the Cytohubba plugin. Lastly, the functions of the hub genes were further analyzed by Gene Expression Profiling Interactive Analysis (GEPIA) online tools, Human Protein Atlas (HPA) databases, and the QuartataWeb database. RESULTS In the 4 Profile datasets, 101 cancer tissues and 67 normal tissues were collected. Among the 78 differentially expressed genes in the 4 datasets, 51 genes were upregulated and 27 genes were downregulated. The PPIs of these differentially expressed genes were visualized using Cytoscape and the Interaction Gene Search Tool (STRING). Then, further analysis of hub genes using the GEPIA tool and Kaplan-Meier curves that showed upregulation of CDK1 and PRC1 is associated with better survival, while AURKA is associated with worse survival. Among these hub genes, only AURKA was closely related to the prognosis of cervical cancer, and 21 potential drugs were found. CONCLUSIONS These results suggest that AURKA and its drug candidates can improve the individualized diagnosis and treatment of cervical cancer in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Gastrointestinal Oncology, Medical College of Xiamen University, Xiamen, Fujian, China (mainland).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yanling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences Xiamen University, Xiamen, Fujian, China (mainland).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Shuyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Gastrointestinal Oncology, Medical College of Xiamen University, Xiamen, Fujian, China (mainland).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guoyan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Gastrointestinal Oncology, Medical College of Xiamen University, Xiamen, Fujian, China (mainland).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences Xiamen University, Xiamen, Fujian, China (mainland).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, China (mainland).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Sci Monit</MedlineTA><NlmUniqueID>9609063</NlmUniqueID><ISSNLinking>1234-1010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D064096">Aurora Kinase A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064096" MajorTopicYN="N">Aurora Kinase A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="Y">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest:</b> None declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>5</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35428744</ArticleId><ArticleId IdType="pmc">PMC9020271</ArticleId><ArticleId IdType="doi">10.12659/MSM.934799</ArticleId><ArticleId IdType="pii">934799</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Global Health. 2020;8(2):E180&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">31862245</ArticleId></ArticleIdList></Reference><Reference><Citation>Canfell K, Kim JJ, Brisson M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: A comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):591&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7043006</ArticleId><ArticleId IdType="pubmed">32007142</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Y, Cai XS, Shen FR, Ma F. HPV post-infection microenvironment and cervical cancer. Cancer Lett. 2021;497:243&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">33122098</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Pan W, Jin L, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020;471:88&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">31812696</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AC, Roane BM, Leath CA., 3rd Novel therapeutics for recurrent cervical cancer: Moving towards personalized therapy. Drugs. 2020;80(3):217&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7033025</ArticleId><ArticleId IdType="pubmed">31939072</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra S, Gupta M, Mathew A, et al. Locally advanced cervical cancer: A study of 5-year outcomes. Indian J Cancer. 2018;55(1):45&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">30147092</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong AJ, Li XT, Tucker M, et al. Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:786&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8384621</ArticleId><ArticleId IdType="pubmed">33568750</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang JW, Deng XN, Wang YL, et al. Analysis of copy number variations by low-depth whole-genome sequencing in fetuses with congenital cardiovascular malformations. Cytogenet Genome Res. 2020;160:643&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">33647914</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondelin J, Martin S, Katainen R, et al. No evidence of EMAST in whole genome sequencing data from 248 colorectal cancers. Genes Chromosomes Cancer. 2021;60:463&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">33527622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai JW, Shi JX, Li CZ, et al. Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival. Nat Commun. 2021;12(1):757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7859411</ArticleId><ArticleId IdType="pubmed">33536423</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ZJ, Grover S, Scott AM, et al. The role and contribution of treatment and imaging modalities in global cervical cancer management: Survival estimates from a simulation-based analysis. Lancet Oncol. 2020;21(8):1089&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7574952</ArticleId><ArticleId IdType="pubmed">32758463</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J, Wang Y, Shi K, Wang Y. Identification of core prognosis-related candidate genes in cervical cancer via integrated bioinformatical analysis. Biomed Res Int. 2020;2020:8959210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097776</ArticleId><ArticleId IdType="pubmed">32258155</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue H, Sun ZJ, Wu WQ, et al. Identification of hub genes as potential prognostic biomarkers in cervical cancer using comprehensive bioinformatics analysis and validation studies. Cancer Manag Res. 2021;13:117&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7802793</ArticleId><ArticleId IdType="pubmed">33447084</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai LY, Hu C, Yu SS, et al. Identification and validation of a six-gene signature associated with glycolysis to predict the prognosis of patients with cervical cancer. Bmc Cancer. 2020;20(1):1133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7686733</ArticleId><ArticleId IdType="pubmed">33228592</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Li Q. The mechanism of CSRP2BP in cervial cancer. Eur J Immunol. 2019;49:1560&#x2013;60.</Citation></Reference><Reference><Citation>Zhao J, Cao HL, Zhang WF, et al. SOX14 hypermethylation as a tumour biomarker in cervical cancer. Bmc Cancer. 2021;21(1):675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185922</ArticleId><ArticleId IdType="pubmed">34098886</ArticleId></ArticleIdList></Reference><Reference><Citation>The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47:D330&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323945</ArticleId><ArticleId IdType="pubmed">30395331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Furumichi M, Sato Y, et al. KEGG: Integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7779016</ArticleId><ArticleId IdType="pubmed">33125081</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DW, Sherman BT, Tan Q, et al. DAVID Bioinformatics Resources: Expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007;35:W169&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1933169</ArticleId><ArticleId IdType="pubmed">17576678</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: Protein&#x2013;protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Elahi A, Babamir SM. Identification of protein complexes based on core-attachment structure and combination of centrality measures and biological properties in PPI weighted networks. Protein J. 2020;39(6):681&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">33040223</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Kang B, Li C, et al. GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602440</ArticleId><ArticleId IdType="pubmed">31114875</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranstam J, Cook JA. Kaplan-Meier curve. Br J Surg. 2017;104(4):442.</Citation><ArticleIdList><ArticleId IdType="pubmed">28199017</ArticleId></ArticleIdList></Reference><Reference><Citation>Digre A, Lindskog C. The Human Protein Atlas-Spatial localization of the human proteome in health and disease. Protein Sci. 2021;30(1):218&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737765</ArticleId><ArticleId IdType="pubmed">33146890</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami E, Gao J, Dogrusoz U, et al. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data (vol 2, pg 401, 2012) Cancer Discovery. 2012;2(10):960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3956037</ArticleId><ArticleId IdType="pubmed">22588877</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HC, Pei F, Taylor DL, Bahar I. QuartataWeb: Integrated chemical-protein-pathway mapping for polypharmacology and chemogenomics. Bioinformatics. 2020;36(12):3935&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320630</ArticleId><ArticleId IdType="pubmed">32221612</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha AD, Neupane D, Vedsted P, Kallestrup P. Cervical cancer prevalence, incidence and mortality in low and middle income countries: A systematic review. Asian Pac J Cancer Prev. 2018;19(2):319&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5980914</ArticleId><ArticleId IdType="pubmed">29479954</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, An Q, Zhao X. A pan-HER-targeted approach for recurrent or late-stage cervical cancer therapy: Mechanisms, recent advances, and clinical prospects. Eur Rev Med Pharmacol Sci. 2020;24(8):4123&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">32373948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingham M, Schwartz GK. Cell-cycle therapeutics come of age. J Clin Oncol. 2017;35(25):2949&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6075824</ArticleId><ArticleId IdType="pubmed">28580868</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Deng K, Wang C, et al. Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control. J Enzyme Inhib Med Chem. 2020;35(1):414&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6968521</ArticleId><ArticleId IdType="pubmed">31899991</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Stanger BZ. Cell cycle regulation meets tumor immunosuppression. Trends Immunol. 2020;41(10):859&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">32800703</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondala PK, Vora AA, Zhou T, et al. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell Stem Cell. 2021;28(4):623&#x2013;36e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8026723</ArticleId><ArticleId IdType="pubmed">33476575</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S, Luo Q, Tan X, et al. Erchen decoction plus huiyanzhuyu decoction inhibits the cell cycle, migration and invasion and induces the apoptosis of laryngeal squamous cell carcinoma cells. J Ethnopharmacol. 2020;256:112638.</Citation><ArticleIdList><ArticleId IdType="pubmed">32007633</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo JK, Kang JH, Shin D, et al. Daurinol enhances the efficacy of radiotherapy in lung cancer via suppression of Aurora kinase A/B expression. Mol Cancer Ther. 2015;14(7):1693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">25882311</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X, Wang J, Zou S, et al. Cinobufagin triggers defects in spindle formation and cap-dependent translation in liver cancer cells by inhibiting the AURKA-mTOR-eIF4E Axis. Am J Chin Med. 2020;48(3):651&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">32349518</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan B, Zhao R, Zhou J, et al. AURKA increase the chemosensitivity of colon cancer cells to oxaliplatin by inhibiting the TP53-mediated DNA damage response genes. Biomed Res Int. 2020;2020:8916729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7439175</ArticleId><ArticleId IdType="pubmed">32851091</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalhal S, Ribeiro SA, Arocena M, et al. The nucleoporin ALADIN regulates Aurora A localization to ensure robust mitotic spindle formation. Molecular biology of the cell. 2015;26(19):3424&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4591688</ArticleId><ArticleId IdType="pubmed">26246606</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Zhang Y, Wu S, et al. Palmatine induces G2/M phase arrest and mitochondrial-associated pathway apoptosis in colon cancer cells by targeting AURKA. Biochem Pharmacol. 2020;175:113933.</Citation><ArticleIdList><ArticleId IdType="pubmed">32224138</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou D, Che Z, Chen P, et al. Suppression of AURKA alleviates p27 inhibition on Bax cleavage and induces more intensive apoptosis in gastric cancer. Cell Death Dis. 2018;9(8):781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6048174</ArticleId><ArticleId IdType="pubmed">30013101</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao SQ, Wang C, Wang SL, et al. Hsa_circ_0075341 is up-regulated and exerts oncogenic properties by sponging miR-149-5p in cervical cancer. Biomed Pharmacother. 2020;121:109582.</Citation><ArticleIdList><ArticleId IdType="pubmed">31706100</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Horn RD, Chu SY, Fan L, et al. Cdk1 activity is required for mitotic activation of Aurora A during G(2)/M transition of human cells. J Biol Chem. 2010;285(28):21849&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898447</ArticleId><ArticleId IdType="pubmed">20444701</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore DC, Gebru T, Muslimani A. Fostamatinib for the treatment of immune thrombocytopenia in adults. Am J Health Syst Pharm. 2019;76(11):789&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">30951590</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Zhang S, Wu W, et al. Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1-mediated EMT. Mol Carcinog. 2021;60(2):151&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">33428809</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkebsi L, Wang X, Ohkawara H, et al. Dasatinib induces endothelial-to-mesenchymal transition in human vascular-endothelial cells: Counteracted by cotreatment with bosutinib. Int J Hematol. 2021;113(3):441&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">33392972</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidoguchi K, Ureshino H, Kizuka-Sano H, et al. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A case series from a single institute. Int J Hematol. 2021;114(2):199&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">33907977</ArticleId></ArticleIdList></Reference><Reference><Citation>Willig JB, Vianna DRB, Beckenkamp A, et al. Imatinib mesylate affects extracellular ATP catabolism and expression of NTPDases in a chronic myeloid leukemia cell line. Purinergic Signal. 2020;16(1):29&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166234</ArticleId><ArticleId IdType="pubmed">31955347</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishio M, Yoshida T, Kumagai T, et al. Brigatinib in Japanese patients with ALK-positive NSCLC previously treated with alectinib and other tyrosine kinase inhibitors: Outcomes of the phase 2 J-ALTA Trial. J Thorac Oncol. 2021;16(3):452&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">33248320</ArticleId></ArticleIdList></Reference><Reference><Citation>Er MM, Araz M, Karabacak M, et al. Pazopanib-associated secondary adrenal insufficiency in a patient with malignant solitary fibrous tumor. J Oncol Pharm Pract. 2021;27(8):2049&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">33977817</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Sun T, Guo X, et al. Sorafenib versus apatinib both combined transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: A comparative retrospective study. Front Oncol. 2021;11:673378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8369468</ArticleId><ArticleId IdType="pubmed">34414104</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouroki M, Inagaki J, Fujisaki T, et al. Nintedanib for treatment of progressive interstitial lung disease after peripheral blood stem cell transplantation in a patient with recurrent acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68(11):e29211.</Citation><ArticleIdList><ArticleId IdType="pubmed">34197046</ArticleId></ArticleIdList></Reference><Reference><Citation>Luvero D, Plotti F, Lopez S, et al. Antiangiogenics and immunotherapies in cervical cancer: An update and future&#x2019;s view. Med Oncol. 2017;34(6):115.</Citation><ArticleIdList><ArticleId IdType="pubmed">28477178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35389773</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2165-5987</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Bioengineered</Title><ISOAbbreviation>Bioengineered</ISOAbbreviation></Journal><ArticleTitle>Kinetochore-associated protein 1 promotes the invasion and tumorigenicity of cervical cancer cells via matrix metalloproteinase-2 and matrix metalloproteinase-9.</ArticleTitle><Pagination><StartPage>9495</StartPage><EndPage>9507</EndPage><MedlinePgn>9495-9507</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21655979.2022.2061144</ELocationID><Abstract><AbstractText>Cervical cancer, a common cancer in women, has become a serious social burden. Kinetochore-associated protein 1 (KNTC1) that regulates the cell cycle by regulating mitosis is related to the malignant behavior of different types of tumors. However, its role in the development of cervical cancer remains unclear. In this study, we initially explored the role of KNTC1 in cervical cancer. KNTC1 expression and relevant information were downloaded from The Cancer Genome Atlas (TCGA) and dataset GSE63514 in the Gene Expression Omnibus (GEO) database for bioinformatics analyses. Cell proliferation was detected by cell counting kit-8 (CCK8) and colony formation assays. Wound healing and Transwell assays were used to evaluate cell migration and invasion abilities. Protein expression levels of matrix metallopeptidase 2 (MMP2) and matrix metallopeptidase 9 (MMP9) were measured by western blotting. Nude mouse models of subcutaneous xenograft tumor were constructed to analyze tumor growth in vivo. CCK8 and colony formation assay results demonstrated that the proliferation rate of SiHa and C-33A cells decreased when KNTC1 was silenced. Western blot and Transwell assays indicated that KNTC1 knockdown weakened the invasion and migration abilities of SiHa and C-33A cells and decreased the expression of MMP-2 and MMP-9. In-vivo experiments suggested that the inhibition of KNTC1 reduced tumor growth. Taken together, our study showed that KNTC1 plays an important role in cervical cancer. Further, we verified the promotional effect of KNTC1 on cervical cancer through in-vivo and in-vitro experiments and speculated that KNTC1 might mediate tumor invasion via MMP9 and MMP2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Caimei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Obstetrics and Gynecology, Yulin Second Hospital, Yulin, Shaanxi Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yiyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Stomatology, The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Congrong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Obstetrics and Gynecology, Yulin Second Hospital, Yulin, Shaanxi Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Obstetrics and Gynecology, Yulin Second Hospital, Yulin, Shaanxi Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hang</LastName><ForeName>Zhongxia</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Obstetrics and Gynecology, Yulin Second Hospital, Yulin, Shaanxi Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Bioengineered</MedlineTA><NlmUniqueID>101581063</NlmUniqueID><ISSNLinking>2165-5979</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489309">KNTC1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.24</RegistryNumber><NameOfSubstance UI="C522361">MMP2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.24</RegistryNumber><NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.35</RegistryNumber><NameOfSubstance UI="C579270">MMP9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.35</RegistryNumber><NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="Y">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020778" MajorTopicYN="Y">Matrix Metalloproteinase 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="Y">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">KNTC1</Keyword><Keyword MajorTopicYN="N">MMP-2</Keyword><Keyword MajorTopicYN="N">MMP-9</Keyword><Keyword MajorTopicYN="N">invasion</Keyword><Keyword MajorTopicYN="N">tumorigenicity</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35389773</ArticleId><ArticleId IdType="pmc">PMC9161993</ArticleId><ArticleId IdType="doi">10.1080/21655979.2022.2061144</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">26808342</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191&#x2013;e203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7025157</ArticleId><ArticleId IdType="pubmed">31812369</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet. 2019;393(10167):169&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheeseman IM. The kinetochore. Cold Spring Harb Perspect Biol. 2014;6(7):a015826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4067989</ArticleId><ArticleId IdType="pubmed">24984773</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol. 2009;10(7):478&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154738</ArticleId><ArticleId IdType="pubmed">19546858</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N, Miura K, Gu Z, et al. siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis. Biochem Biophys Res Commun. 2009;390(4):1235&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">19878654</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu Y, Li J, Cai Q, et al. Hec1/Ndc80 is overexpressed in human gastric cancer and regulates cell growth. J Gastroenterol. 2014;49(3):408&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">23591767</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Gao X, Lu X, et al. The mitotic regulator Hec1 is a critical modulator of prostate cancer through the long non-coding RNA BX647187 in vitro. Biosci Rep. 2015;35(6). DOI:10.1042/BSR20150003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20150003</ArticleId><ArticleId IdType="pmc">PMC4660581</ArticleId><ArticleId IdType="pubmed">26612002</ArticleId></ArticleIdList></Reference><Reference><Citation>Schvartzman JM, Duijf PH, Sotillo R, et al. Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition. Cancer Cell. 2011;19(6):701&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120099</ArticleId><ArticleId IdType="pubmed">21665145</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuyler SC, Wu YF, Kuan VJ. The Mad1-Mad2 balancing act&#x2013;a damaged spindle checkpoint in chromosome instability and cancer. J Cell Sci. 2012;125(Pt 18):4197&#x2013;4206.</Citation><ArticleIdList><ArticleId IdType="pubmed">23093575</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai T, Zhao Y, Liu Y, et al. Effect of KNL1 on the proliferation and apoptosis of colorectal cancer cells. Technol Cancer Res Treat. 2019;18:1533033819858668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6637841</ArticleId><ArticleId IdType="pubmed">31315522</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Zhai R, Lv X, et al. LINC02418 promotes malignant behaviors in lung adenocarcinoma cells by sponging miR-4677-3p to upregulate KNL1 expression. BMC Pulm Med. 2020;20(1):217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427971</ArticleId><ArticleId IdType="pubmed">32795273</ArticleId></ArticleIdList></Reference><Reference><Citation>Song B, Du J, Song DF, et al. Dysregulation of NCAPG, KNL1, miR-148a-3p, miR-193b-3p, and miR-1179 may contribute to the progression of gastric cancer. Biol Res. 2018;51(1):44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6215350</ArticleId><ArticleId IdType="pubmed">30390708</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y, Li X, Cheng L, et al. Circular RNA FAT atypical cadherin 1 (circFAT1)/microRNA-525-5p/spindle and kinetochore-associated complex subunit 1 (SKA1) axis regulates oxaliplatin resistance in breast cancer by activating the notch and Wnt signaling pathway. Bioengineered. 2021;12(1):4032&#x2013;4043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8806415</ArticleId><ArticleId IdType="pubmed">34288822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J, He X, Wang J, et al. Integrative analysis of prognostic value and immune infiltration of spindle and kinetochore-associated family members in breast cancer. Bioengineered. 2021;12(2):10905&#x2013;10923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8809973</ArticleId><ArticleId IdType="pubmed">34845974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Li Z, Zhang R, et al. Identification of differentially expressed and methylated genes associated with rheumatoid arthritis based on network. Autoimmunity. 2020;53(6):303&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">32650679</ArticleId></ArticleIdList></Reference><Reference><Citation>Devarbhavi P, Telang L, Vastrad B, et al. Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules. Reprod Biol Endocrinol. 2021;19(1):31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901211</ArticleId><ArticleId IdType="pubmed">33622336</ArticleId></ArticleIdList></Reference><Reference><Citation>Han HY, Mou JT, Jiang WP, et al. Five candidate biomarkers associated with the diagnosis and prognosis of cervical cancer. Biosci Rep. 2021;41(3):BSR20204394. 10.1042/BSR20204394</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20204394</ArticleId><ArticleId IdType="pmc">PMC7955105</ArticleId><ArticleId IdType="pubmed">33616161</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu HZ, Huang J, Xiang CC, et al. Screening and discovery of new potential biomarkers and small molecule drugs for cervical cancer: a bioinformatics analysis. Technol Cancer Res Treat. 2020;19:1533033820980112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734488</ArticleId><ArticleId IdType="pubmed">33302814</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Wang X, Jia H, et al. Bioinformatics analysis of key genes and pathways of cervical cancer. Onco Targets Ther. 2020;13:13275&#x2013;13283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7778384</ArticleId><ArticleId IdType="pubmed">33402836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2862057</ArticleId><ArticleId IdType="pubmed">20371345</ArticleId></ArticleIdList></Reference><Reference><Citation>Gou X, Chen H, Jin F, et al. Expressions of CD147, MMP-2 and MMP-9 in laryngeal carcinoma and its correlation with poor prognosis. Pathol Oncol Res. 2014;20(2):475&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">24357157</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Zhu J. Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma. Med Oncol. 2010;27(4):1185&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">19921476</ArticleId></ArticleIdList></Reference><Reference><Citation>Azevedo Martins JM, Rabelo-Santos SH, Do Amaral Westin MC, et al. Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis. BMC Cancer. 2020;20(1):660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364527</ArticleId><ArticleId IdType="pubmed">32669083</ArticleId></ArticleIdList></Reference><Reference><Citation>Asha Nair S, Karunagaran D, Nair MB, et al. Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J Cancer Res Clin Oncol. 2003;129(2):123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">12669237</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets&#x2013;update. Nucleic Acids Res. 2013;41(D1):D991&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou G, Soufan O, Ewald J, et al. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res. 2019;47(W1):W234&#x2013;W41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602507</ArticleId><ArticleId IdType="pubmed">30931480</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530.</Citation><ArticleIdList><ArticleId IdType="pubmed">29625059</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CT, Min L, Wang YJ, et al. shRNAmediated knockdown of KNTC1 suppresses cell viability and induces apoptosis in esophageal squamous cell carcinoma. Int J Oncol. 2019;54(3):1053&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">30628654</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasari S, Wudayagiri R, Valluru L. Cervical cancer: biomarkers for diagnosis and treatment. Clin Chim Acta. 2015;445:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">25773118</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Logue T, Kaplan SJ, et al. Less radical surgery for early-stage cervical cancer: a systematic review. Am J Obstet Gynecol. 2021;224(4):348&#x2013;58 e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">33306971</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira MA, Rendon GJ, Munsell M, et al. Radical trachelectomy in early-stage cervical cancer: a comparison of laparotomy and minimally invasive surgery. Gynecol Oncol. 2015;138(3):585&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">26095894</ArticleId></ArticleIdList></Reference><Reference><Citation>Naga Ch P, Gurram L, Chopra S, et al. The management of locally advanced cervical cancer. Curr Opin Oncol. 2018;30(5):323&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">29994902</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta NR, Stutz E, Liu M, et al. Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: a systematic review and meta-analysis. Gynecol Oncol. 2017;145(2):374&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">28188016</ArticleId></ArticleIdList></Reference><Reference><Citation>Karess RE, Glover DM. rough deal: a gene required for proper mitotic segregation in Drosophila. J Cell Biol. 1989;109(6):2951&#x2013;2961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115894</ArticleId><ArticleId IdType="pubmed">2512302</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan GK, Jablonski SA, Starr DA, et al. Human Zw10 and ROD are mitotic checkpoint proteins that bind to kinetochores. Nat Cell Biol. 2000;2(12):944&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">11146660</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaerou F, Starr DA, Piano F, et al. The ZW10 and rough deal checkpoint proteins function together in a large, evolutionarily conserved complex targeted to the kinetochore. J Cell Sci. 2001;114(17):3103&#x2013;3114.</Citation><ArticleIdList><ArticleId IdType="pubmed">11590237</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine MS, Holland AJ. The impact of mitotic errors on cell proliferation and tumorigenesis. Genes Dev. 2018;32(9&#x2013;10):620&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6004076</ArticleId><ArticleId IdType="pubmed">29802124</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Chen Y, Li Y, et al. Targeting mitosis exit: a brake for cancer cell proliferation. Biochim Biophys Acta Rev Cancer. 2019;1871(1):179&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">30611728</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams BR, Amon A. Aneuploidy: cancer&#x2019;s fatal flaw? Cancer Res. 2009;69(13):5289&#x2013;5291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917070</ArticleId><ArticleId IdType="pubmed">19549887</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev. 2007;17(2):157&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">17324569</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng JF, Luo MJ, Li HB. Knockdown of miR-543 inhibits the proliferation and migration of small-cell lung carcinoma cells and induces apoptosis. Crit Rev Eukaryot Gene Expr. 2021;31(2):25&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">34347977</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiru P, Kern DM, McKinley KL, et al. Kinetochore genes are coordinately up-regulated in human tumors as part of a FoxM1-related cell division program. Mol Biol Cell. 2014;25(13):1983&#x2013;1994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4072572</ArticleId><ArticleId IdType="pubmed">24829384</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhengxiang Z, Yunxiang T, Zhiping L, et al. KNTC1 knockdown suppresses cell proliferation of colon cancer. 3 Biotech. 2021;11(11):262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113418</ArticleId><ArticleId IdType="pubmed">33996374</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Fan X, Qiao Y, et al. Knockdown of KNTC1 inhibits the proliferation, migration and tumorigenesis of human bladder cancer cells and induces apoptosis. Crit Rev Eukaryot Gene Expr. 2021;31(1):49&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">33639055</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams BC, Li Z, Liu S, et al. Zwilch, a new component of the ZW10/ROD complex required for kinetochore functions. Mol Biol Cell. 2003;14(4):1379&#x2013;1391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153108</ArticleId><ArticleId IdType="pubmed">12686595</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldas GV, Lynch TR, Anderson R, et al. The RZZ complex requires the N-terminus of KNL1 to mediate optimal Mad1 kinetochore localization in human cells. Open Biol. 2015;5(11):150160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4680571</ArticleId><ArticleId IdType="pubmed">26581576</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen S, Kong J, Qiu Y, et al. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis. J Cell Biochem. 2019;120(6):10069&#x2013;10081.</Citation><ArticleIdList><ArticleId IdType="pubmed">30525236</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Kang M, Zhou Z, et al. Bioinformatics analysis identifies hub genes and pathways in nasopharyngeal carcinoma. Oncol Lett. 2019;18(4):3637&#x2013;3645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6732963</ArticleId><ArticleId IdType="pubmed">31516577</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan X, Wan H, Hao X, et al. Importance of gene expression signatures in pancreatic cancer prognosis and the establishment of a prediction model. Cancer Manag Res. 2019;11:273&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6312063</ArticleId><ArticleId IdType="pubmed">30643453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf M, Korja M, Karhu R, et al. Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication. BMC Cancer. 2010;10(1):181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873396</ArticleId><ArticleId IdType="pubmed">20444257</ArticleId></ArticleIdList></Reference><Reference><Citation>Diniz MG, Silva Jde F, de Souza FT, et al. Association between cell cycle gene transcription and tumor size in oral squamous cell carcinoma. Tumour Biol. 2015;36(12):9717&#x2013;9722.</Citation><ArticleIdList><ArticleId IdType="pubmed">26152289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35279965</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2228-5806</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Cell journal</Title><ISOAbbreviation>Cell J</ISOAbbreviation></Journal><ArticleTitle><i>Circ_0000228</i> Promotes Cervical Cancer Progression via Regulating <i>miR-337-3p</i> /<i>TGFBR1</i> Axis.</ArticleTitle><Pagination><StartPage>91</StartPage><EndPage>98</EndPage><MedlinePgn>91-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.22074/cellj.2022.7914</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study aims to investigate the biological function of circular RNA (circRNA) <i>circ_0000228</i> in the cervical cancer (CC).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">In this experimental study, the GSE113696 dataset was downloaded from the Gene Expression Omnibus (GEO). GEO2R was employed to obtain differentially expressed circRNA between CC tissues and matched paracancerous tissues. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot were employed to detect <i>circ_0000228</i>, microRNA-337-3p (<i>miR-337-3p</i> ) and transforming growth factor, beta receptor I (<i>TGFBR1</i>) expression levels in the CC tissues and cells. Following gain-of-function and loss-of-function models establishment, CCK-8 and BrdU tests were conducted to examine cell proliferation. Transwell experiment was executed to examine CC cells migration and invasion. A lung metastasis model was utilized to determine the ability of <i>circ_0000228</i> on the lung metastasis. Bioinformatics analysis, dual-luciferase reporter experiment and RNA immunoprecipitation (RIP) assay were applied to verify the targeting relationship among <i>miR-337-3p</i> , <i>circ_0000228</i>, and <i>TGFBR1</i>.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED"><i>Circ_0000228</i> expression in the CC tissues and cells was up-modulated. <i>Circ_0000228</i> overexpression markedly enhanced cell proliferation, migration, and invasion, while knocking down <i>circ_0000228</i> remarkably repressed cell proliferation, migration, and invasion. <i>MiR-337-3p</i> could be adsorbed by <i>circ_0000228</i>. <i>TGFBR1</i> was identified as a target gene of <i>miR-337-3p</i> that indirectly and positively modulated by<i>circ_0000228</i> in the CC cells.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED"><i>Circ_0000228</i> up-modulates <i>TGFBR1</i> by targeting <i>miR-337-3p</i> to enhance CC cell proliferation, migration and invasion. Also, <i>Circ_0000228</i> is a promising therapeutic target for the CC.</AbstractText><CopyrightInformation>Copyright&#xa9; by Royan Institute. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yongqian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shengli Oilfield Central Hospital, Dongying, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Xiaona</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shengli Oilfield Central Hospital, Dongying, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Baoli</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shengli Oilfield Central Hospital, Dongying, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu</LastName><ForeName>Pingping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shengli Oilfield Central Hospital, Dongying, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shengli Oilfield Central Hospital, Dongying, Shandong, China. Email: drkongxiang@21cn.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dongmei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shengli Oilfield Central Hospital, Dongying, Shandong, China. Email: jibimibai18507@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>Cell J</MedlineTA><NlmUniqueID>101566618</NlmUniqueID><ISSNLinking>2228-5806</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical Cancer</Keyword><Keyword MajorTopicYN="N">TGFBR1</Keyword><Keyword MajorTopicYN="N">miR-337-3p</Keyword></KeywordList><CoiStatement>There is no conflict of interest in this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>13</Day><Hour>20</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35279965</ArticleId><ArticleId IdType="pmc">PMC8918268</ArticleId><ArticleId IdType="doi">10.22074/cellj.2022.7914</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, et al. Cervical cancer: a global health crisis. Cancer. 2017;123(13):2404&#x2013;2412.</Citation><ArticleIdList><ArticleId IdType="pubmed">28464289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning MS, Ahobila V, Jhingran A, Stecklein SR, Frumovitz M, Schmeler KM, et al. Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. Gynecol Oncol. 2018;148(1):132&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">29089122</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, et al. Circular RNA: a new star of noncoding RNAs. Cancer Lett. 2015;365(2):141&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">26052092</ArticleId></ArticleIdList></Reference><Reference><Citation>Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23446348</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu S, Zhong Y, Shang R, Zhang X, Song W, Kjems J, et al. The emerging landscape of circular RNA in life processes. RNA Biol. 2017;14(8):992&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5680710</ArticleId><ArticleId IdType="pubmed">27617908</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">23446346</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Yuan W, Yang X, Li P, Wang J, Han J, et al. Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/ miR-224 and regulating p21, PTEN expression. Mol Cancer. 2018;17(1):19&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5793418</ArticleId><ArticleId IdType="pubmed">29386015</ArticleId></ArticleIdList></Reference><Reference><Citation>Du WW, Yang W, Li X, Awan FM, Yang Z, Fang L, et al. A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy. Oncogene. 2018;37(44):5829&#x2013;5842.</Citation><ArticleIdList><ArticleId IdType="pubmed">29973691</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Wang Z, Miao Y, Shen Y, Li M, Gong L, et al. A two&#x2011;circRNA signature predicts tumour recurrence in clinical non&#x2011;functioning pituitary adenoma. Oncol Rep. 2019;41(1):113&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278571</ArticleId><ArticleId IdType="pubmed">30542712</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Wang X, Wei S, Chen Y, Chen Y, Fan X, et al. hsa_ circ_0013958: a circular RNA and potential novel biomarker for lung adenocarcinoma. FEBS J. 2017;284(14):2170&#x2013;2182.</Citation><ArticleIdList><ArticleId IdType="pubmed">28685964</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao ZJ, Shen J. Circular RNA participates in the carcinogenesis and the malignant behavior of cancer. RNA Biol. 2017;14(5):514&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5449088</ArticleId><ArticleId IdType="pubmed">26649774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding L, Zhao Y, Dang S, Wang Y, Li X, Yu X, et al. Circular RNA circ-DONSON facilitates gastric cancer growth and invasion via NURF complex dependent activation of transcription factor SOX4. Mol Cancer. 2019;18(1):45&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6437893</ArticleId><ArticleId IdType="pubmed">30922402</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q, Chen Z, Zhao L, Xu H. Circular RNA hsa_circ_0000515 acts as a miR-326 sponge to promote cervical cancer progression through up-regulation of ELK1. Aging (Albany NY). 2019;11(22):9982&#x2013;9999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6914414</ArticleId><ArticleId IdType="pubmed">31772143</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong X, Gao W, Yang X, Guo J. Downregulation of hsa_ circ_0007534 restricts the proliferation and invasion of cervical cancer through regulating miR-498/BMI-1 signaling. Life Sci. 2019;235:116785&#x2013;116785.</Citation><ArticleIdList><ArticleId IdType="pubmed">31445025</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XJ, Deng YR, Wang ZC, Wei WF, Zhou CF, Zhang YM, et al. Hypoxia-induced ZEB1 promotes cervical cancer progression via CCL8-dependent tumour-associated macrophage recruitment. Cell Death Dis. 2019;10(7):508&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602971</ArticleId><ArticleId IdType="pubmed">31263103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao XM. Role of miR-337-3p and its target Rap1A in modulating proliferation, invasion, migration and apoptosis of cervical cancer cells. Cancer Biomark. 2019;24(3):257&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">30883336</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Chen X, Peng R, Liu H, Yin P, Peng H, et al. Let&#x2011;7a suppresses cell proliferation via the TGF&#x2011;&#x3b2;/SMAD signaling pathway in cervical cancer. Oncol Rep. 2016;36(6):3275&#x2013;3282.</Citation><ArticleIdList><ArticleId IdType="pubmed">27748903</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng QH, Li Y, Kong C, Gao XM, Jiang XJ. Circ_0000388 exerts oncogenic function in cervical cancer cells by regulating miR-337- 3p/TCF12 axis. Cancer Biother Radiopharm. 2021;36(1):58&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">32119786</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HD, Jiang LH, Sun DW, Hou JC, Ji ZL. CircRNA: a novel type of biomarker for cancer. Breast Cancer. 2018;25(1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28721656</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Wu Y, Wang S, Jiang J, Zhang C, Jiang Y, et al. Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p. BMC Cancer. 2019;19(1):937&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6785934</ArticleId><ArticleId IdType="pubmed">31601173</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen RX, Liu HL, Yang LL, Kang FH, Xin LP, Huang LR, et al. Circular RNA circRNA_0000285 promotes cervical cancer development by regulating FUS. Eur Rev Med Pharmacol Sci. 2019;23(20):8771&#x2013;8778.</Citation><ArticleIdList><ArticleId IdType="pubmed">31696463</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release. 2013;172(3):962&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891846</ArticleId><ArticleId IdType="pubmed">24075926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">25027649</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan D, Liu W, Liu Y, Luo M. LINC00261 suppresses human colon cancer progression via sponging miR-324-3p and inactivating the Wnt/&#x3b2;-catenin pathway. J Cell Physiol. 2019;234(12):22648&#x2013;22656.</Citation><ArticleIdList><ArticleId IdType="pubmed">31183860</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua FF, Liu SS, Zhu LH, Wang YH, Liang X, Ma N, et al. MiRNA- 338-3p regulates cervical cancer cells proliferation by targeting MACC1 through MAPK signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(23):5342&#x2013;5352.</Citation><ArticleIdList><ArticleId IdType="pubmed">29243777</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Li G. MiR-1284 enhances sensitivity of cervical cancer cells to cisplatin via downregulating HMGB1. Biomed Pharmacother. 2018;107:997&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">30257412</ArticleId></ArticleIdList></Reference><Reference><Citation>Morikawa M, Derynck R, Miyazono K. TGF-&#x3b2; and the TGF-&#x3b2; family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 2016;8(5):a021873&#x2013;a021873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4852809</ArticleId><ArticleId IdType="pubmed">27141051</ArticleId></ArticleIdList></Reference><Reference><Citation>Colasante A, Aiello FB, Brunetti M, di Giovine FS. Gene expression of transforming growth factor beta receptors I and II in non-smallcell lung tumors. Cytokine. 2003;24(5):182&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">14596814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishimoto T, Miyake K, Nandi T, Yashiro M, Onishi N, Huang KK, et al. Activation of transforming growth factor beta 1 signaling in gastric cancer-associated fibroblasts increases their motility, via expression of rhomboid 5 homolog 2, and ability to induce invasiveness of gastric cancer cells. Gastroenterology. 2017;153(1):191&#x2013;204. e16.</Citation><ArticleIdList><ArticleId IdType="pubmed">28390866</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B, Guo W, Sun C, Zhang B, Zheng F. Linc00462 promotes pancreatic cancer invasiveness through the miR-665/TGFBR1- TGFBR2/SMAD2/3 pathway. Cell Death Dis. 2018;9(6):706&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5999603</ArticleId><ArticleId IdType="pubmed">29899418</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao P, Wang H, Yu J, Zhang J, Yang Z, Liu M, et al. miR-3607- 3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2. PLoS Genet. 2018;14(12):e1007790&#x2013;e1007790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6312350</ArticleId><ArticleId IdType="pubmed">30557355</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34834529</PMID><DateRevised><Year>2021</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4426</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>11</Day></PubDate></JournalIssue><Title>Journal of personalized medicine</Title><ISOAbbreviation>J Pers Med</ISOAbbreviation></Journal><ArticleTitle>LASSO and Bioinformatics Analysis in the Identification of Key Genes for Prognostic Genes of Gynecologic Cancer.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1177</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jpm11111177</ELocationID><Abstract><AbstractText>The aim of this study is to identify potential biomarkers for early diagnosis of gynecologic cancer in order to improve survival. Cervical cancer (CC) and endometrial cancer (EC) are the most common malignant tumors of gynecologic cancer among women in the world. As the underlying molecular mechanisms in both cervical and endometrial cancer remain unclear, a comprehensive and systematic bioinformatics analysis is required. In our study, gene expression profiles of GSE9750, GES7803, GES63514, GES17025, GES115810, and GES36389 downloaded from Gene Expression Omnibus (GEO) were utilized to analyze differential gene expression between cancer and normal tissues. A total of 78 differentially expressed genes (DEGs) common to CC and EC were identified to perform the functional enrichment analyses, including gene ontology and pathway analysis. KEGG pathway analysis of 78 DEGs indicated that three main types of pathway participate in the mechanism of gynecologic cancer such as drug metabolism, signal transduction, and tumorigenesis and development. Furthermore, 20 diagnostic signatures were confirmed using the least absolute shrink and selection operator (LASSO) regression with 10-fold cross validation. Finally, we used the GEPIA2 online tool to verify the expression of 20 genes selected by the LASSO regression model. Among them, the expression of PAMR1 and SLC24A3 in tumor tissues was downregulated significantly compared to the normal tissue, and found to be statistically significant in survival rates between the CC and EC of patients (<i>p</i> &lt; 0.05). The two genes have their function: (1.) PAMR1 is a tumor suppressor gene, and many studies have proven that overexpression of the gene markedly suppresses cell growth, especially in breast cancer and polycystic ovary syndrome; (2.) SLC24A3 is a sodium-calcium regulator of cells, and high SLC24A3 levels are associated with poor prognosis. In our study, the gene signatures can be used to predict CC and EC prognosis, which could provide novel clinical evidence to serve as a potential biomarker for future diagnosis and treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Shao-Hua</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0003-1072-7935</Identifier><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, China Medical University, Taichung 404333, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, China Medical University Hospital, Taichung 404333, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Jia-Hua</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Institute of Statistical Science, Academia Sinica, Taipei 11529, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>De-Lun</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Szu-Han</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yi-Zhen</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Yu-Ting</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Asia University Hospital, Taichung 413505, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Jeffrey J P</ForeName><Initials>JJP</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Precision Medicine Research, Asia University, Taichung 41354, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Charles C N</ForeName><Initials>CCN</Initials><Identifier Source="ORCID">0000-0002-7305-3061</Identifier><AffiliationInfo><Affiliation>Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Precision Medicine Research, Asia University, Taichung 41354, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ASIA-108-CMUH-18</GrantID><Agency>Asia University</Agency><Country/></Grant><Grant><GrantID>ASIA-108-CMUH-18</GrantID><Agency>China Medical University Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Pers Med</MedlineTA><NlmUniqueID>101602269</NlmUniqueID><ISSNLinking>2075-4426</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LASSO regression</Keyword><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">endometrial cancer</Keyword><Keyword MajorTopicYN="N">prognostic biomarkers</Keyword></KeywordList><CoiStatement>All authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34834529</ArticleId><ArticleId IdType="pmc">PMC8617991</ArticleId><ArticleId IdType="doi">10.3390/jpm11111177</ArticleId><ArticleId IdType="pii">jpm11111177</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Momenimovahed Z., Salehiniya H. Incidence, mortality and risk factors of cervical cancer in the world. Biomed. Res. Ther. 2017;4:1795&#x2013;1811. doi: 10.15419/bmrat.v4i12.386.</Citation><ArticleIdList><ArticleId IdType="doi">10.15419/bmrat.v4i12.386</ArticleId></ArticleIdList></Reference><Reference><Citation>Diouf D., Diop G., Fall C., Sarr S., Diarra C.A.T., Ngom A.I., Ka S., Lo S., Faye O., Dem A. The Association of Molecular Biomarkers in the Diagnosis of Cervical Pre-Cancer and Cancer and Risk Factors in Senegalese. Asian Pac. J. Cancer Prev. 2020;21:3221&#x2013;3227. doi: 10.31557/APJCP.2020.21.11.3221.</Citation><ArticleIdList><ArticleId IdType="doi">10.31557/APJCP.2020.21.11.3221</ArticleId><ArticleId IdType="pmc">PMC8033140</ArticleId><ArticleId IdType="pubmed">33247678</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez J.E., Gonz&#xe1;lez-Montiel A., Allos-Villalva J.C.C., Cant&#xfa; D., Barquet S., Olivares-Mundo A., Herrera L.A., Prada D. Prognostic molecular biomarkers in endometrial cancer: A review. J. Cancer Res. Ther. 2019;7:17&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8315102</ArticleId><ArticleId IdType="pubmed">34322276</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosse T., Lax S., Abu-Rustum N., Matias-Guiu X. The Role of Predictive Biomarkers in Endocervical Adenocarcinoma: Recommendations From the International Society of Gynecological Pathologists. Int. J. Gynecol. Pathol. 2021;40:S102&#x2013;S110. doi: 10.1097/PGP.0000000000000755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PGP.0000000000000755</ArticleId><ArticleId IdType="pmc">PMC7969151</ArticleId><ArticleId IdType="pubmed">33570867</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyango C.G., Ogonda L., Guyah B., Shiluli C., Ganda G., Orang&#x2019;o O.E., Patel K. Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: A systematic review. Infect. Agents Cancer. 2020;15:68. doi: 10.1186/s13027-020-00335-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13027-020-00335-2</ArticleId><ArticleId IdType="pmc">PMC7670699</ArticleId><ArticleId IdType="pubmed">33292364</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhone C., Longatto-Filho A. Cervical, Ovarian and Endometrial Tumor Markers: Potential Clinical Value. Semin. Ultrasound CT MRI. 2019;40:350&#x2013;357. doi: 10.1053/j.sult.2019.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.sult.2019.03.003</ArticleId><ArticleId IdType="pubmed">31375174</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Pi&#xf1;eros M., Znaor A., Bray F. Cancer statistics for the year 2020: An overview. Int. J. Cancer. 2021;149:778&#x2013;789. doi: 10.1002/ijc.33588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.33588</ArticleId><ArticleId IdType="pubmed">33818764</ArticleId></ArticleIdList></Reference><Reference><Citation>Finocchario-Kessler S., Wexler C., Maloba M., Mabachi N., Ndikum-Moffor F., Bukusi E. Cervical cancer prevention and treatment research in Africa: A systematic review from a public health perspective. BMC Women&#x2019;s Health. 2016;16:29. doi: 10.1186/s12905-016-0306-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12905-016-0306-6</ArticleId><ArticleId IdType="pmc">PMC4893293</ArticleId><ArticleId IdType="pubmed">27259656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.Y., Byun S.J., Kim Y.S., Nam J.H. Disease courses in patients with residual tumor following concurrent chemoradiotherapy for locally advanced cervical cancer. Gynecol. Oncol. 2017;144:34&#x2013;39. doi: 10.1016/j.ygyno.2016.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2016.10.032</ArticleId><ArticleId IdType="pubmed">27789082</ArticleId></ArticleIdList></Reference><Reference><Citation>Charo L.M., Plaxe S.C. Recent advances in endometrial cancer: A review of key clinical trials from 2015 to 2019. F1000Research. 2019;8:F1000 Faculty Rev-849. doi: 10.12688/f1000research.17408.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.17408.1</ArticleId><ArticleId IdType="pmc">PMC6567288</ArticleId><ArticleId IdType="pubmed">31231511</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontham E.T.H., Wolf A.M.D., Church T.R., Etzioni R., Flowers C.R., Herzig A., Guerra C.E., Oeffinger K.C., Shih Y.-C.T., Walter L.C. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA A Cancer J. Clin. 2020;70:321&#x2013;346. doi: 10.3322/caac.21628.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21628</ArticleId><ArticleId IdType="pubmed">32729638</ArticleId></ArticleIdList></Reference><Reference><Citation>Duska L.R., Scalici J.M., Temkin S.M., Schwarz J.K., Crane E.K., Moxley K.M., Hamilton C.A., Wethington S.L., Petroni G.R., Varhegyi N.E. Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer. 2020;126:4948&#x2013;4956. doi: 10.1002/cncr.33136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.33136</ArticleId><ArticleId IdType="pubmed">32910478</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Wu L., Tong R., Yang F., Yin L., Li M., You L., Xue J., Lu Y. PD-1/PD-L1 Inhibitors in Cervical Cancer. Front. Pharmacol. 2019;10:65. doi: 10.3389/fphar.2019.00065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00065</ArticleId><ArticleId IdType="pmc">PMC6367228</ArticleId><ArticleId IdType="pubmed">30774597</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S.H., Kim M., Lee S., Jung W., Kim B. Therapeutic Potential of Natural Products in Treatment of Cervical Cancer: A Review. Nutrients. 2021;13:154. doi: 10.3390/nu13010154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13010154</ArticleId><ArticleId IdType="pmc">PMC7824868</ArticleId><ArticleId IdType="pubmed">33466408</ArticleId></ArticleIdList></Reference><Reference><Citation>San Segundo-Val I., Sanz-Lozano C.S. Introduction to the gene expression analysis. Mol. Genet. Asthma. 2016:29&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">27300529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonoda K. Molecular biology of gynecological cancer (Review) Oncol. Lett. 2016;11:16&#x2013;22. doi: 10.3892/ol.2015.3862.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2015.3862</ArticleId><ArticleId IdType="pmc">PMC4727069</ArticleId><ArticleId IdType="pubmed">26834851</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitale S.G., Capriglione S., Zito G., Lopez S., Gulino F.A., Di Guardo F., Vitagliano A., Noventa M., La Rosa V.L., Sapia F. Management of endometrial, ovarian and cervical cancer in the elderly: Current approach to a challenging condition. Arch. Gynecol. Obstet. 2019;299:299&#x2013;315. doi: 10.1007/s00404-018-5006-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00404-018-5006-z</ArticleId><ArticleId IdType="pubmed">30542793</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S., Liyanage S.H., Sahdev A., Rockall A.G., Reznek R.H. Imaging of endometrial and cervical cancer. Insights Into Imaging. 2010;1:309&#x2013;328. doi: 10.1007/s13244-010-0042-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13244-010-0042-7</ArticleId><ArticleId IdType="pmc">PMC3259382</ArticleId><ArticleId IdType="pubmed">22347925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd A.C., McGettrick M., Tsim S., Halligan D.L., Bylesjo M., Blyth K.G. Survival prediction in mesothelioma using a scalable Lasso regression model: Instructions for use and initial performance using clinical predictors. BMJ Open Respir. Res. 2018;5:e000240. doi: 10.1136/bmjresp-2017-000240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjresp-2017-000240</ArticleId><ArticleId IdType="pmc">PMC5812388</ArticleId><ArticleId IdType="pubmed">29468073</ArticleId></ArticleIdList></Reference><Reference><Citation>Muthukrishnan R., Rohini R. LASSO: A feature selection technique in predictive modeling for machine learning; Proceedings of the 2016 IEEE International Conference on Advances in Computer Applications (ICACA); Coimbatore, India. 24 October 2016; pp. 18&#x2013;20.</Citation></Reference><Reference><Citation>Gautier L., Irizarry R., Cope L., Bolstad B. Description of Affy. Bioconductor Vignettes. 2012.  [(accessed on 3 July 2021)].  Available online:  https://www.bioconductor.org/packages/devel/bioc/vignettes/affy/inst/doc/affy.pdf.</Citation></Reference><Reference><Citation>Gautier L., Cope L., Bolstad B.M., Irizarry R.A. affy&#x2014;Analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20:307&#x2013;315. doi: 10.1093/bioinformatics/btg405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btg405</ArticleId><ArticleId IdType="pubmed">14960456</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek J.T., Johnson W.E., Parker H.S., Jaffe A.E., Storey J.D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28:882&#x2013;883. doi: 10.1093/bioinformatics/bts034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts034</ArticleId><ArticleId IdType="pmc">PMC3307112</ArticleId><ArticleId IdType="pubmed">22257669</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie M.E., Phipson B., Wu D., Hu Y., Law C.W., Shi W., Smyth G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi: 10.1093/nar/gkv007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G., Wang L.-G., Han Y., He Q.-Y. clusterProfiler: An R package for comparing biological themes among gene clusters. Omics A J. Integr. Biol. 2012;16:284&#x2013;287. doi: 10.1089/omi.2011.0118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman J.H., Hastie T., Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J. Stat. Softw. 2010;33:1&#x2013;22. doi: 10.18637/jss.v033.i01.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v033.i01</ArticleId><ArticleId IdType="pmc">PMC2929880</ArticleId><ArticleId IdType="pubmed">20808728</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Xiong D., Ye L., Yang H., Mei S., Wu J., Chen S., Mi R. SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines. Cancer Chemother. Pharmacol. 2019;83:603&#x2013;613. doi: 10.1007/s00280-018-3759-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00280-018-3759-5</ArticleId><ArticleId IdType="pubmed">30627777</ArticleId></ArticleIdList></Reference><Reference><Citation>Annapurna S.D.A., Pasumarthi D., Pasha A., Doneti R., Sheela B., Botlagunta M., Vijaya L.B., Pawar S.C. Identification of Differentially Expressed Genes in Cervical Cancer Patients by Comparative Transcriptome Analysis. BioMed Res. Int. 2021;2021:8810074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8004372</ArticleId><ArticleId IdType="pubmed">33829064</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson R., Jain M., Madhusudhan N., Sheppard N.G., Strittmatter L., Kampf C., Huang J., Asplund A., Mootha V.K. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat. Commun. 2014;5:3128. doi: 10.1038/ncomms4128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4128</ArticleId><ArticleId IdType="pmc">PMC4106362</ArticleId><ArticleId IdType="pubmed">24451681</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei C., Huang L., Deng L., Lin H., Pan W., Pang L. Identification of Candidate Biomarkers Associated with the Diagnosis and Prognosis of Endometrial Cancer: A Bioinformatics Analysis. 2021.  [(accessed on 3 July 2021)].  Research Square. Available online:  https://www.researchsquare.com/article/rs-318398/v1.</Citation></Reference><Reference><Citation>Liu X., Shen X., Zhang J. TRIP13 exerts a cancer-promoting role in cervical cancer by enhancing Wnt/&#x3b2;-catenin signaling via ACTN4. Environ. Toxicol. 2021;36:1829&#x2013;1840. doi: 10.1002/tox.23303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/tox.23303</ArticleId><ArticleId IdType="pubmed">34061428</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S., Qian J., Guo M., Gu C., Yang Y. Insights into a Crucial Role of TRIP13 in Human Cancer. Comput. Struct. Biotechnol. J. 2019;17:854&#x2013;861. doi: 10.1016/j.csbj.2019.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2019.06.005</ArticleId><ArticleId IdType="pmc">PMC6612527</ArticleId><ArticleId IdType="pubmed">31321001</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L.T., Jiang G., Chen Q., Zheng J.N. Ki67 is a promising molecular target in the diagnosis of cancer (Review) Mol. Med. Rep. 2015;11:1566&#x2013;1572. doi: 10.3892/mmr.2014.2914.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2014.2914</ArticleId><ArticleId IdType="pubmed">25384676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitson S., Sivalingam V.N., Bolton J., McVey R., Nickkho-Amiry M., Powell M.E., Leary A., Nijman H.W., Nout R.A., Bosse T. Ki-67 in endometrial cancer: Scoring optimization and prognostic relevance for window studies. Mod. Pathol. 2017;30:459&#x2013;468. doi: 10.1038/modpathol.2016.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/modpathol.2016.203</ArticleId><ArticleId IdType="pmc">PMC5337118</ArticleId><ArticleId IdType="pubmed">27910946</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Wu T., Zhang B., Yao Y., Yin G. Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer. Med. Oncol. 2012;29:3394&#x2013;3399. doi: 10.1007/s12032-012-0283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12032-012-0283-z</ArticleId><ArticleId IdType="pubmed">22752570</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T., Terai Y., Ohmichi M. Association of matrix metalloproteinase-9 and decorin expression with the infiltration of cervical cancer. Oncol. Lett. 2019;17:1306&#x2013;1312. doi: 10.3892/ol.2018.9713.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2018.9713</ArticleId><ArticleId IdType="pmc">PMC6313069</ArticleId><ArticleId IdType="pubmed">30655899</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W.T., Zheng P.S. Kr&#xfc;ppel-like factor 4 functions as a tumor suppressor in cervical carcinoma. Cancer. 2012;118:3691&#x2013;3702. doi: 10.1002/cncr.26698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.26698</ArticleId><ArticleId IdType="pubmed">22170594</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons C.D., Pabona J.M.P., Heard M.E., Friedman T.M., Spataro M.T., Godley A.L., Simmen F.A., Burnett A.F., Simmen R.C.M. Kr&#xfc;ppel-Like Factor 9 Loss-of-Expression in Human Endometrial Carcinoma Links Altered Expression of Growth-Regulatory Genes with Aberrant Proliferative Response to Estrogen1. Biol. Reprod. 2011;85:378&#x2013;385. doi: 10.1095/biolreprod.110.090654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1095/biolreprod.110.090654</ArticleId><ArticleId IdType="pmc">PMC3142261</ArticleId><ArticleId IdType="pubmed">21543766</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo P.H.Y., Tanikawa C., Katagiri T., Nakamura Y., Matsuda K. Identification of novel epigenetically inactivated gene PAMR1 in breast carcinoma. Oncol. Rep. 2015;33:267&#x2013;273. doi: 10.3892/or.2014.3581.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2014.3581</ArticleId><ArticleId IdType="pubmed">25370079</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang R., Ma M., Yu S., Li X., Zhang J., Wu S. High Expression of PAMR1 Predicts Favorable Prognosis and Inhibits Proliferation, Invasion, and Migration in Cervical Cancer. Front. Oncol. 2021;11:742017. doi: 10.3389/fonc.2021.742017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.742017</ArticleId><ArticleId IdType="pmc">PMC8521121</ArticleId><ArticleId IdType="pubmed">34671559</ArticleId></ArticleIdList></Reference><Reference><Citation>Makoukji J., Makhoul N., Khalil M., El-Sitt S., Aldin E., Jabbour M., Boulos F., Gadaleta E., Sangaralingam A., Chelala C. Gene expression profiling of breast cancer in Lebanese women. Sci. Rep. 2016;6:36639. doi: 10.1038/srep36639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36639</ArticleId><ArticleId IdType="pmc">PMC5114572</ArticleId><ArticleId IdType="pubmed">27857161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Xu X., Li P., Zhou F., Kong L., Qiu J., Yuan Z., Tan J. TMT Based Proteomic Analysis of Human Follicular Fluid from Overweight/Obese and Normal-Weight Patients With Polycystic Ovary Syndrome. Front. Endocrinol. 2019;10:821. doi: 10.3389/fendo.2019.00821.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2019.00821</ArticleId><ArticleId IdType="pmc">PMC6966116</ArticleId><ArticleId IdType="pubmed">31983920</ArticleId></ArticleIdList></Reference><Reference><Citation>Tible M., Loupy A., Vernerey D., Suberbielle C., Beuscart T., Cazes A., Guillemain R., Amrein C., Pezzella V., Fabiani J.-N. Pathologic classification of antibody-mediated rejection correlates with donor-specific antibodies and endothelial cell activation. J. Heart Lung Transplant. 2013;32:769&#x2013;776. doi: 10.1016/j.healun.2013.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2013.05.012</ArticleId><ArticleId IdType="pubmed">23856214</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran D.N., Go S.M., Park S.M., Jung E.M., Jeung E.B. Loss of Nckx3 Exacerbates Experimental DSS-Induced Colitis in Mice through p53/NF-&#x3ba;B Pathway. Int. J. Mol. Sci. 2021;22:2645. doi: 10.3390/ijms22052645.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052645</ArticleId><ArticleId IdType="pmc">PMC7961925</ArticleId><ArticleId IdType="pubmed">33807999</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalloul A.H., Szerencsei R.T., Schnetkamp P.P.M. Cation dependencies and turnover rates of the human K+-dependent Na+-Ca2+ exchangers NCKX1, NCKX2, NCKX3 and NCKX4. Cell Calcium. 2016;59:1&#x2013;11. doi: 10.1016/j.ceca.2015.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2015.11.001</ArticleId><ArticleId IdType="pubmed">26631410</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeung E.-B. 189 the Calcium Exchangers Nckx3 and Ncx1 Are Distinctly Expressed and Regulated by Steroids in the Human Endometrium during the Menstrual Cycle. Reprod. Fertil. Dev. 2010;23:195&#x2013;196. doi: 10.1071/RDv23n1Ab189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1071/RDv23n1Ab189</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Kim T.H., Lee H.H., Choi K.C., Jeung E.B. Distinct expression of the calcium exchangers, NCKX3 and NCX1, and their regulation by steroid in the human endometrium during the menstrual cycle. Reprod. Sci. 2011;18:577&#x2013;585. doi: 10.1177/1933719110396229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1933719110396229</ArticleId><ArticleId IdType="pubmed">21321244</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34797350</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>46</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>CNN3 in glioma: The prognostic factor and a potential immunotherapeutic target.</ArticleTitle><Pagination><StartPage>e27931</StartPage><MedlinePgn>e27931</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e27931</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000027931</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Gliomas are the most intrinsic type of primary intracranial tumors. The protein encoded by The calponin 3 (CNN3) has been proven to be a member of the calponin family. Its relationships with cervical cancer, colorectal cancer, gastric cancer, and colon cancer have been emphasized by several studies. Our research aims to explore the prognosis value and immunotherapeutic targetability of CNN3 in glioma patients using bioinformatics approach.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">CNN3 expression in glioma was analyzed based on GEO and TCGA datasets. Gene expression profiling with clinical information was employed to investigate the correlation between clinicopathological features of glioma patients and relative CNN3 expression levels. Survival analysis was conducted using Kaplan-Meier analysis and the Cox proportional-hazards regression model. Gene set enrichment analysis was conducted to select the pathways significantly enriched for CNN3 associations. Correlations between inflammatory activities, immune checkpoint molecules and CNN3 were probed by gene set variation analysis, correlograms, and correlation analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CNN3 was enriched in gliomas, and high expression of CNN3 correlated with worse clinicopathological features and prognosis. Associations between CNN3 and several immune-related pathways were confirmed using a bioinformatics approach. Correlation analysis revealed that CNN3 was associated with inflammatory and immune activities, tumor microenvironment, and immune checkpoint molecules.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results indicate that high CNN3 expression levels predict poor prognosis, and CNN3 may be a promising immunotherapy target.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hao</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3002-5693</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, General Hospital of the Yangtze River Shipping, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Song-Shan</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Suizhou Hospital, Hubei University of Medicine, Suizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jia-Jing</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000597250">CNNM3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016213">Cyclins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082102">Immune Checkpoint Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016213" MajorTopicYN="N">Cyclins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005910" MajorTopicYN="N">Glioma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082102" MajorTopicYN="Y">Immune Checkpoint Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34797350</ArticleId><ArticleId IdType="pmc">PMC8601287</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000027931</ArticleId><ArticleId IdType="pii">00005792-202111190-00080</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wesseling P, Capper D. WHO 2016 Classification of gliomas. Neuropathol Appl Neurobiol 2018;44:139&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">28815663</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrom QT, Gittleman H, Fulop J, et al. . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008&#x2013;2012. Neuro Oncol 2015;17: (Suppl 4): iv1&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4623240</ArticleId><ArticleId IdType="pubmed">26511214</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis DN, Ohgaki H, Wiestler OD, et al. . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1929165</ArticleId><ArticleId IdType="pubmed">17618441</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig K, Kornblum HI. Molecular markers in glioma. J Neurooncol 2017;134:505&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5568999</ArticleId><ArticleId IdType="pubmed">28233083</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan CW, Verhaak RG, McKenna A, et al. . The somatic genomic landscape of glioblastoma. Cell 2013;155:462&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910500</ArticleId><ArticleId IdType="pubmed">24120142</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons DW, Jones S, Zhang X, et al. . An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820389</ArticleId><ArticleId IdType="pubmed">18772396</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellman I, Coukos G, Dranoff GJN. Cancer immunotherapy comes of age 2011;480:480&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3967235</ArticleId><ArticleId IdType="pubmed">22193102</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zhu S, Li T, Liu YJ, Chen W, Chen J. Targeting immune checkpoints in malignant glioma. Oncotarget 2017;8:7157&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5351697</ArticleId><ArticleId IdType="pubmed">27756892</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair VA, Al-Khayyal NA, Sivaperumal S, Abdel-Rahman WM. Calponin 3 promotes invasion and drug resistance of colon cancer cells. World J Gastrointest Oncol 2019;11:971&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6883188</ArticleId><ArticleId IdType="pubmed">31798778</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang ZL, Liang RY, Zhao SP, Wang RQ, Huang RH, Li K. CNN3 is regulated by microrna-1 during muscle development in pigs. Int J Biol Sci 2014;10:377&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979990</ArticleId><ArticleId IdType="pubmed">24719555</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai F, Luo F, Zhou R, et al. . Calponin 3 is associated with poor prognosis and regulates proliferation and metastasis in osteosarcoma. Aging 2020;12:14037&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7425500</ArticleId><ArticleId IdType="pubmed">32667904</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong KS, Kim H, Kim SH, Kim M, Yoo J. Calponin 3 regulates cell invasion and doxorubicin resistance in gastric cancer. Gastroenterol Res Pract 2019;2019:3024970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6398029</ArticleId><ArticleId IdType="pubmed">30911294</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakarai C, Osawa K, Akiyama M, et al. . Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer. Clin Exp Med 2015;15:333&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522272</ArticleId><ArticleId IdType="pubmed">24934327</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia L, Yue Y, Li M, et al. . CNN3 acts as a potential oncogene in cervical cancer by affecting RPLP1 mRNA expression. Sci Rep 2020;10:2427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7016181</ArticleId><ArticleId IdType="pubmed">32051425</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng JW, Song JH. Association between interleukin-2, interleukin-10, secretory immunoglobulin A and immunoglobulin G expression in vaginal fluid and human papilloma virus outcome in patients with cervical lesions. Oncol Lett 2019;18:5543&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6781750</ArticleId><ArticleId IdType="pubmed">31612062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SO, Li CW, Xia W, et al. . Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell 2016;30:925&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5171205</ArticleId><ArticleId IdType="pubmed">27866850</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Qin Z, Chen Z, Xie L, Wang R, Zhao H. Tumor microenvironment in treatment of glioma. Open Medicine 2017;12:247&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558106</ArticleId><ArticleId IdType="pubmed">28828406</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito S, Shiraishi M, Tsuchihashi K, et al. . Fluorescence detection of DNA mismatch repair in human cells. Sci Rep 2018;8:12181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093906</ArticleId><ArticleId IdType="pubmed">30111891</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis 2015;36:1085&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006153</ArticleId><ArticleId IdType="pubmed">26354776</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi Y, Guo N, Luan J, et al. . The emerging role of myeloid-derived suppressor cells in the glioma immune suppressive microenvironment. Front Immunol 2020;11:737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7193311</ArticleId><ArticleId IdType="pubmed">32391020</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Liu F, Liu Z, et al. . Immune checkpoint in glioblastoma: promising and challenging. Front Pharmacol 2017;8:242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5422441</ArticleId><ArticleId IdType="pubmed">28536525</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee L, Gupta M, Sahasranaman S. Immune checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy. J Clin Pharmacol 2016;56:157&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">26183909</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology 2017;6:e1249561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5283642</ArticleId><ArticleId IdType="pubmed">28197366</ArticleId></ArticleIdList></Reference><Reference><Citation>Khair DO, Bax HJ, Mele S, et al. . Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma. Front Immunol 2019;10:453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6435047</ArticleId><ArticleId IdType="pubmed">30941125</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34778035</PMID><DateRevised><Year>2021</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>Tumor-Infiltrating CD8+ T Cells Driven by the Immune Checkpoint-Associated Gene IDO1 Are Associated With Cervical Cancer Prognosis.</ArticleTitle><Pagination><StartPage>720447</StartPage><MedlinePgn>720447</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">720447</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2021.720447</ELocationID><Abstract><AbstractText>Tumor-infiltrating immune cells, associated with tumor progression, are promising prognostic biomarkers. However, the relationship between levels of gene expression and that of immune cell infiltration in cervical cancer prognosis is unknown. In this study, three cervical cancer gene expression microarrays (GSE6791, GSE63678 and GSE55940) were obtained from the GEO database. The IDO1 gene was identified by differentially expressed gene screening. The gene expression profiles of TCGA and GTEx databases along with comprehensive bioinformatics analysis identified that the IDO1 gene was upregulated in cervical cancer with significant difference in expression at different N stages. In addition, it was also upregulated in HPV16 positive sample. The pan-cancer analysis identified that IDO1 was highly expressed in most cancers. TIMER analysis revealed that the expression of IDO1 in CESC shows positive correlation with CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, neutrophils, dendritic cells. IDO1 expression showed remarkable positive correlation with all immune cell markers except M1 macrophages. CD8<sup>+</sup> T cell infiltration GSEA results showed that IDO1 was mainly associated with tumor immune-related signaling pathways.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Zhang, Wan, Chen, Cai, Xu and Chen.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Surgery Department, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Junhui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Obstetrics and Gynaecology Department, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Minjie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Queen Mary College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Desheng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Obstetrics and Gynaecology Department, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Junlan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Obstetrics and Gynaecology Department, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Obstetrics and Gynecology Department, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">differentially expressed genes</Keyword><Keyword MajorTopicYN="N">immune infiltration</Keyword><Keyword MajorTopicYN="N">tumor immunity</Keyword><Keyword MajorTopicYN="N">tumor-infiltrating CD8+ T cells</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>15</Day><Hour>7</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34778035</ArticleId><ArticleId IdType="pmc">PMC8578845</ArticleId><ArticleId IdType="doi">10.3389/fonc.2021.720447</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019. CA: Cancer J Clin (2019) 69(1):7&#x2013;34. doi: 10.3322/caac.21551</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21551</ArticleId><ArticleId IdType="pubmed">30620402</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical Cancer. Lancet (2019) 393(10167):169&#x2013;82. doi: 10.1016/S0140-6736(18)32470-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32470-X</ArticleId><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu MM, Li S, Yang H, Morrisey EE. Foxp4: A Novel Member of the Foxp Subfamily of Winged-Helix Genes Co-Expressed With Foxp1 and Foxp2 in Pulmonary and Gut Tissues. Mech Dev (2002) 119:S197&#x2013;202. doi: 10.1016/S0925-4773(03)00116-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0925-4773(03)00116-3</ArticleId><ArticleId IdType="pubmed">14516685</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the Cervix Uteri. Int J Gynecol. Obstetrics (2018) 143:22&#x2013;36. doi: 10.1002/ijgo.12611</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijgo.12611</ArticleId><ArticleId IdType="pubmed">30306584</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Yang Y, Meng M, Wang W, He S, Zhao Y, et al. . Identification of Prognosis-Related Genes in the Cervical Cancer Immune Microenvironment. Gene (2021) 766:145119. doi: 10.1016/j.gene.2020.145119</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2020.145119</ArticleId><ArticleId IdType="pubmed">32946928</ArticleId></ArticleIdList></Reference><Reference><Citation>Piersma SJ. Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients. Cancer Microenviron (2011) 4(3):361&#x2013;75. doi: 10.1007/s12307-011-0066-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12307-011-0066-7</ArticleId><ArticleId IdType="pmc">PMC3234326</ArticleId><ArticleId IdType="pubmed">21626415</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, L&#xfc; W, Zhang X, L&#xfc; B. Tumor-Infiltrating CD8+ and FOXP3+ Lymphocytes Before and After Neoadjuvant Chemotherapy in Cervical Cancer. Diagn Pathol (2018) 13(1):1&#x2013;8. doi: 10.1186/s13000-018-0770-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13000-018-0770-4</ArticleId><ArticleId IdType="pmc">PMC6260654</ArticleId><ArticleId IdType="pubmed">30474571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura T, Qian B-Z, Pollard JW. Immune Cell Promotion of Metastasis. Nat Rev Immunol (2015) 15(2):73&#x2013;86. doi: 10.1038/nri3789</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3789</ArticleId><ArticleId IdType="pmc">PMC4470277</ArticleId><ArticleId IdType="pubmed">25614318</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x15e;enbabao&#x11f;lu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, et al. . Tumor Immune Microenvironment Characterization in Clear Cell Renal Cell Carcinoma Identifies Prognostic and Immunotherapeutically Relevant Messenger RNA Signatures. Genome Biol (2016) 17(1):1&#x2013;25. doi: 10.1186/s13059-016-1092-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-016-1092-z</ArticleId><ArticleId IdType="pmc">PMC5114739</ArticleId><ArticleId IdType="pubmed">27855702</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheu BC, Chang WC, Lin HH, Chow SN, Huang SC. Immune Concept of Human Papillomaviruses and Related Antigens in Local Cancer Milieu of Human Cervical Neoplasia. J Obstetrics Gynaecol. Res (2007) 33(2):103&#x2013;13. doi: 10.1111/j.1447-0756.2007.00492.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1447-0756.2007.00492.x</ArticleId><ArticleId IdType="pubmed">17441881</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhood B, Najafi M, Mortezaee K. CD8+ Cytotoxic T Lymphocytes in Cancer Immunotherapy: A Review. J Cell Physiol (2019) 234(6):8509&#x2013;21. doi: 10.1002/jcp.27782</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27782</ArticleId><ArticleId IdType="pubmed">30520029</ArticleId></ArticleIdList></Reference><Reference><Citation>Duranti S, Pietragalla A, Daniele G, Nero C, Ciccarone F, Scambia G, et al. . Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data. Cancers (2021) 13(9):2089. doi: 10.3390/cancers13092089</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13092089</ArticleId><ArticleId IdType="pmc">PMC8123488</ArticleId><ArticleId IdType="pubmed">33925884</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities With Durable Clinical Benefit in Melanoma Patients. Clin Cancer Res (2013) 19(19):5300&#x2013;9. doi: 10.1158/1078-0432.CCR-13-0143</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0143</ArticleId><ArticleId IdType="pubmed">24089443</ArticleId></ArticleIdList></Reference><Reference><Citation>De Velasco G, Je Y, Boss&#xe9; D, Awad MM, Ott PA, Moreira RB, et al. . Comprehensive Meta-Analysis of Key Immune-Related Adverse Events From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res (2017) 5(4):312&#x2013;8. doi: 10.1158/2326-6066.CIR-16-0237</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0237</ArticleId><ArticleId IdType="pmc">PMC5418853</ArticleId><ArticleId IdType="pubmed">28246107</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt JM, V&#xe9;tizou M, Daill&#xe8;re R, Roberti MP, Yamazaki T, Routy B, et al. . Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and-Extrinsic Factors. Immunity (2016) 44(6):1255&#x2013;69. doi: 10.1016/j.immuni.2016.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.06.001</ArticleId><ArticleId IdType="pubmed">27332730</ArticleId></ArticleIdList></Reference><Reference><Citation>Munn DH, Mellor AL. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol (2016) 37(3):193&#x2013;207. doi: 10.1016/j.it.2016.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2016.01.002</ArticleId><ArticleId IdType="pmc">PMC4916957</ArticleId><ArticleId IdType="pubmed">26839260</ArticleId></ArticleIdList></Reference><Reference><Citation>Uyttenhove C, Pilotte L, Th&#xe9;ate I, Stroobant V, Colau D, Parmentier N, et al. . Evidence for a Tumoral Immune Resistance Mechanism Based on Tryptophan Degradation by Indoleamine 2, 3-Dioxygenase. Nat Med (2003) 9(10):1269&#x2013;74. doi: 10.1038/nm934</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm934</ArticleId><ArticleId IdType="pubmed">14502282</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra D, Horick NK, Brackett DG, Mouw KW, Hornick JL, Ferrone S, et al. . High IDO1 Expression Is Associated With Poor Outcome in Patients With Anal Cancer Treated With Definitive Chemoradiotherapy. Oncol. (2019) 24(6):e275. doi: 10.1634/theoncologist.2018-0794</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2018-0794</ArticleId><ArticleId IdType="pmc">PMC6656510</ArticleId><ArticleId IdType="pubmed">30755500</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyozumi Y, Baba Y, Okadome K, Yagi T, Ishimoto T, Iwatsuki M, et al. . IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer. Ann Surg (2019) 269(6):1101&#x2013;8. doi: 10.1097/SLA.0000000000002754</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000002754</ArticleId><ArticleId IdType="pubmed">31082908</ArticleId></ArticleIdList></Reference><Reference><Citation>Heeren AM, van Dijk I, Berry DR, Khelil M, Ferns D, Kole J, et al. . Indoleamine 2, 3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer. Front Immunol (2018) 9:1598. doi: 10.3389/fimmu.2018.01598</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01598</ArticleId><ArticleId IdType="pmc">PMC6050387</ArticleId><ArticleId IdType="pubmed">30050535</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai L, Spranger S, Binder DC, Gritsina G, Lauing KL, Giles FJ, et al. . Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res (2015) 21(24):5427&#x2013;33. doi: 10.1158/1078-0432.CCR-15-0420</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0420</ArticleId><ArticleId IdType="pmc">PMC4681601</ArticleId><ArticleId IdType="pubmed">26519060</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Zhang R, Li S, Liu J. IDO1: An Important Immunotherapy Target in Cancer Treatment. Int Immunopharmacol (2017) 47:70&#x2013;7. doi: 10.1016/j.intimp.2017.03.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2017.03.024</ArticleId><ArticleId IdType="pubmed">28365507</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyeon D, Newton MA, Lambert PF, Den Boon JA, Sengupta S, Marsit CJ, et al. . Fundamental Differences in Cell Cycle Deregulation in Human Papillomavirus&#x2013;Positive and Human Papillomavirus&#x2013;Negative Head/Neck and Cervical Cancers. Cancer Res (2007) 67(10):4605&#x2013;19. doi: 10.1158/0008-5472.CAN-06-3619</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-06-3619</ArticleId><ArticleId IdType="pmc">PMC2858285</ArticleId><ArticleId IdType="pubmed">17510386</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun N-X, Ye C, Zhao Q, Zhang Q, Xu C, Wang S-B, et al. . Long Noncoding RNA-EBIC Promotes Tumor Cell Invasion by Binding to EZH2 and Repressing E-Cadherin in Cervical Cancer. PloS One (2014) 9(7):e100340. doi: 10.1371/journal.pone.0100340</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100340</ArticleId><ArticleId IdType="pmc">PMC4090119</ArticleId><ArticleId IdType="pubmed">25007342</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappa KI, Polyzos A, Jacob-Hirsch J, Amariglio N, Vlachos GD, Loutradis D, et al. . Profiling of Discrete Gynecological Cancers Reveals Novel Transcriptional Modules and Common Features Shared by Other Cancer Types and Embryonic Stem Cells. PloS One (2015) 10(11):e0142229. doi: 10.1371/journal.pone.0142229</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0142229</ArticleId><ArticleId IdType="pmc">PMC4641642</ArticleId><ArticleId IdType="pubmed">26559525</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. . Robust Enumeration of Cell Subsets From Tissue Expression Profiles. Nat Methods (2015) 12(5):453&#x2013;7. doi: 10.1038/nmeth.3337</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3337</ArticleId><ArticleId IdType="pmc">PMC4739640</ArticleId><ArticleId IdType="pubmed">25822800</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu XS, Mardis ER. Applications of Immunogenomics to Cancer. Cell (2017) 168(4):600&#x2013;12. doi: 10.1016/j.cell.2017.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.01.014</ArticleId><ArticleId IdType="pmc">PMC5972371</ArticleId><ArticleId IdType="pubmed">28187283</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver H, et al. . Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study. J Clin Oncol (2013) 31(33):4252. doi: 10.1200/JCO.2013.51.3002</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2013.51.3002</ArticleId><ArticleId IdType="pmc">PMC3821014</ArticleId><ArticleId IdType="pubmed">24127443</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YR, Kim HJ, Jang MH, Park SY. Prognostic Value of Tumor Infiltrating Lymphocyte Subsets in Breast Cancer Depends on Hormone Receptor Status. Breast Cancer Res Treat (2017) 161(3):409&#x2013;20. doi: 10.1007/s10549-016-4072-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-016-4072-9</ArticleId><ArticleId IdType="pubmed">27913931</ArticleId></ArticleIdList></Reference><Reference><Citation>Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, et al. . Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma. J Clin Oncol (2012) 30(21):2678&#x2013;83. doi: 10.1200/JCO.2011.37.8539</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.37.8539</ArticleId><ArticleId IdType="pubmed">22711850</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Y, Ekmekcioglu S, Forget M-A, Szekvolgyi L, Hwu P, Grimm EA, et al. . Cervical Cancer Neoantigen Landscape and Immune Activity Is Associated With Human Papillomavirus Master Regulators. Front Immunol (2017) 8:689. doi: 10.3389/fimmu.2017.00689</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00689</ArticleId><ArticleId IdType="pmc">PMC5473350</ArticleId><ArticleId IdType="pubmed">28670312</ArticleId></ArticleIdList></Reference><Reference><Citation>Sailer V, Sailer U, Bawden EG, Zarbl R, Wiek C, Vogt TJ, et al. . DNA Methylation of Indoleamine 2, 3-Dioxygenase 1 (IDO1) in Head and Neck Squamous Cell Carcinomas Correlates With IDO1 Expression, HPV Status, Patients&#x2019; Survival, Immune Cell Infiltrates, Mutational Load, and Interferon &#x3b3; Signature. EBioMedicine (2019) 48:341&#x2013;52. doi: 10.1016/j.ebiom.2019.09.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.09.038</ArticleId><ArticleId IdType="pmc">PMC6838413</ArticleId><ArticleId IdType="pubmed">31628024</ArticleId></ArticleIdList></Reference><Reference><Citation>Maliniemi P, Laukkanen K, V&#xe4;kev&#xe4; L, Dettmer K, Lipsanen T, Jeskanen L, et al. . Biological and Clinical Significance of Tryptophan-Catabolizing Enzymes in Cutaneous T-Cell Lymphomas. Oncoimmunology (2017) 6(3):e1273310. doi: 10.1080/2162402X.2016.1273310</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2016.1273310</ArticleId><ArticleId IdType="pmc">PMC5384345</ArticleId><ArticleId IdType="pubmed">28405495</ArticleId></ArticleIdList></Reference><Reference><Citation>Yentz S, Smith D. Indoleamine 2, 3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy. BioDrugs (2018) 32(4):311&#x2013;7. doi: 10.1007/s40259-018-0291-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-018-0291-4</ArticleId><ArticleId IdType="pubmed">29980987</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhunjhunwala S, Hammer C, Delamarre L. Antigen Presentation in Cancer: Insights Into Tumour Immunogenicity and Immune Evasion. Nat Rev Cancer (2021) 21(5):298&#x2013;312. doi: 10.1038/s41568-021-00339-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-021-00339-z</ArticleId><ArticleId IdType="pubmed">33750922</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoach CE, Bivona TG. The Evolving Understanding of Immunoediting and the Clinical Impact of Immune Escape. J Thorac Dis (2018) 10(3):1248. doi: 10.21037/jtd.2018.03.60</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2018.03.60</ArticleId><ArticleId IdType="pmc">PMC5906217</ArticleId><ArticleId IdType="pubmed">29708132</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijland M, Veenstra RN, Visser L, Xu C, Kushekhar K, van Imhoff GW, et al. . HLA Dependent Immune Escape Mechanisms in B-Cell Lymphomas: Implications for Immune Checkpoint Inhibitor Therapy? Oncoimmunology (2017) 6(4):e1295202. doi: 10.1080/2162402X.2017.1295202</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2017.1295202</ArticleId><ArticleId IdType="pmc">PMC5414870</ArticleId><ArticleId IdType="pubmed">28507804</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou R, Gu R, Yu X, Hu Y, Yu J, Xue X, et al. . Characteristics of Infiltrating Immune Cells and a Predictive Immune Model for Cervical Cancer. J Cancer (2021) 12(12):3501. doi: 10.7150/jca.55970</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.55970</ArticleId><ArticleId IdType="pmc">PMC8120169</ArticleId><ArticleId IdType="pubmed">33995627</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldman AD, Fritz JM, Lenardo MJ. A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice. Nat Rev Immunol (2020) 20(11):651&#x2013;68. doi: 10.1038/s41577-020-0306-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0306-5</ArticleId><ArticleId IdType="pmc">PMC7238960</ArticleId><ArticleId IdType="pubmed">32433532</ArticleId></ArticleIdList></Reference><Reference><Citation>Schatton T, Scolyer RA, Thompson JF, Mihm MC. Tumor-Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis. Mol Diagnostics Melanoma (2014) 1102:287&#x2013;324. doi: 10.1007/978-1-62703-727-3_16</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-62703-727-3_16</ArticleId><ArticleId IdType="pubmed">24258985</ArticleId></ArticleIdList></Reference><Reference><Citation>Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U, et al. . Tumor-Specific Cytotoxic T Lymphocyte Activity Determines Colorectal Cancer Patient Prognosis. J Clin Invest (2015) 125(2):739&#x2013;51. doi: 10.1172/JCI74894</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI74894</ArticleId><ArticleId IdType="pmc">PMC4319435</ArticleId><ArticleId IdType="pubmed">25562322</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo A, Lee H, Kim E, Kim H, Jang M, Lee H, et al. . Tumour-Infiltrating CD8+ Lymphocytes as an Independent Predictive Factor for Pathological Complete Response to Primary Systemic Therapy in Breast Cancer. Br J Cancer (2013) 109(10):2705&#x2013;13. doi: 10.1038/bjc.2013.634</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2013.634</ArticleId><ArticleId IdType="pmc">PMC3833219</ArticleId><ArticleId IdType="pubmed">24129232</ArticleId></ArticleIdList></Reference><Reference><Citation>Thackray SJ, Mowat CG, Chapman SK. Exploring the Mechanism of Tryptophan 2, 3-Dioxygenase. Biochem Soc Trans (2008) 36(6):1120&#x2013;3. doi: 10.1042/BST0361120</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0361120</ArticleId><ArticleId IdType="pmc">PMC2652831</ArticleId><ArticleId IdType="pubmed">19021508</ArticleId></ArticleIdList></Reference><Reference><Citation>Jallad M-AN, Jurjus AR, Rahal EA, Abdelnoor AM. Triple Immunotherapy Overcomes Immune Evasion by Tumor in a Melanoma Mouse Model. Front Oncol (2020) 10:839. doi: 10.3389/fonc.2020.00839</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.00839</ArticleId><ArticleId IdType="pmc">PMC7304320</ArticleId><ArticleId IdType="pubmed">32596146</ArticleId></ArticleIdList></Reference><Reference><Citation>Favre D, Mold J, Hunt PW, Kanwar B, Seu L, Barbour JD, et al. . Tryptophan Catabolism by Indoleamine 2, 3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease. Sci Trans Med (2010) 2(32):32ra6&#x2013;ra6. doi: 10.1126/scitranslmed.3000632</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3000632</ArticleId><ArticleId IdType="pmc">PMC3034445</ArticleId><ArticleId IdType="pubmed">20484731</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardee K, Green AA, Takahashi MK, Braff D, Lambert G, Lee JW, et al. . Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular Components. Cell (2016) 165(5):1255&#x2013;66. doi: 10.1016/j.cell.2016.04.059</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.04.059</ArticleId><ArticleId IdType="pubmed">27160350</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty GL, O&#x2019;Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, et al. . First-In-Human Phase I Study of the Oral Inhibitor of Indoleamine 2, 3-Dioxygenase-1 Epacadostat (INCB024360) in Patients With Advanced Solid Malignancies. Clin Cancer Res (2017) 23(13):3269&#x2013;76. doi: 10.1158/1078-0432.CCR-16-2272</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-16-2272</ArticleId><ArticleId IdType="pmc">PMC5496788</ArticleId><ArticleId IdType="pubmed">28053021</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, et al. . Phase I Study of the Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered With PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clin Cancer Res (2019) 25(11):3220&#x2013;8. doi: 10.1158/1078-0432.CCR-18-2740</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-18-2740</ArticleId><ArticleId IdType="pmc">PMC7980952</ArticleId><ArticleId IdType="pubmed">30770348</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, et al. . Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). J Clin Oncol (2018) 36(32):3223. doi: 10.1200/JCO.2018.78.9602</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2018.78.9602</ArticleId><ArticleId IdType="pmc">PMC6225502</ArticleId><ArticleId IdType="pubmed">30265610</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, et al. . Phase Ia Study of the Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) in Patients With Recurrent Advanced Solid Tumors. J Immunother. Cancer (2018) 6(1):1&#x2013;12. doi: 10.1186/s40425-018-0351-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-018-0351-9</ArticleId><ArticleId IdType="pmc">PMC6009946</ArticleId><ArticleId IdType="pubmed">29921320</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34759952</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-8021</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in genetics</Title><ISOAbbreviation>Front Genet</ISOAbbreviation></Journal><ArticleTitle>The Clinical Significance and Immunization of MSMO1 in Cervical Squamous Cell Carcinoma Based on Bioinformatics Analysis.</ArticleTitle><Pagination><StartPage>705851</StartPage><MedlinePgn>705851</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">705851</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fgene.2021.705851</ELocationID><Abstract><AbstractText><b>Objective:</b> The genetic markers for the detection or treatment of cervical squamous cell carcinoma (CESC) are not yet complete. This study aimed to identify the role of MSMO1 (Alternative name: SC4MOL) in the occurrence and development of CESC. <b>Methods:</b> We evaluated the significance of MSMO1 expression in CESC by using analysis of a public dataset from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database. Oncomine and GEPIA2 were used to validate MSMO1 as an independent prognostic factor in CESC. Multiple tools were used to analyze the factors and functions associated with MSMO1, such as methylation, miRNA, and co-expressed genes. Furthermore, TIMER and TISIDB were used to study the relationship between MSMO1 expression and immunization in CESC. <b>Results:</b> MSMO1 was highly expressed in tumor specimens and could be used as an independent prognostic factor of CESC (<i>p</i> &lt; 0.05). But Casiopeinas chemotherapeutics and p63 loss could reduce the expression of MSMO1. The level of methylation MSMO1 was significantly increased in tumor tissues but there was an insignificant effect on the prognosis. MSMO1 was also closely related to hsa-miR-23a-3p, hsa-miR-23b-3p, hsa-miR-130b-3p, and gene IDI1. Specifically, the expression level of MSMO1 had a significant negative correlation with the infiltration level of CD4<sup>+</sup>T cells, Macrophages, Neutrophils, and DCs in CESC. In addition, GSEA identified differential enrichment in systemic lupus erythematosus, vascular smooth muscle contraction, cytokine receptor interaction, focal adhesion, chemokine signaling pathway, and Leishmania infection pathway in KEGG. <b>Conclusion:</b> Our findings provide evidence of the implications of MSMO1 in tumors, suggesting that MSMO1 is a promising prognostic biomarker in CESC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Zheng, Wang, Fan, Wang, Zhang, Wang, Chen and Jiang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Guangfei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Experimental and Translational Non-Coding RNA Research, Yangzhou University, Yangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>College of Light Industry and Food Engineering, Guangxi University, Nanning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Yuchun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical College, Guangxi University, Nanning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Linli</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Mengling</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Su</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hubei Key Laboratory of Medical Information Analysis and Tumor Diagnosis and Treatment, South-Central University for Nationalities, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lihe</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Light Industry and Food Engineering, Guangxi University, Nanning, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical College, Guangxi University, Nanning, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Experimental and Translational Non-Coding RNA Research, Yangzhou University, Yangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Genet</MedlineTA><NlmUniqueID>101560621</NlmUniqueID><ISSNLinking>1664-8021</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MSMO1</Keyword><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">cervical squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">immunization</Keyword><Keyword MajorTopicYN="N">prognostic analysis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34759952</ArticleId><ArticleId IdType="pmc">PMC8573162</ArticleId><ArticleId IdType="doi">10.3389/fgene.2021.705851</ArticleId><ArticleId IdType="pii">705851</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Afsane B., Malihe H., Soodabeh S., Marjaneh F., Mahdi H. S., Mehrdad M. A., et al. (2018). Genetic Susceptibility in Cervical Cancer: From Bench to Bedside. %J J. Cell. Physiol. 233 (3).</Citation><ArticleIdList><ArticleId IdType="pubmed">28542881</ArticleId></ArticleIdList></Reference><Reference><Citation>Anja H., Daniela S., Sandra B., Jasmin S., Vladimir K., Holger S., et al. (2015). Dependence of Intracellular and Exosomal microRNAs on Viral E6/E7 Oncogene Expression in HPV-Positive Tumor Cells. %J PLoS Pathog. 11 (3), e100471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356518</ArticleId><ArticleId IdType="pubmed">25760330</ArticleId></ArticleIdList></Reference><Reference><Citation>Au Yeung C. L., Tsang T. Y., Yau P. L., Kwok T. T. (2011). Human Papillomavirus Type 16 E6 Induces Cervical Cancer Cell Migration through the p53/microRNA-23b/urokinase-type Plasminogen Activator Pathway. Oncogene 30 (21), 2401&#x2013;2410. 10.1038/onc.2010.613</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2010.613</ArticleId><ArticleId IdType="pubmed">21242962</ArticleId></ArticleIdList></Reference><Reference><Citation>Beibei R., Ngar W. C., Yin T., Yi Z. J., Wa Z. S. S., Chung W. W., et al. (2019). TISIDB: an Integrated Repository portal for Tumor-Immune System Interactions. %J Bioinformatics 35.</Citation><ArticleIdList><ArticleId IdType="pubmed">30903160</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar D. S., Bashel B., Balasubramanya S. A. H., Creighton C. J., Ponce-Rodriguez I., Chakravarthi B. V. S. K., et al. (2017). UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia 19 (8), 649&#x2013;658. 10.1016/j.neo.2017.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2017.05.002</ArticleId><ArticleId IdType="pmc">PMC5516091</ArticleId><ArticleId IdType="pubmed">28732212</ArticleId></ArticleIdList></Reference><Reference><Citation>David L. M. V. D. M., Tatjana D., Sami V., Merja H. (2010). Profiling of Promoter Occupancy by PPARalpha in Human Hepatoma Cells via ChIP-Chip Analysis. %J Nucleic Acids Res. 38 (9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875002</ArticleId><ArticleId IdType="pubmed">20110263</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitra K., Serafeim C., Spyros T., Ilias K. (2018). DIANA-TarBase V8: a Decade-Long Collection of Experimentally Supported miRNA-Gene Interactions. %J Nucleic Acids Res. 46 (D1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753203</ArticleId><ArticleId IdType="pubmed">29156006</ArticleId></ArticleIdList></Reference><Reference><Citation>Dweep H., Sticht C., Pandey P., Gretz N. (2011). miRWalk--database: Prediction of Possible miRNA Binding Sites by "walking" the Genes of Three Genomes. J. Biomed. Inform. 44 (5), 839&#x2013;847. 10.1016/j.jbi.2011.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2011.05.002</ArticleId><ArticleId IdType="pubmed">21605702</ArticleId></ArticleIdList></Reference><Reference><Citation>Ethan C., Jianjiong G., Ugur D., Onur S. S., Arman A. B. (2012). The cBio Cancer Genomics portal: an Open Platform for Exploring Multidimensional Cancer Genomics Data. %J Cancer Discov. 2 (5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3956037</ArticleId><ArticleId IdType="pubmed">22588877</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhad A., Pavlina R., Marc M., Rajmohan M. (2012). Tumor-infiltrating Lymphocyte Grade Is an Independent Predictor of sentinel Lymph Node Status and Survival in Patients with Cutaneous Melanoma. %J J. Clin. Oncol. : official J. Am. Soc. Clin. Oncol. 30 (21).</Citation><ArticleIdList><ArticleId IdType="pubmed">22711850</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman R. C., Farh K. K., Burge C. B., Bartel D. P. (2009). Most Mammalian mRNAs Are Conserved Targets of microRNAs. Genome Res. 19 (1), 92&#x2013;105. 10.1101/gr.082701.108</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.082701.108</ArticleId><ArticleId IdType="pmc">PMC2612969</ArticleId><ArticleId IdType="pubmed">18955434</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia D. M., Baek D., Shin C., Bell G. W., Grimson A., Bartel D. P. (2011). Weak Seed-Pairing Stability and High Target-Site Abundance Decrease the Proficiency of Lsy-6 and Other microRNAs. Nat. Struct. Mol. Biol. 18 (10), 1139&#x2013;1146. 10.1038/nsmb.2115</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2115</ArticleId><ArticleId IdType="pmc">PMC3190056</ArticleId><ArticleId IdType="pubmed">21909094</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Set Enrichment Analysis (2005). A Knowledge-Based Approach for Interpreting Genome-wide Expression Profiles %. J. Proc. Natl. Acad. Sci. United States America 102 (43).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman M. J., Craft B., Hastie M., Repe&#x10d;ka K., McDade F., Kamath A., et al. (2020). Visualizing and Interpreting Cancer Genomics Data via the Xena Platform. Nat. Biotechnol. 38 (227&#x2013;238), 675&#x2013;678. 10.1038/s41587-020-0546-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0546-8</ArticleId><ArticleId IdType="pmc">PMC7386072</ArticleId><ArticleId IdType="pubmed">32444850</ArticleId></ArticleIdList></Reference><Reference><Citation>Granados-L&#xf3;pez A. J., Ruiz-Carrillo J. L., Serv&#xed;n-Gonz&#xe1;lez L. S., Mart&#xed;nez-Rodr&#xed;guez J. L., Reyes-Estrada C. A., Guti&#xe9;rrez-Hern&#xe1;ndez R., et al. (2017). Use of Mature miRNA Strand Selection in miRNAs Families in Cervical Cancer Development. Int. J. Mol. Sci. 18 (2), 407. 10.3390/ijms18020407</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18020407</ArticleId><ArticleId IdType="pmc">PMC5343941</ArticleId><ArticleId IdType="pubmed">28216603</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimson A., Farh K. K., Johnston W. K., Garrett-Engele P., Lim L. P., Bartel D. P. (2007). MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing. Mol. Cel 27 (1), 91&#x2013;105. 10.1016/j.molcel.2007.06.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2007.06.017</ArticleId><ArticleId IdType="pmc">PMC3800283</ArticleId><ArticleId IdType="pubmed">17612493</ArticleId></ArticleIdList></Reference><Reference><Citation>He M., ChangSmith R., Li X., Vockley J. (2014). The Role of Sterol-C4-Methyl Oxidase in Epidermal Biology. Biochim. Biophys. Acta 1841 (3), 331&#x2013;335. 10.1016/j.bbalip.2013.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2013.10.009</ArticleId><ArticleId IdType="pmc">PMC3943829</ArticleId><ArticleId IdType="pubmed">24144731</ArticleId></ArticleIdList></Reference><Reference><Citation>He M., Lisa E. K., Joshua J., Ferris Kratz L., Richard I. K., Ri, JukicKelley D., et al. (2011). Mutations in the Human SC4MOL Gene Encoding a Methyl Sterol Oxidase Cause Psoriasiform Dermatitis, Microcephaly, and Developmental Delay. J. Clin. Invest. 121 (3), 976&#x2013;984. 10.1172/JCI42650</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI42650</ArticleId><ArticleId IdType="pmc">PMC3049385</ArticleId><ArticleId IdType="pubmed">21285510</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;l&#xe8;ne A., Eileen G., Elena L., B H. M. A., Thomas V. E., Matthew O. D., et al. (2015). Sparse Feature Selection Methods Identify Unexpected Global Cellular Response to Strontium-Containing Materials. %J Proc. Natl. Acad. Sci. United States America 112 (14).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394289</ArticleId><ArticleId IdType="pubmed">25831522</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Z., Yao L., MengJie H., YanYan Y., HuaYi X., XiaoXie L., et al. (2021). Ketogenic Diet-Mediated Steroid Metabolism Reprogramming Improves the Immune Microenvironment and Myelin Growth in Spinal Cord Injury Rats According to Gene and Co-expression Network Analyses. %J Aging 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8148504</ArticleId><ArticleId IdType="pubmed">33962394</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiadeng C., Lei J., Xudong Z., Dong D., Siyuan W., Le M., et al. (2020). Insight into the Effects of microRNA-23a-3p on Pancreatic Cancer and its Underlying Molecular Mechanism. %J Oncol. Lett. 19 (1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924110</ArticleId><ArticleId IdType="pubmed">31897129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaoru T., Naoki K., Kenji W., Hitoshi I. (2017). Identification of Circulating miRNAs Differentially Regulated by Opioid Treatment. %J Int. J. Mol. Sci. 18 (9), 1991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5618640</ArticleId><ArticleId IdType="pubmed">28926935</ArticleId></ArticleIdList></Reference><Reference><Citation>Katherine B., Roland V. B. B., Ashwini S., Nancy B., Deanna K., Mona S. (2013). Cervical Cancer Screening Among Young Adult Women in the United States. %J Cancer Epidemiology, Biomarkers &amp; Prevention : a Publication of the American Association for Cancer Research, cosponsored by the. Am. Soc. Prev. Oncol. 22 (4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4480768</ArticleId><ArticleId IdType="pubmed">23355601</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis B. P., Burge C. B., Bartel D. P. (2005). Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes Are microRNA Targets. %J Cell. 120 (1).</Citation><ArticleIdList><ArticleId IdType="pubmed">15652477</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J. H., Liu S., Zhou H., Qu L. H., Yang J. H. (2014). starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and Protein-RNA Interaction Networks from Large-Scale CLIP-Seq Data. Nucleic Acids Res. 42, D92&#x2013;D97. 10.1093/nar/gkt1248</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1248</ArticleId><ArticleId IdType="pmc">PMC3964941</ArticleId><ArticleId IdType="pubmed">24297251</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Wang X. (2019). Prediction of Functional microRNA Targets by Integrative Modeling of microRNA Binding and Target Expression Data. Genome Biol. 20 (1), 18. 10.1186/s13059-019-1629-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1629-z</ArticleId><ArticleId IdType="pmc">PMC6341724</ArticleId><ArticleId IdType="pubmed">30670076</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez A. G., L&#xf3;pez J. (2014). Multistep Model of Cervical Cancer: Participation of miRNAs and Coding Genes %. J. IJMS 15 (9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4200848</ArticleId><ArticleId IdType="pubmed">25192291</ArticleId></ArticleIdList></Reference><Reference><Citation>Md W. S. J., Facro F. A. C. R., Fastro R. N. M. A. B., Ba A. B., Md L. T. C., Do B. J. F., et al. (2017). Cervical Cancer: A Global Health Crisis %. J. Cancer 123 (13).</Citation><ArticleIdList><ArticleId IdType="pubmed">28464289</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza-Villanueva D., Diaz-Chavez J., Uribe-Figueroa L., Rangel-Escare&#xe3;o C., Hidalgo-Miranda A., March-Mifsut S., et al. (2008). Gene Expression Profile of Cervical and Skin Tissues from Human Papillomavirus Type 16 E6 Transgenic Mice. BMC Cancer 8 (1), 347. 10.1186/1471-2407-8-347</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-8-347</ArticleId><ArticleId IdType="pmc">PMC2610035</ArticleId><ArticleId IdType="pubmed">19036130</ArticleId></ArticleIdList></Reference><Reference><Citation>Modhukur V., Iljasenko T., Metsalu T., Lokk K., Laisk-Podar T., Vilo J. (2018). MethSurv: a Web Tool to Perform Multivariable Survival Analysis Using DNA Methylation Data. Epigenomics 10 (3), 277&#x2013;288. 10.2217/epi-2017-0118</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/epi-2017-0118</ArticleId><ArticleId IdType="pubmed">29264942</ArticleId></ArticleIdList></Reference><Reference><Citation>Ping X., Meiying W., Hui C., Junchi X., Minjuan W., Ming L., et al. (2016). Bioinformatics Analysis of Hepatitis C Virus Genotype 2a-Induced Human Hepatocellular Carcinoma in Huh7 Cells. %J OncoTargets Ther. 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4712971</ArticleId><ArticleId IdType="pubmed">26811688</ArticleId></ArticleIdList></Reference><Reference><Citation>Serv&#xed;n-Gonz&#xe1;lez L. S., Granados-L&#xf3;pez A. J., L&#xf3;pez J. A. (2015). Families of microRNAs Expressed in Clusters Regulate Cell Signaling in Cervical Cancer. Int. J. Mol. Sci. 16 (6), 12773&#x2013;12790. 10.3390/ijms160612773</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms160612773</ArticleId><ArticleId IdType="pmc">PMC4490472</ArticleId><ArticleId IdType="pubmed">26057746</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen S., Zhang S., Liu P., Wang J., Du H. (2020). Potential Role of microRNAs in the Treatment and Diagnosis of Cervical Cancer. Cancer Genet. 248-249, 25&#x2013;30. 10.1016/j.cancergen.2020.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cancergen.2020.09.003</ArticleId><ArticleId IdType="pubmed">32987255</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Gable A. L., Lyon D., Junge A., Wyder S., Huerta-Cepas J., et al. (2019). STRING V11: Protein-Protein Association Networks with Increased Coverage, Supporting Functional Discovery in Genome-wide Experimental Datasets. Nucleic Acids Res. 47 (D1), D607. 10.1093/nar/gky1131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Taiwen L., Jingyu F., Binbin W., Nicole T., Qianming C. (2017). TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. %J Cancer Res. 77 (21).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6042652</ArticleId><ArticleId IdType="pubmed">29092952</ArticleId></ArticleIdList></Reference><Reference><Citation>Vikram A., George W. B., Jin-Wu N., David P. B. (2015). Predicting Effective microRNA Target Sites in Mammalian mRNAs. %J eLife. 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4532895</ArticleId><ArticleId IdType="pubmed">26267216</ArticleId></ArticleIdList></Reference><Reference><Citation>Wui-Jin K. R. A-R. N., Sarah B., Kristin B., M C. S., R C. K., Sook C. H., et al. (2019). Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. %J J. Natl. Compr. Cancer Netw. : JNCCN. 17 (1).</Citation><ArticleIdList><ArticleId IdType="pubmed">30659131</ArticleId></ArticleIdList></Reference><Reference><Citation>Youzhi X., Chengping L., Yan G., Rong X., Haiyan Z., Guoli Z. (2019). RNA-seq Analysis Reveals a Negative Role of MSMO1 with a Synergized NSDHL Expression during Adipogenesis of 3T3-L1 %. J. Bioscience, Biotechnology, Biochem. 83 (4).</Citation><ArticleIdList><ArticleId IdType="pubmed">30582412</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu D., Cook M. C., Shin D. M., Silva D. G., Marshall J., Toellner K. M., et al. (2008). Axon Growth and Guidance Genes Identify T-dependent Germinal centre B Cells. Immunol. Cel Biol 86 (1), 3&#x2013;14. 10.1038/sj.icb.7100123</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.icb.7100123</ArticleId><ArticleId IdType="pubmed">17938642</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuhao C., Xiaowei W. (2020). miRDB: an Online Database for Prediction of Functional microRNA Targets. %J Nucleic Acids Res. 48 (D1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6943051</ArticleId><ArticleId IdType="pubmed">31504780</ArticleId></ArticleIdList></Reference><Reference><Citation>Zefang T., Boxi K., Chenwei L., Tianxiang C., Zemin Z. (2019). GEPIA2: an Enhanced Web Server for Large-Scale Expression Profiling and Interactive Analysis. %J Nucleic Acids Res. 47 (W1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602440</ArticleId><ArticleId IdType="pubmed">31114875</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z. M., Wang X. (2011). Regulation of Cellular miRNA Expression by Human Papillomaviruses. Biochim. Biophys. Acta 1809 (11), 668&#x2013;677. 10.1016/j.bbagrm.2011.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagrm.2011.05.005</ArticleId><ArticleId IdType="pmc">PMC3175324</ArticleId><ArticleId IdType="pubmed">21616186</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34690502</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1178-7074</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>International journal of general medicine</Title><ISOAbbreviation>Int J Gen Med</ISOAbbreviation></Journal><ArticleTitle>Biological Function and Clinical Value of VPS13A in Pan-Cancer Based on Bioinformatics Analysis.</ArticleTitle><Pagination><StartPage>6825</StartPage><EndPage>6838</EndPage><MedlinePgn>6825-6838</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/IJGM.S330256</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Vacuolar protein sorting-associated protein 13A (VPS13A) has been shown to be associated with rhabdomyosarcoma, gastric cancer and ovarian cancer, but the pan cancer analysis of VPS13A is still lacking, and the bioinformatics function of VPS13A has not been studied yet.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used TCGA and GEO databases to investigate the distribution, expression and prognosis of VPS13A in 33 tumors for the first time. We used TIMER2, ULCAN databases to obtain the expression differences of VPS13A in tumor tissues and corresponding normal tissues, and further obtain the gene expression in different pathological stages of tumors from the GEPIA database. Mutation types and survival analysis of VPS13A were obtained from cBioPortal database. The relationship between VPS13A and immune infiltration was explored using TIMER2. We used the String website to obtain VPS13A binding proteins and draw the protein-protein interaction network map. JVENN was used for cross analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) were used for gene enrichment analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">VPS13A is highly expressed in most tumors, and gene expression is associated with prognosis in patients with tumors. The expression level of VPS13A was correlated with the infiltration depth of CD8+T cells in DLBC, LUAD, SKCM and TGCT, and was correlated with carcinoma-associated fibroblasts in BRCA, CESC, LIHC and THYM. Compared with normal tissue, VPS13A methylation levels were higher in some primary tumors. KEGG gene enrichment indicates that VPS13A is involved in RNA degradation, autophagy, cell senescence, cell cycle, apoptosis and other pathways.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">VPS13A is closely related to the occurrence and progression of tumors and can be used as a biomarker for tumor screening and diagnosis. The level of VPS13A expression and the presence of mutations affect the prognosis of patients with certain cancers, which can be determined by early genetic testing.</AbstractText><CopyrightInformation>&#xa9; 2021 Zhang and Li.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Xue Qin</ForeName><Initials>XQ</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning, Guangxi, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Li</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5587-5504</Identifier><AffiliationInfo><Affiliation>Department of Gynecology and Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning, Guangxi, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Int J Gen Med</MedlineTA><NlmUniqueID>101515487</NlmUniqueID><ISSNLinking>1178-7074</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">VPS13A</Keyword><Keyword MajorTopicYN="N">biological function</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34690502</ArticleId><ArticleId IdType="pmc">PMC8530525</ArticleId><ArticleId IdType="doi">10.2147/IJGM.S330256</ArticleId><ArticleId IdType="pii">330256</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-Analyzed Tumors. Cell. 2018;173(2):530. doi:10.1016/j.cell.2018.03.059</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.059</ArticleId><ArticleId IdType="pubmed">29625059</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Li H, Jiang S, et al. A survey and evaluation of Web-based tools/databases for variant analysis of TCGA data. Brief Bioinform. 2019;20(4):1524&#x2013;1541. doi:10.1093/bib/bby023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bby023</ArticleId><ArticleId IdType="pmc">PMC6781580</ArticleId><ArticleId IdType="pubmed">29617727</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeshaw WM, van der Zwaag M, Pinto F, et al. Human VPS13A is associated with multiple organelles and influences mitochondrial morphology and lipid droplet motility. Elife. 2019;8:e43561. doi:10.7554/eLife.43561</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.43561</ArticleId><ArticleId IdType="pmc">PMC6389287</ArticleId><ArticleId IdType="pubmed">30741634</ArticleId></ArticleIdList></Reference><Reference><Citation>Urs AB, Augustine J, Khan AA. Chorea-acanthocytosis: a case report with review of oral manifestations. Contemp Clin Dent. 2021;12(1):73&#x2013;75. doi:10.4103/ccd.ccd_207_20</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ccd.ccd_207_20</ArticleId><ArticleId IdType="pmc">PMC8092098</ArticleId><ArticleId IdType="pubmed">33967542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YY. Steap1 Regulation of Tumor Genesis and Chemotherapy Resistance During Peritoneal Metastasis of Gastric Cancer. Jilin University; 2019.</Citation></Reference><Reference><Citation>Zhang Q. Study on the reverse mechanism of LIPG/ RS9958734 multidrug resistance in ovarian cancer based on CRISPR/Cas9. Guangxi Med Univ. 2019;1:5487.</Citation></Reference><Reference><Citation>Xu M, Li Y, Li W, et al. Immune and Stroma Related Genes in Breast Cancer: a Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database. Front Med. 2020;7:64. doi:10.3389/fmed.2020.00064</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00064</ArticleId><ArticleId IdType="pmc">PMC7066229</ArticleId><ArticleId IdType="pubmed">32195260</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556&#x2013;W560. doi:10.1093/nar/gkz430</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz430</ArticleId><ArticleId IdType="pmc">PMC6602440</ArticleId><ArticleId IdType="pubmed">31114875</ArticleId></ArticleIdList></Reference><Reference><Citation>He C, Hua X, Sun S, Li S, Wang J, Huang X. Integrated Bioinformatic Analysis of SARS-CoV-2 Infection Related Genes ACE2, BSG and TMPRSS2 in Aerodigestive Cancers. J Inflamm Res. 2021;14:791&#x2013;802. doi:10.2147/JIR.S300127</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S300127</ArticleId><ArticleId IdType="pmc">PMC7956868</ArticleId><ArticleId IdType="pubmed">33732005</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649&#x2013;658. doi:10.1016/j.neo.2017.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2017.05.002</ArticleId><ArticleId IdType="pmc">PMC5516091</ArticleId><ArticleId IdType="pubmed">28732212</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SN, Friedrich B, Schnaubelt M, Chan DW, Zhang H, Aebersold R. Orthogonal proteomic platforms and their implications for the stable classification of high-grade serous ovarian cancer subtypes. iScience. 2020;23(6):101079. doi:10.1016/j.isci.2020.101079</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101079</ArticleId><ArticleId IdType="pmc">PMC7298555</ArticleId><ArticleId IdType="pubmed">32534439</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Li H, Hu S, Zhou Y. ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19. Aging. 2020;12(8):6518&#x2013;6535. doi:10.18632/aging.103100</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103100</ArticleId><ArticleId IdType="pmc">PMC7202533</ArticleId><ArticleId IdType="pubmed">32339157</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Li X, Liu R, Chen Y, Ren C, Du S. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma. Cancer Med. 2020;9(18):6694&#x2013;6709. doi:10.1002/cam4.3324</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3324</ArticleId><ArticleId IdType="pmc">PMC7520261</ArticleId><ArticleId IdType="pubmed">32700817</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P, Heins ZJ, Muller JT, et al. Integration and Analysis of CPTAC Proteomics Data in the Context of Cancer Genomics in the cBioPortal. Mol Cell Proteomics. 2019;18(9):1893&#x2013;1898. doi:10.1074/mcp</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp</ArticleId><ArticleId IdType="pmc">PMC6731080</ArticleId><ArticleId IdType="pubmed">31308250</ArticleId></ArticleIdList></Reference><Reference><Citation>Unberath P, Knell C, Prokosch HU, Christoph J. Developing new analysis functions for a translational research platform: extending the cbioportal for cancer genomics. Stud Health Technol Inform. 2019;258:46&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">30942711</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou Q, Yu Y, Li A, et al. Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma. Ann Transl Med. 2020;8(5):230. doi:10.21037/atm.2020.01.32</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2020.01.32</ArticleId><ArticleId IdType="pmc">PMC7154492</ArticleId><ArticleId IdType="pubmed">32309377</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509&#x2013;W514. doi:10.1093/nar/gkaa407</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa407</ArticleId><ArticleId IdType="pmc">PMC7319575</ArticleId><ArticleId IdType="pubmed">32442275</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu ZY, Zhao M, Chen W, et al. Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma. Peer J. 2020;8:e9530. doi:10.7717/peerj.9530</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.9530</ArticleId><ArticleId IdType="pmc">PMC7382940</ArticleId><ArticleId IdType="pubmed">32775050</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605&#x2013;D612. doi:10.1093/nar/gkaa1074</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa1074</ArticleId><ArticleId IdType="pmc">PMC7779004</ArticleId><ArticleId IdType="pubmed">33237311</ArticleId></ArticleIdList></Reference><Reference><Citation>Gui Y, Liu X, Wang C, Overexpressing YP. PTTG family genes predict poor prognosis in kidney renal clear cell carcinoma. World J Surg Oncol. 2021;19(1):111. doi:10.1186/s12957-021-02225-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12957-021-02225-2</ArticleId><ArticleId IdType="pmc">PMC8042860</ArticleId><ArticleId IdType="pubmed">33845847</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng R, Zhu HL, Hu BR, Ruan XJ, Cai HJ. Identification of APEX2 as an oncogene in liver cancer. World J Clin Cases. 2020;8(14):2917&#x2013;2929. doi:10.12998/wjcc.v8.i14.2917</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v8.i14.2917</ArticleId><ArticleId IdType="pmc">PMC7385600</ArticleId><ArticleId IdType="pubmed">32775374</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Li Y, Guo Y, Li J, Jin H. Potential roles of PBRM1 on immune infiltration in cholangiocarcinoma. Int J Clin Exp Pathol. 2020;13(10):2661&#x2013;2676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7642697</ArticleId><ArticleId IdType="pubmed">33165423</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho J, Gao S, Stein L, Sternberg PW. Vennter - An interactive analysis tool for WormBase interaction data using Venn diagrams. MicroPubl Biol. 2020;2020. doi:10.17912/micropub.biology.000258</Citation><ArticleIdList><ArticleId IdType="doi">10.17912/micropub.biology.000258</ArticleId><ArticleId IdType="pmc">PMC7251783</ArticleId><ArticleId IdType="pubmed">32550480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Sato Y. KEGG Mapper for inferring cellular functions from protein sequences. Protein Sci. 2020;29(1):28&#x2013;35. doi:10.1002/pro.3711</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3711</ArticleId><ArticleId IdType="pmc">PMC6933857</ArticleId><ArticleId IdType="pubmed">31423653</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Zhang C, Dai DQ. Identification of differentially expressed genes regulated by methylation in colon cancer based on bioinformatics analysis. World J Gastroenterol. 2019;25(26):3392&#x2013;3407. doi:10.3748/wjg.v25.i26.3392</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v25.i26.3392</ArticleId><ArticleId IdType="pmc">PMC6639549</ArticleId><ArticleId IdType="pubmed">31341364</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Xie X, Lei H, Zou B, Xie L. Identification of Key circRNAs/lncRNAs/miRNAs/mRNAs and Pathways in Preeclampsia Using Bioinformatics Analysis. Med Sci Monit. 2019;25:1679&#x2013;1693. doi:10.12659/MSM.912801</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.912801</ArticleId><ArticleId IdType="pmc">PMC6413561</ArticleId><ArticleId IdType="pubmed">30833538</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulveda JL. Using R and Bioconductor in Clinical Genomics and Transcriptomics. J Mol Diagn. 2020;22(1):3&#x2013;20. doi:10.1016/j.jmoldx.2019.08.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmoldx.2019.08.006</ArticleId><ArticleId IdType="pubmed">31605800</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Zheng F, Liu L, et al. Integrated proteome and phosphoproteome analyses of peripheral blood mononuclear cells in primary Sj&#xf6;gren syndrome patients. Aging. 2020;13(1):1071&#x2013;1095. doi:10.18632/aging.202233</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.202233</ArticleId><ArticleId IdType="pmc">PMC7835054</ArticleId><ArticleId IdType="pubmed">33290261</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu K, Zhang Q, Liu Z, et al. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res. 2019;47(D1):D451&#x2013;D458. doi:10.1093/nar/gky1052</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1052</ArticleId><ArticleId IdType="pmc">PMC6323974</ArticleId><ArticleId IdType="pubmed">30380102</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulo JA, Gaun A, Gygi SP. Global analysis of protein expression and phosphorylation levels in nicotine-treated pancreatic stellate cells. J Proteome Res. 2015;14(10):4246&#x2013;4256. doi:10.1021/acs.jproteome.5b00398</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.5b00398</ArticleId><ArticleId IdType="pmc">PMC4868188</ArticleId><ArticleId IdType="pubmed">26265067</ArticleId></ArticleIdList></Reference><Reference><Citation>Arneth B. Tumor Microenvironment. Medicina. 2019;56(1):15. doi:10.3390/medicina56010015</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina56010015</ArticleId><ArticleId IdType="pmc">PMC7023392</ArticleId><ArticleId IdType="pubmed">31906017</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinshaw DC, Shevde LA. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019;79(18):4557&#x2013;4566. doi:10.1158/0008-5472.CAN-18-3962</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-18-3962</ArticleId><ArticleId IdType="pmc">PMC6744958</ArticleId><ArticleId IdType="pubmed">31350295</ArticleId></ArticleIdList></Reference><Reference><Citation>RRibeiro Franco PI, Rodrigues AP, de Menezes LB, Pacheco Miguel M. Tumor microenvironment components: allies of cancer progression. Pathol Res Pract. 2020;216(1):152729. doi:10.1016/j.prp.2019.152729</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prp.2019.152729</ArticleId><ArticleId IdType="pubmed">31735322</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SS, Liu W, Ly D, Xu H, Qu L, Tumor-infiltrating ZL. B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol. 2019;16(1):6&#x2013;18. doi:10.1038/s41423-018-0027-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-018-0027-x</ArticleId><ArticleId IdType="pmc">PMC6318290</ArticleId><ArticleId IdType="pubmed">29628498</ArticleId></ArticleIdList></Reference><Reference><Citation>Marta T, Luca S, Fabio C. Fibroblasts in the Tumor Microenvironment. Adv Exp Med Biol. 2020;1234:15&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">32040852</ArticleId></ArticleIdList></Reference><Reference><Citation>Truffi M, Sorrentino L, Corsi F. Fibroblasts in the Tumor Microenvironment. Adv Exp Med Biol. 2020;1234:15&#x2013;29. doi:10.1007/978-3-030-37184-5_2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-37184-5_2</ArticleId><ArticleId IdType="pubmed">32040852</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EHN, Tang BL. Rab7a and Mitophagosome Formation. Cells. 2019;8(3):224. doi:10.3390/cells8030224</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8030224</ArticleId><ArticleId IdType="pmc">PMC6468461</ArticleId><ArticleId IdType="pubmed">30857122</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeshaw WM, van der Zwaag M, Pinto F, et al. Human VPS13A is associated with multiple organelles and influences mitochondrial morphology and lipid droplet motility. Elife. 2019;8:e4356. doi:10.7554/eLife.43561</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.43561</ArticleId><ArticleId IdType="pmc">PMC6389287</ArticleId><ArticleId IdType="pubmed">30741634</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz-Braceras S, Tornero-&#xe9;cija AR, Vincent O, Escalante R. VPS13A is closely associated with mitochondria and is required for efficient lysosomal degradation. Dis Model Mech. 2019;12(2):dmm036681. doi:10.1242/dmm.036681</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.036681</ArticleId><ArticleId IdType="pmc">PMC6398486</ArticleId><ArticleId IdType="pubmed">30709847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang Lang F, Pelzl L, Sch&#xf6;ls L, et al. Neurons, Erythrocytes and Beyond -The Diverse Functions of Chorein. Neurosignals. 2017;25(1):117&#x2013;126. doi:10.1159/000485457</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000485457</ArticleId><ArticleId IdType="pubmed">29179176</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34395525</PMID><DateRevised><Year>2021</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-889X</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in molecular biosciences</Title><ISOAbbreviation>Front Mol Biosci</ISOAbbreviation></Journal><ArticleTitle>Prognostic Prediction, Immune Microenvironment, and Drug Resistance Value of Collagen Type I Alpha 1 Chain: From Gastrointestinal Cancers to Pan-Cancer Analysis.</ArticleTitle><Pagination><StartPage>692120</StartPage><MedlinePgn>692120</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">692120</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmolb.2021.692120</ELocationID><Abstract><AbstractText><b>Background:</b> Gastrointestinal cancers patients might experience multiple primary tumors in the digestive tract. Therefore, identifying potential biomarkers can help us better understand the underlying mechanism. From the GEO database, four profiles of gastrointestinal cancers were gathered for the screening process, and six hub genes were found by bioinformatics analysis. <i>Collagen type I alpha 1 chain</i> (<i>COL1A1</i>), one of the hub genes, is a component of the extracellular matrix and is critical for tumor microenvironment. However, the expression level, signaling pathway, prognostic prediction, and immunological value of <i>COL1A1</i> in different cancers remain unclear. <b>Methods:</b> We comprehensively analyzed gene expression and genetic alteration patterns of <i>COL1A1</i> among 33 types of malignancies from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression projects. Besides, we explored the correlation of <i>COL1A1</i> with cancer prognosis, immune infiltrates, PD-L1, tumor mutational burden (TMB)/microsatellite instability status (MSI), and the pathway and drug sensitivity of co-expressed genes. <b>Results:</b> The results showed that <i>COL1A1</i> was highly expressed and associated with poor prognosis in the majority of cancers. The most common alteration type of <i>COL1A1</i> was missense mutation, and <i>COL1A1</i> was associated with poor prognosis in KIRP, LGG, MESO, SKCM, and STAD. For the immunologic significance, <i>COL1A1</i> expression was closely related to high TMB in THYM, LAML, ACC, KICH, PRAD, and LGG, and high MSI in TGCT, MESO, PRAD, COAD, SARC, and CESC. In addition, <i>COL1A1</i> was positively correlated with the abundance of CAFs, macrophages, and tumor-infiltrating lymphocytes. However, it was negatively correlated with CD8<sup>+</sup> T cells mainly in CESC, HNSC-HPV+, and SKCM. Besides, as a component of the extracellular matrix, <i>COL1A1</i> was involved in the activation of epithelial-mesenchymal transition (EMT), and high expression of <i>HTRA1</i> was resistant to multiple drugs. <b>Conclusion:</b> <i>COL1A1</i> can serve as a prognostic and immunological biomarker in different cancers.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Liu, Xue, Zhong, Wang, Li and Zhu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Jinshan Hospital of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Clinical Cancer Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Jinmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Jinshan Hospital of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Clinical Cancer Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Maoxi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Jinshan Hospital of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Clinical Cancer Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Jinshan Hospital of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Clinical Cancer Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Jinshan Hospital of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Clinical Cancer Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yuxi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Jinshan Hospital of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Clinical Cancer Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Mol Biosci</MedlineTA><NlmUniqueID>101653173</NlmUniqueID><ISSNLinking>2296-889X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COL1A1</Keyword><Keyword MajorTopicYN="N">gastrointestinal cancers</Keyword><Keyword MajorTopicYN="N">pan-cancer</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">tumor immune microenvironment</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34395525</ArticleId><ArticleId IdType="pmc">PMC8361495</ArticleId><ArticleId IdType="doi">10.3389/fmolb.2021.692120</ArticleId><ArticleId IdType="pii">692120</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akinboro O., Vallejo J., J., Mishra-Kalyani P., S., Larkins E., A., Drezner N., L., Tang S., et al. (2021). Outcomes of Anti-PD-(l1) Therapy in Combination with Chemotherapy versus Immunotherapy (IO) Alone for First-Line (1L) Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) with PD-L1 Score 1-49%: FDA Pooled Analysis. J. Clin. Oncol. 39 (Suppl. 15; abstr 9001). Abstract retrieved from Abstracts in American Society of Clinical Oncology. (Accession No. 9001).</Citation></Reference><Reference><Citation>Arakawa K., Hata K., Yamamoto Y., Nishikawa T., Tanaka T., Kiyomatsu T., et al. (2018). Nine Primary Malignant Neoplasms-Involving the Esophagus, Stomach, colon, Rectum, Prostate, and External Ear Canal-Without Microsatellite Instability: a Case Report. BMC Cancer 18, 24. 10.1186/s12885-017-3973-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-017-3973-2</ArticleId><ArticleId IdType="pmc">PMC5753511</ArticleId><ArticleId IdType="pubmed">29301504</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T., Wilhite S. E., Ledoux P., Evangelista C., Kim I. F., Tomashevsky M., et al. (2013). NCBI GEO: Archive for Functional Genomics Data Sets-Update. Nucleic Acids Res. 41, D991&#x2013;D995. 10.1093/nar/gks1193</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1193</ArticleId><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Boguslawska J., Kedzierska H., Poplawski P., Rybicka B., Tanski Z., Piekielko-Witkowska A. (2016). Expression of Genes Involved in Cellular Adhesion and Extracellular Matrix Remodeling Correlates with Poor Survival of Patients with Renal Cancer. J. Urol. 195, 1892&#x2013;1902. 10.1016/j.juro.2015.11.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2015.11.050</ArticleId><ArticleId IdType="pubmed">26631499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonneville R., Krook M. A., Kautto E. A., Miya J., Wing M. R., Chen H.-Z., et al. (2017). Landscape of Microsatellite Instability across 39 Cancer Types. JCO Precision Oncol., 1, 15 2017. 10.1200/po.17.00073</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/po.17.00073</ArticleId><ArticleId IdType="pmc">PMC5972025</ArticleId><ArticleId IdType="pubmed">29850653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozorgmehr F., Fischer J. R., Bischof M., Atmaca A., Wetzel S., Faehling M., et al. (2020). LBA58 ORR in Patients Receiving Nivolumab Plus Radiotherapy in Advanced Non-small Cell Lung Cancer: First Results from the FORCE Trial. Ann. Oncol. 31, S1187. 10.1016/j.annonc.2020.08.2291</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.08.2291</ArticleId></ArticleIdList></Reference><Reference><Citation>Bratislav T., Branimir N., Mihailo B., Jovan K., Veljovi&#x107; M., Dejan Z. (2015). Synchronous Gastric and Colonic Cancer--A Case Report. Vojnosanit Pregl 72, 642&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">26364460</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer J. Clinicians 68, 394&#x2013;424. 10.3322/caac.21492</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Casalino L., Verde P. (2020). Multifaceted Roles of DNA Methylation in Neoplastic Transformation, from Tumor Suppressors to EMT and Metastasis. Genes 11, 922. 10.3390/genes11080922</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes11080922</ArticleId><ArticleId IdType="pmc">PMC7463745</ArticleId><ArticleId IdType="pubmed">32806509</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami E., Gao J., Dogrusoz U., Gross B. E., Sumer S. O., Aksoy B. A., et al. (2012). The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1. Cancer Discov. 2, 401&#x2013;404. 10.1158/2159-8290.Cd-12-0095</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.Cd-12-0095</ArticleId><ArticleId IdType="pmc">PMC3956037</ArticleId><ArticleId IdType="pubmed">22588877</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar D. S., Bashel B., Balasubramanya S. A. H., Creighton C. J., Ponce-Rodriguez I., Chakravarthi B. V. S. K., et al. (2017). UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia 19, 649&#x2013;658. 10.1016/j.neo.2017.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2017.05.002</ArticleId><ArticleId IdType="pmc">PMC5516091</ArticleId><ArticleId IdType="pubmed">28732212</ArticleId></ArticleIdList></Reference><Reference><Citation>Chivu Economescu M., Necula L. G., Dragu D., Badea L., Dima S. O., Tudor S., et al. (2010). Identification of Potential Biomarkers for Early and Advanced Gastric Adenocarcinoma Detection. Hepatogastroenterology 57, 1453&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pubmed">21443102</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong L., Chen C., Zhang Y., Guo P., Wang Z., Li J., et al. (2021). The Loss of RNA N6-Adenosine Methyltransferase Mettl14 in Tumor-Associated Macrophages Promotes CD8+ T Cell Dysfunction and Tumor Growth. Cancer Cell. 10.1016/j.ccell.2021.04.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2021.04.016</ArticleId><ArticleId IdType="pubmed">34019807</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong S., Zhu P., Zhang S. (2020). Expression of Collagen Type 1 Alpha 1 Indicates Lymph Node Metastasis and Poor Outcomes in Squamous Cell Carcinomas of the Lung. PeerJ 8, e10089. 10.7717/peerj.10089</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.10089</ArticleId><ArticleId IdType="pmc">PMC7531356</ArticleId><ArticleId IdType="pubmed">33062455</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigoroiu M., Tagett R., Draghici S., Dima S., Nastase A., Florea R., et al. (2015). Gene-expression Profiling in Non-small Cell Lung Cancer with Invasion of Mediastinal Lymph Nodes for Prognosis Evaluation. Cancer Genomics Proteomics 12, 231&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">26417026</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu N., Clifford R. J., Yang H. H., Wang C., Goldstein A. M., Ding T., et al. (2010). Genome Wide Analysis of DNA Copy Number Neutral Loss of Heterozygosity (CNNLOH) and its Relation to Gene Expression in Esophageal Squamous Cell Carcinoma. BMC Genomics. 11, 576. 10.1186/1471-2164-11-576</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-11-576</ArticleId><ArticleId IdType="pmc">PMC3091724</ArticleId><ArticleId IdType="pubmed">20955586</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Yang X., Han L., Fan Z., Liu B., Zhang C., et al. (2019). The Prognostic Potential of Alpha-1 Type I Collagen Expression in Papillary Thyroid Cancer. Biochem. Biophysical Res. Commun. 515, 125&#x2013;132. 10.1016/j.bbrc.2019.04.119</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2019.04.119</ArticleId><ArticleId IdType="pubmed">31128912</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D. W., Sherman B. T., Lempicki R. A. (2009). Systematic and Integrative Analysis of Large Gene Lists Using DAVID Bioinformatics Resources. Nat. Protoc. 4, 44&#x2013;57. 10.1038/nprot.2008.211</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.211</ArticleId><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue C., Miki Y., Saito R., Hata S., Abe J., Sato I., et al. (2019). PD-L1 Induction by Cancer-Associated Fibroblast-Derived Factors in Lung Adenocarcinoma Cells. Cancers 11, 1257. 10.3390/cancers11091257</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11091257</ArticleId><ArticleId IdType="pmc">PMC6770125</ArticleId><ArticleId IdType="pubmed">31462002</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Zhan H. (2020). Communication between EMT and PD-L1 Signaling: New Insights into Tumor Immune Evasion. Cancer Lett. 468, 72&#x2013;81. 10.1016/j.canlet.2019.10.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2019.10.013</ArticleId><ArticleId IdType="pubmed">31605776</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.-H., Park B.-S., Kim H. S., Kim J. H. (2017). Synchronous Quintuple Primary Gastrointestinal Tract Malignancies: Case Report. Wjg 23, 173&#x2013;177. 10.3748/wjg.v23.i1.173</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i1.173</ArticleId><ArticleId IdType="pmc">PMC5221281</ArticleId><ArticleId IdType="pubmed">28104993</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch A., De Meyer T., Jeschke J., Van Criekinge W. (2015). MEXPRESS: Visualizing Expression, DNA Methylation and Clinical TCGA Data. BMC Genomics 16, 636. 10.1186/s12864-015-1847-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-015-1847-z</ArticleId><ArticleId IdType="pmc">PMC4549898</ArticleId><ArticleId IdType="pubmed">26306699</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakins M. A., Ghorani E., Munir H., Martins C. P., Shields J. D. (2018). Cancer-associated Fibroblasts Induce Antigen-specific Deletion of CD8 + T Cells to Protect Tumour Cells. Nat. Commun. 9, 948. 10.1038/s41467-018-03347-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03347-0</ArticleId><ArticleId IdType="pmc">PMC5838096</ArticleId><ArticleId IdType="pubmed">29507342</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Fu J., Zeng Z., Cohen D., Li J., Chen Q., et al. (2020). TIMER2.0 for Analysis of Tumor-Infiltrating Immune Cells. Nucleic Acids Res. 48, W509&#x2013;w514. 10.1093/nar/gkaa407</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa407</ArticleId><ArticleId IdType="pmc">PMC7319575</ArticleId><ArticleId IdType="pubmed">32442275</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Zhou J., Zhang J., Li S., Wang H., Du J. (2019). Cancer&#x2010;associated Fibroblasts Promote PD&#x2010;L1 Expression in Mice Cancer Cells via Secreting CXCL5. Int. J. Cancer 145, 1946&#x2013;1957. 10.1002/ijc.32278</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.32278</ArticleId><ArticleId IdType="pmc">PMC6767568</ArticleId><ArticleId IdType="pubmed">30873585</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.-J., Hu F.-F., Xia M.-X., Han L., Zhang Q., Guo A.-Y. (2018a). GSCALite: a Web Server for Gene Set Cancer Analysis. Bioinformatics 34, 3771&#x2013;3772. 10.1093/bioinformatics/bty411</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty411</ArticleId><ArticleId IdType="pubmed">29790900</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Shen J. X., Wu H. T., Li X. L., Wen X. F., Du C. W., et al. (2018b). Collagen 1A1 (COL1A1) Promotes Metastasis of Breast Cancer and Is a Potential Therapeutic Target. Discov. Med. 25, 211&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">29906404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H.-P., Chang H.-L., Bamodu O. A., Yadav V. K., Huang T.-Y., Wu A. T. H., et al. (2019). Collagen 1A1 (COL1A1) Is a Reliable Biomarker and Putative Therapeutic Target for Hepatocellular Carcinogenesis and Metastasis. Cancers 11, 786. 10.3390/cancers11060786</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11060786</ArticleId><ArticleId IdType="pmc">PMC6627889</ArticleId><ArticleId IdType="pubmed">31181620</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieto M. A., Huang R. Y.-J., Jackson R. A., Thiery J. P. (2016). EMT: 2016. Cell 166, 21&#x2013;45. 10.1016/j.cell.2016.06.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.06.028</ArticleId><ArticleId IdType="pubmed">27368099</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng D. H., Rodriguez B. L., Diao L., Chen L., Wang J., Byers L. A., et al. (2020). Collagen Promotes Anti-PD-1/pd-L1 Resistance in Cancer through LAIR1-dependent CD8+ T Cell Exhaustion. Nat. Commun. 11, 4520. 10.1038/s41467-020-18298-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18298-8</ArticleId><ArticleId IdType="pmc">PMC7481212</ArticleId><ArticleId IdType="pubmed">32908154</ArticleId></ArticleIdList></Reference><Reference><Citation>Prockop D. J. (1990). Mutations that Alter the Primary Structure of Type I Collagen. The Perils of a System for Generating Large Structures by the Principle of Nucleated Growth. J. Biol. Chem. 265, 15349&#x2013;15352. 10.1016/s0021-9258(18)55398-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0021-9258(18)55398-9</ArticleId><ArticleId IdType="pubmed">2203776</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes D. R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., et al. (2004). ONCOMINE: a Cancer Microarray Database and Integrated Data-Mining Platform. Neoplasia 6, 1&#x2013;6. 10.1016/s1476-5586(04)80047-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1476-5586(04)80047-2</ArticleId><ArticleId IdType="pmc">PMC1635162</ArticleId><ArticleId IdType="pubmed">15068665</ArticleId></ArticleIdList></Reference><Reference><Citation>Ru B., Wong C. N., Tong Y., Zhong J. Y., Zhong S. S. W., Wu W. C., et al. (2019). TISIDB: an Integrated Repository portal for Tumor-Immune System Interactions. Bioinformatics 35, 4200&#x2013;4202. 10.1093/bioinformatics/btz210</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz210</ArticleId><ArticleId IdType="pubmed">30903160</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P., Markiel A., Ozier O., Baliga N. S., Wang J. T., Ramage D., et al. (2003). Cytoscape: a Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res. 13, 2498&#x2013;2504. 10.1101/gr.1239303</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Wang J., Xin Z., Duan Z., Wang G., Li F. (2015). Transcription Factors and microRNA-Co-Regulated Genes in Gastric Cancer Invasion in Ex Vivo . PLoS One 10, e0122882. 10.1371/journal.pone.0122882</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0122882</ArticleId><ArticleId IdType="pmc">PMC4393113</ArticleId><ArticleId IdType="pubmed">25860484</ArticleId></ArticleIdList></Reference><Reference><Citation>Su S., Dong Z.-Y., Xie Z., Yan L.-X., Li Y.-F., Su J., et al. (2018). Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients with EGFR Mutation. J. Thorac. Oncol. 13, 1668&#x2013;1675. 10.1016/j.jtho.2018.07.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2018.07.016</ArticleId><ArticleId IdType="pubmed">30056164</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Gable A. L., Lyon D., Junge A., Wyder S., Huerta-Cepas J., et al. (2019). STRING V11: Protein-Protein Association Networks with Increased Coverage, Supporting Functional Discovery in Genome-wide Experimental Datasets. Nucleic Acids Res. 47, D607&#x2013;d613. 10.1093/nar/gky1131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z., Kang B., Li C., Chen T., Zhang Z. (2019). GEPIA2: an Enhanced Web Server for Large-Scale Expression Profiling and Interactive Analysis. Nucleic Acids Res. 47, W556&#x2013;w560. 10.1093/nar/gkz430</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz430</ArticleId><ArticleId IdType="pmc">PMC6602440</ArticleId><ArticleId IdType="pubmed">31114875</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsson V., Gibbs D. L., Brown S. D., Wolf D., Bortone D. S., Ou Yang T. H., et al. (2019). The Immune Landscape of Cancer. Immunity 51, 411&#x2013;412. 10.1016/j.immuni.2019.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.08.004</ArticleId><ArticleId IdType="pubmed">31433971</ArticleId></ArticleIdList></Reference><Reference><Citation>Vakili-Ghartavol R., Mombeiny R., Salmaninejad A., Sorkhabadi S. M. R., Faridi-Majidi R., Jaafari M. R., et al. (2018). Tumor-associated Macrophages and Epithelial-Mesenchymal Transition in Cancer: Nanotechnology Comes into View. J. Cel Physiol. 233, 9223&#x2013;9236. 10.1002/jcp.27027</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27027</ArticleId><ArticleId IdType="pubmed">30078227</ArticleId></ArticleIdList></Reference><Reference><Citation>Van De Ven S. E. M., Falger J. M., Verhoeven R. H. A., Baatenburg De Jong R. J., Spaander M. C. W., Bruno M. J., et al. (2021). Increased Risk of Second Primary Tumours in Patients with Oesophageal Squamous Cell Carcinoma: A Nationwide Study in a Western Population. United Eur. Gastroenterol. j., 9. 497&#x2013;506. 10.1177/2050640620977129</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640620977129</ArticleId><ArticleId IdType="pmc">PMC8259340</ArticleId><ArticleId IdType="pubmed">33270530</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachavas E. I., Pilalis E., Papadodima O., Koczan D., Willis S., Klippel S., et al. (2019). Radiogenomic Analysis of F-18-Fluorodeoxyglucose Positron Emission Tomography and Gene Expression Data Elucidates the Epidemiological Complexity of Colorectal Cancer Landscape. Comput. Struct. Biotechnol. J. 17, 177&#x2013;185. 10.1016/j.csbj.2019.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2019.01.007</ArticleId><ArticleId IdType="pmc">PMC6374701</ArticleId><ArticleId IdType="pubmed">30809322</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki S., Higuchi Y., Ishibashi M., Hashimoto H., Yasunaga M., Matsumura Y., et al. (2018). Collagen Type I Induces EGFR-TKI Resistance in EGFR-Mutated Cancer Cells by mTOR Activation through Akt-independent Pathway. Cancer Sci. 109, 2063&#x2013;2073. 10.1111/cas.13624</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13624</ArticleId><ArticleId IdType="pmc">PMC5989854</ArticleId><ArticleId IdType="pubmed">29701925</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y., Du L., Li X., Zhang X., Gao Y. (2019). miR&#x2010;133a&#x2010;3p Suppresses Cell Proliferation, Migration, and Invasion and Promotes Apoptosis in Esophageal Squamous Cell Carcinoma. J. Cel Physiol. 234, 12757&#x2013;12770. 10.1002/jcp.27896</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27896</ArticleId><ArticleId IdType="pubmed">30537034</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida N., Eto K., Kurashige J., Izumi D., Sawayama H., Horinouchi T., et al. (2020). Comprehensive Analysis of Multiple Primary Cancers in Patients with Esophageal Squamous Cell Carcinoma Undergoing Esophagectomy. Ann. Surg. Publish Ahead of Print. 10.1097/sla.0000000000004490</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/sla.0000000000004490</ArticleId><ArticleId IdType="pubmed">32941275</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshikawa T., Aoki K., Mitsuhashi Y., Tomiura S., Suto A., Miura T., et al. (2016). A Case of Double Cancer of Initially Unresectable Sigmoid Colon Cancer and Advanced Gastric Cancer Treated with Curative Resection after mFOLFOX6 Therapy. Gan To Kagaku Ryoho 43, 365&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">27067857</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Liu S., Wang X., Liu H., Zhou X., Liu H. (2021). COL1A1 Is a Potential Prognostic Biomarker and Correlated with Immune Infiltration in Mesothelioma. Biomed. Res. Int. 2021, 1&#x2013;13. 10.1155/2021/5320941</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5320941</ArticleId><ArticleId IdType="pmc">PMC7803428</ArticleId><ArticleId IdType="pubmed">33490271</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Fang C., Wang Y., Zhang J., Yu J., Zhang Y., et al. (2018). COL1A1: A Potential Therapeutic Target for Colorectal Cancer Expressing Wild-type or Mutant KRAS. Int. J. Oncol. 53, 1869&#x2013;1880. 10.3892/ijo.2018.4536</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2018.4536</ArticleId><ArticleId IdType="pmc">PMC6192778</ArticleId><ArticleId IdType="pubmed">30132520</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L., Xing W., Yang Y., Zhang Y., Ma B., Fu X., et al. (2021). The Sequence of Chemotherapy and Anti-PD-1 Antibody Influence the Efficacy of Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Cancer: A Phase II Study. J. Clin. Oncol. 39 (Suppl. 15; abstr 4051). Abstract retrieved from Abstracts in American Society of Clinical Oncology(Accession No. 4051). 10.1200/jco.2021.39.15_suppl.4051</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2021.39.15_suppl.4051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H., Chen H., Wang J., Zhou L., Liu S. (2019). Collagen Stiffness Promoted Non-muscle-invasive Bladder Cancer Progression to Muscle-Invasive Bladder Cancer. Ott. 12, 3441&#x2013;3457. 10.2147/ott.S194568</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ott.S194568</ArticleId><ArticleId IdType="pmc">PMC6511250</ArticleId><ArticleId IdType="pubmed">31123405</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34291084</PMID><DateRevised><Year>2021</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-889X</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in molecular biosciences</Title><ISOAbbreviation>Front Mol Biosci</ISOAbbreviation></Journal><ArticleTitle>An Immune-Gene-Based Classifier Predicts Prognosis in Patients With Cervical Squamous Cell Carcinoma.</ArticleTitle><Pagination><StartPage>679474</StartPage><MedlinePgn>679474</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">679474</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmolb.2021.679474</ELocationID><Abstract><AbstractText><b>Objective:</b> Immunity plays a vital role in the human papilloma virus (HPV) persistent infection, and closely associates with occurrence and development of cervical squamous cell carcinoma (CSCC). Herein, we performed an integrated bioinformatics analysis to establish an immune-gene signature and immune-associated nomogram for predicting prognosis of CSCC patients. <b>Methods:</b> The list of immunity-associated genes was retrieved from ImmPort database. The gene and clinical information of CSCC patients were obtained from The Cancer Genome Atlas (TCGA) website. The immune gene signature for predicting overall survival (OS) of CSCC patients was constructed using the univariate Cox-regression analysis, random survival forests, and multivariate Cox-regression analysis. This signature was externally validated in GSE44001 cohort from Gene Expression Omnibus (GEO). Then, based on the established signature and the TCGA cohort with the corresponding clinical information, a nomogram was constructed and evaluated <i>via</i> Cox regression analysis, concordance index (C-index), receiver operating characteristic (ROC) curves, calibration plots and decision curve analyses (DCAs). <b>Results:</b> A 5-immune-gene prognostic signature for CSCC was established. Low expression of <i>ICOS</i>, <i>ISG20</i> and high expression of <i>ANGPTL4</i>, <i>SBDS</i>, <i>LTBR</i> were risk factors for CSCC prognosis indicating poor OS. Based on this signature, the OS was significantly worse in high-risk group than in low-risk group (<i>p</i>-value &lt; 0.001), the area under curves (AUCs) for 1-, 3-, 5-years OS were, respectively, 0.784, 0.727, and 0.715. A nomogram incorporating the risk score of signature and the clinical stage was constructed. The C-index of this nomogram was 0.76. AUC values were 0.811, 0.717, and 0.712 for 1-, 3-, 5-years OS. The nomogram showed good calibration and gained more net benefits than the 5-immune-gene signature and the clinical stage. <b>Conclusion:</b> The 5-immune-gene signature may serve as a novel, independent predictor for prognosis in patients with CSCC. The nomogram incorporating the signature risk score and clinical stage improved the predictive performance than the signature and clinical stage alone for predicting 1-year OS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Yang, Han and Hao.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Huixia</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Beijing Friendship Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Beijing Friendship Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Zengping</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Beijing Friendship Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Mol Biosci</MedlineTA><NlmUniqueID>101653173</NlmUniqueID><ISSNLinking>2296-889X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PD1/PD-L1</Keyword><Keyword MajorTopicYN="N">cervical squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">gene</Keyword><Keyword MajorTopicYN="N">immune</Keyword><Keyword MajorTopicYN="N">nomogram</Keyword><Keyword MajorTopicYN="N">prognostic</Keyword><Keyword MajorTopicYN="N">signature</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34291084</ArticleId><ArticleId IdType="pmc">PMC8289438</ArticleId><ArticleId IdType="doi">10.3389/fmolb.2021.679474</ArticleId><ArticleId IdType="pii">679474</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agull&#xf3;-Ortu&#xf1;o M. T., G&#xf3;mez-Mart&#xed;n &#xd3;., Ponce S., Iglesias L., Ojeda L., Ferrer I., et al. (2020). Blood Predictive Biomarkers for Patients With Nony&#x2013;small&#x2013;cell Lung Cancer Associated With Clinical Response to Nivolumab. Clin. Lung Cancer 21, 75&#x2013;85. 10.1016/j.cllc.2019.08.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cllc.2019.08.006</ArticleId><ArticleId IdType="pubmed">31562055</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambekar C., Das B., Yeger H., Dror Y. (2010). SBDS-deficiency Results in Deregulation of Reactive Oxygen Species Leading to Increased Cell Death and Decreased Cell Growth. Pediatr. Blood Cancer 55, 1138&#x2013;1144. 10.1002/pbc.22700</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pbc.22700</ArticleId><ArticleId IdType="pubmed">20979173</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin K. M., Gupta M. L., Coats S. A., Tulpule A., Mostoslavsky G., Balazs A. B., et al. (2008). Mitotic Spindle Destabilization and Genomic Instability in Shwachman-Diamond Syndrome. J. Clin. Invest. 118, 1511&#x2013;1518. 10.1172/JCI33764</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI33764</ArticleId><ArticleId IdType="pmc">PMC2263145</ArticleId><ArticleId IdType="pubmed">18324336</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedognetti D., Hendrickx W., Marincola F. M., Miller L. D. (2015). Prognostic and Predictive Immune Gene Signatures in Breast Cancer. Curr. Opin. Oncol. 27, 433&#x2013;444. 10.1097/CCO.0000000000000234</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCO.0000000000000234</ArticleId><ArticleId IdType="pubmed">26418235</ArticleId></ArticleIdList></Reference><Reference><Citation>Boocock G. R. B., Morrison J. A., Popovic M., Richards N., Ellis L., Durie P. R., et al. (2003). Mutations in SBDS Are Associated with Shwachman-Diamond Syndrome. Nat. Genet. 33, 97&#x2013;101. 10.1038/ng1062</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1062</ArticleId><ArticleId IdType="pubmed">12496757</ArticleId></ArticleIdList></Reference><Reference><Citation>Budhu A., Forgues M., Ye Q.-H., Jia H.-L., He P., Zanetti K. A., et al. (2006). Prediction of Venous Metastases, Recurrence, and Prognosis in Hepatocellular Carcinoma Based on a Unique Immune Response Signature of the Liver Microenvironment. Cancer Cell 10, 99&#x2013;111. 10.1016/j.ccr.2006.06.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2006.06.016</ArticleId><ArticleId IdType="pubmed">16904609</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y., Qiao X., Wang X., Yu Q. (2018). Random forest Classifier for Zero-Shot Learning Based on Relative Attribute. IEEE Trans. Neural Netw. Learn. Syst. 29, 1662&#x2013;1674. 10.1109/TNNLS.2017.2677441</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TNNLS.2017.2677441</ArticleId><ArticleId IdType="pubmed">28333644</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H. W., Johnson-Weaver B., Staats H. F., Abraham S. N. (2020). Mast Cells for the Control of Mucosal Immunity. Mucosal Vaccin. Academic Press; 13, 213&#x2013;228. 10.1016/b978-0-12-811924-2.00013-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-12-811924-2.00013-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantinidou A., Alifieris C., Trafalis D. T. (2019). Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in Cancer Active Immunotherapy. Pharmacol. Ther. 194, 84&#x2013;106. 10.1016/j.pharmthera.2018.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2018.09.008</ArticleId><ArticleId IdType="pubmed">30268773</ArticleId></ArticleIdList></Reference><Reference><Citation>Coutant C., Olivier C., Lambaudie E., Fondrinier E., Marchal F., Guillemin F., et al. (2009). Comparison of Models to Predict Nonsentinel Lymph Node Status in Breast Cancer Patients with Metastatic sentinel Lymph Nodes: A Prospective Multicenter Study. Jco 27, 2800&#x2013;2808. 10.1200/JCO.2008.19.7418</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2008.19.7418</ArticleId><ArticleId IdType="pubmed">19349546</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalstein V., Riethmuller D., Pr&#xe9;tet J.-L., Le Bail Carval K., Sauti&#xe8;re J.-L., Carbillet J.-P., et al. (2003). Persistence and Load of High-Risk HPV Are Predictors for Development of High-Grade Cervical Lesions: A Longitudinal French Cohort Study. Int. J. Cancer 106, 396&#x2013;403. 10.1002/ijc.11222</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.11222</ArticleId><ArticleId IdType="pubmed">12845680</ArticleId></ArticleIdList></Reference><Reference><Citation>De Freitas A. C., Coimbra E. C., Leit&#xe3;o Mda C. (2014). Molecular Targets of HPV Oncoproteins: Potential Biomarkers for Cervical Carcinogenesis. Biochim. Biophys. Acta (Bba) - Rev. Cancer 1845, 91&#x2013;103. 10.1016/j.bbcan.2013.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2013.12.004</ArticleId><ArticleId IdType="pubmed">24388872</ArticleId></ArticleIdList></Reference><Reference><Citation>Espert L., Degols G., Lin Y.-L., Vincent T., Benkirane M., Mechti N. (2005). Interferon-induced Exonuclease ISG20 Exhibits an Antiviral Activity against Human Immunodeficiency Virus Type 1. J. Gen. Virol. 86, 2221&#x2013;2229. 10.1099/vir.0.81074-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.81074-0</ArticleId><ArticleId IdType="pubmed">16033969</ArticleId></ArticleIdList></Reference><Reference><Citation>Evander M., Edlund K., Gustafsson A., Jonsson M., Karlsson R., Rylander E., et al. (1995). Human Papillomavirus Infection Is Transient in Young Women: A Populationbased Cohort Study. J. Infect. Dis. 171, 1026&#x2013;1030. 10.1093/infdis/171.4.1026</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/171.4.1026</ArticleId><ArticleId IdType="pubmed">7706782</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch A. J., Hilcenko C., Basse N., Drynan L. F., Goyenechea B., Menne T. F., et al. (2011). Uncoupling of GTP Hydrolysis from eIF6 Release on the Ribosome Causes Shwachman-diamond Syndrome. Genes Dev. 25, 917&#x2013;929. 10.1101/gad.623011</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.623011</ArticleId><ArticleId IdType="pmc">PMC3084026</ArticleId><ArticleId IdType="pubmed">21536732</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenel J.-S., Le Tourneau C., O&#x2019;Neil B., Ott P. A., Piha-Paul S. A., Gomez-Roca C., et al. (2017). Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-positive Cervical Cancer: Results from the Phase IB KEYNOTE-028 Trial. Jco 35, 4035&#x2013;4041. 10.1200/JCO.2017.74.5471</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2017.74.5471</ArticleId><ArticleId IdType="pubmed">29095678</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli S. J., Tsai M. (2012). IgE and Mast Cells in Allergic Disease. Nat. Med. 18, 693&#x2013;704. 10.1038/nm.2755</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2755</ArticleId><ArticleId IdType="pmc">PMC3597223</ArticleId><ArticleId IdType="pubmed">22561833</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganapathi K. A., Austin K. M., Lee C.-S., Dias A., Malsch M. M., Reed R., et al. (2007). The Human Shwachman-Diamond Syndrome Protein, SBDS, Associates with Ribosomal RNA. Blood 110, 1458&#x2013;1465. 10.1182/blood-2007-02-075184</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-02-075184</ArticleId><ArticleId IdType="pmc">PMC1975835</ArticleId><ArticleId IdType="pubmed">17475909</ArticleId></ArticleIdList></Reference><Reference><Citation>Gettinger S., Horn L., Jackman D., Spigel D., Antonia S., Hellmann M., et al. (2018). Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-small-cell Lung Cancer: Results from the CA209-003 Study. Jco 36, 1675&#x2013;1684. 10.1200/JCO.2017.77.0412</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2017.77.0412</ArticleId><ArticleId IdType="pubmed">29570421</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosink L. J., Overall C. C., Reehl S. M., Whitney P. D., Mobley D. L., Baker N. A. (2017). Bayesian Model Averaging for Ensemble-Based Estimates of Solvation-free Energies. J. Phys. Chem. B 121, 3458&#x2013;3472. 10.1021/acs.jpcb.6b09198</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpcb.6b09198</ArticleId><ArticleId IdType="pmc">PMC5398953</ArticleId><ArticleId IdType="pubmed">27966363</ArticleId></ArticleIdList></Reference><Reference><Citation>Gostout B. S., Poland G. A., Calhoun E. S., Sohni Y. R., Giuntoli II R. L., McGovern R. M., et al. (2003). TAP1, TAP2, and HLA-DR2 Alleles Are Predictors of Cervical Cancer Risk&#x2606;. Gynecol. Oncol. 88, 326&#x2013;332. 10.1016/S0090-8258(02)00074-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-8258(02)00074-4</ArticleId><ArticleId IdType="pubmed">12648582</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobmyer S. R., Brennan M. F. (2003). Predictive Variables Detailing the Recurrence Rate of Soft Tissue Sarcomas. Curr. Opin. Oncol. 15, 319&#x2013;326. 10.1097/00001622-200307000-00007</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001622-200307000-00007</ArticleId><ArticleId IdType="pubmed">12874511</ArticleId></ArticleIdList></Reference><Reference><Citation>Grulich A. E., van Leeuwen M. T., Falster M. O., Vajdic C. M. (2007). Incidence of Cancers in People with HIV/AIDS Compared with Immunosuppressed Transplant Recipients: a Meta-Analysis. The Lancet 370, 59&#x2013;67. 10.1016/S0140-6736(07)61050-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61050-2</ArticleId><ArticleId IdType="pubmed">17617273</ArticleId></ArticleIdList></Reference><Reference><Citation>Grzadkowski M. R., Sendorek D. H., P&#x2019;ng C., Huang V., Boutros P. C. (2018). A Comparative Study of Survival Models for Breast Cancer Prognostication Revisited: The Benefits of Multi-Gene Models. BMC Bioinformatics 19, 400. 10.1186/s12859-018-2430-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-018-2430-9</ArticleId><ArticleId IdType="pmc">PMC6215649</ArticleId><ArticleId IdType="pubmed">30390622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley J. A., McNeil B. J. (1982). The Meaning and Use of the Area under a Receiver Operating Characteristic (ROC) Curve. Radiology 143, 29&#x2013;36. 10.1148/radiology.143.1.7063747</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.143.1.7063747</ArticleId><ArticleId IdType="pubmed">7063747</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Q., Wang J., Chen Y., Wang S., Cao M., Lu H., et al. (2020). Dual Regulation of P53 by the Ribosome Maturation Factor SBDS. Cell Death Dis 11, 197. 10.1038/s41419-020-2393-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-2393-4</ArticleId><ArticleId IdType="pmc">PMC7083877</ArticleId><ArticleId IdType="pubmed">32198344</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell F. E., Lee K. L., Mark D. B. (1996). Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors. Stat. Med. 15, 361&#x2013;387. 10.1002/(SICI)1097-025810.1002/(sici)1097-0258(19960229)15:4&lt;361::aid-sim168&gt;3.0.co;2-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-025810.1002/(sici)1097-0258(19960229)15:4&lt;361::aid-sim168&gt;3.0.co;2-4</ArticleId><ArticleId IdType="pubmed">8668867</ArticleId></ArticleIdList></Reference><Reference><Citation>Hato T., Tabata M., Oike Y. (2008). The Role of Angiopoietin-like Proteins in Angiogenesis and Metabolism. Trends Cardiovasc. Med. 18, 6&#x2013;14. 10.1016/j.tcm.2007.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2007.10.003</ArticleId><ArticleId IdType="pubmed">18206803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollebecque A., Meyer T., Moore K. N., Machiels J.-P. H., De Greve J., L&#xf3;pez-Picazo J. M., et al. (2017). An Open-Label, Multicohort, Phase I/II Study of Nivolumab in Patients with Virus-Associated Tumors (CheckMate 358): Efficacy and Safety in Recurrent or Metastatic (R/M) Cervical, Vaginal, and Vulvar Cancers. Jco 35, 5504. 10.1200/jco.2017.35.15_suppl.5504</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2017.35.15_suppl.5504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshida Y., Brunet J.-P., Tamayo P., Golub T. R., Mesirov J. P. (2007). Subclass Mapping: Identifying Common Subtypes in Independent Disease Data Sets. PLoS One 2, e1195. 10.1371/journal.pone.0001195</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001195</ArticleId><ArticleId IdType="pmc">PMC2065909</ArticleId><ArticleId IdType="pubmed">18030330</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Li Y.-Q., Li Q.-G., Ma Y.-L., Peng J.-J., Cai S.-J. (2018). Baseline Peripheral Blood Leukocytosis Is Negatively Correlated with T-Cell Infiltration Predicting Worse Outcome in Colorectal Cancers. Front. Immunol. 9, 2354. 10.3389/fimmu.2018.02354</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02354</ArticleId><ArticleId IdType="pmc">PMC6194313</ArticleId><ArticleId IdType="pubmed">30369930</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z., Xie J., Lin S., Li S., Huang Z., Wang Y., et al. (2016). The Downregulation of ANGPTL4 Inhibits the Migration and Proliferation of Tongue Squamous Cell Carcinoma. Arch. Oral Biol. 71, 144&#x2013;149. 10.1016/j.archoralbio.2016.07.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archoralbio.2016.07.011</ArticleId><ArticleId IdType="pubmed">27505034</ArticleId></ArticleIdList></Reference><Reference><Citation>Intaraphet S., Kasatpibal N., Siriaunkgul S., Sogaard M., Patumanond J., Khunamornpong S., et al. (2013). Prognostic Impact of Histology in Patients with Cervical Squamous Cell Carcinoma, Adenocarcinoma and Small Cell Neuroendocrine Carcinoma. Asian Pac. J. Cancer Prev. 14, 5355&#x2013;5360. 10.7314/APJCP.2013.14.9.5355</Citation><ArticleIdList><ArticleId IdType="doi">10.7314/APJCP.2013.14.9.5355</ArticleId><ArticleId IdType="pubmed">24175825</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishwaran H., Kogalur U. B., Blackstone E. H., Lauer M. S. (2008). Random Survival Forests. Ann. Appl. Stat. 2, 841&#x2013;860. 10.1214/08-AOAS169</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/08-AOAS169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivansson E. L., Juko-Pecirep I., Gyllensten U. B. (2010). Interaction of Immunological Genes on Chromosome 2q33 and IFNG in Susceptibility to Cervical Cancer. Gynecol. Oncol. 116, 544&#x2013;548. 10.1016/j.ygyno.2009.10.084</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2009.10.084</ArticleId><ArticleId IdType="pubmed">19959217</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulasingam S. L., Hughes J. P., Kiviat N. B., Mao C., Weiss N. S., Kuypers J. M., et al. (2002). Evaluation of Human Papillomavirus Testing in Primary Screening for Cervical Abnormalities. Jama 288, 1749&#x2013;1757. 10.1001/jama.288.14.1749</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.288.14.1749</ArticleId><ArticleId IdType="pubmed">12365959</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Ge C., Zhao F., Yan M., Hu C., Jia D., et al. (2011). Hypoxia-inducible Factor 1 Alpha-Activated Angiopoietin-like Protein 4 Contributes to Tumor Metastasis via Vascular Cell Adhesion Molecule-1/integrin &#x3b2;1 Signaling in Human Hepatocellular Carcinoma. Hepatology 54, 910&#x2013;919. 10.1002/hep.24479</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.24479</ArticleId><ArticleId IdType="pubmed">21674552</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Teng C. (2014). Angiopoietin-like Proteins 3, 4 and 8: Regulating Lipid Metabolism and Providing new hope for Metabolic Syndrome. J. Drug Target. 22, 679&#x2013;687. 10.3109/1061186X.2014.928715</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/1061186X.2014.928715</ArticleId><ArticleId IdType="pubmed">24960069</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Wu Z., Wang Y., Nie S., Sun R., Yang J., et al. (2020). A Prognostic Signature Based on Immune-Related Genes for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma. Int. Immunopharmacology 88, 106884. 10.1016/j.intimp.2020.106884</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.106884</ArticleId><ArticleId IdType="pubmed">32795900</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Wu L., Tong R., Yang F., Yin L., Li M., et al. (2019). PD-1/PD-L1 Inhibitors in Cervical Cancer. Front. Pharmacol. 10, 65. 10.3389/fphar.2019.00065</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00065</ArticleId><ArticleId IdType="pmc">PMC6367228</ArticleId><ArticleId IdType="pubmed">30774597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X., Jiang L., Zhang L., Zhu Y., Hu W., Wang J., et al. (2019). Immune Signature-Based Subtypes of Cervical Squamous Cell Carcinoma Tightly Associated with Human Papillomavirus Type 16 Expression, Molecular Features, and Clinical Outcome. Neoplasia 21, 591&#x2013;601. 10.1016/j.neo.2019.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2019.04.003</ArticleId><ArticleId IdType="pmc">PMC6658934</ArticleId><ArticleId IdType="pubmed">31055200</ArticleId></ArticleIdList></Reference><Reference><Citation>Maltby S., Khazaie K., McNagny K. M. (2009). Mast Cells in Tumor Growth: Angiogenesis, Tissue Remodelling and Immune-Modulation. Biochim. Biophys. Acta (Bba) - Rev. Cancer 1796, 19&#x2013;26. 10.1016/j.bbcan.2009.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2009.02.001</ArticleId><ArticleId IdType="pmc">PMC2731828</ArticleId><ArticleId IdType="pubmed">19233249</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam G.-H., Lee E. J., Kim Y. K., Hong Y., Choi Y., Ryu M.-J., et al. (2018). Combined Rho-Kinase Inhibition and Immunogenic Cell Death Triggers and Propagates Immunity against Cancer. Nat. Commun. 9, 2165. 10.1038/s41467-018-04607-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04607-9</ArticleId><ArticleId IdType="pmc">PMC5986820</ArticleId><ArticleId IdType="pubmed">29867097</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman A. M., Liu C. L., Green M. R., Gentles A. J., Feng W., Xu Y., et al. (2015). Robust Enumeration of Cell Subsets from Tissue Expression Profiles. Nat. Methods 12, 453&#x2013;457. 10.1038/nmeth.3337</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3337</ArticleId><ArticleId IdType="pmc">PMC4739640</ArticleId><ArticleId IdType="pubmed">25822800</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie D., Zheng Q., Liu L., Mao X., Li Z. (2019). Up-regulated of Angiopoietin-like Protein 4 Predicts Poor Prognosis in Cervical Cancer. J. Cancer 10, 1896&#x2013;1901. 10.7150/jca.29916</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.29916</ArticleId><ArticleId IdType="pmc">PMC6547978</ArticleId><ArticleId IdType="pubmed">31205547</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie H., Bu F., Xu J., Li T., Huang J. (2020). 29 Immune-Related Genes Pairs Signature Predict the Prognosis of Cervical Cancer Patients. Sci. Rep. 10, 14152. 10.1038/s41598-020-70500-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-70500-5</ArticleId><ArticleId IdType="pmc">PMC7447790</ArticleId><ArticleId IdType="pubmed">32843657</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson B., Gribble B., Dias J., Curryer C., Vo K., Kowal P., et al. (2016). Cervical Cancer Screening Programs and Guidelines in Low- and Middle-Income Countries. Int. J. Gynecol. Obstet. 134, 239&#x2013;246. 10.1016/j.ijgo.2016.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijgo.2016.03.011</ArticleId><ArticleId IdType="pubmed">27350227</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlak E., Karabon L., Wlodarska-Polinska I., Jedynak A., Jonkisz A., Tomkiewicz A., et al. (2010). Influence of CTLA-4/CD28/ICOS Gene Polymorphisms on the Susceptibility to Cervical Squamous Cell Carcinoma and Stage of Differentiation in the Polish Population. Hum. Immunol. 71, 195&#x2013;200. 10.1016/j.humimm.2009.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2009.11.006</ArticleId><ArticleId IdType="pubmed">19913589</ArticleId></ArticleIdList></Reference><Reference><Citation>Popescu D.-M., Botting R. A., Stephenson E., Green K., Webb S., Jardine L., et al. (2019). Decoding Human Fetal Liver Haematopoiesis. Nature 574, 365&#x2013;371. 10.1038/s41586-019-1652-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1652-y</ArticleId><ArticleId IdType="pmc">PMC6861135</ArticleId><ArticleId IdType="pubmed">31597962</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimifar S., Erfani N., Sarraf Z., Ghaderi A. (2010). CTLA-4 Gene Variations May Influence Cervical Cancer Susceptibility. Gynecol. Oncol. 119, 136&#x2013;139. 10.1016/j.ygyno.2010.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2010.06.006</ArticleId><ArticleId IdType="pubmed">20615526</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmani F., Hasanzadeh M., Hassanian S. M., Khazaei M., Esmaily H., Asef-Agah s. A., et al. (2020). Association of a Genetic Variant in the Angiopoietin-like Protein 4 Gene with Cervical Cancer. Pathol. - Res. Pract. 216, 153011. 10.1016/j.prp.2020.153011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prp.2020.153011</ArticleId><ArticleId IdType="pubmed">32534714</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar T., Sabitha K., Vijayalakshmi N., Shirley S., Bose M. V., Gopal G., et al. (2011). Identification and Validation of Genes Involved in Cervical Tumourigenesis. BMC Cancer 11, 80. 10.1186/1471-2407-11-80</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-11-80</ArticleId><ArticleId IdType="pmc">PMC3050856</ArticleId><ArticleId IdType="pubmed">21338529</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich M., Liefeld T., Gould J., Lerner J., Tamayo P., Mesirov J. P. (2006). GenePattern 2.0. Nat. Genet. 38, 500&#x2013;501. 10.1038/ng0506-500</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0506-500</ArticleId><ArticleId IdType="pubmed">16642009</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez A. C., Schiffman M., Herrero R., Wacholder S., Hildesheim A., Castle P. E., et al. (2008). Rapid Clearance of Human Papillomavirus and Implications for Clinical Focus on Persistent Infections. JNCI J. Natl. Cancer Inst. 100, 513&#x2013;517. 10.1093/jnci/djn044</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djn044</ArticleId><ArticleId IdType="pmc">PMC3705579</ArticleId><ArticleId IdType="pubmed">18364507</ArticleId></ArticleIdList></Reference><Reference><Citation>Roepman P., Jassem J., Smit E. F., Muley T., Niklinski J., van de Velde T., et al. (2009). An Immune Response Enriched 72-gene Prognostic Profile for Early-Stage Non-small-cell Lung Cancer. Clin. Cancer Res. 15, 284&#x2013;290. 10.1158/1078-0432.CCR-08-1258</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-08-1258</ArticleId><ArticleId IdType="pubmed">19118056</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh W., Chen P.-L., Reuben A., Spencer C. N., Prieto P. A., Miller J. P., et al. (2017). Integrated Molecular Analysis of Tumor Biopsies on Sequential CTLA-4 and PD-1 Blockade Reveals Markers of Response and Resistance. Sci. Transl. Med. 9, eaah3560. 10.1126/scitranslmed.aah3560</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aah3560</ArticleId><ArticleId IdType="pmc">PMC5819607</ArticleId><ArticleId IdType="pubmed">28251903</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellens J. H. M., Marabelle A., Zeigenfuss S., Ding J., Pruitt S. K., Chung H. C. (2017). Pembrolizumab for Previously Treated Advanced Cervical Squamous Cell Cancer: Preliminary Results from the Phase 2 KEYNOTE-158 Study. Jco 35, 5514. 10.1200/jco.2017.35.15_suppl.5514</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2017.35.15_suppl.5514</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher T. N., Schreiber R. D. (2015). Neoantigens in Cancer Immunotherapy. Science 348, 69&#x2013;74. 10.1126/science.aaa4971</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa4971</ArticleId><ArticleId IdType="pubmed">25838375</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata K., Nakayama T., Hirakawa H., Hidaka S., Nagayasu T. (2010). Clinicopathological Significance of Angiopoietin-like Protein 4 Expression in Oesophageal Squamous Cell Carcinoma. J. Clin. Pathol. 63, 1054&#x2013;1058. 10.1136/jcp.2010.078600</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.2010.078600</ArticleId><ArticleId IdType="pubmed">20861003</ArticleId></ArticleIdList></Reference><Reference><Citation>Song D., Li H., Li H., Dai J. (2015). Effect of Human Papillomavirus Infection on the Immune System and its Role in the Course of Cervical Cancer. Oncol. Lett. 10, 600&#x2013;606. 10.3892/ol.2015.3295</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2015.3295</ArticleId><ArticleId IdType="pmc">PMC4509451</ArticleId><ArticleId IdType="pubmed">26622540</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W., Ren J., Wang C., Ge Y., Fu T. (2020). Analysis of Circular RNA-Related Competing Endogenous RNA Identifies the Immune-Related Risk Signature for Colorectal Cancer. Front. Genet. 11, 505. 10.3389/fgene.2020.00505</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.00505</ArticleId><ArticleId IdType="pmc">PMC7283524</ArticleId><ArticleId IdType="pubmed">32582276</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Z.-y., Chao F., Zhuo Z., Ma Z., Li W., Chen G. (2019). Identification of Hub Genes in Prostate Cancer Using Robust Rank Aggregation and Weighted Gene Co-expression Network Analysis. Aging 11, 4736&#x2013;4756. 10.18632/aging.102087</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.102087</ArticleId><ArticleId IdType="pmc">PMC6660050</ArticleId><ArticleId IdType="pubmed">31306099</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalinger M. R., Manzini R., Hering L., Riggs J. B., Gottier C., Lang S., et al. (2018). PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer. Cel Rep. 22, 1835&#x2013;1848. 10.1016/j.celrep.2018.01.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.01.052</ArticleId><ArticleId IdType="pmc">PMC6636824</ArticleId><ArticleId IdType="pubmed">29444435</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Tamayo P., Mootha V. K., Mukherjee S., Ebert B. L., Gillette M. A., et al. (2005). Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-wide Expression Profiles. Proc. Natl. Acad. Sci. 102, 15545&#x2013;15550. 10.1073/pnas.0506580102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka J., Iri&#xe9; T., Yamamoto G., Yasuhara R., Isobe T., Hokazono C., et al. (2015). ANGPTL4 Regulates the Metastatic Potential of Oral Squamous Cell Carcinoma. J. Oral Pathol. Med. 44, 126&#x2013;133. 10.1111/jop.12212</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jop.12212</ArticleId><ArticleId IdType="pubmed">25060575</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T. C., Conti P. (2004). Mast Cells: The JEKYLL and HYDE of Tumor Growth. Trends Immunol. 25, 235&#x2013;241. 10.1016/j.it.2004.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2004.02.013</ArticleId><ArticleId IdType="pubmed">15099563</ArticleId></ArticleIdList></Reference><Reference><Citation>Utrera-Barillas D., Castro-Manrreza M., Castellanos E., Guti&#xe9;rrez-Rodr&#xed;guez M., Arciniega-Ru&#xed;z de Esparza O., Garc&#xed;a-Cebada J., et al. (2010). The Role of Macrophages and Mast Cells in Lymphangiogenesis and Angiogenesis in Cervical Carcinogenesis. Exp. Mol. Pathol. 89, 190&#x2013;196. 10.1016/j.yexmp.2010.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2010.06.002</ArticleId><ArticleId IdType="pubmed">20599941</ArticleId></ArticleIdList></Reference><Reference><Citation>Varricchi G., Galdiero M. R., Loffredo S., Marone G., Iannone R., Marone G., et al. (2017a). Are Mast Cells MASTers in Cancer? Front. Immunol. 8, 424. 10.3389/fimmu.2017.00424</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00424</ArticleId><ArticleId IdType="pmc">PMC5388770</ArticleId><ArticleId IdType="pubmed">28446910</ArticleId></ArticleIdList></Reference><Reference><Citation>Varricchi G., Galdiero M. R., Marone G., Granata F., Borriello F., Marone G. (2017b). Controversial Role of Mast Cells in Skin Cancers. Exp. Dermatol. 26, 11&#x2013;17. 10.1111/exd.13107</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/exd.13107</ArticleId><ArticleId IdType="pubmed">27305467</ArticleId></ArticleIdList></Reference><Reference><Citation>Vickers A. J., Elkin E. B. (2006). Decision Curve Analysis: A Novel Method for Evaluating Prediction Models. Med. Decis. Making 26, 565&#x2013;574. 10.1177/0272989X06295361</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X06295361</ArticleId><ArticleId IdType="pmc">PMC2577036</ArticleId><ArticleId IdType="pubmed">17099194</ArticleId></ArticleIdList></Reference><Reference><Citation>Walboomers J. M. M., Jacobs M. V., Manos M. M., Bosch F. X., Kummer J. A., Shah K. V., et al. (1999). Human Papillomavirus Is a Necessary Cause of Invasive Cervical Cancer Worldwide. J. Pathol. 189, 12&#x2013;19. 10.1002/(SICI)1096-989610.1002/(sici)1096-9896(199909)189:1&lt;12::aid-path431&gt;3.0.co;2-f</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-989610.1002/(sici)1096-9896(199909)189:1&lt;12::aid-path431&gt;3.0.co;2-f</ArticleId><ArticleId IdType="pubmed">10451482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. S., Bratti M. C., Rodr&#xed;guez A. C., Herrero R., Burk R. D., Porras C., et al. (2009). Common Variants in Immune and DNA Repair Genes and Risk for Human Papillomavirus Persistence and Progression to Cervical Cancer. J. Infect. Dis. 199, 20&#x2013;30. 10.1086/595563</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/595563</ArticleId><ArticleId IdType="pmc">PMC3690375</ArticleId><ArticleId IdType="pubmed">19012493</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels D., Srikantha T., Yi S., Kuhl S., Aravind L., Soll D. R. (2006). The Shwachman-Bodian-Diamond Syndrome Gene Encodes an RNA-Binding Protein that Localizes to the Pseudopod of Dictyostelium Amoebae during Chemotaxis. J. Cel Sci. 119, 370&#x2013;379. 10.1242/jcs.02753</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.02753</ArticleId><ArticleId IdType="pubmed">16410554</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk M., Liszka &#x142;., Pale&#x144; P., Gabriel A., Lauda&#x144;ski P. (2010). Intensity of Angiogenesis and Mast Cell Infiltration in Cervical Intraepithelial and Invasive Lesions - Are They Correlated? Pathol. - Res. Pract. 206, 217&#x2013;222. 10.1016/j.prp.2009.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prp.2009.10.005</ArticleId><ArticleId IdType="pubmed">20188487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolbers M., Koller M. T., Witteman J. C. M., Steyerberg E. W. (2009). Prognostic Models with Competing Risks. Epidemiology 20, 555&#x2013;561. 10.1097/EDE.0b013e3181a39056</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181a39056</ArticleId><ArticleId IdType="pubmed">19367167</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G., Wang L.-G., Han Y., He Q.-Y. (2012a). ClusterProfiler: An R Package for Comparing Biological Themes Among Gene Clusters. OMICS: A J. Integr. Biol. 16, 284&#x2013;287. 10.1089/omi.2011.0118</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L., Han Y., Berens M. E. (2012b). Stable Gene Selection from Microarray Data via Sample Weighting. Ieee/acm Trans. Comput. Biol. Bioinforma. 9, 262&#x2013;272. 10.1109/TCBB.2011.47</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TCBB.2011.47</ArticleId><ArticleId IdType="pubmed">21383420</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Wang X., Chen X., Zhang Q., Hong J. (2020). Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma. Front. Genet. 11, 363. 10.3389/fgene.2020.00363</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.00363</ArticleId><ArticleId IdType="pmc">PMC7174786</ArticleId><ArticleId IdType="pubmed">32351547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Fye S., Borecki I. B., Rader J. S. (2014). Polymorphisms in Immune Mediators Associate with Risk of Cervical Cancer. Gynecol. Oncol. 135, 69&#x2013;73. 10.1016/j.ygyno.2014.07.106</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2014.07.106</ArticleId><ArticleId IdType="pmc">PMC4198466</ArticleId><ArticleId IdType="pubmed">25127987</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z., Wang N., Woodson S. E., Dong Q., Wang J., Liang Y., et al. (2011). Antiviral Activities of ISG20 in Positive-Strand RNA Virus Infections. Virology 409, 175&#x2013;188. 10.1016/j.virol.2010.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2010.10.008</ArticleId><ArticleId IdType="pmc">PMC3018280</ArticleId><ArticleId IdType="pubmed">21036379</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X., Guo X., Wu S., Wei L. (2016). ANGPTL4 Correlates with NSCLC Progression and Regulates Epithelial-Mesenchymal Transition via ERK Pathway. Lung 194, 637&#x2013;646. 10.1007/s00408-016-9895-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-016-9895-y</ArticleId><ArticleId IdType="pubmed">27166634</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34278492</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1791-3004</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Molecular medicine reports</Title><ISOAbbreviation>Mol Med Rep</ISOAbbreviation></Journal><ArticleTitle>hsa_circ_0101119 facilitates the progression of cervical cancer via an interaction with EIF4A3 to inhibit TCEAL6 expression.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">654</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3892/mmr.2021.12293</ELocationID><Abstract><AbstractText>Recently, circular RNAs (circRNAs/circs) have attracted increased attention due to their regulatory role in a variety of cancer types. However, the role and molecular mechanisms of circRNAs in cervical cancer (CC) remain unknown. The present study aimed to investigate the function of hsa_ circ_0101119 on CC and its potential mechanisms. The differentially expressed circRNAs associated with CC were screened out using R software, according to the database of Gene Expression Omnibus (GEO). The expression levels of hsa_circ_0101119, eukaryotic initiation factor&#xa0;4A&#x2011;3 (EIF4A3) and transcription elongation factor A&#x2011;like&#xa0;6 (TCEAL6) in CC cells were detected via reverse transcription&#x2011;quantitative (RT&#x2011;q)PCR, and their expression levels in CC tissues were analyzed based on the database of GEO and the Cancer Genome Atlas. Moreover, the accurate functions of hsa_circ_0101119 and TCEAL6 on the proliferation, apoptosis, migration and invasion of SiHa and HeLa cells was examined using colony formation assay, 5&#x2011;ethynyl&#x2011;20&#x2011;deoxyuridine incorporation assay, flow cytometry and Transwell assay. Next, the underlying mechanisms of hsa_circ_0101119 on CC progression were determined via bioinformatics analysis, RNA immunoprecipitation assay, RNA pull down assay, RT&#x2011;qPCR and western blotting. It was found that hsa_circ_0101119 was highly expressed in CC tissues and cells, while TCEAL6 was lowly expressed. Knockdown of hsa_circ_0101119 or TCEAL6 overexpression significantly inhibited the proliferation, migration and invasion of SiHa and HeLa cells, but facilitated apoptosis. It was also demonstrated that hsa_circ_0101119 could recruit EIF4A3 to inhibit TCEAL6 expression in CC. Furthermore, knockdown of TCEAL6 could reverse the effects of silencing hsa_circ_0101119 on the proliferation, apoptosis, migration and invasion of HeLa cells. In conclusion, the present study revealed that hsa_circ_0101119 could facilitate cell proliferation, migration and invasion, and suppress apoptosis in CC via an interaction with EIF4A3 to inhibit TCEAL6 expression, which may provide a potential therapeutic target for CC treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sui</LastName><ForeName>Xuezuo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gynaecology and Obstetrics, Yantai Hospital of Traditional Chinese Medicine, Yantai, Shandong 264013, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanchun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynaecology and Obstetrics, Yantai Hospital of Traditional Chinese Medicine, Yantai, Shandong 264013, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gynaecology and Obstetrics, Yantai Hospital of Traditional Chinese Medicine, Yantai, Shandong 264013, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Mol Med Rep</MedlineTA><NlmUniqueID>101475259</NlmUniqueID><ISSNLinking>1791-2997</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039621">Eukaryotic Initiation Factor-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000079962">RNA, Circular</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035602">Transcriptional Elongation Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="D039601">Eukaryotic Initiation Factor-4A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C403493">EIF4A3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053487" MajorTopicYN="N">DEAD-box RNA Helicases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039621" MajorTopicYN="N">Eukaryotic Initiation Factor-3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039601" MajorTopicYN="N">Eukaryotic Initiation Factor-4A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079962" MajorTopicYN="N">RNA, Circular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035602" MajorTopicYN="N">Transcriptional Elongation Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">eukaryotic initiation factor&#xa0;4A&#x2011;3</Keyword><Keyword MajorTopicYN="N">hsa_circular RNA_0101119</Keyword><Keyword MajorTopicYN="N">metastasis</Keyword><Keyword MajorTopicYN="N">proliferation</Keyword><Keyword MajorTopicYN="N">transcription elongation factor A&#x2011;like&#xa0;6</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34278492</ArticleId><ArticleId IdType="pmc">PMC8299197</ArticleId><ArticleId IdType="doi">10.3892/mmr.2021.12293</ArticleId><ArticleId IdType="pii">654</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jemal A, Bray F, Center MM, Ferlay J, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69&#x2013;90. doi: 10.3322/caac.20107.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.20107</ArticleId><ArticleId IdType="pubmed">21296855</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7&#x2013;34. doi: 10.3322/caac.21551.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21551</ArticleId><ArticleId IdType="pubmed">30620402</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler TA. Cervical cancer: Prevention and early detection. Semin Oncol Nurs. 2017;33:172&#x2013;183. doi: 10.1016/j.soncn.2017.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.soncn.2017.02.005</ArticleId><ArticleId IdType="pubmed">28343836</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright JD, Chen L, Tergas AI, Burke WM, Hou JY, Neugut AI, Ananth CV, Hershman DL. Population-level trends in relative survival for cervical cancer. Am J Obstet Gynecol. 2015;213:670.e1&#x2013;e7. doi: 10.1016/j.ajog.2015.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2015.07.012</ArticleId><ArticleId IdType="pmc">PMC4631664</ArticleId><ArticleId IdType="pubmed">26210758</ArticleId></ArticleIdList></Reference><Reference><Citation>Hentze MW, Preiss T. Circular RNAs: Splicing's enigma variations. EMBO J. 2013;32:923&#x2013;925. doi: 10.1038/emboj.2013.53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2013.53</ArticleId><ArticleId IdType="pmc">PMC3616293</ArticleId><ArticleId IdType="pubmed">23463100</ArticleId></ArticleIdList></Reference><Reference><Citation>Han B, Chao J, Yao H. Circular RNA and its mechanisms in disease: From the bench to the clinic. Pharmacol Ther. 2018;187:31&#x2013;44. doi: 10.1016/j.pharmthera.2018.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2018.01.010</ArticleId><ArticleId IdType="pubmed">29406246</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzman J. Circular RNA expression: Its potential regulation and function. Trends Genet. 2016;32:309&#x2013;316. doi: 10.1016/j.tig.2016.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2016.03.002</ArticleId><ArticleId IdType="pmc">PMC4948998</ArticleId><ArticleId IdType="pubmed">27050930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebbesen KK, Kjems J, Hansen TB. Circular RNAs: Identification, biogenesis and function. Biochim Biophys Acta. 2016;1859:163&#x2013;168. doi: 10.1016/j.bbagrm.2015.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagrm.2015.07.007</ArticleId><ArticleId IdType="pubmed">26171810</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Zhang P, Xu M, Yan L, Liu N, Wu X. Circular RNA hsa_circ_0000263 participates in cervical cancer development by regulating target gene of miR-150-5p. J Cell Physiol. 2019;234:11391&#x2013;11400. doi: 10.1002/jcp.27796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27796</ArticleId><ArticleId IdType="pubmed">30569515</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou R, Lv J, Zhang Q, Lin F, Zhu L, Huang F, Li X, Li T, Zhao L, Ren Y, Xu Y. circAMOTL1 Motivates AMOTL1 expression to facilitate cervical cancer growth. Mol Ther Nucleic Acids. 2020;19:50&#x2013;60. doi: 10.1016/j.omtn.2019.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.09.022</ArticleId><ArticleId IdType="pmc">PMC6906701</ArticleId><ArticleId IdType="pubmed">31812104</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YM, Huang LM, Li DR, Shao JH, Xiong SL, Wang CM, Lu SM. Hsa_circ_0101996 combined with hsa_circ_0101119 in peripheral whole blood can serve as the potential biomarkers for human cervical squamous cell carcinoma. Int J Clin Exp Pathol. 2017;10:11924&#x2013;11931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6966017</ArticleId><ArticleId IdType="pubmed">31966557</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Y, Zhang L, Li Y. circEIF4G2 modulates the malignant features of cervical cancer via the miR-218/HOXA1 pathway. Mol Med Rep. 2019;19:3714&#x2013;3722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6471440</ArticleId><ArticleId IdType="pubmed">30896864</ArticleId></ArticleIdList></Reference><Reference><Citation>Song T, Xu A, Zhang Z, Gao F, Zhao L, Chen X, Gao J, Kong X. CircRNA hsa_circRNA_101996 increases cervical cancer proliferation and invasion through activating TPX2 expression by restraining miR-8075. J Cell Physiol. 2019;234:14296&#x2013;14305. doi: 10.1002/jcp.28128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.28128</ArticleId><ArticleId IdType="pubmed">30633364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32:453&#x2013;461. doi: 10.1038/nbt.2890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2890</ArticleId><ArticleId IdType="pmc">PMC4121655</ArticleId><ArticleId IdType="pubmed">24811520</ArticleId></ArticleIdList></Reference><Reference><Citation>He JH, Li YG, Han ZP, Zhou JB, Chen WM, Lv YB, He ML, Zuo JD, Zheng L. The CircRNA-ACAP2/Hsa-miR-21-5p/ tiam1 regulatory feedback circuit affects the proliferation, migration, and invasion of colon cancer SW480 cells. Cell Physiol Biochem. 2018;49:1539&#x2013;1550. doi: 10.1159/000493457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000493457</ArticleId><ArticleId IdType="pubmed">30212824</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaichian S, Shafabakhsh R, Mirhashemi SM, Moazzami B, Asemi Z. Circular RNAs: A novel biomarker for cervical cancer. J Cell Physiol. 2020;235:718&#x2013;724. doi: 10.1002/jcp.29009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.29009</ArticleId><ArticleId IdType="pubmed">31240697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauer C, Curk T, Anders S, Schwarzl T, Alleaume AM, Sieber J, Hollerer I, Bhuvanagiri M, Huber W, Hentze MW, Kulozik AE. Improved binding site assignment by high-resolution mapping of RNA-protein interactions using iCLIP. Nat Commun. 2015;6:7921. doi: 10.1038/ncomms8921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8921</ArticleId><ArticleId IdType="pmc">PMC4918375</ArticleId><ArticleId IdType="pubmed">26260686</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Zhang J, Cai J, Liang R, Chen G, Qin G, Han X, Yuan C, Liu Z, Li Y, et al. Systematic analysis of gene expression alteration and co-expression network of eukaryotic initiation factor 4A-3 in CANcer. J Cancer. 2018;9:4568&#x2013;4577. doi: 10.7150/jca.27655.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.27655</ArticleId><ArticleId IdType="pmc">PMC6299400</ArticleId><ArticleId IdType="pubmed">30588240</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh CH, Shatkin AJ. A HeLa-cell-encoded p21 is homologous to transcription elongation factor SII. Gene. 1994;143:285&#x2013;287. doi: 10.1016/0378-1119(94)90112-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0378-1119(94)90112-0</ArticleId><ArticleId IdType="pubmed">8206389</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh CH, Shatkin AJ. Down-regulation of rous sarcoma virus long terminal repeat promoter activity by a hela cell basic protein. Proc Natl Acad Sci USA. 1994;91:11002&#x2013;11006. doi: 10.1073/pnas.91.23.11002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.23.11002</ArticleId><ArticleId IdType="pmc">PMC45154</ArticleId><ArticleId IdType="pubmed">7971997</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillutla RC, Shimamoto A, Furuichi Y, Shatkin AJ. Genomic structure and chromosomal localization of TCEAL1, a human gene encoding the nuclear phosphoprotein p21/SIIR. Genomics. 1999;56:217&#x2013;220. doi: 10.1006/geno.1998.5705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/geno.1998.5705</ArticleId><ArticleId IdType="pubmed">10051408</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CY, Chen YM, Zhao JJ, Chen YB, Jiang SS, Yan SM, Zhao BW, Pan K, Wang DD, Lv L, et al. Decreased expression of transcription elongation factor A-like 7 is associated with gastric adenocarcinoma prognosis. PLoS One. 2013;8:e54671. doi: 10.1371/journal.pone.0054671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0054671</ArticleId><ArticleId IdType="pmc">PMC3555988</ArticleId><ArticleId IdType="pubmed">23372750</ArticleId></ArticleIdList></Reference><Reference><Citation>Orhan C, Bulut P, Dalay N, Ersen E, Buyru N. Downregulation of TCEAL7 expression induces CCND1 expression in non-small cell lung cancer. Mol Biol Rep. 2019;46:5251&#x2013;5256. doi: 10.1007/s11033-019-04982-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-019-04982-6</ArticleId><ArticleId IdType="pubmed">31321645</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien J, Staub J, Avula R, Zhang H, Liu W, Hartmann LC, Kaufmann SH, Smith DI, Shridhar V. Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene. 2005;24:5089&#x2013;5100. doi: 10.1038/sj.onc.1208700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208700</ArticleId><ArticleId IdType="pubmed">15870691</ArticleId></ArticleIdList></Reference><Reference><Citation>Biewenga P, Buist MR, Moerland PD, Ver Loren van Themaat E, van Kampen AH, ten Kate FJ, Baas F. Gene expression in early stage cervical cancer. Gynecol Oncol. 2008;108:520&#x2013;526. doi: 10.1016/j.ygyno.2007.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2007.11.024</ArticleId><ArticleId IdType="pubmed">18191186</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao J, Zhang T, Jiao X, Huang T, Zhao L, Ma D, Cui B. hsa_circ_0000745 promotes cervical cancer by increasing cell proliferation, migration, and invasion. J Cell Physiol. 2020;235:1287&#x2013;1295. doi: 10.1002/jcp.29045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.29045</ArticleId><ArticleId IdType="pmc">PMC6899562</ArticleId><ArticleId IdType="pubmed">31256433</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402&#x2013;408. doi: 10.1006/meth.2001.1262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Inhibition of invasion and MMPs by a nutrient mixture in human cancer cell lines: A correlation study. Ex Oncol. 2010;32:243&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">21270751</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi R, Arora H, Rizvi MA. EMT in cervical cancer: Its role in tumour progression and response to therapy. Cancer Lett. 2015;356:321&#x2013;331. doi: 10.1016/j.canlet.2014.09.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2014.09.021</ArticleId><ArticleId IdType="pubmed">25281477</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87&#x2013;108. doi: 10.3322/caac.21262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21262</ArticleId><ArticleId IdType="pubmed">25651787</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny L. Cervical cancer: Prevention and treatment. Discov Med. 2012;14:125&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">22935209</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragomir M, Calin GA. Circular RNAs in cancer-lessons learned from microRNAs. Front Oncol. 2018;8:179. doi: 10.3389/fonc.2018.00307.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2018.00307</ArticleId><ArticleId IdType="pmc">PMC5992376</ArticleId><ArticleId IdType="pubmed">29911069</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Ding W, Sun T, Tariq MA, Xu T, Li P, Wang J. Biogenesis of circular RNAs and their roles in cardiovascular development and pathology. FEBS J. 2018;285:220&#x2013;232. doi: 10.1111/febs.14191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.14191</ArticleId><ArticleId IdType="pubmed">28783257</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong L, Sun Q, Zhang H, Chen Z, Deng Y, Li D, Zhang L. Increased expression of circRNA_102231 in lung cancer and its clinical significance. Biomed Pharmacother. 2018;102:639&#x2013;644. doi: 10.1016/j.biopha.2018.03.084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.03.084</ArticleId><ArticleId IdType="pubmed">29602132</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Zhao X, Zheng X, Li F. Circular RNA hsa_circ_0023404 exerts an oncogenic role in cervical cancer through regulating miR-136/TFCP2/YAP pathway. Biochem Biophys Res Commun. 2018;501:428&#x2013;433. doi: 10.1016/j.bbrc.2018.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2018.05.006</ArticleId><ArticleId IdType="pubmed">29738762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu C, Wang Y, Li A, Zhang J, Xue F, Zhu L. Overexpressed circ_0067934 acts as an oncogene to facilitate cervical cancer progression via the miR-545/EIF3C axis. J Cell Physiol. 2019;234:9225&#x2013;9232. doi: 10.1002/jcp.27601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27601</ArticleId><ArticleId IdType="pubmed">30362562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Li H, Liang Z. circ-MYBL2 serves as a sponge for miR-361-3p promoting cervical cancer cells proliferation and invasion. Onco Targets Ther. 2019;12:9957&#x2013;9964. doi: 10.2147/OTT.S218976.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S218976</ArticleId><ArticleId IdType="pmc">PMC6877451</ArticleId><ArticleId IdType="pubmed">31819492</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Mao L, Shi R, Wang W, Cheng J. circRNA MYLK accelerates cervical cancer via Up-Regulation of RHEB and activation of mTOR signaling. Cancer Manag Res. 2020;12:3611&#x2013;3621. doi: 10.2147/CMAR.S238172.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CMAR.S238172</ArticleId><ArticleId IdType="pmc">PMC7245433</ArticleId><ArticleId IdType="pubmed">32547198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang L, Wang W, Guo X. Overexpression of circular RNA hsa_circ_0001038 promotes cervical cancer cell progression by acting as a ceRNA for miR-337-3p to regulate cyclin-M3 and metastasis-associated in colon cancer 1 expression. Gene. 2020;733:144273. doi: 10.1016/j.gene.2019.144273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2019.144273</ArticleId><ArticleId IdType="pubmed">31809842</ArticleId></ArticleIdList></Reference><Reference><Citation>Panda AC, Abdelmohsen K, Martindale JL, Di Germanio C, Yang X, Grammatikakis I, Noh JH, Zhang Y, Lehrmann E, Dudekula DB, et al. Novel RNA-binding activity of MYF5 enhances Ccnd1/Cyclin D1 mRNA translation during myogenesis. Nucleic Acids Res. 2016;44:2393&#x2013;2408. doi: 10.1093/nar/gkw023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw023</ArticleId><ArticleId IdType="pmc">PMC4797292</ArticleId><ArticleId IdType="pubmed">26819411</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazloomian A, Araki S, Ohori M, El-Naggar AM, Yap D, Bashashati A, Nakao S, Sorensen PH, Nakanishi A, Shah S, Aparicio S. Pharmacological systems analysis defines EIF4A3 functions in cell-cycle and RNA stress granule formation. Commun Biol. 2019;2:165. doi: 10.1038/s42003-019-0391-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-019-0391-9</ArticleId><ArticleId IdType="pmc">PMC6499833</ArticleId><ArticleId IdType="pubmed">31069274</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Huang M, Xing L, Yang R, Wang X, Jiang R, Zhang L, Chen J. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer. Mol Cancer. 2020;19:73. doi: 10.1186/s12943-020-01183-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-020-01183-9</ArticleId><ArticleId IdType="pmc">PMC7137343</ArticleId><ArticleId IdType="pubmed">32264877</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B, Yang N, Liu Y, Kong P, Han M, Li B. Circ_cse1l Inhibits Colorectal Cancer Proliferation by Binding to eIF4A3. Med Sci Monit. 2020;26:e923876. doi: 10.12659/MSM.923876.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.923876</ArticleId><ArticleId IdType="pmc">PMC7477927</ArticleId><ArticleId IdType="pubmed">32857753</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun HD, Xu ZP, Sun ZQ, Zhu B, Wang Q, Zhou J, Jin H, Zhao A, Tang WW, Cao XF. Down-regulation of circPVRL3 promotes the proliferation and migration of gastric cancer cells. Sci Rep. 2018;8:10111. doi: 10.1038/s41598-018-27837-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-27837-9</ArticleId><ArticleId IdType="pmc">PMC6031698</ArticleId><ArticleId IdType="pubmed">29973643</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W, Wang D, Shao L, Liu X, Zheng J, Xue Y, Ruan X, Yang C, Liu L, Ma J, et al. LINC00680 and TTN-AS1 stabilized by EIF4A3 promoted malignant biological behaviors of glioblastoma cells. Mol Ther Nucleic Acids. 2020;19:905&#x2013;921. doi: 10.1016/j.omtn.2019.10.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.10.043</ArticleId><ArticleId IdType="pmc">PMC7063483</ArticleId><ArticleId IdType="pubmed">32000032</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya T, Tange T&#xd8;, Sonenberg N, Moore MJ. eIF4AIII binds spliced mRNA in the exon junction complex and is essential for nonsense-mediated decay. Nat Struct Mol Biol. 2004;11:346&#x2013;351. doi: 10.1038/nsmb750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb750</ArticleId><ArticleId IdType="pubmed">15034551</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34174849</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2407</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>26</Day></PubDate></JournalIssue><Title>BMC cancer</Title><ISOAbbreviation>BMC Cancer</ISOAbbreviation></Journal><ArticleTitle>Bioinformatics analysis of differentially expressed genes and pathways in the development of cervical cancer.</ArticleTitle><Pagination><StartPage>733</StartPage><MedlinePgn>733</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">733</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-021-08412-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aimed to explore and identify key genes and signaling pathways that contribute to the progression of cervical cancer to improve prognosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Three gene expression profiles (GSE63514, GSE64217 and GSE138080) were screened and downloaded from the Gene Expression Omnibus database (GEO). Differentially expressed genes (DEGs) were screened using the GEO2R and Venn diagram tools. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. Gene set enrichment analysis (GSEA) was performed to analyze the three gene expression profiles. Moreover, a protein-protein interaction (PPI) network of the DEGs was constructed, and functional enrichment analysis was performed. On this basis, hub genes from critical PPI subnetworks were explored with Cytoscape software. The expression of these genes in tumors was verified, and survival analysis of potential prognostic genes from critical subnetworks was conducted. Functional annotation, multiple gene comparison and dimensionality reduction in candidate genes indicated the clinical significance of potential targets.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 476 DEGs were screened: 253 upregulated genes and 223 downregulated genes. DEGs were enriched in 22 biological processes, 16 cellular components and 9 molecular functions in precancerous lesions and cervical cancer. DEGs were mainly enriched in 10 KEGG pathways. Through intersection analysis and data mining, 3 key KEGG pathways and related core genes were revealed by GSEA. Moreover, a PPI network of 476 DEGs was constructed, hub genes from 12 critical subnetworks were explored, and a total of 14 potential molecular targets were obtained.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings promote the understanding of the molecular mechanism of and clinically related molecular targets for cervical cancer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Baojie</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd., Pilot Department, Building 9, 1690 Zhangheng Road Pudong, Shanghai, 201203, China. w3522021987@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xi</LastName><ForeName>Shuyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd., Pilot Department, Building 9, 1690 Zhangheng Road Pudong, Shanghai, 201203, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cancer</MedlineTA><NlmUniqueID>100967800</NlmUniqueID><ISSNLinking>1471-2407</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioinformatics analysis</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Cervical intraepithelial neoplasia</Keyword><Keyword MajorTopicYN="N">Differentially expressed genes</Keyword><Keyword MajorTopicYN="N">Functional enrichments</Keyword></KeywordList><CoiStatement>The author declares that he/she has no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>27</Day><Hour>20</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34174849</ArticleId><ArticleId IdType="pmc">PMC8236200</ArticleId><ArticleId IdType="doi">10.1186/s12885-021-08412-4</ArticleId><ArticleId IdType="pii">10.1186/s12885-021-08412-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394&#x2013;424. doi: 10.3322/caac.21492.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, Gao C, Ma D, Liao S. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Lett. 2020;471:88&#x2013;102. doi: 10.1016/j.canlet.2019.11.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2019.11.039</ArticleId><ArticleId IdType="pubmed">31812696</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto AP, Crum CP. Natural history of cervical neoplasia: defining progression and its consequence. Clin Obstet Gynecol. 2000;43(2):352&#x2013;362. doi: 10.1097/00003081-200006000-00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003081-200006000-00015</ArticleId><ArticleId IdType="pubmed">10863633</ArticleId></ArticleIdList></Reference><Reference><Citation>den Boon JA, Pyeon D, Wang SS, Horswill M, Schiffman M, Sherman M, Zuna RE, Wang Z, Hewitt SM, Pearson R, Schott M, Chung L, He Q, Lambert P, Walker J, Newton MA, Wentzensen N, Ahlquist P. Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S A. 2015;112(25):E3255&#x2013;E3264. doi: 10.1073/pnas.1509322112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1509322112</ArticleId><ArticleId IdType="pmc">PMC4485108</ArticleId><ArticleId IdType="pubmed">26056290</ArticleId></ArticleIdList></Reference><Reference><Citation>Babion I, Miok V, Jaspers A, Huseinovic A, Steenbergen RDM, van Wieringen WN, et al. Identification of deregulated pathways, key regulators, and novel miRNA-mRNA interactions in HPV-mediated transformation. Cancers (Basel). 2020;12(3):700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7140059</ArticleId><ArticleId IdType="pubmed">32188026</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991&#x2013;D995. doi: 10.1093/nar/gks1193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1193</ArticleId><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207&#x2013;210. doi: 10.1093/nar/30.1.207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/30.1.207</ArticleId><ArticleId IdType="pmc">PMC99122</ArticleId><ArticleId IdType="pubmed">11752295</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007;35(Web Server issue):W169&#x2013;W175. doi: 10.1093/nar/gkm415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkm415</ArticleId><ArticleId IdType="pmc">PMC1933169</ArticleId><ArticleId IdType="pubmed">17576678</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27&#x2013;30. doi: 10.1093/nar/28.1.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/28.1.27</ArticleId><ArticleId IdType="pmc">PMC102409</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545&#x2013;15550. doi: 10.1073/pnas.0506580102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstr&#xe5;le M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267&#x2013;273. doi: 10.1038/ng1180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1180</ArticleId><ArticleId IdType="pubmed">12808457</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering C. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607&#x2013;d613. doi: 10.1093/nar/gky1131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498&#x2013;2504. doi: 10.1101/gr.1239303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003;4(1):2. doi: 10.1186/1471-2105-4-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-4-2</ArticleId><ArticleId IdType="pmc">PMC149346</ArticleId><ArticleId IdType="pubmed">12525261</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8 Suppl 4(Suppl 4):S11. doi: 10.1186/1752-0509-8-S4-S11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1752-0509-8-S4-S11</ArticleId><ArticleId IdType="pmc">PMC4290687</ArticleId><ArticleId IdType="pubmed">25521941</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98&#x2013;w102. doi: 10.1093/nar/gkx247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx247</ArticleId><ArticleId IdType="pmc">PMC5570223</ArticleId><ArticleId IdType="pubmed">28407145</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta S, Ewing-Graham PC, Swagemakers SMA, van der Spek PJ, van Doorn HC, Noordhoek Hegt V, Koljenovi&#x107; S, van Kemenade FJ. Precursor lesions of vulvar squamous cell carcinoma - histology and biomarkers: a systematic review. Crit Rev Oncol Hematol. 2020;147:102866. doi: 10.1016/j.critrevonc.2020.102866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2020.102866</ArticleId><ArticleId IdType="pubmed">32058913</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal SM, Jr, Gulley ML. Current and emerging molecular tests for human papillomavirus-related neoplasia in the genomic era. J Mol Diagn. 2017;19(3):366&#x2013;377. doi: 10.1016/j.jmoldx.2017.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmoldx.2017.01.006</ArticleId><ArticleId IdType="pmc">PMC5417044</ArticleId><ArticleId IdType="pubmed">28325688</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, Li H, Zhu L, Hu S, Xi X, Liu Y, Liu J, Zhong T. Bioinformatics analysis shows that TOP2A functions as a key candidate gene in the progression of cervical cancer. Biomed Rep. 2020;13(4):21. doi: 10.3892/br.2020.1328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/br.2020.1328</ArticleId><ArticleId IdType="pmc">PMC7403841</ArticleId><ArticleId IdType="pubmed">32765860</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathevet P, Frappart L, Hittelman W. Cervix dysplasias: study of Rb and p53 gene expression and correlation with mitotic activity. Gynecol Obstet Fertil. 2000;28(1):44&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">10774117</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Liu S, Cui M. Effect of BRCA1 on the concurrent Chemoradiotherapy resistance of cervical squamous cell carcinoma based on transcriptome sequencing analysis. Biomed Res Int. 2020;2020:3598417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7333031</ArticleId><ArticleId IdType="pubmed">32685473</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou YH, Fan WF, Deng J, Xi HL. Establishment and analysis of the prediction model for cervical squamous cell carcinoma. Eur Rev Med Pharmacol Sci. 2017;21(22):5042&#x2013;5048. doi: 10.26355/eurrev_201711_13816.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_201711_13816</ArticleId><ArticleId IdType="pubmed">29228452</ArticleId></ArticleIdList></Reference><Reference><Citation>Suman S, Mishra A. An interaction network driven approach for identifying biomarkers for progressing cervical intraepithelial neoplasia. Sci Rep. 2018;8(1):12927. doi: 10.1038/s41598-018-31187-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-31187-x</ArticleId><ArticleId IdType="pmc">PMC6110773</ArticleId><ArticleId IdType="pubmed">30150654</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Yu H, Zhang L, Chen X, Liu Y, Wang Y, Zhang Y. Effect of hyperoside on cervical cancer cells and transcriptome analysis of differentially expressed genes. Cancer Cell Int. 2019;19(1):235. doi: 10.1186/s12935-019-0953-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-019-0953-4</ArticleId><ArticleId IdType="pmc">PMC6734331</ArticleId><ArticleId IdType="pubmed">31516392</ArticleId></ArticleIdList></Reference><Reference><Citation>Manavi M, Hudelist G, Fink-Retter A, Gschwandtler-Kaulich D, Pischinger K, Czerwenka K. Gene profiling in pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. Gynecol Oncol. 2007;105(2):418&#x2013;426. doi: 10.1016/j.ygyno.2006.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2006.12.032</ArticleId><ArticleId IdType="pubmed">17306351</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Xu X, Jin H. Identification of potential miRNAs and candidate genes of cervical intraepithelial neoplasia by bioinformatic analysis. Eur J Gynaecol Oncol. 2016;37(4):469&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">29894068</ArticleId></ArticleIdList></Reference><Reference><Citation>Iancu IV, Botezatu A, Goia-Ru&#x15f;anu CD, St&#x103;nescu A, Huic&#x103; I, Nistor E, Anton G, Ple&#x15f;a A. TGF-beta signalling pathway factors in HPV-induced cervical lesions. Roum Arch Microbiol Immunol. 2010;69(3):113&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">21434587</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong S, Liu X, Zhou N, Yue Y. E2F7, EREG, miR-451a and miR-106b-5p are associated with the cervical cancer development. Arch Gynecol Obstet. 2019;299(4):1089&#x2013;1098. doi: 10.1007/s00404-018-5007-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00404-018-5007-y</ArticleId><ArticleId IdType="pubmed">30607582</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar T, Sabitha K, Vijayalakshmi N, Shirley S, Bose MV, Gopal G, Selvaluxmy G. Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer. 2011;11(1):80. doi: 10.1186/1471-2407-11-80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-11-80</ArticleId><ArticleId IdType="pmc">PMC3050856</ArticleId><ArticleId IdType="pubmed">21338529</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Liu N, Piao J, Meng F, Li Y. CCNB1 expedites the progression of cervical squamous cell carcinoma via the regulation by FOXM1. Onco Targets Ther. 2020;13:12383&#x2013;12395. doi: 10.2147/OTT.S279951.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S279951</ArticleId><ArticleId IdType="pmc">PMC7721124</ArticleId><ArticleId IdType="pubmed">33299327</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K, Yi Y, Liu F, Wu W, Chen Y, Zhang W. Identification of key pathways and genes in the progression of cervical cancer using bioinformatics analysis. Oncol Lett. 2018;16(1):1003&#x2013;1009. doi: 10.3892/ol.2018.8768.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2018.8768</ArticleId><ArticleId IdType="pmc">PMC6019941</ArticleId><ArticleId IdType="pubmed">29963176</ArticleId></ArticleIdList></Reference><Reference><Citation>Klymenko T, Gu Q, Herbert I, Stevenson A, Iliev V, Watkins G, et al. RNA-Seq Analysis of differentiated keratinocytes reveals a massive response to late events during human papillomavirus 16 infection, including loss of epithelial barrier function. J Virol. 2017;91(24):e01001&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5709591</ArticleId><ArticleId IdType="pubmed">29021401</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Nie S, Gao M, Jiang Y, Wan Y, Ma X, Zhou S, Cheng W. Identification of EPHX2 and RMI2 as two novel key genes in cervical squamous cell carcinoma by an integrated bioinformatic analysis. J Cell Physiol. 2019;234(11):21260&#x2013;21273. doi: 10.1002/jcp.28731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.28731</ArticleId><ArticleId IdType="pubmed">31041817</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu HZ, Huang J, Xiang CC, Li R, Zuo ED, Zhang Y, Shan L, Cheng X. Screening and discovery of new potential biomarkers and small molecule drugs for cervical Cancer: a bioinformatics analysis. Technol Cancer Res Treat. 2020;19:1533033820980112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734488</ArticleId><ArticleId IdType="pubmed">33302814</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HJ, Xue JM, Li J, Wan LH, Zhu YX. Identification of key genes and pathways of diagnosis and prognosis in cervical cancer by bioinformatics analysis. Mol Genet Genomic Med. 2020;8(6):e1200. doi: 10.1002/mgg3.1200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mgg3.1200</ArticleId><ArticleId IdType="pmc">PMC7284022</ArticleId><ArticleId IdType="pubmed">32181600</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Q, Ou-Yang W, Zhang M, Wang H, Yue Q. Decreased expression of NUSAP1 predicts poor overall survival in cervical Cancer. J Cancer. 2020;11(10):2852&#x2013;2863. doi: 10.7150/jca.34640.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.34640</ArticleId><ArticleId IdType="pmc">PMC7086256</ArticleId><ArticleId IdType="pubmed">32226503</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dam PA, Rolfo C, Ruiz R, Pauwels P, Van Berckelaer C, Trinh XB, Ferri Gandia J, Bogers JP, Van Laere S. Potential new biomarkers for squamous carcinoma of the uterine cervix. ESMO Open. 2018;3(4):e000352. doi: 10.1136/esmoopen-2018-000352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/esmoopen-2018-000352</ArticleId><ArticleId IdType="pmc">PMC6045706</ArticleId><ArticleId IdType="pubmed">30018810</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue JM, Liu Y, Wan LH, Zhu YX. Comprehensive analysis of differential gene expression to identify common gene signatures in multiple cancers. Med Sci Monit. 2020;26:e919953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7027371</ArticleId><ArticleId IdType="pubmed">32035007</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu DM, Shi J, Liu T, Deng SH, Han R, Xu Y. Integrated analysis reveals down-regulation of SPARCL1 is correlated with cervical cancer development and progression. Cancer Biomark. 2018;21(2):355&#x2013;365. doi: 10.3233/CBM-170501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/CBM-170501</ArticleId><ArticleId IdType="pubmed">29103025</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Y, Shi X, Li B, Peng M, Zhu T, Lv G, Liu L, Jin H, Li L, Qin D. Integrated analysis of key microRNAs /TFs /mRNAs/ in HPV-positive cervical cancer based on microRNA sequencing and bioinformatics analysis. Pathol Res Pract. 2020;216(6):152952. doi: 10.1016/j.prp.2020.152952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prp.2020.152952</ArticleId><ArticleId IdType="pubmed">32307200</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi Y, Liu Y, Wu W, Wu K, Zhang W. Reconstruction and analysis of circRNA-miRNA-mRNA network in the pathology of cervical cancer. Oncol Rep. 2019;41(4):2209&#x2013;2225. doi: 10.3892/or.2019.7028.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2019.7028</ArticleId><ArticleId IdType="pmc">PMC6412533</ArticleId><ArticleId IdType="pubmed">30816541</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourmenskaya O, Shubina E, Trofimov D, Rebrikov D, Sabdulaeva E, Nepsha O, Bozhenko V, Rogovskaya S, Sukhikh G. Host gene expression profiling of cervical smear is eligible for cancer risk evaluation. J Clin Pathol. 2013;66(4):282&#x2013;285. doi: 10.1136/jclinpath-2012-201313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jclinpath-2012-201313</ArticleId><ArticleId IdType="pubmed">23268324</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Zhang Z, Lou H, Liang J, Yan X, Li W, Xu Y, Ou R. Exploration of the molecular mechanisms of cervical cancer based on mRNA expression profiles and predicted microRNA interactions. Oncol Lett. 2018;15(6):8965&#x2013;8972. doi: 10.3892/ol.2018.8494.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2018.8494</ArticleId><ArticleId IdType="pmc">PMC5958731</ArticleId><ArticleId IdType="pubmed">29805632</ArticleId></ArticleIdList></Reference><Reference><Citation>Papasavvas E, Kossenkov AV, Azzoni L, Zetola NM, Mackiewicz A, Ross BN, Fair M, Vadrevu S, Ramogola-Masire D, Sanne I, Firnhaber C, Montaner LJ. Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women. Carcinogenesis. 2019;40(2):225&#x2013;233. doi: 10.1093/carcin/bgy149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgy149</ArticleId><ArticleId IdType="pmc">PMC6487677</ArticleId><ArticleId IdType="pubmed">30364933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur G, Balasubramaniam SD, Lee YJ, Balakrishnan V, Oon CE. Minichromosome maintenance complex (MCM) genes profiling and MCM2 protein expression in cervical Cancer development. Asian Pac J Cancer Prev. 2019;20(10):3043&#x2013;3049. doi: 10.31557/APJCP.2019.20.10.3043.</Citation><ArticleIdList><ArticleId IdType="doi">10.31557/APJCP.2019.20.10.3043</ArticleId><ArticleId IdType="pmc">PMC6982666</ArticleId><ArticleId IdType="pubmed">31653153</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Zhou Y, Shi F, Cao Y, Dinh TLA, Wan J, Zhao M. Investigation of differentially-expressed microRNAs and genes in cervical cancer using an integrated bioinformatics analysis. Oncol Lett. 2017;13(4):2784&#x2013;2790. doi: 10.3892/ol.2017.5766.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2017.5766</ArticleId><ArticleId IdType="pmc">PMC5403204</ArticleId><ArticleId IdType="pubmed">28454467</ArticleId></ArticleIdList></Reference><Reference><Citation>Mine KL, Shulzhenko N, Yambartsev A, Rochman M, Sanson GF, Lando M, Varma S, Skinner J, Volfovsky N, Deng T, et al. Gene network reconstruction reveals cell cycle and antiviral genes as major drivers of cervical cancer. Nat Commun. 2013;4(1):1806. doi: 10.1038/ncomms2693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2693</ArticleId><ArticleId IdType="pmc">PMC4237593</ArticleId><ArticleId IdType="pubmed">23651994</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dam PA, van Dam PJ, Rolfo C, Giallombardo M, van Berckelaer C, Trinh XB, Altintas S, Huizing M, Papadimitriou K, Tjalma WA, van Laere S. In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment. Oncotarget. 2016;7(3):2780&#x2013;2795. doi: 10.18632/oncotarget.6667.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.6667</ArticleId><ArticleId IdType="pmc">PMC4823071</ArticleId><ArticleId IdType="pubmed">26701206</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Wu Y, Peng Y, Liu X, Bie J, Li S. Systematic analysis to identify a key role of CDK1 in mediating gene interaction networks in cervical cancer development. Ir J Med Sci. 2016;185(1):231&#x2013;239. doi: 10.1007/s11845-015-1283-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-015-1283-8</ArticleId><ArticleId IdType="pubmed">25786624</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L, Zeng X, Wang Z, Ji N, Zhou Y, Liu X, Chen Q. Oral cancer overexpressed 1 (ORAOV1) regulates cell cycle and apoptosis in cervical cancer HeLa cells. Mol Cancer. 2010;9(1):20. doi: 10.1186/1476-4598-9-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-4598-9-20</ArticleId><ArticleId IdType="pmc">PMC2825245</ArticleId><ArticleId IdType="pubmed">20105337</ArticleId></ArticleIdList></Reference><Reference><Citation>Mou Z, Xu X, Dong M, Xu J. MicroRNA-148b acts as a tumor suppressor in cervical Cancer by inducing G1/S-phase cell cycle arrest and apoptosis in a Caspase-3-dependent manner. Med Sci Monit. 2016;22:2809&#x2013;2815. doi: 10.12659/MSM.896862.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.896862</ArticleId><ArticleId IdType="pmc">PMC4982527</ArticleId><ArticleId IdType="pubmed">27505047</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Shen YT, Kapoor A, Ojo D, Wei F, De Melo J, Lin X, Wong N, Yan J, Tao L, et al. Dataset on the effects of CYB5D2 on the distribution of HeLa cervical cancer cell cycle. Data Brief. 2016;6:811&#x2013;816. doi: 10.1016/j.dib.2016.01.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dib.2016.01.036</ArticleId><ArticleId IdType="pmc">PMC4749936</ArticleId><ArticleId IdType="pubmed">26937452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao JL, Zhang L, Guo X, Wang JH, Zhou W, Liu M, Li X, Tang H. miR-212/132 downregulates SMAD2 expression to suppress the G1/S phase transition of the cell cycle and the epithelial to mesenchymal transition in cervical cancer cells. IUBMB Life. 2015;67(5):380&#x2013;394. doi: 10.1002/iub.1381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.1381</ArticleId><ArticleId IdType="pubmed">25988335</ArticleId></ArticleIdList></Reference><Reference><Citation>Das M, Prasad SB, Yadav SS, Modi A, Singh S, Pradhan S, Narayan G. HPV-type-specific response of cervical cancer cells to cisplatin after silencing replication licensing factor MCM4. Tumour Biol. 2015;36(12):9987&#x2013;9994. doi: 10.1007/s13277-015-3782-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-015-3782-7</ArticleId><ArticleId IdType="pubmed">26188903</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Li Y, Zhang WY, Xia QJ, Li HG, Wang R, Yang L, Sun XF, Zhou ZG. mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. Eur J Cancer Prev. 2009;18(1):40&#x2013;45. doi: 10.1097/CEJ.0b013e32830c8d5a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CEJ.0b013e32830c8d5a</ArticleId><ArticleId IdType="pubmed">19077563</ArticleId></ArticleIdList></Reference><Reference><Citation>Gakiopoulou H, Korkolopoulou P, Levidou G, Thymara I, Saetta A, Piperi C, Givalos N, Vassilopoulos I, Ventouri K, Tsenga A, Bamias A, Dimopoulos MA, Agapitos E, Patsouris E. Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications. Br J Cancer. 2007;97(8):1124&#x2013;1134. doi: 10.1038/sj.bjc.6603992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6603992</ArticleId><ArticleId IdType="pmc">PMC2360432</ArticleId><ArticleId IdType="pubmed">17940502</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger M, Denzinger S, Hartmann A, Wieland WF, Stoehr R, Obermann EC. Mcm2 predicts recurrence hazard in stage ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Br J Cancer. 2007;96(11):1711&#x2013;1715. doi: 10.1038/sj.bjc.6603784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6603784</ArticleId><ArticleId IdType="pmc">PMC2359908</ArticleId><ArticleId IdType="pubmed">17505513</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Teng Y, Yang F, Wang M, Hong X, Ye LG, Gao YN, Chen GY. MCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomas. Oncol Rep. 2015;33(5):2599&#x2013;2605. doi: 10.3892/or.2015.3822.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2015.3822</ArticleId><ArticleId IdType="pubmed">25738322</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J. Diagnostic value of MCM2 immunocytochemical staining in cervical lesions and its relationship with HPV infection. Int J Clin Exp Pathol. 2015;8(1):875&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4348922</ArticleId><ArticleId IdType="pubmed">25755789</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Zhang XX, Xi BX, Wan DY, Li L, Zhou J, Wang W, Ma D, Wang H, Gao QL. Sine oculis homeobox homolog 1 promotes DNA replication and cell proliferation in cervical cancer. Int J Oncol. 2014;45(3):1232&#x2013;1240. doi: 10.3892/ijo.2014.2510.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2014.2510</ArticleId><ArticleId IdType="pubmed">24970368</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu G, Wang D, Pei Y, Sun L. Systematic identification of key genes and pathways in the development of invasive cervical cancer. Gene. 2017;618:28&#x2013;41. doi: 10.1016/j.gene.2017.03.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2017.03.018</ArticleId><ArticleId IdType="pubmed">28341182</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Shuai H, Luo X, Wang X, Guan B. The clinical and prognostic value of CXCL8 in cervical carcinoma patients: immunohistochemical analysis. Biosci Rep. 2017;37(5):BSR20171021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5629562</ArticleId><ArticleId IdType="pubmed">28883082</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai L, Yao N, Qiao G, Wu L, Ma X. CXCL5 contributes to the tumorigenicity of cervical cancer and is post-transcriptionally regulated by miR-577. Int J Clin Exp Pathol. 2020;13(12):2984&#x2013;2993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7791384</ArticleId><ArticleId IdType="pubmed">33425099</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B, Chen L, Zhang W, Li Y, Zhang Y, Gao Y, Teng X, Zou L, Wang Q, Jia H, Liu X, Zheng H, Hou P, Yu H, Sun Y, Zhang Z, Zhang P, Zhang L. TOP2A and CENPF are synergistic master regulators activated in cervical cancer. BMC Med Genet. 2020;13(1):145. doi: 10.1186/s12920-020-00800-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-020-00800-2</ArticleId><ArticleId IdType="pmc">PMC7541258</ArticleId><ArticleId IdType="pubmed">33023625</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Wang X, Jia H, Tao Y, Zhou H, Wang M, Wang X, Fang X. Bioinformatics analysis of key genes and pathways of cervical Cancer. Onco Targets Ther. 2020;13:13275&#x2013;13283. doi: 10.2147/OTT.S281533.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S281533</ArticleId><ArticleId IdType="pmc">PMC7778384</ArticleId><ArticleId IdType="pubmed">33402836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang F, Liu J, Xia M, Lin C, Wu X, Ye L, Song L, Li J, Wang J, Guo P, He M. GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer. Oncol Rep. 2017;37(5):2652&#x2013;2662. doi: 10.3892/or.2017.5573.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2017.5573</ArticleId><ArticleId IdType="pmc">PMC5428920</ArticleId><ArticleId IdType="pubmed">28405687</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, He W, Shi Y, Gu H, Li M, Liu Z, Feng Y, Zheng N, Xie C, Zhang Y. High expression of KIF20A is associated with poor overall survival and tumor progression in early-stage cervical squamous cell carcinoma. PLoS One. 2016;11(12):e0167449. doi: 10.1371/journal.pone.0167449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0167449</ArticleId><ArticleId IdType="pmc">PMC5152822</ArticleId><ArticleId IdType="pubmed">27941992</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34169096</PMID><DateRevised><Year>2021</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-889X</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in molecular biosciences</Title><ISOAbbreviation>Front Mol Biosci</ISOAbbreviation></Journal><ArticleTitle>A Novel Identified Long Non-coding RNA, lncRNA MEF2C-AS1, Inhibits Cervical Cancer via Regulation of miR-592/RSPO1.</ArticleTitle><Pagination><StartPage>687113</StartPage><MedlinePgn>687113</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">687113</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmolb.2021.687113</ELocationID><Abstract><AbstractText><b>Purpose:</b> Our purpose was to investigate the effect of lncRNA MEF2C antisense RNA 1 (MEF2C-AS1) on cervical cancer and further explore its underlying molecular mechanisms. <b>Methods:</b> The proliferation, migration and invasion of CC cells were determined by counting Kit-8 (CCK-8), colony formation assay, and transwell assays, respectively. qRT-PCR and western blot were conducted to quantitatively detect the expression of lncRNA MEF2C-AS1, miR-592 and R-spondin1 (RSPO1). Kaplan-Meier survival curve from the Cancer Genome Atlas (TCGA) database and the Gene Expression Profiling Interactive Analysis (GEPIA) website was used to describe the overall survival. Bioinformatics analysis was performed to search the downstream target of lncRNA MEF2C-AS1 and miR-592. Luciferase reporter assay was conducted to detect the interaction between lncRNA MEF2C-AS1 and miR-592 or miR-592 and RSPO1. <b>Results:</b> The data from GEPIA website showed that lncRNA MEF2C-AS1 expression was down-regulated in CC tissues and also associated with survival rate of CC patients. Moreover, the results of qRT-PCR also showed lncRNA MEF2C-AS1 was lowly expressed in CC cells. Subsequently, we confirmed that overexpression of lncRNA MEF2C-AS1 inhibited the proliferation, migration and invasion of CC cells. Further research illustrated that lncRNA MEF2C-AS1 was the target of miR-592, and RSPO1 was the downstream target gene of miR-592. Importantly, functional research findings indicated that lncRNA MEF2C-AS1 inhibited CC via suppressing miR-592 by targeting RSPO1. <b>Conclusion:</b> In our study, we demonstrated the functional role of the lncRNA MEF2C-AS1-miR-592-RSPO1 axis in the progression of CC, which provides a latent target for CC treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Wang, Zhang, Gong and Jiang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gynaecology, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University/ Jinan Maternity and Child Care Hospital, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Changhong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Gynaecology, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University/ Jinan Maternity and Child Care Hospital, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Meixuan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gynaecology, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University/ Jinan Maternity and Child Care Hospital, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Gynaecology, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University/ Jinan Maternity and Child Care Hospital, Jinan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Mol Biosci</MedlineTA><NlmUniqueID>101653173</NlmUniqueID><ISSNLinking>2296-889X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MEF2C antisense RNA 1</Keyword><Keyword MajorTopicYN="N">MiR-592</Keyword><Keyword MajorTopicYN="N">R-spondin 1</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">invasion</Keyword><Keyword MajorTopicYN="N">migration</Keyword><Keyword MajorTopicYN="N">proliferation</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34169096</ArticleId><ArticleId IdType="pmc">PMC8217607</ArticleId><ArticleId IdType="doi">10.3389/fmolb.2021.687113</ArticleId><ArticleId IdType="pii">687113</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abd El Gwad A., Matboli M., El&#x2010;Tawdi A., Habib E. K., Shehata H., Ibrahim D., et al. (2018). Role of Exosomal Competing Endogenous RNA in Patients with Hepatocellular Carcinoma. J. Cel. Biochem. 119 (10), 8600&#x2013;8610. 10.1002/jcb.27109</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.27109</ArticleId><ArticleId IdType="pubmed">30015383</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams B. D., Parsons C., Walker L., Zhang W. C., Slack F. J. (2017). Targeting Noncoding RNAs in Disease. J. Clin. Invest. 127 (3), 761&#x2013;771. 10.1172/jci84424</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci84424</ArticleId><ArticleId IdType="pmc">PMC5330746</ArticleId><ArticleId IdType="pubmed">28248199</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatla N., Aoki D., Sharma D. N., Sankaranarayanan R. (2018). Cancer of the Cervix Uteri. Int. J. Gynecol. Obstet. 143 (Suppl. 2), 22&#x2013;36. 10.1002/ijgo.12611</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijgo.12611</ArticleId><ArticleId IdType="pubmed">30306584</ArticleId></ArticleIdList></Reference><Reference><Citation>Bing Y., Fang Y., Jun G., Guang Y. (2019). Study on the Functional Mechanism of Long-Chain Non-coding RNA MEF2C-AS1 Inhibiting the Proliferation, Migration and Invasion of Breast Cancer Cells by Down-Regulating the Expression of miR-3646. Chin. J. Biomed. Eng. 25 (6), 678&#x2013;684. 10.3760/cma.j.issn.1674-1927.2019.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1674-1927.2019.06.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai C., Yu Q. C., Jiang W., Liu W., Song W., Yu H., et al. (2014). R-spondin1 Is a Novel Hormone Mediator for Mammary Stem Cell Self-Renewal. Genes Dev. 28 (20), 2205&#x2013;2218. 10.1101/gad.245142.114</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.245142.114</ArticleId><ArticleId IdType="pmc">PMC4201283</ArticleId><ArticleId IdType="pubmed">25260709</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y., Sheng W., Meng Y., Cao Y., Li R. (2020). LncRNA PTENP1 Inhibits Cervical Cancer Progression by Suppressing miR-106b. Artif. Cell Nanomedicine, Biotechnol. 48 (1), 393&#x2013;407. 10.1080/21691401.2019.1709852</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21691401.2019.1709852</ArticleId><ArticleId IdType="pubmed">31913710</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatica A., Bozzoni I. (2014). Long Non-coding RNAs: New Players in Cell Differentiation and Development. Nat. Rev. Genet. 15 (1), 7&#x2013;21. 10.1038/nrg3606</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3606</ArticleId><ArticleId IdType="pubmed">24296535</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Q., Du Y., Yang C., Zhang D., Zhang N., Liu X., et al. (2016). An Oncogenic Role of miR-592 in Tumorigenesis of Human Colorectal Cancer by Targeting Forkhead Box O3A (FoxO3A). Expert Opin. Ther. Targets 20 (7), 771&#x2013;782. 10.1080/14728222.2016.1181753</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2016.1181753</ArticleId><ArticleId IdType="pubmed">27167185</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S., Chen J., Wang Y., Zhong Y., Dai Q., Wang Q., et al. (2018). MiR-592 Suppresses the Development of Glioma by Regulating Rho-Associated Protein Kinase. Neuroreport 29 (16), 1391&#x2013;1399. 10.1097/wnr.0000000000001124</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/wnr.0000000000001124</ArticleId><ArticleId IdType="pubmed">30169426</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Zou T., Liang W., Zhang Z., Qie M. (2020). Long Non-coding RNA HAND2-AS1 Delays Cervical Cancer Progression via its Regulation on the microRNA-21-5p/TIMP3/VEGFA axis. Cancer Gene Ther [Epub ahead of print]. 10.1038/s41417-020-00243-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41417-020-00243-y</ArticleId><ArticleId IdType="pubmed">33139818</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong J., He X.-X., Tian D.-A. (2015). Emerging Role of microRNA in Hepatocellular Carcinoma (Review). Oncol. Lett. 9 (3), 1027&#x2013;1033. 10.3892/ol.2014.2816</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2014.2816</ArticleId><ArticleId IdType="pmc">PMC4315036</ArticleId><ArticleId IdType="pubmed">25663852</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregorieff A., Clevers H. (2005). Wnt Signaling in the Intestinal Epithelium: from Endoderm to Cancer. Genes Dev. 19 (8), 877&#x2013;890. 10.1101/gad.1295405</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1295405</ArticleId><ArticleId IdType="pubmed">15833914</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu P., Chen X., Xie R., Xie W., Huang L., Dong W., et al. (2019). A Novel AR Translational Regulator lncRNA LBCS Inhibits Castration Resistance of Prostate Cancer. Mol. Cancer 18 (1), 109. 10.1186/s12943-019-1037-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-019-1037-8</ArticleId><ArticleId IdType="pmc">PMC6585145</ArticleId><ArticleId IdType="pubmed">31221168</ArticleId></ArticleIdList></Reference><Reference><Citation>He S., Zeng S., Zhou Z. W., He Z. X., Zhou S. F. (2015). Hsa-microRNA-181a Is a Regulator of a Number of Cancer Genes and a Biomarker for Endometrial Carcinoma in Patients: a Bioinformatic and Clinical Study and the Therapeutic Implication. Drug Des. Devel Ther. 9, 1103&#x2013;1175. 10.2147/dddt.s73551</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/dddt.s73551</ArticleId><ArticleId IdType="pmc">PMC4342183</ArticleId><ArticleId IdType="pubmed">25733820</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Ge Y., Jiang M., Zhou J., Luo D., Fan H., et al. (2018). MiR-592 Promotes Gastric Cancer Proliferation, Migration, and Invasion through the PI3K/AKT and MAPK/ERK Signaling Pathways by Targeting Spry2. Cell Physiol Biochem 47 (4), 1465&#x2013;1481. 10.1159/000490839</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000490839</ArticleId><ArticleId IdType="pubmed">29949784</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou W., Zhang H., Bai X., Liu X., Yu Y., Song L., et al. (2017). Suppressive Role of miR-592 in Breast Cancer by Repressing TGF-&#x3b2;2. Oncol. Rep. 38 (6), 3447&#x2013;3454. 10.3892/or.2017.6029</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2017.6029</ArticleId><ArticleId IdType="pubmed">29039599</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.-A., Kakitani M., Zhao J., Oshima T., Tang T., Binnerts M., et al. (2005). Mitogenic Influence of Human R-Spondin1 on the Intestinal Epithelium. Science 309 (5738), 1256&#x2013;1259. 10.1126/science.1112521</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1112521</ArticleId><ArticleId IdType="pubmed">16109882</ArticleId></ArticleIdList></Reference><Reference><Citation>Koca&#xf6;z S., &#xd6;z&#xe7;elik H., Talas M. S., Akkaya F., &#xd6;zkul F., Kurtulu&#x15f; A., et al. (2018). The Effect of Education on the Early Diagnosis of Breast and Cervix Cancer on the Women's Attitudes and Behaviors Regarding Participating in Screening Programs. J. Canc Educ. 33 (4), 821&#x2013;832. 10.1007/s13187-017-1193-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13187-017-1193-8</ArticleId><ArticleId IdType="pubmed">28285418</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo T., Zhao J., Lu Z., Bi J., Pang T., Cui H., et al. (2018). Characterization of Long Non-coding RNAs and MEF2C-AS1 Identified as a Novel Biomarker in Diffuse Gastric Cancer. Translational Oncol. 11 (5), 1080&#x2013;1089. 10.1016/j.tranon.2018.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2018.06.007</ArticleId><ArticleId IdType="pmc">PMC6067087</ArticleId><ArticleId IdType="pubmed">30005210</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Z., Rao P., Li W. (2015). MiR-592 Represses FOXO3 Expression and Promotes the Proliferation of Prostate Cancer Cells. Int. J. Clin. Exp. Med. 8 (9), 15246&#x2013;15253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4658899</ArticleId><ArticleId IdType="pubmed">26629010</ArticleId></ArticleIdList></Reference><Reference><Citation>Munksgaard P. S., Blaakaer J. (2011). The Association between Endometriosis and Gynecological Cancers and Breast Cancer: a Review of Epidemiological Data. Gynecol. Oncol. 123 (1), 157&#x2013;163. 10.1016/j.ygyno.2011.06.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2011.06.017</ArticleId><ArticleId IdType="pubmed">21742370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojesina A. I., Lichtenstein L., Freeman S. S., Pedamallu C. S., Imaz-Rosshandler I., Pugh T. J., et al. (2014). Landscape of Genomic Alterations in Cervical Carcinomas. Nature 506 (7488), 371&#x2013;375. 10.1038/nature12881</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12881</ArticleId><ArticleId IdType="pmc">PMC4161954</ArticleId><ArticleId IdType="pubmed">24390348</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Z., Xie R., Song W., Gao C. (2021). MicroRNA-592 Promotes Cell Proliferation, Migration and Invasion in Colorectal Cancer by Directly Targeting SPARC. Mol. Med. Rep. 23 (4), 261. 10.3892/mmr.2021.11900</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2021.11900</ArticleId><ArticleId IdType="pmc">PMC7893699</ArticleId><ArticleId IdType="pubmed">33576452</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Cai J. (2017). The Role of microRNAs in Heart Failure. Biochim. Biophys. Acta (Bba) - Mol. Basis Dis. 1863 (8), 2019&#x2013;2030. 10.1016/j.bbadis.2016.11.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2016.11.034</ArticleId><ArticleId IdType="pubmed">27916680</ArticleId></ArticleIdList></Reference><Reference><Citation>W. H. Organization (2013). Comprehensive Cervical Cancer Prevention and Control: a Healthier Future for Girls and Women. Geneva Switzerland: Who; 28 (3), 271&#x2013;272.</Citation></Reference><Reference><Citation>Xie G., Huang S., Luo Y., Ma L., Lin Z., Sun Y. (2019). LLCLPLDA: a Novel Model for Predicting lncRNA-Disease Associations. Mol. Genet. Genomics 294 (6), 1477&#x2013;1486. 10.1007/s00438-019-01590-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00438-019-01590-8</ArticleId><ArticleId IdType="pubmed">31250107</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang A., Xu M., Mo Y.-Y. (2014). Role of the lncRNA-P53 Regulatory Network in Cancer. J. Mol. Cel Biol. 6 (3), 181&#x2013;191. 10.1093/jmcb/mju013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mju013</ArticleId><ArticleId IdType="pmc">PMC4034727</ArticleId><ArticleId IdType="pubmed">24721780</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., de Vera J., Narushima S., Beck E. X., Palencia S., Shinkawa P., et al. (2007). R-spondin1, a Novel Intestinotrophic Mitogen, Ameliorates Experimental Colitis in Mice. Gastroenterol. 132 (4), 1331&#x2013;1343. 10.1053/j.gastro.2007.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2007.02.001</ArticleId><ArticleId IdType="pubmed">17408649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Zheng H., Chen J. (2020). LncRNA GATA6-AS Inhibits Cancer Cell Proliferation and Promotes Cancer Cell Apoptosis in Cervical Cancer by Down-Regulating miR-205. BMC Women's Health 20 (1), 247. 10.1186/s12905-020-01082-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12905-020-01082-7</ArticleId><ArticleId IdType="pmc">PMC7650211</ArticleId><ArticleId IdType="pubmed">33167959</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Y., Lu Q., Qiu W., Luo Y. (2020). LINC00636 Promotes Lymph Node Metastasis and Cervical Cancer through Targeting NM23. Biosci. Rep. 40 (10), BSR20200367. 10.1042/bsr20200367</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bsr20200367</ArticleId><ArticleId IdType="pmc">PMC7601350</ArticleId><ArticleId IdType="pubmed">33034616</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34151839</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8592</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Cancer biomarkers : section A of Disease markers</Title><ISOAbbreviation>Cancer Biomark</ISOAbbreviation></Journal><ArticleTitle>Screening of cervical cancer-related hub genes based on comprehensive bioinformatics analysis.</ArticleTitle><Pagination><StartPage>303</StartPage><EndPage>315</EndPage><MedlinePgn>303-315</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/CBM-203262</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Since the molecular mechanisms of cervical cancer (CC) have not been completely discovered, it is of great significance to identify the hub genes and pathways of this disease to reveal the molecular mechanisms of cervical cancer.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The study aimed to identify the biological functions and prognostic value of hub genes in cervical cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The gene expression data of CC patients were downloaded from the Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA) database. The core genes were screened out by differential gene expression analysis and weighted gene co-expression network analysis (WGCNA). R software, the STRING online tool and Cytoscape software were used to screen out the hub genes. The GEPIA public database was used to further verify the expression levels of the hub genes in normal tissues and tumour tissues and determine the disease-free survival (DFS) rates of the hub genes. The protein expression of the survival-related hub genes was identified with the Human Protein Atlas (HPA) database.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 64 core genes were screened, and 10 genes, including RFC5, POLE3, RAD51, RMI1, PALB2, HDAC1, MCM4, ESR1, FOS and E2F1, were identified as hub genes. Compared with that in normal tissues, RFC5, POLE3, RAD51,RMI1, PALB2, MCM4 and E2F1 were all significantly upregulated in cervical cancer, ESR1 was significantly downregulated in cervical cancer, and RFC5 expression in CC patients was significantly related to OS. In the DFS analysis, no significant difference was observed in the expression level of RFC5 in cervical cancer patients. Finally, RFC5 protein levels verified by the HPA database were consistently upregulated with mRNA levels in CC samples.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">RFC5 may play important roles in the occurrence and prognosis of CC. It could be further explored and validated as a potential predictor and therapeutic target for CC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Simei</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hao</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaocheng</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Wen</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Kangjing</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Xinyi</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Xinjian</ForeName><Initials>X</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Cancer Biomark</MedlineTA><NlmUniqueID>101256509</NlmUniqueID><ISSNLinking>1574-0153</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055088" MajorTopicYN="N">Early Detection of Cancer</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">gene differential expression analysis</Keyword><Keyword MajorTopicYN="N">hub gene</Keyword><Keyword MajorTopicYN="N">weighted gene co-expression network analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>21</Day><Hour>8</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34151839</ArticleId><ArticleId IdType="doi">10.3233/CBM-203262</ArticleId><ArticleId IdType="pii">CBM203262</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34124265</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-6141</ISSN><JournalIssue CitedMedium="Internet"><Volume>2021</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>BioMed research international</Title><ISOAbbreviation>Biomed Res Int</ISOAbbreviation></Journal><ArticleTitle>PD-1 Coexpression Gene Analysis and the Regulatory Network in Endometrial Cancer Based on Bioinformatics Analysis.</ArticleTitle><Pagination><StartPage>9923434</StartPage><MedlinePgn>9923434</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9923434</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2021/9923434</ELocationID><Abstract><AbstractText>Gynecological malignancies are tumors of the female reproductive system, mainly cervical cancer, endometrial cancer, and ovarian cancer. Endometrial cancer (EC) is the most common gynecological malignant tumor in developed countries. The aim of this study was to construct a network of programmed cell death protein 1 (PD-1) coexpressed genes through bioinformatics analysis and screen the potential biomarkers of PD-1 in endometrial cancer. In addition, genes and pathways involved in PD-1 and modulating tumor immune status were identified. We select the EC transcriptomic dataset in TCGA to retrieve gene sets on the cBioPortal platform, and the PD-1 coexpressed genes were obtained on the platform. GO and KEGG enrichment analysis of coexpressed genes was performed using the DAVID database. The target protein-protein interaction (PPI) network was constructed using Cytoscape 3.7.1 software, and the hub genes were then screened. A total of 976 coexpression genes were obtained. The enrichment analysis showed that PD-1 coexpressed genes were significantly enriched in overall components of the cell structure, the interaction of cytokines with cytokine receptors, chemokine signaling pathways, and cell adhesion molecules (CAMs). Ten hub genes were obtained by node degree analysis. CD3E gene is involved in the prognosis and immune process of EC, and the expression level is related to PD-1 (Pearson correlation coefficient is 0.82, <i>P</i> &lt; 0.01). Patients with low CD3E gene expression in EC have a poor prognosis. The coexpression hub genes of PD-1 are related to immunity, in which CD3E is a prognostic marker that is involved in the PD-1/PD-L1-induced tumor immune escape. This study provides a new area to study the mechanism of PD-1/PD-L1 in EC and the precise treatment with targeted drugs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Lina Wang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Third Central Hospital of Tianjin, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Artificial Cell, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Institute of Hepatobiliary Disease, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Chifeng Municipal Hospital, Chifeng Clinical Medical School of Inner Mongolia Medical University, Chifeng, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wenwen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Aihua</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Artificial Cell, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Pengpeng</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4059-7257</Identifier><AffiliationInfo><Affiliation>Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biomed Res Int</MedlineTA><NlmUniqueID>101600173</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030561" MajorTopicYN="Y">Databases, Nucleic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016889" MajorTopicYN="Y">Endometrial Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="Y">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009363" MajorTopicYN="Y">Neoplasm Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061026" MajorTopicYN="Y">Programmed Cell Death 1 Receptor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34124265</ArticleId><ArticleId IdType="pmc">PMC8172290</ArticleId><ArticleId IdType="doi">10.1155/2021/9923434</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bregar A., Deshpande A., Grange C., et al. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. Gynecologic Oncology. 2017;145(3):446&#x2013;452. doi: 10.1016/j.ygyno.2017.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2017.03.006</ArticleId><ArticleId IdType="pubmed">28347512</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney K. M., Freeman G. J., McDermott D. F. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clinical Therapeutics. 2015;37(4):764&#x2013;782. doi: 10.1016/j.clinthera.2015.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2015.02.018</ArticleId><ArticleId IdType="pmc">PMC4497957</ArticleId><ArticleId IdType="pubmed">25823918</ArticleId></ArticleIdList></Reference><Reference><Citation>Kythreotou A., Siddique A., Mauri F. A., Bower M., Pinato D. J. PD-L1. Journal of clinical pathology. 2018;71(3):189&#x2013;194. doi: 10.1136/jclinpath-2017-204853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jclinpath-2017-204853</ArticleId><ArticleId IdType="pubmed">29097600</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Zhang C., Song Y., et al. Mechanism of immune evasion in breast cancer. Oncotargets and Therapy. 2017;Volume 10:1561&#x2013;1573. doi: 10.2147/OTT.S126424.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S126424</ArticleId><ArticleId IdType="pmc">PMC5359138</ArticleId><ArticleId IdType="pubmed">28352189</ArticleId></ArticleIdList></Reference><Reference><Citation>Motzer R. J., Escudier B., McDermott D. F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine. 2015;373(19):1803&#x2013;1813. doi: 10.1056/NEJMoa1510665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1510665</ArticleId><ArticleId IdType="pmc">PMC5719487</ArticleId><ArticleId IdType="pubmed">26406148</ArticleId></ArticleIdList></Reference><Reference><Citation>Taube J. M. Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. Oncoimmunology. 2014;3(11, article e963413) doi: 10.4161/21624011.2014.963413.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/21624011.2014.963413</ArticleId><ArticleId IdType="pmc">PMC4292419</ArticleId><ArticleId IdType="pubmed">25914862</ArticleId></ArticleIdList></Reference><Reference><Citation>Maker A. V. Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment&#x2014;evidence to turn on the LIGHT. Oncoimmunology. 2016;5(1, article e1069937) doi: 10.1080/2162402X.2015.1069937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2015.1069937</ArticleId><ArticleId IdType="pmc">PMC4760328</ArticleId><ArticleId IdType="pubmed">26942091</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson A. K., Saleh S. N. Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. Clinical, cosmetic and investigational dermatology. 2017;10:p. 325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5580705</ArticleId><ArticleId IdType="pubmed">28883738</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsaab H. O., Sau S., Alzhrani R., et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Frontiers in Pharmacology. 2017;8:p. 561. doi: 10.3389/fphar.2017.00561.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2017.00561</ArticleId><ArticleId IdType="pmc">PMC5572324</ArticleId><ArticleId IdType="pubmed">28878676</ArticleId></ArticleIdList></Reference><Reference><Citation>Jindal V., Gupta S. Expected paradigm shift in brain metastases therapy&#x2014;immune checkpoint inhibitors. Molecular Neurobiology. 2018;55(8):7072&#x2013;7078. doi: 10.1007/s12035-018-0905-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0905-3</ArticleId><ArticleId IdType="pubmed">29383686</ArticleId></ArticleIdList></Reference><Reference><Citation>Polk A., Svane I.-M., Andersson M., Nielsen D. Checkpoint inhibitors in breast cancer - current status. Cancer Treatment Reviews. 2018;63:122&#x2013;134. doi: 10.1016/j.ctrv.2017.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2017.12.008</ArticleId><ArticleId IdType="pubmed">29287242</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Z., Zhu X., Sun Y., Zhang Y. The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer. Oncotarget. 2017;8(34):57826&#x2013;57835. doi: 10.18632/oncotarget.18406.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.18406</ArticleId><ArticleId IdType="pmc">PMC5593686</ArticleId><ArticleId IdType="pubmed">28915714</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandran U. R., Medvedeva O. P., Barmada M. M., et al. TCGA expedition: a data acquisition and management system for TCGA data. PLoS One. 2016;11(10, article e0165395) doi: 10.1371/journal.pone.0165395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0165395</ArticleId><ArticleId IdType="pmc">PMC5082933</ArticleId><ArticleId IdType="pubmed">27788220</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao X., Sherman B. T., Huang D. W., et al. DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics. 2012;28:1805&#x2013;1806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381967</ArticleId><ArticleId IdType="pubmed">22543366</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Morris J. H., Cook H., et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic acids research. 2017;45(D1):D362&#x2013;D368. doi: 10.1093/nar/gkw937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw937</ArticleId><ArticleId IdType="pmc">PMC5210637</ArticleId><ArticleId IdType="pubmed">27924014</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P., Markiel A., Ozier O., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Research. 2003;13(11):2498&#x2013;2504. doi: 10.1101/gr.1239303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharon E., Streicher H., Goncalves P., Chen H. X. Immune checkpoint inhibitors in clinical trials. Chinese Journal of Cancer. 2014;33(9):434&#x2013;444. doi: 10.5732/cjc.014.10122.</Citation><ArticleIdList><ArticleId IdType="doi">10.5732/cjc.014.10122</ArticleId><ArticleId IdType="pmc">PMC4190433</ArticleId><ArticleId IdType="pubmed">25189716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott P. A., Bang Y.-J., Berton-Rigaud D., et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1&#x2013;positive endometrial cancer: results from the KEYNOTE-028 study. Obstetrical &amp; Gynecological Survey. 2018;73(1):26&#x2013;27. doi: 10.1097/01.ogx.0000527579.58363.20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ogx.0000527579.58363.20</ArticleId><ArticleId IdType="pubmed">28489510</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh M. S., Chae Y. K. Deep and durable response with combination CTLA-4 and PD-1 blockade in mismatch repair (MMR)-proficient endometrial cancer. Journal of Immunotherapy. 2019;42(2):51&#x2013;54. doi: 10.1097/CJI.0000000000000244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CJI.0000000000000244</ArticleId><ArticleId IdType="pubmed">30247204</ArticleId></ArticleIdList></Reference><Reference><Citation>Saygin C., Wiechert A., Rao V. S., et al. CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. Journal of Experimental Medicine. 2017;214(9):2715&#x2013;2732. doi: 10.1084/jem.20170438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20170438</ArticleId><ArticleId IdType="pmc">PMC5584126</ArticleId><ArticleId IdType="pubmed">28838952</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigorian I. Y., Linkova N., Polyakova V., Paltseva E., Kozlov K. Signal molecules of endometrium: gerontological and general pathhological aspects. Advances in gerontology. 2015;28:453&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">28509480</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J.-X., Leonard W. J. The common cytokine receptor &#x3b3; chain family of cytokines. Cold Spring Harbor Perspectives in Biology. 2018;10(9):p. a028449. doi: 10.1101/cshperspect.a028449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a028449</ArticleId><ArticleId IdType="pmc">PMC6120701</ArticleId><ArticleId IdType="pubmed">29038115</ArticleId></ArticleIdList></Reference><Reference><Citation>Jie H.-B., Srivastava R. M., Argiris A., Bauman J. E., Kane L. P., Ferris R. L. Increased PD-1+ and TIM-3+ TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients. Cancer Immunology Research. 2017;5(5):408&#x2013;416. doi: 10.1158/2326-6066.CIR-16-0333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0333</ArticleId><ArticleId IdType="pmc">PMC5497750</ArticleId><ArticleId IdType="pubmed">28408386</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva J. M., Dos Santos T. P. M., Sobral L. M., et al. Relevance of CCL3/CCR5 axis in oral carcinogenesis. Oncotarget. 2017;8(31):51024&#x2013;51036. doi: 10.18632/oncotarget.16882.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.16882</ArticleId><ArticleId IdType="pmc">PMC5584227</ArticleId><ArticleId IdType="pubmed">28881626</ArticleId></ArticleIdList></Reference><Reference><Citation>de Saint Basile G., Geissmann F., Flori E., et al. Severe combined immunodeficiency caused by deficiency in either the &#x3b4; or the &#x3b5; subunit of CD3. The Journal of Clinical Investigation. 2004;114(10):1512&#x2013;1517. doi: 10.1172/JCI200422588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200422588</ArticleId><ArticleId IdType="pmc">PMC525745</ArticleId><ArticleId IdType="pubmed">15546002</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodji Q., Klein K., Sravan K., Parikh J. Predictive role of PD-L1 expression in the response of renal medullary carcinoma to PD-1 inhibition. Journal for Immunotherapy of Cancer. 2017;5:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5557570</ArticleId><ArticleId IdType="pubmed">28807004</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S.-P., Liao R.-Q., Tu H.-Y., et al. Stromal PD-L1-positive regulatory T cells and PD-1-positive CD8-positive T cells define the response of different subsets of non-small cell lung cancer to PD-1/PD-L1 blockade immunotherapy. Journal of Thoracic Oncology. 2018;13(4):521&#x2013;532. doi: 10.1016/j.jtho.2017.11.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2017.11.132</ArticleId><ArticleId IdType="pubmed">29269008</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaffney S. G., Perry E. B., Chen P.-M., Greenstein A., Kaech S. M., Townsend J. P. The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment. Oncotarget. 2019;10(44):4532&#x2013;4545. doi: 10.18632/oncotarget.27027.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.27027</ArticleId><ArticleId IdType="pmc">PMC6642048</ArticleId><ArticleId IdType="pubmed">31360302</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao D., Margolis C. A., Gao W., et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359:801&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035749</ArticleId><ArticleId IdType="pubmed">29301960</ArticleId></ArticleIdList></Reference><Reference><Citation>Gettinger S., Choi J., Mani N., et al. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nature Communications. 2018;9:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086912</ArticleId><ArticleId IdType="pubmed">30097571</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34113576</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>A Pan-Cancer Analysis of the Oncogenic Role of Twinfilin Actin Binding Protein 1 in Human Tumors.</ArticleTitle><Pagination><StartPage>692136</StartPage><MedlinePgn>692136</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">692136</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2021.692136</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Understanding common and unique mechanisms driving oncogenic processes in human tumors is indispensable to develop efficient therapies. Recent studies have proposed Twinfilin Actin Binding Protein 1 (TWF1) as a putative driver gene in lung cancer, pancreatic cancer and breast cancer, however a systematic pan-cancer analysis has not been carried out.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Here, we set out to explore the role of TWF1 in 33 tumor types using TCGA (The Cancer Genome Atlas), GEO (Gene Expression Omnibus) dataset, Human Protein Atlas (HPA), and several bioinformatic tools.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">As part of our analysis, we have assessed <i>TWF1</i> expression across tumors. We found that over-expression of <i>TWF1</i> generally predicted poor OS for patients with tumors with high <i>TWF1</i> expression, such as mesothelioma, lung adenocarcinoma, cervical cancer and pancreatic adenocarcinoma. We also assessed the mutation burden of <i>TWF1</i> in cancer and the <i>TWF1</i>-associated survival of cancer patients, compared the phosphorylation of TWF1 between normal and primary tumor tissues and explored putative functional mechanisms in TWF1-mediated oncogenesis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our pan-cancer analysis provides a comprehensive overview of the oncogenic roles of TWF1 in multiple human cancers.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Huo, Wang, Chen, Song, Zhang, Guo, Zuo, Zhu, Cui, Chen, Chen and Chen.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Gengwei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Jining No.1 People's Hospital, Jining, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yali</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jinliang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Jining No.1 People's Hospital, Jining, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Cuicui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuo</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Fuyi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Jinfang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Weidong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Oncology, Jining No.1 People's Hospital, Jining, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wenming</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Oncology, Jining No.1 People's Hospital, Jining, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TWF1</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">phosphorylation</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34113576</ArticleId><ArticleId IdType="pmc">PMC8185641</ArticleId><ArticleId IdType="doi">10.3389/fonc.2021.692136</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blum A, Wang P, Zenklusen JC. Snapshot: Tcga-Analyzed Tumors. Cell (2018) 173:530. &#xa0;10.1016/J.Cell.2018.03.059</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.Cell.2018.03.059</ArticleId><ArticleId IdType="pubmed">29625059</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomczak K, Czerwi&#x144;ska P, Wiznerowicz M. The Cancer Genome Atlas (Tcga): An Immeasurable Source of Knowledge. Contemp Oncol (Pozn) (2015) 19:A68&#x2013;77. &#xa0;10.5114/Wo.2014.47136</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/Wo.2014.47136</ArticleId><ArticleId IdType="pmc">PMC4322527</ArticleId><ArticleId IdType="pubmed">25691825</ArticleId></ArticleIdList></Reference><Reference><Citation>Clough E, Barrett T. The Gene Expression Omnibus Database. Methods Mol Biol (2016) 1418:93&#x2013;110. &#xa0;10.1007/978-1-4939-3578-9_5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3578-9_5</ArticleId><ArticleId IdType="pmc">PMC4944384</ArticleId><ArticleId IdType="pubmed">27008011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lappalainen P, Kessels MM, Cope MJ, Drubin DG. The Adf Homology (Adf-H) Domain: A Highly Exploited Actin-Binding Module. Mol Biol Cell (1998) 9:1951&#x2013;9. &#xa0;10.1091/Mbc.9.8.1951</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/Mbc.9.8.1951</ArticleId><ArticleId IdType="pmc">PMC25446</ArticleId><ArticleId IdType="pubmed">9693358</ArticleId></ArticleIdList></Reference><Reference><Citation>Goode BL, Drubin DG, Lappalainen P. Regulation of the Cortical Actin Cytoskeleton in Budding Yeast By Twinfilin, A Ubiquitous Actin Monomer-Sequestering Protein. J Cell Biol (1998) 142:723&#x2013;33. &#xa0;10.1083/Jcb.142.3.723</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/Jcb.142.3.723</ArticleId><ArticleId IdType="pmc">PMC2148182</ArticleId><ArticleId IdType="pubmed">9700161</ArticleId></ArticleIdList></Reference><Reference><Citation>Poukkula M, Kremneva E, Serlachius M, Lappalainen P. Actin-Depolymerizing Factor Homology Domain: A Conserved Fold Performing Diverse Roles in Cytoskeletal Dynamics. Cytoskeleton (Hoboken) (2011) 68:471&#x2013;90. &#xa0;10.1002/Cm.20530</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/Cm.20530</ArticleId><ArticleId IdType="pubmed">21850706</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmgren S, Vartiainen M, Lappalainen P, Twinfilin A. Molecular Mailman for Actin Monomers. J Cell Sci (2002) 115:881&#x2013;6. 10.1242/jcs.115.5.881</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.115.5.881</ArticleId><ArticleId IdType="pubmed">11870207</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston AB, Collins A, Goode BL. High-Speed Depolymerization at Actin Filament Ends Jointly Catalysed by Twinfilin and Srv2/Cap. Nat Cell Biol (2015) 17:1504&#x2013;11. &#xa0;10.1038/Ncb3252</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/Ncb3252</ArticleId><ArticleId IdType="pmc">PMC4808055</ArticleId><ArticleId IdType="pubmed">26458246</ArticleId></ArticleIdList></Reference><Reference><Citation>Moseley JB, Okada K, Balcer HI, Kovar DR, Pollard TD, Goode BL. Twinfilin Is an Actin-Filament-Severing Protein and Promotes Rapid Turnover of Actin Structures in Vivo. J Cell Sci (2006) 119:1547&#x2013;57. &#xa0;10.1242/Jcs.02860</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/Jcs.02860</ArticleId><ArticleId IdType="pubmed">16569665</ArticleId></ArticleIdList></Reference><Reference><Citation>Helfer E, Nevalainen EM, Naumanen P, Romero S, Didry D, Pantaloni D, et al. . Mammalian Twinfilin Sequesters Adp-G-Actin and Caps Filament Barbed Ends: Implications in Motility. EMBO J (2006) 25:1184&#x2013;95. &#xa0;10.1038/Sj.Emboj.7601019</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/Sj.Emboj.7601019</ArticleId><ArticleId IdType="pmc">PMC1422163</ArticleId><ArticleId IdType="pubmed">16511569</ArticleId></ArticleIdList></Reference><Reference><Citation>Paavilainen VO, Hellman M, Helfer E, Bovellan M, Annila A, Carlier MF, et al. . Structural Basis and Evolutionary Origin of Actin Filament Capping By Twinfilin. Proc Natl Acad Sci USA (2007) 104:3113&#x2013;8. &#xa0;10.1073/Pnas.0608725104</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/Pnas.0608725104</ArticleId><ArticleId IdType="pmc">PMC1805582</ArticleId><ArticleId IdType="pubmed">17360616</ArticleId></ArticleIdList></Reference><Reference><Citation>Meacham CE, Ho EE, Dubrovsky E, Gertler FB, Hemann MT. In Vivo Rnai Screening Identifies Regulators of Actin Dynamics As Key Determinants of Lymphoma Progression. Nat Genet (2009) 41:1133&#x2013;7. &#xa0;10.1038/Ng.451</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/Ng.451</ArticleId><ArticleId IdType="pmc">PMC2756700</ArticleId><ArticleId IdType="pubmed">19783987</ArticleId></ArticleIdList></Reference><Reference><Citation>Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, et al. . Microrna-30c Inhibits Human Breast Tumour Chemotherapy Resistance By Regulating Twf1 and Il-11. Nat Commun (2013) 4:1393. &#xa0;10.1038/Ncomms2393</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/Ncomms2393</ArticleId><ArticleId IdType="pmc">PMC3723106</ArticleId><ArticleId IdType="pubmed">23340433</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Zhang S, Wang Q, Zhang X. Tumor Suppressor Mir-1 Inhibits Tumor Growth and Metastasis by Simultaneously Targeting Multiple Genes. Oncotarget (2017) 8:42043&#x2013;60. &#xa0;10.18632/Oncotarget.14927</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/Oncotarget.14927</ArticleId><ArticleId IdType="pmc">PMC5522048</ArticleId><ArticleId IdType="pubmed">28159933</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, Chandrashekar DS, Varambally S, Creighton CJ. Pan-Cancer Molecular Subtypes Revealed by Mass-Spectrometry-Based Proteomic Characterization of More Than 500 Human Cancers. Nat Commun (2019) 10:5679. &#xa0;10.1038/S41467-019-13528-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41467-019-13528-0</ArticleId><ArticleId IdType="pmc">PMC6908580</ArticleId><ArticleId IdType="pubmed">31831737</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Kang B, Li C, Chen T, Zhang Z. Gepia2: An Enhanced Web Server for Large-Scale Expression Profiling and Interactive Analysis. Nucleic Acids Res (2019) 47:W556&#x2013;60. &#xa0;10.1093/Nar/Gkz430</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/Nar/Gkz430</ArticleId><ArticleId IdType="pmc">PMC6602440</ArticleId><ArticleId IdType="pubmed">31114875</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui X, Zhang X, Liu M, Zhao C, Zhang N, Ren Y, et al. . A Pan-Cancer Analysis of the Oncogenic Role of Staphylococcal Nuclease Domain-Containing Protein 1 (Snd1) in Human Tumors. Genomics (2020) 112:3958&#x2013;67. &#xa0;10.1016/J.Ygeno.2020.06.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.Ygeno.2020.06.044</ArticleId><ArticleId IdType="pubmed">32645525</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SS, Liu W, Ly D, Xu H, Qu L, Zhang L. Tumor-Infiltrating B Cells: Their Role and Application In Anti-Tumor Immunity in Lung Cancer. Cell Mol Immunol (2019) 16:6&#x2013;18. &#xa0;10.1038/S41423-018-0027-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41423-018-0027-X</ArticleId><ArticleId IdType="pmc">PMC6318290</ArticleId><ArticleId IdType="pubmed">29628498</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieci MV, Miglietta F, Guarneri V. Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications. Cells (2021) 10:223. &#xa0;10.3390/Cells10020223</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/Cells10020223</ArticleId><ArticleId IdType="pmc">PMC7911608</ArticleId><ArticleId IdType="pubmed">33498711</ArticleId></ArticleIdList></Reference><Reference><Citation>Sales De S&#xe1; R, Miranda Galvis M, Mariz B, Leite AA, Schultz L, Almeida OP, et al. . Increased Tumor Immune Microenvironment Cd3+ And Cd20+ Lymphocytes Predict A Better Prognosis in Oral Tongue Squamous Cell Carcinoma. Front Cell Dev Biol (2020) 8:622161. &#xa0;10.3389/Fcell.2020.622161</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/Fcell.2020.622161</ArticleId><ArticleId IdType="pmc">PMC7951138</ArticleId><ArticleId IdType="pubmed">33718347</ArticleId></ArticleIdList></Reference><Reference><Citation>Samaeekia R, Adorno-Cruz V, Bockhorn J, Chang YF, Huang S, Prat A, et al. . Mir-206 Inhibits Stemness And Metastasis Of Breast Cancer by Targeting Mkl1/Il11 Pathway. Clin Cancer Res (2017) 23:1091&#x2013;103. &#xa0;10.1158/1078-0432.Ccr-16-0943</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-16-0943</ArticleId><ArticleId IdType="pmc">PMC5247402</ArticleId><ArticleId IdType="pubmed">27435395</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Liu L, Qu B, Li X, Gao X, Zhang M. Twinfilin 1 Enhances Milk Bio-Synthesis and Proliferation of Bovine Mammary Epithelial Cells Via the Mtor Signaling Pathway. Biochem Biophys Res Commun (2017) 492:289&#x2013;94. &#xa0;10.1016/J.Bbrc.2017.08.130</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.Bbrc.2017.08.130</ArticleId><ArticleId IdType="pubmed">28864421</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian C, Zeng S, Luo J. Mcts1 Directly Binds to Twf1 and Synergistically Modulate Cyclin D1 and C-Myc Translation in Luminal A/B Breast Cancer Cells. Onco Targets Ther (2020) 13:5353&#x2013;61. &#xa0;10.2147/Ott.S255675</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/Ott.S255675</ArticleId><ArticleId IdType="pmc">PMC7293984</ArticleId><ArticleId IdType="pubmed">32606753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaishang Z, Xue P, Shaozhong Z, Yingying F, Yan Z, Chanjun S, et al. . Elevated Expression of Twinfilin-1 Is Correlated With Inferior Prognosis of Lung Adenocarcinoma. Life Sci (2018) 215:159&#x2013;69. &#xa0;10.1016/J.Lfs.2018.10.067</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.Lfs.2018.10.067</ArticleId><ArticleId IdType="pubmed">30391462</ArticleId></ArticleIdList></Reference><Reference><Citation>Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, et al. . Microrna-30c Targets Cytoskeleton Genes Involved in Breast Cancer Cell Invasion. Breast Cancer Res Treat (2013) 137:373&#x2013;82. &#xa0;10.1007/S10549-012-2346-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S10549-012-2346-4</ArticleId><ArticleId IdType="pmc">PMC3583223</ArticleId><ArticleId IdType="pubmed">23224145</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua YQ, Zhu YD, Xie GQ, Zhang K, Sheng J, Zhu ZF, et al. . Long Non-Coding Sbf2-As1 Acting as a Competing Endogenous Rna To Sponge Microrna-142-3p to Participate in Gemcitabine Resistance in Pancreatic Cancer Via Upregulating Twf1. Aging (Albany Ny) (2019) 11:8860&#x2013;78. &#xa0;10.18632/Aging.102307</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/Aging.102307</ArticleId><ArticleId IdType="pubmed">31619579</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun LL, Cheng M, Xu XD. Microrna-30c Inhibits Pancreatic Cancer Cell Proliferation by Targeting Twinfilin 1 and Indicates a Poor Prognosis. World J Gastroenterol (2019) 25:6311&#x2013;21. &#xa0;10.3748/Wjg.V25.I42.6311</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/Wjg.V25.I42.6311</ArticleId><ArticleId IdType="pmc">PMC6861845</ArticleId><ArticleId IdType="pubmed">31754292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33966732</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-6263</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Taiwanese journal of obstetrics &amp; gynecology</Title><ISOAbbreviation>Taiwan J Obstet Gynecol</ISOAbbreviation></Journal><ArticleTitle>Decreased expression of CLCA2 and the correlating with immune infiltrates in patients with cervical squamous cell carcinoma: A bioinformatics analysis.</ArticleTitle><Pagination><StartPage>480</StartPage><EndPage>486</EndPage><MedlinePgn>480-486</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tjog.2021.03.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1028-4559(21)00067-X</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Calcium-activated chloride channel 2 (CLCA2) is closely related to the invasion, metastasis, and prognosis of some common malignant tumors. The present study aimed to evaluate the role of CLCA2 in cervical squamous cell carcinoma (CESC) using bioinformatics analysis.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The mRNA sequencing data and the corresponding clinical data were obtained from Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA) database respectively. Then univariate analysis of variance was used to analyze the differential mRNA expression of CLCA2 between normal, cervical Intraepithelial neoplasia (CIN), and CESC tissues and clinicopathological characteristics. The Gene Expression Profiling Interactive Analysis (GEPIA) was used to assess the association between CLCA2 and Disease-Free Survival (DFS), overall survival (OS). The Gene Set Enrichment Analysis (GSEA) was used to explore the associated signaling pathways. The Tumor Immune Estimation Resource (TIMER) was used to predict the potential biological roles of CLCA2 in tumor-immune of CESC.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CLCA2 expression was significantly decreased in CESC tissues compared with normal and CIN tissues (P&#xa0;&lt;&#xa0;0.05). Meanwhile, obese patients had lower levels of CLCA2 expression than normal-weight CESC patients (P&#xa0;&lt;&#xa0;0.05). However, there was no significant difference in the expression level of CLCA2 in patients with different T stage, lymph node status, metastasis, and FIGO stage in CC(P&#xa0;&gt;&#xa0;0.05). The survival analysis indicated that for DFS, CESC with high CLCA2 expression was associated with better prognoses compared with those with low expression levels (P&#xa0;&lt;&#xa0;0.05). But for the OS, there was no difference. GSEA revealed that 4 pathways exhibited significant differential enrichment in the CLCA2 high-expression phenotype, including the P53 signaling pathway, the ERBB signaling pathway, the NOTCH signaling pathway, and the ubiquitin-mediated proteolysis. The TIMER reveals the expression of CLCA2 showed a significant inverse association with the number of B cells, Macrophage cells, and Dendritic Cell infiltration.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The present study indicates that CLCA2 expression may be a potential prognostic marker for patients with CESC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Lanzhou University Second Hospital, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Jin-Long</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Lanzhou University Second Hospital, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Feng-Na</ForeName><Initials>FN</Initials><AffiliationInfo><Affiliation>Lanzhou University Second Hospital, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao-Feng</ForeName><Initials>XF</Initials><AffiliationInfo><Affiliation>Lanzhou University Second Hospital, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Li-Mei</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Lanzhou University Second Hospital, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Lanzhou University Second Hospital, Lanzhou, China. Electronic address: ery_fwang@lzu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China (Republic : 1949- )</Country><MedlineTA>Taiwan J Obstet Gynecol</MedlineTA><NlmUniqueID>101213819</NlmUniqueID><ISSNLinking>1028-4559</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120066">CLCA2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018118">Chloride Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002584" MajorTopicYN="N">Cervix Uteri</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018118" MajorTopicYN="N">Chloride Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioinformatics analysis</Keyword><Keyword MajorTopicYN="N">Calcium-activated chloride channel 2 (CLCA2)</Keyword><Keyword MajorTopicYN="N">Cervical squamous cell carcinoma (CESC)</Keyword><Keyword MajorTopicYN="N">GEO database</Keyword><Keyword MajorTopicYN="N">TCGA database</Keyword></KeywordList><CoiStatement>Declaration of competing interest The author declares that has no conflict of interest regarding the publication of this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33966732</ArticleId><ArticleId IdType="doi">10.1016/j.tjog.2021.03.016</ArticleId><ArticleId IdType="pii">S1028-4559(21)00067-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33883927</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1178-7074</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>International journal of general medicine</Title><ISOAbbreviation>Int J Gen Med</ISOAbbreviation></Journal><ArticleTitle>Expression Analysis of MIST1 and EMT Markers in Primary Tumor Samples Points to MIST1 as a Biomarker of Cervical Cancer.</ArticleTitle><Pagination><StartPage>1293</StartPage><EndPage>1300</EndPage><MedlinePgn>1293-1300</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/IJGM.S307367</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mist1 is a basic transcription factor, which plays an important role in the development of multiple organs, and may also regulate tumor progression by mediating epithelial-mesenchymal transformation. However, there is lack of research on its role of squamous cell carcinoma, especially in cervical squamous cell carcinoma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Bioinformatic methods were used to analyze gene expression, correlation, and patient survival according to the TCGA database. Thirty pairs of cancer tissues and distal cancer tissues from cervical cancer patients who received radical surgery were enrolled in the study. The expression of Mist1 was analyzed using Western blot. Furthermore, the potential associations among Mist1 expression, EMT biomarkers and various clinicopathological characteristics were investigated. All statistical tests employed in this study were two-sided, and <i>P</i> values &lt;0.05 were deemed statistically significant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall survival data were obtained from TCGA-CESC dataset, containing 3 control samples and 305 tumor samples. The expression of Mist1 was significantly higher in primary tumor than in normal tissues (<i>P</i>&lt;0.001). The samples were divided into a low Mist1 expression group (n=144) and a high Mist1 expression group (n=146) according to the median expression level. Kaplan-Meier survival analysis revealed that high expression of Mist1 was significantly correlated with poor overall survival (<i>P</i>=0.032). We further explored the relationships between Mist1 and EMT. Among the 30 primary cervical cancer specimens investigated, the difference in Mist1 expressed statuses between cervical cancer tissues and distal noncancerous cervical tissues was significant (<i>P</i>=0.001). And the epithelial cell marker E-cadherin was downregulated in Mist1 overexpressed cervical cancer cells; however, the mesenchymal marker N-Cadherin and Twist was upregulated.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study found that Mist1 seemed to play the role of oncogene in cervical squamous cell carcinoma and could be a potential biomarker.</AbstractText><CopyrightInformation>&#xa9; 2021 Wang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zhangjian</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8986-3854</Identifier><AffiliationInfo><Affiliation>Department of Surgical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Int J Gen Med</MedlineTA><NlmUniqueID>101515487</NlmUniqueID><ISSNLinking>1178-7074</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mist1</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">epithelial-mesenchymal transformation</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33883927</ArticleId><ArticleId IdType="pmc">PMC8055369</ArticleId><ArticleId IdType="doi">10.2147/IJGM.S307367</ArticleId><ArticleId IdType="pii">307367</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394&#x2013;424. doi:10.3322/caac.21492</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer. 2013;49(15):3262&#x2013;3273. doi:10.1016/j.ejca.2013.04.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2013.04.024</ArticleId><ArticleId IdType="pubmed">23751569</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Zheng R, Baade P, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115&#x2013;132. doi:10.3322/caac.21338</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21338</ArticleId><ArticleId IdType="pubmed">26808342</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J, Wang S, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010;10(10):683&#x2013;695. doi:10.1038/nrc2899</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2899</ArticleId><ArticleId IdType="pmc">PMC4085546</ArticleId><ArticleId IdType="pubmed">20814421</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi J, Mino-Kenudson M, Liss A, et al. Loss of Trefoil Factor 2 from pancreatic duct glands promotes formation of intraductal papillary mucinous neoplasms in mice. Gastroenterology. 2016;151(6):1232&#x2013;44.e10. doi:10.1053/j.gastro.2016.07.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.07.045</ArticleId><ArticleId IdType="pmc">PMC5396548</ArticleId><ArticleId IdType="pubmed">27523981</ArticleId></ArticleIdList></Reference><Reference><Citation>Riera K, Jang B, Min J, et al. Trop2 is upregulated in the transition to dysplasia in the metaplastic gastric mucosa. J Pathol. 2020;251(3):336&#x2013;347. doi:10.1002/path.5469</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.5469</ArticleId><ArticleId IdType="pmc">PMC8010636</ArticleId><ArticleId IdType="pubmed">32432338</ArticleId></ArticleIdList></Reference><Reference><Citation>Alison M. The cellular origins of cancer with particular reference to the gastrointestinal tract. Int J Exp Pathol. 2020;101:132&#x2013;151. doi:10.1111/iep.12364</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iep.12364</ArticleId><ArticleId IdType="pmc">PMC7495846</ArticleId><ArticleId IdType="pubmed">32794627</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh M, Jeng Y, Lee Y. Mist1: a novel nuclear marker for acinic cell carcinoma of the salivary gland. Virchows Archiv Int J Pathol. 2019;475(5):617&#x2013;624. doi:10.1007/s00428-019-02600-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00428-019-02600-1</ArticleId><ArticleId IdType="pubmed">31187185</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar D, Bashel B, Balasubramanya S, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia (New York, NY). 2017;19(8):649&#x2013;658. doi:10.1016/j.neo.2017.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2017.05.002</ArticleId><ArticleId IdType="pmc">PMC5516091</ArticleId><ArticleId IdType="pubmed">28732212</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98&#x2013;W102. doi:10.1093/nar/gkx247</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx247</ArticleId><ArticleId IdType="pmc">PMC5570223</ArticleId><ArticleId IdType="pubmed">28407145</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai M, Che Y, Lu K, Fu L. Analysis of deubiquitinase OTUD5 as a biomarker and therapeutic target for cervical cancer by bioinformatic analysis. PeerJ. 2020;8:e9146. doi:10.7717/peerj.9146</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.9146</ArticleId><ArticleId IdType="pmc">PMC7333649</ArticleId><ArticleId IdType="pubmed">32655987</ArticleId></ArticleIdList></Reference><Reference><Citation>Warde-Farley D, Donaldson S, Comes O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38:W214&#x2013;20. doi:10.1093/nar/gkq537</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq537</ArticleId><ArticleId IdType="pmc">PMC2896186</ArticleId><ArticleId IdType="pubmed">20576703</ArticleId></ArticleIdList></Reference><Reference><Citation>Mej&#xed;a L, Mu&#xf1;oz D, Trueba G, Tinoco L, Zapata S. Prevalence of human papillomavirus types in cervical cancerous and precancerous lesions of Ecuadorian women. J Med Virol. 2016;88(1):144&#x2013;152. doi:10.1002/jmv.24310</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24310</ArticleId><ArticleId IdType="pubmed">26113443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kori M, Yalcin Arga K. Potential biomarkers and therapeutic targets in cervical cancer: insights from the meta-analysis of transcriptomics data within network biomedicine perspective. PLoS One. 2018;13(7):e0200717. doi:10.1371/journal.pone.0200717</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0200717</ArticleId><ArticleId IdType="pmc">PMC6051662</ArticleId><ArticleId IdType="pubmed">30020984</ArticleId></ArticleIdList></Reference><Reference><Citation>Litjens R, Hopman A, van de Vijver K, Ramaekers F, Kruitwagen R, Kruse A. Molecular biomarkers in cervical cancer diagnosis: a critical appraisal. Expert Opin Med Diagn. 2013;7(4):365&#x2013;377. doi:10.1517/17530059.2013.808621</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17530059.2013.808621</ArticleId><ArticleId IdType="pubmed">23777477</ArticleId></ArticleIdList></Reference><Reference><Citation>Nienh&#xfc;ser H, Kim W, Malagola E, et al. Mist1+ gastric isthmus stem cells are regulated by Wnt5a and expand in response to injury and inflammation in mice. Gut. 2020;70:654&#x2013;665. doi:10.1136/gutjnl-2020-320742</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-320742</ArticleId><ArticleId IdType="pmc">PMC10337481</ArticleId><ArticleId IdType="pubmed">32709613</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada S, Yamanoi K, Sato Y, Nakayama J. Diffuse MIST1 expression and decreased &#x3b1;1, 4-linked N-acetylglucosamine (&#x3b1;GlcNAc) glycosylation on MUC6 are distinct hallmarks for gastric neoplasms showing oxyntic gland differentiation. Histopathology. 2020;77(3):413&#x2013;422. doi:10.1111/his.14165</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/his.14165</ArticleId><ArticleId IdType="pubmed">32502322</ArticleId></ArticleIdList></Reference><Reference><Citation>Young C, Baker R, Howlett C, et al. The loss of ATRX increases susceptibility to pancreatic injury and oncogenic KRAS in female but not male mice. Cell Mol Gastroenterol Hepatol. 2019;7(1):93&#x2013;113. doi:10.1016/j.jcmgh.2018.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2018.09.004</ArticleId><ArticleId IdType="pmc">PMC6260375</ArticleId><ArticleId IdType="pubmed">30510993</ArticleId></ArticleIdList></Reference><Reference><Citation>Brembeck F, Schreiber F, Deramaudt T, et al. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res. 2003;63(9):2005&#x2013;2009.</Citation><ArticleIdList><ArticleId IdType="pubmed">12727809</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra C, Schuhmacher A, Ca&#xf1;amero M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007;11(3):291&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">17349585</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Wang W, Xie X, Song Y, Dang C, Zhang H. Methylation-induced silencing of SPG20 facilitates gastric cancer cell proliferation by activating the EGFR/MAPK pathway. Biochem Biophys Res Commun. 2018;500(2):411&#x2013;417. doi:10.1016/j.bbrc.2018.04.089</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2018.04.089</ArticleId><ArticleId IdType="pubmed">29673586</ArticleId></ArticleIdList></Reference><Reference><Citation>Direnzo D, Hess D, Damsz B, et al. Induced Mist1 expression promotes remodeling of mouse pancreatic acinar cells. Gastroenterology. 2012;143(2):469&#x2013;480. doi:10.1053/j.gastro.2012.04.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2012.04.011</ArticleId><ArticleId IdType="pmc">PMC3664941</ArticleId><ArticleId IdType="pubmed">22510200</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung W, Zhou Y, Atfi A, Xu K. Downregulation of notch signaling in Kras-induced gastric metaplasia. Neoplasia (New York, NY). 2019;21(8):810&#x2013;821. doi:10.1016/j.neo.2019.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2019.06.003</ArticleId><ArticleId IdType="pmc">PMC6611983</ArticleId><ArticleId IdType="pubmed">31276933</ArticleId></ArticleIdList></Reference><Reference><Citation>Clevers H, Nusse R. Wnt/&#x3b2;-catenin signaling and disease. Cell. 2012;149(6):1192&#x2013;1205. doi:10.1016/j.cell.2012.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.05.012</ArticleId><ArticleId IdType="pubmed">22682243</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai E, Nakayama M, Oshima H, et al. Combined mutation of Apc, Kras, and Tgfbr2 effectively drives metastasis of intestinal cancer. Cancer Res. 2018;78(5):1334&#x2013;1346. doi:10.1158/0008-5472.CAN-17-3303</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-17-3303</ArticleId><ArticleId IdType="pubmed">29282223</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen V, Hough R, Bernaudo S, Peng C. Wnt/&#x3b2;-catenin signalling in ovarian cancer: insights into its hyperactivation and function in tumorigenesis. J Ovarian Res. 2019;12(1):122. doi:10.1186/s13048-019-0596-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13048-019-0596-z</ArticleId><ArticleId IdType="pmc">PMC6905042</ArticleId><ArticleId IdType="pubmed">31829231</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33842467</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-634X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in cell and developmental biology</Title><ISOAbbreviation>Front Cell Dev Biol</ISOAbbreviation></Journal><ArticleTitle>Identification of Stemness-Related Genes for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma by Integrated Bioinformatics Analysis.</ArticleTitle><Pagination><StartPage>642724</StartPage><MedlinePgn>642724</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">642724</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcell.2021.642724</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Invasion and metastasis of cervical cancer are the main factors affecting the prognosis of patients with cervical squamous cell carcinoma (CESC). Therefore, it is of vital importance to find novel biomarkers that are associated with CESC invasion and metastasis, which will aid in the amelioration of individualized therapeutic methods for advanced patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The gene expression profiles of 10 metastatic and 116 non-metastatic samples were downloaded from The Cancer Genome Atlas (TCGA), where differentially expressed genes (DEGs) were defined. Weighted gene correlation network analysis (WGCNA) was employed to identify the stemness-related genes (SRGs). Univariate and multivariate regression analyses were used to identify the most significant prognostic key genes. Differential expression analysis of transcription factor (TF) and Gene Set Variation Analysis (GSVA) were utilized to explore the potential upstream regulation of TFs and downstream signaling pathways, respectively. Co-expression analysis was performed among significantly enriched TFs, key SRGs, and signaling pathways to construct a metastasis-specific regulation network in CESC. Connectivity Map (CMap) analysis was performed to identify bioactive small molecules which might be potential inhibitors for the network. Additionally, direct regulatory patterns of key genes were validated by ChIP-seq and ATAC-seq data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">DEGs in yellow module acquired <i>via</i> WGCNA were defined as key genes which were most significantly related to mRNAsi. A multivariate Cox regression model was constructed and then utilized to explore the prognostic value of key SRGs by risk score. Area under curve (AUC) of the receiver operating characteristic (ROC) curve was 0.842. There was an obvious co expression pattern between the TF <i>NR5A2</i> and the key gene <i>VIM</i> (<i>R</i> = 0.843, <i>p</i> &lt; 0.001), while <i>VIM</i> was also significantly co-expressed with hallmark epithelial mesenchymal transition (EMT) signaling pathway (<i>R</i> = 0.318, <i>p</i> &lt; 0.001). Naringenin was selected as the potential bioactive small molecule inhibitor for metastatic CESC based on CMap analysis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS"><i>VIM</i> positively regulated by <i>NR5A2</i> affected EMT signaling pathways in metastatic CESC, and naringenin was the inhibitor for the treatment of metastatic CESC <i>via</i> suppressing cancer stemness. This hypothetical signaling axis and potential inhibitors provide biomarkers and novel therapeutic targets for metastatic CESC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Guo, Wang, Ju, Yan, Sun, Li, Wu, Lin, Xian, Yang, Wang and Huang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Hongjun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynaecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Siqiao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gynaecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Penghui</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gynaecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Wenhuizi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhenyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Siyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ruoyi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xian</LastName><ForeName>Shuyuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Daoke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatric Rehabilitation, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zongqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynaecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Dev Biol</MedlineTA><NlmUniqueID>101630250</NlmUniqueID><ISSNLinking>2296-634X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer stemness</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">epithelial mesenchymal transition</Keyword><Keyword MajorTopicYN="N">metastasis</Keyword><Keyword MajorTopicYN="N">naringenin</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33842467</ArticleId><ArticleId IdType="pmc">PMC8027330</ArticleId><ArticleId IdType="doi">10.3389/fcell.2021.642724</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Afify S. M., Seno M. (2019). Conversion of Stem Cells to Cancer Stem Cells: Undercurrent of Cancer Initiation. Cancers 11:345. 10.3390/cancers11030345</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11030345</ArticleId><ArticleId IdType="pmc">PMC6468812</ArticleId><ArticleId IdType="pubmed">30862050</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamad M. S., Siddiqui S., Jafri A., Ahmad S., Afzal M., Arshad M. (2014). Induction of Apoptosis and Antiproliferative Activity of Naringenin in Human Epidermoid Carcinoma Cell through ROS Generation and Cell Cycle Arrest. PLoS One 9:e110003. 10.1371/journal.pone.0110003</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0110003</ArticleId><ArticleId IdType="pmc">PMC4199682</ArticleId><ArticleId IdType="pubmed">25330158</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayob A. Z., Ramasamy T. S. (2018). Cancer stem cells as key drivers of tumour progression. J. Biomed. Sci. 25:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5838954</ArticleId><ArticleId IdType="pubmed">29506506</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth M. J. (2020). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines (R)). J. Natl. Comprehens. Cancer Netw. 18 Xliv&#x2013;Xliv.</Citation></Reference><Reference><Citation>Buenrostro J. D., Giresi P. G., Zaba L. C., Chang H. Y., Greenleaf W. J. (2013). Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10 1213&#x2013;1218. 10.1038/nmeth.2688</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2688</ArticleId><ArticleId IdType="pmc">PMC3959825</ArticleId><ArticleId IdType="pubmed">24097267</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H. L., Chang Y. M., Lai S. C., Chen K. M., Wang K. C., Chiu T. T., et al. (2017). Naringenin inhibits migration of lung cancer cells via the inhibition of matrix metalloproteinases-2 and-9. Exp. Therapeut. Med. 13 739&#x2013;744. 10.3892/etm.2016.3994</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2016.3994</ArticleId><ArticleId IdType="pmc">PMC5348669</ArticleId><ArticleId IdType="pubmed">28352360</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y. S., Han J. M., Kang Y. J., Jung H. J. (2021). Chloroform extract of Citrus unshiu Markovich peel induces apoptosis and inhibits stemness in HeLa human cervical cancer cells. Mol. Med. Rep. 23:11727. 10.3892/mmr.2020.11727</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2020.11727</ArticleId><ArticleId IdType="pmc">PMC7716394</ArticleId><ArticleId IdType="pubmed">33236129</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooke S. L., Temple J., MacArthur S., Zahra M. A., Tan L. T., Crawford R. A. F., et al. (2011). Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer. Br. J. Cancer 104 361&#x2013;368. 10.1038/sj.bjc.6605971</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6605971</ArticleId><ArticleId IdType="pmc">PMC3031882</ArticleId><ArticleId IdType="pubmed">21063398</ArticleId></ArticleIdList></Reference><Reference><Citation>Corces M. R., Granja J. M., Shams S., Louie B. H., Seoane J. A., Zhou W., et al. (2018). The chromatin accessibility landscape of primary human cancers. Science 362:aav1898. 10.1126/science.aav1898</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav1898</ArticleId><ArticleId IdType="pmc">PMC6408149</ArticleId><ArticleId IdType="pubmed">30361341</ArticleId></ArticleIdList></Reference><Reference><Citation>Danielsson F., Peterson M. K., Araujo H. C., Lautenschlager F., Gad A. K. B. (2018). Vimentin Diversity in Health and Disease. Cells 7:147. 10.3390/cells7100147</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells7100147</ArticleId><ArticleId IdType="pmc">PMC6210396</ArticleId><ArticleId IdType="pubmed">30248895</ArticleId></ArticleIdList></Reference><Reference><Citation>De Craene B., Berx G. (2013). Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13 97&#x2013;110. 10.1038/nrc3447</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3447</ArticleId><ArticleId IdType="pubmed">23344542</ArticleId></ArticleIdList></Reference><Reference><Citation>ENCODE (2011). A user&#x2019;s guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 9:e1001046. 10.1371/journal.pbio.1001046</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1001046</ArticleId><ArticleId IdType="pmc">PMC3079585</ArticleId><ArticleId IdType="pubmed">21526222</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayard E., Auwerx J., Schoonjans K. (2004). LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends Cell Biol. 14 250&#x2013;260. 10.1016/j.tcb.2004.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2004.03.008</ArticleId><ArticleId IdType="pubmed">15130581</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan M. B. (2018). Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening in the United States Is It Time? Arch. Pathol. Lab. Med. 142 688&#x2013;692. 10.5858/arpa.2018-0001-ra</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/arpa.2018-0001-ra</ArticleId><ArticleId IdType="pubmed">29848034</ArticleId></ArticleIdList></Reference><Reference><Citation>Flemming A. (2015). CANCER STEM CELLS Targeting the root of cancer relapse. Nat. Rev. Drug Discov. 14 165&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">25722238</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs E., Weber K. (1994). Intermediate Filaments - Structure, Dynamics, Function, and Disease. Annu. Rev. Biochem. 63 345&#x2013;382. 10.1146/annurev.bi.63.070194.002021</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.bi.63.070194.002021</ArticleId><ArticleId IdType="pubmed">7979242</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu P. L., Goodwin B., Chung A. C. K., Xu X. P., Wheeler D. A., Price R. R., et al. (2005). Orphan nuclear receptor LRH-1 is required to maintain Oct4 expression at the epiblast stage of embryonic development. Mol. Cell. Biol. 25 3492&#x2013;3505. 10.1128/mcb.25.9.3492-3505.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.25.9.3492-3505.2005</ArticleId><ArticleId IdType="pmc">PMC1084298</ArticleId><ArticleId IdType="pubmed">15831456</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahne F., Ivanek R. (2016). Visualizing Genomic Data Using Gviz and Bioconductor. Methods Mol. Biol. 1418 335&#x2013;351. 10.1007/978-1-4939-3578-9_16</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3578-9_16</ArticleId><ArticleId IdType="pubmed">27008022</ArticleId></ArticleIdList></Reference><Reference><Citation>Han K. Y., Chen P. N., Hong M. C., Hseu Y. C., Chen K. M., Hsu L. S., et al. (2018). Naringenin Attenuated Prostate Cancer Invasion via Reversal of Epithelial to Mesenchymal Transition and Inhibited uPA Activity. Anticancer Res. 38 6753&#x2013;6758. 10.21873/anticanres.13045</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.13045</ArticleId><ArticleId IdType="pubmed">30504386</ArticleId></ArticleIdList></Reference><Reference><Citation>Heng J. C. D., Feng B., Han J. Y., Jiang J. M., Kraus P., Ng J. H., et al. (2010). The Nuclear Receptor Nr5a2 Can Replace Oct4 in the Reprogramming of Murine Somatic Cells to Pluripotent Cells. Cell Stem Cell 6 167&#x2013;174. 10.1016/j.stem.2009.12.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2009.12.009</ArticleId><ArticleId IdType="pubmed">20096661</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutter C., Zenklusen J. C. (2018). The Cancer Genome Atlas: Creating Lasting Value beyond Its Data. Cell 173 283&#x2013;285. 10.1016/j.cell.2018.03.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.042</ArticleId><ArticleId IdType="pubmed">29625045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanno S., Tomizawa A., Hiura T., Osani Y., Shouji A., Ujibe M., et al. (2005). Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol. Pharmaceut. Bull. 28 527&#x2013;530. 10.1248/bpb.28.527</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.28.527</ArticleId><ArticleId IdType="pubmed">15744083</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A., Fornes O., Stigliani A., Gheorghe M., Castro-Mondragon J. A., van der Lee R., et al. (2018). JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res. 46 D260&#x2013;D266. 10.1093/nar/gkx1126</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1126</ArticleId><ArticleId IdType="pmc">PMC5753243</ArticleId><ArticleId IdType="pubmed">29140473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J. H., Kang J. W., Kim M. S., Bak Y., Park Y. S., Jung K. Y., et al. (2012a). The apoptotic effects of the flavonoid N101-2 in human cervical cancer cells. Toxicol. In Vitro 26 67&#x2013;73. 10.1016/j.tiv.2011.10.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tiv.2011.10.012</ArticleId><ArticleId IdType="pubmed">22056764</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y. K., Kim J. H., Lee Y. C., Kim K. S., Kim H. I., Kim J. W., et al. (2012b). Identification and characterization of cancer stem-like cells in gastric cancer. J. Gastroenterol. Hepatol. 27:430.</Citation></Reference><Reference><Citation>Kisseljov F., Sakharova O., Kondratjeva T. (2008). Cellular and Molecular Biological Aspects of Cervical Intraepithelial Neoplasia. Int. Rev. Cell Mol. Biol. 271 35&#x2013;95. 10.1016/s1937-6448(08)01202-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1937-6448(08)01202-1</ArticleId><ArticleId IdType="pubmed">19081541</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahue B. J., Baginska E., Li S. S., Parisi M. (2015). Health Technology Assessment on Cervical Cancer Screening, 2000-2014. Int. J. Technol. Assess. Health Care 31 171&#x2013;180. 10.1017/s0266462315000197</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s0266462315000197</ArticleId><ArticleId IdType="pmc">PMC4535324</ArticleId><ArticleId IdType="pubmed">26179276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb J., Crawford E. D., Peck D., Modell J. W., Blat I. C., Wrobel M. J., et al. (2006). The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313 1929&#x2013;1935. 10.1126/science.1132939</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1132939</ArticleId><ArticleId IdType="pubmed">17008526</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P., Horvath S. (2008). WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 9:559. 10.1186/1471-2105-9-559</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-9-559</ArticleId><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Larue L., Bellacosa A. (2005). Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3 &#x2019; kinase/AKT pathways. Oncogene 24 7443&#x2013;7454. 10.1038/sj.onc.1209091</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1209091</ArticleId><ArticleId IdType="pubmed">16288291</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Hsu S., Purushotham D., Sears R. L., Wang T. (2019). WashU Epigenome Browser update 2019. Nucleic Acids Res. 47 W158&#x2013;W165. 10.1093/nar/gkz348</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz348</ArticleId><ArticleId IdType="pmc">PMC6602459</ArticleId><ArticleId IdType="pubmed">31165883</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao A. C. H., Kuo C. C., Huang Y. C., Yeh C. W., Hseu Y. C., Liu J. Y., et al. (2014). Naringenin inhibits migration of bladder cancer cells through downregulation of AKT and MMP-2. Mol. Med. Rep. 10 1531&#x2013;1536. 10.3892/mmr.2014.2375</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2014.2375</ArticleId><ArticleId IdType="pubmed">25017119</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A., Birger C., Thorvaldsdottir H., Ghandi M., Mesirov J. P., Tamayo P. (2015). The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1 417&#x2013;425. 10.1016/j.cels.2015.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2015.12.004</ArticleId><ArticleId IdType="pmc">PMC4707969</ArticleId><ArticleId IdType="pubmed">26771021</ArticleId></ArticleIdList></Reference><Reference><Citation>Long H. J. (2007). Management of metastatic cervical cancer: Review of the literature. J. Clin. Oncol. 25 2966&#x2013;2974.</Citation><ArticleIdList><ArticleId IdType="pubmed">17617528</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez J., Poitevin A., Mendoza-Martinez V., Perez-Plasencia C., Garcia-Carranca A. (2012). Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer 12:48. 10.1186/1471-2407-12-48</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-12-48</ArticleId><ArticleId IdType="pmc">PMC3299592</ArticleId><ArticleId IdType="pubmed">22284662</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou C. J., Zhang F. Y., Yang M., Zhao J., Zeng W. F., Fang X. C., et al. (2012). Naringenin Decreases Invasiveness and Metastasis by Inhibiting TGF-beta-Induced Epithelial to Mesenchymal Transition in Pancreatic Cancer Cells. PLoS One 7:e50956. 10.1371/journal.pone.0050956</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0050956</ArticleId><ArticleId IdType="pmc">PMC3530567</ArticleId><ArticleId IdType="pubmed">23300530</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T. T., Makishima M., Repa J. J., Schoonjans K., Kerr T. A., Auwerx J., et al. (2000). Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6 507&#x2013;515. 10.1016/s1097-2765(00)00050-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1097-2765(00)00050-2</ArticleId><ArticleId IdType="pubmed">11030331</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggioni D., Nicolini G., Rigolio R., Biffi L., Pignataro L., Gaini R., et al. (2014). Myricetin and Naringenin Inhibit Human Squamous Cell Carcinoma Proliferation and Migration In Vitro. Nutrit. Cancer Int. J. 66 1257&#x2013;1267. 10.1080/01635581.2014.951732</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01635581.2014.951732</ArticleId><ArticleId IdType="pubmed">25256786</ArticleId></ArticleIdList></Reference><Reference><Citation>Malta T. M., Sokolov A., Gentles A. J., Burzykowski T., Poisson L., Weinstein J. N., et al. (2018). Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173 338&#x2013;354e315. 10.1016/j.cell.2018.03.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.034</ArticleId><ArticleId IdType="pmc">PMC5902191</ArticleId><ArticleId IdType="pubmed">29625051</ArticleId></ArticleIdList></Reference><Reference><Citation>Naga C. H. P., Gurram L., Chopra S., Mahantshetty U. (2018). The management of locally advanced cervical cancer. Curr. Opin. Oncol. 30 323&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">29994902</ArticleId></ArticleIdList></Reference><Reference><Citation>Noordhuis M. G., Fehrmann R. S., Wisman G. B., Nijhuis E. R., van Zanden J. J., Moerland P. D., et al. (2011). Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin. Cancer Res. 17 1317&#x2013;1330. 10.1158/1078-0432.CCR-10-2320</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-10-2320</ArticleId><ArticleId IdType="pubmed">21385933</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojesina A. I., Lichtenstein L., Freeman S. S., Pedamallu C. S., Imaz-Rosshandler I., Pugh T. J., et al. (2014). Landscape of genomic alterations in cervical carcinomas. Nature 506 371&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161954</ArticleId><ArticleId IdType="pubmed">24390348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz-Sanchez E., Santiago-Lopez L., Cruz-Dominguez V. B., Toledo-Guzman M. E., Hernandez-Cueto D., Muniz-Hernandez S., et al. (2016). Characterization of cervical cancer stem cell-like cells: phenotyping, stemness, and Human Papilloma Virus co-receptor expression. Oncotarget 7 31943&#x2013;31954. 10.18632/oncotarget.8218</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.8218</ArticleId><ArticleId IdType="pmc">PMC5077987</ArticleId><ArticleId IdType="pubmed">27008711</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborn M., Weber K. (1984). Actin Paracrystal Induction by Forskolin and by Db-Camp in Cho Cells. Exp. Cell Res. 150 408&#x2013;418. 10.1016/0014-4827(84)90584-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-4827(84)90584-6</ArticleId><ArticleId IdType="pubmed">6319166</ArticleId></ArticleIdList></Reference><Reference><Citation>Paovonen J., Naud P., Salmeron J., Wheeler C. M., Chow S. N., Apter D., et al. (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 301&#x2013;314. 10.1016/s0140-6736(09)61248-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(09)61248-4</ArticleId><ArticleId IdType="pubmed">19586656</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastushenko I., Blanpain C. (2019). EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 29 212&#x2013;226. 10.1016/j.tcb.2018.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2018.12.001</ArticleId><ArticleId IdType="pubmed">30594349</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie M. E., Phipson B., Wu D., Hu Y., Law C. W., Shi W., et al. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e47. 10.1093/nar/gkv007</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson M. D., McCarthy D. J., Smyth G. K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26 139&#x2013;140. 10.1093/bioinformatics/btp616</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato R., Semba T., Saya H., Arima Y. (2016). Concise Review: Stem Cells and Epithelial-Mesenchymal Transition in Cancer: Biological Implications and Therapeutic Targets. Stem Cells 34 1997&#x2013;2007. 10.1002/stem.2406</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2406</ArticleId><ArticleId IdType="pubmed">27251010</ArticleId></ArticleIdList></Reference><Reference><Citation>Small W., Bacon M. A., Bajaj A., Chuang L. T., Fisher B. J., Harkenrider M. M., et al. (2017). Cervical Cancer: A Global Health Crisis. Cancer 123 2404&#x2013;2412. 10.1002/cncr.30667</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.30667</ArticleId><ArticleId IdType="pubmed">28464289</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Narayan R., Corsello S. M., Peck D. D., Natoli T. E., Lu X. D., et al. (2017). A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell 171:1437.e&#x2013;1452.e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990023</ArticleId><ArticleId IdType="pubmed">29195078</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiery J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2 442&#x2013;454. 10.1038/nrc822</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc822</ArticleId><ArticleId IdType="pubmed">12189386</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen M., Fagerberg L., Hallstrom B. M., Lindskog C., Oksvold P., Mardinoglu A., et al. (2015). Tissue-based map of the human proteome. Science 347:1260419.</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Yang J., Liu H., Lu D., Chen X. F., Zenonos Z., et al. (2011). Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1. Proc. Natl. Acad. Sci. U S A. 108 18283&#x2013;18288. 10.1073/pnas.1100893108</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1100893108</ArticleId><ArticleId IdType="pmc">PMC3215025</ArticleId><ArticleId IdType="pubmed">21990348</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S. F., Yang W. E., Kuo W. H., Chang H. R., Chu S. C., Hsieh Y. S. (2008). Antimetastatic potentials of flavones on oral cancer cell via an inhibition of matrix-degrading proteases. Arch. Oral Biol. 53 287&#x2013;294. 10.1016/j.archoralbio.2007.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archoralbio.2007.09.001</ArticleId><ArticleId IdType="pubmed">17936716</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G. C., Wang L. G., Han Y. Y., He Q. Y. (2012). clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. Omics J. Integrat. Biol. 16 284&#x2013;287. 10.1089/omi.2011.0118</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M. B., Guerra J., Firek A., Langridge W. H. R. (2018). Extracellular vimentin modulates human dendritic cell activation. Mol. Immunol. 104 37&#x2013;46. 10.1016/j.molimm.2018.09.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2018.09.017</ArticleId><ArticleId IdType="pmc">PMC6497527</ArticleId><ArticleId IdType="pubmed">30399492</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaim O., Doganlar O., Zreigh M. M., Doganlar Z. B., Ozcan H. (2018). Synthesis, Cancer-Selective Antiproliferative and Apoptotic Effects of Some (+/-)-Naringenin Cycloaminoethyl Derivatives. Chem. Biodivers. 15:e1800016. 10.1002/cbdv.201800016</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbdv.201800016</ArticleId><ArticleId IdType="pubmed">29766645</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng R., Wan C., Mei S., Qin Q., Wu Q., Sun H., et al. (2019). Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res. 47 D729&#x2013;D735. 10.1093/nar/gky1094</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1094</ArticleId><ArticleId IdType="pmc">PMC6324081</ArticleId><ArticleId IdType="pubmed">30462313</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33763482</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-6141</ISSN><JournalIssue CitedMedium="Internet"><Volume>2021</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>BioMed research international</Title><ISOAbbreviation>Biomed Res Int</ISOAbbreviation></Journal><ArticleTitle>Upregulation of <i>CDC7</i> Associated with Cervical Cancer Incidence and Development.</ArticleTitle><Pagination><StartPage>6663367</StartPage><MedlinePgn>6663367</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6663367</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2021/6663367</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cervical cancer is a common malignant tumor of women. Using integrated bioinformatics, this study identified key disease-causing genes in cervical cancer that may provide effective biomarkers or therapeutic targets for early diagnosis and treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We used high-throughput sequencing data from the Gene Expression Omnibus (GEO) to identify new cervical cancer biomarkers. The GSE63678 dataset was downloaded. The data was analyzed via bioinformatics methods, and 61 differentially expressed genes were obtained. These differential genes were analyzed by the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichments analyses. GO analysis demonstrated that the basic biological functions of differential genes were mostly regulating cell division, mitotic nuclear division, and immune response. Analysis of the KEGG pathway showed the primary involved in the cell cycle, p53 signaling pathway, and cytokine-cytokine receptor interactions. Using TCGA database to query differential expression of differential genes in cervical cancer, the <i>CDC7</i> gene was found to be highly expressed. <i>In silico</i> analysis of protein interactions using the STRING database revealed that <i>CDC7</i> interacts with many proteins. These findings were then validated <i>in vitro</i> with immunohistochemistry and qRt-PCR to confirm that <i>CDC7</i> is highly expressed in cervical cancer tissues. Cell function tests demonstrated that inhibition of <i>CDC7</i> expression could inhibit the proliferation and migration of cervical cancer HeLa and SiHa cells and promote apoptosis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">With comprehensive bioinformatics combined with clinical and cellular function analysis, <i>CDC7</i> is important to the development of cervical cancer. Targeting of this biomarker may improve the early diagnosis and treatment of cervical cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Qingwei Wang and Weiping Zheng.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qingwei</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-1956-0812</Identifier><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shaoxing People's Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Weiping</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-7142-4773</Identifier><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Shaoxing People's Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biomed Res Int</MedlineTA><NlmUniqueID>101600173</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="C068619">CDC7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="Y">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="Y">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030561" MajorTopicYN="Y">Databases, Nucleic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015971" MajorTopicYN="Y">Gene Expression Regulation, Enzymologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009363" MajorTopicYN="Y">Neoplasm Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="Y">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="Y">Up-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33763482</ArticleId><ArticleId IdType="pmc">PMC7952153</ArticleId><ArticleId IdType="doi">10.1155/2021/6663367</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferlay J., Soerjomataram I., Dikshit R., et al. Cancer incidence and mortality worldwide: sources methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015;136(5):E359&#x2013;E386. doi: 10.1002/ijc.29210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.29210</ArticleId><ArticleId IdType="pubmed">25220842</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre L. A., Bray F., Siegel R. L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA: a Cancer Journal for Clinicians. 2015;65(2):87&#x2013;108. doi: 10.3322/caac.21262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21262</ArticleId><ArticleId IdType="pubmed">25651787</ArticleId></ArticleIdList></Reference><Reference><Citation>Galani E., Christodoulou C. Human papilloma viruses and cancer in the post-vaccine era. Clinical Microbiology and Infection. 2009;15(11):977&#x2013;981. doi: 10.1111/j.1469-0691.2009.03032.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2009.03032.x</ArticleId><ArticleId IdType="pubmed">19874381</ArticleId></ArticleIdList></Reference><Reference><Citation>Odekunle F. F. Contributions of epidemiological and laboratory methods to the establishment of the causal association of human papillomavirus with cancer of the cervix. International Journal of Advanced Multidisciplinary Research. 2017;4:2166&#x2013;2170.</Citation></Reference><Reference><Citation>Tenca P., Brotherton D., Montagnoli A., Rainoldi S., Albanese C., Santocanale C. CDC7 is an active kinase in human cancer cells undergoing replication stress. Journal of Biological Chemistry. 2007;282(1):208&#x2013;215. doi: 10.1074/jbc.M604457200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M604457200</ArticleId><ArticleId IdType="pubmed">17062569</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudzarova S., Mulholland P., Dey A., Stoeber K., Okorokov A. L., Williams G. H. p53 controls CDC7 levels to reinforce G1 cell cycle arrest upon genotoxic stress. Cell Cycle. 2016;15(21):2958&#x2013;2972. doi: 10.1080/15384101.2016.1231281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2016.1231281</ArticleId><ArticleId IdType="pmc">PMC5105930</ArticleId><ArticleId IdType="pubmed">27611229</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Zhao X. L., Shang S. Q., Shen H. Q., Chen X. Dual inhibition of Cdc7 and Cdk9 by PHA-767491 suppresses hepatocarcinoma synergistically with 5-fluorouracil. Current Cancer Drug Targets. 2015;15(3):196&#x2013;204. doi: 10.2174/1568009615666150212112753.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568009615666150212112753</ArticleId><ArticleId IdType="pubmed">25643258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman B. T., Huang D., Tan Q., et al. DAVID knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics. 2007;8(1):p. 426. doi: 10.1186/1471-2105-8-426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-8-426</ArticleId><ArticleId IdType="pmc">PMC2186358</ArticleId><ArticleId IdType="pubmed">17980028</ArticleId></ArticleIdList></Reference><Reference><Citation>von Mering C., Huynen M., Jaeggi D., Schmidt S., Bork P., Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Research. 2003;31(1):258&#x2013;261. doi: 10.1093/nar/gkg034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkg034</ArticleId><ArticleId IdType="pmc">PMC165481</ArticleId><ArticleId IdType="pubmed">12519996</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Meng F., Dai E., et al. Identification of associations between small molecule drugs and miRNAs based on functional similarity. Oncotarget. 2016;7(25):38658&#x2013;38669. doi: 10.18632/oncotarget.9577.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.9577</ArticleId><ArticleId IdType="pmc">PMC5122418</ArticleId><ArticleId IdType="pubmed">27232942</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer M. K., Niknafs Y. S., Malik R., et al. The landscape of long noncoding RNAs in the human transcriptome. Nature Genetics. 2015;47(3):199&#x2013;208. doi: 10.1038/ng.3192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3192</ArticleId><ArticleId IdType="pmc">PMC4417758</ArticleId><ArticleId IdType="pubmed">25599403</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Sun Y., Wei Y., et al. LIFR is a breast cancer metastasis suppressor upstream of the hippo-YAP pathway and a prognostic marker. Nature Medicine. 2012;18(10):1511&#x2013;1517. doi: 10.1038/nm.2940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2940</ArticleId><ArticleId IdType="pmc">PMC3684419</ArticleId><ArticleId IdType="pubmed">23001183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni A. A., Kingsbury S. R., Tudzarova S., et al. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma. Clinical Cancer Research. 2009;15(7):2417&#x2013;2425. doi: 10.1158/1078-0432.CCR-08-1276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-08-1276</ArticleId><ArticleId IdType="pubmed">19318489</ArticleId></ArticleIdList></Reference><Reference><Citation>Melling N., Muth J., Simon R., et al. Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer. Diagnostic Pathology. 2015;10(1):p. 125. doi: 10.1186/s13000-015-0360-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13000-015-0360-7</ArticleId><ArticleId IdType="pmc">PMC4514957</ArticleId><ArticleId IdType="pubmed">26208856</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta A., Ghatak D., Das S., et al. p53 gain-of-function mutations increase Cdc7-dependent replication initiation. EMBO Reports. 2017;18(11):2030&#x2013;2050. doi: 10.15252/embr.201643347.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201643347</ArticleId><ArticleId IdType="pmc">PMC5666604</ArticleId><ArticleId IdType="pubmed">28887320</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaafari-Ashkavandi Z., Ashraf M. J., Abbaspoorfard A. A. Superexpressao de CDC7 em tumores malignos de glandulas salivares correlaciona-se com a diferencia&#xe7;ao dos tumores. Brazilian Journal of Otorhinolaryngology. 2019;85(2):144&#x2013;149. doi: 10.1016/j.bjorl.2017.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjorl.2017.11.004</ArticleId><ArticleId IdType="pmc">PMC9452223</ArticleId><ArticleId IdType="pubmed">29339028</ArticleId></ArticleIdList></Reference><Reference><Citation>Choschzick M., Lebeau A., Marx A. H., et al. Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer. Human Pathology. 2010;41(3):358&#x2013;365. doi: 10.1016/j.humpath.2009.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humpath.2009.08.008</ArticleId><ArticleId IdType="pubmed">19896697</ArticleId></ArticleIdList></Reference><Reference><Citation>Sclafani R. A., Holzen T. M. Cell cycle regulation of DNA replication. Annual Review of Genetics. 2007;41(1):237&#x2013;280. doi: 10.1146/annurev.genet.41.110306.130308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.genet.41.110306.130308</ArticleId><ArticleId IdType="pmc">PMC2292467</ArticleId><ArticleId IdType="pubmed">17630848</ArticleId></ArticleIdList></Reference><Reference><Citation>Labib K. How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells? Genes &amp; Development. 2010;24(12):1208&#x2013;1219. doi: 10.1101/gad.1933010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1933010</ArticleId><ArticleId IdType="pmc">PMC2885657</ArticleId><ArticleId IdType="pubmed">20551170</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagnoli A., Tenca P., Sola F., et al. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells. Cancer Research. 2004;64(19):7110&#x2013;7116. doi: 10.1158/0008-5472.CAN-04-1547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-04-1547</ArticleId><ArticleId IdType="pubmed">15466207</ArticleId></ArticleIdList></Reference><Reference><Citation>Im J. S., Lee J. K. ATR-dependent activation of p38 MAP kinase is responsible for apoptotic cell death in cells depleted of Cdc7. The Journal of Biological Chemistry. 2008;283(37):25171&#x2013;25177. doi: 10.1074/jbc.M802851200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M802851200</ArticleId><ArticleId IdType="pubmed">18625709</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasi N. K., Bhutkar A., Lanning N. J., MacKeigan J. P., Weinreich M. DDK promotes tumor chemoresistance and survival via multiple pathways. Neoplasia. 2017;19(5):439&#x2013;450. doi: 10.1016/j.neo.2017.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2017.03.001</ArticleId><ArticleId IdType="pmc">PMC5406526</ArticleId><ArticleId IdType="pubmed">28448802</ArticleId></ArticleIdList></Reference><Reference><Citation>Swords R., Mahalingam D., O&#x2019;Dwyer M., et al. Cdc7 kinase-a new target for drug development. European Journal of Cancer. 2010;46(1):33&#x2013;40. doi: 10.1016/j.ejca.2009.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2009.09.020</ArticleId><ArticleId IdType="pubmed">19815406</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagnoli A., Moll J., Colotta F. Targeting cell division cycle 7 kinase:a new approach for cancer therapy. Clinical Cancer Research. 2010;16(18):4503&#x2013;4508. doi: 10.1158/1078-0432.CCR-10-0185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-10-0185</ArticleId><ArticleId IdType="pubmed">20647475</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33671013</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>28</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2442</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22052442</ELocationID><Abstract><AbstractText>Cervical cancer is primarily caused by the infection of high-risk human papillomavirus (hrHPV). Moreover, tumor immune microenvironment plays a significant role in the tumorigenesis of cervical cancer. Therefore, it is necessary to comprehensively identify predictive biomarkers from immunogenomics associated with cervical cancer prognosis. The Cancer Genome Atlas (TCGA) public database has stored abundant sequencing or microarray data, and clinical data, offering a feasible and reliable approach for this study. In the present study, gene profile and clinical data were downloaded from TCGA, and the Immunology Database and Analysis Portal (ImmPort) database. Wilcoxon-test was used to compare the difference in gene expression. Univariate analysis was adopted to identify immune-related genes (IRGs) and transcription factors (TFs) correlated with survival. A prognostic prediction model was established by multivariate cox analysis. The regulatory network was constructed and visualized by correlation analysis and Cytoscape, respectively. Gene functional enrichment analysis was performed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). A total of 204 differentially expressed IRGs were identified, and 22 of them were significantly associated with the survival of cervical cancer. These 22 IRGs were actively involved in the JAK-STAT pathway. A prognostic model based on 10 IRGs (<i>APOD</i>, <i>TFRC</i>, <i>GRN</i>, <i>CSK</i>, <i>HDAC1</i>, <i>NFATC4</i>, <i>BMP6</i>, <i>IL17RD</i>, <i>IL3RA</i>, and <i>LEPR</i>) performed moderately and steadily in squamous cell carcinoma (SCC) patients with FIGO stage I, regardless of the age and grade. Taken together, a risk score model consisting of 10 novel genes capable of predicting survival in SCC patients was identified. Moreover, the regulatory network of IRGs associated with survival (SIRGs) and their TFs provided potential molecular targets.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qun</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vattai</LastName><ForeName>Aurelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilsmaier</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0452-1148</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaltofen</LastName><ForeName>Till</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1137-211X</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steger</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0033-6941</Identifier><AffiliationInfo><Affiliation>Klinik f&#xfc;r Innere Medizin I, Technische Universit&#xe4;t M&#xfc;nchen, 80333 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayr</LastName><ForeName>Doris</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology, LMU Munich, 80377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahner</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeschke</LastName><ForeName>Udo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology, University Hospital Augsburg, Stenglinstr. 2, 86156 Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildegard Heidegger</LastName><ForeName>Helene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Qun Wang</GrantID><Agency>China Scholarship Council</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">KEGG</Keyword><Keyword MajorTopicYN="N">TCGA</Keyword><Keyword MajorTopicYN="N">bioinformatics analysis</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">tumor immune</Keyword></KeywordList><CoiStatement>Sven Mahner reports grants and personal fees from AstraZeneca, personal fees from Clovis, grants, and personal fees from Medac, grants, and personal fees from MSD. He also reports personal fees from Novartis, grants and personal fees from PharmaMar, grants and personal fees from Roche, personal fees from Sensor Kinesis, grants, and personal fees from Tesaro, grants and personal fees from Teva, outside the submitted work. All other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>6</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33671013</ArticleId><ArticleId IdType="pmc">PMC7957482</ArticleId><ArticleId IdType="doi">10.3390/ijms22052442</ArticleId><ArticleId IdType="pii">ijms22052442</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015;65:87&#x2013;108. doi: 10.3322/caac.21262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21262</ArticleId><ArticleId IdType="pubmed">25651787</ArticleId></ArticleIdList></Reference><Reference><Citation>Di J., Rutherford S., Chu C. Review of the Cervical Cancer Burden and Population-Based Cervical Cancer Screening in China. Asian Pac. J. Cancer Prev. 2015;16:7401&#x2013;7407. doi: 10.7314/APJCP.2015.16.17.7401.</Citation><ArticleIdList><ArticleId IdType="doi">10.7314/APJCP.2015.16.17.7401</ArticleId><ArticleId IdType="pubmed">26625735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn K., Kweon S., Kim D.W., Lee H. Different expression of GSK3beta and pS9GSK3beta depending on phenotype of cervical cancer: Possible association of GSK3beta with squamous cell carcinoma and pS9GSK3beta with adenocarcinoma. Obs. Gynecol. Sci. 2019;62:157&#x2013;165. doi: 10.5468/ogs.2019.62.3.157.</Citation><ArticleIdList><ArticleId IdType="doi">10.5468/ogs.2019.62.3.157</ArticleId><ArticleId IdType="pmc">PMC6520545</ArticleId><ArticleId IdType="pubmed">31139591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hass P., Eggemann H., Costa S.D., Ignatov A. Adjuvant hysterectomy after radiochemotherapy for locally advanced cervical cancer. Strahlenther. Onkol. 2017;193:1048&#x2013;1055. doi: 10.1007/s00066-017-1174-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00066-017-1174-1</ArticleId><ArticleId IdType="pubmed">28660291</ArticleId></ArticleIdList></Reference><Reference><Citation>van Meir H., Kenter G.G., Burggraaf J., Kroep J.R., Welters M.J., Melief C.J., Van Der Burg S.H., IE Van Poelgeest M. The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy. Anticancer Agents Med. Chem. 2014;14:190&#x2013;203. doi: 10.2174/18715206113136660372.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/18715206113136660372</ArticleId><ArticleId IdType="pubmed">24237223</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J., Liang T., Wang D., Li L., Cheng Y., Guo Q., Zhang G. IFNalpha-Expressing Amniotic Fluid-Derived Mesenchymal Stem Cells Migrate to and Suppress HeLa Cell-Derived Tumors in a Mouse Model. Stem. Cells Int. 2018;2018:1241323. doi: 10.1155/2018/1241323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/1241323</ArticleId><ArticleId IdType="pmc">PMC5901954</ArticleId><ArticleId IdType="pubmed">29760719</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Che Y., Zhao Y., Wang X. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo. Int. Immunopharmacol. 2019;69:279&#x2013;288. doi: 10.1016/j.intimp.2019.01.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2019.01.024</ArticleId><ArticleId IdType="pubmed">30743204</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormack S.E., Cruz C.R.Y., Wright K.E., Powell A.B., Lang H., Trimble C., Keller M.D., Fuchs E., Bollard C.M. Human papilloma virus-specific T cells can be generated from naive T cells for use as an immunotherapeutic strategy for immunocompromised patients. Cytotherapy. 2018;20:385&#x2013;393. doi: 10.1016/j.jcyt.2017.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2017.11.010</ArticleId><ArticleId IdType="pmc">PMC6731765</ArticleId><ArticleId IdType="pubmed">29331266</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishio H., Iwata T., Aoki D. Current status of cancer immunotherapy for gynecologic malignancies. Jpn. J. Clin. Oncol. 2020;51:167&#x2013;172. doi: 10.1093/jjco/hyaa214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jjco/hyaa214</ArticleId><ArticleId IdType="pubmed">33244581</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Cui Y., Diehn M., Li R. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer. JAMA Oncol. 2017;3:1529&#x2013;1537. doi: 10.1001/jamaoncol.2017.1609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2017.1609</ArticleId><ArticleId IdType="pmc">PMC5710196</ArticleId><ArticleId IdType="pubmed">28687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P., Guo Y.N., Shi L., Li X.J., Yang H., He Y., Li Q., Dang Y., Weei K., Chen G. Development of a prognostic index based on an immunogenomic landscape analysis of papillary thyroid cancer. Aging. 2019;11:480&#x2013;500. doi: 10.18632/aging.101754.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101754</ArticleId><ArticleId IdType="pmc">PMC6366981</ArticleId><ArticleId IdType="pubmed">30661062</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya S., Andorf S., Gomes L., Dunn P., Schaefer H., Pontius J., Berger P., Desborough V., Smith T., Campbell J., et al. ImmPort: Disseminating data to the public for the future of immunology. Immunol. Res. 2014;58:234&#x2013;239. doi: 10.1007/s12026-014-8516-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-014-8516-1</ArticleId><ArticleId IdType="pubmed">24791905</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G., Wang L.G., Han Y., He Q.Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 2012;16:284&#x2013;287. doi: 10.1089/omi.2011.0118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Heagerty P.J., Lumley T., Pepe M.S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337&#x2013;344. doi: 10.1111/j.0006-341X.2000.00337.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0006-341X.2000.00337.x</ArticleId><ArticleId IdType="pubmed">10877287</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris B.J. The advent of human papillomavirus detection for cervical screening. Curr. Opin. Obs. Gynecol. 2019;31:333&#x2013;339. doi: 10.1097/GCO.0000000000000542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GCO.0000000000000542</ArticleId><ArticleId IdType="pubmed">30946033</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewari K.S., Sill M.W., Long H.J., 3rd, Penson R.T., Huang H., Ramondetta L.M., Lisa M.L., Ana O., Thomas J.R., Mario M.L., et al. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 2014;370:734&#x2013;743. doi: 10.1056/NEJMoa1309748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1309748</ArticleId><ArticleId IdType="pmc">PMC4010094</ArticleId><ArticleId IdType="pubmed">24552320</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd E.A., Siegel B.A., Dehdashti F., Grigsby P.W. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110:1738&#x2013;1744. doi: 10.1002/cncr.22974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.22974</ArticleId><ArticleId IdType="pubmed">17786947</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W., Wang M., Liu J., Cui X., Wang H. Identification of a six lncRNAs signature as novel diagnostic biomarkers for cervical cancer. J. Cell Physiol. 2019;235:993&#x2013;1000. doi: 10.1002/jcp.29015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.29015</ArticleId><ArticleId IdType="pubmed">31332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Tian R., Gao H., Yang Y., Williams B.R.G., Gantier M.P., McMillan N.A.J., Xu D., Hu Y., Gao Y. Identification of a histone family gene signature for predicting the prognosis of cervical cancer patients. Sci. Rep. 2017;7:16495. doi: 10.1038/s41598-017-16472-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-16472-5</ArticleId><ArticleId IdType="pmc">PMC5705706</ArticleId><ArticleId IdType="pubmed">29184082</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigo A., Gottardi M., Zamo A., Mauri P., Bonifacio M., Krampera M., Damiani E., Pizzolo G., Vinante F. Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol. Cancer. 2010;9:273. doi: 10.1186/1476-4598-9-273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-4598-9-273</ArticleId><ArticleId IdType="pmc">PMC2964621</ArticleId><ArticleId IdType="pubmed">20946648</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Wei Y., Zhang J. Combined Knockdown of D-dopachrome Tautomerase and Migration Inhibitory Factor Inhibits the Proliferation, Migration, and Invasion in Human Cervical Cancer. Int. J. Gynecol. Cancer. 2017;27:634&#x2013;642. doi: 10.1097/IGC.0000000000000951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IGC.0000000000000951</ArticleId><ArticleId IdType="pubmed">28338494</ArticleId></ArticleIdList></Reference><Reference><Citation>Heusinkveld M., de Vos van Steenwijk P.J., Goedemans R., Ramwadhdoebe T.H., Gorter A., Welters M.J., Hall T.V., Berg S.H. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J. Immunol. 2011;187:1157&#x2013;1165. doi: 10.4049/jimmunol.1100889.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1100889</ArticleId><ArticleId IdType="pubmed">21709158</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza J.L., Martins-Cardoso K., Guimar&#xe3;es I.S., de Melo A.C., Lopes A.H., Monteiro R.Q., Almeida V.H. Interplay Between EGFR and the Platelet-Activating Factor/PAF Receptor Signaling Axis Mediates Aggressive Behavior of Cervical Cancer. Front. Oncol. 2020;17:557280. doi: 10.3389/fonc.2020.557280.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.557280</ArticleId><ArticleId IdType="pmc">PMC7773908</ArticleId><ArticleId IdType="pubmed">33392068</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Zhang R., Yang H., Zhang D., Liu J., Li J., Guo B. GDF15 knockdown suppresses cervical cancer cell migration in vitro through the TGF-&#x3b2;/Smad2/3/Snail1 pathway. FEBS Open Bio. 2020;10:2750&#x2013;2760. doi: 10.1002/2211-5463.13013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2211-5463.13013</ArticleId><ArticleId IdType="pmc">PMC7714065</ArticleId><ArticleId IdType="pubmed">33098235</ArticleId></ArticleIdList></Reference><Reference><Citation>Faulkner S., Griffin N., Rowe C.W., Jobling P., Lombard J.M., Oliveira S.M., Walker M.M., Hondermarck H. Nerve growth factor and its receptor tyrosine kinase TrkA are overexpressed in cervical squamous cell carcinoma. FASEB Bioadv. 2020;2:398&#x2013;408. doi: 10.1096/fba.2020-00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fba.2020-00016</ArticleId><ArticleId IdType="pmc">PMC7354692</ArticleId><ArticleId IdType="pubmed">32676580</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Z., Wang H., Xia J., Yang Y., Jin Z., Xu H., Shi J., De Domenico I., Tricot G., Zhan F. Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation. Cancer Res. 2015;75:2211&#x2013;2221. doi: 10.1158/0008-5472.CAN-14-3804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-14-3804</ArticleId><ArticleId IdType="pmc">PMC4946247</ArticleId><ArticleId IdType="pubmed">25855377</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J.Y., Lee J.K., Lee N.W., Jung H.H., Kim S.H., Lee K.W. Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: Identification of candidate genes in pathogenesis of invasion in cervical. Int. J. Gynecol. Cancer. 2008;18:1051&#x2013;1059. doi: 10.1111/j.1525-1438.2007.01164.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1438.2007.01164.x</ArticleId><ArticleId IdType="pubmed">18217980</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro F.A., Haimila K., Sareneva I., Schmitt M., Lorenzo J., Kunkel N., Kumar R., F&#xf6;rsti A., Kjellberg L., Hallmans G., et al. Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population--a candidate gene approach. Int. J. Cancer. 2009;125:1851&#x2013;1858. doi: 10.1002/ijc.24529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.24529</ArticleId><ArticleId IdType="pubmed">19585495</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodelon C., Madeleine M.M., Johnson L.G., Du Q., Galloway D.A., Malkki M., Petersdorf E.W., Schwartz S.M. Genetic variation in the TLR and NF-kappaB pathways and cervical and vulvar cancer risk: A population-based case-control study. Int. J. Cancer. 2014;134:437&#x2013;444. doi: 10.1002/ijc.28364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.28364</ArticleId><ArticleId IdType="pmc">PMC3883910</ArticleId><ArticleId IdType="pubmed">23824834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugo de Almeida V., Guimaraes I.D.S., Almendra L.R., Rondon A.M.R., Tilli T.M., de Melo A.C., Sternberg C., Monteiro R.Q. Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer. Oncotarget. 2018;9:30594&#x2013;30609. doi: 10.18632/oncotarget.25748.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.25748</ArticleId><ArticleId IdType="pmc">PMC6078136</ArticleId><ArticleId IdType="pubmed">30093972</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanshan H., Lan X., Xia L., Huang W., Meifang Z., Ling Y. Inhibition of protease-activated receptor-2 induces apoptosis in cervical cancer by inhibiting signal transducer and activator of transcription-3 signaling. J. Int. Med. Res. 2019;47:1330&#x2013;1338. doi: 10.1177/0300060518820440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060518820440</ArticleId><ArticleId IdType="pmc">PMC6421370</ArticleId><ArticleId IdType="pubmed">30700181</ArticleId></ArticleIdList></Reference><Reference><Citation>Leo C., Horn L.C., Einenkel J., Hentschel B., Hockel M. Tumor hypoxia and expression of c-met in cervical cancer. Gynecol. Oncol. 2007;104:181&#x2013;185. doi: 10.1016/j.ygyno.2006.07.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2006.07.040</ArticleId><ArticleId IdType="pubmed">16996116</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D., Zhou P., Zhang L., Gong W., Huang G., Zheng Y., He F. HDAC1/DNMT3A-containing complex is associated with suppression of Oct4 in cervical cancer cells. Biochemistry. 2012;77:934&#x2013;940. doi: 10.1134/S0006297912080159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297912080159</ArticleId><ArticleId IdType="pubmed">22860916</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J., Li X., Tu K., Guan Y., Fung K.P., Liu F. Verticillin A suppresses HGF-induced migration and invasion via repression of the c-Met/FAK/Src pathway in human gastric and cervical cancer cells. Onco. Targets Ther. 2019;12:5823&#x2013;5833. doi: 10.2147/OTT.S208683.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S208683</ArticleId><ArticleId IdType="pmc">PMC6668566</ArticleId><ArticleId IdType="pubmed">31440058</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.Y., Chao T.K., Su P.H., Lee H.Y., Shih Y.L., Su H.Y., Chu T.-Y., Yu M.-H., Lin Y.-W., Lai H.-C. Characterization of LMX-1A as a metastasis suppressor in cervical cancer. J. Pathol. 2009;219:222&#x2013;231. doi: 10.1002/path.2589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2589</ArticleId><ArticleId IdType="pubmed">19644956</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye F., Yu Y., Hu Y., Lu W., Xie X. Alterations of dendritic cell subsets in the peripheral circulation of patients with cervical carcinoma. J. Exp. Clin. Cancer Res. 2010;29:78. doi: 10.1186/1756-9966-29-78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-9966-29-78</ArticleId><ArticleId IdType="pmc">PMC2904720</ArticleId><ArticleId IdType="pubmed">20565840</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglia A., Buzzonetti A., Martinelli E., Fanelli M., Petrillo M., Ferrandina G., Scambia G., Fattorossi A. Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010;76:1546&#x2013;1553. doi: 10.1016/j.ijrobp.2009.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2009.10.014</ArticleId><ArticleId IdType="pubmed">20338481</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X., Lv J., Yu L., Zhu X., Wu J., Zou S., Jiang S. Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecol. Oncol. 2009;112:248&#x2013;256. doi: 10.1016/j.ygyno.2008.09.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2008.09.045</ArticleId><ArticleId IdType="pubmed">19007971</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao X.H., Shen J.G., Pan W.L., Dong Y.E., Meng Q., Honn K.V., Jin R. Significance of SHP-1 and SHP-2 expression in human papillomavirus infected Condyloma acuminatum and cervical cancer. Pathol. Oncol. Res. 2008;14:365&#x2013;371. doi: 10.1007/s12253-008-9065-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12253-008-9065-5</ArticleId><ArticleId IdType="pmc">PMC4175450</ArticleId><ArticleId IdType="pubmed">18543080</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Zhang S. The expression of Foxp3 and TLR4 in cervical cancer: Association with immune escape and clinical pathology. Arch. Gynecol. Obstet. 2017;295:705&#x2013;712. doi: 10.1007/s00404-016-4277-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00404-016-4277-5</ArticleId><ArticleId IdType="pubmed">28013346</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J., Yang Z., Wang Z., Li Z., Li H., Yin J., Deng M., Zhu W., Zeng C. Foxp3 is correlated with VEGF-C expression and lymphangiogenesis in cervical cancer. World J. Surg. Oncol. 2017;15:173. doi: 10.1186/s12957-017-1221-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12957-017-1221-5</ArticleId><ArticleId IdType="pmc">PMC5604510</ArticleId><ArticleId IdType="pubmed">28923073</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Q., Zhang S., Wei H., Pang X., Zhang H. Roles of Foxp3 in the occurrence and development of cervical cancer. Int. J. Clin. Exp. Pathol. 2015;8:8717&#x2013;8730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4583848</ArticleId><ArticleId IdType="pubmed">26464616</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Yan Q., Tian P., Wang Y., Wang J., Tao N., Li N., Lin X., Ding L., Liu J.W., et al. CBX7 Inhibits Cell Growth and Motility and Induces Apoptosis in Cervical Cancer Cells. Mol. Ther. Oncolytics. 2019;15:108&#x2013;116. doi: 10.1016/j.omto.2019.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2019.09.002</ArticleId><ArticleId IdType="pmc">PMC6834976</ArticleId><ArticleId IdType="pubmed">31709304</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai N.C., Chi X.M., Li T.Y., Song H.X., Li H.J., Jin X., Ian N.C., Su L.S., Niu J.Q., Tu Z.K. Hepatitis C virus core protein triggers expansion and activation of CD4(+)CD25(+) regulatory T cells in chronic hepatitis C patients. Cell Mol. Immunol. 2015;12:743&#x2013;749. doi: 10.1038/cmi.2014.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2014.119</ArticleId><ArticleId IdType="pmc">PMC4716623</ArticleId><ArticleId IdType="pubmed">25531392</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Xie Y., Wang J. Overexpression of MicroRNA-34a-5p Inhibits Proliferation and Promotes Apoptosis of Human Cervical Cancer Cells by Downregulation of Bcl-2. Oncol. Res. 2018;26:977&#x2013;985. doi: 10.3727/096504017X15037506066252.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096504017X15037506066252</ArticleId><ArticleId IdType="pmc">PMC7844734</ArticleId><ArticleId IdType="pubmed">28893346</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobti R.C., Singh N., Hussain S., Suri V., Bharti A.C., Das B.C. Overexpression of STAT3 in HPV-mediated cervical cancer in a north Indian population. Mol. Cell Biochem. 2009;330:193&#x2013;199. doi: 10.1007/s11010-009-0133-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-009-0133-2</ArticleId><ArticleId IdType="pubmed">19421717</ArticleId></ArticleIdList></Reference><Reference><Citation>Takemoto S., Ushijima K., Kawano K., Yamaguchi T., Terada A., Fujiyoshi N., Nishio S., Tsuda N., Ijichi M., Kakuma T., et al. Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Br. J. Cancer. 2009;101:967&#x2013;972. doi: 10.1038/sj.bjc.6605212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6605212</ArticleId><ArticleId IdType="pmc">PMC2743356</ArticleId><ArticleId IdType="pubmed">19638983</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobti R.C., Singh N., Hussain S., Suri V., Bharadwaj M., Das B.C. Deregulation of STAT-5 isoforms in the development of HPV-mediated cervical carcinogenesis. J. Recept. Signal Transduct. Res. 2010;30:178&#x2013;188. doi: 10.3109/10799891003786218.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10799891003786218</ArticleId><ArticleId IdType="pubmed">20415542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H.Y., Li Q.Q., Liang L., Qiu L.L., Wei H.W., Huang B.Y., Chen G., He R.Q., Huang Z.G., Hou W., et al. Prognostic alternative splicing signature in cervical squamous cell carcinoma. IET Syst. Biol. 2020;14:314&#x2013;322. doi: 10.1049/iet-syb.2019.0095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1049/iet-syb.2019.0095</ArticleId><ArticleId IdType="pmc">PMC8687194</ArticleId><ArticleId IdType="pubmed">33399095</ArticleId></ArticleIdList></Reference><Reference><Citation>Eun J.K., Mi H.H., Jeon Y.J., Yun H.K. Identification and Complete Validation of Prognostic Gene Signatures for Human Papillomavirus-Associated Cancers: Integrated Approach Covering Different Anatomical Locations. J. Virol. 2020:JVI.02354-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094965</ArticleId><ArticleId IdType="pubmed">33361419</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai L.Y., Hu C., Yu S.S., Liu L.X., Yu X.B., Chen J.H., Liu X., Lin F., Zhang C., Li X.Y. Identification and validation of a six-gene signature associated with glycolysis to predict the prognosis of patients with cervical cancer. BMC Cancer. 2020;20:1133. doi: 10.1186/s12885-020-07598-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-020-07598-3</ArticleId><ArticleId IdType="pmc">PMC7686733</ArticleId><ArticleId IdType="pubmed">33228592</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S., Yu M.X. Identification of MMP1 as a Potential Prognostic Biomarker and Correlating with Immune Infiltrates in Cervical Squamous Cell Carcinoma. DNA Cell Biol. 2020;39:255&#x2013;272. doi: 10.1089/dna.2019.5129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dna.2019.5129</ArticleId><ArticleId IdType="pubmed">31977248</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q., Hu L., Huang D., Chen K., Qiu X., Qiu B. Six-lncRNA Immune Prognostic Signature for Cervical Cancer. Front. Genet. 2020;11:533628. doi: 10.3389/fgene.2020.533628.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.533628</ArticleId><ArticleId IdType="pmc">PMC7591729</ArticleId><ArticleId IdType="pubmed">33173530</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Deng Q., Wang W., Tao H., Gao Y. Identification of an autophagy-related gene signature for survival prediction in patients with cervical cancer. J. Ovaian Res. 2020;13:131. doi: 10.1186/s13048-020-00730-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13048-020-00730-8</ArticleId><ArticleId IdType="pmc">PMC7648936</ArticleId><ArticleId IdType="pubmed">33160404</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33631974</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8301</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Future oncology (London, England)</Title><ISOAbbreviation>Future Oncol</ISOAbbreviation></Journal><ArticleTitle>Utility of a metabolic-associated nomogram to predict the recurrence-free survival of stage I cervical cancer.</ArticleTitle><Pagination><StartPage>1325</StartPage><EndPage>1337</EndPage><MedlinePgn>1325-1337</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2217/fon-2020-1024</ELocationID><Abstract><AbstractText><b>Aims:</b> To identify metabolism-associated genes (MAGs) that serve as biomarkers to predict prognosis associated with recurrence-free survival (RFS) for stage I cervical cancer (CC). <b>Patients &amp; methods:</b> By analyzing the Gene Expression Omnibus (GEO)&#xa0;database for 258 cases of stage I CC via univariate Cox analysis, LASSO&#xa0;and multivariate Cox regression analysis, we unveiled 11 MAGs as a signature that was also validated using Kaplan-Meier and receiver operating characteristic analyses. In addition, a metabolism-related nomogram was developed. <b>Results:</b> High accuracy of this signature for prediction was observed (area under the curve at 1, 3 and 5&#xa0;years was 0.964, 0.929 and 0.852 for the internal dataset and 0.759, 0.719 and 0.757 for the external dataset). The high-risk score&#xa0;group displayed markedly worse RFS than did the low-risk score group. The indicators performed well in our nomogram. <b>Conclusions:</b> We identified a novel signature as a biomarker for predicting prognosis and a nomogram to facilitate the individual management of stage I CC patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9502-9775</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics &amp; Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology, Wuhan, 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Obstetrics &amp; Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology, Wuhan, 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jinjin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Obstetrics &amp; Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology, Wuhan, 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shixuan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8610-952X</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics &amp; Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology, Wuhan, 430030, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2016CFA064</GrantID><Agency>Science and technology program of Hubei Province, China</Agency><Country/></Grant><Grant><GrantID>2016YFC1302900</GrantID><Agency>The National Key Research and Development Program of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Future Oncol</MedlineTA><NlmUniqueID>101256629</NlmUniqueID><ISSNLinking>1479-6694</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053858" MajorTopicYN="N">Metabolic Networks and Pathways</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049451" MajorTopicYN="Y">Nomograms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>Lay abstract A high rate of mortality may occur as a result of early cancer&#xa0;recurrence, and this can lead to poor prognosis. We aimed to identify a new hallmark linked to metabolism-associated genes (MAGs) that were associated with recurrence-free survival via comprehensive bioinformatics analysis for use in stage I cervical cancer (CC) patient prognosis. A prognostic model was established and validated based on regression analysis. A high predicted accuracy of the 11 MAGs signature was identified. Additionally, we developed a nomogram. In conclusion, a reliable 11 metabolic gene signature was discovered that may provide a potential biomarker for stage I CC prognosis, and a metabolism-related nomogram was constructed to facilitate the individual management of patients with stage I CC.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">metabolism</Keyword><Keyword MajorTopicYN="N">nomogram</Keyword><Keyword MajorTopicYN="N">recurrence-free survival</Keyword><Keyword MajorTopicYN="N">signature</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>26</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33631974</ArticleId><ArticleId IdType="doi">10.2217/fon-2020-1024</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33447084</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-1322</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Cancer management and research</Title><ISOAbbreviation>Cancer Manag Res</ISOAbbreviation></Journal><ArticleTitle>Identification of Hub Genes as Potential Prognostic Biomarkers in Cervical Cancer Using Comprehensive Bioinformatics Analysis and Validation Studies.</ArticleTitle><Pagination><StartPage>117</StartPage><EndPage>131</EndPage><MedlinePgn>117-131</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/CMAR.S282989</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cervical cancer belongs to one of the most common female cancers; yet, the exact underlying mechanisms are still elusive. Recently, microarray and sequencing technologies have been widely used for screening biomarkers and molecular mechanism discovery in cancer studies. In this study, we aimed to analyse the microarray datasets using comprehensive bioinformatics tools and identified novel biomarkers associated with the prognosis of patients with cervical cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The differentially expressed genes (DEGs) from Gene Expression Omnibus (GEO) datasets including GSE138080, GSE113942 and GSE63514 were analysed using GEO2R tool. The functional enrichment analysis was performed using g:Profiler tool. The protein-protein interaction (PPI) network construction and hub genes identification were performed using the STRING database and Cytoscape software, respectively. The hub genes were subjected to expression and survival analysis in the cervical cancer. The EdU incorporation and Cell Counting Kit-8 assays were performed to evaluate the effects of hub gene knockdown on the proliferation of cervical cancer cells.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 89 overlapping DEGs (63 up-regulated and 26 down-regulated genes) were identified in the microarray datasets. The functional enrichment analysis indicated that the overlapping DEGs were mainly associated with "DNA replication" and "cell cycle". Furthermore, the PPI network analysis revealed that the network contains 87 nodes and 309 edges. Sub-module analysis using the Molecular Complex Detection tool identified 21 hub genes from the PPI network. The expression levels of the 21 hub genes were all up-regulated in the cervical cancer tissues when compared to normal cervical tissues as analysed by GEPIA tool. The survival analysis showed that the low expression of cell division cycle 45 (<i>CDC45</i>), GINS complex subunit 2 (<i>GINS2</i>), minichromosome maintenance complex component 2 (<i>MCM2</i>) and proliferating cell nuclear antigen (<i>PCNA</i>) was significantly correlated with the shorter overall survival of patients with cervical cancer. Moreover, the protein expression levels of <i>GINS2, MCM2</i> and <i>PCNA</i>, but not <i>CDC45,</i> were significantly up-regulated in the cervical cancer tissues when compared to normal cervical tissues. Finally, knockdown of <i>MCM2</i> significantly suppressed the proliferation of HeLa and SiHa cells.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In conclusion, we screened a total of 89 overlapping DEGs from the GEO datasets, and further analysis identified four hub genes (<i>CDC45, GINS2, MCM2</i> and <i>PCNA</i>) that were likely associated with the prognosis of patients with cervical cancer. <i>MCM2</i> knockdown repressed the cervical cancer cell proliferation. The current findings may provide novel insights into understanding the pathophysiology of cervical cancer and develop therapeutic targets for patients with cervical cancer.</AbstractText><CopyrightInformation>&#xa9; 2021 Xue et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Health Management, Shenzhen People's Hospital, Shenzhen City, Guangdong Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Zhaojun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Shenzhen People's Hospital, Shenzhen City, GuangdongProvince, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Weiqing</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Health Management, Shenzhen People's Hospital, Shenzhen City, Guangdong Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Health Management, Shenzhen People's Hospital, Shenzhen City, Guangdong Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Shuping</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Health Management, Shenzhen People's Hospital, Shenzhen City, Guangdong Province, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Cancer Manag Res</MedlineTA><NlmUniqueID>101512700</NlmUniqueID><ISSNLinking>1179-1322</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DEGs</Keyword><Keyword MajorTopicYN="N">cervical cancer: bioinformatics</Keyword><Keyword MajorTopicYN="N">hub genes</Keyword><Keyword MajorTopicYN="N">overall survival</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>The authors report no conflict of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>15</Day><Hour>5</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33447084</ArticleId><ArticleId IdType="pmc">PMC7802793</ArticleId><ArticleId IdType="doi">10.2147/CMAR.S282989</ArticleId><ArticleId IdType="pii">282989</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169&#x2013;182. doi:10.1016/S0140-6736(18)32470-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32470-X</ArticleId><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas KM, van Zandvoort K, Brisson M, Jit M. Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. Lancet Global Health. 2020;8(4):e536&#x2013;e544. doi:10.1016/S2214-109X(20)30022-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(20)30022-X</ArticleId><ArticleId IdType="pmc">PMC7083230</ArticleId><ArticleId IdType="pubmed">32105613</ArticleId></ArticleIdList></Reference><Reference><Citation>Canfell K, Kim JJ, Brisson M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):591&#x2013;603. doi:10.1016/S0140-6736(20)30157-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30157-4</ArticleId><ArticleId IdType="pmc">PMC7043006</ArticleId><ArticleId IdType="pubmed">32007142</ArticleId></ArticleIdList></Reference><Reference><Citation>The L. Eliminating cervical cancer. Lancet. 2020;395(10221):312. doi:10.1016/S0140-6736(20)30247-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30247-6</ArticleId><ArticleId IdType="pubmed">32007146</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ZJ, Grover S, Scott AM, et al. The role and contribution of treatment and imaging modalities in global cervical cancer management: survival estimates from a simulation-based analysis. Lancet Oncol. 2020;21(8):1089&#x2013;1098. doi:10.1016/S1470-2045(20)30316-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30316-8</ArticleId><ArticleId IdType="pmc">PMC7574952</ArticleId><ArticleId IdType="pubmed">32758463</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Liu S, Wu L, Jiang M, Hou Y. High throughput single cell RNA sequencing, bioinformatics analysis and applications. Adv Exp Med Biol. 2018;1068:33&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">29943294</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrick BA, London RE, Bushel PR, Grissom SF, Paules RS. Platforms for biomarker analysis using high-throughput approaches in genomics, transcriptomics, proteomics, metabolomics, and bioinformatics. IARC Sci Publ. 2011;163:121&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">22997859</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomczak K, Czerwi&#x144;ska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemporary Oncol. 2015;19(1a):A68&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322527</ArticleId><ArticleId IdType="pubmed">25691825</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Lachmann A, Ma&#x2019;ayan A. Mining data and metadata from the gene expression omnibus. Biophys Rev. 2019;11(1):103&#x2013;110. doi:10.1007/s12551-018-0490-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12551-018-0490-8</ArticleId><ArticleId IdType="pmc">PMC6381352</ArticleId><ArticleId IdType="pubmed">30594974</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai F, Chen G, Wang Y, et al. Identification of candidate biomarkers correlated with the diagnosis and prognosis of cervical cancer via integrated bioinformatics analysis. Onco Targets Ther. 2019;12:4517&#x2013;4532. doi:10.2147/OTT.S199615</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S199615</ArticleId><ArticleId IdType="pmc">PMC6581759</ArticleId><ArticleId IdType="pubmed">31354287</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang B, Li Y, Wang T. A three miRNAs signature predicts survival in cervical cancer using bioinformatics analysis. Sci Rep. 2017;7(1):5624. doi:10.1038/s41598-017-06032-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-06032-2</ArticleId><ArticleId IdType="pmc">PMC5514022</ArticleId><ArticleId IdType="pubmed">28717180</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Ma Y, Wei Y, Shang H. Genome-wide analysis of aberrant gene expression and methylation profiles reveals susceptibility genes and underlying mechanism of cervical cancer. Eur J Obstet Gynecol Reprod Biol. 2016;207:147&#x2013;152. doi:10.1016/j.ejogrb.2016.10.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejogrb.2016.10.017</ArticleId><ArticleId IdType="pubmed">27863272</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi K, Ratner N. iGEAK: an interactive gene expression analysis kit for seamless workflow using the R/shiny platform. BMC Genomics. 2019;20(1):177. doi:10.1186/s12864-019-5548-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-019-5548-x</ArticleId><ArticleId IdType="pmc">PMC6404331</ArticleId><ArticleId IdType="pubmed">30841853</ArticleId></ArticleIdList></Reference><Reference><Citation>Raudvere U, Kolberg L, Kuzmin I, et al. g: Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47(W1):W191&#x2013;w198. doi:10.1093/nar/gkz369</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz369</ArticleId><ArticleId IdType="pmc">PMC6602461</ArticleId><ArticleId IdType="pubmed">31066453</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607&#x2013;D613. doi:10.1093/nar/gky1131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98&#x2013;w102. doi:10.1093/nar/gkx247</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx247</ArticleId><ArticleId IdType="pmc">PMC5570223</ArticleId><ArticleId IdType="pubmed">28407145</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy &#xc1;, L&#xe1;nczky A, Menyh&#xe1;rt O, Gy&#x151;rffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227. doi:10.1038/s41598-018-27521-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-27521-y</ArticleId><ArticleId IdType="pmc">PMC6003936</ArticleId><ArticleId IdType="pubmed">29907753</ArticleId></ArticleIdList></Reference><Reference><Citation>Fei L, Xu H. Role of MCM2-7 protein phosphorylation in human cancer cells. Cell Biosci. 2018;8:43. doi:10.1186/s13578-018-0242-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13578-018-0242-2</ArticleId><ArticleId IdType="pmc">PMC6056998</ArticleId><ArticleId IdType="pubmed">30062004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishimi Y. Regulation of MCM2-7 function. Genes Genet Syst. 2018;93(4):125&#x2013;133. doi:10.1266/ggs.18-00026</Citation><ArticleIdList><ArticleId IdType="doi">10.1266/ggs.18-00026</ArticleId><ArticleId IdType="pubmed">30369561</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollok S, Bauerschmidt C, S&#xe4;nger J, Nasheuer HP, Grosse F. Human CDC45 is a proliferation-associated antigen. FEBS J. 2007;274(14):3669&#x2013;3684. doi:10.1111/j.1742-4658.2007.05900.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2007.05900.x</ArticleId><ArticleId IdType="pubmed">17608804</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke Y, Guo W, Huang S, et al. RYBP inhibits esophageal squamous cell carcinoma proliferation through downregulating CDC6 and CDC45 in G1-S phase transition process. Life Sci. 2020;250:117578. doi:10.1016/j.lfs.2020.117578</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117578</ArticleId><ArticleId IdType="pubmed">32209426</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Shi R, Zhao S, et al. Cell division cycle 45 promotes papillary thyroid cancer progression via regulating cell cycle. Tumour Biology. 2017;39(5):1010428317705342. doi:10.1177/1010428317705342</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1010428317705342</ArticleId><ArticleId IdType="pubmed">28474999</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Li Y, Lu Z, et al. Analysis of functional hub genes identifies CDC45 as an oncogene in non-small cell lung cancer - a short report. Cellular Oncol. 2019;42(4):571&#x2013;578. doi:10.1007/s13402-019-00438-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13402-019-00438-y</ArticleId><ArticleId IdType="pubmed">30887286</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Ren X, Liang Y, et al. KNK437 restricts the growth and metastasis of colorectal cancer via targeting DNAJA1/CDC45 axis. Oncogene. 2020;39(2):249&#x2013;261. doi:10.1038/s41388-019-0978-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-019-0978-0</ArticleId><ArticleId IdType="pubmed">31477839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Wang L, Li Z, et al. Potential prognostic and diagnostic values of CDC6, CDC45, ORC6 and SNHG7 in colorectal cancer. Onco Targets Ther. 2019;12:11609&#x2013;11621. doi:10.2147/OTT.S231941</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S231941</ArticleId><ArticleId IdType="pmc">PMC6942537</ArticleId><ArticleId IdType="pubmed">32021241</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang L, Wang XM, Xu DY, Zhao WJ. Bioinformatics analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma. World J Gastroenterol. 2018;24(24):2605&#x2013;2616. doi:10.3748/wjg.v24.i24.2605</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v24.i24.2605</ArticleId><ArticleId IdType="pmc">PMC6021769</ArticleId><ArticleId IdType="pubmed">29962817</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Lv Q, Huang H, Zhu M, Meng D. Screening and identification of key biomarkers in inflammatory breast cancer through integrated bioinformatic analyses. Genet Test Mol Biomarkers. 2020;24(8):484&#x2013;491. doi:10.1089/gtmb.2020.0047</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/gtmb.2020.0047</ArticleId><ArticleId IdType="pubmed">32598242</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Nie S, Gao M, et al. Identification of EPHX2 and RMI2 as two novel key genes in cervical squamous cell carcinoma by an integrated bioinformatic analysis. J Cell Physiol. 2019;234(11):21260&#x2013;21273. doi:10.1002/jcp.28731</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.28731</ArticleId><ArticleId IdType="pubmed">31041817</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Liu S, Cui M. Effect of BRCA1 on the concurrent chemoradiotherapy resistance of cervical squamous cell carcinoma based on transcriptome sequencing analysis. Biomed Res Int. 2020;2020:3598417. doi:10.1155/2020/3598417</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/3598417</ArticleId><ArticleId IdType="pmc">PMC7333031</ArticleId><ArticleId IdType="pubmed">32685473</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Zhou Y, Yang X, et al. High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients. Breast Cancer Res Treat. 2014;148(2):423&#x2013;436. doi:10.1007/s10549-014-3172-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-014-3172-7</ArticleId><ArticleId IdType="pubmed">25348432</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng L, Song Z, Chen D, et al. GINS2 regulates matrix metallopeptidase 9 expression and cancer stem cell property in human triple negative Breast cancer. Biomed Pharmacother. 2016;84:1568&#x2013;1574. doi:10.1016/j.biopha.2016.10.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2016.10.032</ArticleId><ArticleId IdType="pubmed">27829549</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y, Song YN, He SF, Zhuang JH, Wang GY, Xia W. GINS2 promotes cell proliferation and inhibits cell apoptosis in thyroid cancer by regulating CITED2 and LOXL2. Cancer Gene Ther. 2019;26(3&#x2013;4):103&#x2013;113. doi:10.1038/s41417-018-0045-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41417-018-0045-y</ArticleId><ArticleId IdType="pubmed">30177819</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen YL, Li HZ, Hu YW, Zheng L, Wang Q. Loss of GINS2 inhibits cell proliferation and tumorigenesis in human gliomas. CNS Neurosci Ther. 2019;25(2):273&#x2013;287. doi:10.1111/cns.13064</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.13064</ArticleId><ArticleId IdType="pmc">PMC6488927</ArticleId><ArticleId IdType="pubmed">30338650</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Chen S, Fan H, Ji D, Chen C, Sheng W. GINS2 promotes EMT in pancreatic cancer via specifically stimulating ERK/MAPK signaling. Cancer Gene Ther. 2020. doi:10.1038/s41417-020-0206-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41417-020-0206-7</ArticleId><ArticleId IdType="pmc">PMC8370876</ArticleId><ArticleId IdType="pubmed">32747685</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Yang S, Xu J, Lu W, Xie X. Transcriptome sequencing profiles of cervical cancer tissues and SiHa cells. Funct Integr Genomics. 2020;20(2):211&#x2013;221. doi:10.1007/s10142-019-00706-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10142-019-00706-y</ArticleId><ArticleId IdType="pubmed">31456134</ArticleId></ArticleIdList></Reference><Reference><Citation>Branca M, Ciotti M, Giorgi C, et al. Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer. Eur J Obstet Gynecol Reprod Biol. 2007;130(2):223&#x2013;231. doi:10.1016/j.ejogrb.2006.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejogrb.2006.10.007</ArticleId><ArticleId IdType="pubmed">17098349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TH, Han JH, Shin E, Noh JH, Kim HS, Song YS. Clinical implication of p16, ki-67, and proliferating cell nuclear antigen expression in cervical neoplasia: improvement of diagnostic accuracy for high-grade squamous intraepithelial lesion and prediction of resection margin involvement on conization specimen. J Cancer Prevention. 2015;20(1):70&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384717</ArticleId><ArticleId IdType="pubmed">25853106</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhumati G, Kavita S, Anju M, Uma S, Raj M. Immunohistochemical expression of cell proliferating nuclear antigen (PCNA) and p53 protein in cervical cancer. J Obstet Gynaecol India. 2012;62(5):557&#x2013;561. doi:10.1007/s13224-012-0180-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13224-012-0180-6</ArticleId><ArticleId IdType="pmc">PMC3526699</ArticleId><ArticleId IdType="pubmed">24082558</ArticleId></ArticleIdList></Reference><Reference><Citation>Issac MSM, Yousef E, Tahir MR, Gaboury LA. MCM2, MCM4, and MCM6 in breast cancer: clinical utility in diagnosis and prognosis. Neoplasia. 2019;21(10):1015&#x2013;1035. doi:10.1016/j.neo.2019.07.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2019.07.011</ArticleId><ArticleId IdType="pmc">PMC6726925</ArticleId><ArticleId IdType="pubmed">31476594</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaginis C, Georgiadou M, Dimakopoulou K, et al. Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity. Dig Dis Sci. 2009;54(2):282&#x2013;291. doi:10.1007/s10620-008-0305-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-008-0305-z</ArticleId><ArticleId IdType="pubmed">18465232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuku S, Proctor I, Loddo M, et al. Do cell-cycle phase-specific markers predict disease grade, stage, and outcome in cervical carcinoma? Int J Gynecological Cancer. 2015;25(6):1066&#x2013;1072. doi:10.1097/IGC.0000000000000356</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IGC.0000000000000356</ArticleId><ArticleId IdType="pubmed">25621411</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaro Filho SM, Nuovo GJ, Cunha CB, et al. Correlation of MCM2 detection with stage and virology of cervical cancer. Int J Biol Markers. 2014;29(4):e363&#x2013;371. doi:10.5301/jbm.5000081</Citation><ArticleIdList><ArticleId IdType="doi">10.5301/jbm.5000081</ArticleId><ArticleId IdType="pubmed">24706378</ArticleId></ArticleIdList></Reference><Reference><Citation>Das M, Prasad SB, Yadav SS, et al. Over expression of minichromosome maintenance genes is clinically correlated to cervical carcinogenesis. PLoS One. 2013;8(7):e69607. doi:10.1371/journal.pone.0069607</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0069607</ArticleId><ArticleId IdType="pmc">PMC3714251</ArticleId><ArticleId IdType="pubmed">23874974</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur G, Balasubramaniam SD, Lee YJ, Balakrishnan V, Oon CE. Minichromosome maintenance complex (MCM) genes profiling and MCM2 protein expression in cervical cancer development. Asian Pacific J Cancer Prevention. 2019;20(10):3043&#x2013;3049. doi:10.31557/APJCP.2019.20.10.3043</Citation><ArticleIdList><ArticleId IdType="doi">10.31557/APJCP.2019.20.10.3043</ArticleId><ArticleId IdType="pmc">PMC6982666</ArticleId><ArticleId IdType="pubmed">31653153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishimi Y, Okayasu I, Kato C, et al. Enhanced expression of Mcm proteins in cancer cells derived from uterine cervix. European J Biochem. 2003;270(6):1089&#x2013;1101. doi:10.1046/j.1432-1033.2003.03440.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1432-1033.2003.03440.x</ArticleId><ArticleId IdType="pubmed">12631269</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng M, Sun J, Xie S, et al. Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin. Mol Med Rep. 2019;20(3):2258&#x2013;2266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6691261</ArticleId><ArticleId IdType="pubmed">31322224</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W, Wang X, Shan C, Li Y, Li F. Minichromosome maintenance protein 2 correlates with the malignant status and regulates proliferation and cell cycle in lung squamous cell carcinoma. Onco Targets Ther. 2018;11:5025&#x2013;5034. doi:10.2147/OTT.S169002</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S169002</ArticleId><ArticleId IdType="pmc">PMC6109654</ArticleId><ArticleId IdType="pubmed">30174440</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33402836</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1178-6930</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>OncoTargets and therapy</Title><ISOAbbreviation>Onco Targets Ther</ISOAbbreviation></Journal><ArticleTitle>Bioinformatics Analysis of Key Genes and Pathways of Cervical Cancer.</ArticleTitle><Pagination><StartPage>13275</StartPage><EndPage>13283</EndPage><MedlinePgn>13275-13283</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/OTT.S281533</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">Globally, cervical cancer (CC) is the fourth most common cancer affecting women. Although effective screening reduces its incidence, it remains one of the most serious cancers threatening the health of women. Therefore, the purpose of this study is to find new genes that can be used as potential biomarkers for the prognosis of CC.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">After downloading three datasets such as GSE6791, GSE63678, and GSE63514 from the Gene Expression Omnibus (GEO), we combined the expression matrixes and analyzed them to obtain the differential expressed genes (DEGs). Next, using the STRING website, we performed the protein interaction network analysis. Subsequently, hub genes were screened using the R and Cytoscape software. Then, the expression difference and survival analyses of the hub genes were confirmed using GIPIA. Here, we established that the <i>KNTC1</i> gene was correlated to the overall survival prognosis of CC. Besides, the expression of the <i>KNTC1</i> gene in the GSE63514 dataset was significantly different from that of the normal cervix, cervical pre-cancerous lesions, and CC. Consequently, immunohistochemistry analysis showed that the results have a definite diagnostic value.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The <i>KNTC1</i> gene could be linked with the pathophysiology of CC and maybe one of the early diagnostic markers for the diagnosis of cervical pre-cancerous lesions.</AbstractText><CopyrightInformation>&#xa9; 2020 Chen et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Huan</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3910-3712</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Huanhuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Guangdong Laboratory Animals Monitoring Institute, Guangdong Key Laboratory of Laboratory Animals, Guangzhou, Guangdong 510663, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Yin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhu Zhou Hospital Affiliated to Xiangya School of Medicine, CSU, Zhuzhou, Hunan 412007, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhu Zhou Hospital Affiliated to Xiangya School of Medicine, CSU, Zhuzhou, Hunan 412007, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Mingyuan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medical Science, Central South University, Changsha, Hunan, 410013, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-6005-9598</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Onco Targets Ther</MedlineTA><NlmUniqueID>101514322</NlmUniqueID><ISSNLinking>1178-6930</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">KNTC1</Keyword><Keyword MajorTopicYN="N">bioinformatics analysis</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">differentially expressed gene</Keyword><Keyword MajorTopicYN="N">pathways</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest for this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>6</Day><Hour>5</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33402836</ArticleId><ArticleId IdType="pmc">PMC7778384</ArticleId><ArticleId IdType="doi">10.2147/OTT.S281533</ArticleId><ArticleId IdType="pii">281533</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kassa U, Dile LS, Zenebe WM. Precancerous lesions of cervix among women infected with HIV in referral hospitals of Amhara region, northwest Ethiopia: a cross sectional study. Afr Health Sci. 2019;19(1):1695&#x2013;1704. doi:10.4314/ahs.v19i1.46</Citation><ArticleIdList><ArticleId IdType="doi">10.4314/ahs.v19i1.46</ArticleId><ArticleId IdType="pmc">PMC6531982</ArticleId><ArticleId IdType="pubmed">31149000</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno K, Iida M, Yanokura M, et al. MicroRNA in cervical cancer: oncomiRs and tumor suppressor miRs in diagnosis and treatment. TheScientificWorldJournal. 2014;2014:178075. doi:10.1155/2014/178075</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/178075</ArticleId><ArticleId IdType="pmc">PMC3910129</ArticleId><ArticleId IdType="pubmed">24516357</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng X, Feng Y, Wang X, Wan X, Xie X, Lu W. The effectiveness of conization treatment for post-menopausal women with high-grade cervical intraepithelial neoplasia. Exp Ther Med. 2013;5(1):185&#x2010;188. doi:10.3892/etm.2012.748</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2012.748</ArticleId><ArticleId IdType="pmc">PMC3524274</ArticleId><ArticleId IdType="pubmed">23251264</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Ding L, Gao T, et al. Association between vaginal micro-environment disorder and cervical intraepithelial neoplasia in a community based population in China. J Cancer. 2020;11(2):284&#x2013;291. doi:10.7150/jca.35022</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.35022</ArticleId><ArticleId IdType="pmc">PMC6930421</ArticleId><ArticleId IdType="pubmed">31897224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez A, Vera E, Gamboa-Dom&#xed;nguez A, Lambert P, Gariglio P, Camacho J. Calcium-activated potassium channels as potential early markers of human cervical cancer. Oncol Lett. 2018;15(5):7249&#x2010;7254. doi:10.3892/ol.2018.8187</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2018.8187</ArticleId><ArticleId IdType="pmc">PMC5920501</ArticleId><ArticleId IdType="pubmed">29725443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342&#x2010;350. doi:10.1038/nrc798</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc798</ArticleId><ArticleId IdType="pubmed">12044010</ArticleId></ArticleIdList></Reference><Reference><Citation>de Freitas AC, Gurgel AP, Chagas BS, Coimbra EC, Do Amaral CM. Susceptibility to cervical cancer: an overview. Gynecol Oncol. 2012;126(2):304&#x2010;311. doi:10.1016/j.ygyno.2012.03.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2012.03.047</ArticleId><ArticleId IdType="pubmed">22484226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wani K, Nair CK. Genetic alterations in cervical cancer. Indian J Exp Biol. 2003;41(8):789&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">15248474</ArticleId></ArticleIdList></Reference><Reference><Citation>Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12&#x2013;19. doi:10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">10451482</ArticleId></ArticleIdList></Reference><Reference><Citation>Drain PK, Holmes KK, Hughes JP, Koutsky LA. Determinants of cervical cancer rates in developing countries. Int J Cancer. 2002;100(2):199&#x2013;205. doi:10.1002/ijc.10453</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.10453</ArticleId><ArticleId IdType="pubmed">12115570</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray HR, Nguyen D, Westbrook TF, McAnce DJ. Biology of human papillomaviruses. Int J Exp Pathol. 2001;82(1):15&#x2013;33. doi:10.1046/j.1365-2613.2001.00177.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2613.2001.00177.x</ArticleId><ArticleId IdType="pmc">PMC2517699</ArticleId><ArticleId IdType="pubmed">11422538</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheurer ME, Danysh HE, Follen M, Lupo PJ. Association of traffic-related hazardous air pollutants and cervical dysplasia in an urban multiethnic population: a cross-sectional study. Environ Health. 2014;13(1):52. doi:10.1186/1476-069X-13-52</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-069X-13-52</ArticleId><ArticleId IdType="pmc">PMC4063240</ArticleId><ArticleId IdType="pubmed">24924773</ArticleId></ArticleIdList></Reference><Reference><Citation>Che LF, Shao SF, Wang LX. Downregulation of CCR5 inhibits the proliferation and invasion of cervical cancer cells and is regulated by microRNA-107. Exp Ther Med. 2016;11(2):503&#x2013;509. doi:10.3892/etm.2015.291110.1126/science.aaa0355</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2015.291110.1126/science.aaa0355</ArticleId><ArticleId IdType="pmc">PMC4734227</ArticleId><ArticleId IdType="pubmed">26893637</ArticleId></ArticleIdList></Reference><Reference><Citation>Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol. 2014;232(2):165&#x2013;177. doi:10.1002/path.4282</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.4282</ArticleId><ArticleId IdType="pmc">PMC4138801</ArticleId><ArticleId IdType="pubmed">24114756</ArticleId></ArticleIdList></Reference><Reference><Citation>Tastan Bishop &#xd6;, Adebiyi EF, Alzohairy AM, et al. Bioinformatics education&#x2013;perspectives and challenges out of Africa. Brief Bioinform. 2015;16(2):355&#x2010;364. doi:10.1093/bib/bbu022</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbu022</ArticleId><ArticleId IdType="pmc">PMC4364068</ArticleId><ArticleId IdType="pubmed">24990350</ArticleId></ArticleIdList></Reference><Reference><Citation>Mel&#xe9; M, Ferreira PG, Reverter F, et al. Human genomics. The human transcriptome across tissues and individuals. Science. 2015;348(6235):660&#x2010;665. doi:10.1126/science.aaa0355</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa0355</ArticleId><ArticleId IdType="pmc">PMC4547472</ArticleId><ArticleId IdType="pubmed">25954002</ArticleId></ArticleIdList></Reference><Reference><Citation>Nannini M, Pantaleo MA, Maleddu A, Astolfifi A, Formica S, Biasco G. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev. 2009;35(3):201&#x2013;209. doi:10.1016/j.ctrv.2008.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2008.10.006</ArticleId><ArticleId IdType="pubmed">19081199</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Wang J, Liu J, et al. Systematic prediction of key genes for ovarian cancer by co-expression network analysis. J Cell Mol Med. 2020:10.1111/jcmm.15271. doi:10.1111/jcmm.15271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15271</ArticleId><ArticleId IdType="pmc">PMC7294139</ArticleId><ArticleId IdType="pubmed">32319226</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyeon D, Newton MA, Lambert PF, et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res. 2007;67(10):4605&#x2010;4619. doi:10.1158/0008-5472.CAN-06-3619</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-06-3619</ArticleId><ArticleId IdType="pmc">PMC2858285</ArticleId><ArticleId IdType="pubmed">17510386</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappa KI, Polyzos A, Jacob-Hirsch J, et al. Profiling of discrete gynecological cancers reveals novel transcriptional modules and common features shared by other cancer types and embryonic stem cells. PLoS One. 2015;10(11):e0142229. doi:10.1371/journal.pone.0142229</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0142229</ArticleId><ArticleId IdType="pmc">PMC4641642</ArticleId><ArticleId IdType="pubmed">26559525</ArticleId></ArticleIdList></Reference><Reference><Citation>den Boon JA, Pyeon D, Wang SS, et al. Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S A. 2015;112(25):E3255&#x2010;E3264. doi:10.1073/pnas.1509322112</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1509322112</ArticleId><ArticleId IdType="pmc">PMC4485108</ArticleId><ArticleId IdType="pubmed">26056290</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Chenwei L, Kang B. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;10.1093/nar/gkx247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5570223</ArticleId><ArticleId IdType="pubmed">28407145</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek JT, Evan Johnson W, Parker HS, et al. sva: surrogate variable analysis. R package version 3.34.0. 2019.</Citation></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607&#x2010;D613. doi:10.1093/nar/gky1131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Zheng Y, Sun Y, et al. Knockdown of NEAT1 induces tolerogenic phenotype in dendritic cells by inhibiting activation of NLRP3 inflammasome. Theranostics. 2019;9(12):3425&#x2013;3442. doi:10.7150/thno.33178</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.33178</ArticleId><ArticleId IdType="pmc">PMC6587165</ArticleId><ArticleId IdType="pubmed">31281488</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson M. org.Hs.eg.db: genome wide annotation for human. R package version 3.10.0. 2019.</Citation></Reference><Reference><Citation>Guangchuang Y, Wang L-G, Han Y, Qing-Yu H. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284&#x2013;287. doi:10.1089/omi.2011.0118</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498&#x2010;2504. doi:10.1101/gr.1239303</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019;47(D1):D506&#x2010;D515. doi:10.1093/nar/gky1049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1049</ArticleId><ArticleId IdType="pmc">PMC6323992</ArticleId><ArticleId IdType="pubmed">30395287</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarfraz S, Hamid S, Ali S, Jafri W, Siddiqui AA. Modulations of cell cycle checkpoints during HCV associated disease. BMC Infect Dis. 2009;9(125). doi:10.1186/1471-2334-9-125</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-9-125</ArticleId><ArticleId IdType="pmc">PMC2739854</ArticleId><ArticleId IdType="pubmed">19664251</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Sun L, Xu F, et al. Screening and identification of APOC1 as a novel potential biomarker for differentiate of Mycoplasma pneumoniae in children. Front Microbiol. 2016;7:1961. doi:10.3389/fmicb.2016.01961</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2016.01961</ArticleId><ArticleId IdType="pmc">PMC5156883</ArticleId><ArticleId IdType="pubmed">28018301</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CT, Min L, Wang YJ, Li P, Wu YD, Zhang ST. shRNA-mediated knockdown of KNTC1 suppresses cell viability and induces apoptosis in esophageal squamous cell carcinoma. Int J Oncol. 2019;54(3):1053&#x2010;1060. doi:10.3892/ijo.2019.4672</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2019.4672</ArticleId><ArticleId IdType="pubmed">30628654</ArticleId></ArticleIdList></Reference><Reference><Citation>Diniz MG, Silva J, de Souza FT, Pereira NB, Gomes CC, Gomez RS. Association between cell cycle gene transcription and tumor size in oral squamous cell carcinoma. Tumour Biol. 2015;36(12):9717&#x2010;9722. doi:10.1007/s13277-015-3735-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-015-3735-1</ArticleId><ArticleId IdType="pubmed">26152289</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf M, Korja M, Karhu R, et al. Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication. BMC Cancer. 2010;10(1):181. doi:10.1186/1471-2407-10-181</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-10-181</ArticleId><ArticleId IdType="pmc">PMC2873396</ArticleId><ArticleId IdType="pubmed">20444257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YR, Chung NG, Kang MR, Yoo NJ, Lee SH. Novel somatic frameshift mutations of genes related to cell cycle and DNA damage response in gastric and colorectal cancers with microsatellite instability. Tumori. 2010;96(6):1004&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">21388066</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen S, Kong J, Qiu Y, Yang X, Wang W, Yan L. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis. J Cell Biochem. 2019;120(6):10069&#x2010;10081. doi:10.1002/jcb.28290</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.28290</ArticleId><ArticleId IdType="pubmed">30525236</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan X, Wan H, Hao X, et al. Importance of gene expression signatures in pancreatic cancer prognosis and the establishment of a prediction model. Cancer Manag Res. 2018;(11):273&#x2010;283. doi:10.2147/CMAR.S185205</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CMAR.S185205</ArticleId><ArticleId IdType="pmc">PMC6312063</ArticleId><ArticleId IdType="pubmed">30643453</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Kang M, Zhou Z, Qin W, Wang R. Bioinformatics analysis identifies hub genes and pathways in nasopharyngeal carcinoma. Oncol Lett. 2019;18(4):3637&#x2010;3645. doi:10.3892/ol.2019.10707</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2019.10707</ArticleId><ArticleId IdType="pmc">PMC6732963</ArticleId><ArticleId IdType="pubmed">31516577</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan GK, Jablonski SA, Starr DA, Goldberg ML, Yen TJ. Human Zw10 and ROD are mitotic checkpoint proteins that bind to kinetochores. Nat Cell Biol. 2000;2(12):944&#x2010;947. doi:10.1038/35046598</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35046598</ArticleId><ArticleId IdType="pubmed">11146660</ArticleId></ArticleIdList></Reference><Reference><Citation>Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 2004;4(12):927&#x2013;936. doi:10.1038/nrc1502</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc1502</ArticleId><ArticleId IdType="pubmed">15573114</ArticleId></ArticleIdList></Reference><Reference><Citation>Sca&#xeb;rou F, Starr DA, Piano F, Papoulas O, Karess RE, Goldberg ML. The ZW10 and rough deal checkpoint proteins function together in a large, evolutionarily conserved complex targeted to the kinetochore. J Cell Sci. 2001;114(Pt 17):3103&#x2010;3114.</Citation><ArticleIdList><ArticleId IdType="pubmed">11590237</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurry JA, K&#xf6;hler S, Washington NL, et al. Navigating the phenotype frontier: the monarch initiative. Genetics. 2016;203(4):1491&#x2010;1495. doi:10.1534/genetics.116.188870</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.116.188870</ArticleId><ArticleId IdType="pmc">PMC4981258</ArticleId><ArticleId IdType="pubmed">27516611</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungall CJ, McMurry JA, K&#xf6;hler S, et al. The monarch initiative: an integrative data and analytic platform connecting phenotypes to genotypes across species. Nucleic Acids Res. 2017;45(D1):D712&#x2010;D722. doi:10.1093/nar/gkw1128</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw1128</ArticleId><ArticleId IdType="pmc">PMC5210586</ArticleId><ArticleId IdType="pubmed">27899636</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33344485</PMID><DateRevised><Year>2020</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>FAM83A as a Potential Biological Marker Is Regulated by miR-206 to Promote Cervical Cancer Progression Through PI3K/AKT/mTOR Pathway.</ArticleTitle><Pagination><StartPage>608441</StartPage><MedlinePgn>608441</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">608441</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2020.608441</ELocationID><Abstract><AbstractText><b>Background and Objective:</b> Chemotherapy and radiotherapy are effective treatment options for cervical cancer (CC), but their efficacy is limited by short survival rate of about 5 years particularly for advance stage CC. Bioinformatics analysis combined with experimental <i>in vivo</i> and <i>in vitro</i> data can identify potential markers of tumorigenesis and cancer progression to improve CC prognosis and survival rate of the patients. This study aims to investigate the prognostic value of family with sequence similarity 83, member A (FAM83A) gene and miR-206 in promoting CC progression and the involved genetic signaling pathways. <b>Method:</b> This was a bioinformatic analysis study based on RNA sequencing data of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases and verification by <i>in vivo</i> and <i>in vitro</i> experimental data. It was designed to evaluate whether the aberrantly expressed gene signatures could serve as new potential biomarker to improve prognosis prediction in CC. The TCGA RNA sequencing data [306 cervical squamous cell carcinoma (SCC) and endocervical adenocarcinoma samples and 13 adjacent samples] and GEO data (GSE9750 and GSE52903 datasets) were integrated and performed a bioinformatics analysis. <b>Results:</b> The results showed that CC-associated FAM83A gene serves as a key regulator of CC development and progression. Functionally, we observed that FAM83A is significantly overexpressed in CC, which is linked to poor overall survival as well as disease-free survival in CC patients. The <i>in-vitro</i> and <i>in-vivo</i> assessments performed after silencing FAM83A revealed that cell proliferation was significantly inhibited and the S-phase cell cycle arrest was induced. Mechanistically, FAM83A plays a role in PI3K/AKT signaling, and its downstream molecules could promote CC cell proliferation. Furthermore, functionality assessments by <i>in-vitro</i> luciferase reporter system and immunoblot analysis showed that miR-206 was the upstream of FAM83A and negatively correlated with FAM83A. <b>Conclusion:</b> The miR-206/FAM83A/PI3K/AKT signaling pathway possibly serves as a critical effector in CC progression indicating the potential prognostic value of FAM83A gene as a novel biomarker for CC progression.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Rong, Li, Li, Ouyang, Ma, Song and Chen.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rong</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Chongqing Public Health Medical Center, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Haiyu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Chongqing Public Health Medical Center, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhaodong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Chongqing Public Health Medical Center, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouyang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yongping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Chongqing Public Health Medical Center, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Fangzhou</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Chongqing Public Health Medical Center, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yaokai</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FAM83A</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">miR-206</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33344485</ArticleId><ArticleId IdType="pmc">PMC7746878</ArticleId><ArticleId IdType="doi">10.3389/fmed.2020.608441</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. . Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. (2019) 5:1749&#x2013;68. 10.1001/jamaoncol.2019.2996</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2019.2996</ArticleId><ArticleId IdType="pmc">PMC6777271</ArticleId><ArticleId IdType="pubmed">31560378</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Juko-Pecirep I, Hammer J, Ivansson E, Enroth S, Gustavsson I, Feuk L, Magnusson PK, McKay JD, WE and GU . Genome-wide association study of susceptibility loci for cervical cancer. J Natl Cancer Inst. (2013) 105:624&#x2013;33. 10.1093/jnci/djt051</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djt051</ArticleId><ArticleId IdType="pubmed">23482656</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilbur DC. Practical issues related to uterine pathology: in situ and invasive cervical glandular lesions and their benign mimics: emphasis on cytology&#x2013;histology correlation and interpretive pitfalls. Mod Pathol. (2016) 29(Suppl. 1):S1&#x2013;11. 10.1038/modpathol.2015.138</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/modpathol.2015.138</ArticleId><ArticleId IdType="pubmed">26715169</ArticleId></ArticleIdList></Reference><Reference><Citation>Berti FCB, Pereira APL, Cebinelli GCM, Trugilo KP, Braj&#xe3;o de Oliveira K. The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma. Cytokine Growth Factor Rev. (2017) 34:1&#x2013;13. 10.1016/j.cytogfr.2017.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2017.03.002</ArticleId><ArticleId IdType="pubmed">28365229</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieringa HW, van der Zee AGJ, de Vries EGE, van Vugt MATM. Breaking the DNA damage response to improve cervical cancer treatment. Cancer Treat Rev. (2016) 42:30&#x2013;40. 10.1016/j.ctrv.2015.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2015.11.008</ArticleId><ArticleId IdType="pubmed">26643553</ArticleId></ArticleIdList></Reference><Reference><Citation>Fetcko K, Gondim DD, Bonnin JM, Dey M. Cervical cancer metastasis to the brain: a case report and review of literature. Surg Neurol Int. (2017) 8:181. 10.4103/sni.sni_111_17</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/sni.sni_111_17</ArticleId><ArticleId IdType="pmc">PMC5569407</ArticleId><ArticleId IdType="pubmed">28868193</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas M, Narayan N, Pim D, Tomai&#x107; V, Massimi P, Nagasaka K, et al. . Human papillomaviruses, cervical cancer and cell polarity. Oncogene. (2008) 27:7018&#x2013;30. 10.1038/onc.2008.351</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2008.351</ArticleId><ArticleId IdType="pubmed">19029942</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadducci A, Guerrieri ME, Greco C. Tissue biomarkers as prognostic variables of cervical cancer. Crit Rev Oncol/Hematol. (2013) 86:104&#x2013;29. 10.1016/j.critrevonc.2012.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2012.09.003</ArticleId><ArticleId IdType="pubmed">23031678</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomczak K, Czerwi&#x144;ska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol. (2015) 19:A68&#x2013;77. 10.5114/wo.2014.47136</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/wo.2014.47136</ArticleId><ArticleId IdType="pmc">PMC4322527</ArticleId><ArticleId IdType="pubmed">25691825</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Zhang G, Zhang L, Wang Q, Li H, Han Y, et al. . Comprehensive review of web servers and bioinformatics tools for cancer prognosis analysis. Front Oncol. (2020) 10:68. 10.3389/fonc.2020.00068</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.00068</ArticleId><ArticleId IdType="pmc">PMC7013087</ArticleId><ArticleId IdType="pubmed">32117725</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C, Yang M, Luo F, Wu FX, Li M, Pan Y, et al. . Prediction of lncRNA-disease associations based on inductive matrix completion. Bioinformatics. (2018) 34:3357&#x2013;64. 10.1093/bioinformatics/bty327</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty327</ArticleId><ArticleId IdType="pubmed">29718113</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone L, Candido S, Salemi R, Basile MS, Scalisi A, McCubrey JA, et al. . Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. Oncotarget. (2016) 7:72758&#x2013;66. 10.18632/oncotarget.11805</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.11805</ArticleId><ArticleId IdType="pmc">PMC5341942</ArticleId><ArticleId IdType="pubmed">27602581</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe1;nczky A, Nagy &#xc1;, Bottai G, Munk&#xe1;csy G, Szab&#xf3; A, Santarpia L, et al. . miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. (2016) 160:439&#x2013;46. 10.1007/s10549-016-4013-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-016-4013-7</ArticleId><ArticleId IdType="pubmed">27744485</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. Peer J Comput Sci. (2016) 4:e1780v1 10.7287/peerj.preprints.1780v1</Citation><ArticleIdList><ArticleId IdType="doi">10.7287/peerj.preprints.1780v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. . NCBI GEO: archive for functional genomics data sets&#x2014;update. Nucleic Acids Res. (2013) 41(D1):D991&#x2013;5. 10.1093/nar/gks1193</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1193</ArticleId><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Neapolitan R, Jiang X. Inferring aberrant signal transduction pathways in ovarian cancer from TCGA Data. Cancer Inform. (2014) 13s1(Suppl. 1):CIN.S13881. 10.4137/CIN.S13881</Citation><ArticleIdList><ArticleId IdType="doi">10.4137/CIN.S13881</ArticleId><ArticleId IdType="pmc">PMC4216062</ArticleId><ArticleId IdType="pubmed">25392681</ArticleId></ArticleIdList></Reference><Reference><Citation>Koehorst JJ, van Dam J, Saccenti E, Martins dos Santos VAP, Suarez-Diez M, Schaap PJ. SAPP: functional genome annotation and analysis through a semantic framework using FAIR principles Bioinformatics. (2017) 34:1401&#x2013;3. 10.1093/bioinformatics/btx767</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btx767</ArticleId><ArticleId IdType="pmc">PMC5905645</ArticleId><ArticleId IdType="pubmed">29186322</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamatjan Y, Agnihotri S, Goldenberg A, Tonge P, Mansouri S, Zadeh G, et al. . Molecular signatures for tumor classification: an analysis of The Cancer Genome Atlas data. J Mol Diagn. (2017) 19:881&#x2013;91. 10.1016/j.jmoldx.2017.07.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmoldx.2017.07.008</ArticleId><ArticleId IdType="pubmed">28867603</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisenberger DJ. Characterizing DNA methylation alterations from the cancer genome atlas. J Clin Invest. (2014) 124:17&#x2013;23. 10.1172/JCI69740</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI69740</ArticleId><ArticleId IdType="pmc">PMC3871233</ArticleId><ArticleId IdType="pubmed">24382385</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei Y, Tang Z, Li Z, Yang X. Repeatability and reproducibility of quantitative corneal shape analysis after orthokeratology treatment using image-pro plus software. J Ophthalmol. (2016) 2016:1732476. 10.1155/2016/1732476</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/1732476</ArticleId><ArticleId IdType="pmc">PMC5059590</ArticleId><ArticleId IdType="pubmed">27774312</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Xu F, Li H, Zhang J, Zhong A, Huang B, et al. . S100A8+ stroma cells predict a good prognosis and inhibit aggressiveness in colorectal carcinoma. Oncoimmunology. (2017) 6:e1260213. 10.1080/2162402X.2016.1260213</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2016.1260213</ArticleId><ArticleId IdType="pmc">PMC5283617</ArticleId><ArticleId IdType="pubmed">28197382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel CA, Jackson MW. HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss. PLoS ONE. (2017) 12(5). 10.1371/journal.pone.0176778</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0176778</ArticleId><ArticleId IdType="pmc">PMC5413028</ArticleId><ArticleId IdType="pubmed">28463969</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Huang J, Liu Z, Liang Q, Zhang N, Jin Y. FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancer. Oncogenesis. (2017) 6:e300. 10.1038/oncsis.2017.3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/oncsis.2017.3</ArticleId><ArticleId IdType="pmc">PMC5533946</ArticleId><ArticleId IdType="pubmed">28287611</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Dong X, Yin Y, Su Y, Xu Q, Zhang Y, et al. . BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer. Neoplasia. (2005) 7:1073&#x2013;80. 10.1593/neo.05406</Citation><ArticleIdList><ArticleId IdType="doi">10.1593/neo.05406</ArticleId><ArticleId IdType="pmc">PMC1501171</ArticleId><ArticleId IdType="pubmed">16354590</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriano R, Miskimen KLS, Bryson BL, Foy CR, Bartel CA, Jackson MW. Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer. Mol Cancer Res. (2014) 12:1156&#x2013;65. 10.1158/1541-7786.MCR-13-0289</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1541-7786.MCR-13-0289</ArticleId><ArticleId IdType="pmc">PMC4135001</ArticleId><ArticleId IdType="pubmed">24736947</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Sun G, Mei X. Elevated FAM83A expression predicts poorer clinical outcome in lung adenocarcinoma. Cancer Biomark. (2019) 26:367&#x2013;73. 10.3233/CBM-190520</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/CBM-190520</ArticleId><ArticleId IdType="pubmed">31594212</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Ma C, Xu Q, Cheng L, Xiao L, Xu D, et al. . A rapid nested polymerase chain reaction method to detect circulating cancer cells in breast cancer patients using multiple marker genes. Oncol Lett. (2014) 7:2192&#x2013;8. 10.3892/ol.2014.2048</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2014.2048</ArticleId><ArticleId IdType="pmc">PMC4049700</ArticleId><ArticleId IdType="pubmed">24932314</ArticleId></ArticleIdList></Reference><Reference><Citation>Richtmann S, Wilkens D, Warth A, Lasitschka F, Winter H, Christopoulos P, et al. . FAM83A and FAM83B as prognostic biomarkers and potential new therapeutic targets in NSCLC. Cancers (Basel). (2019) 11:652. 10.3390/cancers11050652</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11050652</ArticleId><ArticleId IdType="pmc">PMC6562954</ArticleId><ArticleId IdType="pubmed">31083571</ArticleId></ArticleIdList></Reference><Reference><Citation>Snijders AM, Lee SY, Hang B, Hao W, Bissell MJ, Mao JH. FAM83 family oncogenes are broadly involved in human cancers: an integrative multi-omics approach. Mol Oncol. (2017) 11:167&#x2013;79. 10.1002/1878-0261.12016</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1878-0261.12016</ArticleId><ArticleId IdType="pmc">PMC5527452</ArticleId><ArticleId IdType="pubmed">28078827</ArticleId></ArticleIdList></Reference><Reference><Citation>Khenkhar M, Uhlig PC, David KA, Bigley AL, Sherry L. Digital image analysis of automated mRNA in situ hybridization and immunohistochemistry to quantify HER3 expression in cancer tissues. J Clin Oncol. (2016) 34(Suppl. 15):e23172.</Citation></Reference><Reference><Citation>Ahmad N, Haider S, Jagannathan S, Anaissie E, Driscoll JJ. MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia. (2014) 28:732&#x2013;8. 10.1038/leu.2013.262</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2013.262</ArticleId><ArticleId IdType="pubmed">24714346</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Jia Y, Cheng J, Liu G, Song F. LncRNA NCK1-AS1 promotes proliferation and induces cell cycle progression by crosstalk NCK1-AS1/MIR-6857/CDK1 pathway. Cell Death Dis. (2018) 9:198. 10.1038/s41419-017-0249-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-017-0249-3</ArticleId><ArticleId IdType="pmc">PMC5833418</ArticleId><ArticleId IdType="pubmed">29416014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY, Meier R, Furuta S, Lenburg ME, Kenny PA, Xu R, et al. . FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. J Clin Invest. (2012) 122:3211&#x2013;20. 10.1172/JCI60498</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI60498</ArticleId><ArticleId IdType="pmc">PMC3428077</ArticleId><ArticleId IdType="pubmed">22886303</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant S. FAM83A and FAM83B: Candidate oncogenes and TKI resistance mediators. J Clin Invest. (2012) 122:3048&#x2013;51. 10.1172/JCI64412</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI64412</ArticleId><ArticleId IdType="pmc">PMC3428099</ArticleId><ArticleId IdType="pubmed">22886299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu H, Wang F, Wang M, Liu Y, Wu H, Chen X, et al. . FAM83A is amplified and promotes tumorigenicity in non-small cell lung cancer via ERK and PI3K/Akt/mTOR pathways. Int J Med Sci. (2020) 17:807&#x2013;14. 10.7150/ijms.33992</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.33992</ArticleId><ArticleId IdType="pmc">PMC7085261</ArticleId><ArticleId IdType="pubmed">32218702</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Lu W. FAM83A exerts tumor-suppressive roles in cervical cancer by regulating integrins. Int J Oncol. (2020) 57:509&#x2013;21. 10.3892/ijo.2020.5078</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2020.5078</ArticleId><ArticleId IdType="pmc">PMC7307588</ArticleId><ArticleId IdType="pubmed">32626940</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Geng J, Xu S, Meng Q, Chen K, Liu F, et al. . FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC. Aging (Albany NY). (2019) 11:6069&#x2013;88. 10.18632/aging.102163</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.102163</ArticleId><ArticleId IdType="pmc">PMC6738414</ArticleId><ArticleId IdType="pubmed">31444970</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Peng X, Li Y, Liu S, Hou R, Zhang Y, et al. . Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma. Biomed Pharmacother. (2020) 123:109780. 10.1016/j.biopha.2019.109780</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2019.109780</ArticleId><ArticleId IdType="pubmed">31901550</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhyasen GW, Starczynowski DT. Deregulation of microRNAs in myelodysplastic syndrome. Leukemia. (2012) 26:13&#x2013;22. 10.1038/leu.2011.221</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2011.221</ArticleId><ArticleId IdType="pubmed">21852786</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras J, Rao DS. MicroRNAs in inflammation and immune responses. Leukemia. (2012) 26:404&#x2013;13. 10.103-8/leu.2011.356</Citation><ArticleIdList><ArticleId IdType="doi">10.103-8/leu.2011.356</ArticleId><ArticleId IdType="pubmed">22182919</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33312390</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1943-8141</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>American journal of translational research</Title><ISOAbbreviation>Am J Transl Res</ISOAbbreviation></Journal><ArticleTitle>LINC01305 inhibits malignant progression of cervical cancer via miR-129-5p/Sox4 axis.</ArticleTitle><Pagination><StartPage>7581</StartPage><EndPage>7592</EndPage><MedlinePgn>7581-7592</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The association between LINC01305, a newly discovered long non-coding RNA (lncRNA), and cervical cancer (CC) has been poorly analyzed. In the present study, we revealed high expression of LINC01305 in CC by the cancer genome atlas (TCGA) and Gene Expression Omnibus (GEO), and dissected the related mechanisms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">LINC01305, microRNA (miR) -129-5p and SRY-related high-mobility group box 4 (Sox4) mRNA levels were quantitated by quantitative reverse transcription-PCRy qRT-PCR). CC tissues and cell lines and corresponding controls were enrolled for the quantification of LINC01305 expression in CC. Effects of LINC01305 and miR-129-5p on cell proliferation, metastasis, and apoptosis were evaluated by MTT, colony formation, wound healing, Transwell and flow cytometry assays. Sox4 protein levels were tested by Western blot (WB). Bioinformatics analysis, RNA immunoprecipitation (RIP), RNA pull-down and dual-luciferase reporter (DLR) assay were performed to determine molecular mechanisms of LINC01305 in CC. Xenograft models of CC were constructed to evaluate the role of LINC01305 in vivo.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The expression of LINC01305 was evidently elevated in CC tissues and cell lines than that in controls and associated with clinicopathological features. Downregulating LINC01305 suppressed malignant phenotypes (proliferation, migration, invasion) of Hela and SiHa cells. In addition, silencing miR-129-5p by its inhibitor eliminated the inhibition of growth and metastasis induced by LINC01305 siRNA. Sox4 might serve as a direct target for miR-129-5p and was negatively regulated by miR-129-5p and LINC01305.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">LINC01305 acts as a competitive endogenous RNA (ceRNA) and regulates Sox4 via sponging miR-129-5p, contributing to the diagnosis and treatment of CC.</AbstractText><CopyrightInformation>AJTR Copyright &#xa9; 2020.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yuexun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University Zhengzhou 450003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gynaecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine Shanghai 201204, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Hongbin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, Eastern Hepatobiliary Surgery Hospital Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The First Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Qunchao</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Radiation Center, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine Shanghai 201204, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiation Center, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine Shanghai 201204, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Transl Res</MedlineTA><NlmUniqueID>101493030</NlmUniqueID><ISSNLinking>1943-8141</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Sox4</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">lncRNA LINC01305</Keyword><Keyword MajorTopicYN="N">miR-129-5p</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>14</Day><Hour>10</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33312390</ArticleId><ArticleId IdType="pmc">PMC7724335</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu M, Yu J, Awolude OA, Chuang L. Cervical cancer worldwide. Curr Probl Cancer. 2018;42:457&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">30064936</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh J, Roy B, Yadav A, Siddiqui S, Setia A, Ramesh R, Singh K. Cervical cancer awareness and HPV vaccine acceptability among females in Delhi: a cross-sectional study. Indian J Cancer. 2018;55:233&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">30693885</ArticleId></ArticleIdList></Reference><Reference><Citation>Brucker SY, Ulrich UA. Surgical treatment of early-stage cervical cancer. Oncol Res Treat. 2016;39:508&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">27614875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontostathi G, Zoidakis J, Anagnou NP, Pappa KI, Vlahou A, Makridakis M. Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring. Expert Rev Proteomics. 2016;13:731&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">27398979</ArticleId></ArticleIdList></Reference><Reference><Citation>Stumbar SE, Stevens M, Feld Z. Cervical cancer and its precursors: a preventative approach to screening, diagnosis, and management. Prim Care. 2019;46:117&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">30704652</ArticleId></ArticleIdList></Reference><Reference><Citation>Mer AS, Lindberg J, Nilsson C, Klevebring D, Wang M, Gronberg H, Lehmann S, Rantalainen M. Expression levels of long non-coding RNAs are prognostic for AML outcome. J Hematol Oncol. 2018;11:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889529</ArticleId><ArticleId IdType="pubmed">29625580</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z, Xu K, Li Y, Lv Y, Bao J, Qiao L. Long noncoding RNA in liver cancer stem cells. Discov Med. 2017;24:87&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">28972877</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Su Z, Lu S, Fu W, Liu Z, Jiang X, Tai S. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer. Clin Chim Acta. 2018;485:229&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">29981289</ArticleId></ArticleIdList></Reference><Reference><Citation>Charles Richard JL, Eichhorn PJA. Platforms for investigating LncRNA functions. SLAS Technol. 2018;23:493&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6249642</ArticleId><ArticleId IdType="pubmed">29945466</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J, Fang S, Tian H, Zhou C, Zhao X, Tian H, He J, Shen W, Meng X, Jin X, Gong Z. lncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/beta-catenin signaling. Mol Cancer. 2020;19:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6961326</ArticleId><ArticleId IdType="pubmed">31941509</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo M, Liang C. LncRNA LINC00483 promotes gastric cancer development through regulating MAPK1 expression by sponging miR-490-3p. Biol Res. 2020;53:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158027</ArticleId><ArticleId IdType="pubmed">32293550</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SP, Chu DX, Qiu HF, Xie Y, Wang CF, Zhang JY, Li WC, Guo RX. LncRNA LINC01305 silencing inhibits cell epithelial-mesenchymal transition in cervical cancer by inhibiting TNXB-mediated PI3K/Akt signalling pathway. J Cell Mol Med. 2019;23:2656&#x2013;2666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6433725</ArticleId><ArticleId IdType="pubmed">30697971</ArticleId></ArticleIdList></Reference><Reference><Citation>Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013;3:1113&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3801300</ArticleId><ArticleId IdType="pubmed">24072616</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi X, Zhang DH, Wu N, Xiao JH, Wang X, Ma W. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52:710&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">26358722</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Yang HY, Shi XQ, Wang Y. Upregulation of microRNA-129-5p inhibits cell invasion, migration and tumor angiogenesis by inhibiting ZIC2 via downregulation of the Hedgehog signaling pathway in cervical cancer. Cancer Biol Ther. 2018;19:1162&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6301807</ArticleId><ArticleId IdType="pubmed">30260270</ArticleId></ArticleIdList></Reference><Reference><Citation>Issue information-declaration of Helsinki. J Bone Miner Res. 2018;33:BM i&#x2013;BM ii.</Citation><ArticleIdList><ArticleId IdType="pubmed">30351510</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods. 2001;25:402&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 2019;20:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6341724</ArticleId><ArticleId IdType="pubmed">30670076</ArticleId></ArticleIdList></Reference><Reference><Citation>Paraskevopoulou MD, Vlachos IS, Karagkouni D, Georgakilas G, Kanellos I, Vergoulis T, Zagganas K, Tsanakas P, Floros E, Dalamagas T, Hatzigeorgiou AG. DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 2016;44:D231&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702897</ArticleId><ArticleId IdType="pubmed">26612864</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4532895</ArticleId><ArticleId IdType="pubmed">26267216</ArticleId></ArticleIdList></Reference><Reference><Citation>Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015;12:697.</Citation><ArticleIdList><ArticleId IdType="pubmed">26226356</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964941</ArticleId><ArticleId IdType="pubmed">24297251</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, Chiew MY, Tai CS, Wei TY, Tsai TR, Huang HT, Wang CY, Wu HY, Ho SY, Chen PR, Chuang CH, Hsieh PJ, Wu YS, Chen WL, Li MJ, Wu YC, Huang XY, Ng FL, Buddhakosai W, Huang PC, Lan KC, Huang CY, Weng SL, Cheng YN, Liang C, Hsu WL, Huang HD. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018;46:D296&#x2013;D302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753222</ArticleId><ArticleId IdType="pubmed">29126174</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquina G, Manzano A, Casado A. Targeted agents in cervical cancer: beyond Bevacizumab. Curr Oncol Rep. 2018;20:40.</Citation><ArticleIdList><ArticleId IdType="pubmed">29611060</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan X, Wang Y. LncRNA XLOC_006390 facilitates cervical cancer tumorigenesis and metastasis as a ceRNA against miR-331-3p and miR-338-3p. J Gynecol Oncol. 2018;29:e95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6189437</ArticleId><ArticleId IdType="pubmed">30207103</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yang Y, Li L, Liu Y, Geng P, Li G, Song H. LncRNA SNHG1 enhances cell proliferation, migration, and invasion in cervical cancer. Biochem Cell Biol. 2018;96:38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">28930646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Zhang X, Gao W, Hu H, Wang X, Hao D. lncRNA/circRNAmiRNAmRNA ceRNA network in lumbar intervertebral disc degeneration. Mol Med Rep. 2019;20:3160&#x2013;3174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6755180</ArticleId><ArticleId IdType="pubmed">31432173</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Zhong Y, Li L. miR-124 and miR-203 synergistically inactivate EMT pathway via coregulation of ZEB2 in clear cell renal cell carcinoma (ccRCC) J Transl Med. 2020;18:69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7014595</ArticleId><ArticleId IdType="pubmed">32046742</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Wang Y, Xiao X, Cheng W, Hu L, Yao W, Qian Z, Wu W. MiR-204 inhibits hepatocellular cancer drug resistance and metastasis through targeting NUAK1. Biochem Cell Biol. 2019;97:563&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">30807203</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Hu F, Fu X, Jiang Z, Zhang W, Chen K. MiR-128/SOX7 alleviates myocardial ischemia injury by regulating IL-33/sST2 in acute myocardial infarction. Biol Chem. 2019;400:533&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">30265647</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S, Nagpal N, Ghosh PC, Kulshreshtha R. P53-miR-191-SOX4 regulatory loop affects apoptosis in breast cancer. RNA. 2017;23:1237&#x2013;1246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5513068</ArticleId><ArticleId IdType="pubmed">28450532</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun R, Jiang B, Qi H, Zhang X, Yang J, Duan J, Li Y, Li G. SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2. Cell Death Dis. 2015;6:e1990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4670919</ArticleId><ArticleId IdType="pubmed">26583330</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33302814</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-0338</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><PubDate><Year>2020</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Technology in cancer research &amp; treatment</Title><ISOAbbreviation>Technol Cancer Res Treat</ISOAbbreviation></Journal><ArticleTitle>Screening and Discovery of New Potential Biomarkers and Small Molecule Drugs for Cervical Cancer: A Bioinformatics Analysis.</ArticleTitle><Pagination><StartPage>1533033820980112</StartPage><MedlinePgn>1533033820980112</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1533033820980112</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/1533033820980112</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cervical cancer (CC) is the second most common type of malignant tumor survival rate is low in advanced stage, metastatic, and recurrent CC patients. This study aimed at identifying potential genes and drugs for CC diagnosis and targeting therapies.</AbstractText><AbstractText Label="METHODS">Three GEO mRNA microarray datasets of CC tissues and non-cancerous tissues were analyzed for differentially expressed genes (DEGs) by limma package. GO (Gene Ontologies) and KEGG (Kyoto Encyclopedia of Genes and Genomes) were used to explore the relationships between the DEGs. Protein-protein interaction (PPI) of these genes was established by the STRING database. MCODE was used for screening significant modules in the PPI networks to select hub genes. Biochemical mechanisms of the hub genes were investigated with Metascape. GEPIA database was used for validating the core genes. According to these DEGs, molecular candidates for CC were recognized from the CMAP database.</AbstractText><AbstractText Label="RESULTS">We identified 309 overlapping DEGs in the 2 tissue-types. Pathway analysis revealed that the DEGs were involved in cell cycle, DNA replication, and p53 signaling. PPI networks between overlapping DEGs showed 68 high-connectivity DEGs that were chosen as hub genes. The GEPIA database showed that the expression levels of RRM2, CDC45, GINS2, HELLS, KNTC1, MCM2, MYBL2, PCNA, RAD54 L, RFC4, RFC5, TK1, TOP2A, and TYMS in CC tissues were significantly different from those in the healthy tissues and were significantly relevant to the OS of CC. We found 10 small molecules from the CMAP database that could change the trend of gene expression in CC tissues, including piperlongumine and chrysin.</AbstractText><AbstractText Label="CONCLUSIONS">The 14 DEGs identified in this study could serve as novel prognosis biomarkers for the detection and forecasting of CC. Small molecule drugs like piperlongumine and chrysin could be potential therapeutic drugs for CC treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Hui-Zhu</ForeName><Initials>HZ</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Cheng-Cheng</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0003-0323-7145</Identifier><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuo</LastName><ForeName>Er-Dong</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Xu</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-5611-4689</Identifier><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Technol Cancer Res Treat</MedlineTA><NlmUniqueID>101140941</NlmUniqueID><ISSNLinking>1533-0338</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="Y">Biomarkers, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063990" MajorTopicYN="N">Gene Ontology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025941" MajorTopicYN="N">Protein Interaction Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="Y">Small Molecule Libraries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bioinformatics analysis</Keyword><Keyword MajorTopicYN="N">candidate small molecules</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">novel biomarker</Keyword></KeywordList><CoiStatement><b>Declaration of Conflicting Interests:</b> The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>11</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33302814</ArticleId><ArticleId IdType="pmc">PMC7734488</ArticleId><ArticleId IdType="doi">10.1177/1533033820980112</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nwankwo KC, Aniebue UU, Aguwa EN, Anarado AN, Agunwah E. Knowledge attitudes and practices of cervical cancer screening among urban and rural Nigerian women: a call for education and mass screening. Eur J Cancer Care (Engl). 2011;20(3):362&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">20345451</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">25651787</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha AD, Neupane D, Vedsted P, Kallestrup P. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prev. 2018;19(2):319&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5980914</ArticleId><ArticleId IdType="pubmed">29479954</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire R, Kotronoulas G, Simpson M, Paterson C. A systematic review of the supportive care needs of women living with and beyond cervical cancer. Gynecol Oncol. 2015;136(3):478&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">25462200</ArticleId></ArticleIdList></Reference><Reference><Citation>Group IARC Working. Human Papilloma Viruses, IARC Monograph on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer; 1995:65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7681469</ArticleId><ArticleId IdType="pubmed">1683674</ArticleId></ArticleIdList></Reference><Reference><Citation>Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">20592731</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75(3):495&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">8221889</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray HR, McCance DJ. Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression. J Virol. 2003;77(18):9852&#x2013;9861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC224601</ArticleId><ArticleId IdType="pubmed">12941894</ArticleId></ArticleIdList></Reference><Reference><Citation>Gewin L, Myers H, Kiyono T, Galloway DA. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 2004;18(18):2269&#x2013;2282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC517520</ArticleId><ArticleId IdType="pubmed">15371341</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien LN, Adams EK, Flowers LC. Treating cervical cancer: breast and cervical cancer prevention and treatment act patients. Am J Obstet Gynecol. 2011;204(6):533&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">21457917</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedet JL, Pecorelli S, Ngan HY, Pecorelli S. Staging classifications and clinical practice guidelines for gynaecological cancers. Int J Gynaecol Obstet. 2000;70:207&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">11041682</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Shen Y, Zhao Y, et al. Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: a phase II trial. Eur J Surg Oncol. 2015;41(8):1082&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">26033265</ArticleId></ArticleIdList></Reference><Reference><Citation>Katanyoo K, Tangjitgamol S, Chongthanakorn M, et al. Treatment outcomes of concurrent weekly carboplatin with radiation therapy in locally advanced cervical cancer patients. Gynecol Oncol. 2011;123(3):571&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">21955483</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010094</ArticleId><ArticleId IdType="pubmed">24552320</ArticleId></ArticleIdList></Reference><Reference><Citation>Muderspach LI, Blessing JA, Levenback C, Andersen WA. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2001;81(2):213&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">11354055</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M, Bhui K, Singh R, Shukla Y. Tea polyphenols enhance cisplatin chemosensitivity in cervical cancer cells via induction of apoptosis. Life Sci. 2013;939(1):7&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">23399702</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills AA. The chromodomain helicase DNA-binding chromatin remodelers: family traits that protect from and promote cancer. Cold Spring Harb Perspect Med. 2017;7(4):a026450 doi:10.1101/cshperspect.a026450</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378010</ArticleId><ArticleId IdType="pubmed">28096241</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Zhao Y, Wang Y, Wu X. The role of galectins in cervical cancer biology and progression. Biomed Res Int. 2018;2018:2175927 doi:10.1155/2018/2175927</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964433</ArticleId><ArticleId IdType="pubmed">29854732</ArticleId></ArticleIdList></Reference><Reference><Citation>Santin AD, Cane&#x2019; S, Bellone S, et al. The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer. 2003;98(9):1898&#x2013;1904.</Citation><ArticleIdList><ArticleId IdType="pubmed">14584072</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Huang X, Zhang Y. Involvement of human papillomaviruses in cervical cancer. Front Microbiol. 2018;9:2896&#x2013;2910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6279876</ArticleId><ArticleId IdType="pubmed">30546351</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JM, Yang LN, Xu H, Chang C, Wang H-Y, Yang G. Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells. Am J Cancer Res. 2015;5(3):1133&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4449441</ArticleId><ArticleId IdType="pubmed">26045992</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao L, Zheng J, Tian Y, et al. Regulator of chromatin condensation 1 abrogates the G1 cell cycle checkpoint via Cdk1 in human papillomavirus E7-expressing epithelium and cervical cancer cells. Cell Death Dis. 2018;9(6):583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964113</ArticleId><ArticleId IdType="pubmed">29789527</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer M, Quaas M, Wintsche A, Muller GA, Engeland K. Polo-like kinase 4 transcription is activated via CRE and NRF1 elements, repressed by DREAM through CDE/CHR sites and deregulated by HPV E7 protein. Nucleic Acids Res. 2014;42(1):163&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3874167</ArticleId><ArticleId IdType="pubmed">24071582</ArticleId></ArticleIdList></Reference><Reference><Citation>Das M, Prasad SB, Yadav SS. HPV-type-specific response of cervical cancer cells to cisplatin after silencing replication licensing factor MCM4. Tumour Biol. 2015;36(12):9987&#x2013;9994.</Citation><ArticleIdList><ArticleId IdType="pubmed">26188903</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang BY, You H, Bandyopadhyay S, et al. Cervical cancer isolate PT3, super-permissive for adeno-associated virus replication, over-expresses DNA polymerase delta, PCNA, RFC and RPA. BMC Microbiol. 2009;9:79&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2685399</ArticleId><ArticleId IdType="pubmed">19389243</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R, Wei C, Liu J, Luo Y, Tang W. The prognostic value of p53 expression for patients with cervical cancer: a meta analysis. Eur J Obstet Gynecol Reprod Biol. 2015;195:210&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">26595307</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordlund P, Reichard P. Ribonucleotide reductases. Annu Rev Biochem. 2006;75:681&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Hu S, Wu J, et al. Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer. 2009;8(1):11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662784</ArticleId><ArticleId IdType="pubmed">19250552</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Zhang H, Lai L, et al. Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. Clin Sci. 2013;124(9):567&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3562074</ArticleId><ArticleId IdType="pubmed">23113760</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan H, Villegas C, Huang A, Wright JA. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res. 1998;58(8):1650&#x2013;1653.</Citation><ArticleIdList><ArticleId IdType="pubmed">9563477</ArticleId></ArticleIdList></Reference><Reference><Citation>Duxbury MS, Whang EE. RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness. Biochem Biophys Res Commun. 2007;354(1):190&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222798</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Zhan T, Ke T, et al. Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer. Br J Cancer. 2014;110(4):1034&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929894</ArticleId><ArticleId IdType="pubmed">24423925</ArticleId></ArticleIdList></Reference><Reference><Citation>Su YF, Wu TF, Ko JL, et al. The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. PLoS One. 2014;9(3):e91644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3956764</ArticleId><ArticleId IdType="pubmed">24637958</ArticleId></ArticleIdList></Reference><Reference><Citation>Aparicio T, Ibarra A, M&#xe9;ndez J. Cdc45-MCM-GINS, a new power player for DNA replication. Cell Div. 2006;1(1):18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1564009</ArticleId><ArticleId IdType="pubmed">16930479</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo YS, Kang YH. The human replicative helicase, the CMG complex, as a target for anti-cancer therapy. Front Mol Biosci. 2018;5:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885281</ArticleId><ArticleId IdType="pubmed">29651420</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang F, Liu J, Xia M, et al. GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer. Oncol Rep. 2017;37(5):2652&#x2013;2662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5428920</ArticleId><ArticleId IdType="pubmed">28405687</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan T, Liang W, Jiang E, et al. GINS2 regulates cell proliferation and apoptosis in human epithelial ovarian cancer. Oncol Lett. 2018;16(2):2591&#x2013;2598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6036576</ArticleId><ArticleId IdType="pubmed">30013653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Zhou Y, Yang X, et al. High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients. Breast Cancer Res Treat. 2014;148(2):423&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">25348432</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiman T, Muegge K. Lsh, an SNF2/helicase family member, is required for proliferation of mature T lymphocytes. Proc Natl Acad Sci U S A. 2000;97(9):4772&#x2013;4777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18308</ArticleId><ArticleId IdType="pubmed">10781083</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano M, Ouchida M, Shigematsu H, et al. Tumor-specific exon creation of the HELLS/SMARCA6 gene in non-small cell lung cancer. Int J Cancer. 2004;112(1):8&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15305370</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DW, Zhang K, Ning ZQ, et al. Proliferation-associated SNF2-like gene (PASG): a SNF2 family member altered in leukemia. Cancer Res. 2000;60(13):3612&#x2013;3622.</Citation><ArticleIdList><ArticleId IdType="pubmed">10910076</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan GK, Jablonski SA, Starr DA, Goldberg ML, Yen TJ. Human Zw10 and ROD are mitotic checkpoint proteins that bind to kinetochores. Nat Cell Biol. 2000;2(12):944&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">11146660</ArticleId></ArticleIdList></Reference><Reference><Citation>Musa J, Aynaud MM, Mirabeau O, Delattre O, Grunewald TGP. MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 2017;8(6):e2895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5520903</ArticleId><ArticleId IdType="pubmed">28640249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam EW, Morris JD, Davies R, Crook T, Watson RJ, Vousden KH. HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes. EMBO J. 1994;13(4):871&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394886</ArticleId><ArticleId IdType="pubmed">8112300</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt TL, Fraser DJ, Leal S, Hallandras PM, Kroll AR, Kroll DJ. c-Myb trans-activates the human DNA topoisomerase IIalpha gene promoter. J Biol Chem. 1997;272(10):6278&#x2013;6284.</Citation><ArticleIdList><ArticleId IdType="pubmed">9045645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Li H, Liang Z. circ-MYBL2 serves as a sponge for miR-361-3p promoting cervical cancer cells proliferation and invasion. Onco Targets Ther. 2019;12:9957&#x2013;9964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6877451</ArticleId><ArticleId IdType="pubmed">31819492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren L, Liu J, Gou K, Xing C. Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis. J Cancer. 2018;9(12):2082&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6010676</ArticleId><ArticleId IdType="pubmed">29937926</ArticleId></ArticleIdList></Reference><Reference><Citation>Branca M, Ciotti M, Giorgi C, et al. Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer. Eur J Obstet Gynecol Reprod Biol. 2007;130(2):223&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">17098349</ArticleId></ArticleIdList></Reference><Reference><Citation>Jur&#xed;kov&#xe1; M, Danihel &#x13d;, Pol&#xe1;k &#x160;, Varga I. Ki67, PCNA, and MCM proteins: markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 2016;118(5):544&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">27246286</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Wang Q, Tian P, Ying J. Highly expressed CHAF1A and PCNA are positively associated with malignancy of cervical squamous cell carcinoma. Chinese J Cell Mol Immunol. 2017;33(12):1696&#x2013;1701.</Citation><ArticleIdList><ArticleId IdType="pubmed">29382432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu L, Li HL, Li WF, et al. Clinical significance of expression of proliferating cell nuclear antigen and E-cadherin in gastric carcinoma. World J Gastroenterol. 2017;23(20):3721&#x2013;3729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5449429</ArticleId><ArticleId IdType="pubmed">28611525</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Gan S, Ren L, et al. Multifaceted regulation and functions of replication factor C family in human cancers. Am J Cancer Res. 2018;8(8):1343&#x2013;1355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6129478</ArticleId><ArticleId IdType="pubmed">30210909</ArticleId></ArticleIdList></Reference><Reference><Citation>Oku T, Ikeda S, Sasaki H, et al. Functional sites of human PCNA which interact with p21 (Cip1/Waf1), DNA polymerase delta and replication factor C. Genes Cells. 1998;3(6):357&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">9734782</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu G, Wang D, Pei Y, Sun L. Systematic identification of key genes and pathways in the development of invasive cervical cancer. Gene. 2017;618:28&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">28341182</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Zhang XX, Xi BX, et al. Sine oculis homeobox homolog 1 promotes DNA replication and cell proliferation in cervical cancer. Int J Oncol. 2014;45(3):1232&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">24970368</ArticleId></ArticleIdList></Reference><Reference><Citation>SIebos RJC, Yi Y, Ely K, et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12(3 Pt 1):701&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">16467079</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer. 2007;43(2):415&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847595</ArticleId><ArticleId IdType="pubmed">17079134</ArticleId></ArticleIdList></Reference><Reference><Citation>LaTulippe E, Satagopan J, Smith A, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002;62(15):4499&#x2013;4506.</Citation><ArticleIdList><ArticleId IdType="pubmed">12154061</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Frazier M, Evans DB, et al. Single nucleotide polymorphisms of RecQ1, RAD54 L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol. 2006;24(11):1720&#x2013;1728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435378</ArticleId><ArticleId IdType="pubmed">16520463</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Xie W, Wang N, Li C, Wang M. CDC7-dependent transcriptional regulation of RAD54 L is essential for tumorigenicity and radio-resistance of glioblastoma. Transl Oncol. 2018;11(2):300&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884092</ArticleId><ArticleId IdType="pubmed">29413763</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagarlamudi KK, Shaw M. Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker. Biomark Med. 2018;12(9):1035&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">30039979</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill KL, Buckwalter M, Murray BK. Thymidine kinase: diagnostic and prognostic potential. Expert Rev Mol Diagn. 2001;1(4):428&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">11901857</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Jiang X, Dong S, et al. Serum TK1 is a more reliable marker than CEA and AFP for cancer screening in a study of 56,286 people. Cancer Biomark. 2016;16(4):529&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">27002755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Ying M, Chen Y, et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1247 cancer patients in routine clinical settings. Int J Clin Oncol. 2010;15(4):359&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">20354751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallegos-Arreola MP, Zuniga-Gonzalez GM, Sanchez-Lopez JY, et al. TYMS 2R3 R polymorphism and DPYD [IVS]14+1G&gt;A gene mutation in Mexican colorectal cancer patients. Acta Biochim Pol. 2018;65(2):227&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">29906295</ArticleId></ArticleIdList></Reference><Reference><Citation>Ntavatzikos A, Spathis A, Patapis P, et al. Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer. World J Gastroenterol. 2017;23(32):5913&#x2013;5924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5583576</ArticleId><ArticleId IdType="pubmed">28932083</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Z, Jiao Y, Li Y, Ji B, Jia B, Liu B. TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer. Medicine (Baltimore). 2019;98(51):e18487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6940182</ArticleId><ArticleId IdType="pubmed">31861032</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Edwards A, Fang Z, Flemington EK, Zhang K. Integrative genomics and transcriptomics analysis reveals potential mechanisms for favorable prognosis of patients with HPV-positive head and neck carcinomas. Sci Rep. 2016;6:24927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4842993</ArticleId><ArticleId IdType="pubmed">27108969</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriola E, Rodriguez-Pinilla SM, Lambros MB, et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat. 2007;106(2):181&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">17260090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lielsen KV, Ejlertsen B, Moller S, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol. 2008;47(4):725&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">18465341</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezerra DP, Pessoa C, de Moraes MO, Sakar-Neto N, Silveira ER, Costa-Lotufo LV. Overview of the therapeutic potential of piplartine (piperlongumine). Eur J Pharm Sci. 2013;48(3):453&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">23238172</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharadwaj U, Eckols TK, Kolosov M, et al. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene. 2015;34(11):1341&#x2013;1353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4182178</ArticleId><ArticleId IdType="pubmed">24681959</ArticleId></ArticleIdList></Reference><Reference><Citation>Randhawa H, Kibble K, Zeng H, Moyer MP, Reindl KM. Activation of ERK signaling and induction of colon cancer cell death by piperlongumine. Toxicol In Vitro. 2013;27(6):1626&#x2013;1633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3749270</ArticleId><ArticleId IdType="pubmed">23603476</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JL, Kim EH, Park JY, Kim JW, Kwon M, Lee B-H. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer. Oncotarget. 2014;5(19):9227&#x2013;9238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253430</ArticleId><ArticleId IdType="pubmed">25193861</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong LH, Chen XX, Wang H, et al. Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells. Oxid Med Cell Longev. 2014;2014:906804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4034765</ArticleId><ArticleId IdType="pubmed">24895529</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginzburg S, Golovine KV, Makhov PB, Uzzo RG, Kutikov A, Kolenko VM. Piperlongumine inhibits NF-&#x3ba;B activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate. 2014;74(2):177&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4052841</ArticleId><ArticleId IdType="pubmed">24151226</ArticleId></ArticleIdList></Reference><Reference><Citation>Seber S, Sirin DY, Yetisyigit T, Bilgen T. Piperlongumine increases the apoptotic effect of doxorubicin and paclitaxel in a cervical cancer cell line. Niger J Clin Pract. 2020;23(3):386&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">32134040</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj L, Ide T, Gurkar AU, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2011;475(7355):231&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3316487</ArticleId><ArticleId IdType="pubmed">21753854</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Chen X, Qu L, Wu J, Cui R, Zhao Y. Chrysin and its phosphate ester inhibit cell proliferation and induce apoptosis in Hela cells. Bioorg Med Chem. 2004;12(23):6097&#x2013;6105.</Citation><ArticleIdList><ArticleId IdType="pubmed">15519155</ArticleId></ArticleIdList></Reference><Reference><Citation>von Brandenstein MG, Ngum Abety A, Depping R, et al. A p38-p65 transcription complex induced by endothelin-1 mediate signal transduction in cancer cells. Biochim Biophys Acta. 2008;1783(9):1613&#x2013;1622.</Citation><ArticleIdList><ArticleId IdType="pubmed">18457675</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33023625</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1755-8794</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>BMC medical genomics</Title><ISOAbbreviation>BMC Med Genomics</ISOAbbreviation></Journal><ArticleTitle>TOP2A and CENPF are synergistic master regulators activated in cervical cancer.</ArticleTitle><Pagination><StartPage>145</StartPage><MedlinePgn>145</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">145</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12920-020-00800-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Identification of master regulators (MRs) using transcriptome data in cervical cancer (CC) could help us to develop biomarkers and find novel drug targets to fight this disease.</AbstractText><AbstractText Label="METHODS">We performed differential expression (DE) analyses of public microarray and RNA-seq transcriptome data of CC and normal cervical tissues (N). Virtual Inference of Protein activity by Enriched Regulon analysis (VIPER) was used to convert the DE outcomes to differential activity (DA) signature for MRs. Synergy analysis was conducted to study synergistic effect of MR-pairs. TCGA and microarray data were used to test the association of expression of a MR and a clinical feature or a molecular feature (e.g. somatic mutations). Various bioinformatic tools/websites (DAVID, GEPIA2, Oncomine, cBioPortal) were used to analyze the expression of the top MRs and their regulons.</AbstractText><AbstractText Label="RESULTS">Ten DE and 10 DA signatures were generated for CC. Two MRs, DNA topoisomerase II alpha (TOP2A) and centromere protein F (CENPF) were found to be up-regulated, activated and synergistic in CC compared to N across the 10 datasets. The two MRs activate a common set of genes (regulons) with functions in cell cycle, chromosome, DNA damage etc. Higher expression of CENPF was associated with metastasis. High expression of both MRs is associated with somatic mutation of a set of genes including tumor suppressors (TP53, MSH2, RB1) and genes involved in cancer pathways, cell cycle, DNA damage and repair. The magnitude of up-regulation and the absolute expression level of both MRs in CC are significantly higher compared to many other cancer types.</AbstractText><AbstractText Label="CONCLUSION">TOP2A and CENPF are a synergistic pair of MRs that are overexpressed and activated in CC. Their high expression is correlated with some prognosis features (e.g. metastasis) and molecular features (e.g. somatic mutations) and distinctly high in CC vs. many other cancer types. They may be good biomarkers and anticancer drug targets for CC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Beiwei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Laboratory, Hangzhou Jianggan District People's Hospital, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Long</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Xiao shan Hospital, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Weina</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Qingdao Municipal Hospital, Qingdao, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Laboratory, Jinhua People's Hospital, Jinhua, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yibiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Laboratory, Zhejiang Jinhua Guangfu Hospital, Jinhua, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Qingdao Municipal Hospital, Qingdao, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>Xianlin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Laboratory, Jinhua People's Hospital, Jinhua, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Libo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medicine Reproductive Centre, Jinhua People's Hospital, Jinhua, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Tianjia Genomes Tech CO., LTD., Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Hongtao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Tianjia Genomes Tech CO., LTD., Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiangtao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Tianjia Genomes Tech CO., LTD., Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Tianjia Genomes Tech CO., LTD., Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Qingdao Municipal Hospital, Qingdao, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hongyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Qingdao Municipal Hospital, Qingdao, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Qingdao Municipal Hospital, Qingdao, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhiqin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Functional Discipline, School of medicine Jinhua, Jinhua, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Qingdao Municipal Hospital, Qingdao, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Liqin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Laboratory, Hangzhou Jianggan District People's Hospital, Hangzhou, Zhejiang, China. 1939277107@qq.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory, Jinhua People's Hospital, Jinhua, Zhejiang, China. 1939277107@qq.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No.2017C37046</GrantID><Agency>public welfare technology application projects of Zhejiang province</Agency><Country>International</Country></Grant><Grant><GrantID>No.2017WS308</GrantID><Agency>Medical Science and Technology&#xa0; Development Plan of Shandong Province</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Genomics</MedlineTA><NlmUniqueID>101319628</NlmUniqueID><ISSNLinking>1755-8794</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002868">Chromosomal Proteins, Non-Histone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075223">Poly-ADP-Ribose Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C094772">centromere protein F</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.99.1.3</RegistryNumber><NameOfSubstance UI="D004250">DNA Topoisomerases, Type II</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.99.1.3</RegistryNumber><NameOfSubstance UI="C000618811">TOP2A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002868" MajorTopicYN="N">Chromosomal Proteins, Non-Histone</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004250" MajorTopicYN="N">DNA Topoisomerases, Type II</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008840" MajorTopicYN="N">Microfilament Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075223" MajorTopicYN="N">Poly-ADP-Ribose Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Differential activity</Keyword><Keyword MajorTopicYN="N">Differential expression</Keyword><Keyword MajorTopicYN="N">Master regulator</Keyword><Keyword MajorTopicYN="N">Transcriptome</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33023625</ArticleId><ArticleId IdType="pmc">PMC7541258</ArticleId><ArticleId IdType="doi">10.1186/s12920-020-00800-2</ArticleId><ArticleId IdType="pii">10.1186/s12920-020-00800-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169&#x2013;182. doi: 10.1016/S0140-6736(18)32470-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32470-X</ArticleId><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wu X, Cheng X. Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016;27(4):e43. doi: 10.3802/jgo.2016.27.e43.</Citation><ArticleIdList><ArticleId IdType="doi">10.3802/jgo.2016.27.e43</ArticleId><ArticleId IdType="pmc">PMC4864519</ArticleId><ArticleId IdType="pubmed">27171673</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez MJ, Shen Y, Giorgi FM, et al. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nat Genet. 2016;48(8):838&#x2013;847. doi: 10.1038/ng.3593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3593</ArticleId><ArticleId IdType="pmc">PMC5040167</ArticleId><ArticleId IdType="pubmed">27322546</ArticleId></ArticleIdList></Reference><Reference><Citation>Clough E, Barrett T. The gene expression omnibus database. Methods Mol Biol. 2016;1418:93&#x2013;110. doi: 10.1007/978-1-4939-3578-9_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3578-9_5</ArticleId><ArticleId IdType="pmc">PMC4944384</ArticleId><ArticleId IdType="pubmed">27008011</ArticleId></ArticleIdList></Reference><Reference><Citation>Biewenga P, Buist MR, Moerland PD, et al. Gene expression in early stage cervical cancer. Gynecol Oncol. 2008;108(3):520&#x2013;526. doi: 10.1016/j.ygyno.2007.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2007.11.024</ArticleId><ArticleId IdType="pubmed">18191186</ArticleId></ArticleIdList></Reference><Reference><Citation>den Boon JA, Pyeon D, Wang SS, et al. Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S A. 2015;112(25):E3255&#x2013;E3264. doi: 10.1073/pnas.1509322112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1509322112</ArticleId><ArticleId IdType="pmc">PMC4485108</ArticleId><ArticleId IdType="pubmed">26056290</ArticleId></ArticleIdList></Reference><Reference><Citation>Guardado-Estrada M, Medina-Mart&#xed;nez I, Ju&#xe1;rez-Torres E, et al. The Amerindian mtDNA haplogroup B2 enhances the risk of HPV for cervical cancer: de-regulation of mitochondrial genes may be involved. J Hum Genet. 2012;57(4):269&#x2013;276. doi: 10.1038/jhg.2012.17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jhg.2012.17</ArticleId><ArticleId IdType="pubmed">22357541</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Martinez I, Barr&#xf3;n V, Roman-Bassaure E, et al. Impact of gene dosage on gene expression, biological processes and survival in cervical cancer: a genome-wide follow-up study. PLoS One. 2014;9(5):e97842. doi: 10.1371/journal.pone.0097842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0097842</ArticleId><ArticleId IdType="pmc">PMC4039463</ArticleId><ArticleId IdType="pubmed">24879114</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y, Kuick R, Nan B, et al. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res. 2007;67(21):10163&#x2013;10172. doi: 10.1158/0008-5472.CAN-07-2056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2056</ArticleId><ArticleId IdType="pubmed">17974957</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Teng S, Xu J, et al. Microarray is an efficient tool for circRNA profiling. Brief Bioinform. 2019;20(4):1420&#x2013;1433. doi: 10.1093/bib/bby006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bby006</ArticleId><ArticleId IdType="pubmed">29415187</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappa KI, Polyzos A, Jacob-Hirsch J, et al. Profiling of discrete gynecological cancers reveals novel transcriptional modules and common features shared by other Cancer types and embryonic stem cells. PLoS One. 2015;10(11):e0142229. doi: 10.1371/journal.pone.0142229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0142229</ArticleId><ArticleId IdType="pmc">PMC4641642</ArticleId><ArticleId IdType="pubmed">26559525</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyeon D, Newton MA, Lambert PF, et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res. 2007;67(10):4605&#x2013;4619. doi: 10.1158/0008-5472.CAN-06-3619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-06-3619</ArticleId><ArticleId IdType="pmc">PMC2858285</ArticleId><ArticleId IdType="pubmed">17510386</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez Faba O, Palou J, Vila Reyes H, et al. Treatment options and predictive factors for recurrence and cancer-specific mortality in bladder cancer after renal transplantation: a multi-institutional analysis. Opciones terap&#xe9;uticas y factores predictivos de recurrencia y mortalidad c&#xe1;ncer-espec&#xed;fica en pacientes con tumor vesical despu&#xe9;s de trasplante renal: an&#xe1;lisis multiinstitucional. Actas Urol Esp. 2017;41(10):639&#x2013;645. doi: 10.1016/j.acuro.2017.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acuro.2017.05.007</ArticleId><ArticleId IdType="pubmed">29126568</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun NX, Ye C, Zhao Q, et al. Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancer. PLoS One. 2014;9(7):e100340. doi: 10.1371/journal.pone.0100340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100340</ArticleId><ArticleId IdType="pmc">PMC4090119</ArticleId><ArticleId IdType="pubmed">25007342</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinonen R, Sugawara H, Shumway M; International nucleotide sequence database collaboration. The sequence read archive. Nucleic Acids Res 2011;39(Database issue):D19-D21. 10.1093/nar/gkq1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013647</ArticleId><ArticleId IdType="pubmed">21062823</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15&#x2013;21. doi: 10.1093/bioinformatics/bts635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachmann A, Giorgi FM, Lopez G, Califano A. ARACNe-AP: gene network reverse engineering through adaptive partitioning inference of mutual information. Bioinformatics. 2016;32(14):2233&#x2013;2235. doi: 10.1093/bioinformatics/btw216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw216</ArticleId><ArticleId IdType="pmc">PMC4937200</ArticleId><ArticleId IdType="pubmed">27153652</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498&#x2013;2504. doi: 10.1101/gr.1239303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44&#x2013;57. doi: 10.1038/nprot.2008.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.211</ArticleId><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomczak K, Czerwi&#x144;ska P, Wiznerowicz M. The Cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) 2015;19(1A):A68&#x2013;A77. doi: 10.5114/wo.2014.47136.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/wo.2014.47136</ArticleId><ArticleId IdType="pmc">PMC4322527</ArticleId><ArticleId IdType="pubmed">25691825</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Duan T, Ye P, et al. TSVdb: a web-tool for TCGA splicing variants analysis. BMC Genomics. 2018;19(1):405. doi: 10.1186/s12864-018-4775-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-018-4775-x</ArticleId><ArticleId IdType="pmc">PMC5975414</ArticleId><ArticleId IdType="pubmed">29843604</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Genome Atlas Research Network; Albert Einstein College of Medicine; Analytical Biological Services; Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378&#x2013;84. 10.1038/nature21386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5354998</ArticleId><ArticleId IdType="pubmed">28112728</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556&#x2013;W560. doi: 10.1093/nar/gkz430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz430</ArticleId><ArticleId IdType="pmc">PMC6602440</ArticleId><ArticleId IdType="pubmed">31114875</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166&#x2013;180. doi: 10.1593/neo.07112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1593/neo.07112</ArticleId><ArticleId IdType="pmc">PMC1813932</ArticleId><ArticleId IdType="pubmed">17356713</ArticleId></ArticleIdList></Reference><Reference><Citation>Thul PJ, &#xc5;kesson L, Wiking M, et al. A subcellular map of the human proteome. Science. 2017;356(6340)):eaal3321. doi: 10.1126/science.aal3321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal3321</ArticleId><ArticleId IdType="pubmed">28495876</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi: 10.1126/scisignal.2004088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2004088</ArticleId><ArticleId IdType="pmc">PMC4160307</ArticleId><ArticleId IdType="pubmed">23550210</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607&#x2013;D613. doi: 10.1093/nar/gky1131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghandi M, Huang FW, Jan&#xe9;-Valbuena J, et al. Next-generation characterization of the Cancer cell line encyclopedia. Nature. 2019;569(7757):503&#x2013;508. doi: 10.1038/s41586-019-1186-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1186-3</ArticleId><ArticleId IdType="pmc">PMC6697103</ArticleId><ArticleId IdType="pubmed">31068700</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Narayan R, Corsello SM, et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 2017;171(6):1437&#x2013;1452. doi: 10.1016/j.cell.2017.10.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.049</ArticleId><ArticleId IdType="pmc">PMC5990023</ArticleId><ArticleId IdType="pubmed">29195078</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin CM, Astbury K, McEvoy L, O'Toole S, Sheils O, O&#x2019;Leary JJ. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Methods Mol Biol. 2009;511:333&#x2013;359. doi: 10.1007/978-1-59745-447-6_15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-59745-447-6_15</ArticleId><ArticleId IdType="pubmed">19347305</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar T, Sabitha K, Vijayalakshmi N, et al. Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer. 2011;11:80. doi: 10.1186/1471-2407-11-80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-11-80</ArticleId><ArticleId IdType="pmc">PMC3050856</ArticleId><ArticleId IdType="pubmed">21338529</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu DM, Shi J, Liu T, Deng SH, Han R, Xu Y. Integrated analysis reveals down-regulation of SPARCL1 is correlated with cervical cancer development and progression. Cancer Biomark. 2018;21(2):355&#x2013;365. doi: 10.3233/CBM-170501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/CBM-170501</ArticleId><ArticleId IdType="pubmed">29103025</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornesello ML, Buonaguro L, Giorgi-Rossi P, Buonaguro FM. Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int. 2013;2013:519619. doi: 10.1155/2013/519619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/519619</ArticleId><ArticleId IdType="pmc">PMC3872027</ArticleId><ArticleId IdType="pubmed">24383054</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon EP, King LM, Nelson R, et al. Characterization and clinical validation of MCM2 and TOP2A monoclonal antibodies in the BD ProEx&#x2122; C assay: an immunoassay which detects aberrant S-phase induction in cervical tissue. J Immunol Methods. 2017;442:35&#x2013;41. doi: 10.1016/j.jim.2017.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2017.01.002</ArticleId><ArticleId IdType="pubmed">28093271</ArticleId></ArticleIdList></Reference><Reference><Citation>Peres AL, Paz E, Silva KM, de Ara&#xfa;jo RF, et al. Immunocytochemical study of TOP2A and Ki-67 in cervical smears from women under routine gynecological care. J Biomed Sci. 2016;23(1):42. doi: 10.1186/s12929-016-0258-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-016-0258-z</ArticleId><ArticleId IdType="pmc">PMC4864931</ArticleId><ArticleId IdType="pubmed">27175798</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Pino M, Svanholm-Barrie C, Torn&#xe9; A, et al. mRNA biomarker detection in liquid-based cytology: a new approach in the prevention of cervical cancer. Mod Pathol. 2015;28(2):312&#x2013;320. doi: 10.1038/modpathol.2014.106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/modpathol.2014.106</ArticleId><ArticleId IdType="pubmed">25189639</ArticleId></ArticleIdList></Reference><Reference><Citation>Branca M, Giorgi C, Ciotti M, et al. Over-expression of topoisomerase IIalpha is related to the grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict prognosis in cervical cancer or HPV clearance after cone treatment. Int J Gynecol Pathol. 2006;25(4):383&#x2013;392. doi: 10.1097/01.pgp.0000209573.54457.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.pgp.0000209573.54457.32</ArticleId><ArticleId IdType="pubmed">16990717</ArticleId></ArticleIdList></Reference><Reference><Citation>Smrkolj S, Erzen M, Rakar S. Prognostic significance of topoisomerase II alpha and collagen IV immunoexpression in cervical cancer. Eur J Gynaecol Oncol. 2010;31(4):380&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">20882877</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Huang J, Lan J, et al. Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer. Cancer Cell Int. 2019;19:264. doi: 10.1186/s12935-019-0986-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-019-0986-8</ArticleId><ArticleId IdType="pmc">PMC6788011</ArticleId><ArticleId IdType="pubmed">31632198</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuo YJ, Xi M, Wan YP, et al. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer. Int J Mol Med. 2015;35(4):966&#x2013;972. doi: 10.3892/ijmm.2015.2086.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2015.2086</ArticleId><ArticleId IdType="pubmed">25647485</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;bel C, &#xd6;zden C, Schroeder C, et al. Upregulation of centromere protein F is linked to aggressive prostate cancers. Cancer Manag Res. 2018;10:5491&#x2013;5504. doi: 10.2147/CMAR.S165630.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CMAR.S165630</ArticleId><ArticleId IdType="pmc">PMC6234994</ArticleId><ArticleId IdType="pubmed">30519097</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahid M, Kim M, Lee MY, et al. Downregulation of CENPF remodels prostate Cancer cells and alters cellular metabolism. Proteomics. 2019;19(11):e1900038. doi: 10.1002/pmic.201900038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201900038</ArticleId><ArticleId IdType="pmc">PMC6633900</ArticleId><ArticleId IdType="pubmed">30957416</ArticleId></ArticleIdList></Reference><Reference><Citation>Aytes A, Mitrofanova A, Lefebvre C, et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell. 2014;25(5):638&#x2013;651. doi: 10.1016/j.ccr.2014.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2014.03.017</ArticleId><ArticleId IdType="pmc">PMC4051317</ArticleId><ArticleId IdType="pubmed">24823640</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Zhang P, Liu L, Min X, Xiao Y. Weighted gene coexpression network analysis identifies a new biomarker of CENPF for prediction disease prognosis and progression in nonmuscle invasive bladder cancer. Mol Genet Genomic Med. 2019;7(11):e982. doi: 10.1002/mgg3.982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mgg3.982</ArticleId><ArticleId IdType="pmc">PMC6825849</ArticleId><ArticleId IdType="pubmed">31566930</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen EB, Qin X, Peng K, et al. HnRNPR-CCNB1/CENPF axis contributes to gastric cancer proliferation and metastasis. Aging (Albany NY) 2019;11(18):7473&#x2013;7491. doi: 10.18632/aging.102254.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.102254</ArticleId><ArticleId IdType="pmc">PMC6782008</ArticleId><ArticleId IdType="pubmed">31527303</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai Y, Liu L, Zeng T, et al. Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochem Biophys Res Commun. 2013;436(4):711&#x2013;718. doi: 10.1016/j.bbrc.2013.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2013.06.021</ArticleId><ArticleId IdType="pubmed">23791740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho DW, Kai AK, Ng IO. TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma. Front Med. 2015;9(3):322&#x2013;330. doi: 10.1007/s11684-015-0408-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-015-0408-9</ArticleId><ArticleId IdType="pubmed">26276037</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Miao BS, Wei CY, et al. Lymphoid-specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression. Cancer Sci. 2019;110(7):2133&#x2013;2144. doi: 10.1111/cas.14037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.14037</ArticleId><ArticleId IdType="pmc">PMC6609811</ArticleId><ArticleId IdType="pubmed">31066149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Cheng Y, Jiang Y, et al. Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis. Int J Biol Sci. 2018;14(2):124&#x2013;136. doi: 10.7150/ijbs.22619.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.22619</ArticleId><ArticleId IdType="pmc">PMC5821034</ArticleId><ArticleId IdType="pubmed">29483831</ArticleId></ArticleIdList></Reference><Reference><Citation>Haque W, Verma V, Butler EB, Teh BS. Radical Cystectomy Versus Chemoradiation for Muscle-invasive Bladder Cancer: Impact of Treatment Facility and Sociodemographics. Anticancer Res. 2017;37(10):5603&#x2013;5608. doi: 10.21873/anticanres.11994.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.11994</ArticleId><ArticleId IdType="pubmed">28982876</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathish M, Kavitha B, Nayak VL, et al. Synthesis of podophyllotoxin linked &#x3b2;-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors. Eur J Med Chem. 2018;144:557&#x2013;571. doi: 10.1016/j.ejmech.2017.12.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2017.12.055</ArticleId><ArticleId IdType="pubmed">29289881</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahid M, Lee MY, Piplani H, et al. Centromere protein F (CENPF), a microtubule binding protein, modulates cancer metabolism by regulating pyruvate kinase M2 phosphorylation signaling. Cell Cycle. 2018;17(24):2802&#x2013;2818. doi: 10.1080/15384101.2018.1557496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2018.1557496</ArticleId><ArticleId IdType="pmc">PMC6343699</ArticleId><ArticleId IdType="pubmed">30526248</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32946928</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0038</ISSN><JournalIssue CitedMedium="Internet"><Volume>766</Volume><PubDate><Year>2021</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Gene</Title><ISOAbbreviation>Gene</ISOAbbreviation></Journal><ArticleTitle>Identification of prognosis-related genes in the cervical cancer immune microenvironment.</ArticleTitle><Pagination><StartPage>145119</StartPage><MedlinePgn>145119</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gene.2020.145119</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0378-1119(20)30788-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cervical cancer is the fourth most commonly diagnosed cancer in women worldwide. The metastasis and invasion of this type of cancer are closely related to the tumor microenvironment. Immune cells and stromal cells dominate the tumor microenvironment in cervical cancer. Therefore, we should further investigate the complex interplay between the tumor progression with immune cells or stromal cells.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We downloaded the gene expression profiles and clinical data of 307 patients with cervical cancers based on the TCGA database. Subsequently, the Estimation of Stromal and Immune cells in Malignant Tumours using Expression data (ESTIMATE) algorithm was used to calculate the scores of stromal cells and immune cells in order to uncover differential expressed genes, and we analyzed the correlation between their scores and patient survival. Then the Cell type Identification By Estimating Relative Subsets Of known RNA Transcripts (CIBERSORT) deconvolution algorithm was applied to quantify the fraction and infiltration of 22 types of immune cells in cervical cancer. Moreover, we also used R language packs and network tools to analyze GO term, gene enrichment pathway, and protein-protein relationship to trace down genes related to inflammation and immune regulation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The gene expression profiles and corresponding clinical data of 307 patients were obtained from TCGA database. The results showed that the scores were statistically significant between the high immunescore group and the low immunescore group. And the low immunescore group had shorter survival period than the high scores group (P&#xa0;=&#xa0;0.035). Among the 22 types of immune cells, only T cells and mast cells were significantly related to the survival rate of cervical cancer patients. Moreover, PPI network analysis revealed that CCR5 and CXCL9, -10, -11/CXCR3 axis might be a new target for cervical cancer treatment. Finally, Kaplan-Meier survival curves found outnine representative genes significantly related to survival rate including BTNL8, CCR7, CD1E, CD6, CD27, CD79A, GRAP2, SP1B, LY9.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These genes can be used as markers for the prognosis and diagnosis of cervical cancer and also might be used as treatment targets.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lirong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province 650000, China; Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan Province 650000, China; Kunming Medical University, Kunming, Yunnan Province 650500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province 650000, China; Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan Province 650000, China; Kunming Medical University, Kunming, Yunnan Province 650500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Mingyao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province 650000, China; Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan Province 650000, China; Yunnan Cell Biology and Clinical Translation Research Center, Kunming, Yunnan Province 650000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wenju</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province 650000, China; Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan Province 650000, China; Yunnan Cell Biology and Clinical Translation Research Center, Kunming, Yunnan Province 650000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province 650000, China; Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan Province 650000, China; Yunnan Cell Biology and Clinical Translation Research Center, Kunming, Yunnan Province 650000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yiyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province 650000, China; Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan Province 650000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province 650000, China; Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan Province 650000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province 650000, China; Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan Province 650000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shijie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province 650000, China; Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan Province 650000, China; Kunming Medical University, Kunming, Yunnan Province 650500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Zhuying</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province 650000, China; Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan Province 650000, China; Kunming Medical University, Kunming, Yunnan Province 650500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province 650000, China; Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan Province 650000, China; Yunnan Cell Biology and Clinical Translation Research Center, Kunming, Yunnan Province 650000, China. Electronic address: aileenali@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Zongliu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province 650000, China; Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan Province 650000, China; Yunnan Cell Biology and Clinical Translation Research Center, Kunming, Yunnan Province 650000, China. Electronic address: hzl579@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Gene</MedlineTA><NlmUniqueID>7706761</NlmUniqueID><ISSNLinking>0378-1119</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079803" MajorTopicYN="N">Data Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017154" MajorTopicYN="N">Stromal Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioinformatic analysis</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Immune microenvironment</Keyword><Keyword MajorTopicYN="N">Overall survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>18</Day><Hour>20</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32946928</ArticleId><ArticleId IdType="doi">10.1016/j.gene.2020.145119</ArticleId><ArticleId IdType="pii">S0378-1119(20)30788-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32922202</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1449-1907</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>15</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>International journal of medical sciences</Title><ISOAbbreviation>Int J Med Sci</ISOAbbreviation></Journal><ArticleTitle>Potential mechanism of RRM2 for promoting Cervical Cancer based on weighted gene co-expression network analysis.</ArticleTitle><Pagination><StartPage>2362</StartPage><EndPage>2372</EndPage><MedlinePgn>2362-2372</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/ijms.47356</ELocationID><Abstract><AbstractText>Cervical cancer is the most common gynecologic malignant tumor, with a high incidence in 50-55-year-olds. This study aims to investigate the potential molecular mechanism of RRM2 for promoting the development of cervical cancer based on The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). RRM2 was found to be significant upregulated in cervical tissue (<i>P</i>&lt;0.05) by extracting the expression of RRM2 from TCGA, GSE63514, GSE7410, GSE7803 and GSE9750. Survival analysis indicated that the overall survival was significantly worse in the patients with high-expression of RRM2 (<i>P</i>&lt;0.05). The top 1000 positively/negatively correlated genes with RRM2 by Pearson Correlation test were extracted. The gene co-expression network by Weighted Gene Co-Expression Network Analysis (WGCNA) with these genes and the clinical characteristics (lymphocyte infiltration, monocyte infiltration, necrosis, neutrophil infiltration, the number of normal/stromal/tumor cells and the number of tumor nuclei) was constructed. By screening the hub nodes from the co-expression network, results suggested that RRM2 may co-express with relevant genes to regulate the number of stromal/tumor cells and the process of lymphocyte infiltration to promote the progression of cervical cancer. RRM2 is likely to become a novel potential diagnostic and prognostic biomarker of cervical cancer and provide evidence to support the study of mechanisms for cervical cancer.</AbstractText><CopyrightInformation>&#xa9; The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jingtao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Yuexiong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yurou</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Int J Med Sci</MedlineTA><NlmUniqueID>101213954</NlmUniqueID><ISSNLinking>1449-1907</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.17.4.-</RegistryNumber><NameOfSubstance UI="C093713">ribonucleotide reductase M2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.17.4.1</RegistryNumber><NameOfSubstance UI="D012262">Ribonucleoside Diphosphate Reductase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002584" MajorTopicYN="N">Cervix Uteri</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066264" MajorTopicYN="N">Datasets as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025941" MajorTopicYN="N">Protein Interaction Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012262" MajorTopicYN="N">Ribonucleoside Diphosphate Reductase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioinformatics</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Lymphocyte infiltration</Keyword><Keyword MajorTopicYN="N">Ribonucleotide reductase M2</Keyword><Keyword MajorTopicYN="N">Stromal cells</Keyword><Keyword MajorTopicYN="N">Tumor cells</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>14</Day><Hour>5</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32922202</ArticleId><ArticleId IdType="pmc">PMC7484645</ArticleId><ArticleId IdType="doi">10.7150/ijms.47356</ArticleId><ArticleId IdType="pii">ijmsv17p2362</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68:394&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra S, Oden M, Schmeler K, Richards-Kortum R. Low-Cost Instructional Apparatus to Improve Training for Cervical Cancer Screening and Prevention. Obstetrics and gynecology. 2019;133:559&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6407823</ArticleId><ArticleId IdType="pubmed">30741811</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimple SA, Mishra GA. Global strategies for cervical cancer prevention and screening. Minerva ginecologica. 2019;71:313&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">30808155</ArticleId></ArticleIdList></Reference><Reference><Citation>Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ. et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet (London, England) 2011;378:1461&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">21924486</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire R, Kotronoulas G, Simpson M, Paterson C. A systematic review of the supportive care needs of women living with and beyond cervical cancer. Gynecologic oncology. 2015;136:478&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">25462200</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Zhan T, Ke T, Huang X, Ke D, Wang Q. et al. Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer. British journal of cancer. 2014;110:1034&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929894</ArticleId><ArticleId IdType="pubmed">24423925</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordlund P, Reichard P. Ribonucleotide reductases. Annual review of biochemistry. 2006;75:681&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756507</ArticleId></ArticleIdList></Reference><Reference><Citation>Grolmusz VK, Karaszi K, Micsik T, Toth EA, Meszaros K, Karvaly G. et al. Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer. American journal of cancer research. 2016;6:2041&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5043113</ArticleId><ArticleId IdType="pubmed">27725909</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossi F, Dal Bello MG, Salvi S, Puzone R, Pfeffer U, Fontana V. et al. Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer. Disease markers. 2015;2015:302649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664813</ArticleId><ArticleId IdType="pubmed">26663950</ArticleId></ArticleIdList></Reference><Reference><Citation>Han P, Chen RH, Wang F, Zeng JY, Yu ST, Xu LH. et al. Novel chimeric transcript RRM2-c2orf48 promotes metastasis in nasopharyngeal carcinoma. Cell death &amp; disease. 2017;8:e3047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5636969</ArticleId><ArticleId IdType="pubmed">28906488</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Cao Y, Yang S, Zhang S. Overexpression of RRM2 in gastric cancer cell promotes their invasiveness via AKT/NF-kappaB signaling pathway. Die Pharmazie. 2016;71:280&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">27348973</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Pang J, Liu Y, Zhang J, Zhang C, Shen G. et al. Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy. Oncology reports. 2018;40:355&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">29749541</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L, Lin Z, Qiao J, Chen Y, Flemington EK, Qin Z. Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma. Oncogene. 2017;36:5068&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5578886</ArticleId><ArticleId IdType="pubmed">28459467</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Angiolella V, Donato V, Forrester FM, Jeong YT, Pellacani C, Kudo Y. et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell. 2012;149:1023&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3616325</ArticleId><ArticleId IdType="pubmed">22632967</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang W, Tong JH, Chan AW, Zhao J, Wang S, Dong Y. et al. Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma. Oncology reports. 2014;31:2579&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">24756820</ArticleId></ArticleIdList></Reference><Reference><Citation>Morikawa T, Maeda D, Kume H, Homma Y, Fukayama M. Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology. 2010;57:885&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">21166702</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah KN, Wilson EA, Malla R, Elford HL, Faridi JS. Targeting Ribonucleotide Reductase M2 and NF-kappaB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer. Molecular cancer therapeutics. 2015;14:2411&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26333382</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi Y, Liu Y, Wu W, Wu K, Zhang W. Reconstruction and analysis of circRNAmiRNAmRNA network in the pathology of cervical cancer. Oncology reports. 2019;41:2209&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6412533</ArticleId><ArticleId IdType="pubmed">30816541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Li Y, Zhou J. Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells. Oncology letters. 2018;15:3719&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5844123</ArticleId><ArticleId IdType="pubmed">29556274</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M. et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic acids research. 2013;41:D991&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling. 2013;6:pl1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4160307</ArticleId><ArticleId IdType="pubmed">23550210</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemporary oncology (Poznan, Poland) 2015;19:A68&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322527</ArticleId><ArticleId IdType="pubmed">25691825</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia L, Su X, Shen J, Meng Q, Yan J, Zhang C. et al. ANLN functions as a key candidate gene in cervical cancer as determined by integrated bioinformatic analysis. Cancer management and research. 2018;10:663&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5896649</ArticleId><ArticleId IdType="pubmed">29670400</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B. et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (New York, NY) 2017;19:649&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516091</ArticleId><ArticleId IdType="pubmed">28732212</ArticleId></ArticleIdList></Reference><Reference><Citation>Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC bioinformatics. 2011;12:77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference><Reference><Citation>Moolgavkar SH, Chang ET, Watson HN, Lau EC. An Assessment of the Cox Proportional Hazards Regression Model for Epidemiologic Studies. Risk analysis: an official publication of the Society for Risk Analysis. 2018;38:777&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">29168991</ArticleId></ArticleIdList></Reference><Reference><Citation>George B, Seals S, Aban I. Survival analysis and regression models. Journal of nuclear cardiology: official publication of the American Society of Nuclear Cardiology. 2014;21:686&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4111957</ArticleId><ArticleId IdType="pubmed">24810431</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic acids research. 2018;46:D956&#x2013;d63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753188</ArticleId><ArticleId IdType="pubmed">29136207</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao X, Sherman BT, Huang da W, Stephens R, Baseler MW, Lane HC. et al. DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics (Oxford, England) 2012;28:1805&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381967</ArticleId><ArticleId IdType="pubmed">22543366</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead MJ, McCanney GA, Willison HJ, Barnett SC. MyelinJ: an ImageJ macro for high throughput analysis of myelinating cultures. Bioinformatics (Oxford, England) 2019;35:4528&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6821319</ArticleId><ArticleId IdType="pubmed">31095292</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC bioinformatics. 2008;9:559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Scardoni G, Tosadori G, Faizan M, Spoto F, Fabbri F, Laudanna C. Biological network analysis with CentiScaPe: centralities and experimental dataset integration. F1000Research. 2014;3:139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4647866</ArticleId><ArticleId IdType="pubmed">26594322</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research. 2003;13:2498&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J. et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global health. 2020;8:e191&#x2013;e203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7025157</ArticleId><ArticleId IdType="pubmed">31812369</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong D, Sun H, Li Z, Liu S, Dong C, Fu K. et al. An emerging function of circRNA-miRNAs-mRNA axis in human diseases. Oncotarget. 2017;8:73271&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641211</ArticleId><ArticleId IdType="pubmed">29069868</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X, Xu Y, Lu L, Jiao Y, Liu J, Wang L. et al. Identification of key candidate genes and small molecule drugs in cervical cancer by bioinformatics strategy. Cancer management and research. 2018;10:3533&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6145638</ArticleId><ArticleId IdType="pubmed">30271202</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue JM, Liu Y, Wan LH, Zhu YX. Comprehensive Analysis of Differential Gene Expression to Identify Common Gene Signatures in Multiple Cancers. Medical science monitor: international medical journal of experimental and clinical research. 2020;26:e919953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7027371</ArticleId><ArticleId IdType="pubmed">32035007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Zhang F, Sun P. miR-140-3p impedes the proliferation of human cervical cancer cells by targeting RRM2 to induce cell-cycle arrest and early apoptosis. Bioorganic &amp; medicinal chemistry. 2020;28:115283.</Citation><ArticleIdList><ArticleId IdType="pubmed">31902649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Zheng GH, Li GC, Xin L, Wang YS, Chen Y. et al. Long noncoding RNA LINC00958 regulates cell sensitivity to radiotherapy through RRM2 by binding to microRNA-5095 in cervical cancer. Journal of cellular physiology. 2019;234:23349&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">31169309</ArticleId></ArticleIdList></Reference><Reference><Citation>Su YF, Wu TF, Ko JL, Tsai HT, Tee YT, Chien MH. et al. The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. PloS one. 2014;9:e91644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3956764</ArticleId><ArticleId IdType="pubmed">24637958</ArticleId></ArticleIdList></Reference><Reference><Citation>Grisaru DA, Covens A, Franssen E, Chapman W, Shaw P, Colgan T. et al. Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2-IB1-2 cervical carcinoma. Cancer. 2003;97:1904&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12673716</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen GB, Abeler VM, Risberg B, Trop C, Bryne M. Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma. Gynecologic oncology. 1999;74:245&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">10419739</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapp H, Goetzl L, Creasman W, Kohler M, Underwood P, Esnaola N. Combined adverse effect of African American race and deep stromal invasion on survival following radical hysterectomy for cervical cancer. American journal of obstetrics and gynecology. 2008;199:196.e1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18565488</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H, Yang B, Zhang H, Song J, Zhang Y, Xing J. et al. RRM2 is a potential prognostic biomarker with functional significance in glioma. International journal of biological sciences. 2019;15:533&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367584</ArticleId><ArticleId IdType="pubmed">30745840</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Hu S, Wu J, Chen L, Lu J, Wang X. et al. Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Molecular cancer. 2009;8:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662784</ArticleId><ArticleId IdType="pubmed">19250552</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YF, Wang ZY, Tang LY, Hu RH, Huang L, Ding JW. RRM2 overexpression in glioblastoma enhances the proliferation and invasion of cancer cells. International Journal of Clinical and Experimental Pathology. 2016;9:11623&#x2013;30.</Citation></Reference><Reference><Citation>Lu AG, Feng H, Wang PX, Han DP, Chen XH, Zheng MH. Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair. World journal of gastroenterology. 2012;18:4704&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3442208</ArticleId><ArticleId IdType="pubmed">23002339</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Li L, Liu Y, Geng P, Li G, Yang Y. et al. RECK inhibits cervical cancer cell migration and invasion by promoting p53 signaling pathway. Journal of cellular biochemistry. 2018;119:3058&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">29064588</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Hu X, Liu W, Dorrance A, Garzon R, Houghton PJ. et al. P53 suppresses ribonucleotide reductase via inhibiting mTORC1. Oncotarget. 2017;8:41422&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5522210</ArticleId><ArticleId IdType="pubmed">28507282</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh K, Zhou X, Hayakawa H, Cho JY, Libermann TA, Jin J. et al. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. Journal of virology. 2007;81:9737&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045412</ArticleId><ArticleId IdType="pubmed">17609271</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi L, Zhou B, Chen J, Hu W, Bai R, Ye C. et al. Significant prognostic values of differentially expressed-aberrantly methylated hub genes in breast cancer. Journal of Cancer. 2019;10:6618&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6856906</ArticleId><ArticleId IdType="pubmed">31777591</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Li Y, Hao H, Wang Y, Zhou Z, Wang Z. et al. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis. Cell transplantation. 2019;28:76s&#x2013;86s.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7016461</ArticleId><ArticleId IdType="pubmed">31822116</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Lv Y, Gan Z, Zhang Y, Han X, Xu Z. Identification of key genes involved in the metastasis of clear cell renal cell carcinoma. Oncology letters. 2019;17:4321&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447949</ArticleId><ArticleId IdType="pubmed">30988807</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDermed DM, Khodarev NN, Pitroda SP, Edwards DC, Pelizzari CA, Huang L. et al. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC medical genomics. 2010;3:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2876055</ArticleId><ArticleId IdType="pubmed">20459602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Rajasekaran M, Xia H, Zhang X, Kong SN, Sekar K. et al. The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/&#x3b2;-catenin signalling pathway. Gut. 2016;65:1522&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5036256</ArticleId><ArticleId IdType="pubmed">26941395</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32733542</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-8021</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Frontiers in genetics</Title><ISOAbbreviation>Front Genet</ISOAbbreviation></Journal><ArticleTitle>Integrative Bioinformatics Approaches to Screen Potential Prognostic Immune-Related Genes and Drugs in the Cervical Cancer Microenvironment.</ArticleTitle><Pagination><StartPage>727</StartPage><MedlinePgn>727</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">727</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fgene.2020.00727</ELocationID><Abstract><AbstractText>In developing countries, cervical cancer is still the major cause of cancer-related death among women. To better understand the correlation between tumor microenvironment (TME) and prognosis of cervical cancer, we screened 1367 differentially expressed genes (DEGs) of cervical cancer samples in The Cancer Genome Atlas (TCGA) database using Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) algorithm-derived immune scores. Then, we extracted 401 tumor immune microenvironment (TIME)-related DEGs that related to patients' survival outcomes. Protein-protein interaction (PPI) network and functional enrichment analysis revealed that the prognostic genes mainly participated in myeloid leukocyte activation, adaptive immune response regulation, and receptor signaling pathways. A total of 79 key prognostic DEGs were obtained through PPI network. A TF-lncRNA-miRNA-mRNA regulatory network was constructed to explore the potential regulatory mechanism. 4 genes (<i>CCR7</i>, <i>PD-1</i>, <i>ZAP70</i>, and <i>CD28</i>) were validated in another independent cohort of cervical cancer from the Gene Expression Omnibus (GEO) database. Finally, potential drugs for key prognostics DEGs were predicted using DrugBank. In conclusion, we obtained a list of potential prognostic TIME-related genes and potential predicted drugs by integrative bioinformatics approaches. A comprehensive understanding of prognostic genes within the TIME may provide new strategies for cervical cancer treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Zhao, Li, Li, Yuan Wu, Ou-Yang, Liu, Cai and Wang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zitong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of South China, Hengyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jigang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>He</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan Wu</LastName><ForeName>Na-Yi</ForeName><Initials>NY</Initials><AffiliationInfo><Affiliation>Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ou-Yang</LastName><ForeName>Peilin</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Jingting</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Genet</MedlineTA><NlmUniqueID>101560621</NlmUniqueID><ISSNLinking>1664-8021</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GEO</Keyword><Keyword MajorTopicYN="N">TCGA</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">drug</Keyword><Keyword MajorTopicYN="N">multifactor</Keyword><Keyword MajorTopicYN="N">tumor microenvironment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32733542</ArticleId><ArticleId IdType="pmc">PMC7359727</ArticleId><ArticleId IdType="doi">10.3389/fgene.2020.00727</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alonso M., Auss&#xf3; S., Lopez-Doriga A., Cordero D., Guin&#xf3; E., Sol&#xe9; X., et al. (2017). Comprehensive analysis of copy number aberrations in microsatellite stable colon cancer in view of stromal component. J. Br. J. Cancer 117 421&#x2013;431. 10.1038/bjc.2017.208</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2017.208</ArticleId><ArticleId IdType="pmc">PMC5537504</ArticleId><ArticleId IdType="pubmed">28683472</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsadeq A., Fedders H., Vokuhl C., Belau N., Zimmermann M., Wirbelauer T., et al. (2017). The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system. J. Haematol. 102 346&#x2013;355. 10.3324/haematol.2016.147744</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2016.147744</ArticleId><ArticleId IdType="pmc">PMC5286942</ArticleId><ArticleId IdType="pubmed">27686375</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoni R. (2012). Tumor immunotherapy directed at PD-1. Cell 366 2517&#x2013;2519. 10.1056/nejme1205943</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejme1205943</ArticleId><ArticleId IdType="pubmed">22658126</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M., Weiderpass E., Bruni L., de Sanjos&#xe9; S., Saraiya M., Ferlay J., et al. (2020). Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob. Health 8 e191&#x2013;e203. 10.1016/s2214-109x(19)30482-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2214-109x(19)30482-6</ArticleId><ArticleId IdType="pmc">PMC7025157</ArticleId><ArticleId IdType="pubmed">31812369</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman T., Schiller J. (2017). Human papillomavirus in cervical cancer and oropharyngeal cancer: one cause, two diseases. J. Cancer 123 2219&#x2013;2229. 10.1002/cncr.30588</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.30588</ArticleId><ArticleId IdType="pubmed">28346680</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanovich S., Kim Y., Mizutani T., Yasuma R., Tudisco L., Cicatiello V., et al. (2016). Human IgG1 antibodies suppress angiogenesis in a target-independent manner. Signal. Transduct. Target Ther. 1: 15001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4763941</ArticleId><ArticleId IdType="pubmed">26918197</ArticleId></ArticleIdList></Reference><Reference><Citation>Borcoman E., Le Tourneau C. (2017). Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. J. Therap. Adv. Med. Oncol. 9 431&#x2013;439. 10.1177/1758834017708742</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1758834017708742</ArticleId><ArticleId IdType="pmc">PMC5455883</ArticleId><ArticleId IdType="pubmed">28607581</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;ttcher J., Bonavita E., Chakravarty P., Blees H., Cabeza-Cabrerizo M., Sammicheli S., et al. (2018). NK Cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. J. Cell 172 1022&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5847168</ArticleId><ArticleId IdType="pubmed">29429633</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle S., Gieniec K., Gregor C., Faulkner J., McColl S., Kochetkova M. (2017). Interplay between CCR7 and Notch1 axes promotes stemness in MMTV-PyMT mammary cancer cells. J. Mol. Cancer 16:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5282896</ArticleId><ArticleId IdType="pubmed">28137279</ArticleId></ArticleIdList></Reference><Reference><Citation>Che L., Shao S., Wang L. (2016). Downregulation of CCR5 inhibits the proliferation and invasion of cervical cancer cells and is regulated by microRNA-107. J. Exp. Therap. Med. 11 503&#x2013;509. 10.3892/etm.2015.2911</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2015.2911</ArticleId><ArticleId IdType="pmc">PMC4734227</ArticleId><ArticleId IdType="pubmed">26893637</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Zhang Y., Lv J., Li Y., Wang Y., He Q., et al. (2017). genomic analysis of tumor microenvironment immune types across 14 solid cancer types: immunotherapeutic implications. J. Theranost. 7 3585&#x2013;3594. 10.7150/thno.21471</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.21471</ArticleId><ArticleId IdType="pmc">PMC5596445</ArticleId><ArticleId IdType="pubmed">28912897</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H., Chung J., Kim S., Braunschweig T., Kang T., Kim J., et al. (2014). MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer 14:957. 10.1186/1471-2407-14-957</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-14-957</ArticleId><ArticleId IdType="pmc">PMC4301905</ArticleId><ArticleId IdType="pubmed">25510288</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H., Ros W., Delord J., Perets R., Italiano A., Shapira-Frommer R., et al. (2019). Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 37 1470&#x2013;1478. 10.1200/jco.18.01265</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.18.01265</ArticleId><ArticleId IdType="pubmed">30943124</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft M. (2009). The role of TNF superfamily members in T-cell function and diseases. J. Nat. Rev. Immunol. 9 271&#x2013;285. 10.1038/nri2526</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2526</ArticleId><ArticleId IdType="pmc">PMC2737409</ArticleId><ArticleId IdType="pubmed">19319144</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai Y., Tong R., Guo H., Yu T., Wang C. (2017). Association of CXCR4, CCR7, VEGF-C and VEGF-D expression with lymph node metastasis in patients with cervical cancer. J. Eur. J. Obstet. Gynecol. Reprod. Biol. 214 178&#x2013;183. 10.1016/j.ejogrb.2017.04.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejogrb.2017.04.043</ArticleId><ArticleId IdType="pubmed">28535405</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vos van Steenwijk P., Ramwadhdoebe T., Goedemans R., Doorduijn E., van Ham J., Gorter A., et al. (2013). Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma. J. Intern. J. Cancer 133 2884&#x2013;2894.</Citation><ArticleIdList><ArticleId IdType="pubmed">23740735</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer B., Zamarin D., Eskandar R., Mayadev J. (2019). Role of immunotherapy in the management of locally advanced and recurrent/metastatic cervical cancer. J. Natl. Comprehens. Cancer Netw. 17 91&#x2013;97. 10.6004/jnccn.2018.7108</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2018.7108</ArticleId><ArticleId IdType="pubmed">30659133</ArticleId></ArticleIdList></Reference><Reference><Citation>Engblom C., Pfirschke C., Pittet M. (2016). The role of myeloid cells in cancer therapies. J. Nat. Rev. Cancer 16 447&#x2013;462. 10.1038/nrc.2016.54</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2016.54</ArticleId><ArticleId IdType="pubmed">27339708</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman M., Dutcher J., Clark J., Alva A., Miletello G., Curti B., et al. (2019). Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM registry. J. Immunother. Cancer 7:84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6437874</ArticleId><ArticleId IdType="pubmed">30917871</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu D., Liu B., Zang L., Jiang H. (2016). MiR-631/ZAP70: a novel axis in the migration and invasion of prostate cancer cells. J. Biochem. Biophys. Res. Commun. 469 345&#x2013;351. 10.1016/j.bbrc.2015.11.093</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2015.11.093</ArticleId><ArticleId IdType="pubmed">26620225</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia F., Petry K., Muderspach L., Gold M., Braly P., Crum C., et al. (2004). ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. J. Obstetr. Gynecol. 103 317&#x2013;326. 10.1097/01.aog.0000110246.93627.17</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.aog.0000110246.93627.17</ArticleId><ArticleId IdType="pubmed">14754702</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorter A., Prins F., van Diepen M., Punt S., van der Burg S. (2015). The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome. J. Transl. Med. 13:295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4566330</ArticleId><ArticleId IdType="pubmed">26357849</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H., Jae-Won C., Lee S., Yun A., Kim H., Bae D., et al. (2017). TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. J. Nucleic Acids Res. 46(D1) D380&#x2013;D386. 10.1093/nar/gkx1013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1013</ArticleId><ArticleId IdType="pmc">PMC5753191</ArticleId><ArticleId IdType="pubmed">29087512</ArticleId></ArticleIdList></Reference><Reference><Citation>Imming P., Sinning C., Meyer A. (2006). Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5 821&#x2013;834. 10.1038/nrd2132</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2132</ArticleId><ArticleId IdType="pubmed">17016423</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia D., Li S., Li D., Xue H., Yang D., Liu Y. (2018). Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. J. Aging 10 592&#x2013;605. 10.18632/aging.101415</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101415</ArticleId><ArticleId IdType="pmc">PMC5940130</ArticleId><ArticleId IdType="pubmed">29676997</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochems C., Schlom J. (2011). Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. J. Exp. Biol. 236 567&#x2013;579. 10.1258/ebm.2011.011007</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/ebm.2011.011007</ArticleId><ArticleId IdType="pmc">PMC3229261</ArticleId><ArticleId IdType="pubmed">21486861</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce J., Fearon D. (2015). T cell exclusion, immune privilege, and the tumor microenvironment. J. Sci. 348 74&#x2013;80. 10.1126/science.aaa6204</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa6204</ArticleId><ArticleId IdType="pubmed">25838376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kietpeerakool C., Rattanakanokchai S., Jampathong N., Srisomboon J., Lumbiganon P. (2019). Management of drainage for malignant ascites in gynaecological cancer. J. Cochrane Database Syst. Rev. 12:CD007794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6953277</ArticleId><ArticleId IdType="pubmed">31825525</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Nam K., Ahn S., Park D., Kim H., Kim S., et al. (2016). Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. J. Gastr. Cancer 19 42&#x2013;52. 10.1007/s10120-014-0440-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10120-014-0440-5</ArticleId><ArticleId IdType="pubmed">25424150</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura Y., Fujii M., Masuishi T., Nishikawa K., Kunisaki C., Matsusaka S., et al. (2018). Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). J. Gastr. Cancer 21 421&#x2013;427. 10.1007/s10120-017-0766-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10120-017-0766-x</ArticleId><ArticleId IdType="pmc">PMC5906490</ArticleId><ArticleId IdType="pubmed">28936560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolde R., Kolde M. R. (2015). Package &#x2018;Pheatmap&#x2019;. J R Package.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansigan F., Costa C., Zaki B., Yen S., Winer E., Ryan H., et al. (2019). Multicenter, open-label, phase II study of bendamustine and rituximab followed by 90-Yttrium (Y) Ibritumomab tiuxetan for untreated follicular lymphoma (Fol-BRITe). J. Clin. Cancer Res. 25 6073&#x2013;6079. 10.1158/1078-0432.ccr-18-3755</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.ccr-18-3755</ArticleId><ArticleId IdType="pubmed">31243122</ArticleId></ArticleIdList></Reference><Reference><Citation>Laufer J., Lyck R., Legler D. (2018). ZAP70 expression enhances chemokine-driven chronic lymphocytic leukemia cell migration and arrest by valency regulation of integrins. FASEB J. 32 4824&#x2013;4835. 10.1096/fj.201701452rr</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201701452rr</ArticleId><ArticleId IdType="pubmed">29589978</ArticleId></ArticleIdList></Reference><Reference><Citation>Law V., Knox C., Djoumbou Y., Jewison T., Guo A. C., Liu Y., et al. (2014). DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42 D1091&#x2013;D1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965102</ArticleId><ArticleId IdType="pubmed">24203711</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Ma L., Shen S., Guo Y., Cao Q., Cai X., et al. (2019). Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment. J. Exp. Clin. Cancer Res. 38:303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625119</ArticleId><ArticleId IdType="pubmed">31296243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., Liu T., Cui T., Wang Z., Zhang Y., Tan P., et al. (2019). RNAInter in 2020: RNA interactome repository with increased coverage and annotation. J. Nucleic Acids Res. 48 D189&#x2013;D197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6943043</ArticleId><ArticleId IdType="pubmed">31906603</ArticleId></ArticleIdList></Reference><Reference><Citation>Looi C., Chung F., Leong C., Wong S., Rosli R., Mai C. (2019). Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J. Exp. Clin. Cancer Res. 38:162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463646</ArticleId><ArticleId IdType="pubmed">30987642</ArticleId></ArticleIdList></Reference><Reference><Citation>Maolake A., Izumi K., Natsagdorj A., Iwamoto H., Kadomoto S., Makino T., et al. (2018). Tumor necrosis factor-&#x3b1; induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation. J. Cancer Sci. 109 1524&#x2013;1531. 10.1111/cas.13586</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13586</ArticleId><ArticleId IdType="pmc">PMC5980342</ArticleId><ArticleId IdType="pubmed">29575464</ArticleId></ArticleIdList></Reference><Reference><Citation>McLachlan J., Boussios S., Okines A., Glaessgen D., Bodlar S., Kalaitzaki R., et al. (2017). The impact of systemic therapy beyond first-line treatment for advanced cervical cancer. J. Clin. Oncol. 29 153&#x2013;160. 10.1016/j.clon.2016.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clon.2016.10.002</ArticleId><ArticleId IdType="pubmed">27838135</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Martinez I., Barr&#xf3;n V., Roman-Bassaure E., Ju&#xe1;rez-Torres E., Guardado-Estrada M., Espinosa A., et al. (2014). Impact of gene dosage on gene expression, biological processes and survival in cervical cancer: a genome-wide follow-up study. PLoS One 9:e97842. 10.1371/journal.pone.0097842</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0097842</ArticleId><ArticleId IdType="pmc">PMC4039463</ArticleId><ArticleId IdType="pubmed">24879114</ArticleId></ArticleIdList></Reference><Reference><Citation>Meira D., de Almeida V., Moror&#xf3; J., N&#xf3;brega I., Bardella L., Silva R., et al. (2009). Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. Br. J. Cancer 101 782&#x2013;791. 10.1038/sj.bjc.6605216</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6605216</ArticleId><ArticleId IdType="pmc">PMC2736849</ArticleId><ArticleId IdType="pubmed">19654571</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore K., Sill M., Miller D., McCourt C., De Geest K., Rose P., et al. (2012). A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: a gynecologic oncology group study. J. Gynecol. Oncol. 127 456&#x2013;461. 10.1016/j.ygyno.2012.08.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2012.08.030</ArticleId><ArticleId IdType="pubmed">22960004</ArticleId></ArticleIdList></Reference><Reference><Citation>Mootha V., Lindgren C., Eriksson K., Subramanian A., Sihag S., Lehar J., et al. (2003). PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. J. Nat. Genet. 34 267&#x2013;273. 10.1038/ng1180</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1180</ArticleId><ArticleId IdType="pubmed">12808457</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng S., Wang P., Lee Y., Lee C., Yang S., Shen H., et al. (2019). Impact of matrix metalloproteinase-11 gene polymorphisms on development and clinicopathologcial variables of uterine cervical cancer in Taiwanese women. Intern. J. Med. Sci. 16 774&#x2013;782. 10.7150/ijms.33195</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.33195</ArticleId><ArticleId IdType="pmc">PMC6643117</ArticleId><ArticleId IdType="pubmed">31337950</ArticleId></ArticleIdList></Reference><Reference><Citation>Overington J. P., Al-Lazikani B., Hopkins A. L. (2006). How many drug targets are there? Nat. Rev. Drug Discov. 5 993&#x2013;996. 10.1038/nrd2199</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2199</ArticleId><ArticleId IdType="pubmed">17139284</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasini F., Zilberstein B., Snitcovsky I., Roela R., Mangone F., Ribeiro U., et al. (2014). A gene expression profile related to immune dampening in the tumor microenvironment is associated with poor prognosis in gastric adenocarcinoma. J. Gastroenterol. 49 1453&#x2013;1466. 10.1007/s00535-013-0904-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-013-0904-0</ArticleId><ArticleId IdType="pmc">PMC4223540</ArticleId><ArticleId IdType="pubmed">24217965</ArticleId></ArticleIdList></Reference><Reference><Citation>Penson R., Huang H., Wenzel L., Monk B., Stockman S., Long H., et al. (2015). Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG oncology-gynecologic oncology group protocol 240). J. Lancet Oncol. 16 301&#x2013;311. 10.1016/s1470-2045(15)70004-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1470-2045(15)70004-5</ArticleId><ArticleId IdType="pmc">PMC4479218</ArticleId><ArticleId IdType="pubmed">25638326</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitprez F., Vano Y., Becht E., Giraldo N., de Reyni&#xe8;s A., Saut&#xe8;s-Fridman C., et al. (2018). Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. J. Cancer Immunol. Immunother. 67 981&#x2013;988. 10.1007/s00262-017-2058-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-017-2058-z</ArticleId><ArticleId IdType="pmc">PMC11028160</ArticleId><ArticleId IdType="pubmed">28884365</ArticleId></ArticleIdList></Reference><Reference><Citation>Piersma S. (2011). Immunosuppressive tumor microenvironment in cervical cancer patients. J. Cancer Microenviron. 4 361&#x2013;375. 10.1007/s12307-011-0066-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12307-011-0066-7</ArticleId><ArticleId IdType="pmc">PMC3234326</ArticleId><ArticleId IdType="pubmed">21626415</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie M. E., Phipson B., Wu D., Hu Y., Law C. W., Shi W., et al. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e47. 10.1093/nar/gkv007</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P., Markiel A., Ozier O., Baliga N., Wang J., Ramage D., et al. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. J. Genome Res. 13 2498&#x2013;2504. 10.1101/gr.1239303</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Spill F., Reynolds D., Kamm R., Zaman M. (2016). Impact of the physical microenvironment on tumor progression and metastasis. J. Curr. Opin. Biotechnol. 40 41&#x2013;48. 10.1016/j.copbio.2016.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.copbio.2016.02.007</ArticleId><ArticleId IdType="pmc">PMC4975620</ArticleId><ArticleId IdType="pubmed">26938687</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Tamayo P., Mootha V., Mukherjee S., Ebert B., Gillette M., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. J. Proc. Natl. Acad. Sci. U.S.A. 102 15545&#x2013;15550. 10.1073/pnas.0506580102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Gable A., Lyon D., Junge A., Wyder S., Huerta-Cepas J., et al. (2019). STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. J. Nucleic Acids Res. 47 D607&#x2013;D613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng M. W., Galon J., Fridman W.-H., Smyth M. J. (2015). From mice to humans: developments in cancer immunoediting. J. Clin. Invest. 125 3338&#x2013;3346. 10.1172/jci80004</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci80004</ArticleId><ArticleId IdType="pmc">PMC4588291</ArticleId><ArticleId IdType="pubmed">26241053</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewari K., Sill M., Long H., Penson R., Huang H., Ramondetta L., et al. (2014). Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 370 734&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010094</ArticleId><ArticleId IdType="pubmed">24552320</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewari K., Sill M., Penson R., Huang H., Ramondetta L., Landrum L., et al. (2017). Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). J. Lancet 390 1654&#x2013;1663. 10.1016/s0140-6736(17)31607-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(17)31607-0</ArticleId><ArticleId IdType="pmc">PMC5714293</ArticleId><ArticleId IdType="pubmed">28756902</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomczak K., Czerwinska P., Wiznerowicz M. (2015). The cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp. Oncol. 19 A68&#x2013;A77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322527</ArticleId><ArticleId IdType="pubmed">25691825</ArticleId></ArticleIdList></Reference><Reference><Citation>Valle-Mendiola A., Guti&#xe9;rrez-Hoya A., Lagunas-Cruz M. C., Weiss-Steider B., Soto-Cruz I. (2016). Pleiotropic effects of IL-2 on cancer: its role in cervical cancer. J. Med. Inflamm. 2016:2849523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4880719</ArticleId><ArticleId IdType="pubmed">27293315</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Steger A., Mahner S., Jeschke U., Heidegger H. (2019a). The formation and therapeutic update of tumor-associated macrophages in cervical cancer. Intern. J. Mol. Sci. 20:3310. 10.3390/ijms20133310</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20133310</ArticleId><ArticleId IdType="pmc">PMC6651300</ArticleId><ArticleId IdType="pubmed">31284453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Zhang L., Yan Z., Xie L., An Y., Li H., et al. (2019b). OScc: an online survival analysis web server to evaluate the prognostic value of biomarkers in cervical cancer. J. Future Oncol. 15 3693&#x2013;3699. 10.2217/fon-2019-0412</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2019-0412</ArticleId><ArticleId IdType="pubmed">31512935</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D., Huang Y., Kang J., Li K., Bi X., Zhang T., et al. (2015). ncRDeathDB: a comprehensive bioinformatics resource for deciphering network organization of the ncRNA-mediated cell death system. J. Autophagy 11 1917&#x2013;1926. 10.1080/15548627.2015.1089375</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2015.1089375</ArticleId><ArticleId IdType="pmc">PMC4824571</ArticleId><ArticleId IdType="pubmed">26431463</ArticleId></ArticleIdList></Reference><Reference><Citation>Wui-Jin K., Nadeem R. A.-R., Sarah B., Kristin B., Susana M. C., Kathleen R. C., et al. (2019). Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 17:64 10.1097/01.cot.0000365310.49708.ac</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.cot.0000365310.49708.ac</ArticleId><ArticleId IdType="pubmed">30659131</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W., Xu Y., Wang J., Wan F., Wang H., Cao D., et al. (2019). Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. J. Aging 11 6999&#x2013;7020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6756904</ArticleId><ArticleId IdType="pubmed">31493764</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Wang B., Chen L., Luo H., Wu J. (2012). CXCL10 enhances radiotherapy effects in HeLa cells through cell cycle redistribution. J. Oncol. Lett. 3 383&#x2013;386. 10.3892/ol.2011.472</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2011.472</ArticleId><ArticleId IdType="pmc">PMC3362509</ArticleId><ArticleId IdType="pubmed">22740916</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao H., Wang H., Li C., Fang J.-Y., Xu J. (2018). Cancer cell-intrinsic PD-1 and implications in combinatorial immunotherapy. Front. Immunol. 9:1774. 10.3389/fimmu.2018.01774</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01774</ArticleId><ArticleId IdType="pmc">PMC6077319</ArticleId><ArticleId IdType="pubmed">30105035</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara K., Shahmoradgoli M., Mart&#xed;nez E., Vegesna R., Kim H., Torres-Garcia W., et al. (2013). Inferring tumour purity and stromal and immune cell admixture from expression data. J. Nat. Commun. 4:2612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826632</ArticleId><ArticleId IdType="pubmed">24113773</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Chen M., Cheng H., Shen Q., Wang Y., Zhu X. (2018). The role of gene on the biological behavior of squamous cervical cancer in vitro and in vivo. J. Cancer Manag. Res. 10 323&#x2013;338. 10.2147/cmar.s153036</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/cmar.s153036</ArticleId><ArticleId IdType="pmc">PMC5818869</ArticleId><ArticleId IdType="pubmed">29497331</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Lv Z., Yu H., Wang F., Zhu J. (2015). The HLA-DQB1 gene polymorphisms associated with cervical cancer risk: a meta-analysis. J. Biomed. Pharmacother. 73 58&#x2013;64. 10.1016/j.biopha.2015.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2015.06.002</ArticleId><ArticleId IdType="pubmed">26211583</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M., Ma Q., Xu J., Fu S., Chen L., Wang B., et al. (2015). Combining CXCL10 gene therapy and radiotherapy improved therapeutic efficacy in cervical cancer HeLa cell xenograft tumor models. J. Oncol. Lett. 10 768&#x2013;772. 10.3892/ol.2015.3281</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2015.3281</ArticleId><ArticleId IdType="pmc">PMC4508984</ArticleId><ArticleId IdType="pubmed">26622567</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C., Tuong Z. K., Frazer I. H. (2019). Papillomavirus immune evasion strategies target the infected cell and the local immune system. Front. Oncol. 9:682 10.3389/fimmu.2018.0682</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.0682</ArticleId><ArticleId IdType="pmc">PMC6688195</ArticleId><ArticleId IdType="pubmed">31428574</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H., Luo H., Shen Z., Hu X., Sun L., Zhu X. (2016). Transforming growth factor-&#x3b2;1 in carcinogenesis, progression, and therapy in cervical cancer. J. Tumour Biol. 37 7075&#x2013;7083. 10.1007/s13277-016-5028-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-016-5028-8</ArticleId><ArticleId IdType="pubmed">27010470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zighelboim I., Wright J., Gao F., Case A., Massad L., Mutch D., et al. (2013). Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. J. Gynecol. Oncol. 130 64&#x2013;68. 10.1016/j.ygyno.2013.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2013.04.009</ArticleId><ArticleId IdType="pmc">PMC3870479</ArticleId><ArticleId IdType="pubmed">23591400</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32718341</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2407</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC cancer</Title><ISOAbbreviation>BMC Cancer</ISOAbbreviation></Journal><ArticleTitle>Efficient mutation screening for cervical cancers from circulating tumor DNA in blood.</ArticleTitle><Pagination><StartPage>694</StartPage><MedlinePgn>694</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">694</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-020-07161-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Early diagnosis and continuous monitoring are necessary for an efficient management of cervical cancers (CC). Liquid biopsy, such as detecting circulating tumor DNA (ctDNA) from blood, is a simple, non-invasive method for testing and monitoring cancer markers. However, tumor-specific alterations in ctDNA have not been extensively investigated or compared to other circulating biomarkers in the diagnosis and monitoring of the CC. Therfore, Next-generation sequencing (NGS) analysis with blood samples can be a new approach for highly accurate diagnosis and monitoring of the CC.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Using a bioinformatics approach, we designed a panel of 24 genes associated with CC to detect and characterize patterns of somatic single-nucleotide variations, indels, and copy number variations. Our NGS CC panel covers most of the genes in The Cancer Genome Atlas (TCGA) as well as additional cancer driver and tumor suppressor genes. We profiled the variants in ctDNA from 24 CC patients who were being treated with systemic chemotherapy and local radiotherapy at the Jeonbuk National University Hospital, Korea.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">Eighteen out of 24 genes in our NGS CC panel had mutations across the 24 CC patients, including somatic alterations of mutated genes (ZFHX3-83%, KMT2C-79%, KMT2D-79%, NSD1-67%, ATM-38% and RNF213-27%). We demonstrated that the RNF213 mutation could be used potentially used as a monitoring marker for response to chemo- and radiotherapy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We developed our NGS CC panel and demostrated that our NGS panel can be useful for the diagnosis and monitoring of the CC, since the panel detected the common somatic variations in CC patients and we observed how these genetic variations change according to the treatment pattern of the patient.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sun-Young</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Jeonbuk National University Hospital-Jeonbuk National University Medical School, Jeonju, Jeonbuk, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chae</LastName><ForeName>Dong-Kyu</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Clinomics Inc, Suwon, 16229, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sung-Hun</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Clinomics Inc, Suwon, 16229, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Yohan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinomics Inc, Suwon, 16229, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Jahyun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinomics Inc, Suwon, 16229, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chae</LastName><ForeName>Chang Hoon</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Biophysics and Radiation Biology, Lab of Nanochemistry, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Byung Chul</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Clinomics Inc, Suwon, 16229, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhak</LastName><ForeName>Jong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinomics Inc, Suwon, 16229, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KOGIC, UNIST, Ulsan, 44919, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geromics LTD, Cambridge, CB1 1AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolser</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Geromics LTD, Cambridge, CB1 1AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Dong-Hyu</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0002-1557-9575</Identifier><AffiliationInfo><Affiliation>Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea. obgyn2001@jbnu.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Jeonbuk National University Hospital-Jeonbuk National University Medical School, Jeonju, Jeonbuk, Republic of Korea. obgyn2001@jbnu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2017M3A9F7074175</GrantID><Agency>Nation Research Foundation</Agency><Country/></Grant><Grant><GrantID>2017R1A2B4012353</GrantID><Agency>Nation Research Foundation</Agency><Country/></Grant><Grant><GrantID>KOITAR&amp;D150405</GrantID><Agency>Korea Industrial Technology Association</Agency><Country/></Grant><Grant><GrantID>1.180024.01</GrantID><Agency>Ul-san Research Fund of UNIST</Agency><Country/></Grant><Grant><GrantID>1.180017.01</GrantID><Agency>Ulsan Research Fund of UNIST</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cancer</MedlineTA><NlmUniqueID>100967800</NlmUniqueID><ISSNLinking>1471-2407</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074141">Circulating Tumor DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C452979">KMT2C protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120898">KMT2D protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C117307">KRAS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>143258-00-8</RegistryNumber><NameOfSubstance UI="C071660">ZFHX3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="C557998">RNF213 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.137</RegistryNumber><NameOfSubstance UI="D058534">Class I Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.137</RegistryNumber><NameOfSubstance UI="C484760">PIK3CA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000251" MajorTopicYN="N">Adenosine Triphosphatases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074141" MajorTopicYN="N">Circulating Tumor DNA</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058534" MajorTopicYN="N">Class I Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018398" MajorTopicYN="N">Homeodomain Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016283" MajorTopicYN="N">Proto-Oncogene Proteins p21(ras)</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer panel</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Circulating tumor DNA</Keyword><Keyword MajorTopicYN="N">Genomic alteration</Keyword><Keyword MajorTopicYN="N">Next-generation-sequencing</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32718341</ArticleId><ArticleId IdType="pmc">PMC7385901</ArticleId><ArticleId IdType="doi">10.1186/s12885-020-07161-0</ArticleId><ArticleId IdType="pii">10.1186/s12885-020-07161-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allemani C, et al. Global surveillance of cancer survival 1995&#x2013;2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2) Lancet (London, England) 2015;385:977&#x2013;1010. doi: 10.1016/S0140-6736(14)62038-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)62038-9</ArticleId><ArticleId IdType="pmc">PMC4588097</ArticleId><ArticleId IdType="pubmed">25467588</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogoda CS, Roden RB, Garcea RL. Immunizing against Anogenital Cancer: HPV vaccines. PLoS Pathog. 2016;12:e1005587. doi: 10.1371/journal.ppat.1005587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005587</ArticleId><ArticleId IdType="pmc">PMC4873021</ArticleId><ArticleId IdType="pubmed">27196109</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7:11&#x2013;22. doi: 10.1038/nrc2050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2050</ArticleId><ArticleId IdType="pubmed">17186016</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018;18:240&#x2013;254. doi: 10.1038/nrc.2018.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2018.13</ArticleId><ArticleId IdType="pmc">PMC6454884</ArticleId><ArticleId IdType="pubmed">29497146</ArticleId></ArticleIdList></Reference><Reference><Citation>Elit L, Fyles AW, Oliver TK, Devries-Aboud MC, Fung-Kee-Fung M. Follow-up for women after treatment for cervical cancer. Curr Oncol (Toronto, Ont) 2010;17:65&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880906</ArticleId><ArticleId IdType="pubmed">20567627</ArticleId></ArticleIdList></Reference><Reference><Citation>Volik S, Alcaide M, Morin RD, Collins C. Cell-free DNA (cfDNA): clinical significance and utility in Cancer shaped by emerging technologies. Mol Cancer Res. 2016;14:898&#x2013;908. doi: 10.1158/1541-7786.MCR-16-0044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1541-7786.MCR-16-0044</ArticleId><ArticleId IdType="pubmed">27422709</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvi S, et al. Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther. 2016;9:6549&#x2013;6559. doi: 10.2147/OTT.S100901.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S100901</ArticleId><ArticleId IdType="pmc">PMC5087772</ArticleId><ArticleId IdType="pubmed">27822059</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet, O Liquid cancer biopsy: the future of cancer detection? Lancet Oncol. 2016;17:123. doi: 10.1016/S1470-2045(16)00016-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(16)00016-4</ArticleId><ArticleId IdType="pubmed">26868335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Z, Stevanovic S, Hinrichs CS, Cao L. Circulating cell-free DNA for metastatic cervical Cancer detection, genotyping, and monitoring. Clin Cancer Res. 2017;23:6856&#x2013;6862. doi: 10.1158/1078-0432.CCR-17-1553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-17-1553</ArticleId><ArticleId IdType="pmc">PMC7885032</ArticleId><ArticleId IdType="pubmed">28899967</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung TH, et al. Liquid biopsy of HPV DNA in cervical cancer. J Clin Virol. 2019;114:32&#x2013;36. doi: 10.1016/j.jcv.2019.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2019.03.005</ArticleId><ArticleId IdType="pubmed">30913520</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, et al. Using plasma cell free DNA to monitor the chemo-radiotherapy course of cervical cancer. Int J Cancer. 2019;145:2547&#x2013;2557. doi: 10.1002/ijc.32295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.32295</ArticleId><ArticleId IdType="pubmed">30919951</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, et al. KoVariome: Korean National Standard Reference Variome database of whole genomes with comprehensive SNV, indel, CNV, and SV analyses. Sci Rep. 2018;8:5677. doi: 10.1038/s41598-018-23837-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-23837-x</ArticleId><ArticleId IdType="pmc">PMC5885007</ArticleId><ArticleId IdType="pubmed">29618732</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho YS, et al. An ethnically relevant consensus Korean reference genome is a step towards personal reference genomes. Nat Commun. 2016;7:13637. doi: 10.1038/ncomms13637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13637</ArticleId><ArticleId IdType="pmc">PMC5123046</ArticleId><ArticleId IdType="pubmed">27882922</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Genome Atlas Research, N et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378&#x2013;384. doi: 10.1038/nature21386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21386</ArticleId><ArticleId IdType="pmc">PMC5354998</ArticleId><ArticleId IdType="pubmed">28112728</ArticleId></ArticleIdList></Reference><Reference><Citation>Sappino AP, et al. The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damage. Oncogenesis. 2012;1:e7. doi: 10.1038/oncsis.2012.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/oncsis.2012.7</ArticleId><ArticleId IdType="pmc">PMC3412640</ArticleId><ArticleId IdType="pubmed">23552604</ArticleId></ArticleIdList></Reference><Reference><Citation>De La Rosa-Velazquez IA, Rincon-Arano H, Benitez-Bribiesca L, Recillas-Targa F. Epigenetic regulation of the human retinoblastoma tumor suppressor gene promoter by CTCF. Cancer Res. 2007;67:2577&#x2013;2585. doi: 10.1158/0008-5472.CAN-06-2024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-06-2024</ArticleId><ArticleId IdType="pubmed">17363576</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker CJ, et al. Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer. J Natl Cancer Inst. 2015;107:djv249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643635</ArticleId><ArticleId IdType="pubmed">26330387</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudbjartsson DF, et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet. 2009;41:876&#x2013;878. doi: 10.1038/ng.417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.417</ArticleId><ArticleId IdType="pmc">PMC2740741</ArticleId><ArticleId IdType="pubmed">19597491</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Q, et al. ZFHX3 is indispensable for ERbeta to inhibit cell proliferation via MYC downregulation in prostate cancer cells. Oncogenesis. 2019;8:28. doi: 10.1038/s41389-019-0138-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41389-019-0138-y</ArticleId><ArticleId IdType="pmc">PMC6461672</ArticleId><ArticleId IdType="pubmed">30979864</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawkins JB, et al. Reduced expression of histone Methyltransferases KMT2C and KMT2D correlates with improved outcome in pancreatic ductal adenocarcinoma. Cancer Res. 2016;76:4861&#x2013;4871. doi: 10.1158/0008-5472.CAN-16-0481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-16-0481</ArticleId><ArticleId IdType="pmc">PMC5321534</ArticleId><ArticleId IdType="pubmed">27280393</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabello DDA, et al. MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia. Cancer Cell Int. 2018;18:26. doi: 10.1186/s12935-018-0523-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-018-0523-1</ArticleId><ArticleId IdType="pmc">PMC5819641</ArticleId><ArticleId IdType="pubmed">29483845</ArticleId></ArticleIdList></Reference><Reference><Citation>Malan V, et al. Sotos syndrome caused by a paracentric inversion disrupting the NSD1 gene. Clin Genet. 2008;73:89&#x2013;91. doi: 10.1111/j.1399-0004.2007.00916.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0004.2007.00916.x</ArticleId><ArticleId IdType="pubmed">18042263</ArticleId></ArticleIdList></Reference><Reference><Citation>Su X, et al. NSD1 inactivation and SETD2 mutation drive a convergence toward loss of function of H3K36 writers in clear cell renal cell carcinomas. Cancer Res. 2017;77:4835&#x2013;4845. doi: 10.1158/0008-5472.CAN-17-0143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-17-0143</ArticleId><ArticleId IdType="pmc">PMC6211291</ArticleId><ArticleId IdType="pubmed">28754676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaikkonen MU, Spann NJ, Heinz S, et al. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol Cell. 2013;51:310&#x2013;325. doi: 10.1016/j.molcel.2013.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2013.07.010</ArticleId><ArticleId IdType="pmc">PMC3779836</ArticleId><ArticleId IdType="pubmed">23932714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, et al. Enhancer priming by H3K4 methyltransferase MLL4 controls cell fate transition. Proc Natl Acad Sci U S A. 2016;113:11871&#x2013;11876. doi: 10.1073/pnas.1606857113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1606857113</ArticleId><ArticleId IdType="pmc">PMC5081576</ArticleId><ArticleId IdType="pubmed">27698142</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorighi KM, et al. Mll3 and Mll4 facilitate enhancer RNA synthesis and transcription from promoters independently of H3K4 Monomethylation. Mol Cell. 2017;66:568&#x2013;576. doi: 10.1016/j.molcel.2017.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.04.018</ArticleId><ArticleId IdType="pmc">PMC5662137</ArticleId><ArticleId IdType="pubmed">28483418</ArticleId></ArticleIdList></Reference><Reference><Citation>Rickels R, et al. Histone H3K4 monomethylation catalyzed by Trr and mammalian COMPASS-like proteins at enhancers is dispensable for development and viability. Nat Genet. 2017;49:1647&#x2013;1653. doi: 10.1038/ng.3965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3965</ArticleId><ArticleId IdType="pmc">PMC5663216</ArticleId><ArticleId IdType="pubmed">28967912</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao YB, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet. 2014;46:1097&#x2013;1110. doi: 10.1038/ng.3076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3076</ArticleId><ArticleId IdType="pubmed">25151357</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotto GP, Rustgi AK. Squamous cell cancers: a unified perspective on biology and genetics. Cancer Cell. 2016;29:622&#x2013;637. doi: 10.1016/j.ccell.2016.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2016.04.004</ArticleId><ArticleId IdType="pmc">PMC4870309</ArticleId><ArticleId IdType="pubmed">27165741</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith ER, Scott RM. Spontaneous occlusion of the circle of Willis in children: pediatric moyamoya summary with proposed evidence-based practice guidelines. A review. J Neurosurg Pediatr. 2012;9:353&#x2013;360. doi: 10.3171/2011.12.PEDS1172.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2011.12.PEDS1172</ArticleId><ArticleId IdType="pubmed">22462697</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32456463</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-7430</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>DNA and cell biology</Title><ISOAbbreviation>DNA Cell Biol</ISOAbbreviation></Journal><ArticleTitle>A microRNA-Messenger RNA Regulatory Network and Its Prognostic Value in Cervical Cancer.</ArticleTitle><Pagination><StartPage>1328</StartPage><EndPage>1346</EndPage><MedlinePgn>1328-1346</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/dna.2020.5590</ELocationID><Abstract><AbstractText>Cervical cancer (CC) is the fourth commonest cancer in women worldwide. Increasing evidence proves that microRNA (miRNA)-messenger RNA (mRNA) network is involved in CC. In this study, miRNA and mRNA expression profiles were downloaded from The Cancer Genome Atlas (TCGA) database. Differently expressed miRNAs (DE-miRNAs) and mRNAs (DE-mRNAs) were obtained by "Empirical Analysis of Digital Gene Expression Data in R (EdgeR)" package. Then, functional analyses were conducted. With Cytoscape software, a protein-protein interaction (PPI) network was established to identify hub genes that were used for building an miRNA-hub gene network. Next, a prognostic signature based on hub genes was constructed by Cox regression analysis, and its prognostic value was assessed by a nomogram. Finally, the relationship between immune cell infiltration and the three genes in the prognostic model was investigated by using the CIBERSORT algorithm. We screened out 5096 DE-mRNAs and 114 DE-miRNAs between healthy cervical and CC tissues. Then, 102 target DE-mRNAs of upregulated DE-miRNAs and 150 target DE-mRNAs of downregulated DE-miRNAs were obtained. PPI network demonstrated 20 hub nodes with higher connectivity. DE-mRNAs were mostly enriched in pathways in cancer, cell cycle, and proteoglycans in cancer. The miRNA-hub gene network showed that most hub genes could be potentially modulated by miR-200c-3p, miR-23b-3p, and miR-106b-5p. Quantitative real-time PCR proved that 10 miRNAs were downregulated and 6 mRNAs were upregulated markedly in CC tissues. Furthermore, a prognostic signature was established based on enhancer of zeste homolog 2 (<i>EZH2</i>), Fms-related tyrosine kinase 1 (<i>FLT1</i>), and glyceraldehyde 3-phosphate dehydrogenase (<i>GAPDH</i>). The area under the curve value of the 5-year receiver operating characteristic curve was 0.609. The three genes were also found to be related to the infiltration of six types of immune cells, including dendritic cells, macrophages M0 and M1, mast cells, and monocytes. In conclusion, the development of CC is regulated by the miRNA-mRNA network we proposed in this study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jinhui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Siyue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Sipei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Huangyang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Yicong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Wenjun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>DNA Cell Biol</MedlineTA><NlmUniqueID>9004522</NlmUniqueID><ISSNLinking>1044-5498</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="Y">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063990" MajorTopicYN="N">Gene Ontology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025941" MajorTopicYN="N">Protein Interaction Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TCGA</Keyword><Keyword MajorTopicYN="N">bioinformatic analysis</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">miRNAs</Keyword><Keyword MajorTopicYN="N">prognostic value</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32456463</ArticleId><ArticleId IdType="doi">10.1089/dna.2020.5590</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32368784</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1573-4935</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>Bioscience reports</Title><ISOAbbreviation>Biosci Rep</ISOAbbreviation></Journal><ArticleTitle>Identification of crucial aberrantly methylated and differentially expressed genes related to cervical cancer using an integrated bioinformatics analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">BSR20194365</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1042/BSR20194365</ELocationID><Abstract><AbstractText>Methylation functions in the pathogenesis of cervical cancer. In the present study, we applied an integrated bioinformatics analysis to identify the aberrantly methylated and differentially expressed genes (DEGS), and their related pathways in cervical cancer. Data of gene expression microarrays (GSE9750) and gene methylation microarrays (GSE46306) were gained from Gene Expression Omnibus (GEO) databases. Hub genes were identified by 'limma' packages and Venn diagram tool. Functional analysis was conducted by FunRich. Search Tool for the Retrieval of Interacting Genes Database (STRING) was used to analyze protein-protein interaction (PPI) information. Gene Expression Profiling Interactive Analysis (GEPIA), immunohistochemistry staining, and ROC curve analysis were conducted for validation. Gene Set Enrichment Analysis (GSEA) was also performed to identify potential functions.We retrieved two upregulated-hypomethylated oncogenes and eight downregulated-hypermethylated tumor suppressor genes (TSGs) for functional analysis. Hypomethylated and highly expressed genes (Hypo-HGs) were significantly enriched in cell cycle and autophagy, and hypermethylated and lowly expressed genes (Hyper-LGs) in estrogen receptor pathway and Wnt/&#x3b2;-catenin signaling pathway. Estrogen receptor 1 (ESR1), Erythrocyte membrane protein band 4.1 like 3 (EPB41L3), Endothelin receptor B (EDNRB), Inhibitor of DNA binding 4 (ID4) and placenta-specific 8 (PLAC8) were hub genes. Kaplan-Meier method was used to evaluate survival data of each identified gene. Lower expression levels of ESR1 and EPB41L3 were correlated with a shorter survival time. GSEA results showed that 'cell adhesion molecules' was the most enriched item. This research inferred the candidate genes and pathways that might be used in the diagnosis, treatment, and prognosis of cervical cancer.</AbstractText><CopyrightInformation>&#xa9; 2020 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Reproductive Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jinhui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Reproductive Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Yicong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Yankai</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Reproductive Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Wenjun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biosci Rep</MedlineTA><NlmUniqueID>8102797</NlmUniqueID><ISSNLinking>0144-8463</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000588596">EDNRB protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C116887">EPB41L3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506487">ESR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047628">Estrogen Receptor alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490128">ID4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051796">Inhibitor of Differentiation Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011257">Pregnancy Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044023">Receptor, Endothelin B</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="Y">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="Y">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047628" MajorTopicYN="N">Estrogen Receptor alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051796" MajorTopicYN="N">Inhibitor of Differentiation Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008840" MajorTopicYN="N">Microfilament Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011257" MajorTopicYN="N">Pregnancy Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044023" MajorTopicYN="N">Receptor, Endothelin B</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioinformatics analysis</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Differentially expressed genes</Keyword><Keyword MajorTopicYN="N">Gene Expression Omnibus (GEO)</Keyword><Keyword MajorTopicYN="N">Methylation</Keyword></KeywordList><CoiStatement>The authors declare that there are no competing interests associated with the manuscript. The datasets used or analyzed during the current study are available from the GEO (https://www.ncbi.nlm.nih.gov) and Cancer Genome Atlas database (https://cancergenome.nih.gov).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32368784</ArticleId><ArticleId IdType="pmc">PMC7218222</ArticleId><ArticleId IdType="doi">10.1042/BSR20194365</ArticleId><ArticleId IdType="pii">223801</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bae D.S., Cho S.B., Kim Y.J., Whang J.D., Song S.Y., Park C.S. et al. . (2001) Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus. Gynecol. Oncol. 81, 341&#x2013;347 10.1006/gyno.2001.6196</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/gyno.2001.6196</ArticleId><ArticleId IdType="pubmed">11371120</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldin V., Lukas J., Marcote M.J., Pagano M. and Draetta G. (1993) Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7, 812&#x2013;821</Citation><ArticleIdList><ArticleId IdType="pubmed">8491378</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird A. (2002) DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pubmed">11782440</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A. and Jemal A. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394&#x2013;424</Citation><ArticleIdList><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro M., Grau L., Puerta P., Gimenez L., Venditti J., Quadrelli S. et al. . (2010) Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J. Transl. Med. 8, 86 10.1186/1479-5876-8-86</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-8-86</ArticleId><ArticleId IdType="pmc">PMC2955578</ArticleId><ArticleId IdType="pubmed">20849603</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A.S., Tsui W.Y., Chen X., Chu K.M., Chan T.L., Chan A.S. et al. . (2003) Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma. Oncogene 22, 6946&#x2013;6953 10.1038/sj.onc.1206799</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1206799</ArticleId><ArticleId IdType="pubmed">14534543</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H. and Boutros P.C. (2011) VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinformatics 12, 35 10.1186/1471-2105-12-35</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-35</ArticleId><ArticleId IdType="pmc">PMC3041657</ArticleId><ArticleId IdType="pubmed">21269502</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung S.H., Franceschi S. and Lambert P.F. (2010) Estrogen and ERalpha: culprits in cervical cancer? Trends Endocrinol. Metab. 21, 504&#x2013;511 10.1016/j.tem.2010.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2010.03.005</ArticleId><ArticleId IdType="pmc">PMC2914219</ArticleId><ArticleId IdType="pubmed">20456973</ArticleId></ArticleIdList></Reference><Reference><Citation>de Mendez M.T. and Bosch A.L. (2011) Abnormal immunoexpression of cell adhesion molecules (CAMs) in cervical cancer. Int. J. Surg. Pathol. 19, 733&#x2013;742 10.1177/1066896909343435</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1066896909343435</ArticleId><ArticleId IdType="pubmed">20643667</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang J., Zhang H. and Jin S. (2014) Epigenetics and cervical cancer: from pathogenesis to therapy. Tumour Biol. 35, 5083&#x2013;5093 10.1007/s13277-014-1737-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-014-1737-z</ArticleId><ArticleId IdType="pubmed">24554414</ArticleId></ArticleIdList></Reference><Reference><Citation>Galaviz-Hernandez C., Stagg C., de Ridder G., Tanaka T.S., Ko M.S., Schlessinger D. et al. . (2003) Plac8 and Plac9, novel placental-enriched genes identified through microarray analysis. Gene 309, 81&#x2013;89 10.1016/S0378-1119(03)00508-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-1119(03)00508-0</ArticleId><ArticleId IdType="pubmed">12758124</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier L., Cope L., Bolstad B.M. and Irizarry R.A. (2004) affy&#x2013;analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307&#x2013;315 10.1093/bioinformatics/btg405</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btg405</ArticleId><ArticleId IdType="pubmed">14960456</ArticleId></ArticleIdList></Reference><Reference><Citation>Haga T., Uchide N., Tugizov S. and Palefsky J.M. (2008) Role of E-cadherin in the induction of apoptosis of HPV16-positive CaSki cervical cancer cells during multicellular tumor spheroid formation. Apoptosis 13, 97&#x2013;108 10.1007/s10495-007-0132-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-007-0132-2</ArticleId><ArticleId IdType="pubmed">17906929</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirohashi S. (1998) Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am. J. Pathol. 153, 333&#x2013;339 10.1016/S0002-9440(10)65575-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65575-7</ArticleId><ArticleId IdType="pmc">PMC1852964</ArticleId><ArticleId IdType="pubmed">9708792</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M.L., Zou Y., Yang R., Jiang Y., Sheng J.F., Han J.B. et al. . (2019) Placenta specific 8 gene induces epithelial-mesenchymal transition of nasopharyngeal carcinoma cells via the TGF-beta/Smad pathway. Exp. Cell Res. 374, 172&#x2013;180 10.1016/j.yexcr.2018.11.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2018.11.021</ArticleId><ArticleId IdType="pubmed">30496758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov D.B., Philippova M.P. and Tkachuk V.A. (2001) Structure and functions of classical cadherins. Biochem. Biokhim. 66, 1174&#x2013;1186 10.1023/A:1012445316415</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1012445316415</ArticleId><ArticleId IdType="pubmed">11736639</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonska E. and Reszka E. (2017) Selenium and epigenetics in cancer: focus on DNA methylation. Adv. Cancer. Res. 136, 193&#x2013;234 10.1016/bs.acr.2017.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.acr.2017.07.002</ArticleId><ArticleId IdType="pubmed">29054419</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S. and White E. (2007) Role of autophagy in cancer: management of metabolic stress. Autophagy 3, 28&#x2013;31 10.4161/auto.3269</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.3269</ArticleId><ArticleId IdType="pmc">PMC2770734</ArticleId><ArticleId IdType="pubmed">16969128</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimmelman A.C. and White E. (2017) Autophagy and tumor metabolism. Cell Metab. 25, 1037&#x2013;1043 10.1016/j.cmet.2017.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2017.04.004</ArticleId><ArticleId IdType="pmc">PMC5604466</ArticleId><ArticleId IdType="pubmed">28467923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulasingam V. and Diamandis E.P. (2008) Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 5, 588&#x2013;599 10.1038/ncponc1187</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncponc1187</ArticleId><ArticleId IdType="pubmed">18695711</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Zhang Y., Zhang H., Liu X., Gong T., Li M. et al. . (2011) miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol. Cancer Res. 9, 824&#x2013;833 10.1158/1541-7786.MCR-10-0529</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1541-7786.MCR-10-0529</ArticleId><ArticleId IdType="pubmed">21628394</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang H., Yan X., Pan Y., Wang Y., Wang N., Li L. et al. . (2015) MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3. Mol. Cancer 14, 58 10.1186/s12943-015-0327-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-015-0327-z</ArticleId><ArticleId IdType="pmc">PMC4360939</ArticleId><ArticleId IdType="pubmed">25881295</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasif D., Campoy E., Laurito S., Branham R., Urrutia G., Roque M. et al. . (2018) Epigenetic regulation of ID4 in breast cancer: tumor suppressor or oncogene? Clin. Epigenetics 10, 111 10.1186/s13148-018-0542-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13148-018-0542-8</ArticleId><ArticleId IdType="pmc">PMC6108146</ArticleId><ArticleId IdType="pubmed">30139383</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson J.B., Lee W.H., Nguyen S.H., Jarrard D.F., Brooks J.D., Magnuson S.R. et al. . (1997) Methylation of the 5&#x2032; CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res. 57, 35&#x2013;37</Citation><ArticleIdList><ArticleId IdType="pubmed">8988036</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel D., Morton D.J., Carey J., Havrda M.C. and Chaudhary J. (2015) Inhibitor of differentiation 4 (ID4): from development to cancer. Biochim. Biophys. Acta 1855, 92&#x2013;103</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4312723</ArticleId><ArticleId IdType="pubmed">25512197</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathan M., Keerthikumar S., Ang C.S., Gangoda L., Quek C.Y., Williamson N.A. et al. . (2015) FunRich: an open access standalone functional enrichment and interaction network analysis tool. Proteomics 15, 2597&#x2013;2601 10.1002/pmic.201400515</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201400515</ArticleId><ArticleId IdType="pubmed">25921073</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard K.I. (2013) Endocrine therapy: is the first generation of targeted drugs the last? J. Intern. Med. 274, 144&#x2013;152 10.1111/joim.12065</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12065</ArticleId><ArticleId IdType="pubmed">23844917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran B. (2017) Functional association of oestrogen receptors with HPV infection in cervical carcinogenesis. Endocr. Relat. Cancer 24, R99&#x2013;R108 10.1530/ERC-16-0571</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ERC-16-0571</ArticleId><ArticleId IdType="pubmed">28283546</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie M.E., Phipson B., Wu D., Hu Y., Law C.W., Shi W. et al. . (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 10.1093/nar/gkv007</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogeri C.D., Silveira H.C.S., Causin R.L., Villa L.L., Stein M.D., de Carvalho A.C. et al. . (2018) Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor lesions in cervical cancer. Gynecol. Oncol. 150, 545&#x2013;551 10.1016/j.ygyno.2018.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2018.06.014</ArticleId><ArticleId IdType="pubmed">29960712</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer K.A. (1998) The cell cycle: a review. Vet. Pathol. 35, 461&#x2013;478 10.1177/030098589803500601</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/030098589803500601</ArticleId><ArticleId IdType="pubmed">9823588</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L., Xiao L., Heng B., Mo S., Chen W. and Su Z. (2017) Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma. Int. Urol. Nephrol. 49, 1165&#x2013;1176 10.1007/s11255-017-1578-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11255-017-1578-y</ArticleId><ArticleId IdType="pubmed">28349447</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Kuehn H., Gould J., Tamayo P. and Mesirov J.P. (2007) GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 23, 3251&#x2013;3253 10.1093/bioinformatics/btm369</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btm369</ArticleId><ArticleId IdType="pubmed">17644558</ArticleId></ArticleIdList></Reference><Reference><Citation>Swetzig W.M., Wang J. and Das G.M. (2016) Estrogen receptor alpha (ERalpha/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer. Oncotarget 7, 16049&#x2013;16069 10.18632/oncotarget.7533</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.7533</ArticleId><ArticleId IdType="pmc">PMC4941297</ArticleId><ArticleId IdType="pubmed">26909605</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Franceschini A., Wyder S., Forslund K., Heller D., Huerta-Cepas J. et al. . (2015) STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447&#x2013;D452 10.1093/nar/gku1003</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku1003</ArticleId><ArticleId IdType="pmc">PMC4383874</ArticleId><ArticleId IdType="pubmed">25352553</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z., Li C., Kang B., Gao G., Li C. and Zhang Z. (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98&#x2013;W102 10.1093/nar/gkx247</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx247</ArticleId><ArticleId IdType="pmc">PMC5570223</ArticleId><ArticleId IdType="pubmed">28407145</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao K., Wu C., Wu K., Li W., Han G., Shuai X. et al. . (2012) Quantitative analysis of promoter methylation of the EDNRB gene in gastric cancer. Med. Oncol. 29, 107&#x2013;112 10.1007/s12032-010-9805-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12032-010-9805-8</ArticleId><ArticleId IdType="pubmed">21264540</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Morris T.J., Webster A.P., Yang Z., Beck S., Feber A. et al. . (2017) ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics 33, 3982&#x2013;3984 10.1093/bioinformatics/btx513</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btx513</ArticleId><ArticleId IdType="pmc">PMC5860089</ArticleId><ArticleId IdType="pubmed">28961746</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Putte G., Kristensen G.B., Baekelandt M., Lie A.K. and Holm R. (2004) E-cadherin and catenins in early squamous cervical carcinoma. Gynecol. Oncol. 94, 521&#x2013;527 10.1016/j.ygyno.2004.05.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2004.05.046</ArticleId><ArticleId IdType="pubmed">15297198</ArticleId></ArticleIdList></Reference><Reference><Citation>van Leeuwen R.W., Ostrbenk A., Poljak M., van der Zee A.G.J., Schuuring E. and Wisman G.B.A. (2019) DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort. Int. J. Cancer 144, 746&#x2013;754 10.1002/ijc.31897</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.31897</ArticleId><ArticleId IdType="pmc">PMC6587981</ArticleId><ArticleId IdType="pubmed">30259973</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasiljevic N., Scibior-Bentkowska D., Brentnall A.R., Cuzick J. and Lorincz A.T. (2014) Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecol. Oncol. 132, 709&#x2013;714 10.1016/j.ygyno.2014.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2014.02.001</ArticleId><ArticleId IdType="pmc">PMC3989115</ArticleId><ArticleId IdType="pubmed">24508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V. et al. . (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12&#x2013;19 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">10451482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.H., Li Y.H., Tian H.L., Bao X.X. and Wang Z.M. (2018) Long non-coding RNA BLACAT1 promotes cell proliferation, migration and invasion in cervical cancer through activation of Wnt/beta-catenin signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 22, 3002&#x2013;3009</Citation><ArticleIdList><ArticleId IdType="pubmed">29863244</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X.B., Cui N.H., Liu X.N., Ma J.F., Zhu Q.H., Guo S.R. et al. . (2018) Identification of DAPK1 promoter hypermethylation as a biomarker for intra-epithelial lesion and cervical cancer: a meta-analysis of published studies, TCGA, and GEO Datasets. Front. Genet. 9, 258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6056635</ArticleId><ArticleId IdType="pubmed">30065752</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiman K.G. and Zhivotovsky B. (2017) Understanding cell cycle and cell death regulation provides novel weapons against human diseases. J. Intern. Med. 281, 483&#x2013;495 10.1111/joim.12609</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12609</ArticleId><ArticleId IdType="pubmed">28374555</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao S. and Liu T. (2018) Analysis of differential gene expression caused by cervical intraepithelial neoplasia based on GEO database. Oncol. Lett. 15, 8319&#x2013;8324</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5950031</ArticleId><ArticleId IdType="pubmed">29805564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng R., Liu Y., Jiang Z.J., Huang J.P., Wang Y., Li X.F. et al. . (2018) EPB41L3 is a potential tumor suppressor gene and prognostic indicator in esophageal squamous cell carcinoma. Int. J. Oncol. 52, 1443&#x2013;1454</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873871</ArticleId><ArticleId IdType="pubmed">29568917</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Huang Y., Cao X., Xu J., Zhang L., Wang J. et al. . (2016) WNT2 promotes cervical carcinoma metastasis and induction of epithelial-mesenchymal transition. PLoS ONE 11, e0160414 10.1371/journal.pone.0160414</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0160414</ArticleId><ArticleId IdType="pmc">PMC4981407</ArticleId><ArticleId IdType="pubmed">27513465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L., Yang N., Chen J., Zeng T., Yan S., Liu Y. et al. . (2017) LINC00052 upregulates EPB41L3 to inhibit migration and invasion of hepatocellular carcinoma by binding miR-452-5p. Oncotarget 8, 63724&#x2013;63737</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5609956</ArticleId><ArticleId IdType="pubmed">28969024</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32307200</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-0631</ISSN><JournalIssue CitedMedium="Internet"><Volume>216</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Pathology, research and practice</Title><ISOAbbreviation>Pathol Res Pract</ISOAbbreviation></Journal><ArticleTitle>Integrated analysis of key microRNAs /TFs /mRNAs/ in HPV-positive cervical cancer based on microRNA sequencing and bioinformatics analysis.</ArticleTitle><Pagination><StartPage>152952</StartPage><MedlinePgn>152952</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.prp.2020.152952</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0344-0338(19)32928-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cervical squamous cell carcinoma (CESC) is one of the most common malignancies associated with mortality in females. Its onset and prognosis are primarily concerned with persistent infection with high-risk types of human papillomavirus (HPV). However, the molecular mechanisms of HPV-positive CESC remain unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this study, we conducted a high-throughput sequencing to identify differentially expressed miRNAs (DEMs). Besides, three series were selected from the Gene Expression Omnibus (GEO) database to identify differentially expressed genes (DEGs). Then the miRNA-TF-gene regulatory network was constructed using bioinformatic methods. Genes in the network were performed functional enrichment analysis and protein-protein interaction (PPI) network analysis. Ultimately, the expression levels of six key miRNAs, TFs, and mRNAs were validated by 20 HPV-positive CESC tissues and 15 normal cervical samples.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 52 DEMs and 300 DEGs differed between the HPV-positive CESC and normal cervical samples. Then the miRNA-TF-gene regulatory network was constructed consisting of 22 miRNAs, 6 TFs, and 76 corresponding genes, among which miR-149-5p, miRNA-1248 and E2F4 acted as key regulators. PPI network analysis showed that ten genes including TOP2A, AURKA, CHEK1, KIF11, MCM4, MKI67, DTL, FOXM1, SMC4, and FBXO5 were recognized as hub genes with the highest connectivity degrees. Besides, five key molecules miRNA-149-5p, E2F4, KIF11, DTL, and SMC4 were suggested to play crucial roles in the development of HPV-positive CESC.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results present a unique insight into the pathological mechanisms of HPV-positive CESC and possibly provides potential therapeutic targets.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier GmbH. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Yingying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Key Laboratory of Laboratory Medicine of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Xiaoqing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Key Laboratory of Laboratory Medicine of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Bingjie</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Fuwai Central China Cardiovascular Hospital, Zhengzhou 451450, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Mengle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, The Third People's Hospital of Henan Province, Zhengzhou 450050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, People's Hospital of Zhecheng County, Shangqiu 476200, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Guanting</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Blood Transfusion, The Second Affiliated Hospital of Air Force Military Medical University of Chinese PLA, Xian 710032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Key Laboratory of Laboratory Medicine of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Huifang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Blood Transfusion, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Liuxia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gynaecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Electronic address: llxia698@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Dongchun</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Key Laboratory of Laboratory Medicine of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Electronic address: qindongchun@zzu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Pathol Res Pract</MedlineTA><NlmUniqueID>7806109</NlmUniqueID><ISSNLinking>0344-0338</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="N">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioinformatics analysis</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Human papillomavirus</Keyword><Keyword MajorTopicYN="N">Sequencing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32307200</ArticleId><ArticleId IdType="doi">10.1016/j.prp.2020.152952</ArticleId><ArticleId IdType="pii">S0344-0338(19)32928-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32256087</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1178-6930</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>OncoTargets and therapy</Title><ISOAbbreviation>Onco Targets Ther</ISOAbbreviation></Journal><ArticleTitle>miR-145-5p Regulates the Proliferation, Migration and Invasion in Cervical Carcinoma by Targeting KLF5.</ArticleTitle><Pagination><StartPage>2369</StartPage><EndPage>2376</EndPage><MedlinePgn>2369-2376</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/OTT.S241366</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Cervical carcinoma (CC) is a serious threat to women's health and few effective therapeutic methods have been discovered. The purpose of this study is to explore the underlying mechanism of miR-145-5p in CC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Bioinformatics methods were employed to analyze the gene expression data of CC from TCGA database. qRT-PCR was used to detect the expression of miR-145-5p and KLF5 in CC cells, and Western blot was employed for the examination of KLF5 protein level. The targeted relationship between miR-145-5p and KLF5 was verified by a dual-luciferase reporter assay. Moreover, CCK-8, wound healing assay and transwell invasion assay were used to analyze the effects of miR-145-5p overexpression or KLF5 silencing on the proliferation, migration and invasion of CC cells.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">miR-145-5p was shown to be down-regulated in CC tissues and cells, while KLF5 was up-regulated. miR-145-5p could bind to the complementary sequence within the wild type KLF5 3'UTR rather than the mutant one. In addition, miR-145-5p could effectively down-regulate KLF5, in turn inhibiting the proliferation, migration and invasion of CC cells.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">miR-145-5p regulates the proliferation, migration and invasion of CC cells by targeting KLF5.</AbstractText><CopyrightInformation>&#xa9; 2020 Cao et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oncology, Chenzhou First People's Hospital, Chenzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Guihua</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Oncology, Chenzhou First People's Hospital, Chenzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Shiqiang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncology, Chenzhou First People's Hospital, Chenzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Ni</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Oncology, Chenzhou First People's Hospital, Chenzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Huake</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oncology, Chenzhou First People's Hospital, Chenzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Haizhi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oncology, Chenzhou First People's Hospital, Chenzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Oncology, Chenzhou First People's Hospital, Chenzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Yongbin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Oncology, Chenzhou First People's Hospital, Chenzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Onco Targets Ther</MedlineTA><NlmUniqueID>101514322</NlmUniqueID><ISSNLinking>1178-6930</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">KLF5</Keyword><Keyword MajorTopicYN="N">cervical carcinoma</Keyword><Keyword MajorTopicYN="N">invasion</Keyword><Keyword MajorTopicYN="N">miR-145-5p</Keyword><Keyword MajorTopicYN="N">migration</Keyword><Keyword MajorTopicYN="N">proliferation</Keyword></KeywordList><CoiStatement>The authors report no conflict of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32256087</ArticleId><ArticleId IdType="pmc">PMC7094153</ArticleId><ArticleId IdType="doi">10.2147/OTT.S241366</ArticleId><ArticleId IdType="pii">241366</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dizon DS, Mackay HJ, Thomas GM, et al. State of the science in cervical cancer: where we are today and where we need to go. Cancer. 2014;120(15):2282&#x2013;2288. doi:10.1002/cncr.28722</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.28722</ArticleId><ArticleId IdType="pubmed">24737608</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore DH. Cervical cancer. Obstet Gynecol. 2006;107(5):1152&#x2013;1161. doi:10.1097/01.AOG.0000215986.48590.79</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.AOG.0000215986.48590.79</ArticleId><ArticleId IdType="pubmed">16648423</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervical cancer analysis reveals new mutations. Cancer Discov. 2017;7(4):344.</Citation><ArticleIdList><ArticleId IdType="pubmed">28179363</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12&#x2013;F23. doi:10.1016/j.vaccine.2012.07.055</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.07.055</ArticleId><ArticleId IdType="pubmed">23199955</ArticleId></ArticleIdList></Reference><Reference><Citation>Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1&#x2013;17. doi:10.1128/CMR.16.1.1-17.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.16.1.1-17.2003</ArticleId><ArticleId IdType="pmc">PMC145302</ArticleId><ArticleId IdType="pubmed">12525422</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890&#x2013;907. doi:10.1016/S0140-6736(07)61416-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61416-0</ArticleId><ArticleId IdType="pubmed">17826171</ArticleId></ArticleIdList></Reference><Reference><Citation>Snijders PJ, Steenbergen RD, Heideman DA, et al. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol. 2006;208(2):152&#x2013;164. doi:10.1002/(ISSN)1096-9896</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(ISSN)1096-9896</ArticleId><ArticleId IdType="pubmed">16362994</ArticleId></ArticleIdList></Reference><Reference><Citation>Berindan-Neagoe I, Monroig PDC, Pasculli B, et al. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014;64(5):311&#x2013;336. doi:10.3322/caac.21244</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21244</ArticleId><ArticleId IdType="pmc">PMC4461198</ArticleId><ArticleId IdType="pubmed">25104502</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9(1):287&#x2013;314. doi:10.1146/annurev-pathol-012513-104715</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathol-012513-104715</ArticleId><ArticleId IdType="pmc">PMC4009396</ArticleId><ArticleId IdType="pubmed">24079833</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203&#x2013;222. doi:10.1038/nrd.2016.246</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2016.246</ArticleId><ArticleId IdType="pubmed">28209991</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Miao J, Zhang M, et al. miRNA-103a-3p promotes human gastric cancer cell proliferation by targeting and suppressing ATF7 in vitro. Mol Cells. 2018;41(5):390&#x2013;400. doi:10.14348/molcells.2018.2078</Citation><ArticleIdList><ArticleId IdType="doi">10.14348/molcells.2018.2078</ArticleId><ArticleId IdType="pmc">PMC5974616</ArticleId><ArticleId IdType="pubmed">29754469</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Bian T, Feng J, et al. miR-335 inhibited cell proliferation of lung cancer cells by target Tra2&#x3b2;. Cancer Sci. 2018;109(2):289&#x2013;296. doi:10.1111/cas.13452</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13452</ArticleId><ArticleId IdType="pmc">PMC5797811</ArticleId><ArticleId IdType="pubmed">29161765</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Zhao Y, Li F, et al. MiR-144-3p: a novel tumor suppressor targeting MAPK6 in cervical cancer. J Physiol Biochem. 2019;75(2):143&#x2013;152. doi:10.1007/s13105-019-00681-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13105-019-00681-9</ArticleId><ArticleId IdType="pubmed">31016619</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Chu Z-P, Han H, et al. Suppression of miR-93-5p inhibits high-risk HPV-positive cervical cancer progression via targeting of BTG3. Hum Cell. 2019;32(2):160&#x2013;171. doi:10.1007/s13577-018-00225-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13577-018-00225-1</ArticleId><ArticleId IdType="pubmed">30689165</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W, Zhang X, Tan W, et al. miR-145-5p suppresses breast cancer progression by inhibiting SOX2. J Surg Res. 2019;236:278&#x2013;287. doi:10.1016/j.jss.2018.11.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2018.11.030</ArticleId><ArticleId IdType="pubmed">30694767</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Zhao W, Chen Z, et al. Circular RNA CEP128 promotes bladder cancer progression by regulating Mir-145-5p/Myd88 via MAPK signaling pathway. Int J Cancer. 2019;145(8):2170&#x2013;2181. doi:10.1002/ijc.v145.8</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.v145.8</ArticleId><ArticleId IdType="pubmed">30939216</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei H, Wen-Ming C, Jun-Bo J. Plasma miR-145 as a novel biomarker for the diagnosis and radiosensitivity prediction of human cervical cancer. J Int Med Res. 2017;45(3):1054&#x2013;1060. doi:10.1177/0300060517709614</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060517709614</ArticleId><ArticleId IdType="pmc">PMC5536414</ArticleId><ArticleId IdType="pubmed">28534701</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathyanarayanan A, Chandrasekaran KS, Karunagaran D. microRNA-145 modulates epithelial-mesenchymal transition and suppresses proliferation, migration and invasion by targeting SIP1 in human cervical cancer cells. Cell Oncol (Dordr). 2017;40(2):119&#x2013;131. doi:10.1007/s13402-016-0307-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13402-016-0307-3</ArticleId><ArticleId IdType="pubmed">27933466</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Lin J-X, Yu Y-H, et al. Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One. 2012;7(3):e33762. doi:10.1371/journal.pone.0033762</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0033762</ArticleId><ArticleId IdType="pmc">PMC3306296</ArticleId><ArticleId IdType="pubmed">22438992</ArticleId></ArticleIdList></Reference><Reference><Citation>Li MY, Hu XX. Meta-analysis of microRNA expression profiling studies in human cervical cancer. Med Oncol. 2015;32(6):510. doi:10.1007/s12032-015-0510-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12032-015-0510-5</ArticleId><ArticleId IdType="pubmed">25920605</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaleb AM, NANDAN MO, CHANCHEVALAP S, et al. Kr&#xfc;ppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation. Cell Res. 2005;15(2):92&#x2013;96. doi:10.1038/sj.cr.7290271</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cr.7290271</ArticleId><ArticleId IdType="pmc">PMC1317089</ArticleId><ArticleId IdType="pubmed">15740636</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M, Du L, Liu D, et al. Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol. 2012;228(2):148&#x2013;157. doi:10.1002/path.v228.2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.v228.2</ArticleId><ArticleId IdType="pubmed">22287315</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Ding Y, Chen H, et al. Targeting Kr&#xfc;ppel-like factor 5 (KLF5) for cancer therapy. Curr Top Med Chem. 2015;15(8):699&#x2013;713. doi:10.2174/1568026615666150302105052</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026615666150302105052</ArticleId><ArticleId IdType="pubmed">25732792</ArticleId></ArticleIdList></Reference><Reference><Citation>Shindo T, Manabe I, Fukushima Y, et al. Kr&#xfc;ppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med. 2002;8(8):856&#x2013;863. doi:10.1038/nm738</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm738</ArticleId><ArticleId IdType="pubmed">12101409</ArticleId></ArticleIdList></Reference><Reference><Citation>Joura EA, Giuliano AR, Iversen O-E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711&#x2013;723. doi:10.1056/NEJMoa1405044</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1405044</ArticleId><ArticleId IdType="pubmed">25693011</ArticleId></ArticleIdList></Reference><Reference><Citation>Boufraqech M, Zhang L, Jain M, et al. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer. 2014;21(4):517&#x2013;531. doi:10.1530/ERC-14-0077</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ERC-14-0077</ArticleId><ArticleId IdType="pmc">PMC8375571</ArticleId><ArticleId IdType="pubmed">24781864</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei C, Du F, Sun L, et al. miR-143 and miR-145 inhibit gastric cancer cell migration and metastasis by suppressing MYO6. Cell Death Dis. 2017;8(10):e3101. doi:10.1038/cddis.2017.493</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2017.493</ArticleId><ArticleId IdType="pmc">PMC5682659</ArticleId><ArticleId IdType="pubmed">29022908</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye C, Sun N-X, Ma Y, et al. MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells. FEBS Lett. 2015;589(6):702&#x2013;709. doi:10.1016/j.febslet.2015.01.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2015.01.037</ArticleId><ArticleId IdType="pubmed">25666710</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Li LL. miR-145 contributes to the progression of cervical carcinoma by directly regulating FSCN1. Cell Transplant. 2019;28(9&#x2013;10):1299&#x2013;1305. doi:10.1177/0963689719861063</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0963689719861063</ArticleId><ArticleId IdType="pmc">PMC6767894</ArticleId><ArticleId IdType="pubmed">31271056</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S, Li X, Jin Q, et al. MicroRNA-145 sensitizes cervical cancer cells to low-dose irradiation by downregulating OCT4 expression. Exp Ther Med. 2016;12(5):3130&#x2013;3136. doi:10.3892/etm.2016.3731</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2016.3731</ArticleId><ArticleId IdType="pmc">PMC5103756</ArticleId><ArticleId IdType="pubmed">27882128</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Torres A, Ba&#xf1;uelos-Villegas EG, Mart&#xed;nez-Acu&#xf1;a N, et al. MYPT1 is targeted by miR-145 inhibiting viability, migration and invasion in 2D and 3D HeLa cultures. Biochem Biophys Res Commun. 2018;507(1&#x2013;4):348&#x2013;354. doi:10.1016/j.bbrc.2018.11.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2018.11.039</ArticleId><ArticleId IdType="pubmed">30446228</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Lu Y, Wang S, et al. MicroRNA-152 acts as a tumor suppressor microRNA by inhibiting Kr&#xfc;ppel-like factor 5 in human cervical cancer. Oncol Res. 2019;27(3):335&#x2013;340. doi:10.3727/096504018X15252202178408</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096504018X15252202178408</ArticleId><ArticleId IdType="pmc">PMC7848453</ArticleId><ArticleId IdType="pubmed">30131089</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma D, Chang L-Y, Zhao S, et al. KLF5 promotes cervical cancer proliferation, migration and invasion in a manner partly dependent on TNFRSF11a expression. Sci Rep. 2017;7(1):15683. doi:10.1038/s41598-017-15979-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-15979-1</ArticleId><ArticleId IdType="pmc">PMC5691198</ArticleId><ArticleId IdType="pubmed">29146991</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32181600</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2324-9269</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Molecular genetics &amp; genomic medicine</Title><ISOAbbreviation>Mol Genet Genomic Med</ISOAbbreviation></Journal><ArticleTitle>Identification of key genes and pathways of diagnosis and prognosis in cervical cancer by bioinformatics analysis.</ArticleTitle><Pagination><StartPage>e1200</StartPage><MedlinePgn>e1200</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1200</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/mgg3.1200</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cervical cancer as one of the most common malignant tumors lead to bad prognosis among women. Some researches already focus on the carcinogenesis and pathogenesis of cervical cancer, but it is still necessary to identify more key genes and pathways.</AbstractText><AbstractText Label="METHODS">Differentially expressed genes were identified by GEO2R from the gene expression omnibus (GEO) website, then gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyzed by DAVID. Meanwhile, protein-protein interaction network was constructed by STRING, and both key genes and modules were found in visualizing network through Cytoscape. Besides, GEPIA did the differential expression of key genes and survival analysis. Finally, the expression of genes related to prognosis was further explored by UNLCAN, oncomine, and the human protein atlas.</AbstractText><AbstractText Label="RESULTS">Totally 57 differentially expressed genes were founded, not only enriched in G1/S transition of mitotic cell cycle, mitotic nuclear division, and cell division but also participated in cytokine-cytokine receptor interaction, toll-like receptor signaling pathway, and amoebiasis. Additionally, 12 hub genes and 3 key modules were screened in the Cytoscape visualization network. Further survival analysis showed that TYMS (OMIM accession number 188350), MCM2 (OMIM accession number 116945), HELLS (OMIM accession number 603946), TOP2A (OMIM accession number 126430), and CXCL8 (OMIM accession number 146930) were associated with the prognosis of cervical cancer.</AbstractText><AbstractText Label="CONCLUSION">This study aim to better understand the characteristics of some genes and signaling pathways about cervical cancer by bioinformatics, and could provide further research ideas to find new mechanism, more prognostic factors, and potential therapeutic targets for cervical cancer.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Molecular Genetics &amp; Genomic Medicine published by Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hua-Ju</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Clinical Cancer Research Center, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Jin-Min</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Clinical Cancer Research Center, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Clinical Cancer Research Center, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Ling-Hong</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Clinical Cancer Research Center, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yu-Xi</ForeName><Initials>YX</Initials><Identifier Source="ORCID">0000-0001-7563-505X</Identifier><AffiliationInfo><Affiliation>Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Clinical Cancer Research Center, Chongqing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>188350</AccessionNumber><AccessionNumber>116945</AccessionNumber><AccessionNumber>603946</AccessionNumber><AccessionNumber>126430</AccessionNumber><AccessionNumber>146930</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Genet Genomic Med</MedlineTA><NlmUniqueID>101603758</NlmUniqueID><ISSNLinking>2324-9269</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508606">CXCL8 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075223">Poly-ADP-Ribose Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.45</RegistryNumber><NameOfSubstance UI="C000600377">TYMS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.45</RegistryNumber><NameOfSubstance UI="D013940">Thymidylate Synthase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber><NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.12</RegistryNumber><NameOfSubstance UI="C084859">MCM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.12</RegistryNumber><NameOfSubstance UI="D064111">Minichromosome Maintenance Complex Component 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.99.-</RegistryNumber><NameOfSubstance UI="C412063">HELLS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.99.1.3</RegistryNumber><NameOfSubstance UI="D004250">DNA Topoisomerases, Type II</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.99.1.3</RegistryNumber><NameOfSubstance UI="C000618811">TOP2A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004250" MajorTopicYN="N">DNA Topoisomerases, Type II</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064111" MajorTopicYN="N">Minichromosome Maintenance Complex Component 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075223" MajorTopicYN="N">Poly-ADP-Ribose Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="Y">Protein Interaction Maps</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013940" MajorTopicYN="N">Thymidylate Synthase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bioinformatics analysis</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">diagnosis and prognosis</Keyword><Keyword MajorTopicYN="N">differentially expressed genes</Keyword></KeywordList><CoiStatement>There are no conflicts of interest of the authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32181600</ArticleId><ArticleId IdType="pmc">PMC7284022</ArticleId><ArticleId IdType="doi">10.1002/mgg3.1200</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abbas, T. , &amp; Dutta, A. (2011). CRL4Cdt2: Master coordinator of cell cycle progression and genome stability. Cell Cycle, 10(2), 241&#x2013;249. 10.4161/cc.10.2.14530</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.10.2.14530</ArticleId><ArticleId IdType="pmc">PMC3025761</ArticleId><ArticleId IdType="pubmed">21212733</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaro Filho, S. M. , Nuovo, G. J. , Cunha, C. B. , De Oliveira Ramos Pereira, L. , Oliveira&#x2010;Silva, M. , Russomano, F. , &#x2026; Nicol, A. F. (2014). Correlation of MCM2 detection with stage and virology of cervical cancer. The International Journal of Biological Markers, 29(4), e363&#x2013;e371. 10.5301/jbm.5000081</Citation><ArticleIdList><ArticleId IdType="doi">10.5301/jbm.5000081</ArticleId><ArticleId IdType="pubmed">24706378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner, M. , Ball, C. A. , Blake, J. A. , Botstein, D. , Butler, H. , Cherry, J. M. , &#x2026; Sherlock, G. (2000). Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nature Genetics, 25(1), 25&#x2013;29. 10.1038/75556</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett, T. , Wilhite, S. E. , Ledoux, P. , Evangelista, C. , Kim, I. F. , Tomashevsky, M. , &#x2026; Soboleva, A. (2013). NCBI GEO: Archive for functional genomics data sets&#x2013;update. Nucleic Acids Research, 41(D1), D991&#x2013;D995. 10.1093/nar/gks1193</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1193</ArticleId><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandolini, L. , Cristiano, L. , Fidoamore, A. , De Pizzol, M. , Di Giacomo, E. , Florio, T. M. , &#x2026; Cimini, A. (2015). Targeting CXCR1 on breast cancer stem cells: Signaling pathways and clinical application modelling. Oncotarget, 6(41), 43375&#x2013;43394. 10.18632/oncotarget.6234</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.6234</ArticleId><ArticleId IdType="pmc">PMC4791238</ArticleId><ArticleId IdType="pubmed">26517518</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray, F. , Ferlay, J. , Soerjomataram, I. , Siegel, R. L. , Torre, L. A. , &amp; Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394&#x2013;424. 10.3322/caac.21492</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami, E. , Gao, J. , Dogrusoz, U. , Gross, B. E. , Sumer, S. O. , Aksoy, B. A. , &#x2026; Schultz, N. (2012). The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discovery, 2(5), 401&#x2013;404. 10.1158/2159-8290.Cd-12-0095</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.Cd-12-0095</ArticleId><ArticleId IdType="pmc">PMC3956037</ArticleId><ArticleId IdType="pubmed">22588877</ArticleId></ArticleIdList></Reference><Reference><Citation>Cezar&#x2010;dos&#x2010;Santos, F. , Ferreira, R. S. , Okuyama, N. C. M. , Trugilo, K. P. , Sena, M. M. , Pereira, &#xc9;. R. , &#x2026; de Oliveira, K. B. (2019). FOXP3 immunoregulatory gene variants are independent predictors of human papillomavirus infection and cervical cancer precursor lesions. Journal of Cancer Research and Clinical Oncology, 145(8), 2013&#x2013;2025. 10.1007/s00432-019-02951-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00432-019-02951-x</ArticleId><ArticleId IdType="pubmed">31177386</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar, D. S. , Bashel, B. , Balasubramanya, S. A. H. , Creighton, C. J. , Ponce&#x2010;Rodriguez, I. , Chakravarthi, B. , &amp; Varambally, S. (2017). UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia, 19(8), 649&#x2013;658. 10.1016/j.neo.2017.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neo.2017.05.002</ArticleId><ArticleId IdType="pmc">PMC5516091</ArticleId><ArticleId IdType="pubmed">28732212</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, D. , Maruschke, M. , Hakenberg, O. , Zimmermann, W. , Stief, C. G. , &amp; Buchner, A. (2017). TOP2A, HELLS, ATAD2, and TET3 are novel prognostic markers in renal cell carcinoma. Urology, 102, 265.e1&#x2013;265.e7. 10.1016/j.urology.2016.12.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2016.12.050</ArticleId><ArticleId IdType="pubmed">28069330</ArticleId></ArticleIdList></Reference><Reference><Citation>den Boon, J. A. , Pyeon, D. , Wang, S. S. , Horswill, M. , Schiffman, M. , Sherman, M. , &#x2026; Ahlquist, P. (2015). Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling. Proceedings of the National Academy of Sciences of the United States of America, 112(25), E3255&#x2013;E3264. 10.1073/pnas.1509322112</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1509322112</ArticleId><ArticleId IdType="pmc">PMC4485108</ArticleId><ArticleId IdType="pubmed">26056290</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon, E. P. , King, L. M. , Nelson, R. , Simkins, S. G. , Knapp, S. L. , Brough, G. H. , &#x2026; Malinowski, D. P. (2017). Characterization and clinical validation of MCM2 and TOP2A monoclonal antibodies in the BD ProEx C assay: An immunoassay which detects aberrant S&#x2010;phase induction in cervical tissue. Journal of Immunological Methods, 442, 35&#x2013;41. 10.1016/j.jim.2017.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2017.01.002</ArticleId><ArticleId IdType="pubmed">28093271</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgar, R. , Domrachev, M. , &amp; Lash, A. E. (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Research, 30(1), 207&#x2013;210. 10.1093/nar/30.1.207</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/30.1.207</ArticleId><ArticleId IdType="pmc">PMC99122</ArticleId><ArticleId IdType="pubmed">11752295</ArticleId></ArticleIdList></Reference><Reference><Citation>Fields, A. P. , &amp; Justilien, V. (2010). The guanine nucleotide exchange factor (GEF) Ect2 is an oncogene in human cancer. Advances in Enzyme Regulation, 50(1), 190&#x2013;200. 10.1016/j.advenzreg.2009.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.advenzreg.2009.10.010</ArticleId><ArticleId IdType="pmc">PMC2863999</ArticleId><ArticleId IdType="pubmed">19896966</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrielli, B. , Bokhari, F. , Ranall, M. V. , Oo, Z. Y. , Stevenson, A. J. , Wang, W. , &#x2026; McMillan, N. A. J. (2015). Aurora A is critical for survival in HPV&#x2010;transformed cervical cancer. Molecular Cancer Therapeutics, 14(12), 2753&#x2013;2761. 10.1158/1535-7163.Mct-15-0506</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.Mct-15-0506</ArticleId><ArticleId IdType="pubmed">26516156</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, J. , Aksoy, B. A. , Dogrusoz, U. , Dresdner, G. , Gross, B. , Sumer, S. O. , &#x2026; Schultz, N. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signalling, 6(269), pl1 10.1126/scisignal.2004088</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2004088</ArticleId><ArticleId IdType="pmc">PMC4160307</ArticleId><ArticleId IdType="pubmed">23550210</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiman, T. M. , Durum, S. K. , &amp; Muegge, K. (1998). Characterization of gene expression, genomic structure, and chromosomal localization of Hells (Lsh). Genomics, 54(3), 477&#x2013;483. 10.1006/geno.1998.5557</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/geno.1998.5557</ArticleId><ArticleId IdType="pubmed">9878251</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng, F. , Wang, Q. , Li, C. , Liu, J. , Zhang, D. , Zhang, S. , &amp; Pan, Y. (2019). Identification of potential candidate genes of oral cancer in response to chronic infection with porphyromonas gingivalis using bioinformatical analyses. Front Oncol, 9, 91 10.3389/fonc.2019.00091</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.00091</ArticleId><ArticleId IdType="pmc">PMC6394248</ArticleId><ArticleId IdType="pubmed">30847302</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross, A. C. , Cam, H. , Phelps, D. A. , Saraf, A. J. , Bid, H. K. , Cam, M. , &#x2026; Roberts, R. D. (2018). IL&#x2010;6 and CXCL8 mediate osteosarcoma&#x2010;lung interactions critical to metastasis. JCI Insight, 3(16), 10.1172/jci.insight.99791</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.99791</ArticleId><ArticleId IdType="pmc">PMC6141177</ArticleId><ArticleId IdType="pubmed">30135299</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta, M. K. , Kushwah, A. S. , Singh, R. , &amp; Banerjee, M. (2019). Genotypic analysis of XRCC4 and susceptibility to cervical cancer. British Journal of Biomedical Science, 1&#x2013;6, 10.1080/09674845.2019.1637573</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09674845.2019.1637573</ArticleId><ArticleId IdType="pubmed">31250713</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang da, W. , Sherman, B. T. , &amp; Lempicki, R. A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols, 4(1), 44&#x2013;57. 10.1038/nprot.2008.211</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.211</ArticleId><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa, M. , &amp; Sato, Y. (2019). KEGG Mapper for inferring cellular functions from protein sequences. Protein Science, 10.1002/pro.3711</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3711</ArticleId><ArticleId IdType="pmc">PMC6933857</ArticleId><ArticleId IdType="pubmed">31423653</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanal, S. , &amp; Galloway, D. A. (2019). High&#x2010;risk human papillomavirus oncogenes disrupt the Fanconi anemia DNA repair pathway by impairing localization and de&#x2010;ubiquitination of FancD2. PLoS Path, 15(2), e1007442 10.1371/journal.ppat.1007442</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007442</ArticleId><ArticleId IdType="pmc">PMC6413947</ArticleId><ArticleId IdType="pubmed">30818369</ArticleId></ArticleIdList></Reference><Reference><Citation>Khazali, A. S. , Clark, A. M. , &amp; Wells, A. (2018). Inflammatory cytokine IL&#x2010;8/CXCL8 promotes tumour escape from hepatocyte&#x2010;induced dormancy. British Journal of Cancer, 118(4), 566&#x2013;576. 10.1038/bjc.2017.414</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2017.414</ArticleId><ArticleId IdType="pmc">PMC5830588</ArticleId><ArticleId IdType="pubmed">29169181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, H. E. , Symanowski, J. T. , Samlowski, E. E. , Gonzales, J. , &amp; Ryu, B. (2010). Quantitative measurement of circulating lymphoid&#x2010;specific helicase (HELLS) gene transcript: A potential serum biomarker for melanoma metastasis. Pigment Cell and Melanoma Research, 23(6), 845&#x2013;848. 10.1111/j.1755-148X.2010.00753.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-148X.2010.00753.x</ArticleId><ArticleId IdType="pmc">PMC3192016</ArticleId><ArticleId IdType="pubmed">20727106</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuku, S. , Proctor, I. , Loddo, M. , Kadalayil, L. , KhoshZaban, M. , Ledermann, J. , &amp; McCormack, M. (2015). Do cell&#x2010;cycle phase&#x2010;specific markers predict disease grade, stage, and outcome in cervical carcinoma? International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 25(6), 1066&#x2013;1072. 10.1097/IGC.0000000000000356</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IGC.0000000000000356</ArticleId><ArticleId IdType="pubmed">25621411</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, A. , Cherukumilli, M. , Mahmoudpour, S. H. , Brand, K. , &amp; Bandapalli, O. R. (2018). ShRNA&#x2010;mediated knock&#x2010;down of CXCL8 inhibits tumor growth in colorectal liver metastasis. Biochemical and Biophysical Research Communications, 500(3), 731&#x2013;737. 10.1016/j.bbrc.2018.04.144</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2018.04.144</ArticleId><ArticleId IdType="pubmed">29679563</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, X. , Zheng, R. , Li, X. , Shan, H. , Wu, Q. , Wang, Y. , &amp; Chen, W. (2017). Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014. Chinese Journal of Cancer Research, 29(6), 477&#x2013;486. 10.21147/j.issn.1000-9604.2017.06.02</Citation><ArticleIdList><ArticleId IdType="doi">10.21147/j.issn.1000-9604.2017.06.02</ArticleId><ArticleId IdType="pmc">PMC5758729</ArticleId><ArticleId IdType="pubmed">29353970</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, C. , He, H. , Liu, H. , Li, R. , Chen, Y. , Qi, Y. , &#x2026; Xu, J. (2019). Tumour&#x2010;associated macrophages&#x2010;derived CXCL8 determines immune evasion through autonomous PD&#x2010;L1 expression in gastric cancer. Gut, 68(10), 1764&#x2013;1773. 10.1136/gutjnl-2018-316324</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2018-316324</ArticleId><ArticleId IdType="pubmed">30661053</ArticleId></ArticleIdList></Reference><Reference><Citation>Litman&#x2010;Zawadzka, A. , Lukaszewicz&#x2010;Zajac, M. , Gryko, M. , Kulczynska&#x2010;Przybik, A. , &amp; Mroczko, B. (2018). Serum chemokine CXCL8 as a better biomarker for diagnosis and prediction of pancreatic cancer than its specific receptor CXCR2, C&#x2010;reactive protein, and classic tumor markers CA 19&#x2013;9 and CEA. Polish Archives of Internal Medicine, 128(9), 524&#x2013;531. 10.20452/pamw.4307</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.4307</ArticleId><ArticleId IdType="pubmed">30057378</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, F. , Zou, Y. , Wang, F. , Yang, B. , Zhang, Z. , Luo, Y. , &#x2026; Huang, O. (2019). FBXW7 mutations promote cell proliferation, migration, and invasion in cervical cancer. Genet Test Mol Biomarkers, 23(6), 409&#x2013;417. 10.1089/gtmb.2018.0278</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/gtmb.2018.0278</ArticleId><ArticleId IdType="pubmed">31161818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, Y. , Yang, J. , Wang, R. , Zhang, Z. , Qi, X. , Liu, C. , &amp; Ma, M. (2017). Aurora&#x2010;A affects radiosenstivity in cervical squamous cell carcinoma and predicts poor prognosis. Oncotarget, 8(19), 31509&#x2013;31520. 10.18632/oncotarget.15663</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.15663</ArticleId><ArticleId IdType="pmc">PMC5458225</ArticleId><ArticleId IdType="pubmed">28404933</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabuchi, S. , Yokoi, E. , Komura, N. , &amp; Kimura, T. (2018). Myeloid&#x2010;derived suppressor cells and their role in gynecological malignancies. Tumour Biology, 40(7), 1010428318776485. 10.1177/1010428318776485</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1010428318776485</ArticleId><ArticleId IdType="pubmed">30074452</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrero&#x2010;Rodriguez, D. , Taniguchi&#x2010;Ponciano, K. , Subramaniam, M. , Hawse, J. R. , Pitel, K. S. , Arreola&#x2010;De la Cruz, H. , &#x2026; Salcedo, M. (2018). Kruppel&#x2010;Like Factor 10 participates in cervical cancer immunoediting through transcriptional regulation of Pregnancy&#x2010;Specific Beta&#x2010;1 Glycoproteins. Scientific Reports, 8(1), 9445 10.1038/s41598-018-27711-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-27711-8</ArticleId><ArticleId IdType="pmc">PMC6013423</ArticleId><ArticleId IdType="pubmed">29930344</ArticleId></ArticleIdList></Reference><Reference><Citation>Peres, A. L. , Paz, E. S. K. M. , de Araujo, R. F. , de Lima Filho, J. L. , de Melo Junior, M. R. , Martins, D. B. , &amp; de Pontes Filho, N. T. (2016). Immunocytochemical study of TOP2A and Ki&#x2010;67 in cervical smears from women under routine gynecological care. Journal of Biomedical Science, 23(1), 42 10.1186/s12929-016-0258-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-016-0258-z</ArticleId><ArticleId IdType="pmc">PMC4864931</ArticleId><ArticleId IdType="pubmed">27175798</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyeon, D. , Newton, M. A. , Lambert, P. F. , den Boon, J. A. , Sengupta, S. , Marsit, C. J. , &#x2026; Ahlquist, P. (2007). Fundamental differences in cell cycle deregulation in human papillomavirus&#x2010;positive and human papillomavirus&#x2010;negative head/neck and cervical cancers. Cancer Research, 67(10), 4605&#x2013;4619. 10.1158/0008-5472.Can-06-3619</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.Can-06-3619</ArticleId><ArticleId IdType="pmc">PMC2858285</ArticleId><ArticleId IdType="pubmed">17510386</ArticleId></ArticleIdList></Reference><Reference><Citation>Razia, S. , Nakayama, K. , Nakamura, K. , Ishibashi, T. , Ishikawa, M. , Minamoto, T. , &#x2026; Kyo, S. (2019). Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas. Experimental and Therapeutic Medicine, 18(3), 2278&#x2013;2284. 10.3892/etm.2019.7771</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2019.7771</ArticleId><ArticleId IdType="pmc">PMC6676184</ArticleId><ArticleId IdType="pubmed">31410178</ArticleId></ArticleIdList></Reference><Reference><Citation>Saga, Y. , Suzuki, M. , Mizukami, H. , Kohno, T. , Takei, Y. , Fukushima, M. , &amp; Ozawa, K. (2003). Overexpression of thymidylate synthase mediates desensitization for 5&#x2010;fluorouracil of tumor cells. International Journal of Cancer, 106(3), 324&#x2013;326. 10.1002/ijc.11221</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.11221</ArticleId><ArticleId IdType="pubmed">12845668</ArticleId></ArticleIdList></Reference><Reference><Citation>Saga, Y. , Suzuki, M. , Mizukami, H. , Urabe, M. , Fukushima, M. , Ozawa, K. , &amp; Sato, I. (2002). Enhanced expression of thymidylate synthase mediates resistance of uterine cervical cancer cells to radiation. Oncology, 63(2), 185&#x2013;191. 10.1159/000063804</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000063804</ArticleId><ArticleId IdType="pubmed">12239455</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanmamed, M. F. , Perez&#x2010;Gracia, J. L. , Schalper, K. A. , Fusco, J. P. , Gonzalez, A. , Rodriguez&#x2010;Ruiz, M. E. , &#x2026; Melero, I. (2017). Changes in serum interleukin&#x2010;8 (IL&#x2010;8) levels reflect and predict response to anti&#x2010;PD&#x2010;1 treatment in melanoma and non&#x2010;small&#x2010;cell lung cancer patients. Annals of Oncology, 28(8), 1988&#x2013;1995. 10.1093/annonc/mdx190</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdx190</ArticleId><ArticleId IdType="pmc">PMC5834104</ArticleId><ArticleId IdType="pubmed">28595336</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotto, L. , Narayan, G. , Nandula, S. V. , Arias&#x2010;Pulido, H. , Subramaniyam, S. , Schneider, A. , &#x2026; Murty, V. V. (2008). Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: Potential role in progression. Genes, Chromosomes and Cancer, 47(9), 755&#x2013;765. 10.1002/gcc.20577</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gcc.20577</ArticleId><ArticleId IdType="pubmed">18506748</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon, P. , Markiel, A. , Ozier, O. , Baliga, N. S. , Wang, J. T. , Ramage, D. , &#x2026; Ideker, T. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Research, 13(11), 2498&#x2013;2504. 10.1101/gr.1239303</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, H. , Han, X. , Sun, Y. , Shang, C. , Wei, M. , Ba, X. , &amp; Zeng, X. (2018). Chemokine (C&#x2010;X&#x2010;C motif) ligand 1 and CXCL2 produced by tumor promote the generation of monocytic myeloid&#x2010;derived suppressor cells. Cancer Science, 109(12), 3826&#x2013;3839. 10.1111/cas.13809</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13809</ArticleId><ArticleId IdType="pmc">PMC6272093</ArticleId><ArticleId IdType="pubmed">30259595</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, J. M. , Yang, L. N. , Xu, H. , Chang, B. , Wang, H. Y. , &amp; Yang, G. (2015). Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells. American Journal of Cancer Research, 5(3), 1133&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4449441</ArticleId><ArticleId IdType="pubmed">26045992</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki, M. , Tsukagoshi, S. , Saga, Y. , Ohwada, M. , &amp; Sato, I. (1999). Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer. Oncology, 57(1), 50&#x2013;54. 10.1159/000012000</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000012000</ArticleId><ArticleId IdType="pubmed">10394125</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk, D. , Gable, A. L. , Lyon, D. , Junge, A. , Wyder, S. , Huerta&#x2010;Cepas, J. , &#x2026; Mering, C. (2019). STRING v11: Protein&#x2010;protein association networks with increased coverage, supporting functional discovery in genome&#x2010;wide experimental datasets. Nucleic Acids Research, 47(D1), D607&#x2013;d613. 10.1093/nar/gky1131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, Z. , Li, C. , Kang, B. , Gao, G. , Li, C. , &amp; Zhang, Z. (2017). GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Research, 45(W1), W98&#x2013;W102. 10.1093/nar/gkx247</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx247</ArticleId><ArticleId IdType="pmc">PMC5570223</ArticleId><ArticleId IdType="pubmed">28407145</ArticleId></ArticleIdList></Reference><Reference><Citation>The Gene Ontology Consortium . (2019). The gene ontology resource: 20 years and still GOing strong. Nucleic Acids Research, 47(D1), D330&#x2013;D338. 10.1093/nar/gky1055</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1055</ArticleId><ArticleId IdType="pmc">PMC6323945</ArticleId><ArticleId IdType="pubmed">30395331</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosuner, Z. , Turkmen, I. , Arici, S. , Sonmez, C. , Turna, S. , &amp; Onaran, O. (2017). Immunocytoexpression profile of ProExC in smears interpreted as ASC&#x2010;US, ASC&#x2010;H, and cervical intraepithelial lesion. Journal of Cytology, 34(1), 34&#x2013;38. 10.4103/0970-9371.197605</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0970-9371.197605</ArticleId><ArticleId IdType="pmc">PMC5259927</ArticleId><ArticleId IdType="pubmed">28182079</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugurel, S. , Rappl, G. , Tilgen, W. , &amp; Reinhold, U. (2001). Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. Journal of Clinical Oncology, 19(2), 577&#x2013;583. 10.1200/jco.2001.19.2.577</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2001.19.2.577</ArticleId><ArticleId IdType="pubmed">11208853</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen, M. , Zhang, C. , Lee, S. , Sj&#xf6;stedt, E. , Fagerberg, L. , Bidkhori, G. , &#x2026; Ponten, F. (2017). A pathology atlas of the human cancer transcriptome. Science, 357(6352), 10.1126/science.aan2507</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aan2507</ArticleId><ArticleId IdType="pubmed">28818916</ArticleId></ArticleIdList></Reference><Reference><Citation>Umene, K. , Banno, K. , Kisu, I. , Yanokura, M. , Nogami, Y. , Tsuji, K. , &#x2026; Aoki, D. (2013). Aurora kinase inhibitors: Potential molecular&#x2010;targeted drugs for gynecologic malignant tumors. Biomedical Reports, 1(3), 335&#x2013;340. 10.3892/br.2013.91</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/br.2013.91</ArticleId><ArticleId IdType="pmc">PMC3917679</ArticleId><ArticleId IdType="pubmed">24648944</ArticleId></ArticleIdList></Reference><Reference><Citation>van Twest, S. , Murphy, V. J. , Hodson, C. , Tan, W. , Swuec, P. , O'Rourke, J. J. , &#x2026; Deans, A. J. (2017). Mechanism of ubiquitination and deubiquitination in the fanconi anemia pathway. Molecular Cell, 65(2), 247&#x2013;259. 10.1016/j.molcel.2016.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2016.11.005</ArticleId><ArticleId IdType="pubmed">27986371</ArticleId></ArticleIdList></Reference><Reference><Citation>Varney, M. L. , Singh, S. , Li, A. , Mayer&#x2010;Ezell, R. , Bond, R. , &amp; Singh, R. K. (2011). Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Letters, 300(2), 180&#x2013;188. 10.1016/j.canlet.2010.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2010.10.004</ArticleId><ArticleId IdType="pmc">PMC2994987</ArticleId><ArticleId IdType="pubmed">21035946</ArticleId></ArticleIdList></Reference><Reference><Citation>Visciano, C. , Liotti, F. , Prevete, N. , Cali', G. , Franco, R. , Collina, F. , &#x2026; Melillo, R. M. (2015). Mast cells induce epithelial&#x2010;to&#x2010;mesenchymal transition and stem cell features in human thyroid cancer cells through an IL&#x2010;8&#x2010;Akt&#x2010;Slug pathway. Oncogene, 34(40), 5175&#x2013;5186. 10.1038/onc.2014.441</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2014.441</ArticleId><ArticleId IdType="pubmed">25619830</ArticleId></ArticleIdList></Reference><Reference><Citation>Waseem, A. , Ali, M. , Odell, E. W. , Fortune, F. , &amp; Teh, M. T. (2010). Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncology, 46(7), 536&#x2013;542. 10.1016/j.oraloncology.2010.03.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2010.03.022</ArticleId><ArticleId IdType="pubmed">20400365</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao, Y.&#x2010;C. , Yang, Z.&#x2010;B. , Cheng, X.&#x2010;S. , Fang, X.&#x2010;B. , Shen, T. , Xia, C.&#x2010;F. , &#x2026; Li, Y.&#x2010;F. (2015). CXCL8, overexpressed in colorectal cancer, enhances the resistance of colorectal cancer cells to anoikis. Cancer Letters, 361(1), 22&#x2013;32. 10.1016/j.canlet.2015.02.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2015.02.021</ArticleId><ArticleId IdType="pubmed">25687885</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, W. , Liu, Y. , Zhao, N. , Chen, H. , Qiao, L. , Zhao, W. , &amp; Chen, J. J. (2015). Role of Cdk1 in the p53&#x2010;independent abrogation of the postmitotic checkpoint by human papillomavirus E6. Journal of Virology, 89(5), 2553&#x2013;2562. 10.1128/jvi.02269-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02269-14</ArticleId><ArticleId IdType="pmc">PMC4325723</ArticleId><ArticleId IdType="pubmed">25520504</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, W. , Wang, J. , Liu, S. J. , Hua, W. , &amp; Xin, X. Y. (2009). Correlation between Aurora&#x2010;A expression and the prognosis of cervical carcinoma patients. Acta Obstetricia et Gynecologica Scandinavica, 88(5), 521&#x2013;527. 10.1080/00016340902835927</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00016340902835927</ArticleId><ArticleId IdType="pubmed">19306133</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, J. (2015). Diagnostic value of MCM2 immunocytochemical staining in cervical lesions and its relationship with HPV infection. International Journal of Clinical and Experimental Pathology, 8(1), 875&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4348922</ArticleId><ArticleId IdType="pubmed">25755789</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Y. , Zhang, Q. , Gao, G. E. , Zhang, X. , Liu, Y. , Yuan, S. , &#x2026; Chen, J. J. (2016). Role of WDHD1 in human papillomavirus&#x2010;mediated oncogenesis identified by transcriptional profiling of E7&#x2010;expressing cells. Journal of Virology, 90(13), 6071&#x2013;6084. 10.1128/jvi.00513-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00513-16</ArticleId><ArticleId IdType="pmc">PMC4907231</ArticleId><ArticleId IdType="pubmed">27099318</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32083574</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8592</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>2</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Cancer biomarkers : section A of Disease markers</Title><ISOAbbreviation>Cancer Biomark</ISOAbbreviation></Journal><ArticleTitle>Co-expression network analysis identified atypical chemokine receptor 1 (ACKR1) association with lymph node metastasis and prognosis in cervical cancer.</ArticleTitle><Pagination><StartPage>213</StartPage><EndPage>223</EndPage><MedlinePgn>213-223</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/CBM-190533</ELocationID><Abstract><AbstractText>Cervical cancer (CC) is one kind of female cancer. With the development of bioinformatics, targeted specific biomarkers therapy has become much more valuable. GSE26511 was obtained from gene expression omnibus (GEO). We utilized a package called "WGCNA" to build co-expression network and choose the hub module. Search Tool for the Retrieval of Interacting Genes Database (STRING) was used to analyze protein-protein interaction (PPI) information of those genes in the hub module. A Plug-in called MCODE was utilized to choose hub clusters of PPI network, which was visualized in Cytoscape. Clusterprofiler was used to do functional analysis. Univariate and multivariate cox proportional hazards regression analysis were both conducted to predict the risk score of CC patients. Kaplan-Meier curve analysis was done to show the overall survival. Receiver operating characteristic (ROC) curve analysis was utilized to evaluate the predictive value of the patient outcome. Validation of the hub gene in databases, Gene set enrichment analysis (GSEA) and GEPIA were completed. We built co-expression network based on GSE26511 and one CC-related module was identified. Functional analysis of this module showed that extracellular space and Signaling pathways regulating pluripotency of stem cells were most related pathways. PPI network screened GNG11 as the most valuable protein. Cox analysis showed that ACKR1 was negatively correlated with CC progression, which was validated in Gene Expression Profiling Interactive Analysis (GEPIA) and datasets. Survival analysis was performed and showed the consistent result. GSEA set enrichment analysis was also completed. This study showed hub functional terms and gene participated in CC and then speculated that ACKR1 might be tumor suppressor for CC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jinhui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Siyue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Yicong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Shulin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Wenjun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Cancer Biomark</MedlineTA><NlmUniqueID>101256509</NlmUniqueID><ISSNLinking>1574-0153</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C473745">ACKR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004375">Duffy Blood-Group System</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004375" MajorTopicYN="N">Duffy Blood-Group System</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="Y">Protein Interaction Maps</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioinformatics analysis</Keyword><Keyword MajorTopicYN="N">atypical chemokine receptor 1 (ACKR1)</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">lymph node metastasis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32083574</ArticleId><ArticleId IdType="doi">10.3233/CBM-190533</ArticleId><ArticleId IdType="pii">CBM190533</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31949653</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1936-2625</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>12</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>International journal of clinical and experimental pathology</Title><ISOAbbreviation>Int J Clin Exp Pathol</ISOAbbreviation></Journal><ArticleTitle>Discovery of microarray-identified genes associated with the progression of cervical intraepithelial neoplasia.</ArticleTitle><Pagination><StartPage>5667</StartPage><EndPage>5681</EndPage><MedlinePgn>5667-5681</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify genes potentially associated with cervical intraepithelial neoplasia (CIN) progression through bioinformatic approaches and clinicopathological verification.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">mRNA expression microarray data related to CIN progression were screened from the Gene Expression Omnibus (GEO) database and re-analyzed using bioinformatics approaches. Tissue microarray immunohistochemistry was conducted to assess the significant identified genes in CIN, cervical cancer, and normal tissues.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Biological annotation and text mining showed that 14 differentially expressed genes were directly or indirectly related to CIN progression. The expression of 5 up-regulated differentially expressed genes, namely, CCND2, TGFBR2, PRKCB, SH3KBP1 and WNT2B, was examined by tissue microarray immunohistochemistry, with the known CIN progression genes P16 and Ki-67 as the internal reference. Expression of TGFBR2, SH3KBP1, and WNT2B were not detected in CIN and cervical carcinoma, whereas no significant difference in the expression rate of PRKCB was detected (P &gt; 0.05). CCND2, P16, and Ki-67 expression showed a gradual increasing trend in normal, CIN, and cervical cancer.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">14 differentially expressed genes were associated with CIN progression, as indicated by the microarray data analysis results. CCND2 may be a new marker for the prediction of CIN progression in addition to P16 and Ki-67.</AbstractText><CopyrightInformation>IJCEP Copyright &#xa9; 2018.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yanming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University Nanning, Guangxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology, The People's Hospital of Guangxi Zhuang Autonomous Region Nanning, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Fuqiang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Life Sciences Institute, Guangxi Medical University Nanning, Guangxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education Nanning, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yujie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynecology, Liuzhou People's Hospital Liuzhou, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, Liuzhou People's Hospital Liuzhou, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University Nanning, Guangxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education Nanning, Guangxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Clin Exp Pathol</MedlineTA><NlmUniqueID>101480565</NlmUniqueID><ISSNLinking>1936-2625</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical intraepithelial neoplasia</Keyword><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">expression profiling microarray</Keyword><Keyword MajorTopicYN="N">gene</Keyword><Keyword MajorTopicYN="N">immunohistochemistry</Keyword><Keyword MajorTopicYN="N">progression</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31949653</ArticleId><ArticleId IdType="pmc">PMC6963088</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ramondetta L. What is the appropriate approach to treating women with incurable cervical cancer? J Natl Compr Canc Netw. 2013;11:348&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">23486459</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BA, Davey DD. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med. 2000;124:672&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">10782146</ArticleId></ArticleIdList></Reference><Reference><Citation>McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9:425&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">18407790</ArticleId></ArticleIdList></Reference><Reference><Citation>Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M, Elanko N, Coleman D, Yule R, Desai M. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer. 2004;91:942&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2409880</ArticleId><ArticleId IdType="pubmed">15292939</ArticleId></ArticleIdList></Reference><Reference><Citation>Munk AC, Gudlaugsson E, Ovestad IT, Lovslett K, Fiane B, Hidle B, Kruse AJ, Skaland I, Janssen EA, Baak JP. Interaction of epithelial biomarkers, local immune response and condom use in cervical intraepithelial neoplasia 2-3 regression. Gynecol Oncol. 2012;127:489&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">23017821</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovestad IT, Gudlaugsson E, Skaland I, Malpica A, Munk AC, Janssen EA, Baak JP. The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2-3. J Clin Pathol. 2011;64:303&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21421698</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm C, Polterauer S, Natter C, Rahhal J, Hefler L, Tempfer CB, Heinze G, Stary G, Reinthaller A, Speiser P. Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet Gynecol. 2012;120:152&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22914404</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharan R, Ulitsky I, Shamir R. Network-based prediction of protein function. Mol Syst Biol. 2007;3:88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847944</ArticleId><ArticleId IdType="pubmed">17353930</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J, Yin F, Wang Q, Zhang W, Li L. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Int J Clin Exp Pathol. 2015;8:6847&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525906</ArticleId><ArticleId IdType="pubmed">26261572</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and bioconductor. Bioinformatics. 2007;23:1846&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17496320</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Gao Y, Zhao B, Li X, Lu Y, Zhang J, Li D, Li L, Yin F. Discovery of microarray-identified genes associated with ovarian cancer progression. Int J Oncol. 2015;46:2467&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">25891226</ArticleId></ArticleIdList></Reference><Reference><Citation>den Boon JA, Pyeon D, Wang SS, Horswill M, Schiffman M, Sherman M, Zuna RE, Wang Z, Hewitt SM, Pearson R, Schott M, Chung L, He Q, Lambert P, Walker J, Newton MA, Wentzensen N, Ahlquist P. Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S A. 2015;112:E3255&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4485108</ArticleId><ArticleId IdType="pubmed">26056290</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41:D991&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Boutros PC. VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinformatics. 2011;12:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041657</ArticleId><ArticleId IdType="pubmed">21269502</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4:P3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12734009</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615629</ArticleId><ArticleId IdType="pubmed">19033363</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw N, Dijkhuizen T, Hehir-Kwa JY, Carter NP, Feuk L, Firth HV, Kuhn RM, Ledbetter DH, Martin CL, van Ravenswaaij-Arts CM, Scherer SW, Shams S, Van Vooren S, Sijmons R, Swertz M, Hastings R. Diagnostic interpretation of array data using public databases and internet sources. Hum Mutat. 2012;33:930&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5027376</ArticleId><ArticleId IdType="pubmed">26285306</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q. GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol. 2008;9(Suppl 1):S4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2447538</ArticleId><ArticleId IdType="pubmed">18613948</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie D, Sham JS, Zeng WF, Lin HL, Che LH, Wu HX, Wen JM, Fang Y, Hu L, Guan XY. Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer. 2003;107:896&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">14601048</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgieva J, Sinha P, Schadendorf D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol. 2001;54:229&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1731381</ArticleId><ArticleId IdType="pubmed">11253137</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeron C, Ronco G, Reuschenbach M, Wentzensen N, Arbyn M, Stoler M, von Knebel Doeberitz M. The clinical impact of using p16 (INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments. Int J Cancer. 2015;136:2741&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">24740700</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MS, Oh S, Jung EJ, Park JH, Jeon HW, Lee TS, Kim JH, Choi E, Byeon SJ, Park IA. High-risk human papillomavirus load and biomarkers in cervical intraepithelial neoplasia and cancer. APMIS. 2014;122:427&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">24020724</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Ye F, Xie X, Zhou C, Lu W. Significance of PTPRZ1 and CIN85 expression in cervical carcinoma. Arch Gynecol Obstet. 2011;284:699&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">20882291</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao GD, Sellors JW, Sun HK, Zhang X, Bao YP, Jeronimo J, Chen W, Zhao FH, Song Y, Cao Z, Zhang SK, Xi MR, Qiao YL. p16INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: a prospective study in China. Int J Cancer. 2014;134:1715&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">24105727</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H, Shi Y, Tuokan T, Chen R, Wang X. Expression of aquaporin 8 and phosphorylation of Erk1/2 in cervical epithelial carcinogenesis: correlation with clinicopathological parameters. Int J Clin Exp Pathol. 2014;7:3928&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129004</ArticleId><ArticleId IdType="pubmed">25120769</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazumder Indra D, Mitra S, Roy A, Mondal RK, Basu PS, Roychoudhury S, Chakravarty R, Panda CK. Alterations of ATM and CADM1 in chromosomal 11q22.3-23.2 region are associated with the development of invasive cervical carcinoma. Hum Genet. 2011;130:735&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">21643982</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata T, Fujii T, Morii K, Saito M, Sugiyama J, Nishio H, Morisada T, Tanaka K, Yaguchi T, Kawakami Y, Aoki D. Cytokine profile in cervical mucosa of Japanese patients with cervical intraepithelial neoplasia. Int J Clin Oncol. 2015;20:126&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">24578180</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukazawa EM, Baiocchi G, Soares FA, Kumagai LY, Faloppa CC, Badiglian-Filho L, Coelho FR, Goncalves WJ, Costa RL, Goes JC. Cox-2, EGFR, and ERBB-2 expression in cervical intraepithelial neoplasia and cervical cancer using an automated imaging system. Int J Gynecol Pathol. 2014;33:225&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">24681731</ArticleId></ArticleIdList></Reference><Reference><Citation>Samir R, Asplund A, Tot T, Pekar G, Hellberg D. High-risk HPV infection and CIN grade correlates to the expression of c-myc, CD4+, FHIT, E-cadherin, Ki-67, and p16INK4a. J Low Genit Tract Dis. 2011;15:280&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21558960</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda LN, Reginaldo FP, Souza DM, Soares CP, Silva TG, Rocha KB, Jatoba CA, Donadi EA, Andrade JM, Goncalves AK, Crispim JC. Greater expression of the human leukocyte antigen-G (HLA-G) and interleukin-17 (IL-17) in cervical intraepithelial neoplasia: analytical cross-sectional study. Sao Paulo Med J. 2015;133:336&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10876348</ArticleId><ArticleId IdType="pubmed">25351636</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Gobbo A, Bonoldi E, Cribiu FM, Franceschetti I, Matinato C, Fiori S, Gianelli U, Bosari S. Insulin-like growth factor II mRNA binding protein 3 (IMP3) expression in cervical intraepithelial neoplasia and its relationship with HIV-infection status. Sex Health. 2014;12:22&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">25427240</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung SH, Choi YJ, Kim MS, Baek IP, Lee SH, Lee AW, Hur SY, Kim TM, Lee SH, Chung YJ. Progression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix. Oncotarget. 2015;6:4385&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4414197</ArticleId><ArticleId IdType="pubmed">25738363</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruse AJ, Baak JP, Janssen EA, Bol MG, Kjellevold KH, Fianne B, Lovslett K, Bergh J. Low- and high-risk CIN 1 and 2 lesions: prospective predictive value of grade, HPV, and Ki-67 immuno-quantitative variables. J Pathol. 2003;199:462&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">12635137</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K, Li LA, Meng Y, You Y, Fu X, Song L. High expression of astrocyte elevated gene-1 (AEG-1) is associated with progression of cervical intraepithelial neoplasia and unfavorable prognosis in cervical cancer. World J Surg Oncol. 2013;11:297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3866971</ArticleId><ArticleId IdType="pubmed">24256614</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotondo JC, Bosi S, Bassi C, Ferracin M, Lanza G, Gafa R, Magri E, Selvatici R, Torresani S, Marci R, Garutti P, Negrini M, Tognon M, Martini F. Gene expression changes in progression of cervical neoplasia revealed by microarray analysis of cervical neoplastic keratinocytes. J Cell Physiol. 2015;230:806&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">25205602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima T, Asai-Sato M, Akimoto K, Nagashima Y, Taguri M, Sasaki K, Nakaya MA, Asano R, Tokinaga A, Kiyono T, Hirahara F, Ohno S, Miyagi E. Aberrant expression of the cell polarity regulator aPKClambda/iota is associated with disease progression in cervical intraepithelial neoplasia (CIN): a possible marker for predicting CIN prognosis. Int J Gynecol Pathol. 2016;35:106&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">26535980</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda K, Miura S, Kurashige T, Suzuki K, Kondo H, Ihara M, Nakajima H, Masuzaki H, Nakashima M. Significance of p53-binding protein 1 nuclear foci in uterine cervical lesions: endogenous DNA double strand breaks and genomic instability during carcinogenesis. Histopathology. 2011;59:441&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229684</ArticleId><ArticleId IdType="pubmed">22034884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu D, Jiang XH, Jiang YH, Ding WC, Zhang CL, Shen H, Wang XL, Ma D, Hu Z, Wang H. Amplification and overexpression of TP63 and MYC as biomarkers for transition of cervical intraepithelial neoplasia to cervical cancer. Int J Gynecol Cancer. 2014;24:643&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24662128</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Gui LS, Zhao XL, Zhu LL, Li QW. FOXO1 is a tumor suppressor in cervical cancer. Genet Mol Res. 2015;14:6605&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">26125868</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Tao F, Cheng Y, Xu F, Yao F, Feng D, Miao L, Xiao W, Ling B. Up-regulation of ITCH is associated with down-regulation of LATS1 during tumorigenesis and progression of cervical squamous cell carcinoma. Clin Invest Med. 2014;37:E384&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">25618271</ArticleId></ArticleIdList></Reference><Reference><Citation>Rung J, Brazma A. Reuse of public genome-wide gene expression data. Nat Rev Genet. 2013;14:89&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">23269463</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001;29:365&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">11726920</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2011;12:517&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">21779028</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YY, Song SY, Do IG, Kim TJ, Kim BG, Lee JW, Bae DS. Dynamin 2 expression as a biomarker in grading of cervical intraepithelial neoplasia. Eur J Obstet Gynecol Reprod Biol. 2012;164:180&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">22959143</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei H, Wang N, Zhang Y, Wang S, Pang X, Zhang S. Wnt-11 overexpression promoting the invasion of cervical cancer cells. Tumour Biol. 2016;37:11789&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">27034261</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Solano M, Alvarez-Zavala M, Garcia-Castro B, Jave-Suarez LF, Aguilar-Lemarroy A. [Wnt signalling pathway and cervical cancer] . Rev Med Inst Mex Seguro Soc. 2015;53:S218&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">26462520</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Yu W, Xiong X, Kuang X, Ai Y, Xiong X. Astrocyte elevated gene-1 promotes progression of cervical squamous cell carcinoma by inducing epithelial-mesenchymal transition via Wnt signaling. Int J Gynecol Cancer. 2015;25:345&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">25695541</ArticleId></ArticleIdList></Reference><Reference><Citation>Nojima M, Suzuki H, Toyota M, Watanabe Y, Maruyama R, Sasaki S, Sasaki Y, Mita H, Nishikawa N, Yamaguchi K, Hirata K, Itoh F, Tokino T, Mori M, Imai K, Shinomura Y. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene. 2007;26:4699&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">17297461</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S, Singhal S, Lee P, Xu R. Molecular genetics of hepatocellular neoplasia. Am J Transl Res. 2010;2:105&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826827</ArticleId><ArticleId IdType="pubmed">20182587</ArticleId></ArticleIdList></Reference><Reference><Citation>Deka J, Wiedemann N, Anderle P, Murphy-Seiler F, Bultinck J, Eyckerman S, Stehle JC, Andre S, Vilain N, Zilian O, Robine S, Delorenzi M, Basler K, Aguet M. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Res. 2010;70:6619&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">20682801</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurkkala M, Wassen L, Nordstrom I, Gustavsson I, Slavica L, Josefsson A, Eriksson K. Conjugation of HPV16 E7 to cholera toxin enhances the HPV-specific T-cell recall responses to pulsed dendritic cells in vitro in women with cervical dysplasia. Vaccine. 2010;28:5828&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">20600477</ArticleId></ArticleIdList></Reference><Reference><Citation>Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21734724</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 2002;1602:73&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">11960696</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia WH, Zhang B, Matsuo K, Shin A, Xiang YB, Jee SH, Kim DH, Ren Z, Cai Q, Long J, Shi J, Wen W, Yang G, Delahanty RJ, Ji BT, Pan ZZ, Matsuda F, Gao YT, Oh JH, Ahn YO, Park EJ, Li HL, Park JW, Jo J, Jeong JY, Hosono S, Casey G, Peters U, Shu XO, Zeng YX, Zheng W. Genome-wide association analyses in East Asians identify new susceptibility loci for colorectal cancer. Nat Genet. 2013;45:191&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679924</ArticleId><ArticleId IdType="pubmed">23263487</ArticleId></ArticleIdList></Reference><Reference><Citation>Du X, Lin LI, Zhang L, Jiang J. microRNA-195 inhibits the proliferation, migration and invasion of cervical cancer cells via the inhibition of CCND2 and MYB expression. Oncol Lett. 2015;10:2639&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4580043</ArticleId><ArticleId IdType="pubmed">26622903</ArticleId></ArticleIdList></Reference><Reference><Citation>Darragh TM, Colgan TJ, Thomas Cox J, Heller DS, Henry MR, Luff RD, McCalmont T, Nayar R, Palefsky JM, Stoler MH, Wilkinson EJ, Zaino RJ, Wilbur DC Members of the LAST Project Work Groups. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the college of American pathologists and the American society for colposcopy and cervical pathology. Int J Gynecol Pathol. 2013;32:76&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">23202792</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, Malamou-Mitsi V, Paraskevaidis E. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev. 2009;35:210&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784486</ArticleId><ArticleId IdType="pubmed">19261387</ArticleId></ArticleIdList></Reference><Reference><Citation>Omori M, Hashi A, Nakazawa K, Yuminamochi T, Yamane T, Hirata S, Katoh R, Hoshi K. Estimation of prognoses for cervical intraepithelial neoplasia 2 by p16INK4a immunoexpression and high-risk HPV in situ hybridization signal types. Am J Clin Pathol. 2007;128:208&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">17638654</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou WQ, Sheng QY, Sheng YH, Hou WJ, Xu GX, Wu YM, Lu H. Expressions of survivin, P16(INK4a), COX-2, and Ki-67 in cervical cancer progression reveal the potential clinical application. Eur J Gynaecol Oncol. 2015;36:62&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25872337</ArticleId></ArticleIdList></Reference><Reference><Citation>Baak JP, Kruse AJ, Garland SM, Skaland I, Janssen EA, Tabrizi S, Fagerheim S, Robboy S, Nilsen ST. Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions. Am J Surg Pathol. 2005;29:1062&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16006801</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2010;133:395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">20154278</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31369759</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0631</ISSN><JournalIssue CitedMedium="Internet"><Volume>233</Volume><PubDate><Year>2019</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Life sciences</Title><ISOAbbreviation>Life Sci</ISOAbbreviation></Journal><ArticleTitle>Hypomethylation of the lncRNA SOX21-AS1 has clinical prognostic value in cervical cancer.</ArticleTitle><Pagination><StartPage>116708</StartPage><MedlinePgn>116708</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lfs.2019.116708</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0024-3205(19)30635-6</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Cervical cancer seriously affects women's health. The function of methylated alterations in the long non-coding RNAs (lncRNAs) promote the progression and metastasis of cancer. Our study aims to identify the functional effects of lncRNA methylation in cervical carcinogenesis.</AbstractText><AbstractText Label="MAIN METHODS" NlmCategory="METHODS">Genome-wide DNA methylation of 6 samples was assessed using the Illumina Infinium MethylationEPIC BeadChip. RNA sequencing (RNA-seq) data and survival follow-up time of 307 samples from The Cancer Genome Atlas (TCGA) dataset were enrolled in this study. The statistical analysis and graphical work were mainly realized by R language.</AbstractText><AbstractText Label="KEY FINDINGS" NlmCategory="RESULTS">Methylation map identified 3962 hypermethylated CpG sites and 4484 hypomethylated CpG sites in cervical cancer (|&#x394;&#x3b2;|&#x202f;&#x2265;&#x202f;0.20). Bioinformatic analysis of the lncRNA expression identified 363 upregulated and 664 downregulated lncRNAs with log2 (fold change)&#x202f;&#x2265;&#x202f;1.00 in squamous cervical carcinoma (SCC) samples. Weighted gene co-expression network analysis (WGCNA) and Venn diagram revealed that lncRNA MAGI2 antisense RNA 3 (lncRNA MAGI2-AS3), lncRNA WT1 antisense RNA (lncRNA WT1-AS) and lncRNA SOX21 antisense divergent transcript 1 (lncRNA SOX21-AS1) were important methylation changed lncRNAs. Kaplan-Meier survival curves showed only lncRNA SOX21-AS1 had clinical prognostic value in cervical cancer. Gene set enrichment analysis (GSEA) suggest that lncRNA SOX21-AS1 involve in the multiple cellular processes and might significantly suppress cervical tumorigenesis.</AbstractText><AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">These insights into the functional role of lncRNA SOX21-AS1 DNA methylome alterations in cervical cancer might promote clinically new applicable in diagnosis and prognosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruijie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Obstetrics and Gynecology, Academy of Medical Sciences of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cytopathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Peipei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cytopathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Imaging, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaofu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cytopathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address: lixiaofu1964@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Guomei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address: guomei69@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Life Sci</MedlineTA><NlmUniqueID>0375521</NlmUniqueID><ISSNLinking>0024-3205</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000617875">long noncoding RNA SOX21-AS1, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="Y">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062085" MajorTopicYN="N">RNA, Long Noncoding</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">DNA methylation</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">lncRNA</Keyword><Keyword MajorTopicYN="N">lncRNA SOX21-AS1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31369759</ArticleId><ArticleId IdType="doi">10.1016/j.lfs.2019.116708</ArticleId><ArticleId IdType="pii">S0024-3205(19)30635-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31354287</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1178-6930</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>OncoTargets and therapy</Title><ISOAbbreviation>Onco Targets Ther</ISOAbbreviation></Journal><ArticleTitle>Identification of candidate biomarkers correlated with the diagnosis and prognosis of cervical cancer via integrated bioinformatics analysis.</ArticleTitle><Pagination><StartPage>4517</StartPage><EndPage>4532</EndPage><MedlinePgn>4517-4532</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/OTT.S199615</ELocationID><Abstract><AbstractText><b>Background:</b> Cervical carcinoma is one of the most common malignant gynecological tumors and is associated with high rates of morbidity and mortality. Early diagnosis and early treatment can reduce the mortality rate of cervical cancer. However, there is still no specific biomarkers for the diagnosis and detection of cervical cancer prognosis. Therefore, it is greatly urgent in searching biomarkers correlated with the diagnosis and prognosis of cervical cancer. <b>Results:</b> The mRNA and microRNA expression profile datasets (GSE7803, GSE9750, GSE63514, and GSE30656) were downloaded from the Gene Expression Omnibus database (GEO). The three microarray datasets were integrated to one via integrated bioinformatics. Differentially expressed genes (DEGs) and microRNAs (DEMs) were obtained by R software. The protein-protein interaction (PPI) networks of the DEGs were performed from the STRING database and further visualized by Cytoscape software. A total of 83 DEGs and 14 DEMs were screened from the microarray expression profile datasets. The miRNAs validated to be associated with cervical cancer were obtained using HMDD online website and the target genes of DEMs were identified using the miRWalk2.0 online database. <i>ESR1, PPP1R3C, NSG1</i>, and <i>TMPRSS11D</i> were the gene targets of hsa-miR-21; the targets of hsa-miR-16 were <i>GYS2, ENDOU</i>, and <i>KLF4</i>. These targets were all downregulated in cervical cancer. Finally, we verified the expression of those targets in cervical tissues from TCGA and GTEx databases and analyzed their relationship with survival of cervical cancer patients. In the end, the expression of key genes in cervical cancer tissues was verified via experiment method, we found <i>KLF4</i> and <i>ESR1</i> were&#xa0;downregulated in tumor tissues. <b>Conclusion:</b> This study indicates that <i>KLF4</i> and <i>ESR1</i> are downregulated by the upregulated miR21 and miRNA16 in cervical cancer, respectively, using bioinformatics analysis, and the lower expression of <i>KLF4</i> and <i>ESR1</i> is closely related to the poor prognosis. They might be of clinical significance for the diagnosis and prognosis of cervical cancer, and provide effective targets for the treatment of cervical cancer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Dai</LastName><ForeName>Fangfang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Gantao</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Third People's Hospital of Xiantao in Hubei Province, Wuhan 430060, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Youmei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Mengqin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Dongyong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shiyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yanxiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Onco Targets Ther</MedlineTA><NlmUniqueID>101514322</NlmUniqueID><ISSNLinking>1178-6930</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">differentially expressed genes</Keyword><Keyword MajorTopicYN="N">differentially expressed miRNAs</Keyword><Keyword MajorTopicYN="N">integrated bioinformatics</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>6</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31354287</ArticleId><ArticleId IdType="pmc">PMC6581759</ArticleId><ArticleId IdType="doi">10.2147/OTT.S199615</ArticleId><ArticleId IdType="pii">199615</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Di J, Rutherford S, Chu C. Review of the cervical cancer burden and population-based cervical cancer screening in China. Asian Pac J Cancer Prev. 2015;16(17):7401&#x2013;7407. doi:10.7314/APJCP.2015.16.17.7401</Citation><ArticleIdList><ArticleId IdType="pubmed">26625735</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler TA. Cervical cancer: prevention and early detection. Semin Oncol Nurs. 2017;33(2):172&#x2013;183. doi:10.1016/j.soncn.2017.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.soncn.2017.02.005</ArticleId><ArticleId IdType="pubmed">28343836</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra S, Gupta M, Mathew A, et al. Locally advanced cervical cancer: a study of 5-year outcomes. Indian J Cancer. 2018;55(1):45&#x2013;49. doi:10.4103/ijc.IJC_428_17</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijc.IJC_428_17</ArticleId><ArticleId IdType="pubmed">30147092</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadlow R, Ramaswamy S. DNA microarrays in clinical cancer research. Curr Mol Med. 2005;5(1):111&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">15720274</ArticleId></ArticleIdList></Reference><Reference><Citation>Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev. 2009;35(3):201&#x2013;209. doi:10.1016/j.ctrv.2008.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2008.10.006</ArticleId><ArticleId IdType="pubmed">19081199</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Chen X. Identification of potential biomarkers in cervical cancer with combined public mRNA and miRNA expression microarray data analysis. Oncol Lett. 2018;16(4):5200&#x2013;5208. doi:10.3892/ol.2018.9323</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2018.9323</ArticleId><ArticleId IdType="pmc">PMC6144068</ArticleId><ArticleId IdType="pubmed">30250588</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge Y, Zhang C, Xiao S, et al. Identification of differentially expressed genes in cervical cancer by bioinformatics analysis. Oncol Lett. 2018;16(2):2549&#x2013;2558. doi:10.3892/ol.2018.8953</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2018.8953</ArticleId><ArticleId IdType="pmc">PMC6036588</ArticleId><ArticleId IdType="pubmed">30013649</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Zhu S, Li L, et al. Identification of differentially expressed genes and signaling pathways in ovarian cancer by integrated bioinformatics analysis. Onco Targets Ther. 2018;11:1457&#x2013;1474. doi:10.2147/OTT.S152238</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S152238</ArticleId><ArticleId IdType="pmc">PMC5858852</ArticleId><ArticleId IdType="pubmed">29588600</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y, Kuick R, Nan B, et al. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res. 2007;67(21):10163&#x2013;10172. doi:10.1158/0008-5472.CAN-07-2056</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2056</ArticleId><ArticleId IdType="pubmed">17974957</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotto L, Narayan G, Nandula SV, et al. Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer. 2008;47(9):755&#x2013;765. doi:10.1002/gcc.20577</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gcc.20577</ArticleId><ArticleId IdType="pubmed">18506748</ArticleId></ArticleIdList></Reference><Reference><Citation>Den Boon JA, Pyeon D, Wang SS, et al. Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S A. 2015;112(25):E3255&#x2013;E3264. doi:10.1073/pnas.1509322112</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1509322112</ArticleId><ArticleId IdType="pmc">PMC4485108</ArticleId><ArticleId IdType="pubmed">26056290</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilting SM, Snijders PJ, Verlaat W, et al. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene. 2013;32(1):106&#x2013;116. doi:10.1038/onc.2012.20</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2012.20</ArticleId><ArticleId IdType="pubmed">22330141</ArticleId></ArticleIdList></Reference><Reference><Citation>von Mering C, Huynen M, Jaeggi D, et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165481</ArticleId><ArticleId IdType="pubmed">12519996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550&#x2013;563. doi:10.1016/j.cell.2015.12.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.12.028</ArticleId><ArticleId IdType="pmc">PMC4754110</ArticleId><ArticleId IdType="pubmed">26824661</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98&#x2013;W102. doi:10.1093/nar/gkx247</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx247</ArticleId><ArticleId IdType="pmc">PMC5570223</ArticleId><ArticleId IdType="pubmed">28407145</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87&#x2013;108. doi:10.3322/caac.21262</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21262</ArticleId><ArticleId IdType="pubmed">25651787</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IT, Chou SC, Lin YC. Zoledronic acid induces apoptosis and autophagy in cervical cancer cells. Tumour Biol. 2014;35(12):11913&#x2013;11920. doi:10.1007/s13277-014-2460-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-014-2460-5</ArticleId><ArticleId IdType="pubmed">25142231</ArticleId></ArticleIdList></Reference><Reference><Citation>Petryszak R, Burdett T, Fiorelli B, et al. Expression atlas update&#x2013;a database of gene and transcript expression from microarray- and sequencing-based functional genomics experiments. Nucleic Acids Res. 2014;42(Databaseissue):D926&#x2013;D932. doi:10.1093/nar/gkt1270</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1270</ArticleId><ArticleId IdType="pmc">PMC3964963</ArticleId><ArticleId IdType="pubmed">24304889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni M, Liu X, Wu J, et al. Identification of candidate biomarkers correlated with the pathogenesis and prognosis of non-small cell lung cancer via integrated bioinformatics analysis. Front Genet. 2018;9:469. doi:10.3389/fgene.2018.00173</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00173</ArticleId><ArticleId IdType="pmc">PMC6194157</ArticleId><ArticleId IdType="pubmed">30369945</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang GM, Goyal H, Song LL. Bioinformatics analysis of differentially expressed miRNA-related mRNAs and their prognostic value in breast carcinoma. Oncol Rep. 2018;39(6):2865&#x2013;2872. doi:10.3892/or.2018.6393</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2018.6393</ArticleId><ArticleId IdType="pubmed">29693181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744438</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrero-Rodriguez D, la Cruz HA, Taniguchi-Ponciano K, et al. Kruppel like factors family expression in cervical cancer cells. Arch Med Res. 2017;48(4):314&#x2013;322. doi:10.1016/j.arcmed.2017.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2017.06.011</ArticleId><ArticleId IdType="pubmed">29157672</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663&#x2013;676. doi:10.1016/j.cell.2006.07.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.07.024</ArticleId><ArticleId IdType="pubmed">16904174</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster KW, Liu Z, Nail CD, et al. Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene. 2005;24(9):1491&#x2013;1500. doi:10.1038/sj.onc.1208307</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208307</ArticleId><ArticleId IdType="pmc">PMC1361530</ArticleId><ArticleId IdType="pubmed">15674344</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei D, Kanai M, Jia Z, Le X, Xie K. Kruppel-like factor 4 induces p27Kip1 expression in and suppresses the growth and metastasis of human pancreatic cancer cells. Cancer Res. 2008;68(12):4631&#x2013;4639. doi:10.1158/0008-5472.CAN-07-5953</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-07-5953</ArticleId><ArticleId IdType="pmc">PMC2481517</ArticleId><ArticleId IdType="pubmed">18559508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE, Yang VW. Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene. 2004;23(2):395&#x2013;402. doi:10.1038/sj.onc.1207067</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1207067</ArticleId><ArticleId IdType="pmc">PMC1351029</ArticleId><ArticleId IdType="pubmed">14724568</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang WT, Zheng PS. Kruppel-like factor 4 functions as a tumor suppressor in cervical carcinoma. Cancer. 2012;118(15):3691&#x2013;3702. doi:10.1002/cncr.26698</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.26698</ArticleId><ArticleId IdType="pubmed">22170594</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Yang J, Peng L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017;161(2):279&#x2013;287. doi:10.1007/s10549-016-4059-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-016-4059-6</ArticleId><ArticleId IdType="pubmed">27888421</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirn V, Shi R, Heublein S, et al. Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients. J Cancer Res Clin Oncol. 2014;140(10):1681&#x2013;1687. doi:10.1007/s00432-014-1729-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00432-014-1729-9</ArticleId><ArticleId IdType="pubmed">24908329</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho FR, Prado JC, Pereira Sobrinho JS, et al. Estrogen and progesterone receptors in human papilloma virus-related cervical neoplasia. Braz J Med Biol Res. 2004;37(1):83&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">14689048</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Romero R, Garrido-Guerrero E, Rangel-Lopez A, et al. The cervical malignant cells display a down regulation of ER-alpha but retain the ER-beta expression. Int J Clin Exp Pathol. 2013;6(8):1594&#x2013;1602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726975</ArticleId><ArticleId IdType="pubmed">23923078</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y, Bommer GT, Feng Y, Wiese AB, Fearon ER, Cho KR. Loss of estrogen receptor 1 enhances cervical cancer invasion. Am J Pathol. 2010;177(2):884&#x2013;895. doi:10.2353/ajpath.2010.091166</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2010.091166</ArticleId><ArticleId IdType="pmc">PMC2913367</ArticleId><ArticleId IdType="pubmed">20581058</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Liu Y, Qiao Y, Zhang L, Lu S. miR-103 promotes proliferation and metastasis by targeting KLF4 in gastric cancer. Int J Mol Sci. 2017;18(5):910. doi:10.3390/ijms18050910</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18050910</ArticleId><ArticleId IdType="pmc">PMC5454823</ArticleId><ArticleId IdType="pubmed">28445396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X, Zhong T, Jiang L, Huang J, Xia Y, Hu R. miR-25 enhances cell migration and invasion in non-small-cell lung cancer cells via ERK signaling pathway by inhibiting KLF4. Mol Med Rep. 2018;17(5):7005&#x2013;7016. doi:10.3892/mmr.2018.8772</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2018.8772</ArticleId><ArticleId IdType="pmc">PMC5928655</ArticleId><ArticleId IdType="pubmed">29568911</ArticleId></ArticleIdList></Reference><Reference><Citation>Lettlova S, Brynychova V, Blecha J, et al. MiR-301a-3p suppresses estrogen signaling by directly inhibiting ESR1 in ERalpha positive breast cancer. Cell Physiol Biochem. 2018;46(6):2601&#x2013;2615. doi:10.1159/000489687</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000489687</ArticleId><ArticleId IdType="pubmed">29763890</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Wang YL, Wang JF. [Differential expression of miR-21, miR-126, miR-143, miR-373 in normal cervical tissue, cervical cancer tissue and Hela cell]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012;43(4):536&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">22997891</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Gomez Y, Organista-Nava J, Ocadiz-Delgado R, et al. The expression of miR-21 and miR-143 is deregulated by the HPV16 E7 oncoprotein and 17beta-estradiol. Int J Oncol. 2016;49(2):549&#x2013;558. doi:10.3892/ijo.2016.3575</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2016.3575</ArticleId><ArticleId IdType="pubmed">27278606</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubillaga-Guerrero MI, Alarcon-Romero Ldel C, Illades-Aguiar B, et al. MicroRNA miR-16-1 regulates CCNE1 (cyclin E1) gene expression in human cervical cancer cells. Int J Clin Exp Med. 2015;8(9):15999&#x2013;16006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4658993</ArticleId><ArticleId IdType="pubmed">26629104</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30918060</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2379-5042</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>27</Day></PubDate></JournalIssue><Title>mSphere</Title><ISOAbbreviation>mSphere</ISOAbbreviation></Journal><ArticleTitle>Combined Transcriptome and Proteome Analysis of Immortalized Human Keratinocytes Expressing Human Papillomavirus 16 (HPV16) Oncogenes Reveals Novel Key Factors and Networks in HPV-Induced Carcinogenesis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e00129-19</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/mSphere.00129-19</ELocationID><Abstract><AbstractText>Although the role of high-risk human papillomaviruses (hrHPVs) as etiological agents in cancer development has been intensively studied during the last decades, there is still the necessity of understanding the impact of the HPV <i>E6</i> and <i>E7</i> oncogenes on host cells, ultimately leading to malignant transformation. Here, we used newly established immortalized human keratinocytes with a well-defined HPV16 <i>E6E7</i> expression cassette to get a more complete and less biased overview of global changes induced by HPV16 by employing transcriptome sequencing (RNA-Seq) and stable isotope labeling by amino acids in cell culture (SILAC). This is the first study combining transcriptome and proteome data to characterize the impact of HPV oncogenes in human keratinocytes in comparison with their virus-negative counterparts. To enhance the informative value and accuracy of the RNA-Seq data, four different bioinformatic workflows were used. We identified potential novel upstream regulators (e.g., CNOT7, SPDEF, MITF, and PAX5) controlling distinct clusters of genes within the HPV-host cell network as well as distinct factors (e.g., CPPED1, LCP1, and TAGLN) with essential functions in cancer. Validated results in this study were compared to data sets from The Cancer Genome Atlas (TCGA), demonstrating that several identified factors were also differentially expressed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) and HPV-positive head and neck squamous cell carcinomas (HNSCs). This highly integrative approach allows the identification of novel HPV-induced cellular changes that are also reflected in cancer patients, providing a promising omics data set for future studies in both basic and translational research.<b>IMPORTANCE</b> Human papillomavirus (HPV)-associated cancers still remain a big health problem, especially in developing countries, despite the availability of prophylactic vaccines. Although HPV oncogenes have been intensively investigated for decades, a study applying recent advances in RNA-Seq and quantitative proteomic approaches to a precancerous model system with well-defined HPV oncogene expression alongside HPV-negative parental cells has been missing until now. Here, combined omics analyses reveal global changes caused by the viral oncogenes in a less biased way and allow the identification of novel factors and key cellular networks potentially promoting malignant transformation. In addition, this system also provides a basis for mechanistic research on novel key factors regulated by HPV oncogenes, especially those that are confirmed <i>in vivo</i> in cervical cancer as well as in head and neck cancer patient samples from TCGA data sets.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Yang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ruwen</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klimentov&#xe1;</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Pathology and Biology, Faculty of Military Health Sciences, University of Defense, Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;ckel-Krzikalla</LastName><ForeName>Elke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ly</LastName><ForeName>Regina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gmelin</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hotz-Wagenblatt</LastName><ForeName>Agnes</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Core Facility Omics IT and Data Management (ODCF), German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x158;ehulkov&#xe1;</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Pathology and Biology, Faculty of Military Health Sciences, University of Defense, Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stul&#xed;k</LastName><ForeName>Ji&#x159;&#xed;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Pathology and Biology, Faculty of Military Health Sciences, University of Defense, Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>R&#xf6;sl</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Heidelberg, Germany f.roesl@dkfz-heidelberg.de m.niebler@dkfz-heidelberg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Niebler</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Heidelberg, Germany f.roesl@dkfz-heidelberg.de m.niebler@dkfz-heidelberg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>mSphere</MedlineTA><NlmUniqueID>101674533</NlmUniqueID><ISSNLinking>2379-5042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009856">Oncogene Proteins, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052162" MajorTopicYN="N">Human papillomavirus 16</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015603" MajorTopicYN="N">Keratinocytes</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009856" MajorTopicYN="N">Oncogene Proteins, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077195" MajorTopicYN="N">Squamous Cell Carcinoma of Head and Neck</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HPV</Keyword><Keyword MajorTopicYN="N">RNA-Seq</Keyword><Keyword MajorTopicYN="N">SILAC</Keyword><Keyword MajorTopicYN="N">TCGA</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">head and neck cancer</Keyword><Keyword MajorTopicYN="N">integrated analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30918060</ArticleId><ArticleId IdType="pmc">PMC6437273</ArticleId><ArticleId IdType="doi">10.1128/mSphere.00129-19</ArticleId><ArticleId IdType="pii">4/2/e00129-19</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>de Martel C, Plummer M, Vignat J, Franceschi S. 2017. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 141:664&#x2013;670. doi:10.1002/ijc.30716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.30716</ArticleId><ArticleId IdType="pmc">PMC5520228</ArticleId><ArticleId IdType="pubmed">28369882</ArticleId></ArticleIdList></Reference><Reference><Citation>Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12&#x2013;19. doi:10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">10451482</ArticleId></ArticleIdList></Reference><Reference><Citation>Marur S, D'Souza G, Westra WH, Forastiere AA. 2010. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781&#x2013;789. doi:10.1016/S1470-2045(10)70017-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(10)70017-6</ArticleId><ArticleId IdType="pmc">PMC5242182</ArticleId><ArticleId IdType="pubmed">20451455</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Cancer Foundation. 2018. 
Living with anal cancer/anal cancer facts &amp; figures. Anal Cancer Foundation, ACF USA, New York, New York: 
https://www.analcancerfoundation.org/living-with-anal-cancer/facts-figures/. Accessed September 2018.</Citation></Reference><Reference><Citation>Arbyn M, de Sanjose S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL, Denny L, Bornstein J, Abramowitz L, Giuliano A, Tommasino M, Monsonego J. 2012. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 131:1969&#x2013;1982. doi:10.1002/ijc.27650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.27650</ArticleId><ArticleId IdType="pmc">PMC3429628</ArticleId><ArticleId IdType="pubmed">22623137</ArticleId></ArticleIdList></Reference><Reference><Citation>Brisson M, B&#xe9;nard &#xc9;, Drolet M, Bogaards JA, Baussano I, V&#xe4;nsk&#xe4; S, Jit M, Boily M-C, Smith MA, Berkhof J, Canfell K, Chesson HW, Burger EA, Choi YH, De Blasio BF, De Vlas SJ, Guzzetta G, Hontelez JAC, Horn J, Jepsen MR, Kim JJ, Lazzarato F, Matthijsse SM, Mikolajczyk R, Pavelyev A, Pillsbury M, Shafer LA, Tully SP, Turner HC, Usher C, Walsh C. 2016. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health 1:e8&#x2013;e17. doi:10.1016/S2468-2667(16)30001-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(16)30001-9</ArticleId><ArticleId IdType="pmc">PMC6727207</ArticleId><ArticleId IdType="pubmed">29253379</ArticleId></ArticleIdList></Reference><Reference><Citation>Joura E, Bautista O, Luxembourg A. 2015. A 9-valent HPV vaccine in women. N Engl J Med 372:2568&#x2013;2569. doi:10.1056/NEJMc1504359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1504359</ArticleId><ArticleId IdType="pubmed">26107058</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher KE, LaMontagne DS, Watson-Jones D. 2018. Status of HPV vaccine introduction and barriers to country uptake. Vaccine 36:4761&#x2013;4767. doi:10.1016/j.vaccine.2018.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.02.003</ArticleId><ArticleId IdType="pubmed">29580641</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394&#x2013;424. doi:10.3322/caac.21492.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanmugasundaram S, You J. 2017. Targeting persistent human papillomavirus infection. Viruses 9:E229. doi:10.3390/v9080229.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v9080229</ArticleId><ArticleId IdType="pmc">PMC5580486</ArticleId><ArticleId IdType="pubmed">28820433</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaves M. 2015. Evolutionary determinants of cancer. Cancer Discov 5:806&#x2013;820. doi:10.1158/2159-8290.CD-15-0439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-15-0439</ArticleId><ArticleId IdType="pmc">PMC4539576</ArticleId><ArticleId IdType="pubmed">26193902</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesri EA, Feitelson MA, Munger K. 2014. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 15:266&#x2013;282. doi:10.1016/j.chom.2014.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2014.02.011</ArticleId><ArticleId IdType="pmc">PMC3992243</ArticleId><ArticleId IdType="pubmed">24629334</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Clements A, Zhao K, Marmorstein R. 2006. Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem 281:578&#x2013;586. doi:10.1074/jbc.M508455200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508455200</ArticleId><ArticleId IdType="pubmed">16249186</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Zapien D, Ruiz FX, Poirson J, Mitschler A, Ramirez J, Forster A, Cousido-Siah A, Masson M, Vande Pol S, Podjarny A, Trav&#xe9; G, Zanier K. 2016. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature 529:541&#x2013;545. doi:10.1038/nature16481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature16481</ArticleId><ArticleId IdType="pmc">PMC4853763</ArticleId><ArticleId IdType="pubmed">26789255</ArticleId></ArticleIdList></Reference><Reference><Citation>Halbert CL, Demers GW, Galloway DA. 1991. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 65:473&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240541</ArticleId><ArticleId IdType="pubmed">1845902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. 1989. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8:3905&#x2013;3910. doi:10.1002/j.1460-2075.1989.tb08570.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1989.tb08570.x</ArticleId><ArticleId IdType="pmc">PMC402081</ArticleId><ArticleId IdType="pubmed">2555178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanahan D, Weinberg Robert A. 2011. Hallmarks of cancer: the next generation. Cell 144:646&#x2013;674. doi:10.1016/j.cell.2011.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.02.013</ArticleId><ArticleId IdType="pubmed">21376230</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden RBS, Stern PL. 2018. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer 18:240. doi:10.1038/nrc.2018.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2018.13</ArticleId><ArticleId IdType="pmc">PMC6454884</ArticleId><ArticleId IdType="pubmed">29497146</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo D, Munoz JP, Huerta H, Leal G, Corvalan A, Leon O, Calaf GM, Urzua U, Boccardo E, Tapia JC, Aguayo F. 2017. Upregulation of PIR gene expression induced by human papillomavirus E6 and E7 in epithelial oral and cervical cells. Open Biol 7:170111. doi:10.1098/rsob.170111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.170111</ArticleId><ArticleId IdType="pmc">PMC5717337</ArticleId><ArticleId IdType="pubmed">29118270</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicchini L, Blumhagen RZ, Westrich JA, Myers ME, Warren CJ, Siska C, Raben D, Kechris KJ, Pyeon D. 2017. High-risk human papillomavirus E7 alters host DNA methylome and represses HLA-E expression in human keratinocytes. Sci Rep 7:3633. doi:10.1038/s41598-017-03295-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-03295-7</ArticleId><ArticleId IdType="pmc">PMC5473897</ArticleId><ArticleId IdType="pubmed">28623356</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyongyosi E, Szalmas A, Ferenczi A, Poliska S, Konya J, Veress G. 2015. Transcriptional regulation of genes involved in keratinocyte differentiation by human papillomavirus 16 oncoproteins. Arch Virol 160:389&#x2013;398. doi:10.1007/s00705-014-2305-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-014-2305-y</ArticleId><ArticleId IdType="pubmed">25488293</ArticleId></ArticleIdList></Reference><Reference><Citation>Peta E, Sinigaglia A, Masi G, Di Camillo B, Grassi A, Trevisan M, Messa L, Loregian A, Manfrin E, Brunelli M, Martignoni G, Palu G, Barzon L. 2018. HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys. Oncogene 37:1654&#x2013;1668. doi:10.1038/s41388-017-0083-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-017-0083-1</ArticleId><ArticleId IdType="pubmed">29335520</ArticleId></ArticleIdList></Reference><Reference><Citation>Mwapagha LM, Tiffin N, Parker MI. 2017. Delineation of the HPV11E6 and HPV18E6 pathways in initiating cellular transformation. Front Oncol 7:258. doi:10.3389/fonc.2017.00258.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2017.00258</ArticleId><ArticleId IdType="pmc">PMC5672010</ArticleId><ArticleId IdType="pubmed">29164058</ArticleId></ArticleIdList></Reference><Reference><Citation>Feber A, Arya M, de Winter P, Saqib M, Nigam R, Malone PR, Tan WS, Rodney S, Lechner M, Freeman A, Jameson C, Muneer A, Beck S, Kelly JD. 2015. Epigenetics markers of metastasis and HPV-induced tumorigenesis in penile cancer. Clin Cancer Res 21:1196&#x2013;1206. doi:10.1158/1078-0432.CCR-14-1656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-1656</ArticleId><ArticleId IdType="pmc">PMC4351916</ArticleId><ArticleId IdType="pubmed">25538261</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SP, Scarpini CG, Groves IJ, Odle RI, Coleman N. 2016. Identification of host transcriptional networks showing concentration-dependent regulation by HPV16 E6 and E7 proteins in basal cervical squamous epithelial cells. Sci Rep 6:29832. doi:10.1038/srep29832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep29832</ArticleId><ArticleId IdType="pmc">PMC4960560</ArticleId><ArticleId IdType="pubmed">27457222</ArticleId></ArticleIdList></Reference><Reference><Citation>Klymenko T, Gu Q, Herbert I, Stevenson A, Iliev V, Watkins G, Pollock C, Bhatia R, Cuschieri K, Herzyk P, Gatherer D, Graham SV. 2017. RNASeq analysis of differentiated keratinocytes reveals a massive response to late events during human papillomavirus type 16 infection, including loss of epithelial barrier function. J Virol 91:e01001-17. doi:10.1128/JVI.01001-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01001-17</ArticleId><ArticleId IdType="pmc">PMC5709591</ArticleId><ArticleId IdType="pubmed">29021401</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienkowska-Haba M, Luszczek W, Myers JE, Keiffer TR, DiGiuseppe S, Polk P, Bodily JM, Scott RS, Sapp M. 2018. A new cell culture model to genetically dissect the complete human papillomavirus life cycle. PLoS Pathog 14:e1006846. doi:10.1371/journal.ppat.1006846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006846</ArticleId><ArticleId IdType="pmc">PMC5833277</ArticleId><ArticleId IdType="pubmed">29494681</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore PS, Chang Y. 2017. Common commensal cancer viruses. PLoS Pathog 13:e1006078. doi:10.1371/journal.ppat.1006078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006078</ArticleId><ArticleId IdType="pmc">PMC5245784</ArticleId><ArticleId IdType="pubmed">28103305</ArticleId></ArticleIdList></Reference><Reference><Citation>Piboonniyom SO, Timmermann S, Hinds P, Munger K. 2002. Aberrations in the MTS1 tumor suppressor locus in oral squamous cell carcinoma lines preferentially affect the INK4A gene and result in increased cdk6 activity. Oral Oncol 38:179&#x2013;186. doi:10.1016/S1368-8375(01)00042-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1368-8375(01)00042-2</ArticleId><ArticleId IdType="pubmed">11854066</ArticleId></ArticleIdList></Reference><Reference><Citation>Israr M, Rosenthal D, Frejo-Navarro L, DeVoti J, Meyers C, Bonagura VR. 2018. Microarray analysis of human keratinocytes from different anatomic sites reveals site-specific immune signaling and responses to human papillomavirus type 16 transfection. Mol Med 24:23. doi:10.1186/s10020-018-0022-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-018-0022-9</ArticleId><ArticleId IdType="pmc">PMC6016891</ArticleId><ArticleId IdType="pubmed">30134802</ArticleId></ArticleIdList></Reference><Reference><Citation>Villa PL, Jackson R, Eade S, Escott N, Zehbe I. 2018. Isolation of biopsy-derived, human cervical keratinocytes propagated as monolayer and organoid cultures. Sci Rep 8:17869. doi:10.1038/s41598-018-36150-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-36150-4</ArticleId><ArticleId IdType="pmc">PMC6294766</ArticleId><ArticleId IdType="pubmed">30552408</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang S, Tao M, McCoy JP Jr, Zheng ZM. 2006. The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J Virol 80:4249&#x2013;4263. doi:10.1128/JVI.80.9.4249-4263.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.80.9.4249-4263.2006</ArticleId><ArticleId IdType="pmc">PMC1472016</ArticleId><ArticleId IdType="pubmed">16611884</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberger S, De-Castro Arce J, Langbein L, Steenbergen RDM, R&#xf6;sl F. 2010. Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation. Proc Natl Acad Sci U S A 107:7006&#x2013;7011. doi:10.1073/pnas.1002620107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1002620107</ArticleId><ArticleId IdType="pmc">PMC2872467</ArticleId><ArticleId IdType="pubmed">20351270</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham SV, Faizo AA. 2017. Control of human papillomavirus gene expression by alternative splicing. Virus Res 231:83&#x2013;95. doi:10.1016/j.virusres.2016.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2016.11.016</ArticleId><ArticleId IdType="pmc">PMC5335905</ArticleId><ArticleId IdType="pubmed">27867028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Lee S-R, Li L-H, Park H-J, Park J-H, Lee KY, Kim M-K, Shin BA, Choi S-Y. 2011. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 6:e18556. doi:10.1371/journal.pone.0018556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0018556</ArticleId><ArticleId IdType="pmc">PMC3084703</ArticleId><ArticleId IdType="pubmed">21602908</ArticleId></ArticleIdList></Reference><Reference><Citation>Moiani A, Paleari Y, Sartori D, Mezzadra R, Miccio A, Cattoglio C, Cocchiarella F, Lidonnici MR, Ferrari G, Mavilio F. 2012. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest 122:1653&#x2013;1666. doi:10.1172/JCI61852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI61852</ArticleId><ArticleId IdType="pmc">PMC3347495</ArticleId><ArticleId IdType="pubmed">22523069</ArticleId></ArticleIdList></Reference><Reference><Citation>Conesa A, Madrigal P, Tarazona S, Gomez-Cabrero D, Cervera A, McPherson A, Szcze&#x15b;niak MW, Gaffney DJ, Elo LL, Zhang X, Mortazavi A. 2016. A survey of best practices for RNA-seq data analysis. Genome Biol 17:13. doi:10.1186/s13059-016-0881-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-016-0881-8</ArticleId><ArticleId IdType="pmc">PMC4728800</ArticleId><ArticleId IdType="pubmed">26813401</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams CR, Baccarella A, Parrish JZ, Kim CC. 2017. Empirical assessment of analysis workflows for differential expression analysis of human samples using RNA-Seq. BMC Bioinformatics 18:38. doi:10.1186/s12859-016-1457-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-016-1457-z</ArticleId><ArticleId IdType="pmc">PMC5240434</ArticleId><ArticleId IdType="pubmed">28095772</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglesias M, Yen K, Gaiotti D, Hildesheim A, Stoler MH, Woodworth CD. 1998. Human papillomavirus type 16 E7 protein sensitizes cervical keratinocytes to apoptosis and release of interleukin-1alpha. Oncogene 17:1195&#x2013;1205. doi:10.1038/sj.onc.1202054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1202054</ArticleId><ArticleId IdType="pubmed">9771962</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim R, Tummers B, Meyers C, Biryukov JL, Alam S, Backendorf C, Jha V, Offringa R, van Ommen G-J, Melief CJM, Guardavaccaro D, Boer JM, van der Burg SH. 2013. Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Pathog 9:e1003384. doi:10.1371/journal.ppat.1003384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003384</ArticleId><ArticleId IdType="pmc">PMC3662672</ArticleId><ArticleId IdType="pubmed">23717208</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohavanichbutr P, Houck J, Fan W, Yueh B, Mendez E, Futran N, Doody D, Upton M, Farwell D, Schwartz S, Zhao L, Chen C. 2009. Genomewide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices. Arch Otolaryngol Head Neck Surg 135:180&#x2013;188. doi:10.1001/archoto.2008.540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archoto.2008.540</ArticleId><ArticleId IdType="pmc">PMC2761829</ArticleId><ArticleId IdType="pubmed">19221247</ArticleId></ArticleIdList></Reference><Reference><Citation>Almadori G, Cadoni G, Cattani P, Galli J, Bussu F, Ferrandina G, Scambia G, Fadda G, Maurizi M. 2001. Human papillomavirus infection and epidermal growth factor receptor expression in primary laryngeal squamous cell carcinoma. Clin Cancer Res 7:3988.</Citation><ArticleIdList><ArticleId IdType="pubmed">11751491</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldakhakhny S, Zhou Q, Crosbie EJ, Sayan BS. 2018. Human papillomavirus E7 induces p63 expression to modulate DNA damage response. Cell Death Dis 9:127. doi:10.1038/s41419-017-0149-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-017-0149-6</ArticleId><ArticleId IdType="pmc">PMC5833683</ArticleId><ArticleId IdType="pubmed">29374145</ArticleId></ArticleIdList></Reference><Reference><Citation>Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Syrj&#xe4;nen S, Favalli C, Syrj&#xe4;nen K. 2007. Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer. Eur J Obstet Gynecol Reprod Biol 130:223&#x2013;231. doi:10.1016/j.ejogrb.2006.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejogrb.2006.10.007</ArticleId><ArticleId IdType="pubmed">17098349</ArticleId></ArticleIdList></Reference><Reference><Citation>Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. 2001. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-&#x3ba;B-responsive genes in cervical keratinocytes. J Virol 75:4283&#x2013;4296. doi:10.1128/JVI.75.9.4283-4296.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.9.4283-4296.2001</ArticleId><ArticleId IdType="pmc">PMC114174</ArticleId><ArticleId IdType="pubmed">11287578</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey O, Lee S, Park N-H. 2000. Human papillomavirus type 16 E7 oncoprotein represses transcription of human fibronectin. J Virol 74:4912&#x2013;4918. doi:10.1128/JVI.74.10.4912-4918.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.10.4912-4918.2000</ArticleId><ArticleId IdType="pmc">PMC112019</ArticleId><ArticleId IdType="pubmed">10775635</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C, Pauli E-K, Biryukov J, Feister KF, Meng M, White EA, M&#xfc;nger K, Howley PM, Meyers C, Gack MU. 2018. The human papillomavirus E6 oncoprotein targets USP15 and TRIM25 to suppress RIG-I-mediated innate immune signaling. J Virol 92:e01737-17. doi:10.1128/JVI.01737-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01737-17</ArticleId><ArticleId IdType="pmc">PMC5827370</ArticleId><ArticleId IdType="pubmed">29263274</ArticleId></ArticleIdList></Reference><Reference><Citation>Harden ME, Prasad N, Griffiths A, Munger K. 2017. Modulation of microRNA-mRNA target pairs by human papillomavirus 16 oncoproteins. mBio 8:e02170-16. doi:10.1128/mBio.02170-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02170-16</ArticleId><ArticleId IdType="pmc">PMC5210503</ArticleId><ArticleId IdType="pubmed">28049151</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulbahce N, Yan H, Dricot A, Padi M, Byrdsong D, Franchi R, Lee D-S, Rozenblatt-Rosen O, Mar JC, Calderwood MA, Baldwin A, Zhao B, Santhanam B, Braun P, Simonis N, Huh K-W, Hellner K, Grace M, Chen A, Rubio R, Marto JA, Christakis NA, Kieff E, Roth FP, Roecklein-Canfield J, Decaprio JA, Cusick ME, Quackenbush J, Hill DE, M&#xfc;nger K, Vidal M, Barab&#xe1;si A-L. 2012. Viral perturbations of host networks reflect disease etiology. PLoS Comput Biol 8:e1002531. doi:10.1371/journal.pcbi.1002531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1002531</ArticleId><ArticleId IdType="pmc">PMC3386155</ArticleId><ArticleId IdType="pubmed">22761553</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SD, Chatterjee S, Alam S, Salzberg AC, Milici J, van der Burg SH, Meyers C. 2018. Effect of productive human papillomavirus 16 infection on global gene expression in cervical epithelium. J Virol 92:e01261-18. doi:10.1128/JVI.01261-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01261-18</ArticleId><ArticleId IdType="pmc">PMC6158420</ArticleId><ArticleId IdType="pubmed">30045992</ArticleId></ArticleIdList></Reference><Reference><Citation>Beglin M, Melar-New M, Laimins L. 2009. Human papillomaviruses and the interferon response. J Interferon Cytokine Res 29:629&#x2013;635. doi:10.1089/jir.2009.0075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2009.0075</ArticleId><ArticleId IdType="pmc">PMC2956683</ArticleId><ArticleId IdType="pubmed">19715460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowli S, Velidandla R, Creek KE, Pirisi L. 2013. TGF-beta regulation of gene expression at early and late stages of HPV16-mediated transformation of human keratinocytes. Virology 447:63&#x2013;73. doi:10.1016/j.virol.2013.08.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2013.08.034</ArticleId><ArticleId IdType="pmc">PMC3895483</ArticleId><ArticleId IdType="pubmed">24210100</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung SH, Franceschi S, Lambert PF. 2010. Estrogen and ERalpha: culprits in cervical cancer? Trends Endocrinol Metab 21:504&#x2013;511. doi:10.1016/j.tem.2010.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2010.03.005</ArticleId><ArticleId IdType="pmc">PMC2914219</ArticleId><ArticleId IdType="pubmed">20456973</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapat C, Kolytcheff C, Le Romancer M, Auboeuf D, De La Grange P, Chettab K, Sentis S, Corbo L. 2013. hCAF1/CNOT7 regulates interferon signalling by targeting STAT1. EMBO J 32:688&#x2013;700. doi:10.1038/emboj.2013.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2013.11</ArticleId><ArticleId IdType="pmc">PMC3594750</ArticleId><ArticleId IdType="pubmed">23386060</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu X, Zerbini LF, Otu HH, Bhasin M, Yang Q, Joseph MG, Grall F, Onatunde T, Correa RG, Libermann TA. 2007. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 67:4219&#x2013;4226. doi:10.1158/0008-5472.CAN-06-3689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-06-3689</ArticleId><ArticleId IdType="pubmed">17483333</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, Haw R, Jassal B, Korninger F, May B, Milacic M, Roca CD, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Viteri G, Weiser J, Wu G, Stein L, Hermjakob H, D&#x2019;Eustachio P. 2018. The Reactome Pathway Knowledgebase. Nucleic Acids Res 46:D649&#x2013;D655. doi:10.1093/nar/gkx1132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1132</ArticleId><ArticleId IdType="pmc">PMC5753187</ArticleId><ArticleId IdType="pubmed">29145629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuo DX, Zhang XW, Jin B, Zhang Z, Xie BS, Wu CL, Gong K, Mao ZB. 2013. CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site. PLoS One 8:e65679. doi:10.1371/journal.pone.0065679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0065679</ArticleId><ArticleId IdType="pmc">PMC3684612</ArticleId><ArticleId IdType="pubmed">23799035</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lee JJ, Lotan D, Lotan R. 2007. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst 99:1668&#x2013;1682. doi:10.1093/jnci/djm208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djm208</ArticleId><ArticleId IdType="pubmed">18000218</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Dong L, Zhang R, Ying K, Shen H. 2014. Transgelin overexpression in lung adenocarcinoma is associated with tumor progression. Int J Mol Med 34:585&#x2013;591. doi:10.3892/ijmm.2014.1805.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2014.1805</ArticleId><ArticleId IdType="pubmed">24938684</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J. 2017. Aurora kinases: novel therapy targets in cancers. Oncotarget 8:23937&#x2013;23954. doi:10.18632/oncotarget.14893.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.14893</ArticleId><ArticleId IdType="pmc">PMC5410356</ArticleId><ArticleId IdType="pubmed">28147341</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatlekar S, Fields JZ, Boman BM. 2014. HOX genes and their role in the development of human cancers. J Mol Med (Berl) 92:811&#x2013;823. doi:10.1007/s00109-014-1181-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-014-1181-y</ArticleId><ArticleId IdType="pubmed">24996520</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H-C, Klein PS. 2004. The Frizzled family: receptors for multiple signal transduction pathways. Genome Biol 5:234. doi:10.1186/gb-2004-5-7-234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2004-5-7-234</ArticleId><ArticleId IdType="pmc">PMC463283</ArticleId><ArticleId IdType="pubmed">15239825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonner JM, Boulianne GL. 2017. Diverse structures, functions and uses of FK506 binding proteins. Cell Signal 38:97&#x2013;105. doi:10.1016/j.cellsig.2017.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2017.06.013</ArticleId><ArticleId IdType="pubmed">28652145</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjerstorff MF, Andersen MH, Ditzel HJ. 2015. Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget 6:15772&#x2013;15787. doi:10.18632/oncotarget.4694.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.4694</ArticleId><ArticleId IdType="pmc">PMC4599236</ArticleId><ArticleId IdType="pubmed">26158218</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Souza G, Dempsey A. 2011. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med 53(Suppl 1):S5&#x2013;S11. doi:10.1016/j.ypmed.2011.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2011.08.001</ArticleId><ArticleId IdType="pmc">PMC3287051</ArticleId><ArticleId IdType="pubmed">21962471</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Mi Y, Mueller T, Kreibich S, Williams EG, Van Drogen A, Borel C, Frank M, Germain P-L, Bludau I, Mehnert M, Seifert M, Emmenlauer M, Sorg I, Bezrukov F, Bena FS, Zhou H, Dehio C, Testa G, Saez-Rodriguez J, Antonarakis SE, Hardt W-D, Aebersold R. 2019. Multi-omic measurements of heterogeneity in HeLa cells across laboratories. Nat Biotechnol 37:314&#x2013;322. doi:10.1038/s41587-019-0037-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0037-y</ArticleId><ArticleId IdType="pubmed">30778230</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan N. 2016. Signatures of prostate-derived Ets factor (PDEF) in cancer. Tumour Biol 37:14335&#x2013;14340. doi:10.1007/s13277-016-5326-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-016-5326-1</ArticleId><ArticleId IdType="pubmed">27612480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman ML, Czyz M. 2015. MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci 72:1249&#x2013;1260. doi:10.1007/s00018-014-1791-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-014-1791-0</ArticleId><ArticleId IdType="pmc">PMC4363485</ArticleId><ArticleId IdType="pubmed">25433395</ArticleId></ArticleIdList></Reference><Reference><Citation>Copp&#xe9; J-P, Desprez P-Y, Krtolica A, Campisi J. 2010. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5:99&#x2013;118. doi:10.1146/annurev-pathol-121808-102144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathol-121808-102144</ArticleId><ArticleId IdType="pmc">PMC4166495</ArticleId><ArticleId IdType="pubmed">20078217</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao SG, Jackson JG. 2016. SASP: tumor suppressor or promoter? Yes! Trends Cancer 2:676&#x2013;687. doi:10.1016/j.trecan.2016.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trecan.2016.10.001</ArticleId><ArticleId IdType="pubmed">28741506</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruhland MK, Loza AJ, Capietto A-H, Luo X, Knolhoff BL, Flanagan KC, Belt BA, Alspach E, Leahy K, Luo J, Schaffer A, Edwards JR, Longmore G, Faccio R, DeNardo DG, Stewart SA. 2016. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun 7:11762. doi:10.1038/ncomms11762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11762</ArticleId><ArticleId IdType="pmc">PMC4899869</ArticleId><ArticleId IdType="pubmed">27272654</ArticleId></ArticleIdList></Reference><Reference><Citation>Borodkina AV, Deryabin PI, Giukova AA, Nikolsky NN. 2018. &#x201c;Social life&#x201d; of senescent cells: what is SASP and why study it? Acta Naturae 10:4&#x2013;14. doi:10.32607/20758251-2018-10-1-4-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.32607/20758251-2018-10-1-4-14</ArticleId><ArticleId IdType="pmc">PMC5916729</ArticleId><ArticleId IdType="pubmed">29713514</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaittinen M, Kaminska D, K&#xe4;kel&#xe4; P, Eskelinen M, Kolehmainen M, Pihlajam&#xe4;ki J, Uusitupa M, Pulkkinen L. 2013. Downregulation of CPPED1 expression improves glucose metabolism in vitro in adipocytes. Diabetes 62:3747&#x2013;3750. doi:10.2337/db13-0830.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0830</ArticleId><ArticleId IdType="pmc">PMC3806586</ArticleId><ArticleId IdType="pubmed">23939394</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal D, Kassianos AJ, Tran LS, Bergot AS, Gosmann C, Hofmann J, Blumenthal A, Leggatt GR, Frazer IH. 2013. Indoleamine 2,3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7. J Invest Dermatol 133:2686&#x2013;2694. doi:10.1038/jid.2013.222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.2013.222</ArticleId><ArticleId IdType="pmc">PMC3779505</ArticleId><ArticleId IdType="pubmed">23652797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wabnitz GH, Kocher T, Lohneis P, Stober C, Konstandin MH, Funk B, Sester U, Wilm M, Klemke M, Samstag Y. 2007. Costimulation induced phosphorylation of l-plastin facilitates surface transport of the T cell activation molecules CD69 and CD25. Eur J Immunol 37:649&#x2013;662. doi:10.1002/eji.200636320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200636320</ArticleId><ArticleId IdType="pubmed">17294403</ArticleId></ArticleIdList></Reference><Reference><Citation>Koide N, Kasamatsu A, Endo-Sakamoto Y, Ishida S, Shimizu T, Kimura Y, Miyamoto I, Yoshimura S, Shiiba M, Tanzawa H, Uzawa K. 2017. Evidence for critical role of lymphocyte cytosolic protein 1 in oral cancer. Sci Rep 7:43379. doi:10.1038/srep43379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep43379</ArticleId><ArticleId IdType="pmc">PMC5322526</ArticleId><ArticleId IdType="pubmed">28230172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Mehta KP, Laimins LA. 2011. Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J Virol 85:9486&#x2013;9494. doi:10.1128/JVI.05007-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05007-11</ArticleId><ArticleId IdType="pmc">PMC3165741</ArticleId><ArticleId IdType="pubmed">21734056</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YE, Laimins LA. 2000. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 74:4174&#x2013;4182. doi:10.1128/JVI.74.9.4174-4182.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.9.4174-4182.2000</ArticleId><ArticleId IdType="pmc">PMC111932</ArticleId><ArticleId IdType="pubmed">10756030</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang K-W, Alaei-Mahabadi B, Samuelsson T, Lindh M, Larsson E. 2013. The landscape of viral expression and host gene fusion and adaptation in human cancer. Nat Commun 4:2513. doi:10.1038/ncomms3513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3513</ArticleId><ArticleId IdType="pmc">PMC3806554</ArticleId><ArticleId IdType="pubmed">24085110</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson O, Moghraby JS, Ayscough KR, Winder SJ. 2012. Depletion of the actin bundling protein SM22/transgelin increases actin dynamics and enhances the tumourigenic phenotypes of cells. BMC Cell Biol 13:1. doi:10.1186/1471-2121-13-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2121-13-1</ArticleId><ArticleId IdType="pmc">PMC3280177</ArticleId><ArticleId IdType="pubmed">22257561</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahiya N, Becker KG, Wood WH III, Zhang Y, Morin PJ. 2011. Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion. PLoS One 6:e22119. doi:10.1371/journal.pone.0022119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0022119</ArticleId><ArticleId IdType="pmc">PMC3137611</ArticleId><ArticleId IdType="pubmed">21789222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobel G, Paska C, Szabo I, Kiss A, Kadar A, Schaff Z. 2005. Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. Hum Pathol 36:162&#x2013;169. doi:10.1016/j.humpath.2004.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humpath.2004.12.001</ArticleId><ArticleId IdType="pubmed">15754293</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. 2010. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 38:576&#x2013;589. doi:10.1016/j.molcel.2010.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2010.05.004</ArticleId><ArticleId IdType="pmc">PMC2898526</ArticleId><ArticleId IdType="pubmed">20513432</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods 9:357&#x2013;359. doi:10.1038/nmeth.1923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1923</ArticleId><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. doi:10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel H, Bray NL, Puente S, Melsted P, Pachter L. 2017. Differential analysis of RNA-seq incorporating quantification uncertainty. Nat Methods 14:687&#x2013;690. doi:10.1038/nmeth.4324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4324</ArticleId><ArticleId IdType="pubmed">28581496</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RE, Jarvis KL, Hyland KJ. 1989. Protein measurement using bicinchoninic acid: elimination of interfering substances. Anal Biochem 180:136&#x2013;139. doi:10.1016/0003-2697(89)90101-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-2697(89)90101-2</ArticleId><ArticleId IdType="pubmed">2817336</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Tomita M, Ishihama Y. 2008. Phase transfer surfactant-aided trypsin digestion for membrane proteome analysis. J Proteome Res 7:731&#x2013;740. doi:10.1021/pr700658q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr700658q</ArticleId><ArticleId IdType="pubmed">18183947</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Mann M. 2008. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26:1367&#x2013;1372. doi:10.1038/nbt.1511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1511</ArticleId><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M, Cox J. 2016. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 13:731. doi:10.1038/nmeth.3901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3901</ArticleId><ArticleId IdType="pubmed">27348712</ArticleId></ArticleIdList></Reference><Reference><Citation>Doidge R, Mittal S, Aslam A, Winkler GS. 2012. The anti-proliferative activity of BTG/TOB proteins is mediated via the Caf1a (CNOT7) and Caf1b (CNOT8) deadenylase subunits of the Ccr4-not complex. PLoS One 7:e51331. doi:10.1371/journal.pone.0051331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0051331</ArticleId><ArticleId IdType="pmc">PMC3517456</ArticleId><ArticleId IdType="pubmed">23236473</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan AR, Hall IM. 2010. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26:841&#x2013;842. doi:10.1093/bioinformatics/btq033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq033</ArticleId><ArticleId IdType="pmc">PMC2832824</ArticleId><ArticleId IdType="pubmed">20110278</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Langmead B, Salzberg SL. 2015. HISAT: a fast spliced aligner with low memory requirements. Nat Methods 12:357&#x2013;360. doi:10.1038/nmeth.3317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3317</ArticleId><ArticleId IdType="pmc">PMC4655817</ArticleId><ArticleId IdType="pubmed">25751142</ArticleId></ArticleIdList></Reference><Reference><Citation>Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. 2016. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc 11:1650&#x2013;1667. doi:10.1038/nprot.2016.095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.095</ArticleId><ArticleId IdType="pmc">PMC5032908</ArticleId><ArticleId IdType="pubmed">27560171</ArticleId></ArticleIdList></Reference><Reference><Citation>Pertea M, Pertea GM, Antonescu CM, Chang T-C, Mendell JT, Salzberg SL. 2015. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol 33:290&#x2013;295. doi:10.1038/nbt.3122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3122</ArticleId><ArticleId IdType="pmc">PMC4643835</ArticleId><ArticleId IdType="pubmed">25690850</ArticleId></ArticleIdList></Reference><Reference><Citation>Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. 2017. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14:417&#x2013;419. doi:10.1038/nmeth.4197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4197</ArticleId><ArticleId IdType="pmc">PMC5600148</ArticleId><ArticleId IdType="pubmed">28263959</ArticleId></ArticleIdList></Reference><Reference><Citation>Franc V, Rehulka P, Medda R, Padiglia A, Floris G, Sebela M. 2013. Analysis of the glycosylation pattern of plant copper amine oxidases by MALDI-TOF/TOF MS coupled to a manual chromatographic separation of glycans and glycopeptides. Electrophoresis 34:2357&#x2013;2367. doi:10.1002/elps.201200622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/elps.201200622</ArticleId><ArticleId IdType="pubmed">23580492</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehulka P, Zahradnikova M, Rehulkova H, Dvorakova P, Nenutil R, Valik D, Vojtesek B, Hernychova L, Novotny MV. 2018. Microgradient separation technique for purification and fractionation of permethylated N-glycans before mass spectrometric analyses. J Sep Sci 41:1973&#x2013;1982. doi:10.1002/jssc.201701339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jssc.201701339</ArticleId><ArticleId IdType="pubmed">29392831</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. 2017. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45:W98&#x2013;W102. doi:10.1093/nar/gkx247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx247</ArticleId><ArticleId IdType="pmc">PMC5570223</ArticleId><ArticleId IdType="pubmed">28407145</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman M, Craft B, Brooks AN, Zhu J, Haussler D. 
2018. 
The UCSC Xena Platform for cancer genomics data visualization and interpretation. https://www.biorxiv.org/content/10.1101/326470v3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/326470v3</ArticleId></ArticleIdList></Reference><Reference><Citation>Vizcaino JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, Xu QW, Wang R, Hermjakob H. 2016. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res 44:D447&#x2013;D456. doi:10.1093/nar/gkv1145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv1145</ArticleId><ArticleId IdType="pmc">PMC4702828</ArticleId><ArticleId IdType="pubmed">26527722</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30698466</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-7430</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>DNA and cell biology</Title><ISOAbbreviation>DNA Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Identification of a 26-lncRNAs Risk Model for Predicting Overall Survival of Cervical Squamous Cell Carcinoma Based on Integrated Bioinformatics Analysis.</ArticleTitle><Pagination><StartPage>322</StartPage><EndPage>332</EndPage><MedlinePgn>322-332</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/dna.2018.4533</ELocationID><Abstract><AbstractText>As a common malignancy in women, cervical squamous cell carcinoma is a major cause of cancer-related mortality globally. Recent studies have demonstrated that long non-coding RNA (lncRNA) can function as potential biomarkers in cancer prognosis; however, little is known about its role in cervical cancer. In this study, we downloaded the gene expression profiles along with the clinical data of patients with cervical squamous cell carcinoma from The Cancer Genome Atlas. By applying bioinformatics analysis including random forest selection and Least Absolute Shrinkage and Selection Operator (LASSO) cox regression model along with 10-fold cross-validation, we constructed a 26-lncRNAs risk model that can be used to predict the overall survival of cervical squamous cell carcinoma. After that, Kaplan-Meier analysis combined with log-rank p test was applied to assess the predictive accuracy of the 26-lncRNAs risk model. Further analysis showed that the prognostic value of 26-lncRNAs risk model was independent of other clinicopathological factors. At last, lncRNAs in the model were put into gene ontology biological process enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways analysis, which suggested that these lncRNAs might contribute to cancer-associated processes such as cell cycle and apoptosis. This study indicated that lncRNAs signature could be a useful marker to predict the prognosis of cervical squamous cell carcinoma.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Oncology, First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Zhanzhao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Oncology, First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Lixin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Oncology, First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Oncology, First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Oncology, First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Oncology, First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>DNA Cell Biol</MedlineTA><NlmUniqueID>9004522</NlmUniqueID><ISSNLinking>1044-5498</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="Y">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062085" MajorTopicYN="N">RNA, Long Noncoding</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TCGA</Keyword><Keyword MajorTopicYN="N">cervical squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">lncRNA</Keyword><Keyword MajorTopicYN="N">overall survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30698466</ArticleId><ArticleId IdType="doi">10.1089/dna.2018.4533</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30389505</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><PubDate><Year>2018</Year><Month>Nov</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>The Landscape and Implications of Chimeric RNAs in Cervical Cancer.</ArticleTitle><Pagination><StartPage>158</StartPage><EndPage>167</EndPage><MedlinePgn>158-167</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2018.10.059</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(18)30477-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Gene fusions and fusion products have been proven to be ideal biomarkers and drug targets for cancer. Even though a comprehensive study of cervical cancer has been conducted as part of the Cancer Genome Atlas (TCGA) project, few recurrent gene fusions have been found, and none above 3% of frequency.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We believe that chimeric fusion RNAs generated by intergenic splicing represent a new repertoire of biomarkers and/or therapeutic targets. However, they would be missed when only genome sequences and fusions at DNA level are considered. We performed extensive data mining for chimeric RNAs using both our and TCGA cervical cancer RNA-Seq datasets. Multiple criteria were applied. We analyzed the landscape of chimeric RNAs at various levels, and from different angles.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The chimeric RNA landscape changed as different filters were applied. 15 highly frequent (&gt;10%) chimeric RNAs were identified. LHX6-NDUFA8 was detected exclusively in cervical cancer tissues and Pap smears, but not in normal controls. Mechanistically, it is not due to interstitial deletion, but a product of cis-splicing between adjacent genes. Silencing of another recurrent chimera, SLC2A11-MIF, resulted in cell cycle arrest and reduced cellular proliferation. This effect is unique to the chimera, and not shared by the two parental genes.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Highly frequent chimeric RNAs are present in cervical cancers. They can be formed by intergenic splicing. Some have clear implications as potential biomarkers, or for shedding new light on the biology of the disease. FUND: Stand Up To Cancer and the National Science Foundation of China.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Cancer Invasion and Metastasis of the Ministry of Education of China, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Cancer Invasion and Metastasis of the Ministry of Education of China, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Fujun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Shailesh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA; National Institute of Plant Genome Research (NIPGR), New Delhi 110067, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Cancer Invasion and Metastasis of the Ministry of Education of China, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Ding</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Key Laboratory of Cancer Invasion and Metastasis of the Ministry of Education of China, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: dma@tjh.tjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China. Electronic address: hl9r@virginia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015514">Oncogene Proteins, Fusion</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012334">RNA, Neoplasm</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>EBioMedicine. 2018 Dec;38:13-14. doi: 10.1016/j.ebiom.2018.11.013</RefSource><PMID Version="1">30446433</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D059447" MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015514" MajorTopicYN="Y">Oncogene Proteins, Fusion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012334" MajorTopicYN="Y">RNA, Neoplasm</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioinformatics</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Chimeric RNA</Keyword><Keyword MajorTopicYN="N">Gene fusion</Keyword><Keyword MajorTopicYN="N">RNA-Seq</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30389505</ArticleId><ArticleId IdType="pmc">PMC6286271</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2018.10.059</ArticleId><ArticleId IdType="pii">S2352-3964(18)30477-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296855</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer IAfRo A review of human carcinogen: biological agents. IARC. 2012:100B.</Citation></Reference><Reference><Citation>Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">25651787</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanathan P., Dhandapani H., Jayakumar H., Seetharaman A., Thangarajan R. Immunotherapy for cervical cancer: Can it do another lung cancer? Curr Probl Cancer. 2018;42(2):148&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">29500076</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">16254181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Genome Atlas Research N Albert Einstein College of M, Analytical Biological S, Barretos Cancer H, Baylor College of M, Beckman Research Institute of City of H, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5354998</ArticleId><ArticleId IdType="pubmed">28112728</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Wang J., Mor G., Sklar J. A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. Science. 2008;321(5894):1357&#x2013;1361.</Citation><ArticleIdList><ArticleId IdType="pubmed">18772439</ArticleId></ArticleIdList></Reference><Reference><Citation>Chase A., Ernst T., Fiebig A., Collins A., Grand F., Erben P. TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals. Haematologica. 2010;95(1):20&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2805730</ArticleId><ArticleId IdType="pubmed">19797732</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan H., Qin F., Movassagh M., Park H., Golden W., Xie Z. A chimeric RNA characteristic of rhabdomyosarcoma in normal myogenesis process. Cancer Discov. 2013;3(12):1394&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pubmed">24089019</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.S., Yu C.Y., Chuang C.Y., Hsiao M., Kao C.F., Kuo H.C. Integrative transcriptome sequencing identifies trans-splicing events with important roles in human embryonic stem cell pluripotency. Genome Res. 2014;24(1):25&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875859</ArticleId><ArticleId IdType="pubmed">24131564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaphiropoulos P.G. Trans-splicing in Higher Eukaryotes: Implications for Cancer Development? Front Genet. 2012;2:92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268641</ArticleId><ArticleId IdType="pubmed">22303386</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z., Zhu D., Wang W., Li W., Jia W., Zeng X. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat Genet. 2015;47(2):158&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">25581428</ArticleId></ArticleIdList></Reference><Reference><Citation>Chwalenia K., Qin F., Singh S., Tangtrongstittikul P., Li H. Connections between Transcription Downstream of Genes and cis-SAGe Chimeric RNA. Genes (Basel). 2017;8(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5704251</ArticleId><ArticleId IdType="pubmed">29165374</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R., Kumar S., Li H. Absence of Correlation between Chimeric RNA and Aging. Genes (Basel). 2017;8(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748704</ArticleId><ArticleId IdType="pubmed">29240691</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia W, Qiu K, He M, Song P, Zhou Q, Zhou F, et al. SOAPfuse: an algorithm for identifying fusion transcripts from paired-end RNA-Seq data. Genome Biol.14(2):R12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4054009</ArticleId><ArticleId IdType="pubmed">23409703</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Gong M., Yuan H., Park H.G., Frierson H.F., Li H. Chimeric Transcript Generated by cis-Splicing of Adjacent Genes Regulates Prostate Cancer Cell Proliferation. Cancer Discovery. 2012;2(7):598&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">22719019</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin F., Song Z., Babiceanu M., Song Y., Facemire L., Singh R. Discovery of CTCF-Sensitive Cis-Spliced Fusion RNAs between Adjacent Genes in Human Prostate Cells. PLoS Genet. 2015;11(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4450057</ArticleId><ArticleId IdType="pubmed">25658338</ArticleId></ArticleIdList></Reference><Reference><Citation>Babiceanu M., Qin F., Xie Z., Jia Y., Lopez K., Janus N. Recurrent chimeric fusion RNAs in non-cancer tissues and cells. Nucleic Acids Res. 2016;44(2):2859&#x2013;2872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4824105</ArticleId><ArticleId IdType="pubmed">26837576</ArticleId></ArticleIdList></Reference><Reference><Citation>Eden E., Navon R., Steinfeld I., Lipson D., Yakhini Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics. 2009;10:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644678</ArticleId><ArticleId IdType="pubmed">19192299</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabbitts T.H. Chromosomal translocations in human cancer. Nature. 1994;372(6502):143&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969446</ArticleId></ArticleIdList></Reference><Reference><Citation>Heim S., Mitelman F. Molecular screening for new fusion genes in cancer. Nat Genet. 2008;40(6):685&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">18509307</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Wang J., Mor G., Sklar J. A Neoplastic Gene Fusion Mimics Trans-Splicing of RNAs in Normal Human Cells. Science. 2008;321(5894):1357&#x2013;1361.</Citation><ArticleIdList><ArticleId IdType="pubmed">18772439</ArticleId></ArticleIdList></Reference><Reference><Citation>Finta C., Zaphiropoulos P.G. Intergenic mRNA molecules resulting from trans-splicing. J Biol Chem. 2002;277(8):5882&#x2013;5890.</Citation><ArticleIdList><ArticleId IdType="pubmed">11726664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Sinha C., Kalyana-Sundaram S., Chinnaiyan A.M. SLC45A3-ELK4 Chimera in Prostate Cancer: Spotlight on cis-Splicing. Cancer Discovery. 2012;2(7):582&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3597435</ArticleId><ArticleId IdType="pubmed">22787087</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30275981</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2058-7716</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Cell death discovery</Title><ISOAbbreviation>Cell Death Discov</ISOAbbreviation></Journal><ArticleTitle>The role of miR-106p-5p in cervical cancer: from expression to molecular mechanism.</ArticleTitle><Pagination><StartPage>36</StartPage><MedlinePgn>36</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">94</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41420-018-0096-8</ELocationID><Abstract><AbstractText>This study aims to investigate the role of miR-106b-5p in cervical cancer by performing a comprehensive analysis on its expression and identifying its putative molecular targets and pathways based on The Cancer Genome Atlas (TCGA) dataset, Gene Expression Omnibus (GEO) dataset, and literature review. Significant upregulation of miR-106b-5p in cervical cancer is confirmed by meta-analysis with the data from TCGA, GEO, and literature. Moreover, the expression of miR-106b-5p is significantly correlated with the number of metastatic lymph nodes. Our bioinformatics analyses show that miR-106b could promote cervical cancer progression by modulating the expression of GSK3B, VEGFA, and PTK2 genes. Importantly, these three genes play a crucial role in PI3K-Akt signaling, focal adhesion, and cancer. Both the expression of miR-106b-5p and key genes are upregulated in cervical cancer. Several explanations could be implemented for this upregulation. However, the specific mechanism needs to be investigated further.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Yuexiong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, 430071 Hubei People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yanyan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, 430071 Hubei People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Wanrong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, 430071 Hubei People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Kejia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, 430071 Hubei People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, 430071 Hubei People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Death Discov</MedlineTA><NlmUniqueID>101665035</NlmUniqueID><ISSNLinking>2058-7716</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Cell Death Discov. 2019 Jul 10;5:116. doi: 10.1038/s41420-019-0186-2</RefSource><PMID Version="1">31312525</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30275981</ArticleId><ArticleId IdType="pmc">PMC6148547</ArticleId><ArticleId IdType="doi">10.1038/s41420-018-0096-8</ArticleId><ArticleId IdType="pii">96</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Torre LA, et al. Global Cancer Statistics, 2012. CA Cancer J. Clin. 2015;65:87&#x2013;108. doi: 10.3322/caac.21262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21262</ArticleId><ArticleId IdType="pubmed">25651787</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, et al. Cancer Statistics in China. CA Cancer J. Clin. 2016;66:115&#x2013;132. doi: 10.3322/caac.21338.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21338</ArticleId><ArticleId IdType="pubmed">26808342</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7&#x2013;30. doi: 10.3322/caac.21442.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21442</ArticleId><ArticleId IdType="pubmed">29313949</ArticleId></ArticleIdList></Reference><Reference><Citation>Petry KU. HPV and cervical cancer. Scand. J. Clin. Lab. Invest. 2014;74:59&#x2013;62. doi: 10.3109/00365513.2014.936683.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365513.2014.936683</ArticleId><ArticleId IdType="pubmed">25083895</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Xu H, Qi M, Yan S, Tian X. miRNA dysregulation and the risk of metastasis and invasion in papillary thyroid cancer: a systematic review and meta-analysis. Oncotarget. 2018;9:5473&#x2013;5479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5797065</ArticleId><ArticleId IdType="pubmed">29435194</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos JMO, Gil da Costa RM, Medeiros R. Dysregulation of cellular microRNAs by human oncogenic viruses &#x2013; Implications for tumorigenesis. Biochim. Biophys. Acta. 2018;1861:95&#x2013;105. doi: 10.1016/j.bbagrm.2018.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagrm.2018.01.017</ArticleId><ArticleId IdType="pubmed">29378330</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim VN. Small RNAs: classification, biogenesis, and function. Mol. Cells. 2005;19:1&#x2013;15. doi: 10.1016/j.molcel.2005.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2005.05.026</ArticleId><ArticleId IdType="pubmed">15750334</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecellier CH. A cellular microRNA mediates antiviral defense in human cells. Science. 2005;308:557&#x2013;560. doi: 10.1126/science.1108784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1108784</ArticleId><ArticleId IdType="pubmed">15845854</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005;435:839&#x2013;843. doi: 10.1038/nature03677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03677</ArticleId><ArticleId IdType="pubmed">15944709</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Hu G. Shikonin suppresses proliferation and induces apoptosis in endometrioid endometrial cancer cells via modulating miR-106b/PTEN/AKT/mTOR signaling pathway. Biosci. Rep. 2018;0:BSR20171546. doi: 10.1042/BSR20171546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20171546</ArticleId><ArticleId IdType="pmc">PMC5897745</ArticleId><ArticleId IdType="pubmed">29449346</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi DM, Bian XY, Qin CD, Wu WZ. miR-106b-5p promotes stem cell-like properties of hepatocellular carcinoma cells by targeting PTEN via PI3K/Akt pathway. Onco. Targets Ther. 2018;11:571&#x2013;585. doi: 10.2147/OTT.S152611.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S152611</ArticleId><ArticleId IdType="pmc">PMC5790077</ArticleId><ArticleId IdType="pubmed">29416358</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, et al. miR-106b-5p promotes renal cell carcinoma aggressiveness and stem-cell-like phenotype by activating Wnt/&#x3b2;-catenin signalling. Oncotarget. 2017;8:21461&#x2013;21471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5400598</ArticleId><ArticleId IdType="pubmed">28423523</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang W, et al. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma. Oncotarget. 2015;6:4066&#x2013;4079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4414173</ArticleId><ArticleId IdType="pubmed">25714014</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma D, Zhang YY, Guo YL, Li ZJ, Geng L. Profiling of microRNA-mRNA reveals roles of microRNAs in cervical cancer. Chin. Med. J. (Engl.). 2012;125:4270&#x2013;4276.</Citation><ArticleIdList><ArticleId IdType="pubmed">23217399</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, et al. MicroRNA-106b is involved in transforming growth factor &#x3b2;1-induced cell migration by targeting disabled homolog 2 in cervical carcinoma. J. Exp. Clin. Cancer Res. 2016;35:1&#x2013;11. doi: 10.1186/s13046-016-0290-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-016-0290-6</ArticleId><ArticleId IdType="pmc">PMC4714510</ArticleId><ArticleId IdType="pubmed">26769181</ArticleId></ArticleIdList></Reference><Reference><Citation>Piao J, et al. Substrate stiffness affects epithelial-mesenchymal transition of cervical cancer cells through miR-106b and its target protein DAB2. Int. J. Oncol. 2017;50:2033&#x2013;2042. doi: 10.3892/ijo.2017.3978.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2017.3978</ArticleId><ArticleId IdType="pubmed">28498390</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao D, Zhang Y, Zhu M, Liu S, Wang X. MiRNA expression profiles of HPV-infected patients with cervical cancer in the Uyghur population in China. PLoS ONE. 2016;11:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5072605</ArticleId><ArticleId IdType="pubmed">27764149</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, et al. MicroRNA-27b up-regulated by human papillomavirus 16 E7 promotes proliferation and suppresses apoptosis by targeting polo-like kinase2 in cervical cancer. Oncotarget. 2016;7:19666&#x2013;19679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4991410</ArticleId><ArticleId IdType="pubmed">26910911</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L, et al. Expression profiling of stem cell-related genes in neoadjuvant-treated gastric cancer: a NOTCH2, GSK3B and &#x3b2;-catenin gene signature predicts survival. PLoS ONE. 2012;7:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3438181</ArticleId><ArticleId IdType="pubmed">22970250</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa I, et al. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. Mod. Pathol. 2011;24:846&#x2013;854. doi: 10.1038/modpathol.2011.12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/modpathol.2011.12</ArticleId><ArticleId IdType="pubmed">21317880</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassilli E, et al. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. Clin. Cancer Res. 2013;19:3820&#x2013;3831. doi: 10.1158/1078-0432.CCR-12-3289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-12-3289</ArticleId><ArticleId IdType="pubmed">23729362</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;rsel DB, et al. Tight regulation between cell survival and programmed cell death in GBM stem-like cells by EGFR/GSK3b/PP2A signaling. J. Neurooncol. 2015;121:19&#x2013;29. doi: 10.1007/s11060-014-1602-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11060-014-1602-3</ArticleId><ArticleId IdType="pubmed">25344882</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, et al. GSK3&#x3b2; mediates the carcinogenic effect of HPV16 in cervical cancer. Sci. Rep. 2015;5:2&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4642308</ArticleId><ArticleId IdType="pubmed">26560046</ArticleId></ArticleIdList></Reference><Reference><Citation>Rath G, Jawanjal P, Salhan S, Nalliah M, Dhawan I. Clinical significance of inactivated glycogen synthase kinase 3&#x3b2; in HPV-associated cervical cancer: relationship with Wnt/&#x3b2;-Catenin pathway activation. Am. J. Reprod. Immunol. 2015;73:460&#x2013;478. doi: 10.1111/aji.12346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aji.12346</ArticleId><ArticleId IdType="pubmed">25532422</ArticleId></ArticleIdList></Reference><Reference><Citation>V B, G C. The angiogenic switch in carcinogenesis. Semin. Cancer Biol. 2009;19:329&#x2013;337. doi: 10.1016/j.semcancer.2009.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2009.05.003</ArticleId><ArticleId IdType="pubmed">19482086</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Zhang C, Dong P, Guo Y, Mu N. Molecular regulation of cervical cancer growth and invasion by VEGFa. Tumor Biol. 2014;35:11587&#x2013;11593. doi: 10.1007/s13277-014-2463-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-014-2463-2</ArticleId><ArticleId IdType="pubmed">25135429</ArticleId></ArticleIdList></Reference><Reference><Citation>Dibbens JA, et al. Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Mol. Biol. Cell. 1999;10:907&#x2013;919. doi: 10.1091/mbc.10.4.907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.10.4.907</ArticleId><ArticleId IdType="pmc">PMC25213</ArticleId><ArticleId IdType="pubmed">10198046</ArticleId></ArticleIdList></Reference><Reference><Citation>Du K, Gong H, Gong Z. Influence of serum VEGF levels on therapeutic outcome and diagnosis / prognostic value in patients with cervical. Cancer. 2014;15:8793&#x2013;8796.</Citation><ArticleIdList><ArticleId IdType="pubmed">25374209</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong, D., Chen, F. &amp; Sima, N. Focal adhesion kinases crucially regulate TGF&#x3b2;-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin. Onco. Targets. Ther. 10, 1783&#x2013;1792 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5370070</ArticleId><ArticleId IdType="pubmed">28367061</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma K, et al. PTK2-mediated degradation of ATG3 impedes cancer cells susceptible to DNA damage treatment. Autophagy. 2017;13:579&#x2013;591. doi: 10.1080/15548627.2016.1272742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2016.1272742</ArticleId><ArticleId IdType="pmc">PMC5361600</ArticleId><ArticleId IdType="pubmed">28103122</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Ann. Med. 2014;46:372&#x2013;383. doi: 10.3109/07853890.2014.912836.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/07853890.2014.912836</ArticleId><ArticleId IdType="pubmed">24897931</ArticleId></ArticleIdList></Reference><Reference><Citation>Owonikoko TK, Khuri FR. Am. Soc. Clin. Oncol. Educ. Book. 2013. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation; pp. 384&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821994</ArticleId><ArticleId IdType="pubmed">23714559</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai C, et al. Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-&#x3ba;B activation. Naunyn Schmiedebergs Arch. Pharmacol. 2016;389:573&#x2013;584. doi: 10.1007/s00210-016-1217-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-016-1217-7</ArticleId><ArticleId IdType="pubmed">26935715</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003;2:336&#x2013;342. doi: 10.4161/cc.2.4.433.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.2.4.433</ArticleId><ArticleId IdType="pubmed">12851486</ArticleId></ArticleIdList></Reference><Reference><Citation>Eke I, Cordes N. Focal adhesion signaling and therapy resistance in cancer. Semin. Cancer Biol. 2015;31:65&#x2013;75. doi: 10.1016/j.semcancer.2014.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2014.07.009</ArticleId><ArticleId IdType="pubmed">25117005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gari HH, DeGala GD, Ray R, Lucia MS, Lambert JR. PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion. Cancer Lett. 2016;380:505&#x2013;512. doi: 10.1016/j.canlet.2016.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2016.07.017</ArticleId><ArticleId IdType="pmc">PMC5497588</ArticleId><ArticleId IdType="pubmed">27452906</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Z, et al. MicroRNA-7 inhibits metastasis and invasion through targeting focal adhesion kinase in cervical cancer. Int. J. Clin. Exp. Med. 2015;8:480&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358475</ArticleId><ArticleId IdType="pubmed">25785020</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 2016;22:851&#x2013;860. doi: 10.1038/nm.4123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4123</ArticleId><ArticleId IdType="pmc">PMC4935930</ArticleId><ArticleId IdType="pubmed">27376576</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim. Biophys. Acta. 2010;1803:1231&#x2013;1243. doi: 10.1016/j.bbamcr.2010.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2010.06.013</ArticleId><ArticleId IdType="pubmed">20619301</ArticleId></ArticleIdList></Reference><Reference><Citation>Orang, A. V., Safaralizadeh, R. &amp; Kazemzadeh-Bavili, M. Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int. J. Genomics2014, 1&#x2013;15 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142390</ArticleId><ArticleId IdType="pubmed">25180174</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalanotto, C., Cogoni, C. &amp; Zardo, G. MicroRNA in control of gene expression: an overview of nuclear functions. Int. J. Mol. Sci. 17, 1712&#x2013;1729 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5085744</ArticleId><ArticleId IdType="pubmed">27754357</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007;318:1931&#x2013;1934. doi: 10.1126/science.1149460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1149460</ArticleId><ArticleId IdType="pubmed">18048652</ArticleId></ArticleIdList></Reference><Reference><Citation>Truesdell SS, et al. MicroRNA-mediated mRNA translation activation in quiescent cells and oocytes involves recruitment of a nuclear microRNP. Sci. Rep. 2012;2:0&#x2013;11. doi: 10.1038/srep00842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep00842</ArticleId><ArticleId IdType="pmc">PMC3496365</ArticleId><ArticleId IdType="pubmed">23150790</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens K. When microRNAs activate translation. Nat. Methods. 2008;5:122&#x2013;123. doi: 10.1038/nmeth0208-122a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth0208-122a</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CYA, Shyu AB. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem. Sci. 1995;20:465&#x2013;470. doi: 10.1016/S0968-0004(00)89102-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0968-0004(00)89102-1</ArticleId><ArticleId IdType="pubmed">8578590</ArticleId></ArticleIdList></Reference><Reference><Citation>Barreau C, Paillard L, Osborne HB. AU-rich elements and associated factors: Are there unifying principles? Nucleic Acids Res. 2005;33:7138&#x2013;7150. doi: 10.1093/nar/gki1012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gki1012</ArticleId><ArticleId IdType="pmc">PMC1325018</ArticleId><ArticleId IdType="pubmed">16391004</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao H, Lin R. Phosphorylation of recombinant tristetraprolin in vitro. Protein J. 2008;27:163&#x2013;169. doi: 10.1007/s10930-007-9119-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10930-007-9119-7</ArticleId><ArticleId IdType="pmc">PMC2674330</ArticleId><ArticleId IdType="pubmed">18071886</ArticleId></ArticleIdList></Reference><Reference><Citation>Essafi-Benkhadir K, Pouyss&#xe9;gur J, Pag&#xe8;s G. Implication of the ERK pathway on the post-transcriptional regulation of VEGF mRNA stability. Methods Mol. Biol. 2010;661:451&#x2013;469. doi: 10.1007/978-1-60761-795-2_28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-60761-795-2_28</ArticleId><ArticleId IdType="pubmed">20812001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosu T, et al. HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br. J. Cancer. 2011;104:819&#x2013;829. doi: 10.1038/bjc.2011.20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2011.20</ArticleId><ArticleId IdType="pmc">PMC3048211</ArticleId><ArticleId IdType="pubmed">21285980</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SH, et al. Antagonistic function of the RNA-binding protein HuR and miR-200b in post-transcriptional regulation of vascular endothelial growth factor-a expression and angiogenesis. J. Biol. Chem. 2013;288:4908&#x2013;4921. doi: 10.1074/jbc.M112.423871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.423871</ArticleId><ArticleId IdType="pmc">PMC3576095</ArticleId><ArticleId IdType="pubmed">23223443</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazma A, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 2001;29:365&#x2013;371. doi: 10.1038/ng1201-365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1201-365</ArticleId><ArticleId IdType="pubmed">11726920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy A, Mondry A, Holmes CC, Altman DG. Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med. 2008;5:1320&#x2013;1332. doi: 10.1371/journal.pmed.0050184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0050184</ArticleId><ArticleId IdType="pmc">PMC2528050</ArticleId><ArticleId IdType="pubmed">18767902</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46:D956&#x2013;D963. doi: 10.1093/nar/gkx1090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1090</ArticleId><ArticleId IdType="pmc">PMC5753188</ArticleId><ArticleId IdType="pubmed">29136207</ArticleId></ArticleIdList></Reference><Reference><Citation>R. Core Team. R: A Language and Environment for Statistical Computing, Vol. 1 (R Foundation for Statistical Computing, 2017).</Citation></Reference><Reference><Citation>Schwarzer G. meta: An R package for meta-analysis. R. News. 2007;7:40&#x2013;45.</Citation></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629&#x2013;634. doi: 10.1136/bmj.315.7109.629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.315.7109.629</ArticleId><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi: 10.1093/nar/gkv007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Dweep H, Gretz N. MiRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat. Methods. 2015;12:697. doi: 10.1038/nmeth.3485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3485</ArticleId><ArticleId IdType="pubmed">26226356</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics. 2017;33:2938&#x2013;2940. doi: 10.1093/bioinformatics/btx364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btx364</ArticleId><ArticleId IdType="pmc">PMC5870712</ArticleId><ArticleId IdType="pubmed">28645171</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao X, et al. DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics. 2012;28:1805&#x2013;1806. doi: 10.1093/bioinformatics/bts251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts251</ArticleId><ArticleId IdType="pmc">PMC3381967</ArticleId><ArticleId IdType="pubmed">22543366</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, et al. STRINGv10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447&#x2013;D452. doi: 10.1093/nar/gku1003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku1003</ArticleId><ArticleId IdType="pmc">PMC4383874</ArticleId><ArticleId IdType="pubmed">25352553</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin CH, et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 2014;8:S11. doi: 10.1186/1752-0509-8-S4-S11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1752-0509-8-S4-S11</ArticleId><ArticleId IdType="pmc">PMC4290687</ArticleId><ArticleId IdType="pubmed">25521941</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia P, Kao CF, Kuo PH, Zhao Z. A comprehensive network and pathway analysis of candidate genes in major depressive disorder. BMC Syst. Biol. 2011;5:S12. doi: 10.1186/1752-0509-5-S3-S12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1752-0509-5-S3-S12</ArticleId><ArticleId IdType="pmc">PMC3287567</ArticleId><ArticleId IdType="pubmed">22784618</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Pan Z, Hu Y, Zhang L, Wang J. Network and pathway-based analyses of genes associated with Parkinson&#x2019;s disease. Mol. Neurobiol. 2017;54:4452&#x2013;4465. doi: 10.1007/s12035-016-9998-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-9998-8</ArticleId><ArticleId IdType="pubmed">27349437</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes DR, et al. ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform. Neoplasia. 2004;6:1&#x2013;6. doi: 10.1016/S1476-5586(04)80047-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1476-5586(04)80047-2</ArticleId><ArticleId IdType="pmc">PMC1635162</ArticleId><ArticleId IdType="pubmed">15068665</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozomara A, Griffiths-Jones S. MiRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42:68&#x2013;73. doi: 10.1093/nar/gkt1181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1181</ArticleId><ArticleId IdType="pmc">PMC3965103</ArticleId><ArticleId IdType="pubmed">24275495</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehmsmeier, M., Steffen, P., H&#xf6;chsmann, M., Giegerich, R. &amp; Ho, M. Fast and effective prediction of microRNA / target duplexes. RNA10, 1507&#x2013;1517(2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370637</ArticleId><ArticleId IdType="pubmed">15383676</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29922260</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-302X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Frontiers in microbiology</Title><ISOAbbreviation>Front Microbiol</ISOAbbreviation></Journal><ArticleTitle>viGEN: An Open Source Pipeline for the Detection and Quantification of Viral RNA in Human Tumors.</ArticleTitle><Pagination><StartPage>1172</StartPage><MedlinePgn>1172</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1172</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmicb.2018.01172</ELocationID><Abstract><AbstractText>An estimated 17% of cancers worldwide are associated with infectious causes. The extent and biological significance of viral presence/infection in actual tumor samples is generally unknown but could be measured using human transcriptome (RNA-seq) data from tumor samples. We present an open source bioinformatics pipeline viGEN, which allows for not only the detection and quantification of viral RNA, but also variants in the viral transcripts. The pipeline includes 4 major modules: The first module aligns and filter out human RNA sequences; the second module maps and count (remaining un-aligned) reads against reference genomes of all known and sequenced human viruses; the third module quantifies read counts at the individual viral-gene level thus allowing for downstream differential expression analysis of viral genes between case and controls groups. The fourth module calls variants in these viruses. To the best of our knowledge, there are no publicly available pipelines or packages that would provide this type of complete analysis in one open source package. In this paper, we applied the viGEN pipeline to two case studies. We first demonstrate the working of our pipeline on a large public dataset, the TCGA cervical cancer cohort. In the second case study, we performed an in-depth analysis on a small focused study of TCGA liver cancer patients. In the latter cohort, we performed viral-gene quantification, viral-variant extraction and survival analysis. This allowed us to find differentially expressed viral-transcripts and viral-variants between the groups of patients, and connect them to clinical outcome. From our analyses, we show that we were able to successfully detect the human papilloma virus among the TCGA cervical cancer patients. We compared the viGEN pipeline with two metagenomics tools and demonstrate similar sensitivity/specificity. We were also able to quantify viral-transcripts and extract viral-variants using the liver cancer dataset. The results presented corresponded with published literature in terms of rate of detection, and impact of several known variants of HBV genome. This pipeline is generalizable, and can be used to provide novel biological insights into microbial infections in complex diseases and tumorigeneses. Our viral pipeline could be used in conjunction with additional type of immuno-oncology analysis based on RNA-seq data of host RNA for cancer immunology applications. The source code, with example data and tutorial is available at: https://github.com/ICBI/viGEN/.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhuvaneshwar</LastName><ForeName>Krithika</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Innovation Center for Biomedical Informatics, Georgetown University, Washington, DC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Innovation Center for Biomedical Informatics, Georgetown University, Washington, DC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madhavan</LastName><ForeName>Subha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Innovation Center for Biomedical Informatics, Georgetown University, Washington, DC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gusev</LastName><ForeName>Yuriy</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Innovation Center for Biomedical Informatics, Georgetown University, Washington, DC, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA051008</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001409</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Microbiol</MedlineTA><NlmUniqueID>101548977</NlmUniqueID><ISSNLinking>1664-302X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RNA-seq</Keyword><Keyword MajorTopicYN="N">TCGA</Keyword><Keyword MajorTopicYN="N">cancer immunology</Keyword><Keyword MajorTopicYN="N">liver cancer</Keyword><Keyword MajorTopicYN="N">next-generation sequencing</Keyword><Keyword MajorTopicYN="N">variant analysis</Keyword><Keyword MajorTopicYN="N">viral detection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>6</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29922260</ArticleId><ArticleId IdType="pmc">PMC5996193</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2018.01172</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>ACS  (2007). Infections That Can Lead to Cancer 2015. Available online at: http://www.cancer.org/cancer/cancercauses/othercarcinogens/infectiousagents/infectiousagentsandcancer/infectious-agents-and-cancer-viruses</Citation></Reference><Reference><Citation>Alves J. M., de Oliveira A. L., Sandberg T. O., Moreno-Gallego J. L., de Toledo M. A., de Moura E. M., et al. . (2016). GenSeed-HMM: a tool for progressive assembly using profile HMMs as seeds and its application in alpavirinae viral discovery from metagenomic data. Front. Microbiol. 7:269. 10.3389/fmicb.2016.00269</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2016.00269</ArticleId><ArticleId IdType="pmc">PMC4777721</ArticleId><ArticleId IdType="pubmed">26973638</ArticleId></ArticleIdList></Reference><Reference><Citation>Barzon L., Lavezzo E., Militello V., Toppo S., Pal&#xf9; G. (2011). Applications of next-generation sequencing technologies to diagnostic virology. Int. J. Mol. Sci. 12, 7861&#x2013;7884. 10.3390/ijms12117861</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms12117861</ArticleId><ArticleId IdType="pmc">PMC3233444</ArticleId><ArticleId IdType="pubmed">22174638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaduri A., Qu K., Lee C. S., Ungewickell A., Khavari P. A. (2012). Rapid identification of non-human sequences in high-throughput sequencing datasets. Bioinformatics 28, 1174&#x2013;1175. 10.1093/bioinformatics/bts100</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts100</ArticleId><ArticleId IdType="pmc">PMC3324519</ArticleId><ArticleId IdType="pubmed">22377895</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhuvaneshwar K., Sulakhe D., Gauba R., Rodriguez A., Madduri R., Dave U., et al. . (2015). A case study for cloud based high throughput analysis of NGS data using the globus genomics system. Comput. Struct. Biotechnol. J. 13, 64&#x2013;74. 10.1016/j.csbj.2014.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2014.11.001</ArticleId><ArticleId IdType="pmc">PMC4720014</ArticleId><ArticleId IdType="pubmed">26925205</ArticleId></ArticleIdList></Reference><Reference><Citation>Boller K., Sch&#xf6;nfeld K., Lischer S., Fischer N., Hoffmann A., Kurth R., et al. . (2008). Human endogenous retrovirus HERV-K113 is capable of producing intact viral particles. J. Gen. Virol. 89(Pt 2), 567&#x2013;572. 10.1099/vir.0.83534-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.83534-0</ArticleId><ArticleId IdType="pubmed">18198388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges S. (2017). Identifying Viral Sequences In TCGA Data Using Kraken And Centrifuge. (Accessed May 23, 2017). Available online at: https://www.sevenbridges.com/centrifuge/</Citation></Reference><Reference><Citation>Byron S. A., Van Keuren-Jensen K. R., Engelthaler D. M., Carpten J. D., Craig D. W. (2016). Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat. Rev. Genet. 17, 257&#x2013;271. 10.1038/nrg.2016.10</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg.2016.10</ArticleId><ArticleId IdType="pmc">PMC7097555</ArticleId><ArticleId IdType="pubmed">26996076</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao G. W. (2009). Clinical relevance and public health significance of hepatitis B virus genomic variations. World J. Gastroenterol. 15, 5761&#x2013;5769. 10.3748/wjg.15.5761</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.15.5761</ArticleId><ArticleId IdType="pmc">PMC2791267</ArticleId><ArticleId IdType="pubmed">19998495</ArticleId></ArticleIdList></Reference><Reference><Citation>Center-for-Statistical-Genetics  (2013). BAM 2013 (Accessed February 26, 2013). Available online at: http://genome.sph.umich.edu/wiki/BAM</Citation></Reference><Reference><Citation>Cerami E., Gao J., Dogrusoz U., Gross B. E., Sumer S. O., Aksoy B. A., et al. . (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401&#x2013;404. 10.1158/2159-8290.CD-12-0095</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-12-0095</ArticleId><ArticleId IdType="pmc">PMC3956037</ArticleId><ArticleId IdType="pubmed">22588877</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C. C., Chow C. C., Tellier L. C., Vattikuti S., Purcell S. M., Lee J. J. (2015). Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 4:7. 10.1186/s13742-015-0047-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13742-015-0047-8</ArticleId><ArticleId IdType="pmc">PMC4342193</ArticleId><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Yao H., Thompson E. J., Tannir N. M., Weinstein J. N., Su X. (2013). VirusSeq: software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue. Bioinformatics. 29, 266&#x2013;267. 10.1093/bioinformatics/bts665</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts665</ArticleId><ArticleId IdType="pmc">PMC3546792</ArticleId><ArticleId IdType="pubmed">23162058</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox D. R., Oakes D. (2000). Analysis of Survival Data. Boca Raton, FL: Chapman and Hall.</Citation></Reference><Reference><Citation>Datta S., Budhauliya R., Das B., Chatterjee S., Vanlalhmuaka Veer V. (2015). Next-generation sequencing in clinical virology: discovery of new viruses. World J. Virol. 4, 265&#x2013;276. 10.5501/wjv.v4.i3.265</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v4.i3.265</ArticleId><ArticleId IdType="pmc">PMC4534817</ArticleId><ArticleId IdType="pubmed">26279987</ArticleId></ArticleIdList></Reference><Reference><Citation>Downey R. F., Sullivan F. J., Wang-Johanning F., Ambs S., Giles F. J., Glynn S. A. (2015). Human endogenous retrovirus K and cancer: innocent bystander or tumorigenic accomplice? Int J. Cancer. 137, 1249&#x2013;1257. 10.1002/ijc.29003</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.29003</ArticleId><ArticleId IdType="pmc">PMC6264888</ArticleId><ArticleId IdType="pubmed">24890612</ArticleId></ArticleIdList></Reference><Reference><Citation>Hausen H. Z. (2000). Infections Causing Human Cancer. Weinheim: Wiley.</Citation></Reference><Reference><Citation>Jain S., Chang T. T., Chen S., Boldbaatar B., Clemens A., Lin S. Y., et al. . (2015). Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues. Sci. Rep. 5:10478. 10.1038/srep10478</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep10478</ArticleId><ArticleId IdType="pmc">PMC4650678</ArticleId><ArticleId IdType="pubmed">26000761</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury J. D., Tannir N. M., Williams M. D., Chen Y., Yao H., Zhang J., et al. . (2013). Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J. Virol. 87, 8916&#x2013;8926. 10.1128/JVI.00340-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00340-13</ArticleId><ArticleId IdType="pmc">PMC3754044</ArticleId><ArticleId IdType="pubmed">23740984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., Song L., Breitwieser F. P., Salzberg S. L. (2016). Centrifuge: rapid and sensitive classification of metagenomic sequences. Genome Res. 26, 1721&#x2013;1729. 10.1101/gr.210641.116</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.210641.116</ArticleId><ArticleId IdType="pmc">PMC5131823</ArticleId><ArticleId IdType="pubmed">27852649</ArticleId></ArticleIdList></Reference><Reference><Citation>Koboldt D. C., Zhang Q., Larson D. E., Shen D., McLellan M. D., Lin L., et al. . (2012). VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568&#x2013;576. 10.1101/gr.129684.111</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.129684.111</ArticleId><ArticleId IdType="pmc">PMC3290792</ArticleId><ArticleId IdType="pubmed">22300766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostic A. D., Ojesina A. I., Pedamallu C. S., Jung J., Verhaak R. G., Getz G., et al. . (2011). PathSeq: software to identify or discover microbes by deep sequencing of human tissue. Nat. Biotechnol. 29, 393&#x2013;396. 10.1038/nbt.1868</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1868</ArticleId><ArticleId IdType="pmc">PMC3523678</ArticleId><ArticleId IdType="pubmed">21552235</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B., Salzberg S. L. (2012). Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357&#x2013;359. 10.1038/nmeth.1923</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1923</ArticleId><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence M., Huber W., Pag&#xe8;s H., Aboyoun P., Carlson M., Gentleman R., et al. . (2013). Software for computing and annotating genomic ranges. PLoS Comput. Biol. 9:e1003118. 10.1371/journal.pcbi.1003118</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1003118</ArticleId><ArticleId IdType="pmc">PMC3738458</ArticleId><ArticleId IdType="pubmed">23950696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. (2015). Cancer-fighting viruses win approval. Nature 526, 622&#x2013;623. 10.1038/526622a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/526622a</ArticleId><ArticleId IdType="pubmed">26511559</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Dewey C. N. (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformat. 12:323 10.1186/1471-2105-12-323</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-323</ArticleId><ArticleId IdType="pmc">PMC3163565</ArticleId><ArticleId IdType="pubmed">21816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Durbin R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754&#x2013;1760. 10.1093/bioinformatics/btp324</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp324</ArticleId><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Handsaker B., Wysoker A., Fennell T., Ruan J., Homer N., et al. . (2009). The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078&#x2013;2079. 10.1093/bioinformatics/btp352</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp352</ArticleId><ArticleId IdType="pmc">PMC2723002</ArticleId><ArticleId IdType="pubmed">19505943</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J. W., Wan R., Yu C. S., Co N. N., Wong N., Chan T. F. (2013). ViralFusionSeq: accurately discover viral integration events and reconstruct fusion transcripts at single-base resolution. Bioinformatics 29, 649&#x2013;651. 10.1093/bioinformatics/btt011</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt011</ArticleId><ArticleId IdType="pmc">PMC3582262</ArticleId><ArticleId IdType="pubmed">23314323</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang T. J. (2009). Hepatitis B: the virus and disease. Hepatology 49(5 Suppl), S13&#x2013;S21. 10.1002/hep.22881</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.22881</ArticleId><ArticleId IdType="pmc">PMC2809016</ArticleId><ArticleId IdType="pubmed">19399811</ArticleId></ArticleIdList></Reference><Reference><Citation>Locarnini S., Bowden S. (2012). Hepatitis B surface antigen quantification: not what it seems on the surface. Hepatology 56, 411&#x2013;414. 10.1002/hep.25732</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.25732</ArticleId><ArticleId IdType="pubmed">22454331</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra R. Grady P. Lehnert E. Sethi A. Prakasha P. Brandi N. Davis-Dusenbery (eds.) (2017). Enabling scalable and rapid metagenomic profiling of the transcriptome with the Seven Bridges Cancer Genomics Cloud, in BioIT World 2017 (Boston, MA: ).</Citation></Reference><Reference><Citation>Moyes D. L., Martin A., Sawcer S., Temperton N., Worthington J., Griffiths D. J., et al. . (2005). The distribution of the endogenous retroviruses HERV-K113 and HERV-K115 in health and disease. Genomics 86, 337&#x2013;341. 10.1016/j.ygeno.2005.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2005.06.004</ArticleId><ArticleId IdType="pubmed">16024218</ArticleId></ArticleIdList></Reference><Reference><Citation>NCI  (2011). The Cancer Genome Atlas. Available online at: https://tcga-data.nci.nih.gov/</Citation></Reference><Reference><Citation>Nelson P. N., Carnegie P. R., Martin J., Davari Ejtehadi H., Hooley P., Roden D., et al. . (2003). Demystified. Human endogenous retroviruses. Mol. Pathol. 56, 11&#x2013;18. 10.1136/mp.56.1.11</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/mp.56.1.11</ArticleId><ArticleId IdType="pmc">PMC1187282</ArticleId><ArticleId IdType="pubmed">12560456</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J. H. (2004). [Hepatitis B virus surface antigen: a multifaceted protein]. Korean J. Hepatol. 10, 248&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">15613800</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team  (2014). R: A language and environment for statistical computing.
Vienna: R Foundation for Statistical Computing;  Available online at: http://www.R-project.org/</Citation></Reference><Reference><Citation>Robinson L. R., Whelan S. P. (2016). Infectious entry pathway mediated by the human endogenous retrovirus K Envelope Protein. J. Virol. 90, 3640&#x2013;3649. 10.1128/JVI.03136-15</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03136-15</ArticleId><ArticleId IdType="pmc">PMC4794671</ArticleId><ArticleId IdType="pubmed">26792739</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson M. D., McCarthy D. J., Smyth G. K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140. 10.1093/bioinformatics/btp616</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Salyakina D., Tsinoremas N. F. (2013). Viral expression associated with gastrointestinal adenocarcinomas in TCGA high-throughput sequencing data. Hum. Genomics. 7:23. 10.1186/1479-7364-7-23</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-7364-7-23</ArticleId><ArticleId IdType="pmc">PMC3906926</ArticleId><ArticleId IdType="pubmed">24279398</ArticleId></ArticleIdList></Reference><Reference><Citation>Schelhorn S. E., Fischer M., Tolosi L., Altm&#xfc;ller J., N&#xfc;rnberg P., Pfister H., et al. . (2013). Sensitive detection of viral transcripts in human tumor transcriptomes. PLoS Comput. Biol. 9:e1003228. 10.1371/journal.pcbi.1003228</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1003228</ArticleId><ArticleId IdType="pmc">PMC3789765</ArticleId><ArticleId IdType="pubmed">24098097</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer D. H., Tyagi M., Vallania F., Bredemeyer A. J., Pfeifer J. D., Mitra R. D., et al. . (2014). Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data. J. Mol. Diagn. 16, 75&#x2013;88. 10.1016/j.jmoldx.2013.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmoldx.2013.09.003</ArticleId><ArticleId IdType="pmc">PMC3873500</ArticleId><ArticleId IdType="pubmed">24211364</ArticleId></ArticleIdList></Reference><Reference><Citation>Tage-Jensen U., Aldershvile J., Schlichting P. (1985). Immunosuppressive treatment of HBsAg-positive chronic liver disease: significance of HBeAg. Hepatology 5, 47&#x2013;49. 10.1002/hep.1840050111</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.1840050111</ArticleId><ArticleId IdType="pubmed">3881331</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Z., Pionek K., Unchwaniwala N., Maguire M. L., Loeb D. D., Zlotnick A. (2015). The interface between hepatitis B virus capsid proteins affects self-assembly, pregenomic RNA packaging, and reverse transcription. J. Virol. 89, 3275&#x2013;3284. 10.1128/JVI.03545-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03545-14</ArticleId><ArticleId IdType="pmc">PMC4337549</ArticleId><ArticleId IdType="pubmed">25568211</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang K. W., Alaei-Mahabadi B., Samuelsson T., Lindh M., Larsson E. (2013). The landscape of viral expression and host gene fusion and adaptation in human cancer. Nat. Commun. 4:2513. 10.1038/ncomms3513</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3513</ArticleId><ArticleId IdType="pmc">PMC3806554</ArticleId><ArticleId IdType="pubmed">24085110</ArticleId></ArticleIdList></Reference><Reference><Citation>The Cancer Genome Atlas Research Network (2017). Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 169, 1327&#x2013;41.e23. 10.1016/j.cell.2017.05.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.046</ArticleId><ArticleId IdType="pmc">PMC5680778</ArticleId><ArticleId IdType="pubmed">28622513</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran T. T. (2011). Immune tolerant hepatitis B: a clinical dilemma. Gastroenterol. Hepatol. (N Y). 7, 511&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264935</ArticleId><ArticleId IdType="pubmed">22298987</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Sun Y., Ruan J., Chen R., Chen X., Chen C., et al. . (2016). Using small RNA deep sequencing data to detect human viruses. Biomed. Res. Int. 2016:2596782. 10.1155/2016/2596782</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/2596782</ArticleId><ArticleId IdType="pmc">PMC4811048</ArticleId><ArticleId IdType="pubmed">27066498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Jia P., Zhao Z. (2013). VirusFinder: software for efficient and accurate detection of viruses and their integration sites in host genomes through next generation sequencing data. PLoS ONE 8:e64465. 10.1371/journal.pone.0064465</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064465</ArticleId><ArticleId IdType="pmc">PMC3663743</ArticleId><ArticleId IdType="pubmed">23717618</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. Z., Zhu Z., Zhang H. Y., Zhu M. Z., Xu X., Chen C. H., et al. . (2014). Detection of hepatitis B virus A1762T/G1764A mutant by amplification refractory mutation system. Braz. J. Infect. Dis. 18, 261&#x2013;265. 10.1016/j.bjid.2013.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjid.2013.09.005</ArticleId><ArticleId IdType="pmc">PMC9427444</ArticleId><ArticleId IdType="pubmed">24389280</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikipedia  (2004). FASTA Format. Available online at: https://en.wikipedia.org/wiki/FASTA_format</Citation></Reference><Reference><Citation>Wikipedia  (2009). FASTQ Format. Available online at: https://en.wikipedia.org/wiki/FASTQ_format</Citation></Reference><Reference><Citation>Wood D. E., Salzberg S. L. (2014). Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol. 15:R46. 10.1186/gb-2014-15-3-r46</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2014-15-3-r46</ArticleId><ArticleId IdType="pmc">PMC4053813</ArticleId><ArticleId IdType="pubmed">24580807</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao L., Zhou B., Gao H., Ma S., Yang G., Xu M., et al. . (2011). Hepatitis B virus genotype B with G1896A and A1762T/G1764A mutations is associated with hepatitis B related acute-on-chronic liver failure. J. Med. Virol. 83, 1544&#x2013;1550. 10.1002/jmv.22159</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.22159</ArticleId><ArticleId IdType="pubmed">21739444</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara N. (1995). [ELISA for diagnosis of infections by viruses]. Nihon Rinsho. 53, 2277&#x2013;2282.</Citation><ArticleIdList><ArticleId IdType="pubmed">7474393</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29737570</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4644</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of cellular biochemistry</Title><ISOAbbreviation>J Cell Biochem</ISOAbbreviation></Journal><ArticleTitle>MicroRNA expression in cervical cancer: Novel diagnostic and prognostic biomarkers.</ArticleTitle><Pagination><StartPage>7080</StartPage><EndPage>7090</EndPage><MedlinePgn>7080-7090</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jcb.27029</ELocationID><Abstract><AbstractText>Growing evidence has shown that a large number of miRNAs are abnormally expressed in cervical cancer (CC) tissues and play irreplaceable roles in tumorigenesis, progression, and metastasis. This study aimed to identify new biomarkers and pivotal genes associated with CC prognosis through comprehensive bioinformatics analysis. At first, the data of gene expression microarray (GSE30656) was downloaded from GEO database and differential miRNAs were obtained. Additionally, 4 miRNAs associated with the survival time of patients with CC were screened through TCGA differential data analysis, Kaplan-Meier, and Landmark analysis. Among them, the low expression of miR-188 and high expression of miR-223 correlated with the short survival of CC patients, while the down-regulation of miR-99a and miR-125b was closely related to the 5-year survival rate of patients. Then, based on the correspondence between the differentially expressed genes (DEGs) in CC from the TCGA data and the 4 miRNAs target genes, 58 target genes were screened to perform the analysis of function enrichment and the visualization of protein-protein interaction (PPI) networks. The seven pivotal genes of the PPI network as the target genes of four miRNAs related to prognosis, they were directly or indirectly involved in the development of CC. In this study, based on high-throughput data mining, differentially expressed miRNAs and related target genes were analyzed to provide an effective bioinformatics basis for further understanding of the pathogenesis and prognosis of CC. And the results may be a promising biomarker for the early screening of high-risk populations and early diagnosis of cervical cancer.</AbstractText><CopyrightInformation>&#xa9; 2018 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Chundi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departmen of Oncology, Weifang Traditional Chinese Hospital, Weifang, Shandong, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departmen of Oncology, Weifang Traditional Chinese Hospital, Weifang, Shandong, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departmen of Oncology, Weifang Traditional Chinese Hospital, Weifang, Shandong, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Cun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Huayao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Gongxi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Departmen of Oncology, Weifang Traditional Chinese Hospital, Weifang, Shandong, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Junyu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departmen of Oncology, Weifang Traditional Chinese Hospital, Weifang, Shandong, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Changgang</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0778-8788</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, P. R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cell Biochem</MedlineTA><NlmUniqueID>8205768</NlmUniqueID><ISSNLinking>0730-2312</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012334">RNA, Neoplasm</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="Y">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012334" MajorTopicYN="Y">RNA, Neoplasm</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bioinformatics analysis</Keyword><Keyword MajorTopicYN="N">cervical cancer</Keyword><Keyword MajorTopicYN="N">miRNA</Keyword><Keyword MajorTopicYN="N">subsistence analysis</Keyword><Keyword MajorTopicYN="N">target genes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29737570</ArticleId><ArticleId IdType="doi">10.1002/jcb.27029</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">29243775</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2284-0729</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>23</Issue><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>European review for medical and pharmacological sciences</Title><ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation></Journal><ArticleTitle>Independent prognostic Factor of low-expressed LncRNA ZNF667-AS1 for cervical cancer and inhibitory function on the proliferation of cervical cancer.</ArticleTitle><Pagination><StartPage>5353</StartPage><EndPage>5360</EndPage><MedlinePgn>5353-5360</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.26355/eurrev_201712_13920</ELocationID><ELocationID EIdType="pii" ValidYN="Y">13920</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the expression of long non-coding RNA ZNF667-AS1 in cervical cancer and its effect on the proliferation of cervical cancer cell line, SiHa cells.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The expression level of ZNF667-AS1 from two microarray datasets (GSE63514 and GSE6791) and TCGA (The Cancer Genome Atlas) were selected to analyze the difference between cervical cancer tissues and normal cervical tissues with bioinformatics methods. Then, the prognosis of ZNF667-AS1 was calculated in TCGA. The expression of LncRNA ZNF667-AS1 in 30 normal cervical tissues and 60 cervical cancer tissue samples was explored using qRT-PCR. In addition, analysis of the clinical data found that the expression of LncRNA ZNF667-AS1 was correlated with the total survival, tumor size and International Federation of Gynecology and Obstetrics (FIGO) stage. At last, the proliferative ability was detected by CCK8 and colon formation assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Search the relevant microarray datasets using the keywords "cervical cancer" and "GPL570" from the Gene Expression Omnibus (GEO) database. Afterwards, two microarray datasets (GSE63514 and GSE6791) were selected to analyze the differentially expressed genes in cervical cancer tissues and normal cervical tissues using bioinformatics methods. The results showed that the expression of LncRNA ZNF667-AS1 in cervical cancer was significantly lower than that in normal cervical tissues. 30 normal cervical tissues and 60 cervical cancer tissue samples were selected to extract total RNA for qRT-PCR experiment, and found that the expression of LncRNA ZNF667-AS1 in cervical cancer tissues was lower than that in normal cervical tissues, which was consistent with that of TCGA. Analysis of the clinical data found that the expression of LncRNA ZNF667-AS1 was correlated with the total survival, tumor size and FIGO stage. Compared with the negative control group, the proliferation ability and cell cloning ability of cells with over-expressed LncRNA ZNF667-AS1 were significantly decreased (p&lt;0.001), indicating that overexpression of ZNF667-AS1 inhibited the proliferation of SiHa cells.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Expression of LncRNA ZNF667-AS1 was significantly lower in cervical cancer tissues, and its expression was negatively correlated with the overall survival, tumor size and FIGO stage. ZNF667-AS1 inhibited the proliferation of cervical cancer cells and was expected to be the biomarker and potential therapeutic target for predicting cervical cancer and determining its prognosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>L-P</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The 4th Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, China. sunzhigang1818@sina.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>R-H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>D-M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>X-Q</ForeName><Initials>XQ</Initials></Author><Author ValidYN="Y"><LastName>Nian</LastName><ForeName>G-X</ForeName><Initials>GX</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>M-X</ForeName><Initials>MX</Initials></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Z-G</ForeName><Initials>ZG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA><NlmUniqueID>9717360</NlmUniqueID><ISSNLinking>1128-3602</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000611395">MORT long noncoding RNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062085" MajorTopicYN="N">RNA, Long Noncoding</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29243775</ArticleId><ArticleId IdType="doi">10.26355/eurrev_201712_13920</ArticleId><ArticleId IdType="pii">13920</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27863272</PMID><DateCompleted><Year>2017</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2017</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7654</ISSN><JournalIssue CitedMedium="Internet"><Volume>207</Volume><PubDate><Year>2016</Year><Month>Dec</Month></PubDate></JournalIssue><Title>European journal of obstetrics, gynecology, and reproductive biology</Title><ISOAbbreviation>Eur J Obstet Gynecol Reprod Biol</ISOAbbreviation></Journal><ArticleTitle>Genome-wide analysis of aberrant gene expression and methylation profiles reveals susceptibility genes and underlying mechanism of cervical cancer.</ArticleTitle><Pagination><StartPage>147</StartPage><EndPage>152</EndPage><MedlinePgn>147-152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejogrb.2016.10.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0301-2115(16)30965-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aimed to explore the molecular mechanism of cervical cancer (CC) by integrated bioinformatic analyses of gene expression and methylation profiles.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The gene expression and methylation microarrays in CC samples and normal controls were respectively downloaded from the GEO database. After screening the differentially expressed genes (DEGs) with Limma package and the CC-related methylation sites with CpGassoc package in R language, DEGs with CC-related methylation sites were identified from the intersection of the above two groups of results with 50kb upstream and downstream of a gene as the gene region. Then GO enrichment was performed by GenCLIP2.0 software. Sequentially, analysis of metabolic sub-pathways with pathogenic risk was predicted by iSubpathwayMiner package in R language.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1357 DEGs including 721 up-regulated and 636 down-regulated, as well as 666 CC-related methylation sites were screened out. After being analyzed, 26 DEGs with 35 CC-related methylation sites were identified. EDN3 and EDNRB were significantly involved in a function cluster in GO terms of vein smooth muscle contraction, vascular smooth muscle contraction and phasic smooth muscle contraction. LHX2 and PAX6 were significantly involved in a function cluster in GO terms of telencephalon regionalization and forebrain regionalization. ACOX3, CYP39A1 and DPYS were significantly enriched in 25 sub-pathways of 6 major pathways.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">EDN3 and EDNRB might play important roles in the molecular mechanism of CC, and LHX2, ACOX3, CYP39A1 and DPYS might be susceptibility genes and potential risk markers in CC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Hongmei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gynaecology and Obstetrics, Shandong University Affiliated Jinan Center Hospital, Jinan 250013, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yifei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynaecology and Obstetrics, Shandong University Affiliated Jinan Center Hospital, Jinan 250013, Shandong, China. Electronic address: mayifeiyfm@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Yongqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gynaecology and Obstetrics, Shandong University Affiliated Jinan Center Hospital, Jinan 250013, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gynaecology and Obstetrics, Shandong University Affiliated Jinan Center Hospital, Jinan 250013, Shandong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Eur J Obstet Gynecol Reprod Biol</MedlineTA><NlmUniqueID>0375672</NlmUniqueID><ISSNLinking>0301-2115</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000588595">EDN3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000588596">EDNRB protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019334">Endothelin-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489783">LHX2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060850">LIM-Homeodomain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071841">PAX6 Transcription Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000605730">PAX6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044023">Receptor, Endothelin B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002584" MajorTopicYN="N">Cervix Uteri</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="Y">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019334" MajorTopicYN="N">Endothelin-3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060850" MajorTopicYN="N">LIM-Homeodomain Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071841" MajorTopicYN="N">PAX6 Transcription Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016548" MajorTopicYN="N">Prosencephalon</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044023" MajorTopicYN="N">Receptor, Endothelin B</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013687" MajorTopicYN="N">Telencephalon</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Differentially expressed genes</Keyword><Keyword MajorTopicYN="N">Functions enrichment</Keyword><Keyword MajorTopicYN="N">Methylation sites</Keyword><Keyword MajorTopicYN="N">Risk biomarkers</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27863272</ArticleId><ArticleId IdType="doi">10.1016/j.ejogrb.2016.10.017</ArticleId><ArticleId IdType="pii">S0301-2115(16)30965-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27035672</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1791-2431</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Oncology reports</Title><ISOAbbreviation>Oncol Rep</ISOAbbreviation></Journal><ArticleTitle>Characterization of long non-coding RNA expression profiles in lymph node metastasis of early-stage cervical cancer.</ArticleTitle><Pagination><StartPage>3185</StartPage><EndPage>3197</EndPage><MedlinePgn>3185-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3892/or.2016.4715</ELocationID><Abstract><AbstractText>Pelvic lymph node metastasis (PLNM) is an independent prognostic parameter and determines the treatment strategies of cervical cancer. Increasing evidence indicates that long non-coding RNAs (lncRNAs) play a crucial role in the process of tumor biological functions. This study aimed to mine lymph node metastasis-associated lncRNAs and investigate their potential pathophysiological mechanism in cervical cancer lymph node metastasis. We applied the lncRNA-mining approach to identify lncRNA transcripts represented on Affymetrix human genome U133 plus 2.0&#xa0;microarrays from Gene Expression Omnibus (GEO) and then by validation in clinical specimens. The biological role and molecular mechanism of these lncRNAs were predicted by bioinformatic analysis. Subsequently, a receiver operating characteristic (ROC) curve and survival curve were conducted to evaluate the diagnostic and prognostic value of candidate lncRNAs. In total, 234&#xa0;differentially expressed lncRNAs were identified to significantly associate with pelvic lymph node metastasis in early-stage cervical cancer. Our qRT-PCR results were consistent with the mining analysis (P&lt;0.05). The functional enrichment analysis suggested that these lncRNAs may be involved in the biological process of lymph node metastasis. The ROC curves demonstrated satisfactory discrimination power of MIR100HG and AC024560.2 with areas under the curve of 0.801 and 0.837, respectively. Survival curve also indicated that patients with high MIR100HG expression had a tendency of poor prognosis. This is the first study to successfully mine the lncRNA expression patterns in PLNM of early-stage cervical cancer. MIR100HG and AC024560.2 may be a potential biomarkers of PLNM and these lncRNAs may provide broader perspective for combating cervical cancer metastasis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Chunliang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Wenhui</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Preventive Dentistry, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tianyu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Guangxin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Joint Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jiaming</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Peizhen</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yunhe</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Shuzhong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Oncol Rep</MedlineTA><NlmUniqueID>9422756</NlmUniqueID><ISSNLinking>1021-335X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063990" MajorTopicYN="N">Gene Ontology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062085" MajorTopicYN="N">RNA, Long Noncoding</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27035672</ArticleId><ArticleId IdType="pmc">PMC4869942</ArticleId><ArticleId IdType="doi">10.3892/or.2016.4715</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9&#x2013;29. doi: 10.3322/caac.21208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21208</ArticleId><ArticleId IdType="pubmed">24399786</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson RW, Larsen JK, McClure J, Fitzgerald CL, Venook AP, Benson AB, III, Anderson BO. International adaptations of NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2014;12:643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">24812133</ArticleId></ArticleIdList></Reference><Reference><Citation>Selman TJ, Mann C, Zamora J, Appleyard TL, Khan K. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: A systematic review and meta-analysis. CMAJ. 2008;178:855&#x2013;862. doi: 10.1503/cmaj.071124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.071124</ArticleId><ArticleId IdType="pmc">PMC2267838</ArticleId><ArticleId IdType="pubmed">18362381</ArticleId></ArticleIdList></Reference><Reference><Citation>Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350:535&#x2013;540. doi: 10.1016/S0140-6736(97)02250-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(97)02250-2</ArticleId><ArticleId IdType="pubmed">9284774</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosaka M, Watari H, Mitamura T, Konno Y, Odagiri T, Kato T, Takeda M, Sakuragi N. Survival and prognosticators of node-positive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Int J Clin Oncol. 2011;16:33&#x2013;38. doi: 10.1007/s10147-010-0123-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10147-010-0123-0</ArticleId><ArticleId IdType="pubmed">20842404</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y, Wang X, Wang Y, Liu Y, Zhang J, Qian W, Wu S. Validity of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for pretreatment evaluation of patients with cervical carcinoma: A retrospective pathology-matched study. Int J Gynecol Cancer. 2014;24:1642&#x2013;1647. doi: 10.1097/IGC.0000000000000287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IGC.0000000000000287</ArticleId><ArticleId IdType="pubmed">25268748</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogami Y, Banno K, Irie H, Iida M, Kisu I, Masugi Y, Tanaka K, Tominaga E, Okuda S, Murakami K, et al. The efficacy of preoperative positron emission tomography-computed tomography (PET-CT) for detection of lymph node metastasis in cervical and endometrial cancer: Clinical and pathological factors influencing it. Jpn J Clin Oncol. 2015;45:26&#x2013;34. doi: 10.1093/jjco/hyu161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jjco/hyu161</ArticleId><ArticleId IdType="pubmed">25368102</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz JP, Gemignani ML, Pandit-Taskar N, Park KJ, Murray MP, Chi DS, Sonoda Y, Barakat RR, Abu-Rustum NR. Sentinel lymph node biopsy in the management of early-stage cervical carcinoma. Gynecol Oncol. 2011;120:347&#x2013;352. doi: 10.1016/j.ygyno.2010.12.334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2010.12.334</ArticleId><ArticleId IdType="pmc">PMC3951119</ArticleId><ArticleId IdType="pubmed">21216450</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigsby PW, Watson M, Powell MA, Zhang Z, Rader JS. Gene expression patterns in advanced human cervical cancer. Int J Gynecol Cancer. 2006;16:562&#x2013;567. doi: 10.1111/j.1525-1438.2006.00389.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1438.2006.00389.x</ArticleId><ArticleId IdType="pubmed">16681726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Jia HL, Huang JM, Liang YC, Tan H, Geng HZ, Guo LY, Yao SZ. Identification of biomarkers for lymph node metastasis in early-stage cervical cancer by tissue-based proteomics. Br J Cancer. 2014;110:1748&#x2013;1758. doi: 10.1038/bjc.2014.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2014.92</ArticleId><ArticleId IdType="pmc">PMC3974096</ArticleId><ArticleId IdType="pubmed">24569473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, Choi J, Kim WY, Choi CH, Lee J, Bae D, Son D, Kim J, Park BK, Ahn G, et al. Gene expression profiling for the prediction of lymph node metastasis in patients with cervical cancer. Cancer Sci. 2008;99:31&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11158066</ArticleId><ArticleId IdType="pubmed">17986283</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Zheng M, Zhou QM, Zhang MY, Jia WH, Yun JP, Wang HY. Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma. Cancer. 2011;117:3363&#x2013;3373. doi: 10.1002/cncr.25870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.25870</ArticleId><ArticleId IdType="pubmed">21319141</ArticleId></ArticleIdList></Reference><Reference><Citation>Biewenga P, Buist MR, Moerland PD, Ver Loren van Themaat E, van Kampen AHC, ten Kate FJW, Baas F. Gene expression in early stage cervical cancer. Gynecol Oncol. 2008;108:520&#x2013;526. doi: 10.1016/j.ygyno.2007.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2007.11.024</ArticleId><ArticleId IdType="pubmed">18191186</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhan A, Mandal SS. Long noncoding RNAs: Emerging stars in gene regulation, epigenetics and human disease. Chem Med Chem. 2014;9:1932&#x2013;1956. doi: 10.1002/cmdc.201300534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.201300534</ArticleId><ArticleId IdType="pubmed">24677606</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun NX, Ye C, Zhao Q, Zhang Q, Xu C, Wang SB, Jin ZJ, Sun SH, Wang F, Li W. Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancer. PLoS One. 2014;9:e100340. doi: 10.1371/journal.pone.0100340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100340</ArticleId><ArticleId IdType="pmc">PMC4090119</ArticleId><ArticleId IdType="pubmed">25007342</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao S, Liu W, Li F, Zhao W, Qin C. Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer. Int J Clin Exp Pathol. 2014;7:6776&#x2013;6783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4230116</ArticleId><ArticleId IdType="pubmed">25400758</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Liao LM, Liu AW, Wu JB, Cheng XL, Lin JX, Zheng M. Overexpression of long noncoding RNA HOTAIR predicts a poor prognosis in patients with cervical cancer. Arch Gynecol Obstet. 2014;290:717&#x2013;723. doi: 10.1007/s00404-014-3236-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00404-014-3236-2</ArticleId><ArticleId IdType="pubmed">24748337</ArticleId></ArticleIdList></Reference><Reference><Citation>Noordhuis MG, Fehrmann RSN, Wisman GBA, Nijhuis ER, van Zanden JJ, Moerland PD, Ver Loren, van Themaat E, Volders HH, Kok M, ten Hoor KA, et al. Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res. 2011;17:1317&#x2013;1330. doi: 10.1158/1078-0432.CCR-10-2320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-10-2320</ArticleId><ArticleId IdType="pubmed">21385933</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Sun S, Pu JKS, Tsang ACO, Lee D, Man VOY, Lui WM, Wong STS, Leung GKK. Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol Dis. 2012;48:1&#x2013;8. doi: 10.1016/j.nbd.2012.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.06.004</ArticleId><ArticleId IdType="pubmed">22709987</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX, Zhu N, Zhou WP, Yang GS, Wang YZ, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology. 2011;54:1679&#x2013;1689. doi: 10.1002/hep.24563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.24563</ArticleId><ArticleId IdType="pubmed">21769904</ArticleId></ArticleIdList></Reference><Reference><Citation>Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: A multiple random validation strategy. Lancet. 2005;365:488&#x2013;492. doi: 10.1016/S0140-6736(05)17866-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)17866-0</ArticleId><ArticleId IdType="pubmed">15705458</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler J, Parmryd I. Quantifying colocalization by correlation: The Pearson correlation coefficient is superior to the Mander's overlap coefficient. Cytometry A. 2010;77:733&#x2013;742. doi: 10.1002/cyto.a.20896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.20896</ArticleId><ArticleId IdType="pubmed">20653013</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JB, Dai CM, Su XY, Cao L, Qin R, Kong QB. Gene microarray assessment of multiple genes and signal pathways involved in androgen-dependent prostate cancer becoming androgen independent. Asian Pac J Cancer Prev. 2014;15:9791&#x2013;9795. doi: 10.7314/APJCP.2014.15.22.9791.</Citation><ArticleIdList><ArticleId IdType="doi">10.7314/APJCP.2014.15.22.9791</ArticleId><ArticleId IdType="pubmed">25520106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. The Gene Ontology Consortium Gene ontology: Tool for the unification of biology. Nat Genet. 2000;25:25&#x2013;29. doi: 10.1038/75556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545&#x2013;15550. doi: 10.1073/pnas.0506580102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Q, Liu C, Yuan X, Kang S, Miao R, Xiao H, Zhao G, Luo H, Bu D, Zhao H, et al. Large-scale prediction of long non-coding RNA functions in a coding-non-coding gene co-expression network. Nucleic Acids Res. 2011;39:3864&#x2013;3878. doi: 10.1093/nar/gkq1348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq1348</ArticleId><ArticleId IdType="pmc">PMC3089475</ArticleId><ArticleId IdType="pubmed">21247874</ArticleId></ArticleIdList></Reference><Reference><Citation>Macdonald AI, Sun P, Hernandez-Lopez H, Aasen T, Hodgins MB, Edward M, Roberts S, Massimi P, Thomas M, Banks L, et al. A functional interaction between the MAGUK protein hDlg and the gap junction protein connexin 43 in cervical tumour cells. Biochem J. 2012;446:9&#x2013;21. doi: 10.1042/BJ20111144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20111144</ArticleId><ArticleId IdType="pubmed">22657348</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmrich S, Streltsov A, Schmidt F, Thangapandi VR, Reinhardt D, Klusmann JH. LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia. Mol Cancer. 2014;13:171. doi: 10.1186/1476-4598-13-171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-4598-13-171</ArticleId><ArticleId IdType="pmc">PMC4118279</ArticleId><ArticleId IdType="pubmed">25027842</ArticleId></ArticleIdList></Reference><Reference><Citation>Iancu IV, Botezatu A, Goia-Ru&#x15f;anu CD, St&#x103;nescu A, Huic&#x103; I, Nistor E, Anton G, Ple&#x15f;a A. TGF-beta signalling pathway factors in HPV-induced cervical lesions. Roum Arch Microbiol Immunol. 2010;69:113&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">21434587</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Cao HZ, Zheng PS. LGR5 promotes the proliferation and tumor formation of cervical cancer cells through the Wnt/&#x3b2;-catenin signaling pathway. Oncotarget. 2014;5:9092&#x2013;9105. doi: 10.18632/oncotarget.2377.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.2377</ArticleId><ArticleId IdType="pmc">PMC4253421</ArticleId><ArticleId IdType="pubmed">25193857</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Lu X, Yuan L. LncRNA: A link between RNA and cancer. Biochim Biophys Acta. 2014;1839:1097&#x2013;1109. doi: 10.1016/j.bbagrm.2014.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagrm.2014.08.012</ArticleId><ArticleId IdType="pubmed">25159663</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Chen HY, Yu CY, Xu J, Wang JL, Qian J, Zhang X, Fang JY. A long non-coding RNA signature to improve prognosis prediction of colorectal cancer. Oncotarget. 2014;5:2230&#x2013;2242. doi: 10.18632/oncotarget.1895.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.1895</ArticleId><ArticleId IdType="pmc">PMC4039159</ArticleId><ArticleId IdType="pubmed">24809982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampe PD, Lau AF. The effects of connexin phosphorylation on gap junctional communication. Int J Biochem Cell Biol. 2004;36:1171&#x2013;1186. doi: 10.1016/S1357-2725(03)00264-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1357-2725(03)00264-4</ArticleId><ArticleId IdType="pmc">PMC2878204</ArticleId><ArticleId IdType="pubmed">15109565</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhoff I, Leykauf K, Bleyl U, D&#xfc;rst M, Alonso A. Phosphorylation of the gap junction protein Connexin43 in CIN III lesions and cervical carcinomas. Cancer Lett. 2006;235:291&#x2013;297. doi: 10.1016/j.canlet.2005.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2005.04.031</ArticleId><ArticleId IdType="pubmed">15958277</ArticleId></ArticleIdList></Reference><Reference><Citation>Broustas CG, Gokhale PC, Rahman A, Dritschilo A, Ahmad I, Kasid U. BRCC2, a novel BH3-like domain-containing protein, induces apoptosis in a caspase-dependent manner. J Biol Chem. 2004;279:26780&#x2013;26788. doi: 10.1074/jbc.M400159200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M400159200</ArticleId><ArticleId IdType="pubmed">15069058</ArticleId></ArticleIdList></Reference><Reference><Citation>Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM, Lippman SM. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA. 2003;100:9968&#x2013;9973. doi: 10.1073/pnas.1631086100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1631086100</ArticleId><ArticleId IdType="pmc">PMC187904</ArticleId><ArticleId IdType="pubmed">12909723</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
